



... primary transmission lines...

An axon, or nerve fiber, is a long slender projection of a nerve cell, or neuron, that conducts electrical impulses away from the neuron's cell body or soma. Axons are in effect the primary transmission lines of the nervous system, and as bundles they help make up nerves.

Individual axons are microscopic in diameter but may extend to macroscopic lengths. The longest axons in the human body are those of the sciatic nerve, which run from the base of the spine to the big toe of each foot.

Axon Medchem BV
Hanzeplein 1
9713 GZ Groningen
The Netherlands

Tel: +31 50 3118007
Fax: +31 50 3600390
order@axonmedchem.com

info@axonmedchem.com
www.axonmedchem.com

Axon Medchem LLC
12020 Sunrise Valley Drive, STE100
Reston, VA 20191
United States

Tel: (888) 703-9861 (Toll-free)
Fax: (703) 596-8062
usorders@axonmedchem.com

Axon Ligands™ Catalogue

Spring Edition 2025



Introduction

Axon Medchem is a trusted supplier of high-value life science products, providing Axon Ligands™ as world wide recognized bioactive reference compounds or drug standards for pharmacological research. With in stock about 3000 excellent quality small molecule inhibitors or modulators targeting close to 1000 biological targets of cell signaling, gene transcription, apoptosis, cell cycle regulation, CNS and many more areas, Axon Medchem aims to facilitate your scientific research and development.

Axon Medchem is also a leading European CRO in medicinal chemistry, specialized in contract research and high-quality synthesis of bio-active and/or drug-like molecules. We have the proven record in developing novel drug candidates and achieving excellence for a decade by providing our dedicated chemistry services for companies and research institutes active in the field of life sciences around the world.

Contents

Introduction	2
Pharmacological Index	10
Enzymes	10
Enzymes (EC 1.) Oxidoreductases.....	10
Enzymes (EC 1.1.) Dehydrogenases and Reductases, Hydroxides.....	10
Enzymes (EC 1.1.1) Dehydrogenases and Reductases, IDH/MDH.....	12
Enzymes (EC 1.1.1) Dehydrogenases and Reductases, PHGDH.....	12
Enzymes (EC 1.2.) Dehydrogenases and Reductases, Aldehydes.....	12
Enzymes (EC 1.2.1.) Dehydrogenases and Reductases, ALDH.....	13
Enzymes (EC 1.3.) Oxidases, Dehydrogenases.....	13
Enzymes (EC 1.4.3.) Oxidases, Mono-amine Oxidases.....	14
Enzymes (EC 1.13.11.) Oxygenases, LOX.....	15
Enzymes (EC 1.13.11.) Oxygenases, IDO.....	15
Enzymes (EC 1.14.) Oxygenases.....	15
Enzymes (EC 1.14.11.) Oxygenases, Histone demethylases.....	16
Enzymes (EC 1.14.11.) Oxygenases, LSD1.....	16
Enzymes (EC 1.14.11.) Oxygenases, HIF-Proline Hydroxylases.....	17
Enzymes (EC 1.14.13.) Oxygenases, NAD(P)H-dependent.....	17
Enzymes (EC 1.14.13.) Oxygenases, KMO.....	18
Enzymes (EC 1.14.14.) Oxygenases, Monooxygenases.....	18
Enzymes (EC 1.14.19.) Oxygenases, Desaturases.....	18
Enzymes (EC 1.14.99.) Oxygenases, Cyclooxygenases.....	19
Enzymes (EC 1.14.99.) Oxygenases, Steroid 17 α -monooxygenases.....	19
Enzymes (EC 1.15.1) Dismutases.....	20
Enzymes (EC 1.17.3.) Oxygenases, Xanthine Oxidases.....	20
Enzymes (EC 2.) Transferases.....	20
Enzymes (EC 2.1.1.) Methyltransferases.....	20
Enzymes (EC 2.1.1.) Methyltransferases, DNA.....	21
Enzymes (EC 2.1.1.) Methyltransferases, Histone.....	21
Enzymes (EC 2.3.) Acyltransferases.....	23
Enzymes (EC 2.3.1.) Acyltransferases, Histone.....	23
Enzymes (EC 2.3.1.) Acyltransferases, Porcupine.....	24
Enzymes (EC 2.3.2.) Aminoacyltransferases.....	24
Enzymes (EC 2.4.) Glycosyltransferases.....	25
Enzymes (EC 2.4.1.) Glycosyltransferases, GPases.....	25
Enzymes (EC 2.4.2.) Glycosyltransferases, NAMPT.....	26
Enzymes (EC 2.4.2.) Glycosyltransferases, PARP.....	26
Enzymes (EC 2.5.1.) Prenyltransferases.....	27
Enzymes (EC 2.6.1.) Aminotransferases.....	27
Enzymes (EC 2.7.) Phosphorus-containing Group Transferases.....	28
Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors.....	28
Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, GK.....	29
Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, SphK.....	29

Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, PFKFB.....	29
Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, PKM	29
Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, PI3K	30
Enzymes (EC 2.7.7.) Nucleotidyltransferases	31
Enzymes (EC 2.7.10.) Kinases, Tyrosine specific.....	33
Enzymes (EC 2.7.10.) Kinases, BTK	34
Enzymes (EC 2.7.10.) Kinases, FAK	34
Enzymes (EC 2.7.10.) Kinases, PYK	35
Enzymes (EC 2.7.10.) Kinases, JAK.....	35
Enzymes (EC 2.7.10.) Kinases, SRC.....	36
Enzymes (EC 2.7.10.) Kinases, SYK	36
Enzymes (EC 2.7.10.) Oncogene Fusion Proteins.....	37
Enzymes (EC 2.7.10.) Kinases involved in JAK/STAT signaling.....	38
Enzymes (EC 2.7.11.) Kinases, Serine/Threonine specific	38
Enzymes (EC 2.7.11.) Kinases, ATM/ATR.....	42
Enzymes (EC 2.7.11.) Kinases, Aurora.....	43
Enzymes (EC 2.7.11.) Kinases, CHK.....	43
Enzymes (EC 2.7.11.) Kinases, CK	44
Enzymes (EC 2.7.11.) Kinases, DNA-PK.....	45
Enzymes (EC 2.7.11.) Kinases, IRE1	45
Enzymes (EC 2.7.11.) Kinases, LRRK.....	45
Enzymes (EC 2.7.11.) Kinases, mTOR.....	46
Enzymes (EC 2.7.11.) Kinases, PERK.....	47
Enzymes (EC 2.7.11.) Kinases, Pim	47
Enzymes (EC 2.7.11.) Kinases, PDPK.....	47
Enzymes (EC 2.7.11.) Kinases, Raf.....	48
Enzymes (EC 2.7.11.) Kinases, RIP	49
Enzymes (EC 2.7.11.) Kinases, ROCK.....	49
Enzymes (EC 2.7.11.) Kinases, RSK.....	49
Enzymes (EC 2.7.11.) Kinases, PKB/Akt	50
Enzymes (EC 2.7.11.) Kinases, IKK	51
Enzymes (EC 2.7.11.) Kinases, PKC.....	51
Enzymes (EC 2.7.11.) Kinases, PKD.....	52
Enzymes (EC 2.7.11.) Kinases, PLK	52
Enzymes (EC 2.7.11.) Kinases, CDK.....	52
Enzymes (EC 2.7.11.) Kinases, ERK.....	54
Enzymes (EC 2.7.11.) Kinases, JNK	54
Enzymes (EC 2.7.11.) Kinases, p38 MAPK	55
Enzymes (EC 2.7.11.) Kinases, GSK-3.....	55
Enzymes (EC 2.7.11.) Kinases, AMPK	56
Enzymes (EC 2.7.11.) Kinases, ASK	57
Enzymes (EC 2.7.11.) Kinases involved in DNA-damage response.....	57
Enzymes (EC 2.7.11.) Kinases involved in MAPK/ERK signaling	58
Enzymes (EC 2.7.11.) Kinases involved in the NF- κ B signaling.....	60
Enzymes (EC 2.7.11.) Kinases involved in PI3K/AKT/mTOR signaling.....	61

Enzymes (EC 2.7.11.) Kinases involved in Wnt/ β -Catenin signaling.....	62
Enzymes (EC 2.7.12.) Kinases, Dual specificity.....	63
Enzymes (EC 3.) Hydrolases	64
Enzymes (EC 3.1.1.) Carboxylesterases	64
Enzymes (EC 3.1.1.) Carboxylesterases, PLA.....	66
Enzymes (EC 3.1.1.) Carboxylesterases, MAGL	66
Enzymes (EC 3.1.3.) Phosphoprotein phosphatase.....	66
Enzymes (EC 3.1.4.) Phosphodiesterases.....	68
Enzymes (EC 3.1.22.) Endodeoxyribonucleases	69
Enzymes (EC 3.2.1.) Glycosidases.....	70
Enzymes (EC 3.3.2.) Glycosidases.....	70
Enzymes (EC 3.4.) Peptidases	71
Enzymes (EC 3.4.11.) Amino peptidases.....	71
Enzymes (EC 3.4.14.) Di- and tripeptidyl peptidases	71
Enzymes (EC 3.4.19.) Omega peptidases	72
Enzymes (EC 3.4.21.) Serine proteases	73
Enzymes (EC 3.4.21.) Serine proteases, PAI-1	74
Enzymes (EC 3.4.22.) Cysteine proteases	75
Enzymes (EC 3.4.22.) Cysteine proteases, Caspases.....	75
Enzymes (EC 3.4.22.) Cysteine proteases, CTSK.....	75
Enzymes (EC 3.4.23.) Aspartic proteases	76
Enzymes (EC 3.4.23.) Aspartic proteases, Beta-secretase (BACE).....	76
Enzymes (EC 3.4.23.) Aspartic proteases, Gamma-secretase	77
Enzymes (EC 3.4.24.) Metalloproteases	77
Enzymes (EC 3.5.) Amidases	78
Enzymes (EC 3.5.1.) Amidases, LpxC	79
Enzymes (EC 3.5.1.) Amidases, HDAC	79
Enzymes (EC 3.6.) Anhydride hydrolases.....	81
Enzymes (EC 3.6.) Anhydride hydrolases, MTH1	81
Enzymes (EC 3.6.) Anhydride hydrolases, Hsp	82
Enzymes (EC 3.6.3.) Anhydride hydrolases, ion-pump ATPases.....	82
Enzymes (EC 3.6.4.) Anhydride hydrolases, ATPases cellular movement.....	83
Enzymes (EC 3.6.5.) Anhydride hydrolases, GTPases	84
Enzymes (EC 4.) Lyases	86
Enzymes (EC 4.2.99.) Lyases, APE	87
Enzymes (EC 4.6.1.) Lyases, P-O	87
Enzymes (EC 5.) Isomerases	88
Enzymes (EC 5.99.1.) Isomerases, Topo	88
Enzymes (EC 6.) Ligases	89
Enzymes (EC 6.1.1.) Ligases, MetRS.....	90
Enzymes (EC 6.3.2.) Ligases, Ubiquitin.....	90
Enzymes (EC various) Ubiquitin Proteasome System.....	92
Ion Channels	93
Ion Channels: Ligand-gated.....	93
Ion Channels (Ligand-gated) Cys-loop, anionic	93

Ion Channels (Ligand-gated) Cys-loop, cationic.....	94
Ion Channels (Ligand-gated) Glutamate, ionotropic.....	95
Ion Channels (Ligand-gated) P2X.....	96
Ion Channels (Ligand-gated) unclassified.....	96
Ion Channels: Voltage-gated.....	97
Ion Channels (Voltage-gated) Calcium.....	97
Ion Channels (Voltage-gated) Potassium.....	98
Ion Channels (Voltage-gated) Sodium.....	99
Ion Channels (Voltage-gated) Transient Receptor Potential.....	99
Ion Channels: Inward rectifier, Potassium.....	101
Ion Channels: Calcium-activated, Potassium.....	101
Ion Channels: Two-pore-domain, Potassium.....	102
Ion Channels: Voltage-dependent Anion Selective.....	102
Ion Channels: Calcium-activated, Chloride.....	103
Receptors.....	104
Receptors: Cytokine.....	104
Receptors: Enzyme Linked.....	105
Receptors (Enzyme Linked, RTK class I) ErbB receptor family.....	106
Receptors (Enzyme Linked, RTK class II) Insulin receptor family.....	107
Receptors (Enzyme Linked, RTK class III) PDGF receptor family.....	107
Receptors (Enzyme Linked, RTK class IV) VEGF receptor family.....	108
Receptors (Enzyme Linked, RTK class V) FGF receptor family.....	109
Receptors (Enzyme Linked, RTK class VII) Trk receptor family.....	109
Receptors (Enzyme Linked, RTK class X) HGF receptor family.....	110
Receptors (Enzyme Linked, RTK class XI) TAM receptor family.....	111
Receptors (Enzyme Linked, RTK class XIII) EPH receptor family.....	111
Receptors (Enzyme Linked, RTK class XIV) RET receptor family.....	111
Receptors (Enzyme Linked, RTK class XVI) Collagen receptor family.....	112
Receptors (Enzyme Linked, RTK class XIX) LTK receptor family.....	112
Receptors (Enzyme Linked, RSTK class I) ALK receptor family.....	112
Receptors (Enzyme Linked, RSTK class II) Activin receptor family.....	113
Receptors: G protein-coupled (GPCRs).....	113
Receptors (GPCR-A1) Chemokine CC.....	114
Receptors (GPCR-A2) Chemokine CXC, Interleukin.....	115
Receptors (GPCR-A3) Angiotensin.....	116
Receptors (GPCR-A4) Opioid, Somatostatin.....	116
Receptors (GPCR-A5) Neuropeptides, Leukotrienes.....	117
Receptors (GPCR-A6) Cholecystokinin, Orexin, Vasopressin, GnRH.....	118
Receptors (GPCR-A7) Endothelin, Neurotensin, GHS.....	119
Receptors (GPCR-A8) Mas.....	119
Receptors (GPCR-A9) Neurokinin.....	119
Receptors (GPCR-A9) Melatonin.....	120
Receptors (GPCR-A11) GPR40-related, P2Y purine.....	120
Receptors (GPCR-A12) P2Y purine.....	121
Receptors (GPCR-A13) Cannabinoid.....	122

Receptors (GPCR-A13) Lysophospholipid.....	123
Receptors (GPCR-A14) Eicosanoid.....	123
Receptors (GPCR-A15) Cannabinoid.....	124
Receptors (GPCR-A15) Proteinase activated.....	125
Receptors (GPCR-A17) (nor-)Adrenaline.....	125
Receptors (GPCR-A17) Dopamine.....	126
Receptors (GPCR-A17) Non Selective Dopamine/Serotonin.....	128
Receptors (GPCR-A17) Serotonin.....	129
Receptors (GPCR-A17) Trace Amine Associated.....	131
Receptors (GPCR-A18) Acetylcholine, muscarinic.....	131
Receptors (GPCR-A18) Adenosine.....	132
Receptors (GPCR-A18) Histamine.....	133
Receptors (GPCR-A19) Serotonin.....	134
Receptors (GPCR-B1) Calcitocin, CRF, Glucagon-like.....	136
Receptors (GPCR-C) CaSR, GABA-B.....	136
Receptors (GPCR-C) Glutamate.....	137
Receptors (GPCR-F) Smoothened.....	138
Receptors: Nuclear.....	138
Receptors (Nuclear, Class 1) Thyroid Hormone Receptor-like.....	138
Receptors (Nuclear, Class 2) Retinoid X Receptor-like.....	140
Receptors (Nuclear, Class 3) Estrogen Receptor-like.....	141
Receptors (Nuclear, Class 4): Orphan.....	143
Receptors: Sigma.....	143
Receptors: Miscellaneous.....	144
Proteins.....	146
Proteins: Auxiliary.....	146
Proteins: Matrix.....	146
Proteins (Matrix) intracellular.....	146
Proteins (Matrix) extracellular.....	147
Proteins: Regulator.....	149
Proteins (Regulator) Cell Cycle.....	150
Proteins (Regulator) Growth factors.....	151
Proteins (Regulator) BCL2.....	152
Proteins (Regulator) IAP.....	152
Proteins (Regulator) L3MBTL.....	153
Proteins (Regulator) WDR5.....	153
Proteins (Regulator) BRD.....	154
Proteins (Regulator) BRPF1.....	155
Proteins (Regulator) TRAIL.....	155
Proteins (Regulator) Ferroptosis.....	155
Proteins: Transcription Factors.....	156
Proteins (Transcription Factors) class 1.....	156
Proteins (Transcription Factors) class 2.....	157
Proteins (Transcription Factors) class 3.....	157
Proteins (Transcription Factors) class 4.....	158

Proteins (Transcription Factors) coactivators.....	159
Proteins: Transporters	160
Proteins (Transporters) Neurotransmitters.....	160
Proteins (Transporters) ABC.....	162
Proteins (Transporters) Glucose.....	162
Proteins (Transporters) Ions	163
Proteins (Transporters) Synaptic Vesicle Glycoprotein	163
Proteins (Transporters) Triglycerides.....	164
Proteins (Transporters) Phosphatidylglycerides.....	164
Proteins (Transporters) Other.....	165
Biomarkers and Labeling reagents	167
Derivatisation reagents	167
Protein Labeling reagents.....	167
Membrane Labeling reagents	168
Membrane Labeling reagents, Fluorescents	168
NO and HNO donors	168
Axon Ligands™ as Cell Cycle Regulators	169
Axon Ligands™ for Stem Cell Research.....	176
Axon Ligands™ for Epigenetic Research.....	180
Miscellaneous Axon Ligands™	184
Axon Ligands™ inhibitor Sets.....	188
Axon Ligands™ in Alphabetical Order.....	189
Alphabetical Shortlist.....	1012

Axon Medchem is also active in social media:



<http://www.linkedin.com/company/axon-medchem-bv>

Pharmacological Index

Enzymes

A fundamental task of proteins is to act as enzymes: catalysts that increase the rate of virtually all the chemical reactions within cells. They are highly selective, accelerating both the rate and specificity of metabolic reactions, from the digestion of food to the synthesis of DNA. Most enzymes are proteins, although some catalytic RNA molecules have been identified as well. Cells contain thousands of different enzymes, and their activities determine which of the many possible chemical reactions actually take place within the cell. The binding of a substrate to the active site of an enzyme is a very specific interaction. Once a substrate is bound to the active site of an enzyme, multiple mechanisms can accelerate its conversion to the product of the reaction. Examples of enzymatic conversions of substrates include peptide bond formation or cleavage, hydrolysis and condensation, oxidation and reduction, phosphorylation, and many more. In addition to binding their substrates, the active sites of many enzymes bind other ions or small molecules that participate in catalysis. These molecules are called coenzymes and/or cofactors. In contrast to substrates, coenzymes are not irreversibly altered by the reactions in which they are involved. While most enzymes move freely (intra- and extracellular) within the organism, many enzymes are anchored to either membranes or receptors¹.

The Axon Ligands™ that interact with enzymatic processes are arranged into the six major classes of enzymes in line with the rules of classification stated by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology².

¹ The Cell: A Molecular Approach. 2nd edition. Cooper GM. Sunderland (MA): Sinauer Associates; 2000.

² Enzyme Nomenclature 1992. Academic Press, San Diego, California, ISBN 0-12-227164-5.

Enzymes (EC 1.) Oxidoreductases

Oxidoreductases comprise the large class of enzymes that catalyze biological oxidation/reduction reactions. They play an important role in both aerobic and anaerobic metabolism. They can be found in glycolysis, TCA cycle, oxidative phosphorylation, and in amino acid metabolism. Subcategories within this class of biological targets are created based the kind of acceptor molecules involved in the redox reaction they catalyze, and on and the nature of their substrates¹.

¹ Enzyme Nomenclature 1992. Academic Press, San Diego, California, ISBN 0-12-227164-5.

3424 Ebselen.....	<i>Glutathione peroxidase mimic</i>	Page 449
3582 PBENZ-DBRMD	<i>DIO3 inhibitor</i>	Page 749
3209 SBI-183.....	<i>Orally active inhibitor of QSOX1</i>	Page 852

Enzymes (EC 1.1.) Dehydrogenases and Reductases, Hydroxides

There are 7 different alcohol dehydrogenase (ADH; EC 1.1.1.1) isozymes in human: three belong to class-I: alpha, beta, and gamma, one to class-II: pi, one to class-III: chi, one to class-IV: ADH7 and one to class-V: ADH6. Members of the ADH7 family metabolize a wide variety of substrates, including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products. ADH7 is the only ADH not expressed in liver, instead being expressed mainly in the upper gastrointestinal tract. Genome-wide studies have identified significant associations between single-nucleotide polymorphisms in ADH7 with alcoholism, drug dependence and cancer, but the causative variants have not been identified¹. Atorvastatin (Axon 2043) is probably among the best known inhibitors of the enzyme HMG-CoA reductase (EC 1.1.1.88), an enzyme found in liver tissue that plays a key role in the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids. Inhibition of the enzyme decreases de novo cholesterol synthesis, increasing expression of low-density lipoprotein receptors (LDL receptors) on hepatocytes. This increases LDL uptake by the hepatocytes, decreasing the amount of LDL-cholesterol in the blood. Interestingly, like most drugs, degradation of Atorvastatin is initiated by another oxidoreductase enzyme: Cytochrome P450 3A4 (CYP3A4), an enzyme in the class of EC 1.14².

The human genome has 5 isocitrate dehydrogenase (IDH; EC 1.1.1.42) genes, coding for 3 distinct IDH enzymes whose activities are dependent on either NADP (NADP+-dependent IDH1 and IDH2) or NAD (NAD+-dependent IDH3). Both IDH2 and IDH3 are localized in the mitochondria and participate in the citric acid cycle for energy production, whereas IDH1 is localized in the cytoplasm and peroxisomes. IDH enzymes catalyze the oxidative decarboxylation of isocitrate to produce α -ketoglutarate (also known as 2-oxoglutarate) and concomitantly produce NADPH from NADP+. IDH enzymes also catalyze the reductive carboxylation of α -ketoglutarate to form isocitrate and concomitantly produce NADP+ from NADPH. Since IDH1 and IDH2 are mutated in 50%–80% of astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas, Isocitrate dehydrogenase (IDH) enzymes have recently become a focal point for research aimed at understanding the biology of glioma³.

Two 11 β -hydroxysteroid dehydrogenases (11 β -HSD; EC 1.1.1.146) catalyze the interconversion between active and inactive glucocorticoids. The enzyme 11 β -HSD1 is widely expressed and yields increased local tissue concentration of

active glucocorticoid by converting cortisone into cortisol in humans, and 11-dehydrocorticosterone into corticosterone in rodents. In contrast, the enzyme 11 β -HSD2 catalyzes the opposite reaction, the inactivation of active glucocorticoid. 11 β -HSD1 has been proposed as a new target for type 2 diabetes drugs, since they lower blood glucose levels and improve insulin sensitivity⁴.

Aldose reductase (AR; EC 1.1.1.21) is a NADPH-dependent oxidoreductase and considered the key enzyme in the polyol pathway. It catalyzes the reduction of a variety of aldehydes and carbonyls, including monosaccharides, and is primarily known for the conversion of glucose into sorbitol. During states of hyperglycemia, the polyol pathway has increased activity, resulting in elevated sorbitol levels. Increases in sorbitol concentrations result in cellular and organ injury and in the decrease of myo-inositol in the peripheral nerves. When myo-inositol is decreased, there is a resulting decrease in Na⁺,K⁺-ATPase activity, which is essential for nerve conduction. Additionally, increased polyol pathway activity and the overutilization of NADPH by AR may affect a number of other homeostatic mechanisms: NADPH depletion results in decreased nitric oxide (NO) and reduced glutathione production. Inhibition of this enzyme causes a decrease in the accumulation of sorbitol in the cells, and may serve possible treatments for diabetic neuropathy⁵.

In normal tissues, lactate generation is limited to anaerobic conditions where oxygen levels are low. In contrast, cancer cells preferentially convert glucose into lactate through glycolysis, even under normal oxygen concentrations, a phenomenon termed "aerobic glycolysis" or the Warburg effect. Anti-glycolytic therapeutic approaches against cancer have been (re-)evaluated, in consideration of the dependence that cancer cells have on a high glycolytic rate⁶. In particular, human LDH-A (or LDH-5; EC 1.1.1.27), a key glycolytic enzyme that catalyzes the formation of lactate from pyruvate and is frequently upregulated in clinical tumors, is currently being considered as a strategic target for the blockage of glycolysis. Since humans missing the LDH-A enzyme (as a hereditary disease), are healthy, it has been hypothesized that inhibition of LDH-A as an anticancer strategy should give no significant on-target side effects^{7 and 8}.

As the cell wall frames and protects mycobacterial cells, its biosynthesis is a fundamental process for the mycobacterial survival. As a consequence, the enzymes involved in this process represent potential drug targets in tuberculosis (TB) treatment. DprE1 (EC 1.1.98.3) is a decaprenylphosphoryl-D-ribose oxidase, involved in the biosynthesis of decaprenylphosphoryl-D-arabinose (DPA), an essential component of the mycobacterial cell wall. In concert with DprE2, it catalyzes the epimerization of decaprenylphosphoryl-D-ribose (DPR) to DPA, via the formation of the intermediate decaprenylphosphoryl 2-keto-ribose (DPX)⁹.

¹ S. Jairam et al. Single-nucleotide polymorphisms interact to affect ADH7 transcription. *Alcohol Clin Exp Res.* 2014 Apr;38(4):921-9.
² Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. W.D. Feely J. *Clin Pharmacokinet* 2002, 41, 343-370.
³ C. Zhang et al. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. *Neuro Oncol.* 2013, 15, 1114-1126.
⁴ P. Alberts et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. *Endocrinology.* 2003, 144(11), 4755-4762.
⁵ K.E. Schemmel et al. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. *J. Diabetes Complications.* 2010, 24, 354-360.
⁶ R.A. Ward et al. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. *J Med Chem.* 2012 Apr 12;55(7):3285-306.
⁷ C. Granchi et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. *J Med Chem.* 2011 Mar 24;54(6):1599-612.
⁸ C. Granchi et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. *Org Biomol Chem.* 2013 Oct 14;11(38):6588-96.
⁹ G. Riccardi et al. The DprE1 enzyme, one of the most vulnerable targets of *Mycobacterium tuberculosis*. *Appl Microbiol Biotechnol.* 2013 Oct;97(20):8841-8.

2746	AG-120	IDH1 mutant enzyme inhibitor	Page 211
2745	AG-221	IDH2 mutant enzyme inhibitor	Page 212
2883	APPA	Aldose reductase inhibitor	Page 242
2787	ASP 9521	Inhibitor of 17 β -hydroxysteroid dehydrogenase type 5	Page 256
2043	Atorvastatin calcium	Inhibitor of HMG-CoA reductase	Page 259
3863	BAY-1436032	Highly selective, potent and orally available inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1)	Page 287
3638	BAY-179	Potent, selective, and species cross-reactive complex I inhibitor	Page 287
2698	BTZ043	Antimycobacterial DprE1 inhibitor that kills <i>Mycobacterium tuberculosis</i>	Page 332
1756	BVT 2733 hydrochloride	Inhibitor of 11 β -hydroxysteroid dehydrogenase type 1	Page 334
3020	DS44960156	Selective MTHFD2 inhibitor	Page 443
1204	EBPC	Aldose reductase inhibitor	Page 449
3240	Finasteride	Potent, reversible inhibitor of 5 α -reductase	Page 481
3621	GSK2837808A	Potent, selective and NADH-competitive inhibitor of LDH-A	Page 520

2909	IACS-010759	Potent and orally bioavailable inhibitor of complex I of oxidative phosphorylation	Page 554
3978	Imirestat	Potent aldose reductase inhibitor	Page 563
2654	JK184	Hedgehog (Hh) signaling pathway antagonist	Page 578
2480	LW 6	Inhibitor of HIF-1 α stability via MDH2/CHP1 inhibition	Page 625
3319	Methotrexate	Potent, competitive inhibitor of dihydrofolate reductase	Page 647
2450	NHI 2	Selective inhibitor of human lactate dehydrogenase A	Page 701
2626	PBTZ169	Potent irreversible DprE1 inhibitor; tuberculosis therapeutic	Page 750
3444	Rosuvastatin calcium	Inhibitor of HMG-CoA reductase	Page 830
2544	S3QEL 2	Suppressor of superoxide production	Page 838
3443	Simvastatin	Inhibitor of HMG-CoA reductase	Page 866
3317	Trilostane	Orally active, competitive inhibitor of 3 β -hydroxysteroid dehydrogenase	Page 939
4024	Vorasidenib	First-in-class, potent, orally active, brain-penetrant dual mDH1/2	Page 971

Enzymes (EC 1.1.1) Dehydrogenases and Reductases, IDH/MDH

Similar to IDH, malate dehydrogenases (MDH; EC 1.1.1.37) belong to the NAD-dependent dehydrogenases, and catalyze the reversible conversion of malate into oxaloacetate. MDH is a rather ubiquitous enzyme, for which several isoforms have been identified, differing in their subcellular localization and their specificity for the coenzyme NAD or NADP¹. Malate metabolism plays a key role in mitochondrial respiration and as a mediator of hormone-induced enhancement of mitochondrial respiration. MDH is essential for transamination of glutamate by aspartate aminotransferase. These combined reactions are the mitochondrial part of the malate aspartate shuttle and are of importance in gluconeogenesis and ureogenesis and for the release of insulin by pancreatic islets².

¹ P. Minárik et al. Malate dehydrogenases—structure and function. *Gen Physiol Biophys.* 2002 Sep;21(3):257-65.
² L.A. Fahien et al. Regulation of malate dehydrogenase activity by glutamate, citrate, alpha-ketoglutarate, and multienzyme interaction. *J Biol Chem.* 1988 Aug 5;263(22):10687-97.

2122	AGI 5198	Inhibitor of R132 mutant isocitrate dehydrogenase 1 (IDH1)	Page 214
2274	AGI 6780	Selective inhibitor of tumor-associated mutant IDH2 (R140Q)	Page 214

Enzymes (EC 1.1.1) Dehydrogenases and Reductases, PHGDH

The NAD⁺-dependent enzyme 3-phosphoglycerate dehydrogenase (PHGDH; EC 1.1.1.95), which catalyzes the first committed step of serine biosynthesis from glucose via the phosphoserine pathway, is overexpressed in tumors and cancer cell lines via focal amplification and nuclear factor erythroid-2-related factor 2 (NRF2)-mediated up-regulation. Since it was found that proliferation of PHGDH-amplified cancer cell lines, and other lines that overexpress PHGDH without amplification, is inhibited by PHGDH knockdown, PHGDH inhibitors as a targeted therapy for these tumor types represent an exciting clinical opportunity¹.

¹ E. Mullarky et al. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. *Proc Natl Acad Sci U S A.* 2016 Feb 16;113(7):1778-83.

2585	CBR 5884	Inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH)	Page 347
2623	NCT-503	PHGDH inhibitor that suppresses growth of cancer cells	Page 695

Enzymes (EC 1.2.) Dehydrogenases and Reductases, Aldehydes

Inhibition of the enzyme S-nitrosoglutathione reductase (GSNOR; EC 1.2.1.46) affects the metabolism of S-nitrosoglutathione and the maintenance of nitric oxide (NO) homeostasis. GSNOR is a zinc-dependent, NAD⁺- and NADH-dependent, medium chain alcohol dehydrogenase (ADH), but shows only modest affinity towards alcohols. Rather, the enzyme is also known as formaldehyde dehydrogenase, and as such, it targets GSNOR in order to reduce its nitroso group into an unstable S-hydroxylaminoglutathione intermediate. Inhibition of GSNOR by N6022 (Axon 1822) and related

compounds has shown safety and efficacy in animal models of asthma, chronic obstructive pulmonary disease, and inflammatory bowel disease¹.

The mitochondrial pyruvate dehydrogenase complex (PDC) is a complex of three enzymes that convert pyruvate into acetyl-CoA. Pyruvate dehydrogenase (E1) (PDH; EC 1.2.4.1) is the first component enzyme of PDC that controls glycolysis-derived pyruvate entry into the tricarboxylic acid (TCA) cycle where it can be oxidized to support ATP generation or its carbon diverted to anabolism. The activity of PDH (E1) is rapidly regulated by phosphorylation and dephosphorylation events that are catalyzed by PDH kinases (PDKs 1-4) and PDH phosphatases (PDPs), respectively. Phosphorylation of PDH results in inhibition of activity, whereas, dephosphorylation increases it². Besides a crucial role in patients that suffer from pyruvate dehydrogenase deficiency—one of the most common neurodegenerative disorders associated with abnormal mitochondrial metabolism—PDH is also topic of interest of many studies on cancer. In cancer cells pyruvate is abundantly transformed to lactate, regardless of the presence of oxygen. This phenomenon, known historically as the Warburg effect, is called aerobic glycolysis. The biologic basis of this intensified glycolysis and shift of pyruvate transformation to lactate in cancer cells is thought to be related to HIF1 α ³.

¹ Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase. L.S. Green, L.E. Chun, A.K. Patton, X. Sun, G.J. Rosenthal, J.P. Richards. *Biochemistry*. 2012, 51, 2157-2168.
² Z Zachar et al. Non-redox-active lipote derivatives disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. *J. Mol. Med. (Berl)*. 2011, 89(11), 1137-1148.
³ M.I. Koukourakis et al. Pyruvate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression in Non Small Cell Lung Cancer and Tumor-Associated Stroma. *Neoplasia*. Jan 2005, 7, 1-6.

2125	CPI 613	Inhibitor of mitochondrial pyruvate dehydrogenase complex	Page 393
3725	CVT-10216	Highly selective, reversible inhibitor of ALDH-2	Page 399
3612	GAPDH inhibitor compound F8	Covalent GAPDH inhibitor	Page 496
3915	KOTX1	Selective, non-cytotoxic and reversible ALDH1A3 inhibitor	Page 594
3791	LCS3	Reversible and uncompetitive inhibitor of GSR and TXNRD1	Page 606
2480	LW 6	Inhibitor of HIF-1 α stability via MDH2/CHP1 inhibition	Page 625
3880	MCI-INI-3	Potent and selective ALDH1A3 inhibitor	Page 642
1822	N 6022	Inhibitor of S-nitrosoglutathione reductase (GSNOR)	Page 689

Enzymes (EC 1.2.1.) Dehydrogenases and Reductases, ALDH

Detoxification of aldehydes generally occurs either via oxidation to the corresponding carboxylic acid or reduction to the alcohol. The aldehyde dehydrogenase (ALDH; EC 1.2.1.36) superfamily catalyzes the NAD(P)⁺-dependent oxidation of aldehydes to their respective carboxylic acid, only ALDH6A1 generating the CoA thioester product. The human genome encodes for at least 19 distinct ALDH genes. The structure of human ALDHs are similar, functioning as either homodimers or homotetramers, with each monomer comprised of at least three structural domains; a catalytic domain, a cofactor binding domain, and an oligomerization domain. Despite similarities in structure and function, the isoenzymes of the ALDH family of proteins have evolved to recognize different spectrums of aldehyde substrates due to differences in the size and shape of their respective substrate binding sites. These differences have permitted the development of some selective activators and inhibitors for various isoenzymes as therapeutics¹.

¹ C.A. Morgan et al. N,N-diethylaminobenzaldehyde (DEAB) as a substrate and mechanism-based inhibitor for human ALDH isoenzymes. *Chem Biol Interact*. 2015 Jun 5;234:18-28.

2551	Alda 1	Small molecule activator of ALDH2	Page 218
2476	DEAB	Potent inhibitor of cytosolic ALDH enzymes	Page 415

Enzymes (EC 1.3.) Oxidases, Dehydrogenases

Dihydroorotate dehydrogenase (DHODH; EC 1.3.3.1) is a flavin-dependent mitochondrial enzyme that catalyzes the oxidation of dihydroorotate to orotate, the fourth reaction of pyrimidine de-novo synthesis¹. Pyrimidine bases are essential for cellular metabolism and cell growth, and are considered as important precursors used in DNA (thymine and cytosine), RNA (uracil and cytosine), glycoproteins and phospholipids biosynthesis. Inhibitors of DHODH have proven efficacy for the treatment of malaria, autoimmune diseases, cancer, rheumatoid arthritis and psoriasis. Many of the clinically relevant anti-tumor and immunosuppressive drugs target human dihydroorotate dehydrogenase (hDHODH)².

The mitochondrial succinate dehydrogenase (SDH or SQR) complex (consisting of four nuclear encoded subunits) catalyzes the oxidation of succinate to fumarate in the Krebs (TCA) cycle, and feeds electrons to the respiratory chain (RC) ubiquinone (UQ) pool. Contrasting with most dehydrogenases feeding electrons to the RC, SDH is known to be fully activated upon reduction of the RC and in the presence of ATP, due to dissociation of its physiological inhibitor,

oxaloacetate, at the active site³. Germline mutations of the genes that encode the SDH subunits result in hereditary paraganglioma-pheochromocytoma syndromes. Patients with such mutations also develop gastrointestinal stromal tumors (GISTs) that can be recognized by their distinctive multinodular architecture, predominantly epithelioid morphology, and predilection for lymph node metastasis⁴. Recently, evidence has been accumulated that SDH is target of the anti Leishmanial drug Sitamaquine (Axon 1515), as it targets the respiratory chain in digitonin-permeabilized promastigotes⁵.

¹ H. Munier-Lehmann et al. On dihydroorotate dehydrogenases and their inhibitors and uses. *J. Med. Chem.* 2013, 56, 3148-3167.
² V.K. Vyas et al. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. *Mini Rev. Med. Chem.* 2011, 11, 1039-1055.
³ P. Rustin et al. Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. *Eur J Hum Genet.* 2002 May;10(5):289-91.
⁴ S.R. Williamson et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. *Modern Pathology* 2015, 28, 80-94.
⁵ L. Carvalho et al. The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase. *Antimicrob. Agents Chemother.* 2011, 55, 4204-4210.

3943	AVN944	Incompetitive small molecule inhibitor of inosine monophosphate dehydrogenase (IMPDH)	Page 263
3164	Leflunomide	Selective inhibitor of de novo pyrimidine synthesis; DMARD	Page 610
3498	Mycophenolate mofetil	Oral prodrug of MPA; Potent, selective, noncompetitive IMPDH inhibitor	Page 685
3992	PF-06281355	Selective, orally active, mechanism-based myeloperoxidase (MPO) inhibitor	Page 760
1515	Sitamaquine	Succinate dehydrogenase (SDH) inhibitor	Page 867
2377	Vidofludimus	Oral immunomodulatory drug that inhibits DHODH	Page 968

Enzymes (EC 1.4.3.) Oxidases, Mono-amine Oxidases

Mono-amine oxidases play an important role in neurotransmitter metabolism. Inhibitors of this class of enzymes have played a major role in our understanding of the functional roles of dopamine (DA), norepinephrine (NE), and serotonin (5-HT) neurotransmission in the CNS. However, due to their potentially lethal dietary and drug interactions ("cheese effect"), monoamine oxidase inhibitors have historically been reserved as a last-in-line treatment of psychiatric disorders, only to be used when other classes of antidepressant drugs have failed¹.

Semicarbazide-sensitive amine oxidase (SSAO; EC 1.4.3.21) is an enzyme predominantly located in the endothelium and leukocytes. SSAO is unique among other endothelial-expressed adhesins as it is also an ectoenzyme. A soluble form of SSAO is present in plasma and is known as vascular adhesion protein VAP-1. It is well known to regulate two key inflammatory processes which are integral to progressive renal pathology. Besides causing oxidative stress by its oxidation products, oxidative stress, SSAO mediates the transmigration of intraluminal leukocytes into sites of tissue inflammation, which is initially a protective reparative process, but if persistent, can lead to chronic inflammatory cell accumulation². Activation of VAP-1 has been implicated in several pathologies, such as: atherosclerosis, diabetes, Alzheimer's disease, kidney fibrosis, and pulmonary diseases³.

¹ <http://www.mayoclinic.com/health/depression/DS00175/DSECTION=treatments-and-drugs>
² M Wong et al. Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model. *Am J Physiol Renal Physiol*. 2014 Oct 15;307(8):F908-16.
³ T Valente et al. SSAO/VAP-1 protein expression during mouse embryonic development. *Dev Dyn*. 2008 Sep;237(9):2585-93.

1066	Aminotetraline hydrobromide, N-Cyclopropyl-N-methyl-2	MAO inhibitor	Page 229
1067	Aminotetraline hydrochloride, N-Cyclopropyl-2	MAO inhibitor	Page 233
2819	APX-115	First-in-class pan-NADPH oxidase (Nox) inhibitor	Page 243
2737	EN460	Inhibitor of endoplasmic reticulum oxidation 1 (ERO1)	Page 458
3006	GKT137831	First-in-class dual NADPH oxidase (Nox) 1/4 inhibitor	Page 503
3526	GSK2795039	Potent and selective NOX2 inhibitor	Page 520
3629	Moclobemide	Reversible and selective MAO-A inhibitor; Antidepressant	Page 676
1022	N 0425 hydrochloride	MAO inhibitor	Page 687
1018	N 0430 hydrobromide	MAO inhibitor; Dopamine agonist	Page 687
1020	N 0432 hydrobromide	MAO inhibitor; Dopamine agonist	Page 688
2583	PXS 4728A	Inhibitor of VAP-1/SSAO, neutrophil rolling, and tethering	Page 798
3332	R-(-)-Deprenyl hydrochloride	Highly selective MAO-B inhibitor	Page 804

2629	TB5	<i>Competitive and reversible MAO-B inhibitor</i>	Page 913
2977	Toloxatone	<i>Reversible MAO-A inhibitor; Antidepressant</i>	Page 935

Enzymes (EC 1.13.11.) Oxygenases, LOX

12/15-Lipoxygenase (12/15-LO(X); EC 1.13.11.31) is a non-heme, iron-containing enzyme that dioxygenates polyunsaturated fatty acids into bioactive lipid derivatives, more specifically: it can metabolize arachidonic acid to generate corresponding hydroxides such as 12-hydroxyeicosatetraenoic acid (12-HETE) and 15-HETE. 12/15-LOX is widely expressed in the CNS, and has been demonstrated to be involved in the pathogenesis of various neurological diseases. 12/15-LOX exerts a regulatory role in Alzheimer's disease, an inflammatory and neurodegenerative disease¹. Additionally, human 12/15-LOX (aka 15-LOX-1) is also an attractive therapeutic target for its role in atherogenesis, diabetes, newborn periventricular leukomalacia, breast cancer and stroke².

- ¹ J. Xu et al. Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPAR β / δ : a potential therapeutic role for CNS autoimmune disease. *Cell Death Dis.* 2013, 4, e569.
² G. Rai et al. Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. *J. Med. Chem.* 2014, 57, 4035-4048.

2989	15-LOX-1 inhibitor i472	<i>Inhibitor of 15-lipoxygenase-1 (15-LOX-1)</i>	Page 620
2494	Luciferin, D-	<i>Natural substrate of firefly luciferase. Compound for BLI</i>	Page 624
2312	ML 351	<i>Potent and selective inhibitor of 12/15-lipoxygenase (LOX)</i>	Page 669
2873	ML 355	<i>Potent and selective inhibitor of 12-lipoxygenase (LOX)</i>	Page 670
2844	ThioLox	<i>Inhibitor of 15-lipoxygenase-1 (15-LOX-1)</i>	Page 925
3256	Zileuton	<i>Potent and orally active inhibitor of 5-lipoxygenase (5-LOX)</i> ...	Page 1006

Enzymes (EC 1.13.11.) Oxygenases, IDO

Indoleamine 2,3-dioxygenase-1 (IDO1; EC 1.13.11.42) is another enzyme in the eukaryotic tryptophan catabolic pathway. It is a heme-containing, monomeric oxidoreductase that specifically catalyzes the degradation of tryptophan to N-formyl-kynurenine, which can be subsequently metabolized through a series of steps to form nicotinamide adenine dinucleotide (NAD⁺). IDO1 inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. Previous studies suggest that IDO may be an important regulator of the immunosuppressive mechanisms responsible for tumor escape from host immune surveillance. Several groups have demonstrated that blockade of IDO activity can directly increase the ability of tumor-bearing mice to reject tumors¹.

- ¹ X. Liu et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. *Blood.* 2010, 115, 3520-3530.

2489	Brassinin	<i>Dual IDO1/STAT3 inhibitor</i>	Page 326
1733	INCB 024360	<i>Potent inhibitor of indoleamine 2,3-dioxygenase-1 (IDO1)</i>	Page 565
2215	INCB 024360-analog	<i>Potent inhibitor of indoleamine 2,3-dioxygenase-1 (IDO1)</i>	Page 565

Enzymes (EC 1.14.) Oxygenases

Cytochrome P450 monooxygenases (P450s; EC 1.14.11) are versatile biocatalysts that catalyze the regio- and stereospecific oxidation of non-activated hydrocarbons under mild conditions. P450s play a role in the synthesis of many molecules including steroid hormones, certain fats (cholesterol and other fatty acids), and acids used to digest fats (bile acids). There are approximately 60 CYP genes in humans. Cytochrome P450 enzymes (CYPs or P450s) are heme b containing monooxygenases. Heme is a prosthetic group consisting of an iron ion coordinated by four nitrogen atoms of porphyrin. Almost all P450s are external monooxygenases that utilize electrons derived from the pyridine cofactors NADH or NADPH. For catalytic activity P450s must be associated with redox partner proteins that transfer electrons from NAD(P)H to the P450 heme center. The ability of P450s to catalyze the regio-, chemo- and stereospecific oxidation of a vast number of substrates reflects their biological roles and makes them important candidates for scientists to study their role in primary and secondary metabolism, and drug degradation¹.

Besides the large family of cytochrome P450-related (CYP) enzymes, this class of oxidoreductases also includes the well-known family of cyclooxygenases (COX, officially known as prostaglandin-endoperoxide synthase (PTGS))², but also histone demethylases (JMJD), desaturases and aromatases, and many others.

For example, tyrosinases (EC 1.14.18.1) catalyze the oxidations of both monophenols (resolase or monophenolase activity) and o-diphenols (catecholase or diphenolase activity) into reactive o-quinones. Tyrosinase is a multifunctional, glycosylated, and copper-containing oxidase, and it is the key protein involved in mammalian melanogenesis and is

responsible for enzymatic browning reactions in damaged fruits during post-harvest handling and processing³. In view of its role in pigmentation, tyrosinase inhibitors have become increasingly important in the cosmetic and medicinal products used in the prevention of hyperpigmentation (due to UV radiation)⁴.

- ¹ V.B. Urlacher et al. Cytochrome P450 monooxygenases: an update on perspectives for synthetic application. *Trends Biotechnol.* 2012, 30, 26-36.
² Cyclooxygenase enzymes: regulation and function. F.A. Fitzpatrick. *Curr. Pharm. Des.* 2004, 10, 577-588.
³ T.S. Chang. An updated review of tyrosinase inhibitors. *Int J Mol Sci.* 2009 May 26;10(6):2440-75.
⁴ M.T.H. Khan. Molecular design of tyrosinase inhibitors: A critical review of promising novel inhibitors from synthetic origins. *Pure Appl. Chem.*, 2007, 79, 12, 2277-2295.

4054	Fluc inhibitor cpd 48 Recent Addition	<i>Highly potent and reversible Firefly luciferase inhibitor</i>	Page 484
3599	MINA53 inhibitor compound 10	<i>First-in-class, potent and selective MINA53 inhibitor</i>	Page 656

Enzymes (EC 1.14.11.) Oxygenases, Histone demethylases

Reversible histone lysine methylation is a major mechanism for regulating chromatin dynamics and gene expression. Histone demethylases (EC 1.14.11.) are believed to be involved in tumor-suppressive activities. These are Fe²⁺- and α -ketoglutarate-dependent oxygenases that are essential components of regulatory transcriptional chromatin complexes. Until recently, the absence of any selective inhibitors hampered the elucidation of the biological relevance of the demethylase activity of JMJD enzymes in regulating cellular responses. The discovery of the selective inhibitors GSK J1 and its ethyl ester prodrug GSK J4 (Axon 1934 and 1933 resp.) has recently shown the importance as critical determinants of pro-inflammatory gene activation in human primary macrophages¹.

- ¹ A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. L.Kruidenier et al. *Nature* 2012, 488, 404-408.

2573	CPI 455	<i>Selective inhibitor of KDM5 demethylases (H3K4 specific)</i>	Page 392
2622	CPI 4203	<i>Selective inhibitor of KDM5 demethylases (H3K4 specific)</i>	Page 393
3674	Ena21 hydrochloride	<i>Selective and competitive ALKBH5 inhibitor</i>	Page 458
4005	GSK2879552 dihydrochloride	<i>Potent and selective LSD1 inhibitor</i>	Page 521
1934	GSK J1	<i>Histone demethylase JMJD3/UTX inhibitor</i>	Page 529
1933	GSK J4	<i>Histone demethylase JMJD3/UTX inhibitor</i>	Page 530
2160	JIB 04	<i>Jumonji histone demethylase inhibitor</i>	Page 578
3180	JMJD6 inhibitor WL12	<i>First-in-class JMJD6 inhibitor</i>	Page 578
3783	JQKD82 dihydrochloride	<i>Cell-permeable and selective KDM5 inhibitor</i>	Page 583
2809	KDM5 inhibitor compound 48	<i>Selective and orally bioavailable KDM5 inhibitor</i>	Page 589
3562	ML 324	<i>Inhibitor of JMJD2 histone demethylase</i>	Page 667
2081	ML 324 dihydrochloride	<i>Inhibitor of JMJD2 histone demethylase</i>	Page 668
4189	P3FI-63 Recent Addition	<i>KDM3B inhibitor</i>	Page 744
4190	P3FI-90 Recent Addition	<i>KDM3B inhibitor</i>	Page 744
2864	SP 2509	<i>Potent, reversible, and specific LSD1 inhibitor</i>	Page 881
2674	YUKA1	<i>Selective inhibitor of KDM5A demethylase</i>	Page 1000

Enzymes (EC 1.14.11.) Oxygenases, LSD1

The mono- and di-methyl lysine demethylase (LSD1 or KDM1A; EC 1.14.11.27) is a flavin-bound epigenetic enzyme that oxidatively cleaves methyl groups from monomethyl and dimethyl Lys4 of histone H3 (H3K4Me1, H3K4Me2) and can contribute to gene silencing. Based on its enzymatic mechanism, LSD1 cannot demethylate trimethylated H3K4Me3, but members of the iron-dependent JMJD histone demethylases are known to serve this function. LSD1 is highly expressed in patients with AML, and its overexpression has been implicated in various other tumors. Collectively, these data predicted that the use of small-molecule inhibitors that target LSD1 could result in epigenetic reprogramming that enhanced or facilitated the execution of the ATRA-induced differentiation program in AML cells¹².

- ¹ P. Prusevich et al. A selective phenelzine analogue inhibitor of histone demethylase LSD1. *ACS Chem. Biol.* 2014, 9, 1284-1293.
² T. Schenk et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. *Nat. Med.* 2012, 18, 605-611.

2306	Bizine	<i>LSD1 inhibitor with selectivity over MAO-A/B, and LSD2</i>	Page 312
------	---------------------	---	----------

2375	GSK-LSD1	Inhibitor of the KDM1 family histone demethylase LSD1	Page 530
2077	OG-L002 hydrochloride	Inhibitor of lysine specific demethylase 1 (LSD1 aka KDM1A)	Page 730

Enzymes (EC 1.14.11.) Oxygenases, HIF-Proline Hydroxylases

The Hypoxia-inducible factor (HIF) transcription complex, which is activated by low oxygen tension, controls a diverse range of cellular processes including angiogenesis, erythropoiesis, bronchodilatation, and cellular metabolism targeted at increasing oxygen delivery to tissues¹. HIF consists of the subunits HIF α and HIF β . Whereas the HIF β subunit is constitutive, HIF α is tightly regulated by oxygen levels through various mechanisms that include protein stability, transcription co-activator recruitment and subcellular localization. The molecular mechanism that controls HIF α protein stability has been characterized in detail. In normoxia, HIF α is ubiquitinated and degraded at the 26S proteasome, while in hypoxia the protein is stabilized. HIF α ubiquitination in normoxia is mediated by the Von Hippel Lindau (VHL) tumor suppressor factor which is the substrate recognition subunit of a multimeric E3 ubiquitin ligase complex. Physical interaction between VHL and HIF α requires hydroxylation of 2 key prolyl residues in the HIF α sequence (P402 and P564 in human HIF-1 α), which is catalyzed by the specific prolyl-4-hydroxylases, named PHD1- PHD2 and PHD3 (EC 1.14.11.29). Under hypoxia, PHD hydroxylase activity is reduced; HIF α escapes hydroxylation and proteolysis, leading to HIF nuclear accumulation and transcriptional induction of target genes².

¹ S.S. Karuppagounder, R.R. Ratan. Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics? J. Cer. Blood Fl. Met. 2012, 32, 1347-1361.

² J.M. Acevedo, L. Centanin, A. Dekanty, P. Wappner. Oxygen Sensing in Drosophila: Multiple Isoforms of the Prolyl Hydroxylase Fatiga Have Different Capacity to Regulate HIF α /Sima. PLoS One. 2010; 5, e12390.

1977	DMOG	Cell-permeable HIF-PHD inhibitor	Page 435
2570	FG-2216	HIF-PHD inhibitor that increases plasma EPO levels in vivo	Page 479
2588	FG-4592	New-generation oral HIF-PHD inhibitor	Page 480
3615	GSK1278863	Potent, selective and orally active HIF-PHD inhibitor	Page 518
1948	HIF Phd Inhibitor 4	Inhibitor of Hypoxia Inducible Factor PHD2	Page 541
1921	IOX2	Inhibitor of Hypoxia Inducible Factor PHD2	Page 568
3095	MK-8617	Potent, orally active pan-inhibitor of HIF-PHD	Page 663
3288	Vadadustat	Oral HIF-PH inhibitor and HIF stabilizer	Page 960

Enzymes (EC 1.14.13.) Oxygenases, NAD(P)H-dependent

Inhibitors of enzymes of this class of oxidoreductases are frequently applied as antifungal agents. Acting on paired donor substrates, and using NADH or NADPH as donor, CYP51A1 is the most evolutionarily conserved member of the cytochrome P450 superfamily, and is involved in the metabolism the steroid lanosterol, a precursor of cholesterol. Azole fungicides are broad spectrum antifungal compounds used in agriculture and in human and veterinary medicine. The mechanism of antifungal action relies on inhibition of CYP51, resulting in inhibition of fungal cell growth¹.

¹ Mouse Knockout of the Cholesterologenic Cytochrome P450 Lanosterol 14 α -Demethylase (Cyp51) Resembles Antley-Bixler Syndrome. R. Keber et al. Journal of Biological Chemistry 2011, 286, 29086-29097.

3479	BN80933	Potent antioxidant and selective nNOS inhibitor	Page 322
3163	Clotrimazole	Fungal CYP450 enzyme 14 α -demethylase inhibitor	Page 377
3369	Efinaconazole	Fungal CYP450 enzyme 14 α -demethylase inhibitor	Page 452
2105	Fluconazole	Fungal CYP450 enzyme 14 α -demethylase inhibitor	Page 484
2026	PF 04981517	Inhibitor of Cytochrome P450 3A4 (CYP3A4)	Page 768
1557	Posaconazole	Antifungal agent	Page 787
2922	Sulfaphenazole	CYP2C9 inhibitor; Antibiotic	Page 899
1564	Tienilic Acid	CYP2C10 Inhibitor	Page 928
2044	Voriconazole	Orally bioavailable CYP51 inhibitor; Antifungal agent	Page 971
2878	ZL006	Selective inhibitor of the nNOS-PSD-95 interaction	Page 1008

Enzymes (EC 1.14.13.) Oxygenases, KMO

Kynurenine 3-monoxygenase (KMO; EC 1.14.13.9) is an enzyme in the eukaryotic tryptophan catabolic pathway (i.e. kynurenine pathway (KP)). KMO is a FAD-dependent monoxygenase, and is located in the outer mitochondrial membrane where it converts L-kynurenine to 3-hydroxykynurenine (3-HK). Inhibition of KMO has shown to cause amelioration of Huntington's disease-relevant phenotypes in yeast, fruit fly, and mouse models, as well as a mouse model of Alzheimer's disease. The effect of KMO inhibition is a shift in the KP toward kynurenine aminotransferase (KAT; EC 2.6.1.7) mediated enhanced kynurenic acid (KYNA) production which, in turn, may cause reduced neuronal vulnerability. Indeed, the most widely used KMO inhibitor, Ro 61-8048 (Axon 2139), is beneficial in rodent models of brain ischemia, cerebral malaria, and trypanosomiasis, and in a primate model of Levodopa-induced dyskinesias¹. Alterations in the levels of kynurenine pathway metabolites have been linked to the pathogenesis of a spectrum of brain disorders, as well as cancer, and several peripheral inflammatory conditions².

¹ D. Zwilling et al. Kynurenine 3-Monoxygenase Inhibition in Blood Ameliorates Neurodegeneration. Cell 2011, 145, 863-874.

² M. Amaral et al. Structural basis of kynurenine 3-monoxygenase inhibition. Nature. 2013, 496, 382-385.

3597	GNF-PF-3777	Recent Addition	Potent hIDO2 inhibitor	Page 511
3967	LY-3381916		Potent and selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO-1)	Page 630
3662	Nitisinone		Potent, reversible and orally bioavailable 4-HPPD inhibitor	Page 705
3325	PF-06840003		Selective, brain penetrant, and orally bioavailable IDO1 inhibitor	Page 771
2139	RO 61-8048		Inhibitor of kynurenine-3-monoxygenase (KMO)	Page 825
2118	UPF 648		Potent inhibitor of kynurenine-3-monoxygenase (KMO)	Page 955

Enzymes (EC 1.14.14.) Oxygenases, Monoxygenases

Exemestane (Axon 2045) is an orally active inhibitor of steroidal aromatase (CYP19A1; EC 1.14.14.1), an enzyme involved in the bio-synthesis of estrogen. The drug is used for the treatment of a specific type of breast cancer (ER-type, estrogen receptor positive) in post-menopausal women¹. Similar to CYP19A1, CYP2B6 (EC 1.14.14.1; biological target of PPP hydrochloride, Axon 1595) belongs to the same class of oxidoreductases that share the common feature of using reduced flavin or flavoprotein as donor in the molecular conversion of substrates. CYP2B6 not only is involved in the metabolism of nicotine, inhibition may also have a significant effect on the efficacy of other drugs in a wide variety of pathologies that depend on CYP2B6 mediated metabolism (a large number of CYP2B6 substrates including clinically used therapeutics, recreational drugs, endogenous chemicals, pesticides and environmental chemicals have been identified)².

¹ Exemestane: a review of its use in postmenopausal women with breast cancer. E.D. Deeks, L.J. Scott. Drugs. 2009, 69, 889-918.

² CYP2B6: New Insights into a Historically Overlooked Cytochrome P450 Isozyme. H. Wang, L.M. Tompkins. Curr. Drug. Metab. 2008, 9, 598-610.

3316	Anastrozole	Potent, highly selective, and orally active aromatase inhibitor	Page 237
3190	DLCI-1	Potent and selective inhibitor CYP2A6 inhibitor	Page 434
2045	Exemestane	Irreversible steroidal aromatase (CYP19A1) inhibitor	Page 472
3257	Letrozole	Potent, highly selective, non-steroidal aromatase inhibitor	Page 611
3449	Methoxsalen	Potent inhibitor CYP2A6 inhibitor	Page 647
1595	PPP Hydrochloride	CYP2B6 inhibitor	Page 788
3485	Soticlestat	Potent, selective, orally active and brain-penetrant cholesterol 24-hydroxylase (CYP46A1) inhibitor	Page 880
2628	TMS	CYP1B1 inhibitor that induces apoptosis	Page 933

Enzymes (EC 1.14.19.) Oxygenases, Desaturases

Long-chain polyunsaturated fatty acids (PUFA) of the ω 3- and ω 6-series are essential for a number of cellular functions such as maintaining membrane fluidity, providing substrates for eicosanoid signaling, modification of ion channels and regulation of gene expression. In view of that, these fatty acids are involved in several such basic cellular mechanisms, it is not surprising that they influence a number of physiological processes and have been implicated in such diverse conditions as cardiovascular disease, inflammatory diseases, osteoporosis and depression¹. Both Axon 2091 and Axon 2112 are selective inhibitors of these fatty acid converting enzymes (SCD1 and FADS2 or Δ 6-desaturase; EC 1.14.19.1.)

¹ Relationship of $\Delta 6$ -desaturase and $\Delta 5$ -desaturase activities with thyroid hormone status in adolescents with eating disorders and weight loss. I. Swenne, B. Vessby. *Act. Paediatrica* 2013, 102, 416-418.

2091	PluriSIn #1	<i>Inhibitor of stearoyl-coA desaturase (SCD1)</i>	Page 783
2112	SC 26196	<i>Selective $\Delta 6$-desaturase inhibitor</i>	Page 854

Enzymes (EC 1.14.99.) Oxygenases, Cyclooxygenases

Cyclooxygenases (officially: prostaglandin G/H synthase, COX; EC 1.14.99.1) catalyze the first two steps in the biosynthesis of prostaglandins (PGs), being the bis-dioxygenation and subsequent reduction of arachidonic acid (AA) to PGG₂ and PGH₂. The two known isoforms (COX-1 and -2) are the targets of the widely used nonsteroidal anti-inflammatory drugs, indicating a role for these enzymes in pain, fever, inflammation, and tumorigenesis¹. Due to substrate similarities, inhibitors of this class of enzymes have a lot in common with inhibitors of the class discussed above (EC 1.14.19.1).

¹ Cyclooxygenases: structural and functional insights. C.A. Rouzer, L.J. Marnett. *J. Lipid Res.* 2009, 50, S29-34.

2288	ATB 346	<i>Orally active hydrogen sulfide-releasing COX-inhibitor</i>	Page 258
1919	Celecoxib	<i>Selective COX-2 inhibitor</i>	Page 358
3176	Diethylcarbazine citrate	<i>Filaricidal drug</i>	Page 426
3448	Diflunisal	<i>COX-inhibitor; NSAID</i>	Page 427
3451	Etodolac	<i>Selective COX-2 inhibitor</i>	Page 470
3885	Etoricoxib	<i>Potent, selective and orally active cyclooxygenase-2 (COX-2) inhibitor</i>	Page 470
3126	Flurbiprofen	<i>COX-inhibitor; NSAID</i>	Page 487
1974	GW 406381	<i>COX-2 inhibitor</i>	Page 534
3318	Indomethacin	<i>COX-inhibitor; NSAID</i>	Page 565
3712	Isoxicam	<i>COX-inhibitor; NSAID</i>	Page 571
3364	Naproxen sodium	<i>COX-inhibitor; NSAID</i>	Page 692
3374	Nepafenac	<i>Prodrug of Amfenac; COX-inhibitor</i>	Page 697
3818	Oxapropzin	<i>COX-inhibitor; NSAID</i>	Page 741
3311	Parecoxib sodium	<i>Prodrug of Valdecoxib; selective COX-2 inhibitor</i>	Page 747
1523	Pravadoline	<i>COX inhibitor; CB agonist</i>	Page 790
3376	Rofecoxib	<i>Orally active COX-2 inhibitor</i>	Page 827
2108	SC 236	<i>Selective COX-2 inhibitor</i>	Page 853
2106	Valdecoxib	<i>Selective COX-2 inhibitor</i>	Page 960

Enzymes (EC 1.14.99.) Oxygenases, Steroid 17 α -monooxygenases

TAK 700 (Axon 2124) Abiraterone (Axon 1873), and its acetylated prodrug (Axon 1874) are targeting the enzyme 17 α -hydroxylase/C17,20-lyase, a CYP450 complex (CYP17A1; EC 1.14.99.9) that is involved in testosterone production. This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. Both drugs are used for the treatment of castration-resistant prostate cancer (CRPC) with the advantage of the prodrug showing improved bioavailability after oral administration. Alternatively, instead of blocking the enzyme that is responsible for the biosynthesis of testosterone, androgen receptor antagonists like MDV 3100 (Axon 1613) have been studied for the same applications in CRPC¹.

¹ Novel hormonal therapy for castration-resistant prostate cancer. C.N. Sternberg. *Ann. Oncol.* 2012, 23 (S10), x259-x263.

1873	Abiraterone	<i>Inhibitor CYP17A1</i>	Page 199
1874	Abiraterone acetate	<i>Prodrug of Abiraterone; Inhibitor of CYP17A1</i>	Page 199
2124	TAK 700	<i>Highly selective inhibitor of 17,20-lyase (CYP17A1)</i>	Page 907

Enzymes (EC 1.15.1) Dismutases

Dismutation or disproportionation is a type of redox reaction in which a substrate is simultaneously reduced and oxidized to form two different products. As such, the free radical species superoxide is converted into hydrogen peroxide and oxygen by the enzyme Superoxide Dismutase (SOD; EC 1.15.1.1), enzymes responsible for the homeostasis of low levels of reactive oxygen species (ROS). Three forms of superoxide dismutase (SOD1-3) are known to date in mammals, of which SOD1 is located primarily in the cytoplasm, SOD2 in the mitochondria and SOD3 is extracellular. SOD1 and SOD3 are copper/zinc-dependent enzymes, while SOD2 functions by incorporation of manganese in the active site. The harmful species hydrogen peroxide formed by the SOD enzymes can be converted into water (and oxygen) in turn by the enzymes catalase (EC 1.11.1.6) and multiple peroxiredoxins (EC 1.11.1.15), and glutathione¹. Point mutations of SOD1 are reported to be related to the familial form of amyotrophic lateral sclerosis (ALS), a neurological disease that causes the death of motor neurons with consequent muscular paralysis².

¹ I.N. Zelko, T.J. Mariani, R.J. Folz. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. *Fr. Rad. Biol. Med.* 2002, 33, 337-349.

² L. Banci et al. SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization. *PLoS One.* 2008, 3, e1677.

2176	LCS 1	<i>Inhibits SOD1 enzymatic activity. Lung cancer therapeutic</i>	Page 606
------	-------	-------	--	-------	----------

Enzymes (EC 1.17.3.) Oxygenases, Xanthine Oxidases

Xanthine oxidase (XO; EC 1.17.3.2) is an oxidoreductase enzyme that plays an important role in the catabolism of purines in some species, including humans¹. It catalyzes the oxidation of hypoxanthine to xanthine and can further catalyze the oxidation of xanthine to uric acid. Being capable of reducing the production of uric acid in patients suffering from Gout by means of xanthine oxidase inhibition, Febuxostat (TEI 6720, Axon 1175) and Piraxostat (Y-700, Axon 1174) are two important pharmacological tools for the prophylactic treatment of inflammatory arthritis².

¹ Molybdenum-containing hydroxylases. Hille R. *Arch. Biochem. Biophys.* 2005, 433 (1) 107-16.

² Chen LX, Schumacher HR. *J Clin Rheumatol.* 2008, 14 (5 Suppl) S55-62.

1175	TEI 6720	<i>Xanthine oxidase inhibitor</i>	Page 917
3178	Topiroxostat	<i>Potent xanthine oxidoreductase (XOR) inhibitor</i>	Page 936
1174	Y 700	<i>Xanthine oxidase inhibitor</i>	Page 997

Enzymes (EC 2.) Transferases

A transferase is an enzyme that catalyzes the transfer of a functional group from one molecule to another. As such, protein kinases are a significant member of this family of enzymes, being capable of transferring phosphorus-containing groups (phosphate) from a donor (usually adenosine triphosphate (ATP)) to specific amino acid residues with a free hydroxyl group of an acceptor in a covalent way¹. As within the class of oxidoreductases, the class of transferases is divided into subclasses, based on the functional groups the enzymes transfer and the substrate specificity.

¹ The Cell: A Molecular Approach. 2nd edition. Cooper GM. Sunderland (MA): Sinauer Associates; 2000.

3515	AG-270	<i>First-in-class, highly potent, selective, orally bioavailable MAT2A inhibitor</i>	Page 212
------	--------	-------	--	-------	----------

Enzymes (EC 2.1.1.) Methyltransferases

Over the recent years, Axon Medchem has significantly expanded its product line in the field of oncology research tools. Among them, the DNA methyltransferase and histone methyltransferase inhibitors comprise a small, yet significant selection of this set of tools. In view of the recent focus in biology on epigenetics, and DNA methylation being the best-known epigenetic marker (see also section: *Axon Ligands™ for Epigenetic Research*), we aim to be up front with these products to serve researchers in their objective to develop new drugs for the treatment of cancers and study the mechanisms involved in gene expression¹.

¹ Epigenetics in Cancer. M. Esteller. *N Engl J Med* 2008; 358, 1148-1159

2853	Nolatrexed dihydrochloride	<i>Water soluble inhibitor of thymidylate synthase</i>	Page 580
3162	Pemetrexed disodium	<i>Inhibitor of DHFR/TS/GARFT; Antifolate antimetabolite</i>	Page 623

Enzymes (EC 2.1.1.) Methyltransferases, DNA

There are many ways that gene expression is controlled in eukaryotes, but methylation of DNA (not to be confused with histone methylation) is a common epigenetic signaling tool that cells use to lock genes in the "off" position. Methylation is an important component in numerous cellular processes, including embryonic development, genomic imprinting, X-chromosome inactivation, and preservation of chromosome stability.

DNA methylation occurs at the cytosine bases of eukaryotic DNA, which are converted to 5-methylcytosine by DNA methyltransferase (DNMT; EC 2.1.1.37) enzymes using S-adenosyl methionine (SAM) as the methyl donor. The altered cytosine residues are usually immediately adjacent to a guanine nucleotide, resulting in two methylated cytosine residues sitting diagonally to each other on opposing DNA strands. Different members of the DNMT family of enzymes act either as de novo DNMTs, putting the initial pattern of methyl groups in place on a DNA sequence, or as maintenance DNMTs, copying the methylation from an existing DNA strand to its new partner after replication. Although patterns of DNA methylation appear to be relatively stable in somatic cells, patterns of histone methylation can change rapidly during the course of the cell cycle. Despite this difference, several studies have indicated that DNA methylation and histone methylation at certain positions are connected¹.

O6-methylguanine lesions, which are widely accepted as the primary cytotoxic lesions induced by methylating agents, are efficiently repaired by the DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT; EC 2.1.1.63) that removes the methyl adducts from the O6 positions of guanine by transferring it to its internal cysteine residues, resulting in its own inactivation². It is ubiquitously expressed, highly conserved, and vital to the maintenance of DNA integrity. Evidence has been accumulated that tumors expressing MGMT are remarkably resistant to methylating agents, and this problem might be circumvented by specific inhibitors of MGMT³.

¹ T. Phillips. The Role of Methylation in Gene Expression. Nat. Edu. 2008, 1, online publ.

² Y. Huang et al. MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1. Mol. Cancer Res. 2011, 9, 320-331.

³ H.A. Tawbi et al. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br. J. Cancer. 2011, 105, 773-777.

1590	Decitabine.....	DNA methyltransferase inhibitor.....	Page 415
3900	GSK-3484862.....	No-covalent DNMT1-selective inhibitor.....	Page 522
3757	GSK3685032 hydrochloride.....	Potent first-in-class DNMT1-selective inhibitor.....	Page 522
2223	Lomeguatrib.....	Potent, orally active inhibitor of MGMT.....	Page 618
1691	RG 108.....	DNA methyltransferase inhibitor.....	Page 814
2347	SGI 1027 dihydrochloride.....	Inhibitor of DNMT activity in colon cancer cell lines.....	Page 864
1254	Zebularine.....	DNA methyltransferase inhibitor.....	Page 1007

Enzymes (EC 2.1.1.) Methyltransferases, Histone

Covalent modifications of histone tails have fundamental roles in chromatin structure and function. One such modification, lysine methylation, has important functions in many biological processes that include heterochromatin formation, X-chromosome inactivation and transcriptional regulation. The DNA within our cells exists in the form of chromatin. The basic building block of chromatin is the nucleosome, a structure consisting of an octamer of four core histone proteins around which 147 base pairs of DNA is wrapped. Core histones are subject to a large number of covalent modifications (PTMs: Post Translational Modifications) including acetylation, methylation, phosphorylation and ubiquitination. Histone methylation occurs on arginine and lysine residues and is catalyzed by enzymes belonging to three distinct families of proteins: the protein arginine specific methyl transferase (PRMT1) family, the SET-domain-containing protein family, and the non-SET-domain proteins DOT1/DOT1L. Unlike acetylation, which generally correlates with transcriptional activation, histone lysine methylation can signal either activation or repression, depending on the sites of methylation. Similar to the discovery that bromodomains can recognize acetylated lysines, studies on histone methylation identified at least three protein motifs (the Chromo-, the Tudor-, and the WD40-repeat domain) that are capable of forming specific interactions with methylated lysine residues of histone^{1,2}. G9a HMTase (EHMT2; EC 2.1.1.43), a mammalian Histone methyltransferase, is a key enzyme for histone H3 dimethylation at lysine-9 (H3K9me2), which is an epigenetic mark of gene suppression. EHMT2 is highly expressed in human cancer cells and plays a key role in promoting cancer invasion and metastasis³.

¹ C. Martin, Y. Zhang. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 2005, 6, 838-849.

² E.L. Greer, Y. Shi. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genetics 2012, 13, 343-357

³ Z. Lu et al. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells. Anti-Cancer Drugs 2013, 24, 484-493.

2705	A-196.....	Potent and selective inhibitor of SUV4-20.....	Page 195
2863	AMI-1.....	Inhibitor of PRMT.....	Page 227

2635	BAY-598.....	Selective inhibitor of SMYD2.....	Page 290
2735	BCI-121.....	Inhibitor of SMYD3.....	Page 294
1692	BIX 01294 trihydrochloride hydrate.....	HMTase inhibitor (G9a and G9a-like protein).....	Page 311
2210	C 7280948.....	Sulfone inhibitor of PRMT1.....	Page 338
3460	Capecitabine.....	Oral prodrug of fluorouracil; TYMS inhibitor.....	Page 342
2812	CM-272.....	First-in-class potent, selective and reversible inhibitor of G9a/DNMT.....	Page 379
2709	CMP5.....	Inhibitor of PRMT5.....	Page 380
3389	Entacapone.....	Potent, peripherally acting, reversible COMT inhibitor.....	Page 460
4137	EPZ005687 hydrochloride.....	EZH2 HMTase inhibitor.....	Page 463
4216	EPZ011989 hydrochloride Recent Addition	Cell permeable, metabolically stable and orally available EZH2 inhibitor.....	Page 463
2831	EPZ 015666.....	Potent, selective and orally available inhibitor of PRMT5.....	Page 464
3960	EPZ-5676.....	Selective and S-adenosyl methionine (SAM) competitive inhibitor of DOT1L methyltransferase.....	Page 464
2227	EPZ 6438.....	Inhibitor of Histone Lysine Methyltransferase EZH2.....	Page 464
3462	Floxuridine.....	TYMS inhibitor; Antimetabolite.....	Page 484
2140	GSK 126.....	Inhibitor of Histone Lysine Methyltransferase EZH2.....	Page 518
3750	GSK3326595.....	Orally active, potent, selective, SAM uncompetitive, peptide competitive, slow binding inhibitor of protein arginine methyltransferase 5 (PRMT5).....	Page 521
3919	GSK3368715 hydrochloride.....	A first-in-class, orally active, potent and selective, SAM-Noncompetitive inhibitor of Type I Protein Arginine Methyltransferases (PRMTs).....	Page 521
2710	HLCL65 hydrochloride.....	Inhibitor of PRMT5.....	Page 542
3754	JNJ-64619178 dihydrochloride.....	SAM-pocket binding (SAM Competitive) PRMT5 inhibitor.....	Page 579
3796	MRTX1719 hydrochloride.....	Inhibitor of the PRMT5.MTA complex.....	Page 681
3681	MS023 dihydrochloride.....	Potent, cell-active, and Type I selective PRMT inhibitor.....	Page 681
3469	MS1943 trifluoroacetate.....	First-in-class EZH2 selective degrader; PROTAC.....	Page 682
3695	PF-06821497.....	Inhibitor of Histone Lysine Methyltransferase EZH2.....	Page 760
3798	PF-06855800.....	SAM-pocket-binding (SAM competitive) PRMT5 inhibitor.....	Page 761
3692	PF-06939999 dihydrochloride.....	SAM competitive PRMT5 inhibitor.....	Page 761
2211	PRMT3 inhibitor 1.....	Inhibitor of protein arginine methyltransferase 3 (PRMT3).....	Page 791
2945	SGC707.....	First-in-class, potent, selective and cell-active allosteric inhibitor of PRMT3.....	Page 863
2625	SGC2085.....	Potent and selective CARM1 inhibitor (aka PRMT4).....	Page 863
3587	STM2457.....	First-in-class, highly potent and selective catalytic METTL3 inhibitor.....	Page 897
3993	Tolcapone.....	Potent, selective, orally active and reversible COMT inhibitor.....	Page 935
1789	UNC 0224.....	Inhibitor of G9a HMTase.....	Page 952
2418	UNC 0379.....	Substrate competitive inhibitor of the SETD8.....	Page 953
1841	UNC 0631.....	Inhibitor of G9a/GLP Histone Lysine Methyltransferase.....	Page 953
1889	UNC 0638.....	Inhibitor of G9a (EHMT2)/GLP (EHMT1).....	Page 954
1840	UNC 0646.....	Inhibitor of G9a/GLP Histone Lysine Methyltransferase.....	Page 954
3591	UNC6934.....	Potent and selective chemical probe targeting NSD2-PWWP1.....	Page 952
3592	UNC7145.....	Negative control of UNC6934 as a chemical probe targeting NSD2-PWWP1.....	Page 953
3722	Valemetostat.....	Inhibitor of Histone Lysine Methyltransferase EZH1/2.....	Page 960

Enzymes (EC 2.3.) Acyltransferases

The class of acylgroup transferring enzymes includes a multitude of substrate specific enzymes. For example, diacylglycerol O-acyltransferase 1 (DGAT1; EC 2.3.1.20) catalyzes the final step of the synthesis of triglycerides (TG) and plays a critical role in dietary fat absorption in the small intestine. Therefore, it is a potential therapeutic target for treatment of obesity and related metabolic diseases¹. The co-enzyme Acyl-CoA is the donor substrate of the acetyl group that is transferred to the diglyceride substrates of DGAT1.

RU-SKI 43 hydrochloride (Axon 2035) is a specific inhibitor of the enzyme Hedgehog acyltransferase (HHAT; EC 2.3.1.) and catalyzes the attachment of palmitate to the N-terminal cysteine of Sonic hedgehog (ShhN, a Shh precursor) via an amide bond. Mature Shh is a secreted signaling protein that is essential for proper embryonic development. In adults, aberrant Shh signaling drives initiation and maintenance of medulloblastoma and basal cell carcinoma and has been implicated in the progression of prostate cancer, gastrointestinal tumors and pancreatic cancer².

ATP citrate lyase (ACL; EC 2.3.3. 8) is a cytosolic enzyme that catalyzes the synthesis of acetyl-CoA and oxaloacetate using citrate, CoA, and ATP as substrates and Mg²⁺ as a necessary cofactor, and it is expressed in lipogenic tissues such as liver and adipose³. In mammals, the formation of acetyl-CoA is an essential step for the de novo synthesis of fatty acid (FA) and cholesterol for converting the carbohydrate carbon energy source into lipids. Hence, it has been thought that ACL inhibition would be beneficial for the treatment of obesity and dyslipidemia through the simultaneous inhibition of endogenous synthesis of FA and cholesterol⁴. Interestingly, it was found that ACL is also required for increases in histone acetylation in response to growth factor stimulation and during differentiation, and that glucose availability can affect histone acetylation in an ACL-dependent manner⁵.

¹ Y. Hiramane, T. Tanabe. Characterization of acyl-coenzyme A:diacylglycerol acyltransferase (DGAT) enzyme of human small intestine. J. Physiol. Biochem. 2011, 67, 259-264.

² E. Petrova et al. Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling. Nat. Chem. Biol. 2013, 9, 247-249.

³ JJ Li et al. 2-hydroxy-N-arybenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3208-11.

⁴ Z Ma et al. A novel direct homogeneous assay for ATP citrate lyase. J Lipid Res. 2009 Oct;50(10):2131-5.

⁵ KE Wellen et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009 May 22;324(5930):1076-80.

2059	A 922500	Highly potent and selective DGAT-1 inhibitor	Page 193
2960	ATR-101	Potent, selective, and orally active ACAT1 inhibitor	Page 260
3181	BI 99179	Potent, selective and orally active inhibitor of type I fatty acid synthase (FAS)	Page 304
3182	BI 99990	Negative control of BI 99179 as a selective inhibitor of type I fatty acid synthase	Page 305
2506	BMS 303141	Cell-permeable ATP-citrate lyase (ACL) inhibitor	Page 316
3823	Ervogastat	Potent and selective diacylglycerol acyltransferase 2 (DGAT-2) inhibitor	Page 467
3743	HTS-3 hydrochloride, (R)-	First potent, selective, and cell-active LPCAT3 inhibitor	Page 548
4016	LDN-27219	Potent, reversible and slow-binding TGase inhibitor	Page 609
3296	LEI-301	Potent phospholipase A and acyltransferase (PLAAT) inhibitor	Page 610
3554	RP 70676	Potent and orally bioavailable ACAT inhibitor	Page 832
2035	RU-SKI 43 hydrochloride	Hedgehog acyltransferase (HHAT) inhibitor	Page 835
2835	SPT Imidazopyridine 1	Potent serine palmitoyl transferase (SPT) inhibitor	Page 884

Enzymes (EC 2.3.1.) Acyltransferases, Histone

One member of particular interest in the family of acyltransferases is the group of histone acetyltransferases (HATs; EC 2.3.1.48). Enzymes of this kind acetylate core histones, which results in important regulatory effects on chromatin structure and assembly, and gene transcription. In the nucleus of eukaryotic cells, DNA is highly compacted and organized into chromatin, whose basic unit is the nucleosome, composed by DNA and an octamer of core histones (H2A, H2B, H3, H4). The histones expose their N-terminal tails out of the octamer. These tails can be highly post-translationally modified, leading to the transcription regulation. While histone acetylation is a dynamic reversible process, the balance of histone acetylation is important for proper cellular function.

Based on their catalytic domains, HATs can be grouped into three groups, mainly: the GNATs (Gcn5 N-acetyltransferases), the 60 kDa Tat interactive protein (MYSTs) and the orphan HATs. P300/CBP-associated factor (PCAF), Elp3, Hat1, Hpa2 and Nut1 belong to the first group, with the founding member, GCN5. Morf, Ybp2, Sas2 and Tip60 represent the second group. Not containing a precise consensus HAT domain, the third group is called 'orphan', although these enzymes show

an intrinsic HAT activity. p300/CBP, for example, belongs to this group together with Taf1 and several nuclear receptor (NR) co-activators¹.

NAT10 (or human N-acetyltransferase-like protein (hALP); EC 2.3.1.xx) is primarily identified as an activator for up-regulating telomerase activity through stimulation of transcription of hTERT together with histone acetyltransferase activity. This gene also responds to DNA damage, in which the transcriptional activity of the NAT10 promoter may be specifically stimulated, and it thus also serves to enhance cell survival in the presence of genotoxic agents². Additionally, NAT10, that localizes mainly in the nucleolus, can mediate nuclear shape rescue in laminopathic cells via microtubule reorganization (tubulin is a known NAT10 substrate). Down-regulation and mutations of the nuclear-architecture proteins lamin A and C cause misshapen nuclei and altered chromatin organization associated with cancer and laminopathies, including the premature-aging disease Hutchinson-Gilford progeria syndrome (HGPS). Inhibition of NAT10 KAT activity in laminopathic cells reduces microtubule anchorage, thereby releasing an external force on the nuclear envelope, and thus contributes to nuclear shape rescue and global enhancement of cellular fitness³.

Besides HATs, the cell has evolved enzymes that catalyze the removal of acetyl groups from histone as well, termed histone deacetylases (HDACs, section Enzymes (EC 3.5.1.))⁴.

¹ F. Manzo, F. P. Tambaro, A. Mai, L. Altucci. Histone acetyltransferase inhibitors and preclinical studies. Exp. Opin. Ther. Pat. 2009, 19, 761-774.
² Q. Shen et al. NAT10, a nucleolar protein, localizes to the midbody and regulates cytokinesis and acetylation of microtubules. Exp. Cell Res. 2009, 315, 1653-1667.
³ D. Larrieu et al. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science. 2014, 344, 527-532.
⁴ Histone acetyltransferase complexes: one size doesn't fit all. K.K. Lee, J.L. Workman. Nature Reviews Mol. Cell Biol. 2007, 8, 284-295.

1490	Anacardic acid A	HAT inhibitor	Page 236
1781	C 646	HAT inhibitor (p300/CBP selective)	Page 337
2765	CPTH2	HAT inhibitor (Gcn5p specific)	Page 394
2568	EML 425	Potent dual inhibitor of CBP and p300 (HAT/KAT3)	Page 456
2208	Galic acid	Multi-affinity drug. Antioxidant	Page 495
4127	GNE-781	Highly potent, selective, and orally bioavailable CBP inhibitor	Page 510
3959	JG-2016	First inhibitor of the HAT1 enzyme complex	Page 577
2319	L 002	Inhibitor of p300 HAT (KAT3B) and p53 acetylation	Page 601
4011	MC4171	First-in-class potent and selective KAT8 inhibitor	Page 641
1785	MG 149	HAT inhibitor (Tip60 and MOZ specific)	Page 651
2299	Remodelin	Potent NAT 10 inhibitor	Page 811
2339	TH 1834	Tip60 histone acetyltransferase inhibitor	Page 924
2969	WM-1119	Highly potent and selective KAT6A inhibitor	Page 986

Enzymes (EC 2.3.1.) Acyltransferases, Porcupine

Porcupine (PORCN; EC 2.3.1.) is a multi-pass integral membrane-bound O-acyl transferase (MBOAT) that is required for post-translational modification of all Wnt proteins to enable their transport, secretion, and activity. Since PORCN has no known function beyond its role in the biogenesis of Wnts, it is therefore an attractive therapeutic target in diseases with dysregulated Wnt signaling (e.g. diseases related to stem cell biology, proliferation and angiogenesis)¹. Compromised Porcn activity commonly results in developmental disorders including focal dermal hypoplasia (Goltz syndrome), whereas hyperactivity of Porcn is associated with cancerous cell growth. Inhibition of PORCN can be an effective strategy for broadly suppressing Wnt signaling and thus hold potential in regenerative medicine and anticancer applications².

¹ T.M. Covey et al. PORCN moonlights in a Wnt-independent pathway that regulates cancer cell proliferation. PLoS ONE 2012, 7, e34532.

² X. Wang et al. The development of highly potent inhibitors for porcupine. J. Med. Chem. 2013, 56, 2700-2704.

2212	IWP L6	Highly potent porcupine (Porcn) inhibitor	Page 574
2287	Wnt-C59	Highly potent porcupine (Porcn) inhibitor	Page 987

Enzymes (EC 2.3.2.) Aminoacyltransferases

The ribosomal peptidyl transferase center (PTC) resides in the large ribosomal subunit (50S), where two fundamental biological reactions are processed and catalyzed: peptidyl transfer, the formation of a peptide bond during protein synthesis, and peptidyl hydrolysis, the release of the complete protein from the peptidyl tRNA upon completion of translation. Prokaryotic ribosomes consist of two subunits, the large 50S subunit and the smaller 30S subunit; together they form the 70S ribosome, a molecular machine that selects its substrates, aminoacyl-tRNAs (aa-tRNAs), rapidly and accurately and catalyzes the synthesis of peptides from amino acids. The 30S subunit contains the decoding site, where base-pairing

interactions between the mRNA codon and the tRNA anticodon determine the selection of the cognate aa-tRNA. The large ribosomal subunit contains the site of catalysis: the peptidyl transferase (PT; EC 2.3.2.12) center, which is responsible for making peptide bonds during protein elongation and for the hydrolysis of peptidyl-tRNA (pept-tRNA) during the termination of protein synthesis^{1,2}. The peptidyl transferase center is a major target of many natural and synthetic antibiotics.

¹ E.K.Yun Leung et al. The Mechanism of Peptidyl Transfer Catalysis by the Ribosome. *Annu. Rev. Biochem.* 2011, 80, 527-555.

² N. Polacek, A.S. Mankin. The Ribosomal Peptidyl Transferase Center: Structure, Function, Evolution, Inhibition. *Crit. Rev. Biochem. Mol. Biol.* 2005, 40, 285-311.

2042	Azithromycin	<i>Macrolide antibiotic; Binds the 50S ribosomal subunit</i>	Page 279
3445	Clarithromycin	<i>Macrolide antibiotic; Binds the 50S ribosomal subunit</i>	Page 375
2063	Clindamycin	<i>Inhibitor of peptidyl transferase; Antibiotic</i>	Page 375
3667	Homoharringtonine	<i>Protein synthesis inhibitor; Binds the 60S ribosomal subunit</i> ..	Page 545
2048	Linezolid	<i>Protein synthesis inhibitor; antibiotic</i>	Page 615
1762	PNU 100480	<i>Antibacterial agent, inhibitor of ribosomal PTC</i>	Page 785
2606	Solithromycin	<i>Fluoroketolide antibiotic</i>	Page 878
3312	Tedizolid phosphate	<i>Protein synthesis inhibitor; antibiotic</i>	Page 916

Enzymes (EC 2.4.) Glycosyltransferases

Glycosyltransferases catalyze glycosidic bond formation using sugar donors containing a nucleoside phosphate or a lipid phosphate leaving group. Two structural folds, GT-A and GT-B, have been identified for the nucleotide sugar-dependent enzymes, but other folds are now appearing for the soluble domains of lipid phosphosugar-dependent glycosyl transferases. Donor sugar substrates are most commonly activated in the form of nucleoside diphosphate sugars (e.g., UDP Gal, GDP Man); however, nucleoside monophosphate sugars (e.g., CMP NeuAc), lipid phosphates (e.g., dolichol phosphate oligosaccharides), and unsubstituted phosphate are also used. Nucleotide sugar-dependent glycosyltransferases are often referred to as Leloir enzymes. The acceptor substrates utilized by glycosyltransferases are most commonly other sugars but can also be a lipid, protein, nucleic acid, antibiotic, or another small molecule. Glycosyl transfer most frequently occurs to the nucleophilic oxygen of a hydroxyl substituent of the acceptor. However, it can also occur to nitrogen, sulfur, and carbon nucleophiles¹.

¹ L.L. Lairson et al. Glycosyltransferases: Structures, Functions, and Mechanisms. *Ann. Rev. Biochem.* 2008, 77, 521-555.

Enzymes (EC 2.4.1.) Glycosyltransferases, GPases

Glycogen phosphorylase (GP; EC 2.4.1.1) is the enzyme responsible for controlling the rate of glycogen degradation, which involves catalyzing the phosphorylytic cleavage of α 1-4 glycosidic bonds found within macro-glycogen molecules, thus producing glucose-1-phosphate monomers (Glc-1-P), a process referred to as glycogenolysis. Therefore, both glycogen synthesis and glucose liberation are intimately linked, the relationship being controlled by hormonal stimulation (insulin, glucagon, adrenaline, epinephrine). Allosteric effectors binding in specific and localized sites tightly regulate this catalytic activity¹.

Three isoforms of GP have been identified and are located within metabolically active tissues in the human body; the brain (bGP), liver (lGP) and skeletal muscle (mGP). Activation/deactivation of GP is a controlled process sensitive to intra- and extracellular signals. GP is an archetypal control enzyme and fine regulation is made possible through four major sites present on each monomer: catalytic site (C-site), glycogen site (G-site), nucleotide binding site (adenosine monophosphate (AMP)-site) and phosphorylation site (P-site). Interestingly, important regulation steps are performed outside the catalytic cavity making GP a case of study for allosteric interactions. Two states of GP prevail symbolizing its activity state: inactive T state (Tense state) and active R state (Relaxed state). The binding of specific effectors assures the transition between the two states. The inhibition of GP has been proposed as one method for treating type 2 diabetes².

¹ N. Gaboriaud-Kolar, A.L. Skaltsounis. Glycogen phosphorylase inhibitors: a patent review (2008-2012). *Exp. Opin. Ther. Pat.* 2013, 23, 1017-1032.

² D.J. Baker, P.L. Greenhaff, J.A. Timmons. Glycogen phosphorylase inhibition as a therapeutic target: a review of the recent patent literature. *Exp. Opin. Ther. Pat.* 2006, 16, 459-466.

1847	CP 316819	<i>Glycogen Phosphorylase (GPase) inhibitor</i>	Page 388
3588	NGI-1	<i>Potent and cell-permeable inhibitor of oligosaccharyltransferase</i>	Page 701

Enzymes (EC 2.4.2.) Glycosyltransferases, NAMPT

Nicotinamide phosphoribosyltransferase (NAMPT; EC 2.4.2.12), was originally discovered as the cytokine pre-B-cell colony-enhancing factor 1 (PBEF1) or visfatin, and has several suggested functions. It was found to be an important cofactor for stem cell factor- and interleukin (IL)-7-mediated B cell maturation. However, in 2002 the murine homologue of PBEF was found, and this proved to be an enzyme catalyzing the reaction between nicotinamide and 5-phosphoribosyl-1-pyrophosphate yielding nicotinamide mononucleotide (NMN), an intermediate in the biosynthesis of NAD/NADH: central molecules involved in energy metabolism, reductive biosynthesis, and antioxidation, histone deacetylation, cell death, and intracellular calcium release. This widened its potential biological activities. Interestingly, both extracellular (cytokine-like) and intracellular (enzymatic) functions seem to be responsible for its relevance in immunity, metabolism, and stress responses in both physiology and pathophysiology¹.

¹ T.B. Dahl, S. Holm, P. Aukrust, B. Halvorsen. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. *Annu. Rev. Nutr.* 2012, 32, 229-243.

1279	FK 866	<i>NAMPT inhibitor; NAD biosynthesis inhibitor</i>	Page 482
1546	FK 866 hydrochloride	<i>NAMPT inhibitor</i>	Page 483
2602	P7C3	<i>Compound that activates NAMPT</i>	Page 743
3954	SBI-797812	<i>Orally active NAMPT activator</i>	Page 852
2253	STF 118804	<i>Highly specific, next-generation NAMPT inhibitor</i>	Page 895

Enzymes (EC 2.4.2.) Glycosyltransferases, PARP

Poly (ADP-ribose) polymerase (PARP; EC 2.4.2.12) is found in the cell's nucleus. The main role is to detect and signal single strand DNA breaks, preventing healthy cells from malfunctioning and programmed cell death. Cancer cells may also use PARP to repair DNA damage, thus extending their uncontrolled growth. Such cancers can become resistant to treatment (chemotherapy and/or radiation). PARP inhibitors may be especially helpful for the treatment of tumors due to genetic mutations of BRCA1 and BRCA2¹. Human tankyrases (TNKS; EC 2.4.2.30), or TRF1-interacting ankyrin-related ADP-ribose polymerases, are specific PARPs that enhance telomerase access to telomeres, and post-translationally modify multiple proteins involved in processes including maintenance of telomere length, sister telomere association, and trafficking of glut4-containing vesicles.^{2,3} Tankyrase 1 and tankyrase 2 are poly(ADP-ribosyl)ases that are distinguishable from other members of the enzyme family by the structural features of the catalytic domain, and the presence of a sterile α -motif multimerization domain and an ankyrin repeat protein-interaction domain⁴.

¹ A. Patel, S.H. Kaufmann. Development of PARP Inhibitors: An Unfinished Story. *Oncology.* 2010, 24, 66-68.

² Y.J. Chiang et al. Tankyrase 1 and Tankyrase 2 Are Essential but Redundant for Mouse Embryonic Development. *PLoS ONE* 2008, 3, e2639.

³ H. Seimiya. The telomeric PARP, tankyrases, as targets for cancer therapy. *Br. J. Cancer.* 2006, 94, 341-345.

⁴ L. Lehtiö et al. Tankyrases as drug targets. *FEBS J.* 2013, 280, 3576-3593.

1593	ABT 888	<i>PARP inhibitor</i>	Page 202
2888	ABT 888 dihydrochloride	<i>PARP inhibitor</i>	Page 203
1529	AG 014699	<i>PARP1 inhibitor</i>	Page 213
4276	AG14361 Recent Addition	<i>Potent PARP1 inhibitor</i>	Page 211
1496	Aminobenzamide, 3-	<i>Competitive small molecule inhibitor of PARP</i>	Page 228
1464	AZD 2281	<i>PARP inhibitor</i>	Page 269
2241	AZD 2461	<i>PARP inhibitor with poor P-glycoprotein substrate qualities</i>	Page 269
1268	DR 2313	<i>PARP inhibitor</i>	Page 441
3398	E7449 mesylate	<i>Potent, brain penetrable and orally bioavailable dual inhibitor of PARP1/2 and TNKS1/2</i>	Page 448
2885	GeA-69	<i>Selective allosteric and cell-active PARP14 MD2 inhibitor</i>	Page 500
1566	Iniparib	<i>PARP inhibitor</i>	Page 566
2537	Isoquinolinediol, 1,5-	<i>PARP1 inhibitor and neuroprotective agent</i>	Page 571
2510	IWR-1-endo	<i>Inhibitor of the Wnt/β-catenin pathway via TNKS1&2</i>	Page 575
1922	JW 55	<i>Inhibitor of tankyrase (TNKS 1 and 2)</i>	Page 585
2001	KU 0058948 hydrochloride	<i>Potent and specific PARP1 inhibitor</i>	Page 597
4179	KU-0058948	<i>Potent and specific PARP1 inhibitor</i>	Page 597

2759	ME0328	PARP3/ARTD3 inhibitor	Page 645
2928	Niraparib	Potent, selective, and orally available PARP1/2 inhibitor	Page 705
1370	NU 1025	PARP inhibitor	Page 719
2599	NVP-TNKS656	Selective TNKS inhibitor and antagonist of Wnt pathway	Page 726
3795	PDD00017273	First-in-class, selective and cell-active PARG inhibitor	Page 755
3113	Rucaparib camsylate	PARP1 inhibitor	Page 836
2502	Talazoparib	Potent, selective, and orally available PARP1/2 inhibitor	Page 909
2369	UPF 1069	PARP-2 inhibitor with >26 fold selectivity over PARP1	Page 955
1527	XAV 939	Tankyrase (TNKS) inhibitor	Page 991

Enzymes (EC 2.5.1.) Prenyltransferases

Farnesyltransferase is one of the three members of the family of prenyltransferases that catalyzes the formation of a thioether linkage between the C-1 of an isoprenyl group and a cysteine residue fourth from the C-terminus of the farnesyl protein. In general, substrates of the prenyltransferases include Ras, Rho, Rab, other Ras-related small GTP-binding proteins, gamma-subunits of heterotrimeric G-proteins, nuclear lamins, centromeric proteins and many proteins involved in visual signal transduction. The farnesyltransferase inhibitors, such as LB 42708 (Axon 1794), induce growth arrest and apoptosis in various human cancer cells by inhibiting the posttranslational activation of Ras. As a result, they suppress the release of vascular endothelial growth factor (VEGF) from tumor cells. Subsequently LB 42708 can suppress angiogenesis in vitro and in vivo by blocking the mitogen-activated protein kinase/extracellular signal-regulated kinase/p38 mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric-oxide synthase pathways in endothelial cells without altering FAK/Src activation¹.

Glutathione S-transferase P1 (GSTP1 or GSTP- π ; EC 2.5.1.18) is a member of a super-gene family of phase II metabolic enzymes, which are involved in conjugation reaction in phase II metabolism of xenobiotics. GSTP1 catalyzes the reactions between glutathione and a variety of potentially toxic and carcinogenic electrophilic compounds. Moreover, GSTs also play an important role in modulating the induction of other enzymes and proteins for cellular functions, such as DNA repair². GSTP1 genetic polymorphism is being shown to be an important determinant not only of response to cancer chemotherapy but also of individual susceptibility to cancer³. More specifically, analyses of somatic genome alterations in prostatic carcinoma cells have revealed that somatic inactivation of GSTP1, may serve as an initiating genome lesion for prostatic carcinogenesis⁴.

¹ The Farnesyltransferase Inhibitor LB42708 Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Inhibiting Ras-dependent Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signal Pathways. C.K. Kim et al. Mol. Pharmacol. 2010, 78, 142-150.
² Z. Mo et al. An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate. 2009 May 1;69(6):662-88.
³ H.W. Lo et al. The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells. Cancer Res. 2004 Dec 15;64(24):9131-8.
⁴ W.G. Nelson et al. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology. 2001 Apr;57(4 Suppl 1):39-45.

1489	Geranyl pyrophosphate ammonium salt	Geranyl transferase substrate	Page 502
3651	Hydralazine hydrochloride	Orally active antihypertensive drug; GOT1 inhibitor	Page 548
1794	LB 42708	Inhibitor of farnesyltransferase (FTase)	Page 605
2940	Neryl pyrophosphate ammonium salt	Monoterpene synthase substrate	Page 698
2488	Piperlongumine	Natural alkaloid with potent cytotoxic activity	Page 779

Enzymes (EC 2.6.1.) Aminotransferases

Kynurenic acid (KYNA) is formed enzymatically by the irreversible transamination of the pivotal kynurenine pathway metabolite L-kynurenine (L-KYN). This reaction is catalyzed by pyridoxal 5'-phosphate (PLP) dependent aminotransferases. At least four aminotransferases can utilize L-KYN as the amino donor of the transamination reaction in the mammalian brain. However, only one of them, kynurenic acid aminotransferase II (KAT II, E.C. 2.6.1.7), recognizes L-KYN unencumbered by abundant, competing amino acid substrates. This explains why KAT II accounts for the majority of cerebral KYNA synthesis in rat and human brain tissue^{1,2}.

¹ F. Rossi et al. Crystal structure-based selective targeting of the pyridoxal 5'-phosphate dependent enzyme kynurenic acid aminotransferase II for cognitive enhancement. J. Med. Chem. 2010, 53, 5684-5689.
² L. Amori et al. On the relationship between the two branches of the kynurenic acid pathway in the rat brain in vivo. J. Neurochem. 2009, 109, 316-325.

2237	BFF 122	Selective inhibitor of kynurenic acid aminotransferase II (KAT II)	Page 299
------	---------	-------	--	-------	----------

2924	PF 04859989 hydrochloride	Potent, selective, brain-penetrant, irreversible inhibitor of kynurenic acid aminotransferase II	Page 768
------	---------------------------	-------	--	-------	----------

Enzymes (EC 2.7.) Phosphorus-containing Group Transferases

The large group of enzymes that are classified according to the Enzyme Commission number EC 2.7. are officially defined as family of transferases that transfer phosphorus-containing groups from one substrate to another. It comprises general kinases and nucleotidyltransferases, among many other transferases. The section is subdivided according to the acceptor group. The protein kinases in this section are divided into the sub-subclasses protein-tyrosine kinases (EC 2.7.10), protein-serine/threonine kinases (EC 2.7.11), dual-specificity kinases (EC 2.7.12), protein-histidine kinases (EC 2.7.13) and other protein kinases (EC 2.7.99).

Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors

When enzymes are capable of transferring phosphate groups to an alcohol moiety of the acceptor substrate, they are categorized as EC 2.7.1. Ceramide kinase (CerK; EC 2.7.1.138) is an enzyme that phosphorylates endogenous ceramides, a family of waxy lipid molecules composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of cells and are one of the component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer. CerK was cloned and categorized on the basis of homology as a subclass of the family of diacylglycerol kinase (DAGK), distinct from sphingosine kinases (SPHK). CerK bears a Pleckstrin Homology (PH) domain which is required for membrane binding in vitro, sub-cellular localization at membrane compartments, and enzymatic activity. NVP 231 (Axon 1600) potently and selectively inhibits the binding of ceramide to CerK, resulting in decreased levels of the endogenous bioactive lipid ceramide-1-phosphate (C1P), and increased levels of ceramide and reduced cell growth¹. Galactokinase (GALK; EC 2.7.1.6) catalyzes the conversion of α -D-galactose to galactose 1-phosphate, the second step in the pathway of the conversion of β -D-galactose, to the more metabolically useful glucose 1-phosphate (Leloir pathway). Defects in the human enzyme can result in the diseased state referred to as galactosemia². Additionally, galactokinase-like molecules have been shown to act as sensors for the intracellular concentration of galactose and, under suitable conditions, to function as transcriptional regulators.

Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. The effects of ADO on cellular excitability are mediated via interactions with different cell surface receptor subtypes (termed P1 receptors: A1, A2A, A2B, and A3 receptor subtypes) and can result in cellular protection during conditions of physiological stress or trauma, including ischemia, seizures, inflammation, and pain³. The effects of extracellular ADO are terminated by its reuptake and phosphorylation by ADO kinase (ADK; EC 2.7.1.20) and via deamination by adenosine deaminase (ADA; EC 3.5.4.4). By preventing ADO phosphorylation, ADK inhibition increases intracellular ADO concentrations, altering the equilibrium of the bidirectional transport systems responsible for ADO reuptake with the net effect of increasing the local concentration of ADO in the extracellular compartment. Therefore, ADK inhibitors may have therapeutic potential as analgesic and anti-inflammatory agents⁴.

¹ C. Graf et al. Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol. Pharmacol. 2008, 74, 925-932.
² H.M. Holden et al. Galactokinase: structure, function and role in type II galactosemia. Cell. Mol. Life Sci. 2004, 61, 2471-2484.
³ M.F. Jarvis et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory... J Pharmacol Exp Ther. 2000 Dec;295(3):1156-64.
⁴ C.H. Lee et al. Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor. J Med Chem. 2001 Jun 21;44(13):2133-8.

2289	ABT 702	The first, non-nucleoside adenosine kinase (ADK) inhibitor	Page 202
3357	BAMB-4	Membrane permeable ITPKA inhibitor (InsP3Kinase specific)	Page 283
4110	BMS-502	Recent Addition	First-in-class potent and selective dual DGK α/ζ inhibitor	Page 318
4109	BMS-684	Recent Addition	Selective DGK α inhibitor	Page 319
2801	BQR695	PI4K inhibitor	Page 325
3434	GNF362	Potent, selective and orally bioavailable Itpkb inhibitor	Page 510
2845	KDU691	PI4K inhibitor	Page 590
3482	LDC7559	PFKL activator	Page 607
3572	Nicotinamide riboside chloride	NAD ⁺ precursor	Page 702
1600	NVP 231	CerK inhibitor	Page 721
3034	PI-273	A substrate-competitive, subtype-specific inhibitor of PI4KIII α	Page 776
3537	PFK15	Potent and specific PFKFB3 inhibitor	Page 771
2186	SF 1670	Inhibitor of PTEN with inhibitory effect on PTPRC and GALK	Page 863
3005	UCB9608	Potent and orally bioavailable PI4KIII β inhibitor	Page 947

3678	UNC7467	Potent IP6K inhibitor	Page 953
------	---------	-----------------------	----------

Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, GK

The glucose-phosphorylating enzyme glucokinase (GK; EC 2.7.1.2) was identified as an outstanding drug target for developing antidiabetic medicines because it has an exceptionally high impact on glucose homeostasis because of its glucose sensor role in pancreatic β -cells and as a rate-controlling enzyme for hepatic glucose clearance and glycogen synthesis, both processes that are impaired in type 2 diabetes¹. GK facilitates the phosphorylation of glucose to glucose-6-phosphate (G6P), which is the first step of both glycogen synthesis and glycolysis.

¹ Glucokinase Activators for Diabetes Therapy. *Diabetes Care* 2011, 34, S236-S243

3062	AZD1656	Glucokinase (GK) activator	Page 277
1134	RO 28-0450	Glucokinase (GK) activator	Page 824
1355	RO 28-1674	Glucokinase (GK) activator	Page 824
1356	RO 28-1675	Glucokinase (GK) activator	Page 825

Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, SphK

Sphingosine-1-phosphate (S1P), a lipid metabolite, has been recently demonstrated to be an important signaling mediator for vital cellular and physiological processes, such as cell motility, invasion, proliferation, angiogenesis and apoptosis. S1P is produced from ceramide and sphingosine via phosphorylation by two isoenzymes (EC 2.7.1.91), sphingosine kinase-1 (SphK1) and sphingosine kinase-2 (SphK2). The regulation of the levels of these metabolites, a so called "sphingolipid rheostat", is complex and a number of enzymes have been demonstrated to be important. Upon production, S1P interacts with a family of G protein-coupled receptors (S1PR1-5) on the cell surface and/or intracellular targets, such as histone deacetylase (HDAC) and TRAF2, to play a plethora of roles in diverse pathophysiological conditions such as inflammation, immunity and cancer. Although SphK1 and SphK2 share a high degree of homology, they differ significantly in size, tissue distribution, and subcellular localization¹.

¹ K. Liu et al. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyphenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. *PLoS One*. 2013, 8, e56471.

2880	ABC294640	Selective and orally available SphK2 (or SK2) inhibitor	Page 198
2484	K6PC-5	SphK1 (or SK1) activator	Page 587
2235	K 145 hydrochloride	Selective, substrate competitive SphK2 inhibitor	Page 587
2350	PF 543 citrate	Cell-permeant reversible inhibitor of SphK1	Page 760
2782	SKI II	Orally bioavailable SphK inhibitor	Page 871

Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, PFKFB

Unlike normal cells, cancer cells have been noted to shift their energy metabolism toward glycolysis. This phenomenon, originally termed the Warburg effect, allows cancer cells to satisfy increased biosynthetic requirements for biomass and energy. The HIF-1-induced PFKFB3 (EC 2.7.1.105) plays a key role in this adaptation of cancer cells to adopt glycolysis as the major source of metabolic energy production for fast cell growth. It does so by elevating the concentration of Fru-2,6-BP, the most potent glycolysis stimulator. As this metabolic conversion has been suggested to be a hallmark of cancer, PFKFB3 has emerged as a novel target for cancer chemotherapy¹.

¹ M. Seo, J.D. Kim, D. Neau, I. Sehgal, I. Y.H. Lee. Structure-Based Development of Small Molecule PFKFB3 Inhibitors: A Framework for Potential Cancer Therapeutic Agents Targeting the Warburg Effect. *PLoS ONE* 2011, 6, e24179.

2175	3PO	Inhibitor of HIF-1-induced PFKFB3	Page 743
2542	PFK 158	Nanomolar small molecule inhibitor of PFKFB3	Page 772

Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, PKM

PKM2 (EC 2.7.1.40) is an isoenzyme of the glycolytic enzyme pyruvate kinase. Four isoforms of pyruvate kinase have been characterized: the L (PKL) and R (PKR) isoforms, and the M1 (PKM1) and M2 (PKM2) isoforms. The M2 isoform of catalyzes

the final and also a rate-limiting reaction in the glycolytic pathway. The less active form of PKM2 drives glucose through the route of aerobic glycolysis, while active PKM2 directs glucose towards oxidative metabolism. Additionally, PKM2 possesses protein tyrosine kinase activity and plays a role in modulating gene expression and thereby contributing to tumorigenesis. Since all tumor cells exclusively express the embryonic M2 isoform of PK, it is hypothesized that PKM2 is a potential target for cancer therapy. Modulation of PKM2 might also be effective in the treatment of obesity, diabetes, autoimmune conditions, and antiproliferation-dependent diseases¹.

¹ N. Wong et al. PKM2, a Central Point of Regulation in Cancer Metabolism. *Int. J. Cell Biol.* 2013, 2013, 242513.

2149	PKM2 activator 1020	Activator of pyruvate kinase isoenzyme M2 (PKM2)	Page 782
2240	TEPP 46	Potent activator of recombinant PKM2	Page 919

Enzymes (EC 2.7.1.) Kinases, Hydroxide acceptors, PI3K

Another significantly large group of kinases that regulate the transfer phosphate groups to hydroxyl groups of substrates is the class of PI3K's (Phosphatidylinositol 3-kinases, EC 2.7.1.153), a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking. The family may be divided into three different classes (I-III), based on primary structure, regulation, and in vitro lipid substrate specificity¹. Since PI3K's play a crucial role in the PI3K/AKT/mTOR signaling pathway, Axon Ligands™ interacting with this group of kinases are listed individually in the section for PI3K/AKT/mTOR signaling.

¹ PI3K/Akt/mTOR pathway as a target for cancer therapy. *D. Morgensztern, H.L. McLeod Drugs* 2005, 16, 797-803

1831	A 66	PI3K inhibitor (p110 alpha specific)	Page 190
2857	Acalisib	PI3K inhibitor (p110 δ specific)	Page 205
2925	Alpelisib	PI3K inhibitor (p110- α specific)	Page 220
3827	AMG-511	Orally bioavailable, highly potent and selective pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor	Page 225
3837	ARUK2001607	Potent, selective, and brain-penetrant PI5P4Ky inhibitor	Page 250
1424	AS 252424	PI3K inhibitor (p110 gamma specific)	Page 250
1436	AS 252424 bispotassium salt	PI3K inhibitor (p110- γ specific)	Page 251
2748	Autophinib	PIK3C3/Vps34 inhibitor	Page 261
3808	AZD3458	Orally bioavailable potent and selective PI3Ky inhibitor	Page 271
2926	AZD 6482	PI3K inhibitor (p110 β specific)	Page 275
3690	AZD8186	PI3K β/δ isoform-selective inhibitor	Page 276
3778	BAY-091	First potent and highly selective PIP4K2A inhibitor	Page 285
3598	BAY-091 hydrochloride	First potent and highly selective PIP4K2A inhibitor	Page 285
3942	BAY-1082439	PI3K α/β -balanced inhibitor	Page 286
3055	B591	Potent, specific class I PI3K inhibitor	Page 281
1282	BAG 956	PI3K and PDKP1 inhibitor	Page 282
2170	CAL 101	PI3K inhibitor (p110 delta specific)	Page 339
2039	CZC 24832	PI3K inhibitor (p110 gamma specific)	Page 404
1719	D 106669	Potent and selective PI3K inhibitor	Page 406
1377	GDC 0941 bismesylate	PI3K inhibitor	Page 499
2994	GNE 317	Brain-penetrant PI3K inhibitor (p110- α specific)	Page 509
3807	GS-9901	Potent and isoform-selective inhibitor of PI3K δ	Page 516
1912	GSK 2636771 dihydrochloride	PI3K inhibitor (p110 beta specific)	Page 529
2168	IC 87114	Potent and highly selective inhibitor of the PI3K p110 δ	Page 556
4133	IPI-145	PI3K p110 α/γ isoform specific inhibitor	Page 569
4147	IPI-549	Orally bioavailable potent and selective PI3Ky inhibitor	Page 569
1366	LY 294002	PI3K inhibitor	Page 627

3098	ME-401	Potent, selective and orally available PI3K inhibitor (p110 δ specific)	Page 645
1520	NVP-BBD130	Dual PI3K and mTOR kinase inhibitor	Page 722
2029	NVP-BGT226	Orally active dual PI3K/mTOR inhibitor	Page 723
1797	NVP-BKM120	Class I PI3K inhibitor	Page 723
2610	PKI inhibitor 2610	Dual PI3K/PDPK1 inhibitor	Page 756
1380	PI 103 hydrochloride	PI3K inhibitor (p110 specific)	Page 775
3045	PI 3065	PI3K inhibitor (p110 δ specific)	Page 776
1334	PIK 75 hydrochloride	PI3K inhibitor (p110 alpha specific)	Page 777
1362	PIK 90	PI3K inhibitor (p110 alpha specific)	Page 778
3792	PITCOIN3	Potent, highly selective and cell-permeable PI3K2 α inhibitor	Page 780
4172	PITCOIN4	Potent and highly selective PI3K2 α inhibitor	Page 780
2716	SAR405	PIK3C3/Vps34 inhibitor	Page 843
4075	Serabelisib	PI3K p110 α isoform specific inhibitor	Page 861
2927	Taselisib	PI3K inhibitor (p110 β sparing)	Page 911
3974	TG100-115	PI3K P110 γ/δ isoform-selective inhibitor	Page 921
1417	TGX 221	PI3K inhibitor (p110 beta specific)	Page 922
4019	UCL-TRO-1938	Selective allosteric activator of PI3K α	Page 948
3794	Urolithin A	Inhibitor of the PI3K/AKT/mTOR pathway	Page 957
4031	XL-147	PI3K (α , β , γ , δ) inhibitor	Page 993
2607	YM201636	Selective inhibitor of PIKfyve (type III PtdInsP kinase)	Page 999

Enzymes (EC 2.7.4.) Phosphotransferases

Thymidylate kinase (aka TMPK; EC 2.7.4.9) is involved in the pathway dTTP biosynthesis, which is part of Pyrimidine metabolism. It phosphorylates thymidine 5'-monophosphate (dTMP) to thymidine 5'-diphosphate (dTDP), and finally by nucleoside-diphosphate kinase (NDK; EC 2.7.4.6) to thymidine triphosphate (dTTP), a building block of DNA. This pathway is unique in that all other dNDPs, including dUDP, are directly produced by ribonucleotide reductase (RNR; EC 1.17.4.1). TMPK has an important function in cell proliferation, and is well recognized as a potential drug target, with the most notable function being in the activation of anti-HIV nucleoside prodrugs. Recent studies have shown that TMPK is a validated target for antibiotic development against gram-positive bacteria of *M. tuberculosis* and *S. aureus* as well¹, and a modulator that can increase the potential of anticancer agent doxorubicin toward colon cancer cells regardless of p53 status². Mechanistic studies have demonstrated that the lack of TMPK functionality in cancer cells leads to dUTP misincorporation in DNA repair, resulting in cancer cell death³.

¹ L. Song et al. Elaboration of a proprietary thymidylate kinase inhibitor motif towards anti-tuberculosis agents. *Bioorg Med Chem.* 2016 Nov 1;24(21):5172-5182.

² Q. Cui et al. Thymidylate kinase: an old topic brings new perspectives. *Curr Med Chem.* 2013;20(10):1286-305.

³ CM Hu et al. Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair. *Cancer Cell.* 2012 Jul 10;22(1):36-50.

Enzymes (EC 2.7.7.) Nucleotidyltransferases

Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs that inhibit the activity of reverse transcriptase, a viral DNA polymerase that is required for replication of HIV and other retroviruses. Three forms of RTIs are known, of which nucleoside- and nucleotide reverse transcriptase inhibitors (NRTIs and NNRTIs respectively) essentially show similar modes of action, while non-nucleoside reverse-transcriptase inhibitors have a completely different mode of action. NNRTIs block reverse transcriptase by binding at a different site on the enzyme, compared to NRTIs and NtRTIs. NNRTIs are not incorporated into the viral DNA but instead inhibit the movement of protein domains of reverse transcriptase that are needed to carry out the process of DNA synthesis. NNRTIs are therefore classified as non-competitive inhibitors of reverse transcriptase¹.

Telomerase (EC 2.7.7.49), a unique enzyme that contains telomerase reverse transcriptase (TERT) and a template-containing RNA component (TR), facilitates the solution of both chromosome end-related problems: the chromosome end-protection problem and the chromosome end-replication problem. By synthesizing multiple tandem repeats of DNA (called telomeric DNA) encoded by its RNA template, telomerase compensates for the erosion of DNA ends during replication and provides the docking sites for telomeric proteins that bind specifically to the ends of chromosomes to distinguish them from

broken DNA ends. The action of telomerase is required for the survival of continuously dividing cells such as those of unicellular eukaryotes².

RNA polymerases (RNAP or Pol; EC 2.7.7.6) are highly conserved multisubunit enzyme complexes (14, 12, and 17 subunits for RNAP1-3, respectively) in eukaryotes³. By responding to changes in the cellular environment, transcription by RNA polymerase I ultimately determines ribosome production and the potential for cell growth and proliferation. RNAP1 is unique in that in most eukaryotes its sole function is the transcription of genes encoding the large rRNAs. Like Pol II and Pol III, it requires auxiliary factors that mediate promoter recognition, promote transcription elongation, and facilitate transcription termination⁴.

HIV-1 integrase (IN; EC 2.7.7.49) is a polynucleotidyltransferase that catalyzes the integration of the DNA copy of the viral genome into the genome of the host cell. During viral infection, IN catalyzes two consecutive reactions, each proceeding by direct transesterification reactions catalyzed at a single active site in the enzyme's core. In the first reaction, IN removes two nucleotides from the 3'-end of each strand of the nascent viral DNA, leaving a recessed 3'CA dinucleotide. After migration into the nucleus of the infected cell as part of the nucleoprotein complex, IN covalently attaches each 3' processed viral end to the host cell DNA, a reaction termed strand transfer⁵. IN also catalyzes an apparent reversal of the strand transfer reaction, a process known as disintegration⁶.

¹ L.J. Scott, C.M. Perry. Delavirdine: a review of its use in HIV infection. *Drugs.* 2000, 60, 1411-1444.

² J. Nandakumar et al. Finding the end: recruitment of telomerase to telomeres. *Nat. Rev. Mol. Cell Biol.* 2013, 14, 69-82.

³ A. Vannini et al. Conservation between the RNA polymerase I, II, and III transcription initiation machineries. *Mol. Cell.* 2012, 45, 439-446.

⁴ I. Grummt. Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus. *Genes Dev.* 2003, 17, 1691-1702.

⁵ N. Sluis-Cremer et al. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. *Eur J Biochem.* 2002 Nov;269(21):5103-11.

⁶ N. Neamati et al. Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. *Antimicrob Agents Chemother.* 1997 Feb; 41(2): 385-393.

3384	Acyclovir	Highly selective inhibitor of herpes virus DNA polymerase	Page 205
3008	AOH1160	First-in-class, potent and orally available PCNA inhibitor	Page 238
4030	AOH1996	Orally available PCNA inhibitor	Page 238
2301	BIBR 1532	Selective telomerase inhibitor inducing senescence	Page 304
2462	BMH 21	Inhibitor of RNA Polymerase I (RNAP1)	Page 314
3664	Brivudine	Inhibitor of herpes virus DNA polymerase	Page 329
2173	CX 5461	Inhibitor of RNA Polymerase I (RNAP1)	Page 400
1815	Delavirdine	NNRT inhibitor (HIV-1)	Page 418
1534	Dapivirine	NNRT inhibitor	Page 409
2855	Dolutegravir	HIV integrase inhibitor	Page 436
3125	Efavirenz	Highly potent, orally bioavailable NNRT inhibitor (HIV-1)	Page 452
3305	Emtricitabine	Potent and orally bioavailable NRT inhibitor (HIV-1)	Page 457
3239	Entecavir	Competitive inhibitor of HBV viral polymerase	Page 461
3135	Favipiravir	Potent and selective inhibitor of viral RNA polymerase	Page 475
3241	Ganciclovir	Inhibitor of CMV and herpes virus DNA polymerase	Page 495
3417	IMT1B	First-in-class, potent and highly specific allosteric POLRMT inhibitor	Page 564
3191	Islatravir	Potent and long-acting NNRT inhibitor (HIV-1)	Page 570
3002	JH-RE-06	Specific and in vivo active REV1-REV7 interaction inhibitor	Page 577
3304	Lamivudine	Potent NRT inhibitor	Page 604
3334	Loviride	Potent and highly selective NNRT inhibitor (HIV-1)	Page 620
3124	Nevirapine	Potent and selective NNRT inhibitor (HIV-1)	Page 699
3385	Penciclovir	Highly selective inhibitor of herpes virus DNA polymerase	Page 758
2965	PNR-7-02	Potent inhibitor of human DNA polymerase η	Page 785
3120	Raltegravir	Potent, selective and orally bioavailable HIV integrase inhibitor	Page 807
3685	Rilpivirine	Highly active and orally bioavailable NNRT inhibitor (HIV-1)	Page 819
4003	RP-6685	Potent, selective, and orally bioavailable Pol θ inhibitor	Page 831
3301	Sofosbuvir	Potent and selective HCV NS5B polymerase inhibitor	Page 878

3491	Stavudine.....	NRT inhibitor	Page 894
3157	Tenofovir.....	Selective inhibitor of HIV-1 reverse transcriptase.....	Page 918
3302	Tenofovir alafenamide.....	Prodrug of Tenofovir; HIV-1 reverse transcriptase inhibitor.....	Page 919
3506	Vidarabine.....	Inhibitor of herpes virus DNA polymerase.....	Page 968
3382	Zidovudine.....	NRT inhibitor.....	Page 1006

Enzymes (EC 2.7.10.) Kinases, Tyrosine specific

Tyrosine specific kinases form a large family of enzymes that are responsible for catalyzing the transfer of ATP to specific tyrosine residues in target proteins. In turn, the phosphorylation of tyrosine residues causes a change in the function of the protein that they are contained in. They function in a variety of processes, signal transduction pathways, and actions, and may be responsible for key events in the body¹. Axon Ligands™ that interact with tyrosine specific enzymes that are part of the JAK/STAT signaling pathway have been categorized independently in this catalogue (see section below). The remainder of Axon Ligands™ that lack interactions with tyrosine kinases of this particular signaling pathway are listed here, grouped on the basis of their selectivity.

Wee1 (EC 2.7.10.2) is a protein kinase, regulates the G2 checkpoint in response to DNA damage. Preclinical studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer. Wee1 belongs to a family of protein kinases involved in the terminal phosphorylation and inactivation of cyclin-dependent-kinase 1-bound cyclin B. It is the major kinase responsible for the inhibitory phosphorylation of the tyrosine15 residue on Cdk1/Cdc2, near its ATP-binding pocket, and plays a critical role in the proper timing of cell division by controlling the entry into mitosis and DNA replication during S phase. Recent evidence demonstrates that wee1 is also involved in the coordination of DNA replication and the maintenance of stalled replication forks through regulation of cyclin-dependent kinase 2 (Cdk2)².

Activated Cdc42 (cell division cycle 42)-associated tyrosine kinase (ACK1; EC 2.7.10.2), also called TNK2 (tyrosine kinase, non-receptor, 2) is activated in response to multiple cellular signals, including cell adhesion, growth factor receptors and heterotrimeric GPCR-signalling. Interaction of the SH3 (Src homology 3) domain with the EBD (EGFR-binding domain) in ACK1 forms an auto-inhibition of the kinase activity. Release of this auto-inhibition is a key step for activation of ACK1. Mutation of the SH3 domain caused activation of ACK1, independent of cell adhesion, suggesting that cell adhesion-mediated activation of ACK1 is through releasing the auto-inhibition. ACK is amplified and overexpressed in multiple cancers, and associated with tumour progression through promoting cell growth and migration³.

Interleukin-2 inducible T-cell kinase (ITK; EC 2.7.10.2) is a member of the TEC-kinase family which encompasses ITK, RLK, BTK, BMX, and Tec. It is expressed mainly in immune cells such as T-cells, mast cells, NK cells, and NKT cells. Recent work suggests that ITK may be a negative regulator in mast cells as responses of mast cells lacking ITK to FcεR1 signaling are not attenuated and can be increased relative to WT mast cells. In contrast, ITK positively regulates T-cell receptor (TCR) signaling and plays a role in numerous T-cell responses. ITK is activated downstream of the T-cell receptor and is strongly upregulated upon activation of naive T cells. As such, it responds to and drives the expression of IL-2 and activates PLCγ1 by phosphorylation. This leads to the production of IP3 and DAG and triggers the release of intracellular calcium and activation of PKC, respectively⁴.

Lyn is a member of the Src family of intracellular membrane-associated tyrosine kinases (SFK). Each member has a unique N-terminal region (SH4) encoding a myristoylation site, and may contain one (e.g. Lyn) or two (e.g. Fyn) palmitoylation sites, followed by homologous domains for protein interaction (SH3 and SH2), as well as a kinase (SH1) domain. It has been implicated in cell proliferation and differentiation, apoptosis, migration and metabolism. Intriguingly, Lyn can mediate both positive and negative signaling processes within the same or different cellular contexts. Lyn is an important regulator of autoimmune diseases such as asthma and psoriasis, due to its profound ability to influence immune cell signaling. Lyn has also been found to be important for maintaining the leukemic phenotype of many different liquid cancers including acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML) and B-cell lymphocytic leukaemia (BCLL). Lyn is also expressed in some solid tumors and here too it is establishing itself as a potential therapeutic target for prostate, glioblastoma, colon and more aggressive subtypes of breast cancer⁵.

Breast tumor kinase (Brk aka protein tyrosine kinase 6 (PTK6)) belongs to the non-receptor tyrosine kinases, distantly related to the c-Src family kinases, with occurrence in the cytoplasm. Brk is activated downstream of multiple growth factor receptors, including MET, EGF receptor, and ErbB2, and confers aggressive breast cancer phenotypes such as growth factor-induced cell migration, anchorage-independent growth, modulation of EMT markers, metastasis, and resistance to targeted therapies⁶. As Brk is aberrantly expressed in both luminal and triple negative breast cancers (TNBC) subtypes, but is not found in the normal mammary tissue, it is an attractive candidate for selective targeting of invasive breast cancer cells⁷.

¹ Receptor tyrosine kinase signaling: a view from quantitative proteomics. J. Dengjel, I. Kratchmarova, B. Blagoev. Mol. Biosyst. 2009, 5, 1112–1121.

² K. Do et al. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013, 12, 3159–3164.

³ Q. Lin et al. The activation mechanism of ACK1 (activated Cdc42-associated tyrosine kinase 1). Biochem. J. 2012, 445, 255–264.

⁴ C.W. Zapf et al. Covalent inhibitors of interleukin-2 inducible T cell kinase (Itk) with nanomolar potency in a whole-blood assay. J. Med. Chem. 2012, 55, 10047–10063.

⁵ E. Ingle, Functions of the Lyn tyrosine kinase in health and disease. Cell Commun. Signal. 2012, 10, 21.

⁶ TM Regan Anderson et al. Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer. Cancer Res. 2016 Mar 15;76(6):1653–63.

⁷ TM Regan Anderson et al. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res. 2013 Sep 15;73(18):5810–20.

4141	Acalabrutinib.....	Orally active, irreversible, and highly selective second-generation BTK inhibitor.....	Page 205
2031	AIM 100.....	Specific inhibitor of Ack1 tyrosine kinase (TNK2).....	Page 215
1456	AZD 0530 difumarate.....	Inhibitor of SRC and ABL tyrosine kinases.....	Page 266
2294	KRCA 0008.....	Potent and selective dual ALK/ACK1 inhibitor.....	Page 595
3270	Lj-1-60.....	Fyn inhibitor targeting the Fyn/Stat3 pathway.....	Page 617
1494	MK 1775.....	Wee1 kinase inhibitor.....	Page 661
1941	MLR 1023.....	Selective allosteric activator of Lyn kinase.....	Page 675
3466	MT-802.....	Potent and rapid degrader of BTK; PROTAC.....	Page 684
2110	PF 06465469.....	Inhibitor of interleukin-2 inducible T cell kinase (ITK).....	Page 770
3869	RN486.....	Selective and reversible inhibitor of Bruton's tyrosine kinase (BTK).....	Page 822
3668	RP-6306.....	First-in-class, potent, selective, and orally bioavailable PKMYT1 inhibitor.....	Page 831
3759	RP-6306, (aR).....	(aR)-enantiomer of RP-6306 (Axon 3668); PKMYT1 inhibitor.....	Page 831
2560	Tilfrinib.....	Brk inhibitor with antiproliferative activity.....	Page 928
2762	XMD 8-87.....	Potent and selective inhibitor of Ack1 tyrosine kinase (also known as TNK2).....	Page 995

Enzymes (EC 2.7.10.) Kinases, BTK

Bruton's tyrosine kinase (BTK; EC 2.7.10.2) is a non-receptor tyrosine kinase belonging to the Tec family of kinases (TFKs), which form the second largest family of cytoplasmic tyrosine kinases in mammalian cells and include, in addition to BTK, Tec, Itk, Txk (also known as Rlk), and bone marrow tyrosine kinase gene on chromosome X (Bmx). Btk is critical for B-cell development, differentiation, and signaling. Moreover, BTK expression is assumed to be a prerequisite for B-cell proliferation and survival. Btk is the only member of the TFKs reported to be associated with human disease (primary immunodeficiency, named X-linked agammaglobulinemia (XLA) and a milder form: X-linked immunodeficiency (Xid))¹.

¹ A.J. Mohamed. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immun. Reviews. 2009, 228, 58–73.

2226	AVL 292.....	Potent, selective, covalent BTK inhibitor.....	Page 262
2018	CGI 1746.....	Inhibitor of Bruton's tyrosine kinase (BTK).....	Page 361
2862	LFM-A13.....	Inhibitor of Bruton's tyrosine kinase (BTK).....	Page 613
1858	PCI 32765.....	Inhibitor of Bruton's tyrosine kinase (BTK).....	Page 750

Enzymes (EC 2.7.10.) Kinases, FAK

Protein tyrosine kinase 2 (PTK2 a.k.a. Focal Adhesion Kinase (FAK); EC 2.7.10.2) is a cytoplasmic non-receptor tyrosine kinase which is found concentrated in the focal adhesions that form between cells growing in the presence of extracellular matrix constituents. It was originally identified as a substrate for viral Src and as a highly tyrosine-phosphorylated protein that localized to cell adhesion sites known as focal contacts. FAK has been shown to have a key role in both normal and tumor cell migration downstream of growth factor- and integrin- receptors. It is the formation of a FAK–Src signaling complex that is an initial and important event required for maximal FAK activation and cell migration. Activation is involved in modulating 'corrective' cell responses to environmental stimuli, which is provoked by signal-mediated effects on actin polymerization, the assembly or disassembly of focal contacts, and the regulation of protease activation or secretion¹.

¹ S.K. Mitra, D.A. Hanson, D.D. Schlaepfer. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Bio. 2005, 6, 56–68

2574	Defactinib.....	Second generation inhibitor of FAK and PYK2.....	Page 416
------	-----------------	--	----------

3717	GSK2256098	FAK inhibitor	Page 519
2107	PF 431396	Dual FAK(PTK2) and PYK2 inhibitor	Page 763
4215	PF-562271	Potent, selective, ATP-competitive and reversible dual FAK/PYK2 inhibitor	Page 764
1623	PF 573228	FAK inhibitor	Page 764
2459	PND 1186	Orally active dual FAK/PYK2 inhibitor	Page 784
3866	TAE226	Potent and ATP-competitive dual FAK and IGF-1R inhibitor	Page 905
3789	YH-306	FAK inhibitor	Page 997

Enzymes (EC 2.7.10.) Kinases, PYK

Proline-rich tyrosine kinase-2 (PYK2; EC 2.7.10.2) is related to focal adhesion kinase (FAK; EC 2.7.10.2) and shares a similar domain structure (FERM, kinase, proline-rich and FAT domains) as well as common phosphorylation sites. Both kinases act as critical mediators for the activation of signaling pathways that regulate cell migration, proliferation, and survival. By coordinating adhesion and cytoskeletal dynamics with survival and growth signaling, FAK and Pyk2 represent molecular therapeutic targets in cancer cells as malignant cells often exhibit defects in these processes. Despite their structural similarity, PYK2 and FAK display a number of significant differences (distribution, activation). Although PYK2 can be activated following integrin mediated adhesion, PYK2 is primarily activated in response to a variety of stimuli that increase intracellular calcium. Upregulation of PYK2 expression has been noted in several human tumors, gliomas, and with advancing WHO grade, and define it a potential target for disease modulation, particularly as it pertains to invasive cancers, osteoporosis, and inflammatory cellular responses¹.

¹ C.A. Lipinski et al. The Pyk2 FERM domain: a Novel Therapeutic Target. Expert Opin. Ther. Targets. 2010, 14, 95-108.

2574	Defactinib	Second generation inhibitor of FAK and PYK2	Page 416
2107	PF 431396	Dual FAK(PTK2) and PYK2 inhibitor	Page 763
2459	PND 1186	Orally active dual FAK/PYK2 inhibitor	Page 784
2743	STK16-IN-1	ATP-competitive STK16 inhibitor	Page 896

Enzymes (EC 2.7.10.) Kinases, JAK

Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders. Type I and II cytokine receptors associate with Janus family kinases (JAKs; EC 2.7.10.2) to effect intracellular signaling¹. The JAK family in mammals consists of 4 members: JAK1, JAK2, JAK3 and TYK2. The unique structure of the JAK kinases clearly distinguishes them from other members of the protein tyrosine kinase family. The most intriguing feature of these proteins is the presence of two JAK-homology domains (JH1 and JH2), with extensive homology to the tyrosine kinase domains. A second interesting feature is the absence of any Src-homology domains SH2 or SH3. Instead, these proteins encode a group of well-conserved domains termed as JAK homology (JH1-JH7) domains that follow a non-conserved amino terminus of about 30-50 amino acids. Of the dual kinase domains identified, only the JH1 domain appears to be functional². JAK activation occurs upon ligand-mediated receptor multimerization. The activated JAKs subsequently phosphorylate additional targets, including both the receptors and the major substrates, STATs (latent transcription factors that reside in the cytoplasm until activated)³.

¹ M. Pesu et al. Therapeutic targeting of Janus kinases. Immunol. Rev. 2008, 223, 132-142.

² M.M. Seavey, P. Dobrzanski. The many faces of Janus Kinase. Biochem. Pharmacol. 2012, 83, 1136-1145.

³ J.S. Rawlings, K.M. Rosler, D.A. Harrison. The JAK/STAT signaling pathway. J. Cell. Sci. 2004, 117, 1281-1283.

1378	AG 490	JAK2 inhibitor	Page 212
2219	AT 9283	Multitargeted kinase inhibitor (Aurora, JAK, and BCR-AbI)	Page 257
1778	AZ 960	JAK2 inhibitor	Page 265
3855	AZD-4205	Selective and ATP-competitive inhibitor of JAK1	Page 271
1955	Baricitinib	JAK1 and JAK2 inhibitor	Page 284
3813	BMS-911543	Potent, selective and orally active inhibitor of JAK2	Page 320
3671	CEP-33779	Potent, selective and orally bioavailable JAK2 inhibitor	Page 359
1338	CP 690550	JAK3 inhibitor	Page 390

1681	CYT 387	JAK1 and JAK2 inhibitor	Page 404
3861	Decernotinib	Potent and selective, orally bioavailable Janus kinase 3 (JAK3) inhibitor	Page 416
4091	Deucravacitinib	Potent, highly selective, allosteric and orally bioavailable TYK2 inhibitor	Page 422
4006	GLPG-0634	The first orally-available, selective inhibitor of JAK1	Page 505
1843	JAK2 inhibitor 13	JAK2 inhibitor	Page 576
2554	LY 2784544	Selective inhibitor of mutated janus kinase 2 (JAK2V617F)	Page 633
4124	Momelotinib hydrochloride	JAK1 and JAK2 inhibitor	Page 676
2792	NVP-BSK805	Potent, selective and orally bioavailable JAK2 inhibitor	Page 724
3950	Peficitinib	Potent and orally bioavailable JAK inhibitor	Page 757
2217	PF 956980	JAK3 inhibitor; analogue of Axon 1338 and 2072	Page 764
1598	Ruxolitinib	JAK1 and JAK2 inhibitor	Page 836
2539	Solcitinib	Selective JAK1 inhibitor	Page 878
1588	TG 101348	JAK2 inhibitor	Page 921
2072	Tofacitinib citrate	Potent Janus Kinase 3 (JAK3) inhibitor	Page 934
2316	WP 1066	JAK2 and STAT3 inhibitor	Page 987
2231	XL 019	JAK2 inhibitor	Page 992

Enzymes (EC 2.7.10.) Kinases, SRC

The Src family of protein tyrosine kinases (SFKs; EC 2.7.10.2) plays key roles in regulating signal transduction by a diverse set of cell surface receptors in the context of multiple cellular environments. The nine members of the Src family include Src, Lck, Hck, Fyn, Blk, Lyn, Fgr, Yes, and Yrk, and all share a very similar domain structure with a high degree of homology in the SH1 (catalytic), linker, SH2 (p-Tyr binding), SH3 (protein-protein interaction) and SH4 (membrane association) domains. In the auto-inhibited, tail-phosphorylated (Tyr⁵²⁷) state, the SH3 and SH2 domains turn inward and make intramolecular interactions that lock the catalytic domain in an inactive conformation. Several lines of evidence indicate that loss of Tyr⁵²⁷ phosphorylation by protein tyrosine phosphatases (PTPs) leads to activation of Src catalytic activity^{1,2}.

¹ S.M. Thomas, J.S. Brugge. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13, 513-609.

² M.P. Playford, M.D. Schaller. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004, 23, 7928-7946.

1698	A 770041	Orally active Src-family selective lck inhibitor	Page 192
1456	AZD 0530 difumarate	Inhibitor of SRC and ABL tyrosine kinases	Page 266
4010	BLK degrader compound 9	First potent and highly selective monomeric degrader of B-lymphoid tyrosine kinase (BLK)	Page 313
2097	CGP 77675	Src Family kinase (SFK) inhibitor	Page 362
1392	Dasatinib	BCR-ABL and SRC tyrosine kinase inhibitor	Page 410
4079	Insulin sensitizer C59	Insulin sensitizer by targeting Unc119b	Page 567
2648	Nintedanib	RTK inhibitor with antiangiogenic and antineoplastic activities	Page 704
1892	NM-PP1, 1-	Tyrosine kinase inhibitor of Src, Fyn, Abl, CDK, Trk	Page 706
1407	SKI 606	BCR-ABL and SRC tyrosine kinase inhibitor	Page 870
2778	Squarunkin A	Selective UNC119-cargo interaction inhibitor	Page 885
1136	SU 6656	SRC kinase inhibitor	Page 898
3099	TL02-59	Potent, selective and orally active Fgr and Lyn inhibitor	Page 930
2381	WH-4-023	Orally active Src-family selective lck inhibitor	Page 985

Enzymes (EC 2.7.10.) Kinases, SYK

SYK (EC 2.7.10.2) is a non-receptor tyrosine kinase that contains two SRC homology 2 (SH2) domains and a kinase domain (Box 1) and is most highly expressed by haematopoietic cells. It is known to have a crucial role in adaptive immune receptor signaling. However, recent reports indicate that SYK also mediates other biological functions, including cellular adhesion,

innate immune recognition, osteoclast maturation, platelet activation and vascular development. Recruitment of spleen tyrosine kinase (SYK) to plasma membrane receptors occurs through binding of the tandem SH2 domains of SYK to two phosphorylated tyrosine residues of the immunoreceptor tyrosine-based activation motifs (ITAMs) in the receptor complex. SYK is activated by C-type lectins and integrins, and activates new targets, including the CARD9–BCL-10–MALT1 pathway and the NLRP3 inflammasome¹.

¹ A. Mócsai, J. Ruland, V.L.J. Tybulewicz. The SYK tyrosine kinase: a crucial player in diverse biological functions. *Nat. Rev. Immunol.* 2010, 10, 387-402.

3997	ASN-002	Potent dual inhibitor of SYK and pan-JAK kinases	Page 255
2775	Cerdulatinib	Orally active dual Syk/JAK inhibitor	Page 359
4153	GS-9973	Highly selective and orally efficacious inhibitor of spleen tyrosine kinase (Syk)	Page 516
1936	P 505-15	Inhibitor of spleen tyrosine kinase (Syk)	Page 743
1674	R 406	Spleen tyrosine kinase inhibitor	Page 803

Enzymes (EC 2.7.10.) Oncogene Fusion Proteins

A small individual group of tyrosine kinase inhibitors is specifically targeting oncogenic fusion proteins. The expression of these proteins is caused by a reciprocal translocation between chromosomes, 9 and 22 in case of the BCR-ABL fusion protein. About 95% of the patients suffering from chronic myelogenous leukaemia show expression of this particular protein, yet it is also found in two other acute forms of leukaemia^{1,2}. Our product line includes both the very first drug registered on the market inhibiting this specific tyrosine kinase (Axon 1394: STI 571 or Imatinib (Novartis)), as well as well-known follow-up inhibitors, being more potent and/or more active against the emerging Gleevec/Glivec resistant BCR-ABL clones that originate from point mutations inside the kinase domain of the Bcr-Abl protein and disrupt the binding site of Imatinib on the tyrosine kinase (e.g. Axon 1392 and Axon 1396 (Dasatinib and Nilotinib resp.))³

Anaplastic large-cell lymphomas (ALCLs) are a subtype of the high-grade non-Hodgkin's family of lymphomas with distinct morphology, immunophenotype, and prognosis. ALCLs are postulated to arise from T cells and, in rare cases, can also exhibit a B cell phenotype. ALCL presents as a systemic disease afflicting skin, bone, soft tissues, and other organs, with or without the involvement of lymph nodes. ALCL can be subdivided into at least two subtypes, characterized by the presence or absence of chromosomal rearrangements between the anaplastic lymphoma kinase (ALK) gene locus and various fusion partners such as nucleophosmin (NPM). NPM-ALK has constitutive tyrosine kinase activity and has been shown to transform various hematopoietic cell types in vitro and support tumor formation in vivo⁴.

A small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene, and seems to be the cause of non-small-cell lung cancer (NSCLC) cells. The EML4–ALK fusion transcript is detected in approx. 7% of NSCLC patients⁵.

¹ The molecular genetics of Philadelphia chromosome-positive leukemias. Kurzrock, R., Gutterman, J. Talpaz, M. N. *Engl. J. Med.* 1988, 319, 990-998.
² Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. Talpaz M, Shah NP, Kantarjian H, et al. *N. Engl. J. Med.* 2006, 354 2531–2541.
³ BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. An, X.; Tiwari, A.; Sun, Y.; Ding, P.; Ashby Jr, C.; Chen, Z. *Leukemia research* 2010, 34, 1255–1268.
⁴ A.V. Galkin et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. *Proc. Natl. Acad. Sci. USA* 2007, 104 (1), 270-275.
⁵ M. Soda et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature.* 2007, 448, 561-566.

1857	AP 24534	BCR-ABL kinase inhibitor (including T315I mutation)	Page 238
2757	Asciminib	Potent and selective allosteric BCR-ABL1 inhibitor	Page 253
2005	ASP 3026	Inhibitor of the oncogenic fusion kinase EML4-ALK	Page 256
2219	AT 9283	Multitargeted kinase inhibitor (Aurora, JAK, and BCR-Abl)	Page 257
3931	CEP-28122	Highly potent, selective and orally active ALK inhibitor	Page 358
1392	Dasatinib	BCR-ABL and SRC tyrosine kinase inhibitor	Page 410
2123	DCC 2036	An orally active BCR-ABL inhibitor	Page 412
1882	GNF 2	Inhibitor of BCR-ABL tyrosine kinase	Page 509
1394	Imatinib Mesylate	BCR-ABL, c-KIT and PDGFR kinase inhibitor	Page 561
2121	INNO 406	Dual BCR-ABL and LYN kinase inhibitor	Page 567
1396	Nilotinib	BCR-ABL inhibitor	Page 703

3168	Nilotinib hydrochloride	BCR-ABL inhibitor	Page 704
1416	NVP-TAE684	NPM-ALK inhibitor	Page 726
1137	PD 180970	BCR-ABL tyrosine kinase inhibitor (p210 specific)	Page 754
1407	SKI 606	BCR-ABL and SRC tyrosine kinase inhibitor	Page 870
3973	XL-228	Multitargeted protein kinase inhibitor (IGF1R, Aurora, FGFR, ABL, ALK and SRC)	Page 993

Enzymes (EC 2.7.10.) Kinases involved in JAK/STAT signaling

JAKs (Janus Kinase; EC 2.7.10.2: 4 types identified) and STATs (Signal Transducer and Activator of Transcription; 7 types identified) are critical components of many cytokine receptor systems, regulating growth, survival, differentiation and pathogen resistance. (Cytokine) receptor-bound STATs phosphorylated by JAKs dimerize and translocate into the nucleus to regulate target gene transcription. In most cases, a specific JAK-STAT combination has been paired with a specific member of the cytokine receptor family, and this information translated into cell-type specific patterns of cytokine responsiveness and gene expression. Members of the suppressor of cytokine signaling (SOCS) protein family dampen receptor signaling via homologous or heterologous feedback regulation¹². Consequently, Janus kinase mutations are major molecular events in human hematological malignancies³.

¹ The JAK-STAT Signaling Pathway: Input and Output Integration. P.J. Murray, J. Immunol. 2007, 178, 2623-2629.
² A Road Map for Those Who Don't Know JAK-STAT. D.S. Aaronson, C.M. Horvath. *Science* 2002, 296, 1653-1655
³ Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. *Mol. Immunol.* 2007, 44, 2497–506.

1378	AG 490	JAK2 inhibitor	Page 212
1992	AS 1517499	Potent and selective STAT6 inhibitor	Page 252
1778	AZ 960	JAK2 inhibitor	Page 265
2563	AZD 3759	Potent brain-penetrant EGFR tyrosine kinase inhibitor	Page 270
1955	Baricitinib	JAK1 and JAK2 inhibitor	Page 284
2489	Brassinin	Dual IDO1/STAT3 inhibitor	Page 326
1338	CP 690550	JAK3 inhibitor	Page 390
1681	CYT 387	JAK1 and JAK2 inhibitor	Page 404
2568	EML 425	Potent dual inhibitor of CBP and p300 (HAT/KAT3)	Page 456
1843	JAK2 inhibitor 13	JAK2 inhibitor	Page 576
2554	LY 2784544	Selective inhibitor of mutated janus kinase 2 (JAK2V617F) ...	Page 633
2217	PF 956980	JAK3 inhibitor; analogue of Axon 1338 and 2072	Page 764
1598	Ruxolitinib	JAK1 and JAK2 inhibitor	Page 836
2539	Solcitinib	Selective JAK1 inhibitor	Page 878
1588	TG 101348	JAK2 inhibitor	Page 921
2560	Tilfrinib	Brk inhibitor with antiproliferative activity	Page 928
2072	Tofacitinib citrate	Potent Janus Kinase 3 (JAK3) inhibitor	Page 934
2316	WP 1066	JAK2 and STAT3 inhibitor	Page 987
2231	XL 019	JAK2 inhibitor	Page 992

Enzymes (EC 2.7.11.) Kinases, Serine/Threonine specific

The reversible phosphorylation of proteins represents a major post-translational signaling mechanism and regulatory pathway that controls a diverse set of cellular processes. The mode of action of these protein kinases is the reversible hydroxyl-phosphorylation of tyrosine, serine, and/or threonine residues of protein substrates. Since most kinases are specifically targeting tyrosine substrates, or serine/threonine substrates, the Axon Ligands™ in this catalogue targeting kinases have been subdivided into the two corresponding classes.

Moreover, often the protein kinase itself is the substrate for an upstream kinase or undergoes auto-phosphorylation as part of a cascade of protein kinase signaling within the cell. Some representative protein kinase signaling pathways within cells include growth factor signaling and stress-activated signaling responses. Such pathways are highly interconnected and complex and regulate numerous cellular functions such as gene transcription, cell growth, proliferation, and differentiation.

Signaling pathways of interest that will be highlighted individually are the DNA-damage response, the PI3K/AKT/mTOR pathway, the MAPK/ERK pathway, the NF- κ B pathway, the TGF- β pathway, and the Wnt/ β -Catenin pathway. Aberrant protein kinase activity can disrupt the normal control of cellular phosphorylation signaling pathways and lead to tumor formation. Given the critical role that protein kinases have in modulating cellular functions such as tumorigenesis, this class of enzymes has been targeted for the discovery and design of biologics and small-molecule inhibitors as potential therapeutic agents¹.

Clathrin-mediated endocytosis requires the assembly of a protein coat on the membrane in order to induce curvature and form a spherical invagination. Adaptor-associated kinase 1 (AAK1; EC 2.7.11.1) is a regulatory protein in clathrin-coated vesicle endocytic pathway that phosphorylates the μ subunit of the clathrin-adaptor protein complexes. Evidence has accumulated that AAK1 is involved in the regulation of ALS², nociception³, immunology⁴, and Notch signaling⁵.

CaMKII (Ca²⁺/calmodulin-dependent protein kinase II; EC 2.7.11.17) is a serine/threonine kinase with a broad range of substrates, and it is found in most tissues, but it is present in especially high concentrations in neurons. In mammals, the kinase is encoded by four genes, α , β , γ , and δ , with the α and β isozymes predominant in the brain. CaMKII monomers assemble into a large holoenzyme. Monomers of different isozymes are able to coassemble, allowing for a large number of possible holoenzyme compositions, existing of 8-12 subunits⁶. CaMKII is involved in many signaling cascades. Neuronal CaM kinase II regulates important neuronal functions, including neurotransmitter synthesis, neurotransmitter release, modulation of ion channel activity, cellular transport, cell morphology and neurite extension, gene expression, and synaptic plasticity. Moreover, its activity is required for induction of long-term potentiation (LTP) in the CA1 region of the hippocampus. Since defects in LTP often accompany impairments in spatial learning, and animals that lack the α CaMKII isozyme do not learn normally in such tasks, CaMKII is frequently referred to as an important mediator in the process of learning and memory. Furthermore, misregulation of CaMKII is linked to Alzheimer's disease, Angelman syndrome, and heart arrhythmia⁷.

LIM kinase-1 (LIMK1; EC 2.7.11.1) and LIM kinase-2 (LIMK2) are regulated by several upstream signalling pathways, principally acting downstream of Rho GTPases to influence the architecture of the actin cytoskeleton by regulating the activity of the ADF/cofilin family of actin binding and filament severing proteins cofilin1, cofilin2 and destrin⁸. LIM kinases have a unique organization of signalling domains, with two amino-terminal LIM domains (each containing double zinc finger motifs), adjacent PDZ and proline/serine (P/S)-rich regions, followed by a carboxyl-terminal kinase domain. The LIM domains have been shown to play an important role in regulating kinase activity and likely also contribute to LIMK function by acting as sites of protein-to-protein and possibly protein-to-DNA interactions.

Mitogen- and stress-activated kinase 1 (MSK1; EC 2.7.11.1) and MSK2 are nuclear protein kinases that regulate transcription downstream of the ERK1/2 (extracellular-signal-regulated kinase 1/2) and p38 α MAPKs (mitogen-activated protein kinases) via the phosphorylation of CREB (cAMP-response-element-binding protein), ATF1, and histone H3. MSKs are most closely related to the RSK family of kinases and, similar to RSK, they contain two kinase domains in a single polypeptide. Mice lacking MSK1 or MSK2, and also a double knockout of both MSK1 and MSK2, are viable and fertile, but show enhanced inflammation in immune models as well as impairments in some models of memory⁹.

MAP kinase-interacting kinases 1 (MNK1; EC 2.7.11.1) and MNK2, two related MAP kinase-activated protein kinases that are able to integrate signals emanating from both MAP kinase pathways and to phosphorylate eIF4E, were identified recently. Both MNK1 and MNK2 bind tightly to the growth factor-regulated MAP kinases, Erk1 and Erk2, and MNK1, but not Mnk2, also binds strongly to the stress-activated kinase, p38¹⁰. Since MNK1 was found to be a member of the eIF4F complex by binding to the molecular scaffolding protein eIF4G, it represents a likely candidate to be the biological relevant kinase for the cap-binding eukaryotic initiation factor 4E in mitogen- and stress-induced cells¹¹.

Serum and glucocorticoid-regulated kinase 1 (SGK1; EC 2.7.11.1) belongs to a family of kinases that is under acute transcriptional control by several stimuli, including serum and glucocorticoids. It is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. As such, SGK1 plays an important role in cellular stress response. SGK1 is activated by the phosphatidylinositol-3-kinase (PI3-kinase) pathway involving the 3-phosphoinositide (PIP3)-dependent kinase PDK1. Additionally, activation of SGK1 may involve the scaffold protein Na⁺/H⁺ exchanger regulating factor 2 (NHERF2), which mediates the assembly of SGK1 and PDK1. Activation of SGK1 by PDK1 may further involve the mammalian target of rapamycin mTOR and the serine/threonine kinase WNK1. SGK1 has been implicated in renal function and salt appetite, hypertension, extracellular volume regulation, obesity and metabolic syndrome, tumor growth, inflammation, and fibrosis disease¹².

Serine-arginine protein kinases (SRPKs; EC 2.7.11.1) constitute a relatively novel subfamily of serine-threonine kinases that specifically phosphorylate serine residues residing in serine-arginine/arginine-serine dipeptide motifs. Originally considered to be devoted to constitutive and alternative mRNA splicing, SRPKs are now known to expand their influence to additional steps of mRNA maturation, as well as to other cellular activities, such as chromatin reorganization in somatic and sperm cells, cell cycle and p53 regulation, and metabolic signalling¹³.

Haspin is a serine/threonine kinase that phosphorylates Thr-3 of histone H3 in mitosis. This phosphorylation generates a binding site on H3 for Survivin and thereby positions the Chromosome Passenger Complex at centromeres to regulate chromosome segregation, and it also displaces proteins such as TFIID that normally bind to H3 through methylated Lys-4. Depletion of haspin by RNA interference, or microinjection of H3T3p antibodies, causes chromosome alignment defects and failure of normal mitosis. Haspin kinase inhibitors are expected to be useful probes for elucidating the cellular roles of this protein and may have therapeutic utility in treating cancer¹⁴.

Cell division cycle 7 kinase (CDC7; EC 2.7.11.1), is important for both the G1/S phase transition and S phase progression and critical for normal cell cycle progression. It has several structure/function relationships with the CDKs, making it an important target for pharmacological inhibition. Two important regulator proteins, Dbf4 and Drf1, bind to and modulate the kinase activity of human CDC7 which phosphorylates several sites on Mcm2 (minichromosome maintenance protein 2), one of the six subunits of the replicative DNA helicase needed for duplication of the genome. Through regulation of both DNA synthesis and DNA damage response, both key functions in the survival of tumour cells, CDC7 becomes an attractive target for pharmacological inhibition. XL 413 (Axon 2268) is such a potent, selective and orally bioavailable CDC7 inhibitor that induces tumor cell apoptosis and inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells¹⁵.

The single branched-chain α -ketoacid dehydrogenase complex (BCKDC) in mitochondria catalyzes the irreversible oxidative decarboxylation of branch-chain α -ketoacids (BCKA), the second common step in the degradation of branched-chain amino acids (BCAA) leucine, isoleucine, and valine. The homeostasis of BCAA is critical in health and disease, participating in the reduction oxidative stress, which in turn promotes survival in rats with advanced liver cirrhosis and supports mitochondrial biogenesis in cardiac and skeletal muscle. In patients with inherited maple syrup urine disease (MSUD), the accumulation of BCAA and BCKA caused by the dysfunction of BCKDC leads to sometimes fatal acidosis, neurological derangement, and mental retardation. Additionally, high blood BCAA concentrations are linked to the development of insulin resistance and are useful metabolic markers in type 2 diabetes risk assessment¹⁶. Branched-chain α -keto acid dehydrogenase kinase (BDK; EC 2.7.11.4) is one of the regulating enzymes of BCKDC (BDP; EC 3.1.3.16 is the other enzyme), and phosphorylates and inactivates the BCKDC. The inactivation of BCKDC through phosphorylation by BDK results in increased BCAA concentrations in animal tissues. Therefore, modulation of BDK activity constitutes a major mechanism for BCAA homeostasis *in vivo*¹⁷.

The p21-activated kinases (PAKs 1-6; EC 2.7.11.1) are serine/threonine protein kinases whose activity is stimulated by the binding of active Rac and Cdc42 GTPases, both members of the Rho GTPase family of proteins, which are well established key regulators of cell migration and invasion processes involved in cancer metastasis, and control the formation of lamellipodia and filopodia respectively. The GTPase-activated PAKs function as effectors through their kinase activity, and mediate downstream signalling events that bring about the physiological effects of GTPase signalling¹⁸. PAK1 acts as an key mediator to control cell proliferation, survival, death and motility. The PAK family members are categorized into two groups (PAK1-3, group I; PAK4-6, group II) based on their structural and biochemical discrepancies. In general, group I PAKs are comprised of two Src homology 3 (SH-3)-binding motifs and a distinctive p21/GTPase binding domain (PBD) overlapped with an auto-inhibitory domain (AID) at the N-terminal region and a conserved non-classical SH3-binding site for the binding of guanine-nucleotide-exchange factor PAK-interacting exchange factor (PIX). The kinase domain can be found at the C-terminal. In contrast, group II PAKs only have a PBD and a kinase domain¹⁹.

Traf2 and Nck interacting kinase (TNIK; EC 2.7.11.1) is a protein with both scaffolding and kinase domains that had been implicated in postsynaptic signalling (glutamate receptor regulation *in vitro*) as well as in regulation of cell proliferation. As a member of the germinal centre kinase family, TNIK can activate the c-Jun N-terminal kinase pathway similar to many germinal center kinases (GCKs). Moreover, the protein has been implicated in Wnt signaling, as it interacts with TCF4 in the proliferative crypts of mouse small intestine, functioning as a transcriptional activator to promoters of Wnt target genes in a β -catenin-dependent manner²⁰. As such, TNIK also seems to be an important factor in the growth of colorectal cancer cells²¹. In the nervous system, phosphorylation of TNIK seems to be regulated by the activation of NMDA receptors, and I has also been implicated in controlling dendritic outgrowth mediated by a ternary complex involving the E3 ubiquitin ligase Nedd4-1, Rap2A and TNIK. Therefore, the kinase could also play a role in cognitive functions through both synaptic and nuclear signalling pathways²².

Germinal center kinases (GCKs; EC 2.7.11.1) are a family of 'Sterile 20 (STE20) like kinases', that regulate cell proliferation and apoptosis upon extracellular stimuli. They are mitogen-activated protein kinase (MAPK) kinase kinases that are termed MAP4Ks and function as upstream activators of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway²³. MAP4K2 is reported to play an essential role in pathogen-associated molecular pattern signaling and systemic inflammation. Upon pathogen-associated molecular pattern stimulation, MAP4K2 can form a complex with tumor-necrosis factor receptor associated factor 6 and mixed lineage protein kinase 3, which stabilize MAP4K2 to activate JNK/p38 for competent innate immune response²⁴.

Kinase suppressor of Ras (KSR; EC 2.7.11.25) is a MAPK scaffold that is subject to allosteric regulation through dimerization with RAF. While deregulation of the Ras-mitogen activated protein kinase (MAPK) pathway is an early event in many different cancers and a key driver of resistance to targeted therapies, direct targeting of KSR could have important therapeutic implications for cancer. However, due to its status as a pseudokinase and role as a non-catalytic regulator of core signalling enzymes, pharmacological approaches that target KSR have been lacking. This is in contrast to current drug discovery and development efforts that have focused extensively on direct inhibitors of the Ras effector kinases RAF, MEK, and ERK²⁵.

¹ Therapeutic Protein Kinase Inhibitors. S. K. Grant. Cell. Mol. Life Sci. 2009, 66, 1163 – 1177.

² B Shi et al. Dysfunction of endocytic kinase AAK1 in ALS. Int J Mol Sci. 2014 Dec 10;15(12):22918-32.

³ W Kostich et al. Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain. J Pharmacol Exp Ther. 2016 Sep;358(3):371-86.

⁴ R Tourdot et al. Clathrin mediated endocytosis and its role in viral entry. Atlas Genet Cytogenet Oncol Haematol. 2013; 17(8), 583-588

⁵ N Gupta-Rossi et al. The adaptor-associated kinase 1, AAK1, is a positive regulator of the Notch pathway. J Biol Chem. 2011 May 27;286(21):18720-30.

6	LC Griffith. Calcium/calmodulin-dependent protein kinase II: an unforgettable kinase. <i>J Neurosci.</i> 2004 Sep 29;24(39):8391-3.	
7	T Yamauchi. Neuronal Ca2+/calmodulin-dependent protein kinase II—discovery, progress in a quarter of a century, and perspective: implication for learning and memory. <i>Biol Pharm Bull.</i> 2005 Aug;28(8):1342-54.	
8	R.W. Scott et al. LIM kinases: function, regulation and association with human disease. <i>J. Mol. Med.</i> 2007, 85, 555-568.	
9	S. Naqvi et al. Characterization of the cellular action of the MSK inhibitor SB-747651A. <i>Biochem J.</i> 2012, 441(1), 347-357.	
10	A.J. Waskiewicz et al. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. <i>EMBO J.</i> 1997, 16, 1909-1920.	
11	U. Knauf et al. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. <i>Mol. Cell Biol.</i> 2001, 21(16), 5500-5511.	
12	F. Lang et al. The physiological impact of the serum and glucocorticoid-inducible kinase SGK1. <i>Curr. Opin. Nephrol. Hypertens.</i> 2009, 18, 439-448.	
13	T. Giannakouros et al. Serine-arginine protein kinases: a small protein kinase family with a large cellular presence. <i>FEBS J.</i> 2011, 278, 570-586.	
14	GD Cuny et al. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. <i>Bioorg. Med. Chem. Lett.</i> 2012, 22, 2015-2019.	
15	R. Swords et al. Cdc7 kinase - a new target for drug development. <i>Eur. J. Cancer.</i> 2010, 46, 33-40.	
16	S.C. Tso et al. Benzothioephene carboxylate derivatives as novel allosteric inhibitors of branched-chain α -ketoacid dehydrogenase kinase. <i>J. Biol. Chem.</i> 2014, 289, 20583-20593.	
17	S.C. Tso et al. Structure-based design and mechanisms of allosteric inhibitors for mitochondrial branched-chain α -ketoacid dehydrogenase kinase. <i>Proc. Natl. Acad. Sci. USA.</i> 2013, 110, 9728-9733.	
18	R. Kumar et al. p21-activated kinases in cancer. <i>Nat Rev Cancer.</i> 2006 Jun;6(6):459-71.	
19	E.Y. Tse et al. The role of p21-activated kinases in hepatocellular carcinoma metastasis. <i>J Mol Signal.</i> 2014 Aug 1;9:7.	
20	T. Mahmoudi et al. The kinase TNK1 is an essential activator of Wnt target genes. <i>EMBO J.</i> 2009 Nov 4;28(21):3329-40.	
21	M. Shitashige et al. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. <i>Cancer Res</i> 2010; 70: 5024–5033.	
22	M.P. Coba et al. TNK1 is required for postsynaptic and nuclear signaling pathways and cognitive function. <i>J Neurosci.</i> 2012 Oct 3;32(40):13987-99.	
23	H. Yin et al. Germinal center kinases in immune regulation. <i>Cell Mol Immunol.</i> 2012 Nov;9(6):439-45.	
24	J. Zhong et al. GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38. <i>Proc Natl Acad Sci U S A.</i> 2009 Mar 17;106(11):4372-7.	
25	NS Dhawan et al. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. <i>Nature.</i> 2016 Aug 24;537(7618):112-116.	
2720	A-92 Inhibitor of GCN2 (EIF2AK4) Page 196	
2611	APS-2-79 Inhibitor of KSR and oncogenic Ras signaling Page 243	
3041	ARN 3236 Potent, selective, ATP-competitive, and orally available inhibitor of SIK2 Page 248	
2669	AZ13705339 Potent and selective PAK1 inhibitor Page 266	
3832	BAY-1816032 Potent and selective BUB1 (Mitotic checkpoint serine/threonine-protein kinase) inhibitor Page 287	
2334	BT2 Allosteric inhibitor of BCKDC kinase (BDK) and Mcl-1 Page 331	
3350	BX 795 hydrochloride PDPK1, TBK1 and IKK inhibitor Page 0335	
3700	CaMKII α inhibitor compound 4d Ca2+/calmodulin-dependent protein kinase II α (CaMKII α) inhibitor Page 341	
1611	CGP 57380 Mnk1 inhibitor Page 362	
2250	CHR 6494 trifluoroacetate Specific, first-in-class inhibitor of histone kinase Haspin Page 368	
3200	DCLK1-IN-1 Potent, selective and orally bioavailable DCLK1/2 inhibitor Page 414	
4128	EMD638683 Selective SGK1 inhibitor Page 456	
3340	ETC-206 Potent, selective and orally available MNK1/2 inhibitor Page 468	
2331	FRAX 486 Brain penetrating inhibitor of p21-activated kinases (PAKs) Page 492	
3917	GLPG2534 Potent, selective and orally active IRAK4 inhibitor Page 505	
2713	GSK 2982772 Specific inhibitor of RIP1 kinase Page 524	
3895	GSK329 Highly potent and selective TNK1 inhibitor Page 521	
1570	GSK 650394 SGK1 Inhibitor Page 525	
3007	GSK 8612 Potent and highly selective TBK1 inhibitor Page 526	
3024	GSK*872 Potent and selective RIP3 kinase inhibitor Page 526	
2311	HG-9-91-01 Potent and selective SIK inhibitor Page 541	
3217	HS-243 Highly potent and selective IRAK-1/4 inhibitor Page 546	
4235	IRAK1/4 inhibitor 1 Recent Addition Potent IRAK-1/4 inhibitor Page 569	
2566	KN 93 Inhibitor of multifunctional CaMKII Page 593	
2555	KN 93 phosphate Inhibitor of multifunctional CaMKII Page 593	
3557	KPT-9274 Orally bioavailable dual PAK4/NAMPT inhibitor Page 595	

2395	KY 05009 Inhibitor of TNK1 that attenuates Wnt and Smad signaling Page 600
1949	LIMK1 inhibitor BMS 4 LIM Kinase 1 (LIMK1) inhibitor Page 614
3780	LMTK3 inhibitor C28 Potent LMTK3 inhibitor Page 617
2638	LP-935509 Brain penetrant inhibitor of (AAK1) Page 621
3843	LYN-1604 dihydrochloride Potent ULK1 agonist Page 635
2728	NCL-00017509 Nek2 kinase inhibitor Page 695
3571	NMM NAD+ precursor Page 707
3961	PF-03758309 Potent and ATP-competitive inhibitor of p21-activated kinase (PAK4) Page 760
2545	PF 06260933 dihydrochloride Potent and selective MAP4K4 inhibitor Page 770
2232	PKG drug G1 Inducer of oxidative activation of protein kinase G I α Page 782
2905	PKG drug G1 sodium salt Inducer of oxidative activation of protein kinase G I α Page 782
3676	PKN3 inhibitor compound 16 Potent, cell-active protein kinase novel 3 (PKN3) inhibitor Page 783
2677	RIPA-56 RIP1 inhibitor for the treatment of systemic inflammatory response syndrome Page 820
4249	Salubrinal Recent Addition Selective eIF2 α dephosphorylation inhibitor Page 842
1897	SB 747651A Inhibitor of MSK1 Page 851
3395	SGC-STK17B-1 Potent, selective and ATP-competitive STK17B inhibitor Page 864
2714	SPHINX31 Potent and selective inhibitor of SRPK1 kinase activity Page 883
2200	SRPIN 340 Selective ATP competitive inhibitor of SRPK kinase activity Page 890
2721	T56-LIMKi LIM Kinase 2 (LIMK2) inhibitor Page 903
3282	Takinib Potent and selective TAK1 (MAP3K7) inhibitor Page 908
2973	TH 257 Selective allosteric inhibitor of LIMK1/2 Page 922
2974	TH 263 Negative control of TH 257 as an allosteric LIMK1/2 inhibitor Page 923
3810	TPP-UNC-CA157 Highly specific and potent COQ8 inhibitor Page 938
3276	TRULI LATS1/2 inhibitor Page 941
2896	WNK Inhibitor 11 Selective allosteric inhibitor of WNK1 Page 986
2268	XL 413 hydrochloride Potent, selective and orally bioavailable CDC7 inhibitor Page 994
4239	Z29077885 Recent Addition Potent STK33 inhibitor; Antiviral agent Page 1002
4142	Z29077885 hydrochloride Recent Addition Potent STK33 inhibitor; Antiviral agent Page 1002
2937	ZT-12-037-01 Specific STK19 inhibitor Page 1010

Enzymes (EC 2.7.11.) Kinases, ATM/ATR

Ataxia telangiectasia mutated (ATM; EC 2.7.11.1) kinase recognizes and signals to double-strand breaks (DSB), which are among the most critical lesions in chromosomal DNA^{1,2}. ATM is present in the nucleus as an inactive dimer or oligomer, and is activated in response to DSBs in a process that involves autophosphorylation. This causes a dissociation of the dimer to form active monomeric forms, which are able to initiate the phosphorylation of many intermediates, such as p53 and the checkpoint kinase CHK2, which are involved in DNA repair and cell-cycle control³. Similar to ATM, the ataxia-telangiectasia and Rad3-related (ATR; EC 2.7.11.1) protein and the DNA-activated protein kinase (DNA-PK) play an important role in responding to agents and extracellular stress that threaten the DNA replication process⁴. Both ATM and ATR kinases lie upstream in the DNA-damage-response signal-transduction network and are central to the entire DNA-damage response; they will be discussed in the corresponding section as well.

¹ DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. U Moll, R Lau, MA Sypes, MM Gupta, CW Anderson. *Oncogene* 1999, 18, 3114-3126.

² ATM and the DNA damage response. Workshop on ataxia-telangiectasia and related syndromes. Lavin MF, Delia D, Chessa L. *EMBO Rep.* 2006, 7, 154-160.

³ DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Bakkenist CJ, Kastan MB. *Nature.* 2003, 421, 499-506.

⁴ ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. J Yang, Y Yu, H Hamrick, PJ Duerksen-Hughes. *Carcinogenesis* 2003, 24, 1571-1580.

2345	AZ 20 Potent, orally active inhibitor of ATR protein kinase Page 264
------	--

4140	AZD0156	<i>Selective and orally active ATM inhibitor</i>	Page 267
3134	AZD6738	<i>Potent, selective, orally active and bioavailable ATR kinase inhibitor</i>	Page 278
2918	BAY 1895344	<i>Potent, orally available and highly selective inhibitor of ATR protein kinase</i>	Page 288
1495	CP 466722	<i>ATM inhibitor</i>	Page 389
1367	KU 55933	<i>ATM inhibitor</i>	Page 597
1893	VE 821	<i>Inhibitor of the DNA damage response kinase ATR</i>	Page 964
2452	VE 822	<i>ATR inhibitor with cytotoxicity for pancreatic cancer cells</i>	Page 964

Enzymes (EC 2.7.11.) Kinases, Aurora

The Aurora kinase family (EC 2.7.11.1) is a collection of highly related serine/threonine kinases that functions as a key regulator of mitosis, essential for accurate and equal segregation of genomic material from parent to daughter cells. As a result, they play a central role in cell cycle regulation¹. Three related kinases known as Aurora-A, Aurora-B, and Aurora-C have been characterized over the years. Despite significant sequence homology, the localization and functions of these kinases are largely distinct from one another. Given the association of Aurora overexpression and tumorigenesis, these kinases have been targeted for cancer therapy, and a new class of drugs known as Aurora kinase inhibitors has been developed^{2,3}.

¹ Mitotic kinases as regulators of cell division and its checkpoints. E.A. Nigg. Nat. Rev. Mol. Cell Biol. 2001, 2, 21–32.

² Aurora kinases. V.M. Bolanos-Garcia. Int. J. Biochem. & Cell Biol. 2005, 37, 1572–1577

³ Aurora Kinases: New Targets for Cancer Therapy. R.D. Carvajal, A. Tse, G.K. Schwartz. Clin. Cancer Res. 2006, 12, 6869.

1783	AMG 900	<i>Aurora inhibitor (non-specific)</i>	Page 226
3408	AKI603	<i>Inhibitor of Aurora A kinase</i>	Page 216
2219	AT 9283	<i>Multitargeted kinase inhibitor (Aurora, JAK, and BCR-Abl)</i>	Page 257
1597	Aurora A inhibitor I	<i>Aurora A inhibitor</i>	Page 259
1630	Aurora A inhibitor II	<i>Aurora A inhibitor</i>	Page 261
1580	AZD 1152-HQPA	<i>Aurora B inhibitor</i>	Page 268
1836	CCT 137690	<i>Aurora inhibitor (non-specific)</i>	Page 351
4073	CYC-116	<i>Aurora kinases A & B and VEGFR2 inhibitor</i>	Page 402
1152	GMC 1-165	<i>Aurora B inhibitor</i>	Page 507
3920	GSK1070916	<i>Potent, selective and ATP competitive inhibitor of Aurora B and C kinases</i>	Page 517
2096	Hesperadin	<i>Reversible and ATP-competitive inhibitor of Aurora B</i>	Page 540
3758	LY-3295668	<i>Orally available, potent and highly selective Aurora A kinase (AurA) inhibitor</i>	Page 628
1961	MK 5108	<i>Inhibitor of Aurora A kinase</i>	Page 661
2003	MLN 8237	<i>Second generation selective Aurora A inhibitor</i>	Page 674
2023	PF 03814735	<i>ATP-competitive inhibitor of aurora kinase A and B</i>	Page 767
2906	SNS 314 mesylate	<i>Potent and selective Aurora inhibitor (non-specific)</i>	Page 876
1540	VX 680	<i>Aurora inhibitor (non-specific)</i>	Page 980
1541	ZM 447439	<i>Aurora B inhibitor</i>	Page 1009

Enzymes (EC 2.7.11.) Kinases, CHK

Mammalian cells have established highly elaborate surveillance systems to detect DNA damages and other forms of genotoxic stress, which is essential to maintain the genomic integrity and, hence, cellular viability. In normal cells, checkpoint responses are a critical safeguard to prevent tumorigenesis promoted by genetic instability. Two structurally unrelated but functionally similar protein serine/threonine kinases, checkpoint kinase 1 (CHK1; EC 2.7.11.1) and checkpoint kinase 2 (CHK2), have emerged as the major mediators of cell cycle checkpoints in response to genotoxic stress¹. CHK1 is a checkpoint kinase in mammals and regulates G2–M and S-phase cell-cycle checkpoints. It is expressed in the S and G2 phases of proliferating cells and is absent or expressed at very low levels in quiescent and differentiated cells. CHK1 is

activated by phosphorylation in response to various types of DNA damage in mammals, including damage that is induced by IR, ultraviolet (UV) light, hydroxyurea (HU) and topoisomerase inhibitor. Although structurally distinct, CHK2 shares overlapping substrate specificity with CHK1. The observations that CHK2 is rapidly activated following exposure to IR or topotecan, whereas CHK1 is markedly activated by agents that interfere with DNA replication, have led to the idea that cell-cycle progression is blocked by CHK1 when replication is inhibited, and by CHK2 when double-strand breaks (DSBs) are present².

¹ Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Z. Xiao, J. Xue, T.J. Sowin, H. Zhang. Mol. Cancer. Ther. 2006, 5, 1935–1943.

² Targeting the checkpoint kinases: chemosensitization versus chemoprotection. B.B.S. Zhou, J. Bartek. Nat. Rev. Cancer 2004, 4, 216–225.

1399	AZD 7762 hydrochloride	<i>CHK inhibitor</i>	Page 275
4264	ART-446 Recent Addition	<i>Potent CHK2 inhibitor</i>	Page 249
3932	CCT-245737	<i>Orally active, potent and selective CHK1 inhibitor</i>	Page 352
1636	CHIR 124	<i>CHK1 inhibitor</i>	Page 365
4145	LY2606368 mesylate	<i>Potent and selective ATP competitive inhibitor of the CHK protein kinase</i>	Page 627
1379	PF 477736	<i>CHK1 inhibitor</i>	Page 763
3828	SCH900776 dihydrochloride	<i>Potent, selective and orally bioavailable inhibitor of CHK1</i>	Page 857

Enzymes (EC 2.7.11.) Kinases, CK

The casein kinase 1 (CK1; EC 2.7.11.1) family of monomeric serine/threonine protein kinases is involved in many diverse and important cellular functions, such as regulation of membrane transport, cell division, DNA repair, circadian rhythms, and nuclear localization. Moreover, multiple CK1 family members have been implicated in both positively and negatively regulating Wnt and Hedgehog (Hh) signaling. No less than seven family members are currently recognized: α , β , γ 1, γ 2, γ 3, δ , and ϵ . The family members appear to have similar substrate specificity in vitro, and substrate selection is thought to be regulated in vivo via subcellular localization and docking sites in specific substrates¹. CK1 α , CK1 δ , and CK1 ϵ are all known to play roles in modulating circadian rhythms. CK1 δ and CK1 ϵ phosphorylate PER and trigger its proteasomal degradation; mutations in each affect the clock in vivo². Additionally, CK1 δ plays an important role in vesicular trafficking, chromosome segregation, cell cycle progression, cytokinesis, and developmental processes³. Indicative of potential roles in microtubule organization, CK1 δ mediates neurite outgrowth and the function of brain-specific microtubule-associated proteins⁴.

CK2 is a ubiquitous, highly pleiotropic and constitutively active Ser/Thr protein kinase, independent of either second messengers or phosphorylation events. It has been implicated in neoplasia, cell survival, apoptosis, and virus infection. CK2 consists of a tetrameric structure composed of two regulatory β -subunits and two catalytic units (α and α') in a homomeric or heteromeric conformation. The enzyme is known to operate as phosphorylating agent for more than 300 substrates known to date⁵. Casein kinase 2 activity has been reported to be activated following Wnt signaling pathway activation, hence the Axon Ligands™ discussed in this section will also be listed in the section of the Wnt/ β -catenin signaling pathway.

¹ CK1, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. M.A. Price. Genes & Dev. 2006, 20, 399–410.

² J.W. Lee et al. A small molecule modulates circadian rhythms through phosphorylation of the period protein. Angew. Chem. Int. Ed. Engl. 2011, 50, 10608–10611.

³ T. Maritzen et al. Casein kinase I delta (CK1delta) is involved in lymphocyte physiology. Eur. J. Cell Biol. 2003, 82, 369–378.

⁴ D. Zyss et al. Casein kinase I delta controls centrosome positioning during T cell activation. J. Cell Biol. 2011, 195, 781–797.

⁵ One-thousand-and-one substrates of protein kinase CK2? F. Meggio, L.A. Pinna. FASEB J. 2003, 17, 349–368.

2717	Apigenin	<i>Selective inhibitor of Casein kinase 2 (CK2)</i>	Page 241
2202	CK2 inhibitor 10	<i>Potent and ATP-competitive inhibitor of CK2</i>	Page 374
3279	CKI-7 dihydrochloride	<i>Selective inhibitor of Casein kinase 1</i>	Page 375
1965	CX 4945 hydrochloride	<i>Inhibitor of casein kinase 2 (CK2)</i>	Page 399
4056	DYRK1A inhibitor compound 11	<i>Highly selective and ligand-efficient Dyrk1A inhibitor</i>	Page 446
2970	GSK626616	<i>Potent, orally bioavailable inhibitor of DYRK3</i>	Page 525
3627	Harmine	<i>Potent, selective and ATP-competitive DYRK1A inhibitor</i>	Page 539
3538	INDY	<i>Potent, selective and ATP-competitive inhibitor of Dyrk1A</i>	Page 566
2297	LH 846	<i>Inhibitor of Casein kinase 1 (CK1-δ)</i>	Page 614
2998	Longdaysin	<i>Potent CK1δ/CK1α inhibitor</i>	Page 619

1792	PF 4800567	Inhibitor of Casein kinase 1 (CK1-epsilon)	Page 765
3540	ProINDY	Prodrug of INDY; Dyrk1A inhibitor	Page 792
2547	SR 3029	A potent, highly specific CK1δ/CK1ε inhibitor	Page 886
1854	TTP 22	Inhibitor of Casein kinase 2 (CK2)	Page 942

Enzymes (EC 2.7.11.) Kinases, DNA-PK

DNA-activated protein kinase (DNA-PK; EC 2.7.11.1) plays an important role in responding to agents and extracellular stress that threaten the DNA replication process¹. It is a nuclear protein serine/threonine kinase that must bind to DNA double-strand breaks (DSB) to be active. The nonhomologous end-joining (NHEJ) pathway is considered the main pathway for DSB repair in mammalian cells, and is initiated by binding of DNA-dependent protein kinase (DNA-PK) regulatory subunits to free DNA ends, followed by recruitment of the DNA-dependent kinase catalytic subunit protein (DNA-PKcs) to DSBs. This assembly results in DNA-PK kinase activation. The DNA-PK complex serves as a platform that holds both DNA ends together and orchestrates DNA processing and ligation². DNA-PK inhibiting Axon Ligands™ are also listed in the section of the DNA-damage response.

¹ ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. J Yang, Y Yu, H Hamrick, PJ Duerksen-Hughes. Carcinogenesis 2003, 24, 1571-1580.

² Essential role for DNA-PK-mediated phosphorylation of NR4A nuclear orphan receptors in DNA double-strand break repair. M. Malewicz et al. Genes & Dev. 2011, 25, 2031-2040.

4068	AZD7648	DNA-PK inhibitor	Page 275
1584	KU 0060648 trihydrochloride	DNA-PK inhibitor	Page 598
2604	KU 0060648	DNA-PK inhibitor	Page 598
3577	M-3814	DNA-PK inhibitor	Page 638
1463	NU 7441	DNA-PK inhibitor	Page 719

Enzymes (EC 2.7.11.) Kinases, IRE1

Inositol-requiring enzyme 1 (IRE1; EC 2.7.11.1) is an endoplasmic reticulum (ER) transmembrane sensor that activates the unfolded protein response (UPR) through a cytoplasmic kinase domain and an RNase domain to maintain the ER and cellular function¹. On ER stress, IRE1 RNase is activated through conformational change, autophosphorylation, and higher-order oligomerization. The active endoribonuclease domain splices XBP1 mRNA to generate a new C-terminus, converting it into a potent unfolded-protein response transcriptional activator and triggering growth arrest and apoptosis².

¹ IRE1: ER stress sensor and cell fate executor. Y. Chen, F. Brandizzi. Trends Cell Biol. 2013, pii, S0962-8924

² A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. W. Tirasophon, A.A. Welihinda, R.J. Kaufman. Genes Dev. 1998, 12, 1812-1824.

1902	4μ8C	IRE1-alpha inhibitor	Page 189
1656	Irestatin 9389	IRE1 inhibitor; UPR inhibitor	Page 570
4087	IXA4	Highly selective IRE1/XBP1s activator	Page 575
3670	MKC-3946	Potent and selective IRE1α inhibitor	Page 663
3223	MKC8866	Potent IRE1α inhibitor	Page 663
1670	STF 083010	IRE1-alpha inhibitor	Page 895

Enzymes (EC 2.7.11.) Kinases, LRRK

Leucine-rich repeat kinase 2 (LRRK2; EC 2.7.11.1) is a promising therapeutic target for some forms of Parkinson's disease. because of a missense mutation, G2019S, that is frequently found not only in familial but also sporadic Parkinson's disease cases. The LRRK2 G2019S mutation enhances kinase activity, suggesting that small molecule inhibitors may be able to block aberrant LRRK2-dependent signaling in Parkinson's disease¹. However, the physiological function of LRRK2 kinase as well as its endogenous protein substrates remains poorly understood. There have been several papers describing potential cellular substrates as well as endogenous functions for this complex protein in the mammalian neuron. Potential substrates include ezrin, radixin moesin (ERM) proteins, mitogen-activated protein kinase (MAPK), eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP), futsch, autophosphorylation, and 14-3-3 proteins².

¹ A.D. Reith et al. GSK2578215A; a potent and highly selective 2-arylmethoxy-5-substituent-N-arylbzamide LRRK2 kinase inhibitor. Bioorg. Med. Chem. Lett. 2012, 22, 5625-5629.

² R.E. Drolet et al. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions. J. Neurogenet. 2011, 25, 140-151.

2348	GNE 7915	Potent, selective, and brain-penetrable LRRK2 inhibitor	Page 509
2181	GSK 2578215A	Potent and highly selective LRRK2 inhibitor	Page 529
2493	LRRK2-IN-1	Potent, ATP-competitive and selective inhibitor of LRRK2	Page 623
2546	PF 06447475	Selective, brain penetrant, LRRK2 kinase inhibitor	Page 770

Enzymes (EC 2.7.11.) Kinases, mTOR

The mammalian target of rapamycin (mTOR; EC 2.7.11.1), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to energy, nutrients, growth factors and other environmental cues, and it figures prominently in cancer. It belongs to the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family. mTOR assembles into two complexes with distinct inputs and downstream effects. mTOR complex 1 (mTORC1) is defined by its Raptor subunit which is replaced by Rictor in mTOR complex (mTORC2).

mTORC1 regulates cell growth by promoting translation, ribosome biogenesis and autophagy. Its activation requires nutrients and amino acids, which result in the Raptor-mediated recruitment of mTORC1 to lysosomes and late endosomes, and co-localization with its activator, the small GTPase Rheb. mTORC1 substrates include the eIF4E-binding protein 1 (4E-BP1) and ribosomal S6 kinases (S6K).

mTORC2 responds primarily to growth factors, promoting cell-cycle entry, cell survival, actin cytoskeleton polarization and anabolic output. Its substrates include the Ser/Thr protein kinases Akt, SGK and PKC, which share the hydrophobic motif phosphorylation site with S6K1.

Noteworthy, rapamycin, which forms a ternary complex with the FK506-binding protein 12 (FKBP12) and the FRB domain of mTOR, is thought to be an allosteric inhibitor. Rapamycin-FKBP12 inhibits mTORC1 to a variable extent that is substrate and phosphorylation-site dependent, while it does not bind to mTORC2^{1,2}.

Axon Ligands™ that block mTOR activity are also listed in the section for PI3K/AKT/mTOR signaling.

¹ mTOR kinase structure, mechanism and regulation. H. Yang et al. Nature 2013, 497, 217-223.

² mTOR: a protein kinase switching between life and death. L. Asnagli, P. Bruno, M. Priulla, A. Nicolini. Pharmacol. Res. 2004, 50, 545-549.

3996	AZD2014	Orally bioavailable dual mTORC1/mTORC2 inhibitor	Page 269
1561	AZD 8055	mTOR inhibitor	Page 276
1281	BEZ 235	Dual PI3K and mTOR kinase inhibitor	Page 299
2630	eCF309	Highly selective and potent inhibitor of mTOR signalling	Page 450
4149	Everolimus	Selective and orally active mTOR1 inhibitor	Page 471
3584	GDC-0084	Brain-penetrant dual PI3K and mTOR inhibitor	Page 498
1782	GDC 0980	Dual PI3K and mTOR inhibitor	Page 499
1596	GSK 2126458	Dual PI3K and mTOR inhibitor	Page 528
2142	INK 128	Potent and selective mTOR inhibitor	Page 567
1472	KU 0063794	mTOR inhibitor	Page 598
2425	MHY 1485	mTOR activator with an inhibitory effect on autophagy	Page 654
3628	MHY-1685	mTOR inhibitor; Senescence inhibitor	Page 653
1520	NVP-BBD130	Dual PI3K and mTOR kinase inhibitor	Page 722
2029	NVP-BGT226	Orally active dual PI3K/mTOR inhibitor	Page 723
1718	Palomid 529	mTOR inhibitor	Page 746
1807	PKI 587	Dual PI3K and mTOR inhibitor	Page 781
2069	Rapamycin	Specific inhibitor of mTOR; binds to FKBP12	Page 807
1699	Temsirolimus	mTOR inhibitor	Page 918
1833	Torin 1	mTOR inhibitor	Page 936
1834	Torin 2	mTOR inhibitor	Page 937

2951	XL 388	Highly potent, selective, ATP-competitive, and orally bioavailable mTOR inhibitor	Page 994
4009	XL-765	Potent and selective PI3K / mTORC inhibitor	Page 994
1706	XL PI3K/mTOR inhibitor	Dual PI3K and mTOR kinase inhibitor	Page 995

Enzymes (EC 2.7.11.) Kinases, PERK

Protein kinase RNA-like endoplasmic reticulum kinase (PERK; EC 2.7.11.1) is a type I ER membrane protein and one of three (next to IRE1 and ATF6) primary effectors of the unfolded protein response (UPR), which has a demonstrated role in tumor growth and angiogenesis. Increase in unfolded proteins in the ER causes release of ER chaperones from the stress-sensing domain of PERK, which results in its activation via oligomerization and autophosphorylation at multiple serine, threonine, and tyrosine residues. Upon activation, PERK phosphorylates eukaryotic initiation factor 2 α (eIF2 α), rendering it an inhibitor of the ribosome translation initiation complex, consequently reducing overall protein synthesis. The reduction in translation reduces the ER burden, providing time for the cell to process or degrade the accumulated unfolded proteins to restore ER homeostasis¹.

¹ J.M. Axten et al. Discovery of 7-methyl-5-(1-([3-(trifluoromethyl)phenyl]acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). *J. Med. Chem.* 2012, 55, 7193-7207.

2233	GSK 2606414	Potent and selective inhibitor of PERK (EIF2AK3)	Page 529
2278	ISRIB	Inhibitor of integrated stress response and PERK signaling	Page 572

Enzymes (EC 2.7.11.) Kinases, Pim

Pim-1, 2 and 3 (EC 2.7.11.1) make up a distinct and highly homologous family of serine/threonine kinases belonging to the Ca²⁺/calmodulin-dependent protein kinase-related (CAMK) family. Pim proteins are widely expressed with high levels in hematopoietic tissue and are aberrantly expressed in a variety of human malignancies. These proteins are considered to be constitutively active and, therefore, regulated by expression and proteosomal degradation. Gene transcription is initiated by a wide range of cytokines, mitogens and growth factors that transduce signals via the Janus kinase-signal transducers and regulators of transcription (JAK/STAT) pathway, thereby regulating Pim expression¹. Pim kinases play a major role in cell cycle regulation, anti-apoptotic activity and the homing and migration of receptor tyrosine kinases mediated via the JAK/STAT pathway. The discovery of these kinases being up-regulated in many hematological malignancies and solid tumors affords them therapeutic opportunities in oncology².

¹ Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. C. Blanco-Aparicio, A. Carnero. *Biochem. Pharm.* 2013, 85, 629-643.

² Pim kinase inhibitors: a survey of the patent literature. T. Morwick. *Expert Opin. Ther. Pat.* 2010, 20, 193-212.

2795	AZD 1208	Pim kinase inhibitor	Page 268
2305	CX 6258 hydrochloride	Pim Kinase Inhibitor	Page 401
1633	SGI 1776 free base	Pim kinase Inhibitor	Page 864
1923	SMI 4a	ATP-competitive and selective inhibitor of Pim kinases	Page 875

Enzymes (EC 2.7.11.) Kinases, PDK

Among the downstream effectors of PI3Ks (see also section of PI3K/Akt/mTOR signaling), 3-phosphoinositide-dependent protein kinase 1 (PDK1 or PDK1; EC 2.7.11.1) and protein kinase B (PKB)/Akt have a key role in several cancer types. There is evidence that indicates that alteration of PDK1 is a critical component of oncogenic PI3K signaling in breast cancer, suggesting that inhibition of PDK1 can inhibit breast cancer progression¹. PDK1 is the protein kinase responsible for regulating the activity of related kinases in the AGC kinase family (including AKT), by phosphorylating a specific threonine or serine residue within the activation loop (T-loop) which is critical for kinase activation. Many of the kinases activated by PDK1 regulate cellular processes such as cell survival, differentiation, growth, and protein expression, in response to second messenger signals. Activation of PI3K by growth factor signaling results in the production of phosphatidylinositol 3,4-bisphosphate and PIP3, which colocalize AKT and PDK1 to the plasma membrane through interaction with their respective pleckstrin homology (PH) domains, thus allowing PDK1 to phosphorylate AKT in a PIP3-dependent manner. Binding of PIP3 to AKT also induces conformational changes that facilitate PDK1 phosphorylation².

¹ C. Raimondi, M. Falasca. Targeting PDK1 in cancer. *Curr. Med. Chem.* 2011, 18, 2763-2769.

² J.R. Medina. Selective 3-Phosphoinositide-Dependent Kinase 1 (PDK1) Inhibitors: Dissecting the Function and Pharmacology of PDK1. *J. Med. Chem.*, 2013, 56, 2726-2737.

1390	BX 795	PDPK1, TBK1 and IKK inhibitor	Page 335
1130	BX 912	PDPK1 inhibitor	Page 335
1929	GSK2334470	Potent and selective PDK1 inhibitor	Page 519
2525	OSU 03012	ATP competitive PDK-1 inhibitor	Page 739
2610	PDK1 inhibitor 2610	Dual PI3K/PDPK1 inhibitor	Page 756
1870	PHT 427	Inhibitor of Akt and PDPK1	Page 775
1664	PS 47	PDPK1 activator (allosteric)	Page 794
1659	PS 48	PDPK1 activator (allosteric)	Page 794
3534	PS210	Potent and selective activator of PDK1	Page 794

Enzymes (EC 2.7.11.) Kinases, Raf

Three different Raf (EC 2.7.11.1) isoforms originating from 3 independent genes can be distinguished in mammals: Raf-1/c-Raf, B-Raf, and A-Raf. They are *bona fide* Ras (a membrane-associated guanine nucleotide-binding protein) effectors and upstream activators of the ubiquitous ERK pathway, which has drawn the attention to these proteins as potential targets in cancer therapy. All Raf isoforms share a common modular structure consisting of 3 conserved regions (CR) with distinct functions. CR1 contains a Ras-binding domain (RBD), which is necessary for the interaction with Ras and with membrane phospholipids required for membrane recruitment, and a cysteine-rich domain (CRD), which is a secondary Ras-binding site and also necessary for the interaction of CR1 with the kinase domain for Raf auto-inhibition. CR2 contains important inhibitory phosphorylation sites participating in the negative regulation of Ras binding and Raf activation. CR3 features the kinase domain, including the activation segment, whose phosphorylation is crucial for kinase activation. The common and key step in the activation of all 3 Raf isoforms is membrane recruitment by a Ras family protein. In turn, activated Raf kinases phosphorylate both MEK isoforms MEK1 and MEK2 on 2 residues in the activation loop, which in turn can bind, phosphorylate, and activate ERK¹.

Raf kinase inhibitor protein (RKIP) is a member of the phosphatidylethanolamine-binding protein (PEBP) family that interacts with a number of different proteins and regulates multiple signaling pathways. PEBP was identified as a physiologically relevant inhibitor of Raf-MEK-ERK and renamed RKIP. It binds specifically to the Raf-1 kinase, although it is not a direct substrate of Raf. RKIP inhibits the kinase activity of Raf-1 by dissociating the Raf-1/MEK complex and acting as a competitive inhibitor of MEK phosphorylation. What's more, RKIP can bind to the N-region of the Raf-1 kinase domain thereby inhibiting its activation. Besides its role in the Raf-MEK-ERK signaling cascade, it has been shown that (1) RKIP also antagonizes NF- κ B signaling by interacting with several upstream kinases that regulate the I κ B protein, (2) has a positive effect on heterotrimeric G protein-dependent and GSK signaling, (3) inhibits the activation phosphorylation of the transcriptional factor STAT3, (4) and activates Nrf2 by destabilizing the BTB domain containing protein Keap1².

¹ D. Matallanas et al. Raf family kinases: old dogs have learned new tricks. *Genes Cancer.* 201, 2, 232-260.

² J Escara-Wilke et al. Raf kinase inhibitor protein (RKIP) in cancer. *Cancer Metastasis Rev.* 2012 Dec;31(3-4):615-20.

1545	AZ 628	B-Raf and C-Raf protein kinase inhibitor	Page 265
3067	Belvarafenib	Orally bioavailable pan-Raf protein kinase inhibitor	Page 298
3862	BGB-283	Orally available dual RAF kinase/EGFR inhibitor	Page 300
3971	CCT196969	Paradox-breaking pan RAF Inhibitor	Page 351
1459	GDC 0879	B-Raf protein kinase inhibitor	Page 498
1984	GW 5074	Brain-permeable inhibitor of c-Raf with in vivo effects	Page 532
4146	LGX818	Selective ATP-competitive RAF kinase inhibitor	Page 613
2590	Locostatin	Non-toxic Raf kinase inhibitory protein (RKIP) inhibitor	Page 618
3556	LXH254	Potent, selective and orally available type II B/C RAF inhibitor	Page 622
1624	PLX 4032	B-Raf protein kinase inhibitor	Page 783
1474	PLX 4720	B-Raf protein kinase inhibitor	Page 784
2817	RAF709	Potent, selective, and efficacious B-Raf and C-Raf protein kinase inhibitor	Page 806
2504	SB 590885	Selective inhibitor of B-Raf kinase	Page 850
3351	Sorafenib	Protein kinase inhibitor of Raf/MEK/ERK pathway	Page 879
1397	Sorafenib tosylate	Protein kinase inhibitor of Raf/MEK/ERK pathway	Page 879

4033	TAK-632	Potent and selective pan-RAF inhibitor	Page 907
------	---------	--	----------

Enzymes (EC 2.7.11.) Kinases, RIP

Receptor interacting protein (RIP; EC 2.7.11.1) kinases constitute a family of seven members. They are crucial regulators of cell survival and death. Based on sequence similarities, mode of regulation and substrate specificities of their catalytic domain, RIP kinases are closely related to members of the interleukin-1-receptor-associated kinase (IRAK) family. RIP1 and RIP2 (CARDIAK/RICK) also bear a C-terminal domain belonging to the death domain (DD) superfamily, namely, a DD and a caspase recruitment domain (CARD), respectively, allowing recruitment to large protein complexes initiating different signalling pathways. RIP1 is a crucial adaptor kinase on the crossroad of stress-induced signalling pathways (NF- κ B, MAPK, Ubiquitin) and a cell's decision to live or die. It is constitutively expressed in many tissues. However, TNF- α treatment and T-cell activation can also induce RIP1 expression¹.

¹ N. Festjens et al. RIP1, a kinase on the crossroads of a cell's decision to live or die. *Cell Death Differ.* 2007, 14, 400-410.

2608	GSK481	Inhibitor of RIP1 kinase and TNF induced inflammation	Page 518
1258	Necrostatin-1	RIP1 inhibitor	Page 696

Enzymes (EC 2.7.11.) Kinases, ROCK

Rho-kinase (EC 2.7.11.1) is a serine/threonine kinase belonging to the AGC family of protein kinases, originally identified as the first downstream effector of the small GTPase Rho. There are two Rho-kinase members, Rho-kinase α /ROCK2/ROK α and Rho-kinase β /ROCK1/ROK β ; both Rho-kinases are composed of an N-terminal catalytic domain, a central coiled-coil domain, and a C-terminal PH domain interrupted by a Cys-rich region. Rho family small GTPases, such as Rho, Rac, and Cdc42, mediate a broad range of cellular responses that involve the actin cytoskeleton. Rho regulates stress fiber formation and cell contraction, whereas Rac and Cdc42 regulate the formation of lamellipodia and filopodia, respectively, and promote protrusive activities. Rho family GTPases also modulate microtubule dynamics and cell polarity. Furthermore, Rho kinase is involved in smooth muscle contraction and actin organization, cell migration, neuronal architecture and neurite elongation, and cytokinesis, among several other functions^{1,2}.

¹ Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. M. Amano, M. Nakayama, K. Kaibuchi. *Cytoskeleton* 2013, 67, 545-554.

² Rho Kinase (ROCK) Inhibitors. J.K. Liao, M. Seto, K. Noma. *J. Cardiovasc. Pharmacol.* 2007, 50, 17-24.

2187	AS 1892802	Potent, selective, ATP-competitive ROCK inhibitor	Page 253
2166	AT 13148 dihydrochloride	ATP-competitive inhibitor of multi-AGC kinases	Page 258
2753	CCG 232601	Rho/MRTF/SRF transcriptional pathway inhibitor	Page 349
3092	CCG-203971	Rho/MRTF/SRF transcriptional pathway inhibitor	Page 349
3069	CCG-222740	Potent and selective Rho/MRTF/SRF transcriptional pathway inhibitor	Page 350
3848	Fasudil hydrochloride	Orally active ROCK inhibitor; Ca ²⁺ channel antagonist	Page 475
1167	GSK 269962A	ROCK1 and ROCK2 inhibitor	Page 524
2780	KD025	Selective ATP-competitive inhibitor of ROCK2	Page 589
2229	RKI 1447	Potent inhibitor of the Rho-associated ROCK kinases	Page 822
1535	Thiazovivin	ROCK inhibitor and iPSC stimulator; Stem cell related	Page 923
1683	Y 27632 dihydrochloride	ROCK1 and ROCK2 inhibitor	Page 997

Enzymes (EC 2.7.11.) Kinases, RSK

The p70 ribosomal S6 kinases (S6K) and p90 ribosomal S6 kinases (RSK) are distinct families of Ser/Thr kinases (EC 2.7.11.1) that regulate diverse cellular processes by phosphorylation of ribosomal protein S6 (Rps6). They transduce anabolic signals that indicate nutritional status to regulate cell size and growth and metabolism through various mechanisms. These include effects on the translational machinery and on cellular energy levels through the activity of adenosine monophosphate (AMP)-activated protein kinase (AMPK)¹.

RSKs are downstream effectors of the Ras-extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling cascade, and IGF-1 (IIS) and mTOR signaling pathways². RSK phosphorylates a variety of proteins, including transcription factors, immediate-early gene products, translational regulators, enzymes, and structural proteins, that potentially link it to many biological processes such as cell proliferation, cell differentiation, and survival. The ribosomal

protein S6 kinase 1 (S6K1) is one of two mammalian p70rsk proteins, acting as a downstream mediator of mammalian target of rapamycin (mTOR) in the phosphoinositide 3-kinase (PI3K) pathway and/or the Ras-MAPK pathway. It acts to converge growth factor, hormonal, nutrient and energy signals in order to maintain cellular homeostasis³. It has been hypothesized that the mTORC1-S6K1 is a master determinant in longevity control⁴.

¹ Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span. C. Selman et al. *Science* 2009, 326, 140-144.

² R. Anjum, J. Blenis. The RSK family of kinases: emerging roles in cellular signaling. *Nat. Rev. Mol. Cell Biol.* 2008, 9, 747-758.

³ Y. Abe et al. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. *J. Biol. Chem.* 2009, 284, 14939-14948.

⁴ D.C. Bedford. S6K1: reducing the RSKs of aging. *Dis. Model. Mech.* 2010, 3, 123-124.

3328	APIO-EE-07	Dual RSK1/MSK2 inhibitor	Page 241
1528	BI-D1870	RSK inhibitor (p90 RSK specific)	Page 306
3940	Bisindolylmaleimide V	S6K inhibitor	Page 310
1903	DG2	RSK inhibitor (p70 ribosomal S6 kinase 1 specific)	Page 424
1848	FMK	RSK inhibitor (p90 RSK specific)	Page 488
3991	LJI308	Potent RSK inhibitor (p90 RSK specific)	Page 616
2464	LY 2584702 tosylate	Oral, ATP competitive inhibitor of p70 S6 kinase (S6K1)	Page 633
1602	PF 4708671	RSK inhibitor (p70 RSK specific)	Page 765

Enzymes (EC 2.7.11.) Kinases, PKB/Akt

Akt/PKB protein kinase (EC 2.7.11.1), also belongs to the cAMP-dependent protein kinase A, -G, and -C (AGC) super family of protein kinases that share structural homology within their catalytic domain and have the similar mechanism of activation¹. The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli. The Akt/PKB family comprises three highly homologous members known as PKB α /Akt1, PKB β /Akt2 and PKB γ /Akt3 in mammalian cells. The enzyme contributes to activation of a wide variety of cellular processes, including cell survival, growth, proliferation, glucose uptake, metabolism, and angiogenesis². Aberrant loss or gain of Akt activation underlies the pathophysiological properties of a variety of diseases, including type-2 diabetes and cancer. As is well known, Akt/PKB also acts a prominent downstream effector of PI3K signaling pathway, and is activated by Class 1A and Class 1B PI3-Kinases.

¹ The activation of Akt/PKB signaling pathway and cell survival. G. Song, G. Ouyang, S. Bao. *J. Cell. Mol. Med.* 2005, 9, 59-71.

² AKT/PKB Signaling: Navigating Downstream. B.D. Manning, L.C. Cantley. *Cell* 2007, 129, 1261-1274.

2540	Akt Inhibitor VIII	Inhibitor of Akt1 and 2	Page 217
2166	AT 13148 dihydrochloride	ATP-competitive inhibitor of multi-AGC kinases	Page 258
1859	AZD 5363 dihydrochloride	Inhibitor of protein kinase B (Akt)	Page 273
4038	CEP-37440 hydrochloride	Potent, selective and orally active inhibitor of ALK and FAK	Page 359
1239	Deguelin	Akt inhibitor	Page 417
4037	GDC-0068	Potent, ATP-competitive and orally available small molecule pan-Akt inhibitor	Page 497
1729	GSK 690693	ATP-competitive pan-Akt kinase inhibitor	Page 525
2460	GSK 2110183 hydrochloride	Potent, orally bioavailable inhibitor of the Akt kinases	Page 528
3850	M2698	p70S6K/Akt dual inhibitor	Page 637
3247	Miltefosine	PI3K/Akt inhibitor	Page 656
1684	MK 2206	Akt Inhibitor (allosteric)	Page 661
3343	ML-9 hydrochloride	MLCK, Akt and STIM1 inhibitor	Page 667
1663	Perifosine	PI3K/Akt inhibitor	Page 759
1870	PHT 427	Inhibitor of Akt and PDPK1	Page 775
1790	SC 66	Allosteric Akt inhibitor	Page 853
2507	SC 79	Unique specific activator of cytosolic Akt; neuroprotective	Page 853
3958	Uprosertib	Selective and ATP-competitive pan-Akt (PKB) inhibitor	Page 956
1685	YS 49	PI3K/Akt activator	Page 1000

Enzymes (EC 2.7.11.) Kinases, IKK

The IKK kinase complex is the core element of the NF- κ B cascade (see section of Axon Ligands™ interacting with NF- κ B signaling). It is essentially made of two kinases (IKK α (or IKK-1) and IKK β (or IKK-2); EC 2.7.11.10) and a regulatory subunit, NEMO/IKK γ . NF- κ B represents a family of transcription factors that are normally kept inactive in the cytoplasm through interaction with inhibitory molecules of the I κ B family. In response to multiple stimuli such as inflammatory cytokines, bacterial or viral products, or various types of stress, the I κ B molecules become phosphorylated on two critical serine residues. This modification is recognized by a specific E3 ubiquitin ligase complex and undergoes polyubiquitination, which targets them for rapid degradation by the 26S proteasome¹. As a consequence, free NF- κ B enters the nucleus and activates transcription of a variety of genes participating in the immune and inflammatory response, cell adhesion, growth control, and protection against apoptosis².

¹ The I κ B kinase IKK and NF- κ B: key elements of proinflammatory signaling. M. Karin, M. Delhase. *Semin. Immunol.* 2000, 12, 85-98.

² The IKK Complex, a Central Regulator of NF- κ B Activation. A. Israël. *Cold Spring Harb Perspect Biol* 2010, 2, a000158.

2132	BAY 11-7082	IKK inhibitor and anti-inflammatory	Page 286
1731	BMS 345541	Cell-permeable and selective I κ B (IKK) inhibitor	Page 317
1390	BX 795	PDPK1, TBK1 and IKK inhibitor	Page 335
1772	CDDO-Me	IKK-2 inhibitor; Inducer of the Nrf2 pathway	Page 354
2725	IMD-0354	IKK-2 inhibitor	Page 562
3484	IMD-0560	Selective IKK-2 inhibitor	Page 562
3046	MRT 67307	TBK1 and IKK ϵ inhibitor	Page 680
1651	PHA 408	IKK-2 inhibitor	Page 773
1568	PS 1145	IKK Inhibitor	Page 794
3536	SC-514	Potent, selective, reversible and ATP-competitive IKK-2 inhibitor	Page 852
2070	Sulfasalazine	IKK Inhibitor	Page 899

Enzymes (EC 2.7.11.) Kinases, PKC

The protein kinase C (PKC; EC 2.7.11.13) family represents a large group of phospholipid dependent enzymes catalyzing the covalent transfer of phosphate from ATP to serine and threonine residues of proteins, mediating signal transduction for cell proliferation, differentiation, apoptosis and angiogenesis. The PKC family consists of at least twelve members, divided into three subgroups: the classical PKCs (cPKCs: PKC α , PKC β , PKC β II, and PKC γ), which are Ca²⁺ dependent and activated by both phosphatidylserine (PS) and diacylglycerol (DAG); novel PKCs (nPKCs: PKC δ , PKC ϵ , PKC η , and PKC θ), which are Ca²⁺ independent and regulated by DAG and PS; and atypical PKCs (aPKCs: PKC ζ , PKC λ), which are Ca²⁺ independent and do not require DAG for activation, although PS can regulate their activity¹. Many of these kinases show overlapping substrate specificities in vitro. Consistent with their different biological functions, PKC isoforms differ in their structure, tissue distribution, subcellular localization, mode of activation and substrate specificity. Early observations that PKC isozymes are activated by tumor-promoting phorbol esters suggested a key role for PKC in tumor promotion and progression leading to PKC being considered as a target for cancer therapy².

¹ Protein kinase C pharmacology: refining the toolbox. A.X. Wu-Zhang, A.C. Newton. *Biochem. J.* 2013, 452, 195-209.

² Targeting the protein kinase C family: are we there yet? H.J. Mackay, C.J. Twelves. *Nat. Rev. Cancer* 2007, 7, 554-562.

2981	B106	Potent and selective PKC- δ inhibitor	Page 281
3936	Bisindolylmaleimide I	Potent and selective PKC inhibitor	Page 310
3939	Bisindolylmaleimide IV	Potent PKC inhibitor	Page 310
3986	Desmethyltamoxifen hydrochloride, N-	Metabolite of Tamoxifen (Axon 3252); PKC inhibitor	Page 420
1682	Enzastaurin	PKC-beta inhibitor	Page 461
2466	Gö 6983	Broad spectrum PKC inhibitor	Page 511
3851	LXS-196	Potent and selective protein kinase C inhibitor	Page 622
2362	LY 333531 hydrochloride	PKC- β inhibitor	Page 629
1401	LY 333531 mesylate	PKC-beta inhibitor	Page 627

1635	Sotrastaurin	PKC inhibitor	Page 880
------	--------------	---------------	----------

Enzymes (EC 2.7.11.) Kinases, PKD

Protein kinase D (PKD; EC 2.7.11.13) consists of a small family of three members (PKD1-3) of ubiquitous serine-threonine protein kinases that are involved in the regulation of various functions within the cell, including cell proliferation, apoptosis, adhesion, and cell motility. PKD1 was initially recognized as a member of the protein kinase C (PKC) family and named PKC μ . However, distinct differences in the protein structure, variation in substrate(s) and inhibitor specificity, and low homology of the kinase domain to other members of the PKC family resulted in its reclassification. PKD1 is now classified as a member of the protein kinase D (PKD) family, a distinct branch under the calcium/calmodulin-dependent protein kinase¹. Studies revealed that the mechanism of PKD activation is mediated not only by DAG, but also, directly or indirectly, through PKCs².

¹ Emerging Roles of Protein Kinase D1 in Cancer. V. Sundram, S.C. Chauhan, M. Jaggi. *Mol. Cancer Res.* 2011, 9, 985-996.

² Protein Kinase D Signaling. E. Rozengurt, O. Rey, R.T. Waldron. *J. Biol. Chem.* 2005, 280, 13205-13208.

2798	BPKDi	PKD inhibitor	Page 324
1627	CID 755673	PKD inhibitor	Page 370
1976	CID 2011756	ATP-competitive protein kinase D (PKD) inhibitor	Page 370

Enzymes (EC 2.7.11.) Kinases, PLK

The Polo-Like Kinase (PLK; EC 2.7.11.21) family of enzymes is localized in the centrosomes or spindle pole bodies and undergo dramatic subcellular relocation during the cell cycle. They mediate G2/M transitions, activation of cdc25 and mitotic processes including centrosome maturation, bipolar spindle formation, activation of the anaphase-promoting complex (APC), chromosome segregation, and actin ring formation (cytokinesis). Deregulated activities of PLKs often result in abnormalities in centrosome duplication, maturation, and/or microtubule dynamics. PLKs also regulate the function of the Golgi complex. Deregulated expression of human PLK1 is strongly correlated with the development of many types of malignancies, and ectopic expression of PLK1 dominant negative protein leads to rapid cell death¹. PLK3 is a multifunctional stress response protein that responds to signals induced by DNA damage and/or mitotic spindle disruption².

¹ Polo-like kinases: a team that plays throughout mitosis. D.M. Glover, I.M. Hagan Á.A.M. Tavares. *Genes & Dev.* 1998, 12, 3777-3787

² PLK3 Functionally Links DNA Damage to Cell Cycle Arrest and Apoptosis at Least in Part via the p53 Pathway. Xie, S; Wu H, Wang Q, Cogswell J P, Husain I, Conn C, Stambrook P, Jhanwar-Uniyal M, Dai W. *J. Biol. Chem.* 2001, 276, 43305-43312.

1129	BI 2536	PLK1 inhibitor	Page 301
4192	BI 2536, (S)- Recent Addition	Dual PLK1/BRD4 bromodomain inhibitor	Page 302
1473	BI 6727	PLK1 Inhibitor	Page 303
3918	CZS-241 hydrochloride Recent Addition	Highly potent, selective, and orally available PLK4 inhibitor	Page 404
1688	GSK 461364	PLK1 inhibitor	Page 524
1625	GSK 461364 analogue I	PLK1 Inhibitor	Page 524
1626	GSK 461364 analogue II	PLK1 Inhibitor	Page 525
1131	GW 843682X	PLK1 and PLK3 inhibitor	Page 536
1910	MLN 0905	PLK1 inhibitor	Page 673
2358	Mps1-IN-2	Inhibitor of Mps1 kinase with add-on affinity for PLK1	Page 679
4007	NMS-1286937	Orally bioavailable PLK1 inhibitor	Page 707
2950	Rigosertib sodium	Non-ATP-competitive PLK1 inhibitor	Page 818

Enzymes (EC 2.7.11.) Kinases, CDK

The cell cycle, consisting of four distinct phases (G1, S, G2, and M) is controlled by numerous mechanisms ensuring correct cell division. Cyclin-dependent kinases (CDKs; EC 2.7.11.22) are a family of protein kinases first discovered for their role in regulating the cell cycle¹. Their kinase activity requires the binding of a regulatory cyclin subunit, upon which CDKs phosphorylate their substrates on serine and threonine residues. Since cyclins are synthesized and destroyed at specific times during the cell cycle, CDK kinase activity is regulated in a timely manner. Tumor associated mutations frequently deregulate certain CDK-cyclin complexes, resulting in either continued proliferation or unscheduled re-entry into the cell

cycle, two properties characteristic of most human tumor cells^{2,3}. If it is possible to selectively interrupt the cell cycle regulation in cancer cells by interfering with CDK action, the cell will die. Therefore, the development of CDK inhibitors (CKIs) is of great interest.

¹ The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. K. Vermeulen, D.R. Van Bockstaele, Z.N. Berneman. Cell Prolif. 2003, 36, 131-149.

² Cell cycle, CDKs and cancer: a changing paradigm. M.Malumbres, M.Barbacid. Nature Reviews Cancer 2009, 9, 153-166

³ CDK Inhibitors: Cell Cycle Regulators and Beyond. Develop. Cell 2008, 14, 159-169

4071	AMG-925	Potent, selective, and orally available FLT3/CDK4 dual inhibitor	Page 226
1539	AT 7519 mesylate	CDK inhibitor	Page 257
3800	AZD4573	Inhibitor of CDK9	Page 272
1966	AZD 5438	CDK inhibitor (1, 2, and 9 specific)	Page 273
4265	AZD8421	Selective inhibitor of CDK2	Page 276
3935	BAY-1251152	Potent and highly selective CDK9/P-TEFb inhibitor	Page 286
3228	CDK inhibitor CR8	Potent CDK inhibitor (1, 2, 5, 7, and 9 specific)	Page 355
3756	CT7001	Specific CDK7 inhibitor	Page 397
3525	ETP-47799	Potent CDK8/CDK19 inhibitor	Page 470
3730	KB-0742 dihydrochloride	Orally bioavailable, potent and selective CDK9 inhibitor	Page 589
3029	LDC000067	Potent, highly specific, ATP-competitive CDK9 inhibitor	Page 607
2273	LEE 011	Orally bioavailable and highly selective inhibitor of CDK4/6	Page 609
3283	LY2857785	Highly potent, selective, reversible and ATP-competitive CDK9 inhibitor	Page 635
3894	LY-3177833	CDC7 inhibitor	Page 627
1892	NM-PP1, 1-	Tyrosine kinase inhibitor of Src, Fyn, Abl, CDK, Trk	Page 706
2695	NSC 23005 sodium	Novel small molecule inhibitor of INK4C (p18/INK4C) or p18	Page 713
1243	NSC 625987	CDK4 inhibitor	Page 716
2052	Palbociclib isethionate	Orally active cyclin-dependent kinase (CDK4/6) inhibitor	Page 745
1505	PD 0332991 hydrochloride	CDK4 and CDK6 inhibitor	Page 755
3693	PF-06873600	CDK inhibitor (4, 6, and 8 specific)	Page 761
3753	PF-07104091	Specific CDK2 inhibitor	Page 762
3762	PF-07220060	Orally bioavailable and CDK4-Specific Inhibitor	Page 762
2690	PHA-767491	Dual CDC7/CDK9 kinase inhibitor	Page 774
1983	R 547	CDK inhibitor (1, 2, and 4 specific)	Page 803
1530	RO 3306	CDK1 inhibitor	Page 826
1776	SCH 727965	CDK inhibitor (1, 2, 5, and 9 specific)	Page 856
1614	SNS 032	CDK inhibitor (2, 7 and 9 specific)	Page 876
3184	SR-4835	Potent, highly selective and orally bioavailable dual CDK12/CDK13 inhibitor	Page 889
3605	TAK-931	CDC7 inhibitor	Page 908
3560	THZ1	Covalent CDK7 inhibitor	Page 926
3561	THZ1 dihydrochloride	Covalent CDK7 inhibitor	Page 926
3402	THZ531	First-in-class, potent, selective, covalent CDK12/CDK13 inhibitor	Page 926
3801	Voruciclib	Inhibitor of CDK9	Page 972
3535	XY028-140	Potent and selective CDK4/6 inhibitor; PROTAC	Page 996

Enzymes (EC 2.7.11.) Kinases, ERK

Extracellular-signal-regulated kinases (ERKs; EC 2.7.11.24) are members of the larger family of mitogen-activated protein kinases (MAPKs) that includes ERK5, the c-Jun N-terminal protein kinases (JNKs) and the p38 MAP kinases, and transduce extracellular signals from cell surface receptors to the cell nucleus. The activation of ERK is coupled to stimulation of cell surface receptors via several different upstream signaling pathways, and plays critical roles in the regulation of gene expression and cell proliferation. The canonical ERK MAP kinase cascade (see section of kinases involved in MAPK/ERK signaling) is stimulated upon the binding of extracellular growth factors such as EGF and PDGF to their respective transmembrane receptor tyrosine kinases (RTKs). The subsequent auto-phosphorylation of the cytoplasmic tails of the receptor on tyrosine leads to the recruitment of Grb-2, which binds the guanine exchange factor SOS. Recruitment of SOS to the membrane promotes its interaction with the membrane localized small GTPase Ras and results in GTP loading and activation of Ras. This is followed by the sequential recruitment and activation of the kinases Raf, MEK, and ERK. Upon activation, MEK phosphorylates ERK, leading to dissociation and dimerization of ERK and subsequent translocation into the nucleus. In the nucleus ERK may phosphorylate many substrates including transcription factors¹.

¹ J.W. Ramos. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int. J. Biochem. Cell Biol. 2008, 40, 2707-2719.

1808	BIX 02188	MEK5 inhibitor; ERK5 inhibitor	Page 311
1809	BIX 02189	MEK5 inhibitor; ERK5 inhibitor	Page 311
1694	FR 180204	ERK inhibitor; AP-1 inhibitor	Page 491
3741	GDC-0994	ERK1/2 inhibitor	Page 499
3893	LY-3214996	Orally bioavailable, potent and highly selective inhibitor of ERK1 and ERK2	Page 628
3867	SCH772984 hydrochloride	Potent, specific and ATP competitive inhibitor of ERK1 and ERK2	Page 855
3803	SCH900353	ERK1/2 inhibitor	Page 857
1397	Sorafenib tosylate	Protein kinase inhibitor of Raf/MEK/ERK pathway	Page 879
4151	Ulixertinib hydrochloride	Potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases	Page 951
3836	VX-11e	Potent, selective, and orally bioavailable inhibitor of ERK2	Page 979
1846	XMD 8-92	BMK1 inhibitor; ERK5 inhibitor	Page 995
1621	XMD 8-92 trifluoroacetate	BMK1 inhibitor; ERK5 inhibitor	Page 995

Enzymes (EC 2.7.11.) Kinases, JNK

As discussed in the section of Axon Ligands™ that inhibit extracellular-signal-regulated kinases (ERK), c-Jun N-terminal protein kinases (JNKs; EC 2.7.11.24) are also members of the family of mitogen-activated protein kinases (MAPKs) and integral part of the MAPK/ERK and NF-κB signaling pathways. In mammals, there are 3 different JNK genes (JNK 1-3) encoding for at least 10 alternative splicing forms of 46-55 kDa. JNK1 and JNK2 are ubiquitously expressed, but the expression of JNK3 is mainly restricted to central nervous system (CNS) neurons (high level), cardiac smooth muscle, and testis (low levels). Besides c-Jun, JNK can phosphorylate a variety of substrates, including additional transcription factors and even some non-nuclear proteins. JNK is involved in many physiological processes such as embryonic morphogenesis and naturally occurring programmed cell death, while the unusual activated JNK pathway can cause pathological cell death and different diseases, among which are neurological disorders, type 2 diabetes, inflammatory diseases, and cancer¹.

¹ J. Cui et al. JNK pathway: diseases and therapeutic potential. Acta Pharmacol. Sin. 2007, 28, 601-608.

1291	AEG 3482	JNK inhibitor	Page 210
2002	AS 602801	JNK inhibitor, which inhibited JNK1, JNK2 and JNK3	Page 252
2025	CC 401	ATP-competitive JNK inhibitor	Page 348
2634	CC-930	Potent, selective, and orally active anti-fibrotic JNK inhibitor	Page 349
3625	GNE-3511	Potent, selective, orally bioavailable and brain-penetrant DLK inhibitor	Page 510
2361	JNK-IN-8	Remarkably potent and selective covalent inhibitor of JNK	Page 582
2949	JNK inhibitor VIII	Selective, ATP-competitive, and cell-permeable JNK inhibitor	Page 582
2519	SP 600125	Selective, reversible, and ATP-competitive JNK inhibitor	Page 881

2365 SR 3576.....Potent JNK3 inhibitor with >2800-fold selectivity over p38..... Page 886

Enzymes (EC 2.7.11.) Kinases, p38 MAPK

To date, five distinct groups of mitogen activated protein kinases (MAPKs) have been characterized in mammals: extracellular signal-regulated kinases (ERKs) 1 and 2 (ERK1/2), c-Jun amino-terminal kinases (JNKs) 1, 2, and 3, p38 isoforms α , β , γ , and δ , ERKs 3 and 4, and ERK5; all sharing the enzyme commission number EC 2.7.11.24. MAPKs can be activated by a wide variety of different stimuli, but in general, ERK1 and ERK2 are preferentially activated in response to growth factors and phorbol esters, while the JNK and p38 kinases are more responsive to stress stimuli ranging from osmotic shock and ionizing radiation to cytokine stimulation. Although each MAPK has unique characteristics, a number of features are shared by the MAPK pathways studied to date. Each family of MAPKs is composed of a set of three sequentially acting kinases: a MAPK, a MAPK kinase (MAPKK), and a MAPKK kinase (MAPKKK). p38 (also known as CSBP, mHOG1, RK, and SAPK2) is the archetypal member of the second MAPK-related pathway in mammalian cells. The p38 module consists of several MAPKKs, including MEKs 1-4, MLK2 and -3, DLK, ASK1, Tpl2 (a.k.a. Cot), and Tak1, the MAPKKs MEK3 and MEK6 (a.k.a. MKK3 and MKK6, resp.), and the four known p38 isoforms (α , β , γ , and δ). In mammalian cells, the p38 isoforms are strongly activated by environmental stresses and inflammatory cytokines but not appreciably by mitogenic stimuli. Most stimuli that activate p38 also activate JNK, but only p38 is inhibited by the anti-inflammatory drug SB203580 (Axon 1363 and Axon 1465 (HCl salt; water soluble), which has been extremely useful in delineating the function of p38¹.

¹ P.P. Roux, J. Blenis. ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions. *Microbiol. Mol. Biol. Rev.* June 2004, 68, 320-344.

1358 BIRB 796	MAPK inhibitor (p38 specific)	Page 309
2856 BMS 582949	Inhibitor of p38 α MAPK	Page 319
1895 LY 2228820	Inhibitor of p38 MAPK	Page 632
3620 MAPK13 inhibitor compound 61	MAPK13 inhibitor (p38 δ specific)	Page 638
3197 Mitochonic acid 5	Mitochondrial drug; Activator of MAPK-ERK-yap signalling.....	Page 658
3440 MK2 inhibitor III.....	Potent and selective MK-2 inhibitor	Page 659
2366 NG 25 trihydrochloride.....	Type II inhibitor of TAK1 (MAP3K7) and MAP4K2 (GCK)	Page 700
1365 PD 169316.....	MAPK inhibitor (p38 specific)	Page 754
1837 PH 797804.....	Inhibitor of p38 α MAPK	Page 772
2786 PH 797804, (\pm).....	Inhibitor of p38 α MAPK	Page 773
1364 SB 202190.....	MAPK inhibitor (p38 specific)	Page 844
1363 SB 203580.....	MAPK inhibitor (p38 specific)	Page 845
1465 SB 203580 hydrochloride	MAPK inhibitor (p38 specific)	Page 845
2444 SB 706504.....	Selective p38 MAPK inhibitor.....	Page 851
1671 SCIO 469.....	MAPK inhibitor (p38 specific)	Page 858
1357 SD 169.....	MAPK inhibitor (p38-alpha specific)	Page 858
3183 SR-318	Highly potent and selective type-II p38 α/β inhibitor	Page 889
4219 VX-702 Recent Addition	Orally bioavailable p38 MAP kinase inhibitor.....	Page 980
1811 VX 745.....	Inhibitor of p38 α MAP kinase.....	Page 980

Enzymes (EC 2.7.11.) Kinases, GSK-3

GSK-3 (EC 2.7.11.26), originally identified in 1980, is one of the few signaling mediators that play central roles in a diverse range of signaling pathways, including those activated by Wnts, hedgehog, growth factors, cytokines, and G protein-coupled ligands¹. It has been implemented in the mechanisms that regulate cellular proliferation, migration, inflammation and immune responses, glucose regulation, and apoptosis. Although the original name suggests the enzyme is involved only in the process of glycogen metabolism, recent findings have revealed over 50 substrates that are phosphorylated by GSK-3, among them the microtubule-associated protein, tau, that is the predominant component of neurofibrillary tangles in Alzheimer's disease. Despite the impressive number of processes the enzyme is involved in, only four key mechanisms have been identified that contribute to regulating the actions of GSK3 in a substrate-specific manner. The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway activated in response to insulin and many other growth factors

often is a major regulator of GSK3 because Akt phosphorylates GSK3 on these inhibitory serine residues, but several other kinases also can phosphorylate these regulatory serines, such as protein kinase C and protein kinase A².

¹ D. Wu, W. Pan. GSK3: a multifaceted kinase in Wnt signaling. *Trends Biochem Sci.* 2010 Mar;35(3):161-8.

² Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. RS Jope, CJ Yuskaitis, E Beurel. *Neurochem. Res.* 2007, 32, 577-595.

1909 A 1070722	Selective inhibitor of GSK-3.....	Page 194
2167 AR-A 014418	ATP-competitive GSK-3 inhibitor.....	Page 245
2171 AZD 1080	Selective inhibitor of GSK3 α and GSK-3 β	Page 268
3771 AZD 2858	Potent and highly selective GSK-3 β inhibitor	Page 270
2194 AZD 2858 hydrochloride	Potent and highly selective GSK-3 β inhibitor	Page 270
1693 BIO	GSK-3 inhibitor	Page 308
2931 BRD0705	First-in-class, paralog selective GSK3 α inhibitor	Page 326
3153 BRD5648	Negative control compound of BRD0705 as a GSK3 α inhibitor	Page 327
1126 CHIR 98014	GSK-3 inhibitor.....	Page 365
1386 CHIR 99021	GSK-3 inhibitor.....	Page 365
2435 CHIR 99021 dihydrochloride.....	GSK-3 inhibitor.....	Page 365
3509 Cromolyn disodium	GSK-3 β inhibitor.....	Page 396
2511 IM 12.....	GSK-3 β inhibitor attenuating neuronal differentiation	Page 561
3154 rac-BRD0705	GSK3 α inhibitor	Page 804
1303 SB 216763.....	GSK-3 inhibitor.....	Page 846
2010 TDZD 8	Selective and non-ATP competitive inhibitor of GSK-3 β	Page 914
3579 Tideglusib	GSK-3 inhibitor.....	Page 928
1562 TWS 119.....	GSK-3 β inhibitor.....	Page 944

Enzymes (EC 2.7.11.) Kinases, AMPK

AMP-activated protein kinase (AMPK; EC 2.7.11.31) is a heterotrimeric enzyme with a key role in regulating cellular energy metabolism, cell growth and cell polarity. In response to a change in the intracellular AMP:ATP or ADP:ATP ratios it activates energy-producing pathways and inhibits energy-consuming processes. Furthermore, AMPK is regulated by a diverse range of hormones among which leptin, adiponectin, ciliary neurotrophic factor and ghrelin. Of the three subunits α , β , and γ that constitute the protein kinase, the α -subunit hosts the catalytic domain, while the latter two subunits β , and γ fulfill a regulatory function. Activation of AMPK is triggered by phosphorylation of a threonine residue, which lies in the activation segment of the amino-terminal kinase domain of the α -subunit and results in a several-hundred-fold increase in activity. In mammals, calcium/calmodulin-dependent protein kinase kinase- β (CaMKK β), LKB1, and transforming growth factor- β -activated kinase 1 (TAK1) are the predominant kinases upstream of AMPK¹. In turn, activated, phosphorylated AMPK can be inactivated by protein phosphatases (PP), e.g. PP2A, PP2C α and Ppm1E. Currently, AMPK is viewed as an important molecular target since it is believed that novel AMPK modulators may be useful in the therapy of cancer, metabolic, and neurodegenerative diseases, such as type 2 diabetes, Alzheimer's disease, and aging^{2,3}.

NUAK family SNF1-like kinase-1 [NUAK1, also known as ARK5 (AMPK-related kinase 5); EC 2.7.11.1] and the closely related NUAK2 [SNARK (SNF1/AMPK-related kinase)] are members of the AMPK (AMP-activated protein kinase) family of protein kinases that are activated by the LKB1 (liver kinase B1) tumour suppressor protein kinase⁴. They both contain a ubiquitin-associated domain located next to the C-terminal of their catalytic domains, which is required for LKB1 phosphorylation and activation. Studies on NUAK kinases hint at roles in regulating cell adhesion, cancer cell invasion, embryonic development, senescence, proliferation, neuronal polarity and axon branching⁵. In the field of tumor biology, NUAK family members have been reported to promote tumor progression and metastatic capacity via the upregulation of cell proliferation, inhibition of p53-mediated tumor suppression, and increased matrix metalloproteinases (MMPs) in various cancer types. A key finding showing that NUAK1 operates as an essential survival factor in oncogenic Myc-driven tumours and may play a role in regulating tumor proliferation and survival through metabolic alteration in hepatocarcinoma. Therefore, targeting cellular energy homeostasis through inhibition of NUAK1 could be a valuable strategy to eliminate Myc-deregulated tumor cells⁶.

¹ Structure of mammalian AMPK and its regulation by ADP. B. Xiao. *Nature* 2011, 472, 230-233.

² AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. A. Salminen, K. Kaarniranta. *Ageing Res. Rev.* 2012, 11, 230-241.

- ³ AMPK: a nutrient and energy sensor that maintains energy homeostasis. D.G. Hardie, F.A. Ross, S.A. Hawley. *Nature Rev. Mol. Cell Biol.* 2012, 13, 251-262.
- ⁴ J.M. Lizcano et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. *EMBO J.* 2004 Feb 25;23(4):833-43.
- ⁵ S. Banerjee et al. Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. *Biochem J.* 2014 Jan 1;457(1):215-25.
- ⁶ X. Sun et al. The regulation and function of the NUAK family. *J Mol Endocrinol.* 2013 Sep 10;51(2):R15-22.

1466	A 769662	AMPK activator	Page 192
2021	HL 010183	Metformin derivative; AMPK activator	Page 542
2385	WZ 4003	Specific inhibitor of NUAK1 (ARK5) and NUAK2 (SNARK)	Page 990
2445	ZLN 024	Allosteric activator of AMP-activated protein kinase (AMPK)	..	Page 1009

Enzymes (EC 2.7.11.) Kinases, ASK

Being a member of the mitogen-activated protein (MAP) kinase kinase family, the Apoptosis Signal-regulating Kinase 1 (ASK1; EC 2.7.11.35) activates downstream MAP kinases (MAPKs), c-Jun N-terminal kinases (JNKs) and p38 MAPKs, in response to various stresses, such as reactive oxygen species (ROS), endoplasmic reticulum (ER) stress, lipopolysaccharide, and calcium overload. Activation of these pathways induces cellular responses such as apoptosis, differentiation, cell survival, and production of inflammatory cytokines. Evidence is growing that ASK proteins play pivotal roles in the pathogenesis and pathology of a wide range of diseases in which ROS and/or ER stress may be common pathogenic factors, such as cardiovascular, neurodegenerative diseases, and cancers.

At the molecular level, the activation of ASK1 is tightly regulated by phosphorylation of a threonine residue (Thr838 in human ASK1) within the activation loop of the kinase domain, which appears to be a common activation mechanism among the ASK family of proteins, i.e., ASK1, ASK2, NSY-1, and DASK1¹. ASK1 forms a high molecular mass complex termed the ASK1 signalosome. Within the signalosome, ASK1 is homo-oligomerized through its C-terminal coiled-coil (CCC) domain, a process that is critical for ASK1 activation. Among the regulatory proteins that are involved in the activation of ASK1, such as TNF- α receptor-associated factor 2 (TRAF2), TRAF6, protein phosphatase 5 (PP5), and USP9X, the redox protein thioredoxin (Trx) plays a pivotal role: the reduced form of Trx binds to the N-terminal region of ASK1 and inhibits its kinase activity. Upon oxidation in response to ROS, Trx dissociates from ASK1, and ASK1 is then activated by the autophosphorylation of the Thr residue in its kinase domain².

- ¹ R. Hayakawa et al. Therapeutic targets in the ASK1-dependent stress signaling pathways. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 2012, 88, 434-453.
- ² M. Soga, A. Matsuzawa, H. Ichijo. Oxidative Stress-Induced Diseases via the ASK1 Signaling Pathway. *Int. J. Cell Biol.* 2012, 2012, 439587.

2179	ASK1 Inhibitor 10	Potent, selective, and orally bioavailable ASK1 inhibitor	Page 254
1814	NQDI 1	Inhibitor of apoptosis signal-regulating kinase 1 (ASK1)	Page 710
2956	Selonsertib	Potent, highly selective, orally available, and ATP-competitive ASK1 inhibitor	Page 860

Enzymes (EC 2.7.11.) Kinases involved in DNA-damage response

Nuclear DNA is undoubtedly the most precious component of a cell. It is not surprising therefore that any kind of damage that introduces a discontinuity in the DNA double helix elicits a prompt cellular reaction. The DNA damage response (DDR) provides an intrinsic biological barrier against the duplication and partitioning of damaged DNA into daughter cells and impedes the propagation of corrupted genetic information¹. When maintenance of genome integrity fails, it might lead to programmed cell death (apoptosis), or genomic instability (GIN), which in turn can cause cell transformation and oncogenesis². Among the Serine and Threonine specific kinases, a number of them is involved in the processes that play a significant role in the DDR. For example, Ataxia telangiectasia mutated (ATM) kinase recognizes and signals to double-strand breaks (DSB), which are among the most critical lesions in chromosomal DNA^{3,4}. ATM is present in the nucleus as an inactive dimer or oligomer, and is activated in response to DSBs in a process that involves autophosphorylation. This causes a dissociation of the dimer to form active monomeric forms, which are able to initiate the phosphorylation of many intermediates, such as p53 and the checkpoint kinase Chk2, which are involved in DNA repair and cell-cycle control⁵. Similar to ATM, the ataxia-telangiectasia and Rad3-related (ATR) protein and the DNA-activated protein kinase (DNA-PK) play an important role in responding to agents and extracellular stress that threaten the DNA replication process⁶. Interestingly, a normal and robust checkpoint pathway is thought to be a mechanism of resistance to chemotherapy. As a result, ATR-Chk1 pathway components are considered promising therapeutic targets. In particular, inhibition of ATR-Chk1 pathway components could potentially enhance the effectiveness of replication inhibitors⁷.

- ¹ Living on a break: cellular senescence as a DNA-damage response. F d'Adda di Fagagna. *Nature Reviews Cancer* 2008, 8, 512-522.
- ² Cell-cycle checkpoints and cancer. Kastan, M. B. & Bartek, J. *Nature* 2004, 432, 316-323.
- ³ DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. U Moll, R Lau, MA Sypes, MM Gupta, CW Anderson. *Oncogene* 1999, 18, 3114-3126.
- ⁴ ATM and the DNA damage response. Workshop on ataxia-telangiectasia and related syndromes. Lavin MF, Della D, Chessa L. *EMBO Rep.* 2006, 7, 154-160.
- ⁵ DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Bakkenist CJ, Kastan MB. *Nature.* 2003, 421, 499-506.
- ⁶ ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. J Yang, Y Yu, H Hamrick, PJ Duerksen-Hughes. *Carcinogenesis* 2003, 24, 1571-1580.
- ⁷ Prospects for the Use of ATR Inhibitors to Treat Cancer. JM Wagner, SH Kaufmann. *Pharmaceuticals* 2010, 3, 1311-1334.

2639	AMG 232	Selective, and orally bioavailable MDM2-p53 inhibitor	Page 224
1399	AZD 7762 hydrochloride	CHK inhibitor	Page 275
1636	CHIR 124	CHK1 inhibitor	Page 365
2250	CHR 6494 trifluoroacetate	Specific, first-in-class inhibitor of histone kinase Haspin	Page 368
1495	CP 466722	ATM inhibitor	Page 389
2173	CX 5461	Inhibitor of RNA Polymerase I (RNAP1)	Page 400
2537	Isoquinolinediol, 1,5-	PARP1 inhibitor and neuroprotective agent	Page 571
2604	KU 0060648	DNA-PK inhibitor	Page 598
1584	KU 0060648 trihydrochloride	DNA-PK inhibitor	Page 598
1367	KU 55933	ATM inhibitor	Page 597
1494	MK 1775	Wee1 kinase inhibitor	Page 661
2564	NSC 59984	Activator of p53 that restores WT p53 signaling	Page 716
1463	NU 7441	DNA-PK inhibitor	Page 719
2599	NVP-TNKS656	Selective TNKS inhibitor and antagonist of Wnt pathway	Page 726
1379	PF 477736	CHK1 inhibitor	Page 763
1911	RAD51 inhibitor B02	Inhibitor of RAD51	Page 805
2299	Remodelin	Potent NAT 10 inhibitor	Page 811
1885	RI-1	Inhibitor of the central recombination protein RAD51	Page 817
2584	RS-1	Enhancer of CRISPR-based genome editing & HDR/RAD51	..	Page 833
2518	UF 010	Class I selective HDAC inhibitor	Page 949
1893	VE 821	Inhibitor of the DNA damage response kinase ATR	Page 964

Enzymes (EC 2.7.11.) Kinases involved in MAPK/ERK signaling

Similar to the PI3K/AKT/mTOR pathway, the MAPK/Erk signaling cascade is activated by a wide variety of receptors involved in growth and differentiation including receptor tyrosine kinases (RTKs), integrins, ion channels, and extracellular stimuli such as heat and stress. The specific components of the cascade vary greatly among different stimuli, but the architecture of the pathway usually includes a set of adaptors (e.g. Shc, GRB2, Crk, etc.) linking the receptor to a guanine nucleotide exchange factor (SOS, C3G, etc.) transducing the signal to small GTP binding proteins (Ras, Rap1), which in turn activate the core unit of the cascade composed of a MAPKKK (Raf), a MAPKK (MEK1/2), and MAPK (Erk: extracellular signal-regulated kinases). An activated Erk dimer can regulate targets in the cytosol and also translocate to the nucleus where it phosphorylates a variety of transcription factors regulating gene expression^{1,2}. One example of the most recent additions to this class of compounds is FMK (Axon 1848), a potent, highly specific and irreversible inhibitor of p90 ribosomal protein S6 kinase (RSK) 1 and 2. This drug is capable of inducing significant apoptosis in human FGFR3-expressing, t(4;14)-positive multiple myeloma cells³. Actually, MEK enzymes are members of the class of dual specificity mitogen-activated protein kinase kinase (EC 2.7.12.2) and should not be listed within the section of serine/threonine specific kinases (EC 2.7.11.). However, as they are integral members of the group of enzymes involved in MAPK/ERK signaling, and besides having the capability to phosphorylate tyrosine residues, they are also capable of phosphorylating serine/threonine sites of substrates, MEK inhibitors are listed in this section for kinases involved in the MAPK/ERK signaling pathway.

- ¹ Regulatory mechanisms of mitogen-activated kinase signaling. Zhang Y, Dong C. *Cell Mol Life Sci.* 2007, 64, 2771-2789.
- ² Pathological roles of MAPK signaling pathways in human diseases. Kim EK, Choi EJ. *Biochim Biophys Acta.* 2010, 1802, 396-405.
- ³ Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Cohen MS, Zhang C, Shokat KM, Taunton J. *Science* 2005, 308 1318-1321.

1291	AEG 3482	JNK inhibitor	Page 210
2611	APS-2-79	Inhibitor of KSR and oncogenic Ras signaling	Page 243
2002	AS 602801	JNK inhibitor, which inhibited JNK1, JNK2 and JNK3	Page 252
2179	ASK1 Inhibitor 10	Potent, selective, and orally bioavailable ASK1 inhibitor	Page 254
1545	AZ 628	B-Raf and C-Raf protein kinase inhibitor	Page 265
1516	AZD 6244	MEK1 and MEK2 inhibitor	Page 274
1999	AZD 8330	MEK1 inhibitor	Page 276
2178	BCI	Allosteric inhibitor of dual-specificity phosphatases (Dusp)	Page 293
1528	BI-D1870	RSK inhibitor (p90 RSK specific)	Page 306
1358	BIRB 796	MAPK inhibitor (p38 specific)	Page 309
1809	BIX 02189	MEK5 inhibitor; ERK5 inhibitor	Page 311
2025	CC 401	ATP-competitive JNK inhibitor	Page 348
2634	CC-930	Potent, selective, and orally active anti-fibrotic JNK inhibitor	Page 349
1821	CCT 007093	Protein phosphatase 1D (PPM1D) inhibitor	Page 351
1611	CGP 57380	Mnk1 inhibitor	Page 362
2574	Defactinib	Second generation inhibitor of FAK and PYK2	Page 416
1903	DG2	RSK inhibitor (p70 ribosomal S6 kinase 1 specific)	Page 424
1825	Erastin	RAS lethal compound; VDAC2 modulator	Page 465
1848	FMK	RSK inhibitor (p90 RSK specific)	Page 488
1694	FR 180204	ERK inhibitor; AP-1 inhibitor	Page 491
1459	GDC 0879	B-Raf protein kinase inhibitor	Page 498
2466	Gö 6983	Broad spectrum PKC inhibitor	Page 511
1761	GSK 1120212	MEK1 and MEK2 inhibitor	Page 527
1984	GW 5074	Brain-permeable inhibitor of c-Raf with in vivo effects	Page 532
2361	JNK-IN-8	Remarkably potent and selective covalent inhibitor of JNK	Page 582
2590	Locostatin	Non-toxic Raf kinase inhibitory protein (RKIP) inhibitor	Page 618
1895	LY 2228820	Inhibitor of p38 MAPK	Page 632
2017	ML 210	Chemical probe kills cells induced to express mutant RAS	Page 665
1814	NQDI 1	Inhibitor of apoptosis signal-regulating kinase 1 (ASK1)	Page 710
1223	PD 98059	MEK inhibitor	Page 752
1365	PD 169316	MAPK inhibitor (p38 specific)	Page 754
1368	PD 184352	MEK1 inhibitor	Page 754
1408	PD 0325901	MEK1 and MEK2 inhibitor	Page 755
2107	PF 431396	Dual FAK(PTK2) and PYK2 inhibitor	Page 763
1602	PF 4708671	RSK inhibitor (p70 RSK specific)	Page 765
2545	PF 06260933 dihydrochloride	Potent and selective MAP4K4 inhibitor	Page 770
1837	PH 797804	Inhibitor of p38 α MAPK	Page 772
2647	Pirfenidone	Anti-inflammatory and anti-fibrosis agent	Page 779
1624	PLX 4032	B-Raf protein kinase inhibitor	Page 783
1474	PLX 4720	B-Raf protein kinase inhibitor	Page 784
1364	SB 202190	MAPK inhibitor (p38 specific)	Page 844
1363	SB 203580	MAPK inhibitor (p38 specific)	Page 845
1465	SB 203580 hydrochloride	MAPK inhibitor (p38 specific)	Page 845
2504	SB 590885	Selective inhibitor of B-Raf kinase	Page 850
2444	SB 706504	Selective p38 MAPK inhibitor	Page 851

1897	SB 747651A	Inhibitor of MSK1	Page 851
1671	SCIO 469	MAPK inhibitor (p38 specific)	Page 858
1357	SD 169	MAPK inhibitor (p38-alpha specific)	Page 858
1122	SL 327	MEK1 and MEK2 inhibitor	Page 872
1397	Sorafenib tosylate	Protein kinase inhibitor of Raf/MEK/ERK pathway	Page 879
2519	SP 600125	Selective, reversible, and ATP-competitive JNK inhibitor	Page 881
2544	S3QEL 2	Suppressor of superoxide production	Page 838
2365	SR 3576	Potent JNK3 inhibitor with >2800-fold selectivity over p38	Page 886
1811	VX 745	Inhibitor of p38 α MAP kinase	Page 980
1846	XMD 8-92	BMK1 inhibitor; ERK5 inhibitor	Page 995
1621	XMD 8-92 trifluoroacetate	BMK1 inhibitor; ERK5 inhibitor	Page 995

Enzymes (EC 2.7.11.) Kinases involved in the NF- κ B signaling

The NF- κ B signaling pathway is involved in a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B cell development, and lymphoid organogenesis. A remarkable diversity of stimuli lead to the activation of NF- κ B, among which are pro-inflammatory cytokines, LPS, growth factors, and antigen receptors. They activate an IKK complex (IKK β , IKK α , and NEMO), which phosphorylates I κ B proteins. Phosphorylation of I κ B leads to its ubiquitination and proteasomal degradation, freeing NF- κ B/Rel complexes. Active NF- κ B/Rel complexes are further activated by phosphorylation and translocate to the nucleus where, either alone or in combination with other transcription factor families including AP-1, Ets, and Stat, they induce target gene expression^{1,2}. The core elements of NF- κ B signaling pathways are generally several steps removed from the receptor itself. The intervening steps between receptor and IKK form links to parallel signaling pathways. For example, PKC enzymes play important roles in several signal transduction cascades. In NF- κ B signaling, PKC- β connects the B cell receptor to canonical activation of NF- κ B through a signaling complex, including Bcl10/MALT1 and NEMO/IKK γ ³.

¹ Shared principles in NF- κ B signaling. Hayden MS, Ghosh S. Cell. 2008, 132, 344-362.

² Rel/NF- κ B Transcription Factors. Gilmore TD. <http://www.bu.edu/nf-kb/> 2008

³ Protein Kinase C- β -Dependent Activation of NF- κ B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo. G. Lutzny et al. Cancer Cell. 2013, 23, 77-92.

1291	AEG 3482	JNK inhibitor	Page 210
2611	APS-2-79	Inhibitor of KSR and oncogenic Ras signaling	Page 243
2002	AS 602801	JNK inhibitor, which inhibited JNK1, JNK2 and JNK3	Page 252
2132	BAY 11-7082	IKK inhibitor and anti-inflammatory	Page 286
2178	BCI	Allosteric inhibitor of dual-specificity phosphatases (Dusp)	Page 293
1731	BMS 345541	Cell-permeable and selective I κ B (IKK) inhibitor	Page 317
1390	BX 795	PDPK1, TBK1 and IKK inhibitor	Page 335
2025	CC 401	ATP-competitive JNK inhibitor	Page 348
2634	CC-930	Potent, selective, and orally active anti-fibrotic JNK inhibitor	Page 349
1950	CDDO	Potent anti-tumor agent. PPAR-gamma agonist	Page 354
1772	CDDO-Me	IKK-2 inhibitor; Inducer of the Nrf2 pathway	Page 354
2575	C-DIM12	Nurr1 activator stimulating apoptosis in bladder cancer cells	Page 354
2568	EML 425	Potent dual inhibitor of CBP and p300 (HAT/KAT3)	Page 456
1682	Enzastaurin	PKC-beta inhibitor	Page 461
2080	EVP 4593	NF- κ B activation inhibitor; inhibits SOC pathway	Page 471
2466	Gö 6983	Broad spectrum PKC inhibitor	Page 511
2608	GSK481	Inhibitor of RIP1 kinase and TNF induced inflammation	Page 518
1984	GW 5074	Brain-permeable inhibitor of c-Raf with in vivo effects	Page 532
2533	Hydroxypioglitazone	Active metabolite of Pioglitazone (M-IV), a PPAR γ agonist	Page 552
1793	Lenalidomide	Anti-angiogenesis agent and immunomodulator	Page 611

2590	Locostatin	Non-toxic Raf kinase inhibitory protein (RKIP) inhibitor	Page 618
2362	LY 333531 hydrochloride	PKC- β inhibitor	Page 629
1401	LY 333531 mesylate	PKC- β inhibitor	Page 627
1888	ML 130	Potent and selective inhibitor of NOD1 (NLRC1)	Page 663
1258	Necrostatin-1	RIP1 inhibitor	Page 696
2366	NG 25 trihydrochloride	Type II inhibitor of TAK1 (MAP3K7) and MAP4K2 (GCK)	Page 700
2174	PD 90780	Inhibitor of NGFs binding to the P75 NGFR	Page 751
2647	Pirfenidone	Anti-inflammatory and anti-fibrosis agent	Page 779
2545	PF 06260933 dihydrochloride	Potent and selective MAP4K4 inhibitor	Page 770
1651	PHA 408	IKK-2 inhibitor	Page 773
1568	PS 1145	IKK Inhibitor	Page 794
2444	SB 706504	Selective p38 MAPK inhibitor	Page 851
1635	Sotrastaurin	PKC inhibitor	Page 880
2519	SP 600125	Selective, reversible, and ATP-competitive JNK inhibitor	Page 881
2143	SPD 304	Cell permeable inhibitor of TNF α	Page 883
2365	SR 3576	Potent JNK3 inhibitor with >2800-fold selectivity over p38	Page 886
2070	Sulfasalazine	IKK Inhibitor	Page 899

Enzymes (EC 2.7.11.) Kinases involved in PI3K/AKT/mTOR signaling

Within the class Axon Ligands™ targeting Serine/Threonine specific kinases, special interest is offered for those kinases that are part of the PI3K/AKT/mTOR signaling pathway. It is strongly involved in the fundamental cellular processes of protein synthesis and apoptosis, and disturbed activation of this intracellular pathway has been associated with the development of diseases such as cancer, diabetes mellitus, and autoimmunity¹. Upon activation of phosphatidylinositol (PI)-3-kinase (PI3K) by extracellular growth factors, phosphorylation of the inner membrane phosphoinositides activates AKT (also known as Protein Kinase B, PKB) and PDKP1 (3-phosphoinositide dependent protein kinase-1). In turn, mTOR (mammalian target of rapamycin) is activated downstream, which plays an important role in cell cycle progression². In many cancer cells, this PI3K/AKT/mTOR pathway is highly active, which can be the result of amplification or mutation of the PI3-kinase gene; amplification or mutation of the Akt gene; or loss of function of PTEN (Phosphatase and tensin homolog). The latter normally regulates the removal of phosphate groups of the PI3K mediated phosphorylated membrane phospholipids, one of the regulating mechanisms to prevent over activations of this pathway.

¹ PI3K-Akt pathway: its functions and alterations in human cancer. Osaki M, Oshimura M, Ito H. Apoptosis 2004, 9, 667-676.

² PI3K/Akt/mTOR pathway as a target for cancer therapy. D. Morgensztern, H.L. McLeod Drugs 2005, 16, 797-803

1831	A 66	PI3K inhibitor (p110 alpha specific)	Page 190
2540	Akt Inhibitor VIII	Inhibitor of Akt1 and 2	Page 217
2368	Amuvatinib	RTK inhibitor (PDGFR, c-Kit and c-Met)	Page 235
1424	AS 252424	PI3K inhibitor (p110 gamma specific)	Page 250
1436	AS 252424 bispotassium salt	PI3K inhibitor (p110- γ specific)	Page 251
2171	AZD 1080	Selective inhibitor of GSK3 α and GSK-3 β	Page 268
2194	AZD 2858 hydrochloride	Potent and highly selective GSK-3 β inhibitor	Page 270
1859	AZD 5363 dihydrochloride	Inhibitor of protein kinase B (Akt)	Page 273
1561	AZD 8055	mTOR inhibitor	Page 276
1282	BAG 956	PI3K and PDKP1 inhibitor	Page 282
1281	BEZ 235	Dual PI3K and mTOR kinase inhibitor	Page 299
1390	BX 795	PDKP1, TBK1 and IKK inhibitor	Page 335
1130	BX 912	PDKP1 inhibitor	Page 335
2039	CZC 24832	PI3K inhibitor (p110 gamma specific)	Page 404
1719	D 106669	Potent and selective PI3K inhibitor	Page 406

1239	Deguelin	Akt inhibitor	Page 417
2630	eCF309	Highly selective and potent inhibitor of mTOR signalling	Page 450
1377	GDC 0941 bismesylate	PI3K inhibitor	Page 499
1782	GDC 0980	Dual PI3K and mTOR inhibitor	Page 499
2466	G6 6983	Broad spectrum PKC inhibitor	Page 511
1596	GSK 2126458	Dual PI3K and mTOR inhibitor	Page 528
1912	GSK 2636771 dihydrochloride	PI3K inhibitor (p110 beta specific)	Page 529
1729	GSK 690693	ATP-competitive pan-Akt kinase inhibitor	Page 525
2168	IC 87114	Potent and highly selective inhibitor of the PI3K p110 δ	Page 556
2511	IM 12	GSK-3 β inhibitor attenuating neuronal differentiation	Page 561
2142	INK 128	Potent and selective mTOR inhibitor	Page 567
1472	KU 0063794	mTOR inhibitor	Page 598
1366	LY 294002	PI3K inhibitor	Page 627
1684	MK 2206	Akt Inhibitor (allosteric)	Page 661
1520	NVP-BBD130	Dual PI3K and mTOR kinase inhibitor	Page 722
2029	NVP-BGT226	Orally active dual PI3K/mTOR inhibitor	Page 723
1797	NVP-BKM120	Class I PI3K inhibitor	Page 723
2525	OSU 03012	ATP competitive PDK-1 inhibitor	Page 739
1718	Palomid 529	mTOR inhibitor	Page 746
1663	Perifosine	PI3K/Akt inhibitor	Page 759
1855	PF 04691502	PI3K and mTOR tyrosine kinase inhibitor	Page 768
1870	PHT 427	Inhibitor of Akt and PDKP1	Page 775
1380	PI 103 hydrochloride	PI3K inhibitor (p110 specific)	Page 775
1334	PIK 75 hydrochloride	PI3K inhibitor (p110 alpha specific)	Page 777
1362	PIK 90	PI3K inhibitor (p110 alpha specific)	Page 778
1807	PKI 587	Dual PI3K and mTOR inhibitor	Page 781
1664	PS 47	PDKP1 activator (allosteric)	Page 794
1659	PS 48	PDKP1 activator (allosteric)	Page 794
2069	Rapamycin	Specific inhibitor of mTOR; binds to FKBP12	Page 807
1790	SC 66	Allosteric Akt inhibitor	Page 853
2507	SC 79	Unique specific activator of cytosolic Akt; neuroprotective	Page 853
2200	SRPIN 340	Selective ATP competitive inhibitor of SRPK kinase activity	Page 890
1699	Temsirolimus	mTOR inhibitor	Page 918
1417	TGX 221	PI3K inhibitor (p110 beta specific)	Page 922
1833	Torin 1	mTOR inhibitor	Page 936
1834	Torin 2	mTOR inhibitor	Page 937
1706	XL PI3K/mTOR inhibitor	Dual PI3K and mTOR kinase inhibitor	Page 995
1685	YS 49	PI3K/Akt activator	Page 1000

Enzymes (EC 2.7.11.) Kinases involved in Wnt/ β -Catenin signaling

Wnt proteins form a family of highly conserved secreted signaling molecules that regulate cell-to-cell interactions during embryogenesis (embryonic induction, generation of cell polarity, and the specification of cell fate). Mutations in Wnt genes or Wnt pathway components lead to specific developmental defects, while various human diseases, including cancer, are caused by abnormal Wnt signaling. As currently understood, Wnt proteins bind to receptors of the Frizzled and LRP (low density Lipoprotein Receptor-related Protein) families on the cell surface. The result is alleviation of pathway inhibition caused by GSK-3 β , APC, and Axin proteins. This stabilizes β -Catenin and promotes its nuclear translocation where it regulates target gene transcription together with Tcf/Lef proteins. During development, the Wnt/ β -catenin pathway

integrates signals from many other pathways including Retinoic acid, FGF, TGF- β , and BMP in many different cell-types and tissues. In addition, GSK-3 β is also involved in glycogen metabolism and other key pathways, which has made its inhibition relevant to diabetes and neurodegenerative disorders.^{1,2}

¹ Wnt signaling and stem cell control. Nusse, R. Cell Research 2008,18, 523-527.

² Wnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors. M. D. Gordon, R. Nusse. J Biol Chem. 2006, 281, 22429-22433.

1909	A 1070722 Selective inhibitor of GSK-3.....	Page 194
2167	AR-A 014418 ATP-competitive GSK-3 inhibitor.....	Page 245
2171	AZD 1080 Selective inhibitor of GSK3 α and GSK-3 β	Page 268
2194	AZD 2858 hydrochloride Potent and highly selective GSK-3 β inhibitor.....	Page 270
1693	BIO GSK-3 inhibitor.....	Page 308
1126	CHIR 98014 GSK-3 inhibitor.....	Page 365
1386	CHIR 99021 GSK-3 inhibitor.....	Page 365
2202	CK2 inhibitor 10 Potent and ATP-competitive inhibitor of CK2.....	Page 374
1965	CX 4945 hydrochloride Inhibitor of casein kinase 2 (CK2).....	Page 399
2574	Defactinib Second generation inhibitor of FAK and PYK2.....	Page 416
2568	EML 425 Potent dual inhibitor of CBP and p300 (HAT/KAT3).....	Page 456
1766	ICG 001 Specific inhibitor of Wnt/ β -catenin signaling pathway.....	Page 557
2133	iCRT5 β -Catenin-responsive transcription (CRT) inhibitor.....	Page 558
2510	IWR-1-endo Inhibitor of the Wnt/ β -catenin pathway via TNKS1&2.....	Page 575
2212	IWP L6 Highly potent porcine (Porcn) inhibitor.....	Page 574
1922	JW 55 Inhibitor of tankyrase (TNKS 1 and 2).....	Page 585
2036	KY 02111 Canonical Wnt signaling pathway inhibitor.....	Page 600
2599	NVP-TNKS656 Selective TNKS inhibitor and antagonist of Wnt pathway.....	Page 726
1792	PF 4800567 Inhibitor of Casein kinase 1 (CK1-epsilon).....	Page 765
1303	SB 216763 GSK-3 inhibitor.....	Page 846
2084	SKL 2001 Wnt/ β -catenin signaling pathway agonist or activator.....	Page 872
2010	TDZD 8 Selective and non-ATP competitive inhibitor of GSK-3 β	Page 914
1854	TTP 22 Inhibitor of Casein kinase 2 (CK2).....	Page 942
1562	TWS 119 GSK-3 β inhibitor.....	Page 944
2120	Wnt agonist 1 Wnt/ β -catenin signaling pathway agonist or activator.....	Page 987
1527	XAV 939 Tankyrase (TNKS) inhibitor.....	Page 991

Enzymes (EC 2.7.12.) Kinases, Dual specificity

Protein kinases fall into three broad classes, characterised with respect to substrate specificity: Serine/threonine-protein kinases, Tyrosine-protein kinases, and Dual specificity protein kinases (e.g. MEK - phosphorylates both Thr and Tyr on target proteins)¹. Four distinct MAPK cascades have been identified and named according to their MAPK module. These are extra-cellular signal-regulated kinase (ERK1/2), c-Jun N-terminal kinase (JNK), p38 and ERK5. MEK proteins (EC 2.7.12.1) belong to a family of enzymes that lie upstream to their specific MAPK targets in MAP kinase signaling pathways, and so far 7 MEK enzymes have been identified. MEK1 and MEK2 are closely related. They both participate in the Ras/Raf/MEK/ERK signal transduction cascade. MEK1 (a.k.a. MAPKK-1 or MAP2K1) is the prototype member of MEK family proteins².

MPS1 (EC 2.7.12.1), a dual-specificity kinase, is required for the proper functioning of the spindle assembly checkpoint and for the maintenance of chromosomal stability. Deregulation of these processes or uncoupling of its component parts can lead to aneuploidy and chromosomal instability (CIN), which are recognized hallmarks of cancer³.

The cdc2-like kinases (Clks; EC 2.7.12.1) are CMGC group (cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAP kinases), glycogen synthase kinases (GSK) and CDK-like kinases) dual-specificity kinases, capable of autophosphorylation at tyrosine residues while phosphorylating substrates at serine and threonine residues. They make up

an essential and typically large group of kinases found in all eukaryotes. Four isoforms, Clk1–Clk4 are known to date, which impact mRNA splicing by phosphorylating the serine- and arginine-rich (SR) family of splicing proteins⁴.

¹ S.K. Hanks et al. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 1988, 241, 42-52.

² A. Akinleye et al. MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol. 2013, 6, 27-38.

³ Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. N. Kwiatkowski et al. Nat. Chem. Biol. 2010, 6, 359–368.

⁴ T.C. Coombs et al. Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe ML315. Bioorg. Med. Chem. Lett. 2013, 23, 3654–3661.

1642	AZ 3146 MPS1 kinase inhibitor.....	Page 265
4217	AS-703026 Recent Addition Potent, selective and orally bioavailable MEK1/2 inhibitor.....	Page 253
1516	AZD 6244 MEK1 and MEK2 inhibitor.....	Page 274
1999	AZD 8330 MEK1 inhibitor.....	Page 276
3697	Binimetinib Potent, selective, non-ATP-competitive and orally available allosteric inhibitor of MEK1/2.....	Page 308
1808	BIX 02188-Me MEK5 inhibitor; ERK5 inhibitor.....	Page 311
1809	BIX 02189 MEK5 inhibitor; ERK5 inhibitor.....	Page 311
3346	BIX02188 Potent MEK5 inhibitor.....	Page 312
3934	CC-671 Potent and selective dual inhibitor of TTK.....	Page 348
2992	CTx-0294885 Broad-spectrum kinase inhibitor.....	Page 398
4148	GDC-0973 Orally bioavailable, potent and selective small-molecule inhibitor of mitogen-activated protein kinase 1.....	Page 499
1761	GSK 1120212 MEK1 and MEK2 inhibitor.....	Page 527
3059	GW 284543 hydrochloride Selective MEK5 inhibitor.....	Page 533
2358	Mps1-IN-2 Inhibitor of Mps1 kinase with add-on affinity for Gak and Plk1.....	Page 679
1408	PD 0325901 MEK1 and MEK2 inhibitor.....	Page 755
1368	PD 184352 MEK1 inhibitor.....	Page 754
1223	PD 98059 MEK inhibitor.....	Page 752
3874	RDEA119 Potent and highly selective small molecule allosteric MEK inhibitor.....	Page 810
1629	Reversine MPS1 kinase inhibitor.....	Page 814
1122	SL 327 MEK1 and MEK2 inhibitor.....	Page 872
2755	TC Mps1 12 Potent and selective inhibitor of MPS1 kinase.....	Page 913
1765	TG 003 Inhibitor of Cdc2-like kinase (Clk) family.....	Page 921
2520	U 0126 Non-competitive inhibitor of MEK1/2.....	Page 946

Enzymes (EC 3.) Hydrolases

The group of hydrolases (EC 3.-.-) consists of 13 subgroups, as determined by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. Only few of them are represented in the Axon Ligands™ catalogue. The enzymes that catalyze the hydrolysis of various bonds are classified by the nature of the chemical bonds they cleave. Examples of enzymes of this group of enzymes are esterases, peptidases, and deacetylases.

3718	AB-680 ammonium salt CD73 inhibitor.....	Page 197
3027	FEN1 inhibitor 1 Potent flap endonuclease-1 (FEN1) inhibitor.....	Page 478
4228	L-742001 hydrochloride Recent Addition Inhibitor of influenza virus PA endonuclease.....	Page 602
2820	LB-100 Specific, competitive inhibitor of PP2A.....	Page 605
3080	NCGC00249987 Specific, allosteric EYA2 phosphatase inhibitor.....	Page 694
3086	NSC 95397 Potent and selective Cdc25 dual specificity phosphatase (DUSP) inhibitor.....	Page 714
2702	NQ301 Selective allosteric inhibitor of CD45.....	Page 710

2821	PFM01	<i>Inhibitor of MRE11 endonuclease</i>	Page 772
3004	Raphin1	<i>Selective, brain-penetrant, and orally bioavailable inhibitor of PPP1R15B (R15B)</i>	Page 808
2983	Raphin1 acetate	<i>Selective, brain-penetrant, and orally bioavailable inhibitor of PPP1R15B (R15B)</i>	Page 808
2963	SBI-425	<i>Potent, selective and orally bioavailable TNAP inhibitor</i>	Page 852
2892	STX64	<i>Potent steroid sulfatase (STS) inhibitor</i>	Page 897

Enzymes (EC 3.1.1.) Carboxylesterases

Acetylcholinesterase (AChE; EC 3.1.1.7), a type of serine proteases, is found at mainly neuromuscular junctions and cholinergic brain synapses, where its activity serves to terminate synaptic transmission, thereby playing a fundamental role in acetylcholine mediated neurotransmission. Blockade of AChE results in elevated concentrations of acetylcholine in the synaptic cleft with the potential to cause muscular paralysis, convulsions, bronchial constriction, and death by asphyxiation. The gradual loss of AChE activity is hypothesized to be the main cause of Alzheimer's disease, as AChE in healthy organisms plays a key role in the assembly of amyloid fiber¹. Additionally, it has been shown that the main active ingredient in cannabis, tetrahydrocannabinol, is a competitive inhibitor of acetylcholinesterase².

The hydrolysis of the primary and secondary ester bonds between long chain fatty acids and the glycerol backbone in triacylglycerols (TAG) is called "lipolysis" and depends on specific hydrolases commonly designated lipases. To date, three enzymes have been implicated in the complete hydrolysis of TAG molecules in cellular lipid stores: adipose triglyceride lipase (ATGL; EC 3.1.1.3) selectively performs the first and rate-limiting step hydrolyzing TAGs to generate diacylglycerols (DAGs) and non-esterified fatty acids (NEFAs). Hormone-sensitive lipase (HSL; EC 3.1.1.79) is a multifunctional enzyme capable of hydrolyzing a variety of acylesters including TAG, DAG, and monoacylglycerol (MAG). Within the TAG hydrolysis cascade this enzyme is rate-limiting for DAG catabolism. Finally, monoglyceride lipase (MGL; EC 3.1.1.23) efficiently cleaves MAG into glycerol and NEFAs. ATGL deficiency causes cardiomyopathy and premature death in humans and rodents owing to severe TG accumulation in cardiac muscle³.

Lipid-modified proteins are involved in important biological events, such as signal transduction, organisation of the cytoskeleton and vesicular transport. Post-translational S-palmitoylation for example directs the trafficking and membrane localization of hundreds of cellular proteins, often involving a coordinated palmitoylation cycle that requires both protein acyl transferases (PATs) and acyl protein thioesterases (APTs; EC 3.1.2.22). APT1 (a.k.a. LYPLA1) was the first characterized cytosolic protein depalmitoylase, yet initially annotated as a lysophospholipase⁴. Since it was shown that peptides that resemble the dual lipidation motifs of Ras or G-protein α subunits are efficiently palmitoylated and localized at the plasma membrane, the APT1 enzyme is of interest for its role in Ras signaling related oncology research, among other fields of interest⁵.

¹ Acetylcholinesterase — new roles for an old actor. H. Soreq, S. Seidman. Nat. Rev. Neurosc. 2001, 2, 294-302.

² A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology. L.M. Eubanks et al. Mol Pharm. 2006, 3, 773-777.

³ A. Lass et al. Lipolysis – A highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. Prog. Lipid Res. 2011, 50, 14–27.

⁴ S.J. Won et al. Molecular Mechanism for Isoform-Selective Inhibition of Acyl Protein Thioesterases 1 and 2 (APT1 and APT2). ACS Chem Biol. 2016 Oct 31.

⁵ M. Biel et al. Synthesis and evaluation of acyl protein thioesterase 1 (APT1) inhibitors. Chemistry. 2006 May 15;12(15):4121-43.

3682	AMZ30	<i>Potent, selective and covalent PME-1 inhibitor</i>	Page 236
2276	Atglistatin	<i>Selective inhibitor of adipose triglyceride lipase (ATGL)</i>	Page 258
3297	BChE inhibitor 8012-9656	<i>Highly potent, selective and brain-penetrant BChE inhibitor</i>	Page 294
3478	Dehydroevodiamine hydrochloride	<i>Potent acetylcholinesterase inhibitor</i>	Page 418
2982	DO264	<i>Potent, selective, and in vivo active ABHD12 inhibitor</i>	Page 436
1438	Donepezil hydrochloride	<i>Acetylcholinesterase inhibitor</i>	Page 437
3707	GLN-1062	<i>Brain-penetrant prodrug of galantamine; Acetylcholinesterase inhibitor</i>	Page 504
3213	GSK264220A	<i>Potent endothelial lipase (EL) and lipoprotein lipase (LPL) inhibitor</i>	Page 530
2797	Lalistat 2	<i>Selective inhibitor of lysosomal acid lipase (LAL)</i>	Page 603
2646	ML348	<i>Selective inhibitor for APT1 (aka LYPLA1)</i>	Page 669
3658	Neostigmine methyl sulfate	<i>Reversible acetylcholinesterase inhibitor</i>	Page 697
3500	Orlistat	<i>Potent, specific and irreversible inhibitor of pancreatic and gastric lipases</i>	Page 736
3167	Rivastigmine tartrate	<i>Centrally selective acetylcholinesterase inhibitor</i>	Page 821

Enzymes (EC 3.1.1.) Carboxylesterases, PLA

Phospholipases and acetylcholinesterases are members of the subclass of esterases. Hydrolyzing phospholipids into a carboxylic acid and a lysophospholipid, the PLA1 and PLA2 (EC 3.1.1.4) esterases differentiate from PLC (EC 3.1.4.11) and PLD (EC 3.1.4.4) which are responsible for cleaving either sites of the phosphonate bonds present in phospholipids. Due to the importance of PLA2 in inflammatory responses, regulation of the enzyme is essential. PLA2 is regulated by phosphorylation and calcium concentrations. PLA2 is phosphorylated by a MAPK at Serine-505. When phosphorylation is coupled with an influx of calcium ions, PLA2 becomes stimulated and can translocate to the membrane to begin catalysis¹.

¹ Properties and Regulation of Cytosolic Phospholipase A2. C.C. Leslie. J. Biol. Chem. 1997, 272, 16709-16712.

2578	ASB14780	<i>Inhibitor of cPLA2α; antiinflammatory drug</i>	Page 253
2661	AZD2716	<i>Potent secreted phospholipase A2 (sPLA2) inhibitor</i>	Page 277
1609	CDIBA	<i>cPLA2 inhibitor</i>	Page 354
3968	Darapladib	<i>Selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor</i>	Page 410
4077	Varespladib	<i>sPLA2 inhibitor</i>	Page 962
4032	Varespladib methyl	<i>Secretory phospholipase A2 (sPLA2) inhibitor</i>	Page 963

Enzymes (EC 3.1.1.) Carboxylesterases, MAGL

Monoacylglycerol lipase (MAGL; EC 3.1.1.23) is the principal enzyme responsible for the in vivo degradation of 2-arachidonoyl glycerol (2-AG), an endogenous ligand of the cannabinoid receptors. Two other enzymes that participate in the breakdown of 2-AG are α/β -hydrolase domain-containing 6 (ABHD6) and α/β -hydrolase domain-containing 12 (ABHD12). It has been hypothesized that inhibition of MAGL may represent a useful and novel approach for the treatment of neuropathic pain, anxiety and inflammatory bowel diseases, vomiting, and nausea, as well as against the proliferation and migration of cancer cells¹.

¹ J.Z. Patel et al. Loratadine analogues as MAGL inhibitors. Bioorg Med Chem Lett. 2015 Apr 1;25(7):1436-42.

3000	ABX-1431	<i>Highly potent, selective, brain-penetrant, and orally available MAGL inhibitor</i>	Page 203
2486	JZP 361	<i>Selective reversible inhibitor of MAGL; H1 antagonist</i>	Page 586
2580	MJN110	<i>Potent, selective, and in-vivo-active MAGL inhibitor</i>	Page 658
2696	URB602	<i>Non-competitive inhibitor of MAGL</i>	Page 957

Enzymes (EC 3.1.3.) Phosphoprotein phosphatase

The family of phosphoprotein phosphatases includes enzymes that dephosphorylate serine, threonine (EC 3.1.3.16) and tyrosine (EC 3.1.3.48) residues within their substrates. Analogous to kinases, some show certain specificity towards Ser/Thr or Tyr residues, like PPM1D (EC 3.1.3.16). Phosphatases that do not show this selectivity are classified as dual-specificity phosphatases (DUSP).

Protein phosphatase magnesium-dependent 1 δ (PPM1D; EC 3.1.3.16, also known as wip1 (wild type p53 induced protein phosphatase 1)) is a member of the PP2C family of Ser/Thr protein phosphatases, and was initially characterized as a p53-regulated phosphatase responsible for inactivation of p38 MAPK and consequent inactivation of p53. PPM1D also abrogates cell cycle checkpoints by reducing p53 and Chk1 activities through direct dephosphorylation, and it has been shown to be amplified and overexpressed in some human breast and prostate cancers, two steroid hormone-dependent cancers¹².

Protein phosphatase 1 regulatory subunit 15A (PPP1R15A; also known as growth arrest and DNA damage-inducible protein GADD34) is a member of the protein family whose expression is up-regulated by growth arrest and DNA damage. It recruits the serine/threonine-protein phosphatase PP1 to dephosphorylate the translation initiation factor eIF-2A/eIF2S1, thereby reversing the shut-off of protein synthesis initiated by stress-inducible kinases and facilitating recovery of cells from stress³. PPP1R15a down-regulates the TGF- β signaling pathway by promoting dephosphorylation of TGFB1 by PP1, and may promote apoptosis by inducing TP53 phosphorylation on Ser-15⁴.

DUSPs have been implicated as major modulators of critical signalling pathways that are dysregulated in various diseases. DUSPs can be divided into six subgroups on the basis of sequence similarity. Of these subgroups, a great deal of research has focused on the characterization of the mitogen-activated protein kinase phosphatases (MKPs)⁵. While DUSP1 has

been identified as a prototypic MAPK phosphatase (DUSP1), an essential endogenous regulator of the inflammatory response to lipopolysaccharide (LPS)⁶, the DUSP6 functions as a feedback regulator of fibroblast growth factor (FGF) signaling to limit the activity of extracellular signal-regulated kinases (ERKs) 1 and 2⁷.

Tacrolimus (FK506, Axon 2263) is an immunosuppressive agent that suppresses both the immune response and apoptosis through inhibition of the phosphatase activity of calcineurin (calcium dependent serine/threonine protein phosphatase 2B; EC 3.1.3.16). FKBP12, the best-characterized member of the FKBP family of immunophilins, interacts with calcineurin only in the presence of Tacrolimus⁸. Structural studies have shown that the FKBP12–FK506 complex binds 'snugly' to calcineurin and blocks its interaction with substrates. Calcineurin, that is activated by Ca²⁺ and calmodulin, is implicated in both signal transduction events and apoptosis⁹.

The tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN; EC 3.1.3.67), a phosphatidylinositol 3'-phosphatase that converts PtdIns(3,4,5)P₃ to phosphatidylinositol 4,5-bisphosphate, is one of the three regulators (besides PI3K and SHIP) of the cellular level of phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P₃], and one of the most important tumor suppressors by down-regulating the PI3K–Akt–mTOR pathway, through its lipid phosphatase activity¹⁰. Due to its protein phosphatase activity, PTEN plays an important role as one of the key mediators of downstream GPCR signaling. As such, its role is also emerging as an important factor in other diseases, such as diabetes and autism spectrum disorders. For example, depletion of PTEN enhances the sensitivity of neutrophil to chemoattractant stimulation, augments neutrophil recruitment to sites of infection, and prevents neutrophil death. In a neutropenia-related pneumonia model, PTEN-null neutrophils possess an enhanced bacteria-killing capability, and their recruitment to the inflamed lungs is augmented¹¹.

Protein tyrosine phosphatase, receptor type, C (PTPRC or CD45; EC 3.1.3.48) is expressed at high levels on the surface of all nucleated hematopoietic cells, and known to be a signaling molecule that regulate a variety of cellular processes including cell growth, differentiation, mitosis, and oncogenic transformation¹². PTPRC is an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. Throughout the life of a T-cell, PTPRC is differentially glycosylated, and the glycosylation state of PTPRC controls recognition by various binding partners, affects intracellular signaling by the cytoplasmic tyrosine phosphatase domain and modulates the response of the T-cell to antigen¹³. This PTPRC also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling¹⁴.

SHP-2 (EC 3.1.3.48; aka tyrosine-protein phosphatase non-receptor type 11 (PTPN11), protein-tyrosine phosphatase 1D (PTP-1D), or protein-tyrosine phosphatase 2C (PTP-2C)) is a cytoplasmic SH2 (Src-homology 2) domain containing member of the family of protein tyrosine phosphatases (PTP), transducing signal relay from the cell surface to the nucleus¹⁵. It is ubiquitously expressed and shown to be involved in regulation of cellular development and differentiation, survival, and migration by promoting growth factors-induced activation of PI3K/Akt, the extracellular signal-related kinases (ERKs), NF-κB, JAK2/STAT, and other pathways¹⁶.

¹ D.A. Proia et al. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. *J. Biol. Chem.* 2006, 281, 7089-7101.
² L. Jiao et al. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy. *Anticancer Res.* 2014, 34, 2919-2925.
³ H.P. Harding et al. Ppp1r15 gene knockout reveals an essential role for translation initiation factor 2 alpha (eIF2α) dephosphorylation in mammalian development. *Proc Natl Acad Sci U S A.* 2009, 106(6), 1832–1837.
⁴ E. Kojima et al. The function of GADD34 is a recovery from a shutoff of protein synthesis induced by ER stress: elucidation by GADD34-deficient mice. *FASEB J.* 2003 Aug;17(11):1573-5.
⁵ Dual-specificity phosphatases: critical regulators with diverse cellular targets. K.I. Patterson et al. *Biochem. J.* 2009, 418, 475-489.
⁶ Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. M. Hammer et al. *J. Exp. Med.* 2006, 203, 15-20.
⁷ Dusp6(Mkp3) is a negative feedback regulator of FGF stimulated ERK signaling during mouse development Chaoying Li. *Development.* 2007, 134, 167-176.
⁸ C. B. Kang et al. FKBP family proteins: immunophilins with versatile biological functions. *Neurosignals.* 2008, 16, 318-325.
⁹ M. Shirane et al. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. *Nat. Cell Biol.* 2003, 5, 28-37.
¹⁰ Y. Li et al. Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. *Blood.* 2011, 117, 6702-6713.
¹¹ C.A. Worby et al. PTEN. *Annu. Rev. Biochem.* 2014, 83, 641-669.
¹² M.L. Hermiston et al. CD45: a critical regulator of signaling thresholds in immune cells. *Annu Rev. Immunol.* 2003, 21, 107-137.
¹³ L.A. Earl et al. CD45 glycosylation controls T-cell life and death. *Immunol. Cell Biol.* 2008, 86, 608-615.
¹⁴ J. Zikherman et al. Quantitative differences in CD45 expression unmask functions for CD45 in B-cell development, tolerance, and survival. *Proc. Natl. Acad. Sci. USA.* 2012, 109, E3-12.
¹⁵ CK Qu. The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. *Cell Res.* 2000 Dec;10(4):279-88.
¹⁶ J. Kiyan et al. The tyrosine phosphatase SHP-2 controls urokinase-dependent signaling and functions in human vascular smooth muscle cells. *Exp Cell Res.* 2009 Apr 1;315(6):1029-39.

3729	ABBV-CLS-484 hydrochloride	<i>Inhibitor of phosphatase PTPN1/N2 (Protein Tyrosine Phosphatase Non-Receptor Type 1 and 2),</i>	Page 198
2178	BCI	<i>Allosteric inhibitor of dual-specificity phosphatases (Dusp).</i>	Page 293
2852	BCI hydrochloride	<i>Allosteric inhibitor of dual-specificity phosphatases (DUSP)</i> ...	Page 294
1821	CCT 007093	<i>Protein phosphatase 1D (PPM1D) inhibitor</i>	Page 351
3018	DJ001	<i>Selective, non-competitive, allosteric inhibitor of PTPσ</i>	Page 433
3439	FBPase-1 inhibitor	<i>Allosteric inhibitor of fructose-1,6-bisphosphatase (FBPase-1)</i> Page	475

3767	GDC-1971	<i>Orally available, potent, and selective inhibitor of the protein tyrosine phosphatase SHP2</i>	Page 500
3994	GSK2830371	<i>Highly selective Wip1 phosphatase inhibitor</i>	Page 520
3903	IACS-13909 hydrochloride	<i>Potent and specific allosteric inhibitor of SHP2</i>	Page 554
3721	JAB-3068	<i>SHP2 inhibitor</i>	Page 576
3680	LockdownPro	<i>Prodrug of Lockdown; PPM1F inhibitor</i>	Page 617
3559	Myricetin	<i>RNase L inhibitor</i>	Page 686
3267	NCGC00378430	<i>SIX1/EYA2 complex inhibitor</i>	Page 694
3436	PRL-3 inhibitor	<i>Selective inhibitor of PRL-3</i>	Page 791
3868	RMC-4550 hydrochloride	<i>Potent, selective and orally available small molecule allosteric inhibitor of SHP2</i>	Page 822
2524	Sephin 1	<i>Selective PPP1R15A inhibitor</i>	Page 861
2186	SF 1670	<i>Inhibitor of PTEN with inhibitory effect on PTPRC and GALK</i> .	Page 863
3806	SPAA-52	<i>Highly potent, selective, cell permeable and orally bioavailable LMW-PTP inhibitor</i>	Page 882
2263	Tacrolimus	<i>Calcineurin (Ca2+ dependent) inhibitor</i>	Page 904
3865	TNO155	<i>Selective and orally bioavailable allosteric inhibitor of SHP2</i> ..	Page 934
2723	TPI-1	<i>Selective SHP1 inhibitor</i>	Page 937

Enzymes (EC 3.1.4.) Phosphodiesterases

No less than eleven sub-types of the enzyme family of phosphodiesterases (PDE; EC 3.1.4.-) are known to date, many of which exist as splice variants¹. They are essential regulators of cyclic nucleotide signaling with diverse physiological functions. Roughly, the sub-types can be divided into 3 groups: one group of enzymes specifically degrades cyclic adenosine monophosphate (cAMP; PDE4, 7 and 8), another group specifically targets cyclic guanosine monophosphate (cGMP; PDE5, 6, and 9), whereas the third group of enzymes (including PDE1, 2, 3, 10, and 11) are non specific towards either cAMP or cGMP. PDEs influence a vast array of pharmacological processes, including pro-inflammatory mediator production and action, ion channel function, muscle contraction, learning, differentiation, apoptosis, lipogenesis, glycogenolysis and gluconeogenesis. Recent advances in molecular pharmacology of PDE isoenzymes resulted in identification of new potential applications of PDE inhibitors in various therapeutic areas, including dementia, depression and schizophrenia².

Phosphatidic acid (PA) is a lipid second messenger located at the intersection of several lipid metabolism and cell signaling events including membrane trafficking, survival, and proliferation. Generation of signaling PA has long been primarily attributed to the activation of phospholipase D (PLD; EC 3.1.4.4). PLD catalyzes the hydrolysis of phosphatidylcholine into PA. A variety of both receptor-tyrosine kinase and G-protein-coupled receptor stimulations have been shown to lead to PLD activation and PA generation³

¹ Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Bolger G. B. *Cell. Signal.* 1994, 6, 851–859.
² Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Y. H. Jeon, Y. -S. Heo, C. M. Kim, Y. -L. Hyun, T. G. Lee, S. Ro and J. M. Cho. *Cell. Mol. Life Sci.* Vol. 2005, 62, 1198.
³ S.A. Scott et al. Regulation of phospholipase D activity and phosphatidic acid production after purinergic (P2Y6) receptor stimulation. *J. Biol. Chem.* 2013, 288, 20477-20487.

1957	Apremilast	<i>PDE4 inhibitor</i>	Page 243
1178	BAY 19-8004	<i>PDE4 inhibitor</i>	Page 288
3148	BPN14770	<i>Potent, selective, allosteric inhibitor of PDE4D</i>	Page 324
3574	Carbazeran	<i>Potent phosphodiesterase inhibitor and an aldehyde oxidase (AO) substrate</i>	Page 343
3169	Crisaborole	<i>Potent PDE4 inhibitor; Anti-inflammatory agent</i>	Page 395
3772	DPTIP hydrochloride	<i>Potent selective, metabolically stable, and brain-penetrant nSMase2 inhibitor</i>	Page 441
4042	ENPP1 inhibitor compound 43	<i>Potent, selective and orally bioavailable ENPP1 inhibitor</i>	Page 460
2281	FIPI hydrochloride	<i>Phospholipase D (PLD) inhibitor</i>	Page 482
2218	Gisadenafil besylate	<i>Potent and selective inhibitor of PDE5</i>	Page 502

3094	GLPG1690	First-in-class, potent ATX inhibitor	Page 505
3289	GW4869 trifluoroacetate	Noncompetitive, neutral, magnesium-dependent SMase inhibitor	Page 536
4136	HA130	Autotaxin (ATX) inhibitor	Page 538
4234	HA-155 Recent Addition	Potent ATX inhibitor	Page 538
1127	L 454560	PDE4 inhibitor	Page 601
3202	LEI-401	First-in-class, potent, selective and CNS-active NAPE-PLD inhibitor	Page 610
3401	MBCQ	Potent and selective inhibitor of PDE5	Page 640
3314	Milrinone	PDE3 inhibitor	Page 656
1168	Olprinone hydrochloride	PDE3 inhibitor	Page 733
1482	Parogrelil	PDE3 inhibitor	Page 747
1709	PDE5 inhibitor 42	PDE5 inhibitor	Page 756
2825	PDE9A inhibitor C33(S)	Potent and selective PDE9A inhibitor	Page 756
3179	Pentoxifylline	Non-specific inhibitor of cAMP phosphodiesterases	Page 758
2148	PF 04447943	Selective, brain penetrant PDE9A inhibitor	Page 767
3442	PF-8380	Potent, orally bioavailable ATX inhibitor	Page 762
4013	Piclamilast	Potent and selective PDE4 inhibitor	Page 776
2352	Roflumilast	First specific PDE4 inhibitor licensed for treatment of COPD	Page 827
1212	Rolipram	PDE4 inhibitor	Page 827
1229	Rolipram, (R)-(-)	PDE4 inhibitor	Page 827
1432	Rolipram, (S)-(+)	PDE4 inhibitor	Page 828
4002	RS 25344	Selective PDE4 inhibitor	Page 832
1592	SB 207499	PDE4 inhibitor	Page 845
2046	Sildenafil citrate	Inhibitor of cGMP-specific PDE5	Page 866
2399	TAK 063	Highly potent, selective, and orally active PDE10A inhibitor	Page 906
1225	U 73122	PLC inhibitor	Page 946
3396	Vardenafil dihydrochloride	Highly potent, selective and orally bioavailable inhibitor of cGMP-specific PDE5	Page 962
3889	Vinpocetine	Brain-penetrant PDE/IKK inhibitor; Na ⁺ channel blocker	Page 969
1216	Zardaverine	PDE3 and PDE4 inhibitor	Page 1003

Enzymes (EC 3.1.22.) Endodeoxyribonucleases

DNA double strand breaks (DSBs) can be repaired by end joining pathways that do not utilize significant homology at the broken ends, or through homologous recombination (HR). When HR is used for repair, in eukaryotes it is promoted by the recombinase RAD51 (EC 3.1.22.4), which binds to 3'-tailed single strands at the end of DSBs in a helical fashion and promotes pairing with homologous DNA sequences as a prelude to strand invasion and repair of the DSBs¹. Five subtypes of the RAD51 recombinase family are known (RAD51B, RAD51C, RAD51D, XRCC2 and XRCC3), which all act to transduce the DNA damage signal to effector kinases and to promote break repair. RAD51 resides as a small monomeric molecule which assembles into long helical polymers that wrap around the ssDNA tail at the break site. The resulting nucleoprotein filament catalyses pairing with and strand invasion into an intact homologous DNA molecule. Assembly of RAD51 monomers onto ssDNA is a relatively slow process and is facilitated by several mediator proteins. The tumor suppressor protein BRCA2 is the best-characterized loader of RAD51 monomers at DSBs². Overexpression of Rad51 is found in human tumors, and its increase is related to p53 function.

¹ H.L. Klein. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair 2008, 7, 686-693.

² N. Suwakia, K. Klarea, M. Tarsounas. RAD51 paralogs: Roles in DNA damage signaling, recombinational repair and tumorigenesis. Semin. Cell Dev. Biol. 2011, 22, 898-905.

3009	BRD0539	Reversible and cell-permeable Cas9 inhibitor	Page 326
1911	RAD51 inhibitor B02	Inhibitor of RAD51	Page 805

1885	RI-1	Inhibitor of the central recombination protein RAD51	Page 817
2584	RS-1	Enhancer of CRISPR-based genome editing & HDR/RAD51	Page 833

Enzymes (EC 3.2.1.) Glycosidases

Alpha-Mannosidosis is a lysosomal storage disorder caused by deficient activity of the enzyme alpha-D-mannosidase (EC 3.2.1.24). In humans it is known to be caused by an autosomal recessive genetic mutation. causes sugar build up and impairs cell function. Complete absence of functional enzyme leads to death during early childhood due to deterioration of the central nervous system. Enzyme with low residual activity leads to a milder type of the disease, with symptoms like reduced hearing, mental retardation, susceptibility to bacterial infections and skeletal deformities¹.

Miglitol (Axon 2067), an alpha-glucosidase (EC 3.2.1.20) inhibitor, is an oral antihyperglycaemic agent is indicated for the treatment of patients with type 2 diabetes mellitus².

¹ Adult alpha-mannosidosis: clinical progression in the absence of demyelination. A. Gutschalk, I. Harting, M. Cantz, C. Springer, K. Rohrschneider, H.M. Meinck. Neurology. 2004, 63, 1744-1746.

² Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. L.J. Scott, C.M. Spencer. Drugs. 2000, 9, 521-549.

3570	CD38 inhibitor compound 78c	Potent, specific, reversible, and uncompetitive inhibitor of CD38	Page 353
3517	DSRM-3716	Potent and selective SARM1 NADase inhibitor	Page 443
2617	GSK837149	Selective inhibitor of human fatty acid synthase (FAS)	Page 526
1730	Kifunensine, (+)	Alpha-mannosidase inhibitor	Page 591
2067	Miglitol	Alpha-glucosidase inhibitor; oral anti-diabetic	Page 655
3260	OAT-1441	First highly potent, selective and orally bioavailable hAMCase inhibitor	Page 728
3353	OATD-01	First-in-class, highly potent and selective CHIT1 inhibitor	Page 728
3136	Oseltamivir phosphate	Selective and orally available inhibitor of influenza virus neuraminidases	Page 737
2934	TH 5487	Potent and selective active-site OGG1 inhibitor	Page 924
4210	Voglibose Recent Addition	α -Glucosidase inhibitor	Page 970

Enzymes (EC 3.3.2.) Glycosidases

Soluble epoxide hydrolase (sEH; EC 3.3.2.10) is a key enzyme in the metabolism of eicosanoid epoxides, including epoxyeicosatrienoic acids (EETs) and of leukotoxin (LTX). EETs, endothelium-derived hyperpolarizing factors, exhibit potentially beneficial properties, including anti-inflammatory effects and vasodilation. The enzyme is a bifunctional homodimeric complex located in both cytosol and peroxisomes with hydrolase and phosphatase activity¹. GSK2256294A (Axon 2220) is a potent, selective inhibitor of sEH, and attenuates cigarette smoke-induced inflammation by both inhibiting its initiation and/or maintenance and promoting its resolution. GSK2256294A would be an appropriate agent to evaluate the role of sEH in clinical studies, for example in diseases where cigarette smoke is a risk factor, such as chronic obstructive pulmonary disease (COPD) and cardiovascular disease².

Leukotriene A4 hydrolase/aminopeptidase (LTA4H; EC 3.3.2.6) is a ubiquitously expressed bifunctional zinc metalloenzyme with epoxide hydrolase and aminopeptidase activities utilizing the same Zn present active site. It catalyzes biosynthesis of the proinflammatory mediator, LTB4, implicated in chronic inflammatory diseases. Recently, the chemotactic tripeptide Pro-Gly-Pro was identified as the enzyme's endogenous peptidase substrate^{3,4}.

¹ H.C. Shen. Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin. Ther. Pat. 2010, 20, 941-956.

² P.L. Podolin et al. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid. Mediat. 2013, 104-105, 25-31.

³ S. Thangapandian et al. Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design. PLoS One. 2012, 7, e34593.

⁴ A.M. Fourie. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase. Curr. Opin. Investig. Drugs. 2009, 10, 1173-1182.

2307	ARM1	Novel type of LTA4H inhibitor	Page 247
2220	GSK 2256294A	Potent, reversible, tight binding inhibitor of human sEH	Page 528
3022	TUPS	Soluble epoxide hydrolase inhibitor	Page 944

Enzymes (EC 3.4.) Peptidases

Proteases, also known as proteolytic enzymes, are enzymes that catalyze the breakdown of proteins by hydrolysis of peptide bonds. By cleaving proteins, proteases are involved in the control of a large number of key physiological processes such as cell-cycle progression, cell proliferation and cell death, DNA replication, tissue remodeling, haemostasis (coagulation), wound healing and the immune response. So far, inappropriate proteolysis has been found to have a major role in cancer as well as cardiovascular, inflammatory, neurodegenerative, bacterial, viral and parasitic diseases. Because excessive proteolysis can be prevented by blocking the appropriate proteases, this area is widely explored by pharmaceutical companies. Their mechanism of action classifies the large family of proteases as either serine, cysteine or threonine proteases (amino-terminal nucleophile hydrolases), or as aspartic, metallo and glutamic proteases (with glutamic proteases being the only subtype not found in mammals so far)¹. Interestingly, the serine and cysteine proteases act directly as nucleophiles to attack the substrate (by generating covalent acyl enzyme intermediates). On the other hand, the aspartyl and zinc proteases activate water molecules as the direct attacking species on the peptide bond. Proteases of the different classes can be further grouped into families on the basis of amino acid sequence comparison, and families can be assembled into clans based on similarities in their three-dimensional structures².

Proteasomes are protein complexes inside all eukaryotes and archaea, and in some bacteria which main function is to degrade unneeded or damaged proteins by proteolysis. The 26S proteasome is a eukaryotic ATP-dependent protease (EC 3.4.-) that is known to collaborate with the ubiquitin system, the system that tags proteins with polyubiquitin chains as a marker for protein degradation in eukaryotic cells that degrades ubiquitin conjugates³. It consists of no less than 31 principal subunits arranged into two subcomplexes, the 20S core protease (CP) and the 19S regulatory particle (RP). The CP is a broad spectrum ATP- and Ubiquitin-independent protease. It is a cylindrical stack created by the assembly of four heptameric rings. The two peripheral rings are composed of seven related α -subunits and the two central rings are composed of seven related β -subunits. The subunits have active sites with various hydrolase cleavage capacities, enabling the 26S proteasome to cleave most, if not all, peptide bonds⁴. Bortezomib (Axon 1810) is a specific inhibitor of 26S proteasome activity with approved application for use in multiple myeloma⁵.

¹ Targeting proteases: successes, failures and future prospects. Boris Turk. Nature Reviews – Drug Discovery. Volume 5, 2006, 785-799.

² Proteases: Multifunctional Enzymes in Life and Disease. C. López-Otín, J.S. Bond. J. Biol. Chem. 2008, 283, 30433-30437.

³ S. Murata, H. Yashiroda, K. Tanaka. Molecular mechanisms of proteasome assembly. Nat. Rev. Mol. Cell Biol. 2009, 10, 104-115.

⁴ J. Smalle, R.D. Vierstra. The ubiquitin 26S proteasome proteolytic pathway. Annu. Rev. Plant Biol. 2004, 55, 555-590.

⁵ Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines. Y Ling et al. Clin. Cancer Res. 2003, 9, 1145-1154.

1810	Bortezomib	<i>Inhibitor of 26S proteasome</i>	Page 323
4218	Carfilzomib Recent Addition	<i>Irreversible proteasome inhibitor</i>	Page 344
3724	M-3258	<i>Selective inhibitor of LMP7 subunit of the immunoproteasome</i>	Page 637
1869	MG 132	<i>Inhibitor of 26S proteasome</i>	Page 651
2556	MLN 2238	<i>Selective and reversible 20S proteasome inhibitor</i>	Page 673
2557	MLN 9708	<i>Citrate prodrug of MLN 2238</i>	Page 674
2199	ONX 0914	<i>Selective inhibitor of LMP7 subunit of immunoproteasome</i>	Page 734
3849	Oprozomib	<i>Orally active and irreversible inhibitor of 20S proteasome</i>	Page 735

Enzymes (EC 3.4.11.) Amino peptidases

A class of aminopeptidases, widely distributed throughout the animal and plant kingdoms, and found in many subcellular organelles, in cytoplasm, and as membrane components. The aminopeptidase MetAP2 (EC 3.4.11.18) is of particular interest because the enzyme plays a key role in angiogenesis, the growth of new blood vessels, which is necessary for the progression of diseases including solid tumor cancers and rheumatoid arthritis¹.

¹ Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. M.J. Morowitz et al. Clin. Cancer Res. 2005, 11, 2680-2685.

1666	A 357300	<i>MetAP2 inhibitor</i>	Page 191
3208	ERAP1 inhibitor compound 3	<i>Selective ERAP1 inhibitor</i>	Page 465

Enzymes (EC 3.4.14.) Di- and tripeptidyl peptidases

Di- and tripeptidyl peptidases (EC 3.4.14.-) make up an individual class of aminopeptidases. DPP4 (EC 3.4.14.5) is also known as adenosine deaminase complexing protein 2 or CD26 (cluster of differentiation 26). It is an antigenic enzyme expressed on the surface of most cell types and is associated with immune regulation, signal transduction and apoptosis.

It is an intrinsic membrane glycoprotein and a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides. Additionally, it has been proven to be implicated in the pathogenesis of type 2 diabetes¹.

Butabindide oxalate (Axon 1228) has proven to inhibit the cholecystokinin-8 (CCK-8)-inactivating peptidase, which is in fact a membrane-bound isoform of tripeptidyl peptidase II (EC 3.4.14.10). CCK-8 in its sulfated form functions as a neurotransmitter. It is released in response to ingestion of food and is involved in the control of food digestion through regulation of gallbladder contraction, pancreatic secretion, and contraction of the pyloric sphincter to delay gastric emptying. Inhibition of the enzyme therefore could be an opportunity to treat obesity related metabolic diseases².

¹ Vildagliptin, a dipetidyl peptidase-IV inhibitor, improves model-assessed β -cell function in patients with type 2 diabetes. A. Mari et al. J. Clin. Endocrinol. Metab. 2005, 90, 4888-4894.

² Inhibitors of Tripeptidyl Peptidase II. 3. Derivation of Butabindide by Successive Structure Optimizations Leading to a Potential General Approach to Designing Exopeptidase Inhibitors. C.R. Ganellin et al. J. Med. Chem., 2005, 48, 7333-7342.

3310	Alogliptin benzoate	<i>Potent, highly selective and orally active DPP-4 inhibitor</i>	Page 219
1228	Butabindide oxalate	<i>TTP2 inhibitor</i>	Page 333
2354	Linagliptin	<i>Competitive and highly selective DPP-4 inhibitor</i>	Page 615
3438	NDMC101	<i>DPP-4 inhibitor; Osteoclastogenesis inhibitor</i>	Page 696
3492	Perindopril erbumine	<i>Orally bioavailable long-acting ACE inhibitor</i>	Page 759
3655	Quinapril hydrochloride	<i>ACE inhibitor</i>	Page 802
3251	Sitagliptin	<i>Potent, selective and orally active DPP-4 inhibitor</i>	Page 869
3309	Teneligliptin hydrobromide	<i>Highly potent, selective, long-lasting and orally active DPP-4 inhibitor</i>	Page 938
2470	Trelagliptin succinate	<i>Orally active DPP4 inhibitor (type 2 diabetes)</i>	Page 938
1631	Vildagliptin	<i>DPP4 inhibitor</i>	Page 969

Enzymes (EC 3.4.19.) Omega peptidases

The proper regulation of apoptosis is essential for the survival of multicellular organisms. It has become clear that the post-translational modification of apoptotic proteins by ubiquitination regulates key components in cell death signaling cascades. Ubiquitination, which describes the covalent modification of target proteins with ubiquitin, has a profound bearing on the fate and function of its substrates and requires the enzymic activity of an E1, an E2 and an E3 protein (of which many subtypes are known to date). While ubiquitination, similarly to phosphorylation, is a reversible modification, in mammals, approximately 100 DUBs (EC 3.4.19.12) function to depolymerize and remove ubiquitin adducts as well. USP7 and USP47 are just two examples of deubiquitination enzymes that assist in the highly complex processes that regulate apoptosis¹. USP7 (or HAUSP) is most popularly known as a direct antagonist of Mdm2, the E3 ubiquitin ligase for the p53 tumor suppressor protein². Similarly, USP47 was recently identified as a novel interactor of the E3 ubiquitin ligase SCF β -Trcp. However, in contrast with the effects of USP7, USP47 depletion seems not to depend on p53 status³. Human ubiquitin-specific protease 1 (USP1), which is associated with UAF1, has been identified as the deubiquitinase (DUB) responsible for deubiquitinating PCNA, FANCD2 and FANCI in the DNA damage response. USP1 is also required for the FANCD2 foci formation in both mouse and human cells. A high level of genomic instability has been linked to deficiency in human ATAD5 (the human ortholog of yeast Elg1), which mediates PCNA deubiquitination by USP1-UAF1. Together, these observations suggest that the DUB activity of USP1-UAF1 is important for the normal cellular response to DNA damage⁴.

¹ Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. D. Vucic, V.M. Dixit, I.E. Wertz. Nat. Rev. Mol. Cell Biol. 2011, 12, 439-452.

² M. Li, D. Chen, A. Shiloh, J. Luo, A.Y. Nikolaev, J. Qin, W. Gu. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002, 416, 648-653.

³ The ubiquitin-specific protease USP47 is a novel β -TRCP interactor regulating cell survival. A. Peschiaroli, J.R. Skaar, M. Pagano, G. Melino. Oncogene 2010, 29, 1384-1393.

⁴ Q. Liang et al. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat Chem. Biol. 2014, 10, 298-304.

1798	Eeyarestatin I	<i>Inhibitor of ER associated protein degradation (ERAD)</i>	Page 449
3732	HBX 41,108	<i>Inhibitor of deubiquitinase USP7</i>	Page 539
3426	IU1-47	<i>Potent and selective inhibitor deubiquitinase USP14</i>	Page 574
3770	KSQ-2479	<i>An allosteric, first-in-class USP1 (Ubiquitin Specific Protease 1) inhibitor</i>	Page 596
2449	LDN 57444	<i>Reversible, competitive inhibitor of UCH-L1 deubiquitinase</i>	Page 609
2309	ML 323	<i>Inhibitor of the USP1-UAF1 deubiquitinase complex</i>	Page 667

2995	ML 367	Inhibitor of ATAD5 stabilization	Page 670
2678	ML364	Inhibitor of the deubiquitinase USP2	Page 671
4191	MS102 Recent Addition	Orally available USP2 inhibitor	Page 682
2228	NSC 687852	Inhibitor of 19S DUBs: UCHL5 and USP14	Page 717
2011	P 005091	Inhibitor of deubiquitinase USP7 and USP47	Page 744
1906	P 22077	Inhibitor of deubiquitinase USP7 and USP47	Page 743
2512	Spautin 1	Inhibitor of USP10 and USP13 and autophagy	Page 883
3608	STD1T	Inhibitor of the deubiquitinase USP2a	Page 894
2333	TCID	Potent inhibitor of UCHL3 with good selectivity over UCHL1	Page 914
2991	USP7-USP47 inhibitor	Selective inhibitor of deubiquitinase USP7 and USP47	Page 958
3905	USP14 inhibitor IU1	Selective and reversible inhibitor of Usp14	Page 958
4089	Usp22i-S02	First potent Usp22-specific inhibitor	Page 958
4121	USP25/28 inhibitor AZ1 Recent Addition	Selective dual USP25/USP28 inhibitor	Page 959
1779	WP 1130	Deubiquitinase Inhibitor	Page 987

Enzymes (EC 3.4.21.) Serine proteases

The large family of serine proteases (almost one-third of all proteases; EC 3.4.21.-) is characterized by its general mechanism of action to cleave peptide bonds in proteins, in which serine serves as the nucleophilic amino acid at the (enzyme's) active site. The members of this family can be divided roughly into four sub-groups based on their structure, being chymotrypsin-like (trypsin-like), subtilisin-like, carboxypeptidase Y-like, and Clp-like¹.

Factor Xa is a serine endopeptidase located at the confluence of the intrinsic and extrinsic pathways of the blood coagulation cascade, and composed of two disulfide-linked subunits that converts prothrombin to thrombin. Factor Xa cleaves after the arginine residue in its preferred cleavage site Ile-(Glu or Asp)-Gly-Arg and it will occasionally cleave at other basic residues. However, it will not cleave at a site followed by proline or arginine. fXa has emerged as an attractive target for developing safer anticoagulant drugs. Inhibition of fXa should prevent production of new thrombin without affecting its basal level, which should ensure primary hemostasis².

HCV is a plus-stranded RNA virus, and its genome with a large open reading frame encodes a poly protein precursor of about 3010 amino acid residues having an internal ribosome entry site at 5' untranslated region (UTR), vital for the translation. This poly protein precursor is cleaved to generate at least 10 proteins, among which the HCV NS3-4A protein. The NS3-4A serine protease is a non-covalent, heterodimer complex formed by two HCV-encoded proteins, the N-terminal serine protease domain of NS3 (catalytic subunit) and the NS4A cofactor (activation subunit). The NS3-4A serine protease is responsible for the proteolytic cleavage at four junctions of the HCV polyprotein precursor: NS3/NS4A (self cleavage), NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B³. It is hypothesized that development of a specific inhibitors of NS3 protease activity would be an attractive target for new anti-HCV drugs, since the inhibition of NS3/4A protease will interfere with the viral life cycle and restore the pathways of innate immunity⁴.

Human leukocyte elastase, which is also referred to as neutrophil elastase (HLE or HNE; EC 3.4.21.47), is a highly cationic, broad-spectrum serine protease (30 kDa) primarily located in the azurophilic granules of polymorphonuclear leukocytes in very high concentrations. The serine proteinase is a member of the same family as chymotrypsin and preferentially cleaves substrates C-terminally to small hydrophobic residues⁵. Under normal circumstances, the proteolytic activity of HLE is effectively controlled by its natural inhibitors. However, an imbalance between elastase and its endogenous inhibitors may result in several pathophysiological states such as chronic obstructive pulmonary disease, asthma, emphysema, cystic fibrosis, and chronic inflammatory diseases. It is anticipated that an orally active HLE inhibitor could be useful for the treatment of these diseases⁶. HLE also participates in direct intracellular killing of phagocytosed bacteria in phagolysosomes in combination with myeloperoxidase and reactive oxygen species generated by the NADPH oxidase complex. It exerts its antimicrobial activity on Gram-negative bacteria by cleaving the outer membrane protein A⁷.

Heparin cofactor II (HCII; EC 3.4.21.xx) is a serine protease inhibitor (serpin) that inactivates thrombin rapidly in the presence of certain glycosaminoglycans (GAGs; dermatan sulfate, heparan sulfate, or heparin), but does not inhibit other proteases involved in coagulation or fibrinolysis. Heparin cofactor II (HCII) has several biochemical properties that distinguish it from other serpins: it specifically inhibits thrombin, and the mechanism of inhibition involves binding of an acidic domain in HCII to thrombin exosite I. The rate of inhibition increases dramatically (more than 1000-fold) in the presence of heparin, heparan sulfate, or dermatan sulfate. HCII has been proposed to regulate coagulation or to participate in processes such as inflammation, atherosclerosis, and wound repair^{8,9}.

¹ L. Hedstrom. Serine Protease Mechanism and Specificity. Chem. Rev. 2002, 102, 4501-4524.

² M. de Candia et al. Novel factor Xa inhibitors: a patent review. Exp. Opin. Ther. Pat. 2009, 19, 1535-1580.

³ C. Lin. HCV NS3-4A Serine Protease. In: S.L. Tan, editor. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience; 2006. Chapter 6.

⁴ S. Idrees et al. HCV Infection and NS-3 Serine Protease Inhibitors. Virol Mycol 2013, 2, 112.

⁵ U. Meyer-Hoffert et al. Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation. J. Invest. Dermatol. 2004, 123, 338-345.

⁶ J. Pharmacol. Exp. Ther. 2003, 305, 451-459. Z. Kapui et al. Biochemical and pharmacological characterization of 2-(9-(2-piperidinoethoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-ylloxymethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor.

⁷ B. Korkmaz et al. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol. Rev. 2010, 62, 726-759.

⁸ D.M. Tollesen et al. Heparin cofactor II modulates the response to vascular injury. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 454-460.

⁹ L. He et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J. Clin. Invest. 2002, 109, 213-219.

3590	ACT001	PAI-1 inhibitor	Page 206
1754	Apixaban	Factor Xa inhibitor	Page 241
2822	BAY-678	Potent, selective and orally active human neutrophil elastase (HNE) inhibitor	Page 291
3568	Col003	Potent, competitive collagen-Hsp47 interaction inhibitor	Page 382
3117	Dabigatran etexilate	Prodrug of Dabigatran; Thrombin inhibitor	Page 406
2093	Daclatasvir dihydrochloride	Hepatitis C virus (HCV) NS5A protein inhibitor	Page 407
1669	Danoprevir	HCV NS3/4A serine protease inhibitor	Page 408
3116	Edoxaban tosylate	Potent, selective and orally active factor Xa inhibitor	Page 451
2364	GW 311616A	Potent human neutrophil elastase (HNE) inhibitor	Page 533
3294	HSP47 inhibitor III	Inhibitor of the collagen-specific chaperone HSP47	Page 533
3300	Ledipasvir	Potent and orally available NS5A inhibitor	Page 609
1536	Odiparvil	Thrombin inhibitor (via Heparin CoFII)	Page 729
4171	OTS514	Highly potent TOPK inhibitor	Page 739
3876	OTS-964	TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor	Page 740
4097	OTS964 hydrochloride	TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor	Page 740
3710	PAZ-417	Potent, orally active and CNS-penetrant PAI-1 inhibitor	Page 749
3875	PCI-27483	PCI-27483 is a potent and selective small-molecule inhibitor of activated factor VII (factor VIIa)	Page 750
3175	Rivaroxaban	Highly potent, selective and oral direct FXa inhibitor	Page 821
1269	SSR 69071	HLE inhibitor	Page 890
3618	uPA inhibitor BC-11 hydrobromide	Highly specific urokinase-plasminogen activator (uPA) inhibitor	Page 955
3173	Velpatasvir	Hepatitis C virus NS5A inhibitor	Page 964
2911	Y 29794 tosylate	Orally active, brain penetrant, potent and specific prolyl endopeptidase (PPCE) inhibitor	Page 997

Enzymes (EC 3.4.21.) Serine proteases, PAI-1

Plasminogen activator inhibitor (PAI-1; EC 3.4.21.68) a serine protease inhibitor, is involved in numerous processes including thrombosis and fibrosis. Its inhibition may thus yield important cardio- and reno-protective benefits. Studies in mice overexpressing human PAI-1 also implicate its involvement in broader biological abnormalities, including alopecia, amyloidosis, and polycystic ovarian syndrome¹.

¹ Y. Izuahara et al. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J. Cereb. Blood Flow Metab. 2010, 30, 904-912.

2838	SK-216	Specific inhibitor of PAI-1	Page 870
1769	T 1776Na	Inhibitor of plasminogen activator inhibitor-1	Page 901
1383	Tiplaxtinin	Plasminogen activator inhibitor-1 (PAI-1) inhibitor	Page 929
2344	TM 5275	Selective and orally active inhibitor of PAI-1	Page 931
2734	TM 5441	Orally active inhibitor of PAI-1	Page 931

Enzymes (EC 3.4.22.) Cysteine proteases

A wide variety of cysteine proteases (CPs) exists, that share the common feature of hydrolyzing substrates by direct nucleophilic attack of a deprotonated cysteine residue at the enzyme's catalytic site. CPs are responsible for many biochemical processes occurring in living organisms and they have been implicated in the development and progression of several diseases that involve abnormal protein turnover. The activity of CPs is regulated among others by their specific inhibitors: cystatins. Mammalian cysteine proteinases fall into two classes: caspases and the papain superfamily comprising the papain family, calpains and bleomycin hydrolases¹.

Mucosa-associated-lymphoid-tissue (MALT1; EC 3.4.22.xx) cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. The caspase-like domain of MALT1 cleaves substrates following arginine residues, unlike conventional caspase that cleave after aspartate residues. MALT1 cleaves and disables A20 (TNFAIP3) and CYLD, both negative regulators of NF- κ B, thereby potentiating NF- κ B signaling². Human rhinoviruses (HRVs) comprise over 100 different serotypes and are the predominant cause of the common cold. Although HRV infections are generally mild and self-limiting, they can also be associated with more serious illnesses, specifically, exacerbation of disease in individuals with underlying respiratory disorders. HRVs are a group of small single-stranded positive-sense RNA viruses that translate their genetic information into a polyprotein precursor that is mainly processed by a virally encoded 3C protease (3Cpro; EC 3.4.22.28) to generate functional viral proteins and enzymes. The enzymatic activity of HRV 3Cpro is essential to viral replication, and is distinguished from most other proteases by the fact that it has a cysteine nucleophile but with a chymotrypsin-like serine protease folding. This unique protein structure together with its essential role in viral replication made the 3Cpro an excellent target for antiviral intervention³.

¹ M. Rzychon, D. Chmiel, J. Stec-Niemczyk. Modes of inhibition of cysteine proteases. Act. Biochim. Pol. 2004, 51, 861-873.

² R.M. Young et al. A New "Brew" of MALT1 Inhibitors. Cancer Cell, 2012, 22(6), 706-707.

³ Q.M. Wang et al. Human rhinovirus 3C protease as a potential target for the development of antiviral agents. Curr Protein Pept. Sci. 2007, 8, 19-27.

1571	AG 7088	HRV3C protease inhibitor	Page 213
3744	KEA1-97	Thioredoxin-caspase 3 interaction disruptor	Page 590
2054	MALT1 inhibitor MI-2	Highly potent and selective MALT1 inhibitor	Page 640
3082	SIC5-6	Specific, noncovalent separase inhibitor	Page 865
2193	Thioridazine hydrochloride	DA and alpha-1 adrenoceptor antagonist; MALT1 inhibitor	Page 926
3857	VX-765	Caspase-1 inhibitor	Page 980

Enzymes (EC 3.4.22.) Cysteine proteases, Caspases

Proteases play critical roles in the initiation and execution of apoptosis. The caspases (EC 3.4.22.xx), a family of cysteine-dependent aspartate-directed proteases, are prominent among the death proteases. Caspases are synthesized as relatively inactive zymogens that become activated by scaffold-mediated transactivation or by cleavage via upstream proteases in an intracellular cascade. Regulation of caspase activation and activity occurs at several different levels. Once activated, caspases cleave a variety of intracellular polypeptides, including major structural elements of the cytoplasm and nucleus, components of the DNA repair machinery, and a number of protein kinases. Collectively, these scissions disrupt survival pathways and disassemble important architectural components of the cell, contributing to the stereotypic morphological and biochemical changes that characterize apoptotic cell death¹.

¹ W.C. Earnshaw et al. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 1999, 68, 383-424.

2006	Apoptosis Activator 2	A cell-permeable apoptosis activator	Page 242
2158	Boc-D-FMK	Broad spectrum caspase inhibitor	Page 323
1375	Ivachtin	Caspase-3 inhibitor	Page 574
1883	NS 3694	Inhibitor of apoptosis; Inhibits formation of apoptosome	Page 711
1743	PAC 1	Procaspase activating compound 1	Page 744
2159	Z-VAD-FMK	Pan-caspase inhibitor with in vivo activity	Page 1003

Enzymes (EC 3.4.22.) Cysteine proteases, CTSK

Cathepsin K (Cat K, CTSK; EC 3.4.22.8) is a member of the CA1 family of lysosomal cysteine proteases and of the papain family. It is considered to be the major enzyme responsible for degradation of the organic bone matrix. It is highly and selectively expressed in osteoclasts and, under acidic conditions, has the unique ability to degrade type I collagen helical

regions. Unlike the other cathepsins, Cat K not only degrades type I collagen in the telopeptide regions, but is capable of cleaving the triple helical domains at multiple sites. The protease is an attractive target for inhibition of bone resorption¹.

¹ S.B. Rodan et al. Cathepsin K – A new molecular target for osteoporosis. IBMS BoneKey 2008, 5, 16-24.

2154	Balicatib	Selective inhibitor of cathepsin K	Page 282
1771	MK 0822	Inhibitor of cathepsin K	Page 661
2156	ONO 5334	Potent and orally available inhibitor of cathepsin K	Page 733

Enzymes (EC 3.4.23.) Aspartic proteases

Five subfamilies of aspartic proteases (EC 3.4.23.-) are classified, all sharing a highly conserved sequence of Asp-Thr-Gly. Compared to the three other types of proteases, serine, cysteine, and metalloproteases, aspartic proteases comprise a relatively small group. The aspartic proteases of many pathogens represent attractive targets for inhibitor design to control the progression of these diseases. The development of effective HIV protease inhibitor drugs for the treatment of HIV infection in AIDS illustrates the importance of this approach. Most of the aspartic proteases belong to a pepsin structural superfamily, having homologous primary and tertiary structures and nearly identical catalytic apparatus¹.

¹ R. Mannhold, H. Kubinyi, G. Folkers (Editors). Aspartic Acid Proteases as Therapeutic Targets. Methods and Principles in Medicinal Chemistry.. 2010. Wiley-VCH Verlag GmbH & Co. KGaA. ISBN: 9783527318117.

1441	BMS 232632	Protease inhibitor	Page 316
1753	Compound 120	Deuterated Protease inhibitor (see Axon 1441)	Page 384
3137	Darunavir	HIV-1 protease inhibitor	Page 410
3138	Lopinavir	HIV-1 protease inhibitor	Page 619
1553	Nelfinavir mesylate	HIV-1 protease inhibitor	Page 697
3139	Ritonavir	HIV-1 protease inhibitor	Page 821

Enzymes (EC 3.4.23.) Aspartic proteases, Beta-secretase (BACE)

The neurotoxic amyloid β -peptide ($A\beta$) is a highly hydrophobic peptide, which aggregates to form oligomers. If these oligomers aggregate further, they start forming fibers, which eventually precipitate and accumulate in amyloid plaques, as defined in Alzheimer's disease. Generation of $A\beta$ occurs by processing of the β -amyloid precursor protein (APP) via proteases called secretases. Three secretases are known, α -, β -, and γ -secretase. While β - and γ -secretase mediate the amyloidogenic cleavage events, α -secretase on the contrary prevents $A\beta$ generation by cleaving APP in the middle of the $A\beta$ domain. β -Secretase (EC 3.4.23.46; also called BACE-1 for β -site APP-cleaving enzyme) was identified as a type 1 transmembrane protein containing aspartyl protease activity and belongs to the pepsin family of aspartyl proteases, but defines a novel subgroup of membrane-associated hydrolases. BACE-1 mediates the primary amyloidogenic cleavage of APP and generates a membrane-bound APP C-terminal fragment (APP CTF β), which is the immediate precursor for the intramembraneous γ -secretase cleavage. In contrast, BACE-2 exhibits an α -secretase-like activity, which cleaves APP in the middle of the $A\beta$ domain at amino acids 19 and 20. Thus, BACE-2 does not contribute to the amyloidogenic processing of APP, which is consistent with the complete lack of $A\beta$ generation in a BACE-1 knockout^{1,2}.

¹ C. Haass. Take five-BACE and the γ -secretase quartet conduct Alzheimer's amyloid β -peptide generation. EMBO J. 2004 February 11; 23(3): 483-488.

² BACE1 as a potential biomarker for Alzheimer's disease. B. Decourt, M.N. Sabbagh. J Alzheimers Dis. 2011, 24, Suppl 2, 53-59.

1125	BACE-1 Inhibitor	BACE 1 inhibitor	Page 279
2957	BACE-2 Inhibitor	Potent and highly selective BACE 2 inhibitor	Page 282
2869	LX2343	BACE 1 inhibitor	Page 626
2225	LY 2811376	The first orally available non-peptidic BACE1 inhibitor	Page 634
1964	LY 2886721 hydrochloride	BACE 1 inhibitor	Page 634
4166	Verubecestat	First-in-class, potent, orally bioavailable high-affinity BACE1 inhibitor	Page 967

Enzymes (EC 3.4.23.) Aspartic proteases, Gamma-secretase

The γ -secretase enzyme (EC 3.4.23.46) is a multi-subunit enzyme complex that consists of four core components (presenilin, nicastrin, APH-1, and PEN-2). Presenilin is an aspartic protease and the catalytic component of the complex. γ -Secretase has the unusual ability to regulate intramembrane proteolysis (RIP) for a growing list of type 1 integral membrane proteins, including, APP, APP-like proteins (APLPs), E-Cadherin, ErbB4, ephrinB2, CD44, lipoprotein receptor-related protein (LRP), Notch, sterol regulatory element-binding protein (SREBP), interferon response element (IRE1), and activated transcription factor 6 (ATF-6)¹. Especially for its capability to hydrolyze APP into amyloid-beta (A β) peptide whose abnormally folded fibrillar form is the primary component of amyloid plaques, γ -secretase is a well-known pharmacological target in the field of Alzheimer's disease².

- ¹ S. Krishnaswamy et al. The structure and function of Alzheimer's gamma secretase enzyme complex. *Crit. Rev. Clin. Lab. Sc.* 2009, 46, 282-301.
² C. Kaether, C. Haass, H. Steiner. Assembly, trafficking and function of gamma-secretase. *Neurodegener Dis.* 2006, 3, 275-283.

2117	Begacestat.....	Selective Gamma secretase inhibitor (GSI).....	Page 297
1487	BZ, γ -Secretase Inhibitor	Gamma Secretase inhibitor.....	Page 336
1484	DAPT	Gamma Secretase inhibitor.....	Page 410
1488	DBZ, γ -Secretase Inhibitor.....	Gamma Secretase inhibitor.....	Page 412
2521	RO 4929097	Potent γ -secretase inhibitor (GSI) targeting Notch signaling ...	Page 826

Enzymes (EC 3.4.24.) Metalloproteases

Matrix metalloproteinases (MMPs; EC 3.4.24.-), also called matrixins, function in the extracellular environment of cells and degrade both matrix and non-matrix proteins. They play central roles in morphogenesis, wound healing, tissue repair and remodeling in response to injury, e.g. after myocardial infarction, and in progression of diseases such as atheroma, arthritis, cancer and chronic tissue ulcers. The activities of most matrixins are very low or negligible in the normal steady-state tissues, but expression is transcriptionally controlled by inflammatory cytokines, growth factors, hormones, cell-cell and cell-matrix interaction. MMPs are classified as the matrixin subfamily of zinc metalloprotease family (M10)¹.

TNF- α converting enzyme (TACE or ADAM17; EC 3.4.24.86), a pro-inflammatory cytokine, catalyzes the formation of TNF- α from membrane bound TNF- α precursor protein. It is believed to play pathophysiological roles in inflammation, anorexia, cachexia, septic shock, viral replication and so on. What's more, TNF- α is a key player in inflammation and joint damage in rheumatoid arthritis. To control the level of TNF- α release, inhibition of TACE activity has long been considered as a promising way of treating related inflammatory diseases for which one of the most attractive strategies is the development of low molecular mass inhibitors of TACE².

A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5; EC 3.2.24.xx) plays a role in cartilage degradation, arthritis, procollagen processing, degradation of proteoglycans, and cancer, among others. It is a member of the metzincins superfamily of zinc-based proteinases³, and 1 of the 19 members of a family of secreted metalloproteinases in humans. ADAMTS-5, also termed ADAMTS-11, aggrecanase-2 or implantin, falls under the subfamily of proteoglycanases within the ADAMTS family. All of the members of ADAMTS family have a similar structural organization with an N-terminal metalloproteinase domain followed by various ancillary domains at the C-terminal region⁴. Several members of the ADAMTS family possess some degree of aggreganolytic activity in vitro, including ADAMTS-5. It cleaves human aggrecan to produce the fragments found in synovial fluid and cartilage⁵.

Endothelin-1 (ET-1) is a potent mitogen for a variety of cell types, including vascular smooth muscle cells, fibroblasts and endothelial cells, and is able to coordinate the proliferative effects of other peptide growth factors. The endothelin system has been implicated in the pathobiology of numerous human cancers including those of the prostate, lung, breast, colon and cervix, and plays a role in the aetiology of other pathologies such as hepatic fibrosis and atherosclerosis. ET-1 is generated via processing of inactive big-ET-1 by endothelin-converting enzyme-1 (ECE-1; EC 3.4.24.71). ECE-1 is upregulated in a number of cancers, including prostate cancer, leading to increased levels of ET-1 peptide⁶.

The proteolytic degradation of A β is a major route of clearance and plays an important role in the pathology of Alzheimer's Disease (AD). A variety of A β degrading enzymes have been found. Of these enzymes, neprilysin (NEP or CD10 or common acute lymphoblastic leukemia antigen (CALLA); EC 3.4.24.11) is considered one of the most important for the control of cerebral A β levels. Neprilysins (NEPs, neutral endopeptidases) and the neprilysin-like peptidases are typically type II integral membrane proteins with their active sites facing the extracellular environment⁷. They are members of the family of zinc-metalloproteases and have been known to play a central role in the regulatory processes of cell-cell signalling. Being thermolysin-like metalloendopeptidases, the family of NEPs comprise angiotensin-converting enzymes (ACE), endothelin-converting enzymes (ECE) and thimet oligopeptidases (TOP)⁸.

- ¹ H. Nagase, R. Visse, G. Murphy. Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc. Res.* 2006, 69, 562-573.
² P. R. Murumkar et al. Novel TACE inhibitors in drug discovery: a review of patented compounds. *Expert Opin. Ther. Pat.* 2010, 20, 31-57.
³ T. Shiomi et al. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. *Pathol. Int.* 2010, 60, 477-496.

- ⁴ S. Kumar et al. ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity. *Am. J. Pathol.* 2012, 181, 1056-1068.
⁵ R. H. Song et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. *Arthritis Rheum.* 2007, 56, 575-585.
⁶ A. R. Whyteside et al. Endothelin-Converting Enzyme-1 (ECE-1) is post-transcriptionally regulated by alternative polyadenylation. *PLoS ONE* 2014, 9, e83260.
⁷ N. D. Bland et al. Bioinformatic analysis of the neprilysin (M13) family of peptidases reveals complex evolutionary and functional relationships. *BMC Evol. Biol.* 2008, 8, 16.
⁸ B. Spanier et al. Caenorhabditis elegans neprilysin NEP-1: an effector of locomotion and pharyngeal pumping. *J. Mol. Biol.* 2005, 352, 429-437.

2083	ADAMTS-5 inhibitor	Selective inhibitor of ADAMTS-5 (aggrecanase-2)	Page 207
3856	AHU-377 tris salt.....	Inhibitor of Neprilysin	Page 215
3891	Clioquinol.....	MMP14/CLK-1 inhibitor; Metal chelator.....	Page 376
2104	CP 471474.....	MMP inhibitor	Page 389
1918	Dagliutril	Orally active, dual ECE/NEP inhibitor.....	Page 408
3030	JNJ0966	Highly selective pro-MMP9 activation inhibitor	Page 581
2162	NSC 405020	MT1-MMP inhibitor specifically targeting PEX-domain.....	Page 716
1271	PD 166793.....	MMP inhibitor	Page 753
1181	PF 00356231	MMP-12 inhibitor	Page 766
2328	PTIQ	Neuroprotectant;attenuating effects on MMP-3 expression.....	Page 796
2370	SB-3CT	Potent inhibitor of Gelatinases MMP-2 and MMP-9.....	Page 844
1507	TMI 005	TACE/MMP inhibitor.....	Page 932
2111	UK 356618.....	Potent MMP-3 (aka Stromelysin-1) inhibitor.....	Page 950
2073	UK 383367.....	Inhibitor of bone morphogenetic protein 1 (BMP-1, aka PCP).Page	951

Enzymes (EC 3.5.) Amidases

Amidases are ubiquitous enzymes and biological functions of these enzymes vary widely. Their proteins structures revealed that aliphatic amidases share the typical a/b hydrolase fold (like nitrilase superfamily) and signature amidases are evolutionary related to aspartic proteinases. They hydrolyze a wide variety of amides (short chain aliphatic amides, mid-chain amides, arylamides, α -aminoamides and α -hydroxyamides) and can be grouped on the basis of their catalytic site and preferred substrate¹.

Termination of the anandamide (arachidonoyl ethanolamide, an endocannabinoid) signaling in the central nervous system and in peripheral tissues is mediated by the fatty acid amide hydrolase (FAAH; EC 3.5.1.99)², an integral membrane serine hydrolase that degrades the fatty acid amide family of signaling lipids. Genetic or pharmacological inactivation of FAAH leads to analgesic and anti-inflammatory phenotypes in rodents without showing the undesirable side effects observed with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for the treatment of inflammatory pain and other nervous system disorders³.

Sulbactam sodium (Axon 2041) is a rather classical, yet weak inhibitor of beta-lactamase (sub-family of cyclic amid hydrolases; EC 3.5.2.6), used to enhance the antibacterial activity of penicillins and cephalosporins against β -lactamase-producing organisms. β -lactamases may be grouped into four classes, of which A, C, and D are serine hydrolases, and B encompasses metallo- β -lactamases. During several decades, not only have the class A and C enzymes become widely disseminated so as to become the most widespread causes of β -lactam antibiotic-resistant Gram-negative infections in Europe and North America, but many mutant forms have also evolved which are capable of hydrolyzing the expanded-spectrum β -lactam antibiotics⁴.

Arginases (EC 3.5.3.1) catalyze the divalent cation dependent hydrolysis of L-arginine to produce L-ornithine and urea, the final step of the urea cycle. While arginase I (or liver arginase) is cytosolic, and is the best characterized of the mammalian arginases, arginase II (or kidney arginase), is mitochondrial in location. Due to its generation of L-ornithine, arginase is involved in several important downstream metabolic pathways⁵. Most importantly, the enzyme is crucially involved in various aspects of inflammation. Arginase has been shown to be either responsible for or to participate in, for example, inflammation-triggered immune dysfunction, tumour immune escape, fibrosis, immunosuppression and immunopathology of infectious diseases⁶. Small-molecule arginase inhibitors are currently described as promising therapeutics for the treatment of several diseases, including allergic asthma, inflammatory bowel disease, ulcerative colitis, cardiovascular diseases (atherosclerosis and hypertension), diseases associated with pathogens (e.g., *Helicobacter pylori*, *Trypanosoma cruzi*, *Leishmania*, *Mycobacterium tuberculosis* and *Salmonella*), cancer and induced or spontaneous immune disorders⁷.

Adenosine deaminase (ADA; EC 3.5.4.4) is a ubiquitous enzyme that catabolizes adenosine and deoxyadenosine to inosine and deoxyinosine. During an ischemic brain event, the extracellular adenosine concentration increases over 10-fold and adenosine is deaminated to inosine by ADA. Congenital ADA deficiency results in severe combined immunodeficiency

(SCID), caused by an increase in deoxy-adenosine levels in the serum and tissues. This increases deoxy-ATP levels in the T-cells and causes T-cell apoptosis⁸, and primarily affects lymphocyte development, viability, and function when diagnosed in infancy.

- ¹ Amidases: versatile enzymes in nature. M. Sharma, N.N. Sharma, T.C. Bhalla. Rev. Environ. Sci. Biotechnol. 2009, 8, 343-366.
- ² D.G. Deutsch, N. Ueda, S. Yamamoto. The fatty acid amide hydrolase (FAAH). Prost. Leuk. Ess. Fat. Ac. 2002, 66, 201-210.
- ³ D.S. Johnson et al. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med. Chem. Lett. 2011, 2, 91-96.
- ⁴ T. Stachyra et al. Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor. Antimicrob. Agents Chemother. 2010, 54, 5132-5138.
- ⁵ D.E. Ash et al. Structure and function of arginases. J. Nutr. 2004, 134, 2760S-2764S.
- ⁶ M. Munder. Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol. 2009, 158, 638-651.
- ⁷ Y.A. Ivanenkov et al. Small-molecule arginase inhibitors. Pharm. Pat. Anal. 2014, 3, 65-85.
- ⁸ R. Tamura et al. Neuroprotective effects of adenosine deaminase in the striatum. J Cereb Blood Flow Metab. 2016 Jan 8.

3299	Avibactam sodium	Covalent, reversible inhibitor of β-lactamase	Page 262
2373	BEC hydrochloride	Slow-binding pH-dependent inhibitor of Arginase I and II	Page 296
3747	BPTES	Potent and selective allosteric GLS inhibitor	Page 324
3738	CB-1158 dihydrochloride	Orally bioavailable, potent and selective inhibitor of human arginase I	Page 346
2434	Deazaadenosine, 1-	Adenosine deaminase (ADA) inhibitor	Page 415
3531	GSK484 hydrochloride	Highly potent, selective, and reversible PAD4 inhibitor	Page 522
1711	PF 3845	Selective fatty acid amide hydrolase (FAAH) inhibitor	Page 760
2041	Sulbactam sodium	An irreversible inhibitor of β-lactamase	Page 899
3820	Tazobactam acid	Inhibitor of β-lactamase	Page 913
3532	Telaglenastat	Potent, selective, and orally bioavailable glutaminase inhibitor	Page 917
4222	URB597 Recent Addition	Highly potent, selective and orally available FAAH inhibitor	Page 956
3359	URB937	Potent, orally available, and peripherally restricted FAAH inhibitor	Page 957

Enzymes (EC 3.5.1.) Amidases, LpxC

Gram-negative bacteria differ from Gram-positive bacteria in that they possess a unique outer membrane, with the outer leaflet of the outer membrane enriched with lipid A, the membrane anchor of lipopolysaccharide (LPS) and the active component of bacterial endotoxin¹. LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase; EC 3.5.1.108) is a metalloenzyme that catalyzes the first committed step in the biosynthesis of lipid A, an essential component of the outer membrane of Gram-negative bacteria. As such, LpxC is an attractive antibacterial target as there is no human homologue and it is highly conserved in Gram-negative bacteria. The LpxC inhibitors block LPS synthesis by blockade of the sepsis cascade, and show enhanced opsonophagocytic killing of the bacteria².

- ¹ X. Liang et al. Synthesis, Structure, and Antibiotic Activity of Aryl-Substituted LpxC Inhibitors. J. Med. Chem., 2013, 56, 6954-6966.
- ² Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections. Justin I. Montgomery et al. J. Med. Chem., 2012, 55, 1662-1670.

2000	CHIR 090	Potent and selective LpxC inhibitor	Page 364
1939	LpxC inhibitor 1a	Potent antibacterial LpxC inhibitor (gram-negative infections)	Page 622
2113	PF 05081090	LpxC inhibitor for treatment of gram-negative infections	Page 769

Enzymes (EC 3.5.1.) Amidases, HDAC

Histone deacetylases (HDACs; EC 3.5.1.98) are a class of enzymes that remove acetyl groups from an ε-N-acetyl lysine amino acid of histones. Inhibitors of this class of enzymes have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptics. Moreover, Histone deacetylase inhibitors (HDIs) are being studied as an alleviator or treatment for neurodegenerative diseases¹. Recently, this class of enzymes is emerging as an exciting new class of potential anticancer agents for the treatment of solid and hematological malignancies² by inhibiting the proliferation and induction of differentiation and/or apoptosis of tumor cells in culture and in animal models³. HDAC inhibition causes acetylated nuclear histones to accumulate in both tumor and normal tissues, providing a surrogate marker for the biological activity of HDAC inhibitors in vivo⁴. HDAC inhibition not only results in acetylation of histones but also transcription factors such as p53, GATA-1 and estrogen receptor-α. The functional significance of acetylation of non-histone proteins and the precise mechanisms whereby HDAC inhibitors induce tumor cell growth arrest, differentiation and/or apoptosis are

currently the focus of intensive research. Several HDAC inhibitors have shown impressive antitumor activity in vivo with remarkably little toxicity in preclinical studies.

Besides HDACs, multiple sirtuins (NAD⁺-dependent deacetylase sirtuin, SIRT; EC 3.5.1.98) are known to show deacetylase activity. They are considered class III histone deacetylases that deacetylate histones and transcription factors⁵. In turn, sirtuins can be inhibited by nicotinamide, which binds to a specific receptor site of the enzyme, so it is thought that drugs that interfere with this binding should increase sirtuin activity. Development of new agents that would specifically block the nicotinamide-binding site could provide an avenue for development of newer agents to treat degenerative diseases such as cancer, Alzheimer's, diabetes, atherosclerosis, and gout⁶.

SIRT1 is involved in other signaling pathways as well, since it competes with HDAC1 in deacetylation of PTEN, an important phosphatase involved in cell signaling via phosphoinositols and the PI3K/AKT/mTOR signaling pathway. Aiming to keep up with these recent developments in oncology research, Axon Medchem recently added a significant number of HDAC inhibitors to its ever broadening range of products.

- ¹ Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. E. Hahnenet al. Expert Opin Investig Drugs. 2008, 17, 169-84.
- ² The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance. Maiso P. et al. Cancer Res 2006, 66, 5781.
- ³ Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6. AP Kozikowski et al. J. Med. Chem. 2008, 51, 4370-4373.
- ⁴ Histone deacetylase inhibitors in cancer treatment. Vigushin DM, Coombes RC. Anticancer Drugs. 2002, 13, 1-13.
- ⁵ Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. S. Hisahara et al. PNAS 2008, 105, 15599-15604.
- ⁶ Sirtuin activators. F.J. Alcaín, J.M. Villalba. Exp. Opin. Ther. Pat. 2009, 19, 403-414.

3039	ACY-241	Selective and orally available HDAC6 inhibitor	Page 207
2269	AK 1	Potent inhibitor of SIRT2	Page 216
2270	AK 7	Potent, brain-permeable and selective inhibitor of SIRT2	Page 216
2394	AR-42	HDAC inhibitor	Page 245
3115	Belinostat	HDAC inhibitor	Page 297
3397	BG45	HDAC inhibitor (1, 2, 3 Selective)	Page 299
3399	BML-210	HDAC inhibitor	Page 314
2471	BRD 73954	Dual HDAC 6/8 inhibitor with excellent selectivity	Page 327
2803	Cambinol	Inhibitor of SIRT1 and SIRT2	Page 340
2014	CI 994	HDAC inhibitor causes histone hyperacetylation in cells	Page 369
3038	CXD101	HDAC inhibitor (1, 2, 3 Selective)	Page 401
4138	CUDC-101	Potent HDAC, EGFR, and HER2 inhibitor	Page 398
3989	Givinostat hydrochloride	Orally active HDAC inhibitor	Page 503
1645	HDAC6 inhibitor ISOX	HDAC6 Inhibitor	Page 539
2529	JNJ 26481585 dihydrochloride	Orally available second-generation pan-HDAC inhibitor	Page 579
3529	KA2507 Recent Addition	Highly potent, selective and orally available HDAC6 inhibitor	Page 588
1548	LBH 589	HDAC1 Inhibitor	Page 606
2430	LW 479	HDAC inhibitor with cytotoxicity in breast cancer cell lines	Page 625
4099	Martinostat hydrochloride	HDAC inhibitor (1, 2, 3, 6 Selective)	Page 639
2505	Mocetinostat	Class I selective HDAC inhibitor	Page 675
1707	MC 1568	HDAC inhibitor (class IIA selective)	Page 641
4238	M344 Recent Addition	Potent HDAC inhibitor	Page 638
1803	MS 275	Inhibitor of HDAC (1 and 3 Selective)	Page 683
2359	Nexturastat A	HDAC6 inhibitor with selectivity over HDAC1 and HDAC8	Page 699
3409	NKL 22	HDAC inhibitor	Page 705
2843	OSS-128167	Selective SIRT6 inhibitor	Page 738
1853	PCI 34051	HDAC8 Inhibitor	Page 751
1801	Pyroxamide	HDAC1 Inhibitor	Page 797
2195	RGFP 966	HDAC3 specific inhibitor	Page 816
2704	Salermide	Potent inhibitor of SIRT1 and SIRT2	Page 841
2495	Santacruzamate A	HDAC2 inhibitor with little inhibition of HDAC4 and HDAC6	Page 842

1777	SB 939	HDAC inhibitor (1, 2, 4 Selective)	Page 844
2453	SirReal 2	SIRT2 inhibitor with selectivity over SIRT1 and SIRT3	Page 867
2968	SIRT7 inhibitor 97491	Inhibitor of SIRT7	Page 868
3908	Sirtinol	Specific SIRT inhibitor	Page 868
2209	Sodium butyrate	Noncompetitive inhibitor of multiple HDACs	Page 877
4034	SR-4370	Synthetic inhibitor of histone deacetylase (HDAC)	Page 886
1875	SRT 1720 tetrahydrochloride	Activator of the sirtuin subtype SIRT1	Page 888
2008	Tenovin 1	Activates p53 through inhibition of SIRT 1 and 2	Page 919
2249	Tenovin 6	Small water soluble p53 activator and SIRT inhibitor	Page 919
2996	TH 34	HDAC inhibitor (6, 8, 10 Selective)	Page 923
2180	TMP 195	HDAC inhibitor (class IIA selective)	Page 933
4270	TNG-260 Recent Addition	First-in-class, orally active, potent, and CoREST-selective deacetylase inhibitor	Page 933
3691	Tubacin	HDAC6 inhibitor	Page 942
2004	Tubastatin A hydrochloride	Potent and selective HDAC6 inhibitor	Page 943
2893	Tucidinostat	Orally bioavailable HDAC inhibitor (1, 2, 3, 10 Selective)	Page 943
2518	UF 010	Class I selective HDAC inhibitor	Page 949
3114	Vorinostat	HDAC inhibitor	Page 972
3995	WT-161	Potent, selective, and bioavailable HDAC6 inhibitor	Page 988

Enzymes (EC 3.6.) Anhydride hydrolases

ATPases belong to the class of acid anhydride hydrolases. The most common ATPases (24 proteins) contain the classical mononucleotide-binding motif, which is known as the P-loop or Walker motif. A second subfamily exists as the GHL ATPase family, including Hsp90, PMS2, MutL and DNA gyrase B, and share the same left-handed β - α - β -fold. Four conserved sequence motifs have been identified in these enzymes. Finally, β -actin, Hsp70 and FtsA contain a more complex nucleotide-binding site and form the third and last subfamily of ATPases. The presence of various types of nucleotide-binding site in ATPases is of interest for drug discovery, as it might allow the design of compounds that specifically target only one type¹.

¹ ATPases as drug targets: learning from their structure. P. Chène. Nat. Rev. Drug Discov. 2002, 1, 665-673.

Enzymes (EC 3.6.) Anhydride hydrolases, MTH1

MTH1 (EC 3.6.1.56) is an oxidized purine nucleoside triphosphatase of the nudix hydrolase family, that sanitizes oxidized dNTP pools to prevent incorporation of damaged bases during DNA replication, thereby preventing the cytotoxicity and neurotoxicity of oxidized purine nucleotides. In close collaboration with OGG1 (with 8-oxoG DNA glycosylase activity, thus avoiding the accumulation of 8-oxoG in DNA), both MTH1 and OGG1 are expressed in postmitotic neurons as well as in proliferative tissues, and it is localized both in the mitochondria and nucleus. This suggests that MTH1 plays an important role in the prevention of the mutagenicity and cytotoxicity of such oxidized purines as 8-oxoG which are known to accumulate in the cellular genome¹.

¹ Y. Nakabeppu et al. MTH1, an oxidized purine nucleoside triphosphatase, prevents the cytotoxicity and neurotoxicity of oxidized purine nucleotides. DNA Repair. 2006, 5, 761-772.

2296	Crizotinib, (S)-	MTH1 inhibitor	Page 395
3216	DCZ0415	AAA-ATPase TRIP13 inhibitor	Page 414
2271	TH 287 hydrochloride	First-in-class MTH1 inhibitor	Page 923
2272	TH 588 hydrochloride	First-in-class MTH1 inhibitor	Page 923

Enzymes (EC 3.6.) Anhydride hydrolases, Hsp

The class of Heat-shock proteins (Hsps; EC 3.6.-.-), the molecular chaperones, comprises five major and broadly conserved families: Hsp100s, Hsp90s, Hsp70s, Hsp60s, and small heat shock proteins (sHsps). The stress proteins are typically named after their molecular size in kilodaltons. They are required for the correct folding and maintenance of client proteins in biologically active conformations, and to stabilize them against heat stress and toxic chemicals (particularly heavy metals). Although Hsps are ubiquitously expressed proteins, increased expression of Hsps in a stressed cell is mediated primarily by so-called heat shock transcription factors (HSFs, 1-4). Hsps bind adenosine triphosphate (ATP), and ATP hydrolysis is required for its function, and is the key driving force for conformational conversions within the chaperone. Although inactive heat shock proteins exhibit weak to nonexistent ATPase activity, the presence of a substrate peptide in the binding domain stimulates the ATPase activity of Hsps, increasing its normally slow rate of ATP hydrolysis^{1,2}. In addition, a variety of co-chaperones, immunophilins, and other proteins are involved in the Hsp90-mediated protein folding pathway³. Heat shock cognate protein 70 (Hsc70; EC 3.6.4.10) is a constitutively expressed molecular chaperone which belongs to the family of heat shock protein 70 (Hsp70). Hsc70 shares some of the structural and functional similarity with Hsp70. Hsc70 also has different properties compared with Hsp70 and other heat shock family members. Hsc70 and Hsp70 show significant differences in their carboxyl-terminal domain which is involved in mediating substrate specificity and particular biological functions. Additionally, Hsc70 and Hsp70 have different expression patterns. Hsc70 is the constitutively expressed form and only mildly induced during stress situation while Hsp70 is highly inducible during stress. Hsc70 performs its full functions by the cooperation of co-chaperones. It interacts with many other molecules as well and regulates various cellular functions⁴.

¹ K. Richter et al. Intrinsic Inhibition of the Hsp90 ATPase Activity. J. Biol. Chem. 2006, 281, 11301-11311.

² J. Verghese et al. Biology of the Heat Shock Response and Protein Chaperones: Budding Yeast (*Saccharomyces cerevisiae*) as a Model System. Microbiol. Mol. Biol. Rev. 2012, 76, 115-158.

³ M. Rowlands et al. Detection of the ATPase Activity of the Molecular Chaperones Hsp90 and Hsp72 Using the Transcreeper™ ADP Assay Kit. J. Biomol. Screen. 2010, 15, 279-286.

⁴ T. Liu et al. Comprehensive review on the Hsc70 functions, interactions with related molecules and involvement in clinical diseases and therapeutic potential. Pharmacol. Ther. 2012, 136, 354-374.

2251	Apoptozole	Inhibitor of ATPase activity of Hsc70 and Hsp70	Page 242
1543	CNF 2024	Hsp90 inhibitor	Page 381
3923	CUDC-305	Orally bioavailable inhibitor of Heat Shock Proteins	Page 398
3261	CXL146	GRP78 inhibitor	Page 402
3264	DDO-6600	Targeted covalent inhibitor of Hsp90	Page 415
2703	ML346	Hsp70 activator	Page 671
1542	NVP-AUY922	Hsp90 inhibitor	Page 722
4278	Pifithrin- μ Recent Addition	Inhibitor of p53 protein; HSP70 inhibitor	Page 777
1856	PU-H71 trihydrochloride	Hsp90 inhibitor	Page 797
3701	SL-145	C-terminal HSP90 inhibitor	Page 872
1968	STA 9090	Hsp90 inhibitor	Page 893
1608	VER 155008	Hsp70 inhibitor	Page 965

Enzymes (EC 3.6.3.) Anhydride hydrolases, ion-pump ATPases

Enzymes in this class are ATPases that are involved in catalyzing transmembrane movement of substances, e.g. the exchange of extracellular potassium (K^+) for cytoplasmic ions, being either Na^+ and/or Ca^{2+} (EC 3.6.3.9) in order to maintain the resting potential avail transport, and regulate cellular volume, or H^+ (EC 3.6.3.10) in order to promote gastric acid secretion. Digoxigenin (Axon 1649) and its active metabolite (Axon 1695) for example, are known to be a unique medication with pharmacological effects resulting in hemodynamic, sympatholytic, and electrophysiologic changes. Their primary mechanism of action is inhibition of the Na^+/K^+ ATPase pump, thereby promoting Na^+/Ca^{2+} exchange, which results in an influx of intracellular Ca^{2+} and increased myocardial contraction¹. Besides this, recent studies revealed that digoxin also targets the transcription factor Hypoxia inducible factor HIF-1 by potentially inhibiting HIF-1 α mRNA translation. As a result, Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within one week².

¹ M. Ehle et al. Digoxin: Clinical Highlights: A Review of Digoxin and Its Use in Contemporary Medicine. Crit. Path. Cardiol. J. E. B. Med. 2011, 10, 93-98.

² H. Zhang et al. Digoxin and other cardiac glycosides inhibit HIF-1 α synthesis and block tumor growth. PNAS 2008, 105, 19579-19586.

4039	CB-103	orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex	Page 346
------	--------	---	----------

2684	CDN1163	Allosteric Activator of SERCA2b	Page 356
1695	Digoxigenin bis-digitoxiside	Metabolite of Digoxigenin	Page 427
1649	Digoxin	Na ⁺ /K ⁺ ATPase pump inhibitor	Page 428
3244	Lansoprazole	Proton pump inhibitor (PPI)	Page 604
3161	Pantoprazole sodium	Proton pump inhibitor (PPI)	Page 747
3663	Rabeprazole sodium	Proton pump inhibitor (PPI)	Page 805
3589	Soraprazan	Highly potent, reversible, and fast-acting inhibitor of gastric H ⁺ /K ⁺ ATPase	Page 879
1971	TAK 438	Potassium-competitive acid blocker (P-CAB)	Page 906

Enzymes (EC 3.6.4.) Anhydride hydrolases, ATPases cellular movement

Myosin (EC 3.6.4.1) and p97 (also known as Cdc48 or valosin containing protein (VCP; EC 3.6.4.6)) are both ATPases involved in cellular and subcellular movement. Myosin is an ATPase that converts chemical energy into directed movement via its cyclic interactions with actin filaments in all eukaryotic cells and can be viewed as a molecular motor¹. Although this protein comes in many shapes and sizes, all known myosin superfamily members show widely conserved regions: the myosin head is commonly subdivided into the motor domain, which is the actin activated ATPase, and the lever arm, which is an extended helix containing a variable number of consensus calmodulin or calmodulin-like light chain binding sites; this is followed by a region of coiled coil in two-headed myosins and may contain sequences that act as elements for protein folding; last is the targeting domain, which binds the myosin to its cellular target. More than 35 classes of myosin have been discovered, 13 of which are represented in humans². CK 1827452 (Axon 1835), is an agent that directly activates myosin, for use in the treatment of heart failure.

Nearly all aspects of RNA metabolism, from transcription and translation to mRNA decay, involve RNA helicases, which are enzymes that use ATP to bind or remodel RNA and DNA and their protein complexes (e.g. ribonucleoprotein (RNP) complexes). RNA helicases are found in all three domains of life, and many viruses also encode one or more of these proteins. Together with the structurally related DNA helicases that function in replication, recombination and repair, the RNA helicases are classified into superfamilies and families, based on sequence and structural features. Herpes Simplex Virus (HSV) encodes seven proteins essential for the initiation and propagation of viral chromosomal replication. These proteins include an origin-binding protein that also contains helicase activity, a heterotrimeric DNA polymerase, a single-stranded (ss)DNA-binding protein and a heterotrimeric helicase-primase³. BAY 57-1293 (Axon 2266) is a potent helicase-primase inhibitor (HPI) effective against herpes simplex virus (HSV) infections and was found to be superior compared to all compounds currently used to treat HSV infections⁴.

VCP/p97 is a member of the large family of ATP-hydrolyzing enzymes involved in the heterotypic fusion of membrane vesicles with target membranes and the homotypic fusion of various membrane compartments. It belongs to the AAA-type (ATPase associated with a variety of cell activities) ATPase superfamily and contains two ATPase domains (D1-2). It can convert the energy of ATP hydrolysis to structurally remodel or unfold client proteins. ATP hydrolysis in D2 seems to generate the main driving force. A globular N-domain that resides at the periphery of D1 is essential for substrate binding. It can stabilize unfolded proteins, may regulate ATP hydrolysis and even couple substrate and adaptor binding to ATP hydrolysis. Although VCP/p97 associates with a large number of interaction partners and protein cofactors, the largest family of cofactors are proteins containing a ubiquitin-X (UBX) domain or UBX-like domain1, and that its key function is to unfold proteins and disassemble protein complexes^{5,6}.

During mitosis, chromosomes establish connections to mitotic spindle microtubules (MTs) via specialized protein complexes, called kinetochores, and subsequently translocate to the midzone of the bipolar spindle. This process is known as "congression", and is dynamic in nature: the chromosomes are constantly moving in an oscillatory pattern, with paired chromosomes displaying coordinated movements. Proper mitotic chromosome alignment is highly dependent on the activity of kinesin-8 motors, including Kif18A (EC 3.6.4.4)^{7, 8}. Although the molecular process is not yet elucidated, proof was found that Kif18A is a motile microtubule depolymerase essential for chromosome congression⁹, and controls the persistent movement of chromosomes by both increasing the rate at which they make directional switches and slowing the velocity of their movement. Moreover, it is hypothesized that Kif18A forms a gradient along kinetochore-microtubules (kMTs) that directly regulates their length and dynamics to facilitate chromosome alignment at the spindle equator¹⁰.

Another member of the kinesin superfamily of microtubule-based motors that plays a critical role in the early stages of mitosis as it mediates centrosome separation and bipolar spindle assembly and maintenance, is the Kinesin spindle protein (KSP or Eg5; EC 3.6.4.4). It is a slow, plus end-directed motor of the kinesin-5 subfamily, and forms a homotetrameric structure capable of binding antiparallel microtubules and sliding them apart¹¹. Centrosome separation and bipolar spindle assembly are essential for proper segregation of chromosomes. Failure of KSP function, by immunodepletion or knockdown of KSP mRNA by small interfering RNA, leads to cell cycle arrest in mitosis with monoastral microtubule arrays. It is most abundant in proliferating human tissues and is highly expressed in tumors of the breast, colon, lung, ovary, and uterus¹².

¹ I. Rayment. The Structural Basis of the Myosin ATPase Activity. J. Biol. Chem. 1996, 271, 15850-15853.

² H.L. Sweeney, A. Houdusse. Structural and Functional Insights into the Myosin Motor Mechanism. Annu. Rev. Biophys. 2010, 39, 539-557.
³ J.J. Crute et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 2002, 8, 386 – 391.
⁴ U.A. Betz et al. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. 2002, 46, 1766-1772.
⁵ H. Meyer, M. Bug, S. Bremer. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat. Cell Biol. 2012, 14, 117-123.
⁶ K. Yamanaka, Y. Sasagawa, T. Ogura. Recent advances in p97/VCP/Cdc48 cellular functions. Biochim. Biophys. Acta. Mol. Cell Res. 2012, 1823, 130-137.
⁷ J. Stumpff et al. Kif18A and chromokinesins confine centromere movements via microtubule growth suppression and spatial control of kinetochore tension. Dev Cell. 2012 May 15;22(5):1017-29.
⁸ J. Braun et al. Synthesis and Biological Evaluation of Optimized Inhibitors of the Mitotic Kinesin Kif18A. ACS Chem Biol. 2015 Feb 20;10(2):554-60.
⁹ M.I. Mayr et al. The human kinesin Kif18A is a motile microtubule depolymerase essential for chromosome congression. Curr Biol. 2007 Mar 20;17(6):488-98.
¹⁰ J. Stumpff et al. The kinesin-8 motor Kif18A suppresses kinetochore movements to control mitotic chromosome alignment. Dev Cell. 2008 Feb;14(2):252-62.
¹¹ D. Huszar et al. Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev. 2009 Jun;28(1-2):197-208.
¹² V. Sarli et al. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res. 2008 Dec 1;14(23):7583-7.

4000	Aficamten	Next-in-class cardiac myosin inhibitor	Page 211
3465	Amenamevir	Potent helicase-primase inhibitor	Page 223
2266	BAY 57-1293	Potent helicase-primase inhibitor, effective against HSV	Page 290
3074	Blebbistatin, (-)	Selective inhibitor of class II myosins; Active enantiomer of (±)-Blebbistatin	Page 312
3144	Blebbistatin, (+)	Negative control of (±)-Blebbistatin as an inhibitor of class II myosins	Page 312
2718	Blebbistatin, (±)	Potent and specific inhibitor of class II myosins	Page 313
2407	BTB 1	Reversible inhibitor of the mitotic motor protein Kif18A	Page 331
4170	CB-5083	First-in-class potent, selective, and orally bioavailable inhibitor of p97 AAA ATPase	Page 347
1835	CK 1827452	Cardiac specific myosin ATPase activator	Page 374
1826	DBeQ	Inhibitor of p97 ATPase	Page 411
2439	Dimethylenastron	Specific potent and cell-permeable inhibitor of Eg5 (KSP)	Page 432
4120	eIF4A i28	RNA-competitive, ATP-uncompetitive eIF4A inhibitor	Page 453
3852	GSK923295	Allosteric inhibitor of centromere-associated protein E (CENP-E)	Page 527
4214	HRO761	Potent, selective, orally active and allosteric WRN inhibitor	Page 553
2446	Ispinesib	Potent and specific small-molecule inhibitor of human KSP	Page 572
3143	KUS121	ATPase inhibitor of valosin-containing protein (VCP)	Page 599
2683	MYK-461	Cardiac specific myosin ATPase inhibitor	Page 685
2663	Rbin-1	Potent, reversible, and specific inhibitor of Midasin	Page 809
2712	Rbin-2	Potent, reversible, and specific inhibitor of Midasin	Page 809
3285	TH1760	First-in-class, potent, selective and cell-active NUDT15 inhibitor	Page 924
4271	VVD-214	Potent, selective, allosteric inhibitor of WRN helicase	Page 979

Enzymes (EC 3.6.5.) Anhydride hydrolases, GTPases

The hydrolysis of guanosine triphosphate (GTP) is a key process in numerous vital processes. Intracellular signal transduction, protein synthesis, vesicular and nucleocytoplasmic transport, protein targeting, growth control and differentiation, are all, among other processes, controlled enzymatically by the conversion of GTP into GDP and inorganic phosphate. GTPases are the molecular switches that catalyze this reaction. They cycle between two conformational states: one bound to GTP ('active' state), the other bound to GDP ('inactive' state), and they hydrolyze GTP to GDP and inorganic phosphate. In the 'on' (GTP) state, GTPases recognize target proteins and generate a response until GTP hydrolysis returns the switch to the 'off' state¹. GTPases can be classified into six families of heterotrimeric G-protein, small monomeric, protein-synthesizing, signal-recognition-particle, dynamin, and tubulin GTPases (EC 3.6.5.1 – EC 3.6.5.6 respectively). GTP-hydrolysis by GTPases is intrinsically very slow but can be accelerated by orders of magnitude upon interaction with GTPase-activating proteins (GAPs)². In order to bring the GTPase back in the GTP bound 'on' state, so called guanine

nucleotide exchange factors (GEFs), which cause the GDP to dissociate from the GTPase, leading to its association with new GTP.

RAS proteins are small GTPases that act as molecular switches to transduce signals from activated receptors. When in its GTP-bound state, RAS can bind to and activate a range of downstream effector proteins, which may then result in diverse cellular outcomes like cell proliferation, survival, differentiation, and neoplastic transformation. Three RAS genes code for four highly homologous RAS proteins, NRAS, HRAS, and KRAS4B/KRAS4A. These proteins have identical effector binding domains and hence can interact with the same set of downstream effectors. However, RAS isoforms have been shown to differ in their abilities to activate various downstream proteins. Mutations affecting the three prototype Ras oncoproteins, HRAS, NRAS and KRAS, show a high degree of tumor-type specificity³. Oncogenic versions of HRAS are better than NRAS or KRAS at transforming fibroblast cells, whereas NRAS is better at transforming hematopoietic cells. Nearly 30% of human cancers, including solid tumors and hematologic malignancies, are associated with mutations in RAS genes⁴. Therapies that target the RAS proteins and the signalling pathways that they control would therefore be very valuable in treating tumours that have activating RAS mutations. However, their potential might be even greater, as many tumours that lack RAS mutations have found other ways to activate the same pathways⁵.

Rab7 (EC 3.6.5.2) belongs to the superfamily of Ras small GTPases and is a regulator of intracellular endocytic/membrane trafficking. Additionally, it has been indicated that Rab proteins also regulate cell signalling, cell growth, cell survival and development. Rab proteins and their associated regulators or effectors have been implicated in many diseases, such as cancer, pigmentation disorder, neuropathy and lipid metabolism disorders. Rab7, with one of its effectors, RILP (Rab7-interacting lysosomal protein), recruit the dynein-dynactin motor complex to lysosomes facilitating lysosome trafficking along microtubules towards the cell nucleus. Moreover, in addition to its recognized role in vesicle trafficking, Rab7 has recently garnered attention as a regulator of apoptosis in response to growth factor withdrawal and has been proposed to function as a tumor suppressor protein^{6,7}.

Two other members of the family of Ras-like small GTPases, RalA and RalB (EC 3.6.5.2), act downstream of Ras in the Ral guanine nucleotide exchange factor (RalGEF)/Ral GTPase pathway, and activate cellular processes through effectors, including Ral-binding protein 1 (RALBP1; also known as RLIP76 and RIP1), the human exocyst subunits SEC5 and EXO84, filamin and phospholipase D1. These effectors mediate regulation of cell adhesion (anchorage independence), membrane trafficking (exocytosis and endocytosis), mitochondrial fission, and transcription. RalA and RalB are important drivers of the proliferation, survival and metastasis of multiple human cancers, including skin, lung, pancreatic, colon, prostate, and bladder cancers⁸.

Ras-related C3 botulinum toxin substrate 1 (Rac1; EC 3.6.5.2) is a small (~21 kDa) signaling G protein (more specifically a GTPase), and a member of the Rac subfamily of the small monomeric Ras homolog (Rho) family of GTPases. Members of the Rho family, including Rho, Rac, and Cdc42, control the assembly and organization of the actin cytoskeleton in mammalian cells. They mediate diverse biological processes, including neuronal morphogenesis, tumor invasion, and bone formation, and act in a coordinated manner to modulate cellular functions⁹.

Cell division control protein 42 homolog (Cdc42; EC 3.6.5.2) plays important roles in cytoskeleton organization, cell cycle progression, signal transduction, and vesicle trafficking. Overactive Cdc42 has been implicated in the pathology of cancers, immune diseases and neuronal disorders. Therefore, Cdc42 inhibitors would be useful in probing molecular pathways and could have therapeutic potential¹⁰.

The regulator of G protein signaling 4 (RGS4) is a protein of the class of GTPase activating proteins (GAP) and shows no GTPase activity by itself. Instead, RGS proteins are negative regulators of G alpha subunits of heterotrimeric G proteins (Gi, Go, and Gq)¹¹. Because its functions is inherently part of the well functioning of these heterotrimeric G proteins (EC 3.6.5.1), inhibitors of RGS4 are listed in this particular section.

The guanine nucleotide-binding protein 1 (GBP1; EC 3.6.5.6) is one of the 7 members of the large GTPase family and most strongly induced by interferons. Members of this family share the ability to undergo oligomerization with a high-turnover GTPase activity. Structural hallmarks of GBP1 are a large globular α/β -domain harboring the GTPase activity, and an elongated C-terminal part organized in an α -helical structure with unique features¹². GBP1 is highly expressed in endothelial cells, and is activated by inflammatory cytokines *in vitro* and *in vivo*¹³. The functional role of GBP1 has not been fully elucidated to date, but it was shown to inhibit the invasiveness and tube-forming capability of endothelial cells, play a role in cell-autonomous immunity and bacterial infection, and to exhibit antiviral properties. Since GBP1 is also known to interact with β III-tubulin, where it operates as a crucial element to incorporate pro-survival kinases such as PIM1 and NEK6 into microtubules, and seems to be involved in the drug resistance to paclitaxel, it is of interest for the development of a new class of anticancer agents against Paclitaxel resistant cancer cells¹⁴.

¹ S. Etienne-Manneville, A. Hall. Rho GTPases in cell biology. Nature 2002, 420, 629-635.

² K. Scheffzek, M.R. Ahmadian, Wittinghofer. GTPase-activating proteins: helping hands to complement an active site. Trends Biochem Sci. 1998, 23, 257-262.

³ A. Berns et al. Kras and Hras—what is the difference? Nat. Genet. 2008, 40, 1149-1150.

⁴ C. Parikh et al. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res. 2007, 67, 7139-7146.

⁵ J. Downward et al. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 2003, 3, 11-22.

⁶ J.J. Steffan et al. Supporting a role for the GTPase Rab7 in prostate cancer progression. PLoS One. 2014, 9, e87882.

⁷ A.L. Edinger. Growth factors regulate cell survival by controlling nutrient transporter expression. Biochem. Soc. Trans. 2005, 33, 225-227.

⁸ C. Yan et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 2014 Nov 20;515(7527):443-7.

⁹ M. Onish et al. Inhibition of Rac1 promotes BMP-2-induced osteoblastic differentiation. Cell Death Dis. 2013, 4, e698

¹⁰ L. Hong et al. Characterization of a Cdc42 GTPase Inhibitor and its Use as a Molecular Probe. J. Biol. Chem. 2013, 288, 8531-8543.

¹¹ N. Grillet et al. Generation and Characterization of Rgs4 Mutant Mice. Mol. Cell Biol. 2005, 25, 4221-4228.

¹² E. Guenzi et al. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J. 2003 Aug 1;22(15):3772-82.

¹³ M. Fukumoto et al. Guanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistance. Cancer Sci. 2014 Oct;105(10):1351-9.

¹⁴ M. Andreoli et al. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem. 2014 Oct 9;57(19):7916-32.

3575	AMG510	Highly potent, selective, and orally bioavailable KRAS-G12C inhibitor.....	Page 225
3084	ARS-1620	Potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor.....	Page 249
3053	BAY-293	Potent, selective and cell-active inhibitor of KRAS-SOS1 interaction.....	Page 289
3471	BI-3406	Inhibitor of KRAS/Son of Sevenless 1 (SOS1) interaction.....	Page 302
2397	BQU 57	Inhibitor of the RAS-like small GTPases RalA and RalB.....	Page 325
3987	CASIN	Selective Cdc42 inhibitor.....	Page 345
1931	CCG 50014	Inhibitor of RGS proteins (RGS4 selective).....	Page 350
2184	CID 1067700	First inhibitor of Rab7 GTPase.....	Page 370
3879	Dynasore	Noncompetitive cell-permeable dynamin inhibitor.....	Page 446
4029	Dyngo-4a	Recent Addition	Cell-permeable dynamin inhibitor; MUS81-EME1/2 inhibitor... Page 446	
2351	EHop 016	Rac GTPase inhibitor specific for Rac1 and Rac3.....	Page 453
2829	Fendiline hydrochloride	KRAS inhibitor; Ca ²⁺ channel blocker (L-type voltage gated). Page 478	
3768	GDC-6036	Inhibitor of KRAS G12C.....	Page 500
4197	Golgicide A	Potent, highly specific and reversible inhibitor of GBF1.....	Page 512
2302	Kobe 0065	HRAS inhibitor.....	Page 594
2777	MBQ-167	Dual Rac and Cdc42 inhibitor.....	Page 640
2017	ML 210	Chemical probe kills cells induced to express mutant RAS.... Page 665	
3761	MRTX1133	First-in-class, noncovalent, selective & reversible inhibitor of KRASG12D mutant.....	Page 680
3733	MRTX1257	Irreversible covalent inhibitor of KRAS G12C.....	Page 680
4036	MRTX849	Potent, mutation-selective, and irreversible covalent inhibitor of KRAS-G12C.....	Page 681
1578	NSC 23766	Rac1 inhibitor.....	Page 712
2393	NSC 756093	Potent <i>in vitro</i> inhibitor of GBP1:PIM1 interaction.....	Page 717
2396	RBC 8	Inhibitor of the RAS-like small GTPases RalA and RalB.....	Page 808
2138	ZCL 278	Cdc42 GTPase inhibitor, targeting Cdc42-ITSN interaction.... Page 1004	
3790	ZINC69391	Specific Rac1 inhibitor.....	Page 1006

Enzymes (EC 4.) Lyases

Lyases are enzymes that catalyze the cleavage of C-C, C-O, C-N bonds by other means than by hydrolysis or oxidation. More specifically, these bonds are cleaved by the process of elimination and the resulting product is the formation of a double bond or a new ring. Lyases differ from other enzymes in that two substrates are involved in one reaction direction, but only one substrate is involved in the other direction. To generate either a double bond or a new ring, the enzyme is acted upon the single substrate and a molecule is eliminated. Lyases can be seen in the reactions of the Citric Acid Cycle (Krebs cycle) and in glycolysis.

Cytosolic Phosphoenolpyruvate carboxykinase (cPEPCK; EC 4.1.1.32) is an enzyme in the lyase family used in the metabolic pathway of gluconeogenesis. It converts oxaloacetate into phosphoenolpyruvate and carbon dioxide. cPEPCK has become a virtual marker for hepatic gluconeogenesis, and the level of its gene transcription in the liver is considered an important indicator in the evaluation of type 2 diabetes¹.

The first topical carbonic anhydrase inhibitor for clinical use Dorzolamide HCl (Axon 1517) has been prescribed widely for the treatment of glaucoma and ocular hypertension. It inhibits carbonic anhydrase II (CA-II; EC 4.2.1.1) selectively, which is the main CA iso-enzyme involved in aqueous humor secretion. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Dorzolamide also accumulates in red blood cells as a result of CA-II binding, as CA-II is found

predominantly in erythrocytes. However, sufficient CA-II activity remains so that adverse effects due to systemic CA inhibition are not observed².

Membrane-associated carbonic anhydrase (CA, EC 4.2.1.1) IX (CA IX) is strongly overexpressed in a broad range of tumor types, and the expression of CA IX negatively correlates with the prognosis of cancer patients. In normal tissues CA IX expression is much more restricted with abundant expression mainly present in the mucosa of the glandular stomach. S4 is a carbonic anhydrase (CA) IX and XII inhibitor (K_i values 7 nM and 2 nM, respectively) and showed a positive response in *in vitro* assays for tumor cell migration and spreading. Moreover, CAIX inhibitor S4 effectively inhibited the spontaneous metastasis formation in MDA-MB-231 xenografts³.

Soluble guanylate cyclase (sGC; EC 4.6.1.2), a heme-containing heterodimer, is the only proven receptor for the gaseous ligand NO and plays a crucial role in the NO/cGMP signaling pathway and downstream functional effects, e.g., vasorelaxation, platelet aggregation, or neurotransmission. Activation of the enzyme by NO leads to a five coordinated heme-nitrosyl complex, and facilitates conversion of GTP to the intracellular second messenger cGMP. It is this latter molecule cGMP, which mediates the majority of biological actions attributed to NO. sGC is expressed in virtually all mammalian cells and is important in mediating numerous physiological processes, including vascular and non-vascular smooth muscle relaxation, peripheral and central neurotransmission, platelet reactivity and phototransduction⁴.

¹ A Perspective on the Biology of Phosphoenolpyruvate Carboxykinase 55 Years After Its Discovery. R.W. Hanson. J. Biol. Chem. Them. Minirev. Ser. 2009, 1-6.
² Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. J.A. Balfour, M.I. Wilde. Drugs Aging. 1997, 10, 384-403.
³ R.G. Gieling et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012, 55(11), 5591-600.
⁴ A.J. Hobbs et al. Soluble guanylate cyclase. Exp. Opin. Ther. Targets 2000, 4, 735-749

3988	Brinzolamide	Potent carbonic anhydrase inhibitor	Page 328
2662	CAIX Inhibitor S4	Carbonic anhydrase (CA) IX/XII inhibitor	Page 339
1165	cPEPCK inhibitor	cPEPCK inhibitor	Page 392
4229	Dideoxyadenosine, 2',5'- Recent Addition	P-Site inhibitor of adenylate cyclase	Page 426
1517	Dorzolamide hydrochloride	Carbonic anhydrase inhibitor	Page 438
3817	Eflornithine hydrochloride	Selective, irreversible ODC inhibitor	Page 452
3290	Sardomozide dihydrochloride	Potent and selective SAMDC inhibitor	Page 843
2666	S-Propargyl-Cysteine	Modulator of endogenous hydrogen disulfide	Page 884

Enzymes (EC 4.2.99.) Lyases, APE

Base excision repair (BER) is the predominant system correcting simple DNA base lesions formed by oxidation or other DNA damaging agents. Repair of apurinic/aprimidinic (AP) sites arising in the genome spontaneously or as intermediates of BER is critical owing to their toxic and mutagenic effects. The mammalian apurinic/aprimidinic endonuclease Ape1 (EC 4.2.99.18) is a Mg²⁺-dependent multifunctional protein operating in protection of cells from oxidative stress via its DNA repair, redox, and transcription regulatory activities. The human AP endonuclease Ape1, also called Ref-1 is the major and crucial enzyme for the recognition and processing of AP sites in the base excision repair (BER) of DNA¹. APE1 operates by incising the DNA phosphodiester backbone 5' to AP sites, generating a nick with 3'-hydroxyl and 5'-deoxyribose phosphate (dRP) termini. Repair of the resulting nick is completed by DNA polymerase and DNA ligase. In addition to its endonuclease activity, APE1 is known to have 3'-phosphodiesterase and 3'-phosphatase activity and 3' to 5' exonuclease activity as well as a role in regulating the redox state of several transcription factors².

¹ S.Madlenera et al. Essential role for mammalian apurinic/aprimidinic (AP) endonuclease Ape1/Ref-1 in telomere maintenance. PNAS 2013, publ. online before print.
² K.M. Schermerhorn, S. Delaney. Transient-State Kinetics of Apurinic/Apyrimidinic (AP) Endonuclease 1 Acting on an Authentic AP Site and Commonly Used Substrate Analogs: The Effect of Diverse Metal Ions and Base Mismatches. Biochem. 2013, 52, 7669-7677.

2137	APE1 Inhibitor III	Inhibitor of apurinic/aprimidinic endonuclease 1 (APE1)	Page 240
2136	AR03	Inhibitor of apurinic/aprimidinic endonuclease 1 (APE1)	Page 244

Enzymes (EC 4.6.1.) Lyases, P-O

Soluble guanylate cyclase (sGC; EC 4.6.1.2), a heme-containing heterodimer, is the only proven receptor for the gaseous ligand NO and plays a crucial role in the NO/cGMP signaling pathway and downstream functional effects, e.g., vasorelaxation, platelet aggregation, or neurotransmission. Activation of the enzyme by NO leads to a five coordinated heme-nitrosyl complex, and facilitates conversion of GTP to the intracellular second messenger cGMP. It is this latter

molecule cGMP, which mediates the majority of biological actions attributed to NO. sGC is expressed in virtually all mammalian cells and is important in mediating numerous physiological processes, including vascular and non-vascular smooth muscle relaxation, peripheral and central neurotransmission, platelet reactivity and phototransduction¹.

Another member of the family of P-O lyases is adenylate cyclase (or adenylyl cyclase; EC 4.6.1.1), an enzyme with key regulatory roles in essentially all cells. At least nine closely related isoforms of adenylate cyclases (ACs), the enzymes responsible for the synthesis of cyclic AMP (cAMP) from ATP, have been cloned and characterized in mammals. In addition to their ability to respond to Gas and to FSK, the different isoforms can receive signals from a variety of sources, including other G proteins, e.g. G_{ai} and G_{βγ}, protein kinases (PKA, PKC, and calmodulin (CaM) kinase), phosphatases (calcineurin), calcium, and Ca²⁺/CaM, and these isoforms are able to support and integrate differential regulatory pathways through cross-talk with other signal transduction systems. All isoforms are expressed in brain cells, although the expression of any individual isoform is restricted to discrete structures of the central nervous system. In the peripheral tissues, the pattern of AC expression is more specific². Although many drugs inhibit or stimulate AC activity through the respective upstream G-protein coupled receptors, ACs themselves have not been major drug targets. Over the past decade studies on the physiological functions of the different mammalian AC isoforms as well as advances in the development of isoform-selective AC inhibitors and activators suggest that ACs could be useful drug targets³.

¹ A.J. Hobbs et al. Soluble guanylate cyclase. Exp. Opin. Ther. Targets 2000, 4, 735-749
² J. Hanoune et al. Regulation and role of adenylyl cyclase isoforms. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 145-174.
³ S. Pierre et al. Capturing adenylyl cyclases as potential drug targets. Nat. Rev. Drug Discov. 2009, 8, 321-335.

2172	BAY 58-2667 hydrochloride	Nitric oxide-independent guanylyl cyclase (sGC) activator	Page 290
2264	Forskolin	Activator of adenylate cyclase. Naturally occurring	Page 490
2664	LRE1	Allosteric soluble adenylyl cyclase (sAC) inhibitor	Page 623
3600	MCUF-651	Selective and orally bioavailable PAM of GC-A	Page 642
3558	Vericiguat	Potent and orally available sGC stimulator	Page 966

Enzymes (EC 5.) Isomerases

From a mechanistic point of view, isomerases are enzymes that catalyze the structural rearrangement of isomers. Five subclasses are recognized by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes. Cyclophilin A (CypA; EC 5.2.1.8) is a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family, which catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and accelerates the folding of proteins. They are known to bind to cyclosporine, an immunosuppressant which is usually used to suppress rejection after internal organ transplants. More specifically, the cyclosporin-cyclophilin A complex inhibits a calcium/calmodulin-dependent phosphatase, calcineurin, the inhibition of which is thought to halt the production of the pro-inflammatory molecules interleukin 2 and TNF alpha¹.

Microsomal prostaglandin E (PGE) synthase-1 (mPGES-1; EC 5.3.99.3) is a member of the MAPEG (membrane-associated proteins involved in eicosanoid and glutathione metabolism) superfamily, showing significant homology with other MAPEG superfamily proteins, including microsomal glutathione-S-transferase (GST)-1-like 1 (MGST-1), 5-lipoxygenase (LOX)-activating protein (FLAP) and leukotriene C4 synthase (LTC4). It is a glutathione dependent inducible enzyme that couples with cyclooxygenase-2 (COX-2) for the biosynthesis of Prostaglandin E2 (PGE2); a bioactive lipid that can elicit a wide range of biological effects associated with inflammation and cancer.²

¹ The cyclophilins. P. Wang, J. Heitman. Genome Biol. 2005, 6, 226.
² M. Nakanishi et al. mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie. 2010, 92, 660-664.

1166	DC 838	CypA inhibitor	Page 412
3565	FPBA, 2-	First potent, reversible and slow-onset inhibitor of mandelate racemase (MR)	Page 490
2020	PF 4693627	Selective and orally bioavailable inhibitor of mPGES-1	Page 765

Enzymes (EC 5.99.1.) Isomerases, Topo

Topoisomerases are a family of enzymes that catalyze the unwinding and unknotting of DNA sequences. By introducing transient 'nicks', these enzymes can relieve the topological pile-up of DNA that is caused by processes such as replication and transcription. DNA Topoisomerase I (Topo1; EC. 5.99.1.2) regulates the overwinding or underwinding of DNA in an ATP-independent manner. It binds to single-stranded DNA and cuts the phosphate backbone of the DNA. This intermediate break allows the DNA to be untangled or unwound, and, at the end of these processes, the DNA backbone is resealed

again. Since the overall chemical composition and connectivity of the DNA do not change, the tangled and untangled DNAs are chemical isomers, differing only in their global topology¹.

In slight contrast, topoisomerase IV (Topo IV; EC 5.99.1.3) is an essential ATP-dependent type II topoisomerase that transports one segment of DNA through a transient double-strand break in a second segment of DNA. In vivo, Topo IV unlinks catenated chromosomes before cell division and relaxes positive supercoils generated during DNA replication². Topoisomerase inhibitors work by interfering with mammalian-type eukaryotic topoisomerases in cancer cells. This induces breaks in the DNA that ultimately lead to programmed cell death (apoptosis). However, this DNA-damaging effect, outside of its potentially curative properties, may also lead to secondary neoplasms in the patient.

¹ DNA topoisomerases: structure, function, and mechanism. J.J. Champoux. Annu. Rev. Biochem. 2001, 70, 369-413.

² K.C. Neuman, G. Charvin, D. Bensimon, V. Croquette. Mechanisms of chiral discrimination by topoisomerase IV. PNAS 2009, 106, 6986-6991.

3220	ARN24139	Orally active topoisomerase II poison	Page 247
2391	CS1	TOPO IIa inhibitor with in vitro antitumor effects	Page 396
4072	Doxorubicin hydrochloride	A cytotoxic anthracycline antibiotic	Page 439
1687	Homocamptothecin, (±)-E-	Potent topoisomerase I (Topo 1) inhibitor	Page 545
3171	Gatifloxacin hydrochloride	Inhibitor of bacterial DNA gyrase and topoisomerase IV	Page 496
2198	Genz 644282	Topo I inhibitor lacking MDR1 and BCRP affinity	Page 502
3370	Irinotecan hydrochloride	Prodrug of SN-38; Topoisomerase I (Topo 1) inhibitor	Page 570
2242	Levofloxacin Q-acid	Inhibitor of bacterial DNA gyrase and topoisomerase IV	Page 612
2914	TAS-103 dihydrochloride	Dual inhibitor of topoisomerase I (Topo 1) and topoisomerase II (Topo 2)	Page 910
2100	Trovafoxacin mesylate	Inhibitor of bacterial DNA gyrase and Topo IV	Page 940

Enzymes (EC 6.) Ligases

Ligases (EC 6.-.-) form a major class of enzymes that catalyze the ligation (i.e. linking together) of two molecules with concomitant hydrolysis of the pyrophosphate bond in adenosine 5'-triphosphate (ATP) or a similar triphosphate, forming C–C, C–O, C–S, P–O or C–N bonds¹. Originally, biochemical nomenclature distinguished synthetases and synthases. Under the original definition, synthetases do not use energy from nucleoside triphosphates (such as ATP, GTP, CTP, TTP, and UTP), whereas synthetases do use nucleoside triphosphates. It is also said that a synthase is a lyase (a lyase is an enzyme that catalyzes the breaking of various chemical bonds by means other than hydrolysis and oxidation, often forming a new double bond or a new ring structure) and does not require any energy, whereas a synthetase is a ligase (a ligase is an enzyme that binds two chemicals or compounds) and thus requires energy. However, the Joint Commission on Biochemical Nomenclature (JCBN) dictates that "synthase" can be used with any enzyme that catalyses synthesis (whether or not it uses nucleoside triphosphates), whereas "synthetase" is to be used synonymously.

DNA ligases together with RNA ligases and mRNA capping enzymes constitute the nucleotidyl transferase superfamily. DNA ligases play a vital role in the diverse processes of DNA replication, recombination and repair, catalyzing the joining of interruptions in the phosphodiester backbone of duplex DNA, thereby utilizing either ATP or NAD⁺ as nucleotide cofactor. Multiple DNA ligases exist, yet all the eukaryotic ATP-dependent DNA ligases are related in sequence and structure, sharing a common catalytic region comprising a DNA-binding domain, a nucleotidyltransferase (NTase) domain, and an oligonucleotide/oligosaccharide binding (OB)-fold domain². Deficiency in either DNA ligase I, DNA ligase III, or DNA ligase IV causes different phenotypes of mammalian cell lines³.

DNA ligase IV (EC 6.5.1.1), which is conserved in all eukaryotes, is part of a family of ATP-dependent DNA ligases that are involved in DNA replication, recombination and repair. It is a nuclear enzyme that joins the breaks in the phosphodiester backbone of DNA by the process of non-homologous end joining (NHEJ)⁴. DNA ligases have two common domains: a catalytic domain (CD) that contains several conserved nucleotide-binding motifs, and a conserved non-catalytic domain (NCD). In addition, DNA ligase IV has a long C-terminal extension comprising of two BRCT domains (after the C-terminal domain of a breast cancer susceptibility protein, BRCA1), which are phosphopeptide-binding modules found in many proteins that regulate DNA damage responses (such as BRCA1, MDC1 and BARD1). These BRCT domains are connected to a short linker region that is required for the binding of the XRCC4 protein, which is important for ligase activity⁵.

¹ A. D. McNaught, A. Wilkinson. IUPAC. Compendium of Chemical Terminology, 2nd ed. (the "Gold Book"). Blackwell Scientific Publications, Oxford (1997).

² T Ellenberger et al. Eukaryotic DNA ligases: structural and functional insights. Annu Rev Biochem. 2008;77:313-38.

³ IV Martin et al. ATP-dependent DNA ligases. Genome Biol. 2002;3(4):REVIEWS3005. Epub 2002 Mar 19.

⁴ IV Martin et al. ATP-dependent DNA ligases. Genome Biol. 2002;3(4):REVIEWS3005. Epub 2002 Mar 19.

⁵ T Ellenberger et al. Eukaryotic DNA ligases: structural and functional insights. Annu Rev Biochem. 2008;77:313-38.

3108	BC-LI-0186	Specific inhibitor of the LRS-RagD interaction	Page 295
3816	Carbamyl-L-glutamic acid, N-	CPS1 activator	Page 343
2549	L67	Cytotoxic inhibitor of DNA ligase I and III	Page 601
3622	NAV-2729	Dual Arf1/Arf6 inhibitor; FATP2 inhibitor	Page 690
2531	SCR7 pyrazine	DNA ligase IV mediated inhibitor of NHEJ	Page 858

Enzymes (EC 6.1.1.) Ligases, MetRS

Methionine- (or methionyl-) tRNA synthetase (MetRS or MRS, EC 6.1.1.10) belongs to the fairly large family of aminoacyl-tRNA synthetases (ARSs) that catalyze the condensation of a specific amino acid with its cognate tRNA in a reaction that is dependent on ATP. This is the first essential step of protein translation using the genetic code to translate genetic information (in the form of messenger RNA) to produce protein, and is also referred to as tRNA charging. There is at least one ARS enzyme designated for each amino acid¹. MetRS have long been recognized as potential targets for antibacterial agents (gram positive microbes). Inhibition of a tRNA synthetase essentially mimics starvation for amino acids by lowering the ratio of charged to uncharged tRNA within the cell².

¹ A. Antonellis, E.D. Green. The Role of Aminoacyl-tRNA Synthetases in Genetic Diseases. Annu. Rev. Genomics Hum. Genet. 2008, 9:87-107.

² Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase. U.A. Ochsner, C.L. Young, K.C. Stone, F.B. Dean, N. Janjic, I.A. Critchley. Antimicrob. Agents Chemother. 2005, 49, 4253-4262.

1705	REP 3123 dihydrochloride	MetRS inhibitor	Page 812
1704	REP 8839	MetRS inhibitor	Page 812

Enzymes (EC 6.3.2.) Ligases, Ubiquitin

The attachment of ubiquitin and ubiquitin-like polypeptides to intracellular proteins is a key mechanism in regulating many cellular and organismal processes. Assembly of a chain of at least four ubiquitins linked together via their Lys48 residue marks cellular proteins for degradation by the 26S proteasome. In contrast, monoubiquitination or polyubiquitination with chains linked together via Lys63 serve as nonproteolytic signals in intracellular trafficking, DNA repair, and signal transduction pathways. Ubiquitination of proteins is achieved through an enzymatic cascade involving ubiquitin-activating (E1), ubiquitin-conjugating (E2), and ubiquitin-ligating (E3) enzymes (EC 6.3.2.19). Two major types of E3s exist in eukaryotes, defined by the presence of either a HECT or a RING domain¹. The SCF (Skp1, Cullins, F-box proteins) multisubunit E3 ubiquitin ligase, also known as CRL (Cullin-RING ubiquitin Ligase) is the largest E3 ubiquitin ligase family that promotes the ubiquitination of various regulatory proteins for targeted degradation, thus regulating many biological processes, including cell cycle progression, signal transduction, and DNA replication².

The vast majority of p53-regulated genes are induced in response to various stress signals and are responsible for maintaining genetic stability, DNA repair, regulation of crucial cell-cycle check points, and finally induction of apoptosis. The activity of p53 is tightly controlled by two major negative regulators including murine double minute 2 (MDM2; EC 6.3.2.19) and 4 (MDM4 or MDMX) proteins. Human MDM2 and MDMX are structurally related and contain three well-conserved domains: an N-terminal domain (responsible for p53 binding), a zinc-finger domain (function largely unknown) and a C-terminal RING domain (responsible for formation of homo- and heterodimers). Additionally, the RING domain of MDM2 confers E3 ubiquitin ligase activity. Concentration/activity of p53 is kept at low level in unstressed cells. This is accomplished by three parallel mechanisms mediated by MDM2 and/or MDMX. First, MDM2 and MDMX bind the N-terminal transactivation domain (TAD) of p53, preventing thereby its interaction with the transcription machinery and resulting in the inhibition of p53-responsive gene expression. Second, MDM2/X proteins export p53 outside the nucleus into the cytoplasm where it can no longer activate transcription. Finally, MDM2 marks p53 for proteasomal degradation³. Many tumors overproduce MDM2 to impair p53 function. Therefore, restoration of p53 activity by inhibiting the p53-MDM2 binding represents an attractive novel approach to cancer therapy⁴.

When directed to the nucleus by TGF-β or BMP signals, Smad proteins undergo cyclin-dependent kinase 8/9 (CDK8/9) and glycogen synthase kinase-3 (GSK3) phosphorylations that mediate the binding of YAP and Pin1 for transcriptional action, and of ubiquitin ligases Smurf1 and Nedd4L for Smad destruction⁵. Smad ubiquitylation regulatory factor-1 (Smurf1; EC 6.3.2.19) has been identified as a HECT type E3, and has been related to multiple biological processes such as cell growth and migration, and explored for several physiological functions in bone formation, embryonic development, and tumorigenesis⁶. Smurf1 was identified as a negative regulator of BMP signaling, as it ubiquitinates Smad1 and Smad5 for proteasomal degradation to prevent the mild BMP signal from bursting into an overwhelming consequence. CDK8-mediated phosphorylation of Smad1/5 facilitates the transcriptional complex in activating its target genes. Furthermore, it promotes GSK3-mediated phosphorylation of Smad1/5, which leads to the capture of Smad1/5 by Smurf1⁷.

¹ R.J. Deshaies, C.A.P. Joazeiro. RING Domain E3 Ubiquitin Ligases. Annu. Rev. Biochem. 2009, 78, 399-434.

- ² L. Jia et al. SCF E3 ubiquitin ligases as anticancer targets. *Curr Cancer Drug Targets*. 2011 Mar;11(3):347-56.
³ K. Zak et al. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present). *Exp. Opin. Ther. Pat.* 2013, 23, 425-448.
⁴ B. T. Vu, L. Vassiliev. Small-Molecule Inhibitors of the p53-MDM2 Interaction. *Curr. Top. Microbiol. Immun.* 2011, 348, 151-172.
⁵ E. Aragón et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. *Genes Dev.* 2011 Jun 15;25(12):1275-88.
⁶ Y. Cao et al. A Smurf1 tale: function and regulation of an ubiquitin ligase in multiple cellular networks. *Cell Mol Life Sci.* 2013 Jul;70(13):2305-17.
⁷ Y. Cao et al. Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation. *Sci Rep.* 2014 May 14;4:4965.

2639	AMG 232 Selective, and orally bioavailable MDM2-p53 inhibitor Page 224
3194	Apcin Inhibitor of APC/C-Cdc20 Page 239
3898	BC-1215 Selective and reversible Fbxo3 inhibitor Page 293
3211	BC1618 Potent, orally bioavailable, and metabolically stable Fbxo48 inhibitor Page 293
3846	C25-140 First-in-class TRAF6-Ubc13 inhibitor Page 337
3763	CFT-7455 Orally active monofunctional degrader for IKZF1/3 Page 360
2935	COH000 First-in-class, highly specific, covalent allosteric inhibitor of SUMO E1 Page 382
3292	dCeMM1 Glue degrader of RBM39 Page 413
3293	dCeMM2 Glue degrader of Cyclin K Page 413
3709	DKM 2-93 Selective inhibitor of UBA5 Page 433
3765	DS-3032 Orally available, potent and selective inhibitor of the p53-MDM2 interaction Page 443
3613	EN219 Covalent RNF114 ligand Page 458
4106	FX12 Selective inhibitor and degrader of RNF5 E3 ubiquitin ligase Page 493
1643	HLI 373 HDM2 inhibitor Page 542
3064	HOIPIN 11a Selective, cell-permeable and covalent inhibitor of RBR E3 ubiquitin ligase HOIP Page 544
2972	HOIPIN-8 Potent linear ubiquitin chain assembly complex (LUBAC) inhibitor Page 544
1538	JNJ 26854165 HDM2 inhibitor Page 579
1586	JNJ 26854165 dihydrochloride HDM2 inhibitor, water soluble Page 580
2939	JTP 0819958 Selective linear ubiquitin chain assembly complex (LUBAC) inhibitor Page 584
2947	JTP 1048196 Prodrug of JTP 0819958; LUBAC inhibitor Page 585
4143	MG degrader compound E14 Recent Addition Potent molecular glue degrader targeting IKZF1/3, GSPT1 and 2 Page 652
3109	ML-792 Potent and selective inhibitor of SUMO-activating enzyme (SAE) Page 673
3829	MLN7243 Cell permeable small molecule inhibitor targeting ubiquitin-activating enzymes (UAE, also known as E1 enzymes) Page 674
2565	N106 Activator of E1 ligase mediated SERCA2a SUMOylation Page 687
2228	NSC 687852 Inhibitor of 19S DUBs: UCHL5 and USP14 Page 717
1585	Nutlin 3 MDM2 inhibitor (p53 specific) Page 719
1880	Nutlin-3a Inhibitor of MDM2 Page 720
1881	Nutlin-3b Less potent (+)-enantiomer of Nutlin-3 Page 720
3751	NVP-CGM097 Inhibitor of MDM2 Page 724
3752	NVP-CGM097 dihydrochloride Inhibitor of MDM2 Page 724
4130	PELL1/EGFR disruptor S62 Recent Addition Potent PELL1/EGFR disruptor Page 757
1953	PRT 4165 E3 Ubiquitin ligase Bmi1/Ring1A inhibitor Page 793
4035	RG-7388 Potent and selective MDM2 antagonist Page 815
2009	RITA Activates p53 through inhibition of MDM2 Page 820

2741	SAR405838 MDM2-p53 inhibitor Page 843
3737	Siremadlin Potent, selective, and orally bioavailable MDM2-p53 inhibitor Page 867
2164	SJ 172550 Small molecule inhibitor of MDMX Page 869
1904	SMER 3 Inhibitor of an SCF family E3 Ubiquitin ligase Page 874
2426	SMURF1 inhibitor A01 Inhibitor of E3 ubiquitin-protein ligase SMURF1 Page 875
2437	SP 141 MDM2 inhibitor with therapeutic effects in breast cancer Page 881
2894	STF 62247 Inducer of apoptosis and autophagy in VHL-deficient RCC cells Page 894
3797	TAK-981 oxalate Inhibitor of SUMOylation Page 908
2810	VH298 Inhibitor of E3 ubiquitin-protein ligase VHL Page 968
2984	WS-383 Highly potent, selective, and cellular active inhibitor of DCN1-UBC12 protein-protein interaction Page 988

Enzymes (EC various) Ubiquitin Proteasome System

The ubiquitin-proteasome system (UPS) targets numerous cellular proteins for degradation. It is a highly complex, temporally controlled, and tightly regulated process that plays major roles in a variety of basic cellular processes¹. Degradation of a protein via the ubiquitin-proteasome pathway involves two discrete and successive steps: (1) tagging of the substrate by covalent attachment of multiple ubiquitin molecules to synthesize the polyubiquitin chain proteolytic signal and (2) degradation of the tagged protein by the 26S proteasome complex with release of free and reusable ubiquitin catalyzed by ubiquitin-recycling enzymes (DUBs)². Conjugation of ubiquitin to the protein substrate proceeds via a three-step cascade mechanism. Initially, the ubiquitin-activating enzyme E1 activates ubiquitin in an ATP-requiring reaction resulting in a high-energy thiol ester intermediate. Subsequently, this intermediate is transferred to a member of the ubiquitin-carrier proteins family of enzymes, E2 (also known as a ubiquitin-conjugating enzyme [UBC]). Finally, from E2, the activated ubiquitin moiety is attached to the substrate that is specifically bound to an E3, a member of the ubiquitin-protein ligase family of proteins. By successively adding additional activated ubiquitin moieties to internal Lys residues on the previously conjugated ubiquitin molecule, a polyubiquitin chain is synthesized. The degradation signal that is recognized by the 26S proteasome complex is made of a Lys48 polyubiquitin chain. Conjugation to other Lys residues, Lys63 for example, serves nonproteolytic functions of the system, such as activation of transcription³.

- ¹ Drug discovery in the ubiquitin-proteasome system. G. Nalepa, M. Rolfe, J.W. Harper. *Nature Reviews Drug Discovery* 2006, 5, 596-613.
² Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines. Y Ling et al. *Clin. Cancer Res.* 2003, 9, 1145-1154.
³ The Ubiquitin Proteasome System in Neurodegenerative Diseases: Sometimes the Chicken, Sometimes the Egg. A. Ciechanover, P. Brundin. *Neuron* 2003, 40, 427-446.

1810	Bortezomib Inhibitor of 26S proteasome Page 323
1798	Eeyarestatin I Inhibitor of ER associated protein degradation (ERAD) Page 449
2038	MLN 4924 Inhibitor of NEDD8 Activating Enzyme (NAE) Page 674
2016	NSC 319726 Reactivator of the p53 mutant p53R175 Page 715
2199	ONX 0914 Selective inhibitor of LMP7 subunit of immunoproteasome Page 734
2011	P 005091 Inhibitor of deubiquitinase USP7 and USP47 Page 744
1906	P 22077 Inhibitor of deubiquitinase USP7 and USP47 Page 743
1871	Pifithrin- α Hydrobromide Inhibitor of p53 protein Page 777
2512	Spatin 1 Inhibitor of USP10 and USP13 and autophagy Page 883
1779	WP 1130 Deubiquitinase Inhibitor Page 987

Ion Channels

Ion channels are pore-forming membrane proteins that act as gated pathways for the movement of ions across cell membranes. They are found in both surface and intracellular membranes, and play essential roles in the physiology of all cell types. Ion channels are especially prominent components of the nervous system as they underlie the nerve impulse and because "transmitter-activated" channels mediate conduction across the synapses of a nerve cell's axon. In addition, ion channels are key components in a wide variety of biological processes that involve rapid changes in cells, such as cardiac, skeletal, and smooth-muscle contraction, epithelial transport of nutrients and ions, T-cell activation and pancreatic beta-cell insulin release. Many human diseases are caused by defects in ion channel function, which can lead to disease in a number of different ways: Gain, or loss, of channel function (channelopathies), defective regulation of channel activity by intracellular or extracellular ligands or by channel modulators, by autoantibodies binding to ion channel proteins, or even by ion channels that act as lethal agents¹.

Ion channels can be categorized based upon multiple characteristics, e.g. their selectivity in permeability for a certain type of ion, the number of pores, or by their mechanism of activation. The wide range of Axon Ligands™ in this catalogue targeting ion channels has been categorized into ligand gated ion channels and voltage gated ion channels. Both categories are subdivided on the basis of their selectivity towards activating ligand or the type of ion.

¹ Taken from Oxford Textbook of Medicine, fifth edition, 2010. ISBN 9780470987261.

Ion Channels: Ligand-gated

Whereas the voltage-gated ion channels underlying the action potential typically allow only one type of ion to permeate, channels activated by extracellular ligands are usually less selective, allowing two or more types of ions to pass through the channel pore¹. In most cases, these ligand gated ion channels have allosteric binding sites, and can be regulated by endogenous chemical signals originating from neurotransmitters and/or cytoplasmic modulators. Ligand gated ion channels (LGICs) can be classified in three superfamilies. The superfamily of Cys-loop receptors resembles the structure and mechanism of the nicotinic acetylcholine receptors, and all share a characteristic loop formed by a disulfide bond between two cysteine residues in the N terminal extracellular domain. Most conspicuously, all the receptors of this superfamily possess four hydrophobic amino-acid sequences, which are long enough to span the plasma membrane. Accordingly, they sometimes are termed four-transmembrane (4TM)-sequence receptors. This first class of LGICs includes both anionic receptors (glycine (GlyR), GABAA (GABAAR), as well as cationic receptors (nicotinic acetylcholine (nAChR), Zinc-activated ion channel (ZAC), and one class of serotonin receptors (5-HT3R)).

Secondly, the superfamily of ionotropic glutamate receptors (iGluR) share the feature of being activated by the neurotransmitter glutamate. They form tetramers with each subunit consisting of three domains. The one domain consisting of three transmembrane helices (TMD) actually forms the ions channel. The members of this superfamily are AMPA (GluA), Kainate (GluK), NMDA (GluN), and orphan (GluD) receptors.

Finally, the third superfamily of LGICs is represented by a class of ATP-gated channels. The only members known to date are the P2X receptors (P2X 1-7) which form trimers with only two transmembrane helices per subunit².

¹ Neuroscience. 2nd edition. Purves D, Augustine GJ, Fitzpatrick D, et al., editors. Sunderland (MA): Sinauer Associates; 2001

² Ligand-Gated Ion Channels. F. Hucho, C. Weise. Angew.Chem.Int.Ed. 2001, 40, 3100-3116.

4213	TMDJ-011	Recent AdditionInactive analogue of TMDJ-035.....	Page 932
4111	TMDJ-035	Recent AdditionFirst highly potent and selective RyR2 inhibitor.....	Page 932

Ion Channels (Ligand-gated) Cys-loop, anionic

The Cys-loop class of LGICs forms a superfamily of ionotropic receptors that includes two types of anion-permeable channels, which are represented by receptors for the neurotransmitters GABA (gamma-aminobutyric acid) and glycine, and allow negatively charged chloride ions to migrate through the cell membrane. Activation of these receptors in general leads to rapid inhibitory synaptic transmission¹.

Upon activation, the GABAA receptor selectively conducts Cl⁻ through its pore, resulting in hyperpolarization of the neuron. This causes an inhibitory effect on neurotransmission by diminishing the chance of a successful action potential occurring. Mild inhibition of neuronal firing by drugs acting at the GABAA receptor causes a reduction of anxiety in the patient (an anxiolytic effect) while more pronounced inhibition induces general anesthesia².

As a consequence of its high affinity binding to its natural inhibitor, strychnine, the GlyR was the first nicotinic receptor isolated from mammalian nervous tissue. Structurally and functionally, the glycine receptor is most closely related to the GABAA receptor. GlyRs are primarily expressed in spinal cord, brain stem, caudal brain, and retina. In adult neurons, the inhibitory chloride influx upon glycine receptor activation stabilizes the resting potential of the cell, rendering them electrically quiescent. Reduced channel expression and/or reduced activity of mutants often result in channelopathies involving muscle tone regulation, such as human startle disease (hyperekplexia)³.

¹ Novel animal-health drug targets from ligand-gated chloride channels. V. Raymond, D.B. Sattelle. Nat. Rev. Drug Discov. 2002, 1, 427-436.

² Structure, Function, and Modulation of GABAA Receptors. E. Sigel M.E. Steinmann. J. Biol. Chem. 2012, 287, 40224-40231.

³ Structure and Function of the Glycine Receptor and Related Nicotinic Receptors. M. Cascio. J. Biol. Chem. 2004, 279, 19383-19386.

3698	AC-5216Selective translocator protein (TSPO) ligand.....	Page 204
3042	AZD 6280Selective, orally active, allosteric GABA-A α 2/3 receptor modulator.....	Page 275
1604	CP 615003 mesylateGABAA agonist.....	Page 390
3406	DemoxepamMetabolite of Chlordiazepoxide.....	Page 419
3388	EtifoxinePAM of GABAA.....	Page 469
3331	Etifoxine hydrochloridePAM of GABAA.....	Page 469
4047	FluralanerGABA/L-glutamate gated chloride channel inhibitor.....	Page 487
1301	GabapentinGABA modulator; Anti-convulsant.....	Page 495
3390	L-655,708Selective inverse agonist of GABAA- α 5.....	Page 601
1196	L 838417GABAA-alpha1 antagonist.....	Page 602
1121	NBI 34060PAM of GABAA-alpha1.....	Page 694
1457	NS 11394PAM of GABAA.....	Page 712
1594	Pagoclon, (+)-GABAA-alpha2 and GABAA-alpha3 agonist.....	Page 745
1208	PK 11195Benzodiazepine antagonist.....	Page 780
2785	PK 11195, (R)-(-)-Benzodiazepine antagonist.....	Page 780
2784	PK 11195, (R)-(-)-N-Desmethyl-Radioligand precursor of the benzodiazepine antagonist (R)-(-)-PK 11195.....	Page 781
2833	PK 11195, N-Desmethyl-Radioligand precursor of the benzodiazepine antagonist PK 11195.....	Page 781
1195	SL 651498GABAA-alpha2 agonist.....	Page 872
3119	StiripentolPAM of GABAA.....	Page 896
1422	TP 003GABAA-alpha3 agonist.....	Page 937
1646	ZaleplonGABAA-alpha1 agonist.....	Page 1003
1197	ZopicloneBenzodiazepine agonist.....	Page 1010

Ion Channels (Ligand-gated) Cys-loop, cationic

Nicotinic acetylcholine receptors are made up of 5 subunits, symmetrically arranged around a central pore (ion channel). It is considered the best-characterized LGIC and a prototypical structure for the class of 4TM receptors. nAChRs are found mainly in postsynaptic membranes of central nervous system synapses and of the neuromuscular endplate. The physiological signal to which nAChR responds is the neurotransmitter acetylcholine, but it is also activated by nicotine. The assembly of combinations of subunits (17 distinct subunits have been identified) results in a large number of different receptors with a high variety of functional diversity as a result¹.

5-HT₃ differ from all other 5-HT (serotonin) receptors whose actions are mediated via G proteins. Their structure and function has placed them in the Cys-loop family of cationic ligand-gated ion channels. 5-HT₃ receptors are located in both the peripheral (PNS) and central (CNS) nervous systems. In the CNS, 5-HT₃ receptors may play roles in a variety of functions including emesis, cognition and anxiety, whereas in the PNS they play a role in a variety of sympathetic, parasympathetic and sensory functions (e.g. signaling in gastrointestinal tract, gut motility and peristalsis)².

¹ Ligand-Gated Ion Channels. F. Hucho, C. Weise. Angew.Chem.Int.Ed. 2001, 40, 3100-3116.

² 5-HT₃ Receptors. A. J. Thompson, S. C. R. Lummis. Curr Pharm Des. 2006; 12(28): 3615-3630.

2694	4BP-TQSAllosteric agonist of α 7 nAChR.....	Page 325
1097	Alosetron hydrochloride5-HT ₃ antagonist.....	Page 219
2401	AT 1001High affinity and selective α 3 β 4 nAChR ligand.....	Page 257
1096	Azasetron hydrochloride5-HT ₃ antagonist.....	Page 266
2535	Azasetron hydrochloride, (-)-5-HT ₃ antagonist.....	Page 267
2534	Azasetron hydrochloride, (+)-5-HT ₃ antagonist.....	Page 266

1153	B-HT 920 dihydrochloride	D2 agonist, alpha-2 adrenoceptor agonist; 5-HT3 antagonist	Page 301
4113	Encenicline hydrochloride Recent Addition	Selective and brain-penetrant $\alpha 7$ nicotinic acetylcholine receptor (nAChR) partial agonist	Page 459
1078	Epibatidine dihydrochloride, (-)	Nicotinic acetylcholine receptor agonist	Page 461
1077	Epibatidine dihydrochloride, (+)	Nicotinic acetylcholine receptor agonist	Page 462
1076	Epibatidine dihydrochloride, (\pm)	Nicotinic acetylcholine receptor agonist	Page 462
1449	Granisetron hydrochloride	5-HT3 antagonist	Page 514
2860	GTS 21 dihydrochloride	Selective $\alpha 7$ nicotinic acetylcholine receptor (nAChR) partial agonist	Page 531
3101	Palonosetron hydrochloride	Highly potent, selective and orally active 5-HT3 antagonist	Page 746
3286	Penehyclidine hydrochloride	Anticholinergic drug	Page 758
2109	PHA 543613 dihydrochloride	nAChR agonist (selective for $\alpha 7$ sub-unit)	Page 774
2908	PNU 282987 hydrochloride	nAChR agonist ($\alpha 7$ sub-unit selective)	Page 786
3151	QND7	nAChR antagonist ($\alpha 7$ sub-unit selective)	Page 801
1384	Varenicline dihydrochloride	Nicotinic acetylcholine receptor agonist	Page 962
2074	Varenicline tartrate	$\alpha 4\beta 2$ nicotinic acetylcholine receptor (nAChR) partial agonist	Page 962

Ion Channels (Ligand-gated) Glutamate, ionotropic

L-glutamate is the major excitatory neurotransmitter in the central nervous system. The glutamate system represents an attractive molecular target in the treatment of epilepsy, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, Huntington's chorea), schizophrenia, ischemia, pain, alcoholism and mood disorders¹.

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) is an artificial glutamate analogue. Its receptor (originally named quisqualate receptor) is a non-NMDA-type ionotropic transmembrane receptor for glutamate that mediates fast synaptic transmission in the central nervous system. Like all ionotropic glutamate receptors, it consists of tetramers of four different types of subunits (GluR1-GluR4). The AMPA receptor GluA2 (GluR2) tetramer was the first and currently only glutamate receptor ion channel to be crystallized².

Kainate, a natural product, is an excitotoxic glutamate analogue produced by an algae, while NMDA is N-methyl-D-aspartate. Although all three glutamate receptor subtypes respond to glutamate, they can be distinguished by their response to these artificial agonists. Their distribution in the brain, physiological function, and mechanism and kinetics of activation and regulation are very different³. In two ways, the NMDA receptor is distinct from the other LGICs. First, it is both ligand-gated and voltage-dependent. Second, it requires co-activation by two ligands: glutamate and either D-serine or glycine. What's more, the receptor controls a cation channel that is highly permeable to multiple monovalent ions and calcium⁴.

¹ Molecular structure of ionotropic glutamate receptors. A.A. Kaczor, D. Matusiuk. *Curr Med Chem.* 2010,17, 2608-2635.

² AMPA receptors as drug targets in neurological disease—advantages, caveats, and future outlook. P.K. Chang, D. Verbich, R.A. McKinney. *Eur. J. Neurosci.* 2012, 35, 1908-1916.

³ Kainate receptors. P. Pinheiro, C. Mülle. *Cell and Tissue Research.* 2006, 326, 457-482.

⁴ The Role of N-Methyl-D-Aspartate (NMDA) Receptors in Pain: A Review. A.B. Petrenko et al. *Anest. Analg.* 2003, 97, 1108-1116

3415	AMPA	Highly selective AMPA receptor agonist	Page 235
3335	AZD6765 dihydrochloride	Noncompetitive NMDA antagonist	Page 278
3088	BCP, 1-	Brain-penetrant modulator of AMPA receptor	Page 295
4169	CIQ	First NMDA NR2C/NR2D PAM	Page 373
1217	CFM 2	AMPA antagonist	Page 360
2079	CMPDA	Positive allosteric modulator of AMPA receptor	Page 380
1200	CNQX	AMPA/Kainate antagonist	Page 381
2522	CNQX disodium salt	AMPA/Kainate antagonist	Page 381
2254	CP 101606	NMDA NR2B antagonist	Page 387
1406	CP 101606 mesylate	NMDA NR2B antagonist	Page 387
3089	CX516	Positive allosteric modulator of AMPA receptor	Page 400
3090	CX546	Positive allosteric modulator of AMPA receptor	Page 400
3841	Dextromethorphan hydrobromide	Noncompetitive NMDA receptor antagonist	Page 423

1201	DNQX	AMPA/Kainate antagonist	Page 436
1246	Eliprodil	NMDA antagonist	Page 455
1262	Gavestinel	NMDA antagonist (glycine site)	Page 496
1374	GYKI 53655	AMPA antagonist	Page 536
1156	Ifenprodil	NMDA antagonist	Page 559
2793	JNJ 55511118	Negative modulator of AMPA receptor (TARP- $\gamma 8$ selective)	Page 581
1353	Lamotrigine	Glutamate antagonist; Na ⁺ channel blocker	Page 604
1249	N 20C hydrochloride	NMDA antagonist	Page 687
3472	NMDA	Selective NMDA agonist	Page 706
3349	NMDAR-TRPM4 blocker C19 dihydrochloride	NMDAR/TRPM4 interaction interface inhibitor	Page 706
3348	NMDAR-TRPM4 blocker C8 dihydrochloride	NMDAR/TRPM4 interaction interface inhibitor	Page 706
1434	RGH 896	NMDA NR2B antagonist	Page 816
3499	Riluzole	Glutamatergic neurotransmission blocker; neuroprotectant	Page 819
3576	Riluzole hydrochloride	Glutamatergic neurotransmission blocker; neuroprotectant	Page 819
1314	RO 25-6981 hydrochloride	NMDA NR2B antagonist	Page 823
2601	RO 25-6981 maleate	NMDA NR2B antagonist	Page 824
1788	S 18986	Positive allosteric modulator of AMPA receptor	Page 840
2708	TCN-201	NMDA NR2A antagonist	Page 914
1312	YM 90K hydrochloride	AMPA antagonist	Page 998
2261	ZD 9379	Antagonist of the glycine site on the NMDA receptor complex	Page 1005

Ion Channels (Ligand-gated) P2X

P2X receptors belong to a larger family of receptors known as the purinergic receptors¹. Unlike the G-protein coupled P1 and P2Y receptors, the P2X receptors are ATP-gated cation channels with important roles in diverse pathophysiological processes (afferent signaling (including pain), regulation of renal blood flow, vascular endothelium, and inflammatory responses)².

¹ ATP-gated P2X cation-channels. M.F. Jarvisa, B.S. Khakh. *Neuropharm.* 2009, 56, 208–215.

² Signaling at Purinergic P2X Receptors. A. Surprenant, R.A. North. *Ann. Rev. Physiol.* 2009, 71, 333-359.

3835	A-438079 hydrochloride	Competitive P2X7 antagonist	Page 191
2182	A 804598	Potent and selective P2X7 antagonist	Page 193
3845	BAY-1797	Potent and selective P2X4 inhibitor	Page 287
2523	BX 430	Allosteric antagonist of human P2X4 receptor channels	Page 334
1967	GW 791343 hydrochloride	P2X7 receptor antagonist and allosteric modulator	Page 535
3262	HEI3090	Positive modulator of the P2X7 receptor	Page 540
3429	Indophagolin	Potent autophagy inhibitor	Page 566
2890	JNJ 47965567	Potent, brain-penetrant P2X7 antagonist	Page 581

Ion Channels (Ligand-gated) unclassified

Cystic fibrosis transmembrane conductance regulator (CFTR) is an ABC (ATP-binding cassette) transporter-class ion channel that transports chloride and thiocyanate ions across epithelial cell membranes¹. Like the P2X receptors, the CFTR has an ATP binding domain, and is considered a cAMP-activated ATP-gated anion channel. It is found in the epithelial cells of many organs including the lung, liver, pancreas, digestive tract, reproductive tract, and skin. Chloride transport through the CFTR channel works in concert with sodium transport through epithelial sodium channels (ENaC) to maintain salt, fluid, and pH homeostasis in various epithelial tissues. Mutations of the CFTR gene affect functioning of the chloride ion channels in these cell membranes, leading to cystic fibrosis and congenital absence of the vas deferens².

¹ The ABC protein turned chloride channel whose failure causes cystic fibrosis. D.C. Gadsby, P. Vergani, L. Csanády. *Nature* 2006, 440, 477-483.

² Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. K.D. MacDonald, K.R. McKenzie, P.L. Zeitlin. Paediatr. Drugs 2007, 9, 1-10.

2552	Adjudin	Male contraceptive with anti-proliferative activity	Page 208
4049	Ataluren	CFTR-G542X suppressor	Page 258
1763	CoPo 22	Modulator of CFTR (delta-F508 Selective)	Page 385
2572	GlyH 101	Highly potent and selective CFTR inhibitor	Page 506
3234	Lumacaftor	Selective and orally bioavailable CFTR corrector	Page 625
2295	PPQ 102	CFTR inhibitor	Page 788
2169	VX 661	Corrector of the CFTR	Page 979
2503	VX 770	Orally bioavailable CFTR potentiator	Page 981

Ion Channels: Voltage-gated

Ion channels are specialized proteins embedded in the membrane. The ion selectivity of the channel is a property associated with its permeation pathway, normally called the pore. The magnitude of the current across the membrane depends on the density of channels, the conductance of the open channel, and how often the channel spends in its open position or its open probability. The salient feature of channels involved in excitable membranes is that the open probability is regulated by the transmembrane voltage or membrane potential. Changes in the membrane potential can be picked up by a voltage sensor that detects the voltage and transfers its energy to the pore to control its gate¹. Despite their differences in ion selectivity and gating capabilities, voltage-gated channels in general share a number of structural features. They have a common structure with 24 transmembrane segments and a specialized pore region. Voltage-gated Na⁺ and Ca²⁺ channels are composed of a single pore-forming polypeptide (the alpha subunit), plus various auxiliary subunits. The alpha subunits of these channels contain four repeats of a core motif, which consists of six predicted transmembrane regions, S1-S6. Voltage-activated K⁺ channels are tetramers, with each subunit containing a single core motif. The ion-selective pore of these channels are formed by loops between the S5 and S6 regions, often called the P-regions or P-loops; four of these loops approach close together at the axis of the pore².

¹ The Voltage Sensor in Voltage-Dependent Ion Channels. F. Bezanilla. Physiol. Rev. 2000,80, 555-592.

² The moving parts of voltage-gated ion channels. G. Yellen. Q. Rev. Bioph. 1998, 31, 239-295.

Ion Channels (Voltage-gated) Calcium

Calcium channels have long been the target of therapeutic drugs aimed at treating the symptoms of cardiovascular disease and migraine headache. They regulate the permeability of the cell membrane towards calcium. Axon Medchem offers pharmacological standards that interact at each of the 2 main classes within the family of calcium channels, the voltage-gated, and the ligand-gated channels (see also section of non-calcium-selective ligand-gated ion channels)¹.

¹ International Union of Pharmacology. XLVIII. Nomenclature and Structure-Function Relationships of Voltage-Gated Calcium Channels. WA Catterall, E Perez-Reyes, TP Snutch, J Striessnig. Pharmacol Rev 57:411-425, 2005

3785	ABT-639	Peripherally acting, selective and orally bioavailable T-type Ca ²⁺ channel blocker	Page 202
3015	Amlodipine besylate	Ca ²⁺ channel blocker	Page 234
3013	Aranidipine	Ca ²⁺ channel antagonist	Page 246
3160	Azelnidipine	Calcium channel blocker	Page 278
3014	Barnidipine hydrochloride	Potent Ca ²⁺ channel blocker (L-type voltage gated)	Page 284
1697	BAY K 8644	Ca ²⁺ channel activator (L-type voltage-gated)	Page 292
1758	BAY K 8644, (R)-(+)-	Ca ²⁺ channel blocker (L-type voltage-gated)	Page 292
1759	BAY K 8644, (S)-(-)-	Ca ²⁺ channel opener (L-type voltage-gated)	Page 292
3131	Benidipine hydrochloride	Ca ²⁺ channel blocker	Page 298
3981	Calcium influx inducer compound 634	Ca ²⁺ influx inducer	Page 340
4066	CM-4620	Selective Orai1 channel inhibitor; SOCE inhibitor	Page 379
1868	CRAC inhibitor 44	Potent and selective CRAC ion channel blocker	Page 394
3323	Diltiazem hydrochloride	Ca ²⁺ channel antagonist (L-type voltage gated)	Page 429
3450	Dronedrone hydrochloride	Ca ²⁺ /K ⁺ /Na ⁺ channel blocker; Antiarrhythmic agent	Page 442

2952	Fantofarone	Highly potent and specific Ca ²⁺ channel antagonist	Page 474
1448	Felodipine	Ca ²⁺ channel blocker	Page 477
3501	Isradipine	Ca ²⁺ channel antagonist	Page 572
3185	L651582	Ca ²⁺ channel blocker	Page 602
4202	Manidipine dihydrochloride	Recent Addition Ca ²⁺ channel antagonist	Page 639
3254	Nicardipine	Ca ²⁺ channel antagonist	Page 702
2068	Nifedipine	Ca ²⁺ channel blocker (L-type voltage gated)	Page 702
3158	Otilonium bromide	Ca ²⁺ channel blocker	Page 790
3887	Pinaverium bromide	Ca ²⁺ channel blocker (L-type voltage gated)	Page 778
1823	Pregabalin	Reduces synaptic signaling by binding to α2δ subunits	Page 790
3644	Propafenone hydrochloride	Ca ²⁺ /K ⁺ /Na ⁺ channel blocker; Antiarrhythmic agent	Page 792
3507	Ranolazine	Ca ²⁺ /K ⁺ /Na ⁺ channel blocker; Anti-anginal agent	Page 807
1221	SKF 96365 hydrochloride	Ca ²⁺ channel blocker	Page 870
3452	Verapamil hydrochloride	Ca ²⁺ channel antagonist	Page 965
3025	Z944	Highly selective, orally available Ca ²⁺ channel blocker (T-type voltage gated)	Page 1002

Ion Channels (Voltage-gated) Potassium

Potassium channels are a diverse and ubiquitous family of membrane proteins present in both excitable and non-excitable cells. Members of this channel family play critical roles in cellular signaling processes regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume regulation. Over 50 human genes encoding various potassium channels have been cloned during the past decade¹. Based on the structure of the potassium channels, four main classes can be identified. The basis of all channels consists of four subunits that are clustered to form the ion-permeation pathway across the membrane. Each of the four subunits is build up of two transmembrane helices and a short loop between them. Distinct features characterize the four main classes²: inwardly rectifying potassium channels (2TM/P channels), voltage and/or ligand gated ion channels (6TM/P channels), hybrid channels made from the two previously mentioned classes (8TM/2P channels), and dimer channels (4TM/2P channels) made from two repeats of the inwardly rectifying channels, and are often referred to as 'leakage channels'. Also the hyperpolarization-activated and cyclic nucleotide-gated (HCN) channels belong to the superfamily of voltage-gated K⁺ (Kv) and cyclic nucleotide-gated (CNG) channels. They are sometimes referred to as "pacemaker channels" because they help to generate rhythmic activity within groups of heart and brain cells.

Axon Medchem offers a variety of potassium channel openers and blockers, including the racemate and optically pure enantiomers of BMS 204352 (Axon 1112, Axon 1308, and Axon 1309), modulators of the Maxi-K channel (or BK channel, member of 6TM/P channel class), and Zatebradine HCl (Axon 1248, HCN channel blocker).

¹ Potassium Channels: Molecular Defects, Diseases, and Therapeutic Opportunities. C.C. Shieh, M. Coghlan, J.P. Sullivan, M. Gopalakrishnan. Pharmacological Reviews, 2000, 52, 557-594.

² Ion conduction pore is conserved among potassium channels. Lu, Z., Klem, A. M. & Ramu, Y. Nature 2001, 413, 809-813.

2979	ASP 2905	Potent, selective and orally active KCNH3 (Kv12.2) inhibitor	Page 255
2243	AVE 0118 hydrochloride	Potassium channel blocker (Kv1.5, Kv4.3, Kir3.4, and IKr)	Page 261
1294	Chromanol 293B	KCNQ1 channel blocker	Page 368
1322	DMP 543	K ⁺ channel blocker; Ach release stimulator	Page 435
2103	Dofetilide	Kv11.1 (hERG) channel blocker	Page 436
4173	Ebio1	Recent Addition Potent and highly selective KCNQ2 activator	Page 449
1437	Flupirtine maleate	Analgesic	Page 486
2724	ICA-069673	KCNQ2/KCNQ3 channel opener; Anti-convulsant	Page 556
3091	ICA-110381	KCNQ2/KCNQ3 channel opener; Anti-convulsant	Page 557
3495	Ivabradine hydrochloride	Selective sinus node I(f) channel inhibitor	Page 574
3516	KCa modulator RA-2	Potent and selective KCa2/3 pan inhibitor	Page 589
1735	Kv1.3 Channel blocker 42	Kv1.3 potassium channel blocker	Page 599

3032	LUF7244	Potent negative allosteric modulator (NAM) of the Kv11.1 (hERG) channel.....	Page 624
2747	ML 213	KCNQ2/KCNQ4 channel opener.....	Page 665
2615	ML252	Selective and brain penetrant KCNQ2 inhibitor.....	Page 666
3196	ML277	Potent and selective KCNQ1 channel activator.....	Page 667
2094	NS 6180	KCa3.1 channel blocker.....	Page 711
3365	Repaglinide	K ⁺ channel blocker (SUR1/Kir6.2 selective).....	Page 812
1525	Retigabine	KCNQ channel opener; Anti-convulsant.....	Page 813
2252	Retigabine dihydrochloride	KCNQ channel opener; Anti-convulsant.....	Page 813
1657	S 9947	Ikur/Kv1.5 channel Inhibitor.....	Page 839
3951	Senicapoc	Potent and selective antagonist of the Gardos channel.....	Page 860
3265	XAF-1407	Potent and highly selective IKACH inhibitor.....	Page 991
1987	XE 991	KCNQ channel and M-current blocker.....	Page 992
1305	XE 991 dihydrochloride	KCNQ channel and M-current blocker.....	Page 992
1248	Zatebradine hydrochloride	HCN channel blocker.....	Page 1004

Ion Channels (Voltage-gated) Sodium

Voltage-gated sodium channels, which produce the inward membrane current necessary for regenerative action potential production within the mammalian nervous system, are expressed in primary sensory neurons and have emerged as important targets in the study of the molecular pathophysiology of pain and in the search for new pain therapies¹. Nine members of the family of voltage-gated sodium channels have been identified thus far, consisting of a large alpha subunit that associates with other proteins, such as beta subunits². An alpha subunit, consisting on its own of four repeating transmembrane domains forming the actual pore, forms the core of the channel and is functional on its own. When accessory proteins assemble with alpha subunits, the resulting complex can display altered voltage dependence and cellular localization. Ligand gated sodium channels (e.g. nicotinic receptors) are activated by endogenous acetylcholine. Activation causes a conformational change of the receptor, leading to the opening of the internal pore, and enabling extra-cellular sodium ions to flow into the cell.

As the quest for new selective molecules targeting sodium channels for the treatment of chronic pain continues, Axon Medchem intends to expand its range of sodium channel modulators accordingly.

¹ Sodium channels and pain. S.G. Waxman*, S. Dib-Hajj, T.R. Cummins, J.A. Black. Proc. Natl. Acad. Sci. USA 1999, 96, 7635-7639.
² International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. W.A. Catterall, A.L. Goldin, S.G. Waxman. Pharmacol Rev. 2005, 57, 397-409.

1915	A 803467	Blocker of the voltage-gated Nav1.8 channel.....	Page 193
1113	AM 36 dihydrochloride	Na ⁺ channel blocker.....	Page 221
2548	CNV 1014802 hydrochloride	Na ⁺ channel blocker; anti-convulsant.....	Page 381
4080	DNA binder S20 hydrochloride	Orally bioavailable Nav1.7/Nav1.8/Nav1.9 channel antagonist; DNA binder.....	Page 435
1899	GSK2	Na ⁺ channel blocker; anti-convulsant.....	Page 517
1444	Lacosamide	Na ⁺ channel blocker; anti-convulsant.....	Page 603
3454	Mexiletine hydrochloride	Na ⁺ channel blocker; Antiarrhythmic agent.....	Page 651
1791	Nav1.7 blocker 24	Nav1.7 blocker.....	Page 693
1780	Nav1.7 blocker 52	Nav1.7 Inhibitor.....	Page 693
2056	XEN 907	Sodium channel blocker (voltage-gated Nav1.7).....	Page 992

Ion Channels (Voltage-gated) Transient Receptor Potential

The largest group of receptors that function as noxious stimuli detectors in nociceptors is the transient receptor potential (TRP) channel family. TRPs have been subclassified into the C, V, M, A, P, and ML subfamilies. The members are principal transducers of thermal stimuli that depolarize nerve terminals to the action potential threshold. A role of TRP channels specifically in pain and thermosensation was first suggested by the finding that mammalian TRPV1 is activated by both noxious heat and capsaicin, the active ingredient of chilli peppers. Although there is little amino-acid conservation among

distant TRP channels, they share a similar architecture of six-transmembrane domains with cytoplasmic amino and carboxy termini. TRP channels are thought to function as tetramers, mostly as homomers. Six of the 28 TRP channels from the three distinct TRP family subtypes are activated by temperature (TRPV1-4, TRPM8 and TRPA1). Three other TRP channels (TRPM2, TRPM4 and TRPM5) are strongly modulated by warm temperatures as well; however, the lack of expression in nociceptor neurons argues against a role in nociception¹.

The Vanilloid receptor (TRPV1), member of the Transient Receptor Potential Channel super family, is an ion channel which is selective for calcium and magnesium over sodium ions. It is believed to be activated through a variety of mechanisms, among which the binding of molecules containing a vanillyl moiety, also present in capsaicin. ABT 102 (Axon 1504) does not show this particular vanillyl moiety, yet is a member of the class of di(arylalkyl)- and aryl(arylalkyl)ureas, a class of compounds that also include two SB compounds (SB 705498, and SB 452533), which have entered clinical trials².

The transient receptor potential ankyrin-repeat 1 (TRPA1) channel is the sole member of the TRPA branch of the TRP ion channel gene family. TRPA channels resemble TRPN channels that were implicated in mechanotransduction and hearing in *Drosophila* and zebrafish. However, the ion channel domain of TRPA channels is evolutionarily distant from TRPN channels³. TRPA1 channels are required for neuronal excitation, the release of inflammatory neuropeptides, and subsequent pain hypersensitivity⁴. TRPA1 is also activated by the release of inflammatory agents from nonneuronal cells in the area of tissue injury or disease, and by environmental irritants and pungent chemicals, such as cinnamaldehyde and mustard oil. Extracellular Ca²⁺ is a key regulator of TRPA1 activity, both potentiating and subsequently inactivating it⁵. The transient receptor potential, subfamily C (TRPC) channels are ubiquitously expressed among cell types and mediate signals in response to phospholipase C (PLC)-coupled receptors⁶. Among the TRPs, the 6 members of the human TRPC subfamily are unique in that they are not only responsible for agonist-activated nonselective cation currents, but they also participate in the so-called slow sustained mode of Ca²⁺ signaling, which requires sustained elevations of intracellular Ca²⁺ ([Ca²⁺]_i)⁷.

For all organisms, detection and adaptation to cold temperature is crucial to survival. Cold sensing in the innocuous range of cold (>10-15 °C) in the mammalian peripheral nervous system is thought to rely primarily on transient receptor potential (TRP) ion channels, most notably the menthol receptor, TRPM8. The TRP cation channel, subfamily C member 5 (TRPC5), is found to be highly sensitive to cold in the temperature range 37–25 °C, and is thus hypothesized to play a role in sensing cold⁸. Additionally, the channel may have an important role in the pathogenesis of hypertension⁹.

¹ A. Patapoutian et al. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov. 2009 Jan;8(1):55-68.
² (R)-(-)-5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-Evoked Firing of Spinal Dorsal Horn Neurons in Vivo. C.S. Surowy et al. J. Pharmacol. Exp. Ther. 2008, 326, 879-888.
³ W.B. Liedtke, S. Heller, editors. TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades. Boca Raton (FL): CRC Press; 2007.
⁴ D.M. Bautista et al. TRPA1: A gatekeeper for inflammation. Annu Rev Physiol. 2013;75:181-200.
⁵ Y.Y. Wang et al. The nociceptor ion channel TRPA1 is potentiated and inactivated by permeating calcium ions. J Biol Chem. 2008 Nov 21;283(47):32691-703.
⁶ J. Soboloff et al. TRPC channels: integrators of multiple cellular signals. Handb Exp Pharmacol. 2007;(179):575-91.
⁷ L. Birnbaumer. The TRPC class of ion channels: a critical review of their roles in slow, sustained increases in intracellular Ca(2+) concentrations. Annu Rev Pharmacol Toxicol. 2009;49:395-426.
⁸ K. Zimmermann et al. Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system. Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18114-9.
⁹ K.T. Cheng et al. Contribution and regulation of TRPC channels in store-operated Ca2+ entry. Curr Top Membr. 2013;71:149-79.

1816	A 784168	TRPV1 receptor antagonist.....	Page 192
1504	ABT 102	TRPV1 antagonist.....	Page 200
3026	AC1903	Selective TRPC5 inhibitor.....	Page 203
3356	AMG 9810	Potent and selective vanilloid receptor-1 (TRPV1) antagonist.....	Page 227
3036	BI 749327	Potent, selective and orally bioavailable TRPC6 inhibitor.....	Page 304
2458	Clemizole	Inhibitor of the transient receptor potential channel TRPC5.....	Page 375
2742	GSK 2193874	Orally active TRPV4 antagonist.....	Page 523
3726	JT010	Potent and selective TRPA1 agonist.....	Page 584
2423	M8-B hydrochloride	Selective and potent antagonist of the TRPM8 channel.....	Page 637
2980	ML2-SA1	Potent and selective activator of TRPML2.....	Page 671
4193	ML-SA1	Potent and specific TRPML1 agonist.....	Page 675
3633	Ononetin	Potent and selective TRPM3 antagonist.....	Page 734
2374	Optovin	Reversible photoactivated TRPA1 agonist.....	Page 735
2483	PF 05105679	TRPM8 inhibitor with >100-fold selectivity.....	Page 769
2498	RQ 00203078	Selective, potent, and orally active TRPM8 antagonist.....	Page 832
3287	SET2	Potent and selective TRPV2 inhibitor.....	Page 862
4100	TRPML3 activator SN2	First selective TRPML3 activator.....	Page 940

Ion Channels: Inward rectifier, Potassium

A group of potassium channels with a predicted membrane topology of two TMDs (M1–M2) and a pore (P) domain comprises inward rectifier channels (K_{ir}) and ATP-sensitive (K_{ATP}) channels. Currently, seven subfamilies (Kir1–7) have been identified, the majority of which form K^+ channels with varying degrees of inward rectification when expressed in heterologous expression systems. They can be classified into four functional groups: classical Kir channels (Kir2.x) are constitutively active, G protein-gated Kir channels (K_G or Kir3.x) are regulated by G protein-coupled receptors, ATP-sensitive K^+ channels (Kir6.x) are tightly linked to cellular metabolism, and K^+ transport channels (Kir1.x, Kir4.x, Kir5.x, and Kir7.x)¹.

K_{ATP} channels couple cell metabolism to electrical activity of the plasma membrane by regulating membrane K^+ fluxes. A reduction in metabolism opens K_{ATP} channels, producing K^+ efflux, membrane hyperpolarization, and suppression of electrical activity. Conversely, increased metabolism closes K_{ATP} channels. The consequent membrane depolarization stimulates electrical activity and may thereby trigger cellular responses such as the release of hormones and neurotransmitters, or muscle contraction. Given their critical role in regulating electrical excitability in many cells, it is evident that disruption of K_{ATP} channel function can lead to disease. To date, mutations in K_{ATP} channel genes have been shown to cause neonatal diabetes, hyperinsulinemia, and dilated cardiomyopathy in humans. The K_{ATP} channel is an octameric complex of 4 Kir6.x and 4 SURx subunits².

G protein-gated Kir Channels (Kir3.x, a.k.a. K_G channels or GIRKs) are one of the targets of GPCRs, that, upon activation of the GPCR by its ligand (hormone or neurotransmitter) release two intracellular effector molecules (G_{α} and $G_{\beta\gamma}$) that can effectuate channel opening resulting in hyperpolarization of the cell. The K_G channels can be activated by intracellular GTP (GTPi) in the presence of agonist or by intracellular GTP γ S even in the absence of agonist. After a long controversy, it was finally established that K_G channels are activated by $G_{\beta\gamma}$ subunits of PTX-sensitive G proteins. Functional K_G channels are tetrameric assemblies of Kir3 family subunits and can be either homomeric or heteromeric. The composition of subunit of K_G channels varies among different cells and tissues which allows them to play diverse functional roles¹.

¹ H. Hibino et al. Inwardly rectifying potassium channels: their structure, function, and physiological roles. *Physiol Rev.* 2010 Jan;90(1):291-366.

² ATP-sensitive potassium channelopathies: focus on insulin secretion. *F.M. Ashcroft. J. Clin. Invest.* 2005, 115, 2047-2058.

2064	Glibenclamide potassium salt	<i>K_{ATP} channel blocker; inhibits SUR1</i>	Page 503
3503	Glipizide	<i>K_{ATP} channel blocker; inhibits SUR1</i>	Page 504
1757	HMR 1098	<i>K⁺ channel blocker (SUR1/Kir6.2 selective)</i>	Page 543
4046	Levosimendan	<i>Calcium sensitizer</i>	Page 613
3490	Minoxidil	<i>K⁺ channel opener (ATP sensitive, vascular)</i>	Page 657
2436	ML 297	<i>Selective activator of the GIRK potassium channel</i>	Page 666
3641	Nateglinide	<i>K_{ATP} channel blocker; inhibits SUR1</i>	Page 693
1647	NN 414	<i>K⁺ channel opener (SUR1/Kir6.2 selective)</i>	Page 707
1274	PNU 37883 hydrochloride	<i>K⁺ channel blocker (ATP sensitive, vascular)</i>	Page 785
3593	VU0468554	<i>Selective cardiac GIRK inhibitor</i>	Page 973
3675	VU6036720 hydrochloride	<i>First potent and selective inhibitor of heteromeric Kir4.1/5.1 inward rectifier potassium channels</i>	Page 978
3799	VU6036721 hydrochloride	<i>Inactive enantiomer of VU6036720 hydrochloride</i>	Page 978

Ion Channels: Calcium-activated, Potassium

Calcium-activated potassium channels are a large family of potassium channels that are found throughout the central nervous system and in many other cell types. These channels are activated by rises in cytosolic calcium largely in response to calcium influx via voltage-gated calcium channels that open during action potentials¹. The International Union of Pharmacology has put the Ca^{2+} activated K^+ channels into one family which can be subdivided into two functionally but genetically unrelated groups. One group include Small conductance KCa channels (KCa 2.1 (SK1), 2.2 (SK2) and 2.3 (SK3)). These channels are sensitive to block by apamin (100 pM–10 nM), which distinguishes them from all other KCa channels. The group additionally is made up of Intermediate conductance channels (KCa 3.1 (IK)). These channels are voltage-insensitive and are activated by low concentrations of internal calcium (less than 1.0 micromM). Both IK and SK channels play roles in processes involving calcium-dependent signaling in both electrically excitable and nonexcitable cells. Unless they do not bind calcium directly they detect it by virtue of calmodulin, which is constitutively bound to the C-terminal region. Binding of calcium to this calmodulin results in conformational changes that are in turn responsible for channel gating. The second group of Ca^{2+} activated K^+ channels include Large conductance KCa channels (KCa 1.1, also known as

BK channel, Slo or Slo1), a voltage-sensitive channel that binds calcium independently of calmodulin but mediated by at least three divalent cation binding sites in the cytoplasmic carboxyl domain of each channel subunit. Other members of this group are KCa 4.1 (Slick or Slo2.2), KCa 4.2 (Slick or Slo2.1), and KCa 5.1 (Slo3)².

¹ Calcium-Activated Potassium Channels: Multiple Contributions to Neuronal Function. E.S.L. Faber and P. Sah. *Neuroscientist* 2003, 9, 181-194.

² A.D. Wei et al. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. *Pharmacol. Rev.* 2005, 57, 463-472.

1112	BMS 204352	<i>Maxi K⁺ channel opener</i>	Page 315
1308	BMS 204352, (±)	<i>K⁺ channel opener</i>	Page 315
1309	BMS 204352, (R)-(-)	<i>K⁺ channel opener</i>	Page 316
1313	EBIO, 1-	<i>K⁺ channel opener (Ca²⁺ activated)</i>	Page 447
2329	NS 19504	<i>Activator of LC Ca²⁺-activated potassium (BK) channels</i>	Page 712
2854	NS 1619	<i>Selective activator of large-conductance Ca²⁺-activated potassium (BK) channels</i>	Page 711

Ion Channels: Two-pore-domain, Potassium

TASK-3 (KCNK9 or $K_{2P9.1}$) is a member of the family of leak or two-pore-domain potassium channels, which have 4 transmembrane segments and 2 P-domains, and is one of the major determinants of cell membrane potential and input resistance¹. TASK-3 (TWIK-related acid-sensitive K^+ channel) is involved in cortical function and might also be involved in the formation of cortical neural circuits. The ion channel is >50% identical to TASK-1 at the amino acid level, and in whole-cell recordings the two channels have similar physiological properties but different pH sensitivities. TASK-1 and TASK-3 are co-expressed in a number of different cell types, suggesting the possibility that they form heterodimeric channels². TASK-3 is particularly abundant in the hippocampus, cerebellum and cortex, and in specific nuclei including the locus coeruleus, paraventricular nuclei of thalamus and the dorsal raphe. Its activity has been shown to regulate both neurotransmitter release as well as mediating the effects of neurotransmitter activation including the activity of 5-HT-releasing neurons of the dorsal raphe. TASK-3 inhibitors could lead to therapeutic agents against neurological conditions including sleep disorders, neurodegeneration, cognitive impairment, Parkinson's disease, Huntington's disease, or major depressive disorder³.

¹ Y. Bando et al. Dysfunction of KCNK potassium channels impairs neuronal migration in the developing mouse cerebral cortex. *Cereb Cortex.* 2014 Apr;24(4):1017-29.

² E.M. Talley et al. Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels: volatile anesthetics and neurotransmitters share a molecular site of action. *J Biol Chem.* 2002 May 17;277(20):17733-42.

³ C.A. Coburn et al. Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel $K_{2P9.1}$ (TASK-3). *ChemMedChem.* 2012 Jan 27;7(1):123-33.

3019	A2764 dihydrochloride	<i>Selective inhibitor of the TRESK potassium channel</i>	Page 195
3060	A2793	<i>Inhibitor of the TRESK and TASK-1 potassium channel</i>	Page 195
4122	C101248 Recent Addition	<i>First potent and selective THIK-1 inhibitor</i>	Page 337
2872	ML 335	<i>Selective activator of the TREK-1 and TREK-2 potassium channel</i>	Page 668
2840	ML 365	<i>Potent and selective inhibitor of the TASK-1 potassium channel</i>	Page 670
2403	PK-THPP	<i>Potent and selective TASK-3 antagonist</i>	Page 781

Ion Channels: Voltage-dependent Anion Selective

Not an ion channel in the sense of a gateway for ions to change the transmembrane voltage or membrane potential, but rather the mitochondrial voltage-dependent anion channel (VDAC) controls the transit of adenine nucleotides, Ca^{2+} , and other metabolites both into and out of the mitochondrion in a voltage dependent manner. It is constituent of the mitochondrial permeability transition pore (PTP). Three kinds of VDACS (1-3) are known to date¹.

The assumption has generally been that VDAC is constantly open during metabolism. Recent data, however, suggest that VDAC has the ability to close and inhibit exchange of metabolites within intact cells². In the closed state, ions, but not small molecule metabolites, can penetrate VDAC pores; in the open state, both ions and metabolites pass through VDAC channels. In addition, the closed state is cation-selective, whereas the open state is anion-selective. VDACS are increasingly linked with the control of apoptosis^{3,4}. Since VDAC channels close early in the evolution of apoptosis with the consequence that mitochondria cannot release ATP or take up ADP, Pi and respiratory substrates from the cytosol, they induce

mitochondrial dysfunction, release of oxidative species and, ultimately, non-apoptotic, oxidative cell death⁵. This process has a degree of selectivity for cells with activated RAS–RAF–MEK signalling.

- ¹ Ca²⁺-dependent control of the permeability properties of the mitochondrial outer membrane and voltage-dependent anion-selective channel (VDAC). Báthori G, Csordás G, Garcia-Perez C, Davies E, Hajnóczky G. *J Biol Chem* 2006, 281, 17347-17358.
- ² Voltage-dependent anion channel (VDAC) as mitochondrial governor—Thinking outside the box. J.J. Lemasters, E. Holmuhamedov. *Biochim. Biophys. Acta.* 2006, 1762, 181 – 190.
- ³ The voltage-dependent anion channel (VDAC): function in intracellular signaling, cell life and cell death. Shoshan-Barmatz V, Israelson A, Brdiczka D, Sheu SS. *Curr Pharm Des* 2006, 12, 2249-2270.
- ⁴ The mitochondrial permeability transition pore may comprise VDAC molecules. I. Binary structure and voltage dependence of the pore. Szabó I, Zoratti M. *FEBS Lett* 1993, 330, 201-205.
- ⁵ Mitochondrial outer membrane permeability change and hypersensitivity to digitonin early in staurosporine-induced apoptosis. S. Duan, P. Hajek, C. Lin, S.K. Shin, G. Attardi, A. Chomyn. *J. Biol. Chem.* 2003, 278, 1346 – 1353.

3524	AKOS-022	<i>VDAC1 inhibitor</i>	Page 217
1825	Erastin	<i>VDAC2 modulator</i>	Page 465

Ion Channels: Calcium-activated, Chloride

At least eight families of chloride channels have been identified as membrane or intracellular chloride channels/binding proteins; they include the ligand-gated chloride channels (e.g., GABAA and glycine), cystic fibrosis transmembrane conductance regulator (CFTR), CLC, bestrophins, calcium-activated chloride channel regulator (CLCA), chloride intracellular channel (CLIC), Tweety, and the most recently characterized TMEM16/anoctamin family. Only the latter four of these chloride channel families contain members regulated by calcium¹. Calcium activated Chloride Channels (CaCCs) are anion-selective channels that are activated by increases in cytosolic Ca²⁺. They have been implicated in a variety of cellular functions such as fertilization of the oocyte, transepithelial fluid transport, repolarization and action potential duration in cardiac myocytes, olfactory transduction, and regulation of smooth muscle tone. Within the airways, they contribute to epithelial fluid secretion.²

TMEM16A (alternative name, anoctamin-1, ANO1) was identified as a CaCC, as its heterologous expression in oocytes and mammalian cells produced outwardly rectifying, Ca²⁺-sensitive Cl⁻ currents. It is expressed in epithelial cells in airways, salivary gland, intestine, and other tissues, as well as in arterial smooth muscle, intestinal pacemaker cells, sensory neurons, and various tumors. Evidence was found for involvement of ANO1 in chloride secretion in salivary gland and airway epithelia, intestinal and vascular smooth muscle contraction, nociception, and bile formation³.

- ¹ G Gallos et al. Calcium-Activated Chloride Channels. Chapter in "Calcium Signaling In Airway Smooth Muscle Cells". Y.-X. Wang (ed.), Springer International Publishing Switzerland 2014.
- ² J Eggermont et al. Calcium-activated chloride channels: (un)known, (un)loved? *Proc Am Thorac Soc.* 2004;1(1):22-7.
- ³ W Namkung et al. Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. *FASEB J.* 2011 Nov;25(11):4048-62.

2576	Eact	<i>Activator of TMEM16A (ANO1)</i>	Page 448
------	-------------------	--	----------

Receptors

All cells in a multicellular organism are constantly exposed to a variety of extracellular signals that they need to interpret and translate into an appropriate response to their environment. These signals can be soluble factors generated locally (for example, synaptic transmission) or distantly (for example, hormones and growth factors), ligands on the surface of other cells, or the extracellular matrix itself. To achieve this, cells maintain a diversity of receptors on their surface that respond specifically to individual stimuli. These receptors fall into families, based primarily on the way in which they generate the intracellular signals that give rise to the particular functional responses. Moreover, the activity of a given receptor can be modulated by other signalling pathways in a variety of ways, generating the flexibility required of such a complex system. Axon Ligands™ that target receptors are categorized based on the major classification proposed by the IUPAC, including G-protein coupled receptors, enzyme linked receptors, (ligand gated) ion channels, nuclear receptors, and cytokine receptors¹.

¹ I.J. Uings, S.N. Farrow. *Cell receptors and cell signaling.* Mol. Pathol. 2000, 53, 295-299.

Receptors: Cytokine

Cytokines and chemokines are both small proteins made by cells in the immune system. They are important in the production and growth of lymphocytes, and in regulating responses to infection or injury such as inflammation and wound healing. Cytokines are the general category of messenger molecules, while chemokines are a special type of cytokine that direct the migration (chemotaxis) of white blood cells to infected or damaged tissues. Unlike most other cytokines, chemokines regulate their action through interactions with seven-transmembrane, rhodopsin-like G protein-coupled receptors (GPCRs)¹. Cytokines are secreted in the mammalian immune system, and used as messenger molecules to control the duration and strength of the immune response to foreign microorganisms. Many cytokines produced by T cells direct the immune response of various white blood cells (leukocytes) to a foreign microorganism in the body. Among the important varieties are the interleukin (IL) molecules and interferon alpha and beta. The ILs help regulate inflammation, fever, and wound healing, among other things, while the interferons block the replication of viruses^{2,3}.

As part of the superfamily of cytokine receptors belongs to the large family of GPCR receptors (GPCR-A1 and A2), among which the CCR and CXC type chemokine receptors, Axon Ligands™ that interact with these receptors have thus been listed in the corresponding sections of the GPCR receptors as well. Additionally, the superfamily of cytokine receptors differentiates tumor necrosis factor (TNF) type receptors and interleukin (IL) type receptors, and a small sub-family of other cytokine receptors that do not fit into the previously listed subfamilies, based on either structure or function.

Colony-stimulating factor 1 (CSF1) and interleukin-34 (IL-34) are functional ligands of the CSF1 receptor (CSF1R) and thus are key regulators of the monocyte/macrophage lineage. CSF1, also known as M-CSF, regulates the survival, proliferation, differentiation, and chemotaxis of cells of the monocyte/macrophage lineage. It is produced by multiple cell types, including monocytes/macrophages, endothelial cells, fibroblasts, and bone marrow stromal cells. The biological effects of CSF1 are mediated by a single CSF1 receptor (CSF1R), which is encoded by the *c-fms* proto-oncogene. Ligand binding to CSF1R in macrophages triggers multiple signal transduction pathways resulting in activation of AKT and cAMP responsive element-binding protein (CREB) and mitogen-activated protein kinase⁴. Interestingly, high levels of CSF1 have been implicated in the pathophysiology of Alzheimer's disease⁵.

The members of the TNF ligand family exert their biological functions via interaction with their cognate membrane receptors, comprising the TNF receptor (TNF-R) family. The members of the TNF-R family contain one to six cysteine-rich repeats in their extracellular domain, typically each with three cysteine bridges. Two receptors, TNF-R1 (TNF receptor type 1; CD120a; p55/60) and TNF-R2 (TNF receptor type 2; CD120b; p75/80) bind membrane-integrated TNF (memTNF) as well as soluble TNF (sTNF), but also the secreted homotrimeric molecule lymphotoxin-alpha (LTalpha). TNF-R1 is constitutively expressed in most tissues, whereas expression of TNF-R2 is highly regulated and is typically found in cells of the immune system. In the vast majority of cells, TNF-R1 appears to be the key mediator of TNF signalling, whereas in the lymphoid system TNF-R2 seems to play a major role. The cytokine TNF, produced by macrophages/monocytes during acute inflammation may be considered to represent a major proinflammatory mediator, with an optional capacity to induce necrosis and apoptosis⁶. In (patho)physiological situations, TNF shows a remarkable functional duality, being strongly engaged both in tissue regeneration/expansion and destruction⁷.

Among cytokine receptors, Glycoprotein 130 (gp130) is the most promiscuous, meaning that it can transduce signals from many different ligands: it is part of the receptor signaling complexes for at least 9 cytokines of the Interleukin (IL)-6 family, a group of functionally and structurally related proteins that utilize gp130 as a common signal transducer within their receptor complex that is required for signaling. Ligand binding induces the association of gp130 with a cytokine-specific receptor- α chain, followed by the activation of downstream signaling cascades including JAK/STAT, RAS/RAF/MAPK, and PI3K/AKT pathways. As a ubiquitously expressed receptor, gp130 is involved in a wide range of important biologic processes including inflammation, immune response, cancer, stem cell maintenance, embryonic development, hematopoiesis, cardiovascular action, and neuronal survival^{8,9}.

¹ M.J. Cameron, D.J. Kelvin. Cytokines, Chemokines, and Their Receptors. *Mdm. Curie Biosc. Dbase* [Internet]. Landes Bioscience 2000. <http://www.ncbi.nlm.nih.gov/books/NBK6294/>

² L.C. Borish, J.W. Steinke. 2. Cytokines and chemokines. *J. Allergy Clin. Immunol.* 2003, 111, S460-75.

³ C.A. Dinarello. Historical Review of Cytokines. *Eur. J. Immunol.* 2007, 37, S34-S45.

- ⁴ J. Luo et al. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. *J Exp Med.* 2013 Jan 14;210(1):157-72.
- ⁵ A. Olmos-Alonso et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. *Brain.* 2016 Jan 8. pii: awv379.
- ⁶ H. T. Idriss et al. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). *Microsc. Res. Tech.* 2000, 50, 184-195.
- ⁷ H. Wajant et al. Tumor necrosis factor signaling. *Cell Death Differ.* 2003, 10, 45-65.
- ⁸ S. Xu et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. *Mol Cancer Ther.* 2013 Jun;12(6):937-49.
- ⁹ U.A. White et al. The gp130 receptor cytokine family: regulators of adipocyte development and function. *Curr Pharm Des.* 2011;17(4):340-6.

3189	4-CPPC	First potent, selective and reversible inhibitor of MIF-2	Page 393
1179	A1B1	CCR1 antagonist	Page 196
1738	AMD 3100	CXCR4 antagonist	Page 223
1930	AMD 3465	Potent and selective CXCR4 antagonist	Page 223
2082	BX 471	Selective CCR1 receptor antagonist	Page 335
3428	CSF1R inhibitor compound 22	Potent, cellular active and orally bioavailable CSF1R inhibitor	Page 396
1800	CXCR3 Antagonist 6c	CXCR3 antagonist	Page 401
2887	DRI-C21045	Inhibitor of the CD40-CD40L costimulatory protein-protein interaction	Page 441
2800	Ensemble Compound 159	Cytokine inhibitor; IL-17A inhibitor	Page 460
2571	GW 2580	Orally bioavailable inhibitor of cFMS kinase and CSF1R	Page 531
4237	IL-4-inhibitor-1	Recent Addition First IL-4 inhibitor	Page 561
3949	ISO-1	MIF inhibitor	Page 570
1793	Lenalidomide	TNFa inhibitor. Immunomodulator	Page 611
2966	NSC745887	DcR3 inhibitor	Page 718
1501	PD 0220245	IL8R antagonist	Page 755
2501	Pexidartinib	Mutil-targeted RTK inhibitor of c-Kit, FLT3, and CSF1R	Page 760
3054	PLX5622	Potent, specific, orally bioavailable and brain-penetrant inhibitor of CSF1R	Page 784
3166	Pomalidomide	TNFa inhibitor. Immunomodulator	Page 786
2999	RCGD 423	gp130 signalling modulator	Page 809
1559	SB 265610	CXCR2 antagonist	Page 847
2324	SC 144 hydrochloride	The first-in-class small-molecule gp130 inhibitor	Page 853
4084	Sotuletinib	Potent, selective and brain-penetrant inhibitor of CSF1R	Page 881
2143	SPD 304	Cell permeable inhibitor of TNFa	Page 883
1369	STA 5326	Cytokine production inhibitor (IL-12/IL-23)	Page 893
3324	Thalidomide	TNFa inhibitor. Immunomodulator	Page 924
3410	UTL-5g	TNFa modulator	Page 959
1620	WZ 811	CXCR4 antagonist	Page 989

Receptors: Enzyme Linked

Many of the Axon Ligands™ in this class of compounds target receptors of various growth factors, such as EGF, VEGF, and PDGF. These receptors are members of the class of enzyme linked receptors, which, as integral membrane proteins, possess both receptor functionality (extra-cellular) as well as enzymatic catalytic functionality (intracellular)^{1,2}. The majority of the enzymatic activity of this class of receptors is characterized by kinase-like activity. Based on this feature, five main classes can be distinguished³: Receptor Tyrosine Kinases (RTKs), and Receptor Serine/Threonine Kinases (RSTKs, participating in MAPK and TGF-beta signaling pathways, among others) are well known. Additionally, there are classes of Receptor Guanylyl Cyclases, Histidine Kinase associated Receptors (receptors that associate with proteins that have histidine kinase activity), and finally a class of Tyrosine Kinase associated Receptors (e.g. Cytokine Receptors). In addition, some transmembrane tyrosine phosphatases (Receptor-like) Protein Tyrosine Phosphatases (PTPs), which remove phosphate from phosphotyrosine side chains of specific proteins, are thought to function as receptors, although for the most part their ligands are unknown. Within each of these main classes, sub-classes exist, based on the specific endogenous

ligands. Many of the enzyme linked receptors play a role in the regulation of cell proliferation, programmed cell death (apoptosis), cell differentiation, and embryonic development, and therefore are of great interest as targets for the treatment of cancer⁴. Furthermore, malfunctioning of receptors of this kind is associated with the development of neurodegenerative diseases, such as multiple sclerosis and Alzheimer's disease⁵.

¹ Catalytic Receptors. S.P.H. Alexander, A. Mathie, and J.A. Peters. *Br. J. Pharmacol.* 2007, 150(S1): S122-S127

² Cell Signaling by Receptor Tyrosine Kinases. M.A. Lemmon, J. Schlessinger. *Cell* 2010, 141, 1117-1134

³ Molecular Biology of the Cell. 4th edition. Alberts B, Johnson A, Lewis J, et al. New York: Garland Science; 2002.

⁴ Tyrosine kinase receptors as attractive targets of cancer therapy. Bannasroune A, Gardin A., Aunis D., Crémel G., Hubert P. *Crit. Rev. Oncol. Hematol.* 2004, 50, 23-38.

⁵ The EGF receptor family: spearheading a merger of signaling and therapeutics. Bublil E.M., Yarden Y. *Curr. Opin. Cell Biol.* 2007, 19,124-134.

Receptors (Enzyme Linked, RTK class I) ErbB receptor family

The ErbB receptor tyrosine kinase family consists of four cell surface receptors: ErbB1/EGFR/HER1, and ErbB2-4/HER2-4¹. ErbB receptor tyrosine kinases have important roles in human cancer. The gene symbol, ErbB, is derived from the name of a viral oncogene to which these receptors are homologous: Erythroblastic Leukemia Viral Oncogene. Insufficient ErbB signaling in humans is associated with the development of neurodegenerative diseases, such as multiple sclerosis and Alzheimer's disease.² Additionally, research revealed that the expression or activation of epidermal growth factor receptor and ErbB2 are altered in many epithelial tumors, and clinical studies indicate that they have important roles in tumor aetiology and progression³.

¹ Regulation of ERBB Receptors. C.S. Gerbin. *Nature Education* 2010, 3(9), 36

² The EGF receptor family: spearheading a merger of signaling and therapeutics. E.M. Bublil, Y. Yarden. *Curr. Opin. Cell Biol.* 2007, 19 (2), 124-134.

³ ERBB receptors and cancer: the complexity of targeted inhibitors. N.E.Hynes, H.A. Lane. *Nat Rev Cancer.* 2005, 5(5),341.

3040	Abivertinib	Potent oral, irreversible, third-generation EGFR TKI with selectivity for mutant EGFRs	Page 199
1653	AAE 788	EGFR, ErbB2 and VEGFR tyrosine kinase inhibitor	Page 210
2031	AIM 100	Specific inhibitor of Ack1 tyrosine kinase (TNK2)	Page 215
1986	AST 1306 tosylate	ErbB2 and EGFR inhibitor	Page 256
4074	AZ5104	EGFR inhibitor	Page 264
2563	AZD 3759	Potent brain-penetrant EGFR tyrosine kinase inhibitor	Page 270
2342	AZD 9291	Third-generation EGFR TKI.selectivity for mutant EGFRs	Page 277
1544	BIBW 2992	EGFR and ErbB2/HER2 tyrosine kinase inhibitor	Page 306
3853	BMS-599626	Potent and selective EGFR and ErbB2 inhibitor	Page 319
1433	CI 1033	EGFR tyrosine kinase inhibitor	Page 369
1537	CP 724714	ErbB2/HER2 kinase inhibitor	Page 390
3235	Dacomitinib	Potent irreversible pan-HER inhibitor	Page 407
2680	EAI045	Allosteric EGFR inhibitor (L858R/T790M-specific)	Page 448
1760	EGFR Inhibitor 324674	Highly selective EGFR tyrosine kinase inhibitor	Page 452
3192	EMI48	Inhibitor of EGFR triple mutants	Page 456
1128	Erlotinib hydrochloride	EGFR tyrosine kinase inhibitor	Page 466
1393	Gefitinib	EGFR tyrosine kinase inhibitor	Page 501
1395	Lapatinib ditosylate	EGFR and ErbB2/HER2 tyrosine kinase inhibitor	Page 604
1526	Neratinib	EGFR and ErbB2/HER2 tyrosine kinase inhibitor	Page 698
4144	Olmutinib	Orally bioavailable and irreversible Tyrosine Kinase Inhibitor	Page 732
1632	OSI 420	EGFR tyrosine kinase inhibitor	Page 738
1665	Pelitinib	EGFR tyrosine kinase inhibitor	Page 757
2920	Pozitotinib	Irreversible pan-HER inhibitor	Page 757
4272	TAS2940	Recent Addition Orally active, brain-penetrable, and irreversible pan-ERBB inhibitor	Page 911
2053	TAK 165	ErbB2/HER2 kinase inhibitor	Page 906
3232	TAK-788	Potent and selective EGFR and ErbB-2/HER2 tyrosine kinase inhibitor	Page 907

3802	TAS6417	EGFR inhibitor	Page 911
1411	Vandetanib	VEGFR and EGFR tyrosine kinase inhibitor	Page 954
1506	WZ 4002	EGFR kinase inhibitor (T790M specific)	Page 990

Receptors (Enzyme Linked, RTK class II) Insulin receptor family

The pleiotropic actions of insulin are mediated by a single receptor tyrosine kinase. A generally accepted paradigm is that insulin receptors, acting through insulin receptor substrates (insulin, and Insulin-like growth factors (IGF) I and II), stimulate the lipid kinase activity of phosphatidylinositol 3-kinase¹. The rapid rise in Tris-phosphorylated inositol (PIP3) that ensues triggers a cascade of PIP3-dependent serine/threonine kinases. Among the latter, Akt and atypical protein kinase C isoforms are thought to be involved in insulin regulation of glucose transport and oxidation; glycogen, lipid, and protein synthesis; and modulation of gene expression. "Insulin insensitivity", or a decrease in insulin receptor signaling, leads to diabetes mellitus type 2 – the cells are unable to take up glucose, and the result is hyperglycemia (an increase in circulating glucose), and all the sequelae that result from diabetes.

¹ The Insulin Receptor and Its Cellular Targets. Y. Kido, J. Nakae, D. Accili. J. Clin.Endocrin. Met. 2001, 86, 972-979.

2153	AZD 3463	Potent inhibitor of ALK and IGF1R	Page 270
2267	GSK 1838705A	IGF-1R and insulin receptor (IR) kinase inhibitor	Page 528
3830	GSK1904529A	Potent, selective and orally active inhibitor of the insulin-like growth factor-1 receptor (IGF-1R)	Page 518
2238	NT 157	Unique allosteric inhibitor of IGF1R signaling	Page 718
1702	OSI 906	IGF1R tyrosine kinase inhibitor	Page 738
3341	PQ401	Potent IGF1R tyrosine kinase inhibitor	Page 789

Receptors (Enzyme Linked, RTK class III) PDGF receptor family

The PDGF family of growth factors consists of five different disulphide-linked dimers built up of four different polypeptide chains encoded by four different genes. These five isoforms act via two receptor tyrosine kinases, PDGF receptors alpha and beta¹. The PDGFs have a common structure with the typical growth factor domain involved in the dimerization of the two subunits, and in receptor binding and activation. All four PDGF chains contain a highly conserved growth factor domain, denoted the PDGF/VEGF homology domain². Upon activation by their endogenous ligands, these receptors dimerize, and are activated by auto-phosphorylation of several sites on their cytosolic domains, which serve to mediate binding of co-factors and subsequently activate signal transduction, for example, through the PI3K and the MAPK pathways. Both PDGF and VEGF family members are potent mitogenic and angiogenic factors with critical roles in tumor formation as well as embryonic development and wound healing³.

FLT3 (Fms-liketyrosine kinase 3, aka CD135) is a cytokine receptor which belongs to the class III receptor tyrosine kinase family. It is expressed on the surface of many hematopoietic progenitor cells. Notably, approximately one-third of acute myeloid leukemia (AML) patients have mutations of this gene, and such mutations are one of the most frequently identified types of genetic alterations in AML. The majority of the mutations involve an internal tandem duplication (ITD) in the juxtamembrane (JM) domain of FLT3, which is specifically found in AML⁴.

Stem cell factor (SCF, also called Steel factor or Kit ligand) is a dimeric molecule that exerts its biological functions by binding to and activating the receptor tyrosine kinase c-KIT or CD117. It is also classified as cytokine receptor. Activation of c-Kit leads to its autophosphorylation and initiation of signal transduction. Signaling proteins are recruited to activated c-Kit by certain interaction domains (e.g., SH2 and PTB) that specifically bind to phosphorylated tyrosine residues in the intracellular region of c-Kit. It is expressed by fibroblasts and endothelial cells throughout the body, and activation of c-Kit signaling has been found to mediate cell survival, migration, and proliferation depending on the cell type. Signaling from c-Kit is crucial for normal hematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous system. Deregulated c-Kit kinase activity has been found in a number of pathological conditions, including cancer and allergy⁵.

¹ The PDGF family: four gene products form five dimeric isoforms. L. Fredriksson, H. Li, U. Eriksson. Cytokine Growth Factor Rev. 2004,15, 197-204.
² Vascular endothelial growth factors Vegf-B and Vegf-C. V. Joukov, A. Kaipainen, M. Jeltsch, K. Pajusola, B. Olofsson, V. Kumar et al. J. Cell Physiol. 1997, 173, 211–215.
³ Role of platelet-derived growth factors in physiology and medicine. J. Andrae, R. Gallini, C. Betsholtz. Genes Dev. 2008, 22, 1276-1312.
⁴ S. Takahashi. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J. Hematol. Oncol. 2011, 4, 13.
⁵ J. Lennartsson et al. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol. Rev. 2012, 92, 1619-1649.

1419	AB 1010	PDGFR, c-KIT and FGFR3 tyrosine kinase inhibitor	Page 196
1638	ABT 869	PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor	Page 202

1696	AC 220 dihydrochloride	FLT3 inhibitor	Page 204
1414	AG 013736	PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor	Page 213
1768	AMG 706	Multiple receptor tyrosine kinase inhibitor	Page 225
2368	Amuvatinib	RTK inhibitor (PDGFR, c-Kit and c-Met)	Page 235
2061	CID 11654378	Highly potent FMS kinase inhibitor	Page 371
3969	Crenolanib	Selective small molecule inhibitor of PDGFRα, PDGFRβ and FLT3	Page 394
1415	CT 53518	PDGFR, c-KIT and FLT3 tyrosine kinase inhibitor	Page 396
2571	GW 2580	Orally bioavailable inhibitor of cFMS kinase and CSF1R	Page 531
1420	GW 786034	PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor	Page 534
2648	Nintedanib	RTK inhibitor with antiangiogenic and antineoplastic activities	Page 704
1547	OSI 930	c-Kit and VEGFR2 tyrosine kinase inhibitor	Page 738
2501	Pexidartinib	Multitargeted RTK inhibitor of CSF1R, c-Kit, and FLT3	Page 760
1678	Regorafenib	Multi-kinase RTK inhibitor	Page 811
1891	SU 6668	Inhibitor of RTK targeting PDGFR, VEGF and FGFR	Page 898
2767	SU11652	Multi-targeted receptor tyrosine kinase inhibitor	Page 899
1398	Sunitinib malate	Multi-targeted receptor tyrosine kinase inhibitor	Page 900
3624	Toceranib phosphate	Multi-targeted receptor tyrosine kinase inhibitor	Page 934

Receptors (Enzyme Linked, RTK class IV) VEGF receptor family

VEGF is one of the key regulators of angiogenesis, vasculogenesis, and developmental hematopoiesis. It is a mitogen and survival factor for vascular endothelial cells while also promoting vascular endothelial cell and monocyte motility¹. Binding of growth factors to the ectodomain of their transmembrane receptors leads to receptor dimerization, protein kinase activation, trans-autophosphorylation, and initiation of signaling pathways. The VEGF family of receptors consists of three protein-tyrosine kinases (VEGFR1-3) and two non-protein kinase co-receptors (neuropilin-1 and 2)². Targeting VEGF receptors proved to be a successful therapeutic approach for disorders with non-physiologic angiogenesis including age-related macular degeneration of the eye, diabetic retinopathy, rheumatoid arthritis, tumor growth and metastasis¹.

¹ Vascular endothelial growth factor (VEGF) signaling during tumor progression. A comprehensive review of the discovery of the VEGF family of ligands and receptors. R. Roskoski Jr. Crit. Rev. Oncol. Hematol. 2007, 62, 179–213.
² VEGF receptor protein-tyrosine kinases: Structure and regulation. Mini Review. R. Roskoski Jr. Biochem. Biophys. Res. Com. 2008, 375, 287–291.

1419	AB 1010	PDGFR, c-KIT and FGFR3 tyrosine kinase inhibitor	Page 196
1638	ABT 869	PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor	Page 202
1414	AG 013736	PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor	Page 213
1768	AMG 706	Multiple receptor tyrosine kinase inhibitor	Page 225
2849	Apatinib	Inhibitor of VEGFR2	Page 239
1850	BMS 540215	Inhibitor of VEGFR (subtype 2 and 3 selective)	Page 318
2837	BMS 605541	Potent, selective, orally active, and ATP-competitive VEGFR2 inhibitor	Page 319
1864	Brivanib alaninate	Prodrug of BMS 540215; Inhibitor of VEGFR	Page 328
1819	Cabozantinib S-malate	Inhibitor of MET and VEGFR2	Page 338
1461	Cediranib	VEGFR tyrosine kinase inhibitor	Page 356
1662	CP 547632	VEGFR2 tyrosine kinase inhibitor	Page 389
1942	E 3810 dihydrochloride	Dual VEGFR/FGFR tyrosine kinase inhibitor	Page 447
1582	Foretinib	c-MET and VEGFR2 tyrosine kinase inhibitor	Page 489
1959	Golvatinib	Potent inhibitor of c-MET (HGFR) and VEGFR2	Page 513
1420	GW 786034	PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor	Page 534
3165	Lenvatinib	Multi-targeted receptor tyrosine kinase inhibitor	Page 611
3998	MGCD516	Orally bioavailable receptor tyrosine kinase (RTK) inhibitor	Page 652

2648	Nintedanib	RTK inhibitor with antiangiogenic and antineoplastic activities	Page 704
2865	NVP-ACC789	Inhibitor of VEGFR2	Page 721
1547	OSI 930	c-Kit and VEGFR2 tyrosine kinase inhibitor	Page 738
2501	Pexidartinib	Multi-targeted RTK inhibitor of CSF1R, c-Kit, and FLT3	Page 760
1678	Regorafenib	Multi-kinase RTK inhibitor	Page 811
1667	SU 5402	Fibroblast growth factor receptor (FGFR) inhibitor	Page 898
1891	SU 6668	Inhibitor of RTK targeting PDGFR, VEGF and FGFR	Page 898
1398	Sunitinib malate	Multi-targeted receptor tyrosine kinase inhibitor	Page 900
3338	Taxifolin	Inhibitor of VEGFR2	Page 912
1717	Tivozanib	VEGFR1, 2, and 3 tyrosine kinase inhibitor	Page 929
1411	Vandetanib	VEGFR and EGFR tyrosine kinase inhibitor	Page 954
1637	Vatalanib	VEGFR tyrosine kinase inhibitor	Page 963
1978	ZM 323881 Hydrochloride	Inhibitor of VEGFR-2	Page 1009

Receptors (Enzyme Linked, RTK class V) FGF receptor family

The fibroblast growth factor receptors (FGFRs) include the four highly conserved transmembrane receptor tyrosine kinases FGFR1, FGFR2, FGFR3, and FGFR4. One additional receptor, FGFR5 (FGFRL-1), is devoid of kinase activity but able to bind FGFs and may act as a negative regulator of signaling¹. The FGF signaling pathway plays a critical role in many physiological processes during embryonal development and maintenance of adult organ systems, including angiogenesis and wound repair, cell proliferation, migration, differentiation, and cell survival. Aberrations in this signaling pathway can give rise to tumor progression and growth of multiple cancer types. In addition, it may serve as a mechanism of resistance to antivascular endothelial growth factor targeted therapy. As such this pathway has emerged as a relevant therapeutic target, and several agents that can inhibit or modulate its signaling are in various stages of development.²

¹ Structural and functional diversity in the FGF receptor multigene family. D.E. Johnson, L.T. Williams. Adv Cancer Res. 1993, 60, 1–41
² FGF receptor inhibitors: role in cancer therapy. Daniele G, Corral J, Mollife LR, de Bono JS. Curr. Oncol. Rep. 2012 14(2):111-119.

2930	Alofanib	Allosteric inhibitor of FGFR2	Page 218
1917	AZD 4547	Potent and selective FGFR inhibitor	Page 270
1942	E 3810 dihydrochloride	Dual VEGFR/FGFR tyrosine kinase inhibitor	Page 447
4067	Formononetin	Potent FGFR2 inhibitor	Page 489
1981	LY 2874455	Potent and selective FGFR inhibitor	Page 634
2648	Nintedanib	RTK inhibitor with antiangiogenic and antineoplastic activities	Page 704
1775	NVP-BGJ398	Inhibitor of FGFR tyrosine kinases 1, 2, 3 and 4	Page 722
1944	NVP-BGJ398 Phosphate	Inhibitor of FGFR tyrosine kinases 1, 2, 3 and 4	Page 723
2098	PD 161570	Selective FGFR1 inhibitor	Page 753
1673	PD 173074	FGFR1 and FGFR3 inhibitor	Page 754
2953	Roblitinib	First-in-class, highly selective and potent FGFR4 inhibitor	Page 826
2234	SSR 128129E	Allosteric inhibitor of FGF receptor signaling	Page 891
1667	SU 5402	Fibroblast growth factor receptor (FGFR) inhibitor	Page 898
1891	SU 6668	Inhibitor of RTK targeting PDGFR, VEGF and FGFR	Page 898

Receptors (Enzyme Linked, RTK class VII) Trk receptor family

Tropomyosin-related kinases (Trks) are receptor tyrosine kinases normally expressed in neuronal tissue where they play important role in both development and function of the nervous system.¹ The Trk receptor family is composed of three members (A, B, and C) activated by specific ligands called neurotrophins (NTs). Activations upon ligand binding triggers oligomerization of the receptors, phosphorylation of specific tyrosine residues in the kinase domain, and downstream signal transduction pathways, including survival, proliferation, and differentiation in normal and neoplastic neuronal cells. Deregulation of TrkA and TrkB and their cognate ligands has been described in numerous types of cancers including prostate, breast, colorectal, ovarian, lung, pancreas, melanoma, thyroid, and neuroblastoma and occurs mainly through

wild type receptor overexpression, activation, amplification, and/or mutation. Importantly, increased Trks activation in tumor tissues correlates with an aggressive phenotype and poor clinical outcome².

The recently added PD 90780 (Axon 2174) is an inhibitor of NGFs binding to the P75 NGF-receptor, a.k.a. Low-Affinity Nerve Growth Factor Receptor. In general, mature NTs bind preferentially to Trk and p75NTR, whereas proneurotrophins, which contain an N-terminal domain proteolytically removed in "mature" forms, interact with p75NTR and through their N-terminal domains, with the sorting receptor sortilin. p75NTR interacts with Trks and modulates Trk signaling but is also independently coupled to various prosurvival and proapoptotic signaling systems. Depending on the operative ligands, co-expression of Trk or other receptors, and expression of downstream signaling elements, p75NTR promotes cell survival or death and modulates neurite outgrowth³.

¹ Trk receptors: mediators of neurotrophin action. A. Papatoutian, L. F. Reichardt. Curr. Opin. Neurobiol. 2001, 11, 272-280.

² Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors. Stéphane L. Raeppe, Frédéric Gaudette, Hannah Nguyen, et al. Int. J. Med. Chem. 2012, Article ID 412614.

³ Small, Nonpeptide p75NTR Ligands Induce Survival Signaling and Inhibit proNGF-Induced Death. S.M. Massa et al. J. Neuroscience. 2006, 26, 5288-5300.

2468	ANA 12	TrkB antagonist with anxiolytic and antidepressant activity	Page 236
1610	AZ 23	TrkA and TrkB inhibitor	Page 264
2089	Dihydroxyflavone, 7,8-	Tyrosine kinase receptor B (TrkB) agonist	Page 429
2248	GNF 5837	Potent tropomyosin receptor kinase (Trk) inhibitor	Page 510
1251	GW 441756	TrkA inhibitor	Page 534
3407	LOXO-101 sulfate	First-in-class, potent, highly selective and ATP-competitive TRK inhibitor	Page 621
3901	LOXO-195	Trk inhibitor	Page 621
1892	NM-PP1, 1-	Tyrosine kinase inhibitor of Src, Fyn, Abl, CDK, Trk	Page 706
2174	PD 90780	Inhibitor of NGFs binding to the P75 NGFR	Page 751
3775	TrkB agonist prodrug R13	Prodrug of 7,8-Dihydroxyflavone; TrkB agonist	Page 940

Receptors (Enzyme Linked, RTK class X) HGF receptor family

c-Met (MET or MNNG HOS Transforming gene) is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR). It was originally identified as an oncogene activated in vitro after treatment of a human osteogenic sarcoma (HOS) cell line.¹ Currently, c-Met receives great interest for its role of aberrant signaling in tumorigenesis, particularly in the development of the invasive and metastatic phenotypes. Signaling via the Met–HGF/SF pathway has been shown to lead to a wide range of biological activities including proliferation (mitosis), scattering (motility), and branching morphogenesis, embryological development, wound healing, tissue regeneration, angiogenesis, growth, invasion, and morphogenic differentiation.²

¹ Molecular cloning of a new transforming gene from a chemically transformed human cell line. C.S. Cooper, M. Park, D.G. Blair et al. Nature 1984, 311, 29–33.

² M. Jeffers, L. Schmidt, N. Nakaigawa, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA. 1997, 94, 11445–11450.

1916	AMG 208	Inhibitor of c-MET receptor tyrosine kinase (RTK)	Page 224
3946	Altiratinib	Balanced inhibition of MET, TIE2 (TEK), and VEGFR2 (KDR) kinases	Page 220
3945	AMG-337	Potent and exquisitely selective inhibitor of wild-type and some mutant forms of c-Met	Page 225
1838	ARQ 197	c-MET tyrosine kinase Inhibitor	Page 250
4040	BMS-777607	potent, selective and orally bioavailable c-Met inhibitor	Page 320
4266	BPI-9016M Recent Addition	Potent, orally active, and selective c-Met and AXL inhibitor	Page 324
1819	Cabozantinib S-malate	Inhibitor of MET and VEGFR2	Page 338
3423	Capmatinib	Highly potent, selective, ATP competitive and orally bioavailable c-MET inhibitor	Page 342
1582	Foretinib	c-MET and VEGFR2 tyrosine kinase inhibitor	Page 489
1959	Golvatinib	Potent inhibitor of c-MET (HGFR) and VEGFR2	Page 513
2553	LY 2801653	Multi-kinase inhibitor with potent activity against c-MET	Page 633

3975	MGCD265 dihydrochloride	Orally active, potent MET/SMO dual inhibitor	Page 652
1660	PF 02341066	c-MET Inhibitor; NPM-ALK inhibitor	Page 766
1583	PF 04217903 mesylate	c-MET tyrosine kinase Inhibitor	Page 767
1914	SGX 523	ATP-competitive inhibitor of c-MET	Page 865
1581	SU 11274	ATP-competitive inhibitor of c-MET	Page 898
3864	Volitinib dihydrochloride	ATP-competitive small molecule c-Met kinase inhibitor	Page 971

Receptors (Enzyme Linked, RTK class XI) TAM receptor family

The protein encoded by this gene is a member of the receptor tyrosine kinase subfamily. Axl belongs to the TAM (Tyro3, Axl, and Mer) RTK family, whose members function as inhibitors of innate inflammatory responses in dendritic cells and are essential to the prevention of lupus-like autoimmunity. Additionally, the members of this family of RTKs have been implicated in the development and metastasis of many cancers, including hematological malignancies and solid tumors of the colon, brain and breast.¹ Although it is similar to other receptor tyrosine kinases, this protein represents a unique structure of the extracellular region that juxtaposes IgL and FNIII repeats. It transduces signals from the extracellular matrix into the cytoplasm by binding growth factors like vitamin K-dependent protein growth-arrest-specific gene 6. It is involved in the stimulation of cell proliferation and can also mediate cell aggregation by homophilic binding².

¹ Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. R.M.A. Linger et al. *Oncogene* 2012, 1–12.

² Identification of Axl as a downstream effector of TGF- β 1 during Langerhans cell differentiation and epidermal homeostasis. Bauer T, Zagórska A, Jurkin J, Yasmin N, Köffel R, Richter S, Gesslbauer B, Lemke G, Strobl H. *J. Exp. Med.* 2012, 209, 2033-2047

2553	LY 2801653	Multi-kinase inhibitor with potent activity against c-MET	Page 633
1946	R 428 dihydrochloride	Selective inhibitor of Axl receptor tyrosine kinases	Page 803
2086	UNC 569	Reversible and ATP-competitive inhibitor of Mer (RTK)	Page 952
2346	UNC 2250	Potent and selective Mer kinase inhibitor	Page 954

Receptors (Enzyme Linked, RTK class XIII) EPH receptor family

The Eph receptor tyrosine kinases and their ephrin ligands have intriguing expression patterns in cancer cells and tumor blood vessels, which suggest important roles for their bidirectional signals in many aspects of cancer development and progression.¹ They have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumor growth, invasiveness, angiogenesis and metastasis in vivo.

¹ Eph receptors and ephrins in cancer: bidirectional signaling and beyond. E.B. Pasquale. *Nature Reviews Cancer* 10, 165-180 (March 2010)

1829	NVP-BHG712	Inhibitor of EphB4 kinase	Page 723
------	------------	---------------------------	----------

Receptors (Enzyme Linked, RTK class XIV) RET receptor family

The RET ("rearranged during transfection") proto-oncogene encodes a receptor-type tyrosine kinase with an intracellular domain, a transmembrane domain, and an intracellular tyrosine kinase domain. The ligands for RET have been identified as neurotrophic factors of the glial cell-line derived neurotrophic factor (GDNF) family, including GDNF, neurturin, artemin, and persephin. All these factors activate RET via different glycosyl phosphatidylinositol-linked GFRa receptors.¹ The receptor appears to be essential for the normal development of several kinds of nerve cells, including nerves in the intestine (enteric neurons) and the autonomic nervous system. The RET protein is also necessary for normal kidney development and the production of sperm (spermatogenesis).² Mutations in the RET gene have been found in a number of human diseases, including several different cancers of neuroendocrine origin and a gut syndrome characterized by intestinal obstruction known as Hirschsprung's disease³.

¹ The RET proto-oncogene in human cancers. S.M. Jhiang. *Oncogene* 2000, 19, 5590-5597

² Signaling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. S. Taraviras, V. Pachnis et al. *Development* 1999, 126, 2785-2797.

³ CF Ibáñez et al. Structure and physiology of the RET receptor tyrosine kinase. *Cold Spring Harb Perspect Biol.* 2013 Feb 15;2(2), pii: a009134.

3854	BLU-667	Highly potent and selective next generation inhibitor of oncogenic RET fusion and activating mutation	Page 314
1678	Regorafenib	Multi-kinase RTK inhibitor	Page 811

3226	RET agonist Q525	Highly selective RET agonist	Page 813
2667	RET Inhibitor 2667	RTK inhibitor active against wild-type RET and its mutants	Page 813
3195	Selpercatinib	Potent, highly selective, and ATP-competitive RET inhibitor	Page 860

Receptors (Enzyme Linked, RTK class XVI) Collagen receptor family

Discoidin domain receptors 1 and 2 (DDR1 and DDR2) are structurally-related membrane protein tyrosine kinases activated by different types of a major extracellular matrix component, triple-helical collagen. Collagen is probably the most abundant protein in man, with at least 29 families of genes encoding proteins, which undergo splice variation and post-translational processing, and may exist in monomeric or polymeric forms, producing a triple-stranded, twine-like structure. DDRs participate in several processes such as cell adhesion, migration, proliferation, and matrix remodeling. DDR1 is found in highly invasive tumor cells, suggesting its involvement in tumor progression. DDR1 appears to be preferentially expressed in tumor cells (epithelial), whereas DDR2 is expressed in tumor stroma^{1,2}.

¹ K. Valencia et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. *Clin. Cancer Res.* 2012, 18, 969-980.

² R.R. Valiathan et al. Discoidin domain receptor tyrosine kinases: new players in cancer progression. *Cancer Metastasis Rev.* 2012, 31, 295-321.

2265	DDR1-IN-1	Selective DDR1 receptor tyrosine kinase (RTK) inhibitor	Page 415
------	-----------	---	----------

Receptors (Enzyme Linked, RTK class XIX) LTK receptor family

As a result of their high degree of similarity, Anaplastic Lymphoma Kinase (ALK) and Leukocyte Tyrosine Kinase (LTK) were originally identified as a member of the ros/insulin receptor subfamily of receptor tyrosine kinases.¹ ALK was first discovered as the constitutively active nucleophosmin (NPM)-ALK oncoprotein in anaplastic large cell lymphomas (ALCL). Full length ALK is abundantly expressed in neural tissue during embryogenesis, but levels fall during early development. Consequently, it has been hypothesized to play a critical role in normal development and differentiation of the central and peripheral nervous system². ALK fusions derived from gene translocations are associated with large cell lymphomas and inflammatory myofibrilastic tumors.

¹ ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). S.W. Morris, C. Naevae, P. Mathew, P.L. James, M.N. Kirstein, X. Cui, D.P. Witte. *Oncogene* 1997, 14, 2175-2188

² ALK inhibitors, a pharmaceutical perspective. E. Ardini, A. Galvani. *Front. Oncol.* 2012, 17, 1-8.

2153	AZD 3463	Potent inhibitor of ALK and IGF1R	Page 270
2978	Brigatinib	Potent, selective, and orally active anaplastic lymphoma kinase (ALK) inhibitor	Page 327
1884	CH 5424802	Orally available and selective ALK inhibitor	Page 364
2294	KRCA 0008	Potent and selective dual ALK/ACK1 inhibitor	Page 595
2224	LDK 378	Selective anaplastic lymphoma kinase (ALK) inhibitor	Page 607
1509	LDN 193189	BMP-ALK inhibitor	Page 608
1661	SB 431542	TGF-betaR1 inhibitor; ALK inhibitor	Page 849
1660	PF 02341066	c-MET Inhibitor; NPM-ALK inhibitor	Page 766
2600	PF 06463922	Potent, ALK/ROS1 selective inhibitor	Page 770

Receptors (Enzyme Linked, RSTK class I) ALK receptor family

Transforming growth factor- β (TGF- β) family, including TGF- β , activin, Nodal, bone morphogenetic proteins (BMPs) and others, play vital roles in diverse cellular processes, including cell proliferation, differentiation, apoptosis, cell plasticity and migration. The type I receptor serine/threonine kinases (RSTKs) are also known as activin receptor-like kinases (ALKs) for which a systematic nomenclature has been proposed (ALK1-7) Its dysfunctions can result in various kinds of diseases, such as cancer and tissue fibrosis. Ligand binding leads to formation of the receptor heterocomplex, in which TGF- β R1I phosphorylates threonine and serine residues of TGF- β R1 and thus activates TGF- β R1. The activated TGF- β R1 recruits and phosphorylates a subset of SMAD proteins (SMAD 2/3) which are then translocated to the nucleus where they form transcription complexes with DNA binding factors and co-activators/co-repressors to regulate transcription of the target genes¹. In normal cells, TGF- β , acting through its signaling pathway, stops the cell cycle at the G1 stage to stop proliferation,

induce differentiation, or promote apoptosis. When a cell is transformed into a cancer cell, parts of the TGF- β signaling pathway are mutated, and TGF- β no longer controls the cell. These cancer cells proliferate².

¹ Regulation of TGF- β receptor activity. F. Huang Y.G. Chen. Cell Biosci. 2012, 2-9.

² Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Shi Y, Massagué J. Cell. 2003, 113, 685-700.

1744	A 77-01	TGF-betaR1 inhibitor; ALK 5 inhibitor	Page 194
1421	A 83-01	TGF-betaR1 inhibitor; ALK 5 inhibitor	Page 194
4168	BMS-986260	Potent, selective and orally bioavailable TGF- β R 1 inhibitor	Page 321
3914	CDD-1653	First-in-class, highly potent, and selective BMPR2 kinase inhibitor	Page 353
1708	Dorsomorphin	Inhibitor of BMP signaling. Inhibits ALK2, 3 and 6	Page 438
2150	Dorsomorphin dihydrochloride	Inhibitor of BMP signaling. Inhibits ALK2, 3 and 6	Page 438
1832	GW 788388	Inhibitor TGF- β R1	Page 535
2236	IN 1130	TGF- β R 1 inhibitor	Page 564
2189	K 02288	Inhibitor of BMP signaling. Inhibits ALK1, 2, and 6	Page 587
1509	LDN 193189	BMP-ALK inhibitor	Page 608
3552	LDN 212854	Potent ALK2-biased BMP type I receptor kinase inhibitor	Page 608
2201	LDN 212854 trihydrochloride	Potent ALK2-biased BMP type I receptor kinase inhibitor	Page 608
3892	LY-3200882	TGF- β R 1 inhibitor	Page 628
3404	LY-364947	Potent, selective and ATP-competitive TGF- β R 1 inhibitor	Page 631
4165	SB4	Potent BMP agonist	Page 848
1661	SB 431542	TGF-betaR1 inhibitor; ALK inhibitor	Page 849
2197	SB 505124	Selective inhibitor of TGF- β type I receptors ALK4 and ALK5	Page 849
2285	SB 525334	Selective inhibitor of the TGF- β R1 (ALK5) receptor	Page 849
1387	SD 208	TGF-betaR 1 inhibitor	Page 858
2903	SJ000291942	Activator of the canonical BMP signaling pathway	Page 869

Receptors (Enzyme Linked, RSTK class II) Activin receptor family

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include type I and type II receptors, and transduce signals through Smad-dependent and independent mechanisms. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases^{1,2}.

¹ Activin receptor signaling: a potential therapeutic target for osteoporosis. S. Lotinun, R.S.Pearsall, W.C. Horne, R. Baron Curr. Mol. Pharmacol. 2012, 5, 195-204.

² Activin receptor antagonists for cancer-related anemia and bone disease. S.Z. Fields et al. Exp. Opin. Invest. Drugs 2013, 22, 87-101.

2323	ITD-1	Selective inhibitor of TGF β /Smad signaling	Page 573
2467	ITD-1, (+)	Selective inhibitor of TGF β /Smad signaling	Page 573
1491	LY 2157299	TGF-betaR2 inhibitor	Page 632
2943	SRI-011381 hydrochloride	TGF- β signaling agonist	Page 890
3076	TJ191	Potent and selective anti-cancer agent targeting low T β RIII-expressing malignant T-cell leukemia/lymphoma cells	Page 929

Receptors: G protein-coupled (GPCRs)

G-protein coupled receptors (GPCRs) are a diverse super-family of proteins located within the plasma membrane of eukaryotic cells which have a common architecture consisting of seven-transmembrane (7-TM) segments, connected by extracellular (ECL) and intracellular (ICL) loops. They differ from other 7-TM proteins in their ability to activate guanine-

nucleotide binding proteins or β -arrestin and so initiate a signaling cascade. Therefore, they are among the most important pharmaceutical drug targets^{1,2}. GPCRs are activated by a wide variety of stimulants, including light, odorant molecules, peptide and non-peptide neurotransmitters, hormones, growth factors and lipids, and control a wide variety of physiological processes including sensory transduction, cell-cell communication, neuronal transmission, and hormonal signaling³. Upon activation by a stimulant (binding or conformational change of ligand), the conformation of the receptor is altered, which can result into two principal signal transduction pathways involving the G protein-coupled receptors: the cAMP signal pathway and the phosphatidylinositol signal pathway⁴.

Analysis of the human genome revealed at least 799 unique GPCRs. One widely adopted scheme classify the GPCRs into six families, with the most important and extensively studied being: family A (Rhodopsin-like); family B (Secretin); family C (Metabotropic glutamate/pheromone); family D (Fungal mating hormone); family E (Cyclic AMP); family F (Frizzled/Smoothed)⁵.

Besides the increasing number of categorized GPCRs with assigned endogenous ligands and (partially) elucidated signaling pathways, a large number of GPCRs remain whose endogenous ligands are unknown, and are classified as orphan GPCRs. Traditionally this class of GPCRs has been difficult to study and although molecular biological and bioinformatics techniques made the identification of orphan GPCRs amenable, the development of therapeutic compounds targeting these receptors has been extremely slow. Nevertheless, these GPCRs are considered important targets based on their distribution and behavioral phenotype as revealed by animals lacking the receptor^{6 and 7}. GPR139 for example (a.k.a. or GPRg1 or GPCR12), is an orphan receptor first identified as a rhodopsin family GPCR with exclusive expression in the central nervous system. Its closest homolog, GPR142, however, is expressed primarily in the pancreas and other peripheral tissues⁸. GPR139 is coupled with Gq signaling and appears to be constitutively active when recombinantly expressed in mammalian cells⁹.

¹ Modeling the 3D structure of GPCRs: advances and application to drug discovery. Becker O.M., Shacham S., Marantz Y., Noiman S. Current Opinion in Drug Discovery & Development [2003, 6(3):353-361]

² G protein coupled receptors – exploiting flexible conformations. K.L. Chapman, J.B.C. Findlay, G.K. Kinsella. Eur. Pharm. Rev. 2012, 6

³ Tools for GPCR drug discovery. R. Zhang, X. Xie. Acta Pharmacologica Sinica (2012) 33: 372-384

⁴ G proteins: transducers of receptor-generated signals. Gilman A.G. Annu. Rev. Biochem. 1987, 56, 615-49

⁵ P. Joost, A. Methner. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. Gen. Biol. 2002, 3, 0063.

⁶ S Chung et al. Orphan GPCR research. Br J Pharmacol. 2008 Mar;153 Suppl 1:S339-46.

⁷ JA Stockert et al. Advancements in therapeutically targeting orphan GPCRs. Front Pharmacol. 2015 May 8;6:100.

⁸ C. Liu et al. GPR139, an Orphan Receptor Highly Enriched in the Habenula and Septum, Is Activated by the Essential Amino Acids L-Tryptophan and L-Phenylalanine. Mol Pharmacol. 2015 Nov;88(5):911-25.

⁹ CA Dvorak et al. Identification and SAR of Glycine Benzamides as Potent Agonists for the GPR139 Receptor. ACS Med Chem Lett. 2015 Jul 20;6(9):1015-8.

3017	BRD4780	Potent and selective imidazoline1 (I1) receptor ligand; TMED9 binder	Page 326
2915	CID 1375606	Selective surrogate agonist for GPR27	Page 370
3926	CID 5157334	Selective surrogate agonist for GPR27	Page 370
2895	D3- β Arr	Positive allosteric modulator (PAM) of TSH receptor	Page 406
2962	FTBMT	Potent, selective and orally available GPR52 agonist	Page 492
3522	GPR52 Comp-43	Highly potent and specific GPR52 antagonist	Page 513
4160	IGGI-11me	Membrane permeable prodrug of IGGI-11; GIV-Gai inhibitor	Page 560
2569	JNJ 63533054	Potent, brain-penetrant, selective agonist of GPR139	Page 581
3603	LSL60101	Selective imidazoline2 (I2) receptor ligand	Page 622
2870	ML 221	Apelin receptor (APJ) antagonist	Page 665
2609	NCRW0005-F05	GPR139 antagonist	Page 695
3269	PSB-KD107	Selective agonist for GPR18	Page 795
3551	Sandalore	Selective agonist of the olfactory receptor OR2AT4; Synthetic odorant	Page 842
4090	YL-365	Potent and selective GPR34 antagonist	Page 998

Receptors (GPCR-A1) Chemokine CC

Peptide receptors, in general, are members of the large family of G-protein coupled receptors. Their endogenous ligands are neuropeptides and proteins of various kinds, such as chemokine (subfamily A1), vasopressin (subfamily A6), neurokinin (subfamily A9), and thrombin (subfamily A15). The diversity of endogenous ligands implies the wide range of biological processes they are involved in: include learning, memory, response to stress, pain, addiction, feeding behavior,

sexual behavior, reproduction, the immune response, thermal control, kidney function, cardiovascular function (including blood pressure and heart rate) and many others¹. The discovery that peptide receptors (somatostatin (subfamily A4) in particular) are over-expressed in most human neuroendocrine tumors has focused the recent interest in peptide receptors as potential targets for the treatment of cancers².

The CCR1 receptor is a member of the beta chemokine receptor family. Chemokines and their receptors are critical for the recruitment of effector immune cells to the site of inflammation. The ligands of this receptor include macrophage inflammatory protein 1 alpha (MIP-1 alpha), regulated on activation normal T expressed and secreted protein (RANTES), monocyte chemoattractant protein 3 (MCP-3), and myeloid progenitor inhibitory factor-1 (MPIF-1). Following interaction with their specific chemokine ligands, chemokine receptors trigger a flux in intracellular calcium (Ca²⁺) ions (calcium signaling). This causes cell responses, including the onset of a process known as chemotaxis that traffics the cell to a desired location within the organism³.

Fractalkine is a transmembrane protein and chemokine involved in the adhesion and migration of leukocytes. The protein encoded by this gene is a receptor for fractalkine (CX3CR1). CX3CR1 and its ligand help control the migration and recruitment of immune effector cells in numerous inflammatory diseases and may play a role in cancer progression, immune evasion, and metastasis. Increasing evidence indicates that CX3CR1 is required for monocyte homeostasis and differentiation and regulates the fate of monocyte-derived cells in other inflammatory diseases such as cardiovascular disease and liver fibrosis. However, precisely how CX3CR1 regulates tumor-associated macrophages (TAMs) subtypes in the tumor microenvironment remains unknown⁴. Besides, evidence is found that the fractalkine receptor also is a coreceptor for HIV-1, and some variations in this gene lead to increased susceptibility to HIV-1 infection and rapid progression to AIDS⁵.

¹ Designing peptide receptor agonists and antagonists. V.J. Hruby. Nature Reviews Drug Discovery 2002, 1, 847-858.

² Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. Reubi J.C. J. Nucl. Med. 1995, 36, 1825-1835.

³ Chemokine receptors and their role in inflammation and infectious diseases. Murdoch C., Finn A. Blood 2000, 95, 3032-3043

⁴ J. Zheng et al. Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis. Mol. Cancer. 2013, 12, 141.

⁵ R. Cotter et al. Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia. J. Neurovirol. 2002, 8, 585-598.

1179	A1B1	CCR1 antagonist	Page 196
2842	AZD 2098	Potent, selective and bioavailable CCR4 receptor antagonist	Page 269
2082	BX 471	Selective CCR1 receptor antagonist	Page 335
2255	CX3CR1 antagonist 18a	Antagonist of the Fractalkine receptor (FKN or CX3CR1)	Page 401
4167	RS504393	Selective CCR2 antagonist	Page 833
2685	Vercimron	CCR9 antagonist	Page 966
2636	YJC-10592	CCR2 antagonist	Page 998

Receptors (GPCR-A2) Chemokine CXC, Interleukin

CXC chemokine receptors are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. CXCR1 and CXCR2 (IL8R- α and IL8R- β respectively) are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif; they are both expressed on the surface of neutrophils in mammals. While CXCR3 is expressed predominantly on T lymphocytes, the CXCR4 receptor has a wide cellular distribution, with expression on most immature and mature hematopoietic cell types¹.

¹ Chemokine receptors and their role in inflammation and infectious diseases. Murdoch C., Finn A. Blood 2000, 95, 3032-3043

1738	AMD 3100	CXCR4 antagonist	Page 223
1930	AMD 3465	Potent and selective CXCR4 antagonist	Page 223
3844	CITFA	Selective GPER agonist	Page 373
1800	CXCR3 Antagonist 6c	CXCR3 antagonist	Page 401
2921	LIT-927	Selective, locally and orally active CXCL12 neutraligand	Page 616
3774	LN6023 dihydrochloride	First-in-class, selective ACKR3/CXCR7 superagonist	Page 617
1501	PD 0220245	IL8R antagonist	Page 755
1559	SB 265610	CXCR2 antagonist	Page 847
2593	SB 332235	CXCR2 antagonist exhibiting anti-inflammatory effects	Page 848
2993	UNBS5162	Pan-antagonist of CXCL chemokine expression	Page 952
1620	WZ 811	CXCR4 antagonist	Page 989
2861	ZK 756326 dihydrochloride	CCR8 agonist	Page 1008

Receptors (GPCR-A3) Angiotensin

The angiotensin receptors are activated by the vasoconstricting peptide angiotensin II. They are important for the renin-angiotensin system (RAS) or the renin-angiotensin-aldosterone system (RAAS); a hormone system that regulates blood pressure and water (fluid) balance. Effects mediated by the AT2 receptor are suggested to include inhibition of cell growth, fetal tissue development, modulation of extracellular matrix, neuronal regeneration, apoptosis, cellular differentiation, and maybe vasodilatation and left ventricular hypertrophy¹.

¹ The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor-Mediated Hypertrophy. A. Amore, M.J. Black, W.G. Thomas. Hypertension. 2005, 46, 1347-1354

3363	Azilsartan	Potent AT1 antagonist	Page 279
3104	Candesartan cilexetil	Potent and highly specific AT2 receptor antagonist	Page 341
3550	Fimasartan	Potent and orally active angiotensin II receptor antagonist	Page 481
3102	Losartan	Non-peptide, potent and orally active angiotensin II receptor antagonist	Page 620
1969	M 24	First non-peptide selective AT2 receptor agonist	Page 637
3105	Olmesartan	Potent and selective AT1 antagonist	Page 732
1276	PD 123319 ditrifluoroacetate	AT2 antagonist	Page 752
3890	PD 123319 ditrifluoroacetate, (R)-(-)	Opposite enantiomer of PD123319 ditrifluoroacetate	Page 751
3103	Telmisartan	Non-peptide, highly potent and selective AT1 receptor antagonist	Page 917
3106	Valsartan	Potent, highly selective, and orally active AT1 antagonist	Page 961

Receptors (GPCR-A4) Opioid, Somatostatin

Three members of the family of opioid receptors are known to date. The family name originates from the active hallucinating component of *Papaver somniferum* (opium), whereas the first assignment of names of each member was based on the most potent opiate used to study the three subtypes: mu (morphine, OP3), kappa (ketocyclazocine, OP2), and sigma (SKF 10047)¹. The later discovery of another subtype², named delta (named after the species was deferred used for this study, OP1), and the finding that the sigma receptor was actually a non-opioid receptor³ resulted in the currently know classification of mu, kappa, and delta receptor subtypes (OP1-OP3)⁴. A fourth opioid receptor subtype (Nociceptin, OP4) has been identified as a result of cloning techniques. This receptor shows a significant degree of homology in the cDNA coding for this and the other subtypes⁵. Opiate receptors are abundantly present in the brain, and present in the spinal cord and digestive tract. Besides the fact that these receptors are well known for their key interactions with opiates mediating hallucinating and analgesic effects, they do interact with endogenous ligands (endorphins) as well. Activation of opioid receptors by endogenous and exogenous ligands results in a multitude of effects, which include analgesia, respiratory depression, euphoria, feeding, the release of hormones, inhibition of gastrointestinal transit, and effects on anxiety.

Neuropeptide somatostatin (SST) is a cyclic neuropeptide containing a disulfide bond and is produced by specialized cells in a large number of human organs and tissues. SST primarily acts as inhibitor of endocrine and exocrine secretion via the activation of five G-protein-coupled receptors (GPCR-A4 subfamily), named SST1-5. SST is ubiquitously expressed in humans, with high concentrations in brain, liver, lungs, pancreas, thyroid, gastrointestinal tract, and adrenal gland mainly acting as an inhibitor of exocrine and endocrine secretions on target organs. SST suppresses GH, prolactin, and TSH production from pituitary gland, insulin, glucagon and exocrine secretions from pancreas, and several gastrointestinal peptides. In the brain, SST acts as neuromodulator, with physiological effects on neuroendocrine, motor, and cognitive functions, and as neurotransmitter, exerting both stimulatory and inhibitory effects^{6,7}.

¹ The effects of morphine- and nalorphine-like drugs in the nondependent and morphine dependent chronic spinal dog. Martin, W.R., Eades, C.G., Thompson, J.A., Huppler, R.E., Gilbert, P.E. J. Pharmacol. Exp. Ther. 1976, 197, 517-532.

² Endogenous opioid peptides: multiple agonists and receptors. N Lord JA, Waterfield AA, Hughes J, Kosterlitz HW. Nature. 1977, 267, 495-499

³ Psychotomimetic sigma-opiates and PCP. Mannaïack, D.T., Beart, P.M., Gundlach, A.L. Trends Pharmacol. Sci. 1986, 7, 448-451.

⁴ International Union of Pharmacology. XII. Classification of opioid receptors. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghesi PS, Hamon M. Pharmacol. Rev. 1996, 48, 567-92.

⁵ ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisan C, Chalon P, Caput D, Vassart G, Meunier JC. FEBS Lett. 1994, 341, 33-38.

⁶ Classification and nomenclature of somatostatin receptors. Hoyer D. et al. Trends Pharmacol. Sci. 1995, 16, 86-88

⁷ F. Barbieri et al. Peptide receptor targeting in cancer: the somatostatin paradigm. Int. J. Pept. 2013, 926295.

1751	ADL 5859	Selective delta-opioid receptor agonist	Page 208
------	----------	-------	---	-------	----------

1784	BAN ORL 24.....	NOP receptor antagonist.....	Page 282
1163	Binaltorphimine dihydrochloride, nor.....	Kappa-opioid antagonist.....	Page 307
1140	Fedotozine tartrate.....	Kappa(1a) opioid agonist.....	Page 477
1607	FK 960.....	Somatostatin agonist.....	Page 483
3198	FK962.....	Enhancer of somatostatin release.....	Page 483
1213	Funaltrexamine hydrochloride, beta-.....	Mu-opioid antagonist.....	Page 493
1226	GNTI dihydrochloride.....	Kappa-opioid antagonist.....	Page 511
2781	HS666 hydrochloride.....	Kappa-opioid partial agonist.....	Page 546
1805	JTC 801.....	NOP receptor antagonist.....	Page 584
3640	Loperamide hydrochloride.....	Potent Mu-opioid agonist.....	Page 619
1577	Nalbuphine hydrochloride.....	Analgesic. K-opioid agonist and μ -opioid partial agonist.....	Page 690
1573	Nalmefene hydrochloride.....	Opioid antagonist.....	Page 691
1205	Naloxonazine dihydrochloride.....	Opioid antagonist.....	Page 691
1230	Naloxone Benzoylhydrazone.....	Kappa-opioid agonist.....	Page 691
2415	Naloxone hydrochloride.....	Neutral opioid antagonist.....	Page 691
2416	Naltrexone hydrochloride.....	Opioid antagonist with preference for μ - and κ -receptors.....	Page 691
3840	Paltusotine.....	Potent, selective, and orally bioavailable SST2 agonist.....	Page 746
4064	Paltusotine dihydrochloride.....	Potent, selective, and orally bioavailable SST2 agonist.....	Page 746
1413	SB 612111 hydrochloride.....	NOP antagonist.....	Page 849
1412	SNC 80.....	Delta-opioid agonist.....	Page 876
1202	U 50488 hydrochloride.....	Kappa-opioid agonist.....	Page 946

Receptors (GPCR-A5) Neuropeptides, Leukotrienes

Subfamily A5 of the GPCRs consist of seven members of receptors that are activated by either neuropeptides or leukotriene-derivatives (galanin, leukotrienes and cysteinyl leukotrienes, relaxin, melanin, urotensin, and kisspeptin (a.k.a. metastin)).

The cysteinyl leukotrienes (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent GPCRs, termed the CysLT1 and CysLT2. Their endogenous ligands are LTC4, LTD4, and LTE4 are peptide-conjugated lipids that are prominent products of activated eosinophils, basophils, mast cells (MCs), and macrophages. These leukotrienes are commonly recognized as potent inflammatory mediators that initiate and propagate a diverse array of biologic responses. Consequently, clinically efficacious receptor antagonists and inhibitors of cys-LT synthesis have been introduced to treat asthma, immune responses, inflammation, tissue repair, and fibrosis¹.

Melanin concentrating hormone (MCH) is an orexigenic cyclic nonadeca-peptide, predominantly expressed in the lateral hypothalamus and zona incerta, acting at the G-protein coupled receptors (GPCRs) MCHR1 and MCHR2 widely expressed in the brain. MCH is an important mediator of energy homeostasis, stimulating food intake in rats after intra cerebroventricular (icv) injection, and increasing body weight². Additionally, an emerging body of literature supports a role for MCH and MCHR1 in the endocrine and behavioral responses to stress, suggesting that drugs interacting at this receptor might have an antidepressant and/or anxiolytic effect³.

¹ Y Kanaoka et al. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol. 2004 Aug 1;173(3):1503-10.

² Melanin concentrating hormone receptor 1 (MCHR1) antagonists—Still a viable approach for obesity treatment? T. Högberg, T.M. Frimurer, P.K. Sasmalc. Bioorg. Med.Chem.Lett. 2012, 22, 6039-6047

³ Preclinical Evaluation of Melanin-Concentrating Hormone Receptor 1 Antagonism for the Treatment of Obesity and Depression. D.R. Gehlert, et al. J.Pharm.Exp.Ther. 2009, 329, 429-438

2738	CysLT1 Antagonist Q8.....	Antagonist of the cysteinyl leukotriene receptor 1 (CysLT1)....	Page 344
1569	GW 803430.....	MCH1 antagonist.....	Page 443
3236	Montelukast sodium.....	Potent and selective CysLT1 receptor antagonist.....	Page 557
2620	Quinib.....	Antagonist of CysLT1 and -2.....	Page 659

Receptors (GPCR-A6) Cholecystokinin, Orexin, Vasopressin, GnRH

Cholecystokinin receptors (CCK1 and CCK2, a.k.a. CCK-A and CCK-B respectively) are activated by gastrin as well as by cholecystokins (CCK) CCK-4; CCK-8; and CCK-33. Activation of these receptors evokes secretion of amylase by pancreatic acinar cells, acid and pepsin by stomach mucosal cells, and contraction of the pylorus and gallbladder. Several CCK-A (CCK1) antagonists have been developed over the years for the treatment of stomach ulcers (Proglumide, Lorglumide, and Devazepide), but also for their potential as drugs to limit the development of gastrointestinal cancers such as colon cancer¹. However, by far the main focus of CCK antagonist research has focused on the development of selective CCK-B antagonists as novel medications which have been primarily investigated for the treatment of anxiety and panic attacks, as well as for other roles such as analgesic effects, sexual behavior, learning, and memory².

Orexin-A and orexin-B (also known as hypocretin-1 and hypocretin-2, respectively) are neuropeptides that bind to the GPCRs orexin-1 and orexin-2. The orexin system has been implicated in the regulation of functions such as reward seeking, feeding behavior, locomotion and physical activity, and arousal from sleep and the sleep-wake cycle. Upon receptor activation, intracellular calcium levels increase. Orexin deficiency has been linked to narcoleptic symptoms such as sudden sleep attacks and cataplexy³.

Vasopressin, also known as antidiuretic hormone, is a nonapeptide, and found to be essential for cardiovascular homeostasis. The antidiuretic effect of vasopressin has been exploited clinically for over half a century to treat diabetes insipidus. Three receptor subtypes are known to date (V1A-B, and V2 (original designation) or V1-3 (where V1A=V1 and V1B=V3)). Although all three of these proteins are G-protein coupled receptors (GPCRs), activation of V1A (V1) and V1B (V3) stimulate phospholipase C, while activation of V2 stimulates adenylate cyclase⁴.

The gonadotropin-releasing hormone (GnRH) receptor is expressed on the surface of pituitary gonadotrope cells as well as lymphocytes, breast, ovary, and prostate. The fundamental role of hypothalamic GnRH in the reproductive system by stimulation of pituitary gonadotropin secretion has made it a prime drug target for treatment of infertility, sex hormone-dependent diseases and for novel contraception in man⁵.

The vertebrate Neuropeptide S (NPSR-NPS) system has been established as an important signaling system in the central nervous system and is involved in physiological processes such as locomotor activity, wakefulness, asthma pathogenesis, anxiety and food intake. The NPSR-NPS system is closely related to the vasopressin-like receptor-vasopressin/oxytocin peptide (VPR-VP/OT) system. Single nucleotide polymorphisms (SNPs) and isoforms in the human NPSR gene are associated with risks of asthma, bronchial hyper-responsiveness, immunological disorders such as rhinoconjunctivitis, respiratory distress syndrome and irritable bowel syndrome. Consequently, potent NPSR antagonists have potential for multiple clinical applications for the treatment of obesity, hypersomnia and anxiety disorders⁶.

¹ Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. C. González-Puga et al. Journal of Pineal Research 2005, 39, 243-250

² The CCKB antagonist CI988 reduces food intake in fasted rats via a dopamine mediated pathway. L. Frommelt. Peptides, 2013, 39, 111-118.

³ Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial. P. Hoeffer et al. Clin. Pharm. Ther. 2012, 91, 975-985.

⁴ Science Review: Vasopressin and the cardiovascular system part 1 – receptor physiology. C.L. Holmes, D.W. Landry J.T. Granton. Critical Care 2003, 7, 427-434.

⁵ GnRHs and GnRH receptors. R.P.Millar, Anim Reprod Sci. 2005, 88, 5-28.

⁶ R. Valsalan et al. Evolutionary history of the neuropeptide S receptor/neuropeptide S system. Gen Comp Endocrinol. 2014 Dec 1;209:11-20.

2012	EMPA.....	Orexin type 2 (OX2) receptor antagonist.....	Page 456
2146	Fedovapagon.....	Selective vasopressin V2 receptor agonist.....	Page 477
3071	LIT-001.....	Potent and specific oxytocin receptor agonist.....	Page 616
3805	MK-3697.....	Potent and selective Orexin receptor antagonist.....	Page 659
2321	ML 154.....	Selective, and brain penetrant NPS receptor antagonist.....	Page 664
2095	SB 334867.....	First selective orexin 1 (OX1) antagonist.....	Page 848
2192	SB 674042.....	Nonpeptide OX1 selective antagonist.....	Page 850
1245	SR 27897.....	CCK1 antagonist.....	Page 887
1256	SR 49059.....	Vasopressin (V1A) antagonist.....	Page 888
1114	SSR 149415.....	Vasopressin (V1B) antagonist.....	Page 891
1270	T 98475.....	GnRH or LHRH antagonist.....	Page 903
2744	TCS1102.....	Dual orexin (OX1/2) receptor antagonist.....	Page 915
1591	Tolvaptan.....	Vasopressin (V2) antagonist.....	Page 935
1867	Vasopressin antagonist 1867.....	Orally available and selective V1b receptor antagonist.....	Page 963
2711	WAY-267464 dihydrochloride.....	Oxytocin receptor agonist.....	Page 985

Receptors (GPCR-A7) Endothelin, Neurotensin, GHS

Endothelins are very potent vasoconstrictors that bind to smooth muscle endothelin receptors, of which there are two subtypes: ETA and ETB receptors. Their activation causes the release of calcium by the sarcoplasmic reticulum (SR) and increased smooth muscle contraction and vasoconstriction. The receptors have been implicated in the pathogenesis of hypertension, coronary vasospasm, and heart failure¹.

Neurotensin (NTS) is a 13 amino acid peptide that functions as both a neurotransmitter and a hormone through the activation of the three neurotensin receptors known to date (NTSR1-3). NTS shows a wide range of biological activities. In the brain, NTS modulates opioid-independent analgesia, the inhibition of food intake and the activity of dopaminergic systems. Consequently, it plays an important role in Parkinson's disease and the pathogenesis of schizophrenia, the modulation of dopamine neurotransmission, hypothermia, antinociception, and in promoting the growth of cancer cells².

Originally thought of as a stomach-derived endocrine peptide acting via its receptors in the central nervous system to stimulate food intake and growth hormone expression, ghrelin and its receptor (growth hormone secretagogue receptor (GHS-R)) are widely expressed in a number of organ systems, including cancer cells. Ghrelin is currently known to be the most potent endogenous inducer of the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis and of food intake in mammals³. Endogenous ghrelin also appears to be an important modulator of physiological functions relevant to aging. Since endogenous ghrelin activity declines during aging, it has been hypothesized that GHS-R1a agonists may prove beneficial as interventional agents⁴.

¹ Endothelins and Endothelin Receptor Antagonists. Therapeutic Considerations for a Novel Class of Cardiovascular Drugs. T.F. Lüscher, M. Barton. Circulation. 2000, 102, 2434-2440

² Structure of the agonist-bound neurotensin receptor. Jim F. White et al. Nature 2012, 490, 508–513

³ Ghrelin and the Growth Hormone Secretagogue Receptor Constitute a Novel Autocrine Pathway in Astrocytoma Motility. V.D. Dixit et al. J. Biol. Chem. 2006, 281, 16681-16690

⁴ Ghrelin Receptor (GHS-R1A) Agonists Show Potential as Interventive Agents during Aging. R.G. Smith et al. Ann. N.Y. Acad. Sci. 2007, 119, 147-164

1648	Ambrisentan.....	Endothelin-A (ETA) antagonist.....	Page 222
4058	Atrasentan.....	Highly potent, selective, and orally active endothelin-A (ETA) antagonist.....	Page 260
2340	AZ-GHS-22.....	Orally available Ghrelin receptor (GHS-R1a) inverse agonist.....	Page 279
2147	CpdD hydrochloride.....	Ghrelin receptor (GhrR aka GHSR-1a) antagonist.....	Page 392
1975	Dilept.....	Neurotensin and dopamine receptor antagonist.....	Page 429
1376	MK 677.....	Growth hormone secretagogue (GHS) agonist.....	Page 660
2632	ML314.....	Nonpeptidic β -Arrestin biased agonist of NTR1.....	Page 667
1255	SR 142948.....	Neurotensin antagonist.....	Page 888
1164	SR 48692.....	Neurotensin 1 antagonist.....	Page 887
3486	TM-N1324.....	Highly potent and selective GPR39 agonist.....	Page 932

Receptors (GPCR-A8) Mas

The renin-angiotensin-system (RAS) constitutes an important hormonal system in the physiological regulation of blood pressure. The classic RAS can be defined as the ACE-Ang II-AT1R axis that promotes vasoconstriction, sodium retention, and other mechanisms to maintain blood pressure, as well as increased oxidative stress, fibrosis, cellular growth, and inflammation in pathological conditions. In contrast, the non-classical RAS composed of the ACE2-Ang-(1-7)-Mas receptor axis generally opposes the actions of a stimulated Ang II-AT1R axis through an increase in nitric oxide and prostaglandins and mediates vasodilation, inhibition of cell growth, anti-thrombosis and anti-arrhythmogenic effects, natriuresis, diuresis, and oxidative stress¹. The Mas receptor is expressed in brain, testis, heart, and kidney, and is proven to be a Gq-coupled receptor that in early studies was suggested to be an angiotensin II (ANG II) receptor².

¹ M.C. Chappell et al. Update on the angiotensin converting enzyme 2-angiotensin (1-7)-Mas receptor axis: fetal programming, sex differences, and intracellular pathways. Front. Endocrinol. 2014, 4, 00201.

² A.C. Simões e Silva et al. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol. 2013, 169, 477-492.

2191	AR 244555.....	Inverse agonist of Mas G-protein signaling.....	Page 244
3386	AVE0991.....	Selective and orally active Mas receptor agonist.....	Page 262

Receptors (GPCR-A9) Neurokinin

The mammalian tachykinins are a group of neuropeptides that include substance P, neurokinin A (NKA; also known as tachykinin precursor 1) and neurokinin B (NKB; also known as tachykinin 3). These tachykinins are widely distributed in the

central nervous system (CNS) but they have distinct expression patterns. The biological actions of substance P, NKA and NKB are mediated via the activation of G protein-coupled seven-transmembrane domain receptors designated as tachykinin receptor 1 (TACR1; also known as the NK1 receptor), TACR2 (also known as the NK2 receptor) and TACR3 (also known as the NK3 receptor), respectively. Both NK1 and NK3 receptors are widely distributed in the CNS, whereas the NK2 receptor is found in the smooth muscle of the gastrointestinal, respiratory and urinary tracts, but it has also been located in discrete regions of the rodent CNS. The development of drugs interacting with NK receptors has focused predominantly on the treatment of social anxiety disorders (SAD). Unfortunately, clinical trials with several NK1 antagonists showed inconsistent or no positive results for the treatment of SAD¹.

¹ T.E. Klassert et al. Tachykinins and Neurokinin Receptors in Bone Marrow Functions: Neural-Hematopoietic Link. J. Rec. Lig. Chann. Res. 2010, 2010, 51-61.

1486	Aprepitant.....	Substance P antagonist (SPA); NK1 inhibitor.....	Page 243
1901	Casopitant mesylate.....	NK1 antagonist.....	Page 345
3403	Fezolinetant.....	Orally bioavailable NK3 antagonist.....	Page 479
1119	GR 159897.....	NK2 antagonist.....	Page 514
2499	Netupitant.....	Selective NK1 antagonist; Prevents nausea and vomiting.....	Page 698
1618	Orvepitant maleate.....	NK1 antagonists.....	Page 736
1533	Osanetant.....	NK3 antagonist.....	Page 737
3435	VU0637120, (S)-.....	First-in-class, selective neuropeptide Y4 receptor allosteric antagonist.....	Page 974

Receptors (GPCR-A9) Melatonin

Melatonin is considered an important hormonal output of the circadian system mediating the entrainment of the circadian rhythms of several biological functions¹. Besides, it is involved in numerous physiological processes including blood pressure regulation, oncogenesis, retinal physiology, seasonal reproduction, ovarian physiology, immune function and most recently in inducing osteoblast differentiation. It interacts at either of the two melatonin receptor subtypes (MT1 and MT2) present in humans and other mammals².

The MT1 subtype is present in high concentrations in the pituitary gland and the suprachiasmatic nuclei (SCN) of the hypothalamus, whereas the MT2 subtype is mainly present in the retina.

¹ Melatonin: therapeutic and clinical utilization. Altun A, Ugur-Altun B. Int J Clin Pract. 2007, 61, 835-845.

² Melatonin receptors step into the light: cloning and classification of subtypes. Reppert S.M., Weaver D.R., Godson C. Trends Pharmacol Sci. 1996, 17, 100-102.

1492	Agomelatine.....	Melatonin agonist; 5-HT2C antagonist.....	Page 214
1335	AH 001.....	Melatonin agonist.....	Page 215
1336	AH 002.....	Melatonin agonist.....	Page 215
1351	DH 97.....	Melatonin (MT2) antagonist.....	Page 424
1350	Luzindole.....	Melatonin antagonist.....	Page 625

Receptors (GPCR-A11) GPR40-related, P2Y purine

Free fatty acids (FFAs) are essential nutrients. An ever-increasing number of studies have demonstrated that FFAs are important signaling molecules as well, contributing to many cellular functions. FFAs have been found to activate several G protein-coupled receptors (GPCRs), which are named free fatty acid receptors (FFARs), including G protein-coupled receptor 40 (GPR40 aka FFAR1), GPR41 (FFAR3), GPR43 (FFAR2), GPR84, GPR119, and GPR120 (FFAR4)¹. The FFAR's are a critical component of the body's nutrient sensing apparatus, and small molecule agonists and antagonists of these receptors show considerable promise in the management of obesity, dyslipidemia, and diabetes. Unlike the classic 'lock and key' relationship between receptors and their ligands, nutrient receptors are considered to be promiscuous in that they can be activated by a range of ligands². GPR84 is activated by medium-chain FFAs (MCFAs) with 9-14 carbons and classified as A18 GPCR (and not class A11 as other FFARs). It is expressed mainly in the immune-related tissues, such as thymus, spleen, bone marrow, and peripheral blood leukocytes, and is significantly upregulated in monocytes/macrophages upon lipopolysaccharide (LPS) stimulation. In activated T cells, GPR84 has been found to regulate early interleukin 4 (IL-4) gene expression³.

The potent effects of purines were first reported in 1929. The first purinoceptors were defined in 1978 only, while arguably, they are the most abundant receptors in living organisms and appeared early in evolution. Separate membrane receptors for adenosine (P1 receptors) and ATP (P2 receptors) were recognized in 1978 and, later, P2 receptors were divided into

ionotropic P2X and metabotropic P2Y receptors on the basis of mechanism of action, pharmacology and molecular cloning⁴. P2X receptors are classical cationic ligand-operated channels that upon ATP binding open the pore permeable to Na⁺, K⁺ and Ca²⁺. They are trimers formed from individual subunits encoded by seven distinct genes (designated P2X1-7). Based on phylogenetic similarity, presence of amino acids important for ligand binding and selectivity of G-protein coupling, two distinct P2Y subgroups with a high level of sequence divergence are recognized: the P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 subgroup and the P2Y12, P2Y13, and P2Y14 subgroup. Receptors of the first subgroup principally use Gq/G11 to activate the phospholipase C/inositol triphosphate (InsP3) endoplasmic reticulum Ca²⁺-release pathway, whereas receptors of the second subgroup almost exclusively couple to Gi/o, which inhibits adenyllyl cyclase and modulate ion channels⁵. P2Y receptors can be stimulated by a wider range of nucleotides such as ATP, ADP, UTP, UDP and UDP-glucose. GPR109A is a Gi/Go protein-coupled receptor of the A11 subfamily of GPCR receptors. It is both a receptor for nicotinate (niacin or vitamin B3) and mediates the lipid-lowering actions of the vitamin, as well as it is a receptor for butyrate in the colon. Nicotinic acid and its derivative, e.g., Acipimox, have been used clinically in the treatment of hyperlipidemia. These substances are known to lower elevated plasma concentration of low-density lipoprotein (LDL), intermediate-density lipoprotein, very low-density lipoprotein (VLDL), triglycerides (TG), and lipoprotein Lp(a), and also increase plasma high density lipoprotein (HDL) concentrations, resulting in an improvement of mortality rate against coronary artery disease⁶. GPR109A expression in colon is induced by gut microbiota and is downregulated in colon cancer. GPR109A in immune cells plays a nonredundant function in niacin-mediated suppression of inflammation and atherosclerosis⁷.

¹ Q Zhang et al. Discovery and Characterization of a Novel Small-Molecule Agonist for Medium-Chain Free Fatty Acid Receptor G Protein-Coupled Receptor 84. *J Pharmacol Exp Ther.* 2016 May;357(2):337-44.
² Free fatty acid receptors: emerging targets for treatment of diabetes and its complications V. Vangaveti, V. Shashidhar, G. Jarrod, B.T. Baune, R.L. Kennedy. *Ther. Adv. Endocrinol. Metab.* 2010, 1, 165-175
³ J Wang et al. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. *J Biol Chem.* 2006 Nov 10;281(45):34457-64.
⁴ Purinergic signaling in the nervous system: an overview. Maria P. Abbracchio1, Geoffrey Burnstock2, Alexei Verkhratsky3, 4, Herbert Zimmermann. *Trends Neurosci.* 2009, 32, 19-29
⁵ International Union of Pharmacology. Update and subclassification of the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. M.P. Abbracchio et al. *Pharmacol. Rev.* 2006, 58, 281-341
⁶ T. Soga et al. Molecular identification of nicotinic acid receptor. *Biochem. Biophys. Res. Commun.* 2003, 303, 364-369.
⁷ N. Singh et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity.* 2014, 40, 128-139.

2405	AMG 837	Orally bioavailable partial agonist of GPR40 (FFA1)	Page 226
2794	AR 420626	GPR41 receptor agonist (FFA3)	Page 244
3057	DC260126	GPR40 receptor antagonist (FFA1)	Page 412
2582	GSK 137647A	Potent and selective FFA4/GPR120 agonist	Page 523
2013	GW 9508	GPR40 receptor agonist (FFA1)	Page 532
1576	MK 0354	GPR109a partial agonist; affects HDL levels in blood	Page 660
1862	MRS 2578	P2Y6 nucleotide receptor antagonist	Page 680
3056	NF-56-EJ40	High-affinity, human-selective SUCNR1 (GPR91) antagonist	Page 700
2075	TUG 891	Potent and selective GPR120 (FFA4) agonist	Page 943
3078	TUG-1375	Potent GPR43 receptor agonist (FFA2)	Page 943
2616	ZQ-16	Potent and selective GPR84 agonist	Page 1007

Receptors (GPCR-A12) P2Y purine

The P2Y14 purinergic receptor is activated by the endogenous ligand UDP-glucose and other UDP-sugars. It is probably the most atypical P2Y receptor, which is distributed in the immune system, including in dendritic cells and the central nervous system. It has been implicated in extending the known immune system functions of P2Y receptors by participating in the regulation of the stem cell compartment, and it may also play a role in neuroimmune function¹.

¹ Development of selective agonists and antagonists of P2Y receptors. K.A. Jacobson, A.A. Ivanov, S. de Castro, T.K.Harden, H. Ko. *Purinergic Signaling* 2009, 5, 75-89

1958	P2Y14 Antagonist Prodrug 7j HCl	Prodrug of P2Y14 receptor antagonist	Page 744
3420	PPTN hydrochloride	High affinity and specific P2Y14 receptor antagonist	Page 788
3111	Ticagrelor	Selective, reversible and orally available P2Y12 antagonist	Page 927

Receptors (GPCR-A13) Cannabinoid

Cannabinoids, which include the bioactive constituents of the marijuana plant *Cannabis sativa*, as well as endogenous lipids (endocannabinoids) and synthetic compounds with cannabinoid-like activity, interact with specific receptors to cause their effects on target tissues. To date, three receptors have been identified by molecular cloning; these are the transient receptor potential vanilloid type 1 receptor (TRPV1) ion channel, and the G protein-coupled receptors (GPCRs) CB1 and CB2. At the phylogenetic level, CB1 and CB2 are most related to the family of lipid receptors, formerly EDG receptors, which are activated by the sphingolipids sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA). CB1 and CB2 are also lipid receptors, and recognize acylethanolamide analogues, typified by anandamide (arachidonylethanolamide, AEA), and 2-arachidonoylglycerol (2-AG). TRPV1 is activated by various lipids including acylethanolamides such as AEA. Recently, two orphan GPCRs have emerged as candidate non-CB1/CB2 receptors. These are GPR119, which is reportedly a receptor for OEA, and GPR55, which is reportedly activated by various cannabinoids¹. Whereas CB1 receptors are predominantly located in the brain, and are therefore responsible for the euphoric and anticonvulsive effects of cannabinoids, CB2 receptors can be found in the immune system and are believed to be responsible for the anti-inflammatory effect of cannabinoids². Besides the general effects of cannabinoids already mentioned, multiple synthetic drugs interacting at CB receptors have proven a functional role for the treatment of obesity (Axon 1220, and analogues Axon 1218, Axon 1219, Axon 1713, and Axon 1714), or as analgesic (Axon 1497, Axon 1498, Axon 1522, and Axon 1523).

As stated earlier, Based on a phylogenetic analysis, the family of cannabinoid receptors should be separated into two different classes of the rhodopsin-like family of GPCRs. While CB1 and CB2 receptors share a group together with lysophospholipid (LPL) and melanocortin receptors (A13), the newly recognized GPR55, GPR119, (and GPR18) receptors are officially member of another group (A15), together with protein activated receptors (PAR) and other LPL receptors³.

¹ A.J. Brown. Novel cannabinoid receptors. *Br. J. Pharmacol.* 2007, 152, 567-575.
² Is lipid signaling through cannabinoid 2 receptors part of a protective system? Pacher P, Mechoulam R. *Prog Lipid Res.* 2011, 50, 193-211.
³ P. Joost, A. Methner. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. *Gen. Biol.* 2002, 3, 0063.

1218	AM 251	CB1 antagonist	Page 221
1219	AM 281	CB1 antagonist	Page 221
2791	AM 4113	CB1 antagonist	Page 222
2541	APD 597	Orally bioavailable selective GPR119 agonist	Page 240
1235	Cannabidiol, Abnormal	Cannabinoid agonist	Page 342
3955	CB2R PAM C2	First synthetic, potent and orally active CB2 receptor PAM	Page 346
2015	CP 945598	CB1 antagonist	Page 391
2119	CP 945598 hydrochloride	CB1 antagonist	Page 391
3097	DBPR211	Potent and selective peripherally restricted CB1 antagonist/inverse agonist	Page 411
3632	Genistein	CB1 antagonist	Page 501
1925	GW 842166X	Cannabinoid CB2 receptor agonist	Page 535
1440	HU 308	CB2 agonist	Page 548
1574	Iodopravadoline	CB2 antagonist	Page 568
1498	JWH 018	CB2 agonist	Page 585
1497	JWH 073	CB2 agonist	Page 586
1418	JWH 133	CB2 agonist	Page 586
1522	JWH 250	CB1 agonist; CB2 agonist	Page 586
1550	MK 0364	CB1 antagonist/inverse agonist	Page 660
1565	PSNCBAM 1	CB1 antagonist (allosteric)	Page 795
1713	SLV 319	CB1 antagonist	Page 873
1714	SLV 319, (R)-(+)-	Inactive enantiomer of SLV 319	Page 873
1712	SLV 319, rac-(±)-	Racemate of CB1 antagonist Ibipinabant (Axon 1713)	Page 874
1220	SR 141716A	CB1 antagonist	Page 888
1924	SR 144528	CB2 receptor antagonist and/or an inverse agonist	Page 888
2543	ZCZ 011	Brain penetrant CB1 positive allosteric modulator (PAM)	Page 1004

Receptors (GPCR-A13) Lysophospholipid

Members of the family of Lysophospholipid receptors are GPCRs that are important for lipid signaling¹. Their endogenous ligands encompass lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P). The principal effects of LPA and S1P are growth related, including induction of cellular proliferation, alterations in differentiation and survival, and suppression of apoptosis. LPA and S1P also evoke cellular effector functions, which are dependent on cytoskeletal responses such as contraction, secretion, adhesion, and chemotaxis^{2,3}. There are five S1PRs known to date, that activate different intracellular signaling pathways and differentially regulate endothelial cell function. S1PR1 couples to Gi and activates the phosphatidylinositol 3-kinase (PI3K) pathway, Rac, cortical actin assembly, and cell migration. In sharp contrast, S1PR2 antagonizes S1PR1-Gi-PI3K signaling in the endothelium through activation of the G12/13-Rho-Rho kinase (ROCK)-PTEN pathway. This implies that the balance between S1PR1 and S1PR2 signaling in a specific vascular bed will determine the endothelial responses to S1P⁴. The classical S1PR1 ligand Fingolimod (FTY 720, Axon 1485) is known for its characteristics as an immunomodulating drug, approved for treating multiple sclerosis. Interestingly, recent studies indicated the ligand could also be a candidate therapeutic drug for the treatment of heart failure and arrhythmias by activation of the P21-activated kinase-1 (Pak1)⁵.

¹ International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. J Chun, EJ Goetzl, T Hla, Y Igarashi, KR Lynch, W Moolenaar, S Pyne, G Tigyi. Pharmacol Rev 2002, 54, 265–269.

² Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. EJ Goetzl, S An. FASEB J 1998, 12, 1589-1598.

³ Lysophospholipid receptors: signaling, pharmacology and regulation by lysophospholipid metabolism. D Meyer zur Heringdorf, KH Jakobs. Biochim. Biophys. Acta 2007, 1768, 923–940.

⁴ G. Zhang et al. Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation. Blood. 2013 Jul 18;122(3):443-55.

⁵ FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. EE Egom, Y Ke, H Musa, T Mohamed, T Wang, E Cartwright, RJ Solaro, M Lei. J. Mol. Cell. Cardiol. 2010, 48, 406-414.

2367	AM 095 (parent compound)	Novel potent and selective LPA1 antagonist	Page 221
3096	Amiselimod hydrochloride	S1PR modulator	Page 234
3609	AS2717638	Highly potent, selective, orally active, and brain-penetrant LPA receptor 5 antagonist	Page 252
1485	Fingolimod	S1PR1 agonist; Immunosuppressant	Page 482
1866	JTE 013	S1PR2 antagonist	Page 584
1615	KRP 203	S1PR1 agonist	Page 596
1947	RP 001 hydrochloride	A picomolar S1PR1 agonist	Page 831
1672	SEW 2871	S1PR1 agonist	Page 862
2404	TY 52156	Selective, competitive, and orally active S1P3 antagonist	Page 944
3207	UCM-05194 ammonium salt	Potent and selective LPA1 receptor agonist	Page 948

Receptors (GPCR-A14) Eicosanoid

Prostanoids are a subclass of eicosanoids consisting of the prostaglandins, the thromboxanes, and the prostacyclins. They are the cyclooxygenase metabolites of arachidonic acid, and include prostaglandin (PG) D2, PGE2, PGF2 α , PGI2, and thromboxane A2¹. Their activities are related to a diversity of endogenous processes such as inflammation, platelet aggregation, and vasoconstriction/relaxation. Prostanoid receptors belong to the large family of GPCRs, and can be grouped into three categories, based on the type of heterotrimeric G-protein activated by the different receptors, and thus the cellular response evoked (Gs (DP1, EP2), Gq (EP1), and Gi (EP3)).

Prostaglandin D2 (PGD2) is an acidic lipid mediator that is derived from arachidonic acid by the sequential action of cyclooxygenase(s) (COX) and PGD2 synthase(s). Arachidonic acid is converted by COX-1 and COX-2 in a two-step process to first PGG2 and then PGH2. These unstable endoperoxide intermediates are converted to PGD2 by either the haematopoietic or lipocalin PGD2 synthase. PGD2 is produced in the brain where it might be involved in the regulation of sleep and other central nervous system (CNS) activities, including pain perception. In peripheral tissues, the richest cellular source of PGD2 is the mast cell². The CRTH2 receptor is an important mediator of the inflammatory effects of PGD2. Strikingly, it has low homology to the rest of the prostaglandin receptors, but high sequence homology to chemoattractant receptors such as the N-formyl peptide receptors and cysteinyl leukotriene receptors. The receptor is expressed on TH2 cells, but not on TH1 cells, and hence the name chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2)³.

The Prostacyclin (PGI₂) receptor, also termed the prostaglandin I2 receptor or just IP, is coupled to a guanosine nucleotide-binding α -stimulatory protein (Gas). IP is found on a variety of cell types and exhibits broad physiological effects. PGI₂ regulates both the innate and adaptive immune systems and its effects are, for the most part, thought to be anti-inflammatory or immunosuppressive in nature. For a long time, PGI₂ has been understood to play a role in cardiovascular health, specifically having powerful vasodilatory effects via relaxation of smooth muscle and inhibiting of platelet aggregation⁴.

¹ Prostanoid Receptors: Structures, Properties, and Functions. S Narumiya, Y Sugimoto, F Ushikubi. Physiol Rev 1999, 79, 1193-1226.

² R. Pettipher et al. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 2007, 6, 313-325.

³ T. Ulven et al. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin. Ther. Pat. 2010, 20, 1505-1530.

⁴ SL Dorris et al. PGI2 as a regulator of inflammatory diseases. Mediators Inflamm. 2012;2012:926968.

2062	Alprostadil	Prostaglandin EP (1-4) receptor antagonist	Page 220
2145	AZD 1981	Selective CRTH2 (aka DP2) antagonist	Page 268
3073	BAY 1316957	Highly potent, specific, and selective PGE2 receptor hEP4 antagonist	Page 286
2788	ER-819762	Highly selective, and orally available PGE2 receptor EP4 antagonist	Page 465
1210	ICI 192605	Thromboxane A2 antagonist	Page 558
3787	Grapiprant	Potent, selective, competitive and orally bioavailable prostaglandin EP4 receptor antagonist	Page 515
1480	MK 0524 sodium salt	PGD2 receptor DP1 antagonist	Page 660
1913	OC 000459	Selective DP2 (CRTH2) antagonist	Page 728
1512	ONO 8711 dicyclohexyl amine salt	PGE1 receptor EP1 antagonist	Page 734
2024	PF 04418948	Prostaglandin EP2 receptor antagonist	Page 767
2874	Ralinepag	Potent, orally active IP receptor (PGI2) agonist	Page 806
1605	S 5751	PGD2 receptor DP1 antagonist	Page 837
2605	Selexipag	Prodrug of MRE 269, a potent IP receptor (PGI2) agonist	Page 859
1447	Seratrodast	Thromboxane A2 antagonist	Page 861
3212	TG11-77 hydrochloride	Potent, selective, water soluble, brain-permeable EP2 receptor antagonist	Page 921
3966	TM30089 sodium	Selective CRTH2 antagonist	Page 931

Receptors (GPCR-A15) Cannabinoid

Based on phylogenetic analysis, the family of cannabinoid receptors is separated into two different classes of the rhodopsin-like family of GPCRs. While CB1 and CB2 receptors share a group together with lysophospholipid (LPL) and melanocortin receptors (A13), the newly recognized GPR55, GPR119, and GPR18 receptors are officially member of another group (A15), together with protein activated receptors (PAR) and other LPL receptors¹.

Two orphan GPCRs have recently been implicated as novel cannabinoid receptors; these are GPR119, which has been proposed as a receptor for oleoylethanolamide, and GPR55 which has been proposed as a receptor activated by multiple different cannabinoid ligands.

GPR55 has been demonstrated to interact with chemically unrelated cannabinoid ligands, in both mammalian and non-mammalian recombinant expression systems, and by independent research groups. Clearly, there is some relationship between the ligand-binding sites of GPR55 and CB1/CB2; however, the endogenous agonist and physiological relevance of GPR55 are not yet clear. Studies have suggested that L- α -lysophosphatidylinositol (LPI), which activates GPR55 but not CB1 or CB2 receptors, could be its endogenous ligand. Conversely, cannabidiol (CBD) is a GPR55 antagonist².

GPR119 is strongly implicated in the regulation of energy balance and body weight. However, further corroborating data of the activity of acylethanolamides at GPR119 will be required before it can be regarded unequivocally as a cannabinoid receptor³.

¹ P. Joost, A. Methner. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. Gen. Biol. 2002, 3, 0063.

² S. Syantayev et al. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc. Nat. Acad. Sci. USA 2013, 110, 5193-5198.

³ A.J. Brown. Novel cannabinoid receptors. Br. J. Pharmacol. 2007, 152, 567-575.

2380	APD 668	Potent and selective, orally active GPR119 agonist	Page 240
1572	AR 231453	Cannabinoid GPR119 Agonist	Page 244
3430	AS1269574	Selective and orally available GPR119 agonist	Page 251
1234	Cannabidiol	GPR55 antagonist	Page 342
2092	MBX 2982	Potent and selective GPR119 agonist	Page 640

3028	ML184	Potent and selective GPR55 agonist	Page 670
4125	ML193	Highly potent and selective GPR55 antagonist	Page 665
3230	ML401	Potent functional antagonist of EBI-2	Page 672
3788	NE52-QQ57	Selective and orally bioavailable GPR4 antagonist	Page 696
3231	NIBR189	Potent and selective EBI-2 antagonist	Page 701
1211	Palmityloethanolamide	Endocannabinoid; GPR55 agonist	Page 746

Receptors (GPCR-A15) Proteinase activated

Proteinase-activated receptors (PARs), a family of four seven-transmembrane G protein-coupled receptors, act as targets for signaling by various proteolytic enzymes. PARs are characterized by a unique activation mechanism involving the proteolytic unmasking of a tethered ligand that stimulates the receptor. Given the broad spectrum of roles that PARs have in normal and pathological tissue function, these receptors are emerging as potential therapeutic targets for several diseases including arthritis, colitis, asthma, neurodegenerative conditions, tumor invasion and cardiovascular diseases. The proteolytic mechanisms that regulate PAR activity are more complex than initially anticipated. Thus, via a proteinase, a PAR can be: activated by a tethered ligand mechanism; disarmed for further activation by an activating proteinase; or activated via a non-canonical mechanism involving cleavage at a site distinct from the one that reveals the canonical tethered ligand sequence¹.

¹ Targeting proteinase-activated receptors: therapeutic potential and challenges. R. Ramachandran, F. Noorbakhsh, K. DeFea, M.D. Hollenberg. Nat. Rev. Drug Disc. 2012, 11, 69-86.

2898	AC 264613	Potent, selective, and metabolically stable PAR2 agonist	Page 204
2030	E 5555 hydrobromide	Potent and orally active PAR1 antagonist	Page 447
1622	GB 83	PAR2 antagonist	Page 497
3043	I-191	Potent PAR2 antagonist	Page 554
1928	ML 161	Allosteric inhibitor of PAR1	Page 664
2899	ML354	Potent and selective PAR4 antagonist	Page 669
1755	SCH 530348	PAR1 antagonist	Page 856
1275	SCH 79797 dihydrochloride	PAR1 antagonist	Page 855
2055	Q94 hydrochloride	Negative allosteric modulator of PAR1 (Gaq linkage)	Page 801

Receptors (GPCR-A17) (nor-)Adrenaline

The classification of alpha and beta subtypes of the adrenergic receptor results from the diverse responses towards adrenergic stimulation. Epinephrine and norepinephrine are the primary adrenergic neurotransmitters. The receptors are part of the super family of metabotropic G-protein coupled receptors (GPCRs), and are often referred to as being responsible for the 'flight or fight response'. Activation of the alpha subtype generally results in vasoconstriction, whereas activation of the beta subtype leads to vasodilatation. While beta blockers are generally known for their management of cardiac arrhythmias, cardioprotection after myocardial infarction (heart attack), angina and hypertension (e.g. Axon 1159 (Celiprolol hydrochloride), and Axon 1518 (Timolol maleate))¹, in contrast, drugs interacting at the alpha adrenergic receptors are often used for a variety of medical disorders; e.g. for the treatment of hemorrhagic shock (Axon 1154, B-HT 933 dihydrochloride)², as an antidepressant, antidiabetic, or to prevent central neurodegenerative disorders (e.g. Axon 1155, Efaroxan hydrochloride)³, or for the treatment of narcolepsy and sleep disorders (e.g. Axon 1296, Modafinil)⁴.

¹ G-Protein-coupled receptors: Better beta-blockers. J. Owens. Nature Reviews Drug Discovery 2005, 4, 371.

² Pressor effects of the alpha 2-adrenoceptor agonist B-HT 933 in anaesthetized and haemorrhagic rats: comparison with the haemodynamic effects of amidephrine. M. R. MacLean, M. Thomson, C. R. Hiley. Br J Pharmacol. 1989, 97, 419-432.

³ Use of efaroxan and derivatives thereof for the treatment of Alzheimer's disease. F. Colpaert et al. US patent US4855385, 1989.

⁴ Randomized trial of modafinil as a treatment for the excessive daytime somnolence in narcolepsy. Becker PM, et al. Neurology 2000, 54, 1166-1175.

1371	Atipamezole hydrochloride	Alpha-2 adrenoceptor antagonist	Page 258
4204	Bambuterol hydrochloride	Recent Addition Long acting, orally active β_2 adrenoceptor agonist prodrug	Page 283
1154	B-HT 933 dihydrochloride	Alpha-2 adrenoceptor agonist	Page 301
3458	Bisoprolol fumarate	Potent and cardioselective β_1 antagonist	Page 311
2335	Brexipiprazole dihydrochloride	Antipsychotic drug candidate	Page 327

1555	Brimonidine tartrate	Alpha-2 adrenoceptor agonist	Page 328
1157	Bromobutanol	Beta-2 agonist	Page 329
3456	Carvedilol	β - and α_1 adrenoceptor receptor antagonist	Page 344
1159	Celiprolol hydrochloride	Beta-1 antagonist	Page 358
3488	CGP-12177A, (+)-	β_1/β_2 adrenoceptor antagonist, β_3 adrenoceptor agonist	Page 362
3044	Clonidine hydrochloride	α_2 adrenoceptor agonist	Page 377
3065	Dexmedetomidine hydrochloride	Selective α_2 adrenoceptor agonist	Page 423
4082	DFPQ	Potent and selective β -arrestin-biased NAM for the β_2 -adrenergic receptor	Page 423
3665	Droxidopa	Brain-penetrant norepinephrine prodrug	Page 442
1155	Efaroxan hydrochloride	Alpha-2 adrenoceptor antagonist	Page 451
3383	Guanfacine hydrochloride	Selective α_2 adrenoceptor agonist	Page 531
3654	Isoprenaline hydrochloride	β_1/β_2 adrenoceptor agonist	Page 571
3066	Medetomidine hydrochloride	Potent and selective α_2 adrenoceptor agonist	Page 645
1750	MIBG	Radiopharmaceutical; Noradrenaline analogue	Page 654
2414	Mirabegron	Selective and orally active agonist of the β_3 -adrenoceptor	Page 657
1296	Modafinil	Alpha-1 adrenoceptor agonist	Page 675
3643	Phenoxybenzamine hydrochloride	Selective α_1/α_2 -adrenoceptor antagonist; Calmodulin inhibitor	Page 774
3510	Phentolamine mesylate	Orally active α_1 - and α_2 adrenoceptor antagonist	Page 774
2040	Prazosin hydrochloride	Peripherally acting Alpha-1 adrenoceptor antagonist	Page 790
3647	Ritodrine hydrochloride	Selective β_2 adrenoceptor agonist	Page 821
3112	Silodosin	Selective α_1A adrenoceptor antagonist	Page 866
3645	Sotalolol hydrochloride	Orally bioavailable, competitive β -adrenoceptor antagonist	Page 880
1290	ST 91	Alpha-2 adrenoceptor agonist	Page 892
1519	Sunepitron hydrochloride	Anxiolytic and antidepressant drug	Page 900
2579	TAK 259	Selective and orally active α_1D adrenoceptor antagonist	Page 906
3512	Terazosin hydrochloride	Selective, orally active α_1 adrenoceptor antagonist	Page 920
2193	Thioridazine hydrochloride	DA and alpha-1 adrenoceptor antagonist; MALT1 inhibitor	Page 926
1518	Timolol maleate	beta-1 adrenergic antagonist	Page 928
3497	Tizanidine hydrochloride	Centrally acting α_2 adrenoceptor agonist	Page 929

Receptors (GPCR-A17) Dopamine

Dopamine receptors are widespread in the body of vertebrates, playing major roles in processes of the central nervous system, as well as in the periphery. In the CNS, dopaminergic neurons are critically involved in voluntary movement, memory, learning, sleep, attention, feeding, and rewarding. Well known examples of disorders as a result of malfunction of the central dopaminergic system are Parkinson's disease (loss of striatal dopaminergic innervations in the brain), schizophrenia, depression, ADHD, and addiction (among many others). In the periphery, dopamine plays important physiological roles in the regulation of olfaction, retinal processes, hormonal regulation, cardiovascular functions, sympathetic regulation, immune system, renal functions, and more¹. Five major classes (D1-D5) have been identified thus far, which can be grouped into two sub classes. The group of D1-like receptors (members D1 and D5; all stimulating the second messenger system adenylate cyclase), and the group of D2-like receptors (members D2, D3 and D4; all inhibiting adenylate cyclase). As widespread and abundant as dopaminergic neurons are in the body of vertebrates, as comprehensive and diverse is the list of Axon Ligands™ interacting at all subtypes of dopaminergic receptors (selectively, or specific combinations).

¹ The Physiology, Signaling, and Pharmacology of Dopamine Receptors. J-M Beaulieu, R.R. Gainetdinov. Pharmacol. Rev. 2011, 63, 182-217

2944	A 381393	Potent, brain-penetrant, selective antagonist of the dopamine D4 receptor	Page 192
------	----------	---	----------

1250	ABT 724 trihydrochloride	D4 agonist	Page 202
1579	ACR16 hydrochloride	Dopaminergic stabilizer that stabilizes psychomotor activity ...	Page 206
1044	Aminotetraline hydrobromide, 5,6-Dihydroxy-2-	Dopamine agonist	Page 228
1045	Aminotetraline hydrobromide, 6,7-Dihydroxy-2-	Dopamine agonist	Page 228
1021	Aminotetraline hydrobromide, 6,7-Dihydroxy-N-methyl-N-propyl-	Dopamine agonist	Page 228
1043	Aminotetraline hydrobromide, 6,7-Dimethoxy-2-	Dopamine agonist	Page 228
1049	Aminotetraline hydrochloride, (R)-(+)-5-Methoxy-2- ...	Dopamine agonist	Page 229
1026	Aminotetraline hydrochloride, (R)-5-Methoxy-N-propyl-2-	Dopamine agonist	Page 229
1050	Aminotetraline hydrochloride, (S)-(-)-5-Methoxy-2-	Dopamine agonist	Page 230
1027	Aminotetraline hydrochloride, (S)-5-Methoxy-N-propyl-2-	Dopamine agonist	Page 231
1019	Aminotetraline hydrochloride, 5,6-Dihydroxy-N-methyl-N-propyl-	Dopamine agonist	Page 231
1048	Aminotetraline hydrochloride, 5-Methoxy-2-	Dopamine agonist	Page 232
1025	Aminotetraline hydrochloride, 5-Methoxy-N-propyl-2- ..	Dopamine agonist	Page 232
1023	Aminotetraline hydrochloride, N-Methyl-N-propyl-2- ...	Dopamine agonist	Page 233
1064	Aminotetraline hydrochloride, Prop-2-ynyl-2-	Dopamine agonist	Page 233
1381	Amisulpride	D2 and D3 antagonist	Page 234
1144	Aripiprazole, thio-	Atypical antipsychotic	Page 246
1153	B-HT 920 dihydrochloride	D2 agonist, alpha-2 adrenoceptor agonist; 5-HT3 antagonist .	Page 301
1337	B-HT 958 dihydrochloride	D2 agonist; Alpha-2 adrenoceptor agonist	Page 301
2335	Brexipiprazole dihydrochloride	Antipsychotic drug candidate	Page 327
1521	CP 226269	D4 agonist	Page 388
1047	Dihydro-2H-1-benzopyran-8-ol hydrochloride, 3-(Dipropylamino)-3,4-	Dopamine agonist	Page 428
1975	Dilept	Neurotensin and dopamine receptor antagonist	Page 429
3666	DOPA, L-	Dopamine precursor	Page 437
1061	Dopamine hydrobromide, N,N-dibutyl	Dopamine agonist	Page 437
1001	Dopamine hydrobromide, N,N-Dipropyl	Dopamine agonist	Page 437
1554	Droperidol	D2 and alpha-1 adrenoceptor antagonist	Page 442
1162	Ethylorapomorphine hydrochloride, R(-)-N-	D2 agonist	Page 469
1347	GR 103691	D3 antagonist	Page 514
3610	Haloperidol	D2, D3 and D4 antagonist	Page 538
1013	Hydroxy-DPAT hydrobromide, (R)-(+)-7-	D3 agonist	Page 549
1007	Hydroxy-DPAT hydrobromide, (R)-5-	D2 antagonist	Page 550
1010	Hydroxy-DPAT hydrobromide, (R)-6-	Dopamine agonist	Page 550
1014	Hydroxy-DPAT hydrobromide, (S)-(-)-7-	D3 agonist	Page 550
1008	Hydroxy-DPAT hydrobromide, (S)-5-	D2 agonist	Page 551
1011	Hydroxy-DPAT hydrobromide, (S)-6-	Dopamine agonist	Page 551
1006	Hydroxy-DPAT hydrobromide, 5-	D2 agonist	Page 551
1009	Hydroxy-DPAT hydrobromide, 6-	Dopamine agonist	Page 552
1012	Hydroxy-DPAT hydrobromide, 7-	D3 agonist	Page 552
1802	JNJ 37822681 dihydrochloride	D2 antagonist	Page 580
1063	Methyl-prop-2-ynyl-(1,2,3,4-tetrahydro-naphthalen-2-yl)-amine hydrochloride, (-)-enantiomer	Dopamine agonist	Page 649

1062	Methyl-prop-2-ynyl-(1,2,3,4-tetrahydro-naphthalen-2-yl)-amine hydrochloride, (+)-enantiomer	Dopamine agonist	Page 649
3263	ML417	Potent, highly selective D3 dopamine receptor agonist	Page 672
1101	Molindone hydrochloride	D2 antagonist; MAO inhibitor	Page 676
4004	MPP+ iodide	Metabolite of MPTP (Axon 1075); Dopamine neurotoxin	Page 678
1075	MPTP hydrochloride	Dopamine neurotoxin	Page 679
1065	N 0426 hydrochloride	Dopamine agonist	Page 687
1038	N 0437 hydrochloride	Dopamine agonist	Page 688
1041	N 0734 hydrochloride	Dopamine agonist	Page 688
1039	N 0924 hydrochloride	Dopamine agonist; less active enantiomer of N-0437 (1038) ..	Page 689
1405	NNC 756	D1 antagonist	Page 708
1160	Norapomorphine hydrobromide, R(-)-	Dopamine agonist	Page 708
1742	NS 30678 hydrochloride	D2 ligand; competitive-like D2 antagonist properties	Page 712
1074	PD 128907 hydrochloride, (-)-	D3 agonist	Page 752
1073	PD 128907 hydrochloride, (+)-	D3 agonist	Page 753
1072	PD 128907 hydrochloride, (±)-	D3 agonist	Page 753
1002	Phenol hydrobromide, 3-[2-(Dipropylamino)ethyl]	Dopamine agonist	Page 774
1071	PHNO hydrochloride, (+)-	D2 agonist	Page 775
1070	PHNO hydrochloride, (±)-	D2 agonist; racemate of PHNO (Axon 1071)	Page 775
1198	Piribedil	Dopamine agonist	Page 779
1035	PPHT hydrochloride	D2 agonist	Page 787
1036	PPHT hydrochloride, (R)-	(R)-enantiomer of PPHT (Axon 1035); D2 agonist	Page 787
1037	PPHT hydrochloride, (S)-	(S)-enantiomer of PPHT (Axon 1035); D2 agonist	Page 788
1161	Propylorapomorphine hydrochloride, R(-)-N-	D2 agonist	Page 793
1514	Ropinirole hydrochloride	D2, D3 and D4 agonist	Page 829
1040	Rotigotine	Dopamine agonist; more active enantiomer of N-0437 (1038)	Page 830
1003	RU 24213	D2 agonist	Page 834
1920	SB 277011A	D3 dopamine receptor antagonist	Page 848
2115	Sonepiprazole hydrochloride	Selective dopamine D4 antagonist	Page 877
1342	ST 148	D2 antagonist	Page 892
1343	ST 198	D3 antagonist	Page 892
2193	Thioridazine hydrochloride	DA and alpha-1 adrenoceptor antagonist; MALT1 inhibitor	Page 926
1004	TL 102 hydrobromide	Dopamine agonist	Page 930
1005	TL 232 hydrobromide	Dopamine agonist	Page 930
1060	TL 99 hydrobromide	Dopamine agonist	Page 930
1069	U 99194 maleate	D3 antagonist	Page 947
2562	UNC 9994 hydrochloride	β-Arrestin-biased dopamine D2R agonist	Page 955

Receptors (GPCR-A17) Non Selective Dopamine/Serotonin

Most Axon Ligands™ in this category of compounds are labeled antipsychotic (typical, or atypical), since many of the common drugs to treat this class of mental disorders show affinity for both dopaminergic and serotonergic receptors (among several others). The first generation of antipsychotics (typical), developed in the 1950's consisted of mainly phenothiazines (chlorpromazine)¹, and butyrophenones (haloperidol)². Though still considered benchmark antipsychotics³, they are known for their unwanted side effects such as dry mouth, extra pyramidal side effects, and tardive dyskinesia⁴. The atypical antipsychotics, or second generation antipsychotics, are less likely to cause the aforementioned side effects, and improve the quality of life compared to the typical antipsychotics. However, this class of drugs is also far from free of side effects⁵. Among them, many Clozapine (Axon 1146) analogues, Aripiprazole (Axon 1143), and Ziprazidone (Axon 1446).

Based on a phylogenetic analysis, the family of serotonin (5-HT) receptors should be separated into two different classes among the subgroup of biogenic amine receptors of the rhodopsin-like family of GPCRs. The GPCR-A17 class includes all 5-HT2 and 5-HT6 receptors, while 5-HT1, 5-HT4 5HT-5 and 5HT7 receptors form an individual class: GPCR-A19⁶.

- ¹ Recherches sur les diméthylaminopropyl-N phénothiazines substituées. Charpentier P, Gailliot P, Jacob R, et al. Comptes rendus de l'Académie des sciences (Paris). 1952, 235, 59-60.
² Haloperidol: fifteen years of clinical experience. Ayd FJ. Diseases of the Nervous System 1972, 33, 459-69.
³ Haloperidol versus chlorpromazine for treatment of schizophrenia. C. Leucht, M. Kitzmantel, L. Chua, J. Kane, and S. Leucht. Schizophr Bull 2008, 34, 813-815.
⁴ Antipsychotics - the future of schizophrenia treatment. G. Beaumont. Curr Med Res Opin. 2000, 16, 37-42.
⁵ Side effects of atypical antipsychotics: a brief overview. A. Üçok and W. Gaebel. World Psychiatry. 2008, 7, 58-62.
⁶ P. Joost, A. Methner. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. Gen. Biol. 2002, 3, 0063.

1143	Aripiprazole.....	Atypical antipsychotic.....	Page 246
1503	Asenapine maleate.....	Atypical antipsychotic.....	Page 254
1508	Bifepunox mesylate.....	D2 agonist; 5-HT1A agonist.....	Page 307
2353	Blonanserin.....	Potent dopamine D2 and serotonin 5-HT2 antagonist.....	Page 313
2335	Brexpiprazole dihydrochloride.....	Antipsychotic drug candidate.....	Page 327
1146	Clozapine.....	Atypical antipsychotic.....	Page 378
2846	Clozapine, N-Desmethyl-.....	Metabolite of Clozapine.....	Page 378
2127	Fluphenazine decanoate dihydrochloride.....	Antipsychotic with high affinity for D- and 5-HT receptors.....	Page 486
1151	GMC 1-116.....	Clozapine analogue.....	Page 506
1148	GMC 1-169.....	Atypical antipsychotic.....	Page 507
1150	GMC 2-83.....	Atypical antipsychotic.....	Page 508
1149	GMC 61-39.....	Atypical antipsychotic.....	Page 509
1493	Iloperidone.....	Atypical antipsychotic.....	Page 561
1147	Isoclozapine.....	Typical antipsychotic.....	Page 571
3378	Metoclopramide.....	Dopamine D2 and serotonin 5-HT3 antagonist.....	Page 650
1298	Olanzapine.....	Atypical antipsychotic.....	Page 731
1354	Quetiapine fumarate.....	Atypical antipsychotic.....	Page 801
1454	Risperidone.....	Atypical antipsychotic.....	Page 820
1236	SKF 83566 hydrobromide.....	D1 antagonist.....	Page 870
1519	Sunepitron hydrochloride.....	Anxiolytic and antidepressant drug.....	Page 900
2424	WAY 100635 maleate.....	5-HT1A antagonist with D4 agonist properties.....	Page 982
1086	WAY 100635 trihydrochloride.....	5-HT1A antagonist.....	Page 982
1087	WAY 100635 trihydrochloride, desmethyl-.....	Building Block for labelled 5-HT1A antagonist.....	Page 983
1446	Ziprasidone hydrochloride.....	Atypical antipsychotic.....	Page 1007

Receptors (GPCR-A17) Serotonin

All members of the large family of serotonin receptors (5-HT1 – 5-HT7) are members of the large family of G-protein coupled receptors, except for the 5-HT3 receptor subtype, which is considered a ligand gated ion channel¹. Serotonin receptors are abundantly present in the CNS, and in the periphery, predominantly in the gastrointestinal tract, and in the blood². They are involved in a wide variety of processes, such as the regulation of mood, sleep, appetite, memory, and learning (CNS), but also in cardiovascular processes and the regulation of intestinal movements (periphery). Probably the best known examples of failure of serotonergic deregulation (low concentrations) in the brain are anxiety³, schizophrenia⁴, and depression, although recent publications put serious question marks near the serotonin hypothesis of depression, since direct proof of serotonin deficiency as the cause of depressions is still lacking⁵. For each member of the family of serotonin receptors, Axon Medchem can offer pharmacological standards with high quality, selectivity, and efficacy.

Based on a phylogenetic analysis, the family of serotonin (5-HT) receptors should be separated into two different classes among the subgroup of biogenic amine receptors of the rhodopsin-like family of GPCRs. The GPCR-A17 class includes all 5-HT2 and 5-HT6 receptors, while 5-HT1, 5-HT4 5HT-5 and 5HT7 receptors form an individual class: GPCR-A19⁶.

The 5-HT6R is among the latest identified members of the 5-HT receptor family and is a particularly interesting receptor subtype because of its relatively low level of sequence homology (<50%) compared to other serotonin receptors. They include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third

cytoplasmatic loop, as compared to most other serotonergic receptors. The 5-HT6R has shown enormous expectation as a drug target for the development of cognitive enhancers, based on localization, pharmacology, and behavioral data accumulated⁷. Since cognition dysfunction is one of the primary manifestations of several neurodegenerative diseases such as Alzheimer's disease (AD), the localization of 5-HT6 receptors in brain areas involved in learning and memory processes has identified this receptor as a putative target for AD⁸.

Being among the most recently discovered receptors for serotonin, the 5-HT7R is also one of the least well characterized. A physiological role for the 5-HT7 receptor within the central nervous has been clearly established in circadian rhythm regulation and in thermoregulation. The early finding that several antipsychotics and antidepressants have high affinity for the 5-HT7R, as well as its demonstrated presence in relevant regions of the brain, has prompted several preclinical studies evaluating the possible involvement of the 5-HT7 receptor in psychiatric disorders and other pathological processes of the nervous system. Interesting findings have also been made in studies focusing on learning and memory. Moreover, a role for the 5-HT7R has also been suggested in neuroendocrine regulation. Possible functions in the periphery are mostly related to the presence of 5-HT7 receptors on smooth muscle cells. Thus, a role for the 5-HT7 receptor has been suggested in irritable bowel syndrome, the control of micturition, and in the reproductive system⁹.

- ¹ Neuronal 5-HT receptors in the periphery. J.R. Fozard. Neuropharmacology 1984, 23, 1473-1486.
² International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharane, P.R. Saxena and P.P. Humphrey. Pharmacol. Rev. 1994, 46, 157-203.
³ The Functional Anatomy, Neurochemistry, and Pharmacology of Anxiety. P.T. Ninan. J Clin Psychiatry 1999, 60, 12-17.
⁴ Depression: the case for a monoamine deficiency. P.L. Delgado. J Clin Psychiatry 2000, 61, Suppl 6, 7-11
⁵ Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature. J.R. Lacasse, J. Leo. PLoS Med 2005, 2, e392.
⁶ P. Joost, A. Methner. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. Gen. Biol. 2002, 3, 0063.
⁷ D. Marazziti et al. Serotonin receptors of type 6 (5-HT6): from neuroscience to clinical pharmacology. Curr. Med. Chem. 2013, 20, 371-377.
⁸ B. Benhamü et al. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. J. Med. Chem. 2014, 57, 7160-7181.
⁹ P.B. Hedlund et al. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl). 2009, 206, 345-354.

2335	Brexpiprazole dihydrochloride.....	Antipsychotic drug candidate.....	Page 327
1068	Chloro-DPAT hydrochloride, 6-.....	Bioactive tetralin derivative.....	Page 366
1439	Eplivanserin.....	5-HT2A antagonist/inverse agonist.....	Page 462
1499	Flibanserin.....	5-HT1A agonist and 5-HT2A antagonist.....	Page 484
2851	GMC 1-161.....	Clozapine analog with 5-HT2A, M1 and D2 affinity, devoid of D1 affinities.....	Page 507
1575	5-HT6 antagonist 29.....	Selective brain penetrant 5-HT6 receptor antagonist.....	Page 547
3925	IHCH-7079.....	5-HT2A receptor arrestin-biased agonist.....	Page 560
1450	Ketanserin.....	5-HT2A antagonist.....	Page 590
2144	Lu AE58054 hydrochloride.....	Selective 5-HT6 antagonist with good oral bioavailability.....	Page 624
1105	MDL 100009.....	5-HT2A antagonist.....	Page 643
1103	MDL 100151.....	5-HT2A antagonist.....	Page 643
1104	MDL 100907.....	5-HT2A antagonist.....	Page 643
1108	MDL 105725, (-).....	5-HT2A antagonist.....	Page 644
1107	MDL 105725, (+).....	5-HT2A antagonist.....	Page 644
1106	MDL 105725, (±).....	5-HT2A antagonist.....	Page 644
1138	Mirtazapine.....	5-HT antidepressant.....	Page 655
1214	MK 212 hydrochloride.....	5-HT2C agonist.....	Page 659
1849	MS 245 oxalate.....	5-HT6 antagonist.....	Page 680
2811	NBOH hydrochloride, 25CN-.....	Selective brain penetrant 5-HT2A receptor agonist.....	Page 694
1102	Nefazodone hydrochloride.....	Antidepressant; 5-HT2A antagonist.....	Page 696
1247	PNU 22394 hydrochloride.....	5-HT2C agonist.....	Page 785
1330	RO 04-6790 hydrochloride.....	5-HT6 antagonist.....	Page 823
1118	RO 60-0175.....	5-HT2C agonist.....	Page 825
4092	SB 242084.....	Selective 5-HT2C receptor antagonist.....	Page 846
1745	SB 242084 dihydrochloride.....	Selective 5-HT2C receptor antagonist.....	Page 846
2183	SB 269970 hydrochloride.....	Potent and selective 5-HT7 antagonist.....	Page 847

1099	SB 271046 hydrochloride	5-HT ₆ antagonist	Page 847
1382	SB 742457	5-HT ₆ antagonist	Page 851
1141	Sertindole	5-HT ₂ , D ₂ and alpha-1 adrenoceptor antagonist	Page 861
1927	SGS 518	Selective 5-HT ₆ antagonist	Page 865
2715	SUVN-502	Selective, orally active, brain-penetrant 5-HT ₆ receptor antagonist	Page 901
2889	VA012	Positive allosteric modulator (PAM) of 5-HT _{2C} receptor	Page 960
1710	WAY 208466 dihydrochloride	Potent and selective 5-HT ₆ receptor agonist	Page 983

Receptors (GPCR-A17) Trace Amine Associated

Identification of the trace amine-associated receptor 1 (TAAR1) provided evidence for a direct biological effect of so-called trace amines (TAs) such as p-tyramine (pTyr), β-phenylethylamine (PEA), octopamine, and tryptamine. These biogenic amines previously denoted as false neurotransmitters, are metabolites of amino acids with structural similarity to classical biogenic amines. Although they are only found at low concentrations in the brain, TAs have been implicated in a wide range of neuropathological disorders, including schizophrenia, major depression, anxiety states, Parkinson's disease, and attention deficit hyperactivity disorder. TAAR1, a member of the TAAR family, is a G protein-coupled receptor that signals through Gs to elevate intracellular cAMP levels in response to TAs. It is expressed throughout the limbic and monoaminergic systems, including the ventral tegmental area (VTA) and dorsal raphe nucleus (DRN) and has been implicated in the negative modulation of monoaminergic neurotransmission¹.

¹ F.G. Revel et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8485-90.

2419	EPPTB	First, potent and selective full antagonist of TAAR1	Page 463
------	-------	--	----------

Receptors (GPCR-A18) Acetylcholine, muscarinic

The class of transmembrane acetylcholine receptors can be divided into two main groups: the muscarinic (metabotropic) and the nicotinic (ionotropic) receptors. This as a result of the specific binding affinities once determined of the two types of receptors for muscarine and nicotine respectively^{1,2}. The latter type is classified as a ligand gated ion channel, since activation of this receptor allows sodium ions to enter a cells interior and potassium and/or calcium ions to exit (section Ion channels (Ligand gated, Cys-loop, cationic)³. Unlike the nicotinic acetylcholine receptor, the muscarinic type is part of the family of G-protein coupled receptors. In general, muscarinic acetylcholine receptors are known to play highly important and diverse roles in many basic physiological processes including gastrointestinal, cardiovascular, motor, attention, learning, memory, pain, sleep, and other functions⁴. Four subtypes have been identified, localized and characterized (M1-M4), whereas a fifth member has been cloned (M5), yet its function has not been revealed completely^{5,6}. In order to facilitate the study of this most recent addition to the family of mACh receptors, Axon Medchem offers VU 0238429 (Axon 1786) as a high affinity drug (EC₅₀ of approximately 1.16 μM at M5) with >30-fold selectivity versus M1 and M3, and no M2 or M4 potentiator activity.

GPR84 is activated by medium-chain FFAs (MCFAs) with 9-14 carbons and classified as A18 GPCR (and not class A11 as other FFARs). It is expressed mainly in the immune-related tissues, such as thymus, spleen, bone marrow, and peripheral blood leukocytes, and is significantly upregulated in monocytes/macrophages upon lipopolysaccharide (LPS) stimulation. In activated T cells, GPR84 has been found to regulate early interleukin 4 (IL-4) gene expression⁷.

¹ The pharmacology of flaxedil with observations on certain analogs. Riker WF, Wescoe WC. Ann NY Acad Sci 1951, 54, 373–394.

² The Chemical Transmission of Nerve Action. O. Loewi. Nobel Lecture, December 12, 1936.

³ Purves, Dale, George J. Augustine, David Fitzpatrick, William C. Hall, Anthony-Samuel LaMantia, James O. McNamara, and Leonard E. White (2008). Neuroscience, 4th ed.. Sinauer Associates, pp. 122–6. ISBN 978-0-87893-697-7.

⁴ Cloning and Expression of the Human and Rat m5 Muscarinic Acetylcholine Receptor Genes. Bonner, T. I.; Young, A. C.; Brann, M. R.; Buckley, N. J. Neuron 1988, 1, 403–410.

⁵ Muscarinic acetylcholine receptor subtypes: localization and structure/function. Brann MR, Ellis J, Jørgensen H, Hill-Eubanks D, Jones SV. Prog Brain Res. 1993, 98, 121-7.

⁶ Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. Bridges TM, Marlo JE, Niswender CM, et al. J. Med. Chem. 2009, 52, 3445–8.

⁷ Wang et al. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem. 2006 Nov 10;281(45):34457-64.

3513	Bethanechol chloride	Muscarinic receptor (mAChR) agonist	Page 298
2796	Clozapine N-oxide	Muscarinic DREADD agonist	Page 378
3965	Deschloroclozapine	Potent, selective, brain penetrable DREADD agonist	Page 419

3669	Dimethindene maleate, (S)-(+)	Potent and selective M2 muscarinic receptor antagonist	Page 431
4086	Emraclidine	Highly selective, brain-penetrant PAM of M4 mAChR	Page 457
1289	GMC 1-109	Clozapine analog devoid of DA, 5-HT ₂ , H1 and α1 affinities, but with high M1 affinity	Page 506
1679	MDL 201012	Muscarinic M3 antagonist	Page 644
3280	JHU37152	Potent and CNS-active DREADD agonist	Page 577
3281	JHU37160	Potent and CNS-active DREADD agonist	Page 577
3505	Oxybutynin hydrochloride	Competitive M1/M2/M3 mAChR antagonist	Page 742
2463	TBPB	Allosteric activator of the M1 acetylcholine receptor	Page 913
2049	Tolterodine L-tartrate	Muscarinic receptor (mAChR) antagonist	Page 935
3648	Tropium chloride	Specific, orally active and competitive muscarinic receptor (mAChR) antagonist	Page 940
1988	VU 0029767	PAM of mAChR M1; potentiates the agonistic effect of Ach	Page 974
1483	VU 0152100	PAM of M4 mAChR	Page 974
1786	VU 0238429	Selective PAM of M5 mAChR (CHRM5)	Page 974
1787	VU 0255035	Selective M1 mAChR Antagonist	Page 975
1703	VU 0357017 hydrochloride	PAM of M1 mAChR	Page 975
1943	VU 0365114	Selective PAM of M5 mAChR (CHRM5)	Page 975
2739	VU 6008667	Selective NAM of M5 mAChR (CHRM5)	Page 976
2832	VU 6008667, rac-(±)	Selective NAM of M5 mAChR (CHRM5)	Page 977
3271	VU0486846	Potent and highly selective PAM of M1 mAChR	Page 977
1273	Zamifenacin fumarate	Muscarinic M3 antagonist	Page 1003
2616	ZQ-16	Potent and selective GPR84 agonist	Page 1007

Receptors (GPCR-A18) Adenosine

Four subtypes of adenosine receptors (ARs) have been identified among vertebrates so far (A1, A2A, A2B and A3). These receptors all have a distinctive pharmacological profile, tissue distribution and effector coupling¹.

All four members are coupled to a G-protein (A1 and A3 subtypes to Gi, and A2 subtypes to Gs). As a result, stimulation of A1 and A3 subtypes in general results in neurotransmission through the inhibition of adenylate cyclase and phospholipase C, whereas stimulation of the A2 subtypes leads to enhanced neurotransmission. More specifically, A1 and A2A receptors play a role in regulating myocardial oxygen consumption and coronary blood flow. Besides, stimulation of the A1 receptor has a myocardial depressant effect by decreasing the conduction of electrical impulses and suppressing pacemaker cell function, resulting in a decrease in heart rate.

Recently, clinical evidence was found for the A3 receptor to be involved in rheumatoid arthritis, among other myocardial functions.² Interestingly, evidence is growing for a certain role of adenosine receptors in the field of oncology.³

¹ International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification

of adenosine receptors—an update. B.B. Fredholm, A.P. Ijzerman, K.A. Jacobson, J. Linden, C.E. Muller. Pharmacol. Rev. 2011, 63, 1-34.

² Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. MH Silverman et al. J. Rheumatol. 2008, 35, 41-48.

³ Adenosine receptors and cancer. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Biochim Biophys Acta. 2011, 1808, 1400-12.

1188	Adenosine amine congener	Adenosine A1 agonist	Page 207
4069	AZD4635	Potent and selective adenosine A2A antagonist	Page 272
2317	BAY 60-6583	Potent and highly selective A2BAR (Adenosine) agonist	Page 290
3736	CGS 15943	Potent and selective adenosine antagonist	Page 363
1319	CGS 21680 hydrochloride	Adenosine A2A agonist	Page 363
1190	Chloroadenosine, 2-	Adenosine A1 and A2A agonist	Page 366
3085	CPI-444	Potent, selective and oral adenosine A2A antagonist	Page 392
3847	DPTN	Highly potent A3 receptor antagonist	Page 441
1287	GR 79236	Adenosine A1 agonist	Page 513

1423	KW 6002	Adenosine A2A antagonist	Page 599
3684	MRS 1220	Potent and selective hA3 receptor antagonist	Page 679
2076	MRS 1523	Adenosine A3 receptor antagonist	Page 679
4132	PBF-509	Selective Adenosine 2A receptor antagonist	Page 749
1603	Rolofylline	Adenosine A1 antagonist	Page 828
1852	Rolofylline metabolite M1-cis	Adenosine A1 antagonist	Page 828
1851	Rolofylline metabolite M1-trans	Adenosine A1 antagonist	Page 828
1253	SCH 58261	Adenosine A2A antagonist	Page 855
1264	SCH 442416	Adenosine A2A antagonist	Page 855
2283	SCH 442416, Desmethyl	Radiloligand precursor of A2A antagonist SCH 442416	Page 855
1265	SDZ-WAG 994	Adenosine A1 agonist	Page 859
1193	UK 432097	Adenosine A2A agonist	Page 950
3519	VCP171	Positive allosteric modulator (PAM) of A1 receptors	Page 963
3626	Vipadenant	Potent, selective and orally active adenosine A2A antagonist	Page 969
4001	ZM241385	Potent and selective adenosine A2A antagonist	Page 1009

Receptors (GPCR-A18) Histamine

Histamine exerts a range of effects on many physiological and pathological processes and new roles are still being elucidated. The best characterized roles of histamine are those in (allergic) inflammation, gastric acid secretion and as a neurotransmitter¹. The four histamine receptors known to date (H1-H4) all belong to the large family of G-protein coupled receptors. Activation of the H1 receptor results in elevated levels of inositol phosphate through coupling to the Gq protein. These receptors are expressed on multiple cell types including endothelial cells and smooth muscle cells, where they mediate vasodilatation and bronchoconstriction. Antagonists of H1 receptors have been used for many years in the treatment of allergic inflammatory responses. H2 receptors activate Gs (actually member of GPCR-A17 family) and increase cyclic AMP formation. They regulate various functions of histamine, including heart contraction, gastric acid secretion, cell proliferation and differentiation, and immune responses².

H3 receptors mediate their function through Gi/o proteins, leading to inhibition of cAMP formation, enhancing calcium mobilization and activating mitogen-activated protein kinases (MAPKs) and ion channels. Their activation stimulates the negative feedback mechanism that reduces central histaminergic activity. Besides, this subtype seems to play roles in cognition, sleep-wake status, obesity and (neuro-) inflammation³.

Activation of the H4 receptor in primary cells appears to be mainly coupled to pertussis-toxin-sensitive Gi/o proteins, which signal through increases in intracellular calcium. Although there is still much work to be done to uncover the function of the H4 receptor, it has been implicated in mast cell, eosinophil and dendritic cell chemotaxis, as well as cytokine production from T cells and dendritic cells. The development of ligands selectively interacting at this receptor, such as JNJ 7777120 (Axon 1306), and JNJ 10191584 (Axon 1307) can play an important role in revealing the biological function of the most recent member of the family of histamine receptors⁴.

¹ The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. R.L. Thurmond, E.W. Gelfand, P.J. Dunford. *Nature Rev. Drug Discov.* 2008, 7, 41-53.

² Definition and antagonism of histamine H2-receptors. Black, J. W., Duncan, W. A. M., Durant, C. J., Ganellin, C. R. & Parsons, E. M. *Nature* 1972, 236, 385-390.

³ The histamine H3 receptor: from gene cloning to H3 receptor drugs. Leurs, R., Bakker, R. A., Timmerman, H., de Esch, I. J. P. *Nature Rev. Drug Discov.* 2005, 4, 107-120.

⁴ Development and chemistry of histamine H4 receptor ligands as potential modulators of inflammatory and allergic responses. Venable, J. D., Thurmond, R. L. *Antinflamm. Allergy Agents Med. Chem.* 2006, 5, 307-322.

1990	A 943931	Selective histamine H4 receptor antagonist	Page 194
1510	ABT 239 tartrate	H3 antagonist/inverse agonist	Page 201
1207	Amthamine dihydrobromide	H2 agonist	Page 235
3649	Azelastine hydrochloride	H1 antagonist	Page 278
4233	Bavisant Recent Addition	Potent, high affinity, orally active and brain-penetrant H3 antagonist	Page 285
3884	Bilastine	Selective H1 antagonist	Page 307
3373	Cetirizine dihydrochloride	Highly selective H1 antagonist	Page 360

1993	Ciproxifan maleate	H3-receptor antagonist (Ki: 0.5-1.9 nM in vitro)	Page 373
1209	Clobenpropit dihydrobromide	H3 antagonist	Page 376
3511	Cyproheptadine hydrochloride	5-HT2A and H1 antagonist	Page 403
3659	Desloratadine	Potent and selective H1 antagonist	Page 420
1324	Dimaprit dihydrochloride	H2 agonist	Page 430
1445	Dimebon	Alzheimer's disease therapeutic and anti-histaminergic drug	Page 430
3812	Dimethindene maleate	Potent and selective histamine H1 antagonist	Page 431
3871	Dimethindene maleate, (R)-(-)	Potent histamine H1 antagonist	Page 431
1453	Fexofenadine hydrochloride	H1 antagonist	Page 479
1325	Imetit dihydrobromide	H3 agonist	Page 563
1326	Immepip dihydrobromide	H3 and H4 agonist	Page 563
1327	Immethridine dihydrobromide	H3 agonist	Page 564
1328	Iodophenpropit dihydrobromide	H3 antagonist	Page 568
1307	JNJ 10191584	H4 antagonist	Page 579
1306	JNJ 7777120	H4 antagonist	Page 579
2486	JZP 361	Selective reversible inhibitor of MAGL; H1 antagonist	Page 586
1299	Loratadine	H1 antagonist	Page 620
1261	Methylhistamine dihydrochloride, 4-	H4 agonist	Page 650
3734	Norastemizole	H1 antagonist	Page 708
3642	Olopatadine hydrochloride	Selective H1 antagonist	Page 732
1458	PF 3654746	H3 antagonist	Page 764
3129	Roxatidine acetate hydrochloride	H2 antagonist	Page 830
4043	Rupatadine fumarate	Potent and orally active dual histamine H1/PAF antagonist	Page 836
2126	VUF 10460	Selective histamine H4 receptor agonist	Page 978

Receptors (GPCR-A19) Serotonin

All members of the large family of serotonin receptors (5-HT1 – 5-HT7) are members of the large family of G-protein coupled receptors and belong to a large family of rhodopsin-like biogenic amine receptors, except for the 5-HT3 receptor subtype, which is considered a ligand gated ion channel¹. Based on a phylogenetic analysis, the family of serotonin (5-HT) receptors should be separated into two different classes among the subgroup of biogenic amine receptors of the rhodopsin-like family of GPCRs. The GPCR-A17 class includes all 5-HT2 and 5-HT6 receptors, while 5-HT1, 5-HT4 5HT-5 and 5HT7 receptors form an individual class: GPCR-A19².

Serotonin receptors are abundantly present in the CNS, and in the periphery, predominantly in the gastrointestinal tract, and in the blood³. They are involved in a wide variety of processes, such as the regulation of mood, sleep, appetite, memory, and learning (CNS), but also in cardiovascular processes and the regulation of intestinal movements (periphery). Probably the best known examples of failure of serotonergic deregulation (low concentrations) in the brain are anxiety⁴, schizophrenia⁵, and depression, although recent publications put serious question marks near the serotonin hypothesis of depression, since direct proof of serotonin deficiency as the cause of depressions is still lacking⁶.

¹ Neuronal 5-HT receptors in the periphery. J.R. Fozard. *Neuropharmacology* 1984, 23, 1473-1486.

² P. Joost, A. Methner. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. *Gen. Biol.* 2002, 3, 0063.

³ International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharane, P.R. Saxena and P.P. Humphrey. *Pharmacol. Rev.* 1994, 46, 157-203.

⁴ The Functional Anatomy, Neurochemistry, and Pharmacology of Anxiety. P.T. Ninan. *J Clin Psychiatry* 1999, 60, 12-17.

⁵ Depression: the case for a monoamine deficiency. P.L. Delgado. *J Clin Psychiatry* 2000, 61, Suppl 6, 7-11

⁶ Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature. J.R. Lacasse, J. Leo. *PLoS Med* 2005, 2, e392.

1058	Aminotetraline hydrochloride, (R)-(+)-8-Methoxy-2-	Building Block; 5-HT1A agonist	Page 229
1059	Aminotetraline hydrochloride, (S)-(-)-8-Methoxy-2-	Building Block; 5-HT1A agonist	Page 230
1057	Aminotetraline hydrochloride, 8-Methoxy-2-	Building Block; 5-HT1A agonist	Page 233
2335	Brexipiprazole dihydrochloride	Antipsychotic drug candidate	Page 327

1995	Bupirone hydrochloride	5-HT1A partial agonist	Page 333
1996	Hydroxybupirone hydrochloride, 6-	5-HT1A partial agonist	Page 549
1206	CGS 12066B	5-HT1B agonist	Page 363
1068	Chloro-DPAT hydrochloride, 6-	Bioactive tetralin derivative	Page 366
1945	CP 94253 hydrochloride	Potent and selective serotonin 5-HT1B receptor agonist	Page 387
2102	CP 135807	Selective 5-HT1D receptor agonist	Page 388
2750	DU125530	5-HT1A antagonist	Page 444
2050	Eletriptan hydrobromide	Selective 5-HT1B/1D receptor agonist	Page 454
1142	Elitoprazine hydrochloride	5-HT1A and 5-HT1B agonist	Page 455
1499	Flibanserin	5-HT1A agonist and 5-HT2A antagonist	Page 484
1080	GMC 2-29	5-HT1B and 5-HT1D antagonist	Page 508
1083	GMC 2-113	5-HT1B antagonist	Page 507
1084	GMC 2-118	5-HT1B antagonist	Page 508
1081	GMC 3-15	5-HT1B and 5-HT1D antagonist	Page 508
1082	GMC 15-27	5-HT1B and 5-HT1D antagonist	Page 508
1079	GR 127935	5-HT1B and 5-HT1D antagonist	Page 514
1813	GR 127935 hydrochloride	5-HT1B and 5-HT1D antagonist	Page 514
1997	Hydroxybupirone hydrochloride, (R)-6-	5-HT1A partial agonist	Page 549
1998	Hydroxybupirone hydrochloride, (S)-6-	5-HT1A partial agonist	Page 549
1016	Hydroxy-DPAT hydrobromide, (R)-(+)-8-	5-HT1A agonist	Page 550
1017	Hydroxy-DPAT hydrobromide, (S)-(-)-8-	5-HT1A agonist	Page 551
1015	Hydroxy-DPAT hydrobromide, 8-	5-HT1A agonist	Page 552
1612	LY 334370 hydrochloride	5-HT1F Antagonist	Page 629
1139	LY 393558	SSRI; 5-HT1B and 5-HT1D antagonist	Page 631
1094	LY 426965 dihydrochloride	5-HT1A antagonist	Page 631
1093	LY 426965 dihydrochloride, (±)	5-HT1A antagonist	Page 631
1095	LY 426965 dihydrochloride, (R)-(-)	5-HT1A antagonist	Page 631
1138	Mirtazapine	5-HT antidepressant	Page 655
1090	MPPF, p-	5-HT1A antagonist	Page 678
1091	MPPI, p-	5-HT1A antagonist	Page 678
1092	NPPCC, (-)	5-HT1A agonist	Page 710
1098	Pibeserod hydrochloride	5-HT4 antagonist	Page 776
1479	Prucalopride	5-HT4 agonist	Page 794
1088	S 14506	5-HT1A agonist	Page 839
1089	S 14506, desmethyl-	Building Block for labelled 5-HT1A agonist	Page 839
3990	SB-204741	Selective 5-HT2B antagonist	Page 846
1085	SB 216641 hydrochloride	5-HT1B antagonist	Page 845
1100	SB 258741 hydrochloride	5-HT7 antagonist	Page 847
1469	SB 699551A	5-HT5A antagonist	Page 850
1352	Sumatriptan succinate	5-HT1B and 5-HT1D agonist	Page 900
3130	Tandospirone citrate	5-HT1A partial agonist	Page 910
2060	TD 5108	Selective 5-HT4 receptor agonist	Page 914
1285	U 92016A	5-HT1A agonist	Page 946
3634	UCSF648 dihydrochloride	Negative control of UCSF678 as a 5-HT5A receptor partial agonist	Page 948
3636	UCSF678 dihydrochloride	Selective 5-HT5A receptor partial agonist	Page 949

3635	UCSF686 dihydrochloride	5-HT1A/5-HT2B/5-HT7 receptor ligand	Page 949
3595	Usmarapride	Potent, selective and orally bioavailable 5-HT4 receptor partial agonist	Page 957
1360	WAY 100135 dihydrochloride	5-HT1A antagonist	Page 982
1359	WAY 100135 dihydrochloride, (-)	5-HT1A antagonist	Page 982
1341	WAY 100135 dihydrochloride, (+)	5-HT1A antagonist	Page 982

Receptors (GPCR-B1) Calcitonin, CRF, Glucagon-like

The Secretin family is a small family of 15 GPCRs that all have an extracellular hormone-binding domain and bind peptide hormones. The members of this family are the calcitonin and calcitonin-like receptors (CALCR, CALCRL); the corticotropin-releasing hormone receptors (CRHR1, CRHR2); the glucagon receptor (GCGR); the gastric inhibitory polypeptide receptor (GIPR); the glucagon-like peptide receptors (GLP1R, GLP2R); the growth-hormone-releasing hormone receptor (GHRHR); the adenylate cyclase activating polypeptide receptor (PAC1/ADCYAP1R1); the parathyroid hormone receptors (PTH1R, PTHR2); the secretin receptor (SCTR); and the vasoactive intestinal peptide receptors (VIPR1, VIPR2). The Secretin receptors have a large potential as targets for further drug development owing to their importance in central homeostatic functions. GLP1R and GLP2R are particularly interesting because of their role in appetite regulation and in the treatment of type 2 diabetes¹. The corticotropin releasing hormone receptor (CRF1, or CRHR1) is likely to be involved in mental disorders, and both infection and autoimmune disorders².

The calcitonin gene-related peptide (CGRP) is an alternative product of the calcitonin gene and was first described in 1982. It is a potent vasodilator with multiple reported pharmacological activities (e.g. treatment of migraine)³.

¹ Structural diversity of G protein-coupled receptors and significance for drug discovery. M.C. Lagerström, H.B. Schiöth. Nature Reviews Drug Discovery 2008, 7, 339-357.

² CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists. K.C. Rice et al. Bioorg. Med. Chem. 2002, 10, 175-183.

³ CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine? S.D. Brain, D.R. Poyner, R.G. Hill. Trends Pharmacol Sci, 2002, 23, 51-53

2388	Adomeglivant	Potent, selective, orally administered, and competitive human glucagon receptor (GR) antagonist	Page 209
1321	Antalamin hydrochloride	CRF1 antagonist	Page 237
4104	BAY 2686013 hydrochloride	Potent and selective allosteric hPAC1 receptor antagonist	Page 289
2259	BETP	Positive allosteric modulator (PAM) at the GLP-1 receptor	Page 298
1116	CP 154526 hydrochloride	CRF1 antagonist	Page 388
1907	GLP-1R agonist DMB	GLP-1 Receptor (GLP1R) agonist	Page 504
1132	GLP-1R antagonist	GLP-1 Receptor (GLP1R) antagonist	Page 504
1145	SB 268262	CGRP1 antagonist	Page 847
1799	SSR 125543A	Selective, and orally active CRF1 antagonist	Page 891

Receptors (GPCR-C) CaSR, GABA-B

The calcium-sensing receptor (CaSR), a receptor which senses extracellular levels of calcium ion, is also classified as a member of the family of class C GPCRs. The release of parathyroid hormone (PTH) is inhibited in response to elevations in plasma calcium concentrations and activation of the calcium receptor by activating the phospholipase C pathway, presumably through a Gqα type of G protein¹.

A second member of the class C family of GPCRs comprises the GABA-B receptors (GABAB1-3); metabotropic transmembrane receptors for gamma-aminobutyric acid (GABA) that are linked via G-proteins to potassium channels. They can stimulate the opening of K⁺ channels which brings the neuron closer to the equilibrium potential of K⁺, hyperpolarizing the neuron. This prevents sodium channels from opening, action potentials from firing, and VDCCs from opening, and so stops neurotransmitter release. Thus GABAB receptors are considered inhibitory receptors².

¹ Calcium-sensing receptor and calcimimetic agents. J.W. Coburn, L. Elangovan, W.G. Goodman, J.M. Frazzao. Kidney Int. Suppl. 1999, 73, S52-58.

² The 'ABC' of GABA receptors: a brief review. M. Chebib, G.A.R. Johnston. Clin. Exp. Pharmacol. Physiol. 1999, 26, 937-940

1818	Calhex 231 hydrochloride	NAM of the extracellular CaSR	Page 340
1732	CaSR antagonist 18c	Calcium-sensing receptor (CaSR) antagonist	Page 345

2942	DJ-V-159	Selective GPRC6A agonist.....	Page 433
1820	GS 39783	PAM of GABA-B Receptor.....	Page 515

Receptors (GPCR-C) Glutamate

The first metabotropic glutamate receptor was cloned in 1991 (mGluR1). Since then, eight different genes encoding for mGlu receptors have been identified¹. They can be divided into 3 groups, based on their coupling to the second messenger system of G-proteins: group I is coupled to Gq proteins (mGlu1 and mGlu5), group II (mGlu2 and mGlu3) and group III (mGlu4, mGlu6 and mGlu7) are both coupled to Gi proteins (the latter in recombinant systems), yet are activated primarily by different ligands (2R,4R-aminopiperidindicarboxylic acid and 2-amino-4-phosphonobutyrate respectively). Besides the metabotropic glutamate receptors, ionotropic glutamate receptors do exist as well. The receptors are named after a potent agonist for each receptor subtype (NMDA or N-methyl-D-aspartate, AMPA or alpha-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid, and kainate). Both metabotropic and ionotropic glutamate receptors show the ability to modulate the synaptic plasticity/strength in response to activity which seems a fundamental property of the nervous system and may be an essential component of learning and memory². As a result, the malfunctioning of glutamate receptors (often due to excitotoxicity or overstimulation) is often linked to neurodegenerative diseases such as Alzheimer's, Huntington's and multiple sclerosis. Besides classical agonists and antagonists of glutamate receptors (binding to a specific binding site), many positive allosteric modulators (PAM) and negative allosteric modulators (NAM, e.g.: recently added Axon 1972) have been identified to interact at this type of receptors. These compounds are inactive on their own, but potentiate or attenuate respectively the action of orthosteric (inverse) agonists³. Recent advances in the research for treatment of Parkinson's disease have implied that stimulation of the metabotropic glutamate receptor 4 (mGluR4) represents a promising new approach to the symptomatic treatment of this neurodegenerative disorder. Our recently added PAMs of the mGluR4 (Axon 1830, Axon 1842, and Axon 1845) may contribute to this research.

¹ Metabotropic Glutamate 1 Receptor: Current Concepts and Perspectives. F. Ferraguti, L. Crepaldi, F. Nicoletti. Pharmacol. Rev. 2008, 60, 536-581.

² Brain plasticity and ion channels. Debanne D, Daoudal G, Sourdlet V, Russier M. J Physiol. 2003, 97, 403-14.

³ Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, and Kemp JA. Proc Natl Acad Sci U S A 2001, 98, 13402-13407.

2155	A 841720	Non-competitive mGluR1 antagonist.....	Page 193
2732	ADX71743	Negative allosteric modulator (NAM) of mGluR7.....	Page 210
1747	AZ 12216052	PAM of mGluR8.....	Page 265
1644	Biphenyl-indanone A	PAM of mGluR2.....	Page 309
2691	CHPG	mGluR5 agonist.....	Page 368
3333	Cinnabarinic acid	mGluR4 agonist.....	Page 372
1431	CPPHA	PAM of mGluR5.....	Page 394
1972	CTEP	Negative allosteric modulator of mGluR5.....	Page 397
1739	DHPG, (RS)-3,5-	mGluR1 and mGluR5 agonist (rac. Axon 1740).....	Page 424
1740	DHPG, (S)-3,5-	mGluR1 and mGluR5 agonist.....	Page 425
1345	Fenobam	mGluR5 antagonist.....	Page 478
1224	LY 367385, (+)-	mGluR1a antagonist.....	Page 630
1222	MPEP hydrochloride	mGluR5 antagonist.....	Page 678
3422	RO-0711401	Potent and orally available PAM of mGluR1.....	Page 823
1894	VU 0357121	Potent allosteric modulator (PAM) of mGluR5.....	Page 975
3421	VU0360172 hydrochloride	Selective and orally active PAM of mGluR5.....	Page 973
1795	VU 0360223	Potent antagonist of mGlu5.....	Page 975
1842	VU 0361737	PAM of mGluR4.....	Page 976
1830	VU 0364439	PAM of mGluR4.....	Page 976
1845	VU 0364770	PAM of mGluR4.....	Page 976
1425	VU 29	PAM of mGluR5.....	Page 973
3487	VU6005649	Brain penetrant PAM of mGluR7/8.....	Page 977
1260	YM 298198 hydrochloride	mGluR1 antagonist.....	Page 999
1259	YM 298198 hydrochloride, desmethyl	mGluR1 antagonist.....	Page 1000

Receptors (GPCR-F) Smoothened

Smoothened (SMO) is a G-protein coupled receptor protein encoded by the SMO gene of the Hedgehog (Hh) pathway. Most often SMO functions during embryonic development, in processes such as digit patterning in the chick limb bud and left-right asymmetry of vertebrate embryos. In addition, Smo function is also fundamental for the maintenance of tissue homeostasis in adults, and deregulated Smo signaling is implicated in tumorigenesis¹. Hh ligands signal through binding to the membrane receptor Patched (Ptc) to reverse the Ptc-mediated inhibition of signaling by the trans-membrane protein Smoothened (Smo). This allows Smo to activate the intracellular signaling components, resulting in stabilization of downstream transcriptional activator(s) and activation of target genes².

¹ The cell biology of Smo signaling and its relationships with GPCRs. A. Ruiz-Gómez, et al. Biochim. Biophys. Acta 2007, 1768, 901-912.

² Regulation of Hedgehog signaling: a complex story. S.K. Ogden et al. Biochem. Pharm. 2004, 67(5), 805-814.

2356	BMS 833923	Oral antagonist of Smoothened (SMO).....	Page 320
1500	GDC 0449	Hedgehog (Hh) pathway inhibitor.....	Page 498
2196	LY 2940680	Antagonist of the Smoothened (SMO) receptor.....	Page 634
1938	MRT 10	Smoothened (SMO) receptor antagonist.....	Page 680
1619	NVP-LDE225	Smoothened (SMO) receptor antagonist.....	Page 725
2027	PF 5274857 hydrochloride	Smoothened (SMO) antagonist.....	Page 766
1690	Purmorphamine	Hedgehog signaling pathway activator.....	Page 797

Receptors: Nuclear

The nuclear receptor superfamily describes a related but diverse array of transcription factors (nuclear hormones). Upon activation by glucocorticoids, mineralocorticoids, sex steroids (estrogen, progesterone, and androgen), thyroid hormones, or vitamin D3, the nuclear receptors can bind a highly specific DNA sequence¹. As a result, they regulate the expression of adjacent genes, thereby controlling the development, homeostasis, and metabolism of the organism. In the human genome, 48 different nuclear receptors are encoded, which can be classified into 6 evolutionary groups, based on their sequence alignment and phylogenetic tree². All NR proteins exhibit a characteristic modular structure that consists of five to six domains of homology on the basis of regions (A-F) of conserved sequence and function. The DNA-binding domain (DBD, region C), absent in DAX-1 and SHP, and the ligand-binding domain (LBD; region E) are the most highly conserved domains. These two regions are the most important and can function independently.

¹ Nuclear Receptor Minireview Series. J.M. Olefsky. J. Biol. Chem. 2001, 276, 36863-36864.

² Overview of Nomenclature of Nuclear Receptors. P. Germain et al. Pharmacol Rev 2006, 58, 685-704.

3683	L6H21	Specific MD-2 inhibitor.....	Page 602
3728	LHC-165	Agonist (activator) of Toll-like Receptor 7.....	Page 614
3585	Vesatolimod	Potent, selective and orally available TLR7 agonist.....	Page 967

Receptors (Nuclear, Class 1) Thyroid Hormone Receptor-like

Retinoic Acid receptors (class 1B, RARs, α , β , γ) are nuclear receptors related to the steroid and thyroid hormone Receptors, a family of proteins that function as ligand-dependent transcription factors. The RARs show spatially restricted distribution patterns during embryogenesis, which have led to speculation on a variety of roles for retinoic acid (RA) in developmental processes. These receptors are retained in the nucleus regardless of the ligand binding status and in addition bind as hetero-dimers (usually with RXR) to DNA. RAR/RXR heterodimers regulate the transcriptional activation of primary RA target genes through binding to DNA-response elements termed RA response elements (RAREs)¹.

A second member of this family of nuclear receptors consists of peroxisome proliferator-activated receptors (class 1C, PPAR, α - δ). They play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. The clinical importance of PPARs originates with fibrates and thiazolidinediones (TZDs), which respectively act on PPAR- α and PPAR- γ . They are used to ameliorate hyperlipidemia and hyperglycemia in subjects with type 2 diabetes mellitus. More recently, proof was found that PPARs also contribute to the regulation of certain physiological activities of the prostacyclin (PGI2) system in cardiovascular tissues².

The Liver X receptor-like (LXR) family of NRs hosts 3 members, including the Farnesoid X receptor (FXR). High expression of LXRA is restricted to spleen, liver, adipose tissue, intestine, kidney and lung whereas LXRB is expressed in all tissues examined. Upon ligand-induced activation both isoforms form obligate heterodimers with the retinoid X receptor (RXR) and regulate gene expression through binding to LXR response elements (LXREs) in the promoter regions of the target genes. Identification of oxysterols as endogenous LXR ligands pointed to a role for these receptors in regulating expression of genes involved in cholesterol homeostasis, and lead to the hypothesis that activation of these receptors might have an antiatherosclerotic effect³. The FXR, besides a key regulator of cholesterol homeostasis like the LXR α s, is also involved in

triglyceride synthesis and lipogenesis⁴. Since the recognition that FXR has a significant role in the regulation of bile acids, numerous efforts have been undertaken to search for and design potent and selective FXR agonists. Vitamin D is involved in mineral and bone homeostasis, immune responses, anti-inflammation, anti-infection, and cancer prevention. Vitamin D deficiency is a critical factor in the pathology of at least 17 varieties of cancer, as well as autoimmune diseases, diabetes, osteoarthritis, periodontal disease, and more. Vitamin D receptor (VDR) is a nuclear receptor that mediates most biological functions of 1,25(OH)₂D₃ or vitamin D₃, the active form of vitamin D. VDR is highly expressed in metabolic tissues, such as intestine, kidney, skin, and thyroid gland, and moderately expressed in nearly all tissues. Activation of VDR signaling affects many processes, including calcium metabolism, apoptosis, immunity, and autophagy. Upon activation, the VDR binds to vitamin D response elements (VDREs) located in promoter regions of target genes, thereby controlling the transcription of at least 913 genes in human SCC25 cells⁵.

Thyroid hormone (TH aka triiodothyronine or T₃) exerts a pleiotropic effect on development, differentiation, and metabolism through thyroid hormone receptors (TR or THR)⁶. In part because of associated hypercholesterolemia, hypothyroidism is associated with increased rates of atherosclerosis, while excessive levels of TH can lead to adverse effects, particularly in heart and bone. The beneficial metabolic effects of TH are mediated by the thyroid hormone receptor β isoform (THR- β , the predominant liver TH receptor), while the adverse heart and bone effects are primarily due to the interaction of TH with the THR- α ⁷.

¹ Retinoids, Retinoic Acid Receptors, and Cancer. X.H. Tang, L.J. Gudas. Annu. Rev. Pathol. Mech. Dis. 2011, 6, 345-364

² Peroxisome Proliferator-Activated Receptors (PPARs): A Target with a Broad Therapeutic Potential for Human Diseases: An Overview. M.P. Singh, D. Pathak, G.K. Sharma, C.S. Sharma. Pharmacologyonline 2011, 2, 58-89.

³ Biological role for Liver X Receptors. M. Baranowski. J. Physiol. Pharm. 2008, 59, 31-55.

⁴ Farnesoid X receptor modulators: a patent review. M.L. Crawley. Exp. Opin. Ther. Pat. 2010, 20, 1047-1057.

⁵ S. Wu et al. Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection. Discov. Med. 2011, 11, 325-335.

⁶ K Moriama et al. Molecular characterization of human thyroid hormone receptor β isoform 4. Endocr Res. 2016;41(1):34-42.

⁷ M.J. Kelly et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydroxyridazin-3-ylloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196). J Med Chem. 2014 May 22;57(10):3912-23.

2948	AM 580RAR- α agonist.....	Page 222
3904	BAY-0069Potent covalent PPAR γ inverse agonist.....	Page 285
3809	BAY-4931Potent covalent PPAR γ inverse agonist.....	Page 289
1194	BMS 189961RAR gamma agonist.....	Page 315
1173	BMS 270394RAR gamma agonist.....	Page 316
1676	BXL 628Vitamin D receptor (VDR) agonist.....	Page 336
2964	CD12681Potent ROR γ inverse agonist.....	Page 352
1950	CDDOPotent anti-tumor agent. PPAR-gamma agonist.....	Page 354
1241	CH 55RAR agonist.....	Page 364
2114	CP 775146Potent and selective PPAR α agonist.....	Page 390
3021	DL5050Potent and highly selective hCAR agonist.....	Page 434
1746	DoxercalciferolVitamin D2 analog, VDR agonist.....	Page 438
2561	DY 268Highly potent FXR antagonist with a promising in vitro profile.....	Page 446
2727	ElafibranorDual PPAR α/δ agonist.....	Page 454
2686	FH535Dual inhibitor of PPAR and Wnt/ β -catenin signaling.....	Page 480
2706	FH535 sodium saltDual inhibitor of PPAR and Wnt/ β -catenin signaling.....	Page 480
2152	FXR agonist Cpd 22Potent farnesoid X receptor (FXR) agonist.....	Page 494
2363	GSK 2033The first potent cell-active LXR antagonist.....	Page 518
1628	GSK 3787PPAR-delta antagonist.....	Page 518
1266	GW 3965 hydrochlorideLiver X receptor agonist.....	Page 532
1237	GW 7647PPAR-alpha agonist.....	Page 532
2262	GW 9662Selective PPAR γ antagonist.....	Page 533
2533	HydroxyioglitazoneActive metabolite of Pioglitazone (M-IV), a PPAR γ agonist.....	Page 552
2019	INT 131Selective PPAR- γ modulator (partial agonist).....	Page 567
1567	KRP 297PPAR-alpha agonist; PPAR-gamma agonist.....	Page 596
1242	LE 135RAR antagonist.....	Page 608
2357	LXR 623Partial agonist of Liver X Receptor.....	Page 626

2637	LY 2955303 hydrochlorideRAR γ antagonist for treatment of osteoarthritis pain.....	Page 634
3740	LYC-55716Potent ROR γ agonist.....	Page 635
2657	MGL-3196Oral, liver-targeted, thyroid hormone receptor β -agonist.....	Page 653
2814	MHY 553PPAR α agonist.....	Page 653
2402	MHY 908PPAR α/γ agonist, inhibitor of mushroom tyrosinase.....	Page 651
3174	Obeticholic acidPotent and selective FXR agonist.....	Page 729
3255	Pioglitazone hydrochloridePPAR γ agonist; antidiabetic drug.....	Page 779
2902	QX77Chaperone-mediated autophagy (CMA) activator.....	Page 802
3321	Retinoic acidRAR ligand.....	Page 814
3739	RGX-104Liver X receptor (LXR) agonist.....	Page 817
2443	RosiglitazonePPAR γ agonist; antidiabetic drug and stem cell differentiator.....	Page 830
3999	Saroglitazar magnesiumPotent dual PPAR α/γ agonist.....	Page 844
4126	SobetiromeHigh-affinity and selective thyroid hormone receptor β -agonist.....	Page 877
2807	SPA70Potent and selective human pregnane X receptor (hPXR) antagonist.....	Page 882
4236	SR1078Recent Addition.....First ROR α/γ agonist.....	Page 885
2598	SR 9243LXR inverse agonist inhibiting the Warburg effect.....	Page 886
2754	T0901317Liver X receptor (LXR) agonist.....	Page 903
2516	TacalcitolVitamin D receptor (VDR) agonist with antitumor activity.....	Page 904
3411	TCPOBOPCAR agonist.....	Page 915
1749	WAY 362450Farnesoid X receptor (FXR) agonist.....	Page 984
1227	WY 14643PPAR-alpha agonist.....	Page 989
1991	WYE 672Liver X receptor (LXR) agonist.....	Page 989

Receptors (Nuclear, Class 2) Retinoid X Receptor-like

Vitamin A and its derivatives, retinoids, have profound effects in development, differentiation, homeostasis and various aspects of metabolism. The discovery of retinoid receptors substantially contributed to understanding how these small, lipophilic molecules, most importantly retinoic acid (RA), exert their pleiotropic effects. After the identification of the all-trans retinoic acid receptor (ATRA), another receptor termed retinoid X receptor (RXR) was discovered, that was capable of mediating retinoid signaling pathways. Most importantly, RXR was shown to form heterodimers with many other nuclear receptors, making it unique among the members of the nuclear receptor family. The two families of retinoid receptors (RARs and RXRs) now consist of three isotypes, α , β , and γ , encoded by separate genes and giving rise to numerous alternatively spliced variants¹. Bexarotene (Axon 1700) is an oral antineoplastic RXR antagonist developed for the treatment of cutaneous T cell lymphoma originally. Recently, it has been reported that bexarotene is also capable of reducing amyloid plaque and improving mental functioning in a small sample of mice engineered to exhibit Alzheimer's-like symptoms. It is hypothesized that this is mediated by Bexarotene-stimulated expression of apolipoprotein E (ApoE), which leads to intracellular clearance of β -amyloid².

HNF4 is a member of the nuclear hormone receptor family of transcription factors. It binds DNA as a homodimer and, although initially believed to be an orphan receptor, its activity may be modulated by the binding of fatty acyl-CoA thioesters. The existence of a ligand for HNF4 has been somewhat controversial, but linoleic acid (LA) has been identified as the endogenous ligand of native HNF4 expressed in mouse liver. In addition, HNF4 is acetylated, phosphorylated, and can bind SMADS 3 and 4, suggesting that its activity may be controlled by multiple pathways. HNF4 generally acts as a positive transcriptional regulator of many hepatocyte genes and can rescue the expression of liver genes in dedifferentiated hepatoma cell lines³.

¹ Retinoid X receptors: X-ploring their (patho)physiological functions. A. Szanto, V. Narkar, Q. Shen, I.P. Uray, P.J. Davies, L. Nagy. Cell Death Differ. 2004, Suppl. 2, 126-143.

² ApoE-Directed Therapeutics Rapidly Clear β -Amyloid and Reverse Deficits in AD Mouse Models. P.E. Cramer, et al. Science 2012, 335, 1503-1506.

³ A.J. Watt et al. HNF4: a central regulator of hepatocyte differentiation and function. Hepatology. 2003, 37, 1249-1253.

1700	BexaroteneRetinoid X Receptor antagonist.....	Page 299
1940	BI 6015Potent hepatocyte nuclear factor 4a (HNF4a) antagonist.....	Page 303
3003	HX600RXR-Nurr1 heterodimer complex agonist.....	Page 548

2408	NRX 194204	<i>Potent and specific RXR agonist devoid of any RAR activity ..</i>	Page 711
3727	SR11237	<i>Selective retinoid X Receptor agonist.....</i>	Page 885

Receptors (Nuclear, Class 3) Estrogen Receptor-like

The third class of nuclear receptors includes estrogen and estrogen-related receptors, as well as the 3-ketosteroid receptors (progesterone (PR), androgen (AR), gluco- and mineralocorticoid (GR and MR, respectively) receptors).

Estrogen is a key regulator of growth, differentiation and function in a broad range of target tissues, including the male and female reproductive tracts, mammary gland, bone, brain and the cardiovascular system. The biological effects of estrogen are mediated through estrogen receptors α and β (ER α , β). The classical mechanism of activation of ERs depends on ligand binding to the receptors, after which the receptors dimerize and bind to estrogen response elements (EREs) located in the promoters of estrogen-responsive genes. ERs may also regulate gene expression in the absence of DNA-binding by modulating the activities of other transcription factors via protein-protein interactions on DNA. This mechanism is referred to as cross-talk and is common for several nuclear receptors¹. As the name implies, the family of estrogen receptor-related receptors (ERRs) is a subfamily of the orphan nuclear receptors, which is closely related to the estrogen receptor (ER) family, and comprises three subtypes (ERR α - γ). Sequence analyses comparing all the class 3 NRs have shown that both ERs and ERRs together form the same branch of class 3, which recognizes a specific hormone response element (HRE), whereas the other four steroid receptors (PR, AR, GR, and MR) recognize a different, yet specific HRE, thereby forming another branch².

The progesterone receptor (PR) is a progestin-activated steroid receptor with two subtypes known to date (A and B). It plays a central role in diverse reproductive events associated with establishment and maintenance of pregnancy, alveolar development in the breast and sexual behavior. PR dysfunction has been associated with cancer (ovarian cancer, breast cancer, endometrial cancer, prostate cancer), metabolic disorders (progesterone resistance, obesity, osteoporosis), cardiovascular defects (aortic aneurysm), neurological defects (migraine, vertigo) and reproductive conditions (endometriosis, infertility)³. Noteworthy, Org OD-2 (Axon 2085) is a selective agonist of the membrane bound progesterone receptor (mPR). Although mPRs typically consist of 7-TM domains, mPRs do not belong to the large family of GPCRs, nor do they belong to the family of nuclear PRs, even though they are sharing the same endogenous ligand.⁴

Androgens ((dihydro-) and testosterone) are the male sex hormones that belong to the steroid hormone family. They are mainly produced in testes, ovaries and adrenals. In early life, testicular androgens induce differentiation processes that lead to the development of the male phenotype. During adulthood, androgens remain essential for the maintenance of the male reproductive function, as well as a number of gender-dependent parameters like bone and muscle mass, hair growth and behavior. The androgen receptor (AR), holds a specific position within the group of steroid receptors, since several selective androgen response elements (selAREs) have been described that are not recognized by the other 3-ketosteroid receptors⁵. Corticosteroid receptors include mineralocorticoid (MR) and glucocorticoid (GR) receptors. They play a crucial role in the regulation of a variety of physiological processes, including reproduction, metabolism, salt balance, inflammation, and immunity. Cortisol is the principal glucocorticoid that induces the transcriptional activities of both the GR and MR, whereas the mineralocorticoid aldosterone also activates only MR, but not GR⁶.

The MR belongs to the cytosolic receptor family where the ligand diffuses into cells, interacts with the receptor and results in a signal transduction affecting specific gene expression in the nucleus. The GR, however, upon activation may up-regulate the expression of anti-inflammatory proteins in the nucleus or repress the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol into the nucleus. In the absence of hormone, the MR and GR reside in the cytosol complexed with a variety of proteins including heat shock protein 70 and 90 (hsp70, hsp90), high-mobility group box proteins (HMGBs), and FKBP52 (FK506-binding protein 52)⁷.

¹ Estrogen receptor-dependent activation of AP-1 via non-genomic signaling. L. Björnström, M. Sjöberg. Nuclear Receptor 2004, 2, 3.
² The Orphan Nuclear Receptors, Estrogen Receptor-related Receptors: their Role as New Biomarkers in Gynecological Cancer. P. Sun, L. Wei, C. Denkert, W. Lichtenegger, J. Sehoulis. Anticancer Res. 2006, 26 (2C), 1699-1706.
³ Progesterone receptors: various forms and functions in reproductive tissues. S. Gadkar-Sable, C. Shah, G. Rosario, G. Sachdeva, C. Puri. Front. Biosci. 2005, 10, 2118-2130.
⁴ P. Thomas et al. Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells. Neuroendocrinology. 2012, 96, 162-171.
⁵ Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. F. Claessens et al. Nucl Recept Signal. 2008, 6, e008.
⁶ Dissecting mineralocorticoid receptor structure and function. F.M. Rogerson, F.E. Brennan, P.J. Fuller. J Steroid Biochem. Mol. Biol. 2003, 85, 389-396.
⁷ Mechanisms of Mineralocorticoid Action. P.J. Fuller, M.J. Young. Hypertension 2005, 46, 1227-1235.

3742	Aparanone	<i>Potent and highly selective nonsteroidal mineralocorticoid receptor (MR) antagonist.....</i>	Page 238
1979	ARN 509	<i>Antagonist of androgen receptor (AR).....</i>	Page 248
1675	Asoprisnil	<i>Progesterone receptor (PR) modulator.....</i>	Page 255
1748	Bazedoxifene Hydrochloride	<i>Selective estrogen receptor modulator (SERM).....</i>	Page 293
3882	Beclomethasone dipropionate	<i>Glucocorticoid.....</i>	Page 296
2790	BHPI	<i>ER-α antagonist.....</i>	Page 301

3313	Bicalutamide	<i>Androgen receptor (AR) antagonist.....</i>	Page 306
4232	BMS-986365 Recent Addition	<i>Highly potent and selective androgen receptor (AR) degrader.....</i>	Page 322
1426	Ciclesonide	<i>Glucocorticoid.....</i>	Page 369
3650	Clomiphene citrate	<i>Selective estrogen receptor modulator (SERM).....</i>	Page 377
3883	Cyproterone acetate	<i>Androgen receptor (AR) antagonist.....</i>	Page 403
4022	Deflazacort	<i>Glucocorticoid prodrug.....</i>	Page 417
3322	Dehydroepiandrosterone	<i>Endogenous steroid hormone precursor.....</i>	Page 418
3502	Desonide	<i>Corticosteroid.....</i>	Page 421
3258	Dexamethasone	<i>Glucocorticoid agonist.....</i>	Page 422
3345	Dexamethasone palmitate	<i>Prodrug of Dexamethasone; Glucocorticoid agonist.....</i>	Page 422
3461	Dienogestrel	<i>Progesterone receptor (PR) agonist.....</i>	Page 426
1427	Diflorasone Diacetate	<i>Corticosteroid.....</i>	Page 426
1428	Difluprednate	<i>Corticosteroid.....</i>	Page 427
1232	DPN	<i>Estrogen receptor (ER- beta) agonist.....</i>	Page 440
3118	DS45500853	<i>ERRα agonist.....</i>	Page 443
4095	Elacestrant dihydrochloride	<i>Orally bioavailable selective estrogen receptor degrader (SERD).....</i>	Page 453
2190	Endoxifen	<i>Selective estrogen receptor modulator (SERM).....</i>	Page 459
2221	Endoxifen, (Z)-	<i>More active (Z)-isomer of (E/Z)-Endoxifen (SERM).....</i>	Page 459
2707	Endoxifen hydrochloride	<i>Selective estrogen receptor modulator (SERM).....</i>	Page 459
1898	ERB 041	<i>Estrogen receptor (ER-beta) agonist.....</i>	Page 465
3594	ErSO	<i>Orally bioavailable a-UPR activator.....</i>	Page 466
3704	ErSO, (S)-	<i>Inactive enantiomer of ErSO.....</i>	Page 466
1926	Estrol	<i>Estrogen receptor agonist (preference for the Era).....</i>	Page 468
4212	Estradiol, α- Recent Addition	<i>Endogenous estrogen receptor ligand.....</i>	Page 468
1429	Flunisolide	<i>Corticosteroid.....</i>	Page 485
1169	Flumethasone	<i>Selective and potent glucocorticoid receptor agonist.....</i>	Page 485
2247	Flumethasone pivalate	<i>Topical glucocorticoid receptor agonist.....</i>	Page 485
1172	Fluticasone furoate	<i>Glucocorticoid agonist; MRP4 inhibitor.....</i>	Page 487
1404	Fluticasone propionate	<i>Glucocorticoid agonist.....</i>	Page 488
4275	Fulvestrant Recent Addition	<i>Potent estrogen receptor antagonist; Antiestrogen.....</i>	Page 493
4093	Hydroxytamoxifen, (Z)-4-	<i>The more active metabolite of Tamoxifen (SERM; Axon 3252).....</i>	Page 553
2065	Levonorgestrel	<i>Progesterone receptor (PR) agonist.....</i>	Page 612
2066	Methylprednisolone	<i>Synthetic glucocorticoid drug; anti-inflammatory.....</i>	Page 650
1613	MDV 3100	<i>Androgen receptor (AR) antagonist.....</i>	Page 644
3268	Metapristone	<i>Metabolite of Mifepristone (Axon 1502); PI3K/AKT inhibitor....</i>	Page 646
1502	Mifepristone	<i>Progesterone receptor (PR) antagonist.....</i>	Page 655
3249	Nilutamide	<i>Androgen receptor (AR) antagonist.....</i>	Page 704
2085	Org OD 02-0	<i>Selective agonist of membrane progesterone receptor (mPR).....</i>	Page 736
1231	PPT	<i>Estrogen (ER-alpha) agonist.....</i>	Page 788
3250	Raloxifene	<i>Selective estrogen receptor modulator (SERM).....</i>	Page 806
1532	RD 162	<i>Androgen receptor (AR) antagonist.....</i>	Page 810
1558	RU 42698	<i>Metabolite of Mifepristone (Axon 1502).....</i>	Page 835
1680	RU 58841	<i>Androgen receptor (AR) antagonist.....</i>	Page 835
4248	SC912 Recent Addition	<i>AR-V7 inhibitor.....</i>	Page 857

3928	SKBG-1, (R)-	Covalent RNA-binding protein NONO ligand	Page 870
3929	SKBG-1, (S)-	Inactive enantiomer of (R)-SKBG-1	Page 871
4184	SLU-PP-332	Pan ERRA/β/γ agonist	Page 873
2967	SR 19881	Potent dual agonist of ERRβ/γ	Page 887
3252	Tamoxifen	Selective estrogen receptor modulator (SERM)	Page 909
1176	Trifluoro-3-(5-fluoro-2-methoxy-phenyl)-3-methylbutan-2-one, 1,1,1-	Glucocorticoid ligand	Page 938
2051	TSE 424	Selective estrogen receptor modulator (SERM)	Page 941
2697	WAY-200070	Brain penetrant ERβ-selective agonist	Page 984
2337	XCT 790	ERRα inverse agonist and potent mitochondrial uncoupler	Page 991
2652	ZB716	Steroidal, orally bioavailable SERD	Page 1004
2239	ZK 216348, (+)-	Selective nonsteroidal glucocorticoid receptor (GR) agonist	Page 1008

Receptors (Nuclear, Class 4): Orphan

NR4A family orphan nuclear receptors are an important class of transcription factors for development and homeostasis of dopaminergic neurons that also inhibit expression of inflammatory genes in glial cells¹. Nur77 (NGIF-B/NR4A1), Nurr1 (NOT/NR4A2), and NOR-1 (MINOR/NR4A3) form a family of orphan nuclear receptors with a highly conserved DNA-binding domain and COOH-terminal ligand-binding domain, but minimal homology in their NH₂-terminal region. Nurr1 is an atypical member of the NR superfamily, which are primarily ligand-activated receptors, which regulate gene expression via recognition of specific DNA-binding sequences. Nurr1 is important for dopaminergic neuron function via regulation of tyrosine hydroxylase expression. Preliminary reports suggest a role for Nurr1 in rheumatoid arthritis and cancer through modulation of apoptosis².

¹ BR De Miranda et al. The Nurr1 Activator 1,1-Bis(3'-Indolyl)-1-(p-Chlorophenyl)Methane Blocks Inflammatory Gene Expression in BV-2 Microglial Cells by Inhibiting Nuclear Factor κB. *Mol Pharmacol.* 2015 Jun;87(6):1021-34.
² T. Inamoto et al. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. *Mol Cancer Ther.* 2008 Dec;7(12):3825-33.

4081	4A7C-301	Brain-penetrant Nurr1 agonist	Page 189
2575	C-DIM12	Nurr1 activator stimulating apoptosis in bladder cancer cells	Page 354
2828	C-DIM5	Nur77 agonist	Page 354
2827	C-DIM8	Nur77 antagonist	Page 355

Receptors: Sigma

Based on the ligand selectivity in the receptor binding assay as seen in different tissues, the sigma receptor was found to consist of two subtypes, the sigma-1 and sigma-2 receptors. The incorrect early assumption that the sigma receptors would be members of the family of opioid receptors has been declined since the early 1990's¹. After many years of research, now it has been revealed that the sigma-1 receptor is a unique ligand-regulated molecular chaperone in the endoplasmic reticulum of cells². Evidence was found that the most prominent action of sigma-1 receptors in biological systems is the regulation and modulation of voltage-regulated and ligand-gated ion channels, including Ca(2+)-, K(+)-, Na(+), Cl(-), and SK channels, and NMDA and IP3 receptors. Stimulation of the receptor by sigma-1 agonists causes inhibition of all above-mentioned voltage-gated ion channels, while on the other hand it potentiates ligand-gated channels³. In contrast, little is known to date of the sigma-2 receptor which is still to be cloned. Activation of the receptor seems to cause apoptosis⁴.

¹ Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: Characterization by ligand binding and photoaffinity labeling. S.B. Hellewell, A. Bruce, G. Feinstein, J. Orringer, W. Williams, W.D. Bowen. *Eur. J. Pharmacol.* 1994, 268, 9-18.
² The sigma-1 receptor chaperone as an inter-organelle signaling modulator. T.P. Su, T. Hayashi, T. Maurice, S. Buch, A.E. Ruoho. *Trends Pharmacol. Sc.* 2010, 31, 557-566.
³ The pharmacology of sigma-1 receptors. T. Maurice, T.P. Su. *Pharmacol. Ther.* 2009, 124, 195-206
⁴ Sigma receptors: recent advances and new clinical potentials. W.D. Bowen. *Pharm. Acta Helv.* 2000, 74, 211-218.

1215	BD 1047 dihydrobromide	Sigma-1 antagonist	Page 295
2088	BD 1063 dihydrochloride	Selective sigma-1 (σ-1) receptor antagonist	Page 296
2919	IBP, 4	Selective sigma-1 (σ-1) receptor agonist	Page 556
1272	PB 28 dihydrochloride	Sigma-2 agonist	Page 749

3063	PRE-084 hydrochloride	Highly selective sigma-1 (σ-1) agonist	Page 790
3859	Roluperidone	Sigma-2 and 5-HT _{2A} receptor antagonist	Page 829
1767	SA 4503	Sigma-1 receptor antagonist	Page 841

Receptors: Miscellaneous

For example, mPRs are 7-TM proteins expressed on the plasma membranes of cells and bind progestins in a specific, displaceable, high affinity, limited capacity manner, characteristic of steroid membrane receptors and activate G-proteins in several cell types. The mPRs however, do not belong to the GPCR superfamily, nor do they belong to the family of nuclear receptors N3RC like the progesterone receptor (PR). In contrast, mPRs are members of the progestin and adipoQ receptor (PAQR) family. Noteworthy, the Axon ligands™ DIMNF and Stemregenin 1 (1935 and 1865, respectively) modulating the activity of the aryl hydrocarbon receptor (AHR) are listed and discussed in the section of transcription factors as well, since their biological target has been defined as a class 1 transcription factor¹.

Adiponectin is an adipokine with anti-inflammatory and insulin-sensitizing properties. Clinically, circulating levels of adiponectin are reduced in obesity and type II diabetes, whereas weight loss elevates serum adiponectin. Candidate adiponectin receptors, AdipoR1 and AdipoR2, were initially identified by expression cloning and reported to mediate the insulin-sensitizing actions of adiponectin. These proteins are predicted to have seven transmembrane domains with the opposite topology of GPCRs. Both AdipoR1 and AdipoR2 are reported to be ubiquitously expressed with the highest expression in skeletal muscle and liver, respectively. In addition to its metabolic role, adiponectin has been shown to be associated with various clinical cardiovascular disorders including myocardial infarction, peripheral artery disease, and endothelial dysfunction².

VLA-4 (very late antigen 4, 3 α4β1-integrin, CD49d/CD29) plays a major role in the regulation of immune cell recruitment to inflamed endothelia and sites of inflammation. It is expressed on the cellular surface of mononuclear leucocytes: eosinophils, basophils, lymphocytes and monocytes, and mediates cell-cell adhesion to vascular cell adhesion molecule-1 (VCAM1) on the endothelium³. VLA-4 thus participates in antigen presenting cell-lymphocyte interactions, retention and mobilization of immature progenitors in the bone marrow, cancer cell trafficking, metastasis, and other events⁴. In recent years, VLA-4 antagonists have shown great promise in treating inflammatory disorders in a number of animal models⁵.

Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are the intracellular pattern recognition receptors (PRRs) that trigger innate immunity and provide protection to the host against invading pathogens. NLRs are divided into three major subgroups: NALP (N-terminal, nucleotide-binding oligomerization domain [NACHT], leucine-rich repeat [LRR], and PYD-containing proteins), NOD (NACHT, LRR, and caspase activation and recruitment domain [CARD]-containing proteins), and NAIP (neuronal apoptosis inhibitor proteins). The NOD subgroup constituted of five receptor proteins, of which NOD1 is a cytosolic signaling host PRR comprising of the CARD at the central NACHT domain and a series of LRR domains at the C-terminal that recognize the pathogen-associated molecular patterns (PAMPs) and activates downstream signaling. Upon ligand recognition and binding, the downstream signaling adaptor molecule receptor-interacting serine/threonine kinase (RICK) is recruited which results in NF-κB phosphorylation and induction of cytokine gene expression⁶.

Thrombopoietin (TPO) was shown to be the major regulator of megakaryocytopoiesis and platelet formation. Its receptor (TpoR aka CD110 or c-mpl) is homologous with members of the hematopoietic receptor superfamily, and has two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs. It can be found on megakaryocyte precursor cells megakaryocytes, and platelets, as well on stem cells and early bone marrow progenitor cells of all lineage. TPO affects late maturation only of megakaryocytes and platelets but is required to maintain the viability of stem cells and precursors of all lineages⁷. Upon binding to thrombopoietin, the receptor undergoes dimerization that results in a number of signal transduction events (JAK/STAT, and MAPK signaling pathway, among other pathways) that prevent apoptosis, improve cell viability, promote growth, and possibly increase differentiation. In addition, binding to the receptor provides the major mechanism by which thrombopoietin is removed from the circulation by platelets and possibly megakaryocytes⁸.

Mammalian Toll-like receptors (TLRs) comprise a large family consisting of at least 11 members, a class of proteins that play a key role in the innate immune system. The cytoplasmic portion of this family of transmembrane receptors shows homology with the cytoplasmic domains of Drosophila Toll and the IL-1 receptor family, and is termed a Toll/IL-1 receptor (TIR) domain⁹. Despite this similarity, the extracellular portions of both types of receptors are structurally unrelated. TLRs bear leucine-rich repeats (LRRs) in the extracellular domain, critical for recognition of the microbial components derived from pathogens including bacteria, fungi, protozoa and viruses. Specifically, TLR3 is implicated in the recognition of double-stranded RNA (dsRNA) from virus, degraded bacteria, damaged tissues and necrotic cells¹⁰ and results in TRIF-dependent activation of IRF-3 and NF-κB¹¹.

¹ V. Sauzeau et al. Receptor (Ahr) Controls Cardiovascular and Respiratory Functions by Regulating the Expression of the Vav3 Proto-oncogene. *J. Biol. Chem.* 2011, 286, 2896-2909.
² J.L. Parker-Duffen et al. Divergent roles for AdipoR1 and AdipoR2 in mediating revascularization and metabolic dysfunction in vivo. *J. Biol. Chem.* 2014, 289, 16200-16213.
³ Z. Diamant et al. Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. *Clin. Exp. Allergy.* 2005, 35, 1080-1087.

- ⁴ A. Chigaeiev et al. Discovery of very late antigen-4 (VLA-4, alpha4beta1 integrin) allosteric antagonists. *J. Biol. Chem.* 2011, 286, 5455-5463.
⁵ K.C. Lin et al. Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. *Curr. Opin. Chem. Biol.* 1998, 2, 453-457.
⁶ B.R. Sahoo et al. Activation of nucleotide-binding oligomerization domain 1 (NOD1) receptor signaling in *Labes rohita* by iE-DAP and identification of ligand-binding key motifs in NOD1 by molecular modeling and docking. *Appl. Biochem. Biotechnol.* 2013, 170, 1282-1309.
⁷ D.J. Kuter et al. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. *Annu. Rev. Med.* 2009, 60, 193-206.
⁸ K. Kaushansky et al. Thrombopoietin: the primary regulator of platelet production. *Blood.* 1995, 86, 419-431.
⁹ F.L. Rock et al. A family of human receptors structurally related to *Drosophila* Toll. *Proc. Natl. Acad. Sci. USA.* 1998, 95, 588-593.
¹⁰ W. Gong et al. A novel 1,2-benzenediamine derivative FC-99 suppresses TLR3 expression and ameliorates disease symptoms in a mouse model of sepsis. *Br. J. Pharmacol.* 2014, 171, 4866-4878.
¹¹ K. Takeda et al. Toll-like receptors in innate immunity. *Int. Immunol.* 2005, 17, 1-14.

3048	ADH-503	Allosteric agonist of integrin CD11b/CD18	Page 208
2275	AdipoRon	Orally active small-molecule AdipoR agonist	Page 208
2692	AX-024 hydrochloride	T cell receptor inhibitor	Page 263
3877	BMS-986299	First-in-class NLRP3 agonist	Page 321
3155	CU-115	Selective TLR8 inhibitor	Page 398
2455	CU-T12-9	Selective TLR1/TLR2 agonist	Page 399
3475	Dapansutrile	Selective and orally active NLRP3 inflammasome inhibitor	Page 409
1935	DiMNF	Selective aryl hydrocarbon receptor modulator (SAhRM)	Page 432
1872	Eltrombopag	Thrombopoietin receptor (TpoR or c-MPL) agonist	Page 455
2318	FC 99 hydrochloride	Inhibitor of TLR3 expression and inflammatory responses	Page 476
2858	FPS-ZM1	High affinity RAGE-specific inhibitor	Page 491
1616	HMR 1031	VLA-4 antagonist	Page 543
3107	Imiquimod	TLR7/TLR8 agonist	Page 563
3839	JC2-11	Inhibitor of the NLRP3/NLRC4/AIM2 inflammasomes	Page 576
4063	KIN1148	IRF3 agonist; Influenza vaccine adjuvant	Page 591
4061	KIN1400	IRF3 agonist; RLR pathway agonist	Page 591
4062	KIN1408 Recent Addition	IRF3 agonist; RLR pathway agonist	Page 592
4052	MCC950 sodium salt	Highly potent and selective NLRP3 inflammasome inhibitor	Page 642
1888	ML 130	Potent and selective inhibitor of NOD1 (NLRC1)	Page 663
2783	Motolimod	Highly potent and selective TLR8 agonist	Page 677
3483	NBD-556	HIV-1 entry inhibitor; gp120-CD4 interaction blocker	Page 690
3210	RA375	Potent RPN13 inhibitor	Page 805
3215	RIG012	Potent antagonist of the RIG-I innate immune receptor	Page 818
3980	SA-15-P	First-in-class LAG-3 inhibitor	Page 840
3150	SP-8008	Potent and selective inhibitor of SIPA	Page 882
1865	Stemregenin 1	Aryl hydrocarbon receptor (AHR) antagonist	Page 894

Proteins

This section lists all Axon Ligands™ that interact with proteins that do not show enzymatic activity or transduce signals by any signaling pathway mechanism. Among the pharmacological tools listed here are ligands that interact with transporters of any kind, proteins that affect intra- and/or extracellular structures, transcription factors, and proteins that assist enzymes without showing catalytic activity by itself.

Proteins: Auxiliary

Nucleophosmin (NPM, also known as B23, numatrin1 or NO38) is able to bind to many partners in distinct cellular compartments, including nucleolar factors, transcription factors, histones, proteins involved in cell proliferation (for example, DNA polymerase-alpha), mitosis, (for example, NUMA and NEK2A) and the response to oncogenic stress (for example, ARF and p53). NPM also associates with both DNA and RNA, and it has been reported to have endoribonuclease activity to ribosomal RNA (rRNA). Furthermore, it forms complexes with the second messenger PIP3 in the nucleus in response to anti-apoptotic factors. NPM takes part in various cellular processes, such as the regulation of cell growth, proliferation and transformation, the transport of pre-ribosomal particles and ribosome biogenesis, the response to stress stimuli, the maintenance of genomic stability through the control of cellular ploidy and the participation in DNA-repair processes, and the regulation of DNA transcription through modulation of chromatin condensation and decondensation events. NPM is also involved in regulating the activity and stability of crucial tumor suppressors such as p53 and ARF. Its expression rapidly increases in response to mitogenic stimuli, and increased amounts of the protein are detected in highly proliferating and malignant cells. NPM¹.

α -Synuclein (α -Syn) is a 140-amino acid protein, which is encoded by the gene SNCA. α -Syn was first isolated from the cholinergic neurons of *Torpedo californica*. The protein localizes only to synaptic vesicles and portions of the nucleus, hence the name synuclein. Three additional synuclein family members have been identified and are named β -syn, γ -syn, and synoretin. Only α - and β -syn are expressed in the mammalian brain². α -Synuclein is a typical intrinsically disordered protein, but can adopt a number of different conformational states depending on conditions and cofactors. These include the helical membrane-bound form, a partially-folded state that is a key intermediate in aggregation and fibrillation, various oligomeric species, and fibrillar and amorphous aggregates. Although the normal function (or functions) of α -syn remains unknown, its localization at presynaptic terminals, its association with the distal reserve pool of synaptic vesicles and the deficiencies in synaptic transmissions observed in response to knockdown or overexpression of α -syn suggest that α -syn has a role in the regulation of neurotransmitter release, synaptic function and plasticity³. Human genetics has indicated a causal role for the protein α -synuclein in the pathogenesis of familial Parkinson's disease (PD). In both sporadic and dominant familial forms of PD and related neurodegenerative disorders α -Syn is misfolded and deposited within insoluble protein aggregates, which are robustly expressed within Lewy bodies (LBs). This accumulation of misfolded α -synuclein is widely recognized as a hallmark of multiple forms of neural degeneration^{4,5}.

¹ S. Grisendi et al. Nucleophosmin and cancer. *Nat. Rev. Cancer* 2006, 6, 493-505.

² P.K. Auluck et al. α -Synuclein: membrane interactions and toxicity in Parkinson's disease. *Annu Rev Cell Dev Biol.* 2010;26:211-33.

³ J. Bendor et al. The Function of α -Synuclein. *Neuron.* 2013, 18, 79, 10.

⁴ H.A. Lashuel et al. The many faces of α -synuclein: from structure and toxicity to therapeutic target. *Nat. Rev Neurosci.* 2013, 14, 38-48.

⁵ L. Breydo et al. α -Synuclein misfolding and Parkinson's disease. *Biochim. Biophys. Acta.* 2012, 1822, 261-285.

2382	ELN 484228	α -Synuclein modulator; potential therapeutic for Parkinson's	Page 455
3910	MitoBloCK-10	Tim44 inhibitor	Page 657
1402	NSC 348884	NPM inhibitor	Page 715
2907	Nucleozin	Influenza A nucleoprotein targeting molecule	Page 720

Proteins: Matrix

Cellular matrices embed specialized molecular structures that typically provide structural and biochemical support to the surroundings. This section lists pharmacologically active compounds that influence the formation of e.g. microtubules or affect cell-cell adhesion interactions, among many others. Individual sections are created for Axon Ligands™ that affect the extracellular matrix, and ligands that interfere with molecular structures within cells.

Proteins (Matrix) intracellular

Microtubules are non-covalent cytoskeletal polymers found in all eukaryotic cells that are involved in mitosis, cell motility, intracellular transport, secretion, the maintenance of cell shape and cell polarization. They are polarized structures composed of α - and β -tubulin heterodimer subunits assembled into linear protofilaments. Microtubules typically consist of 12 or 13 protofilaments aligned in parallel with the same polarity [i.e., one end at which there is a rapid assembly of tubulin (plus end) and the opposite end at which slow assembly or even disassembly occurs (minus end)]¹. Most microtubules occur as single tubes and form cellular structures such as the mitotic spindle and the interphase network². The properties of microtubules depend on the tubulin isoforms they are made up of — there are three α -tubulins ($\alpha 1$, $\alpha 2$ and $\alpha 4$) and five

beta-tubulins (β I, β II, β III, β IVa and β IVb) — and on how they have been altered by various forms of post-translational modification. Post-translational modifications of tubulin subunits mark subpopulations of microtubules and selectively affect their functions³. Microtubule associated proteins offer the potential for new targets for anticancer agents, as they have diverse functions including some actions that stabilize the microtubule, others that are involved in tubulin dissociation, and additional proteins that act as motor proteins to transport substances along the microtubule. This class of anti-cancers agents inhibits cell mitosis by binding to the protein tubulin in the mitotic spindle and preventing polymerization or depolymerization into the microtubules⁴.

Formins participate in the assembly of the actin and microtubule cytoskeletons in processes like cell division, migration, and development. The mammalian Diaphanous-related (mDia) formin family of Rho-effector proteins generates linear actin filaments (F-actin) and modulates microtubule dynamics to support the establishment and maintenance of polarity in cells. These structural changes occur in response to demands during developmental and immunologic processes. Defects in formin genes are associated with an array of human diseases including inherited deafness, autism, and kidney disease⁵. Diaphanous-related formins (DRF) contain an N-terminal GTPase-binding domain (GBD) and a C-terminal diaphanous autoregulatory domain (DAD). DRFs are regulated by an autoinhibitory interaction of the C-terminal DAD with the DRF N-terminal armadillo repeat-like region in the DID or GBD/FH3 domain. This autoinhibition is released upon competitive binding of an activated Rho GTPase to the GBD. The release of DAD allows the catalytic formin homology 2 (FH2) domain to then nucleate and elongate nonbranched actin filaments⁶.

¹ F. Pellegrini, D.R. Budman. Review: tubulin function, action of antitubulin drugs, and new drug development. *Cancer Invest.* 2005, 23, 264-273.

² J. Hammond et al. Tubulin modifications and their cellular functions. *Curr. Opin. Cell Biol.* 2008, 20, 71-76.

³ C. Condeelis, A. Cáceres. Microtubule assembly, organization and dynamics in axons and dendrites. *Nat. Rev. Neurosci.* 2009, 10, 319-332

⁴ M.A. Jordan. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. *Curr. Med. Chem. Anticancer Agents.* 2002, 2, 1-17.

⁵ L.L. Lash et al. Small-molecule intramimics of formin autoinhibition: a new strategy to target the cytoskeletal remodeling machinery in cancer cells. *Cancer Res.* 2013 Nov 15;73(22):6793-803.

⁶ H.N. Higgs et al. Formin proteins: a domain-based approach. *Trends Biochem Sci.* 2005 Jun;30(6):342-53.

3748	C-82 Specific inhibitor of Wnt/ β -catenin signaling pathway Page 338
2916	Cevipabulin Potent microtubule-active antitumor agent Page 360
3243	CK-666 Arp2/3 complex inhibitor Page 374
3371	Colchicine Tubulin polymerization inhibitor Page 382
1233	Combretastatin-A4 Tubulin polymerization inhibitor Page 381
3715	E-7386 CBP/ β -catenin modulator Page 447
1650	HTI 286 Tubulin polymerization inhibitor Page 547
2406	IMM 01 Agonist of mammalian Diaphanous (mDia)-related formins Page 563
3948	ISX9 Wnt/ β -catenin signaling pathway agonist Page 573
1310	Myoseverin Tubulin polymerization inhibitor Page 686
3368	Podophyllotoxin Tubulin polymerization inhibitor Page 786
3749	PRI-724 Specific inhibitor of Wnt/ β -catenin signaling pathway Page 791
3746	PTI-125 dihydrochloride Orally available molecule targeting filamin A (FLNA) Page 796
3083	PVHD121 Microtubule inhibitor Page 797
3804	Sabizabulin Orally bioavailable and highly potent tubulin polymerization inhibitor Page 841
2815	SP-6-27 Microtubule inhibitor Page 882
2398	Suprafenacine Destabilizer of microtubules that causes cell cycle arrest Page 901
3400	Tubulin inhibitor 6 Tubulin polymerization inhibitor; iHAP Page 943
1804	Wiskostatin Inhibitor of Wiskott-Aldrich syndrome protein (N-WASP) Page 986

Proteins (Matrix) extracellular

In order for cells to function, they must be properly supported, having contacts with neighboring cells and/or the extracellular matrix (ECM). The ECM provides much of the structural support available to parenchymal cells in tissues. The primary proteins present in the ECM and indeed the entire body are the collagens, a family of proteins with at least 29 members. They share a common structural motif of helical fibrils formed by three protein subunits. Another cytoplasmic protein, β -Catenin, plays essential roles in two different cellular processes: calcium-dependent intercellular adhesion and Wnt-mediated transcriptional activation. For cell-cell adhesion, β -catenin binds the cytoplasmic domain of cadherin adhesion receptors along with the actin binding protein, α -catenin, to bridge the extracellular adhesive activity of cadherins with the underlying actin cytoskeleton. This cadherin-bound pool of β -catenin ultimately form the so-called adherens junctions and

serves to link the cytoskeletal networks of adjacent cells, which is considered essential for normal tissue architecture and morphogenesis^{1,2}.

Aggregation of extracellular amyloid- β (A β) is thought to play a major part in the pathogenesis of Alzheimer's disease. Amyloid plaques form when levels of the monomeric, soluble A β peptide build up in the extracellular interstitial fluid (ISF) in the brain. Caprospinol (Axon 1442) has the ability to bind A β 42, prevent β -amyloid aggregation, and block the formation of A β 42 oligomers, thereby protecting organisms against β -amyloid (A β 42)-induced neurotoxicity³.

Aggrecan is a proteoglycan, and it possesses a core protein with covalently attached sulfated glycosaminoglycan (GAG) chains. Within the extracellular matrix aggrecan occurs only in the form of proteoglycan aggregates. The GAG chains provide aggrecan with its high anionic charge whereas aggregation endows it with a large size. Both the charge and size properties are essential for normal aggrecan function and hence articular cartilage function⁴. As a structural proteoglycan, aggrecan appears to be important in mediating chondrocyte-chondrocyte and chondrocyte-matrix interactions⁵.

The extracellular matrix of connective tissues represents a complex alloy of variable members of diverse protein families defining structural integrity and various physiological functions. Collagen is the major protein of the extracellular matrix (ECM) and is the most abundant protein found in mammals. It acts as a structural scaffold in tissues. The central feature of all collagen molecules is their stiff, triple-stranded helical structure. So far, 26 genetically distinct collagen types have been described⁶. Collagen and collagen-derived fragments control many cellular functions, including cell shape and differentiation, migration, the synthesis of a number of proteins, and it is a key component of a healing wound⁷.

Lectins are carbohydrate-binding proteins that can recognize various carbohydrates attached to proteins and lipids, known as glycoconjugates, on cell surfaces and extracellular matrices. Galectins are a family of proteins first identified as galactoside-binding lectins in extracts of vertebrate tissue, and all share a common amino acid sequence, the carbohydrate recognition domain (CRD). They are known to perform a high diversity of functions inside the cells and in the extracellular space: they are regulators of cell cycle, inflammation, immune responses, cancer progression, cell adhesion, cell signalling events and so on. Regarding their overall structure galectins are clustered in three families: prototype galectins consisting of one CRD, chimera-type galectins with one CRD and a non-lectin domain (galectin-3), and tandem-repeat galectins which have two different CRDs linked by a short peptide⁸. Different galectins are specific for different oligosaccharides, as they differ in their ability to accommodate certain saccharides attached to galactose⁹. Evidence has accumulated that Galectin-1 and galectin-3 are also implicated in cancer cell proliferation, invasion and tumour angiogenesis. Galectin-1 is overexpressed in tumour cells and tumour-associated endothelial cells. Upregulation has been linked with poor clinical prognosis and metastases development in a wide range of malignancies¹⁰.

Dystrophin or utrophin are associated with integral and peripheral membrane proteins that can be classified as the dystroglycan complex (DGC): a multimeric protein assembly that links the extracellular matrix to the actin cytoskeleton. The DGC mediates three major functions: structural stability of the plasma membrane, ion homeostasis, and transmembrane signaling. The DGC is critical for integrity of muscle fibers by linking the actin cytoskeleton to the extracellular matrix (ECM), and has been studied in the context of muscle dystrophies and cardiomyopathies for this¹¹. In patients suffering from Duchenne muscular dystrophy (DMD), the gene encoding the dystrophin protein shows mutations, resulting in the absence or very low levels of this protein. Utrophin shows sequence and structural similarity to dystrophin and can functionally compensate for the lack of dystrophin under these conditions. However, utrophin does not anchor nNOS to the sarcolemma, which is a requirement to regulate blood flow to the muscle and to ensure that all of its metabolic needs are met¹².

¹ S.H. Kim, J. Turnbull, S.Guimond. Extracellular matrix and cell signaling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. *J. Endocrin.* 2011, 209, 139-151.

² F.H. Brembeck, M. Rosário, W. Birchmeier. Balancing cell adhesion and Wnt signaling, the key role of β -catenin. *Curr. Opin. Genet. Dev.* 2006, 16, 51-59.

³ L. Lecanu et al. Caprospinol reduces amyloid deposits and improves cognitive function in a rat model of Alzheimer's disease. *Neuroscience* 2010, 165, 427-435.

⁴ C. Kiani et al. Structure and function of aggrecan. *Cell Res.* 2002, 12, 19-32.

⁵ P.J. Roughley et al. The role of aggrecan in normal and osteoarthritic cartilage. *J. Exp. Orthopaed.* 2014, 1, 8.

⁶ K. Gelse et al. Collagens—structure, function, and biosynthesis. *Adv. Drug Deliv. Rev.* 2003, 55, 1531-1546.

⁷ D. Brett. A review of collagen and collagen-based wound dressings. *Wounds.* 2008, 20, 347-353.

⁸ C.E. Römer et al. Galectins: Structures, Binding Properties and Function in Cell Adhesion, Biomaterials - Physics and Chemistry, Prof. Rosario Pignatello (Ed.), (2011). ISBN: 978-953-307-418-4. InTech.

⁹ F.T. Liu et al. Galectins as modulators of tumour progression. *Nat. Rev. Cancer.* 2005, 5, 29-41.

¹⁰ L. Astorgues-Xerri et al. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. *Eur. J. Cancer.* 2014, 50, 2463-2477.

¹¹ T. Haenggi et al. Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue. *Cell Mol Life Sci.* 2006, 63, 1614-31.

¹² R.J. Fairclough et al. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. *Nat Rev Genet.* 2013 Jun;14(6):373-8.

1442	Caprospinol Alzheimer's disease therapeutic Page 343
2161	CCT 031374 hydrobromide Inhibitor of genes of Wnt signaling pathway Page 351
1443	Genipin Protein cross-linker; stimulates insulin secretion Page 501
1766	ICG 001 Specific inhibitor of Wnt/ β -catenin signaling pathway Page 557
2133	iCRT5 β -Catenin-responsive transcription (CRT) inhibitor Page 558
2135	iCRT14 Inhibitor of the Wnt/wingless signaling; CRT inhibitor Page 559

2378	Kartogenin	<i>Promotor of chondrocyte differentiation from human MSCs</i>	Page 588
3342	MSAB	<i>Potent and selective inhibitor of Wnt/β-catenin signaling pathway</i>	Page 683
2332	OTX 008	<i>Selective allosteric inhibitor of galectin-1</i>	Page 740
3152	PAWI-2	<i>Inhibitor which targets both Wnt signaling and ATM/p53</i>	Page 748
2084	SKL 2001	<i>Wnt/β-catenin signaling pathway agonist or activator</i>	Page 872
2481	SMT C1100	<i>Orally active, non-toxic upregulator of utrophin production</i>	Page 875
2120	Wnt agonist 1	<i>Wnt/β-catenin signaling pathway agonist or activator</i>	Page 987

Proteins: Regulator

Although the mechanisms of action of a number of Axon Ligands™ remain ambiguous, they can significantly affect biological processes of various kinds. While interacting with regulator proteins in this section, they may have therapeutic applications as their target proteins play a role in the regulation and/or facilitation of processes within the cell, without having enzymatic or transporting properties by themselves. Additionally, their mode of action may not have been elucidated in great detail, yet evidence has been found for a certain role in, for example: signaling pathways, apoptosis, or stem cell differentiation.

Calmodulin (CaM) is a ubiquitous regulatory protein that communicates the presence of calcium to its molecular targets and correspondingly modulates their function. This key signaling protein is important for controlling the activity of hundreds of membrane channels and transporters¹. CaM contains two globular domains each containing a pair of helix-loop-helix Ca²⁺-binding sites (EF-hands). Upon Ca²⁺ binding, conformational transitions in calmodulin are induced that changes its affinity to target proteins². One example of the proteins function being regulated by CaM is the family of aquaporins (AQPs): water channels that facilitate the flux of water molecules across membranes. Regulation of the water permeability by CaM is achieved through a Ca²⁺-dependent interaction between Ca²⁺-CaM and the cytoplasmic C-terminal domain of the AQP³. Avridine (Axon 2099), for example, is a lipoidal amine with interferon-inducing and adjuvant properties specifically related to Newcastle disease⁴. What's more, although avridine is a synthetic non-immunogenic adjuvant, it is also known to induce arthritis in rats in a predictable and T-cell dependent way. However, the mechanism of action by which this Avridine Induced Arthritis (AVIA) is triggered, or acts as adjuvant of the Newcastle disease antigen has not been elucidated in detail⁵. Shz-1 (Axon 1701) has the ability to mediate stem cell differentiation for the treatment of myocardial infarction and heart failure. It triggers cardiac mRNA and protein expression of the signature gene Nkx2.5, one of the earliest lineage-restricted genes to be expressed in cardiovascular progenitor cells, in a variety of embryonic and adult stem/progenitor cells, including human mobilized peripheral blood mononuclear cells (M-PBMCs)⁶. The exact mechanisms of gene activation and stem cell differentiation remain unclear.

The vertebrate-specific clarin (CLRN) protein family is characterized by four transmembrane-domains, conserved sequence motifs and a single glycosylation consensus site between TM1 and TM2.⁷ A mutation in the clarin-1 gene is related to Usher syndrome 3A, which is an autosomal recessive disorder, characterized by progressive loss of hearing and vision.⁸

¹ S.L. Reichow et al. Allosteric mechanism of water-channel gating by Ca²⁺-calmodulin. *Nat. Struct. Mol. Biol.* 2013, 20, 1085-1092.

² N.V. Valejev et al. Elucidating the mechanisms of cooperative calcium-calmodulin interactions: a structural systems biology approach. *BMC Systems Biol.* 2008, 2, 48.

³ S.L. Reichow et al. Allosteric mechanism of water-channel gating by Ca²⁺-calmodulin. *Nat. Struct. Mol. Biol.* 2013, 20, 1085-1092.

⁴ M.M. Rweyemamu et al. Efficacy of avridine as an adjuvant for Newcastle disease virus antigen in chickens. *Am. J. Vet. Res.* 1986, 47, 1243-1248.

⁵ C. Vingsbro, R. Jonsson, R. Holmdahl. Avridine-induced arthritis in rats; a T cell-dependent chronic disease influenced both by MHC genes and by non-MHC genes. *Clin Exp Immunol* 1995, 99, 359-363.

⁶ H. Sadek. Cardiogenic small molecules that enhance myocardial repair by stem cells. *PNAS* 2008, 105, 6063-6068.

⁷ A Adato et al. USH3A transcripts encode clarin-1, a four-transmembrane-domain protein with a possible role in sensory synapses. *Eur J Hum Genet.* 2002 Jun;10(6):339-50.

⁸ R Geng et al. Usher syndrome IIIA gene clarin-1 is essential for hair cell function and associated neural activation. *Hum Mol Genet.* 2009 Aug 1;18(15):2748-60.

2830	(R)-CE3F4	<i>Potent inhibitor of EPAC1</i>	Page 355
3631	ABR-238901	<i>Potent S100A8/A9 blocker</i>	Page 200
3755	Abscisic acid, (+)-	<i>LANCL2 ligand</i>	Page 200
3687	ADU-S100	<i>Cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING)</i>	Page 210
3433	ARB-272572	<i>Potent, cellular active PD-L1 inhibitor</i>	Page 246
2099	Avridine	<i>Lipoidal amine; interferon-inducing and adjuvant properties</i> ...	Page 263
2774	Barbadin	<i>β-Arrestin/β-Adaptin inhibitor</i>	Page 284
3327	BO-264	<i>Highly potent, orally active TACC3 inhibitor</i>	Page 322

2749	BT-11	<i>First-in-class, orally active LANCL2 binding compound</i>	Page 330
3437	BTYNB	<i>Potent and selective IMP1 inhibitor</i>	Page 332
2645	CC-885	<i>Cereblon (CRBN) modulator with potent anti-tumour activity</i> ..	Page 348
2929	CE3F4	<i>Inhibitor of EPAC1</i>	Page 356
3688	cGAMP	<i>Endogenous agonist for the STING</i>	Page 361
1252	CGS 9343B	<i>Calmodulin inhibitor</i>	Page 363
3689	E-7766	<i>STING agonist</i>	Page 448
2847	ESI-08	<i>Selective EPAC antagonist</i>	Page 467
4018	FSEN1	<i>Uncompetitive FSP1 inhibitor</i>	Page 492
3326	HJC0197	<i>Potent EPAC antagonist</i>	Page 542
2730	HJC0350	<i>Highly potent and selective EPAC2 antagonist</i>	Page 542
3470	Homo-PROTAC cereblon degrader 1	<i>Highly potent and efficient CRBN degrader; PROTAC</i>	Page 545
3441	KL001	<i>Cryptochrome stabilizer</i>	Page 592
2036	KY 02111	<i>Canonical Wnt signaling pathway inhibitor</i>	Page 600
3896	ML162	<i>Covalent GPX4 inhibitor; Ferroptosis inducer</i>	Page 664
3298	MSA-2	<i>Selective and orally available non-nucleotide STING agonist</i> .	Page 683
3583	OICR-9429	<i>First-in-class, potent, highly selective and cell-active antagonist of the Wdr5-MLL interaction</i>	Page 731
2875	PD-1 inhibitor compound 9	<i>Inhibitor of programmed death-1 (PD-1) protein</i>	Page 755
3694	PD-1 Inhibitor 16	<i>PD-1 inhibitor</i>	Page 751
4083	PDS0330 Recent Addition	<i>Potent and selective first-generation claudin-1 inhibitor</i>	Page 757
3639	PTX80	<i>First-in-class inhibitor of protein degradation by targeting p62/SQSTM1</i>	Page 797
3012	QStatin	<i>Potent and selective Vibrio Quorum Sensing (QS) inhibitor</i>	Page 801
3093	Risdiplam	<i>Selective SMN2 gene splicing modifier</i>	Page 820
3611	RSL3	<i>GPX4 inhibitor; Ferroptosis inducer</i>	Page 833
3617	RSL3,1R,3R-	<i>Negative control of 1S,3R-RSL3 as GPX4 inhibitor</i>	Page 834
1701	Shz-1	<i>Stem cell differentiating agent; Nkx2.5 inducer</i>	Page 865
3427	SRS11-92	<i>Inhibitor of ferroptosis</i>	Page 890
3673	STING activator C53	<i>Highly potent STING activator</i>	Page 895
2923	STING inhibitor C-176	<i>Highly potent and selective STING antagonist</i>	Page 896
3058	STING inhibitor C-178	<i>Highly potent and selective STING antagonist</i>	Page 896
3602	tBT-HBT	<i>Noncovalent, tight-binding inhibitor of HhC cholesterolysis</i>	Page 913
2700	TD52	<i>CIP2A inhibitor; Erlotinib derivative</i>	Page 915
2188	WAY 262611 dihydrochloride	<i>Inhibitor of Dickkopf-1 (DKK1); Wnt/β-Catenin agonist</i>	Page 984
2325	WAY 316606 hydrochloride	<i>Potent inhibitor of sFRP-1 that stimulates Wnt signaling</i>	Page 984
4119	XIE62-1004 Recent Addition	<i>Autophagy inducer; p62-LC3 interaction facilitator</i>	Page 992
3206	YW2065	<i>Inhibitor of Wnt/β-catenin signalling; AMPK activator</i>	Page 1001
3735	ZZW-115 trihydrochloride	<i>Potent NUPR1 inhibitor</i>	Page 1011

Proteins (Regulator) Cell Cycle

B cell-specific Moloney murine leukemia virus integration site 1 (BMI1) is considered a stem cell factor: a regulator protein of the Polycomb Group of multimeric protein complexes that is reported to regulate the proliferation activity of normal, stem, and progenitor cells¹. BMI1 plays a role in cell cycle, cell immortalization, and senescence, and is associated with a number of human malignancies where its expression is frequently upregulated. Unfortunately, there is an enormous body of evidence suggesting that increased expression of BMI1 could facilitate chemoresistance, and BMI1 is positively correlated with poor prognosis in cancer patients². In healthy cells, BMI1 controls self-renewal and cell cycle by regulating the tumor

suppressor proteins p16INK4a and p14ARF in cells. BMI1 contains a conserved ring finger domain in its N terminal end and a central helix-turn-helix-turn-helix-turn motif (H-T-H-T), which is essential for inducing telomerase activity. Additionally, BMI1 contains two nuclear localization signals, KRKR and KRMR³.

RPA has been referred to by multiple names in the literature including replication protein A, replication factor A (RFA), and human or HeLa single stranded DNA-binding protein (HSSB). It is a protein of heterotrimer composed of three tightly associated subunits of ~70, 32, and 14 kDa (referred as to RPA70, RPA32, and RPA14, respectively) that binds nonspecifically to ssDNA and interacts with and/or modifies the activities of multiple proteins. It is required for multiple processes in eukaryotic DNA metabolism, including DNA replication, DNA repair, and recombination. RPA is found to be potentially involved in cell cycle checkpoints and DNA damage checkpoints, and may have a role in modulating gene expression⁴. In cells, RPA is phosphorylated by DNA-dependent protein kinase when RPA is bound to single-stranded DNA (during S phase and after DNA damage)⁵.

The SMN protein is a 294-amino acid polypeptide that is expressed in all metazoans and in all cell types of vertebrates and forms part of a large protein complex, the SMN complex. This complex is composed of the SMN protein and 7 additional proteins, Gemin 2-8, and is essential for the biogenesis of spliceosomal small nuclear ribonucleoproteins and likely functions in the assembly, metabolism, and transport of a diverse number of other ribonucleoproteins, neuronal pathfinding, formation and function of neuromuscular junctions, myoblast fusion and maintenance of muscle architecture. Mechanistically, the SMN complex directly recognizes and binds to both the protein and the RNA components of the ribonucleoproteins and facilitates their interaction, thereby ensuring a strict specificity of the small nuclear ribonucleoprotein assembly process. Mutations in the human survival motor neuron 1 (SMN) gene are the primary cause of spinal muscular atrophy (SMA), a devastating neuromuscular disorder, recognized as the most prevalent genetic cause of early childhood mortality^{6,7}.

Transforming acidic coiled-coil (TACC), an evolutionarily conserved protein family, has been shown to be involved in the process of mitotic spindle assembly by the coordinated action of centrosomes and kinetochore microtubules, ultimately enhancing microtubule polymerization. TACC3 was originally identified within a translocation breakpoint region that was associated with multiple myelomas, and subsequent studies have indicated that it is aberrantly expressed in various cancers, and thus considered to be a potential molecular target for cancer chemotherapy⁸.

¹ A. Kreso et al. Self-renewal as a therapeutic target in human colorectal cancer. *Nat Med.* 2014 Jan;20(1):29-36.

² H.R. Siddique et al. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling. *PLoS One.* 2013 May 6;8(5):e60664.

³ H.R. Siddique et al. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. *Stem Cells.* 2012 Mar;30(3):372-378.

⁴ Y. Zou et al. Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses. *J Cell Physiol.* 2006 Aug;208(2):267-73.

⁵ M.S. Wold. Replication protein A: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism. *Annu Rev Biochem.* 1997;66:61-92.

⁶ S.J. Kolb et al. Molecular functions of the SMN complex. *J Child Neurol.* 2007 Aug;22(8):990-4.

⁷ K. Praveen et al. SMA-causing missense mutations in survival motor neuron (Smn) display a wide range of phenotypes when modeled in *Drosophila*. *PLoS Genet.* 2014 Aug 21;10(8):e1004489.

⁸ R. Yao et al. A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells. *Oncogene.* 2014 Aug 14;33(33):4242-52.

2438	Cuspin-1	Upregulator of the SMN by Ras signaling activation	Page 399
2701	EED226	Potent, selective and orally bioavailable PRC2 inhibitor	Page 451
2390	HAMNO	Novel protein interaction inhibitor of replication protein A	Page 538
2901	KHS101 hydrochloride	Selective, brain-penetrable inducer of neuronal differentiation and TACC3 inhibitor	Page 591
2420	PTC 209	Inhibitor of the canonical self-renewal regulator BMI-1	Page 796
2474	SPL-B	Inhibitor of TACC3	Page 884

Proteins (Regulator) Growth factors

Midkine (MDK) is a heparin-binding growth factor that is highly expressed in many malignant tumors. MDK activates the PI3K pathway and induces anti-apoptotic activity, in turn enhancing the survival of tumors. Therefore, the inhibition of MDK is considered a potential strategy for cancer therapy. Midkine (MDK) and the related heparin-binding growth associated molecule (HB-GAM)/Pleiotrophin (Ptn) are widely expressed in healthy cells as well, and are involved in a wide range of biological processes. Originally identified as retinoic acid inducible genes, midkines are widely expressed during embryogenesis with particularly high levels in the developing nervous system. During postnatal stages, midkine expression generally ceases but is often up-regulated under disease conditions, most notably those affecting the nervous system. Midkines are known as neurotrophic factors, as they promote neurite outgrowth and neuron survival in cell culture. In addition, several studies reported that MDK and Ptn acted as survival factors for neurons and that this activity was mediated through inhibition of apoptosis by modulating the MAPK pathway. Evidence was found that inhibition of MDK or its putative receptor anaplastic lymphoma kinase (Alk) results in reduced proliferation and induced apoptosis, hence further supporting the role of MDK as survival factor for neurons and a crucial factor for neurogenesis in vivo.¹

¹ C. Winkler et al. The midkine family of growth factors: diverse roles in nervous system formation and maintenance. *Br. J. Pharmacol.* 2014, 171, 905-912.

2258	iMDK	Specific inhibitor of Midkine (MDK) expression	Page 562
------	------	--	----------

Proteins (Regulator) BCL2

BCL-2 family proteins have been studied extensively for their importance in the regulation of apoptosis, tumorigenesis and cellular responses to anti-cancer therapy. BCL-2 family members have classically been grouped into three classes. One class inhibits apoptosis (BCL-2, BCL-XL, BCL-W, MCL1, BCL-B (also known as BCL-2L10) and A1 (also known as BCL-2A1)), whereas a second class promotes apoptosis (BAX, BAK and BOK (also known as MTD)). A third divergent class of BH3-only proteins (BAD, BIK (also known as BLK or NBK), BID, HRK (also known as death protein-5 (DP5)), BIM (also known as BOD), BMF, NOXA and PUMA (also known as BBC3)) has a conserved BH3 domain that can bind and regulate the anti-apoptotic BCL-2 proteins to promote apoptosis. Simultaneous over-expression of the anti-apoptotic Bcl-2 and the proto-oncogene myc may produce aggressive B-cell malignancies including lymphoma¹. ABT-199 (Axon 2141), is a so-called BH3-mimetic drug designed to block the function of the Bcl-2 protein, on patients with chronic lymphocytic leukemia².

¹ J.E. Chipuk et al. The BCL-2 family reunion. *Mol Cell.* 2010, 37, 299-310.

² R.J. Youle, A. Strasser. The BCL-2 protein family: opposing activities that mediate cell death. *Nat. Rev. Mol. Cell Biol.* 2008, 9, 47-59.

3957	A-1155463 dihydrochloride	BH3 mimetic Ligand of BCL protein BCL-XL	Page 190
4008	A-1210477	Potent and selective inhibitor of MCL-1	Page 190
3972	A-1331852	BH3 mimetic Ligand of BCL protein BCL-XL	Page 191
2141	ABT 199	Potent, orally bioavailable BCL-2-selective inhibitor	Page 201
3821	ABT-263	Potent, selective and orally bioavailable inhibitor of B-cell lymphoma-2 (BCL-2) family proteins	Page 201
3686	AMG-176	Potent and selective Mcl-1 inhibitor	Page 224
3814	AZD4320	BH3-mimetic inhibitor of BCL-2 protein	Page 272
3731	AZD5991	BH3-Groove binding Mcl-1 inhibitor	Page 274
2185	BAM 7	Selective small-molecule activator of proapoptotic BAX	Page 282
3714	BCL-201 dihydrochloride	BH3-mimetic inhibitor of BCL-2 protein	Page 295
1828	BH3-1	Inhibitor of Bcl-2 family protein	Page 300
3047	BI-6C9	Inhibitor of BID protein	Page 305
3295	BIA	TMBIM6 antagonist	Page 305
3431	BTSA1	Potent activator of proapoptotic BAX	Page 331
3766	DT-2216	Selective B-cell lymphoma-extra large (Bcl-XL) targeted protein degrader	Page 444
2007	HA 14-1	Bcl-2 inhibitor and apoptosis inducer of tumor cells	Page 538
3713	MIK665	BH3-Groove binding Mcl-1 inhibitor	Page 655
2823	ML 311	Potent and selective inhibitor of the protein-protein interaction of Mcl-1 and Bim	Page 666
3079	NPB	Potent, site-specific Bcl-2-associated death promoter (BAD) inhibitor	Page 709
4152	Obatoclox	B-cell lymphoma-2 (BCL-2) inhibitor	Page 729
3723	S63845	BH3-Groove binding Mcl-1 inhibitor	Page 840
3068	WEHI-9625	First-in-class, potent, and selective mBAK-mediated apoptosis inhibitor	Page 985

Proteins (Regulator) IAP

An important part of the apoptotic machinery are the inhibitor of apoptosis protein (IAP) family, regulating caspase activity, cell division or cell survival pathways through binding to their baculovirus AIP repeat (BIR) domains and/or by their ubiquitin-ligase RING zinc finger (RZF) activity. IAPs are also involved in immunity, inflammation, cell cycle and migration¹.

human IAP family consists 8 members known to date: NAIP (neuronal apoptosis inhibitory protein; BIRC1), cIAP1 and cIAP2 (cellular inhibitor of apoptosis 1 and 2; BIRC2 and BIRC3, respectively), XIAP (X-chromosome binding IAP; BIRC4), survivin (BIRC5), BRUCE (Apollon; BIRC6), livin (BIRC7) and Ts-IAP (testis-specific IAP; BIRC8). Increased IAP expression was found in variety of human cancers, including hematological malignancies, such as leukemias and B-cell lymphomas. A correlation between the progression of those diseases and high levels of survivin or XIAP has been reported. Thus, targeting IAPs with small-molecule inhibitors by their antisense approaches or natural IAP antagonist mimetics, may be an attractive strategy of anti-cancer treatment.²

¹ M.C. de Almagro, D. Vucic. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. *Exp. Oncol.* 2012, 34, 200-211.

² P. Smolewski, T. Robak. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. *Curr. Mol. Med.* 2011, 11, 633-649.

1985	AT 406	Inhibitor of apoptosis proteins (IAPs)	Page 257
4139	AZD5582 dihydrochloride	Apoptosis proteins (IAPs) inhibitor	Page 274
4150	Birinapant	Bivalent Smac mimetic and potent antagonist for XIAP and cIAP1 inhibitor	Page 309
4023	Embelin	Potent and cell-permeable inhibitor of XIAP	Page 456
3902	LCL-161	IAP inhibitor	Page 606
3344	LQZ-71	Orally active survivin-targeting inhibitor	Page 623
2165	S 12	Survivin inhibitor	Page 838
1639	YM 155	Survivin suppressant	Page 999

Proteins (Regulator) L3MBTL

Histone lysine methylation has emerged as a key post-translational modification (PTM) implicated in both gene activation and silencing depending on the site and methylation degree of PTM, however the mechanisms involved are complex and not well understood. To date, seven different histone lysine residues have been identified as functionally relevant sites of methylation (K4, K9, K27, K36 and K79 of histone H3, K20 of histone H4 and K26 of histone H1b). Each of these lysine residues can be mono-, di- or tri-methylated, often with functional consequences¹. L3MBTL3 is a member of the MBT (malignant brain tumor) family of methyl-lysine (Kme) reader proteins, a chromatin-interacting transcriptional repressor that functions as a mediator of protein-to-protein interactions. MBT domains selectively recognize mono- and dimethyllysine versus unmethylated and trimethylated lysine and have been functionally associated with repression of gene expression, and their misregulation has been shown to contribute to various disease phenotypes. Some of the human MBT proteins are known to be part of larger chromatin-remodeling complexes. Recently, a family-wide systematic analysis of MBT-histone interactions was reported, suggesting that some MBT domains recognize Kme histone peptides in a sequence-selective fashion, whereas others, such as L3MBTL3, are more promiscuous².

¹ Y. Guo et al. Methylation-state-specific recognition of histones by the MBT repeat protein L3MBTL2. *Nucl. Acids Res.* 2009, 37, 2204-2210.

² L.I. James et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. *Nat. Chem. Biol.* 2013, 9, 184-191.

2163	UNC 669	Antagonist of Kme reader protein L3MBTL1 and 3	Page 952
1994	UNC 1215	Antagonist of L3MBTL3 methyllysine reader domain	Page 954

Proteins (Regulator) WDR5

The WD40 protein WDR5 is a core subunit of the human MLL and SET1 (hCOMPASS) histone H3 Lys4 (H3K4) methyltransferase complexes¹. WDR5 consists of 334 amino acids and contains seven typical WD40 repeat domains, each approximately 40 amino acids, adopting a seven-bladed beta-propeller fold. It has been proposed that WDR5 is the component of the MLL complex that interacts directly with dimethylated H3K4 and is required for transition to trimethylation by the MLL complex. More recently, however, it has been demonstrated that yeast CPS30 and its mammalian homolog, WDR5, are required for complex assembly and that no H3K4 methylation is observed in their absence, indicating that WDR5 is central for complex assembly and activity. WDR5 plays important roles in developmental events, transcriptional regulation, and leukemogenesis². Interestingly, it has been revealed that WDR5 was not only localized in the nucleus, but also abundantly localized in the cytoplasm, and hypothesized to play a role in viral infections³.

¹ R.C. Trievel et al. WDR5, a complexed protein. *Nat Struct Mol Biol.* 2009 Jul;16(7):678-80.

² M. Wu et al. MLL1/WDR5 complex in leukemogenesis and epigenetic regulation. *Chin J Cancer.* 2011 Apr; 30(4): 240-246.

³ Y. Y. Wang et al. WDR5 is essential for assembly of the VISA-associated signaling complex and virus-triggered IRF3 and NF-kappaB activation. *Proc Natl Acad Sci U S A.* 2010 Jan 12; 107(2):815-20.

2411	WDR5-0103	Inhibitor of WDR5 and associated activity of MLL	Page 985
------	-----------	--	----------

Proteins (Regulator) BRD

Acetylation of lysine residues is a post-translational modification with broad relevance to cellular signaling and disease biology. Enzymes that 'write' (histone acetyltransferases, HATs) and 'erase' (histone deacetylases, HDACs) acetylation sites are an area of extensive research in current drug development. The principal readers of ε-N-acetyl lysine (Kac) marks are Bromo and extra terminal (BET) proteins (BRD2, BRD3, BRD4 and BRDT; EC 2.7.11.1), which are in turn transcriptional regulators required for efficient expression of several growth promoting and anti-apoptotic genes as well as for cell cycle progression¹. Moreover, they have an important role in the targeting of chromatin-modifying enzymes to specific sites. Often they act with other protein-interaction modules to guarantee a high level of targeting specificity for these essential enzymes².

¹ PFI-1 - A highly Selective Protein Interaction Inhibitor Targeting BET bromodomains. S. Picaud et al. *Cancer Res.* 2013, 73, 3336-3346.

² Bromodomains as therapeutic targets. S. Muller, P. Filippakopoulos, S. Knapp. *Expert Rev. Mol. Med.* 2011, 13, e29.

3696	ABBV-075	Highly potent and orally bioavailable BET bromodomain (BRD) inhibitor	Page 197
4263	ABBV-467	Recent Addition Potent and selective MCL-1 inhibitor	Page 197
3956	ABBV-744	First-in-class highly BDII (Bromodomain II)-selective BET bromodomain inhibitor	Page 198
3944	ARV-825	Potent and selective protein BRD4 degrader	Page 250
3833	AZD5153 HNT salt	Potent, selective, and orally available BET/BRD4 bromodomain inhibitor	Page 273
3037	BI 894999	Potent, selective and orally active BET inhibitor	Page 304
3716	BMS-986158	BET bromodomain (BRD) inhibitor	Page 321
3933	CCS-1477	Potent, selective and orally bioavailable inhibitor of the Bromodomain of p300 and CBP	Page 350
2776	CD161	Potent, selective, and orally active BET bromodomain inhibitor	Page 353
3764	CFT-8634	Selective orally bioavailable BRD9 degrader	Page 361
2594	CPI 0610	Selective inhibitor of BET bromodomains	Page 393
3922	dBET1	BET bromodomain degrader	Page 411
4131	DW-71177	Recent Addition Potent, orally bioavailable and BD1-selective BET inhibitor	Page 445
3769	FHD-286	Selective inhibitor of the BAF chromatin remodeling complex ATPases (BRG1/BRM)	Page 481
3921	GSK046	Domain-selective and orally active inhibitor of BET with immunomodulatory activity	Page 517
4135	I-BET151	BET bromodomain inhibitor	Page 555
3860	I-BET726	Potent and selective, tetrahydroquinoline-based small molecule ligand binding to BET proteins	Page 555
4134	I-BET762	BET bromodomain inhibitor	Page 555
1989	JQ-1, (+)	BET bromodomain inhibitor (BRD4 selective)	Page 582
3873	JQ-1, (-)	Inactive enantiomer of (+)-JQ1	Page 583
3822	JQ1 carboxylic acid, (+)	(+)-JQ1 derivative; PROTAC precursor	Page 583
3186	NVS-BPTF-1	Potent, selective and cell active chemical probe for BPTF	Page 727
3329	ODM-207	Highly potent, selective and orally active pan-BET inhibitor	Page 730
2530	OTX 015	Potent inhibitor of BRD2, BRD3, and BRD4	Page 740
1887	PFI-1	BET bromodomain (BRD) inhibitor	Page 771
2245	RVX 208	BET bromodomain inhibitor specific for BD2s	Page 837
3623	SGC-SMARCA-BRDVIII	Potent, highly selective and cell-active SMARCA2/4 and PB1(5) bromodomain inhibitor	Page 863

Proteins (Regulator) BRPF1

BRPFs (bromodomain and PHD finger-containing proteins) are multidomain proteins of the Trithorax group (TrxG): regulatory proteins composed of diverse, evolutionary conserved units that form chromatin-associated complexes accounting for epigenetic transcriptional memory. Three BRPFs are known to date, sharing >65% homology in their ~100 amino acid counting sequences, all sharing an acetylated lysine (KAc) recognition site that closely resembles other bromodomains, including those of the BETs¹. BRPF1 (also known as Br140 and Peregrin) is a component of complexes containing the MOZ/MORF transcriptional coactivators, that links the catalytic HATs to the other subunits ING5 and hEAF6. Furthermore, BRPF1 contains PHD fingers, a bromodomain and a PWWP domain². It has been shown that BRPF1 has a central role during development, since mutations have shown to display anterior transformations of pharyngeal arches due to progressive loss of anterior Hox gene expression. What's more, translocations of MOZ are associated with aggressive subtypes of leukemia, and make BRPF1 an interesting target in oncology related research³.

¹ E.H. Demont et al. 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5.

² K. Laue et al. The multidomain protein Brpf1 binds histones and is required for Hox gene expression and segmental identity. Development. 2008 Jun;135(11):1935-46.

³ L. You et al. The chromatin regulator brpf1 regulates embryo development and cell proliferation. J Biol Chem. 2015 May 1;290(18):11349-64.

2410	GSK 5959	Potent, cell permeable inhibitor of BRPF1 bromodomain	Page 523
2442	OF-1	Potent bromodomain inhibitor (BRPF1 and BRPF2 selective)	Page 730

Proteins (Regulator) TRAIL

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family and a powerful inducer of apoptosis in a wide range of human cancer cell lines via proapoptotic death receptor 4 (DR4; TRAIL-R1) and death receptor 5 (DR5; TRAIL-R2). The induction of apoptosis is accomplished via FADD/DISC/caspase-8 signaling in several cell types including neurons and oligodendroglia. This pathway is important in the pathogenesis of adult stroke, trauma, infection and multiple sclerosis (MS), but there is limited information available with respect to the involvement of TRAIL and its receptors in the demise of immature neurons, such as in neonatal Hypoxia-ischemia (HI). In humans, four membrane bound and one soluble receptor for TRAIL have been identified. On contrast with DR4 and DR5, DcR1 (TRAIL-R3), DcR2 (TRAIL-R4) and the soluble osteoprotegerin (OPG) lack functional death domains and are considered to function as decoy receptors.¹

¹ A. Kichev et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling and cell death in the immature central nervous system after hypoxia-ischemia and inflammation. J. Biol. Chem. 2014, 289, 9430-9439.

2300	TIC 10 active isomer	Small molecule that transcriptionally induces TRAIL	Page 927
3581	ONC212	TRAIL inducer; Selective GPR132 agonist	Page 733

Proteins (Regulator) Ferroptosis

The oncogenic RAS-selective lethal small molecule erastin triggers a unique iron-dependent form of non-apoptotic cell death termed *ferroptosis*. Ferroptotic death is morphologically, biochemically and genetically distinct from apoptosis, various forms of necrosis, and autophagy. This process is characterized by the overwhelming, iron-dependent accumulation of lethal lipid ROS. Unlike other forms of apoptotic and non-apoptotic death, this requirement for ROS accumulation appears to be universal.

The specific role of iron in ferroptosis is yet unclear. Ferroptosis cannot be explained by a simple increase in H₂O₂-dependent, iron-catalyzed ROS production (i.e. Fenton chemistry), as H₂O₂-induced death is distinct from RSL-induced ferroptosis¹. Glutathione (GSH) peroxidase 4 (GPX4) is a crucial inhibitor of ferroptosis, and its activity relies on GSH levels. Despite a clear mechanistic overlap between oxytosis and ferroptosis, including the dependence on inhibition of the system X_c⁻ Cys/Glu antiporter, a decrease in GSH levels and the presence of lipid peroxidation, ferroptosis seems to depend mainly on iron instead of calcium signaling².

¹ S.J. Dixon et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012, 149, 1060-1072.

² T. Vanden Berghe et al. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 2014, 15, 135-147.

2293	Ferostatin 1	Potent inhibitor of erastin-induced ferroptosis	Page 479
2990	Liproxstatin-1	Potent inhibitor of ferroptosis	Page 615

Proteins: Transcription Factors

Transcription factors (TFs) are key cellular components that control the first step of gene expression, the transcription of DNA into RNA sequences. By ensuring the correct expression of specific genes, the transcriptional regulatory system plays a central part in controlling many biological processes, ranging from cell cycle progression and maintenance of intracellular metabolic and physiological balance, to cellular differentiation and developmental time courses. TFs may be constitutively active or conditionally active. The most common classification of TFs is based on the structure of their DNA-binding domains. Grouping TFs by structural domain has been extremely useful in uncovering how they recognize and bind specific DNA sequences, as well as providing insights into their evolutionary histories. Moreover, in some instances the DNA-binding domain provides clues to their function¹. A comprehensive classification recognizes four superfamilies with well-defined structural homology: basic domains TFs (1), Zinc-coordinating domains TFs (2), helix-turn-helix domains TFs (3), and beta-scaffold domains with Minor Groove Contacts TFs (4). Additionally, a fifth family of orphan TFs exists for which no superclass assignment can be done yet because of lack of structural information².

¹ J.M. Vaquerizas et al. A census of human transcription factors: function, expression and evolution. Nat. Rev. Genetics 2009, 10, 252-263.

² P. Stegmaier, A.E. Kel, E. Wingender. Systematic DNA-binding domain classification of transcription factors. Genome Inform. 2004, 15, 276-286.

4269	OICR-12694	Recent Addition	Selective and orally bioavailable inhibitor of B cell lymphoma 6 (BCL6)	Page 731
------	------------	-----------------	---	----------

Proteins (Transcription Factors) class 1

Transcription factors with basic DNA-binding domains, including Leucine zipper (bZIP), Helix-loop-helix (bHLH), hybrid (bHLH-ZIP), NF-1, RF-X and bHSH factors¹.

¹ P. Stegmaier, A.E. Kel, E. Wingender. Systematic DNA-binding domain classification of transcription factors. Genome Inform. 2004, 15, 276-286.

3760	Belzutifan	Second-generation potent, selective and orally active HIF-2 α inhibitor	Page 297
4028	BI-87G3	Highly potent covalent NPAS3 heterodimer inhibitor	Page 304
3224	CLK8	CLOCK/BMAL1 interaction inhibitor	Page 376
1935	DIMNF	Selective aryl hydrocarbon receptor modulator (SAhRM)	Page 432
2222	10058-F4	c-Myc inhibitor inducing cell-cycle arrest at G0/G1 phase	Page 474
2975	Fatostatin hydrobromide	Specific inhibitor of SREBP cleavage-activating protein (SCAP)	Page 475
2959	FM19G11	Potent HIF α inhibitor	Page 488
2034	HIF-2 inhibitor 2	Allosteric inhibitor of HIF-2 α	Page 541
2614	HIF-2 α Translation Inhibitor 76	HIF-2 α translation inhibitor that works independent of mTOR	Page 541
2480	LW 6	Inhibitor of HIF-1 α stability via MDH2/CHP1 inhibition	Page 625
2641	ML334	Activator of NRF2 by inhibition of Keap1-NRF2 interactions	Page 668
2733	ML329	Inhibitor of the MITF molecular pathway	Page 671
2671	ML385	Inhibitor of NRF2	Page 672
3229	MYC975	MYC inhibitor	Page 685
3520	PY108	Potent, orally bioavailable AHR agonist	Page 798
3521	PY109	Potent, orally bioavailable AHR agonist	Page 799
3061	RBPJ inhibitor RIN1	First-in-class, potent and selective RBPJ inhibitor	Page 809
2497	RTA 408	Triterpenoid activator of NRF2 and inhibitor of NF- κ B	Page 834
2764	SIS3	Potent and selective inhibitor of Smad3 and TGF- β R1 signaling	Page 868
1865	Stemregenin 1	Aryl hydrocarbon receptor (AHR) antagonist	Page 894
3596	ZG-2033	Potent and orally bioavailable HIF-2 α agonist	Page 1005

Proteins (Transcription Factors) class 2

Superfamily of transcription factors with Zinc-coordinating DNA-binding domains, including Cys4 zinc finger domain containing TFs, such as the nuclear receptors for steroids and thyroid hormones, Cys2His2 zinc finger domain TFs, Cys6 cysteine-zinc cluster TFs and other zinc finger domain containing TFs¹.

The GLI genes, GLI1 and GLI2, are zinc finger transcription factors that regulate target genes at the distal end of the canonical Hedgehog (HH) signaling pathway (SHH- > PTCH- > SMO- > GLI). They play a role in normal cellular processes of embryogenesis, tissue patterning, and differentiation. Being oncogenes, both GLI1 and GLI2 can induce transformation and tumorigenesis, and are constitutively activated in many types of human cancers. Oncogenic pathways, including KRAS/BRAF that occur in high frequency in colon cancer, circumvent the canonical HH-GLI axis by converging on and further driving GLI to a higher activating state in tumor cells, promoting cellular proliferation, tumor progression and survival².

¹ P. Stegmaier, A.E. Kel, E. Wingender. Systematic DNA-binding domain classification of transcription factors. *Genome Inform.* 2004, 15, 276-286.
² R Zhang et al. Targeting GLI by GANT61 involves mechanisms dependent on inhibition of both transcription and DNA licensing. *Oncotarget.* 2016 Dec 6;7(49):80190-80207.

3361	BI-3802	<i>Highly potent and efficacious BCL6 degrader</i>	Page 303
1863	CID 5951923	<i>Inhibitor of Krüppel-like factor 5 (KLF5)</i>	Page 371
2642	GANT61	<i>Inhibitor of GLI-mediated transcription and Hh signaling</i>	Page 496
3927	NVP-DKY709	<i>First-in-class selective CRBN glue degrader of IKZF2</i>	Page 725

Proteins (Transcription Factors) class 3

Transcription factors of the helix-turn-helix (HTH) superclass constitute a particularly large and heterogeneous family of transcription factors, and comprise 6 subclasses, characterized by the presence of a homeo domain, a paired box, a fork head / winged helix domain, heat shock factors (HSFs), tryptophan clusters, or a transcriptional enhancer factor (TEA) domain¹. As stated earlier, grouping transcription factors (TFs) by structural domain has been extremely useful. In some instances the DNA-binding domain provides clues to their function. Homeodomain-containing TFs (>250 discovered) are often associated with developmental processes, and those in the interferon regulatory factor family are generally associated with triggering immune responses against viral infections. The homeodomain in DNA is defined by a 180 bp homeobox region encoding a helix–turn–helix DNA-binding². Nkx2.5 is an important member of the family of homeobox-containing TFs. This transcription factor functions in heart formation and development. Mutations in this gene cause atrial septal defect with atrioventricular conduction defect, and also tetralogy of Fallot, which are both heart malformation diseases³.

Transcriptional activation of the heat shock response is orchestrated by heat shock factor 1 (HSF1), which rapidly translocates to *hsp* genes and induces their expression. Vertebrates have evolved a family of four HSF members, HSF1-4. HSF1 is constitutively expressed in most tissues and cell types and appears to be regulated primarily through posttranslational mechanisms. In addition to elevated temperatures or hyperthermia, HSF1 is activated by oxidative stress, heavy metals, and bacterial and viral infections, as well as by small-molecule modulators⁴.

The POU domain family of transcription factors (TF class 3.1.10.5) regulates developmental processes ranging from specification of the early embryo to terminal differentiation. About half of these factors display substantial affinity for an 8 bp DNA site termed the octamer motif, and are hence known as Oct proteins⁵. Oct4 (Pou5f1) is a well-known Oct factor, with varied and essential roles in development and a key regulator for ESC pluripotency. Reduced expression of Oct4 results in differentiation of ESCs into trophectodermal cells, and overexpression of Oct4 leads to differentiation of ESCs along the mesodermal and primitive endodermal lineages⁶.

Forkhead box (Fox) proteins are a family of evolutionarily conserved transcriptional regulators defined by a common DNA-binding domain (DBD) termed the forkhead box or winged helix domain⁷. The transcription factor FOXM1 (TF class 3.3.1.1) specifically binds to sequence-specific motifs on DNA (C/TAAACA) and activates proliferation- and differentiation-associated genes critical to mitotic spindle assembly, chromosome segregation and G2/M transition, with depletion leading to cell cycle arrest. Aberrant upregulation of FOXM1 has been shown to be a key driver of cancer progression and has been proposed as an initiating factor of oncogenesis. Furthermore, FOXM1 overexpression has been implicated in the development of chemotherapeutic resistance in human breast cancer⁸.

The tryptophan clusters within the family of HTH containing transcription factors comprise several tryptophan residues with a spacing of 12-21 amino acid residues; the subclass of myb-type DNA-binding domains typically exhibit a spacing of 19-21 amino acid residues. The ETS family (E26 transformation-specific), a group of 29 transcription factors containing tryptophan clusters, can be divided in 12 subfamilies which all share the feature that they bind a central GGA(A/T) DNA sequence. Many ETS-domain transcription factors are known to represent nuclear targets of signalling pathways. In particular, the MAPK pathways have been linked with a diverse series of regulatory events that involve ETS-domain proteins⁹. The closely related TFs ERG and ETS variant 1 (ETV1) are frequently found to be involved in protein fusions causing, or playing a crucial role in, prostate cancer¹⁰, among others, where they are often dysregulated by genomic derangement. ETV1 is an ETS factor gene that undergoes chromosomal translocation in prostate cancers and Ewing's sarcomas amplification in melanomas, and lineage dysregulation in gastrointestinal stromal tumors. ETV1 is phosphorylated downstream of mitogen-activated protein kinase (MAPK) signaling, which enhances its protein stability. In addition, the

histone acetyltransferase (HAT) p300 binds and acetylates ETV1 at lysine residues, leading to increased protein half-life and enhanced transcriptional activity¹¹. ETV1 targets MMP7, MMP13, FKBP10 and GLYATL2 genes, among several others¹².

The endothelial transcription factor ERG (another member of the ETS family of TFs) drives expression of vascular endothelial (VE)-cadherin and controls junctional integrity in angiogenesis. During mammalian embryogenesis, ERG is first expressed in endothelium and later in the kidney, urogenital tract and hematopoietic cells. The embryonic activation pattern of ERG is relevant to oncogenesis, since ERG transcription is specifically strongly upregulated in prostate cancer epithelial cells, and in prostate endothelial cells as well. This may provide an example of oncogenic reactivation of an embryonic transcription factor¹³.

¹ P. Stegmaier, A.E. Kel, E. Wingender. Systematic DNA-binding domain classification of transcription factors. *Genome Inform.* 2004, 15, 276-286.
² S. Banerjee-Basu et al. Molecular evolution of the homeodomain family of transcription factors. *Nucleic Acids Res.* 2001 August 1; 29(15): 3258-3269.
³ Y. Zhang et al. GATA and Nkx factors synergistically regulate tissue-specific gene expression and development in vivo. *Development.* 2007 Jan;134(1):189-98.
⁴ J. Anckar, L. Sistonen. Regulation of HSF1 Function in the Heat Stress Response: Implications in Aging and Disease. *Ann. Rev. Biochem.* 2011, 80, 1089-1115.
⁵ D. Tantin et al. Oct transcription factors in development and stem cells: insights and mechanisms. *Development.* 2013 Jul;140(14):2857-66.
⁶ W. Li et al. Identification of Oct4-activating compounds that enhance reprogramming efficiency. *Proc Natl Acad Sci U S A.* 2012 Dec 18;109(51):20853-8.
⁷ S.S. Myatt et al. The emerging roles of forkhead box (Fox) proteins in cancer. *Nat Rev Cancer.* 2007 Nov;7(11):847-59.
⁸ M.V. Gornally et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. *Nat Commun.* 2014 Nov 12;5:5165.
⁹ A.D. Sharrocks. The ETS-domain transcription factor family. *Nat Rev Mol Cell Biol.* 2001 Nov;2(11):827-37.
¹⁰ S. Rahim et al. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. *PLoS One.* 2011 Apr 29;6(4):e19343.
¹¹ M.S. Pop et al. A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. *Mol Cancer Ther.* 2014 Jun;13(6):1492-502.
¹² S. Rahim et al. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model. *PLoS One.* 2014 Dec 5;9(12):e114260.
¹³ K. Rostad et al. ERG upregulation and related ETS transcription factors in prostate cancer. *Int J Oncol.* 2007 Jan;30(1):19-32.

2839	AS 1842856	<i>Inhibitor of the Forkhead box protein O1 (FOXO1)</i>	Page 251
2699	CCT251236	<i>HSF1 stress pathway inhibitor</i>	Page 352
3546	DB2313 hydrochloride Recent Addition	<i>Potent PU.1 inhibitor</i>	Page 411
3412	DTHIB	<i>Direct and selective HSF1 inhibitor</i>	Page 444
2384	FDI 6	<i>Inhibitor of the Forkhead box protein M1 (FOXM1)</i>	Page 476
1890	HSF1A	<i>Human HSF1 activator</i>	Page 546
2101	HSF1B	<i>Human HSF1 activator</i>	Page 547
2538	KRIBB11	<i>HSF1 inhibitor; blocks the induction of HSP27 and HSP70</i>	Page 595
4020	O414	<i>Metabolically stable next-generation endogenous Oct4 inducer</i>	Page 728
2651	OAC2	<i>Oct4 and Nanog activating compound</i>	Page 728
4050	STL427944	<i>Selective FOXM1 inhibitor</i>	Page 897
2469	YK 4-279	<i>Inhibitor of ETV1, ERG, EWS-FLI1 and RNA helicase A</i>	Page 998

Proteins (Transcription Factors) class 4

This superfamily of transcription factors with β -scaffold DNA-binding domains with minor groove contacts comprises 11 subclasses: RHR, STAT, p53, MADS box, β -Barrel α -helix transcription factors, TATA binding proteins, HMG-box, Heteromeric CCAAT factors, grainyhead, Cold-shock domain factors, and Runt¹. Late SV40 Factor (LSF), also known as alpha-globin transcription factor CP2 (TFCP2), functions as part of the SSP (stage selector protein) complex, and binds a variety of cellular and viral promoters including fibrinogen, alpha-globin, SV40 and HIV-1 promoters².

Sex-determining Region Y (SRY) box 9 (SOX-9; TF 4.7.1) is a member of a highly conserved family of transcription factors defined by their similarity to the high mobility group DNA-binding domain of SRY (HMG-box family). It is crucial for multiple aspects of development, such as regulating the production of extracellular matrix (ECM) cartilage and cell proliferation, among others³. SOX9 is also expressed in a wide range of cancers, where it regulates cell proliferation. Functionally, SOX-9 knockdown impairs cell proliferation in glioma cell lines, induces the cell arrest in G2/M phase of cell cycle and enhances the apoptosis in glioma cells. The inhibition of its activity mediates the impaired cell cycle progression and reduced cell invasion induced by miR-145 tumor suppressor⁴.

¹ P. Stegmaier, A.E. Kel, E. Wingender. Systematic DNA-binding domain classification of transcription factors. *Genome Inform.* 2004, 15, 276-286.
² P.K. Santhekadur et al. The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. *Am. J. Cancer Res.* 2012, 2, 269-285.
³ J. Pritchett et al. Understanding the role of SOX9 in acquired diseases: lessons from development. *Trends Mol. Med.* 2011, 17, 166-174.
⁴ A.M. de la Rocha et al. Role of SOX family of transcription factors in central nervous system tumors. *Am. J. Cancer Res.* 2014, 4, 312-324.

3834	Alantolactone	<i>STAT3 inhibitor; NLRP3 inhibitor</i>	Page 218
1992	AS 1517499	<i>Potent and selective STAT6 inhibitor</i>	Page 252
3786	BP-1-102	<i>Orally bioavailable STAT3 inhibitor</i>	Page 323
2489	Brassinin	<i>Dual IDO1/STAT3 inhibitor</i>	Page 326
3394	CADD522	<i>Potent inhibitor of RUNX2-DNA binding</i>	Page 339
3035	Compound 10	<i>Tool compound targeting the NFAT:AP-1 transcriptional complex on DNA</i>	Page 383
2841	COTI-2	<i>Reactivator of mutant p53</i>	Page 385
2879	CP 31398	<i>Stabilizer of p53 and inducer of apoptosis</i>	Page 386
3518	DCZ0805	<i>NF-κB activation inhibitor</i>	Page 414
3457	Fludarabine	<i>Inhibitor of DNA synthesis; STAT-1 activation inhibitor</i>	Page 485
2157	FQI 1	<i>Inhibitor of alpha-globin transcription factor CP2 (LSF)</i>	Page 491
2349	JSH 23	<i>Inhibitor of NF-κB transcription translocation of p65</i>	Page 583
3607	Micheliolide	<i>NF-κB activation inhibitor</i>	Page 654
2517	Napabucasin	<i>Oral cancer stemness inhibitor targeting STAT3</i>	Page 692
3909	NFATc1 inhibitor A04	<i>Potent RANKL-induced osteoclastogenesis inhibitor</i>	Page 699
3387	NF-κB Activation Inhibitor IV	<i>Potent NF-κB activation inhibitor</i>	Page 700
2564	NSC 59984	<i>Activator of p53 that restores WT p53 signaling</i>	Page 716
2016	NSC 319726	<i>Reactivator of the p53 mutant p53R175</i>	Page 715
3277	NSC194598	<i>p53 DNA-binding inhibitor</i>	Page 718
3614	Parthenolide	<i>NF-κB activation inhibitor</i>	Page 748
1871	Pifithrin-α Hydrobromide	<i>Inhibitor of p53 protein</i>	Page 777
3051	Pifithrin-β	<i>Inhibitor of p53 protein; Condensation product of Pifithrin-α</i>	Page 777
2488	Piperlongumine	<i>Natural alkaloid with potent cytotoxic activity</i>	Page 779
4268	Rezatapopt Recent Addition	<i>First-in-class p53 reactivator</i>	Page 814
2313	S31 201	<i>Potent, cellular STAT3 inhibitor</i>	Page 838
2244	SCH 529074	<i>Small molecule activator of mutant p53</i>	Page 856
2731	STAT5 Inhibitor 1 [285986-31-4]	<i>Nonpeptidic small-molecule inhibitor of STAT5 activation</i>	Page 893
2314	Stattic	<i>Inhibitor of STAT3 activation, dimerization, and translocation</i>	Page 893
2316	WP 1066	<i>JAK2 and STAT3 inhibitor</i>	Page 987

Proteins (Transcription Factors) coactivators

Mediating the functional connection between transcription factors and the general transcription apparatus are the coactivators. Coactivator refers to a protein or protein complex that increases the rate of transcription by interacting with transcription factors but does not itself bind to DNA in a sequence-specific manner. Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α). PGC-1s are proteins that enhance the transcriptional activity of transcription factors through direct protein-protein interactions. PGC-1α serves as an inducible coregulator in the control of energy homeostasis, and its expression is induced rapidly by physiological conditions known to increase the demand for mitochondrial ATP production such as cold exposure, exercise, and fasting. It has been shown to regulate adaptive thermogenesis, mitochondrial biogenesis, glucose and fatty acid metabolism, the peripheral circadian clock, fiber-type switching in skeletal muscle, and heart development.¹²³

¹ L.N. Zhang et al. Novel small-molecule PGC-1α transcriptional regulator with beneficial effects on diabetic db/db mice. *Diabetes*. 2013, 62, 1297-1307.
² P. Puigserver et al. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. *Endocr. Rev.* 2003, 24, 78-90.
³ B.N. Finck et al. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. *Circulation*. 2007, 115, 2540-2548.

4267	FX-909 Recent Addition	<i>Peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist</i>	Page 493
3480	PY-60	<i>Specific YAP activator targeting ANXA2</i>	Page 799

3824	TEAD inhibitor TM2	<i>Potent reversible pan-TEAD inhibitor</i>	Page 916
3354	Verteporfin	<i>Inhibitor of TEAD-YAP association; Photosensitizer</i>	Page 967
2379	ZLN 005	<i>Regulator of peroxisome PPAR-γ coactivator-1α (PGC-1α)</i>	Page 1008

Proteins: Transporters

Four fundamentally different classes of membrane-bound transport proteins exist in organisms: ion channels; transporters; aquaporins; and ATP-powered pumps. Transport proteins serve the function of moving other materials within an organism. Basically, there are two different types of transport proteins: those that carry molecules to "distant" locations (within a cell or an organism), and those that serve as gateways, carrying molecules across otherwise impermeable membranes¹. One example of a specific transporter that plays a key role in the metabolism of many organisms is the sodium dependent glucose co-transporter (SGLT), for example. A protein highly abundant in kidneys, that serves renal glucose reabsorption, and therefore is of high interest as a target for the treatment of diabetes² (for example SGLT2 inhibitor Remogliflozin (Axon 1634)).

Aquaporins (AQP) are integral membrane proteins that serve as channels in the transfer of water, and in some cases, small solutes across the membrane. Structural analyses of the molecules have revealed the presence of a pore in the center of each aquaporin molecule. In mammalian cells, more than 10 isoforms (AQP0-AQP10) have been identified so far. They are differentially expressed in many types of cells and tissues in the body³. Aquaporin 4 (AQP4) has been identified in a wide variety of tissues, including brain, lung, intestine, muscle, and kidney. It is highly expressed in the peri-vascular and subpial endfeet of glial cells, as well as in smaller amounts along the peri-neuronal membranes, and is presumed to play a vital role in maintaining homeostatic water balance across the blood-brain barrier. Furthermore, its presence as the primary water transporter in the human brain has led to considerable interest in better understanding its roles in human physiology and pathology⁴.

¹ J.M. Berg, J.L. Tymoczko, L. Stryer. *Biochemistry*, 2002, 5th edition. New York. W. H. Freeman.
² Remogliflozin etabonate, in a Novel Category of Selective Low-Affinity / High-Capacity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models. Y. Fujimori, K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, M. Isaji. *J. Pharmacol. Exp. Ther.* 2008, 327, 268-276.
³ K. Takata et al. Aquaporins: water channel proteins of the cell membrane. *Prog Histochem Cytochem.* 2004;39(1):1-83.
⁴ V.J. Huber et al. Identification of aquaporin 4 inhibitors using in vitro and in silico methods. *Bioorg Med Chem.* 2009 Jan 1;17(1):411-7.

2941	ARN 272	<i>Selective inhibitor of FAAH-like anandamide transporter (FLAT)</i>	Page 224
2987	DFP00173	<i>Potent and selective AQP3 inhibitor</i>	Page 358
2904	Exo1	<i>Inhibitor of the exocytic pathway</i>	Page 393
3031	NIC3	<i>Inhibitor of nucleus accumbens-associated protein-1 (NAC1) homodimerization</i>	Page 576
2422	TGN 020	<i>Aquaporin 4 (AQP4) inhibitor. Useful pharmacological tool</i>	Page 761

Proteins (Transporters) Neurotransmitters

Intercellular communication in the central nervous system requires the precise control of the duration and the intensity of neurotransmitter action at the specific receptors. After they have been released at the synapse, neurotransmitters activate pre- and/or postsynaptic receptors. To terminate synaptic transmission, neurotransmitters can, in turn, be inactivated by either enzymatic degradation or active transport into neuronal and/or glial cells by neurotransmitter transporters¹. Reuptake inhibitors of neurotransmitters have a direct effect on extracellular concentrations of neurotransmitters in the synapses, and therefore influence neurotransmission.

Glutamate transporters control the glutamate homeostasis in the central nervous system. Until now, five subtypes of high-affinity glutamate transporters (excitatory amino acid transporters, EAATs 1-5) have been identified that belong to the solute carrier 1 (SLC1) family of transmembrane proteins. These EAATs are secondary-active transporters, taking up glutamate into the cell against a substantial concentration gradient. EAAT1 and EAAT2 are predominantly but not exclusively expressed in glial cells; for example, EAAT2 is also expressed in mammalian retina² and the most abundant glutamate transporter found in the brain and, by some estimates, accounts for ~90% of the total glutamate uptake in the brain³.

The serotonin norepinephrine reuptake inhibitors (SNRIs) are dual action antidepressants that inhibit thereuptake of both serotonin (5-hydroxytryptamine) and norepinephrine (noradrenaline). SNRIs are a useful alternative to SSRIs and are often used in patients with anxiety disorders, following a partial response or non-response to SSRI treatment⁴. In fact, SNRIs are widely considered to be the first choice for antidepressant therapy: dual-action antidepressants may provide a faster speed of onset and higher rates of remission than the older TCAs and MAOIs while avoiding their intolerable side effects. However,

the SNRIs are not side-effect free; venlafaxine is associated with an increased risk of sustained hypertension, especially at high doses⁵.

- ¹ Neurotransmitter Transporters in the Central Nervous System. J. Masson, C. Sagné, M. Hamon, S. El Mestikawy. Pharm. Rev. 1999, 51, 439-464.
² T. Rauert et al. Structural and functional dynamics of Excitatory Amino Acid Transporters (EAAT). AIMS Mol. Science 2014, 1, 99-125.
³ C.B. Divito et al. Excitatory amino acid transporters: roles in glutamatergic neurotransmission. Neurochem Int. 2014 Jul;73:172-80.
⁴ B. Dell'Osso et al. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol. 2010 Jan;25(1):17-29. doi: 10.1002/hup.1074.
⁵ R. Jain et al. Single-Action Versus Dual-Action Antidepressants. Prim Care Companion J Clin Psychiatry. 2004; 6(suppl 1): 7-11.

1238	ALX 5407 hydrochloride	GlyT-1 inhibitor	Page 220
1333	Amoxapine	Tricyclic antidepressant; reuptake inhibitor of (NRI)	Page 235
3777	AS-1, (R)-	First-in-class highly selective and orally bioavailable PAM of EAAT2	Page 251
1297	Atomoxetine Hydrochloride	NRI inhibitor	Page 259
1462	Azaphen	Antidepressant	Page 266
1257	BTS 54-505	5-HT uptake inhibitor	Page 331
1451	Bupropion hydrochloride	DRI and NRI; nicotinic acetylcholine receptor antagonist	Page 332
3619	Chlorphentermine hydrochloride	Serotonin transporter (SERT) substrate	Page 367
1320	Citalopram hydrobromide	SSRI; Antidepressant	Page 373
1722	Deshydroxy Venlafaxine HCl	Metabolite of Venlafaxine; SNRI	Page 419
3578	Desmethylvenlafaxine, O-	Metabolite of Venlafaxine; SNRI	Page 420
1720	Desmethylvenlafaxine, R-(-)-O-	Metabolite of Venlafaxine; SNRI	Page 420
1721	Desmethylvenlafaxine, S-(+)-O-	Metabolite of Venlafaxine; SNRI	Page 420
2116	Desmethylvenlafaxine succinate, O-	Metabolite of Venlafaxine; SNRI	Page 421
3555	Desvenlafaxine hydrochloride	Metabolite of Venlafaxine; SNRI	Page 421
1726	Dinorvenlafaxine	Metabolite of Venlafaxine; SNRI	Page 433
3315	Escitalopram oxalate	SSRI; Antidepressant	Page 467
3881	ECSi#6	First uncompetitive serotonin transporter (SERT) inhibitor	Page 450
1302	Fluoxetine Hydrochloride	SSRI	Page 486
1556	Fluvoxamine maleate	SSRI	Page 488
1203	GBR 12783 dihydrochloride	Dopamine uptake inhibitor	Page 497
4201	Iclepertin Recent Addition	Potent, selective and orally active GlyT-1 inhibitor	Page 558
3355	IDT307	DAT/NET/SERT substrate; Fluorescent dye	Page 559
2260	LDN 212320	Activator of EAAT2 translation; neuroprotectant	Page 608
3128	Levomilnacipran hydrochloride	SNRI	Page 612
2587	ML352	Potent and selective inhibitor of the presynaptic CHT	Page 666
1563	ORG 25935	GlyT-1 inhibitor	Page 736
1452	Paroxetine hydrochloride	SSRI	Page 748
1123	Radafaxine hydrochloride	NDRI	Page 806
1240	Reboxetine mesylate	NARI	Page 810
1300	Sertraline Hydrochloride	SSRI; Antidepressant	Page 862
1549	SSR 504734	GlyT-1 inhibitor	Page 892
2640	TFB-TBOA	Very potent blocker of human EAAT1-2	Page 920
1727	Venlafaxine hydrochloride	SNRI	Page 965
2670	VU6001221	Choline transporter inhibitor	Page 977
1725	WY 46689	Metabolite of Venlafaxine; SNRI	Page 989
1724	WY 45494 hydrochloride	Metabolite of Venlafaxine; SNRI	Page 988
1723	WY 45960 hydrochloride	Metabolite of Venlafaxine; SNRI	Page 989

4057	ZINC000006658090 Recent Addition	Potent, conformationally selective and non-competitive SERT inhibitor	Page 1006
------	---	---	-----------

Proteins (Transporters) ABC

The ATP-binding cassette (ABC) transporter family (ATP-dependent pumps) consist of ubiquitously membrane-bound proteins, present in all prokaryotes, as well as plants, fungi, yeast and animals. These pumps can move substrates in (influx) or out (efflux) of cells, using the favorable chemical energy of ATP hydrolysis to translocate molecules across membranes in a thermodynamically unfavorable direction¹. In mammals, ABC transporters are expressed predominantly in the liver, intestine, blood-brain barrier, blood-testis barrier, placenta and kidney. Besides, the nucleotide binding domain (NBD or ATP binding cassette), these transporters also contain trans-membrane domains (TMDs), each of which comprises several hydrophobic α -helices. The ABC transporter core unit consists of four domains, two NBDs and two TMDs. The two NBDs together bind and hydrolyze ATP (thereby providing the driving force for transport), while the TMDs participate in substrate recognition and translocation across the lipid membrane². To date, 48 different ABC transporters have been identified in the human genome, divided into seven different classes (A-G; ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White) based on sequence similarities³. The p-glycoprotein (PGP, P-gp) and the breast cancer resistance protein (BCRP) both are members of this large family of transporters.

P-gp is known as the multidrug resistance protein 1 (MDR1), or cluster of differentiation 243 (CD243), and transports neutral and cationic hydrophobic compounds across the cell membrane to the cells exterior. It is expressed in only a limited number of tissues with barrier function, including epithelia of the liver, kidney, small and large intestine and capillary endothelial cells in brain, ovary, and testis. As P-gp is one of the important proteins involved in multidrug resistance of tumors, extensive research has been undertaken to find drugs that can reverse the resistance.

¹ D.C. Rees, E. Johnson, O. Lewinson. ABC transporters: the power to change. Nat. Rev. Mol. Cell Biol. 2009, 10, 218-227.

² V. Vasilou et al. Human ATP-binding cassette (ABC) transporter family. Hum. Genomics. 2009, 3, 281-290.

³ S.V. Ambudkar et al. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22, 7468-7485.

3564	ABCA1 inducer compound G	ABCA1 inducer targeting OSBPL7	Page 199
1654	CP 100356 Hydrochloride	P-gp inhibitor	Page 387
1896	Elacridar hydrochloride	P-gp inhibitor (3rd generation ABCB1 modulator)	Page 454
1409	KO 143	BCRP inhibitor	Page 593
2508	KS 176	Inhibitor of the ABC-transporter BCRP	Page 597
1839	LY 335979	Inhibitor of P-glycoprotein	Page 630
2591	MC70 hydrochloride	P-gp inhibitor with good selectivity towards BCRP pump	Page 641
3784	PGP-4008	Selective P-glycoprotein (Pgp) inhibitor	Page 772
3222	Reversan	Potent, selective and non-toxic MRP1 inhibitor	Page 814
1960	Tariquidar	Inhibitor of P-glycoprotein (P-gp, ABCB1)	Page 910

Proteins (Transporters) Glucose

One specific form of transport that plays a key role in the metabolism of many organisms is that of glucose. It involves membrane bound glucose transporters (GLUT or SLC2A) and sodium-dependent glucose co-transporters (or sodium-glucose linked transporters, SGLT). The latter (SGLT), for example, is a protein highly abundant in kidneys, that serves renal glucose reabsorption, and therefore is of high interest as a target for the treatment of diabetes¹ (for example SGLT2 inhibitor Remogliflozin (Axon 1634)). SGLTs are secondary-active cell-membrane co-transporters, driven by the Na⁺/K⁺-ATPase pump, which actively extrudes sodium across the basolateral membrane, in conjunction with the inward transfer of specific hexose sugars or some other molecules against their concentration gradient from the small intestine and kidney (SGLT1 and SGL2 respectively). SGLTs should not be confused with facilitated glucose transporters (GLUTs) that mediate passive transfer of glucose across cell membranes down a concentration gradient. However, as in both the intestine and kidney, the two different types of transporters can operate in tandem: SGLTs transfer glucose into the cell across the luminal membrane whereas GLUTs transfer glucose out of the cell across the basolateral membrane².

¹ Remogliflozin etabonate, in a Novel Category of Selective Low-Affinity / High-Capacity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models. Y. Fujimori, K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, M. Isaji. J. Pharmacol. Exp. Ther. 2008, 327, 268-276.

² A.A. Tahrani et al. SGLT inhibitors in management of diabetes. Lancet Diab. Endocrin. 2013, 1, 140-151.

2660	BAY-876	Inhibitor of glucose transporter 1 (GLUT1)	Page 291
3122	Canagliflozin	Highly potent and selective SGLT2 inhibitor	Page 341

3121	Dapagliflozin	Potent and selective hSGLT2 inhibitor	Page 409
3367	Empagliflozin	Potent and selective SGLT2 inhibitor	Page 457
1634	Remogliflozin	SGLT2 inhibitor	Page 811
1905	STF 31	Inhibitor of glucose transporter 1 (GLUT1)	Page 894

Proteins (Transporters) Ions

Sodium proton exchangers (NHEs) constitute a large family of polytopic membrane protein transporters found in organisms across all domains of life. They work by exchanging extracellular sodium or lithium ions for intracellular protons. In animal cells, they are linked to a variety of physiological roles with the most important being regulation of intracellular pH and cell volume. To date nine isoforms (NHE1-9) have been identified in the human NHE family. The Na⁺/H⁺ exchanger isoform 1 (NHE-1) has a multitude of important and specific tasks and its basic role of maintaining intracellular pH and cell volume affect cell growth, proliferation, migration and apoptosis, and plays important roles in heart disease and cancer¹. The transporter protein consists of 12 transmembrane (TM) segments with the amino and carboxyl termini of the protein both being located on the cytoplasmic side, although recently, there is some controversy on the fundamental structure of the protein².

Genipin (Axon 1443) is an excellent natural cross-linker for proteins, collagen, gelatin, and chitosan. Besides, it has been shown to inhibit uncoupling protein 2 (UCP2), is a mitochondrial carrier protein that negatively regulates insulin secretion by inhibiting UCP2 mediated proton leak. As UCP2 is an important mediator of β-cell dysfunction, it has been hypothesized that UCP2 inhibitors lacking adverse side effects could be useful drugs for treatment of β-cell dysfunction and type 2 diabetes³. Other functions addressed to UCP2 are the suppression of production of mitochondrial reactive oxygen species (ROS) and the ability to mitigate oxidative stress in drug-resistant cancer cells⁴.

¹ E. Slepkov, L. Fliegel. Structure and function of the NHE1 isoform of the Na⁺/H⁺ exchanger. *Biochem. Cell. Biol.* 2002, 80, 499-508.

² G. Kemp et al. Structure and function of the human Na⁺/H⁺ exchanger isoform 1. *Channels* 2008, 2, 329-336.

³ C.Y. Zhang et al. Genipin inhibits UCP2-mediated proton leak and acutely reverses obesity- and high glucose-induced beta cell dysfunction in isolated pancreatic islets. *Cell. Metab.* 2006, 3, 417-427.

⁴ R.J. Mailloux et al. Genipin-Induced Inhibition of Uncoupling Protein-2 Sensitizes Drug-Resistant Cancer Cells to Cytotoxic Agents. *PLoS One.* 2010, 5, e13289.

4175	AJ2-30	First-in-class SLC15A4 inhibitor	Page 216
2976	BI 01383298	4-Piperidinecarboxamide, 1-[(3,5-dichlorophenyl)sulfonyl]-N-[(4-fluorophenyl)methyl]-	Page 301
3699	BMS-466442	Selective asc-1 inhibitor	Page 318
3358	CTPI-2	Specific SLC25A1 inhibitor	Page 398
4108	Feeblin Recent Addition	SLC15A4 inhibitor; Nucleic acid-sensing TLR7/8 pathway inhibitor	Page 477
1443	Genipin	Protein cross-linker; inhibits UCP2	Page 501
2751	SEA0400	Inhibitor of Na ⁺ /Ca ²⁺ exchanger (NCX)	Page 859
3604	YM-244769 dihydrochloride	Highly potent inhibitor of reverse Na ⁺ /Ca ²⁺ exchanger (NCX) activity	Page 999
2022	Zoniporide hydrochloride	Inhibitor of Na ⁺ /H ⁺ exchanger isoform 1 (NHE-1)	Page 1010

Proteins (Transporters) Synaptic Vesicle Glycoprotein

Synaptic vesicle protein 2 (SV2) is a membrane glycoprotein found only in the secretory vesicles of neural and endocrine cells. Three isoforms of this 90-kDa protein exist: SV2A, SV2B, and SV2C, of which, SV2A is the most widely distributed. The molecular mechanism by which these proteins regulate secretion is not clear¹. Based on predicted structure and amino acid sequences, the SV2 proteins belong to the major facilitator superfamily of transporter proteins, with a high degree of homology with glucose transporters (GLUTs) and plasma membrane transporters for neurotransmitters². Other studies demonstrated that SV2A deletion results in reduced action potential-dependent release of the inhibitory neurotransmitter GABA in the hippocampus. These observations have given rise to the hypothesis that SV2A dysfunction is associated with calcium accumulation during repeated action potential generation. The effect, in turn, leads to increased neurotransmitter release and a destabilization of neuronal circuits, facilitated by excitatory transmission and a concurrent attenuation of inhibition. It would explain why SV2A knockout mice have spontaneous seizures from birth and typically die within 3 weeks³. Similar studies also revealed that SV2A is the brain binding site of levetiracetam (Axon 1110), an antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy⁴.

¹ A. Pitkänen. SV2A: More Than Just a New Target for AEDs. *Epilepsy Curr.* 2005, 5, 14-16.

² M.B. Feany et al. The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. *Cell.* 1992, 70, 861-867.

³ G.J. Sillis. SV2A in Epilepsy: The Plot Thickens. *Epilepsy Curr.* 2010, 10, 47-49.

⁴ B.A. Lynch et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. *Proc. Natl. Acad. Sci. USA.* 2004, 101, 9861-9866.

1109	Etiracetam	Racemate of Axon 1110 and Axon 1111	Page 469
1110	Levetiracetam	Binds synaptic vesicle protein 2A (SV2A)	Page 611
1111	UCB-L 060	Least active enantiomer of Axon 1109	Page 948

Proteins (Transporters) Triglycerides

Cholesteryl Ester Transfer Protein (CETP) is a hydrophobic glycoprotein secreted mainly from the liver and circulates in plasma, bound mainly to HDL. It reduces circulating HDL cholesterol levels by promoting the transfer of cholesteryl esters from antiatherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs in exchange for triglyceride¹. Its activity is associated with conditions linked with accelerated atherosclerosis including diabetes, metabolic syndrome and the dyslipidaemia typically found in myocardial infarction survivors. CETP is a member of a family of proteins expressed in species including man and rabbit, which are susceptible to atherosclerosis, but not in rats, which are resistant to atherogenesis². Dalcetrapib and Torcetrapib (Axon 1962 and 2047 respectively) both inhibit CETP activity, resulting in increased levels of HDL cholesterol, and decreased levels of LDL cholesterol. However, in case of Torcetrapib, not Dalcetrapib³, the beneficial pharmacological effects are accompanied by an increased risk of cardiovascular events leading to mortality and morbidity⁴.

The microsomal triglyceride transfer protein (MTP) plays a crucial role in the assembly of triglycerides (TG), cholesterol esters, and phospholipids into ApoB-containing lipoproteins and is integral in the assembly of very low-density lipoprotein-cholesterol (VLDL-C) in the liver. As a result, inhibition of hepatic MTP could be a promising alternative strategy for the control of circulating levels of LDL-C and TG⁵.

¹ P.J. Barter et al. Cholesteryl Ester Transfer Protein. A Novel Target for Raising HDL and Inhibiting Atherosclerosis. *Arterioscl. Thromb. Vasc. Biol.* 2003, 23, 160-167.

² P.N. Durrington. Cholesteryl Ester Transfer Protein (CETP) Inhibitors. *Br. J. Cardiol.* 2012, 19, 126-133.

³ T.F. Luscher et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. *Eur. Heart J.* 2012, 33, 857-865.

⁴ P.J. Barter et al. Effects of torcetrapib in patients at high risk for coronary events. *N. Engl. J. Med.* 2007, 357, 2109-2122.

⁵ E. Kim et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLX-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. *J. Pharmacol. Exp. Ther.* 2011, 337, 775-785.

4277	BMS 309403 Recent Addition	Potent, selective and orally active aFABP inhibitor	Page 317
2216	CP 346086	Microsomal triglyceride transfer protein (MTP) inhibitor	Page 388
1962	Dalcetrapib	Inhibitor of cholesterylester transfer protein (CETP)	Page 408
2286	Evacetrapib	Potent, and selective inhibitor of CETP	Page 471
4161	FABP4 inhibitor C3 Recent Addition	Potent and highly selective inhibitor of FABP4	Page 474
2917	Lomitapide	Potent microsomal triglyceride transfer protein (MTP) inhibitor	Page 618
2047	Torcetrapib	Inhibitor of cholesterylester transfer protein (CETP)	Page 936

Proteins (Transporters) Phosphatidylglycerides

Inositol lipids have specialized functions in eukaryotic organisms. Not only do they provide a source of second messengers but they are also recognized as signaling molecules. Moreover, inositol lipids are required as substrates for PLC and PI3K activities, as well as having a role in cytoskeletal reorganization and vesicular traffic. The cytosolic protein Phosphatidylinositoltransfer protein (PIPT) is a key regulator of the cellular mechanism that can compartmentalize the synthesis of these phosphoinositides¹. PIPTs mediate the transfer of monomeric phosphatidylinositol (PI) or phosphatidylcholine (PC) molecules between two membrane compartments of a cell. Sec14p is a PIPT found in yeast, and is the prototype for a protein module called the SEC14 domain. SEC14 domains are found in proteins from plants, yeast, invertebrates, and mammals (named CRAL_TRIO domain), suggesting an ancient evolutionary origin. Many proteins with a SEC14 domain consist only of this module, while others are larger proteins with additional protein-protein interaction or catalytic domains. It appears likely that the SEC14-only proteins are bona fide lipid transport proteins, while the multi-domain SEC14-containing proteins have more complex functions in signal transduction, transport, and organelle biology, where they integrate lipid metabolism with other biochemical processes². Aberrant functioning of Sec14, either due to individual deficiencies, genetic mutations or chemical inhibition, impairs cell viability through compromised

Phosphatidylinositol (PtdIns) trafficking through the trans-Golgi network (TGN) and endosomal systems, phosphatidylserine decarboxylation to phosphatidylethanolamine, fatty acid metabolism, polarized growth, and fungal dimorphism. Mutations in PITPs, or PITP-like proteins, are also root causes of mammalian neurodegenerative and lipid homeostatic diseases³.

¹ S. Cockcroft. Phosphatidylinositol transfer proteins: a requirement in signal transduction and vesicle traffic. *Bioessays*. 1998 May;20(5):423-32.

² K. Saito et al. The lipid-binding SEC14 domain. *Biochim Biophys Acta*. 2007 Jun;1771(6):719-26.

³ A.H. Nile et al. PITPs as targets for selectively interfering with phosphoinositide signaling in cells. *Nat Chem Biol*. 2014 Jan;10(1):76-84.

2387 **SMI 481** *First small-molecule inhibitor (SMI) of the yeast PITP Sec14*.. Page 875

Proteins (Transporters) Other

PDE δ was originally identified as a fourth subunit of rod-specific cGMP PDE. PDE δ is thought to be a specific soluble transport factor for certain prenylated (farnesyl) proteins and Arl2-GTP, a regulator of PDE-mediated transport. PDE δ sustains the spatial organization of KRAS by facilitating its diffusion in the cytoplasm. Conversely, PDE δ down-modulation randomizes RAS distributions to all membranes in the cell and suppresses regulated signalling through wild-type RAS and also constitutive oncogenic RAS signalling in cancer cells.^{1,2}

FLI 06 (Axon 2277) is an inhibitor of endoplasmic reticulum (ER) export. This compound has the unique property to inhibit cargo recruitment to ER exit sites (ERESs): it disrupts the Golgi apparatus in a manner distinct from that of brefeldin A and golgicide A. FLI-06 inhibits general secretion at a step before exit from the endoplasmic reticulum (ER), which is accompanied by a tubule-to-sheet morphological transition of the ER, rendering it the first small molecule acting at such an early stage in secretory traffic. As such, it effectuates the accumulation of Notch Δ E-eGFP in intracellular membranes³.

Retromer is a multiprotein complex that acts to sort and traffic cargo from endosomes to the trans-Golgi network or to the cell surface. By mediating the localisation of many membrane proteins, the activity of the retromer complex has been linked to processes such as lysosome biogenesis, and aspects of metazoan development⁴. Additionally, retromer-mediated transport has been implicated in a growing number of neurological diseases, but was first linked to Alzheimer's disease (AD). The neuronal retromer traffics the amyloid-precursor protein (APP) away from endosomes, a site where APP is cleaved into pathogenic fragments in Alzheimer's disease. It has been hypothesized that deficiencies in specific vacuolar protein sorting (VPS) proteins that build up the retromer complex, are important for mediating the trafficking and pathogenic processing of APP⁵.

Uric acid is the end product of purine metabolism in humans. Its synthesis is catalyzed by xanthine oxidoreductase and is mainly produced in liver, muscles, and intestine. Uric acid transporter URAT1, a 12-transmembrane domain-containing protein found in the apical membrane of proximal tubule epithelial cells and transports urate in exchange for Cl⁻ or organic anions⁶, contributes significantly to reabsorption of uric acid in humans to maintain a constant serum uric acid (SUA) level. Alterations of SUA level are linked to various human diseases, such as hypertension, cardiovascular disease, kidney disease, multiple sclerosis, Parkinson's disease, Alzheimer's disease, and optic neuritis⁷. Gout is yet another example of a commonly occurring disease that is triggered by the crystallization of uric acid within the joints; a type of inflammatory arthritis and is often associated with hyperuricemia⁸.

XPO1 is the best-characterized nuclear exporter of the karyopherin- β superfamily of nuclear transport proteins, which includes 15 different importin and exportin proteins. XPO1 is involved in transporting approximately 220 proteins and certain RNA species from the nucleus to the cytoplasm through the nuclear pore complex. In the nucleus, XPO1 forms a quaternary complex with one of a diverse array of cargo proteins, Ran-GTP, and Ran-BP3. In the cytoplasm, the complex is dissociated through the combined action of Ran-GAP and Ran-BP1. Selective inhibitors of nuclear export (SINE) have proven to be effective as inhibitors of the replication of various influenza A and B virus strains⁹, and as anti-cancer agents¹⁰, for example.

¹ A. Chandra et al. The GDI-like solubilizing factor PDE δ sustains the spatial organization and signalling of Ras family proteins. *Nat. Cell Biol*. 2011, 14, 148-158.

² G. Zimmermann et al. Small molecule inhibition of the KRAS-PDE δ interaction impairs oncogenic KRAS signalling. *Nature*. 2013, 497, 638-642.

³ A. Krämer et al. Small molecules intercept Notch signaling and the early secretory pathway. *Nat. Chem. Biol*. 2013, 9, 731-738.

⁴ M.N. Seaman. The retromer complex - endosomal protein recycling and beyond. *J Cell Sci*. 2012 Oct 15;125(Pt 20):4693-702.

⁵ V.J. Mecozzi et al. Pharmacological chaperones stabilize retromer to limit APP processing. *Nat Chem Biol*. 2014 Jun;10(6):443-9.

⁶ A So et al. Uric acid transport and disease. *J Clin Invest*. 2010 Jun 1; 120(6): 1791-1799.

⁷ M Sato et al. Identification and functional characterization of uric acid transporter Urat1 (Slc22a12) in rats. *Biochim Biophys Acta*. 2011 Jun;1808(6):1441-7.

⁸ K Hyon et al. Pathogenesis of Gout. *Ann Intern Med*. 2005;143:499-516.

⁹ O Perwitasari et al. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. *J Virol*. 2014 Sep 1;88(17):10228-43.

¹⁰ K Parikh et al. Selective inhibitors of nuclear export (SINE)—a novel class of anti-cancer agents. *J Hematol Oncol*. 2014 Oct 15;7:78.

3838 **AZD0095** *Potent, selective and orally active MCT4 inhibitor* Page 267

4070 **AZD3965** *Monocarboxylate transporter 1 (MCT1) inhibitor* Page 271

2284 **Deltarasin trihydrochloride** *Inhibitor of PDE δ and the KRAS-PDE δ interaction* Page 418

2277 **FLI 06** *Notch signaling inhibitor* Page 483

2336 **KPT-330** *Potent, selective and orally available XPO-1 inhibitor* Page 594

2597 **KPT 335**..... *XPO1 inhibitor; selective inhibitor of nuclear export (SINE)*..... Page 594

2303 **R 55** *Retromer chaperone. Potential Alzheimer's therapeutic*..... Page 803

3702 **SLF1081851 hydrochloride**..... *Spns2 inhibitor*..... Page 873

3533 **Tafamidis** *Selective TTR stabilizer*..... Page 905

4021 **Tafamidis meglumine** **Recent Addition** *Selective TTR stabilizer*..... Page 905

3930 **TGN-073**..... *AQP4 facilitator* Page 922

2805 **UK 5099** *Inhibitor of mitochondrial pyruvate carrier (MPC)* Page 949

2581 **UR 1102** *Selective inhibitor of the renal urate transporter URAT1* Page 956

2938 **Verinurad** *Highly potent and selective inhibitor of the renal urate transporter URAT1*..... Page 966

4088 **Voxelotor** *First-in-class, potent and orally bioavailable allosteric HbS effector* Page 972

2988 **Z433927330** *Potent and selective AQP7 inhibitor* Page 1002

Biomarkers and Labeling reagents

Biomarkers include tools and technologies that can aid in understanding the prediction, cause, diagnosis, progression, regression, or outcome of treatment of disease. The application of biomarkers in the diagnosis and management of cardiovascular disease, infections, immunological and genetic disorders, and cancer are well known. Their use in research has grown out of the need to have a more direct measurement of exposures in the causal pathway of disease that is free from recall bias, and that can also have the potential of providing information on the absorption and metabolism of the exposures. Molecular biomarkers will, in the hands of clinical investigators, provide a dynamic and powerful approach to understanding the spectrum of various diseases with obvious applications in analytic epidemiology, clinical trials and disease prevention, diagnosis, and disease management¹.

¹ R. Mayeux. Biomarkers: Potential Uses and Limitations. *NeuroRx*. 2004, 1, 182-188.

Derivatisation reagents

Analyte derivatization has played an important role in analysis using combined gas chromatography–mass spectrometry (GC/MS). In GC/MS, derivatization is performed to enhance the volatility of the analyte, to alter its ionization characteristics, or to influence its fragmentation behavior. In combined liquid chromatography–MS (LC–MS), however, where soft ionization techniques like electrospray (ESI) and atmospheric pressure chemical ionization (APCI) are applied, derivatization is generally not needed and avoided as much as possible. In LC–MS, derivatization is primarily used to improve ionization characteristics, especially for analytes that are not (efficiently) ionized by ESI or APCI such as aldehydes, sugars, and steroids. Derivatization strategies are then directed at the incorporation of a group with a permanent charge (cationic groups for positive-ion mode and strong acidic functionalities for negative-ion mode) or other groups that enhance ionization (secondary or tertiary amine for positive-ion mode or aromatic nitro groups in negative-ion mode). In addition, derivatization may be directed at improving the fragmentation characteristics in tandem MS (MS/MS)¹.

¹ M. Eggink et al. Development of a selective ESI-MS derivatization reagent: synthesis and optimization for the analysis of aldehydes in biological mixtures. *Anal Chem*. 2008, 80, 9042-9051.

1878	Aminoacidone, 2-.....	Labeling agent of malondialdehyde (Fluorescent).....	Page 203
1876	APC, 4-.....	Derivatisation reagent for aldehydes.....	Page 216
1877	APEBA, 4-.....	Derivatisation reagent for aldehydes and carboxylic acids.....	Page 218
2756	Fluorescent probe QG-1.....	Reversible labeling agent of glutathione (Fluorescent).....	Page 406

Protein Labeling reagents

To date, it is nearly impossible to visualize a single protein by its natural fluorescence. Therefore, to see a protein by visible light, a fluorescence probe or a green fluorescence protein (GFP) attached to the target protein is required. Over the last decade, rapid advances have been witnessed in the area and the recognition of this field was awarded with Nobel Prize of Chemistry in 2008. A fluorescent protein or a fluorescent probe can report a wealth of information about the target protein, allowing its location to be tracked, and its interactions with partners or surrounding environment to be recorded¹. Functionalized phenylboronic acid reagents for example, may be used for palladium-catalyzed oxidative Heck reaction to protein-bound alkenes and Suzuki-Miyaura cross coupling for labeling of protein bound phenylhalides². Another technique, *in-vivo* bioluminescent imaging (BLI), is progressively becoming a widely utilized method for modern biological research. The noninvasive character of this method using light emitted from luciferase-expressing bioreporter cells is applicable to living animals, and has been used to study a wide range of biomolecular functions such as gene function, drug discovery and development, cellular trafficking, protein-protein interactions, and especially tumorigenesis, cancer treatment, and disease progression. Firefly luciferase (FLuc) is the best studied of a large number of luminescent, and catalyzes the oxidation of reduced luciferin in the presence of ATP-Mg²⁺ and oxygen to generate CO₂, AMP, PPI, oxyluciferin, and yellow-green light at a wavelength of 562 nm³.

¹ W.H. Chang et al. Bio-orthogonal Protein Labeling Methods for Single Molecule FRET. *J. Chin. Chem. Soc.* 2010, 57, 505-513.

² M.E. Ouralidou et al. Aqueous oxidative Heck reaction as a protein-labeling strategy. *ChemBiochem*. 2014, 15, 209-212.

³ D.M. Close et al. In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals. *Sensors (Basel)*. 2011;11(11):180-206.

2256	Biotinyl-phenylboronic acid.....	Biotinylated arylboronic acid for bio-orthogonal chemistry.....	Page 308
2257	Dansyl-PEG-phenylboronic acid.....	Protein labeling reagent.....	Page 408

Membrane Labeling reagents

Membrane Labeling reagents, Fluorescents

Among the labeling methods, fluorescent labeling has the upper hand due to its non-destructive nature and the high sensitivity of the fluorescence technique, as well as meeting the requirements of small measurement volume and low concentration of the fluorescent material. Fluorescent labeling is generally accomplished by using a reactive derivative of the fluorophore that selectively binds to a functional group contained in the target biomolecule.

Mostly, the followed fluorescent labeling techniques generally adopted, allow specific labeling with functional groups attached to an amino acid with high selectivity and specificity. The fluorophores are designed with a reacting moiety, which may be bound covalently or non-covalently to the target biomolecules. Fluorescent molecule attachment to the biomolecules can be achieved chemically or biologically¹.

Voltage sensitive dyes offer the opportunity to monitor cell electrical activity, e.g. in neurons. The chromophore is believed to undergo a large electronic charge shift as a result of excitation from the ground to the excited state and this underlies the putative electrochromic mechanism for the sensitivity of these dyes to membrane potential².

¹ H Sahoo. Fluorescent labeling techniques in biomolecules: a flashback. *RSC Adv*. 2012;2:7017-7029.

² LM Loew. Potentiometric dyes: Imaging electrical activity of cell membranes. *Pure & Appl Chem*. 1996;68(7):1405-1409.

2655	Di-8-ANEPPS.....	Potentiometric fluorescent dye.....	Page 425
------	------------------	-------------------------------------	----------

NO and HNO donors

Comparisons of the pharmacological effects of nitric oxide (NO) and nitroxyl (HNO) donors have demonstrated that the responses to these redox-related nitrogen oxides are nearly universally dissimilar. These analyses have suggested the existence of mutually exclusive signaling pathways as a result of discrete chemical interactions of HNO and NO with a variety of critical biomolecules. The pharmacological responses to HNO are promising for clinical treatment of cardiovascular diseases such as heart failure, myocardial infarction and stroke¹.

¹ KM Miranda. Donors of HNO. *Curr Top Med Chem*. 2005;5(7):649-64.

2653	CXL-1020.....	HNO donor useful for the treatment of heart failure.....	Page 402
3842	Cimlanod.....	HNO donor.....	Page 372
2603	Nitrosocyclohexyl acetate, 1-.....	HNO donor.....	Page 705

Axon Ligands™ as Cell Cycle Regulators

This class of Axon Ligands™ consists of compounds that affect the processes occurring in eukaryotic cells responsible for cell replication. Cells that are not in a quiescent state exist in either 1 of the 4 known stages of cell duplication: G1, S, G2, or M. The first 3 stages (G1, S, G2) together form the so-called "Interphase" during which the cell increases in size, accumulates required nutrients, and replicates the DNA in the cell nucleus. The correctness of these complex processes is evaluated at checkpoints at the end of each of the individual stages. If all checkpoints are passed successfully, the cell cycle enters the stage of the actual cell division/mitosis¹. During mitoses, again, 4 distinct phases can be discriminated as pro-, meta-, ana-, and telophase.

¹ J.M. Berg, J.L. Tymoczko, L. Stryer. Biochemistry, 2002, 5th edition. New York. W. H. Freeman.

2222	10058-F4	<i>c-Myc inhibitor inducing cell-cycle arrest at G0/G1 phase</i>	Page 474
1529	AG 014699	<i>PARP1 inhibitor</i>	Page 213
2269	AK 1	<i>Potent inhibitor of SIRT2</i>	Page 216
2270	AK 7	<i>Potent, brain-permeable and selective inhibitor of SIRT2</i>	Page 216
3408	AKI603	<i>Inhibitor of Aurora A kinase</i>	Page 216
3549	Aloperine	<i>Potent multifunctional anti-tumor agent</i>	Page 219
2639	AMG 232	<i>Selective, and orally bioavailable MDM2-p53 inhibitor</i>	Page 224
1783	AMG 900	<i>Aurora inhibitor (non-specific)</i>	Page 226
4071	AMG-925	<i>Potent, selective, and orally available FLT3/CDK4 dual inhibitor</i>	Page 226
2368	Amuvatinib	<i>RTK inhibitor (PDGFR, c-Kit and c-Met)</i>	Page 235
3682	AMZ30	<i>Potent, selective and covalent PME-1 inhibitor</i>	Page 236
4030	AOH1996	<i>Orally available PCNA inhibitor</i>	Page 238
2717	Apigenin	<i>Selective inhibitor of Casein kinase 2 (CK2)</i>	Page 241
2251	Apoptozole	<i>Inhibitor of ATPase activity of Hsc70 and Hsp70</i>	Page 242
4264	ART-446 Recent Addition	<i>Potent CHK2 inhibitor</i>	Page 249
4217	AS-703026 Recent Addition	<i>Potent, selective and orally bioavailable MEK1/2 inhibitor</i>	Page 253
1985	AT 406	<i>Inhibitor of apoptosis proteins (IAPs)</i>	Page 257
1539	AT 7519 mesylate	<i>CDK inhibitor</i>	Page 257
1597	Aurora A inhibitor I	<i>Aurora A inhibitor</i>	Page 259
1630	Aurora A inhibitor II	<i>Aurora A inhibitor</i>	Page 261
1642	AZ 3146	<i>MPS1 kinase inhibitor</i>	Page 265
4074	AZ5104	<i>EGFR inhibitor</i>	Page 264
4140	AZD0156	<i>Selective and orally active ATM inhibitor</i>	Page 267
1580	AZD 1152-HQPA	<i>Aurora B inhibitor</i>	Page 268
2241	AZD 2461	<i>PARP inhibitor with poor P-glycoprotein substrate qualities</i>	Page 269
1966	AZD 5438	<i>CDK inhibitor (1, 2, and 9 specific)</i>	Page 273
4139	AZD5582 dihydrochloride	<i>Apoptosis proteins (IAPs) inhibitor</i>	Page 274
4068	AZD7648	<i>DNA-PK inhibitor</i>	Page 275
1399	AZD 7762 hydrochloride	<i>CHK inhibitor</i>	Page 275
2185	BAM 7	<i>Selective small-molecule activator of proapoptotic BAX</i>	Page 282
3832	BAY-1816032	<i>Potent and selective BUB1 (Mitotic checkpoint serine/threonine-protein kinase) inhibitor</i>	Page 287
3397	BG45	<i>HDAC inhibitor (1, 2, 3 Selective)</i>	Page 299
3862	BGB-283	<i>Orally available dual RAF kinase/EGFR inhibitor</i>	Page 300
1828	BH3I-1	<i>Inhibitor of Bcl-2 family protein</i>	Page 300
1129	BI 2536	<i>PLK1 inhibitor</i>	Page 301
4192	BI 2536, (S)- Recent Addition	<i>Dual PLK1/BRD4 bromodomain inhibitor</i>	Page 302

3361	BI-3802	<i>Highly potent and efficacious BCL6 degrader</i>	Page 303
1473	BI 6727	<i>PLK1 Inhibitor</i>	Page 303
3697	Binimetinib	<i>Potent, selective, non-ATP-competitive and orally available allosteric inhibitor of MEK1/2</i>	Page 308
2462	BMH 21	<i>Inhibitor of RNA Polymerase I (RNAP1)</i>	Page 314
3399	BML-210	<i>HDAC inhibitor</i>	Page 314
3853	BMS-599626	<i>Potent and selective EGFR and ErbB2 inhibitor</i>	Page 319
3877	BMS-986299	<i>First-in-class NLRP3 agonist</i>	Page 321
4266	BPI-9016M Recent Addition	<i>Potent, orally active, and selective c-Met and AXL inhibitor</i>	Page 324
2397	BQU 57	<i>Inhibitor of the RAS-like small GTPases RalA and RalB</i>	Page 325
2471	BRD 73954	<i>Dual HDAC 6/8 inhibitor with excellent selectivity</i>	Page 327
2407	BTB 1	<i>Reversible inhibitor of the mitotic motor protein Kif18A</i>	Page 331
3431	BTSA1	<i>Potent activator of proapoptotic BAX</i>	Page 331
3394	CADD522	<i>Potent inhibitor of RUNX2-DNA binding</i>	Page 339
3934	CC-671	<i>Potent and selective dual inhibitor of TTK</i>	Page 348
1836	CCT 137690	<i>Aurora inhibitor (non-specific)</i>	Page 351
3971	CCT196969	<i>Paradox-breaking pan RAF Inhibitor</i>	Page 351
3932	CCT-245737	<i>Orally active, potent and selective CHK1 inhibitor</i>	Page 352
1636	CHIR 124	<i>CHK1 inhibitor</i>	Page 365
2014	CI 994	<i>HDAC inhibitor causes histone hyperacetylation in cells</i>	Page 369
2184	CID 1067700	<i>First inhibitor of Rab7 GTPase</i>	Page 370
1863	CID 5951923	<i>Inhibitor of Krüppel-like factor 5 (KLF5)</i>	Page 371
2250	CHR 6494 trifluoroacetate	<i>Specific, first-in-class inhibitor of histone kinase Haspin</i>	Page 368
1543	CNF 2024	<i>Hsp90 inhibitor</i>	Page 381
3371	Colchicine	<i>Tubulin polymerization inhibitor</i>	Page 382
1495	CP 466722	<i>ATM inhibitor</i>	Page 389
2594	CPI 0610	<i>Selective inhibitor of BET bromodomains</i>	Page 393
3756	CT7001	<i>Specific CDK7 inhibitor</i>	Page 397
2438	Cuspin-1	<i>Upregulator of the SMN by Ras signaling activation</i>	Page 399
2173	CX 5461	<i>Inhibitor of RNA Polymerase I (RNAP1)</i>	Page 400
2305	CX 6258 hydrochloride	<i>Pim Kinase Inhibitor</i>	Page 401
3459	Dacarbazine	<i>DNA alkylating agent; antineoplastic agent</i>	Page 407
3216	DCZ0415	<i>AAA-ATPase TRIP13 inhibitor</i>	Page 414
3518	DCZ0805	<i>NF-κB activation inhibitor</i>	Page 414
2496	Dimethylcelecoxib, 2,5-	<i>Celecoxib analog lacking COX-2 inhibitory activity</i>	Page 432
2439	Dimethylenastron	<i>Specific potent and cell-permeable inhibitor of Eg5 (KSP)</i>	Page 432
3765	DS-3032	<i>Orally available, potent and selective inhibitor of the p53-MDM2 interaction</i>	Page 443
3766	DT-2216	<i>Selective B-cell lymphoma-extra large (Bcl-XL) targeted protein degrader</i>	Page 444
3412	DTHIB	<i>Direct and selective HSF1 inhibitor</i>	Page 444
4056	DYRK1A inhibitor compound 11	<i>Highly selective and ligand-efficient Dyrk1A inhibitor</i>	Page 446
3398	E7449 mesylate	<i>Potent, brain penetrable and orally bioavailable dual inhibitor of PARP1/2 and TNKS1/2</i>	Page 448
2351	EHop 016	<i>Rac GTPase inhibitor specific for Rac1 and Rac3</i>	Page 453
2568	EML 425	<i>Potent dual inhibitor of CBP and p300 (HAT/KAT3)</i>	Page 456
3674	Ena21 hydrochloride	<i>Selective and competitive ALKBH5 inhibitor</i>	Page 458

4137	EPZ005687 hydrochloride	EZH2 HMTase inhibitor	Page 463
2227	EPZ 6438	Inhibitor of Histone Lysine Methyltransferase EZH2	Page 464
1825	Erastin	RAS lethal compound; VDAC2 modulator	Page 465
4216	EPZ011989 hydrochloride	Cell permeable, metabolically stable and orally available EZH2 inhibitor	Page 463
2384	FDI 6	Inhibitor of the Forkhead box protein M1 (FOXM1)	Page 476
2293	Ferostatin 1	Potent inhibitor of erastin-induced ferroptosis	Page 479
3769	FHD-286	Selective inhibitor of the BAF chromatin remodeling complex ATPases (BRG1/BRM)	Page 481
4148	GDC-0973	Orally bioavailable, potent and selective small-molecule inhibitor of mitogen-activated protein kinase 1	Page 499
3920	GSK1070916	Potent, selective and ATP competitive inhibitor of Aurora B and C kinases	Page 517
3767	GDC-1971	Orally available, potent, and selective inhibitor of the protein tyrosine phosphatase SHP2	Page 500
1152	GMC 1-165	Aurora B inhibitor	Page 507
2140	GSK 126	Inhibitor of Histone Lysine Methyltransferase EZH2	Page 518
2410	GSK 5959	Potent, cell permeable inhibitor of BRPF1 bromodomain	Page 523
1688	GSK 461364	PLK1 inhibitor	Page 524
1625	GSK 461364 analogue I	PLK1 Inhibitor	Page 524
1626	GSK 461364 analogue II	PLK1 Inhibitor	Page 525
2460	GSK 2110183 hydrochloride	Potent, orally bioavailable inhibitor of the Akt kinases	Page 528
1131	GW 843682X	PLK1 and PLK3 inhibitor	Page 536
2007	HA 14-1	Bcl-2 inhibitor and apoptosis inducer of tumor cells	Page 538
2390	HAMNO	Novel protein interaction inhibitor of replication protein A	Page 538
1643	HLI 373	HDM2 inhibitor	Page 542
1890	HSF1A	Human HSF1 activator	Page 546
2101	HSF1B	Human HSF1 activator	Page 547
2533	Hydroxypropylglucosamine	Active metabolite of Pioglitazone (M-IV), a PPAR γ agonist	Page 552
3811	Icaritin	Natural flavonoid with potent cytotoxic and osteogenic activity	Page 557
2406	IMM 01	Agonist of mammalian Diaphanous (mDia)-related formins	Page 563
1827	IMS 2186	Apoptosis inducer. Inhibitor of PGE2/TNF- α production	Page 564
2537	Isoquinolinediol, 1,5-	PARP1 inhibitor and neuroprotective agent	Page 571
2446	Ispinesib	Potent and specific small-molecule inhibitor of human KSP	Page 572
3426	IU1-47	Potent and selective inhibitor deubiquitinase USP14	Page 574
3721	JAB-3068	SHP2 inhibitor	Page 576
1538	JNJ 26854165	HDM2 inhibitor	Page 579
1586	JNJ 26854165 dihydrochloride	HDM2 inhibitor, water soluble	Page 580
2529	JNJ 26481585 dihydrochloride	Orally available second-generation pan-HDAC inhibitor	Page 579
2566	KN 93	Inhibitor of multifunctional CaMKII	Page 593
2555	KN 93 phosphate	Inhibitor of multifunctional CaMKII	Page 593
2302	Kobe 0065	HRAS inhibitor	Page 594
2336	KPT-330	Potent, selective and orally available XPO-1 inhibitor	Page 594
2538	KRIBB11	HSF1 inhibitor; blocks the induction of HSP27 and HSP70	Page 595
3770	KSQ-2479	An allosteric, first-in-class USP1 (Ubiquitin Specific Protease 1) inhibitor	Page 596
1367	KU 55933	ATM inhibitor	Page 597

4179	KU-0058948	Potent and specific PARP1 inhibitor	Page 597
2001	KU 0058948 hydrochloride	Potent and specific PARP1 inhibitor	Page 597
1584	KU 0060648 trihydrochloride	DNA-PK inhibitor	Page 598
1548	LBH 589	HDAC1 Inhibitor	Page 606
3902	LCL-161	IAP inhibitor	Page 606
2449	LDN 57444	Reversible, competitive inhibitor of UCH-L1 deubiquitinase	Page 609
2273	LEE 011	Orally bioavailable and highly selective inhibitor of CDK4/6	Page 609
2430	LW 479	HDAC inhibitor with cytotoxicity in breast cancer cell lines	Page 625
3851	LXS-196	Potent and selective protein kinase C inhibitor	Page 622
1963	LY 573636	Anti-tumor agent; causes growth arrest and apoptosis	Page 632
2464	LY 2584702 tosylate	Oral, ATP competitive inhibitor of p70 S6 kinase (S6K1)	Page 633
4145	LY2606368 mesylate	Potent and selective ATP competitive inhibitor of the CHK protein kinase	Page 627
3894	LY-3177833	CDC7 inhibitor	Page 627
3758	LY-3295668	Orally available, potent and highly selective Aurora A kinase (AurA) inhibitor	Page 628
3404	LY-364947	Potent, selective and ATP-competitive TGF- β R 1 inhibitor	Page 631
3850	M2698	p70S6K/Akt dual inhibitor	Page 637
3577	M-3814	DNA-PK inhibitor	Page 638
3268	Metapristone	Metabolite of Mifepristone (Axon 1502); PI3K/AKT inhibitor	Page 646
1494	MK 1775	Wee1 kinase inhibitor	Page 661
1961	MK 5108	Inhibitor of Aurora A kinase	Page 661
2017	ML 210	Chemical probe kills cells induced to express mutant RAS	Page 665
2309	ML 323	Inhibitor of the USP1-UAF1 deubiquitinase complex	Page 667
2641	ML334	Activator of NRF2 by inhibition of Keap1-NRF2 interactions	Page 668
1910	MLN 0905	PLK1 inhibitor	Page 673
2003	MLN 8237	Second generation selective Aurora A inhibitor	Page 674
2505	Mocetinostat	Class I selective HDAC inhibitor	Page 675
2358	Mps1-IN-2	Inhibitor of Mps1 kinase with add-on affinity for Gak and Plk1	Page 679
2327	NEO 212	DNA alkylating agent; chemotherapeutic	Page 697
2322	Neuropathiazol	Inducer of neural differentiation of adult hippocampal NPCs	Page 698
2359	Nexturastat A	HDAC6 inhibitor with selectivity over HDAC1 and HDAC8	Page 699
3588	NGI-1	Potent and cell-permeable inhibitor of oligosaccharyltransferase	Page 701
2450	NHI 2	Selective inhibitor of human lactate dehydrogenase A	Page 701
4045	Nimustine hydrochloride	Water-soluble DNA alkylating agent	Page 704
3409	NKL 22	HDAC inhibitor	Page 705
2408	NRX 194204	Potent and specific RXR agonist devoid of any RAR activity	Page 711
1883	NS 3694	Inhibitor of apoptosis; Inhibits formation of apoptosome	Page 711
2564	NSC 59984	Activator of p53 that restores WT p53 signaling	Page 716
2016	NSC 319726	Reactivator of the p53 mutant p53R175	Page 715
1402	NSC 348884	NPM inhibitor	Page 715
1243	NSC 625987	CDK4 inhibitor	Page 716
2228	NSC 687852	Inhibitor of 19S DUBs: UCHL5 and USP14	Page 717
1463	NU 7441	DNA-PK inhibitor	Page 719
1585	Nutlin 3	MDM2 inhibitor (p53 specific)	Page 719

1880	Nutlin-3a	Inhibitor of MDM2	Page 720
1881	Nutlin-3b	Less potent (+)-enantiomer of Nutlin-3	Page 720
1542	NVP-AUY922	Hsp90 inhibitor	Page 722
2029	NVP-BGT226	Orally active dual PI3K/mTOR inhibitor	Page 723
3751	NVP-CGM097	Inhibitor of MDM2	Page 724
3752	NVP-CGM097 dihydrochloride	Inhibitor of MDM2	Page 724
2442	OF-1	Potent bromodomain inhibitor (BRPF1 and BRPF2 selective)	Page 730
4269	OICR-12694	Recent Addition Selective and orally bioavailable inhibitor of B cell lymphoma 6 (BCL6)	Page 731
3583	OICR-9429	First-in-class, potent, highly selective and cell-active antagonist of the Wdr5-MLL interaction	Page 731
4171	OTS514	Highly potent TOPK inhibitor	Page 739
4097	OTS964 hydrochloride	TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor	Page 740
2332	OTX 008	Selective allosteric inhibitor of galectin-1	Page 740
2052	Palbociclib isethionate	Orally active cyclin-dependent kinase (CDK4/6) inhibitor	Page 745
3582	PBENZ-DBRMD	DIO3 inhibitor	Page 749
1505	PD 0332991 hydrochloride	CDK4 and CDK6 inhibitor	Page 755
1379	PF 477736	CHK1 inhibitor	Page 763
2023	PF 03814735	ATP-competitive inhibitor of aurora kinase A and B	Page 767
1855	PF 04691502	PI3K and mTOR tyrosine kinase inhibitor	Page 768
3695	PF-06821497	Inhibitor of Histone Lysine Methyltransferase EZH2	Page 760
3693	PF-06873600	CDK inhibitor (4, 6, and 8 specific)	Page 761
3753	PF-07104091	Specific CDK2 inhibitor	Page 762
3762	PF-07220060	Orally bioavailable and CDK4-Specific Inhibitor	Page 762
3537	PFK15	Potent and specific PFKFB3 inhibitor	Page 771
3643	Phenoxybenzamine hydrochloride	Selective $\alpha 1/\alpha 2$ -adrenoceptor antagonist; Calmodulin inhibitor	Page 774
1871	Pifithrin- α Hydrobromide	Inhibitor of p53 protein	Page 777
2459	PND 1186	Orally active dual FAK/PYK2 inhibitor	Page 784
3368	Podophyllotoxin	Tubulin polymerization inhibitor	Page 786
2420	PTC 209	Inhibitor of the canonical self-renewal regulator BMI-1	Page 796
1856	PU-H71 hydrochloride	Hsp90 inhibitor	Page 797
4076	Pyridostatin hydrochloride	G-quadruplex DNA stabilizing agent	Page 799
1983	R 547	CDK inhibitor (1, 2, and 4 specific)	Page 803
1911	RAD51 inhibitor B02	Inhibitor of RAD51	Page 805
2396	RBC 8	Inhibitor of the RAS-like small GTPases RalA and RalB	Page 808
3874	RDEA119	Potent and highly selective small molecule allosteric MEK inhibitor	Page 810
2299	Remodelin	Potent NAT 10 inhibitor	Page 811
1629	Reversine	MPS1 kinase inhibitor	Page 814
1885	RI-1	Inhibitor of the central recombination protein RAD51	Page 817
2009	RITA	Activates p53 through inhibition of MDM2	Page 820
1530	RO 3306	CDK1 inhibitor	Page 826
2443	Rosiglitazone	PPAR γ agonist; antidiabetic drug and stem cell differentiator	Page 830
2497	RTA 408	Triterpenoid activator of NRF2 and inhibitor of NF- κ B	Page 834

3804	Sabizabulin	Orally bioavailable and highly potent tubulin polymerization inhibitor	Page 841
2495	Santacruzamate A	HDAC2 inhibitor with little inhibition of HDAC4 and HDAC6	Page 842
2324	SC 144 hydrochloride	The first-in-class small-molecule gp130 inhibitor	Page 853
4248	SC912	Recent Addition AR-V7 inhibitor	Page 857
2244	SCH 529074	Small molecule activator of mutant p53	Page 856
1776	SCH 727965	CDK inhibitor (1, 2, 5, and 9 specific)	Page 856
3828	SCH900776 dihydrochloride	Potent, selective and orally bioavailable inhibitor of CHK1	Page 857
3623	SGC-SMARCA-BRDVIII	Potent, highly selective and cell-active SMARCA2/4 and PB1(5) bromodomain inhibitor	Page 863
1633	SGI 1776 free base	Pim kinase Inhibitor	Page 864
1701	Shz-1	Stem cell differentiating agent; Nkx2.5 inducer	Page 865
2487	Silibinin	Natural flavonolignan, cytoprotectant, antioxidant	Page 866
3737	Siremadlin	Potent, selective, and orally bioavailable MDM2-p53 inhibitor	Page 867
2453	SirReal 2	SIRT2 inhibitor with selectivity over SIRT1 and SIRT3	Page 867
1515	Sitamaquine	anti-leishmanial agent	Page 867
1614	SNS 032	CDK inhibitor (2, 7 and 9 specific)	Page 876
2437	SP 141	MDM2 inhibitor with therapeutic effects in breast cancer	Page 881
2474	SPL-B	Inhibitor of TACC3	Page 884
3727	SR11237	Selective retinoid X Receptor agonist	Page 885
4034	SR-4370	Synthetic inhibitor of histone deacetylase (HDAC)	Page 886
3427	SRS11-92	Inhibitor of ferroptosis	Page 890
1968	STA 9090	Hsp90 inhibitor	Page 893
1581	SU 11274	ATP-competitive inhibitor of c-MET	Page 898
2398	Suprafenacine	Destabilizer of microtubules that causes cell cycle arrest	Page 901
3605	TAK-931	CDC7 inhibitor	Page 908
2502	Talazoparib	Potent, selective, and orally available PARP1/2 inhibitor	Page 909
4272	TAS2940	Recent Addition Orally active, brain-penetrable, and irreversible pan-ERBB inhibitor	Page 911
2333	TCID	Potent inhibitor of UCHL3 with good selectivity over UCHL1	Page 914
1765	TG 003	Inhibitor of Cdc2-like kinase (Cik) family	Page 921
2326	Temozolomide	DNA methylating agent; apoptosis inducer	Page 917
2249	Tenovin 6	Small water soluble p53 activator and SIRT inhibitor	Page 919
1535	Thiazovivin	iPSC stimulator; Stem cell related	Page 923
3560	THZ1	Covalent CDK7 inhibitor	Page 926
3561	THZ1 dihydrochloride	Covalent CDK7 inhibitor	Page 926
3865	TNO155	Selective and orally bioavailable allosteric inhibitor of SHP2	Page 934
3624	Toceranib phosphate	Multi-targeted receptor tyrosine kinase inhibitor	Page 934
3276	TRULI	LATS1/2 inhibitor	Page 941
3691	Tubacin	HDAC6 inhibitor	Page 942
3400	Tubulin inhibitor 6	Tubulin polymerization inhibitor; iHAP	Page 943
2518	UF 010	Class I selective HDAC inhibitor	Page 949
2418	UNC 0379	Substrate competitive inhibitor of the SETD8	Page 953
2369	UPF 1069	PARP-2 inhibitor with >26 fold selectivity over PARP1	Page 955
3794	Urolithin A	Inhibitor of the PI3K/AKT/mTOR pathway	Page 957
3722	Valemetostat	Inhibitor of Histone Lysine Methyltransferase EZH1/2	Page 960

1893	VE 821	Inhibitor of the DNA damage response kinase ATR	Page 964
2452	VE 822	ATR inhibitor with cytotoxicity for pancreatic cancer cells	Page 964
1608	VER 155008	Hsp70 inhibitor	Page 965
1540	VX 680	Aurora inhibitor (non-specific)	Page 980
4219	VX-702 Recent Addition	Orally bioavailable p38 MAP kinase inhibitor	Page 980
2411	WDR5-0103	Inhibitor of WDR5 and associated activity of MLL	Page 985
3995	WT-161	Potent, selective, and bioavailable HDAC6 inhibitor	Page 988
2268	XL 413 hydrochloride	Potent, selective and orally bioavailable CDC7 inhibitor	Page 994
3535	XY028-140	Potent and selective CDK4/6 inhibitor; PROTAC	Page 996
1639	YM 155	Survivin suppressant	Page 999
4239	Z29077885 Recent Addition	Potent STK33 inhibitor; Antiviral agent	Page 1002
4142	Z29077885 hydrochloride Recent Addition	Potent STK33 inhibitor; Antiviral agent	Page 1002
3790	ZINC69391	Specific Rac1 inhibitor	Page 1006
1541	ZM 447439	Aurora B inhibitor	Page 1009
3735	ZZW-115 trihydrochloride	Potent NUPR1 inhibitor	Page 1011

Axon Ligands™ for Stem Cell Research

Special attention is offered to the class of Axon Ligands™ that finds its application (among other applications in most cases) in stem cell research projects world wide. The medical use of stem cells, cells with the ability to perpetuate themselves through self-renewal and to differentiate into a particular cell type through differentiation, is receiving extensive interest as they might regenerate damaged tissue under the right conditions¹. This unique capacity could serve patients suffering from organ malfunction, cell deficiency, and/or neurodegenerative diseases such as Alzheimer's and Parkinson's disease by replacing affected/deficient cells with healthy new cells². The pharmacological tools in this category could interact in any way with the complex cell differentiating processes involved in the transformation of an un-programmed stem cell into its destination cell type.

¹ Stem cells, cancer, and cancer stem cells. Tannishtha Reya, Sean J. Morrison, Michael F. Clarke, Irving L. Weissman. Nature, Vol 414, 2001, 105.
² Embryonic stem cells in drug discovery. J. McNeish. Nature Rev. Drug Disc. 2004, 3, 70.

1421	A 83-01	TGF-betaR 1 inhibitor; ALK 5 inhibitor	Page 194
1466	A 769662	AMPK activator	Page 192
1909	A 1070722	Selective inhibitor of GSK-3	Page 194
2551	Alda 1	Small molecule activator of ALDH2	Page 218
1738	AMD 3100	CXCR4 antagonist	Page 223
3827	AMG-511	Orally bioavailable, highly potent and selective pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor	Page 225
2167	AR-A 014418	ATP-competitive GSK-3 inhibitor	Page 245
2187	AS 1892802	Potent, selective, ATP-competitive ROCK inhibitor	Page 253
1642	AZ 3146	MPS1 kinase inhibitor	Page 265
2171	AZD 1080	Selective inhibitor of GSK3α and GSK-3β	Page 268
3996	AZD2014	Orally bioavailable dual mTORC1/mTORC2 inhibitor	Page 269
3771	AZD2858	Potent and highly selective Glycogen Synthase Kinase-3β inhibitor	Page 270
2194	AZD 2858 hydrochloride	Potent and highly selective GSK-3β inhibitor	Page 270
1516	AZD 6244	MEK1 and MEK2 inhibitor	Page 274
1399	AZD 7762 hydrochloride	CHK inhibitor	Page 275
1561	AZD 8055	mTOR inhibitor	Page 276
1697	BAY K 8644	Ca ²⁺ channel activator (L-type voltage-gated)	Page 292
1758	BAY K 8644, (R)-(+)	Ca ²⁺ channel blocker (L-type voltage-gated)	Page 292
1759	BAY K 8644, (S)-(-)	Ca ²⁺ channel opener (L-type voltage-gated)	Page 292
2117	Begacestat	Selective γ-secretase inhibitor (GSI)	Page 297
1528	BI-D1870	RSK inhibitor (p90 RSK specific)	Page 306
1693	BIO	GSK-3 inhibitor	Page 308
1692	BIX 01294 trihydrochloride hydrate	HMTase inhibitor (G9a and G9a-like protein)	Page 311
1808	BIX 02188	MEK5 inhibitor; ERK5 inhibitor	Page 311
2356	BMS 833923	Oral antagonist of Smoothened (SMO)	Page 320
3786	BP-1-102	Orally bioavailable STAT3 inhibitor	Page 323
3419	Bromo-2'-deoxyuridine, 5-	Thymidine analog; Labeling agent of cell proliferation	Page 329
1487	BZ, γ-Secretase Inhibitor	Gamma Secretase inhibitor	Page 336
3748	C-82	Specific inhibitor of Wnt/β-catenin signaling pathway	Page 338
2550	Cardiogenol C hydrochloride	Stem cell differentiator	Page 344
3987	CASIN	Selective Cdc42 inhibitor	Page 345
3934	CC-671	Potent and selective dual inhibitor of TTK	Page 348
3932	CCT-245737	Orally active, potent and selective CHK1 inhibitor	Page 352
1636	CHIR 124	CHK1 inhibitor	Page 365

1386	CHIR 99021	GSK-3 inhibitor	Page 365
2435	CHIR 99021 dihydrochloride	GSK-3 inhibitor	Page 365
2202	CK2 inhibitor 10	Potent and ATP-competitive inhibitor of CK2	Page 374
3279	CKI-7 dihydrochloride	Selective inhibitor of Casein kinase 1	Page 375
1484	DAPT	Gamma Secretase inhibitor	Page 410
1488	DBZ, γ -Secretase Inhibitor	Gamma Secretase inhibitor	Page 412
2476	DEAB	Potent inhibitor of cytosolic ALDH enzymes	Page 415
1590	Decitabine	DNA methyltransferase inhibitor	Page 415
3669	Dimethindene maleate, (S)-(+)	Potent and selective M2 muscarinic receptor antagonist	Page 431
1708	Dorsomorphin	Inhibitor of BMP signaling. Inhibits ALK2, 3 and 6	Page 438
2150	Dorsomorphin dihydrochloride	Inhibitor of BMP signaling. Inhibits ALK2, 3 and 6	Page 438
3715	E-7386	CBP/beta-catenin modulator	Page 447
3525	ETP-47799	Potent CDK8/CDK19 inhibitor	Page 470
2277	FLI 06	Notch signaling inhibitor	Page 483
2320	FH 1	Promotes the differentiation of iPSCs to hepatocytes	Page 480
2355	FPH 2	Proliferation inducer of mature human primary hepatocytes	Page 490
1500	GDC 0449	Hedgehog (Hh) pathway inhibitor	Page 498
1377	GDC 0941 bismesylate	PI3K inhibitor	Page 499
3767	GDC-1971	Orally available, potent, and selective inhibitor of the protein tyrosine phosphatase SHP2	Page 500
2466	Gö 6983	Broad spectrum PKC inhibitor	Page 511
1167	GSK 269962A	ROCK1 and ROCK2 inhibitor	Page 524
3900	GSK-3484862	No-covalent DNMT1-selective inhibitor	Page 522
3757	GSK3685032 hydrochloride	Potent first-in-class DNMT1-selective inhibitor	Page 522
1440	HU 308	CB2 agonist	Page 548
3811	Icaritin	Natural flavonoid with potent cytotoxic and osteogenic activity	Page 557
1766	ICG 001	Specific inhibitor of Wnt/ β -catenin signaling pathway	Page 557
2135	iCRT14	Inhibitor of the Wnt/wingless signaling; CRT inhibitor	Page 559
2511	IM 12	GSK-3 β inhibitor attenuating neuronal differentiation	Page 561
2236	IN 1130	TGF- β R 1 inhibitor	Page 564
3948	ISX9	Wnt/ β -catenin signaling pathway agonist	Page 573
2323	ITD-1	Selective inhibitor of TGF β /Smad signaling	Page 573
2467	ITD-1, (+)	Selective inhibitor of TGF β /Smad signaling	Page 573
2212	IWP L6	Highly potent porcupine (Porcn) inhibitor	Page 574
2510	IWR-1-endo	Inhibitor of the Wnt/ β -catenin pathway via TNKS1&2	Page 575
3721	JAB-3068	SHP2 inhibitor	Page 576
1922	JW 55	Inhibitor of tankyrase (TNKS 1 and 2)	Page 585
1472	KU 0063794	mTOR inhibitor	Page 598
2036	KY 02111	Canonical Wnt signaling pathway inhibitor	Page 600
1509	LDN 193189	BMP-ALK inhibitor	Page 608
3552	LDN 212854	Potent ALK2-biased BMP type I receptor kinase inhibitor	Page 608
2297	LH 846	Inhibitor of Casein kinase 1 (CK1- δ)	Page 614
2223	Lomeguatrib	Potent, orally active inhibitor of MGMT	Page 618
1366	LY 294002	PI3K inhibitor	Page 627
1491	LY 2157299	TGF-betaR2 inhibitor	Page 632

4145	LY2606368 mesylate	Potent and selective ATP competitive inhibitor of the CHK protein kinase	Page 633
2553	LY 2801653	Multi-kinase inhibitor with potent activity against c-MET	Page 633
2196	LY 2940680	Antagonist of the Smoothened (SMO) receptor	Page 634
3880	MCI-INI-3	Potent and selective ALDH1A3 inhibitor	Page 642
3628	MHY-1685	mTOR inhibitor; Senescence inhibitor	Page 653
1494	MK 1775	Wee1 kinase inhibitor	Page 661
2358	Mps1-IN-2	Inhibitor of Mps1 kinase with add-on affinity for Gak and Plk1	Page 679
1938	MRT 10	Smoothened (SMO) receptor antagonist	Page 680
2517	Napabucasin	Oral cancer stemness inhibitor targeting STAT3	Page 692
2322	Neuropathiazol	Inducer of neural differentiation of adult hippocampal NPCs	Page 698
1578	NSC 23766	Rac1 inhibitor	Page 712
1619	NVP-LDE225	Smoothened (SMO) receptor antagonist	Page 725
2599	NVP-TNKS656	Selective TNKS inhibitor and antagonist of Wnt pathway	Page 726
4020	O414	Metabolically stable next-generation endogenous Oct4 inducer	Page 728
2442	OF-1	Potent bromodomain inhibitor (BRPF1 and BRPF2 selective)	Page 730
2602	P7C3	Compound that activates NAMPT	Page 743
3614	Parthenoide	NF- κ B activation inhibitor	Page 748
1223	PD 98059	MEK inhibitor	Page 752
1673	PD 173074	FGFR1 and FGFR3 inhibitor	Page 754
1368	PD 184352	MEK 1 inhibitor	Page 754
1408	PD 0325901	MEK1 and MEK2 inhibitor	Page 755
1379	PF 477736	CHK1 inhibitor	Page 763
2027	PF 5274857 hydrochloride	Smoothened (SMO) antagonist	Page 766
2091	PluriSin #1	Inhibitor of stearoyl-coA desaturase (SCD1)	Page 783
1823	Pregabalin	Reduces synaptic signaling by binding to α 2 δ subunits	Page 790
3749	PRI-724	Specific inhibitor of Wnt/ β -catenin signaling pathway	Page 791
1659	PS 48	PDPK1 activator (allosteric)	Page 794
2420	PTC 209	Inhibitor of the canonical self-renewal regulator BMI-1	Page 796
3480	PY-60	Specific YAP activator targeting ANXA2	Page 799
1629	Reversine	MPS1 kinase inhibitor	Page 814
1691	RG 108	DNA methyltransferase inhibitor	Page 814
2229	RKI 1447	Potent inhibitor of the Rho-associated ROCK kinases	Page 822
2521	RO 4929097	Potent γ -secretase inhibitor (GSI) targeting Notch signaling	Page 826
2313	S3I 201	Potent, cellular STAT3 inhibitor	Page 838
1303	SB 216763	GSK-3 inhibitor	Page 846
1661	SB 431542	TGF-betaR1 inhibitor; ALK inhibitor	Page 849
2197	SB 505124	Selective inhibitor of TGF- β type I receptors ALK4 and ALK5	Page 849
2285	SB 525334	Selective inhibitor of the TGF- β R1 (ALK5) receptor	Page 849
2504	SB 590885	Selective inhibitor of B-Raf kinase	Page 850
3828	SCH900776 dihydrochloride	Potent, selective and orally bioavailable inhibitor of CHK1	Page 857
1387	SD 208	TGF-betaR 1 inhibitor	Page 858
1701	Shz-1	Stem cell differentiating agent; Nkx2.5 inducer	Page 865
2164	SJ 172550	Small molecule inhibitor of MDMX	Page 869
2084	SKL 2001	Wnt/ β -catenin signaling pathway agonist or activator	Page 872

2627	SMER 28	Enhancer of rapamycin enhancing autophagy	Page 874
2519	SP 600125	Selective, reversible, and ATP-competitive JNK inhibitor	Page 881
2314	Stattic	Inhibitor of STAT3 activation, dimerization, and translocation	Page 893
1865	Stemregenin 1	Aryl hydrocarbon receptor (AHR) antagonist	Page 894
1667	SU 5402	Fibroblast growth factor receptor (FGFR) inhibitor	Page 898
1136	SU 6656	SRC kinase inhibitor	Page 898
2010	TDZD 8	Selective and non-ATP competitive inhibitor of GSK-3 β	Page 914
1535	Thiazovivin	iPSC stimulator; Stem cell related	Page 923
3579	Tideglusib	GSK-3 inhibitor	Page 928
3865	TNO155	Selective and orally bioavailable allosteric inhibitor of SHP2	Page 934
3276	TRULI	LATS1/2 inhibitor	Page 941
1562	TWS 119	GSK-3beta inhibitor	Page 944
2520	U 0126	Non-competitive inhibitor of MEK1/2	Page 946
1527	XAV 939	Tankyrase (TNKS) inhibitor	Page 991
1683	Y 27632 dihydrochloride	ROCK1 and ROCK2 inhibitor	Page 997
2381	WH-4-023	Orally active Src-family selective lck inhibitor	Page 985
1254	Zebularine	DNA methyltransferase inhibitor	Page 1007
2445	ZLN 024	Allosteric activator of AMP-activated protein kinase (AMPK)	Page 1009

Axon Ligands™ for Epigenetic Research

Epigenetics is typically defined as the study of heritable changes in gene expression that are not due to changes in DNA sequence. Epigenetic modifications of chromatin have been shown to play a major role in cancer onset and development. Acetylation and methylation are the most-studied chromatin marks, having fundamental functions in the epigenetic regulation of gene expression^{1,2}. Epigenetic modification of histones is a reversible process. Histone acetyltransferases (HATs) are the enzymes responsible for the introduction of acetyl groups on histones, whereas methyl groups can be introduced both on DNA and histones by DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs)³. The removal of methyl and acetyl groups is enzymatically mediated by the action of histone demethylases (HDMs) and histone deacetylases (HDACs), respectively. In turn, epigenetic marks can be recognized by and bound to specific protein domains, such as bromodomain and malignant brain tumor (MBT). These complexes are important intermediates in the epigenetic regulation of gene expression⁴.

¹ Epigenetics in Cancer. Manel Esteller. N Engl J Med 2008; 358, 1148-1159.

² Epigenetic protein families: a new frontier for drug discovery. CH Arrowsmith et al. Nature 2012, 11, 384-400.

³ Histone acetyltransferases as emerging drug targets. FJ Dekker and HJ Haisma. Drug Discov. Today 2009, 14(19-20), 942-948.

⁴ Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family. Filippakopoulos, P. et al. Cell 2012, 149, 214-231.

3696	ABBV-075	Highly potent and orally bioavailable BET bromodomain (BRD) inhibitor	Page 197
3956	ABBV-744	First-in-class highly BDII (Bromodomain II)-selective BET bromodomain inhibitor	Page 198
2274	AGI 6780	Selective inhibitor of tumor-associated mutant IDH2 (R140Q)	Page 214
2269	AK 1	Potent inhibitor of SIRT2	Page 216
2270	AK 7	Potent, brain-permeable and selective inhibitor of SIRT2	Page 216
1490	Anacardic acid A	HAT inhibitor	Page 236
3834	Alantolactone	STAT3 inhibitor; NLRP3 inhibitor	Page 218
3944	ARV-825	Potent and selective protein BRD4 degrader	Page 250
2241	AZD 2461	PARP inhibitor with poor P-glycoprotein substrate qualities	Page 269
3833	AZD5153 HNT salt	Potent, selective, and orally available BET/BRD4 bromodomain inhibitor	Page 273
3397	BG45	HDAC inhibitor (1, 2, 3 Selective)	Page 299
4192	BI 2536, (S)-	Recent Addition Dual PLK1/BRD4 bromodomain inhibitor	Page 302
1692	BIX 01294 trihydrochloride hydrate	HMTase inhibitor (G9a and G9a-like protein)	Page 311
2306	Bizine	LSD1 inhibitor with selectivity over MAO-A/B, and LSD2	Page 312
3399	BML-210	HDAC inhibitor	Page 314
3716	BMS-986158	BET bromodomain (BRD) inhibitor	Page 321
3009	BRD0539	Reversible and cell-permeable Cas9 inhibitor	Page 326
2471	BRD 73954	Dual HDAC 6/8 inhibitor with excellent selectivity	Page 327
1781	C 646	HAT inhibitor (p300/CBP selective)	Page 337
2014	CI 994	HDAC inhibitor causes histone hyperacetylation in cells	Page 369
2184	CID 1067700	First inhibitor of Rab7 GTPase	Page 370
2594	CPI 0610	Selective inhibitor of BET bromodomains	Page 393
4138	CUDC-101	Potent HDAC, EGFR, and HER2 inhibitor	Page 398
2305	CX 6258 hydrochloride	Pim Kinase Inhibitor	Page 401
4073	CYC-116	Aurora kinases A & B and VEGFR2 inhibitor	Page 402
3922	dBET1	BET bromodomain degrader	Page 411
3861	Decernotinib	Potent and selective, orally bioavailable Janus kinase 3 (JAK3) inhibitor	Page 416
1590	Decitabine	DNA methyltransferase inhibitor	Page 415
4131	DW-71177	Recent Addition Potent, orally bioavailable and BD1-selective BET inhibitor	Page 445
2568	EML 425	Potent dual inhibitor of CBP and p300 (HAT/KAT3)	Page 456

2573	CPI 455	Selective inhibitor of KDM5 demethylases (H3K4 specific)	Page 392
2622	CPI 4203	Selective inhibitor of KDM5 demethylases (H3K4 specific)	Page 393
3398	E7449 mesylate	Potent, brain penetrable and orally bioavailable dual inhibitor of PARP1/2 and TNKS1/2	Page 448
3424	Ebselen	Glutathione peroxidase mimic	Page 449
3674	Ena21 hydrochloride	Selective and competitive ALKBH5 inhibitor	Page 458
4137	EPZ005687 hydrochloride	EZH2 HMTase inhibitor	Page 463
4216	EPZ011989 hydrochloride	Recent Addition Cell permeable, metabolically stable and orally available EZH2 inhibitor	Page 463
3960	EPZ-5676	Selective and S-adenosyl methionine (SAM) competitive inhibitor of DOT1L methyltransferase	Page 464
2227	EPZ 6438	Inhibitor of Histone Lysine Methyltransferase EZH2	Page 464
2384	FDI 6	Inhibitor of the Forkhead box protein M1 (FOXM1)	Page 476
2570	FG-2216	HIF-PHD inhibitor that increases plasma EPO levels in vivo	Page 479
2588	FG-4592	New-generation oral HIF-PHD inhibitor	Page 480
2277	FLI 06	Notch signaling inhibitor	Page 483
3989	Givinostat hydrochloride	Orally active HDAC inhibitor	Page 503
4006	GLPG-0634	The first orally-available, selective inhibitor of JAK1	Page 505
4127	GNE-781	Highly potent, selective, and orally bioavailable CBP inhibitor	Page 510
3921	GSK046	Domain-selective and orally active inhibitor of BET with immunomodulatory activity	Page 517
2140	GSK 126	Inhibitor of Histone Lysine Methyltransferase EZH2	Page 518
4005	GSK2879552 dihydrochloride	Potent and selective LSD1 inhibitor	Page 521
3750	GSK3326595	Orally active, potent, selective, SAM uncompetitive, peptide competitive, slow binding inhibitor of protein arginine methyltransferase 5 (PRMT5)	Page 521
3919	GSK3368715 hydrochloride	A first-in-class, orally active, potent and selective, SAM-Noncompetitive inhibitor of Type I Protein Arginine Methyltransferases (PRMTs)	Page 521
3900	GSK-3484862	No-covalent DNMT1-selective inhibitor	Page 522
3757	GSK3685032 hydrochloride	Potent first-in-class DNMT1-selective inhibitor	Page 522
2410	GSK 5959	Potent, cell permeable inhibitor of BRPF1 bromodomain	Page 523
1934	GSK J1	Histone demethylase JMJD3/UTX inhibitor	Page 529
1933	GSK J4	Histone demethylase JMJD3/UTX inhibitor	Page 530
2375	GSK-LSD1	Inhibitor of the KDM1 family histone demethylase LSD1	Page 530
1645	HDAC6 inhibitor ISOX	HDAC6 Inhibitor	Page 539
1948	HIF Phd Inhibitor 4	Inhibitor of Hypoxia Inducible Factor PHD	Page 541
2614	HIF-2a Translation Inhibitor 76	HIF-2a translation inhibitor that works independent of mTOR	Page 541
4135	I-BET151	BET bromodomain inhibitor	Page 555
3860	I-BET726	Potent and selective, tetrahydroquinoline-based small molecule ligand binding to BET proteins	Page 555
4134	I-BET762	BET bromodomain inhibitor	Page 555
3417	IMT1B	First-in-class, potent and highly specific allosteric POLRMT inhibitor	Page 564
1921	IOX2	Inhibitor of Hypoxia Inducible Factor PHD	Page 568
2537	Isoquinolinediol, 1,5-	PARP1 inhibitor and neuroprotective agent	Page 571
3959	JG-2016	First inhibitor of the HAT1 enzyme complex	Page 577
2160	JIB 04	Jumonji histone demethylase inhibitor	Page 578
2529	JNJ 26481585 dihydrochloride	Orally available second-generation pan-HDAC inhibitor	Page 579

3754	JNJ-64619178 dihydrochloride	SAM-pocket binding (SAM Competitive) PRMT5 inhibitor	Page 579
1989	JQ-1, (+)	BET bromodomain inhibitor (BRD4 selective)	Page 582
3873	JQ-1, (-)	Inactive enantiomer of (+)-JQ1	Page 583
3822	JQ1 carboxylic acid, (+)	(+)-JQ1 derivative; PROTAC precursor	Page 583
3783	JQKD82 dihydrochloride	Cell-permeable and selective KDM5 inhibitor	Page 583
3529	KA2507	Recent Addition Highly potent, selective and orally available HDAC6 inhibitor	Page 588
4179	KU-0058948	Potent and specific PARP1 inhibitor	Page 597
2319	L 002	Inhibitor of p300 HAT (KAT3B) and p53 acetylation	Page 601
1548	LBH 589	HDAC1 Inhibitor	Page 606
2223	Lomeguatrib	Potent, orally active inhibitor of MGMT	Page 618
2430	LW 479	HDAC inhibitor with cytotoxicity in breast cancer cell lines	Page 625
4238	M344	Recent Addition Potent HDAC inhibitor	Page 638
3601	Mandipropamid	Highly cell-permeable chemical inducer of proximity (CIP); Antifungal	Page 639
4099	Martinostat hydrochloride	HDAC inhibitor (1, 2, 3, 6 Selective)	Page 639
1707	MC 1568	HDAC inhibitor (class IIA selective)	Page 641
1785	MG 149	HAT inhibitor (Tip60 and MOZ specific)	Page 651
2615	ML252	Selective and brain penetrant KCNQ2 inhibitor	Page 666
3562	ML 324	Inhibitor of JMJD2 histone demethylase	Page 667
2081	ML 324 dihydrochloride	Inhibitor of JMJD2 histone demethylase	Page 668
4011	MC4171	First-in-class potent and selective KAT8 inhibitor	Page 641
2505	Mocetinostat	Class I selective HDAC inhibitor	Page 675
4124	Momelotinib hydrochloride	JAK1 and JAK2 inhibitor	Page 676
3796	MRTX1719 hydrochloride	Inhibitor of the PRMT5.MTA complex	Page 681
3681	MS023 dihydrochloride	Potent, cell-active, and Type I selective PRMT inhibitor	Page 681
3469	MS1943 trifluoroacetate	First-in-class EZH2 selective degrader; PROTAC	Page 682
1803	MS 275	Inhibitor of HDAC (1 and 3 Selective)	Page 683
2359	Nexturastat A	HDAC6 inhibitor with selectivity over HDAC1 and HDAC8	Page 699
3409	NKL 22	HDAC inhibitor	Page 705
2077	OG-L002 hydrochloride	Inhibitor of lysine specific demethylase 1 (LSD1 aka KDM1A)	Page 730
3583	OICR-9429	First-in-class, potent, highly selective and cell-active antagonist of the Wdr5-MLL interaction	Page 731
4189	P3FI-63	Recent Addition KDM3B inhibitor	Page 744
4190	P3FI-90	Recent Addition KDM3B inhibitor	Page 744
3614	Parthenolide	NF-κB activation inhibitor	Page 748
1853	PCI 34051	HDAC8 Inhibitor	Page 751
3795	PDD00017273	First-in-class, selective and cell-active PARG inhibitor	Page 755
3695	PF-06821497	Inhibitor of Histone Lysine Methyltransferase EZH2	Page 760
3798	PF-06855800	SAM-pocket-binding (SAM competitive) PRMT5 inhibitor	Page 761
3692	PF-06939999 dihydrochloride	SAM competitive PRMT5 inhibitor	Page 761
1887	PFI-1	BET bromodomain (BRD) inhibitor	Page 771
2211	PRMT3 inhibitor 1	Inhibitor of protein arginine methyltransferase 3 (PRMT3)	Page 791
2420	PTC 209	Inhibitor of the canonical self-renewal regulator BMI-1	Page 796
1801	Pyroxamide	HDAC1 Inhibitor	Page 797
2299	Remodelin	Potent NAT 10 inhibitor	Page 811
1691	RG 108	DNA methyltransferase inhibitor	Page 814

2195	RGFP 966	HDAC3 specific inhibitor	Page 816
2245	RVX 208	BET bromodomain inhibitor specific for BD2s	Page 837
2495	Santacruzamate A	HDAC2 inhibitor with little inhibition of HDAC4 and HDAC6	Page 842
1777	SB 939	HDAC inhibitor (1, 2, 4 Selective)	Page 844
3954	SBI-797812	Orally active NAMPT activator	Page 852
2453	SirReal 2	SIRT2 inhibitor with selectivity over SIRT1 and SIRT3	Page 867
3908	Sirtinol	Specific SIRT inhibitor	Page 868
2209	Sodium butyrate	Noncompetitive inhibitor of multiple HDACs	Page 877
4034	SR-4370	Synthetic inhibitor of histone deacetylase (HDAC)	Page 886
1875	SRT 1720 tetrahydrochloride	Activator of the sirtuin subtype SIRT1	Page 888
3587	STM2457	First-in-class, highly potent and selective catalytic METTL3 inhibitor	Page 897
2263	Tacrolimus	Calcineurin (Ca2+ dependent) inhibitor	Page 904
2502	Talazoparib	Potent, selective, and orally available PARP1/2 inhibitor	Page 909
2008	Tenovin 1	Activates p53 through inhibition of SIRT 1 and 2	Page 919
2249	Tenovin 6	Small water soluble p53 activator and SIRT inhibitor	Page 919
2339	TH 1834	Tip60 histone acetyltransferase inhibitor	Page 924
3402	THZ531	First-in-class, potent, selective, covalent CDK12/CDK13 inhibitor	Page 926
3691	Tubacin	HDAC6 inhibitor	Page 942
2518	UF 010	Class I selective HDAC inhibitor	Page 949
1789	UNC 0224	Inhibitor of G9a HMTase	Page 952
2418	UNC 0379	Substrate competitive inhibitor of the SETD8	Page 953
1841	UNC 0631	Inhibitor of G9a/GLP Histone Lysine Methyltransferase	Page 953
1889	UNC 0638	Inhibitor of G9a (EHMT2)/GLP (EHMT1)	Page 954
1840	UNC 0646	Inhibitor of G9a/GLP Histone Lysine Methyltransferase	Page 954
1994	UNC 1215	Antagonist of L3MBTL3 methyllysine reader domain	Page 954
2163	UNC 669	Antagonist of KMe reader protein L3MBTL1 and 3	Page 952
3591	UNC6934	Potent and selective chemical probe targeting NSD2-PWWP1	Page 952
3592	UNC7145	Negative control of UNC6934 as a chemical probe targeting NSD2-PWWP1	Page 953
2369	UPF 1069	PARP-2 inhibitor with >26 fold selectivity over PARP1	Page 955
3722	Valemetostat	Inhibitor of Histone Lysine Methyltransferase EZH1/2	Page 960
2411	WDR5-0103	Inhibitor of WDR5 and associated activity of MLL	Page 985
3995	WT-161	Potent, selective, and bioavailable HDAC6 inhibitor	Page 988
2231	XL 019	JAK2 inhibitor	Page 992
3973	XL-228	Multitargeted protein kinase inhibitor (IGF1R, Aurora, FGFR, ABL, ALK and SRC)	Page 993
1254	Zebularine	DNA methyltransferase inhibitor	Page 1007

Miscellaneous Axon Ligands™

Not targeting a specific enzyme, protein or receptor, or too small in number to form an individual category in our catalogue, the compounds in this category have various applications.

Tenilsetam (Axon 1470), for example, is an inhibitor of protein crosslinking by advanced glycosylation. It acts via covalent attachment to glycosylated proteins, thus blocking the reactive sites for further polymerization reactions. The beneficial effect of the drug in Alzheimer's disease could come from the interference with AGE-derived crosslinking of amyloid plaques and a decreased inflammatory response by diminished activation of phagocytosing microglia¹. Other Axon Ligands™ in this category range from antioxidants (e.g. vitamin C esters Axon 1316, and Axon 1317) to an inhibitor of Wiskott-Aldrich syndrome protein (Axon 1804).

Obviously, all compounds in this category meet our high standards of quality control.

¹ G. Münch et al. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J. Neural. Transm. Park. Dis. Dement. Sect. 1994, 8, 193-208.

3416	AA147	Endoplasmic reticulum (ER) proteostasis regulator	Page 196
3549	Aloperine	Potent multifunctional anti-tumor agent	Page 219
4014	Aprindine hydrochloride	Orally active long-acting antiarrhythmic agent	Page 243
3159	Ambroxol hydrochloride	Expectorant and mucokinetic compound	Page 223
3140	Arbidol hydrochloride	Broad-spectrum antiviral agent	Page 246
3303	Artemether	Antimalarial drug	Page 249
3886	Artesunate	Antimalarial drug	Page 249
1317	Ascorbyl dodecanoate, L-	Vitamin C ester; Antioxidant	Page 254
1316	Ascorbyl octanoate, L-	Vitamin C ester; Antioxidant	Page 254
3527	Atovaquone	Broad-spectrum antiprotozoal drug	Page 259
3477	Auxinole	Potent antagonist of the SCF(TIR1) auxin receptor complex	Page 261
2567	Azoramide	Modulator of the unfolded protein response (UPR)	Page 279
2736	BAM15	Mitochondrial protonophore uncoupler	Page 283
2867	Bilialtesone	Reactive natural toxin	Page 307
3661	Bisacodyl	Laxative	Page 310
3419	Bromo-2'-deoxyuridine, 5-	Thymidine analog; Labeling agent of cell proliferation	Page 329
2804	Broxaldine	Antiprotozoal drug	Page 330
3481	BTYNB isomer	Ring-closed isomer of BTYNB	Page 332
3380	Butenafine hydrochloride	Broad-spectrum antifungal agent	Page 333
3508	Butoconazole nitrate	Potent antifungal agent	Page 334
3906	CA77.1	Orally bioavailable and brain-penetrant CMA activator	Page 338
3393	CB096	Selective RAN inhibitor	Page 345
3360	CBS1117	Virus entry inhibitor	Page 348
3494	Cefdinir	Orally active cephalosporin antibiotic	Page 356
3123	Cefoperazone	Broad-spectrum antibiotic	Page 357
3819	Cefoxitin sodium	Cephalosporin antibiotic	Page 357
4044	Cefsulodin sodium	Cephalosporin antibiotic	Page 357
3156	Cenithaquin	Centrally acting hypotensive agent	Page 358
2866	Chloro-8-fluoro-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one, 2-	Building Block; unknown pharmacology	Page 366
2431	Chloroquine diphosphate	Classical antimalarial drug causing necrosis and apoptosis	Page 367
3842	Cimlanod	HNO donor	Page 372
4205	Cinepazide maleate	Vasodilator	Page 372
3474	Clovamide, trans-	Potent antioxidant	Page 378
3653	Cloxacillin sodium	Orally active penicillin antibiotic	Page 378

2479	CM1	Orally active iron chelator with anti-malarial activity	Page 379
3970	CNDAC hydrochloride	Induces DNA damage and apoptosis	Page 380
3453	Colistin sulfate	Antibiotic for treatment of gram-negative bacterial infections	Page 382
3911	Conoidin A	Covalent, cell-permeable inhibitor of peroxiredoxin II	Page 385
3825	Cordycepin	Nucleoside analogue; Anticancer and anti-inflammatory agent	Page 385
3238	Cytarabine	Inhibitor of DNA synthesis; Antimetabolite	Page 404
3459	Dacarbazine	DNA alkylating agent; antineoplastic agent	Page 407
3580	DC-LC3in-D5	Autophagy inhibitor	Page 413
3375	Deferasirox	Orally active iron chelator	Page 417
3141	DHQZ 36	Potent retrograde trafficking inhibitor	Page 425
2496	Dimethylcelecoxib, 2,5-	Celecoxib analog lacking COX-2 inhibitory activity	Page 432
3011	DMNQ	Redox cycling agent	Page 435
4209	Doxofylline Recent Addition	Bronchodilator; Anti-inflammatory agent	Page 439
3745	Elesclomol	Apoptosis inducer	Page 454
3782	Epigoitrin (optically pure)	Antiviral agent	Page 462
2292	EUK 134	Antioxidant with SOD and catalase mimetic characteristics	Page 470
3377	Ezetimibe	Potent, orally active inhibitor of cholesterol absorption	Page 473
4206	Faropenem sodium Recent Addition	Orally active broad-spectrum antibiotic	Page 474
2850	Fenfluramine hydrochloride	5-HT releasing agent	Page 478
2320	FH 1	Promotes the differentiation of iPSCs to hepatocytes	Page 480
4208	Flucloxacillin sodium Recent Addition	Orally active penicillin antibiotic	Page 485
2355	FPH 2	Proliferation inducer of mature human primary hepatocytes	Page 490
3233	Gemcitabine hydrochloride	Specific inhibitor of DNA synthesis; Antimetabolite	Page 501
3781	Goitrin (optically pure)	Antithyroid factor; Antiviral agent	Page 512
1120	Glutapyrone	Atypical neuromodulator	Page 506
3897	Honokiol	Neuroprotectant; Antioxidant; Anti-inflammatory agent	Page 545
2432	Hydroxychloroquine sulfate	Antimalarial drug; immunosuppressant; anti-inflammatory	Page 549
3811	Icaritin	Natural flavonoid with potent cytotoxic and osteogenic activity	Page 557
4048	Iguratomod	Orally active DMARD	Page 560
2933	IITZ-01	Potent lysosomotropic autophagy inhibitor	Page 561
1827	IMS 2186	Apoptosis inducer. Inhibitor of PGE2/TNF- α production	Page 564
2859	J147	Potent and orally active neurotrophic drug	Page 576
3432	K22	Inhibitor of membrane-bound coronaviral RNA synthesis	Page 587
2802	KKL-10	Ribosome rescue inhibitor	Page 592
2997	KKL-35	Ribosome rescue inhibitor	Page 592
3776	Lac-Phe	Blood-borne signaling metabolite; Suppressor of feeding and obesity	Page 603
1970	Laquinimod	Selective autoimmune suppressant; Immunomodulator	Page 605
3242	Levamisole hydrochloride	Anthelmintic agent	Page 611
3601	Mandipropamid	Highly cell-permeable chemical inducer of proximity (CIP); Antifungal	Page 639
3245	Mercaptopurine, 6-	Purine analog; Immunosuppressant	Page 646
3246	Mesna	Chemoprotective agent	Page 646
3815	Metaxalone	Skeletal muscle relaxant	Page 647
4026	Metolazone	Diuretic agent	Page 651

3381	Minocycline hydrochloride	Orally active and brain-penetrant broad-spectrum antibiotic	Page 656
3248	Mitotane	Adrenocortolytic drug	Page 658
3188	MK-4482	Potent and orally bioavailable broad-spectrum antiviral agent	Page 662
2871	ML 239	Selective inhibitor of breast cancer stem cells	Page 666
1267	MNITMT	Immunosuppressant	Page 675
3306	Moxifloxacin hydrochloride	Broad-spectrum antibiotic	Page 677
2932	MSL-7	Autophagy enhancer	Page 683
2876	MSTP	Thiol blocking reagent	Page 684
3656	Naftifine hydrochloride	Topical broad-spectrum antifungal agent	Page 689
3493	Natamycin	Antifungal agent	Page 692
3476	NidR, 5-	Potent inhibitor of translesion DNA synthesis (TLS)	Page 702
2327	NEO 212	DNA alkylating agent; chemotherapeutic	Page 697
2322	Neuropathiazol	Inducer of neural differentiation of adult hippocampal NPCs	Page 698
4207	Nifuratel Recent Addition	Broad-spectrum antibiotic	Page 703
3391	Nifurtimox	Antiprotozoal drug	Page 703
4045	Nimustine hydrochloride	Water-soluble DNA alkylating agent	Page 704
2603	Nitrosocyclohexyl acetate, 1-	HNO donor	Page 705
3858	NUC-1031	DNA synthesis inhibitor	Page 719
3826	NUC-7738	Prodrug of Cordycepin; Anticancer agent	Page 719
1752	NXV 059	Free radical scavenger, neuroprotectant	Page 727
4211	Ofloxacin Recent Addition	Broad-spectrum antibiotic	Page 730
3652	Oxacillin sodium	Orally active penicillin antibiotic	Page 741
3308	Oxcarbazepine	Anti-convulsant	Page 741
3907	PEO-IAA	IAA and auxin antagonist	Page 759
3307	Pidotimod	Orally bioavailable immunostimulant	Page 777
2647	Pirfenidone	Anti-inflammatory and anti-fibrosis agent	Page 779
4203	Pramiracetam Recent Addition	Nootropic drug	Page 789
3177	Primaquine diphosphate	Transmission-blocking anti-malarial drug	Page 791
3586	Pseudouridine	Uridine isomer	Page 795
3888	Pyrantel pamoate	Anthelmintic agent	Page 799
4076	Pyridostatin hydrochloride	G-quadruplex DNA stabilizing agent	Page 799
3110	Remdesivir	Potent and selective inhibitor of Ebola virus (EBOV); Broad-spectrum antiviral agent	Page 811
3573	Ribavirin	Antiviral agent; Suppressor of eIF4E activity	Page 817
3372	Rifabutin	Potent broad-spectrum antibiotic	Page 818
4183	Rilematovir	Potent and orally bioavailable RSV inhibitor	Page 818
3953	Ropidoxuridine	Thymidine analog; Radiosensitizer	Page 829
2868	Roquinimex	Immunomodulator	Page 829
2487	Silibinin	Natural flavonolignan, cytoprotectant, antioxidant	Page 866
4085	Sisunatovir	Orally bioavailable inhibitor of RSV fusion protein	Page 868
2627	SMER 28	Enhancer of rapamycin enhancing autophagy	Page 874
2688	Sodium ionophore III	Sodium ionophore	Page 877
3660	Sodium picosulfate	Laxative	Page 878
1467	Stobadine	Antioxidant	Page 897
3170	Tavorole	Broad-spectrum antifungal agent	Page 912
3149	TC11	Anti-tumor agent; Apoptosis inducer	Page 914

2326	Temozolomide	DNA methylating agent; apoptosis inducer	Page 917
1470	Tenilsetam	Alzheimer's disease therapeutic	Page 918
3379	Terbinafine	Orally active broad-spectrum antifungal agent	Page 920
3253	Thioguanine, 6-	Purine analog; Immunosuppressant	Page 925
3514	Trolox	Vitamin E analog; Antioxidant	Page 939
3553	Trolox, (S)-	Vitamin E analog; Antioxidant	Page 940
4200	Tryptanthrin	Natural alkaloid with antiprotozoal, antioxidant, antimicrobial and antitumor activities	Page 941
3127	Valproic acid sodium salt	Anti-convulsant	Page 961
3362	Vistonuridine	Uridine prodrug	Page 970

Axon Ligands™ inhibitor Sets

Axon Ligands™ are a unique collection of biological molecules, as world-wide recognized research tools and drug standards in different application fields such as neurological disorders, cardiovascular disease, pain and inflammation, and cancer. Featured ligands with our expertise including CNS reagents, ion channel modulators, signal transduction regulators (such as kinase inhibitors) and much more. Besides the wide range of single products, Axon Medchem also offers specific sets of Axon Ligands™ that can be applied for specific research areas. Special attention is offered to the class of Axon Ligands™ that finds its application (among other applications in most cases) in stem cell research projects. The medical use of stem cells, cells with the ability to perpetuate themselves through self-renewal and to differentiate into a particular cell type through differentiation, is receiving extensive interest as they might regenerate damaged tissue under the right conditions¹. This unique capacity could serve patients suffering from organ malfunction, cell deficiency, and/or neurodegenerative diseases such as Alzheimer's and Parkinson's disease by replacing affected/deficient cells with healthy new cells²[2]. We have selected several combinations of Axon Ligands™ that have been used frequently as a combined set for epigenetic research. These sets include, for example inhibitors of GSK3, FGFR, MEK, SRC, etc. Compound libraries of Axon Ligands™ can generally be offered with bulk discount. All Axon Ligands™ in the libraries are individually identified and analyzed to meet the strong requirements to pass our QC for drug standards.

¹ Stem cells, cancer, and cancer stem cells. Tannishtha Reya, Sean J. Morrison, Michael F. Clarke, Irving L. Weissman. Nature, Vol 414, 2001, 105.

² Embryonic stem cells in drug discovery. J. McNeish. Nature Rev. Drug Disc. 2004, 3, 70

5011	Naïve Stem Cell 5i inhibitor Set	Inhibitors for induction&maintenance of naive stem cell pluripotency
5010	Naïve Stem Cell NHSM inhibitor Set	Inhibitors for generation, derivatization and stabilization of naive hPSCs
2128	Stem Cell 2i inhibitor Set	Set of PD0325901 and CHIR99021
2129	Stem Cell 3i inhibitor Set	Set of SU5402, PD184352, and CHIR99021
5009	Stem Cell 4i inhibitor Set	Set of Thiazovivin, SB 431542, PD 0325901, CHIR 99021
5007	Stem Cell 5i inhibitor Set	Set of five inhibitors for neural differentiation of human PSCs.
2130	Stem Cell Alternative 2i inhibitor Set	Set of CGP77675 and CHIR99021
5006	Stem Cell CSD inhibitor Set	Set of CHIR 99021, SU5402, and DAPT
5004	Stem Cell LSB inhibitor Set	Set of LDN 193189 and SB 431542
5005	Stem Cell LSC inhibitor Set	Set of LDN 193189, SB 431542 and CHIR 99021
5008	Stem Cell RG-BIX inhibitor Set	Set of RG 108 and BIX 01294

Axon Ligands™ in Alphabetical Order

2X-121

See E7449 mesylate

Axon 3398

Page 448

3TC

See Lamivudine


Axon 3304

Page 604

4A7C-301

[N.A.]
Purity: 98%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C27H38ClN9 MW: 524.10



Axon 4081

mg	Price
10	online
50	online


Biological activity

4A7C-301 is a brain-penetrant *Nurr1* agonist with an EC_{50} value of 6.53 μ M and exhibits robust neuroprotective effects *in vitro*. In addition, 4A7C-301 protects midbrain dopamine neurons in the MPTP-induced male mouse model of PD and improves both motor and non-motor olfactory deficits without dyskinesia-like behaviors. Furthermore, 4A7C-301 significantly ameliorates neuropathological abnormalities and improves motor and olfactory dysfunctions in AAV2-mediated α -synuclein-overexpressing male mouse models.

4 μ 8C

[14003-96-4]
Purity: 99%

Soluble in DMSO
C11H8O4 MW: 204.18



Axon 1902

mg	Price
10	online
50	online

Biological activity

Potent and selective IRE1 α inhibitor (IC_{50} : 60 nM). 4 μ 8C blocks substrate access to the active site of IRE1 and selectively inactivates both *Xbp1* splicing and IRE1-mediated mRNA degradation

5A6-48

See UCSF648 dihydrochloride

Axon 3634

Page 948

5A6-78

See UCSF678 dihydrochloride

Axon 3636

Page 949

5A6-86

See UCSF686 dihydrochloride

Axon 3635

Page 949

566C80

See Atovaquone

Axon 3527

Page 259

6748-481

See SMI 481

Axon 2387

Page 875

A-002

See Varespladib methyl

Axon 4032

Page 963

A01

See SMURF1 inhibitor A01

Axon 2426

Page 875

AO128

See Voglibose **Recent Addition**


Axon 4210

Page 970

A-1155463 dihydrochloride

[N.A.]
Purity: 99%

Soluble in DMSO
C35H32FN5O4S2.2HCl MW: 742.71



Axon 3957

mg	Price
5	online
10	online

Biological activity


A-1155463 is a proteolytically stable, cell-permeable and high affinity BH3 mimetic Ligand of BCL protein BCL-XL, binding to the target potently and selectively with a K_i value of <0.01nM (<10 pM), highly selective against closely related proteins of BCL-2 (K_i = 74nM, >7000-fold selectivity), BCL-W (K_i = 8 nM, >800-fold selectivity), and MCL-1 (K_i >444nM, >40000-fold selectivity). A-1155463, together with A-1331852 (Axon 3972), represent the first-in-class small molecule BCL-XL selective inhibitors achieving clear-on-target *in vivo* activity with high potency and selectivity. In living cells, A-1155463, as anticipated, exerts an effort to disrupt the tight-binding BCL-XL-BIM, but not BCL-2-BIM, complexes, killing BCL-XL-dependent Molt-4 cells (EC_{50} =70nM) without measurable cytotoxicity against BCL-2-dependent RS4, inducing the hallmarks of intrinsic apoptosis.

Source Information: Sold in collaboration with Chemietek

A-1210477

[1668553-26-1]
Purity: 99%

Soluble in DMSO
C46H55N7O7S MW: 850.04



Axon 4008

mg	Price
10	online
50	online

Biological activity

A-1210477 is a proteolytically stable, cell-permeable and high affinity BH3 mimetics of anti-apoptotic protein MCL-1, binding to the target potently and selectively with a K_i value of 0.45 nM, highly selective against closely related proteins of BCL-2 (K_i = 132 nM, >290-fold selectivity) and BCL-XL (K_i > 660 nM, >1400-fold selectivity). A-1210477

is the first-in-class small molecule MCL-1 inhibitor with sufficient potency to disrupt the tight-binding MCL-1-BIM complex in living cells, achieving the hallmarks of intrinsic apoptosis, and demonstrating clear-on-target cancer cell killing capability either as a single agent or in combination with ABT-263 (Axon 3821).

Source Information: Sold in collaboration with Chemietek

A127722

See *Atrasentan*


Axon 4058

Page 260

A-1331852

[1430844-80-6]
Purity: 99%

Soluble in DMSO
C38H38N6O3S MW: 658.81



Axon 3972

mg	Price
5	online
25	online


Biological activity

A-1331852 is a high affinity BH3 mimetic Ligand of BCL protein BCL-XL, binding to the target potently and selectively with a K_i value of <0.01 nM (<10 pM), highly selective against closely related proteins of BCL-2 ($K_i = 6$ nM, >600 -fold selectivity), BCL-W ($K_i = 4$ nM, >400 -fold selectivity), and MCL-1 ($K_i = 142$ nM, >14000 -fold selectivity). A-1331852, together with A-1155463 (Axon 3957), represent the first-in-class small molecule BCL-XL selective inhibitors achieving clear-on-target in vivo activity with high potency and selectivity.

A-438079 hydrochloride

[899431-18-6]
Purity: 99%

Soluble in water, DMSO and EtOH
C13H9Cl2N5.HCl MW: 342.61



Axon 3835

mg	Price
10	online
50	online

Biological activity

A-438079 hydrochloride is a competitive P2X7 antagonist with a pIC_{50} value of 6.9. A-438079 was found to possess antinociceptive activity in a model of neuropathic pain.

A1443

See *Fluralaner*


Axon 4047

Page 487

A 66

[1166227-08-2]
Purity: 99%

optically pure
Soluble in DMSO
C17H23N5O2S2 MW: 393.53



Axon 1831

mg	Price
5	online
25	online

Biological activity

Potent and specific PI3K $p110\alpha$ inhibitor (IC_{50} : 32 nM); highly selective for $p110\alpha$ over other PI3Ks and having a high degree of specificity as it does not target other protein kinases tested; highly recommended tool in researching $p110\alpha$ isoform


A 357300

[369358-07-6]

Axon 1666

mg Price

Purity: 98%
optically pure
Soluble in DMSO
C15H22ClN3O3S MW: 359.87



5	online
25	online


Biological activity

Potent and reversible inhibitor of methionine aminopeptidase-2 (MetAP-2)

A 381393

[726174-00-1]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C20H24N4 MW: 320.43



Axon 2944

mg	Price
10	online
50	online

Biological activity

Potent, brain-penetrant, selective antagonist of the dopamine D4 receptor with both in vitro and in vivo activity (K_i value of 1.5 nM). A 381393 lacks any significant intrinsic agonist activity.

A4166

See *Nateglinide*

Axon 3641

Page 693

A56268

See *Clarithromycin*


Axon 3445

Page 375

A 769662

[844499-71-4]
Purity: 99%

Soluble in DMSO
C20H12N2O3S MW: 360.39



Axon 1466

mg	Price
5	online
25	online


Biological activity

Potent and selective activator of AMP-activated protein kinase (AMPK) $\beta 1$ subunit-containing complexes

A 770041

[869748-10-7]
Purity: 99%

Soluble in DMSO
C34H39N9O3 MW: 621.73



Axon 1698

mg	Price
5	online
25	online

Biological activity

Selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling


A 784168

Axon 1816

mg Price

[824982-41-4]
Purity: 98%

Soluble in DMSO
C19H15F6N3O3S MW: 479.40



5	online
25	online


Biological activity

Potent and selective antagonist of transient receptor potential vanilloid 1 (TRPV1) receptors (IC₅₀: 24 nM); displayed potent anti-nociceptive effects in a broad range of animal pain models upon oral dosing. This analgesic activity results from its ability to penetrate the central nervous system

A 803467

[944261-79-4]
Purity: 98%

Soluble in DMSO
C19H16ClNO4 MW: 357.79



Axon 1915

mg	Price
10	online
50	online


Biological activity

Sodium channel blocker, potent and selective at voltage-gated Nav1.8 channel (IC₅₀: 8 nM)

A 804598

[1125758-85-1]
Purity: 99%
>99% e.e.

Soluble in DMSO
C19H17N5 MW: 315.37



Axon 2182

mg	Price
10	online
50	online


Biological activity

Potent and selective P2X7 antagonist (IC₅₀ values 10 nM, 9 nM, and 11 nM for rat, mouse, and human receptors respectively). A 804598 potently blocked agonist stimulated release of IL-1 β and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors. In another study, A 804598 was found to produce a concentration-dependent inhibition of BZ-ATP-stimulated calcium influx (IC₅₀ value 28.71 nM) in cells expressing the rat recombinant P2X7 receptor; a useful tool for autoradiographic localization of P2X7 receptors in the rat brain and spinal cord.

A 841720

[869802-58-4]
Purity: 99%

Soluble in DMSO
C17H21N5OS MW: 343.45



Axon 2155

mg	Price
5	online
25	online

Biological activity

Potent and selective non-competitive mGlu1 receptor antagonist (IC₅₀: 10 nM); showing 34-fold selectivity over mGluR5 and no significant activity at other mGluR receptors, neurotransmitter receptors, ion channels, and transporters. A 841720 demonstrated full efficacy in various in vivo animal pain models.

A 861695 dihydrochloride

See ABT 888 dihydrochloride

Axon 2888

Page 203

A 922500


[959122-11-3]

Axon 2059

mg	Price
----	-------

Purity: 98%
97% d.e.

Soluble in DMSO
C26H24N2O4 MW: 428.48



5	online
25	online


Biological activity

Highly potent and selective diacylglycerol acyltransferase (DGAT) isomer 1 (DGAT-1) inhibitor with nanomolar potency

A 943931

[1027330-97-7]
Purity: 99%
optically pure

Soluble in DMSO
C17H21N5 MW: 295.38



Axon 1990

mg	Price
2	online
5	online


Biological activity

Potent and selective histamine H4 receptor antagonist

A 1070722

[1384424-80-9]
Purity: 99%

Soluble in DMSO
C17H13F3N4O2 MW: 362.31



Axon 1909

mg	Price
5	online
25	online


Biological activity

Potent and selective glycogen synthase kinase GSK-3 inhibitor (K_i=6 nM). Brain penetrating and centrally active GSK3 inhibitor for the treatment of psychiatric and neurodegenerative disorders

A 77-01

[607737-87-1]
Purity: 99%

Soluble in DMSO
C18H14N4 MW: 286.33



Axon 1744

mg	Price
5	online
25	online


Biological activity

Potent inhibitor of TGF- β type I receptor superfamily activin-like kinase ALK5 with IC₅₀ of 25 nM. A-77-01 is a close analogue of A-83-01 (Axon 1421) and has a very similar biological profile of A-83-01. A-83-01 is found to decompose to A-77-01 under certain circumstances and A-77-01 is likely an active component or metabolite of its prodrug A-83-01

A 83-01

[909910-43-6]
Purity: 98%

Soluble in DMSO
C25H19N5S MW: 421.52



Axon 1421

mg	Price
5	online
25	online


Biological activity

Potent inhibitor of TGF- β type I receptor superfamily activin-like kinase ALK5 and its relatives ALK4 and ALK7 (IC50 to be 12, 45 and 7.5 nM respectively). A-83-01 inhibits smad signaling and epithelial-to-mesenchymal transition by transforming growth factor- β , but had no effect on BMP signaling; Used to generate rat and human iPS cells towards a mouse ES cell like self-renewal state.

A-196

[1982372-88-2]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C18H16Cl2N4 MW: 359.25



Biological activity


A-196 is a potent and selective inhibitor of SUV420H1 and SUV420H2 (IC50 values of 25 and 144 nM, respectively). In cells, A-196 induced a global decrease in H4K20me2 and H4K20me3 and a concomitant increase in H4K20me1. A-196 inhibited 53BP1 foci formation upon ionizing radiation and reduced NHEJ-mediated DNA-break repair but did not affect homology-directed repair.

A2764 dihydrochloride

TRESK inhibitor A2764

[861038-72-4]
Purity: 99%

Soluble in water and DMSO
C15H19ClN2O2.HCl MW: 351.70




Biological activity

A2764 dihydrochloride is a selective inhibitor of TRESK (KCNK18) with an IC50 value of 11.8 μ M. The degree of inhibition by 100 μ M A2764 was larger in the activated state of TRESK than in the resting state of the channel. A2764 can inhibit TRESK in native cells, leading to cell depolarization and increased excitability.

A2793

[88349-90-0]
Purity: 98%

Soluble in DMSO
C13H12ClNO3 MW: 265.69



Biological activity

A2793 is an inhibitor of TRESK (IC50 value of 6.8 μ M for mTRESK) and TASK-1. A2793 may be considered as a tool to discriminate between the resting and activated channels in heterologous expression systems, and to block TRESK activated by calcineurin in the native cells, which do not express TASK-1.

A-64077

See Zileuton

Axon 2705

mg Price

10 online

50 online

Axon 3019

mg Price

10 online

50 online

Axon 3060

mg Price

10 online

50 online


Axon 3256

Page 1006

A-92

[1448693-69-3]
Purity: 99%

Soluble in DMSO
C19H18N10O MW: 402.41




Biological activity

A-92 inhibits the stress response of general control nonderepressible 2 kinase (GCN2 or EIF2AK4) (IC50 value of <0.3 μ M). Possible chemotherapeutic drug for the treatment of cancer.

A1B1 Hydrochloride

[N.A.]
Purity: 99%
>98% ee

Soluble in DMSO
C23H25Cl1FN3O2.HCl MW: 466.38




Biological activity

Potent and orally active chemokine CCR1 antagonist

AA147

[393121-74-9]
Purity: 99%

Soluble in DMSO
C16H17NO2 MW: 255.31



Biological activity

AA147 is an endoplasmic reticulum (ER) proteostasis regulator. The ER reprogramming afforded by AA147 requires activation of endogenous ATF6 and occurs independent of global ER stress. Also, AA147 is broad-spectrum inhibitor of dengue and Zika virus infections.

AA 2414

See Seratrodast

AAE 581

See Balicatib

AB, 3-


See Aminobenzamide, 3-

AB 1010

Masitinib mesylate

[1048007-93-7]
Purity: 99%

Soluble in water and DMSO
C28H30N6O3S.CH4O3S.CH4O3S
MW: 594.75



Axon 2720

mg Price

5 online

25 online

Axon 1179

mg Price

5 online

25 online

Axon 3416

mg Price

10 online

50 online

Axon 1447

Page 861

Axon 2154

Page 282

Axon 1496

Page 228

Axon 1419

mg Price

5 online

25 online


Biological activity

A potent oral tyrosine kinase inhibitor, targeting c-KIT, PDGFR and FGFR3; oncology drug under clinical trial

AB-680 ammonium salt

Quemliclustat ammonium salt

[N.A.]
Purity: 99%
99% e.e.
Soluble in water and DMSO
C20H30ClFN6O9P2 MW: 614.89



Axon 3718

mg	Price
5	online
10	online

Biological activity

AB-680 (Quemliclustat) is a highly potent and selective inhibitor of CD73 (K_i hCD73 = 4.9 pM on human CD8+ T-cells) and an immune-oncology modulator, highly selective against the closely-related CD39 (10,000-fold selectivity), and a large panel of unrelated enzymes, receptors, and ion channels. It potently reverses AMP and ADO-mediated suppression of immune function in vitro, robustly restores, in the presence high AMP concentration, CD25 expression, IFN- γ production and proliferation of human CD4+ and CD8+ T-cells, and reverses ADO-mediated immune suppression.

Source Information: Sold in collaboration with Chemietek

ABA

See Abscisic acid, (+)-

Axon 3755

Page 200

ABA, 3-

See Aminobenzamide, 3-

Axon 1496


Page 228

ABBV-075

Mivebresib

[1445993-26-9]
Purity: 98%

Soluble in DMSO and EtOH
C22H19F2N3O4S MW: 459.47



Axon 3696

mg	Price
5	online
25	online

Biological activity


ABBV-075 is a highly potent and orally bioavailable BET bromodomain (BRD) inhibitor with a K_i value of 1.5 nM for BRD4 (TR-FRET assay).

ABBV-467 Recent Addition

[2287186-66-5]
Purity: 98%
98% e.e.
Soluble in DMSO
C53H51Cl2FN6O9S MW: 1037.98

Axon 4263

mg	Price
5	online



Biological activity


ABBV-467 is a highly potent and selective MCL-1 inhibitor ($K_i < 0.01$ nM). ABBV-467 induces tumor regression in xenograft models of MM and AML when combined with Venetoclax (Axon 2141).

Source Information: Sold in collaboration with Chemietek

ABBV-744

[2138861-99-9]
Purity: 99%

Soluble in DMSO
C28H30FN3O4 MW: 491.55



Axon 3956

mg	Price
5	online
10	online

Biological activity


ABBV-744 is an orally available first-in-class highly BDII (Bromodomain II)-selective (>100 X selectivity over BDI) BET bromodomain inhibitor, currently is being investigated to treat AML and metastatic castration-resistant prostate cancer.

Source Information: Sold in collaboration with Chemietek

ABBV-CLS-484 hydrochloride

Osunprotafib

[N.A.]
Purity: 99%
99% e.e.
Soluble in DMSO
C17H24FN3O4S.HCl MW: 421.91



Axon 3729

mg	Price
5	online
10	online

Biological activity

ABBV-CLS-484 hydrochloride is an inhibitor of phosphatase PTPN2/N1 (Protein Tyrosine Phosphatase Non-Receptor Type 2/1), and a highly effective immunotherapy agent with monotherapy efficacy across mouse tumor models.


Source Information: Sold in collaboration with Chemietek

ABC294640

Opaganib

[915385-81-8]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C23H25ClN2O MW: 380.91



Axon 2880

mg	Price
10	online
50	online


Biological activity

ABC294640 is a selective and orally available Sphingosine kinase 2 inhibitor (SphK2 or SK2) *in vitro*, acting as a competitive inhibitor with respect to sphingosine with a K_i of 9.8 μM , and attenuates S1P formation in intact cells. In tissue culture, ABC294640 suppresses the proliferation of a broad panel of tumor cell lines, and inhibits tumor cell migration concomitant with loss of microfilaments. ABC294640 shows *in vivo* SK inhibitory activity in mice. Drug candidate for the treatment of cancer and other diseases.

ABCA1 inducer compound G

Cpd G

[1269826-44-9]
Purity: 99%
100% e.e.
Soluble in DMSO and EtOH
C20H19Cl2F3N2O3 MW: 463.28



Axon 3564

mg	Price
5	online
25	online


Biological activity

ABCA1 inducer compound G is an inducer of ABCA1-mediated cholesterol efflux by targeting oxysterol binding protein like 7 (OSBPL7).

Abiraterone

CB 7598

[154229-19-3]
Purity: 100%
optically pure
Moderately soluble in DMSO
C24H31NO MW: 349.51



Axon 1873

mg	Price
10	online
50	online


Biological activity

Inhibitor of the steroidal enzyme 17 α -hydroxylase/C17,20 lyase (CYP17A1); a drug used in castration-resistant prostate cancer (CRPC); active component of its formulated prodrug abiraterone acetate (Axon 1874), which is also available

Abiraterone acetate

CB 7630; JNJ 212082

[154229-18-2]
Purity: 100%
optically pure
Poorly soluble in DMSO
C26H33NO2 MW: 391.55



Axon 1874

mg	Price
10	online
50	online

Biological activity


Orally administered prodrug of Abiraterone (Axon 1873); inhibitor of the steroidal enzyme 17 α -hydroxylase/C17,20 lyase (CYP17A1); a drug used in castration-resistant prostate cancer (CRPC)

Abivertinib

AC 0010; Avitinib

[1557267-42-1]
Purity: 99%

Soluble in DMSO
C26H26FN7O2 MW: 487.53



Axon 3040

mg	Price
10	online
50	online

Biological activity

Abivertinib is a potent, selective, orally available and irreversible third-generation EGFR inhibitor with an IC_{50} value of 0.18 nM against EGFR L858R/T790M double mutations.

ABL001

See Asciminib

Axon 2757

Page 253

Abn-CBD

See Cannabidiol, Abnormal

Axon 1235

Page 342

ABR 21261

See Roquinimex

Axon 2868

Page 829

ABR 215062

See Laquinimod


Axon 1970

Page 605

ABR-238901

[1638200-22-2]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C11H9BrClN3O4S MW: 394.63



Axon 3631

mg	Price
5	online
25	online


Biological activity

ABR-238901 is a S100A8/A9 blocker that potently inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4).

Abscisic acid, (+)-

ABA

[21293-29-8]
Purity: 99%
Optically pure
Soluble in 0.1N NaOH(aq), DMSO and EtOH
C15H20O4 MW: 264.32



Axon 3755


mg	Price
10	online
50	online

Biological activity

The phytohormone (+)-Abscisic acid is a ligand of lanthionine synthetase C-like 2 (LANCL2) and targets cells of the innate immune response, mesenchymal and hemopoietic stem cells and cells involved in the regulation of systemic glucose homeostasis.

ABT 102

[808756-71-0]
Purity: 99%
optically pure
Soluble in DMSO
C21H24N4O MW: 348.44



Axon 1504

mg	Price
5	online
25	online

Biological activity


Potent and selective antagonist of transient receptor potential vanilloid 1 (TRPV1) receptors (IC50 values to be 5-7 nM) under clinical trials; TRPV1 receptor antagonism is a promising approach for pain management

ABT 199

GDC 0199

[1257044-40-8]
Purity: 98%

Soluble in DMSO
C45H50ClN7O7S MW: 868.44




Biological activity

A highly potent, orally bioavailable BCL-2-selective inhibitor; a new Bcl-2-specific BH3 mimetic efficacious in vivo against mouse lymphomas without provoking thrombocytopenia

ABT 239 tartrate

[460748-71-4]
Purity: 99%
>98% ee
Soluble in DMSO
C22H24N2O.C4H6O6 MW: 480.51




Biological activity

Potent and selective histamine H3 receptor antagonist or inverse agonist; a highly recommended tool for animal research into H3 antagonist / inverse agonist

ABT-263

Novitoclax

[923564-51-6]
Purity: 99%
99% e.e.
Soluble in DMSO
C47H55ClF3N5O6S3 MW: 974.61



Biological activity

ABT-263 is a potent, selective and orally bioavailable inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, binding potently to both BCL-2 and BCL-XL with Ki values of <1 nM.
Source Information: Sold in collaboration with Chemietek

ABT627

See Atrasentan

Axon 2141

mg	Price
5	online
25	online

Axon 1510

mg	Price
5	online
25	online

Axon 3821


mg	Price
10	online
50	online

Axon 4058

Page 260

ABT-639

[1235560-28-7]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C20H20ClF2N3O3S MW: 455.91




Biological activity

ABT-639 is a peripherally acting, selective and orally bioavailable T-type Ca²⁺ channel blocker. ABT-639 blocks recombinant human T-type (Ca_v3.2) Ca²⁺ channels in a voltage-dependent fashion (IC₅₀ value of 2 μM) and attenuates LVA currents in rat DRG neurons (IC₅₀ value of 8 μM).

ABT 702

[214697-26-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H19BrN6O MW: 463.33




Biological activity

The first, non-nucleoside adenosine kinase (ADK) inhibitor (IC₅₀ value 2 nM and 50 nM in cytosolic and intact cell assays, respectively). ABT702 is orally active to reduce pain and inflammation in animal models, yet found to be clastogenic in an in vitro Chinese Hamster micronucleus assay.

ABT 724 trihydrochloride

[587870-77-7]
Purity: 99%

Soluble in water
C17H19N5.3HCl MW: 402.75



Biological activity


Dopamine D4 partial agonist

ABT 869

Linifanib

[796967-16-3]
Purity: 99%

Soluble in DMSO
C21H18FN5O MW: 375.40



Biological activity

A multi-targeted receptor tyrosine kinase (RTK) inhibitor, targeting VEGFRs, PDGFRs, Fms-like tyrosine kinase-3 and c-KIT. In cellular assays ABT869 inhibits RTK phosphorylation (IC₅₀ = 2, 4, and 7 nM for PDGFR-β, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC₅₀ = 0.2 nM for human endothelial cells)

ABT 888

Veliparib

Axon 3785

mg	Price
5	online
25	online

Axon 2289

mg	Price
5	online
25	online

Axon 1250

mg	Price
10	online
50	online


Axon 1638

mg	Price
5	online
10	online

Axon 1593

mg	Price
----	-------

[912444-00-9]
Purity: 99%
>98% ee
Soluble in DMSO
C13H16N4O MW: 244.29




2	online
5	online

Biological activity

Potent and orally bioavailable PARP inhibitor, with K_i values to be 5.2 nM for PARP1 and 2.9 nM for PARP2 respectively; inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents

ABT 888 dihydrochloride

[912445-05-7]
Purity: 99%
Optically pure
Soluble in water and DMSO
C13H14N4O₂HCl MW: 317.21



Axon 2888

mg	Price
10	online
50	online

Biological activity

Potent and orally bioavailable PARP inhibitor, with K_i values to be 5.2 nM for PARP1 and 2.9 nM for PARP2 respectively; inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents

ABT-378

See Lopinavir

Axon 3138

Page 619

ABT-538


See Ritonavir

Axon 3139

Page 821

ABX-1431

[1446817-84-0]
Purity: 98%
Soluble in DMSO
C20H22F9N3O2 MW: 507.39



Axon 3000

mg	Price
5	online
25	online

Biological activity

ABX-1431 is a highly potent, selective, and orally available, CNS-penetrant MGLL (MAGL) inhibitor with an IC_{50} value of 0.014 μ M. In vivo, ABX-1431 inhibits MGLL activity in rodent brain (ED_{50} value of 0.5-1.4 mg/kg), increases brain 2-AG concentrations, and suppresses pain behavior in the rat formalin pain model.

AC 0010

See Abivertinib

Axon 3040

Page 199

AC1802

See Aprindine hydrochloride

Axon 4014

Page 243

AC1903


[831234-13-0]
Purity: 99%

Soluble in DMSO and EtOH

Axon 3026

mg	Price
10	online
50	online

C19H17N3O MW: 303.36



Biological activity


AC1903 is a selective inhibitor of TRPC5 with an IC_{50} value of 14.7 μ M.

AC 220 dihydrochloride

Quizartinib dihydrochloride

[1132827-21-4]
Purity: 98%

Soluble in DMSO
C29H32N6O4S₂HCl MW: 633.59



Axon 1696

mg	Price
5	online
25	online


Biological activity

A uniquely potent, selective and efficacious inhibitor of FMS-Like Tyrosine kinase-3 (FLT3) for the treatment of AML; Second-generation FLT3 inhibitor that is highly potent with low nanomolar potency both in vitro and in cellular assays, and has a highly focused and selective interaction pattern across the human protein kinome.

AC 264613

[1051487-82-1]
Purity: 98%

Soluble in DMSO
C19H18BrN3O2 MW: 400.27



Axon 2898

mg	Price
5	online
25	online

Biological activity

AC 264613 is a potent, selective, and metabolically stable protease activated receptor 2 (PAR2) agonist (pEC_{50} value of 6.7). The potency of AC 264613 in the cellular proliferation assay was approximately 50 nM, and was virtually the same at wild-type PAR2 receptors. Incubation of macrophages with AC 264613 caused a decrease of IRF5 expression and also significantly reduced p53 protein expression.

AC480

See BMS-599626

Axon 3853


Page 319

AC-5216

XBDI73; Emapunil

[226954-04-7]
Purity: 99%

Soluble in DMSO and EtOH
C23H23N5O2 MW: 401.46



Axon 3698

mg	Price
5	online
25	online


Biological activity

AC-5216 is a selective translocator protein (TSPO; MBR) ligand. AC-5216 showed high affinity for MBRs prepared from rat whole brain (K_i value of 0.297 nM), rat glioma cells (IC_{50} value of 3.04 nM) and human glioma cells (IC_{50} value of 2.73 nM), but only negligible affinity for the other main receptors including central benzodiazepine receptors.

Acalabrutinib

ACP-196

[1420477-60-6]
Purity: 99%
Optically pure
Soluble in DMSO
C₂₆H₂₃N₇O₂ MW: 465.51



Axon 4141

mg	Price
10	online
50	online

Biological activity


Acalabrutinib is a second-generation irreversible inhibitor of BTK (Bruton's tyrosine kinase). The optically pure Acalabrutinib potently inhibits BTK activity with an IC₅₀ of 3 nM (enzymatic assay) and EC₅₀ of 8 nM (human whole-blood CD69 B cell activation assay). Comparing with the first-generation BTK inhibitor Ibrutinib, ACP-196 is more selective. The improved selectivity is largely attributed to the reduced intrinsic reactivity of electrophile (Acalabrutinib's Propiolamide vs Ibrutinib's acrylamide). As a result, Acalabrutinib was shown to have improved target specificity and in vivo coverage, thus better therapeutic indexes, over Ibrutinib. It displays minimal, or no activities against off-target kinases such as ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1.

Source Information: Sold in collaboration with Chemietek

Acalisib

GS 9820; CAL 120

[870281-34-8]
Purity: 99%
Optically pure
Soluble in DMSO
C₂₁H₁₆FN₇O MW: 401.40



Axon 2857

mg	Price
10	online
50	online

Biological activity

Acalisib is a potent and selective PI3K δ-isoform inhibitor (p110δ; IC₅₀ value of 12.7 nM).

Acelarin

See NUC-1031

Axon 3858

Page 719

ACNU

See Nimustine hydrochloride

Axon 4045


Page 704

Acyclovir

ACV

[59277-89-3]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C₈H₁₁N₅O₃ MW: 225.20



Axon 3384

mg	Price
50	online

Biological activity

Acyclovir is a nucleoside antiviral drug which exhibits in vitro activity against herpes simplex virus types 1 and 2, varicella zoster virus, Epstein-Barr virus and, to a lesser degree, cytomegalovirus. The mechanism of action of acyclovir involves highly selective inhibition of herpes virus DNA replication.

ACC789

See NVP-ACC789

Axon 2865

Page 721

ACP-104

See Clozapine, N-Desmethyl-

Axon 2846

Page 378

ACP-196

See Acalabrutinib

Axon 4141


Page 205

ACR16 hydrochloride

Pridopidine hydrochloride

[882737-42-0]
Purity: 99%

Soluble in water and DMSO
C₁₅H₂₃N₂O₂S.HCl MW: 317.87



Axon 1579

mg	Price
5	online
25	online


Biological activity

Dopaminergic stabilizer (K_i values 17550 nM and 7521 for D₂(low) and D₂(high), respectively) that state-dependently stabilizes psychomotor activity by the dual actions of functional dopamine D₂ receptor antagonism and strengthening of cortical glutamate functions in various settings of perturbed neurotransmission. Useful for ameliorating several neurological and psychiatric disorders, including Huntington's disease. Note: This item is currently suspended due to the concern of the IP right of the developer. You may request a quotation for contract research synthesis. Please contact us for conditions and more detailed information.

ACT001

Dimethylaminomichelolide; DMAMCL

[1403357-81-2]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq), DMSO and EtOH
C₁₇H₂₇N₃O MW: 293.40



Axon 3590

mg	Price
5	online
25	online

Biological activity

Dimethylaminomichelolide (DMAMCL) is a PAI-1 inhibitor. The inhibition of PAI-1 induces glioma inhibition, and DMAMCL has a synergistic effect with cisplatin through the inhibition of the PAI-1/PI3K/AKT pathway. Also, DMAMCL exerts antitumor effects on neuroblastoma (NB) both in vitro and in vivo by suppressing aerobic glycolysis. PFKL could be a potential target of DMAMCL in NB. Its active parent drug Michelolide (or MCL) is available as Axon 3607.

ACT 293987

See Selexipag

Axon 2605

Page 859

Active isomer 2

See TIC 10 active isomer

Axon 2300

Page 927

ACV

See Acyclovir

Axon 3384


Page 205

ACY-241

Citarinostat

[1316215-12-9]
Purity: 98%

Soluble in DMSO
C24H26ClN5O3 MW: 467.95



Biological activity

ACY-241 is a selective, orally available histone deacetylase (HDAC) 6 inhibitor with an IC50 value of 2.6 nM.

AD 5423

See Blonanserin

AD-4833

See Pioglitazone hydrochloride

ADAC

See Adenosine amine congener

Adagrasib


See MRTX849

ADAMTS-5 inhibitor

Compound 12

[929634-33-3]
Purity: 100%

Soluble in 0.1N NaOH(aq) and DMSO
C16H11ClF3N3OS3 MW: 449.92



Biological activity

Inhibitor of ADAMTS-5 (A Disintegrin And Metalloproteinase with Thrombospondin motifs 5 or aggrecanase-2; IC50 1.1 μM) with >40-fold functional selectivity over ADAMTS-4. ADAMTS-5 is involved in the catabolism of aggrecan and collagen in the articular cartilage matrix during Osteoarthritis (OA).

Adelatinib

See Decemotininb

Adenosine amine congener

ADAC

[96760-69-9]
Purity: 98%

Moderately soluble in DMSO
C28H32N8O6 MW: 576.60

Axon 3039

mg	Price
10	online

Axon 2353

Page 313

Axon 3255

Page 779

Axon 1188

Page 207

Axon 4036

Page 681

Axon 2083


mg	Price
5	online
25	online

Axon 3861

Page 416

Axon 1188

mg	Price
10	online
50	online



Biological activity

Potent A1 adenosine receptor agonist

Adenosine, 2-MeS-

See Methylthioadenosine, 2-

Axon 1192


Page 650

ADH-503

Leukadherin-1 choline salt;
LA1

[2055362-74-6]
Purity: 99%

Soluble in DMSO
C22H14NO4S2.C5H14NO MW:
524.65




Biological activity

ADH-503 is an allosteric agonist of integrin CD11b/CD18 (also known as Mac-1) with an EC50 value of 4 mM. ADH-503 suppresses myeloid cell infiltration into inflamed or infected sites by increasing CD11b-dependent cell adhesion to ICAM-1 on the endothelium, preventing subsequent extravasation. Moreover, partial activation of CD11b by ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhanced dendritic cell responses.

AdipoRon

[924416-43-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C27H28N2O3 MW: 428.52



Biological activity

Orally active small-molecule AdipoR agonist (Kd values 1.8 and 3.1 μM for AdipoR1 and AdipoR2 respectively) that exerts antidiabetic effects via activation of AMPK and PPAR-α pathways. AdipoRon ameliorated insulin resistance, glucose intolerance, and diabetes of genetically obese rodent model db/db mice, thereby prolonging the shortened lifespan of db/db mice on a high-fat diet.

Adjudin

AF 2364

[252025-52-8]
Purity: 99%


Soluble in DMSO
C15H12Cl2N4O MW: 335.19

Axon 2275

mg	Price
10	online
50	online

Axon 2552

mg	Price
10	online
50	online




Biological activity

Non-hormonal male contraceptive that exerts its effect by disrupting Sertoli-germ cell adhesion junctions, most notably apical ectoplasmic specialization (apical ES), by targeting testin and actin filament bundles that disrupt the actin-based cytoskeleton in Sertoli cells. Adjudin is a potent blocker of Cl⁻ channels. Moreover, Adjudin is shown to induce apoptosis in cancer cells through a Caspase-3-dependent pathway, and triggers mitochondrial dysfunction in cancer cells, apparently affecting the mitochondrial mass, inducing the loss of mitochondrial membrane potential. Furthermore, Adjudin possesses anti-inflammation, anti-neurodegeneration, and anti-ototoxicity activities based on studies using different in vitro and in vivo models.

ADL 5859

[850173-95-4]
Purity: 99%

Soluble in DMSO
C₂₄H₂₈N₂O₃.HCl MW: 428.95



Biological activity


Highly potent and selective δ opioid receptor agonist with K_i value to be 0.84 nM and ED₅₀ value to be 20 nM

Adomeglivant

LY2409021

[1488363-78-5]
Purity: 99%
Optically pure

Soluble in DMSO
C₃₂H₃₆F₃N₄ MW: 555.63



Biological activity

Adomeglivant is a potent, selective, orally administered, and competitive antagonist of the human glucagon receptor with a K_i value of 6.66 nM and >200-fold selectivity vs related receptors.

Adriamycin hydrochloride

See Doxorubicin hydrochloride

ADTN, 5,6-

See Aminotetraline hydrobromide, 5,6-Dihydroxy-2-

ADTN, 6,7-

See Aminotetraline hydrobromide, 6,7-Dihydroxy-2-

Axon 1751

mg Price

10 online

50 online

Axon 2388

mg Price

5 online

25 online

Axon 4072

Page 439

Axon 1044

Page 228

Axon 1045

Page 228

ADU-S100

MIW815; NVP-MIW815


[1638750-95-4]

Purity: 99%

99% e.e.

Soluble in water

C₂₀H₂₂N₁₀Na₂O₁₀P₂S₂ MW:
734.51



Biological activity

ADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system. ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression of cytokines and chemokines, leading to a robust and durable antigen-specific T-cell mediated immune response against cancer cells.

Source information: Sold in collaboration with Chemietek


ADX71743

[N.A.]

Purity: 99%

Soluble in DMSO

C₁₇H₁₉NO₂ MW: 269.34



Biological activity

ADX71743 is a selective mGluR7 negative allosteric modulator.

AEB 071

See Sotrastaurin

AEE 788

NVP-AEE 788


[497839-62-0]

Purity: 98%

>98% ee

Soluble in DMSO

C₂₇H₃₂N₆ MW: 440.58



Biological activity

A dual family EGFR/ErbB2 and VEGFR kinase inhibitor with antitumor and antiangiogenic activity


AEG 3482

[63735-71-7]

Purity: 99%

Soluble in DMSO

C₁₀H₈N₄O₂S₂ MW: 280.33



Biological activity

Inhibitor of JNK signaling

Axon 3687

mg Price

1 online

Axon 2732

mg Price

10 online

50 online

Axon 1635

Page 880

Axon 1653

mg Price

5 online

25 online

Axon 1291

mg Price

10 online

50 online

AEGR-733

See Lomitapide

Axon 2917

Page 618

AeroBid

See Flunisolide

Axon 1429

Page 485

AF 2364

See Adjudin

Axon 2552

Page 208

Afatinib

See BIBW 2992


Axon 1544

Page 306

Aficamten

CK274; CK3773274

[2364554-48-1]
Purity: 99%
100% e.e.
Soluble in DMSO and EtOH
C18H19N5O2 MW: 337.38



Axon 4000

mg	Price
5	online
25	online

Biological activity

Aficamten is a next-in-class cardiac myosin inhibitor with an IC50 value of 1.4 μM.

Afimoxifene, (Z)-

See Hydroxytamoxifen, (Z)-4-

Axon 4093

Page 553

Afuresertib hydrochloride

See GSK 2110183 hydrochloride


Axon 2460

Page 528

AG-120

Ivosidenib

[1448347-49-6]
Purity: 99%
99.9% e.e.
Soluble in DMSO
C28H22ClF3N6O3 MW: 582.96



Axon 2746

mg	Price
10	online
50	online

Biological activity

AG-120 (Ivosidenib) is an oral, selective, first-in-class, potent inhibitor of mutant IDH1. Treatment with AG-120 decreased intracellular 2-HG levels, inhibited growth factor independent proliferation and restored erythropoietin (EPO)-induced differentiation in TF-1 IDH1-R132H cells. Similarly, pharmacological inhibition of mutant IDH1 enzyme with AG-120 in primary human blast cells cultured ex vivo provided an effective way to lower intracellular 2-HG levels and induced myeloid differentiation.


AG14361 Recent Addition

Axon 4276

mg Price

[328543-09-5]

Purity: 99%
98% e.e.
Soluble in 0.1N HCl(aq), DMSO and EtOH
C19H20N4O MW: 320.39



5	online
25	online

Biological activity


AG14361 is a potent PARP1 inhibitor with a Ki value of 5.8 nM (human full-length PARP1). Moreover, AG14361 is the first high-potency PARP1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer.

AG-221

Enasidenib

[1446502-11-9]
Purity: 99%

Soluble in DMSO
C19H17F6N7O MW: 473.38



Axon 2745

mg	Price
10	online
50	online


Biological activity

AG-221 (Enasidenib) is an oral, selective, first-in-class inhibitor of the mutant IDH2 enzyme (IC50 value of 100 nM). AG-221 demonstrates excellent pharmaceutical properties, including adequate solubility, low clearance, and good oral bioavailability, and potently inhibits 2HG production by both the IDH2R140Q/WT heterodimer and IDH2R140Q homodimer. AG-221 suppressed 2HG production and induced cellular differentiation in primary human IDH2 mutation-positive acute myeloid leukaemia (AML) cells ex vivo and in xenograft mouse models.

AG-270

[2201056-66-6]
Purity: 98%

Soluble in DMSO
C30H27N5O2 MW: 489.57



Axon 3515

mg	Price
5	online
25	online

Biological activity

AG-270 is a first-in-class, highly potent, selective, orally bioavailable MAT2A inhibitor with an IC50 value of 0.014 μM.

AG 337

See Nilotrexed dihydrochloride

Axon 2853


Page 708

AG 490

Tyrphostin AG 490; Tyrphostin B42

[133550-30-8]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO, and Ethanol
C17H14N2O3 MW: 294.30



Axon 1378

mg	Price
10	online
50	online

Biological activity
Janus Kinase 2 (JAK2) inhibitor

AG 1343

See Nelfinavir mesylate


Axon 1553

Page 697

AG 7088

Rupintrivir; Rupintrivir

[223537-30-2]
Purity: 98%
optically pure
Soluble in DMSO
C31H39FN4O7 MW: 598.66



Axon 1571

mg	Price
1	online
5	online

Biological activity


An irreversible human rhinovirus (HRV) 3C protease inhibitor

AG 013736

Axitinib

[319460-85-0]
Purity: 99%

Soluble in DMSO
C22H18N4OS MW: 386.47



Axon 1414

mg	Price
5	online
25	online

Biological activity


A tyrosine kinase inhibitor (TKI), targeting VEGFR/PDGFR/c-KIT; orally bioavailable drug exerting an anti-angiogenic effect.

AG 014699

PF 01367338; Rucaparib

[459868-92-9]
Purity: 98%

Soluble in water and DMSO
C19H18FN3O2.H3O4P MW: 421.36



Axon 1529

mg	Price
2	online
5	online

Biological activity

A PARP 1 inhibitor with potential chemosensitizing, radiosensitizing and antineoplastic activities; selectively binds to PARP1 (K_i=1.4 nM) and inhibits PARP1-mediated DNA repair, thereby enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. AG-014699 is the phosphate salt of AG 014447 (CAS 283173-50-2) and has improved aqueous solubility

AG-1749

See Lansoprazole

Axon 3244

Page 604

AG881

See Vorasidenib

Axon 4024

Page 971

AG-EE 623ZW

See Repaglinide


Axon 3365

Page 812

AGI 5198

[1355326-35-0]
Purity: 100%

Soluble in DMSO
C27H31FN4O2 MW: 462.56



Axon 2122

mg	Price
2	online
5	online


Biological activity

Potent inhibitor of mutant isocitrate dehydrogenase 1 (IDH1); selective for IDH1 R132H and R132C mutants in vitro with IC₅₀ values of 0.07 and 0.16 μM, respectively; it delays growth and promotes differentiation of glioma cells

AGI 6780

[1432660-47-3]
Purity: 99%

Soluble in DMSO
C21H18F3N3O3S2 MW: 481.51



Axon 2274

mg	Price
5	online
25	online

Biological activity

Inhibitor of isocitrate dehydrogenases (IDH) selective for mutant IDH2. AGI 6780 potently and selectively inhibits the tumor-associated mutant IDH2/R140Q (EC₅₀ value <20 nM for reduction of 2HG levels in cell lines) in an allosteric manner at the dimer interface, and induces differentiation of TF-1 erythroleukemia and primary human acute myelogenous leukemia cells in vitro.

AGN 4204

See NRX 194204

Axon 2408

Page 711

AGN 192403 hydrochloride

See BRD4780

Axon 3017

Page 326

AGN 194204

See NRX 194204


Axon 2408

Page 711

Agomelatine

[138112-76-2]
Purity: 99%

Soluble in DMSO
C15H17NO2 MW: 243.30



Axon 1492

mg	Price
10	online
50	online

Biological activity


Potent melatonin agonist; first melatonin antidepressant; also known as a norepinephrine dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT_{2C} receptor

AH 001

M-ADOT, 8-

[80270-68-4]
Purity: 98%

Soluble in DMSO
C13H17NO2 MW: 219.28



Axon 1335


mg	Price
10	online
50	online

AH 002

M-PDOT, 8-

[134865-70-6]
Purity: 98%

Soluble in DMSO
C14H19NO2 MW: 233.31



Axon 1336

mg	Price
10	online
50	online


Biological activity

Melatonin agonist; less potent in comparison with AH-001 (Axon 1335), but more selective on MT2 vs MT1

AHU-377 tris salt

Sacubitril tris salt

[565453-99-8]
Purity: 99%
Optically pure
Soluble in DMSO
C24H29NO5.C4H11NO3 MW:
532.63



Axon 3856

mg	Price
5	online
10	online


Biological activity

AHU-377 is a prodrug which is activated in vivo by hydrolytic enzyme esterases to form an active compound LBQ657 that selectively and potently inhibits the enzyme Neprilysin with K_i at low nM. Neprilysin is a protease responsible for the degradation of atrial and brain natriuretic peptides. Inhibition of the enzyme prevents the degradation of natriuretic peptides and activates cGMP signaling pathways that regulate volume and blood pressure. AHU-377 is an investigational antihypertensive drug being studied for use in combination with Valsartan (Axon 3106) in a molar ratio of 1:1.

Source Information: Sold in collaboration with Chemietek

AIM 100

[873305-35-2]
Purity: 99%
98% e.e.
Soluble in DMSO
C23H21N3O2 MW: 371.43



Axon 2031

mg	Price
5	online
10	online


Biological activity

Specific inhibitor of Ack1 tyrosine kinase (also known as TNK2); AIM-100 inhibits Ack1 activity and also suppresses androgen receptor (AR) Tyr(267) phosphorylation and its recruitment to the ATM enhancer (Ack1/AR/ATM signaling)

AJ2-30

[2700322-79-6]
Purity: 99%

Soluble in DMSO and EtOH
C23H22N4 MW: 354.45



Biological activity

AJ2-30 is a first-in-class SLC15A4 inhibitor which suppresses SLC15A4-mediated endolysosomal TLR and NOD functions in a variety of human and mouse immune cells.


AK-01

See LY-3295668

AK 1

[330461-64-8]
Purity: 100%

Soluble in DMSO
C19H21N3O5S MW: 403.45



Biological activity


Potent inhibitor of SIRT with good selectivity for SIRT2 over SIRT1 and SIRT3 (IC50 values >50 μ M, 12.5 μ M, and >50 μ M for SIRT1, SIRT2, and SIRT3 respectively). Short-term treatment with AK 1 produced large statistically significant changes in RNA expression in untransduced, Htt171-18Q- and Htt171-82Q-expressing neurons and confirm the hypothesis that AK 1-mediated neuroprotection is correlated with the negative regulation of sterol biosynthesis.

AK 1 is among the first brain-permeable SIRT2 inhibitors that mediate neuroprotective reduction of cholesterol biosynthesis in an in vitro Huntington's disease model. More potent in vitro than its analogue AK 7 (Axon 2270).

AK 7

[420831-40-9]
Purity: 100%

Soluble in DMSO
C19H21BrN2O3S MW: 437.35



Biological activity

Potent, brain-permeable and selective inhibitor of SIRT2 (IC50 values >50 μ M, 15.5 μ M, and >50 μ M for SIRT1, SIRT2, and SIRT3 respectively). Treatment with AK 7 showed a SIRT2-dependent nucleo-cytoplasmic trafficking in primary striatal neurons of the master regulator of cholesterol biosynthesis, SREBP-2, and resulted in protection of neurons in an in vitro model of Huntington's disease (HD).

AK 7 is slightly less potent in vitro than its analogue AK 1 (Axon 2269).

AKI603

[1432515-73-5]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C19H23N9O2 MW: 409.45

Axon 4175

mg	Price
10	online
50	online

Axon 3758

Page 628

Axon 2269


mg	Price
10	online
50	online

Axon 2270

mg	Price
10	online
50	online

Axon 3408

mg	Price
5	online
25	online



Biological activity

AKI603 significantly inhibited Aurora A kinase (IC50 value of 12.3 nM) and induced cell-cycle arrest. In addition, the intragastric administration of AKI603 reduced xenograft tumor growth.

AKB6548

See Vadadustat

Axon 3288


Page 960

AKOS-022

AKOS022075291

[878983-38-1]
Purity: 99%

Soluble in DMSO
C22H21ClF3N3O3 MW: 467.87



Axon 3524

mg	Price
10	online
50	online

Biological activity

AKOS-022 is a voltage-dependent anion channel 1 (VDAC1) inhibitor. AKOS-022 was found to inhibit VDAC1 oligomerization and apoptosis.

AKOS022075291

See AKOS-022

Axon 3524


Page 217

Akt Inhibitor VIII

Akti-1/2

[612847-09-3]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C34H29N7O MW: 551.64



Axon 2540

mg	Price
5	online
25	online

Biological activity

Non-ATP competitive inhibitor of Akt isoforms 1 and 2 (IC50 values 58 nM and 210 nM for Akt1 and Akt2, respectively). Moreover, the Akt inhibitor efficiently inhibits Ca²⁺/CaM-dependent protein kinase (CaMKI α) activity (IC50 value 3.99 μ M) and prevents TCDD induced nuclear translocation of aryl hydrocarbon receptor (AhR) in MCF-7 cells. Akti-1/2 inhibitory effects towards CaMKI α and TCDD-induced EROD activity in function of Akti-1/2 concentrations were quite similar (IC50 \pm SD, 3.99 \pm 0.82 μ M and 5.86 \pm 1.85 μ M, respectively).

Akti-1/2

See Akt Inhibitor VIII

Axon 2540

Page 217

AL1576

See Imirestat

Axon 3978

Page 563

AL 3810 dihydrochloride

See E 3810 dihydrochloride

Axon 1942

Page 447

AL4862

See Brinzolamide

Axon 3988

Page 328

AL4943A


See Olopatadine hydrochloride

Axon 3642

Page 732

Alantolactone

[546-43-0]
Purity: 98%
Optically pure
Soluble in DMSO
C15H20O2 MW: 232.32



Axon 3834

mg	Price
10	online
50	online


Biological activity

Alantolactone is a STAT3 inhibitor which completely suppressed inducible and constitutively activated STAT3 and blocked the nuclear translocation and the DNA-binding activity of STAT3 in MDA-MB-231 cells. Also, Alantolactone inhibited activity of NLRP3 inflammasomes by directly targeting the NACHT domain of NLRP3.

Alda 1

[349438-38-6]
Purity: 99%

Soluble in DMSO
C15H11Cl2NO3 MW: 324.16



Axon 2551

mg	Price
10	online
50	online

Biological activity

Small molecule activator of ALDH2 (EC50 value ca 6 μ M for ALDH2 mediated acetaldehyde metabolism) with the ability to activate wild-type ALDH2 and restore near-wild-type activity to ALDH2*2. When administered to rats before an ischemic event, Alda 1 reduced infarct size by 60%, most likely through its inhibitory effect on the formation of cytotoxic aldehydes. Alda-1 was effective in protecting against rotenone-induced apoptotic cell death in both SH-SY5Y cells and primary cultured substantia nigra (SN) dopaminergic neurons, and significantly reduced rotenone- or MPTP-induced death of SN tyrosine hydroxylase

Aleplasinin

See PAZ-417

Axon 3710

Page 749

Alisertib

See MLN 8237

Axon 2003

Page 674

Aliudanexin

See NMDAR-TRPM4 blocker C19 dihydrochloride

Axon 3349

Page 218


Alofanib

RPT835; ES000835

Axon 2930

mg	Price
----	-------

[1612888-66-0]


Purity: 99%		10	online
Soluble in 0.1N NaOH(aq) and DMSO C19H15N3O6S MW: 413.40		50	online

Biological activity
Alofanib is an allosteric inhibitor of FGFR2 and significantly inhibited bFGF-induced proliferation of HUVEC cells (IC50 value of 11 nM) and suppressed proliferation of SVEC-4-10 cells (IC50 value of 58 nM). Moreover, Alofanib suppressed the migration activity of endothelial cells, and their ability to form vessel-like structures in vitro. Also, Alofanib significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo.

Alogliptin benzoate

SYR-322

[850649-62-6]
Purity: 99%
Optically pure
Soluble in water and DMSO
C18H21N5O2.C7H6O2 MW: 461.51




Axon 3310

mg	Price
10	online
50	online

Biological activity
Alogliptin benzoate is a potent, highly selective and orally active DPP-4 inhibitor with an IC50 value of 6.9 nM.

Aloperine

[56293-29-9]
Purity: 98%
Optically pure
Soluble in water, 0.1N HCl(aq), DMSO and EtOH
C15H24N2 MW: 232.36




Axon 3549

mg	Price
50	online

Biological activity
The natural alkaloid Aloperine is a potent anticancer agent which also exhibits broad-spectrum antibacterial and antiviral activities. The wide range of anti-tumor effect is mainly accomplished through apoptosis induction, cell cycle arrest, growth inhibition and suppression of migration, which hinder the survivability and metastasis of tumor cells.

Alosetron hydrochloride

[122852-42-0]
Purity: 99%
Soluble in water and DMSO
C17H18N4O MW: 294.35



Axon 1097

mg	Price
10	online
50	online

Biological activity
Potent and selective 5-HT3 antagonist; a drug for irritable bowel syndrome (IBS) in women

ALP201

See Faropenem sodium **Recent Addition**


Axon 4206

Page 474

Alpelisib

NVP-BYL719; ; BYL-719

[1217486-61-7]
Purity: 98%
Optically pure
Soluble in DMSO
C19H22F3N5O2S MW: 441.47



Biological activity
Alpelisib is a potent and selective PI3K α -isoform inhibitor with an IC50 value of 5 nM. Moreover, Alpelisib has shown good efficacy in inhibiting the growth of PI3K α -isoform driven tumors in animal xenograft models as well as good tolerability.

Axon 2925

mg	Price
10	online
50	online

Alphagan-P

See Brimonidine tartrate

Axon 1555


Page 328

Alprostadil

Prostaglandin E1; PGE1

[745-65-3]
Purity: 100%

Soluble in DMSO
C20H34O5 MW: 354.48



Axon 2062

mg	Price
10	online
50	online

Altitratinib


A prostaglandin drug used in the treatment of erectile dysfunction with vasodilatory properties; Binds EP receptors with Ki values of 36, 10, 1.1 and 2.1 nM for EP1, EP2, EP3 and EP4 respectively and 33 nM for IP receptor
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Altitratinib

DCC-2701

[1345847-93-9]
Purity: 99%

Soluble in DMSO
C26H21F3N4O4 MW: 510.46



Axon 3946

mg	Price
5	online
10	online

Biological activity
Altitratinib was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer. Specifically, Altitratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment through balanced inhibition of MET, TIE2 (TEK), and VEGFR2 (KDR) kinases. This profile was achieved by optimizing binding into the switch control pocket of all three kinases, inducing type II inactive conformations. Altitratinib durably inhibits MET, both wild-type and mutated forms, in vitro and in vivo. Through its balanced inhibitory potency versus MET, TIE2, and VEGFR2, Altitratinib provides an agent that inhibits three major evasive (re)vascularization and resistance pathways (HGF, ANG, and VEGF) and blocks tumor invasion and metastasis. Altitratinib exhibits properties amenable to oral administration and exhibits substantial blood-brain barrier penetration, an attribute of significance for eventual treatment of brain cancers and brain metastases.
Source Information: Sold in collaboration with Chemietek

Alunbrig

See Brigatinib


Axon 2978

Page 327

ALX 5407 hydrochloride

NFPS

[200006-08-2]
Purity: 99%
98% ee
Soluble in DMSO
C24H24FNO3.HCl MW: 429.91



Axon 1238

mg	Price
10	online
50	online


Biological activity

Potent, selective, irreversible hGlyT-1 glycine transporter inhibitor

AM 36 dihydrochloride

[199467-52-2]
Purity: 98%

Moderately soluble in water
C27H39ClN2O2.2HCl MW: 531.99



Axon 1113

mg	Price
10	online
50	online


Biological activity

Na⁺ channel blocker; neuroprotective agent

AM 251

[183232-66-8]
Purity: 99%

Soluble in DMSO and Ethanol
C22H21Cl2IN4O MW: 555.24



Axon 1218


mg	Price
10	online
50	online

Biological activity

Cannabinoids CB1 antagonist, structurally very close to SR 141716A (rimonabant). AM251: Ki 7.5 nM for CB1 receptor vs SR 141716A (Ki value of 11.5 nM). However AM251 is about two-fold more selective for the CB1 receptor when compared to SR 141716A

AM 095 (parent compound)

[1228690-36-5]
Purity: 99%
Optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C27H24N2O5 MW: 456.49



Axon 2367

mg	Price
10	online
50	online

Biological activity

A novel potent and selective LPA1 antagonist (IC50 values 0.025 μM and 0.023 μM for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHO cells, respectively). AM 095 attenuates bleomycin-induced dermal fibrosis.


AM 281

[202463-68-1]
Purity: 99%

Axon 1219

mg	Price
10	online

Soluble in DMSO
C21H19Cl2IN4O2 MW: 557.21



50 online


Biological activity

Potent and selective CB1 cannabinoid receptor antagonist/inverse agonist

AM 4113

[614726-85-1]
Purity: 99%

Soluble in DMSO
C17H12Cl3N3O MW: 380.66



Axon 2791

mg	Price
10	online
50	online

Biological activity


Cannabinoid CB1 receptor antagonist. AM 4113 was able to bind with high affinity to CB1 receptors, exhibiting 100-fold selectivity for CB1 vs CB2 receptors (Ki values of 0.89 and 92 nM for CB1 and hCB2, respectively). AM 4113 does not show inverse agonist properties (ie no effects on cyclic-AMP production).

AM 580

CD336; NSC 608001; RO 40-6055

[102121-60-8]
Purity: 99%

Soluble in DMSO
C22H25NO3 MW: 351.44



Axon 2948

mg	Price
10	online
50	online

Biological activity

AM 580 is a RAR-α agonist with EC50 values of 0.3 nM, 8.6 nM and 13.0 nM for RAR-α, RAR-β and RAR-γ, respectively.

AM 630

See Iodopravadoline

Axon 1574

Page 568

AM-1155 hydrochloride

See Gatifloxacin hydrochloride


Axon 3171

Page 496

Ambrisentan

BSF 208075; Letairis; Volibris

[177036-94-1]
Purity: 98%
optically pure
Soluble in DMSO
C22H22N2O4 MW: 378.42



mg	Price
5	online
25	online


Biological activity

Orally active non-peptide endothelin-A (ETA) receptor antagonist; therapeutic agent for the treatment of pulmonary arterial hypertension

Ambroxol hydrochloride

[23828-92-4]
Purity: 99%

Soluble in water and DMSO
C13H18Br2N2O.HCl MW: 414.56



Axon 3159

mg	Price
50	online
250	online

Biological activity


Ambroxol hydrochloride is an expectorant and mucokinetic compound. Ambroxol hydrochloride is shown to exert several activities: i) secretolytic activity ii) anti-inflammatory and antioxidant activity; and iii) a local anaesthetic effect through sodium channel blocking at the level of the cell membrane.

AMD 3100

Plerixafor; SID 791; JM 3100

[155148-31-5]
Purity: 100%

Soluble in water
C28H54N8.8HCl MW: 794.47



Axon 1738

mg	Price
10	online
50	online


Biological activity

Highly potent and selective chemokine CXCR4 receptor antagonist, with IC50 values to be 0.02-0.13 and >25 µM for CXCR4 and all other chemokine receptors respectively); HIV inhibitor; an immunostimulant used to multiply hematopoietic stem cells in cancer patients

AMD 3465

[185991-07-5]
Purity: 98%

Soluble in water and DMSO
C24H38N6.6HBr MW: 896.07



Axon 1930

mg	Price
5	online
25	online

Biological activity


Potent and selective CXCR4 antagonist; Potent anti-HIV agent that specifically blocks the interaction of HIV gp120 with CXCR4. Compared to AMD 3100 (Axon 1738), AMD3465 was even 10-fold more effective as a CXCR4 antagonist, while showing no interaction whatsoever with CCR5; AMD3465 has the potential to mobilize hematopoietic stem cells

Amenamevir

ASP2151

[841301-32-4]
Purity: 100%

Soluble in DMSO
C24H26N4O5S MW: 482.55



Axon 3465

mg	Price
5	online
25	online

Biological activity

Amenamevir is a non-nucleoside herpesvirus helicase-primase complex inhibitor. Amenamevir possesses potent antiviral activity against not only HSV-1 and HSV-2 but also VZV.

Amethopterin

See Methotrexate

Axon 3319

Page 647

Amfebutamone

See Bupropion hydrochloride

Axon 1451

Page 332

AMG 131

See INT 131


Axon 2019

Page 567

AMG-176

Tapotoclax

[1883727-34-1]
Purity: 99%
99% e.e.
Soluble in DMSO
C33H41ClN2O5S MW: 613.21



Axon 3686

mg	Price
1	online

Biological activity


AMG 176 (Tapotoclax) is an orally bioavailable, highly potent and selective Mcl-1 inhibitor, binding reversibly to BH3- groove of the protein with a Ki value in picomolar range. Demonstrate in vitro and in vivo antitumor efficacy in Mcl-1 dependent cancer models. It is currently in clinical evaluation for the treatment of hematologic malignancies.

Source Information: Sold in collaboration with Chemietek

AMG 208

[1002304-34-8]
Purity: 99%

Read COA for solubility
C22H17N5O2 MW: 383.40



Axon 1916


mg	Price
10	online
50	online

Biological activity

Potent and selective inhibitor of c-MET receptor tyrosine kinase (RTK); AMG208 inhibits both ligand-dependent and ligand-independent c-MET activation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival

AMG 232

[1352066-68-2]
Purity: 100%
Optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C28H35Cl2NO5S MW: 568.55



Axon 2639

mg	Price
5	online
25	online


Biological activity

Potent, selective, and orally bioavailable MDM2-p53 inhibitor (IC50 value 9.1 nM, Kd 0.045 nM), demonstrating remarkable pharmacokinetic properties and in vivo antitumor activity in the SJS-A-1 osteosarcoma xenograft

model. Moreover, AMG 232 activates p53 pathway activity in vivo, and potentiates the activity of p53-inducing cytotoxic agents

AMG-337

[1173699-31-4]
Purity: 99%
99% e.e.
Soluble in DMSO
C23H22FN7O3 MW: 463.46



Biological activity


AMG-337 is an orally bioavailable, potent and exquisitely selective inhibitor of wild-type and some mutant forms of c-Met. In competitive binding assays on 402 human kinases, enantiomerically (optically) pure AMG-337 hits c-Met only (with an IC50 < 5 nM). In a cell viability study, the only cell lines that responded to an AMG 337 were gastric cancer cells harboring c-Met gene amplification. None of the other cell lines were sensitive to the AMG-337 and none harbored c-Met gene amplification. It inhibited HGF-dependent c-Met phosphorylation with an IC50 of less than 10 nM in cellular assay. Orally administered AMG-337 in c-Met amplified gastric cancer xenograft models resulted in a robust dose-dependent anti-tumor efficacy.

Source Information: Sold in collaboration with Chemietek

AMG510

Sotorasib

[2296729-00-3]
Purity: 99%
Optically pure
Soluble in DMSO
C30H30F2N6O3 MW: 560.59




Biological activity

AMG510 is a highly potent, selective, orally bioavailable, well-tolerated and covalent KRASG12C inhibitor with an IC50 value of 68 nM (p-ERK).

AMG-511

[1253573-53-3]
Purity: 99%
99% e.e.
Soluble in DMSO
C22H28FN9O3S MW: 517.58



Biological activity

AMG-511 is an orally bioavailable, highly potent and selective pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor with in vitro Ki values of 4nM/6nM/2nM/1nM for p110α/β/δ/γ isoforms, respectively, and is highly selective over mTOR (IC50 > 10000 nM), hVPS34 (IC50 > 9000 nM), DNAPK (IC50 = 12000 nM), and a broad panel of other protein kinases. It effectively inhibited pAKT in tumor tissue in a dose- and time-dependent manner (up to 16 hours). In animal studies it efficaciously inhibited tumor growth in PTEN-null, KRAS mutant, and HER2 amplified xenograft models. It is currently in clinical trials for cancer treatment.

Source Information: Sold in collaboration with Chemietek

AMG 706

Motesanib diphosphate

Axon 3945

mg	Price
5	online
10	online

Axon 3575

mg	Price
5	online
25	online

Axon 3827


mg	Price
5	online
10	online

Axon 1768

mg	Price
----	-------

[857876-30-3]
Purity: 99%

Soluble in water
C22H23N5O.2H3O4P MW: 569.44




5	online
25	online

Biological activity

A potent and orally bioavailable multiple receptor tyrosine kinase inhibitor, targeting VEGFR/PDGFR/c-KIT (IC50: 2, 3, 6, 84, 8 and 59 nm for VEGFR1, VEGFR2, VEGFR3, PDGFR, KIT and Ret receptors respectively);potently inhibits angiogenesis and induces regression in tumor xenografts.

AMG 837

[1291087-14-3]
Purity: 99%
Optically pure
Soluble in DMSO
C26H20F3O3.½Ca MW: 457.47



Axon 2405


mg	Price
5	online
25	online

Biological activity

Orally bioavailable partial agonist of the GPR40 (EC50 value 13.5 nM for AMG 837 stimulated Ca2+ flux in CHO cells expressing human GPR40) with a superior pharmacokinetic profile. AMG837 stimulated robust glucose-dependent insulin secretion (EC50 value 142±20 nM) in isolated rodent islets, and lowered post-prandial glucose in normal rats. AMG-837 exhibits a potential utility for the treatment of type 2 diabetes.

AMG 900

[945595-80-2]
Purity: 98%
Soluble in DMSO
C28H21N7OS MW: 503.58



Axon 1783

mg	Price
5	online
25	online


Biological activity

Potent and highly selective inhibitor of pan-aurora kinases with activity in taxane-resistant tumor cell lines

AMG-925

FLX925

[1401033-86-0]
Purity: 99%
Soluble in DMSO
C26H29N7O2 MW: 471.55



Axon 4071

mg	Price
10	online
50	online

Biological activity


AMG 925 is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with in vitro IC50 values of 2 nM and 3 nM, respectively. In acute myeloid leukemia (AML) cell lines MOLM13 and Mv4-11, AMG 925 inhibits cell growth (with Cellular IC50 values of 19nM and 18nM, respectively) through inhibiting P-FLT3 and P-STAT5 and inducing apoptosis. AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body weight loss. The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, respectively. In addition, it was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 (Axon 1696) and Sorafenib (Axon 1397)).

Source Information: Sold in collaboration with Chemietek

AMG 9810

[545395-94-6]
Purity: 99%

Soluble in DMSO and EtOH
C21H23NO3 MW: 337.41



Biological activity


AMG 9810 is a potent and selective vanilloid receptor-1 (TRPV1) antagonist with antihyperalgesic properties (IC50 value for human TRPV1, 24.5 +/- 15.7 nM; rat TRPV1, 85.6 +/- 39.4 nM). Also, AMG 9810 blocks all known modes of TRPV1 activation, including protons (IC50 value for rat TRPV1, 294 +/- 192 nM; human TRPV1, 92.7 +/- 72.8 nM), heat (IC50 value for rat TRPV1, 21 +/- 17 nM; human TRPV1, 15.8 +/- 10.8 nM), and endogenous ligands, such as anandamide, N-arachidonyl dopamine, and oleoyldopamine.

AMI-1

AMI-1 sodium salt

[20324-87-2]
Purity: 99%

Soluble in water and DMSO
C21H14N2Na2O9S2 MW: 548.45



Biological activity

AMI-1 specifically inhibits protein arginine N-methyltransferase (PRMT) activity in vitro (IC50 values of 8.81 and 3.04 μM for PRMT1 and Hmt1p, respectively). Furthermore, AMI-1 prevents in vivo arginine methylation of cellular proteins and can modulate nuclear receptor-regulated transcription from estrogen and androgen response elements, thus operating as a brake on certain hormone actions. HIV-1 integrase inhibitor (IC50 value of 4 μM).

AMI-1 sodium salt

See AMI-1

α-Amino-2-chloro-5-hydroxybenzeneacetic acid

See CHPG


Amino-10-methylfolic acid, 4-

See Methotrexate

Aminoacridone, 2-

[27918-14-5]
Purity: 100%

Soluble in DMSO
C13H10N2O MW: 210.23



Biological activity

Excellent derivatisation reagent tuned toward the mild labeling of malondialdehyde and subsequent identification by fluorescence. Derivatisation can be carried out in aqueous citrate buffer at 40 °C. Also as Fluorescent label for glycans and saccharides

Axon 3356

mg	Price
10	online
50	online

Axon 2863

mg	Price
10	online
50	online

Axon 2863

Page 227

Axon 2691

Page 368

Axon 3319

Page 647

Axon 1878


Mg	Price
10	online
50	online

Aminobenzamide, 3-

3-AB; 3-ABA

[3544-24-9]
Purity: 99%

Soluble in water and DMSO
C7H8N2O MW: 136.15



Biological activity


A competitive small molecule inhibitor of poly(ADP-ribose) polymerase (PARP)

Aminotetraline hydrobromide, 5,6-Dihydroxy-2-

ADTN, 5,6-

[37096-30-3]
Purity: 98%

No solubility data
C10H13NO2.HBr MW: 260.13



Biological activity


Dopamine receptor agonist

Aminotetraline hydrobromide, 6,7-Dihydroxy-2-

ADTN, 6,7-

[13575-86-5]
Purity: 98%

Soluble in water
C10H13NO2.HBr MW: 260.13




Biological activity

Dopamine receptor agonist

Aminotetraline hydrobromide, 6,7-Dihydroxy-N-methyl-N-propyl-

[1246094-90-5]
Purity: 98%

No solubility data
C14H21NO2.HBr MW: 316.23




Biological activity

Dopamine receptor agonist

Aminotetraline hydrobromide, 6,7-Dimethoxy-2-

[40069-26-9]
Purity: 99%

Soluble in water
C12H17NO2.HBr MW: 288.18



Axon 1496

mg	Price
10	online
50	online

Axon 1044

Mg	Price
10	online
50	online

Axon 1045

mg	Price
10	online
50	online

Axon 1021

mg	Price
10	online
50	online

Axon 1043

mg	Price
25	online
100	online


Biological activity
Dopamine receptor agonist

Aminotetraline hydrobromide, N-Cyclopropyl-N-methyl-2-

CMAT

[1246094-80-3]
Purity: 99%

Soluble in water
C14H19N.HBr MW: 282.22




Axon 1066

mg	Price
10	online
50	online

Biological activity
MAO inhibitor

Aminotetraline hydrochloride, (R)-(+)-5-Methoxy-2-

[58349-15-8]
Purity: 98%
>98% ee
No solubility data
C11H15NO.HCl MW: 213.70




Axon 1049

mg	Price
100	online
1000	online

Biological activity
Dopamine receptor agonist

Aminotetraline hydrochloride, (R)-(+)-7-Methoxy-N-propyl-2-

[93503-08-3]
Purity: 98%
>98% ee
No solubility data
C14H21NO.HCl MW: 255.78




Axon 1030

mg	Price
100	online
1000	online

Biological activity
Building Block; unknown pharmacology

Aminotetraline hydrochloride, (R)-(+)-8-Methoxy-2-

[119363-61-0]
Purity: 98%
>98% ee
No solubility data
C11H15NO.HCl MW: 213.70




Axon 1058

mg	Price
100	online
1000	online

Biological activity
Building Block; 5-HT1A agonist

Aminotetraline hydrochloride, (R)-5-Methoxy-N-propyl-2-

[93601-85-5]
Purity: 98%
>98% ee
No solubility data
C14H21NO.HCl MW: 255.78




Axon 1026

mg	Price
100	online
1000	online

Biological activity
Dopamine receptor agonist

Aminotetraline hydrochloride, (R)-7-Methoxy-2-

[170638-05-8]
Purity: 98%
>98% ee
No solubility data
C11H15NO.HCl MW: 213.70




Axon 1055

mg	Price
5	online
1000	online

Biological activity
Building Block; unknown pharmacology

Aminotetraline hydrochloride, (R)-8-Methoxy-N-propyl-2-

[78095-32-6]
Purity: 98%
>98% ee
Soluble in DMSO
C14H21NO.HCl MW: 255.78




Axon 1033

mg	Price
100	online
1000	online

Biological activity
Building Block; unknown pharmacology

Aminotetraline hydrochloride, (S)-(-)-5-Methoxy-2-

[58349-17-0]
Purity: 98%
>98% ee
Soluble in water and DMSO
C11H15NO.HCl MW: 213.70




Axon 1050

mg	Price
10	online
50	online

Biological activity
Dopamine receptor agonist

Aminotetraline hydrochloride, (S)-(-)-7-Methoxy-N-propyl-2-

[93503-09-4]
Purity: 98%
>98% ee
No solubility data
C14H21NO.HCl MW: 255.78




Axon 1031

mg	Price
100	online
1000	online

Biological activity
Building Block; unknown pharmacology

Aminotetraline hydrochloride, (S)-(-)-8-Methoxy-2-

[197446-42-7]
Purity: 98%
>98% ee
No solubility data
C11H15NO.HCl MW: 213.70




Axon 1059

mg	Price
100	online
1000	online

Biological activity

Aminotetraline hydrochloride, (S)-5-Methoxy-N-propyl-2-

[93601-86-6]
 Purity: 98%
 >98% ee
 No solubility data
 C14H21NO.HCl MW: 255.78


Axon 1027


mg	Price
100	online
1000	online

Biological activity

Dopamine receptor agonist

Aminotetraline hydrochloride, (S)-7-Methoxy-2-

[158223-16-6]
 Purity: 98%
 >98% ee
 No solubility data
 C11H15NO.HCl MW: 213.70


Axon 1056


mg	Price
100	online
1000	online

Biological activity

Building Block; unknown pharmacology

Aminotetraline hydrochloride, (S)-8-Methoxy-N-propyl-2-

[78095-35-9]
 Purity: 98%
 >98% ee
 Soluble in DMSO
 C14H21NO.HCl MW: 255.78


Axon 1034


mg	Price
100	online
1000	online

Biological activity

Building Block; unknown pharmacology

Aminotetraline hydrochloride, 5,6-Dihydroxy-N-methyl-N-propyl-

[55218-13-8]
 Purity: 98%
 No solubility data
 C14H21NO2.HCl MW: 271.78


Axon 1019


mg	Price
10	online
50	online

Biological activity

Dopamine receptor agonist

Aminotetraline hydrochloride, 5,6-Dimethoxy-2-

[21489-75-8]
 Purity: 98%
 No solubility data
 C12H17NO2.HCl MW: 243.73


Axon 1042

mg	Price
25	online
100	online


Biological activity

Building Block; unknown pharmacology

Aminotetraline hydrochloride, 5-Methoxy-2-

SKF 87967 hydrochloride

[3880-88-4]
 Purity: 98%
 No solubility data
 C11H15NO.HCl MW: 213.70


Axon 1048


mg	Price
1000	online
5000	online

Biological activity

Dopamine receptor agonist

Aminotetraline hydrochloride, 5-Methoxy-N-propyl-2-

[3904-24-3]
 Purity: 98%
 No solubility data
 C14H21NO.HCl MW: 255.78


Axon 1025


mg	Price
1000	online
5000	online

Biological activity

Dopamine receptor agonist

Aminotetraline hydrochloride, 6-Methoxy-N-propyl-2-

[69788-83-6]
 Purity: 98%
 No solubility data
 C14H21NO.HCl MW: 255.78


Axon 1028


mg	Price
100	online
1000	online

Biological activity

Building Block; unknown pharmacology

Aminotetraline hydrochloride, 7-Methoxy-2-

[3880-78-2]
 Purity: 98%
 No solubility data
 C11H15NO.HCl MW: 213.70


Axon 1054


mg	Price
1000	online
5000	online

Biological activity

Building Block; unknown pharmacology

Aminotetraline hydrochloride, 7-Methoxy-N-propyl-2-

[93601-93-5]
 Purity: 98%
 No solubility data
 C14H21NO.HCl MW: 255.78



Axon 1029

mg	Price
1000	online
5000	online

Biological activity

Aminotetraline hydrochloride, 8-Methoxy-2-

 [3880-76-0]
 Purity: 98%

 No solubility data
 C11H15NO.HCl MW: 213.70

Axon 1057


mg	Price
1000	online
5000	online

Biological activity

Building Block; 5-HT1A agonist

Aminotetraline hydrochloride, 8-Methoxy-N-propyl-2-

 [87394-71-6]
 Purity: 98%

 No solubility data
 C14H21NO.HCl MW: 255.78

Axon 1032


mg	Price
1000	online
5000	online

Biological activity

Building Block; unknown pharmacology

Aminotetraline hydrochloride, N-Cyclopropyl-2-

 [1246094-94-9]
 Purity: 98%

 Soluble in water
 C13H17N.HCl MW: 223.74

Axon 1067


mg	Price
10	online
50	online

Biological activity

MAO inhibitor

Aminotetraline hydrochloride, N-Methyl-N-propyl-2-

 [134467-74-6]
 Purity: 98%

 No solubility data
 C14H21N.HCl MW: 239.78

Axon 1023


mg	Price
10	online
50	online

Biological activity

Dopamine receptor agonist

Aminotetraline hydrochloride, Prop-2-ynyl-2-

 [134467-59-7]
 Purity: 98%

 No solubility data
 C13H15N.HCl MW: 221.73

Axon 1064

mg	Price
10	online
50	online


Biological activity

Dopamine receptor agonist

Amiselimod hydrochloride

MT-1303

 [942398-84-7]
 Purity: 99%

 Soluble in DMSO
 C19H31ClF3NO3 MW: 413.90

Axon 3096

mg	Price
10	online
50	online


Biological activity

Amiselimod hydrochloride is a prodrug sphingosine 1-phosphate (S1P) receptor modulator. Amiselimod is converted to its active metabolite, (S)-amiselimod phosphate (amiselimod-P), by sphingosine kinases. Amiselimod-P showed potent selectivity for S1P1 and high selectivity for S1P5 receptors, with minimal agonist activity for S1P4 and no distinct agonist activity for S1P2 or S1P3 receptors and approximately five-fold weaker GIRK activation than fingolimod-P.

Amisulpride

DAN 2163

 [71675-85-9]
 Purity: 99%

 Soluble in 0.1N HCl(aq)
 C17H27N3O4S MW: 369.48

Axon 1381

mg	Price
10	online
50	online

Biological activity

Dopamine D2 and D3 receptor antagonist (Ki 2.8 and 3.2 nM for D2 and D3 respectively); Claimed to be atypical antipsychotic with low incidence of EPS

Amlodipine benzenesulfonate

See Amlodipine besylate


Axon 3015

Page 234

Amlodipine besylate

Amlodipine benzenesulfonate

 [111470-99-6]
 Purity: 99%

 Soluble in DMSO
 C20H25ClN2O5.C6H6O3S MW:
 567.05

Axon 3015

mg	Price
10	online
50	online

Biological activity

Amlodipine besylate is an intrinsically long-acting, vasoselective dihydropyridine calcium antagonist that inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Amlodipine besylate is indicated for treatment of hypertension and stable angina.

AMN 107

See Nilotinib

Axon 1396

Page 703

AMN 107 hydrochloride

See Nilotinib hydrochloride


Axon 3168

Page 704

Amoxapine

[14028-44-5]
Purity: 99%

Soluble in DMSO
C17H16ClN3O MW: 313.78



Axon 1333

mg	Price
50	online
250	online

Biological activity


Tricyclic antidepressant; a strong reuptake inhibitor of norepinephrine and weak reuptake inhibitor of serotonin. One of its major metabolites, 7-hydroxyamoxapine, has a dopamine receptor blocking effect.

AMPA

(RS)-AMPA

[77521-29-0]
Purity: 99%

Soluble in water, 0.1N HCl(aq) and DMSO
C7H10N2O4 MW: 186.17



Axon 3415

mg	Price
10	online
50	online

Biological activity

AMPA, a biosistere of glutamic acid, is a highly selective AMPA receptor agonist.

AMPA, (RS)-

See AMPA

Axon 3415

Page 235

Ampalex

See CX516

Axon 3089

Page 400

AMR-69

See Pirfenidone


Axon 2647

Page 779

Amthamine dihydrobromide

[142457-00-9]
Purity: 99%

Soluble in water
C6H11N3S.2HBr MW: 319.06



Axon 1207

mg	Price
10	online
50	online

Biological activity


Standard selective histamine H2 agonist

Amuvatinib

MP 470

[850879-09-3]
Purity: 99%

Soluble in DMSO
C23H21N5O3S MW: 447.51



Axon 2368

mg	Price
10	online
50	online

Biological activity


RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met (IC50 values low μ M range in vivo). Amuvatinib influences various survival and DNA repair related proteins such as pAKT, RAD51 and GSK3 β , inhibits cell proliferation, induces cell growth arrest and promotes apoptosis in prostate LNCaP cancer cells with low μ M IC50 values. When combined with Erlotinib (Axon 1128), Amuvatinib abolished HER family/PI3K/Akt pathway with associated tumor growth inhibition in prostate cancer.

AMZ30

ML136

[1313613-09-0]
Purity: 99%

Soluble in DMSO and EtOH
C19H12FN3O6S2 MW: 461.44



Axon 3682

mg	Price
10	online
50	online

Biological activity

AMZ30 is a potent, selective and covalent inhibitor of protein phosphatase methylesterase-1 (PME-1) with an IC50 value of 600 nM.

AN2690

See Tavaborole

Axon 3170

Page 912

AN2728

See Crisaborole


Axon 3169

Page 395

ANA 12

[219766-25-3]
Purity: 100%

Soluble in DMSO
C22H21N3O3S MW: 407.49



Axon 2468

mg	Price
5	online
25	online

Biological activity


Selective TrkB antagonist (IC50 value 45.6 ± 8.4 nM for the high-affinity TetOn-rhTrkB) with anxiolytic and antidepressant activity in mice that inhibits processes downstream of TrkB without altering TrkA and TrkC functions. A valuable tool for studying BDNF/TrkB signaling. ANA-12 is also capable of reversing the diminished self-administration of cocaine in male CocSired rats by means of enhanced BDNF expression.

Anacardic acid A

Pentadecylsalicylic acid, 6-

[16611-84-0]
Purity: 98%

Soluble in DMSO
C22H36O3 MW: 348.52



Axon 1490

mg	Price
10	online
50	online

Biological activity

A cell-permeable, non-competitive inhibitor of histone acetyl transferase (HAT)

Anandron

See Nilutamide

Axon 3249


Page 704

Anastrozole

Arimidex; ZD1033; ICI D1033

[120511-73-1]
Purity: 99%

Soluble in DMSO
C17H19N5 MW: 293.37



Axon 3316

mg	Price
10	online
50	online

Biological activity

Anastrozole is a potent, highly selective, and orally active fourth-generation aromatase inhibitor (IC₅₀ value of 15 nM) with no intrinsic hormonal activities.

Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, (6a,11b,16a,17a)-

See Axon 1171

Axon 1171

Page 264

Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, (6a,11b,16a,17a)-

See Axon 1170

Axon 1170

Page 263

Angular TIC 10

See TIC 10 active isomer

Axon 2300

Page 927

Anhydroicaritin

See Icaritin


Axon 3811

Page 557

Antalarmin hydrochloride

[220953-69-5]
Purity: 99%

Soluble in DMSO
C24H34N4.HCl MW: 415.01



Axon 1321

mg	Price
10	online
50	online

Biological activity

Non-peptide CRF1 corticotropin-releasing factor receptor antagonist

Antisedan

See Atipamezole hydrochloride

Axon 1371

Page 258

AOB 87172

See MLN7243


Axon 3829

Page 674

AOH1160

[2089314-57-6]
Purity: 99%

Soluble in DMSO
C25H20N2O3 MW: 396.44



Biological activity

First-in-class, potent and orally available PCNA inhibitor which selectively kills a broad range of cancer cells at a below micromolar concentration (IC₅₀ values ranging from 0.11 μM to 0.53 μM), but is not associated with significant toxicity to non-malignant cells.


Axon 3008

mg	Price
5	online
25	online

AOH1996

[2089314-64-5]
Purity: 98%

Soluble in DMSO
C26H22N2O4 MW: 426.46



Biological activity

AOH1996 is an orally administrable and metabolically stable PCNA inhibitor which suppresses tumor growth as a monotherapy or as a combination treatment but causes no discernable side effects. AOH1996 enhances the interaction between PCNA and the largest subunit of RNA polymerase II, RPB1, and dissociates PCNA from actively transcribed chromatin regions, while inducing DNA double-stranded breaks in a transcription-dependent manner.

Axon 4030

mg	Price
10	online
50	online

AP-06-202

See DFPQ

Axon 4082


Page 423

AP 24534

Ponatinib

[943319-70-8]
Purity: 98%

Soluble in DMSO
C29H27F3N6O MW: 532.56



Biological activity

Potent and orally active tyrosine kinase inhibitor, targeting BCR-ABL and multiple RTK

Axon 1857

mg	Price
5	online
25	online

AP 26113

See Brigatinib

Axon 2978

Page 327

AP32788

See TAK-788

Axon 3232

Page 907

Apararenone


MT3995

[945966-46-1]

Axon 3742

mg	Price
----	-------

Purity: 99%	10	online
Soluble in DMSO C17H17FN2O4S MW: 364.39	50	online




Biological activity

Apararenone is a potent and highly selective nonsteroidal mineralocorticoid receptor (MR) antagonist (K_i value of 0.104 μ M). Apararenone exhibited a more potent antihypertensive and organ-protective activity than steroidal MRA eplerenone in a primary aldosteronism rat model obtained by infusing aldosterone in uninephrectomized rats.

Apatinib

[1218779-75-9] Purity: 99%	10	online
Soluble in DMSO C25H27N5O4S MW: 493.58	50	online



Biological activity


Potent and selective inhibitor of VEGFR2 tyrosine kinase (IC_{50} value of 1 nM) and in vivo. Apatinib could also potently suppress the activities of RET, c-KIT and c-Src with IC_{50} values of 0.13, 0.429 and 0.53 μ M, respectively. In vivo, apatinib alone and in combination with chemotherapeutic agents effectively inhibited the growth of several established human tumor xenograft models with little toxicity.

Apatinib mesylate

See Apatinib

APC, 4-

VUF 11000	5	online
[1076196-38-7] Purity: 99%	25	online
Soluble in DMSO C11H19BrN2O.HBr MW: 356.10		




Biological activity

Excellent derivatisation reagent for aldehydes, yielding adducts with LC-MS-tuned identifiers and properties. Very mild derivatisation conditions (NaBH₃CN, water, pH 5.7, 4 °C). Attractive selectivity profile (including over ketones) and specific fragmentation properties in MS/MS profiling sensitivity and specificity.* Sold in collaboration with VU (VU University Amsterdam)

Apcin

[300815-04-7] Purity: 99%	10	online
Soluble in DMSO C13H14Cl3N7O4 MW: 438.65	50	online



Biological activity

Axon 2849

mg	Price
10	online
50	online

Axon 2849

Page 239

Axon 1876

mg	Price
5	online
25	online

Axon 3194

mg	Price
10	online
50	online


Apcin is an inhibitor of APC/C-Cdc20. Apcin binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates. Apcin causes either net APC/C inhibition, prolonging mitosis when spindle assembly checkpoint (SAC) activity is low, or net APC/C activation, shortening mitosis when SAC activity is high.

APD 597

JNJ 38431055

[897732-93-3]
Purity: 99%

Soluble in DMSO
C21H29N5O6S MW: 479.55



Biological activity


Orally bioavailable selective GPR119 agonist (EC_{50} value 44 nM for hGPR119, IC_{50} value 13 μ M) with a good balance between agonist potency, intrinsic activity, metabolic profile and in particular on its good solubility and reduced drug-drug interaction potential. In clinical trial, JNJ 38431055 was well tolerated and not associated with hypoglycaemia

APD 668

JNJ 28630368

[832714-46-2]
Purity: 100%

Soluble in DMSO
C21H24FN5O5S MW: 477.51



Biological activity

Potent and selective, orally active G protein-coupled receptor 119 agonist (EC_{50} values 2.7 nM and 23 nM for hGPR119 and rGPR119, respectively) with in vivo activity in rodent models of glucose control. APD 668 significantly improved blood glucose handling during glucose challenge in several diabetic and non-diabetic rodent models, showing a clear glucose-dependent effect on insulin release in a hyperglycemic clamp model in the Sprague-Dawley rat. APD 668 is not genotoxic, and shows no significant inhibition of any of the five major CYP isoforms with the exception of CYP2C9 (K_i value 0.1 μ M).


APD 811

See Ralinepag

APE1 Inhibitor III

[524708-03-0]
Purity: 99%

Soluble in DMSO
C19H21N3OS2 MW: 371.52



Biological activity

Cell permeable and competitive inhibitor of apurinic/apyrimidinic (AP) endonuclease 1 (Ape1) activity, exhibiting 2.0 micromolar activity against the purified APE1 enzyme

Axon 2541

mg	Price
5	online
25	online

Axon 2380

mg	Price
5	online
25	online

Axon 2874

Page 806

Axon 2137


mg	Price
10	online
50	online

APEBA, 4-

VUF 10996

[1226984-28-6]
Purity: 99%

Soluble in DMSO
C18H24Br2N2O.HBr MW: 525.12



Axon 1877

mg Price

5 online

25 online

Biological activity


Excellent derivatisation reagent for aldehydes and carboxylic acids. Very mild derivatisation conditions. Selectivity for aldehydes or carboxylic acids is obtained by changing co-reagent. In addition to the retained features of the 1st generation reagent 4-APC, 4-APEBA and its adducts contain additional unique properties (Br-isotope identifier, specific bromophenethyl fragmentation, increased lipophilicity). * Sold in collaboration with VU (VU University Amsterdam).

Apigenin

LY080400

[520-36-5]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C15H10O5 MW: 270.24



Axon 2717

mg Price

50 online

Biological activity

Apigenin is a natural plant flavonoid and selective CK2 inhibitor that targets CK2-dependent signaling pathways. Moreover, Apigenin has been reported to inhibit protein kinase C activity and mitogen activated protein kinase (MAPK).

Apilimod

See STA 5326


Axon 1369

Page 893

APIO-EE-07

[1606160-46-6]
Purity: 98%

Soluble in DMSO
C18H11FN2O4 MW: 338.29



Axon 3328

mg Price

5 online

25 online

Biological activity


APIO-EE-07 is a dual-target inhibitor of RSK1 and MSK2. APIO-EE-07 inhibited cell growth and induced apoptosis and also increased expression of Bax as well as cleaved caspase-3 and -PARP in colon cancer cells by downregulating RSK1 and MSK2 downstream targets, including CREB and ATF1.

Apixaban

BMS 562247-01

[503612-47-3]
Purity: 98%

Soluble in DMSO
C25H25N5O4 MW: 459.50



Axon 1754

mg Price

10 online

50 online


Biological activity

Direct factor Xa inhibitor; being investigated as an anticoagulant

Apoptosis Activator 2

[79183-19-0]
Purity: 99%

C15H9Cl2NO2 MW: 306.14



Axon 2006

mg Price

10 online

50 online


Biological activity

A cell-permeable apoptosis activator; activates caspases in a cytochrome c-dependent manner and induces apoptosis in tumor cells by promoting the oligomerization of Apaf-1 into the mature apoptosome

Apoptozole

[1054543-47-3]
Purity: 100%

Soluble in DMSO
C33H25F6N3O3 MW: 625.56



Axon 2251

mg Price

10 online

50 online

Biological activity

An apoptosis-inducing small molecule that inhibits the ATPase activity of heat shock cognate 70 (Hsc70) and Hsp70 by binding to its ATPase domain (Kd values 0.21 and 0.14 μ M for Hsc70 and Hsp70, respectively as determined by surface plasmon resonance (SPR) spectroscopy). Apoptozole has high cellular potency to restore the chloride channel activity of mutant CFTR by promoting its membrane trafficking.

APP+

See IDT307


Axon 3355

Page 559

APPA

[100750-39-8]
Purity: 99%

Soluble in DMSO
C14H13NO3 MW: 243.26



Axon 2883

mg Price

10 online

50 online

Biological activity

APPA is an aldose reductase inhibitor with an IC50 value of 0.0223 μ M. APPA could inhibit apoptosis in rat glomerular mesangial cells in vitro. In addition, APPA improved the pathological symptoms of streptozotocin-induced diabetic nephropathy (DN) in rats by affecting antioxidant activities and reducing the levels of TGF- β , collagen IV, and laminin.

Apratastat

See TMI 005


Axon 1507

Page 932

Apremilast

CC 10004

[608141-41-9]
Purity: 99%
optically pure
Soluble in DMSO
C22H24N2O7S MW: 460.50



Axon 1957


mg	Price
5	online
25	online

Biological activity

Orally active inhibitor of phosphodiesterase-4 (PDE4); an investigational drug for ankylosing spondylitis, psoriasis, and psoriatic arthritis. Apremilast reduces TNF α production from human synovial cells and significantly suppresses experimental arthritis

Aprepitant

[170729-80-3]
Purity: 99%
optically pure
Soluble in DMSO
C23H21F7N4O3 MW: 534.43



Axon 1486

mg	Price
5	online
25	online

Biological activity


Substance P antagonist (SPA), having effect by blocking the neurokinin 1 (NK1) receptor

Aprindine hydrochloride

AC1802

[33237-74-0]
Purity: 100%

Soluble in water, DMSO and EtOH
C22H30N2.HCl MW: 358.95



Axon 4014

mg	Price
10	online
50	online


Biological activity

Aprindine hydrochloride is a long-acting antiarrhythmic agent, effective when administered orally or intravenously in the treatment of ventricular arrhythmias of varying etiologies.

APS-2-79

[2002381-31-7]
Purity: 98%

Soluble in DMSO
C23H21N3O3.HCl MW: 423.89



Axon 2611

mg	Price
5	online
25	online

Biological activity

Small molecule that stabilizes the KSR (Kinase suppressor of Ras) inactive state and antagonizes oncogenic Ras signalling (IC₅₀ value 120 nM against ATP-biotin probe-labelling of KSR2). Furthermore, APS-2-79 modulates KSR-dependent MAPK signaling, and increases the potency of several MEK inhibitors, specifically within Ras-mutant cell lines by antagonizing release of negative feedback signaling.

APX-115


Ewha-18278

Axon 2819

mg	Price
----	-------

[1395946-75-4]
Purity: 99%

Soluble in DMSO
C17H17N3O.HCl MW: 315.80



5	online
25	online


Biological activity

APX-115 is a first-in-class pan-NADPH oxidase (Nox) inhibitor with a K_i value of 0.57–1.08 μ M for Nox isozymes. Blocking the activity of Nox with APX-115 inhibited the responses of BMMs to RANKL, including reactive oxygen species (ROS) generation, activation of mitogen-activated protein (MAP) kinases and NF- κ B, and OC differentiation. Drug candidate for treatment of osteoporosis. Promising therapeutic for diabetic nephropathy.

AR03

[510721-85-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C15H15N3 MW: 237.30



Axon 2136

mg	Price
10	online
50	online


Biological activity

Specific inhibitor of apurinic/apyrimidinic (AP) endonuclease 1 (Ape1) activity

AR 231453

[733750-99-7]
Purity: 99%

Soluble in DMSO
C21H24FN7O5S MW: 505.52



Axon 1572

mg	Price
5	online
25	online


Biological activity

Potent and orally active agonist of cannabinoid receptor GPR119

AR 244555

[858350-62-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C23H23ClF2N2O MW: 416.89



Axon 2191

mg	Price
5	online
25	online

Biological activity

Inverse agonist of Mas G-protein signaling (IC₅₀ values 186 and 348 nM in human and rat inositol phosphatase (IP) G α coupling assays respectively). AR 244555 caused a dose-dependent inhibition of inositol 1,4,5-trisphosphate accumulation in AdMas-infected cells, and attenuated the sarcomeric organization and cell enlargement observed in Mas overexpressing myocytes. AR 244555 caused a modest but significant increase in coronary flow in rat hearts without causing arrhythmias, and provides protection from ischemia-reperfusion injury if administered either before ischemia or immediately before reperfusion.


AR 420626

[1798310-55-0]
Purity: 99%

Axon 2794

mg	Price
10	online

Soluble in DMSO
C21H18Cl2N2O3 MW: 417.29




50 online

Biological activity

AR 420626 is an allosteric FFA3 (GPR41) receptor agonist (pEC50 value of 5.74) which enhances mucosal defenses and prevents NSAID-induced enteropathy via the GLP-2 pathway in rats.

AR-42

[935881-37-1]
Purity: 99%
optically pure
Soluble in DMSO
C18H20N2O3 MW: 312.36



Axon 2394

mg Price

10 online

50 online


Biological activity

AR-42 is a novel HDAC inhibitor (IC50 value of 16 nM) with potent anticancer effects in pancreatic cancer cells at submicromolar concentrations by inducing cell cycle arrest, stimulating apoptosis, and regulating expression of several miRNAs. Also demonstrated anticancer activity in many other cancers, including acute myeloid leukemia, multiple myeloma, prostate cancer, ovarian cancer, human glioma cells, and bladder cancer.

AR-A 014418

SN 4521

[487021-52-3]
Purity: 99%



Axon 2167

mg Price

5 online

25 online

Soluble in DMSO
C12H12N4O4S MW: 308.31

Biological activity

Specific glycogen synthase kinase GSK-3 inhibitor; ATP-competitive

Ara-A

See Vidarabine

Axon 3506

Page 968

Arabinofuranosyladenine, 9-β-D-

See Vidarabine

Axon 3506

Page 968

Arabinofuranosylcytosine, 1-β-D-

See Cytarabine

Axon 3238

Page 404

Arabinofuranosyl-2-fluoroadenine, 9-β-D-

See Fludarabine

Axon 3457

Page 485

Ara-C

See Cytarabine


Axon 3238

Page 404

Aranidipine

MPC-1304; Sapresta

[86780-90-7]
Purity: 98%



Soluble in DMSO
C19H20N2O7 MW: 388.37

Axon 3013

mg Price

10 online

50 online


Biological activity

Calcium antagonist with potent and long-lasting vasodilating and antihypertensive activities.

ARB-272572

PD-L1 inhibitor compound A

[2368182-63-0]
Purity: 99%



Soluble in 0.1N HCl(aq), DMSO and
EtOH
C32H36N6O4 MW: 568.67

Axon 3433

mg Price

5 online

25 online

Biological activity

ARB-272572 is a potent, cellular active PD-L1 inhibitor with an IC50 value of 400 pM for inhibition of PD-1/PD-L1 cell signaling (HTRF assay). ARB-272572 inhibits the PD-1/PD-L1 axis by inducing cell surface PD-L1 dimerization followed by rapid internalization into the cytosol. In addition, ARB-272572 is the first small-molecule checkpoint inhibitor inducing T cell proliferative and IFNγ responses to HBV peptides.

Arcyriarubin A

See Bisindolylmaleimide IV


Axon 3939

Page 310

Arbidol hydrochloride

Umifenovir

[131707-23-8]
Purity: 99%



Soluble in DMSO
C22H25BrN2O3S.HCl MW: 513.88

Axon 3140

mg Price

10 online

50 online

Biological activity

Broad-spectrum antiviral agent.

Ariflo

See SB 207499

Axon 1592

Page 845

Arimidex

See Anastrozole

Axon 3316

Page 237

Aripiprazole

OPC 14597; OPC 31


Axon 1143

mg Price

246

[129722-12-9]
Purity: 99%

Soluble in DMSO
C23H27Cl2N3O2 MW: 448.39




10	online
50	online

Biological activity
Partial dopamine D2 and 5-HT1A receptor agonist and 5-HT2A receptor antagonist; T1/2 about 46 hrs; oral active; atypical antipsychotic

Aripiprazole, thio-

[573691-04-0]
Purity: 98%

No solubility data
C23H27Cl2N3OS MW: 464.45



Axon 1144	
mg	Price
5	online
25	online

Biological activity
Atypical antipsychotic

ARL 15896AR


See AZD6765 dihydrochloride

Axon 3335
Page 247

ARM1

[1049743-03-4]
Purity: 99%

Soluble in DMSO
C16H14N2S.HBr MW: 347.27




Axon 2307	
mg	Price
10	online
50	online

Biological activity
Novel type of LTA4H inhibitor (IC50 value of ~0.5 μM in human neutrophils, and Ki value of 2.3 μM for purified LTA4H) that selectively blocks the conversion of LTA4 into proinflammatory mediator LTB4, although leaving the aminopeptidase activity intact for cleavage and inactivation of Pro-Gly-Pro.

ARN24139

[2699768-78-8]
Purity: 99%

Soluble in DMSO
C24H16F3N3O4S MW: 499.46



Axon 3220	
mg	Price
5	online
25	online


Biological activity
ARN24139 is an orally active topoisomerase II poison with an IC50 value of 7.3 μM against human topolla. ARN24139 showed antiproliferative activity against DU145, HeLa and A549 cell lines with IC50 values of 4.7 μM, 3.8 μM and 3.1 μM, respectively.

ARN 272

[488793-85-7]
Purity: 98%

Axon 2941	
mg	Price
5	online

Soluble in DMSO
C27H20N4O2 MW: 432.47




25	online
----	--------

Biological activity
ARN 272 is a selective competitive antagonist of the interaction of anandamide with FAAH-like anandamide transporter (IC50 value of 1.8 μM). Moreover, ARN 272 prevents anandamide internalization in vitro, interrupts anandamide deactivation in vivo, and exerts profound analgesic effects in rodent models of nociceptive and inflammatory pain, which are mediated by CB1 cannabinoid receptors.

ARN 3236

[1613710-01-2]
Purity: 98%

Soluble in DMSO
C19H16N2O2S MW: 336.41




Axon 3041	
mg	Price
5	online
25	online

Biological activity
ARN 3236 is a potent, selective, ATP-competitive, and orally available inhibitor of SIK2 (IC50 value of < 1 nM) and inhibits SIK1 and SIK3 with IC50 values of 21.63 and 6.63 nM, respectively. Moreover, ARN 3236 inhibits ovarian cancer cell growth and sensitizes ovarian cancer cells and xenografts to paclitaxel by inhibiting centrosome splitting and AKT/survivin signaling.

ARN 509

[956104-40-8]
Purity: 99%

Soluble in DMSO
C21H15F4N5O2S MW: 477.43



Axon 1979	
mg	Price
5	online
25	online

Biological activity
A competitive and potent antagonist of androgen receptor (AR); a promising therapeutic in both castration-sensitive and castration-resistant forms of prostate cancer (CSPC & CRPC)

ARO-002

See Crenolanib

Axon 3969
Page 394

Aromasin

See Exemestane

Axon 2045
Page 472

ARRY-470

See LOXO-101 sulfate

Axon 3407
Page 621

ARRY 142886


See AZD 6244

Axon 1516

Page 274

ARS-1620

[1698055-85-4]
Purity: 99%
99.2% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C21H17ClF2N4O2 MW: 430.84



Axon 3084


mg	Price
5	online
25	online

Biological activity

ARS-1620 is a potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor. ARS-1620 inhibits KRAS with high potency in cells and animals. Moreover, ARS-1620 achieves rapid and sustained in vivo target occupancy to induce tumor regression.

ART-446 Recent Addition

[2984543-29-3]
Purity: 98%
98% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C20H19F5N8O MW: 482.41



Axon 4264

mg	Price
10	online

Biological activity


ART-446 is a potent small molecule CHK2 (Checkpoint kinase 2) inhibitor (IC₅₀ = 9 nM). It exhibits promising potential in enhancing the therapeutic effects of Olaparib (Axon 1464) and Irinotecan (Axon 3370).

Source Information: Sold in collaboration with Chemietek

Artemether

β-Artemether

[71963-77-4]
Purity: 98%
Optically pure
Soluble in DMSO and EtOH
C16H26O5 MW: 298.37



Axon 3303

mg	Price
50	online

Biological activity

Artemether is an antimalarial drug. Experiments on experimental rheumatoid arthritis have shown that artemether could be offered as a second-line drug treatment of rheumatoid arthritis. In addition, artemether has been shown to have anti-inflammatory effects in a mouse model of colitis.

Artemether, β-

See Artemether

Axon 3303


Page 249

Artesunate

[88495-63-0]
Purity: 100%
Optically pure
Soluble in 0.1N NaOH(aq), DMSO and EtOH
C19H28O8 MW: 384.42

Axon 3886

mg	Price
50	online




Biological activity

Artesunate is an antimalarial agent which acts by increasing the oxidant stress on the intra-erythrocytic plasmodia.

ARUK2001607

[2924824-56-4]
Purity: 99%
Soluble in DMSO
C14H13N3O2S2 MW: 319.40



Axon 3837

mg	Price
5	online
50	online


Biological activity

ARUK2001607 is a potent, selective, and brain-penetrant PI5P4Ky inhibitor with a KD value of 7.1 nM.

ARQ 197

Tivantinib

[905854-02-6]
Purity: 98%
Soluble in DMSO
C23H19N3O2 MW: 369.42



Axon 1838


mg	Price
5	online
25	online

Biological activity

Selective, non-ATP competitive and orally bioavailable inhibitor of c-MET receptor tyrosine kinase (RTK)

ARV-825

[1818885-28-7]
Purity: 99%
Optically pure
Soluble in DMSO
C46H47ClN8O9S MW: 923.43



Axon 3944

mg	Price
5	online
10	online


Biological activity

ARV-825, dubbed as PROTAC (Proteolysis Targeting Chimera), is a potent and selective protein BRD4 degrader with DC50 value of <1 nM. It is a hetero-bifunctional molecule consisting of two high-affinity binding ligands, Thienodiazepine for BRD4 and Phthalimide for E3 ubiquitin ligase cereblon (CRBN), linked by a spacer. Bindings of two ligands to their respective receptors recruit the target protein BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 in all BL cell lines tested. Consequently, ARV-825 suppresses more effectively c-MYC levels and downstream signaling than small-molecule BRD4 inhibitors, resulting in more effective cell proliferation inhibition and apoptosis induction in BL.

Source Information: Sold in collaboration with Chemietek

AS-1, (R)-

[2506367-95-7]
Purity: 100%
98% e.e.
Soluble in DMSO and EtOH
C14H16N2O3 MW: 260.29



Axon 3777

mg	Price
10	online
50	online


Biological activity

(R)-AS-1 is a first-in-class highly selective and orally bioavailable positive allosteric modulator (PAM) of EAAT2. (R)-AS-1 is shown to have robust antiseizure properties in a broad range of epilepsy models in mice and zebrafish, as well as an excellent tolerability and safety profile in both in vitro and in vivo studies.

AS1269574

[330981-72-1]
Purity: 100%

Soluble in 0.1N HCl(aq) and DMSO
C13H14BrN3O MW: 308.17



Axon 3430

mg	Price
10	online
50	online


Biological activity

AS1269574 is a selective and orally available GPR119 agonist with an EC50 value of 2.5 μ M. Antihyperglycemic agent.

AS 1842856

[836620-48-5]
Purity: 99%

Soluble in DMSO
C18H22FN3O3 MW: 347.38



Axon 2839

mg	Price
10	online
50	online


Biological activity

AS 1842856 is an orally active, potent and selective inhibitor of Forkhead box protein O1 transcription factor (IC50 value of 33 nM). AS 1842856 reduces glucose production through the inhibition of glucose-6 phosphatase and phosphoenolpyruvate carboxykinase mRNA levels in a rat hepatic cell line. Therapeutic drug for treating type 2 diabetes.

AS 252424

[900515-16-4]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C14H8FNO4S MW: 305.28



Axon 1424

mg	Price
5	online
25	online

Biological activity

Potent and selective PI3K p110 γ inhibitor; IC50 values for inhibition of human recombinant PI3K γ , α , β , and δ are 30, 940, 20,000, and 20,000 nM respectively

AS 252424 bispotassium salt


AS 252424K

[900515-16-4] (parent)
Purity: 99%

Axon 1436

mg	Price
5	online

Soluble in water and DMSO
C14H6FNO4S.K2 MW: 381.46



25 online

Biological activity

Potent and selective PI3K p110 γ inhibitor; IC50 values for inhibition of human recombinant PI3K γ , α , β , and δ to be 30, 940, 20,000, and 20,000 nM respectively; water-soluble bispotassium salt form of AS 252424 (Axon 1424).

AS 252424K

See AS 252424 bispotassium salt


Axon 1436

Page 250

AS2717638

[2148339-28-8]
Purity: 99%

Soluble in DMSO and EtOH
C25H25N3O5 MW: 447.48



Axon 3609

mg	Price
5	online
25	online

Biological activity


AS2717638 is a highly potent, selective, orally active, and brain-penetrant lysophosphatidic acid (LPA) receptor 5 antagonist (IC50 value of 0.038 μ M). AS2717638 blunted LPA-induced phosphorylation of STAT1 and STAT3, p65, and c-Jun and consequently reduced the secretion of pro-inflammatory cyto-/chemokines (IL-6, TNF α , IL-1 β , CXCL10, CXCL2, and CCL5) at non-toxic concentrations. Moreover, AS271763 modulated the expression of intracellular (COX-2 and Arg1) and plasma membrane-located (CD40, CD86, and CD206) polarization markers and attenuated the neurotoxic potential of LPA-activated BV-2 cell-conditioned medium towards CATH.a neurons.

AS 602801

Bentamapimod

[848344-36-5]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C25H23N5O2S MW: 457.55



Axon 2002

mg	Price
5	online
25	online


Biological activity

Potent, orally active and selective Jun kinase (JNK) inhibitor, which inhibited JNK1, JNK2 and JNK3 with IC50 values of 80, 90 and 230 nM respectively. It blocked T-lymphocyte proliferation and induced apoptosis

AS 1517499

[919486-40-1]
Purity: 99%

Soluble in DMSO
C20H20ClN5O2 MW: 397.86



Axon 1992


mg	Price
10	online
50	online

Biological activity

Potent and selective STAT6 inhibitor (IC50: 21 nM)

AS 1892802

[928320-12-1]
Purity: 100%
>99% e.e.
Soluble in DMSO
C20H19N3O2 MW: 333.38



Axon 2187

mg	Price
5	online
25	online


Biological activity

Potent, selective, ATP-competitive, and orally active ROCK inhibitor (in vitro IC₅₀ values 1.69 μM and 0.10 μM for ROCK1 and ROCK2 resp.) that reduces both inflammatory and non-inflammatory pain in rat models. Another group published IC₅₀ values of 122, 52, and 57 nM for human ROCK1, ROCK2, and rat ROCK2 respectively. AS 1892802 dose dependently prevented the formation of tibial cartilage lesions due to MIA induction of osteoarthritis (OA), and completely inhibited IL-1α-induced PGE₂ production. Additionally, it potently inhibited the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.

AS-703026 Recent Addition

Pimasertib; MSC1936369B

[1236699-92-5]
Purity: 99%
>99% e.e.
Soluble in DMSO
C15H15FIN3O3 MW: 431.20



Axon 4217

mg	Price
10	online
50	online

Biological activity


AS-703026 is a potent, selective and orally bioavailable small molecular inhibitor of MEK1/2 with antineoplastic activity.

Source Information: Sold in collaboration with Chemietek

ASB14780

[1069046-00-9]
Purity: 99%

Soluble in DMSO
C31H27NO3.C4H11NO3 MW:
582.69



Axon 2578

mg	Price
10	online
50	online

Biological activity

Potent, orally available inhibitor of cytosolic phospholipase A₂ (cPLA₂; IC₅₀ value 0.020 μM in vitro and 0.54 - 0.64 μM in whole blood assay (guinea pig and human, respectively)) with anti-inflammatory efficacy in ear edema and asthma models, and potentially useful for the treatment of nonalcoholic fatty liver diseases, including fatty liver and hepatic fibrosis. ASB14780 markedly attenuated expression of smooth muscle α-actin (α-SMA) protein and the mRNA expression of collagen 1a2, α-SMA, and TGFβ1 in the liver, and inhibited the expression of monocyte/macrophage markers. Sold as tromethamine (THAM) salt, as it was used in original publication.

Asciminib


ABL001

[1492952-76-7]
Purity: 98%
100% e.e.
Soluble in 0.1N HCl(aq), DMSO and
EtOH

Axon 2757

mg	Price
5	online
25	online

C20H18CIF2N5O3 MW: 449.84




Biological activity

Asciminib is a potent and selective allosteric BCR-ABL1 inhibitor with an IC₅₀ value of 0.5 nM (caliper assay). Moreover, Asciminib is the first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. In vivo, the combination of ABL001 and Nilotinib (Axon 1396) led to complete disease control and eradicated CML xenograft tumours without recurrence after the cessation of treatment.

Ascorbyl dodecanoate, L-

[16690-40-7]
Purity: 99%
>98% ee
No solubility data
C18H30O7 MW: 358.43



Axon 1317


mg	Price
25	online
100	online

Biological activity

Fat-soluble Vitamin C ester; antioxidant

Ascorbyl octanoate, L-

[16690-38-3]
Purity: 99%
>98% ee
No solubility data
C14H22O7 MW: 302.32



Axon 1316

mg	Price
25	online
100	online

Biological activity


Fat-soluble Vitamin C ester; antioxidant

Asenapine maleate

ORG 5222

[85650-56-2]
Purity: 99%

Soluble in DMSO
C17H16ClNO.C4H4O4 MW: 401.84



Axon 1503

mg	Price
10	online
50	online


Biological activity

An atypical antipsychotic for the treatment of schizophrenia and acute mania associated with bipolar disorder; Displays high affinity antagonistic activities at many receptors, including dopamine (D) and serotonin (5-HT) receptor subtypes. However, it has much lower affinity (pK_i < 5) for the muscarinic acetylcholine receptors

ASK1 Inhibitor 10

[1005775-56-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C21H21N5O.2HCl MW: 432.35



Axon 2179

mg	Price
10	online
50	online

Biological activity


Potent, selective, and orally bioavailable ASK1 inhibitor (IC₅₀: 14 nM) with no affinity for a representative panel of kinases (IC₅₀: >10 μM), except for ASK2 (IC₅₀: 0.51 μM). Compound 10 shows a high ligand-lipophilicity efficiency (LLE; pIC₅₀-logD = 4.69) value, which avoids issues of undesirable physical properties and ADME (absorption, distribution, metabolism, and elimination) profiles and interactions with other protein kinases and adverse biological activities.

ASN-002

Gusacitinib

[1425381-60-7]
Purity: 99%

Soluble in DMSO
C24H28N8O2 MW: 460.53



Biological activity

ASN-002 is an orally available potent dual inhibitor of SYK (Spleen Tyrosine Kinase) and pan-JAK (Janus kinases) with IC₅₀ values of 5-46 nM in biochemical assays. In mechanistic cell-based studies involving IgE and cytokine stimulations, ASN002 strongly suppressed the SYK and JAK family kinase signaling pathways measured as pLAT and pSTAT levels, respectively. The compound showed anti-proliferative activity in a broad panel of human cancer cell lines including DHL6, DHL4, OCI-LY10, H929, Pfeiffer, HT-1376, and Lovo, suggesting activity in both solid and hematological tumor types. In a multiple myeloma (H929) xenograft model, ASN002 exhibited significant efficacy in inhibiting tumor growth (>95%). It also significantly delayed the onset of hind limb paralysis in the human erythroleukemia (HEL) mouse model


Source Information: Sold in collaboration with Chemietek

Asoprisnil

J 867

[199396-76-4]
Purity: 98%

Soluble in DMSO
C28H35NO4 MW: 449.58



Biological activity

A selective progesterone receptor (PR) modulator, tested for treatment of progesterone sensitive myomata

ASP015K

See Peficitinib

ASP 1517

See FG-4592

ASP2151

See Amenamevir

ASP 2905

[792184-90-8]
Purity: 98%

Soluble in DMSO
C20H17FN8 MW: 388.40

Axon 3997

mg	Price
10	online
50	online

Axon 1675

mg	Price
5	online
25	online

Axon 3950

Page 757

Axon 2588


Page 480

Axon 3465

Page 223

Axon 2979

mg	Price
10	online
50	online




Biological activity

ASP 2905 is a potent, selective and orally active inhibitor of the potassium channel KCNH3 (Kv12.2) with an IC₅₀ value of 9.0 nM. ASP 2905 may enhance cognitive performance and shows potential in the treatment of attention deficit/hyperactivity disorder.

ASP 3026

[1097917-15-1]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C29H40N8O3S MW: 580.74




Biological activity

Selective inhibitor of the oncogenic fusion kinase EML4-ALK; ASP3026 has a broad safety margin and inhibitory activity at the gatekeeper mutation; potential agent in EML4-ALK fusion positive NSCLC patients, that have relapsed to Crizotinib (Axon 1660)

ASP 9521

[1126084-37-4]
Purity: 99%

Soluble in DMSO
C19H26N2O3 MW: 330.42




Biological activity

ASP 9521 is a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5; AKR1C3) with IC₅₀ values of 11 and 49 nM in recombinant human and cynomolgus monkey AKR1C3, respectively.

AST 1306 tosylate

[1050500-29-2]
Purity: 98%

Soluble in DMSO
C24H18ClFN4O2.C7H8O3S
MW: 621.08



Biological activity

A selective, irreversible ErbB2 and EGFR inhibitor whose growth-inhibitory effects are more potent in ErbB2-overexpressing cells; AST1306 potently inhibits wild-type EGFR and ErbB2, as well as EGFR mutant T790M/L858R, in both cell-free and intact cell assays; IC₅₀ values to be 0.5, 3.0, 0.8 and 12 nM for EGFR, ErbB2, ErbB4 and EGFR mutant T790M/L858R, respectively

Axon 2005

mg	Price
2	online
5	online


Axon 2787

mg	Price
10	online
50	online

AT 406

SM 406

[1071992-99-8]
Purity: 100%
optically pure
Soluble in DMSO
C32H43N5O4 MW: 561.71




Biological activity

Potent and orally available antagonist of the inhibitor of apoptosis proteins (IAPs); binds to XIAP, cIAP1, and cIAP2 proteins with K_i of 66.4, 1.9, and 5.1 nM, respectively

AT 1001

[1314801-63-2]
Purity: 100%
Relative stereochemistry
Soluble in 0.1N HCl(aq) and DMSO
C15H21BrN2 MW: 309.24




Biological activity

High affinity and selective $\alpha 3\beta 4$ nAChR ligand (K_i value 2.6 nM at $\alpha 3\beta 4$ nAChR) with both partial agonistic and antagonistic effects, and >90-fold selective over the other major subtypes, the $\alpha 4\beta 2$ and $\alpha 7$ nAChR. AT-1001 potently and dose-dependently blocks nicotine self-administration in rats, without affecting food responding, and shows a mechanism of action very different from varenicline.

AT 7519 mesylate

[902135-89-1]
Purity: 99%
Soluble in water
C16H17Cl2N5O2.CH4O3S
MW: 478.35




Biological activity

A small molecule inhibitor of multi-CDK, which inhibits CDK 1, 2, 4, 5, 6, and 9 in vitro and induces apoptosis in multiple myeloma via GSK-3 β activation and RNA polymerase II inhibition

AT 9283

[896466-04-9]
Purity: 99%
Soluble in water and DMSO
C19H23N7O2 MW: 381.43



Biological activity


A multitargeted kinase inhibitor with high affinity for Aurora A and B, JAK2/3, and BCR-Abi(T3151) (IC50 values 3, 3, 1.2, 1.1, and 4 nM respectively). AT 9283 has a potent anti-proliferative activity in a panel of Ba/F3 and human cell lines expressing the BCR-Abi fusion protein or its mutant forms including T3151, and it has the potential to significantly benefit patients with imatinib-resistant CML or with Ph+ ALL.

Axon 1985

mg	Price
5	online
25	online

AT 13148 dihydrochloride

[1056901-62-2]
Purity: 98%
Soluble in DMSO
C17H16ClN3O2.HCl MW: 386.70



Biological activity

An oral, ATP-competitive inhibitor of multi-AGC kinases with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors. AT13148 caused substantial blockade of AKT, p70S6K (S6K1), PKA, ROCK, and SGK substrate phosphorylation and induced apoptosis in cancer cells, with IC50 values of 38, 402, 50, 8, 3, 6, 4, 63 nM for AKT1, AKT2, AKT3, p70S6K, PKA, ROCK1, ROCK2, and SGK3 respectively.

Axon 2166

mg	Price
2	online
5	online

AT 1001

Axon 2401


mg	Price
10	online
50	online

Ataluren

PTC124

[775304-57-9]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C15H9FN2O3 MW: 284.24



Biological activity

Ataluren is an orally bioavailable suppressor of the human CFTR-G542X nonsense allele.

Axon 4049

mg	Price
50	online

AT 7519 mesylate

Axon 1539

mg	Price
5	online
50	online

Atazanavir

See BMS 232632

Atazanavir, deuterated

See Compound 120

Axon 1441

Page 316


Axon 1753

Page 258

ATB 346

[1226895-20-0]
Purity: 99%

Soluble in DMSO
C21H19NO3S MW: 365.45



Biological activity

Orally active hydrogen sulfide-releasing cyclooxygenase inhibitor and a derivative of Naproxen (significantly reduced exudate leukocyte and PGE2 levels at 30 μ mol/kg oral administration). ATB-346 exhibits anti-inflammatory properties similar to naproxen. In a mouse airpouch model, ATB-346 suppressed cyclooxygenase-2 activity and inhibited leukocyte infiltration more effectively than naproxen but with substantially reduced gastrointestinal toxicity (100-fold safer than naproxen).

Axon 2288

mg	Price
10	online
50	online

AT 9283


Axon 2219

mg	Price
5	online
25	online

Atglistatin

[1469924-27-3]
Purity: 98%

Soluble in DMSO
C17H21N3O MW: 283.37



Axon 2276

mg	Price
5	online
25	online

Biological activity

Highly potent and selective inhibitor of adipose triglyceride lipase (ATGL; IC50 value 0.7 μM) that reduces fatty acid mobilization in vitro and in vivo.


Atglistatin does not inhibit HSL, monoglyceride lipase, pancreatic lipase, lipoprotein lipase and two lysophospholipases of the patatin-like phospholipase domain-containing protein family (PNPLA) exhibiting homology to ATGL.

Atipamezole hydrochloride

Antisedan; MPV 1248

[104075-48-1]
Purity: 99%

Soluble in water
C14H16N2.HCl MW: 248.75



Axon 1371

mg	Price
5	online
25	online


Biological activity

A competitive α2-adrenergic antagonist; used to antagonize (reverse) the action of the α2 adrenoceptor agonists medetomidine, xylazine and detomidine

Atomoxetine Hydrochloride

[82248-59-7]
Purity: 99%
>98% ee

Soluble in water
C17H21NO.HCl MW: 291.82



Axon 1297

mg	Price
10	online
50	online

Biological activity

Norepinephrine reuptake inhibitor (NRI), or noradrenaline reuptake inhibitor (NARI)

Atopaxar hydrobromide

See E 5555 hydrobromide

Axon 2030


Page 447

Atorvastatin calcium

Lipitor

[134523-03-8]
Purity: 99%

Soluble in DMSO
C33H34FN2O5.1/2Ca MW: 597.71



Axon 2043

mg	Price
10	online
50	online

Biological activity

An inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to lower the LDL ("bad") cholesterol and triglycerides in your blood. It can raise your HDL ("good") cholesterol as well.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Atovaquone


566C80

[95233-18-4]
Purity: 100%

Axon 3527

mg	Price
50	online

Soluble in DMSO
C22H19ClO3 MW: 366.84



Biological activity


Atovaquone is an antiparasitic agent with broad-spectrum activity against Plasmodium spp., P. carinii, Babesia spp., and Toxoplasma gondii.

ATR-101

PD 132301-2; Nevanimibe hydrochloride

[133825-81-7]
Purity: 98%

Soluble in DMSO
C27H39N3O.HCl MW: 458.08



Axon 2960

mg	Price
10	online
50	online

Biological activity

ATR-101 is a potent, selective and orally efficacious acyl coenzyme A:cholesterol acyltransferase isoform 1 (ACAT1) inhibitor (IC50 value of 0.009 μM). ATR-101 potently lowers plasma total cholesterol in various animal models of hypercholesterolemia but is an adrenal toxicant. Furthermore, ATR-101 inhibits cholesterol efflux and cortisol secretion by ATP-binding cassette transporters, causing cytotoxic cholesterol accumulation in ACC cells.

ATRA

See Retinoic acid


Axon 3321

Page 814

Atrasentan

A127722; ABT627

[173937-91-2]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C29H38N2O6 MW: 510.62



mg	Price
5	online
25	online


Biological activity

Atrasentan is a highly potent, selective, and orally active ETA-selective endothelin receptor antagonist with an IC50 value of 0.055 nM.

Aurora A inhibitor I

[1158838-45-9]
Purity: 99%

Soluble in DMSO
C31H31ClFN7O2 MW: 588.07



Axon 1597

mg	Price
5	online
25	online


Biological activity

Potent and selective inhibitor of Aurora A kinase (AurA), with IC50 values to be 3.4 nM (Aurora A) and unusually high selectivity 1000 fold against Aurora B; a useful tool compound for investigating the cellular role of Aurora A kinases. This ligand has much higher selectivity of Aurora A vs Aurora B than another recently described relatively selective Aurora A inhibitor MLN8054, which shows 43-fold selectivity for Aurora A over Aurora B in enzymatic assays

Aurora A inhibitor II

[1158838-43-7]
Purity: 99%

Soluble in DMSO
C31H29ClFN7O3 MW: 602.06



Axon 1630

mg	Price
5	online
25	online


Biological activity

Potent and selective inhibitor of Aurora A kinase (AurA), with IC50 values to be 4.3 nM (Aurora A) and unusually high selectivity 860 fold against Aurora B; a useful tool compound for investigating the cellular role of Aurora A kinases

Autophinib

[1644443-47-9]
Purity: 99%

Soluble in DMSO
C14H11ClN6O3 MW: 346.73



Axon 2748

mg	Price
10	online
50	online


Biological activity

Autophinib targets the lipid kinase vacuolar protein sorting 34 (VPS34), which is a promising target for selective autophagy modulation (IC50 value of 0.019 μM). Autophinib inhibits autophagy induced by starvation or rapamycin with IC50 values of 0.04 μM and 0.09 μM, respectively.

Auxinole

[86445-22-9]
Purity: 99%

Soluble in DMSO and EtOH
C20H19NO3 MW: 321.37



Axon 3477

mg	Price
10	online
50	online

Biological activity

Auxinole is a potent TIR1 antagonist. Auxinole binds TIR1 to block the formation of the TIR1-IAA-Aux/IAA complex and so inhibits auxin-responsive gene expression.

AV 951

See Tivozanib

Axon 1717

Page 929

AVE 0118 hydrochloride


[498577-53-0 (parent)]

Axon 2243

mg Price

Purity: 99%

Soluble in water and DMSO
C30H29N3O3.HCl MW: 516.63



5	online
25	online


Biological activity

Potassium channel blocker. AVE0118 caused concentration-dependent inhibition of Kv1.5 (IKur), Kv4.3 (Ito), Kir3.4 (IKAch), and IKr currents (IC50 values 6.2 μM, 3.4 μM, 4.5 μM, and 10 μM resp.). A potent and atrium selective antiarrhythmic compound with no apparent effect on ventricular repolarization. Noteworthy, the atrial selective and dose-dependent prolongation of atrial refractoriness (ERP) by AVE 0118 has been claimed to be an inhibitory effect of sodium channel activity in an atrial-selective manner, and may therefore contribute to anti-AF properties of AVE0118.

AVE0991

[304462-19-9]
Purity: 98%

Soluble in DMSO
C29H32N4O5S2 MW: 580.72



Axon 3386

mg	Price
5	online
25	online


Biological activity

AVE0991, a non-peptide Ang-(1-7) mimetic, is a selective and orally active Mas receptor agonist (IC50 value of 21 nM).

Avibactam sodium

NXL104

[1192491-61-4]
Purity: 98%
Optically pure
Soluble in water and DMSO
C7H10N3NaO6S MW: 287.23



Axon 3299

mg	Price
10	online
50	online

Biological activity

Avibactam sodium is a covalent and reversible β-lactamase inhibitor with potent activity against both class A and class C enzymes (IC50 value of 38 nM for KPC-2).

Avitinib

See Abivertinib

Axon 3040


Page 199

AVL 292

CC 292

[1202757-89-8]
Purity: 98%

Soluble in DMSO
C22H22FN5O3 MW: 423.44



Axon 2226

mg	Price
5	online
25	online

Biological activity


A potent, selective, orally bioavailable, covalent Bruton's tyrosine kinase (Btk) inhibitor with potential antineoplastic activity (IC50 value <0.5 nM and >1400 selective over a number of Src family kinases and B cell signaling components in full length recombinant Btk protein assay). More specific for BTK than PCI 32765 (Ibrutinib, Axon

1858) is, and with a shorter half-life. AVL 292 reduces migration of CLL cells towards CXCL12 and CXCL13, and reduces viability as well as markers of BCR activation, such as CCL3 and CCL4 chemokine production, in primary CLL cells cultured with Nurse-like Cells (NLC).

AVN944

VX-944

[297730-17-7]
Purity: 99%
99% e.e.
Soluble in DMSO
C25H27N5O5 MW: 477.51



Axon 3943

mg	Price
5	online
10	online

Biological activity

AVN-944 is an orally available, uncompetitive small molecule inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme catalyzing the rate limiting step in the biosynthesis of guanine nucleotides. As IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies, thus inhibition of this enzyme will result in depletion of guanine nucleotide pools, cessation of DNA synthesis, cell cycle block at the G(1)/S interface and interference with cell division, and induction of apoptosis. The reduction in guanine nucleotide pools will also interfere with the ability of G-coupled proteins to act as intracellular signal transducers.


Source Information: Sold in collaboration with Chemietek

Avridine

CP 20961

[35607-20-6]
Purity: 99%

Soluble in DMSO and EtOH
C43H90N2O2 MW: 667.19



Axon 2099

mg	Price
10	online
50	online

Biological activity


A lipoidal amine with interferon-inducing and adjuvant properties; an effective adjuvant for Newcastle disease antigen (NDA) in chickens; a potent adjuvant that can induce arthritis in most rat strains; immunomodulator

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

AX-024 hydrochloride

[1704801-24-0]
Purity: 99%

Soluble in water and DMSO
C21H22FNO2.HCl MW: 375.86



Axon 2692

mg	Price
5	online
25	online

Biological activity

AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). By modulating TCR signaling, the inhibitor prevented the development of psoriasis and asthma and, furthermore, exerted a long-lasting therapeutic effect in a model of autoimmune encephalomyelitis.

Axitinib

See AG 013736

Axon 1414

Page 213

Axon 1170


Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, (6a,11b,16a,17a)-

Axon 1170

mg	Price
----	-------

[28416-82-2]
Purity: 98%

No solubility data
C21H26F2O5 MW: 396.42



500 online

2000 online

Biological activity


Steroid derivative; precursor for e.g. fluticasone

Axon 1171

Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, (6a,11b,16a,17a)-

[80473-92-3]
Purity: 98%

No solubility data
C21H26F2O4S MW: 412.49



500 online


1000 online

Biological activity

Steroid derivative; precursor for e.g. fluticasone

AZ 20

[1233339-22-4]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C21H24N4O3S MW: 412.51




Biological activity

Potent, orally active and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity (IC50 value 5 nM). AZ 20 potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro, and is a useful compound to explore ATR pharmacology in vivo.

AZ 23

[915720-21-7]
Purity: 99%
optically pure
Soluble in DMSO
C17H19ClFN7O MW: 391.83



Biological activity

Potent and selective tyrosine kinase (Trk) inhibitor with IC50 to 2 and 8 nM for TrkA and TrkB respectively; AZ-23 showed in vivo TrkA kinase inhibition and efficacy in mice following oral administration; having potential for therapeutic utility in neuroblastoma and multiple other cancer indications

AZ5104

[1421373-98-9]
Purity: 99%


Soluble in DMSO and EtOH
C27H31N7O2 MW: 485.58

Axon 1610

mg	Price
2	online
5	online

Axon 4074

mg	Price
10	online
50	online



Biological activity


AZ5104 is an active circulating metabolite of AZD9291. It shares the similar overall activity profile with AZD9219, but is more potent against mutant EGFR forms, while hitting the wild-type EGFR form at a lower concentration thus demonstrating a smaller selectivity margin compared with the parent. Like AZD9291, AZ5104 displays potent antitumor activities both in vitro and in vivo.

Source Information: Sold in collaboration with Chemietek

AZ 628

[878739-06-1]
Purity: 99%

Soluble in DMSO
C27H25N5O2 MW: 451.52



Axon 1545


mg	Price
5	online
25	online

Biological activity

Selective RAF inhibitor, showing strong selectivity for RAF kinases among a panel of 150 tested kinases; IC50 values: ca 30 nM for BRAF V600E and wild-type CRAF and 100 nM for wild-type BRAF

AZ 960

[905586-69-8]
Purity: 98%
optically pure
Soluble in DMSO
C18H16F2N6 MW: 354.36



Axon 1778

mg	Price
2	online
5	online


Biological activity

Potent, selective and ATP competitive JAK2 inhibitor; AZ960 inhibits JAK2 kinase with a Ki of 0.45 nM in vitro and induces growth arrest and apoptosis in adult T-cell leukemia (ATL) cell

AZ 3146

[1124329-14-1]
Purity: 99%

Soluble in DMSO
C24H32N6O3 MW: 452.55



Axon 1642

mg	Price
5	online
25	online

Biological activity

Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor, with IC50 to be 35 nM for human Mps1 and selectivity against 46 out of a panel of 50 other kinases and only four kinases were inhibited by >40%, namely FAK, JNK1, JNK2, and KIT. AZ3146 overrides the spindle checkpoint

AZ 12216052


[1290628-31-7]
Purity: 98%

Soluble in DMSO

Axon 1747

mg	Price
10	online
50	online

C19H22BrNOS MW: 392.35




Biological activity

A positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 8 (mGluR8)

AZ13705339

[2016806-57-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C33H36FN7O3S MW: 629.75



Axon 2669

mg	Price
5	online
25	online

Biological activity

AZ13705339 is a potent and selective PAK1 inhibitor (IC50 value of 0.33 nM). In vitro probe compound.

Azafen

See Azaphen

Axon 1462


Page 266

Azaphen

Azafen; Azaphenonxazine dihydrochloride

[24853-80-3]
Purity: 99%

Soluble in water
C16H19N5O.2HCl MW: 370.28



Axon 1462

mg	Price
10	online
50	online

Biological activity

An antidepressant having effects on the autonomic nervous system; the drug is especially effective for mild and moderate depressions and a combination of Azaphen and Thymol is applicable for severa depressions. Azaphen improves sleep too

Azaphenonxazine dihydrochloride

See Azaphen


Axon 1462

Page 266

Azasetron hydrochloride

[123040-16-4]
Purity: 98%

No solubility data
C17H20ClN3O3.HCl MW: 386.27



Axon 1096

mg	Price
10	online
50	online

Biological activity


Selective 5-HT3 antagonist

Azasetron hydrochloride, (+)-

Axon 2534

mg Price

[123040-94-8]
Purity: 100%
Optically pure
Soluble in water and DMSO
C17H20ClN3O3.HCl MW: 386.27




10	online
50	online

Biological activity
Selective 5-HT3 antagonist. (-)-enantiomer of Axon 1096 (racemic)

Azasetron hydrochloride, (-)-

[123040-96-0]
Purity: 100%
Optically pure
Soluble in water and DMSO
C17H20ClN3O3.HCl MW: 386.27




Axon 2535	
mg	Price
10	online
50	online

Biological activity
Selective 5-HT3 antagonist. (-)-enantiomer of Axon 1096 (racemic)

AZD0095

[2750001-23-9]
Purity: 98%
100% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C27H32N8O2 MW: 500.60




Axon 3838	
mg	Price
5	online
25	online

Biological activity
AZD0095 is a potent, selective and orally active MCT4 inhibitor with an IC50 value of 1.3 nM.

AZD0156

[1821428-35-6]
Purity: 99%
Soluble in DMSO
C26H31N5O3 MW: 461.56




Axon 4140	
mg	Price
5	online
25	online

Biological activity
AZD0156 is potent, selective, and orally available inhibitor of ATM kinase. AZD0156 prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death in ATM-overexpressing tumor cells. In addition, AZD0156 also sensitizes tumor cells to chemo- and radiotherapy.

AZD 0530 difumarate

Saracatinib

[893428-72-3]
Purity: 99%
Soluble in DMSO
C27H32ClN5O5.2C4H4O4
MW: 774.17




Axon 1456	
mg	Price
5	online
25	online

Biological activity
An orally bioavailable tyrosine kinase inhibitor, specifically targeting Src and Abl, those kinases often overexpressed in chronic myeloid leukemia cells. Optimal water-soluble form

AZD 1080

[612487-72-6]
Purity: 98%
Soluble in DMSO
C19H18N4O2 MW: 334.37




Biological activity
Potent and selective inhibitor of Glycogen synthase kinase 3 (GSK3), with Ki values of 6.9 nM and 31 nM for GSK-3α and GSK-3β respectively. In phase 1 clinical studies, AZD 1080 inhibits tau phosphorylation in cells expressing human tau and in intact rat brain. Interestingly, subchronic but not acute administration with AZD 1080 reverses MK-801-induced deficits, measured by long-term potentiation in hippocampal slices and in a cognitive test in mice.

Axon 2171	
mg	Price
5	online
25	online

AZD 1152-HQPA

[722544-51-6]
Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO
C26H30FN7O3 MW: 507.56




Biological activity
AZD 1152-HQPA is a highly potent and selective inhibitor of Aurora B, with Ki values to be 0.36 (Aurora B) and 1369 nM (Aurora A) respectively and has a high specificity versus a panel of 50 other kinases. The dihydrogen phosphate prodrug, AZD 1152 (Barasertib), is converted rapidly to active AZD1152-HQPA in plasma

Axon 1580	
mg	Price
5	online
25	online

AZD 1208

[1204144-28-4]
Purity: 98%
optically pure
Soluble in DMSO
C21H21N3O2S MW: 379.48




Biological activity
AZD 1208 is a pan-Pim kinase inhibitor (IC50 values of 0.4 nM, 5.0 nM and 1.9 nM for Pim-1, Pim-2 and Pim-3, respectively) which does not inhibit FLT3. AZD 1208 treatment resulted in growth inhibition and cell size reduction in AML cell lines including FLT3-WT (OCI-AML-3, KG-1a, MOLM-16) and FLT3-ITD mutated (MOLM-13, MV-4-11).

Axon 2795	
mg	Price
5	online
25	online

AZD 1981

[802904-66-1]
Purity: 99%
Soluble in 0.1N NaOH(aq) and DMSO
C19H17ClN2O3S MW: 388.87




Biological activity
Potent, orally bio-available and selective CRTh2 (also known as DP2) antagonist; AZD1981 inhibited PGD2 binding to human CRTh2 with an IC50 of 4 nM

Axon 2145	
mg	Price
5	online
25	online

AZD2014

Vistusertib

[1009298-59-2]
Purity: 99%
Optically pure
Soluble in DMSO
C25H30N6O3 MW: 462.54



Biological activity


AZD2014 is a potent and orally bioavailable dual mTORC1/mTORC2 inhibitor with IC50 at lower nM, demonstrating on-target in vitro and in vivo activities in experimental models.

Source information: Sold in collaboration with Chemietek

AZD 2098

[566203-88-1]
Purity: 99%

Soluble in DMSO
C11H9Cl2N3O3S MW: 334.18



Biological activity

Potent, selective and bioavailable CCR4 receptor antagonist (pIC50 value of 7.8).

AZD 2171


See Cediranib

AZD 2281

Olaparib; KU 0059436

[763113-22-0]
Purity: 99%

Soluble in DMSO
C24H23FN4O3 MW: 434.46




Biological activity

Highly potent, oral and selective inhibitor of poly(ADP-ribose) polymerase (PARP); with IC50 = 5nM (PARP-1) and 1 nM (PARP-2). It blocks enzymes that repair DNA damage caused by cancer treatments such as radiation and drugs

AZD 2461

[1174043-16-3]
Purity: 99%

Soluble in DMSO
C22H22FN3O3 MW: 395.43



Biological activity

Axon 3996

mg	Price
10	online
50	online

Axon 2842

mg	Price
10	online
50	online

Axon 1461

Page 356

Axon 1464

mg	Price
5	online
25	online

Axon 2241


mg	Price
10	online
50	online

PARP inhibitor (IC50 value 5 nM) with poor P-glycoprotein substrate qualities. Unlike treatment with AZD 2281 (Olaparib, Axon 1464), AZD 2461 successfully circumvents drug resistance of Pgp-proficient tumors, and inactivation of p53-binding protein 1 (53BP1) as a causal factor in PARP1 resistance.

AZD2858

[486424-20-8]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C21H23N7O3S MW: 453.52




Biological activity

Potent and highly selective Glycogen Synthase Kinase-3 β (GSK-3 β ; Ki value 4.9 nM) inhibitor for Alzheimer's disease with good BBB permeability in a bovine endothelial cell assay. AZD2858 inhibits GSK-3 β -mediated tau phosphorylation (IC50 value 76 nM) in vitro, and shows a good overall selectivity versus a panel of 26 kinases and >100 fold selectivity over CDK2 (Ki value 540 nM). In rats, oral AZD2858 treatment caused a dose-dependent increase in trabecular bone mass by GSK-3 mediated inhibition of Wnt canonical signaling, making AZD2858 a possible therapeutic candidate for osteoporosis. The water-soluble salt form, AZD2858 hydrochloride (Axon 2194), is also available.

AZD 2858 hydrochloride

[486424-21-9]
Purity: 98%

Soluble in water and DMSO
C21H23N7O3S.HCl MW: 489.98




Biological activity

Potent and highly selective Glycogen Synthase Kinase-3 β (GSK3 β ; Ki value 4.9 nM) inhibitor for Alzheimer's disease with good BBB permeability in a bovine endothelial cell assay. AZD 2858 inhibits GSK3 β -mediated tau phosphorylation (IC50 value 76 nM) in vitro, and shows a good overall selectivity versus a panel of 26 kinases and >100 fold selectivity over CDK2 (Ki value 540 nM). In rats, oral AZD2858 treatment caused a dose-dependent increase in trabecular bone mass by GSK3 mediated inhibition of Wnt canonical signaling, making AZD2858 a possible therapeutic candidate for osteoporosis.

AZD 3463

[1356962-20-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C24H25ClN6O MW: 448.95




Biological activity

Potent inhibitor of ALK and IGF1R; AZD3463 is potent in ALK-driven preclinical models and in a variety of crizotinib-resistant models

AZD 3759

[1626387-80-1]
Purity: 98%

Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C22H23ClF2N5O3 MW: 459.90



Axon 3771

mg	Price
5	online
25	online

Axon 2194

mg	Price
5	online
25	online

Axon 2153

mg	Price
5	online
25	online

Axon 2563


mg	Price
10	online
50	online

Biological activity

Potent, orally active, brain-penetrant, EGFR tyrosine kinase inhibitor (IC50 value 7.2 nM for inhibition of cellular phosphorylation on L858R cell lines), that shows tumor regression in the mouse model with brain metastasis. At 1 μM, AZD 3759 showed <50% inhibition against 115 out of a panel of 124 recombinant protein and lipid kinases, and was neither a direct inhibitor nor a time-dependent inhibitor for a series of Cytochrome isoforms.

AZD3458

[2132961-46-5]
Purity: 99%
99% e.e.
Soluble in DMSO
C20H23N3O4S2 MW: 433.54



Axon 3808

mg	Price
5	online
10	online


Biological activity

AZD3458 is an orally bioavailable potent and selective PI3Kγ inhibitor, and an immuno-oncology modulator. It selectively inhibits PI3Kγ with a cellular IC50 of 8 nM, a 100-fold selective over PI3Kδ in vitro. AZD3458 inhibits pAKTS308/S473 in human macrophages and mouse CD11b activation at 32nM and 30nM free IC50 respectively. Application of AZD3458 in vivo with checkpoint inhibitors α-PD-1 or α-PD-L1 had greater anti-tumor effects than checkpoint inhibitor alone in 4T1, LLC, CT-26 and MC-38 mouse syngeneic models, suggesting that AZD3458 can reverse myeloid suppressive tumor microenvironment and revert tumor resistance to immunotherapy in myeloid-enriched immunosuppressive tumor types.

Source Information: Sold in collaboration with Chemietek

AZD3965

[1448671-31-5]
Purity: 99%
99% e.e.
Soluble in DMSO
C21H24F3N5O5S MW: 515.51



Axon 4070

mg	Price
10	online
50	online

Biological activity


AZD3965 is a first-in-class, cell permeable high affinity ligand of monocarboxylate transporter 1 (MCT1), binding to the protein with a Ki value of 1.6 nM, with 6 fold selectivity over the closely related MCT2, and does not bind to MCT4 at a concentration of 10 μM. AZD3965 offers a novel mechanism for targeting the metabolic phenotype in tumors that preferentially express MCT1 such as lymphoma cancer cell lines, in which both lactate transport and cell growth are potently inhibited by AZD3965, and a strong cytotoxic effect is also induced by AZD3965 for other cell lines that are preferentially express MCT1. Blocking lactate transport in vitro also leads to a rapid inhibition of glucose uptake in the RajiBurkitt's lymphoma cell line. In vitro combination studies show that the cell death can be enhanced by Doxorubicin through lactate transport inhibition in which AZD3965 experts the effort. In vivo, AZD3965 is well tolerated and induces a dose and time dependent accumulation of lactate in the tumors, suppressing tumor growth in the Raji model, potentiating the effects of Rituxan, Doxorubicin (Axon 4072) and Bendamustine.

Source Information: Sold in collaboration with Chemietek

AZD-4205

Golidocitinib

[2091134-68-6]
Purity: 99%
100% e.e.
Soluble in DMSO
C25H31N9O2 MW: 489.57



Axon 3855

mg	Price
5	online
10	online


Biological activity

AZD-4205 is a potent, selective and ATP-competitive inhibitor of JAK1 with a Ki of 2.8 nM, highly selective against JAK2 (IC50 =13233 nM, >4000 fold selectivity) and JAK3 (IC50 >30000 nM, >10000 fold selectivity). Demonstrates potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and excellent selectivity across the kinome. Exhibits excellent pharmacokinetics, and in vitro and in vivo antitumor efficacy.

Source Information: Sold in collaboration with Chemietek

AZD4320

[1357576-48-7]
Purity: 99%
100% (e.e. and d.e.)
Soluble in DMSO
C45H48ClF3N4O7S3 MW: 945.53



Axon 3814

mg	Price
5	online
10	online

Biological activity


AZD4320 is a BH3 mimetic and highly potent dual Bcl-2/Bcl-XL inhibitor with binding affinity in low nanomolar range similar to ABT-263, but with a better therapeutic index (lower toxicities) and amenable to I. V. administration. It rapidly induces caspase-3 (CC3) cleavage and cell death in both Bcl-2-driven (SuDHL4, GI50 <50 nM) and Bcl-XL-driven (SuDHL8, GI50 <50 nM) diffuse large B-cell lymphoma (DLBCL) cell lines; Achieves complete and sustained (>24 days) tumor regressions in a mouse RS4;11 acute lymphocytic leukemia xenograft model (20 mg/kg, i.v.).

Source Information: Sold in collaboration with Chemietek

AZD 4547

[1035270-39-3]
Purity: 99%

Soluble in DMSO
C26H33N5O3 MW: 463.57



Axon 1917


mg	Price
5	online
25	online

Biological activity

Orally available, potent and selective FGFR inhibitor

AZD4573

[2057509-72-3]
Purity: 99%
99% e.e.
Soluble in DMSO
C22H28ClN5O2 MW: 429.94



Axon 3800

mg	Price
5	online
10	online

Biological activity

AZ4573 is a potent inhibitor of CDK9 with a biochemical IC50 of <3 nM, highly selective (>10 fold) against all other CDKs and kinases. AZD4573 rapidly induces cell death in hematological tumor models (both in vitro and in vivo) through depletion of Mcl-1.

Source Information: Sold in collaboration with Chemietek

AZD4635


HTL-1071; Imaradenant

Axon 4069

mg	Price
----	-------

[1321514-06-0]
Purity: 99%

Soluble in DMSO
C15H11ClFN5 MW: 315.73



10	online
50	online

Biological activity


AZD4635 is an orally bioavailable, potent and selective A2A (Adenosine 2A) receptor antagonist, binding to human A2A receptor with a K_i value of 1.7 nM, and with > 30-fold selectivity over other adenosine receptors. High adenosine level in tumors, produced by stimulating A2A receptors, is immune suppressive, which prevents T-cells within the immune system from being activated thus reduces their ability to destroy cancer cells. Antagonizing A2A receptors can therefore promote the anti-cancer response of T-cells within the tumour microenvironment.

Source Information: Sold in collaboration with Chemietek

AZD 5363 dihydrochloride

[1143532-39-1]
Purity: 98%

Soluble in water and DMSO
C21H25ClN6O2.2HCl MW: 501.84



Axon 1859

mg	Price
5	online
25	online


Biological activity

Orally bioavailable, selective and potent protein kinase B (Akt) inhibitor in low nM potency; AZD5363 dihydrochloride is directly water-soluble

AZD 5438

[602306-29-6]
Purity: 99%

Soluble in DMSO
C18H21N5O2S MW: 371.46



Axon 1966


mg	Price
5	online
25	online

Biological activity

Potent and orally bioavailable inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC50: 16, 6, and 20 nM, respectively); AZD5438 showed significant antiproliferative activity in human tumor cell lines (IC50: 0.2-1.7 μM)

AZD5153 HNT salt

[1869912-40-2]
Purity: 99%
99% e.e.
Soluble in DMSO
C25H33N7O3.C11H8O3 MW: 667.75



Axon 3833

mg	Price
5	online
10	online

Biological activity


AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor with a bivalent binding mode. Unlike many previously reported monovalent inhibitors, AZD5153 ligates two bromodomains in BRD4 simultaneously. The enhanced avidity afforded through bivalent binding translates into increased cellular and antitumor activity in preclinical hematologic tumor models. In vivo administration of AZD5153 led to tumor stasis or regression in multiple xenograft models of acute myeloid leukemia, multiple myeloma, and diffuse large B-cell

lymphoma. The relationship between AZD5153 exposure and efficacy suggests that prolonged BRD4 target coverage is a primary efficacy driver. AZD5153 treatment markedly affects transcriptional programs of MYC, E2F, and mTOR. Transcriptional modulation of MYC and HEXIM1 was confirmed in AZD5153-treated human whole blood.

Source Information: Sold in collaboration with Chemietek

AZD5582 dihydrochloride

[1883545-51-4]
Purity: 99%
Optically pure
Soluble in water and DMSO
C58H78N8O8.2HCl MW: 1088.21



Axon 4139

mg	Price
10	online
50	online


Biological activity

AZD5582 is a cell permeable, novel class of dimeric SMAC mimetic designed to mimic the AVPI motif of SMAC. It is a potent and selective inhibitor of X-linked (XIAP) and cellular (cIAP) inhibitor of apoptosis protein with IC50 values of 15, 15 and 21 nM for XIAP, cIAP1 and cIAP2, respectively. At nanomolar concentrations AZD5582 causes extensive degradation of cIAP-1 and cIAP-2, and induces apoptosis in MDA-MB-231 breast cancer cells. It causes substantial tumor regressions following two weekly doses of 3.0 mg/kg in MDA-MB-231 xenograft-bearing mice.

Source Information: Sold in collaboration with Chemietek

AZD5991

[2143061-81-6]
Purity: 99%
99% e.e.
Soluble in DMSO
C35H36ClN5O3S2 MW: 674.28



Axon 3731

mg	Price
5	online
10	online

Biological activity

AZD5991 is a potent and selective BH3-groove-binding Mcl-1 inhibitor with sub-nanomolar affinity for the target. It demonstrates all the hallmarks of a true Mcl-1 inhibitor: 1. potent, selective, and rapid apoptosis in Mcl-1-dependent cell lines (e.g., GI50 as low as 10 nM in multiple myeloma cell lines); 2. loss of activity upon overexpression of Bcl-xL or siRNA-mediated knockout of Bak; 3. Mcl-1:Bak complex disruption as demonstrated by co-immunoprecipitation. AZD5991 is active in vivo, with complete (100%) tumor regression demonstrated in several mouse xenograft models after a single tolerated dose.

Source Information: Sold in collaboration with Chemietek

AZD6094 dihydrochloride

See Votitinib dihydrochloride

Axon 3864

Page 971

AZD 6244

ARRY 142886; Selumetinib


[606143-52-6]
Purity: 99%

Soluble in DMSO

Axon 1516

mg	Price
2	online
25	online

C17H15BrClFN4O3 MW: 457.68




Biological activity

An orally active, highly potent and selective inhibitor of MEK 1/2 that has shown tumor-suppressive activity in a wide range of preclinical models. IC50 value to be 14 nM against purified MEK1

AZD 6280

[942436-93-3]
Purity: 99%

Soluble in DMSO
C20H22N4O3 MW: 366.41



Biological activity


AZD 6280 is a selective, orally active, allosteric GABA-A α 2/3 receptor modulator with an A2 pKi value of 7.7.

AZD 6482

KIN-193

[1173900-33-8]

Purity: 99%
Optically pure
Soluble in DMSO
C22H24N4O4 MW: 408.45




Biological activity

AZD 6482 is a potent and selective inhibitor of the p110 β isoform of PI3K with an IC50 value of 0.69 nM. In addition, AZD 6482 can inhibit the growth of tumors driven by p110 β or PTEN-loss in vivo.

AZD7648

[2230820-11-6]
Purity: 99%

Soluble in DMSO
C18H20N8O2 MW: 380.40




Biological activity

AZD7648 is an orally available potent and selective next generation DNA-dependent protein kinase (DNA-PK) inhibitor with enzymatic and cellular IC50 values of 0.6 nM and 91 nM, respectively.

AZD 7762 hydrochloride

[860352-01-8]

Purity: 99%
>98% ee
Soluble in water and DMSO
C17H19FN4O2S.HCl MW: 398.88



Axon 3042

mg Price

10 online

50 online

Axon 2926

mg Price

5 online

25 online

Axon 4068

mg Price

10 online

50 online

Axon 1399

mg Price

2 online

5 online


Biological activity

Checkpoint kinase (CHK) inhibitor

AZD 8055

[1009298-09-2]

Purity: 99%
optically pure
Soluble in 0.1N HCl(aq) and DMSO
C25H31N5O4 MW: 465.54




Biological activity

Potent and selective mTOR inhibitor, with IC50 values to be 0.8 nM and selectivity ca 1000-fold against class I PI3K and other PIKKs

AZD8186

[1627494-13-6]

Purity: 99%
99% e.e.
Soluble in DMSO
C24H25F2N3O4 MW: 457.47



Biological activity

AZD8186 is a metabolically stable and pharmacologically excellent PI3K β / δ isoform-selective inhibitor. It is orally available, potent and selective. Enantiomerically pure AZD8186 inhibits PI3K β and PI3K δ in cellular assays with IC50 values of 3 nM and 17 nM, respectively, highly selective over PI3K α (IC50 = 752 nM). It has demonstrated a profound pharmacodynamics modulation of p-Akt in PTEN-deficient PC3 prostate tumor bearing mice after oral administration, and showed a complete inhibition of tumor growth in the mouse PTEN-deficient PC3 prostate tumor xenograft model.


Source Information: Sold in collaboration with Chemietek

AZD 8330

[869357-68-6]

Purity: 98%

Soluble in DMSO
C16H17FN3O4 MW: 461.23



Biological activity

Potent, highly specific non-ATP-competitive MEK inhibitor; AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation

AZD8421 Recent Addition

[N.A.]

Purity: 98%
98% e.e.
Soluble in DMSO
C18H32N8O3S MW: 440.57

Axon 1561

mg Price

5 online

25 online

Axon 3690

mg Price

10 online

Axon 1999

mg Price


5 online

25 online

Axon 4265

mg Price

10 online



Biological activity


AZD8421 is an orally bioavailable selective inhibitor of CDK2 (IC50 = 9 nM), highly selective over other CDK inhibitors such as CDK1, CDK4, CDK6 and CDK9.

Source Information: Sold in collaboration with Chemietek

AZD 9291

[1421373-65-0]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C28H33N7O2 MW: 499.61




Biological activity

A potent oral, third-generation EGFR TKI, that irreversibly and selectively targets both sensitizing and resistant T790M+ mutant EGFR while harboring less activity toward wild-type EGFR (IC50 values 1 nM, 12nM, 5 nM, and 184 nM against L858R/T790M-, L858R-, L861Q-mutant, and WT EGFR, respectively).

AZD1656

[919783-22-5]
Purity: 99%
Optically pure
Soluble in DMSO
C24H26N6O5 MW: 478.50




Biological activity

AZD1656 is a potent, selective glucokinase (GK) activator that progressed to Phase IIb trials for the treatment of type 2 diabetes.

AZD2716

[1845753-81-2]
Purity: 99%
98% e.e.
Soluble in 0.1N NaOH (aq) and DMSO
C24H23NO3 MW: 373.44



Biological activity

AZD2716 is a novel, potent sPLA2 inhibitor (IC50 values of 10, 40, and 400 nM for sPLA2-IIa, -V, and -X, respectively) with excellent preclinical pharmacokinetic properties across species, clear in vivo efficacy, and minimized safety risk. When incubated with HepG2 cells, AZD2716 effectively inhibited sPLA2 activity (IC50 value of <14 nM) and suppressed production of sPLA2-IIa (IC50 value of 176 nM). AZD2716 also demonstrated significant sPLA2 activity inhibition (IC50 value of 56 nM) in atherosclerotic plaque homogenates.


AZD6140

See Ticagrelor

AZD6738

Ceralasertib

[1352226-88-0]
Purity: 99%
98% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C20H24N6O2S MW: 412.51




Biological activity

AZD6738 is a potent, selective, orally active and bioavailable ATR kinase inhibitor with an IC50 value of 0.001 μM against the isolated enzyme and 0.074 μM against ATR kinase-dependent CHK1 phosphorylation in cells.

AZD6765 dihydrochloride

Lanicemine dihydrochloride; FPL 15896AR; ARL 15896AR

[153322-06-6]
Purity: 99%
100% e.e.
Soluble in water and DMSO
C13H14N2.2HCl MW: 271.19




Biological activity

AZD6765 dihydrochloride is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with an IC50 value of 1.3 μM.

Azelastine hydrochloride

[79307-93-0]
Purity: 99%

Soluble in water, DMSO and EtOH
C22H24ClN3O.HCl MW: 418.36



Biological activity

Azelastine hydrochloride is a histamine H1 receptor antagonist. Antiallergic agent.

Azepexole


See B-HT 933 dihydrochloride

Azelnidipine

CS-905

[123524-52-7]
Purity: 99%

Soluble in DMSO
C33H34N4O6 MW: 582.65



Axon 3111

Page 927

Axon 3134

mg	Price
5	online
25	online

Axon 3335

mg	Price
10	online
50	online

Axon 3649

mg	Price
50	online

Axon 1154

Page 301

Axon 3160

mg	Price
10	online
50	online


Biological activity

Azelnidipine is a calcium channel blocker that has a gradual and long-lasting antihypertensive action with little tachycardia in vivo (spontaneously hypertensive rat, SHR).

AZ-GHS-22

[1143020-91-0]
Purity: 98%

Soluble in 0.1N HCl (aq) and DMSO
C27H33ClN6O5S2 MW: 621.17



Axon 2340

mg	Price
5	online
25	online

Biological activity

Orally available high affinity Ghrelin receptor (GHS-R1a) inverse agonist (IC50 0.77 nM) with very low CNS exposure.

Azidothymidine

See Zidovudine

Axon 3382


Page 1006

Azilsartan

TAK536; AZL

[147403-03-0]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C25H20N4O5 MW: 456.45



Axon 3363

mg	Price
10	online
50	online


Biological activity

Azilsartan is a potent angiotensin II type 1 (AT1) receptor antagonist with an IC50 value of 2.6 nM.

Azithromycin

CP 62993; Zithromax

[117772-70-0]
Purity: 98%
Optically pure
Soluble in DMSO
C38H72N2O12 MW: 748.98



Axon 2042

mg	Price
10	online
50	online

Biological activity

Macrolide antibiotic; inhibits bacterial protein synthesis through binding to the 50S ribosomal subunit
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

AZL

See Azilsartan

Axon 3363


Page 279

Azoramide

[932986-18-0]

Purity: 99%

Soluble in DMSO
C15H17ClN2OS MW: 308.83



10	online
50	online

Biological activity

Small-molecule modulator of the unfolded protein response (UPR) with antidiabetic activity (IC50 value 8.826 μ M for azoramide-induced increase of ASGR-Cluc secretion in HuH7 cells). Azoramide is a dual-function ER modulator that improves ER protein-folding ability and activates ER chaperone capacity to protect cells against ER stress. Moreover, Azoramide improves insulin sensitivity and pancreatic β -cell function.

AZT

See Zidovudine

Axon 3382

Page 1006

B 9302-107

See Roflumilast

Axon 2352


Page 827

B106

BJE6-106

[1564249-38-2]
Purity: 98%

Soluble in DMSO
C26H23NO2 MW: 381.47



Axon 2981

mg	Price
5	online
25	online


Biological activity

B106 is a potent and selective PKC- δ inhibitor with an IC₅₀ value for PKC- δ of <0.05 μ M and targeted selectivity over classical PKC isozymes (a 1000-fold PKC- δ selectivity over PKC- α). B106 efficiently induced apoptosis in several cell lines.

B591

[1498412-41-1]
Purity: 99%

Soluble in DMSO
C25H24Br2N2O MW: 528.28



Axon 3055

mg	Price
10	online
50	online

Biological activity

B591 is a specific pan-PI3K inhibitor with potent inhibitory activity against class I PI3K isoforms (IC₅₀ values of 1.300, 0.364, 0.107 and 1.580 μ M for PI3K α , PI3K β , PI3K $\beta\gamma$, PI3K δ , respectively), which showed effective inhibition of cellular PI3K/mTOR signaling pathway and robust antitumor activity in a set of cancer cell lines. Cancer stem cells (CSCs) targeting agent.

b-AP15

See NSC 687852

Axon 2228

Page 717

BA-14


See BCP, 1-

Axon 3088

Page 281

BACE-1 Inhibitor

[797035-11-1]
Purity: 98%
optically pure
Soluble in DMSO
C31H38N4O5S MW: 578.72



Axon 1125

mg	Price
2	online
5	online


Biological activity

Potent and selective cell-permeable inhibitor of human β -secretase (BACE-1)

BACE-2 Inhibitor

BACE2 Inhibitor 3I

[1676107-08-6]
Purity: 99%
Optically pure
Soluble in DMSO
C36H38F3N3O3 MW: 617.70



Axon 2957

mg	Price
5	online
25	online

Biological activity

Potent and highly selective human β -secretase 2 (BACE-2) inhibitor with a K_i value of 1.6 nM and >500-fold selectivity over BACE-1.

BACE2 Inhibitor 3I

See BACE-2 Inhibitor

Axon 2957

Page 282

BAF

See Boc-D-FMK

Axon 2158

Page 323

Bafetinib

See INNO 406

Axon 2121


Page 282

BAG 956

NVP-BAG956

[853910-02-8]
Purity: 99%

Soluble in DMSO
C28H21N5 MW: 427.50



Axon 1282

mg	Price
5	online
25	online

Biological activity


Potent, ATP-competitive and selective dual PI3K and PDK1 inhibitor in vitro and in vivo, with IC₅₀ values to be 56, 444, 34, 117 and 240 nM for PI3K p110 α , β , δ and γ and PDK1 kinases, respectively

Balicatib

AAE 581

[354813-19-7]
Purity: 99%

Soluble in DMSO
C23H33N5O2 MW: 411.54



Axon 2154

mg	Price
2	online
5	online

Biological activity

Selective inhibitor of the osteoclastic enzyme cathepsin K


BAM 7

[331244-89-4]
Purity: 98%

Axon 2185

mg	Price
10	online

Soluble in DMSO
C21H19N5O2S MW: 405.47



50 online


Biological activity

Selective small-molecule activator of proapoptotic BAX (IC50 value 3.3 μM) that binds to the BH3 binding domain without interacting with other BH3-binding pockets of antiapoptotic proteins or proapoptotic BAK. BAM 7 triggers in vitro BAX oligomerization, BAX-mediated pore formation and BAX-dependent cell death.

BAM15

[210302-17-3]
Purity: 99%

Soluble in DMSO
C16H10F2N6O MW: 340.29



Axon 2736

mg Price

10 online

50 online


Biological activity

BAM15 is a mitochondrial protonophore uncoupler, which does not depolarize the plasma membrane. Compared to FCCP, an uncoupler of equal potency, BAM15 treatment of cultured cells stimulates a higher maximum rate of mitochondrial respiration and is less cytotoxic. Furthermore, BAM15 is bioactive in vivo and dose-dependently protects mice from acute renal ischemic-reperfusion injury.

BAMB-4

[891025-25-5]
Purity: 99%

Soluble in DMSO
C15H12N2O2 MW: 252.27



Axon 3357

mg Price

10 online

50 online


Biological activity

BAMB-4 is a specific, membrane permeable inhibitor against the InsP3Kinase activity of inositol-1,4,5-trisphosphate-3-kinase A (ITPKA) with an IC50 value of 20 μM.

Bambuterol hydrochloride Recent Addition

[81732-46-9]
Purity: 98%

Soluble in water, DMSO and H2O
C18H29N3O5.HCl MW: 403.90



Axon 4204

mg Price


50 online

Biological activity

Bambuterol hydrochloride is a long acting, orally active β2 adrenoceptor agonist prodrug.

BAN ORL 24

[475150-69-7]
Purity: 99%
optically pure
Soluble in water, DMSO, and Ethanol
C27H35N3O2.2HCl MW: 506.51



Axon 1784

mg Price

5 online

25 online


Biological activity

Highly potent and selective NOP receptor antagonist (IC50: 0.27 nM); more than 2500 fold selective over other opioid receptors

Barbadin

[356568-70-2]
Purity: 99%

Soluble in DMSO
C19H15N3OS MW: 333.41



Axon 2774

mg Price

10 online

50 online

Biological activity

Selective β-arrestin/β2-adaptin interaction inhibitor (IC50 values of 19.1 and 15.6 μM for β-arrestin1 and β-arrestin2, respectively). Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors, but does not affect β-arrestin-independent (transferrin) or AP2-independent (endothelin-A) receptor internalization.

Bardoxolone

See CDDO

Axon 1950

Page 354

Bardoxolone methyl

See CDDO-Me

Axon 1772


Page 354

Baricitinib

INCB 028050, LY 3009104

[1187594-09-7]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C16H17N7O2S MW: 371.42



Axon 1955

mg Price

5 online

25 online


Biological activity

Selective and orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM); INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM

Barnidipine hydrochloride

YM 09730-5; Mepirodipine hydrochloride

[104757-53-1]
Purity: 99%
Optically pure
Soluble in DMSO
C27H29N3O6.HCl MW: 528.00



Axon 3014

mg Price

10 online

50 online

Biological activity

Barnidipine hydrochloride is a potent calcium antagonist with a Ki value of 0.205 nM. Barnidipine hydrochloride produces its antihypertensive effect by selective blockade of calcium ion influx via the L-subtype 'voltage-operated' channels in the excitable membranes of vascular smooth muscle cells, as a result of interaction with specific L-type calcium channel receptors.

Batoprotafib

See TNO155

Axon 3865

Page 934

Bavisant Recent Addition

JNJ31001074


[929622-08-2]

Purity: 99%

98% e.e.

Soluble in water, 0.1N HCl(aq), DMSO and EtOH

C19H27N3O2 MW: 329.44



Axon 4233

mg	Price
10	online
50	online

Biological activity

Bavisant is a potent, high affinity, orally active and brain-penetrant histamine H3 receptor antagonist with a Ki value of 5.4 nM.


BAY-0069

[420826-65-9]

Purity: 99%

Soluble in DMSO and EtOH

C22H16BrN3O4 MW: 466.28



Axon 3904

mg	Price
10	online
50	online

Biological activity

BAY-0069 is a potent covalent PPAR γ inverse-agonist with an IC50 value of 0.22 nM.

BAY-091


[N.A.]

Purity: 98%

98% e.e.

Soluble in DMSO and EtOH

C26H21FN4O2 MW: 440.47



Axon 3778

mg	Price
5	online
25	online

Biological activity

BAY-091 is a potent and highly selective PIP4K2A inhibitor with an IC50 value of 16 nM (high ATP PIP4K2A HTRF assay). The hydrochloride salt form is available as Axon 3598. The hydrochloride salt form, BAY-091 hydrochloride (Axon 3598) is also available.

BAY-091 hydrochloride


[N.A.]

Purity: 98%

99% e.e.

Soluble in DMSO

C26H21FN4O2.HCl MW: 476.93



Axon 3598

mg	Price
5	online
25	online

Biological activity

BAY-091 hydrochloride is a potent and highly selective PIP4K2A inhibitor with an IC50 value of 16 nM (high ATP PIP4K2A HTRF assay). The free base BAY-091 is available as Axon 3778.

BAY 1021189

See Vericiguat

Axon 3558

Page 966

BAY-1082439


[1375469-38-7]

Purity: 99%

99% e.e.

Soluble in DMSO

C25H30N6O5 MW: 494.54



Axon 3942

mg	Price
5	online
10	online

Biological activity

BAY-1082439 is an oral, highly selective and balanced PI3K α/β inhibitor, with IC50 values of 4.9 nM and 15 nM for PI3K α and PI3K β isoforms respectively, and >1000-fold selectivity against mTOR kinase. BAY-1082439 demonstrated potent activity in tumors with activated PI3K α and loss-of-function of PTEN. In vivo, it also showed clear advantages over the strong PI3K α inhibitor BAY80-6946 (Copanlisib) in PTEN/PI3K β -driven tumor models. BAY-1082439 represents a new type of PI3K inhibitor with unique pharmacological and pharmacodynamic properties to be further explored.

Source Information: Sold in collaboration with Chemietek

BAY-1251152


Enitociclib; VIP-152

[1610358-53-6]

Purity: 99%

Soluble in DMSO

C19H18F2N4O2S MW: 404.43



Axon 3935

mg	Price
5	online
10	online

Biological activity

BAY-1251152 is the next-generation, potent and highly selective CDK9/P-TEFb inhibitor. In comparison to BAY-1143572 (the first oral CDK9/P-TEFb inhibitor), BAY-1251152 shows significantly increased biochemical (IC50 CDK9 = 3 nM) and cellular potency (IC50 MOLM13 = 29 nM), and an increased selectivity against CDK2 as well as high permeability and no efflux. The significantly reduced therapeutic dosage and high solubility of BAY-1251152 enable the desired i.v. application. It demonstrated excellent in vivo efficacy upon i.v. treatment in xenograft models (e.g. MOLM13) in mice and rats. Cyclin-dependent kinase 9 (CDK9), a subunit of the positive transcription elongation factor b (P-TEFb) complex, regulates gene transcription elongation by phosphorylating the carboxy-terminal domain (CTD) of RNA polymerase II (RNAPII). The deregulation of CDK9/P-TEFb has implicated in many cancer types.

Source Information: Sold in collaboration with Chemietek


BAY 1316957

[1613264-40-6]

Purity: 98%

Soluble in DMSO

C27H27N3O3 MW: 441.52



Axon 3073


mg	Price
5	online

Biological activity

BAY 1316957 is a highly potent, specific, and selective hEP4-R antagonist (IC50 value of 15.3 nM) with excellent drug metabolism and pharmacokinetics properties.

BAY-1436032

[1803274-65-8]
Purity: 99%
99% e.e.
Soluble in DMSO
C26H30F3N3O3 MW: 489.53



Axon 3863

mg	Price
5	online
10	online


Biological activity

BAY-1436032 is a highly selective, potent and orally available inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1). Optically pure BAY-1436032 is a double-digit nanomolar and selective pan-inhibitor of the enzymatic activity of various IDH1-R132X mutants in vitro and displayed potent inhibition of "oncometabolite" 2-hydroxyglutarate (2-HG) release (nM range) in patient derived and engineered cell lines expressing different IDH1 mutants. In line with the proposed mode of action, a concentration-dependent lowering of 2HG was observed in vitro accompanied by differentiation of maturation of mIDH1 tumor cells. It also showed a favorable selective profile against wildIDH1/2 and a large panel of off-target proteins. Demonstrated a single agent in vivo efficacy in mIDH1 patient derived glioma and intrahepatic cholangiocarcinoma solid tumor model. It is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. BBB penetrant.

Source Information: Sold in collaboration with Chemietek

BAY-179

[2764880-87-5]
Purity: 99%
Soluble in DMSO
C23H21N5OS MW: 415.51



Axon 3638


mg	Price
5	online
25	online

Biological activity

BAY-179 is a potent, selective, and species cross-reactive complex I inhibitor with an IC50 value of 79 nM.

BAY-1797

[2055602-83-8]
Purity: 98%
Soluble in DMSO and EtOH
C20H17ClN2O4S MW: 416.88



Axon 3845


mg	Price
10	online
50	online

Biological activity

BAY-1797 is a potent and selective P2X4 inhibitor with an IC50 value of 211 nM (human P2X4 HEK cells). Anti-inflammatory and anti-nociceptive effects of BAY-1797 were demonstrated in mouse CFA inflammatory pain models.

BAY-1816032

[1891087-61-8]
Purity: 99%
Soluble in DMSO
C27H24F2N6O4 MW: 534.51



Axon 3832

mg	Price
5	online
10	online


Biological activity

BAY-1816032 is an orally available, highly potent and selective BUB1 (Mitotic checkpoint serine/threonine-protein kinase) inhibitor, with an enzymatic IC50 of 7 nM, and highly selective against other 395 kinases. Mechanistically BAY 1816032 abrogated nocodazole-induced Thr-120 phosphorylation of the major BUB1 target protein histone H2A in HeLa cells with an IC50 of 29 nM, induced lagging chromosomes and mitotic delay (ref 1). Demonstrated in vitro and in vivo antitumor efficacy when applied in combination with taxanes.

Source Information: Sold in collaboration with Chemietek

BAY 1895344

[1876467-74-1]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C20H21N7O MW: 375.47



Axon 2918

mg	Price
5	online
25	online


Biological activity

BAY 1895344 is a potent, highly selective and orally available ATR inhibitor (IC50 value of 7 nM), which potently inhibits proliferation of a broad spectrum of human tumor cell lines (median IC50 value of 78 nM). BAY 1895344 exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models of different indications that are characterized by DDR deficiencies, inducing stable disease in ovarian and colorectal cancer or even complete tumor remission in mantle cell lymphoma models.

BAY 11-7082

BAY 11-7821

[19542-67-7]
Purity: 99%



Soluble in DMSO
C10H9NO2S MW: 207.25

Axon 2132

mg	Price
10	online
50	online

Biological activity

IKK inhibitor and broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. BAY strongly suppressed the production of nitric oxide, prostaglandin E2, and TNF- α and reduced the translocation of p65, major subunit of nuclear factor- κ B, and its upstream signaling events such as phosphorylation of I κ B α , IKK, and Akt. In addition, BAY also inhibits the phosphorylation or activation of extracellular signal-related kinase, p38, TANK-binding protein, and JAK-2.

BAY 11-7821

See BAY 11-7082

Axon 2132

Page 286

BAY 12-8039

See Moxifloxacin hydrochloride

Axon 3306


Page 677

BAY 19-8004

Lirimilast

[329306-27-6]
Purity: 97.0%

Soluble in DMSO
C17H12Cl2N2O6S MW: 443.26



Axon 1178

mg	Price
5	online
25	online

Biological activity

Selective inhibitor of phosphodiesterase-4 (PDE4)

BAY2502


See Nifurtimox

Axon 3391

Page 703

BAY 2686013 hydrochloride Recent Addition

[3058853-08-7]
Purity: 99%
98% e.e.
Soluble in DMSO
C17H14F6N2O2.HCl MW: 428.76



Axon 4104

mg Price

5 online


25 online

Biological activity

BAY 2686013 hydrochloride is a potent and selective allosteric hPAC1 receptor antagonist with IC50 values of 0.92 μM and 0.40 μM for cAMP HTRF and Ca2+ release assays, respectively.

BAY-293

[2244904-70-7]
Purity: 98%
100% e.e.
Soluble in DMSO
C25H28N4O2S MW: 448.58



Axon 3053

mg Price

5 online

25 online

Biological activity

BAY-293 is a potent, selective and cell-active inhibitor of KRAS-SOS1 interaction with an IC50 value of 21 nM. BAY-293 efficiently inhibited pERK levels in K-562 cells after incubation for 60 min without affecting total protein levels of ERK. A synergistic effect is observed between BAY-293 and ARS-853 in a KRASG12C-mutated cancer cell line.

BAY 38-9456

See Vardenafil dihydrochloride

Axon 3396

Page 962

BAY 43-9006

See Sorafenib tosylate

Axon 1397

Page 879

BAY 43-9006


See Sorafenib

Axon 3351

Page 879

BAY-4931

[423150-91-8]
Purity: 100%
Soluble in DMSO and EtOH
C22H16ClN3O4 MW: 421.83



Axon 3809

mg Price

10 online

50 online

Biological activity


BAY-4931 is a potent covalent PPARγ inverse-agonist with an IC50 value of 0.17 nM.

BAY 57-1293

Pritelivir; AIC 316

[348086-71-5]
Purity: 99%

Soluble in DMSO
C18H18N4O3S2 MW: 402.49



Axon 2266

mg Price

5 online

25 online

Biological activity


Potent helicase-primase inhibitor (HPI) effective against herpes simplex virus (HSV) infections with IC50 value of 20 nM for inhibition of the replication of both HSV-1 and HSV-2 in Vero cells, and ED50 value of 0.5 mg/kg for both HSV-1 and HSV-2 in the murine lethal challenge model of disseminated herpes. BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections, and is active also against acyclovir-resistant mutant strains which carry mutations in the tk or DNA pol genes.

BAY 58-2667 hydrochloride

Cinaciguat hydrochloride

[646995-35-9]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C36H39NO5.HCl MW: 602.16



Axon 2172

mg Price

5 online

25 online

Biological activity

Potent nitric oxide (NO)-independent soluble guanylyl cyclase (sGC) activator with haemodynamic effect similar to that of nitroglycerin (Ki value 6-8 nM in competition binding studies). Acts specifically on oxidized/haem-free sGC by binding to the enzyme's haem pocket and mimicking the nitric-oxide-bound haem group. BAY 58-2667 is in clinical development for the treatment of acute decompensated heart failure (ADHF).

BAY 59-7939


See Rivaroxaban

Axon 3175

Page 821

BAY-598

[1906919-67-2]
Purity: 98%
99% e.e.
Soluble in DMSO
C22H20Cl2F2N6O3 MW: 525.34



Axon 2635

mg Price

2 online

5 online

Biological activity

BAY-598 is a potent, selective, and cell-active, substrate-competitive inhibitor of SMYD2 (IC50 values of 27 nM and 58 nM for biochemical and cellular activity, respectively). BAY-598 also shows PAR1 antagonism, but there is a greater than 50-fold selectivity for SMYD2 relative to PAR1.

BAY 60-6583

BR 4887; BAY 60


[910487-58-0]
Purity: 99%

Axon 2317

mg Price

10 online

Soluble in DMSO
C19H17N5O2S MW: 379.44




50 online

Biological activity

Potent and highly selective A2BAR (Adenosine) agonist (K_i value 0.33-0.75 nM, species dependent). BAY 60-6583 potently stimulated cAMP production in HEK 293 cells expressing mouse A2BARs (EC_{50} value 2.83 nM), and BAY 60-6583 produced a biphasic effect on fMLP-stimulated superoxide production.

BAY-678

[675103-36-3]
Purity: 99%
99% ee
Soluble in DMSO
C20H15F3N4O2 MW: 400.35



Axon 2822

mg	Price
10	online
50	online

Biological activity

BAY-678 is a potent, selective and orally active human neutrophil elastase (HNE) inhibitor (IC_{50} value of 20 nM).

BAY 73-4506

See Regorafenib

Axon 1678

Page 811

BAY 869766


See RDEA119

Axon 3874

Page 810

BAY-876

[1799753-63-1]
Purity: 99%
Soluble in DMSO
C24H16F4N6O2 MW: 496.42



Axon 2660

mg	Price
5	online
25	online

Biological activity

BAY-876 is a highly selective GLUT1 inhibitor (IC_{50} value 2 nM). In vitro PK data showed that BAY-876 was very stable in liver microsomes and hepatocytes; preliminary in vivo PK studies demonstrated a good oral bioavailability and long terminal half-life.

BAY b 5097

See Clotrimazole

Axon 3163


Page 377

BAY K 8644

BAY K 8644, (\pm)-

[71145-03-4]
Purity: 98%

Soluble in DMSO and Ethanol
C16H15F3N2O4 MW: 356.30



Axon 1697

mg	Price
10	online
50	online

Biological activity

A L-type calcium channel activator that facilitates Ca^{2+} influx specifically at voltage-gated Ca^{2+} channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool. Bay-K8644 in combination of BIX-01294 (Axon 1692) enables reprogramming of Oct4/Klf4-transduced mouse embryonic fibroblasts

BAY K 8644, (\pm)-

See BAY K 8644

Axon 1697

Page 292

BAY K8644, (-)-

See BAY K 8644, (S)-(-)-

Axon 1759

Page 292

BAY K8644, (+)-

See BAY K 8644, (R)-(+)-

Axon 1758


Page 292

BAY K 8644, (R)-(+)-

BAY K8644, (+)-

[98791-67-4]

Purity: 100%
99% ee
Soluble in DMSO and Ethanol
C16H15F3N2O4 MW: 356.30



Axon 1758

mg	Price
5	online
25	online

Biological activity


L-type Ca^{2+} -channel blocker with negative inotropic and vasodilatory effects in vivo; (R)-Enantiomer showing opposite effects to the racemate (\pm)-Bay K8644 (Axon 1697) and (S)-(-)-Bay K8644 (Axon 1759)

BAY K 8644, (S)-(-)-

BAY K8644, (-)-

[98625-26-4]

Purity: 99%
99% ee
Soluble in DMSO and Ethanol
C16H15F3N2O4 MW: 356.30



Axon 1759

mg	Price
5	online
25	online

Biological activity

L-type Ca^{2+} -channel activator with positive inotropic, vasoconstrictive and behavioral effects in vivo. (S)-Enantiomer of Bay K8644 (Axon 1697)

Bazedoxifene acetate

See TSE 424

Axon 2051


Page 941

Bazedoxifene hydrochloride

WAY 140424; TSE 424 Hydrochloride

[198480-56-7]
Purity: 98%

Soluble in DMSO
C30H34N2O3.HCl MW: 507.06



Axon 1748

mg	Price
5	online
25	online

Biological activity

Third generation selective estrogen receptor modulator (SERM)

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

BBD 130

See NVP-BBD130

Axon 1520

Page 722

BBI 608

See Napabucasin


Axon 2517

Page 692

BC-1215

[1507370-20-8]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C26H26N4 MW: 394.51



Axon 3898

mg	Price
10	online
50	online


Biological activity

BC-1215 is a selective and reversible Fbxo3 inhibitor. BC-1215 reduced TRAF protein levels, which potently inhibited cytokine release from human blood mononuclear cells. BC-1215 effectively lessened the severity of viral pneumonia, septic shock, colitis, and cytokine-driven inflammation systemically in murine models.

BC1618

[2222094-18-8]
Purity: 99%

Soluble in DMSO and EtOH
C24H24F3NO2 MW: 415.45



Axon 3211

mg	Price
10	online
50	online

Biological activity

BC1618 is a potent, orally bioavailable, and metabolically stable Fbxo48 inhibitor and Ampk activator. Specifically, BC1618 increases the biological activity of Ampk not by stimulating the activation of Ampk, but rather by preventing activated pAmpka from Fbxo48-mediated degradation. BC1618 promotes mitochondrial fission, facilitates autophagy, and improves hepatic insulin sensitivity in high fat diet-induced obese mice.

BCH189, (-)-

See Lamivudine


Axon 3304

Page 604

BChE inhibitor 8012-9656

[446266-84-8]
Purity: 98%

Soluble in DMSO
C21H17N7O2 MW: 399.41



Biological activity

BChE inhibitor 8012-9656 is a highly potent, selective and brain-penetrant inhibitor of butyrylcholinesterase with IC50 values of 0.18 and 0.32 μM for eqBChE and hBChE, respectively. BChE in a noncompetitive manner and could occupy the binding pocket forming diverse interactions with the target.

Axon 3297


mg	Price
5	online
25	online

BCI

NSC 150117

[1245792-51-1]
Purity: 99%

Soluble in DMSO
C22H23NO MW: 317.42



Biological activity

Allosteric inhibitor of dual-specificity phosphatases (DUSP). BCI treatment of Dusp6-Myc-transfected cells blocks DUSP6 or DUSP1 activity, but not Dusp5 (IC50 values 12.3 μM and 11.5 μM for DUSP6 and DUSP1 inhibition, resp.). BCI mediated DUSP6 inhibition can induce expansion of myocardial progenitors that ultimately increases heart size in zebrafish embryos. BCI also inhibits lung cancer and uveal melanoma cells viability (IC50 values ranging from 0.1 to 90 μM).

Axon 2178


mg	Price
10	online
50	online

BCI hydrochloride

NSC 150117 hydrochloride

[95130-23-7]
Purity: 100%

Soluble in DMSO
C22H23NO.HCl MW: 353.89



Biological activity

Allosteric inhibitor of dual-specificity phosphatases (DUSP). BCI treatment of DUSP6-Myc-transfected cells blocks DUSP6 or DUSP1 activity, but not DUSP5 (IC50 values 12.3 μM and 11.5 μM for DUSP6 and DUSP1 inhibition, resp.). BCI mediated DUSP6 inhibition can induce expansion of myocardial progenitors that ultimately increases heart size in zebrafish embryos. BCI also inhibits lung cancer and uveal melanoma cells viability (IC50 values ranging from 0.1 to 90 μM). The dual-specificity phosphatase 6 (DUSP6) functions a feedback regulator of fibroblast growth factor (FGF) signaling to limit the activity of extracellular signal-regulated kinases (ERKs) 1 and 2.

The free base BCI is also available as Axon 2178.


Axon 2852

mg	Price
10	online
50	online

BCI-121

[432529-82-3]
Purity: 99%

Soluble in DMSO
C14H18BrN3O2 MW: 340.22



Biological activity

Axon 2735


mg	Price
10	online
50	online

BCI-121 induces a significant reduction in SMYD3 activity both in vitro and in CRC cells, as suggested by the analysis of global H3K4me2/3 and H4K5me levels. Moreover, BCI-121 inhibits chromatin recruitment and is effective in reducing proliferation in various cancer cell types.

BCL-201 dihydrochloride

S55746 dihydrochloride

[N.A.]
Purity: 99%
99% e.e.
Soluble in DMSO
C43H42N4O6.2HCl MW: 783.74



Axon 3714

mg	Price
5	online
10	online

Biological activity


BCL-201 (S55746, Servier-1) is an orally bioavailable, potent and selective BH3-mimetic inhibitor of BCL-2 protein with a K_i of 1.3 nM, highly selective over BCL-XL (70- 400 fold), and no significant binding to MCL-1 and BFL-1 (BCL2A1/A1). BCL-201 induces hallmarks of apoptosis including externalization of phosphatidylserine, caspase-3 activation and PARP cleavage. Ex vivo, it induces apoptosis in the low nanomolar range in primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples. Finally, BCL-201 (S55746) administered by oral route daily in mice demonstrated robust anti-tumor efficacy in two hematological xenograft models with no weight lost and no change in behavior.

Source Information: Sold in collaboration with Chemietek

BC-LI-0186

[695207-56-8]
Purity: 99%

Soluble in DMSO
C22H27N3O4S MW: 429.53



Axon 3108

mg	Price
10	online
50	online

Biological activity


BC-LI-0186 is a specific inhibitor of the interaction between Leucyl-tRNA synthetase (LRS) and RagD (IC50 of 46.11 nM). BC-LI-0186 bound to LRS with a K_d value of 42.1 nM. BC-LI-0186 efficiently inhibited leucine-dependent mTORC1 activity and the growth of cancer cells that express drug-resistant MTOR mutations.

BCP, 1-

BA-14

[34023-62-6]
Purity: 99%

Soluble in water and DMSO
C13H15NO3 MW: 233.26



Axon 3088

mg	Price
10	online
50	online

Biological activity

1-BCP is a centrally active modulator of the AMPA receptor. 1-BCP rapidly crosses the blood-brain barrier and enhances monosynaptic responses in the hippocampus of freely moving rats.


BD 1047 dihydrobromide

[138356-21-5]

Axon 1215

mg	Price
----	-------

Purity: 99%
Soluble in water
C13H20Cl2N2.2HBr MW: 437.04



10	online
50	online


Biological activity

Sigma-1 receptor antagonist

BD 1063 dihydrochloride

[206996-13-6]
Purity: 100%

Soluble in water and DMSO
C13H18Cl2N2.2HCl MW: 346.12



Axon 2088

mg	Price
10	online
50	online

Biological activity

Potent and selective sigma-1 (σ -1) receptor antagonist ($K_i=9$ nM); about 50-fold more selective for sigma-1 over sigma-2 and >100-fold more selective over 9 other tested neurotransmitter receptors; shown to antagonize cocaine effects

BDP-12

See CX516

Axon 3089


Page 296

BEC hydrochloride

S-(2-Boronoethyl)-L-cysteine hydrochloride

[222638-67-7]
Purity: 99%

Soluble in water and DMSO
C5H12BNO4S.HCl MW: 229.49




mg	Price
5	online
25	online

Biological activity

Slow-binding pH-dependent inhibitor of human Arginase I and II (K_d value 270 nM and 220 nM for Arginase I and II, respectively. K_i values 310 nM and 30 nM at pH 7.5 and pH 9.5, respectively for Arginase II). Valuable reagent to probe the physiological relationship between arginase and nitric oxide (NO) synthase in regulating the NO-dependent smooth muscle relaxation in human penile corpus cavernosum tissue. BEC does not inhibit NO synthase, and effectively prevented ACh tolerance in aortic and mesenteric artery preparations.

Beclomethasone dipropionate

[5534-09-8]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C28H37ClO7 MW: 521.04



Axon 3882

mg	Price
50	online


Biological activity

Beclomethasone dipropionate is an inhaled glucocorticoid used for maintenance treatment of asthma. Beclomethasone dipropionate is a prodrug activated in lung when hydrolyzed to its major active metabolite beclomethasone-17-monopropionate.

Begacestat

GSI 953

[769169-27-9]
Purity: 99%
Optically pure
Soluble in DMSO
C9H8ClF6NO3S2 MW: 391.74



Axon 2117

mg	Price
5	online
25	online

Biological activity


Potent and selective γ -secretase inhibitor (gamma secretase inhibitor, GSI); Capable of reducing both A β 40 and A β 42 production in a cell line stably expressing human recombinant APP (EC50 values of 14.8 and 12.4 nM for A β 40 and A β 42 respectively). Begacestat was found to have >16-fold selectivity in vitro for the inhibition of APP processing over Notch

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Belzutifan

PT2977; MK-6482

[1672668-24-4]
Purity: 99%
100% e.e.
Soluble in DMSO
C17H12F3NO4S MW: 383.34



Axon 3760

mg	Price
5	online
25	online

Biological activity


Belzutifan is a second-generation potent, selective and orally active HIF-2 α inhibitor with an IC50 value of 0.009 μ M.

Belinostat

PXD101

[866323-14-0]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C15H14N2O4S MW: 318.35



Axon 3115

mg	Price
10	online
50	online

Biological activity

Belinostat is an inhibitor of histone deacetylase activity that inhibits histone deacetylase activity in HeLa cell extracts with an IC50 value of 27 nM and induces a concentration-dependent (0.2–5 μ M) increase in acetylation of histone H4 in tumor cell lines. Belinostat is cytotoxic in vitro in a number of tumor cell lines with IC50 values in the range 0.2–3.4 μ M as determined by a clonogenic assay and induces apoptosis.

Belnacasan

See VX-765

Axon 3857

Page 980

Belumosudil

See KD025

Axon 2780


Page 589

Belvarafenib

GDC-5573; HM95573

[1446113-23-0]
Purity: 99%

Soluble in DMSO
C23H16ClF6N6O3 MW: 478.93



Axon 3067

mg	Price
5	online
25	online

Biological activity


Belvarafenib is an oral type II pan-RAF kinase inhibitor.

Benidipine hydrochloride

KW-3049

[91599-74-5]
Purity: 99%

Soluble in DMSO
C28H31N3O6.HCl MW: 542.02



Axon 3131

mg	Price
50	online
250	online

Biological activity

Dihydropyridine vasoselective long acting calcium channel blocker. Antihypertensive agent.

Bentamapimod

See AS 602801

Axon 2002

Page 252

Betanis

See Mirabegron

Axon 2414


Page 657

Bethanechol chloride

Carbamyl- β -methylcholine chloride

[590-63-6]
Purity: 98%

Soluble in water, DMSO and EtOH
C7H17ClN2O2 MW: 196.68



Axon 3513

mg	Price
50	online

Biological activity


Bethanechol chloride is a direct-acting muscarinic receptor agonist.

BETP

Compound B

[1371569-69-5]
Purity: 99%

Soluble in DMSO
C20H17F3N2O2S MW: 406.42



Axon 2259

mg	Price
10	online
50	online

Biological activity


Positive allosteric modulator (PAM) at the glucagon-like peptide 1 receptor (GLP-1; EC50 value 0.66 μ M) with good selectivity over GLP-2, GIP, PTH, and glucagon receptors. BETP has a significant effect on cAMP accumulation, i Ca $^{2+}$ mobilization, and β -arrestin1 and β -arrestin2 recruitment in Flp-In-CHO cells stably expressing the human GLP-1R (pEC50 values 5.2, 5, 5.0, and 5.0, respectively). BETP induced glucose-dependent insulin secretion in vitro and in vivo, and increased calcium influx in CHO cells expressing GLP-1R.

Bexarotene

SR 11247; Targretin

[153559-49-0]
Purity: 99%

Soluble in DMSO
C24H28O2 MW: 348.48



Axon 1700

mg	Price
10	online
50	online

Biological activity

Selective agonist for retinoid X receptors (RXR); An oral antineoplastic agent indicated for cutaneous T cell lymphoma (CTCL)

Bextra


See Valdecoxib

BEZ 235

NVP-BEZ235

[915019-65-7]
Purity: 99%

Moderately soluble in DMSO
C30H23N5O MW: 469.54



Axon 2106

Page 960

Axon 1281

mg	Price
5	online
10	online

Biological activity

Orally active PI3K tyrosine kinase inhibitor; Dual PI3K/mTOR inhibition; BEZ235 showed high target specificity and demonstrated antiproliferative activity against tumor cell lines in animal models of cancer


BF 5

See BFF 122

BFF 122

BF 5

[1152314-49-2]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C17H19FN4O4 MW: 362.36



Axon 2237

Page 299

Axon 2237

mg	Price
5	online
25	online

Biological activity

Potent and selective inhibitor of kynurenine aminotransferase II (IC50 values ca. 1 μ M and >30 μ M for KAT II and KAT I respectively). Intrastriatal BFF 122 decreased newly formed KYNA by 66%, without influencing 3-HK or QUIN production in naive rats.


BG45

Axon 3397

mg	Price
----	-------

[926259-99-6]
Purity: 99%

Soluble in DMSO
C11H10N4O MW: 214.22



10 online

50 online

Biological activity


BG45 is a HDAC class I inhibitor which preferentially inhibits HDAC3 (IC50 value of 0.289 μ M), but also inhibits HDAC1 and HDAC2 with IC50 values of 2 μ M and 2.2 μ M, respectively.

BGB-283

Lifirafenib

[1446090-77-2]
Purity: 99%
99% e.e.

Soluble in DMSO
C25H17F3N4O3 MW: 478.42



Axon 3862

mg	Price
5	online
10	online

Biological activity

BGB-283 is an orally available dual RAF kinase/EGFR inhibitor. It potently inhibits BRAF family proteins (wild-type ARAF, BRAF, CRAF and BRAF V600E), BRAF(V600E)-activated ERK phosphorylation and cell proliferation, and demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAF(V600E) and EGFR mutation/amplification. Further, it uniquely displays inhibitory activity towards both BRAF monomeric and dimeric forms, and is considered to be the next generation inhibitor to potentially address resistances associated with increased BRAF dimer formation in response to treatment with first-generation BRAF inhibitors.

Source Information: Sold in collaboration with Chemietek

BGJ 398

See NVP-BGJ398

Axon 1775

Page 722

BGT 226

See NVP-BGT226

Axon 2029


Page 723

BH31 1

BHI 1

[300817-68-9]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C15H14BrNO3S2 MW: 400.31



Axon 1828

mg	Price
10	online
50	online

Biological activity

Cell permeable antitumor agent targeting Bcl-2 family protein, more specifically as Bcl-xL antagonist; apoptosis inducer, inducing a dose- and time-dependent apoptosis in H460 and H1792 cells

BHG 712

See NVP-BHG712

Axon 1829

Page 723

BHI 1

See BH31-1


Axon 1828

Page 300

BHPI

[56632-39-4]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C21H17NO3 MW: 331.36



Axon 2790

mg	Price
10	online
50	online

Biological activity


BHPI is a potent noncompetitive ER α inhibitor that selectively blocks proliferation of drug-resistant ER α -positive breast and ovarian cancer cells (IC₅₀ values of 27 and 15 nM in MDA-468 and T47D cell lines, respectively). Moreover, BHPI induced rapid and substantial tumor regression in a mouse xenograft model of breast cancer.

B-HT 920 dihydrochloride

Talipexole

[36085-73-1]
Purity: 99%

Soluble in water and DMSO
C10H15N3S.2HCl MW: 282.23



Axon 1153

mg	Price
10	online
50	online

Biological activity


Dopamine D₂ receptor agonist, α 2-adrenoceptor agonist and 5-HT₃ receptor antagonist

B-HT 933 dihydrochloride

Azepexole

[36067-72-8]
Purity: 98%

Soluble in water and DMSO
C9H15N3O.2HCl MW: 254.16



Axon 1154

mg	Price
10	online
50	online


Biological activity

Selective α 2-adrenoceptor agonist

B-HT 958 dihydrochloride

[36085-44-6]
Purity: 99%

Soluble in water
C14H16ClN3S.2HCl MW: 366.74



Axon 1337

mg	Price
10	online
50	online

Biological activity

Dopamine D₂ receptor agonist, α 2-adrenoceptor partial agonist


BI 01383298

[2227549-00-8]
Purity: 99%

Soluble in DMSO
C19H19Cl2FN2O3S MW: 445.34

Axon 2976

mg	Price
10	online
50	online



Biological activity

BI 01383298 is a potent and selective inhibitor of SLC13A5 with an apparent IC₅₀ value of 56 nM in HEK cells overexpressing SLC13A5 and 24nM in HepG2 cell expressing endogenous SLC13A5. BI 01383298 is more than 1000-fold selective over the closest family members: human SLC13A2/SLC13A3 that share physiological substrates citrate and succinate; chemical probe developed by SGC.

BI10773

See Empagliflozin

Axon 3367

Page 457

BI 1356

See Linagliptin

Axon 2354

Page 615

BI 1482694

See Olmutinib

Axon 4144

Page 732


BI 2536

[755038-02-9]

Purity: 99%

>99% ee

Moderately soluble in DMSO
C28H39N7O3 MW: 521.65



Biological activity

Potent and selective polo-like kinase (PLK) 1 inhibitor

Axon 1129

mg	Price
2	online
5	online


BI 2536, (S)- Recent Addition

[1241725-90-5]

Purity: 99%

100% e.e.

Soluble in DMSO and EtOH
C28H39N7O3 MW: 521.65



Biological activity

(S)-BI 2536 is a dual PLK1 kinase/BRD4 bromodomain inhibitor with K_i values of 0.42 nM and 54 nM for PLK1 and BRD4, respectively. (S)-BI 2536 is the less active enantiomer of BI 2536 (Axon 1129, R-enantiomer).

Axon 4192

mg	Price
10	online
50	online

BI-3406

[2230836-55-0]


Purity: 99%

99% d.e.

Soluble in DMSO
C23H25F3N4O3 MW: 462.46

Axon 3471

mg	Price
5	online
25	online



Biological activity


BI-3406 is an orally bioavailable, highly potent and selective KRAS/Son of Sevenless 1 (SOS1) interaction inhibitor (IC₅₀ = 6 nM), binding to the catalytic domain of the guanine nucleotide exchange factor (GEF) SOS1 thereby preventing the interaction with KRAS-GDP. BI-3406 does not block the interaction of KRAS with SOS2 but elicits activity on a broad panel of KRAS oncogenic variants, including all major G12 and G13 oncoproteins. In KRAS-dependent cancers, BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling both in vitro and in vivo. Down-modulation of this signaling cascade by BI-3406 in KRAS G12 or G13 mutant cells effectively limits cell proliferation. As a monotherapy, BI-3406 modulates signaling, as assessed by p-ERK and target genes, and displays marked anti-tumor efficacy in KRAS mutant xenografts.

Source Information: Sold in collaboration with Chemietek

BI-3802

[2166387-65-9]
Purity: 99%

Soluble in DMSO
C24H29ClN6O3 MW: 484.98



Biological activity

BI-3802 is a highly potent and efficacious BCL6 degrader probe compound (IC₅₀ value of ≤ 3 nM) which binds the BTB domain of the oncogenic transcription factor BCL6 and results in proteasomal degradation.


BI425809

See Iclepertin **Recent Addition**

BI 6015

[93987-29-2]
Purity: 99%

Soluble in DMSO
C15H13N3O4S MW: 331.35




Biological activity

Potent hepatocyte nuclear factor 4α (HNF4α) antagonist; found to be selectively cytotoxic to cancer cell lines in vitro and in vivo

BI 6727

Volasertib

[755038-65-4]
Purity: 99%
optically pure
Moderately soluble in DMSO
C34H50N8O3 MW: 618.81



Axon 3361

mg	Price
2	online
5	online

Axon 4201

Page 558

Axon 1940

mg	Price
10	online
50	online

Axon 1473

mg	Price
2	online
5	online
25	online


Biological activity

A highly potent and selective polo-like kinase (PLK) 1 inhibitor (enzyme IC₅₀ = 0.87 nM, EC₅₀ = 11-37 nM on a panel of cancer cell lines), which exhibited significant anti-proliferative in multiple cancer models, including a model of taxane-resistant colorectal cancer. A high volume of distribution, indicating good tissue penetration, and a long terminal half-life have emerged as distinct features of BI 6727, which may have a favorable effect on antitumor efficacy in vivo.

BI 749327

[2361241-23-6]
Purity: 99%

Soluble in DMSO
C23H21F3N4O2 MW: 442.43



Biological activity


BI 749327 is a potent, selective and orally bioavailable TRPC6 inhibitor with IC₅₀ values of 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6, respectively.

BI-87G3

NPAS3 heterodimer inhibitor compound 6

[2207-44-5]
Purity: 98%

Soluble in DMSO
C10H5N3O2S3 MW: 295.36




Biological activity

BI-87G3 is a highly potent covalent NPAS3 heterodimer inhibitor with a biochemical EC₅₀ value of 282 nM. BI-87G3 effectively down-regulated NPAS3's transcriptional function by disrupting the interface of NPAS3-ARNT complexes at cellular level.

BI 894999

[1660117-38-3]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C25H27N5O2 MW: 429.51



Biological activity

BI 894999 is a potent, selective and orally active BET inhibitor. BI 894999 inhibits the binding of the BRD4-BD1 and BRD4-BD2 bromodomains to acetylated histones with IC₅₀ values of 5 nM and 41 nM, respectively. Moreover, BI 894999 was highly selective for BRD2/3/4 and BRDT, with at least a 200-fold selectivity vs. BRD4-BD1.

BI 99179

[1291779-76-4]
Purity: 99%
98% ee
Soluble in DMSO
C23H25N3O3 MW: 391.46

Axon 3036

mg	Price
5	online
25	online

Axon 4028


mg	Price
10	online
50	online

Axon 3037

mg	Price
5	online
25	online

Axon 3181

mg	Price
5	online
25	online




Biological activity

BI 99179 is a potent and selective inhibitor of type I fatty acid synthase (FAS) with significant exposure (both peripheral and central) upon oral administration in rats.

BI 99990

[1338468-86-2]
Purity: 98%
98%ee
Soluble in DMSO
C23H25N3O3 MW: 391.46




Biological activity

BI 99990 is a negative control compound of the active enantiomer BI 99179, which is available as Axon 3181.

BI-6C9

[791835-21-7]
Purity: 99%
Soluble in DMSO
C23H25N3O4S2 MW: 471.59




Biological activity

BI-6C9 is an inhibitor of BID, a member of the BH3-only proteins. BI-6C9 is an antiapoptotic molecule targeting Bcl-2 as shown by the ability to inhibit tBID-induced SMAC release, caspase-3 activation, and cell death. BI-6C9 reduces proapoptotic activity of BID in vitro and in cells.

BIA

TMBIM6 antagonist BIA

[134271-74-2]
Purity: 99%
Soluble in DMSO
C15H12N2O3 MW: 268.27



Biological activity

BIA is an inhibitor of the interaction between TMBIM6 and mTORC2, which ultimately blocks AKT activation and cancer progression.

BIBF-1120

See Nintedanib

BIBR 1532

Axon 3182

mg	Price
5	online
25	online

Axon 3047

mg	Price
5	online
25	online

Axon 3295

mg	Price
10	online
50	online

Axon 2648


Page 704

Axon 2301

mg	Price
----	-------

[321674-73-1]
Purity: 99%

Soluble in DMSO
C21H17NO3 MW: 331.36



5	online
25	online

Biological activity


Potent and selective inhibitor of native and recombinant human telomerase (IC50 values of ca. 100 nM), capable of inducing senescence in human cancer cells. BIBR1532 is a mixed-type non-competitive inhibitor of the human telomerase reverse transcriptase and human telomerase RNA components with similar potency primarily by interfering with the processivity of the enzyme. BIBR 1532 defines a novel class of mixed-type non-competitive telomerase inhibitor with mechanistic similarities to non-nucleosidic inhibitors of HIV1 reverse transcriptase.

BIBW 2992

Afatinib

[439081-18-2]
Purity: 99%

Soluble in DMSO
C24H25ClFN5O3 MW: 485.94



Axon 1544

mg	Price
2	online
5	online


Biological activity

Second generation tyrosine kinase inhibitor (TKI) that irreversibly inhibits human epidermal receptor 2 (Her2 or ErbB 2) and EGFR (HER1) kinases. An investigational drug for breast cancer as well as other EGFR and Her2 driven cancers such as NSCLC and Head-and-Neck

Bicalutamide

[90357-06-5]
Purity: 99%

Soluble in DMSO
C18H14F4N2O4S MW: 430.37



Axon 3313

mg	Price
50	online


Biological activity

Bicalutamide is an orally active, non-steroidal, peripherally selective antiandrogen.

BI-D1870

[501437-28-1]
Purity: 99%

Soluble in DMSO and Ethanol
C19H23F2N5O2 MW: 391.42



Axon 1528

mg	Price
2	online
5	online

Biological activity

Potent and specific inhibitor of the p90 ribosomal S6 kinase (RSK) isoforms in vitro and in vivo, which inhibits RSK1, RSK2, RSK3 and RSK4 in vitro with an IC50 of 10–30 nM

BIIB 021

See CNF 2024

Axon 1543

Page 381

BIMT 17

See Flibanserin

Axon 1499


Page 484

Bifeprunox mesylate

DU 127090

[350992-13-1]
Purity: 99%

Soluble in DMSO
C25H27N3O5S MW: 481.56



Axon 1508

mg	Price
10	online
50	online

Biological activity

Dopamine D2 and 5-HT1A partial agonist in development as a potential treatment for schizophrenia and other psychotic indications; Pharmacology profile makes it an atypical antipsychotic and a new approach for the treatment of schizophrenia

BIIB014

See Vipadenant

Axon 3626


Page 969

Bilastine

F-96221-BM1

[202189-78-4]
Purity: 99%

Soluble in 0.1N NaOH(aq), 0.1N
HCl(aq) and DMSO
C28H37N3O3 MW: 463.61



Axon 3884

mg	Price
10	online
50	online


Biological activity

Bilastine is a selective histamine H1 receptor antagonist with K_i and IC_{50} values of 64 nM and 180 nM, respectively.

Biliatresone

[1801433-90-8]
Purity: 98%

Soluble in DMSO
C18H16O6 MW: 328.32



Axon 2867

mg	Price
10	online

Biological activity

Reactive natural toxin that causes selective atresia of the extrahepatic biliary tree in zebrafish.

BINA

See Biphenyl-indanone A

Axon 1644

Page 309


Binaltorphimine dihydrochloride, nor-

[113158-35-3]
Purity: 98%

Axon 1163

mg	Price
10	online

No solubility data
C40H43N3O6.2HCl MW: 734.71



50 online

Biological activity


Potent and selective kappa opioid receptor antagonist

Binimetinib

MEK162

[606143-89-9]
Purity: 99%

Soluble in DMSO
C17H15BrF2N4O3 MW: 441.23



Axon 3697

mg	Price
10	online
50	online


Biological activity

Binimetinib is a potent, selective, non-ATP-competitive and orally available allosteric inhibitor of MEK1 and MEK2.

BIO

[667463-62-9]
Purity: 98%

Soluble in DMSO
C16H10BrN3O2 MW: 356.17



Axon 1693

mg	Price
10	online
50	online

Biological activity

Potent, reversible, ATP-competitive and selective inhibitor of glycogen synthase kinase GSK-3 (IC_{50} : 5 nM); Inhibition of GSK by BIO results in the activation of the Wnt signaling pathway and sustained pluripotency in human and murine embryonic stem cells

Biochanin B

See Formononetin

Axon 4067

Page 489

BIOLF62

See Ganciclovir


Axon 3241

Page 495

Biotinyl-phenylboronic acid

[N.A.]
Purity: 99%

Soluble in 0.1N NaOH(aq), MeOH and
DMSO
C16H22BN3O4S MW: 363.24



Axon 2256

mg	Price
5	online
25	online

Biological activity


Biotin functionalized arylboronic acid for the use of palladium-catalyzed oxidative Heck reaction to protein-bound alkenes and Suzuki-Miyaura cross-coupling for labeling of protein bound phenylhalides in high yields and with excellent chemoselectivity. Reagent for bio-orthogonal protein-ligation. Signal enhancement with streptavidin-HRP. Sold in collaboration with RuG (University of Groningen)

Biphenyl-indanone A

BINA; LS 193571

[866823-73-6]
Purity: 99%

Soluble in DMSO
C30H30O4 MW: 454.56



Axon 1644

mg	Price
5	online
25	online

Biological activity

Potent and selective positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 2 (mGluR2)

BIBR 277

See Telmisartan

Axon 3103

Page 917

BIBR 1048

See Dabigatran etexilate

Axon 3117


Page 406

BIRB 796

Doramapimod

[285983-48-4]
Purity: 99%

Soluble in water and DMSO
C31H37N5O3 MW: 527.66



Axon 1358

mg	Price
5	online
10	online

Biological activity


Small molecule inhibitor of p38 mitogen-activated protein (MAP) kinase (MAPK); more potent than SB 203580 on p38 α and p38 β MAPKs; potential agent for the treatment of inflammatory diseases

Birinapant

TL32711

[1260251-31-7]
Purity: 99%
>99% e.e.

Soluble in DMSO
C42H56F2N8O6 MW: 806.94



Axon 4150

mg	Price
10	online
50	online

Biological activity

Birinapant is a cell permeable, orally bioavailable, synthetic bivalent small molecule peptido mimetics of second mitochondrial-derived activator of caspases (SMAC) and potent and selective inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins with K_d values of 45 nM and <1 nM for XIAP and cIAP1, respectively. SMAC mimetics Birinapant and LCL-161 (our Prod No CT-LCL161) are also negative regulators of HIV-1 transcription, promoting reversal of viral latency.

Source Information: Sold in collaboration with Chemietek

BI-RG-587

See Nevirapine

Axon 3124

Page 699

BrdU, 5-

See Bromo-2'-deoxyuridine, 5-


Axon 3419

Page 329

Bisacodyl

[603-50-9]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C22H19NO4 MW: 361.39



Biological activity

Bisacodyl is a laxative.

Axon 3661


mg	Price
50	online

Bisindolylmaleimide I

GF109203X

[133052-90-1]
Purity: 98%

Soluble in DMSO
C25H24N4O2 MW: 412.48



Biological activity

Bisindolylmaleimide I is a potent and selective inhibitor of protein kinase C with IC₅₀ values of 20 nM, 17 nM, 16 nM and 20 nM for subtypes PKC α , PKC β 1, PKC β 2 and PKC γ , respectively. Bisindolylmaleimide I is also a potent GSK-3 inhibitor.

Axon 3936


mg	Price
10	online
50	online

Bisindolylmaleimide IV

Arcyriarubin A

[119139-23-0]
Purity: 98%

Soluble in DMSO and EtOH
C20H13N3O2 MW: 327.34



Biological activity

Bisindolylmaleimide IV is a potent inhibitor of protein kinase C with an IC₅₀ value of 0.55 μ M.

Axon 3939

mg	Price
10	online
50	online

Bisindolylmaleimide V


Ro 31-6045

[113963-68-1]
Purity: 99%

Axon 3940

mg	Price
5	online

Soluble in DMSO and EtOH
C21H15N3O2 MW: 341.36



25 online

Biological activity


Bisindolylmaleimide V is an in vivo S6K inhibitor (IC50 value of 8 μM) and also the inactive analogue of the protein kinase C inhibitor Ro 31-8220.

Bisoprolol fumarate

EMD33512

[104344-23-2]
Purity: 99%

Soluble in water, DMSO and EtOH
C18H31NO4.0.5C4H4O4 MW:
383.48



Axon 3458

mg	Price
10	online
50	online


Biological activity

Bisoprolol fumarate is a potent and cardioselective β1-adrenoceptor antagonist.

BIX 01294 trihydrochloride hydrate

[935693-62-2]
Purity: 99%

Soluble in water and DMSO
C28H38N6O2.3HCl MW: 600.02



Axon 1692

mg	Price
10	online
50	online


Biological activity

G9a-like protein and G9a histone lysine methyltransferase (HMTase) inhibitor; Recently, BIX-01294 and RG108 (Axon 1691) have been reported to enhance the efficiency of iPSC cell generation

BIX02188-Me

[334951-92-7]
Purity: 99%

Soluble in DMSO
C26H26N4O2 MW: 426.51



Axon 1808

mg	Price
5	online
25	online


Biological activity

BIX02188-Me is a N-methyl analogue of BIX02188 and BIX02189. BIX02188-ME is a selective dual MEK5 and ERK kinase inhibitor similar to BIX02188 and BIX02189.

BIX 02189

[1094614-85-3]
Purity: 99%

Soluble in DMSO
C27H28N4O2 MW: 440.54



Axon 1809

mg	Price
5	online
25	online


Biological activity

Selective dual MEK5 and ERK5 (or BMK1) kinase inhibitor, with IC50 values of 1.5, 59, 580 and >6200 nM for MEK5, ERK5, TGFβR1 and other closely related kinases respectively

BIX02188

[334949-59-6]
Purity: 98%

Soluble in DMSO
C25H24N4O2 MW: 412.48



Axon 3346

mg	Price
5	online
25	online


Biological activity

Selective and potent MEK5 kinase inhibitor, with IC50 values of 4.3, 810, 1800, and >6300 nM for MEK5, ERK5, TGFβR1 and other closely related kinases respectively.

Bizine

[1591932-50-1] (parent)
Purity: 98%

Soluble in water and DMSO
C18H23N3O.HCl MW: 333.86



Axon 2306

mg	Price
10	online
50	online

Biological activity

Potent LSD1 inhibitor in vitro and selective versus monoamine oxidases A/B and the LSD1 homologue, LSD2 with Ki(inact) values 0.059 μM, 2.6 μM, 6.5 μM, and ca 11 μM for LSD1, MAO-A, MAO-B, and LSD2 respectively. Bizine was found to be effective at modulating bulk histone methylation in cancer cells. Moreover, neurons exposed to oxidative stress were protected by the presence of bizine, suggesting potential applications in neurodegenerative disease.

BJE6-106

See B106

Axon 2981

Page 281

BKM 120

See NVP-BKM120


Axon 1797

Page 723

Blebbistatin, (-)

[856925-71-8]
Purity: 98%

99.7% e.e.
Soluble in DMSO
C18H16N2O2 MW: 292.33



Axon 3074

mg	Price
2	online
5	online

Biological activity

(-)-Blebbistatin is a selective inhibitor of myosin II ATPase activity (IC50 value of 2.16 μM). Active enantiomer of (±)-Blebbistatin (Axon 2718).


Blebbistatin, (+)

[1177356-70-5]
Purity: 99%

99.5% e.e.
Soluble in DMSO
C18H16N2O2 MW: 292.33

Axon 3144

mg	Price
2	online
5	online




Biological activity

(+)-Blebbistatin is the inactive enantiomer of (±)-Blebbistatin (Axon 2718) with an IC₅₀ value of >100 μM for ATPase activity; Negative control for non-muscle myosin II studies.

Blebbistatin, (±)-

[674289-55-5]
Purity: 99%

Soluble in DMSO
C18H16N2O2 MW: 292.33



Axon 2718

mg	Price
5	online
25	online

Biological activity

Blebbistatin is a potent and specific inhibitor of the motor functions of class II myosins (IC₅₀ values of 6.47 μM, 3.58 μM, 2.30 μM and 1.57 μM for inhibiting actin-activated ATPase activities of Smm, NM2a, NM2b and NM2c, respectively). Blebbistatin inhibited contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly. Moreover, Blebbistatin inhibited both the ATPase and gliding motility activities of human platelet nonmuscle myosin II without inhibiting my

BLK degrader 1

See BLK degrader compound 9

Axon 4010


Page 313

BLK degrader compound 9

BLK degrader 1

[N.A.]
Purity: 98%

Solubel in DMSO and EtOH
C32H25F3N6O2 MW: 582.59



Axon 4010

mg	Price
5	online
25	online

Biological activity


BLK degrader compound 9 is a first potent and highly selective monomeric degrader of B-lymphoid tyrosine kinase (BLK) with DC₅₀ and IC₅₀ values of 49 nM and 443 nM, respectively.

Blonanserin

AD 5423

[132810-10-7]
Purity: 100%

Soluble in 0.1N HCl(aq) and DMSO
C23H30FN3 MW: 367.50



Axon 2353

mg	Price
10	online
50	online


Biological activity

Potent dopamine D₂ and serotonin 5-HT₂ antagonist (K_i values 0.14 nM and 0.81 nM for human D₂L and 5-HT₂A receptors respectively) with weak adrenaline-α₁ and virtually no dopamine D₁ affinity.

BLU-667

Pralsetinib; RG 6396

[2097132-94-8]
Purity: 98%
Optically pure
Soluble in DMSO and EtOH
C27H32FN9O2 MW: 533.60



Biological activity

BLU-667 is a highly potent and selective RET inhibitor with an IC₅₀ value of 0.4 nM. In vivo, BLU-667 potently inhibited growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR2.

Axon 3854

mg	Price
5	online
25	online

BLZ945

See Sotuletinib

Axon 4084

Page 881

BM14190

See Carvedilol


Axon 3456

Page 344

BMH 21

[896705-16-1]
Purity: 99%

Soluble in 0.1N HCl (aq)
C21H20N4O2 MW: 360.41



Biological activity

RNA polymerase I (RNAP1) inhibitor (IC₅₀ values 0.05 μM and 0.07 μM for degradation of RPA194 and translocation of NCL, respectively). BMH-21 intercalates with GC-rich rDNA, inhibits Pol I, and causes activation of p53 and proteasome-mediated degradation of RPA194. Furthermore, BMH21 showed broad and potent anticancer activity in NCI60 cancer cell lines and reduced tumor burden in mouse xenograft assays.

Axon 2462


mg	Price
10	online
50	online

BML-210

SAOA

[537034-17-6]
Purity: 99%

Soluble in DMSO
C20H25N3O2 MW: 339.43



Biological activity

BML-210 is an inhibitor of histone deacetylase with an IC₅₀ value of 87 μM.

Axon 3399

mg	Price
10	online
50	online

BMN 195

See SMT C1100

BMN 673


See Talazoparib

BMS 4

See LIMK1 inhibitor BMS 4

BMS 189961

 [185629-22-5]
Purity: 98%

 Soluble in DMSO
C23H26FNO4 MW: 399.46

Biological activity

Nuclear retinoic acid receptor (RAR) gamma agonist; its more active (R)-(+)-enantiomer is BMS 270394 (Axon 1173)

BMS-200475


See Entecavir

BMS 201038

See Lomitapide

BMS 204352


Flindokalner; BMS 204352, (S)-(+)-

 [187523-35-9]
Purity: 99%
99% ee
Soluble in DMSO
C16H10ClF4NO2 MW: 359.70

Biological activity

Maxi-K channel opener, potential therapeutic for the treatment of stroke; more active S-(+)-enantiomer in comparison with R-(-)-enantiomer (Axon 1309)

BMS 204352, (±)-

 [183720-28-7]
Purity: 98%

 Soluble in DMSO
C16H10ClF4NO2 MW: 359.70

Biological activity

Potassium channel opener; racemate of more active S-(+)-enantiomer, BMS-204352 (Flindokalner, Axon 1112), and less active R-(-)-enantiomer (Axon 1309)

Axon 2481

Page 875

Axon 2502

Page 909

Axon 1949

Page 614

Axon 1194

mg	Price
10	online
50	online

Axon 3239

Page 461

Axon 2917

Page 618


Axon 1112

mg	Price
5	online
25	online

Axon 1308

mg	Price
5	online
25	online

BMS 204352, (R)-(-)-

 [187523-36-0]
Purity: 98%
>98% ee
Soluble in DMSO
C16H10ClF4NO2 MW: 359.70

Biological activity

Less active opposite R-(-)-enantiomer of S-(+)-enantiomer, BMS-204352 (Flindokalner, Axon 1112), a Maxi-K channel opener


BMS 204352, (S)-(+)-

See BMS 204352

BMS 232632

Atazanavir

 [198904-31-3]
Purity: 99%

 Soluble in DMSO
C38H52N6O7 MW: 704.86

Biological activity


Orally active protease inhibitor (PI); antiretrovirals used to treat infection of human immunodeficiency virus (HIV)

BMS 247615 dihydrochloride

See TAS-103 dihydrochloride

BMS 270394

BMS 270394, (R)-(+)-

 [262433-54-5]
Purity: 99%
>98% ee
Soluble in DMSO and Ethanol
C23H26FNO4 MW: 399.46

Biological activity

Nuclear retinoic acid receptor (RAR) gamma agonist; more active enantiomer of BMS 189961 (Axon 1194)

BMS 270394, (R)-(+)-

See BMS 270394

BMS 303141

 [943962-47-8]
Purity: 100%

Axon 1309

mg	Price
5	online
25	online

Axon 1112

Page 315

Axon 1441

mg	Price
5	online
25	online

Axon 2914

Page 910

Axon 1173

mg	Price
5	online
25	online


Axon 1173

Page 316

Axon 2506

mg	Price
10	online

Soluble in DMSO and Ethanol
C19H15Cl2NO4S MW: 424.30



50 online


Biological activity

Cell-permeable ATP-citrate lyase (ACL) inhibitor (IC₅₀ value 0.13 μM in vitro, and 8 μM for inhibition of total lipid syntheses in HepG2 cells). When administered to mice fed on a high-fat diet, it produced an approximate 20–30% lowering in plasma cholesterol and triglycerides, as well as a 30–50% decrease in fasting plasma glucose, as well as an inhibition of weight gain. BMS 303141 also showed inhibitory effects for other metabolic disease related targets such as ACC1 and ACC2 (IC₅₀ values 6 μM and 12 μM, respectively).

BMS 309403 Recent Addition

[300657-03-8]
Purity: 98%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C31H26N2O3 MW: 474.55



Axon 4277

mg	Price
10	online
50	online


Biological activity

Potent, selective and orally active adipocyte fatty acid binding protein (aFABP) inhibitor with K_i values of <2 nM for both mouse and human aP2 (FABP4), 250 nM for muscle FABP (FABP3) and 350 nM for mal1 (FABP5).

BMS 345541

[547757-23-3]
Purity: 98%

Soluble in water and DMSO
C14H17N5.HCl MW: 291.78



Axon 1731

mg	Price
5	online
10	online

Biological activity

A cell-permeable and highly selective IKK kinase (IKK) inhibitor, binds at allosteric site of the enzyme; blocks NF-κB-dependent transcription in mice; Displays ~10-fold greater selectivity at IKK-2 over IKK-1

BMS 354825

See Dasatinib

Axon 1392

Page 410

BMS 387032

See SNS 032

Axon 1614

Page 876

BMS 442606 hydrochloride

See Hydroxybuspirone hydrochloride, (S)-6-

Axon 1998

Page 549

BMS 442608 hydrochloride


See Hydroxybuspirone hydrochloride, (R)-6-

Axon 1997

Page 549

BMS-466442

[1598424-76-0]
Purity: 98%
100% e.e.
Solubility in DMSO and EtOH
C31H30N4O5 MW: 538.59



Axon 3699


mg	Price
5	online
25	online

Biological activity

BMS-466442 is a selective asc-1 inhibitor with IC₅₀ values of 37 nM and 20 nM in human asc-1 expressing cells and primary cultures, respectively.

BMS-502 Recent Addition

[2407854-18-4]
Purity: 99%
Soluble in DMSO
C27H22F2N6O3 MW: 516.50



Axon 4110

mg	Price
10	online
50	online

Biological activity

BMS-502 is a first-in-class potent and selective dual DGKα/ζ lipid kinase inhibitor with IC₅₀ values of 5 nM and 2 nM for DGKα and DGKζ, respectively. BMS-502 demonstrated dose-dependent immune stimulation in the mouse OT-1 model.

BMS-512148

See Dapagliflozin

Axon 3121

Page 409

BMS 528215

See Hydroxy-buspirone hydrochloride, 6-


Axon 1996

Page 549

BMS 540215

Brivanib

[649735-46-6]
Purity: 98%
optically pure
Soluble in DMSO
C19H19FN4O3 MW: 370.38



Axon 1850

mg	Price
5	online
25	online

Biological activity

Potent and ATP-competitive inhibitor of VEGF; it inhibits VEGFR-2, -1 and -3 with IC₅₀ of 25, 380 and 10 nM respectively; also showed good selectivity for FGFR-1, -2, and -3 with IC₅₀ of 148, 125 and 68 nM. BMS 540215 is the active component of its prodrug, Brivalib alaninate (BMS 582664, Axon 1864), which hydrolyzes to BMS 540215 in vivo quickly

BMS 562247-01

See Apixaban

Axon 1754


Page 241

BMS 582664

See Brivanib alaninate

BMS 582949


 [623152-17-0]
 Purity: 98%

 Soluble in DMSO
 C22H26N6O2 MW: 406.48

Biological activity

BMS 582949 is a highly selective p38α MAP kinase inhibitor (IC50 value of 13 nM).

BMS-599626

AC480


 [714971-09-2]
 Purity: 99%
 99% e.e.
 Soluble in DMSO
 C27H27FN8O3 MW: 530.55

Biological activity

BMS-599626 is an orally bioavailable, potent and selective EGFR and ErbB2 inhibitor with IC50 values of 22 nM and 32 nM respectively, and inhibits HER4 with reduced potency (IC50 = 190 nM). Inhibits EGFR and ErbB2 with 100-fold greater potency than MEK and Lck. It is an antiproliferative agent in vitro and anti-tumorigenic agent in vivo.

Source Information: Sold in collaboration with Chemietek

BMS 605541

 [639858-32-5]
 Purity: 98%

 Soluble in DMSO
 C19H17F2N5OS MW: 401.43

Biological activity

BMS 605541 is potent, selective, orally active, ATP-competitive inhibitor of VEGFR2 (IC50 value of 23 nM). Orally active in human lung (L2987) and colon (HCT-116) carcinoma xenograft models at multiple dose levels.

BMS649

See SR11237

BMS-684 Recent Addition

 [313552-29-3]
 Purity: 99%

Soluble in DNMSO

Axon 1864

Page 328

Axon 2856

mg	Price
5	online
25	online

Axon 3853

mg	Price
5	online
10	online

Axon 2837

mg	Price
5	online
25	online


Axon 3727

Page 885

Axon 4109

mg	Price
5	online
25	online


C27H26N4O3 MW: 454.52


Biological activity

BMS-684 is a selective DGKα inhibitor with an IC50 value of 15 nM. BMS-684 inhibited DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ and did not inhibit any of the other seven DGK isozymes.

BMS-777607

 [1025720-94-8]
 Purity: 99%

 Soluble in DMSO
 C25H19ClF2N4O4 MW: 512.89

Biological activity

 A potent, selective and orally bioavailable c-Met inhibitor.
 Source Information: Sold in collaboration with Chemietek


BMS 790052 dihydrochloride

See Daclatasvir dihydrochloride

BMS 833923

XL 139

 [1059734-66-5]
 Purity: 99%

 Soluble in DMSO
 C30H27N5O MW: 473.57

Biological activity

Oral, small molecule antagonist of the Hedgehog (Hh) signaling component Smoothed (SMO). Treatment with BMS 833923 leads to a decreased expression of GLI1 and PTCH1 in EGI-1 cells, reduced tumor growth in vitro, and a prolongation of survival in vivo in different human cancers. Additionally, SMO inhibition by BMS 833923 leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells (EACs).

BMS 863233 hydrochloride

See XL 413 hydrochloride

BMS-911543

 [1271022-90-2]
 Purity: 99%

Soluble in DMSO

Axon 4040

mg	Price
10	online
50	online

Axon 2093

Page 407

Axon 2356

mg	Price
5	online
25	online


Axon 2268

Page 994

Axon 3813

mg	Price
5	online
10	online

C23H28N8O MW: 432.52




Biological activity

BMS-911543 is a potent, selective and orally active inhibitor of JAK2 ($K_i = 0.48$ nM), highly selective over JAK1 ($K_i = 1117$ nM) and JAK3 ($K_i = 357$ nM).

Source Information: Sold in collaboration with Chemietek

BMS-986158

[1800340-40-2]
Purity: 99%
99% e.e.
Soluble in DMSO
C30H33N5O2 MW: 495.62



Axon 3716

mg	Price
5	online
10	online

Biological activity

BMS-986158 is an orally bioavailable, potent and domain-selective BET protein inhibitor, binding to the acetyl-lysine binding site of BET bromodomain of BRD4 (Bromodomain-containing 4) with an $IC_{50} < 5$ nM (FRET). Display excellent pharmacokinetic properties and efficacy in vitro and in vivo antitumor activity.

Source Information: Sold in collaboration with Chemietek

BMS986165


See Deucravacitinib

Axon 4091

Page 422

BMS-986260

[2001559-19-7]
Purity: 98%
Soluble in 0.1N HCl(aq), DMSO and EtOH
C18H12ClFN6O MW: 382.78



Axon 4168


mg	Price
5	online
25	online

Biological activity

BMS-986260 is a potent, selective and orally bioavailable TGF- β R 1 inhibitor with an IC_{50} value of 1.6 nM. BMS-986260 is an immuno-oncology agent.

BMS-986299

[2242952-69-6]
Purity: 100%
Soluble in DMSO
C18H19N7O MW: 349.39



Axon 3877

mg	Price
5	online
25	online

Biological activity

BMS-986299 is a first-in-class NLRP3 agonist with an EC_{50} value of 1.28 μ M.

BMS986231

See Cimlanod


Axon 3842

Page 372

BMS-986365 Recent Addition

CC-94676

[2446928-30-7]
Purity: 98%
Optically pure
Soluble in DMSO and EtOH
C41H45F3N8O5S MW: 818.91



Axon 4232

mg	Price
5	online
25	online

Biological activity

BMS-986365 is a highly potent and selective androgen receptor (AR) degrader that induces rapid and deep degradation of both wildtype and mutant forms of the receptor residing in either the cytoplasmic or nuclear compartments of the cell. Moreover, BMS-986

BYM 13754

See Nefazodone hydrochloride

Axon 1102

Page 696

BN 80245


See Homocamptothecin, (\pm)-E-

Axon 1687

Page 322

BN80933

[214348-10-4]
Purity: 98%
100% e.e.
Soluble in DMSO and EtOH
C29H34N4O3S MW: 518.67



Axon 3479

mg	Price
5	online
25	online

Biological activity

BN80933 is a dual inhibitor of lipid peroxidation (IC_{50} value of 0.29 μ M) and neuronal nitric oxide synthase (nNOS) (K_i value of 0.92 μ M); Neuroprotectant.

BN83495

See STX64


Axon 2892

Page 897

BO-264

[2408648-20-2]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C18H19N5O3 MW: 353.38



Axon 3327

mg	Price
5	online
25	online

Biological activity

BO-264 is a highly potent, orally active TACC3 inhibitor with an IC_{50} value of 188 nM. BO-264 is a potential anti-cancer agent, inducing spindle abnormalities and mitotic cell death.

Boc-Asp(Ome)-fluoromethyl ketone

See Boc-D-FMK

Axon 2158


Page 323

Boc-D-FMK

Boc-Asp(Ome)-fluoromethyl ketone; BAF

[187389-53-3]

Purity: 98%
optically pure
Soluble in water and DMSO
C₁₁H₁₈FNO₅ MW: 263.26



Axon 2158

mg	Price
5	online
25	online

Biological activity


Broad spectrum caspase inhibitor. Causes concentration-dependent inhibition of only TNF α -stimulated apoptosis (IC₅₀ value 39 μ M). Boc-D-FMK could significantly promote the survival of spinal motoneurons after root avulsion in neonates, but not in adult rats. Boc-D-FMK treatment reduces acute cell death after traumatic brain injury (TBI) by inhibiting mitochondrial release of cytochrome c, possibly via a mechanism involving initiator caspases-2, and -3-like, but not -8).

Bortezomib

PS 341

[179324-69-7]

Purity: 99%
optically pure
Soluble in DMSO
C₁₉H₂₅BN₄O₄ MW: 384.24



Axon 1810

mg	Price
5	online
25	online

Biological activity

Highly selective and reversible inhibitor of the 26S proteasome; a chemotherapy agent used in the treatment of multiple myeloma; shown to have anti-tumor activity in B cell malignancies

Bosutinib

See SKI 606

Axon 1407


Page 870

BP-1-102

[1334493-07-0]

Purity: 99%

Soluble in DMSO and EtOH
C₂₉H₂₇F₅N₂O₆S MW: 626.59



Axon 3786

mg	Price
5	online
25	online


Biological activity

BP-1-102 is an orally bioavailable inhibitor of transcription factor Stat3 with an IC₅₀ value of 6.8 μ M. BP-1-102 binds Stat3 with an affinity (KD) of 504 nM, blocks Stat3-phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4-6.8 μ M, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells.

BPI-9016M Recent Addition

[1528546-94-2]

Purity: 98%
98% e.e.
Moderate, low or no solubility
C₂₅H₁₈F₂N₄O₃ MW: 460.43



Axon 4266

mg	Price
10	online

Biological activity

BPI-9016M is a potent, orally active, and selective tyrosine kinase inhibitor targeting both c-MET and AXL. It significantly suppressed tumor cell growth in lung adenocarcinoma PDX models, particularly in the tumors with high expression of c-Met.


Source Information: Sold in collaboration with Chemietek

BPKDi

[1201673-28-0]

Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C₂₁H₂₈N₆O MW: 380.49



Axon 2798

mg	Price
5	online
25	online

Biological activity


BPKDi is an inhibitor of protein kinase D (IC₅₀ values of 1, 9, and 1 nM for PKD1, PKD2 and PKD3, respectively). BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes and concomitantly suppresses hypertrophy of these cells.

BPN14770

[1606974-33-7]

Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C₂₁H₁₅ClF₃N₂O₂ MW: 405.80



Axon 3148

mg	Price
5	online
25	online

Biological activity


BPN14770 is a potent, selective, allosteric inhibitor of PDE4D with an IC₅₀ value of 7.8 nM (PDE4D7-S129D). BPN14770 showed increased potency in humanized PDE4D mice as compared to wild-type mice. Moreover, BPN14770 increased brain cAMP, increased phosphorylation of CREB, augmented the late phase of hippocampal long-term potentiation (LTP), improved short and long-term memory, and increased production of brain-derived neurotrophic factor (BDNF) in hippocampus.

BPTES

[314045-39-1]

Purity: 98%

Soluble in DMSO
C₂₄H₂₄N₆O₂S₃ MW: 524.68



Axon 3747

mg	Price
10	online
50	online


Biological activity

BPTES is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) with an IC₅₀ value of 3.3 μ M.

BP-TQS, 4-

[360791-49-7]
Purity: 99%

Soluble in DMSO
C18H17BrN2O2S MW: 405.31



Axon 2694

mg	Price
10	online
50	online


Biological activity

4BP-TQS is an allosteric agonist of $\alpha 7$ nicotinic acetylcholine receptors (nAChR). The agonism was shown to act through a site topographically distinct from the ACh site. 4BP-TQS was a more potent and efficacious agonist of $\alpha 7$ nAChR than ACh (8-fold lower EC50 and 45-fold larger maximal response). The bioactive enantiomer of 4BP-TQS, GAT107 (Axon 2621), is also available.

BQU 57

[1637739-82-2]
Purity: 99%

Soluble in DMSO
C16H13F3N4O MW: 334.30



Axon 2397

mg	Price
5	online
25	online

Biological activity


Inhibitor of the RAS-like small GTPases RalA and RalB (Kd value 7.7 μ M for RalB-GDP; IC50 values 2.0 mM and 1.3 mM for growth inhibition in H358 and H2122 tumor xenografts, respectively). BQU57 shows selectivity for Ral relative to the GTPases Ras and RhoA. Mechanistically, BQU-57 inhibits the binding of Ral proteins in their GDP-bound form to its effector RALBP1, as well as inhibiting Ral-mediated cell spreading of murine embryonic fibroblasts and anchorage-independent growth of human cancer cell lines. Close analogue of RBC 8 (Axon 2396)

BQR695

NVP-BQR695

[1513879-21-4]
Purity: 99%

Soluble in DMSO
C19H20N4O3 MW: 352.39



Axon 2801

mg	Price
5	online
25	online

Biological activity

BQR695 is a PI4K inhibitor which displays potency against both human PI4KIII β and Plasmodium falciparum asexual blood stages (IC50 values of 90 nM and 71 nM, respectively). Antimalarial compound.

BR1

See PRL-3 inhibitor

Axon 3436

Page 791

BR 4887

See BAY 60-6583


Axon 2317

Page 290

Brassinin

[105748-59-2]
Purity: 98%

Soluble in DMSO
C11H12N2S2 MW: 236.36



Biological activity

Bioavailable dithiocarbamate with affinity for indoleamine 2,3-dioxygenase (IDO; Ki value 28 μ M for human IDO) showing antifungal and anticancer activity. Moreover, Brassinin suppressed both constitutive and IL-6-inducible STAT3 activation through modulation of PIAS-3 and SOCS-3, thereby attenuating tumor growth and increasing sensitivity to paclitaxel.


Axon 2489

mg	Price
10	online
25	online

BRD0539

[1403838-79-8]
Purity: 98%
99% e.e.

Soluble in DMSO and EtOH
C25H25FN2O3S MW: 452.54



Biological activity

BRD0539 is a reversible and cell-permeable inhibitor of SpCas9 with an apparent IC50 value of 22 μ M (in vitro DNA cleavage assay).


Axon 3009

mg	Price
5	online
25	online

BRD0705

[2056261-41-5]
Purity: 99%
100% e.e.

Soluble in DMSO
C20H23N3O MW: 321.42



Biological activity

BRD0705 is a first-in-class, paralog selective GSK3 α inhibitor with an IC50 value of 0.066 μ M. BRD0705 induced differentiation, reduced transcriptional programs of stemness and impaired colony formation in AML cell lines and primary patient samples without affecting normal hematopoietic cell growth. Importantly, BRD0705 did not induce β -catenin stabilization or nuclear translocation at concentrations efficacious in multiple mouse models of AML, resulting in leukemia initiation impairment and prolonged survival. The negative control BRD5648 is available as Axon 3153. The racemic mixture of both enantiomers is available as Axon 3154.

Axon 2931


mg	Price
5	online
25	online

BRD4780

AGN 192403 hydrochloride

[175521-95-6]
Purity: 99%

Soluble in water and DMSO
C10H19N.HCl MW: 189.73



Biological activity


BRD4780 is a potent and selective imidazoline1 (I1) receptor ligand with a Ki value of 42 nM. Moreover, BRD4780 binds cargo receptor TMED9, releases MUC1-fs, and re-routes it to lysosome.

Axon 3017

mg	Price
5	online
25	online

BRD5648

[2056261-42-6]
Purity: 99%
100% e.e.
Soluble in DMSO
C20H23N3O MW: 321.42



Axon 3153

mg	Price
5	online
25	online

Biological activity

BRD5648 is the inactive enantiomer of rac-BRD0705 (Axon 3154); negative control compound of the active enantiomer BRD0705, which is available as Axon 2931.

BRD 9424


See FPH 2

Axon 2355

Page 490

BRD 73954

[1440209-96-0]
Purity: 99%



Axon 2471

mg	Price
5	online
25	online

Soluble in DMSO
C16H16N2O3 MW: 284.31

Biological activity

First dual HDAC 6/8 inhibitor (IC50 values 9000 nM, >33000 nM, 36 nM, and 120 nM for HDAC2, 4, 6, and 8, respectively) with excellent selectivity over the other class I and II HDACs tested (75- and 130-fold less potent for the next closest isoforms). Simultaneous inhibition of HDAC6 and HDAC8 has many potential therapeutic applications, providing a larger therapeutic window than inhibition of HDAC1-3.

BRD K4477

See FH 1


Axon 2320

Page 480

Brexipiprazole dihydrochloride

OPC 34712 dihydrochloride

[913612-38-1]
Purity: 98%



Axon 2335

mg	Price
5	online
25	online

Soluble in DMSO
C25H27N3O2S.2HCl MW: 506.49

Biological activity

Drug candidate in clinical development for psychiatric disorders with high affinity for h5-HT1A (partial agonist), h5-HT2A (antagonist), hD2L (partial agonist), hα1B (antagonist) and hα2C-adrenergic (antagonist) receptors (Ki values <1 nM). Brexipiprazole also shows substantial affinity (Ki <5 nM) for hD3, h5-HT2B, h5-HT7, hα1A and hα1D adrenergic receptors, and moderate affinity for hH1 (Ki =19 nM).

Brigatinib


AP 26113; Alunbrig

[1197953-54-0]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C29H39ClN7O2P MW: 584.09

Axon 2978

mg	Price
10	online
50	online




Biological activity

Brigatinib is a potent and selective inhibitor of ALK (IC50 value of 0.6 nM), capable of overcoming mechanisms of resistance associated with crizotinib (Axon 1660). Besides inhibition of ALK, FLT3 and ROS1 were also potently inhibited. Brigatinib was highly active against both sensitive and resistant H3122 cells, decreasing cell growth, suppressing ALK phosphorylation, and inducing apoptosis.

Brimonidine tartrate

Alphagan-P

[70359-46-5]
Purity: 99%



Soluble in water and DMSO
C11H10BrN5.C4H6O6 MW: 442.22

Axon 1555

mg	Price
10	online
50	online


Biological activity

Selective alpha 2-adrenergic receptor agonist, a drug used to treat open-angle glaucoma or ocular hypertension

Brinzolamide

AL4862

[138890-62-7]
Purity: 100%
Optically pure
Soluble in 0.1N HCl(aq), DMSO and
EtOH
C12H21N3O5S3 MW: 383.51



Axon 3988

mg	Price
10	online
50	online

Biological activity

Brinzolamide is a potent carbonic anhydrase (CA) inhibitor with IC50 values of 3.2 nM and 45.3 nM against CAII and CAIV, respectively.

Brivanib

See BMS 540215


Axon 1850

Page 318

Brivanib alaninate

BMS 582664

[649735-63-7]
Purity: 99%
optically pure
Soluble in DMSO
C22H24FN5O4 MW: 441.46



Axon 1864

mg	Price
2	online
5	online


Biological activity

Brivanib alaninate (BMS 582664) is the orally active prodrug of BMS 540215 (Axon 1850). Brivanib alaninate hydrolyzes in vivo quickly to BMS 540215, which is a potent and ATP-competitive VEGFR inhibitor with IC50 of 25, 380 and 10 nM for VEGFR-2, -1 and -3 respectively; also showed good selectivity for FGFR-1, -2, and -3 with IC50 of 148, 125 and 68 nM

Brivudine

BVdU

[69304-47-8]
Purity: 99%
Optically pure
Soluble in water, DMSO and EtOH
C11H13BrN2O5 MW: 333.14



Axon 3664

mg	Price
50	online

Biological activity

Brivudine is an analog of thymidine, and is incorporated into the viral DNA. It blocks the action of DNA polymerases, thus inhibiting viral replication. Antiherpetic agent.

BRL39123

See Penciclovir

Axon 3385

Page 758

BRL 43694

See Granisetron hydrochloride

Axon 1449

Page 514

BRL 49653

See Rosiglitazone

Axon 2443

Page 830

Brobenzoxaldine

See Broxaldine


Axon 2804

Page 330

Bromo-2'-deoxyuridine, 5-

BUdR; 5-BrdU; Broxuridine

[59-14-3]
Purity: 99%
Optically pure
Soluble in water and DMSO
C9H11BrN2O5 MW: 307.10



Axon 3419

mg	Price
50	online


Biological activity

Broxuridine is a nucleoside analog which is frequently used in analysis of neural stem cell biology, in particular to label and to fate-map dividing cells. Broxuridine is incorporated into newly synthesized DNA and has been shown to increase the susceptibility of incorporating cells to ionizing radiation. Moreover, Broxuridine inhibits cancer cell proliferation in vitro and in vivo.

Bromobuterol

[41937-02-4]
Purity: 98%

Soluble in DMSO and Ethanol
C12H18Br2N2O MW: 366.09



Axon 1157

mg	Price
10	online
50	online


Biological activity

Beta-2 agonist

Bromomethyl-1-(tetrahydro-pyran-2-yl)-1H-indazole, 5-

[368426-64-6]
Purity: 97.0%

No solubility data
C13H15BrN2O MW: 295.18



Axon 1177

mg	Price
1000	online
5000	online

Biological activity

Key precursor for making e.g. non-covalent thrombin inhibitors

Brophenexin

See NMDAR-TRPM4 blocker C8 dihydrochloride

Axon 3348


Page 706

Broxaldine

Brobenzoxaldine

[3684-46-6]
Purity: 99%

Soluble in DMSO
C17H11Br2NO2 MW: 421.08



Axon 2804

mg	Price
10	online
50	online

Biological activity

Broxaldine is an antiprotozoal drug.

Broxuridine

See Bromo-2'-deoxyuridine, 5-

Axon 3419

Page 329

BS100-141

See Guanfacine hydrochloride

Axon 3383

Page 531

BSF 208075

See Ambrisentan

Axon 1648

Page 222

BSI 201

See Iniparib

Axon 1566

Page 566

BSK 805

See NVP-BSK805


Axon 2792

Page 724

BT-11

[1912399-75-7]
Purity: 99%

Soluble in DMSO
C30H24N8O2 MW: 528.56



Axon 2749

mg	Price
5	online
25	online


Biological activity

BT-11 is a first-in-class, orally active lanthionine synthetase C-like 2 (LANCL2) binding compound (K_d value of 7.7 μM) for treating inflammatory bowel disease (IBD). Moreover, BT-11 downregulates expression of pro-inflammatory cytokines (e.g., TNF-α or interferon-γ, which are hallmarks of IBD), and promotes IL-10-mediated anti-inflammatory responses in the GI tract.

BT2

[34576-94-8]
Purity: 99%

Soluble in DMSO
C9H4Cl2O2S MW: 247.10



Axon 2334

mg	Price
5	online
25	online

Biological activity


Allosteric inhibitor of branched-chain α-ketoacid dehydrogenase (BCKDC) kinase (BDK; IC₅₀ value 3.19 μM). BT 2 binding to BDK results in the dissociation of BDK from the BCKDC accompanied by accelerated degradation of the released kinase in vivo. BT 2 is also known to inhibit the Bcl-2 family member Mcl-1 (K_i value 59 μM).

BTB 1

NSC 156750; NSC 658180

[86030-08-2]
Purity: 99%

Soluble in DMSO and Ethanol
C12H8ClNO4S MW: 297.71



Axon 2407

mg	Price
10	online
50	online


Biological activity

The first small molecule reversible inhibitor of the mitotic motor protein Kif18A (IC₅₀ value 1.69 μM for inhibition of Kif18A ATPase activity) that acts in an ATP-competitive and microtubule (Mt) uncompetitive manner. BTB-1 (aka NSC 156750 or NSC 658180) was previously tested and found to inhibit HIV-1 replication (IC₅₀ value 29.2 μM in cellular anti-HIV-1 assay), yet BTB1 proved to be cytotoxic at low micromolar concentrations.

BTS 54-505

[84484-78-6]
Purity: 98%

No solubility data
C15H21N2HCl MW: 288.26



Axon 1257

mg	Price
10	online
50	online


Biological activity

5-HT uptake inhibitor; A major pharmacologically active metabolite of the anti-obesity drug, sibutramine

BTSA1

[314761-14-3]
Purity: 99%

Soluble in DMSO
C21H14N6O5S MW: 430.51



Axon 3431

mg	Price
10	online
50	online

Biological activity


BTSA1 is a potent BAX activator with an IC₅₀ value of 250 nM and an EC₅₀ value of 144 nM. BTSA1-induced BAX activation effectively and selectively promotes apoptosis of acute myeloid leukemia cells.

BTYNB

BTYNB IMP1 inhibitor

[304456-62-0]
Purity: 98%

Soluble in DMSO and EtOH
C12H9BrN2OS MW: 309.18



Axon 3437

mg	Price
10	online
50	online

Biological activity


BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA with an IC₅₀ value of 5 μM. The ring-closed derivative of BTYNB is also available as Axon 3481.

BTYNB isomer

BTYNB IMP1 inhibitor isomer

[1262217-87-7]
Purity: 99%

Soluble in DMSO and EtOH
C12H9BrN2OS MW: 309.18



Axon 3481

mg	Price
10	online
50	online

Biological activity

Ring-closed isomer of BTYNB (Axon 3437). Investigated as potential angiogenesis inhibitor.

BTYNB IMP1 inhibitor

See BTYNB

Axon 3437

Page 332

BTYNB IMP1 inhibitor isomer

See BTYNB isomer


Axon 3481

Page 332

BTZ043

BTZ10526043

[1161233-85-7]
Purity: 100%
Optically pure
Soluble in DMSO
C17H16F3N3O5S MW: 431.39



Axon 2698

mg	Price
10	online
50	online

Biological activity

Antimycobacterial agent that kills Mycobacterium tuberculosis (MIC values 2.3 nM and 9.2 nM against M. tuberculosis H37Rv and M. smegmatis, respectively) in vitro, ex vivo, and in mouse models of TB through inhibition of decaprenylphosphoryl-b-D-ribose 2'-epimerase (DprE1).

BUdR

See Bromo-2'-deoxyuridine, 5-

Axon 3419

Page 329

Bupropion hydrochloride


BW 322U; BVF 033; Amfebutamone

[31677-93-7]
Purity: 99%

Axon 1451

mg	Price
50	online

Soluble in water and DMSO
C13H18ClNO.HCl MW: 276.20



250 online

Biological activity

A dopamine and noradrenaline reuptake inhibitor and nicotinic acetylcholine receptor antagonist indicated for the treatment of major depressive disorder (MDD) and for the prevention of seasonal major depressive episodes in patients with seasonal affective disorder (SAD)

Buspar

See Buspirone hydrochloride

Axon 1995


Page 333

Buspirone hydrochloride

Buspar

[33386-08-2]
Purity: 100%

Soluble in water and DMSO
C21H31N5O2.HCl MW: 421.96




mg Price
25 online
100 online

Biological activity

Serotonin 5-HT1A receptor partial agonist; an anxiolytic psychoactive drug used primarily to treat generalized anxiety disorder (GAD); Suggestive evidence that buspirone reverses SSRI-induced sexual dysfunction

Butabindide oxalate

[185213-03-0]
Purity: 99%
optically pure
Soluble in water
C17H25N3O2.C2H2O4 MW: 393.43



Axon 1228
mg Price
10 online
50 online

Biological activity

Inhibitor of tripeptidyl peptidase II (TPPII)

Butanoic acid, sodium salt

See Sodium butyrate

Axon 2209


Page 877

Butenafine hydrochloride

KP363

[101827-46-7]
Purity: 100%

Soluble in DMSO
C23H27N.HCl MW: 353.93



mg Price
50 online


Biological activity

Butenafine hydrochloride is an antifungal agent which exhibits a wide spectrum activity in vitro against particularly dermatophytes, and also against Aspergillus, Cryptococcus neoformans and yeasts of genus Candida.

Butoconazole nitrate

[64872-77-1]
Purity: 99%

Soluble in DMSO and EtOH
C19H17Cl3N2S.HNO3 MW: 474.79



Biological activity

Butoconazole nitrate is a potent antifungal agent.

Axon 3508

mg Price
50 online

BVF 033

See Bupropion hydrochloride

Axon 1451

Page 332

BVD-523 hydrochloride

See Ulixertinib hydrochloride

Axon 4151

Page 951

BVdU

See Brivudine


Axon 3664

Page 329

BVT 2733 hydrochloride

[376641-65-5]
Purity: 99%

Soluble in DMSO
C17H21ClN4O3S2.HCl MW: 465.42



Biological activity

Selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1

Axon 1756

mg Price
5 online
25 online

BW 306U

See Radafaxine hydrochloride

Axon 1123

Page 806

BW 322U

See Bupropion hydrochloride

Axon 1451

Page 332

BWA509U

See Zidovudine


Axon 3382

Page 1006

BX 430

[688309-70-8]
Purity: 99%

Soluble in DMSO
C15H15Br2N3O MW: 413.11



Biological activity


Axon 2523

mg Price
10 online
50 online

Noncompetitive, allosteric antagonist of human P2X4 receptor channels (IC50 value 0.54 μ M as determined by Patch-clamp electrophysiology) with 10-100 fold selectivity over P2X1–P2X3, P2X5, and P2X7. A useful molecular probe to assess the specific role of P2X4 in inflammatory and neuropathic conditions, where ATP signaling has been shown to be dysfunctional. BX430 has no effect on mouse and rat P2X4Rs.

BX 471

[217645-70-0]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C21H24ClFN4O3 MW: 434.89




Biological activity

Potent, orally active and selective chemokine receptor CCR1 antagonist

BX 795

[702675-74-9]
Purity: 98%

Soluble in DMSO
C23H26IN7O2S MW: 591.47




Biological activity

BX 795 was initially developed as a PDPK1 inhibitor. Recent study highlighted on its bioactivity as a potent and relatively specific inhibitor of TBK1 and closely related IKK ϵ , with IC50 values to be 6, 41, and 111 nM for TBK1, IKK ϵ and PDPK1 respectively

BX 795 hydrochloride

[1472611-45-2]
Purity: 98%

Soluble in DMSO
C23H26IN7O2S.HCl MW: 627.93




Biological activity

The hydrochloride salt form of BX 795 (Axon 1390), which was initially developed as a PDPK1 inhibitor. Recent study highlighted on its bioactivity as a potent and relatively specific inhibitor of TBK1 and closely related IKK ϵ , with IC50 values to be 6, 41, and 111 nM for TBK1, IKK ϵ and PDPK1 respectively. The free base BX 795 is available as Axon 1390.

BX 912

[702674-56-4]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO, and Ethanol
C20H23BrN8O MW: 471.35



Biological activity

Inhibitor of 3-Phosphoinositide-dependent Kinase-1 (PDPK1)

Axon 2082

mg	Price
5	online
25	online

Axon 1390

mg	Price
2	online
5	online

Axon 3350

mg	Price
5	online
25	online

Axon 1130


mg	Price
2	online
5	online

BXL 628

Elocalcitol; RO 26-9228

[199798-84-0]
Purity: 99%

Soluble in DMSO and Ethanol
C29H43FO2 MW: 442.65



Biological activity

A vitamin D3 analog having agonistic activities at vitamin D receptor (VDR); BXL-628 inhibits prostate cell growth and RhoA/Rho-kinase signaling, a calcium sensitizing pathway; having anti-proliferative and anti-inflammatory properties in benign prostatic hyperplasia (BPH) treatment

BY 217

See Roflumilast

BYK 20869

See Roflumilast

BYK61359

See Soraprazan


BYL-719

See Alpelisib

BZ, γ -Secretase Inhibitor

Compound E

[209986-17-4]
Purity: 99%
optically pure
Soluble in DMSO
C27H24F2N4O3 MW: 490.50



Biological activity

Very potent and cell-permeable inhibitor of γ -secretase; potently inhibits Notch processing (IC50 values to be 2.2 nM in SupT1 cells); inhibits β -amyloid production in cell culture with an IC50 of 0.3 nM

Axon 1676

mg	Price
2	online
5	online

Axon 2352

Page 827

Axon 2352

Page 827

Axon 3589

Page 879

Axon 2925

Page 220


Axon 1487

mg	Price
1	online
5	online

C101248 Recent Addition

[361368-24-3]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C15H12N6O MW: 292.30


Biological activity

C101248 is a first potent and selective inhibitor of THIK-1 with an IC50 value of 50 nM. Moreover, C101248 was inactive against K2P family members TREK-1 and TWIK-2, and Kv2.1.

Axon 4122

mg	Price
10	online
50	online

C20

See YL-365


Axon 4090

Page 998

C25-140

[1358099-18-9]
Purity: 99%

Soluble in DMSO and EtOH
C26H31N7O MW: 457.57


Biological activity

C25-140 is a first-in-class TRAF6-Ubc13 inhibitor which reduces TRAF6-Ubc13 activity both in vitro and in cells. C25-140 impedes NF-κB activation in various immune and inflammatory signaling pathways also in primary human and murine cells. Moreover, C25-140 ameliorated inflammation and improved disease outcomes of autoimmune psoriasis and rheumatoid arthritis in preclinical in vivo mouse models.

Axon 3846

mg	Price
10	online
50	online

C33, (S)-

See PDE9A inhibitor C33(S)

Axon 2825

Page 756

C59

See Wnt-C59


Axon 2287

Page 987

C 646

[328968-36-1]
Purity: 99%

Moderately soluble in DMSO
C24H19N3O6 MW: 445.42


Biological activity

Competitive p300/CBP histone acetyltransferase (HAT) inhibitor with a Ki of 400 nM; Selective versus other acetyltransferases

Axon 1781

mg	Price
2	online
10	online

C65780

See DNA binder S20 hydrochloride


Axon 4080

Page 435

C 7280948

[587850-67-7]
Purity: 99%

Soluble in DMSO
C14H16N2O2S MW: 276.35


Biological activity


Sulfone inhibitor of PRMT1 (IC50 values 12.75 μM and 26.7 μM for oligopeptide that contains the amino acids 1–21 of human histone H4 and non-histone protein Npl3 as methylation substrates respectively). Useful tool in studying the epigenetic role of PRMT1. PRMT1 has been linked to the activation of estrogen and androgen receptors as well. PRMT1 is a necessary component for oncogenic transformation induced by a mixed lineage leukemia (MLL) complex, and therefore may represent a new treatment option for hormone-dependent cancer.

Axon 2210

mg	Price
10	online
50	online

C-82

[1422253-37-9]
Purity: 99%
99% e.e.
Soluble in DMSO
C33H34N6O4 MW: 578.66


Biological activity

C-82 is the second-generation, potent and specific inhibitor of CBP/β-catenin complex, and a modulator of the β-catenin dependent canonical Wnt signaling pathway in cancer stem cells. C-82 is the active form that exerts its effect on the designated target. It is rapidly generated (via dephosphorylation) in vivo from its pre-drug PRI-724 available as Axon 3748.

Source Information: Sold in collaboration with Chemietek

Axon 3748

mg	Price
2	online
5	online

CA 4

See Combretastatin-A4


Axon 1233

Page 381

CA77.1

[2412270-22-3]
Purity: 98%

Soluble in DMSO
C16H12ClN3O MW: 297.74


Biological activity

CA77.1 is an orally bioavailable and brain-penetrant CMA activator.

Axon 3906

mg	Price
10	online
50	online


Cabozantinib S-malate

XL 184

[1140909-48-3]

Axon 1819


mg	Price
----	-------

Purity: 99%		10	online
Soluble in DMSO C28H24FN3O5.C4H6O5 MW: 635.59		50	online

Biological activity
A orally available and potent inhibitor of multiple receptor tyrosine kinases (RTK), specifically MET and VEGFR2. It also inhibits KIT, FLT3, Tie-2, RET and AXL

CADD522

[199735-88-1]
Purity: 98%
Soluble in 0.1N NaOH(aq), DMSO and EtOH
C15H13Cl2NO3 MW: 326.17



Axon 3394

mg	Price
10	online
50	online

Biological activity
CADD522 is a potent inhibitor of RUNX2-DNA binding with an IC50 value of 10 nM. In vitro and in vivo studies reveal that CADD522 suppresses breast cancer growth and metastasis. Additionally, CADD522 inhibits mitochondrial oxidative phosphorylation by decreasing the mitochondrial oxygen consumption rate (OCR) and ATP production in human breast cancer cells in a RUNX2-independent manner.

CADO

See Chloroadenosine, 2-

Axon 1190

Page 366

CAI


See L651582

Axon 3185

Page 602

CAIX Inhibitor S4

[1330061-67-0]
Purity: 99%
Soluble in DMSO
C15H17N3O4S MW: 335.38



Axon 2662


mg	Price
10	online
50	online

Biological activity
S4 is a carbonic anhydrase (CA) IX and XII inhibitor (Ki values 7 nM and 2 nM, respectively) and showed a positive response in in vitro assays for tumor cell migration and spreading. Moreover, CAIX inhibitor S4 effectively inhibited the spontaneous metastasis formation in MDA-MB-231 xenografts.

CAL 101

Idelalisib

[870281-82-6]
Purity: 99%
Optically pure
Soluble in DMSO
C22H18FN7O MW: 415.42



Axon 2170

mg	Price
5	online
25	online

Biological activity

Orally active and selective inhibitor of PI3K delta-isoform (IC50 p110δ: 2.5nM), displaying clinical activity in chronic lymphocytic leukemia (CLL). Cal 101 is 40- to 300-fold more selective for PI3K-delta (δ) isoform relative vs other PI3K class I enzymes (p110α, p110β, and p110γ IC50 were 820, 565, and 89nM, respectively). It does not promote apoptosis in normal T cells or natural killer cells, nor does it diminish antibody-dependent cellular cytotoxicity.

CAL 120


See Acalisib

Axon 2857

Page 205

Calcium influx inducer compound 634

[882291-37-4]
Purity: 99%
Soluble in DMSO and EtOH
C15H15N3O4S3 MW: 397.49




Biological activity

Calcium influx inducer compound 634 enhanced the release of extracellular vesicles (EVs) with immunostimulatory potency via induction of Ca2+ influx. Moreover, compound 634 enhanced the number of EVs released by murine bone marrow-derived dendritic cells (mBMDCs) and increased costimulatory molecule expression on parental mBMDCs in a SOCE-dependent manner.

Calhex 231 hydrochloride

[N.A.]
Purity: 99%
optically pure
Soluble in DMSO
C25H27ClN2O.HCl MW: 443.41



Biological activity

Negative allosteric modulator (NAM) of the extracellular Calcium-sensing receptor (CaSR or CaR); inhibit Ca2+-induced accumulation of [3H]inositol phosphates in HEK293 cells (IC50: 0.39 microm)

Calixarene 0118

See OTX 008


Axon 2332

Page 740

Cambinol

NSC 112546

[14513-15-6]
Purity: 99%
Soluble in DMSO
C21H16N2O2S MW: 360.43




Biological activity

Cambinol inhibits NAD-dependent deacetylase activity of human SIRT1 and SIRT2 (IC50 values of 56 and 59 μM, respectively). Consistent with the role of SIRT1 in promoting cell survival during stress, inhibition of SIRT1 activity with cambinol during genotoxic stress leads to hyperacetylation of key stress response proteins and promotes cell cycle arrest. Cambinol exerts antitumor activity in vitro and in mouse xenograft studies. Moreover, cambinol is an uncompetitive nSMase2 inhibitor (Ki value of 7 μM).

CaMKII α inhibitor compound 4d

[3031484-08-6]
Purity: 98%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C14H11ClO4 MW: 278.69



Axon 3700

mg	Price
5	online
25	online

Biological activity

CaMKII α inhibitor compound 4d is a high-affinity ligand with enhanced pharmacokinetic properties interacting strongly with the CaMKII α hub domain (K_i value of 0.027 μ M). Powerful tool for potential allosteric regulation of CaMKII α kinase activity.

Camptothecin 11

See Irinotecan hydrochloride


Axon 3370

Page 570

Canagliflozin

JNJ-28431754; TA-7284

[842133-18-0]
Purity: 99%
Optically pure
Soluble in DMSO
C24H25FO5S MW: 444.52



Axon 3122

mg	Price
10	online
50	online

Biological activity


Canagliflozin is a highly potent and selective SGLT2 inhibitor with an IC50 value of 2.2 nM (hSGLT2). Canagliflozin showed pronounced anti-hyperglycemic effects in high-fat diet fed KK (HF-KK) mice.

Candesartan cilexetil

TCV-116

[145040-37-5]
Purity: 99%

Soluble in DMSO
C33H34N6O6 MW: 610.66



Axon 3104

mg	Price
50	online
250	online

Biological activity

Candesartan cilexetil is a potent and highly specific angiotensin II receptor antagonist. Prodrug which is metabolized to the active form Candesartan.

Canertinib dihydrochloride

See CI 1033

Axon 1433


Page 369

Cannabidiol

CBD

[13956-29-1]
Purity: 97.0%

Soluble in DMSO
C21H30O2 MW: 314.46



Axon 1234

mg	Price
10	online
50	online

Biological activity


Cannabidiol does not bind to CB1 or CB2 receptors but it does block the effects of cannabinoid agonists by an unknown indirect way. Recently it was found to be an antagonist at the putative new cannabinoid receptor, GPR55, a GPCR expressed in the caudate nucleus and putamen; a promising therapeutic agent for the treatment of psychosis, hyperalgesia, seizures, and stroke

Cannabidiol, Abnormal

Abn-CBD

[22972-55-0]
Purity: 98%

Soluble in DMSO
C21H30O2 MW: 314.46



Axon 1235

mg	Price
10	online
50	online

Biological activity

A regioisomer of cannabidiol without psychotropic activity; inactive at CB1 or CB2 receptors. However, it activates a third type of non-CB1/CB2 endo-cannabinoid receptor. Mechanism is under study

Cannabiscetin

See Myricetin


Axon 3559

Page 686

Capecitabine

Ro 09-1978

[154361-50-9]
Purity: 99%
Optically pure
Soluble in water, 0.1N HCl(aq), DMSO and EtOH
C15H22FN3O6 MW: 359.35



Axon 3460

mg	Price
50	online

Biological activity


Capecitabine is an oral prodrug that is converted to its only active metabolite fluorouracil, which is a TYMS inhibitor.

Capmatinib

INC280; INCB28060

[1029712-80-8]
Purity: 99%

Soluble in DMSO
C23H17FN6O MW: 412.42



Axon 3423

mg	Price
10	online
50	online

Biological activity


Capmatinib is a highly potent, selective, ATP competitive and orally bioavailable c-MET inhibitor with an IC50 value of 0.13 nM.

Caprospinol

SP 233

[4952-56-1]
Purity: 99%

Moderately soluble in Ethanol
C33H52O4 MW: 512.76



Axon 1442

mg	Price
10	online
50	online

Biological activity

An efficacious therapeutic indicated in Alzheimer's disease (AD); clearing beta-amyloid plaque in-vivo; restoring memory in rats

Carbamyl-β-methylcholine chloride

See Bethanechol chloride

Axon 3513

Page 298

Carbamylglutamate

See Carbamyl-L-glutamic acid, N-


Axon 3816

Page 343

Carbamyl-L-glutamic acid, N-

Carlumic acid; Carbamylglutamate

[1188-38-1]
Purity: 98%
Optically pure
Soluble in water, 0.1N NaOH(aq),
DMSO and EtOH
C6H10N2O5 MW: 190.15



Axon 3816

mg	Price
1000	online

Biological activity


N-Carbamyl-L-glutamic acid, a deacylase-resistant analogue of N-acetylglutamate, is a carbamyl phosphate synthetase 1 (CPS1) activator. N-Carbamyl-L-glutamic acid is used to treat primary N-acetyl-L-glutamate synthase deficiency and hyperammonemia associated with organic acidemias such as methylmalonic aciduria, propionic aciduria, and isovaleric aciduria.

Carbazeran

UK31557

[70724-25-3]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and
EtOH
C18H24N4O4 MW: 360.41



Axon 3574

mg	Price
5	online
25	online

Biological activity

Carbazeran is a potent phosphodiesterase inhibitor and an aldehyde oxidase (AO) substrate. Carbazeran produced positive inotropic responses in rabbit isolated heart preparations that were associated with increases in intracellular cyclic AMP and cyclic GMP concentrations.

Carboxyamidotriazole

See L651582


Axon 3185

Page 602

Cardiogenol C hydrochloride

[1049741-55-0]
Purity: 99%

Soluble in water and DMSO
C13H16N4O2.HCl MW: 296.75



Axon 2550

mg	Price
5	online
25	online


Biological activity

Selective and efficient inducer of the differentiation of ESCs to cardiomyocytes (EC50 value 0.1 μM for inducing the differentiation of myosin heavy chain (MHC) positive cardiomyocytes from ESCs in P19CL6 cells) Cardiogenol C induces cardiomyogenic function in lineage-committed progenitor cells, and can thus be considered a promising tool to improve cardiac repair by cell therapy.

Carfilzomib Recent Addition

PR-171

[868540-17-4]
Purity: 99%
Optically pure
Soluble in DMSO
C40H57N5O7 MW: 719.91



Axon 4218

mg	Price
10	online
50	online

Biological activity

An epoxomicin derivate with potential antineoplastic activity. It irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-m

Source Information: Sold in collaboration with Chemietek

Carlumic acid

See Carbamyl-L-glutamic acid, N-

Axon 3816


Page 343

Carvedilol

BM14190

[72956-09-3]
Purity: 99%

Soluble in DMSO and EtOH
C24H26N2O4 MW: 406.47



Axon 3456

mg	Price
50	online

Biological activity

Carvedilol is a β-adrenoceptor antagonist which also causes peripheral vasodilation primarily via α1-adrenergic blockade (Ki values of 0.81, 0.96 and 2.2 nM for β1-, β2-, and α1-adrenoceptors, respectively). Carvedilol produces its antihypertensive effect partly by reducing total peripheral resistance by blocking α1-adrenoceptors and by preventing β-adrenoceptor-mediated compensatory mechanisms.

CAS 997

See Tenilsetam

Axon 1470


Page 918

CASIN

Pir11-related compound 2

[425399-05-9]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C20H22N2O MW: 306.40



Axon 3987

mg	Price
10	online
50	online


Biological activity

CASIN is a selective Cdc42 activity inhibitor. Treatment with CASIN (5µM) reduced the elevated level of active Cdc42 observed in aged primitive hematopoietic cells to the level observed in young cells. CASIN treatment did not alter cell cycle status or apoptosis in aged LT-HSCs. In response to treatment with CASIN, LT-HSCs from aged mice showed a dose-dependent increase in the percentage of polarized cells, becoming progressively indistinguishable from young cells.

Casopitant mesylate

GW 679769B

[414910-30-8]
Purity: 100%
optically pure
Soluble in water and DMSO
C30H35F7N4O2.CH4O3S
MW: 712.72



Axon 1901


mg	Price
2	online
5	online

Biological activity

Potent, selective and orally active neurokinin 1 (NK1) receptor antagonist

CaSR antagonist 18c

[802916-30-9]
Purity: 99%
optically pure
Soluble in DMSO
C32H35N3O6 MW: 557.64



Axon 1732

mg	Price
5	online
25	online

Biological activity

Calcium-sensing receptor (CaSR) antagonist (IC50: 76 nM); potential anabolic agent for the treatment of osteoporosis

CAY10471 sodium

See TM30089 sodium

Axon 3966

Page 931

CAY 10683

See Santacruzamate A

Axon 2495

Page 842


CB096

Axon 3393

mg	Price
----	-------

[108883-90-5]
Purity: 99%

Soluble in DMSO
C14H11N3O4 MW: 285.25



10	online
50	online

Biological activity


CB096 selectively inhibited repeat associated non-ATG (RAN) translation and decreased the production of poly(GP) DPRs without affecting r(G4C2)66 mRNA levels in an HEK293T cellular model of c9ALS/FTD, alleviated dysfunctional nucleocytoplasmic transport, and selectively reduced the abundance of r(G4C2)66-induced stress granules. Moreover, CB096 is a selective binder to the r(G4C2)8 hairpin over r(G2C4)8 (antisense), r(GGCC)10 (base pair) RNAs, and other 1×1 internal loops.

CB-103

Limantrafin

[218457-67-1]
Purity: 99%

Soluble in DMSO
C15H18N2O MW: 242.32



Axon 4039

mg	Price
10	online
50	online

Biological activity


CB-103 is an orally available NOTCH pathway inhibitor. Exhibited anti-tumor efficacy in multiple in vivo models and patient-derived xenograft models. It is currently under evaluation as therapies for Advanced or Metastatic Solid Tumors and Hematological Malignancies.

Source Information: Sold in collaboration with Chemietek

CB-1158 dihydrochloride

Numidargistat dihydrochloride; INCB-01158 dihydrochloride

[N.A.]
Purity: 98%
99% e.e.
Soluble in water
C11H22BN3O5.2HCl MW: 360.04



Axon 3738

mg	Price
5	online
10	online

Biological activity

CB-1158 is an orally bioavailable, potent (IC50 = 98 nM), and selective (minimal off-target activity at 50000 nM) inhibitor of human arginase I, an immune-mediated anti-tumor agent. L-arginine is a critical metabolite for T-cell receptor signaling and subsequent T-cell proliferation, and depletion of arginine arrests T-cell growth. In the tumor microenvironment, infiltrating myeloid-derived suppressor cells (MDSCs), macrophages, and neutrophils produce arginase, which depletes local arginine concentrations and dampens T cell-mediated immune surveillance. Pharmacological inhibition of arginase is expected to restore arginine levels and allow T-cells to proliferate, thereby leading to an immune-mediated anti-tumor response. In culture, human granulocytes release arginase and deplete media arginine to levels that inhibit T-cell proliferation. In a co-culture system of human granulocytes and T-cells, CB-1158 potently blocks granulocyte-derived arginase activity, maintains extracellular arginine levels, and restores proliferation of T-cells. CB-1158 has single agent efficacy in mouse tumor models and synergistically enhances the antitumor efficacy of checkpoint inhibitors.

Source Information: Sold in collaboration with Chemietek

CB2R PAM C2


Ec2la

[2244579-87-9]
Purity: 99%

Soluble in DMSO
C21H24BrFN2O2 MW: 435.33

Axon 3955

mg	Price
5	online
25	online



Biological activity

CB2R PAM C2 is the first synthetic, potent and orally active CB2 receptor positive allosteric modulator (PAM).

CB-5083

[1542705-92-9]
Purity: 98%

Soluble in DMSO and EtOH
C₂₄H₂₃N₅O₂ MW: 413.47


Biological activity

CB-5083 is a first-in-class, potent, selective, and orally bioavailable inhibitor of p97 AAA ATPase with an IC₅₀ value of 11 nM.

CB 7598

See Abiraterone

CB 7630

See Abiraterone acetate

CB-839

See Telaglenastat

CBD

See Cannabidiol


CBLC4H10

See Reversan

CBR 5884

[681159-27-3]
Purity: 99%

Soluble in DMSO
C₁₄H₁₂N₂O₄S₂ MW: 336.39


Biological activity

Noncompetitive inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH; IC₅₀ value 33 μM) with selective toxicity towards cancer cell lines with high serine biosynthetic activity. CBR-5884 shows no inhibitory effect on two

Axon 4170

mg	Price
5	online
25	online

Axon 1873

Page 199

Axon 1874

Page 199

Axon 3532

Page 917

Axon 1234

Page 342

Axon 3222

Page 814

Axon 2585


mg	Price
10	online
50	online

other NAD⁺-dependent dehydrogenases, lactate dehydrogenase (LDH) and MDH1A. A useful tool to study the biology of de novo serine synthesis enabling preclinical evaluation of PHGDH as a target in cancer.

CBS1117

[959245-08-0]
Purity: 100%

Soluble in 0.1N HCl(aq) and DMSO
C₁₅H₂₀Cl₂N₂O MW: 315.24


Biological activity

CBS1117 is a virus entry inhibitor with an IC₅₀ value of 0.07 μM and a selectivity index of ~4000 against A/Puerto Rico/8/34 (H1N1) infection in human lung epithelial cell line (A549).

CBTC

See HSP47 inhibitor III


CC 292

See AVL 292

CC 401

[395104-30-0]
Purity: 99%

Soluble in DMSO and EtOH
C₂₂H₂₄N₆O MW: 388.47



Biological activity

A second generation ATP-competitive c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity

CC-671

[1618658-88-0]
Purity: 99%

Soluble in DMSO
C₂₈H₂₈N₆O₄ MW: 512.56


Biological activity


CC-671 is a potent and selective dual inhibitor of TTK (Human Protein Kinase Monopolar Spindle 1 (hMps1)) / CLK2 (CDC2-like Kinase), with IC₅₀ values of 5 nM and 3 nM, respectively, a unique feature targeting both TTK (mitotic exit) and CLK2 (mRNA splicing). It displays a strong single agent in vivo antitumor efficacy in multiple TNBC (Triple negative breast cancer) xenograft models.

Source Information: Sold in collaboration with Chemietek

CC-885

[1010100-07-8]
Purity: 99%

Soluble in DMSO
C₂₂H₂₁ClN₄O₄ MW: 440.88


Axon 3360

mg	Price
10	online
50	online

Axon 3294

Page 547

Axon 2226

Page 262

Axon 2025

mg	Price
5	online
25	online

Axon 3934

mg	Price
5	online
10	online

Axon 2645

mg	Price
5	online
25	online


Biological activity

Cereblon (CRBN) modulator with potent anti-tumour activity which is mediated through the cereblon-dependent ubiquitination and degradation of the translation termination factor GSPT1. CC-885 exhibits potent anti-proliferative activity in patient-derived acute myeloid leukaemia (AML) tumour cell lines.

CC-930

Tanzisertib

[899805-25-5]
Purity: 99%
Optically pure
Soluble in 0.1N HCl (aq) and DMSO
C21H23F3N6O2 MW: 448.44



Axon 2634

mg	Price
5	online
25	online

Biological activity

Potent, selective, and orally active anti-fibrotic JNK inhibitor (IC₅₀ values 61 nM, 7 nM, 6 nM, 480 nM, and 3400 nM for JNK1, JNK2, JNK3, ERK1, and p38α, respectively) for treatment of idiopathic pulmonary fibrosis (IPF).

CC-4047

See Pomalidomide

Axon 3166

Page 786

CC 5013

See Lenalidomide

Axon 1793

Page 611

CC 10004

See Apremilast

Axon 1957

Page 243

CC-94676

See BMS-986365 Recent Addition


Axon 4232

Page 322

CCG 232601

[1922099-21-5]
Purity: 99%

Soluble in DMSO
C24H20ClF2N3O2 MW: 455.88



Axon 2753

mg	Price
5	online
25	online


Biological activity

Inhibitor of the Rho/MRTF/SRF signaling pathway (IC₅₀ value of 0.55 μM (SRE.L assay)) as potential antifibrotic therapeutic for systemic sclerosis. CCG-232601 inhibited the development of bleomycin-induced dermal fibrosis in mice when administered orally.

CCG-203971

[1443437-74-8]
Purity: 99%

Soluble in DMSO
C23H21ClN2O3 MW: 408.88



Axon 3092

mg	Price
10	online
50	online


Biological activity

CCG-203971 is an inhibitor of the Rho/MKL1/SRF-mediated gene transcription pathway (IC₅₀ value of 4.2 μM).

CCG-222740

[1922098-69-8]
Purity: 98%

Soluble in DMSO
C23H19ClF2N2O3 MW: 444.86



Axon 3069

mg	Price
5	online
25	online


Biological activity

CCG-222740 is a potent and selective second-generation MRTF/SRF inhibitor with an IC₅₀ value of 5 μM in a fibroblast-mediated collagen contraction assay. CCG-222740 is more potent at preventing alpha-smooth muscle actin protein expression, is less cytotoxic, and effectively prevents scar tissue formation in a preclinical model of fibrosis (vs CCG-203971).

CCG 50014

[883050-24-6]
Purity: 99%

Soluble in DMSO
C16H13FN2O2S MW: 316.35



Axon 1931

mg	Price
10	online
50	online

Biological activity

Potent and selective inhibitor of regulator of G-protein signaling (RGS) proteins. It has an IC₅₀ value of 30 nM for RGS4 and 20 fold selectivity for RGS4 over other RGS proteins

CCI 779

See Temsirolimus

Axon 1699

Page 918

CCRG 81045

See Temozolomide

Axon 2326


Page 917

CCS-1477

Inobrodib

[2222941-37-7]
Purity: 99%
99% e.e.

Soluble in DMSO
C30H32F2N4O3 MW: 534.60



Axon 3933

mg	Price
5	online
10	online

Biological activity


CCS-1477 is a potent, selective and orally bioavailable inhibitor of the Bromodomain of p300 and CBP, binding to the targets with high affinity (K_d = 1.3/1.7nM) and selectivity (K_d = 222nM; BRD4). E1A binding protein (p300) and CREB binding protein (CBP) are two closely related transcriptional activators of androgen receptor (AR) and its variant forms. CCS-1477 enhances degradation of numerous cellular proteins including the AR and AR variants in prostate cancer cells; Demonstrates potent single-agent efficacy using in vitro and in vivo models of prostate cancer, and enhances the efficacy of Enzalutamide when used in combination. It is currently in clinical evaluation for the treatment of castrate resistant prostate cancer by down-regulation of AR, AR-SV and c-MYC expression

and function, which represents a new therapeutic option for prostate cancer patients who have progressed after failure of anti-androgen therapy and in combination with anti-androgens such as enzalutamide or abiraterone.
Source Information: Sold in collaboration with Chemietek

CCT 007093

[176957-55-4]
Purity: 99%

Moderately soluble in DMSO
C15H12OS2 MW: 272.39




Biological activity

An effective PPM1D inhibitor that selectively reduces viability of human tumour cell lines; apoptosis inducer

CCT 031374 hydrobromide

[1219184-91-4]
Purity: 98%

Soluble in DMSO
C23H19N3O.HBr MW: 434.33




Biological activity

Inhibitor of TCF-dependent transcription of genes of Wnt signaling pathway with in vivo activity in SW480 colon cancer cells (IC50 of 6.1 μM in a HEK293-based reporter cell line). CCT 031374 acts at the β-catenin level based on the observation that it blocked the nuclear β-catenin/transcription factor (TCF) transcription complex dependent transcription induced by a stabilized form of β-catenin, but not by a constitutively active TCF-VP16 fusion protein.

CCT 137690

[1095382-05-0]
Purity: 98%

Moderately soluble in DMSO
C26H31BrN8O MW: 551.48




Biological activity

Potent and orally bioavailable Aurora kinase inhibitor, with IC50 values to be 15, 25 and 19 nM for Aurora A, B and C kinases respectively

CCT196969

[1163719-56-9]
Purity: 99%

Soluble in DMSO
C27H24FN7O3 MW: 513.52



Biological activity

CCT196969 is a paradox-breaking pan RAF Inhibitor, targeting simultaneously RAF and SFKs. BRAF and MEK inhibitors are effective in treating BRAF mutant melanoma however most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or mutant NRAS, which

Axon 1821

mg	Price
10	online
50	online

Axon 2161

mg	Price
2	online
5	online

Axon 1836

mg	Price
10	online
50	online

Axon 3971

mg	Price
10	online
50	online


drive paradoxical reactivation of the pathway. By targeting pan RAF and SFKs, CCT196969 demonstrates efficacious inhibitory activity towards MEK/ERK in BRAF and NRAS mutant melanoma, while showing no effect on paradoxical pathway activation.

Source Information: Sold in collaboration with Chemietek

CCT-245737

PNT-737

[1489389-18-5]
Purity: 99%
99% e.e.
Soluble in DMSO
C16H16F3N7O MW: 379.34



Biological activity


CCT-245737 is an orally active, potent and selective CHK1 inhibitor, with an enzymatic IC50 value of 1.4 nM against CHK1 enzyme, and exhibited >1,000-fold selectivity against CHK2 and CDK1. It potently inhibited cellular CHK1 activity (IC50 30-220nM) and enhanced gemcitabine and SN38 cytotoxicity in multiple human tumor cell lines and human tumor xenograft models. Mouse oral bioavailability was complete (100%) with extensive tumor exposure. Genotoxic-induced CHK1 activity (pS296 CHK1) and cell cycle arrest (pY15 CDK1) were inhibited both in vitro and in human tumor xenografts by CCT-245737, causing increased DNA damage and apoptosis. CCT-245737 uniquely enhanced gemcitabine antitumor activity to a greater degree than for higher doses of either agent alone, without increasing toxicity, indicating a true therapeutic advantage for this combination. Furthermore, development of a novel ELISA assay for pS296 CHK1 autophosphorylation, allowed the quantitative measurement of target inhibition in a RAS mutant human tumor xenograft of NSCLC at efficacious doses of CCT-245737. Finally, CCT-245737 also showed significant single-agent activity against a MYC-driven mouse model of B-cell lymphoma.

Source Information: Sold in collaboration with Chemietek

CCT251236

[1693731-40-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C32H32N4O5 MW: 552.62



Biological activity

Highly potent, orally bioavailable inhibitor of the HSF1 stress pathway. CCT251236 displayed the desired balance of in vitro properties, while maintaining excellent cellular activity for inhibition of HSF1-mediated HSP72 induction (IC50 value of 19 nM). Moreover, CCT251236 displayed efficacy in a human ovarian carcinoma xenograft model. Promising chemical probe to investigate the role of HSF1 pathway inhibition and piriin binding in vitro and in vivo.


CCX282-B

See Vercimron

CD12681

[1952239-59-6]
Purity: 99%

Soluble in DMSO
C25H33N3O4S MW: 471.61



Biological activity

CD12681 is a potent RORγ inverse agonist with an IC50 value of 19 nM. CD12681 showed in vivo activity in an IL-23 induced skin inflammation model in mouse. Preclinical candidate for the topical treatment of psoriasis.

Axon 3932

mg	Price
5	online
10	online

Axon 2699

mg	Price
5	online
25	online

Axon 2685

Page 966


Axon 2964

mg	Price
10	online
50	online

CD161

[1627716-22-6]
Purity: 98%

Soluble in DMSO
C26H21N5O2 MW: 435.48



Biological activity

CD161 is a potent, orally active and selective BET bromodomain inhibitor (K_i values of 8.2 nM and 1.4 nM for BRD4 BD1 and BD2, respectively). CD161 inhibits cell growth in acute leukemia cell lines and breast cancer cell lines. Moreover, CD161 has an excellent oral pharmacokinetic profile and, orally administered, effectively inhibits tumor growth in mice.

CD336

See AM 580

CD38i 78c


See CD38 inhibitor compound 78c

CD38 inhibitor compound 78c

CD38i 78c

[1700637-55-3]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C22H27N3O3S MW: 413.53



Biological activity

CD38 inhibitor compound 78c is a potent, specific, reversible, and uncompetitive inhibitor of CD38 with IC_{50} values of 7.3 nM and 1.9 nM for human and mice, respectively. Compound 78c was given to diet induced obese (DIO) C57Bl6 mice, elevating NAD > 5-fold in liver and >1.2-fold in muscle versus control animals at a 2 h time point. Moreover, Compound 78c reverses age-related NAD⁺ decline and improves several physiological and metabolic parameters of aging, including glucose tolerance, muscle function, exercise capacity, and cardiac function in mouse models of natural and accelerated aging.


CDK8/19i

See ETP-47799

CDD-1653

[N.A.]
Purity: 98%

Soluble in DMSO
C21H22N6O4S MW: 454.50



Biological activity

CDD-1653 is a first-in-class, highly potent, and selective BMPR2 kinase inhibitor with an IC_{50} value of 2.8 nM.

Axon 2776

mg	Price
5	online
25	online

Axon 2948

Page 222

Axon 3570

Page 353

Axon 3570

mg	Price
5	online
25	online

Axon 3525

Page 470

Axon 3914


mg	Price
5	online
25	online

CDDO

Bardoxolone, RTA 401

[218600-44-3]
Purity: 98%

Soluble in DMSO
C31H41NO4 MW: 491.66



Biological activity


A potent multifunctional anti-tumor agent; CDDO induces apoptosis *in vitro* in malignant cells through both intrinsic and extrinsic pathways, and it controls cellular differentiation, apoptosis, and growth inhibition by serving as a ligand for the transcription factor PPAR gamma; highly active inhibitor of nitric oxide production in mouse macrophages; it shows antiinflammatory activity against thioglycollate-interferon-gamma-induced mouse peritonitis* Parent acid of CDDO-Me (Axon 1772)

CDDO-Me

Bardoxolone methyl; RTA 402

[218600-53-4]
Purity: 98%

Soluble in DMSO
C32H43NO4 MW: 505.69




Biological activity

Orally-available antioxidant inflammation modulator (AIM), being the most potent known inducer of the Nrf2 pathway; induces apoptosis of human tumor cells by disruption of redox balance and directly blocks IKK β activity and thereby the NF- κ B pathway

CDIBA

[479422-22-5]
Purity: 100%

Soluble in DMSO
C31H26ClNO3 MW: 496.00



Biological activity


Potent and selective cytosolic phospholipase A2 (cPLA2) inhibitor

C-DIM5

DIM-C-pPhOCH3

[33985-68-1]
Purity: 99%

Soluble in DMSO
C24H20N2O MW: 352.43



Biological activity

C-DIM5 is a Nur77 agonist. Activation of the orphan nuclear receptor Nur77 by C-DIM5 is associated with decreased cancer cell survival, induction of apoptosis, induced expression of the apoptosis gene/protein TRAIL, and inhibited tumor growth *in vivo*. C-DIM5 induces G0-G1-phase to S-phase arrest in Panc1 cells, and this is accompanied by Nur77-dependent induction of the cyclin-dependent kinase inhibitor p21.

Axon 1950

mg	Price
10	online
50	online

Axon 1772

mg	Price
5	online
25	online

Axon 1609

mg	Price
5	online
25	online

Axon 2828


mg	Price
10	online
50	online

C-DIM8

DIM-C-pPhOH

[151358-47-3]
Purity: 98%

Soluble in DMSO
C23H18N2O MW: 338.40



Axon 2827

mg	Price
10	online
50	online


Biological activity

C-DIM8 is a Nur77 (NR4A1) antagonist. Treatment of pancreatic and colon cancer cells with C-DIM8 mimics the effects of NR4A1 knockdown and decreases β 1-integrin expression, β 1-integrin regulated genes and responses including migration and adhesion.

CE3F4, (R)-

[1593478-56-8]
Purity: 99%

98% e.e.
Soluble in DMSO
C11H10Br2FNO MW: 351.01



Axon 2830

mg	Price
5	online
25	online

Biological activity


(R)-CE3F4 is an inhibitor of EPAC1 (IC50 value of 5.8 μ M) with a 10-fold selectivity for EPAC1 over EPAC2. (R)-CE3F4 prevents EPAC1 activation in vitro and in living cultured cells by inhibiting the GEF activity of EPAC1.

C-DIM12

DIM-C-pPhCl

[178946-89-9]
Purity: 99%

Soluble in DMSO
C23H17ClN2 MW: 356.85



Axon 2575

mg	Price
10	online
50	online


Biological activity

Potent and specific Nurr1 activator that stimulates Nurr1 mediated apoptosis axis in bladder cancer cells and tumors and inhibits NF- κ B-dependent gene expression in glial cells by stabilizing nuclear corepressor proteins, which reduces binding of p65 to inflammatory gene promoters. C-DIM12 protects against loss of dopamine neurons in the substantia nigra as well as dopamine terminals in the striatum in MPTP induced mouse models for Parkinson's disease.

CDK inhibitor CR8

(R)-CR8

[294646-77-8]
Purity: 99%
100% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C24H29N7O MW: 431.53



Axon 3228

mg	Price
5	online
25	online

Biological activity


CDK inhibitor CR8 is a potent cyclin-dependent kinase (CDK) inhibitor with IC50 values of 0.09, 0.072, 0.041, 0.11, 1.10 and 0.18 μ M for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p25, CDK7/cyclin H and

CDK9/cyclin T, respectively. Moreover, CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K.

CDN1163

[892711-75-0]
Purity: 100%

Soluble in DMSO
C20H20N2O2 MW: 320.39




Biological activity

CDN1163 is an allosteric activator of sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis in a genetic model of insulin resistance and type 2 diabetes (ob/ob mice). CDN1163 treatment significantly reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis. Moreover, CDN1163 increased ER calcium content, rescued neurons from ER stress-induced cell death in vitro, and showed significant efficacy in the rat 6-hydroxydopamine (6-OHDA) model of Parkinson's disease.

CE3F4

[143703-25-7]
Purity: 98%

Soluble in DMSO
C11H10Br2FNO MW: 351.01



Biological activity


CE3F4 is an inhibitor of EPAC1 with an IC50 value of 23 μ M. CE3F4 blocked EPAC1 guanine nucleotide exchange activity toward its effector Rap1 both in cell-free systems and in intact cells.

Cediranib

AZD 2171

[288383-20-0]
Purity: 99%

Soluble in DMSO
C25H27FN4O3 MW: 450.51




Biological activity

highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGF receptor; thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth

Cefdinir

FK482; PD134393; C1983

[91832-40-5]
Purity: 99%
Optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C14H13N5O5S2 MW: 395.41



Biological activity

Cefdinir is an orally active cephalosporin antibiotic.

Ceflatonin

See Homoharringtonine


Axon 3667

Page 545

Cefoperazone

T-1551

[62893-19-0]
Purity: 98%
Optically pure
Soluble in DMSO
C25H27N9O8S2 MW: 645.67



Axon 3123

mg	Price
50	online
250	online


Biological activity

Cefoperazone, a semisynthetic cephalosporin, is a broad-spectrum antibiotic. Cefoperazone has a broader spectrum of activity than related cephalosporins, including cefamandole and cefazolin and is significantly active against *Pseudomonas aeruginosa*, *Serratia marcescens*, and *Enterobacter cloacae*.

Cefoxitin sodium

MK306

[33564-30-6]
Purity: 100%
Optically pure
Soluble in water and DMSO
C16H16N3NaO7S2 MW: 449.43



Axon 3819

mg	Price
50	online


Biological activity

Cefoxitin sodium is a β -lactam cephalosporin antibiotic.

Cefsulodin sodium

GCP7174/E; SCE129

[52152-93-9]
Purity: 99%
Optically pure
Soluble in water and DMSO
C22H19N4NaO8S2 MW: 554.53



Axon 4044

mg	Price
50	online

Biological activity

Cefsulodin sodium is a third-generation β -lactam cephalosporin antibiotic. Cefsulodin sodium binds to penicillin-binding protein 1b and, through a series of complex events, inhibits the biosynthesis of the peptidoglycan component of the cell wall.

Celebra

See Celecoxib

Axon 1919

Page 358

Celebrex

See Celecoxib

Axon 1919


Page 358

Celecoxib

SC 58635; Celebrex; Celebra

[169590-42-5]
Purity: 99%

Soluble in DMSO
C17H14F3N3O2S MW: 381.37



Axon 1919

mg	Price
10	online
50	online

Biological activity


Selective cyclooxygenase-2 (COX-2) inhibitor (IC50: 15 and 0.04 μ M for COX-1 and COX-2 respectively); inhibition of COX-2 inhibits only prostaglandin synthesis without affecting thromboxane (TXA2) and thus offers no cardioprotective effects of NSAIDs, which inhibits both COX-1 and COX-2 non-selectively

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

Celiprolol hydrochloride

[57470-78-7]
Purity: 98%

Soluble in water and DMSO
C20H33N3O4.HCl MW: 415.95



Axon 1159

mg	Price
10	online
50	online

Biological activity

A β -blocker possessing strong β 1-adrenoceptor antagonist and mild β 2-agonist properties

CEM 101

See Solithromycin

Axon 2606


Page 878

Cenithaquin

Cenithaquin

[57961-90-7]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H25N3 MW: 331.45



Axon 3156

mg	Price
10	online
50	online

Biological activity

Cenithaquin is a centrally acting hypotensive agent predominantly inhibiting the neuronal norepinephrine release.

Cenithaquin

See Cenithaquin


Axon 3156

Page 358

CEP-28122

[1022958-60-6]
Purity: 99%
99% e.e.

Soluble in 0.1N HCl(aq) and DMSO
C28H35ClN6O3 MW: 539.07



Axon 3931

mg	Price
5	online
10	online

Biological activity


CEP-28122 is a highly potent, selective and orally active ALK inhibitor (Ezymatic IC₅₀: 1.9 nM, 3 nM, Cellular IC₅₀: 30 nM, Cellular IC₅₀ in 75% murine: 300 nM), displaying a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacologic efficacy against ALK-positive human cancer cells and tumor xenograft models in mice.

Source Information: Sold in collaboration with Chemietek

CEP-33779

[1257704-57-6]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C24H26N6O2S MW: 462.57



Axon 3671

mg	Price
5	online
25	online


Biological activity

CEP-33779 is a potent, selective and orally bioavailable JAK2 inhibitor with an IC₅₀ value of 1.8 nM.

CEP-37440 hydrochloride

[N.A.]
Purity: 99%
99% e.e.

Soluble in 0.1N HCl(aq) and DMSO
C30H38ClN7O3.HCl MW: 616.58



Axon 4038

mg	Price
10	online
50	online

Biological activity

CEP-37440 is a highly potent, selective and orally active inhibitor of ALK (Ezymatic IC₅₀: 3.5 nM, Cellular IC₅₀: 40 nM, Cellular IC₅₀ in 75% human plasma: 120 nM) and FAK (Ezymatic IC₅₀: 2.3 nM, Cellular IC₅₀: 88 nM), displaying a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacologic efficacy against ALK/FAK mediated human cancer cells and tumor xenograft models in mice.

Source Information: Sold in collaboration with Chemietek

Ceralasertib

See AZD6738

Axon 3134


Page 359

Cerdulatinib

PRT 062070

[1198300-79-6]
Purity: 98%

Soluble in DMSO
C20H27N7O3S MW: 445.54



Axon 2775

mg	Price
5	online
25	online

Biological activity

Cerdulatinib is an orally active kinase inhibitor that demonstrates activity against Syk and JAK with IC₅₀ values of 32 nM, 12 nM, 6 nM and 8 nM for Syk, JAK1, JAK2 and JAK3, respectively. Cellular assays demonstrated specific inhibitory activity against signaling pathways that use Syk and JAK1/3. Limited inhibition of JAK2 was observed. Potent antitumor activity was observed in a subset of B-cell lymphoma cell lines.

Ceritinib

See LDK 378

Axon 2224

Page 607

Cerovive

See NXY 059


Axon 1752

Page 727

Cetirizine dihydrochloride

[83881-52-1]
Purity: 99%

Soluble in water and DMSO
C21H25ClN2O3.2HCl MW: 461.81



Axon 3373

mg	Price
50	online

Biological activity


Cetirizine is a highly selective histamine H₁ receptor antagonist, with very low affinity for several other types of receptors, including adrenergic and serotonergic receptors.

Cevipabulin

TTI-237

[849550-05-6]
Purity: 98%

Soluble in 0.1N HCl (aq) and DMSO
C18H18ClF5N6O MW: 464.82



Axon 2916

mg	Price
5	online


Biological activity

Cevipabulin is a potent microtubule-active antitumor agent with an IC₅₀ value of 34 nM for cytotoxicity. Cevipabulin inhibits binding of vinblastine at the Vinca alkaloid site of the αβ-tubulin heterodimer. Moreover, Cevipabulin enhances the aggregation of microtubule protein at stoichiometric concentrations and also induces aggregation of highly purified tubulin in the absence of GTP. At low concentrations with cells, Cevipabulin induces mitotic spindle perturbations that do not cause mitotic block but lead to the production of multinuclear G₁ cells. Cevipabulin shows good antitumor activity in nude mouse xenograft models of human cancer.

CFM 2

[178616-26-7]
Purity: 98%

Soluble in DMSO
C17H17N3O3 MW: 311.34



Biological activity

Potent and selective AMPA antagonist


Axon 1217

mg	Price
10	online
50	online

CFT-7455

[2504235-67-8]
Purity: 99%
98% e.e.

Soluble in DMSO
C28H27N3O4 MW: 469.53



Axon 3763

mg	Price
5	online
10	online


Biological activity

CFT-7455 is an orally active monofunctional degrader for IKZF1/3 with picomolar IC₅₀ and DC₅₀, and an immunomodulatory agent.

Source Information: Sold in collaboration with Chemietek

CFT-8634

[2704617-96-7]
Purity: 99%
99% e.e.
Soluble in DMSO
C37H45F3N6O5 MW: 710.79



Axon 3764

mg	Price
5	online
10	online

Biological activity


CFT-8634 is a selective orally bioavailable BRD9 degrader.

Source Information: Sold in collaboration with Chemietek

cGAMP

2', 3'-Cyclic GMP-AMP Sodium salt

[2734858-36-5]
Purity: 99%
99% e.e.
Soluble in water
C20H22N10Na2O13P2 MW: 718.37



Axon 3688

mg	Price
1	online


Biological activity

2',3'-cGAMP (cyclic [G(2',5')pA(3',5')p]) is the endogenous agonist for the STING (STimulator of Interferon Genes), a receptor crucial to activate the innate immune system. It is a noncanonical cyclic dinucleotide (CDN) produced as a second messenger in mammalian cells by the cytosolic cGAS (cGAMP synthase) in response to double-stranded DNA in the cytoplasm. The binding potency of noncanonical 2',3'-cGAMP for human STING is much better than that of the canonical 3',3'-cyclic dinucleotides (CDNs) produced in bacterial, with a K_d of 4.6 nM compared to >1 μ M for bacterial 3',3'-CDNs.

Source Information: Sold in collaboration with Chemietek

CGI 1746

[910232-84-7]
Purity: 99%
Soluble in DMSO
C34H37N5O4 MW: 579.69



Axon 2018

mg	Price
2	online
5	online

Biological activity

Potent and highly selective inhibitor of Bruton's tyrosine kinase (Btk) (IC₅₀: 1.9 nM); CGI1746 inhibits B cell signaling and functional effects

CGM097

See NVP-CGM097

Axon 3751

Page 724

CGM097 dihydrochloride

See NVP-CGM097 dihydrochloride


Axon 3752

Page 724

CGP-12177A, (±)-

[64208-32-8]
Purity: 98%

Soluble in water and DMSO
C14H21N3O3.HCl MW: 315.80



Axon 3488

mg	Price
5	online

Biological activity

(±)-CGP-12177A is a β 1/ β 2-adrenoceptor antagonist and a β 3-adrenoceptor agonist with K_i values of 0.9, 4 and 88 nM for β 1-, β 2-, and β 3-adrenoceptor subtypes, respectively.

CGP48664A

See Sardomozide dihydrochloride

Axon 3290

Page 843

CGP48664 dihydrochloride

See Sardomozide dihydrochloride

Axon 3290

Page 843

CGP 48933

See Valsartan

Axon 3106

Page 961

CGP 57148B

See Imatinib Mesylate


Axon 1394

Page 561

CGP 57380

[522629-08-9]
Purity: 99%

Soluble in DMSO
C11H9FN6 MW: 244.23



Axon 1611

mg	Price
5	online
25	online

Biological activity

Inhibitor of MAP-kinase interacting kinase-1 (Mnk1, MKNK1) that displays selectivity over p38, JNK1, ERK1, ERK2, PKC and c-src family kinases

CGP7174/E

See Cefsulodin sodium


Axon 4044

Page 357

CGP 77675

[234772-64-6]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C26H29N5O2 MW: 443.54



Axon 2097

mg	Price
5	online
25	online

Biological activity


Potent and selective Src family kinase (SFK) inhibitor; CGP77675 inhibited phosphorylation of peptide substrates and autophosphorylation of purified Src (IC₅₀: 5-20 and 40 nM, respectively). The dual inhibition of Src and GSK3 signaling by CGP77675 and CHIR99021 (termed alternative 2i) was found to maintain mouse embryonic stem

cell (mESC) self-renewal and pluripotency marker expression as efficiently as the dual inhibition of MAPK and GSK3 by PD0325901 and CHIR99021 (conventional 2i). This alternative 2i method provides a versatile tool not only for the maintenance of mESCs in serum-free conditions but also for the derivation of ESCs from mouse embryos

CGS 15943

[104615-18-1]
Purity: 99%

Soluble in DMSO
C13H8ClN5O MW: 285.69



Axon 3736

mg	Price
10	online
50	online

Biological activity


CGS 15943 is a potent and selective adenosine receptor antagonist with K_i values of 3.5 nM, 4.2 nM, 16 nM and 51 nM for human A1, A2A, A2B and A3 receptors, respectively.

CGS 9343B

Zaldaride maleate

[109826-27-9]
Purity: 98%

Soluble in DMSO
C26H28N4O2.C4H4O4 MW: 544.60



Axon 1252

mg	Price
5	online
25	online


Biological activity

Inhibitor of Calmodulin activity

CGS 12066B

[109028-10-6]
Purity: 99%

Soluble in DMSO
C17H17F3N4.2C4H4O4
MW: 566.48



Axon 1206

mg	Price
10	online
50	online

Biological activity

Selective serotonin 5-HT1B receptor agonist

CGS 20267

See Letrozole


Axon 3257

Page 611

CGS 21680 hydrochloride

[124182-57-6]
Purity: 98%

Soluble in DMSO
C23H29N7O6.HCl MW: 535.98



Axon 1319

mg	Price
5	online
25	online

Biological activity

Selective A2A adenosine receptor agonist

CH2P4, 19-

See Org OD 02-0


Axon 2085

Page 736

CH 55

[110368-33-7]
Purity: 99%

Soluble in DMSO and Ethanol
C24H28O3 MW: 364.48



Axon 1241

mg	Price
10	online
50	online


Biological activity

Potent retinoic acid receptor (RAR) agonist

CH 5424802

[1256580-46-7]
Purity: 99%

Moderately soluble in DMSO
C30H34N4O2 MW: 482.62



Axon 1884

mg	Price
5	online
25	online

Biological activity

Potent, orally available and selective anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant

Champix

See Varenicline tartrate

Axon 2074

Page 962

Chantix

See Varenicline tartrate

Axon 2074

Page 962

Chembridge ID 5128535

See CID 5157334

Axon 3926

Page 370

Chidamide


See Tucidinostat

Axon 2893

Page 943

CHIR 090

[728865-23-4]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C24H27N3O5 MW: 437.49



Axon 2000


mg	Price
5	online
25	online

Biological activity

Very potent and selective UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC inhibitor (K_i : 1-2 nM and slow, tight-binding)

CHIR 124

[405168-58-3]
Purity: 98%
>98% ee
Soluble in 0.1N HCl(aq) and DMSO
C23H22ClN5O MW: 419.91



Axon 1636

mg	Price
2	online
5	online

Biological activity


Potent, cell permeable and selective Chk1 inhibitor (IC50: 0.32 nM and 697 nM for Chk1 and Chk2 respectively)

CHIR 98014

CT 98014

[252935-94-7]
Purity: 98%

Moderately soluble in DMSO
C20H17Cl2N9O2 MW: 486.31



Axon 1126

mg	Price
5	online
25	online

Biological activity


Very potent, selective, cell-permeable reversible inhibitor of GSK-3; highly recommended tool

CHIR 99021

CT 99021

[252917-06-9]
Purity: 99%

Soluble in DMSO
C22H18Cl2N8 MW: 465.34



Axon 1386

mg	Price
2	online
5	online

Biological activity


Very potent and specific glycogen synthase kinase GSK-3 inhibitor; highly recommended tool

CHIR 99021 dihydrochloride

CT 99021 dihydrochloride

[252917-06-9] (parent)
Purity: 99%

Soluble in water and DMSO
C22H18Cl2N8.2HCl MW: 538.26



Axon 2435

mg	Price
2	online
10	online

Biological activity

Very potent and specific glycogen synthase kinase GSK-3 inhibitor; highly recommended tool.
* CHIR99021 and PD0325901 (Axon 1408) are often used together as 2i in stem cell research.
Water soluble hydrochloride salt of CHIR 99021 (Axon 1386, parent molecule)

Chloro-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine, 4-


[157286-81-2]
Purity: 98%

No solubility data

Axon 1117

mg	Price
1000	online
5000	online

C17H18ClN3 MW: 299.80




Biological activity

Building Block

Chloro-4-(methylthio)-benzeneacetic acid methyl ester, 3-

[436141-65-0]
Purity: 98%

No solubility data
C10H11ClO2S MW: 230.71



Axon 1295

mg	Price
1000	online
5000	online

Biological activity

Building Block

Chloro-5-hydroxyphenylglycine, (RS)-2-

See CHPG


Axon 2691

Page 368

Chloro-8-fluoro-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one, 2-

[N.A.]
Purity: 99%

C13H8ClFN2O MW: 262.67



Axon 2866

mg	Price
50	online
250	online

Biological activity


Building block; starting material for preparation of Clozapine (Axon 1146) analogs.

Chloroadenosine, 2-

CADO

[146-77-0]
Purity: 99%

Soluble in DMSO
C10H12ClN5O4 MW: 301.69



Axon 1190

mg	Price
50	online
1000	online


Biological activity

A1 and A2A adenosine receptor agonist. The compound has a potent effect on the peripheral and central nervous system

Chloro-DPAT hydrochloride, 6-

[1246094-87-0]
Purity: 98%

Soluble in water
C16H24ClN.HCl MW: 302.28



Axon 1068


mg	Price
10	online
50	online

Biological activity

Chlorphentermine hydrochloride

[151-06-4]
Purity: 100%

Soluble in water, DMSO and EtOH
C10H14ClN.HCl MW: 220.14



Axon 3619

mg	Price
10	online
50	online


Biological activity

Chlorphentermine hydrochloride is a serotonin transporter (SERT) substrate with a K_i value of 338 nM for [3H]5-HT uptake.

Chloropurine riboside, 6-

Chloropurine 9- β -D-ribofuranoside; NSC 4910

[5399-87-1]
Purity: 98%
Optically pure
N.A.
C10H11ClN4O4 MW: 286.67



Axon 2417

mg	Price
1000	online
5000	online

Biological activity

Useful building block in the synthesis of 6-substituted purine ribosides

Chloropurine 9- β -D-ribofuranoside

See Chloropurine riboside, 6-


Axon 2417

Page 367

Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole, 3-

[131986-28-2]
Purity: 99%

N.A.
C7H4ClN3S MW: 197.64



Axon 2592

mg	Price
1000	online


Biological activity

Useful building block for the synthesis of FP-TZTP

Chloroquine diphosphate

NSC 14050

[50-63-5]
Purity: 99%
Racemate
Soluble in water
C18H26ClN3.2H3PO4 MW: 515.86



Axon 2431

mg	Price
50	online
250	online


Biological activity

Classical antimalarial drug (CQ) with lysosomotropic effects causing necrosis and apoptosis. Inhibitor of hemozoin (β -hematin) formation in malaria (*Plasmodium* strains) affected red blood cells. Nowadays, most of the *Plasmodium falciparum* strains are resistant to this drug. Chloroquine was found to inhibit the human thiamine transporter ThTr-2 (SLC19A3), and to inhibit cell growth and to induce cell death in A549 lung cancer cells.

CHPG

[170846-74-9]
Purity: 98%

Soluble in DMSO
C8H8ClNO3 MW: 201.61



Axon 2691

mg	Price
10	online
50	online


Biological activity

The mGluR5 receptor agonist CHPG selectively activates mGluR5a receptors (EC_{50} value of 750 μ M), compared to mGluR1a receptors, when expressed in CHO cells. CHPG also potentiates NMDA-induced depolarizations in rat hippocampal slices, and is suggested to act directly on mGluR5 in dopaminergic neurons to induce the release of DA. Also CHPG promotes proliferation of human embryonic cortical NSCs with activation of the MAPKs signaling pathway.

CHR 6494 trifluoroacetate

[1458630-17-5]
Purity: 99%

Soluble in DMSO
C16H16N6.C2HF3O2 MW: 406.36



Axon 2250

mg	Price
10	online
50	online


Biological activity

Specific, first-in-class inhibitor of histone kinase Haspin, which blocks H3T3 phosphorylation in association with a characteristic spindle and centrosome phenotype (IC_{50} values are 500 nM, 473 nM and 752 nM for apoptosis induction in HCT-116, HeLa and MDA-MB-231 cells, respectively). CHR 6494 causes arrest in G2/M, induces apoptosis and possesses ex vivo anti-angiogenesis features and antitumoral properties in a nude mice xenograft model. Haspin function is critical in mitosis, favouring chromosome cohesion, metaphase alignment and progression through the cell cycle.

Chromanol 293B

[163163-23-3]
Purity: 99%

Soluble in DMSO
C15H20N2O4S MW: 324.40



Axon 1294

mg	Price
10	online
50	online

Biological activity

Blocker of the slow delayed rectifier K^+ current via KCNQ1 channels

CI879

See Pramiracetam Recent Addition

Axon 4203

Page 789

CI906

See Quinapril hydrochloride

Axon 3655

Page 802

CI 945

See Gabapentin

Axon 1301

Page 495

CI983

See Cefdinir

Axon 3494


Page 356

CI 994

PD 123654; Tacedinaline

[112522-64-2]
Purity: 98%

Soluble in DMSO
C15H15N3O2 MW: 269.30



Axon 2014

mg	Price
10	online
50	online

Biological activity


Orally bioavailable histone deacetylase (HDAC) inhibitor that causes histone hyperacetylation in living cells. CI-994 inhibited HDAC1 and HDAC2 in a concentration-dependent fashion; mediates G1 cell cycle arrest, inhibits proliferation and induces apoptosis in vitro and in vivo

CI 1033

Canertinib dihydrochloride

[289499-45-2]
Purity: 99%

Soluble in water and DMSO
C24H25ClFN5O3.2HCl MW: 558.86



Axon 1433

mg	Price
5	online
25	online

Biological activity

An orally bioavailable tyrosine kinase inhibitor, targeting EGFR, irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation; water-soluble form

CI 1040

See PD 184352

Axon 1368

Page 754

CI 1043

See Pagoclone, (+)-


Axon 1594

Page 745

Ciclesonide

[126544-47-6]
Purity: 99%

Soluble in DMSO
C32H44O7 MW: 540.69



Axon 1426

mg	Price
10	online
50	online

Biological activity

A glucocorticoid used to treat obstructive airway disease

CID1261822

See ML193

Axon 4125


Page 665

CID 5157334

Chembridge ID 5128535

[651295-98-6]
Purity: 99%

Soluble in DMSO and EtOH
C19H14Cl2N2O3S MW: 421.30



Axon 3926

mg	Price
10	online
50	online


Biological activity

CID 5157334 is a selective surrogate agonist for GPR27 (pEC50 value of 6.38 for GPR27V2).

CID 755673

[521937-07-5]
Purity: 98%

Soluble in DMSO
C12H11NO3 MW: 217.22



Axon 1627

mg	Price
10	online
50	online

Biological activity

Selective protein kinase D (PKD) inhibitor

CID 767276

See ML346


Axon 2703

Page 671

CID 1067700

[314042-01-8]
Purity: 99%

Soluble in DMSO
C18H18N2O4S2 MW: 390.48



Axon 2184

mg	Price
10	online
50	online

Biological activity

First inhibitor of Rab7 GTPase exhibiting significant inhibitory potency on Rab7 nucleotide binding with nanomolar inhibitor (Ki) values and an inhibitory response of ≥97% for BODIPY-GTP and BODIPY-GDP binding (Ki values 13 nM and 19 nM, and EC50 values 11 and 21 nM respectively). CID 1067700 is a competitive guanine nucleotide binding inhibitor characterized for the Ras-super family of GTPases.

CID 12387471

See ML329


Axon 2733

Page 671

CID 1375606

[313493-80-0]
Purity: 98%

Soluble in DMSO
C20H14Cl2N2O2 MW: 385.24



Axon 2915

mg	Price
10	online
50	online


Biological activity

CID 1375606 is a selective surrogate agonist for GPR27 (pEC50 value of 6.34 for GPR27V2).

CID 2011756

[638156-11-3]
Purity: 99%

Soluble in DMSO
C22H21ClN2O3 MW: 396.87


Axon 1976

mg	Price
10	online
50	online

Biological activity

ATP-competitive and cell-permeable protein kinase D (PKD) inhibitor

CID 3111211

See ML 213


Axon 2747

Page 665

CID 5951923

[749872-43-3]
Purity: 100%

Soluble in DMSO
C16H18N2O7S MW: 382.39


Axon 1863

mg	Price
10	online
50	online

Biological activity


Inhibitor of the transcription factor Krüppel-like factor 5 (KLF5); significantly reduces endogenous KLF5 protein levels and decreases viability of colon cancer cells, without affecting the nontransformed intestinal epithelial cells IEC-6

CID 11654378

FMS inhibitor compound 8; FMS inhibitor compound 1b

[885704-21-2]
Purity: 99%

Soluble in DMSO
C23H30N6O MW: 406.52


Axon 2061

mg	Price
5	online
25	online

Biological activity

A highly potent FMS kinase inhibitor (IC50 = 0.8 nM); a proof-of-concept candidate in a collagen-induced model of arthritis in mice

CID 49766530

See ML 210

Axon 2017

Page 665

CID 49843203

See ML 239

Axon 2871

Page 666

CID 73169083

See ML401

Axon 3230

Page 672

CID 921541

See ML 367

Axon 2995

Page 670

CID2440433

See ML184

Axon 3028

Page 670

Ciforadenant

See CPI-444

Axon 3085

Page 392

Cilomilast

See SB 207499

Axon 1592


Page 845

Cimlanod

BMS986231; CXL1427

[1620330-72-4]
Purity: 99%

Soluble in water, DMSO and EtOH
C5H7NO4S MW: 177.18


Axon 3842

mg	Price
10	online
50	online

Biological activity

Cimlanod is a second-generation HNO donor.

Cinaciguat hydrochloride

See BAY 58-2667 hydrochloride


Axon 2172

Page 290

Cinepazide maleate Recent Addition

[26328-04-1]
Purity: 99%

Soluble in water and DMSO
C26H35N3O9 MW: 533.57


Axon 4205

mg	Price
50	online


Biological activity

Cinepazide maleate is a vasodilator.

Cinnabarinic acid

[606-59-7]
Purity: 98%

Soluble in 0.1N NaOH and DMSO
C14H8N2O6 MW: 300.22


Axon 3333

mg	Price
5	online
25	online

Biological activity

Cinnabarinic acid is an orthosteric mGlu4 receptor agonist. Cinnabarinic acid is a kynurenine metabolite generated by oxidative dimerization of 3-hydroxyanthranilic acid.

Cipralex

See Escitalopram oxalate

Axon 3315


Page 467

Ciproxifan maleate

FUB 359 maleate

[184025-19-2]
Purity: 99%

Soluble in DMSO
C16H18N2O2.C4H4O4 MW: 386.40



Axon 1993

mg	Price
5	online
25	online


Biological activity

Orally bioavailable, extremely potent and selective H3-receptor antagonist (Ki: 0.5-1.9 nM in vitro); a potential therapeutic agent in the treatment of Alzheimer's disease

CIQ

[486427-17-2]
Purity: 99%

Soluble in DMSO and EtOH
C26H26ClNO5 MW: 467.94



Axon 4169

mg	Price
10	online
50	online

Biological activity

CIQ is a first NMDA receptor-positive allosteric modulator with subunit-selectivity for NR2C and NR2D (EC50 values of 2.7 and 2.8 μM for NR2C and NR2D, respectively).

Citalopram oxalate, (S)-(+)-

See Escitalopram oxalate

Axon 3315


Page 467

Citalopram hydrobromide

ZD 211; LU 10-171

[59729-32-7]
Purity: 98%

Soluble in DMSO
C20H21FN2O.HBr MW: 405.30



Axon 1320

mg	Price
10	online
50	online

Biological activity

A very selective serotonin reuptake inhibitor (SSRI); Citalopram is used as an antidepressant drug on the market

Citarinostat

See ACY-241

Axon 3039

Page 207

CITFA


[2379989-52-1]

Axon 3844

mg	Price
----	-------

Purity: 99%

Soluble in DMSO
C25H35NO2 MW: 381.55



5	online
25	online

Biological activity

CITFA is a selective GPER agonist with an EC50 value of 38.7 nM. CITFA significantly increased axonal and dendritic growth in neurons extracted from embryonic day 18 (E18) fetal rat hippocampal neurons.

CJ-023,423

See Grapiprant


Axon 3787

Page 515

CK2 inhibitor 10

[1361229-76-6]
Purity: 99%

Soluble in DMSO
C18H14N2O4S MW: 354.38



Axon 2202

mg	Price
10	online
50	online

Biological activity

Potent and ATP-competitive inhibitor of protein kinase (CK2; IC50 values of 32 nM and 46 nM for CK2α and CK2α' respectively). At 0.30 μM, compound 10 exhibited a >50% inhibitory effect against 9 out of 70 other kinases besides CK2α and CK2α', while at 30 nM >75% inhibition was observed for two other kinases (DYRK1B and FLT3) only. It exhibited potent cytotoxicity towards lung cancer cells A549, colorectal cancer cells HCT-116, and breast cancer cells MCF-7.

CK3773274

See Aficamten

Axon 4000

Page 211

CK 452

See CK 1827452

Axon 1835


Page 374

CK 1827452

Omeceamtiv Mecarbil; CK-452

[873697-71-3]
Purity: 99%

Soluble in DMSO
C20H24FN5O3 MW: 401.43



Axon 1835

mg	Price
5	online
25	online

Biological activity

Selective cardiac specific myosin activator; clinically tested for its role in the treatment of left ventricular systolic heart failure

CK274

See Aficamten

Axon 4000


Page 211

CK-666

CK-0944666


Axon 3243

mg	Price
----	-------


[442633-00-3] Purity: 99%		10	online
Soluble in DMSO C18H17FN2O MW: 296.34		50	online

Biological activity
CK-666 is an Arp2/3 complex inhibitor with an IC50 value of 4 μM for inhibiting the HsArp2/3 complex. CK-666 binds to different sites on Arp2/3 complex and inhibits its ability to nucleate actin filaments.


CK-0944666 See CK-666	Axon 3243 Page 374
---------------------------------	------------------------------

CKI-7 dihydrochloride	Axon 3279		
[1177141-67-1] Purity: 99%		mg	Price
Soluble in water and DMSO C11H14Cl3N3O2S MW: 358.67		5	online
		25	online

Biological activity
CKI-7 dihydrochloride is a selective casein kinase I inhibitor with an IC50 value of 6 μM. CKI-7 dihydrochloride inhibits SGK as potently as CK1, and several other kinases, such as ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1).

Clarithromycin A56268: TE031	Axon 3445		
[81103-11-9] Purity: 98% Optically pure Soluble in DMSO and EtOH C38H69NO13 MW: 747.95		mg	Price
		50	online


Biological activity
Clarithromycin is an acid-stable orally administered macrolide antimicrobial drug, which has a broad spectrum of antimicrobial activity. The antibacterial effect of clarithromycin has been attributed to reversible binding to the 50S ribosomal subunit within the bacterial cell, thus inhibiting translocation of aminoacyl transfer-RNA and consequent protein synthesis.

Clemizole NSC 46261	Axon 2458		
[442-52-4] Purity: 99%		mg	Price
Soluble in 0.1N HCl(aq) and DMSO C19H20ClN3 MW: 325.84		10	online
		50	online


Biological activity

Inhibitor of the transient receptor potential channel TRPC5 with selectivity over other TRCP channels (IC50 values 9.1 μM, 6.4 μM, 1-1.3 μM, 11.3 μM, and 26.5 μM for TRPC3, TRPC4, TRPC5, TRPC6, and TRPC7). Only weakly affected TRPM3 and TRPM8, and TRPV1-4 at markedly higher concentrations of Clemizole. Clemizole was originally developed as antihistaminergic drug and found to inhibit monoamine reuptake in the brain. Clemizole was also found to exhibit antiviral activity by inhibition of NS4B binding to RNA in HCV.


Clindamycin Dalacine; U 21251	Axon 2063
---	------------------

[18323-44-9] Purity: 100%		mg	Price
Soluble in DMSO C18H33ClN2O5S MW: 424.98		10	online
		50	online

Biological activity
A bacterial protein synthesis inhibitor; a Lincosamide antibiotic; stops the growth of bacteria by disrupting their production of proteins; inhibits the ribosomal peptidyltransferase
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.


Clioquinol	Axon 3891		
[130-26-7] Purity: 98%		mg	Price
Soluble in 0.1N NaOH(aq), DMSO and EtOH C9H5ClINO MW: 305.50		50	online

Biological activity
Clioquinol is a MMP14/CLK-1 inhibitor and a metal chelator.

CLK8	Axon 3224		
[898920-65-5] Purity: 98%		mg	Price
Soluble in DMSO C29H26N2O6 MW: 498.53		5	online
		25	online

Biological activity
CLK8, a specific CLOCK-binding small molecule, inhibits the interaction between CLOCK and BMAL1 and interferes with nuclear translocation of CLOCK both in vivo and in vitro. CLK8 can be used to enhance circadian rhythm.

CLN-081 See TAS6417	Axon 3802 Page 911
-------------------------------	------------------------------

Clobenpropit dihydrobromide VUF 9153 dihydrobromide	Axon 1209		
[145231-35-2] Purity: 99%		mg	Price
Soluble in water C14H17ClN4S.2HBr MW: 470.65		10	online
		50	online

Biological activity

Potent histamine H3 receptor antagonist

Clomid

See Clomiphene citrate

Axon 3650


Page 377

Clomiphene citrate

Clomifene; Clomid

[50-41-9]
Purity: 99%

Soluble in water, DMSO and EtOH
C26H28ClNO.C6H8O7 MW: 598.08



Axon 3650

mg	Price
50	online

Biological activity

Clomiphene citrate is a selective estrogen receptor modulator. Clomiphene blocks hypothalamic estrogen receptors, signaling a lack of circulating estrogen to the hypothalamus and inducing a change in the pattern of pulsatile release of GnRH.

Clomifene

See Clomiphene citrate


Axon 3650

Page 377

Clonidine hydrochloride

[4205-91-8]
Purity: 99%

Soluble in water and DMSO
C9H9Cl2N3.HCl MW: 266.55



Axon 3044

mg	Price
50	online

Biological activity


Clonidine hydrochloride is an α 2-adrenergic receptor agonist. Antihypertensive agent with a primary site of action in the central nervous system. Also showed analgesic, anxiolytic and cognitive enhancing effects.

Clotrimazole

BAY b 5097

[23593-75-1]
Purity: 98%

Soluble in DMSO
C22H17ClN2 MW: 344.84



Axon 3163


mg	Price
50	online
250	online

Biological activity

Clotrimazole is an orally applicable antifungal substance with broad-spectrum activity. Clotrimazole inhibits the microsomal cytochrome P450 (CYP450)-dependent event 14- α -lanosterol demethylation, which is a vital step in ergosterol biosynthesis by fungi. Moreover, Clotrimazole is a strong inhibitor of epidermal polycyclic aromatic hydrocarbon (PAH) carcinogen metabolism, of the enzyme-mediated binding of PAH to DNA, and of PAH-induced skin cancer. Also, Clotrimazole is a potent inhibitor of epoxide hydrolase activity in vitro with an IC50 value of 0.1 mM.

Clovamide, trans-

[53755-02-5]
Purity: %
Optically pure
Soluble in water, DMSO and EtOH
C18H17NO7 MW: 359.33



Axon 3474


mg	Price
5	online
25	online

Biological activity

trans-Clovamide is a naturally occurring caffeoyl conjugate and a potent antioxidant. trans-Clovamide is able to protect neurons from injury in three in vitro models of neuronal death: oxidative stress, excitotoxicity and OGD/reoxygenation. Moreover, trans-Clovamide is a powerful oxygen radical scavenger, partially contributed by its molecular catechol moieties. Also, trans-Clovamide is believed to exhibit preventive effects on A β aggregation.

Cloxacillin sodium

[642-78-4]
Purity: 99%
Optically pure
Soluble in water, DMSO and EtOH
C19H17ClN3NaO5S MW: 457.86



Axon 3653

mg	Price
50	online


Biological activity

Cloxacillin sodium is an orally active penicillinase (beta-lactamase) resistant antibiotic which belongs to the group of penicillins.

Clozapine

[5786-21-0]
Purity: 99%

Soluble in DMSO
C18H19ClN4 MW: 326.82



Axon 1146

mg	Price
10	online
50	online


Biological activity

A putative atypical antipsychotic; Clozapine has been shown to be superior in efficacy in treating schizophrenia, however, the drug is not indicated for first-line use because of its association with agranulocytosis and seizures

Clozapine N-oxide

[34233-69-7]
Purity: 99%

Soluble in water and DMSO
C18H19ClN4O MW: 342.82



Axon 2796

mg	Price
10	online
50	online

Biological activity

Metabolite of the atypical antipsychotic agent Clozapine (Axon 1146). Muscarinic DREADD (designer receptor exclusively activated by a designer drug) agonist.

Clozapine, N-Desmethyl-


Norclozapine; Normethylclozapine; ACP-104

[6104-71-8]
Purity: 99%

Axon 2846

mg	Price
5	online

Soluble in 0.1N HCl(aq) and DMSO
C17H17ClN4 MW: 312.80



25 online

Biological activity

Major metabolite of Clozapine (Axon 1146). *N*-Desmethylclozapine is a relatively potent and efficacious partial agonist at the D2 and D3 dopamine receptors, while showing inverse agonism at the 5-HT2A receptor. Moreover, *N*-Desmethylclozapine is a potent partial agonist at the muscarinic M1 receptor and a selective agonist at δ opioid receptor.

CLT-003

See TC11


Axon 3149

Page 914

CM1

[1643659-63-5]
Purity: 100%

Soluble in water and DMSO
C14H22N2O3 MW: 266.34



Axon 2479

mg Price

10 online

50 online


Biological activity

Orally active iron chelator with high affinity and selectivity for iron(III) (relative metal complex stability constants of $pFe^{3+}=20.3$; $pCu^{2+}=9.8$; $pZn^{2+}=6.2$.) and a suit-able partition coefficient to permeate membranes. CM1 is able to penetrate hepatocytes and relatively non toxic. Potential therapeutic for patients suffering from thalassaemia related iron overload. Moreover, CM1 shows an inhibitory effect on the growth of *Plasmodium falciparum* (malaria parasite; IC50 value 35 μ M).

CM-272

[1846570-31-7]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C28H38N4O3 MW: 478.63



Axon 2812

mg Price

5 online

25 online

Biological activity


CM-272 is a first-in-class potent, selective and reversible inhibitor of histone methyltransferase G9a and DNA-methyltransferase 1 with IC50 values of 8nM and 382 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death. Moreover, CM-272 significantly prolongs survival of AML, ALL and DLBCL xenogeneic models.

CM-4620

Zegocractin

[1713240-67-5]
Purity: 98%

Soluble in DMSO and EtOH
C19H11ClF3N3O3 MW: 421.76



Axon 4066

mg Price

5 online

25 online

Biological activity

CM4620 is a selective Orai1 channel inhibitor. CM4620 inhibits Ca²⁺ entry via store operated Ca²⁺ entry (SOCE) channels formed by stromal interaction molecule 1 (STIM1)/Orai complexes, attenuates acinar cell pathology and acute pancreatitis in mouse experimental models.

CMAT

See Aminotetraline hydrobromide, N-Cyclopropyl-N-methyl-2-


Axon 1066

Page 229

CMP5

[1030021-40-9]
Purity: 99%

Soluble in water and DMSO
C21H22ClN3 MW: 351.87



Axon 2709

mg Price

10 online

50 online


Biological activity

CMP5 is a selective PRMT5 inhibitor that blocked EBV-driven B-lymphocyte transformation and survival while leaving normal B cells unaffected. Also CMP5 inhibited Th1 cell proliferation (IC50 value 3.7 μ M) more potently than Th2 cell proliferation (IC50 value 9.2 μ M). In vivo, PRMT5 blockade efficiently suppressed recall T cell responses and reduced inflammation in delayed-type hypersensitivity and clinical disease in experimental autoimmune encephalomyelitis mouse models.

CMPDA

[380607-77-2]
Purity: 99%

Soluble in DMSO
C16H28N2O4S2 MW: 376.53



Axon 2079

mg Price

5 online

10 online

Biological activity

Positive allosteric modulator (PAM) of AMPA receptor; more specifically, CMPDA allosterically modulates AMPA subunit GluA2 receptor (GluR2) and its desensitization and deactivation

CN 801

See Modafinil

Axon 1296


Page 675

CNDAC hydrochloride

DFP-10917 hydrochloride; TAS-109 hydrochloride

[134665-72-8]
Purity: 99%
99% e.e.

Soluble in water and DMSO
C10H12N4O4.HCl MW: 288.69



Axon 3970

mg Price

5 online

25 online

Biological activity

CNDAC is an orally available deoxycytosine nucleoside analog with potential antineoplastic activity. Upon administration, CNDAC is phosphorylated to generate its nucleotide form, functioning as a deoxycytosine mimic and is incorporated into DNA in tumor cells. This causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, resulting in G2/M phase-arrest and tumor cell apoptosis.


Source Information: Sold in collaboration with Chemietek

CNF 2024

BIIB 021

[848695-25-0]
Purity: 99%

Soluble in DMSO
C14H15ClN6O MW: 318.76



Biological activity

Oral inhibitor of heat shock protein 90 (Hsp90) under clinical development


CNO

See Clozapine N-oxide

CNQX

[115066-14-3]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C9H4N4O4 MW: 232.15




Biological activity

A competitive AMPA/kainate receptor antagonist

CNQX disodium salt

[479347-85-8]
Purity: 99%

Soluble in water and DMSO
C9H2N4Na2O4 MW: 276.12



Biological activity


A competitive AMPA/kainate receptor antagonist. Water soluble form of CNQX (Axon 1200)

CNV 1014802 hydrochloride

GSK 1014802 HCl; GSK2 hydrochloride; Raxatrigine hydrochloride

[934240-31-0]
Purity: 99%

Soluble in water and DMSO
C18H19FN2O2.HCl MW: 350.82



Biological activity

Sodium channel blocker with potent anticonvulsant activity; potential for novel treatment for Schizophrenia. CNV 1014802 (GSK2) was tested in clinical trials for treatment of trigeminal neuralgia, and shows selectivity for the Nav1.7 subtype over the other subtypes tested (Nav1.1, Nav1.2, Nav1.3, Nav1.5, Nav1.6 and TTX-R), for both the resting and depolarized state. The parent molecule of CNV 1014802 (Axon 1899) is available as well.

Axon 1543

mg Price

5 online

25 online

Axon 2796

Page 378

Axon 1200

mg Price

10 online

50 online

Axon 2522

mg Price

10 online

50 online

Axon 2548

mg Price

5 online

25 online


Cobimetinib

See GDC-0973

COH000

[1534358-79-6]
Purity: 98%

Soluble in DMSO
C25H25NO5 MW: 419.47




Biological activity

COH000 is a first-in-class, highly specific, covalent allosteric inhibitor of the SUMO E1 activating enzyme. COH000 has been demonstrated to induce strong anti-tumor effects in colorectal cancer cells as well as mouse and patient-derived xenograft models.

Col003

[328565-16-8]
Purity: 99%

Soluble in DMSO
C14H11NO4 MW: 257.24



Biological activity

Col003 is a potent, competitive collagen-heat-shock protein 47 (Hsp47) interaction inhibitor with an IC50 value of 1.8 μM.


Coleonol

See Forskolin

Colchicine

[64-86-8]

Purity: 99%
Optically pure
Soluble in water and DMSO
C22H25NO6 MW: 399.44



Biological activity

Colchicine is a classical anti-mitotic drug which blocks mitotic cells in metaphase. It binds to soluble tubulin to form tubulin-colchicine complexes in a poorly reversible manner, which then binds to the ends of microtubules to prevent the elongation of the microtubule polymer.

Colistin sulfate

Polymixin E sulfate

[1264-72-8]

Purity: 98%
Optically pure
Soluble in water

Axon 4148

Page 499

Axon 2935

mg Price

5 online

25 online

Axon 3568

mg Price

10 online

50 online

Axon 2264

Page 490

Axon 3371

mg Price


50 online

Axon 3453

mg Price

50 online

C52H98N16O13.3H2SO4 MW:
1253.51



Biological activity


Colistin sulfate has potent antiendotoxic properties and antibacterial activity against Pseudomonas aeruginosa and many of the Enterobacteriaceae. Colistin sulfate is an amphipathic molecule that interacts with lipopolysaccharide in the bacterial outer membrane.

Combretastatin-A4

CA 4

[117048-59-6]
Purity: 98%

Soluble in DMSO
C18H20O5 MW: 316.35



Biological activity

A potent inhibitor of tubulin polymerization and displays strong inhibitory activity on tumor cell growth

Compound 1

See PRMT3 inhibitor 1

Compound 2

See HIF-2 inhibitor 2

Compound 3

See Rolofylline metabolite M1-trans

Compound 4

See Rolofylline metabolite M1-cis

Compound 6c

See CXCR3 Antagonist 6c

Compound 10

[841210-82-0]
Purity: 99%

Soluble in DMSO

Axon 1233

mg	Price
10	online
50	online

Axon 2211

Page 791

Axon 2034

Page 541

Axon 1851

Page 828

Axon 1852

Page 828


Axon 1800

Page 401

Axon 3035

mg	Price
5	online
25	online

C22H19N5O2S MW: 417.48



Biological activity

Tool compound targeting the NFAT:AP-1 transcriptional complex on DNA

Compound 12

See ADAMTS-5 inhibitor

Compound 12i

See Vasopressin antagonist 1867

Compound 18a

See CX3CR1 antagonist 18a

Compound 24

See Nav1.7 blocker 24


Compound 52

See Nav1.7 blocker 52

Compound 120

Atazanavir, deuterated

[1092540-56-1] (parent)
Purity: 99%
optically pure
Soluble in DMSO
C38H37D15N6O7.H2SO4
MW: 818.03



Biological activity

A partially deuterated analog of Atazanavir (Axon 1441), an oral HIV protease inhibitor; A deuterium-containing medicine with improved ADME properties; Compound 120 showed an approximately 50% increase in half life compared with Atazanavir.

Compound 211

See NQ301

Compound B

See BETP

Axon 2083

Page 207

Axon 1867

Page 963

Axon 2255

Page 401

Axon 1791

Page 693

Axon 1780

Page 693

Axon 1753

mg	Price
2	online
5	online

Axon 2702

Page 710

Axon 2259

Page 298

Compound E

See BZ, γ -Secretase Inhibitor


Axon 1487

Page 336

Conoidin A

[18080-67-6]
Purity: 98%

Soluble in DMSO and EtOH
C10H8Br2N2O2 MW: 347.99



Axon 3911

mg	Price
10	online
50	online

Biological activity


Conoidin A is a covalent, cell permeable inhibitor of *T. gondii* PrxII with an IC50 value of 25.1 μ M.

CoPo 22

Methoxybenzamide, N-([2-[(3-cyano-5,7-dimethyl-2-quinolinyl)amino]ethyl]-3-

[606101-83-1]
Purity: 99%

Soluble in DMSO
C22H22N4O2 MW: 374.44



Axon 1763

mg	Price
5	online
25	online


Biological activity

Corrector and potentiator (Co-Po) for Δ F508-cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel function in cystic fibrosis, with low micromolar EC50

Cordycepin

3'-Deoxyadenosine

[73-03-0]
Purity: 99%
Optically pure
Soluble in water, 0.1N HCl(aq), DMSO and EtOH
C10H13N5O3 MW: 251.24



Axon 3825

mg	Price
10	online
50	online


Biological activity

Cordycepin is a nucleoside analogue similar in structure to adenosine and it has been proposed as an anticancer drug due to its numerous biological and pharmacological actions including inhibition of cell proliferation, induction of apoptosis, antimetastatic effect, and immune system activation. Cordycepin is also an anti-inflammatory agent.

COTI-2

[1039455-84-9]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C19H22N6S MW: 366.48



Axon 2841

mg	Price
10	online
50	online

Biological activity

COTI-2 is an anti-cancer drug which appears to act both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. Proposed to cause cancer cell death via apoptosis. COTI-2 exhibits potent anti-

proliferative activity against a wide variety of human cancer cell lines in vitro (at nanomolar concentrations) and against human tumor xenografts.

Coumate, 667

See STX64

Axon 2892

Page 897

CP 20961

See Avidine

Axon 2099

Page 263

CP 26154

See MLR 1023


Axon 1941

Page 675

CP 31398

[1217195-61-3]
Purity: 98%

Soluble in water and DMSO
C22H28Cl2N4O MW: 435.39



Axon 2879

mg	Price
10	online
50	online

Biological activity

CP 31398 stabilizes the core domain of the tumour suppressor p53 in vitro and is an effective anti-cancer drug by virtue of rescuing destabilized mutants of p53. Moreover, CP 31398 can induce apoptosis of human cancer cells.

CP456773

See MCC950 sodium salt

Axon 4052

Page 642

CP 45899 sodium

See Sulbactam sodium

Axon 2041

Page 899

CP 62993

See Azithromycin

Axon 2042

Page 279

CP-868596

See Crenolanib

Axon 3969

Page 394

CP 88059

See Ziprasidone hydrochloride

Axon 1446

Page 1007

CP 93393 hydrochloride

See Sunepitron hydrochloride

Axon 1519

Page 900

CP 93393-1

See Sunepitron hydrochloride


Axon 1519

Page 900

CP 94253 hydrochloride

[845861-39-4]
Purity: 99%

Soluble in water and DMSO
C15H19N3O.HCl MW: 293.79



Axon 1945

mg	Price
10	online
50	online

Biological activity

Potent and selective serotonin 5-HT1B receptor agonist, with K_i values to be 2 nM for 5-HT1B and 89, 860, 49 and 1600 nM for 5-HT1A, 5-HT1C, 5-HT1D and 5-HT2 receptors respectively


CP 99219 mesylate

See Trovafloxacin mesylate

CP 100356 Hydrochloride

[142715-48-8]
Purity: 98%

Soluble in DMSO
C31H36N4O6.HCl MW: 597.10



Axon 2100

Page 940

Axon 1654

mg	Price
10	online
50	online

Biological activity


Potent inhibitor of P-glycoprotein (P-gp), with K_i to be 58 and 94 nM for 1a and 1b isomers of P-gp; an in vivo probe to selectively assess MDR1/BCRP-mediated drug efflux

CP 101606

Traxoprodil

[134234-12-1]
Purity: 99%
98% d.e.

Soluble in water and DMSO
C20H25NO3 MW: 327.42



Axon 2254

mg	Price
10	online
50	online

Biological activity


Potent and NR2B selective antagonist of NMDA glutamate receptors A water soluble form, CP 101606 mesylate (Axon 1406) is readily available as well.

CP 101606 mesylate

Traxoprodil mesylate

[134234-12-1]
Purity: 99%
optically pure

Soluble in water and DMSO
C20H25NO3.CH4O3S MW: 423.52



Axon 1406


mg	Price
5	online
25	online

Biological activity

Potent and NR2B selective antagonist of NMDA glutamate receptors. The parent compound CP 101606 (Axon 2254) is readily available as well.

CP 135807

[151272-90-1]
Purity: 99%
Optically pure
Soluble in DMSO
C19H21N5O2 MW: 351.40



Biological activity

Selective 5-HT agonist which binds with high affinity to central 5-HT1D receptors. In functional studies CP 135807 produces dose-dependent decreases in extracellular serotonin

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.


Axon 2102

mg	Price
5	online
25	online

CP 154526 hydrochloride

[257639-98-8]
Purity: 99%

Soluble in DMSO and Ethanol
C23H32N4.HCl MW: 400.99



Biological activity

Corticotropin-releasing factor CRF1 antagonist


Axon 1116

mg	Price
10	online
50	online

CP 226269

[220941-93-5]
Purity: 99%

Soluble in DMSO
C18H19FN4 MW: 310.37



Biological activity


Selective dopamine D4 agonist; highly recommended tool for researching the role of D4 receptor in the brain

Axon 1521

mg	Price
5	online
25	online

CP 316819

[186392-43-8]
Purity: 99%
optically pure
Soluble in DMSO
C21H22ClN3O4 MW: 415.87



Biological activity

Potent glycogen phosphorylase (GPase) inhibitor (IC50: 40 nM against human liver GPα). CP-316819 facilitates glycogen utilization in the brain, prevents neuronal cell death and maintains brain electrical currents


Axon 1847

mg	Price
10	online
50	online

CP 346086

[186390-48-7]
Purity: 99%

Soluble in DMSO
C26H22F3N5O MW: 477.48



Axon 2216

mg	Price
10	online
50	online

Biological activity

Potent microsomal triglyceride transfer protein (MTP, MTTP) inhibitor that inhibits both human and rodent MTP activity (IC50 value 2.0 nM). After a 2 week treatment CP 346086 reduced total and LDL cholesterol and triglycerides by 47%, 72%, and 75%, relative to either individual baselines or placebo, with little change in HDL cholesterol. More potent in MTP inhibition than SLX 4090 and Lomitapide (Juxtapid; IC50 value 8 nM and 5-7 nM respectively).

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

CP 358774

See Erlotinib hydrochloride

Axon 1128


Page 466

CP 466722

[1080622-86-1]

Purity: 99%

Soluble in DMSO
C17H15N7O2 MW: 349.35



Axon 1495

mg	Price
2	online
5	online

Biological activity


Specific ATM inhibitor; no inhibition of PI3K or PI3K-like protein kinases (PIKK) or Abl kinase in cells; does inhibit cellular ATM-dependent phosphorylation events and disruption of ATM function resulted in characteristic cell cycle checkpoint defects; highly recommended tool to rapidly and reversibly regulate ATM activity

CP 471474

[210755-45-6]

Purity: 0%

Soluble in DMSO
C16H17FN2O5S MW: 368.38



Axon 2104

mg	Price
10	online
50	online

Biological activity

CP 471474 is a matrix metalloprotease inhibitor with sub-nanomolar affinity for MMP-2 and 13 among a broad range of MMPs (IC50: 1170, 0.7, 16, 13, 0.9 for MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13 respectively). It attenuates early left ventricular dilation after experimental myocardial infarction in mice. Similarly, CP-471474 attenuated both the early inflammatory response and the emphysematous lesions induced by chronic exposure to cigarette smoke in guinea pigs.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

CP 526555-18

See Varenicline tartrate

Axon 2074

Page 962

CP 529414

See Torcetrapib

Axon 2047


Page 936

CP 547632

[252003-65-9]

Purity: 98%

Soluble in DMSO
C20H24BrF2N5O3S MW: 532.40



Axon 1662

mg	Price
2	online
5	online

Biological activity

A potent and oral tyrosine kinase inhibitor (TKI), targeting VEGFR-2 and basic FGF kinases (IC50 to be 11 and 9 nM respectively); selective relative to EGFR, PDGF-β, and other related TKs; inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay with an IC50 value of 6 nM

CP 597396 hydrochloride

See Zoniporide hydrochloride

Axon 2022


Page 1010

CP 615003 mesylate

[1259477-42-3]

Purity: 99%

Soluble in water and DMSO
C20H24FN3O3.C4H10O3S
MW: 469.53



Axon 1604

mg	Price
5	online
25	online

Biological activity

A potent and subtype selective GABAA receptor partial agonist potentially useful in treating generalized anxiety disorder; the Mdr1 P-glycoprotein (P-gp) substrate


CP 690550

Tasocitinib; Tofacitinib

[477600-75-2]

Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C16H20N6O MW: 312.37



Axon 1338

mg	Price
2	online
5	online

Biological activity

Janus Kinase 3 (JAK3) inhibitor; an immunosuppressive agent exhibiting potent effects in preclinical transplantation and arthritis models; clinically safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis

CP 690550-10

See Tofacitinib citrate

Axon 2072


Page 935

CP 724714

[383432-38-0]

Purity: 98%

Soluble in DMSO
C27H27N5O3 MW: 469.53



Axon 1537

mg	Price
2	online
5	online

Biological activity

An oral, selective and potent ErbB-2 (HER2) kinase inhibitor; reported to inhibit HER2-driven cell line

CP 775146

[702680-17-9]


Purity: 99%

Optically pure

Axon 2114

mg	Price
5	online

Soluble in DMSO
C26H33NO4 MW: 423.54



25 online

Biological activity

Potent and selective PPAR α agonist ($K_i=24.5$ nM and >10 μ M for PPAR β and PPAR γ), supporting robust recruitment of co-activator peptides in vitro. CP775146 markedly potentiates chimeric transcription systems in cell-based assays and strikingly lowers serum triglycerides in vivo


Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

CP 945598

Otenabant

[686344-29-6]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C25H25Cl2N7O MW: 510.42



Axon 2015

mg	Price
10	online
50	online

Biological activity

Potent and selective cannabinoid CB1 receptor antagonist (K_i values 0.7 nM and 0.2 nM in binding and functional assays, respectively) for the management of obesity. CP945598 exhibits a >10000 fold selectivity over CB2, and lacks significant, or meaningful, activity at a large panel of receptors, enzymes, and ion channels. Available as HCl salt as well (Axon 2119)


Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

CP 945598 hydrochloride

Otenabant hydrochloride

[686347-12-6]
Purity: 99%

Soluble in DMSO
C25H25Cl2N7O.HCl MW: 546.88



Axon 2119

mg	Price
10	online
50	online

Biological activity

Hydrochloride form of the potent and selective cannabinoid CB1 receptor antagonist CP-945,598 (Otenabant HCl; K_i values 0.7 nM and 0.2 nM in binding and functional assays, respectively) for the management of obesity. CP945598 HCl exhibits a >10000 fold selectivity over CB2, and lacks significant, or meaningful, activity at a large panel of receptors, enzymes, and ion channels. Parent molecule available as well (Axon 2015)

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Cpd G

See ABCA1 inducer compound G


Axon 3564

Page 199

CpdD hydrochloride

GhrR antagonist CpdD

[N.A.]
Purity: 99%
Optically pure
Soluble in water and DMSO
C25H33BrN4O3S.HCl MW: 585.98



Axon 2147

mg	Price
5	online
25	online


Biological activity

Selective ghrelin receptor (GhrR aka GHSR-1a) antagonist

cPEPCK inhibitor

[628279-07-2]
Purity: 98%

Soluble in DMSO
C25H26FN5O3 MW: 463.50



Axon 1165

mg	Price
5	online
25	online


Biological activity

The first GTP-competitive inhibitor of human cytosolic phosphoenolpyruvate carboxykinase (PEPCK or cPEPCK) with low submicromolar IC_{50} values

CPI-444

Ciforadenant

[1202402-40-1]
Purity: 99%
100% e.e.
Soluble in DMSO
C20H21N7O3 MW: 407.43



Axon 3085

mg	Price
5	online
25	online


Biological activity

CPI-444 is potent, selective and oral A2A adenosine receptor (A2aR) antagonist inhibitor (K_i value of 3.5 nM) which has demonstrated high selectivity and ability to block A2aR in in vitro studies. CPI-444 dramatically enhances immunologic responses in models of checkpoint therapy and ACT in cancer. Moreover, CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models.

CPI 455

[1628208-23-0]
Purity: 99%

Soluble in DMSO
C16H14N4O MW: 278.31



Axon 2573

mg	Price
5	online
25	online


Biological activity

Selective inhibitor of KDM5 demethylases (IC_{50} value 10 nM for inhibition of full length KDM5A) that specifically alters H3K4 methylation in several cell contexts and reduces survival of drug-tolerant cancer cells. CPI-455 possesses the target specificity required for an in vitro tool compound for exploring KDM5-dependent disease biology, including drug tolerance. Note: CPI 455 can be used in combination with a less potent control compound, by the authors of the 2016 Nature publication referred to as CPI 4203 (Axon 2622).

CPI 0610

[1380087-89-7]
Purity: 99%

Soluble in DMSO
C20H16ClN3O2 MW: 365.81




Biological activity

Selective and metabolically stable inhibitor of the BET family of bromodomains (BET-BRD; IC50 values 0.12 - 0.17 μ M and 0.22 μ M for inhibition of BD-1 of BRD2-4 and BRDT, respectively), demonstrating a correlation between BET-driven reduction in MYC gene expression and tumor growth inhibition in a xenograft study. CPI 0610 displays essentially no activity in TR-FRET- or AlphaLisabased assays against the bromodomains of CBP, BRD9, BRPF1, PCAF, BRG1, ATAD2, TRIM24, BRD8 (IC50 value > 15 μ M), and no meaningful inhibition in a CEREP express panel of about 50 GPCRs, ion Constellation Pharmaceuticals Inc compound; sold under agreement with Constellation Pharmaceuticals Inc.

CPI 613

[95809-78-2]
Purity: 100%

Soluble in 0.1N NaOH(aq) and DMSO
C22H28O2S2 MW: 388.59




Biological activity

A small molecular inhibitor of a mitochondrial enzyme pyruvate dehydrogenase (PDH) complex; CPI-613 selectively attacks the regulatory aspects of tumor cell mitochondrial metabolism, activating both apoptotic (programmed cell death) and non-apoptotic (necrosis-like) cell death pathways

CPI 4203

[1628214-07-2]
Purity: 99%

Soluble in DMSO
C16H14N4O MW: 278.31




Biological activity

Selective inhibitor of KDM5 demethylases, structurally related to CPI 455 (Axon 2573) but ~25-fold less potent (IC50 value 250 nM for inhibition of full length KDM5A). Control compound to be used in combination with CPI 455 (Axon 2573)

CPPC, 4-

[29553-70-6]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C14H9NO6 MW: 287.22



Biological activity

4-CPCC is the first potent, selective and reversible inhibitor of pro-inflammatory protein macrophage migration inhibitory factor-2 (MIF-2 or D-DT) with a Ki value of 33 μ M and an IC50 value of 27 μ M. 4-CPCC shows competitive binding with a 13-fold selectivity for human MIF-2 versus human MIF-1.


Axon 2594

mg	Price
5	online
10	online

CPPHA

[693288-97-0]
Purity: 99%

Soluble in DMSO
C22H15ClN2O4 MW: 406.82



Biological activity

A positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 5 (mGluR5)


CPT-11

See Irinotecan hydrochloride

CPTH2

[357649-93-5]
Purity: 100%

Soluble in DMSO
C14H14ClN3S MW: 291.80



Biological activity

CPTH2 is a histone acetyltransferase (HAT) inhibitor modulating Gcn5p network in vitro and in vivo.


CR8, (R)-

See CDK inhibitor CR8

CRAC inhibitor 44

[944917-72-0]
Purity: 99%

Soluble in DMSO
C22H19F2N3OS MW: 411.47



Biological activity

Potent and selective CRAC ion channel inhibitor (or blocker). The compound inhibits the activity of CRAC ion channels and the production of IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF- α , and IFN γ

CRD401


See Diltiazem hydrochloride

Crenolanib

CP-868596; ARO-002, Plarotinib

[670220-88-9]
Purity: 99%

Soluble in DMSO
C26H29N5O2 MW: 443.54



Axon 1431

mg	Price
5	online
25	online

Axon 3370

Page 570

Axon 2765

mg	Price
10	online
50	online

Axon 3228

Page 355

Axon 1868

mg	Price
5	online
25	online

Axon 3323

Page 429

Axon 3969

mg	Price
10	online
50	online

Biological activity

Crenolanib is an orally bioavailable, selective small molecule inhibitor of the Platelet-derived growth factor receptor (PDGFR) tyrosine kinase, inhibiting both purified PDGFR α and PDGFR β with IC50s of 0.9 nM and 1.8 nM, respectively. It is also a type I pan-FLT3 inhibitor, highly selective over the closely related protein tyrosine kinase KIT, capable of inhibiting both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo. It is considered to be an important next-generation FLT3 inhibitor.

Source Information: Sold in collaboration with Chemietek

CRID3

See MCC950 sodium salt


Axon 4052

Page 642

Crisaborole

AN2728

[906673-24-3]
Purity: 99%



Soluble in DMSO
C14H10BNO3 MW: 251.05

Axon 3169

mg	Price
10	online
50	online

Biological activity

Crisaborole is a potent inhibitor of PDE4 (IC50 value of 0.49 μ M) and inflammation-related cytokine release in vitro and in vivo. Anti-inflammatory agent.

Crizotinib


See PF 02341066

Axon 1660

Page 766

Crizotinib, (S)-

[1374356-45-2]
Purity: 99%
98.5 % e.e.
Soluble in DMSO
C21H22Cl2FN5O MW: 450.34



Axon 2296

mg	Price
5	online
25	online

Biological activity

(S)-Crizotinib is a selective inhibitor of the human mutT homologue MTH1 (also known as NUDT1; IC50 value 72 nM; Kd value 48 nM). MTH1 inhibition by (S)-Crizotinib induced an increase in DNA single-strand breaks, activated DNA repair in human colon carcinoma cells, and effectively suppressed tumor growth in animal models. It is the opposite (S)-enantiomer of (R)-Crizotinib (PF-02341066, Axon 1660), which is a ALK/MET inhibitor.

CRL 40476

See Modafinil

Axon 1296

Page 675

CRN00808

See Paltusotine dihydrochloride

Axon 4064

Page 746

CRN00808

See Paltusotine


Axon 3840

Page 746

Cromolyn disodium

FPL670; Disodium cromoglycate

[15826-37-6]
Purity: 100%



Soluble in water and DMSO
C23H14Na2O11 MW: 512.33

Biological activity

Cromolyn disodium is a mast cell stabilizer antiallergic agent and a GSK-3 β inhibitor (IC50 value of 2.0 μ M).

Axon 3509

mg	Price
50	online

CRT Inhibitor iCRT5

See iCRT5

Axon 2133

Page 558

CRT Inhibitor iCRT14


See iCRT14

Axon 2135

Page 559

CS1

[1448009-94-6]
Purity: 99%



Soluble in DMSO
C16H12O3 MW: 252.26

Axon 2391

mg	Price
10	online
50	online

Biological activity

TOPO IIa inhibitor with broad-spectrum in vitro antitumor effects (IC50 values 4.3 μ M, 11.5 μ M, and 4.6 μ M for inhibition of proliferation of breast cancer MDA-MB-231, human lung cancer A549 and human cervical cancer HeLa cell lines, respectively). CS1 functions as a Topo II poison to stabilize Topo II/DNA complex, which leads to DNA damage, cell cycle arrest at G2/M phase and apoptosis, and is 6–10-fold less cytotoxic against HL7702 and HUVEC cells compared with etoposide.

CS 055

See Tucidinostat

Axon 2893

Page 943

CS-905


See Azelidipine

Axon 3160

Page 278

CSF1R inhibitor compound 22

[2095849-04-8]
Purity: 99%



Soluble in DMSO
C25H20F3N5O2 MW: 479.45

Axon 3428

mg	Price
5	online
25	online

Biological activity


CSF1R inhibitor compound 22 is a potent, cellular active and orally bioavailable CSF1R inhibitor with an IC50 value of 0.9 nM.

CT 53518

MLN 518; Tandutinib

[387867-13-2]
Purity: 99%

Soluble in DMSO
C31H42N6O4 MW: 562.70



Biological activity

An oral tyrosine kinase inhibitor (TKI), targeting FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGFR, thereby inhibiting cellular proliferation and inducing apoptosis.

CT7001

Samuraciclib, ICEC0942

[N.A.]
Purity: 99%
99% e.e.
Soluble in water and DMSO
C22H30N6O.2HCl MW: 467.44


Biological activity

CT-7001 (ICEC0942) (Samuraciclib) is a potent, selective and orally bioavailable CDK7 (Cyclin-Dependent Kinase 7) inhibitor.

Source Information: Sold in collaboration with Chemietek

CT 98014

See CHIR 98014

CT 99021

See CHIR 99021


CT 99021 dihydrochloride

See CHIR 99021 dihydrochloride

CTEP

[871362-31-1]
Purity: 99%

Soluble in DMSO
C19H13ClF3N3O MW: 391.77


Biological activity

Potent, orally bioavailable, long lasting and selective mGluR5 allosteric antagonist or negative allosteric modulator; CTEP binds mGluR5 with low nanomolar affinity and shows >1000-fold selectivity against other targets, including all known mGlu receptors. CTEP has considerably improved properties over older mGluR5 antagonists such as MPEP (Axon 1222) and Fenobam (Axon 1345)

Axon 1415

mg	Price
5	online
25	online

Axon 3756

mg	Price
5	online
10	online

Axon 1126

Page 365

Axon 1386

Page 365

Axon 2435

Page 365


Axon 1972

mg	Price
5	online
25	online

CTPI-2

[68003-38-3]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C13H9ClN2O6S MW: 356.74



Biological activity

CTPI-2 is a specific inhibitor of the mitochondrial citrate carrier SLC25A1 with a Kd value of 3.5 μM.

CTx-0294885

[1439934-41-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H24ClN7O MW: 437.93



Biological activity

CTx-0294885 is a broad-spectrum kinase inhibitor, exhibiting inhibitory activity against a broad range of kinases in vitro. Powerful reagent for analysis of kinome signaling networks that may facilitate development of targeted therapeutic strategies.

CU-115

[2471982-20-2]
Purity: 98%

Soluble in DMSO
C21H11F7INO2 MW: 569.21



Biological activity

CU-115 is a selective TLR8 inhibitor (IC50 value of 1.04 μM). Biological evaluation of CU-115 using human monocyte THP-1, RAW264.7, and Hek 293-Blue TLR cells confirmed that CU-115 is active for inhibiting ssRNA-sensing pathways at low concentrations and does not inhibit other non-endosomal TLR and cytosolic NA-sensing pathways (<5 μM).

CUDC-101

[1012054-59-9]
Purity: 99%

Soluble in DMSO
C24H26N4O4 MW: 434.49


Biological activity

CUDC-101 is a multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human epidermal growth factor receptor 2 tyrosine kinase (HER2/neu or ErbB2) with potential antineoplastic activity. This agent may help overcome resistance to inhibition of EGFR and Her2 through a simultaneous, synergistic inhibition of EGFR, Her2, and HDAC.

Source Information: Sold in collaboration with Chemietek

CUDC-305

DEBIO-0932

[1061318-81-7]

Axon 3358

mg	Price
10	online
50	online

Axon 2992

mg	Price
5	online
25	online

Axon 3155


mg	Price
10	online
50	online

Axon 4138

mg	Price
10	online
50	online

Axon 3923

mg	Price
----	-------

Purity: 99%		5	online
Soluble in DMSO		10	online
C22H30N6O2S MW: 442.58			

Biological activity


CUDC-305 is an orally bioavailable inhibitor of Heat Shock Proteins, displaying high affinity for HSP90α/β (about 100 nM in IC50) and HSP90 complex derived from cancer cells (IC50= 48.8 nM). Exhibits high oral bioavailability (96.0%) and selective retention in tumor (half-life, 20.4 hours) compared with normal tissues. BBB Penetrant.

Source Information: Sold in collaboration with Chemietek

Cuspin-1

[337932-29-3]
Purity: 99%

Soluble in DMSO
C13H10BrNO MW: 276.13



Axon 2438

mg	Price
10	online
50	online


Biological activity

Small molecule upregulator of the Survival of Motor Neuron protein (SMN; EC50 value 18 μM in SMA patient fibroblast cells); a tool compound that revealed that increasing Ras signaling upregulates SMN protein levels by increased phosphorylation of Erk, an important member of the Ras-Raf-MEK signaling cascade.

CU-T12-9

[1821387-73-8]
Purity: 100%

Soluble in DMSO
C17H13F3N4O2 MW: 362.31



Axon 2455

mg	Price
10	online
50	online

Biological activity

Selective TLR1/TLR2 agonist (IC50 value 54.4 nM in a competitive binding assay with Pam3CSK4) that facilitates the TLR1/2 heterodimeric complex formation, but not TLR2/6 complex formation. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and inducible NOS.

CV4093; Franidipine

See Manidipine dihydrochloride **Recent Addition**

Axon 4202

Page 639

CVL231

See Emraclidine

Axon 4086

Page 457

CVT-10216


GS455534

[1005334-57-5]
Purity: 98%

Soluble in DMSO
C24H19NO7S MW: 465.48

Axon 3725

mg	Price
5	online
25	online



Biological activity


CVT-10216 is a highly selective, reversible inhibitor of ALDH-2 with an IC50 value of 29 nM. CVT-10216 shows both anxiolytic and antipsychotic properties.

CX516

BDP-12; Ampalex

[154235-83-3]
Purity: 99%

Soluble in DMSO
C14H15N3O MW: 241.29



Axon 3089

mg	Price
10	online
50	online


Biological activity

CX516 is a centrally and orally active, positive allosteric modulator (PAM) of the AMPA receptor.

CX546

[215923-54-9]
Purity: 99%

Soluble in DMSO
C14H17NO3 MW: 247.29



Axon 3090

mg	Price
10	online
50	online

Biological activity


CX546 is a positive allosteric modulator (PAM) of the AMPA receptor. CX546 increased agonist affinity threefold on nondesensitizing AMPA receptors by slowing agonist unbinding.

CX 4945 hydrochloride

Silmitasertib hydrochloride

[1009820-21-6 (parent)]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C19H12ClN3O2.HCl MW: 386.23



Axon 1965

mg	Price
5	online
25	online


Biological activity

Orally available, potent and selective casein kinase 2 (CK2) inhibitor

CX 5461

[1138549-36-6]
Purity: 99%

Soluble in 0.1N HCl(aq)
C27H27N7O2S MW: 513.61



Axon 2173

mg	Price
5	online
25	online


Biological activity

First selective inhibitor of RNA Polymerase I (Pol I or RNAP1, IC50 of 0.88 μ M) transcription with in vivo activity in tumor growth efficacy models; potent and orally bioavailable. CX 5461 demonstrated approximately 200-fold selectivity against Pol I relative to Pol II. It selectively kills tumor cells by activating p53-dependent apoptosis. It also shows potent antiproliferative capacity in human hematologic tumor cells.

CX 6258 hydrochloride

[1353859-00-3]
Purity: 99%

Soluble in DMSO
C26H24ClN3O3.HCl MW: 498.40



Biological activity


Potent, selective, and orally efficacious pan-Pim kinases inhibitor (IC50 values 5 nM, 25 nM, and 16 nM for Pim-1, Pim-2, and Pim-3 respectively) with 5-40 fold selectivity over Flt-3 (IC50 values 0.134 μ M). CX 6258 exhibited dose dependent efficacy in a mouse MV-4-11 xenograft study, with a 50 mg/kg dose producing 45% tumor growth inhibition (TGI) and a 100 mg/kg dose producing 75% TGI, and was well tolerated throughout the study.

CX3CR1 antagonist 18a

Compound 18a

[911715-90-7]
Purity: 99%

Optically pure
Soluble in DMSO
C19H25N5OS2 MW: 403.56



Biological activity


Potent and selective antagonist of the Fractalkine receptor (FKN or CX3CR1; Ki value 3.9 nM) with a 720 fold selectivity over the CXCR2 receptor, a 246-fold selectivity versus hCCR1 and 187-fold versus hCCR2 and no significant antagonism of the CCR4, CCR5, CCR6, CXCR3, and CXCR5 receptors. Compound 18a displayed adequate metabolic stability and solubility and high Caco-2 permeability. Notably, compound 18a exhibited a significant interaction (>50% activity at 10 μ M) for the adenosine A1 receptor only, and the selectivity was later determined to be 33-fold.

CXCR3 Antagonist 6c

Compound 6c

[870998-13-3]
Purity: 99%

Soluble in DMSO
C30H32Cl3N5O3 MW: 616.97



Biological activity

Potent chemokine CXCR3 antagonist, exhibiting IC50 value of 60 nM in a calcium mobilization functional assay; dose-dependently inhibiting CXCR3 functional response to CXCL11 as measured by T-cell chemotaxis, with a potency of about 100 nM

CXD101

[934828-12-3]
Purity: 99%


Axon 3038	
mg	Price
5	online

Axon 2305	
mg	Price
5	online
25	online

Axon 2255	
mg	Price
2	online
5	online

Axon 1800	
mg	Price
10	online
50	online

Soluble in DMSO
C24H29N5O MW: 403.52



25 online


Biological activity

CXD101 is a class 1 selective histone deacetylase inhibitor with IC50 values of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively.

CXL-1020

2-MSPA

[950834-06-7]
Purity: 99%



C7H9NO5S2 MW: 251.28

Axon 2653

mg	Price
10	online
50	online

Biological activity

Nitroxyl (HNO) is a reactive nitrogen species that improves myocardial function by direct positive cAMP-independent lusitropic and inotropic effects and by combined venous and arterial dilation. CXL-1020 is an HNO donor which nonenzymatically decomposes to produce pure HNO. HNO donors are potentially useful for the treatment of heart failure.

CXL1427

See Cimlanod


Axon 3842

Page 372

CXL146

[2244586-41-0]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C24H20N2O5 MW: 416.43



Axon 3261

mg	Price
5	online
25	online


Biological activity

CXL146 is a selective inhibitor of HL60/MX2 cell proliferation by targeting GRP78 overexpression. CXL146 treatment activated the unfolded protein response (UPR). CXL146-induced UPR activation led to a series of downstream events, including extracellular signal-regulated kinase 1/2 and c-Jun N-terminal kinase activation, which contributed to CXL146-induced apoptosis.

CYC-116

[693228-63-6]
Purity: 99%

Soluble in DMSO
C18H20N6OS MW: 368.46



Axon 4073

mg	Price
10	online
50	online

Biological activity

An orally-active inhibitor of Aurora kinases A and B, and VEGFR2.

Source Information: Sold in collaboration with Chemietek

Cyclic GMP-AMP Sodium salt, 2', 3'-

See cGAMP

Axon 3688

Page 361

Cyclopropyl-2-aminotetraline hydrochloride, N-

See Aminotetraline hydrochloride, N-Cyclopropyl-2-

Axon 1067

Page 233

Cyclopropyl-N-methyl-2-aminotetraline hydrobromide, N-

See Aminotetraline hydrobromide, N-Cyclopropyl-N-methyl-2-

Axon 1066

Page 229

CYP3cide

See PF 04981517

Axon 2026


Page 768

Cyproheptadine hydrochloride

[969-33-5]

Purity: 100%

Soluble in DMSO and EtOH
C21H21N.HCl MW: 323.86



Axon 3511

mg Price

50 online

Biological activity

Cyproheptadine hydrochloride is an antagonist of the histamine receptor (H1) and serotonin receptor (5-HT2A), and has been clinically used as an antiallergy drug. Moreover, cyproheptadine hydrochloride inhibits the enzymatic activity of Set7/9 with an IC50 value of 1.0 μM. Antipruritic drug.

Cyproterone acetate


SH714

[427-51-0]

Purity: 100%

Optically pure

Soluble in DMSO and EtOH
C24H29ClO4 MW: 416.94



Axon 3883

mg Price

50 online

Biological activity

Cyproterone acetate is an androgen receptor (AR) antagonist (IC50 value of 7.1 nM), but also being a partial AR agonist at relatively high concentrations (EC50 value of 4.0 μM).

CYR101

See Risperidone

Axon 3859


Page 829

CysLT1 Antagonist Q8

[1541762-55-3]

Purity: 99%

Soluble in DMSO
C17H14ClNO2 MW: 299.75



Axon 2738

mg Price

10 online

50 online

Biological activity


CysLT1 antagonist Q8 inhibits developmental angiogenesis in transgenic fluorescent zebrafish, and inhibits human microvascular endothelial cell (HMEC-1) proliferation, tubule formation, and migration. CysLT1 antagonist Q8 elicits antiangiogenic effects in a VEGF-independent in vitro model of angiogenesis and exerts an additive antiangiogenic response with the anti-VEGF biologic bevacizumab.

CYT 387

[1056634-68-4]

Purity: 99%

Soluble in DMSO
C23H22N6O2 MW: 414.46



Axon 1681

mg Price

5 online

25 online

Biological activity

Selective and ATP-competitive Janus Kinase JAK1/JAK2 inhibitor, with IC50 to be 11 and 18 nM for JAK1 and JAK2 respectively and far less activity against other kinases, including JAK3 (IC50=155 nM)

CYT387 hydrochloride

See Momelotinib hydrochloride

Axon 4124

Page 676

Cytarabine


1-β-D-Arabinofuranosylcytosine; Ara-C; Cytosine arabinoside

[147-94-4]

Purity: 99%

Optically pure

Soluble in water and DMSO
C9H13N3O5 MW: 243.22



Axon 3238

mg Price

50 online

250 online

Biological activity

Cytarabine is a cytidine-based antimetabolite and an inhibitor of DNA synthesis. Cytarabine undergoes initial phosphorylation by deoxycytidine kinase to monophosphate with subsequent phosphorylations catalyzed by pyrimidine monophosphate and diphosphate kinases. The active form, triphosphorylated Cytarabine, exhibits its anticancer activity via the inhibition of DNA polymerase and/or DNA chain elongation.

Cytosine arabinoside

See Cytarabine

Axon 3238


Page 404

CZC 24832

[1159824-67-5]

Purity: 99%

Soluble in DMSO
C15H17FN6O2S MW: 364.40



Axon 2039

mg Price

5 online

10 online

Biological activity

Potent and selective PI3K p110γ inhibitor, with efficacy in in vitro and in vivo models of inflammation

CZS-241 hydrochloride Recent Addition

[N.A.]

Purity: 99%

Soluble in DMSO and EtOH


Axon 3918

mg Price

5 online

25 online

C26H24ClF2N9O.HCl MW: 588.44



Biological activity

CZS-241 hydrochloride is a highly potent, selective, and orally available polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.6 nM. CZS-241 effectively inhibited leukemia cells in 29 tested cell lines, especially chronic myeloid leukemia (CML) cell

D 21266

See Perifosine

Axon 1663

Page 759

D 23129

See Retigabine

Axon 1525

Page 813

D 23129 hydrochloride

See Retigabine dihydrochloride

Axon 2252

Page 813

d4T

See Stavudine

Axon 3491

Page 894

D 9998

See Flupirtine maleate


Axon 1437

Page 486

D 106669

[938444-93-0]
Purity: 98%

Soluble in DMSO
C17H18N6O MW: 322.36



Axon 1719

mg	Price
2	online
5	online
25	online

Biological activity


Highly potent and selective PI3K inhibitor, selectively inhibiting class I PI3K (PI3Kα IC50 <10 nM, >3 log selectivity against tyrosine or serine/threonine kinases, except ERK1 and 2) and showed some activity in A549(lung cancer) xenografts mouse model at oral dose of 30 mg/kg twice daily

D3-βArr

NCGC 00379308

[662164-09-2]
Purity: 99%

Soluble in DMSO
C20H23N5 MW: 333.43



Axon 2895

mg	Price
10	online
50	online

Biological activity

D3-βArr is a positive allosteric modulator (PAM) of the thyrotropin (TSH) receptor with an EC50 value of 11.6 μM.

DA7218

See Tedizolid phosphate

Axon 3312

Page 916

Dabigatran etexilate


BIBR 1048

Axon 3117

mg	Price
[211915-06-9]	

Purity: 98% 10 online

Soluble in 0.1N HCl(aq) and DMSO
C34H41N7O5 MW: 627.73




Biological activity

Dabigatran etexilate is a prodrug of Dabigatran, a potent thrombin inhibitor (IC50 value of 0.0093 μM) and anticoagulant in vivo. Dabigatran etexilate exhibited strong and long-lasting anticoagulant effects after oral administration in different animal species.

Dacarbazine

DTIC; NSC45388

[4342-03-4]
Purity: 100%



Soluble in water, 0.1N HCl(aq) and DMSO
C6H10N6O MW: 182.18


Biological activity

Dacarbazine is a cell cycle nonspecific antineoplastic agent that functions as an alkylating agent after activation in the liver.

Daclatasvir dihydrochloride

BMS 790052 dihydrochloride

[1009119-65-6]
Purity: 99%
Optically pure
Soluble in DMSO
C40H50N8O6.2HCl MW: 811.80



Biological activity


Potent hepatitis C virus (HCV) NS5A protein inhibitor with picomolar EC50 value

Dacomitinib

PF-00299804

[1110813-31-4]
Purity: 100%

Soluble in 0.1N HCl(aq) and DMSO
C24H25ClFN5O2 MW: 469.94



Biological activity

Dacomitinib is a potent irreversible pan-ERBB inhibitor with IC50 values of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2 and ERBB4, respectively. Dacomitinib is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo. Additionally, Dacomitinib is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers.

10 online
50 online

Axon 3459

mg Price
50 online

Axon 2093

mg Price
2 online
5 online


Axon 3235

mg Price
10 online
50 online

Dagliutril

SLV 306

[182821-27-8]
Purity: 99%
Optically pure
Soluble in DMSO
C31H38N2O6 MW: 534.64



Biological activity

An orally active, dual endothelin converting enzyme (ECE)/neutral endopeptidase (NEP) inhibitor that reduces proteinuria and urinary albumin excretion in diabetic rats. Simultaneous augmentation of ANP and inhibition of ET-1 production by Daglutril treatment is of potential therapeutic benefit in cardiovascular disease, and for treatment of overt nephropathy and reduction of albuminuria in hypertensive patients with type 2 diabetes.

Dalacine


See Clindamycin

Dalcetrapib

JTT 705

[211513-37-0]
Purity: 99%

Soluble in DMSO and Ethanol
C23H35NO2S MW: 389.59



Biological activity

Potent cholesterylester transfer protein (CETP) inhibitor


DAN 2163

See Amisulpride

Danoprevir

ITMN 191; RG 7227

[850876-88-9]
Purity: 99%
optically pure
Soluble in DMSO
C35H46FN5O9S MW: 731.83



Biological activity

Potent and orally active inhibitor of hepatitis C virus (HCV) NS3/4A serine protease (replicon IC50: 1.6 nM)

Dansyl-PEG-phenylboronic acid

[N.A.]
Purity: 98%

Axon 1918

mg Price
2 online
5 online

Axon 2063

Page 375

Axon 1962

mg Price
10 online
50 online

Axon 1381

Page 234


Axon 1669

mg Price
2 online
5 online

Axon 2257

mg Price
5 online

Soluble in 0.1N HCl(aq), MeOH and DMSO
C30H41BN4O9S MW: 644.54




Biological activity

Dansylamide functionalized PEG-phenylboronic acid for the use of palladium-catalyzed oxidative Heck reaction to protein-bound alkenes and Suzuki-Miyaura cross coupling for labeling of protein bound phenylhalides in high yields and with excellent chemoselectivity. Reagent for bio-orthogonal protein-ligation. Sold in collaboration with RuG (University of Groningen)

Dapagliflozin

BMS-512148

[461432-26-8]
Purity: 100%
Optically pure
Soluble in DMSO
C21H25ClO6 MW: 408.87



Axon 3121


mg	Price
10	online
50	online

Biological activity

Dapagliflozin is a potent and selective hSGLT2 inhibitor (EC50 value of 1.1 nM) which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats.

Dapansutrile

[54863-37-5]
Purity: 99%



Soluble in water, DMSO and EtOH
C4H7NO2S MW: 133.17

Axon 3475

mg	Price
10	online
50	online


Biological activity

Dapansutrile is a selective and orally active NLRP3 inflammasome inhibitor which reverses the metabolic cost of inflammation. In vitro, nanomolar concentrations of Dapansutrile reduced IL-1 β and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLRP4 and AIM2 inflammasomes, suggesting specificity for NLRP3.

Dapivirine

R 147681; TMC 110

[244767-67-7]
Purity: 99%



Soluble in DMSO
C20H19N5 MW: 329.40

Axon 1534

mg	Price
5	online
25	online

Biological activity

Potent non-nucleoside reverse transcriptase inhibitor (NNRTI); an antiretroviral compound designed to prevent or interrupt HIV replication in human cells; safe and tolerable as potential vaginal microbicide

Daprodustat


See GSK1278863

Axon 3615

Page 518

DAPT

[208255-80-5]
Purity: 99%
optically pure
Soluble in DMSO
C23H26F2N2O4 MW: 432.46



Biological activity


Inhibitor of γ -secretase

Darapladib

SB-480848

[356057-34-6]
Purity: 99%

Soluble in DMSO
C36H38F4N4O2S MW: 666.77



Biological activity

Darapladib is a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Source Information: Sold in collaboration with Chemietek

Darovasertib

See LXS-196


Axon 3851

Page 622

Darunavir

UIC-94017; TMC114

[206361-99-1]
Purity: 99%
Optically pure
Soluble in DMSO
C27H37N3O7S MW: 547.66



Biological activity


Darunavir is a potent human immunodeficiency virus type 1 (HIV-1) protease inhibitor with an IC50 value of 0.003 μ M (HIV-1LA1). Moreover, Darunavir shows potent activity against multi-protease inhibitor-resistant HIV in vitro.

Dasatinib

BMS 354825; Sprycel

[302962-49-8]
Purity: 99%

Soluble in DMSO
C22H26ClN7O2S MW: 488.01



Axon 1392

mg	Price
10	online
50	online

Biological activity

Orally active dual BCR-ABL and Src family tyrosine kinases inhibitor

Daxas

See Roflumilast


Axon 2352

Page 827

DB2313 hydrochloride Recent Addition

[2170606-75-2]
Purity: 98%

Soluble in DMSO
C42H41FN8O2.4HCl MW: 858.70


Axon 3546

mg	Price
10	online
50	online


Biological activity

DB2313 hydrochloride is a potent inhibitor of the essential transcriptional factor PU.1 with an IC50 value of 14 nM.

DBeQ

[177355-84-9]
Purity: 99%

Soluble in DMSO
C22H20N4 MW: 340.42


Axon 1826


mg	Price
10	online
50	online

Biological activity

Potent, cell-permeable, selective and reversible p97 ATPase inhibitor; impairs both ubiquitin-dependent and autophagic protein clearance pathways and induces executioner caspases 3 and 7

dBET1

[1799711-21-9]
Purity: 99%
Optically pure
Soluble in DMSO
C38H37ClN8O7S MW: 785.27


Axon 3922

mg	Price
5	online
10	online

Biological activity

dBET1 is a potent and selective BRD4 protein degrader. The molecule, dubbed "degronimid", is harnessed by combining two specific high affinity protein ligands, (+)-JQ1 (Axon 1989) for BRD4 and Thalidomide (Axon 3324) for E3 ubiquitin ligase cereblon (CRBN), tethered by a linker. Fully exploiting the cells' own protein-degrading machinery, the molecule drags the ubiquitin ligase complex into the tagged protein, leading to a fast, sustainable, CRBN-dependent and ligand-guided BRD4 degradation. It is so selective that only three proteins, BRD2, 3, 4, of >7000 within the cell, were affected. dBET1 demonstrated powerful anti-leukemia activities both in cell and in animal model, with few noticeable side effects.

Source Information: Sold in collaboration with Chemietek


DBPR211

[1429239-98-4]
Purity: 98%

Axon 3097

mg	Price
5	online

Soluble in DMSO
C33H31Cl2F3N6O3S2 MW: 751.67




25 online

Biological activity

DBPR211 is a potent and selective peripherally restricted CB1 antagonist and/or inverse agonist (Ki value of 0.3 nM). DBPR211 shows significant weight-loss efficacy in diet-induced obese mice.

DBZ, γ-Secretase Inhibitor

[209984-56-5]
Purity: 99%
optically pure
Soluble in DMSO
C26H23F2N3O3 MW: 463.48


Axon 1488

mg	Price
1	online
5	online


Biological activity

Very potent and cell-permeable inhibitor of γ-secretase; potently inhibits Notch processing (IC50 values to be 1.7 nM in SupT1 cells)

DC 838

[508186-08-1]
Purity: 99%

Soluble in DMSO
C27H29N5O4 MW: 487.55


Axon 1166

mg	Price
10	online
50	online


Biological activity

Potent human cyclophilin A (CypA) inhibitor

DC260126

[346692-04-4]
Purity: 99%

Soluble in DMSO
C16H18FNO2S MW: 307.38


Axon 3057

mg	Price
10	online
50	online

Biological activity

DC260126 is a GPR40 antagonist with an IC50 value of 6.58 μM. DC260126 improves insulin tolerance but not glucose tolerance in obese Zucker rats. Although DC260126 could not provide benefit for improving hyperglycemia, it could protect against pancreatic β-cells dysfunction through reducing overload of β-cells, and it increases insulin sensitivity possibly via alleviation of hyperinsulinemia in db/db mice.

DCC 2036


Rebastinib

[1020172-07-9]
Purity: 99%

Axon 2123

mg	Price
5	online

Soluble in DMSO
C30H28FN7O3 MW: 553.59



25 online

Biological activity

An orally active Bcr-ABL inhibitor; being a ABL Switch-control inhibitor that potently inhibits BCR-ABL1 gatekeeper mutant T315I (IC50: 0.8 nM for native ABL1 and 4 nM in a ABL1T315I kinase assay). DCC-2036 has efficacy in a mouse model of T315I-induced CML and against cells of patients with CML. In addition, DCC-2036 also inhibited the SRC family kinases SRC, LYN, FGR, and HCK, and the receptor TKs KDR, FLT3, and TIE2, but not c-KIT (IC50 of 34 nM, 29 nM, 38 nM, 40 nM, 4 nM, 2 nM, 6 nM, and 481 nM respectively)

DCC-2701


See Altiratinib

Axon 3946

Page 220

dCeMM1

[118719-16-7]
Purity: 99%



Soluble in 0.1N NaOH(aq) and DMSO
C14H13BrN2O3S MW: 369.23

Axon 3292


mg	Price
10	online
50	online

Biological activity

dCeMM1 is a glue degrader of RBM39 that functions by re-directing the activity of the CRL4DCAF15 ligase.

dCeMM2

[296771-07-8]
Purity: 99%



Soluble in DMSO
C16H11ClN6OS MW: 370.82

Axon 3293


mg	Price
10	online
50	online

Biological activity

dCeMM2 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12:cyclin K with a CRL4B ligase complex. The pronounced destabilization of cyclin K by dCeMM2 occurred alongside a milder destabilization of both associated kinases CDK12 and CDK13.

DC-LC3in-D5

[2868312-73-4]
Purity: 99%



Soluble in 0.1N HCl(aq), DMSO and EtOH
C19H22Cl2N2O3 MW: 397.30

Axon 3580

mg	Price
5	online
25	online

Biological activity


DC-LC3in-D5 is an autophagy inhibitor which exhibits potent covalent reactivity and selectivity to LC3A/B in HeLa cells. DC-LC3in-D5 inhibits autophagy by attenuating LC3B lipidation, which subsequently reduces the extent of autophagic structure formation and later substrate degradation.

DCLK1-IN-1

FMF-03-146-1

[2222635-15-4]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C26H28F3N7O2 MW: 527.54



Axon 3200

mg	Price
5	online
25	online

Biological activity

DCLK1-IN-1 is a potent, selective and orally bioavailable DCLK1/2 inhibitor. DCLK1-IN-1 exhibits binding assay IC50 values of 9.5 nM and 31 nM for DCLK1 and DLCK2, respectively. Moreover, DCLK1-IN-1 exhibits kinase assay IC50 values of 57.2 nM and 103 nM for DCLK1 and DLCK2, respectively.

DCN1-UBC12 interaction inhibitor E31

See WS-383

Axon 2984

Page 988

DCZ

See Deschloroclozapine


Axon 3965

Page 419

DCZ0415

[2242470-43-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C23H20N2O2 MW: 356.42



Axon 3216


mg	Price
5	online
25	online

Biological activity

DCZ0415 is an AAA-ATPase TRIP13 inhibitor with a Kd value of 2.42 μM. DCZ0415 induced antimyeloma activity in vitro (IC50 values of 1.0-10 μM in multiple myeloma cell lines), in vivo, and in primary cells derived from drug-resistant patients with myeloma. Moreover, DCZ0415 impaired nonhomologous end joining repair and inhibited NF-κB activity.

DCZ0805

[2361147-16-0]
Purity: 99%
Mixture of diastereomers
Soluble in DMSO and EtOH
C33H33N2O9P MW: 632.60



Axon 3518

mg	Price
5	online
25	online


Biological activity

DCZ0805 is a suppressor of the NF- κ B signaling pathway activation. DCZ0805 treatment arrested the cell at the G0/G1 phase and suppressed multiple myeloma cells survival by inducing apoptosis via extrinsic and intrinsic pathways.

DDR1-IN-1

[1449685-96-4]
Purity: 98%

Soluble in DMSO
C30H31F3N4O3 MW: 552.59


Axon 2265

mg	Price
5	online
25	online


Biological activity

Potent and selective DDR1 receptor tyrosine kinase (RTK) inhibitor (IC50 values 105 and 413 nM for DDR1 and DDR2 respectively); a useful pharmacological probe for DDR1-dependent signal transduction.

DDO-6600

[2640292-37-9]
Purity: 99%

Soluble in DMSO and EtOH
C26H28N4O2 MW: 428.53


Axon 3264

mg	Price
5	online
25	online

Biological activity


DDO-6600 is a targeted covalent inhibitor of heat shock protein 90 (Hsp90). DDO-6600 covalently bound to Cys598 on the Hsp90 C terminus and exhibited antiproliferative activities against multiple tumor cells without inhibiting ATPase activity.

DEAB

NSC 8782

[120-21-8]
Purity: 99%

Soluble in DMSO
C11H15NO MW: 177.24


Axon 2476

mg	Price
10	online
50	online

Biological activity

Potent inhibitor of cytosolic (class 1) aldehyde dehydrogenase (ALDH) enzymes (IC50 values 0.057 μ M, 1.2 μ M, 3.0 μ M, 1.2 μ M, 0.16 μ M, and 13 μ M for inhibition of ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH5A1, respectively). DEAB was also found to be an excellent substrate for ALDH3A1, and an irreversible inhibitor of ALDH7A1 (KI value 100 μ M). Low turn-over rates and/or covalent bonding of the ALDH substrate DEAB are the cause of its inhibitory effect on the enzymes. At the time of development DEAB was found to be a potent inhibitor of cytosolic ALDH1 but not mitochondrial ALDH2. Commonly used as "selective" inhibitor of ALDH isoenzymes in cancer stem cell biology.

Deazaadenosine, 1-


[14432-09-8]
Purity: 99%

Optically pure
Soluble in 0.1N HCl (aq) and DMSO

Axon 2434

mg	Price
5	online
25	online

C11H14N4O4 MW: 266.25


Biological activity

Inhibitor of adenosine deaminase (ADA; IC50 value 0.38 μ M) 1-Deazaadenosine showed cytostatic activity against multiple cell lines in vitro

DEBIO-0932

See CUDC-305

Axon 3923

Page 398

DEC

See Diethylcarbamazine citrate

Axon 3176

Page 426


Decernotinib

VX-509; VRT-831509; Adelatnib

[944842-54-0]

Purity: 99%
99% e.e.

Soluble in DMSO
C18H19F3N6O MW: 392.38


Axon 3861

mg	Price
5	online
10	online

Biological activity

Decernotinib is an orally bioavailable Janus kinase 3 (JAK3) inhibitor, potently and selectively inhibiting the enzyme with an in vitro Ki of 2.5 nM, and IC50 of 50-170 nM in cellular assays dependent on JAK3 activity. Highly selective, displaying no activity (with limited or no measurable potency) towards other JAK and non-JAK enzymes. Showed in vivo activity in two animal models of aberrant immune function, and demonstrated dose-dependent reduction in ankle swelling and paw weight and improved paw histopathology scores in the rat collagen-induced arthritis model.


Source Information: Sold in collaboration with Chemietek

Decitabine

[2353-33-5]

Purity: 99%

Soluble in water and DMSO
C8H12N4O4 MW: 228.21


Axon 1590

mg	Price
10	online
50	online

Biological activity

DNA methyltransferase inhibitor; a therapeutic agent to treat myelodysplastic syndromes (MDS)

Defactinib

VS 6063; PF 04554878


[1073154-85-4]

Purity: 98%

Soluble in DMSO
C20H21F3N8O3S MW: 510.49

Axon 2574

mg	Price
5	online
25	online


Biological activity


Orally available second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (PYK2) with an acceptable safety profile in clinical trials (IC50 values 0.6 nM for each kinase, and >100-fold greater selectivity for FAK and PYK2 than for other, non-target kinases).

Deferasirox

ICL670

[201530-41-8]
Purity: 100%

Soluble in 0.1N NaOH(aq) and DMSO
C21H15N3O4 MW: 373.36


Axon 3375


mg	Price
10	online
50	online

Biological activity

Deferasirox is an orally active iron chelator. Deferasirox was found to demonstrate a two- to fivefold higher potency than deferoxamine in mobilizing tissue iron and promoting its excretion in various in vitro and in vivo models. ICL670 is highly selective for iron and does not induce the excretion of zinc or copper.

Deflazacort

[14484-47-0]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C25H31NO6 MW: 441.52


Axon 4022

mg	Price
50	online

Biological activity

Deflazacort is a glucocorticoid and inactive prodrug which is converted rapidly to the active metabolite 21-desacetyldeflazacort.

Degrasyn

See WP 1130


Axon 1779

Page 987

Deguelin

[522-17-8]
Purity: 98%

Soluble in DMSO and Ethanol
C23H22O6 MW: 394.42


Axon 1239

mg	Price
5	online
10	online


Biological activity

Inhibitor of activated Akt. Anticancer, chemopreventive agent

Dehydroepiandrosterone

DHEA

[53-43-0]
Purity: 100%
Optically pure
Soluble in DMSO
C19H28O2 MW: 288.42


Axon 3322

mg	Price
50	online

Biological activity


Dehydroepiandrosterone is a steroidal hormone and serves as an indirect precursor to estrogen and testosterone and other steroid hormones.

Dehydroevodiamine hydrochloride

DHED

[111664-82-5]
Purity: 99%

Soluble in water, DMSO and EtOH
C19H15N3O.HCl MW: 337.80


Axon 3478

mg	Price
10	online
50	online

Biological activity


Dehydroevodiamine hydrochloride inhibited acetylcholinesterase activity in a dose-dependent and non-competitive manner (IC50 value of 37.8 μM).

Delavirdine

U 90152; Rescriptor

[136817-59-9]
Purity: 99%

Moderately soluble in DMSO
C22H28N6O3S MW: 456.56


Axon 1815


mg	Price
10	online
50	online

Biological activity

Non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1); Selectively inhibits HIV-1 reverse transcriptase (RNA-dependent DNA polymerase) over other cellular polymerases; Inhibitor of cytochrome P450 isozyme CYP3A4; Interacts with many medications

Deltarasin trihydrochloride

[1440898-82-7]
Purity: 99%
Optically pure
Soluble in water and DMSO
C40H37N5O.3HCl MW: 713.14


Axon 2284

mg	Price
5	online
25	online

Biological activity


Small molecule inhibitor of the KRAS-PDEδ interaction that impairs oncogenic KRAS signalling by altering its localization to endomembranes (in cell Kd value 41 nM for deltarasin binding to PDEδ). Deltarasin suppresses in vitro and in vivo MAPK signaling and proliferation of human pancreatic ductal adenocarcinoma (PDAC) cells that are dependent on oncogenic KRAS.

Demoxepam

RO 5-2092

[963-39-3]
Purity: 99%

Soluble in DMSO
C15H11ClN2O2 MW: 286.71



Biological activity

Demoxepam is a major metabolite of the benzodiazepine Chlordiazepoxide, which is an anticonvulsant.

Axon 3406

mg	Price
10	online
50	online

Deoxyadenosine 5'-O-phenyl-(benzoxy-L-alaninyl)-phosphate, 3'-

See NUC-7738

Axon 3826

Page 719

Deoxyadenosine, 3'-

See Cordycepin

Axon 3825

Page 385

Deoxy-β-D-ribofuranosyl)-5-iodo-2-pyrimidinone, 1-(2-

See Ropidoxuridine

Axon 3953

Page 829

Depocid

See Sulfaphenazole

Axon 2922

Page 899

Depotsulfonamide

See Sulfaphenazole

Axon 2922


Page 899

Deschloroclozapine

DCZ

[1977-07-7]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C18H20N4 MW: 292.38



Biological activity

Deschloroclozapine is a potent, selective, brain penetrable, metabolically stable and fast-acting DREADD agonist with K_i values of 6.3 nM for hM3Dq and 4.2 nM for hM4Di.

Axon 3965


mg	Price
10	online
50	online

Deshydroxy Venlafaxine HCl

Venlafaxine Impurity G

[1076199-92-2 (parent)]
Purity: 98%

Soluble in DMSO
C17H27NO.HCl MW: 297.86



Biological activity

Axon 1722

mg	Price
5	online
25	online


Metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI)

Desloratadine

NSC675447

[100643-71-8]
Purity: 100%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C19H19ClN2 MW: 310.82



Biological activity

Desloratadine is a potent and selective histamine H1 receptor antagonist. Desloratadine showed potent antiallergic and anti-inflammatory activity.


Axon 3659

mg	Price
50	online

Desmethyltamoxifen hydrochloride, N-

[15917-65-4]
Purity: 99%

Soluble in DMSO and EtOH
C25H27NO.HCl MW: 393.95



Biological activity

N-Desmethyltamoxifen is the major free metabolite of Tamoxifen (Axon 3252) in human serum. Also, N-Desmethyltamoxifen is a protein kinase C inhibitor with an IC_{50} value of 8 μ M.


Axon 3986

mg	Price
5	online
25	online

Desmethylvenlafaxine, R-(-)-O-

R-(-)-O-Desvenlafaxine

[142761-11-3]
Purity: 98%
optically pure
Soluble in DMSO
C16H25NO2 MW: 263.38



Biological activity

Active metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI)


Axon 1720

mg	Price
5	online
25	online

Desmethylvenlafaxine, S-(+)-O-

S-(+)-O-Desvenlafaxine

[142761-12-4]
Purity: 100%
optically pure
Soluble in DMSO
C16H25NO2 MW: 263.38



Biological activity

Active metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI)

Axon 1721

mg	Price
5	online
25	online

Desmethylvenlafaxine, O-


Desvenlafaxine; DVS 233

[93413-62-8]

Axon 3578

mg	Price
----	-------

Purity: 99%
Soluble in 0.1N HCl(aq), DMSO and EtOH
C16H25NO2 MW: 263.38



10 online
50 online

Biological activity

Active metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI). Racemate of Axon 1720 and 1721. Also the succinate salt is available as Axon 2116.

Desmethylvenlafaxine hydrochloride, O-

See Desvenlafaxine hydrochloride


Axon 3555

Page 421

Desonide

Prednacinolone

[638-94-8]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C24H32O6 MW: 416.51



Axon 3502

mg Price
50 online

Biological activity


Desonide is a low-potency topical corticosteroid.

Desvenlafaxine hydrochloride

O-Desmethylvenlafaxine hydrochloride; DVS 233 hydrochloride

[448904-47-0]
Purity: 100%

Soluble in water, DMSO and EtOH
C16H25NO2.HCl MW: 299.84



Axon 3555

mg Price
10 online
50 online

Biological activity

Active metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI). Racemate of Axon 1720 and 1721. Also the succinate salt is available as Axon 2116.

Desvenlafaxine

See Desmethylvenlafaxine, O-

Axon 3578


Page 420

Desmethylvenlafaxine succinate, O-

DVS 233 succinate

[448904-47-0]
Purity: 100%

Soluble in water and DMSO
C16H25NO2.C4H6O4 MW: 381.46



Axon 2116

mg Price
10 online
50 online

Biological activity

Active metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI). Racemate of Axon 1720 and 1721.


Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Deucravacitinib

BMS986165

[1609392-27-9]
Purity: 99%

Soluble in DMSO
C20H19D3N8O3 MW: 425.46



Axon 4091

mg Price
5 online
25 online

Biological activity

Deucravacitinib is a potent, highly selective, allosteric and orally bioavailable inhibitor of tyrosine kinase 2 (TYK2) with an IC50 value of 0.20 nM. Deucravacitinib shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.

Desvenlafaxine, R-(-)-O-

See Desmethylvenlafaxine, R-(-)-O-

Axon 1720

Page 420

Desvenlafaxine, S-(+)-O-

See Desmethylvenlafaxine, S-(+)-O-

Axon 1721

Page 420

DEV 4


See ML 239

Axon 2871

Page 666

Dexamethasone

[50-02-2]
Purity: 99%
Optically pure
Soluble in DMSO
C22H29FO5 MW: 392.46



Axon 3258

mg Price
50 online
250 online


Biological activity

Dexamethasone, an anti-inflammatory steroid, is a glucocorticoid receptor agonist. Dexamethasone was shown to have benefit in treatment of patients which are critically ill with COVID-19.

Dexamethasone palmitate

DXP

[14899-36-6]
Purity: 100%
Optically pure
Soluble in DMSO
C38H59FO6 MW: 630.87



Axon 3345

mg Price
10 online
50 online


Biological activity

Dexamethasone palmitate is a lipophilic prodrug of Dexamethasone (Axon 3258), a glucocorticoid receptor agonist.

Dexmedetomidine hydrochloride

(+)-Medetomidine hydrochloride

[4205-91-8]
Purity: 100%
Optically pure
Soluble in water and DMSO
C13H16N2.HCl MW: 236.74



Axon 3065


mg	Price
10	online
50	online

Biological activity

Dexmedetomidine hydrochloride is a selective α_2 -adrenergic receptor agonist. Active enantiomer of Medetomidine hydrochloride (Axon 3066).

Dextromethorphan hydrobromide

[125-69-9]
Purity: 100%
Optically pure
Soluble in water, DMSO and EtOH
C18H25NO.HBr MW: 352.31



Axon 3841

mg	Price
50	online

Biological activity

Dextromethorphan hydrobromide is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, which is widely used as an antitussive agent.

DFBA

See Difluprednate

Axon 1428

Page 427

dFdC

See Gemcitabine hydrochloride


Axon 3233

Page 501

DFP00173

[672286-03-2]
Purity: 98%

Soluble in DMSO
C11H7Cl2N3O3S MW: 332.16



Axon 2987

mg	Price
5	online
25	online

Biological activity

DFP00173 is a potent and selective AQP3 inhibitor which inhibited mouse and human AQP3 with an IC50 value of ~0.1-0.4 μ M. DFP00173 had low efficacy toward mouse AQP7 and AQP9.

DFP-10917 hydrochloride

See CNDAC hydrochloride

Axon 3970

Page 380

DFPQ

AP-06-202


[911678-60-9]
Purity: 99%

Soluble in DMSO and EtOH

Axon 4082

mg	Price
10	online
50	online

C20H20F2N4 MW: 354.40



Biological activity

DFPQ is a potent and selective β -arrestin-biased negative allosteric modulator (NAM) for the β_2 -adrenergic receptor. DFPQ selectively inhibits β -arrestin interaction with the β_2 AR without affecting β -agonist-promoted cAMP production. DFPQ attenuates functional desensitization of the β_2 AR in airway smooth muscle, augmenting the ability of β -agonists to sustain bronchorelaxation and inhibition of cell migration under conditions of chronic β -agonist treatment.

DFMO

See Eflornithine hydrochloride

Axon 3817


Page 452

DG2

S6K1 Inhibitor DG2

[871340-88-4]
Purity: 99%

Soluble in DMSO
C16H17BrN6O MW: 389.25



Axon 1903

mg	Price
10	online
50	online


Biological activity

Potent and selective inhibitor of p70 ribosomal S6 kinase 1 (S6K1) (IC50: 9.1 nM for S6K1); no Akt activity (IC50: 22000 nM); ATP-competitive and cell-permeable

DH 97

[343263-95-6]
Purity: 99%

Soluble in DMSO
C22H26N2O MW: 334.45



Biological activity

Melatonin antagonist; MT2 selective

Axon 1351

mg	Price
10	online
50	online

DHEA

See Dehydroepiandrosterone

Axon 3322

Page 418

DHED

See Dehydroevodiamine hydrochloride

Axon 3478

Page 418

DHF, 7,8-

See Dihydroxyflavone, 7,8-

Axon 2089

Page 429

DHPG

See Ganciclovir


Axon 3241

Page 495

DHPG, (RS)-3,5-

[146255-66-5]
Purity: 99%

Soluble in water and DMSO
C8H9NO4 MW: 183.16



Axon 1739

mg	Price
10	online
50	online

Biological activity


Selective group I metabotropic glutamate receptor agonist which activates both mGluR1 and mGluR5. More specifically, the agonist activity is found only in its S-enantiomer, (S)-3,5-DHPG (Axon 1740).

DHPG, (S)-3,5-

Dihydroxyphenylglycine, (S)-3,5-

[162870-29-3]
Purity: 99%
>99%

Soluble in water and DMSO
C8H9NO4 MW: 183.16



Axon 1740

mg	Price
5	online
10	online


Biological activity

Potent and selective agonist of group I metabotropic glutamate (mGlu) receptors (mGluRs) mGluR1 and mGluR5; having therapeutic effects in the treatment of neuronal injury, cognitive enhancement and Alzheimer's disease.* (S)-3,5-DHPG is the active enantiomer of 3,5-DHPG (Axon 1739)

DHQZ 36

[1542098-94-1]
Purity: 98%

Soluble in DMSO
C21H18F2N2OS MW: 384



Axon 3141

mg	Price
10	online
50	online


Biological activity

DHQZ 36 is a potent inhibitor of retrograde trafficking (IC50 values of 8.1 and 24 μM against JCPyV and HPV16 infectivity, respectively). Protects cells from infections by human polyoma- and papillomaviruses.

Di-8-ANEPPS

[157134-53-7]
Purity: 99%

Poorly soluble in DMSO
C36H52N2O3S MW: 592.87



Axon 2655

mg	Price
10	online

Biological activity

Fast-responsive membrane potentiometric fluorescent dye for monitoring the electrical activity, e.g. in neurons and myocytes.

Didehydro-3'-deoxythymidine, 2',3'-


See Stavudine

Axon 3491

Page 894

Dideoxyadenosine, 2',5'- Recent Addition

[6698-26-6]
Purity: 99%
Optically pure
Soluble in water and DMSO
C10H13N5O2 MW: .00



Axon 4229

mg	Price
5	online
25	online

Biological activity

2',5'-Dideoxyadenosine is a P-Site inhibitor of adenylate cyclase.

Didesmethyl Venlafaxine, N,N-

See Dinorvenlafaxine

Axon 1726

Page 433

Didesmethyl Venlafaxine, N,O-

See WY 46689

Axon 1725

Page 989

Dienogest

See Dienogestril


Axon 3461

Page 426

Dienogestril

STS557; Dienogest

[65928-58-7]
Purity: 100%
Optically pure
Soluble in DMSO and EtOH
C20H25NO2 MW: 311.42



Axon 3461

mg	Price
10	online
50	online


Biological activity

Dienogestril is a progestogen which exhibits highly selective binding to the progesterone receptor. It has high progestational and significant antiandrogenic activity, but only moderate antigonadotrophic activity. Dienogestril inhibits ovulation, produces secretory transformation of the endometrium and has antiproliferative effects.

Diethylcarbamazine citrate

Hetrazan; DEC

[1642-54-2]
Purity: 99%
N.A.
Soluble in water and DMSO
C16H29N3O8 MW: 391.42



Axon 3176

mg	Price
50	online
250	online

Biological activity

Diethylcarbamazine citrate (DEC) is a filaricidal drug. Pharmacological studies showed that DEC interferes with arachidonic acid metabolism, acting as an anti-inflammatory drug. It has been found that DEC blocks a number of steps in both the cyclooxygenase (COX) and lipoxygenase pathways, including the inhibition of leucocyte chemotaxis, granulocyte degranulation, and peripheral vasodilation.


Diflorasone Diacetate

[33564-31-7]

Axon 1427

mg	Price
----	-------

Purity: 99%
Soluble in DMSO
C26H32F2O7 MW: 494.52




10 online
50 online

Biological activity
A corticosteroid used as anti-inflammatory and anti-itching agent

Diflunisal
MK647

[22494-42-4]
Purity: 99%
Soluble in 0.1N NaOH(aq), DMSO and EtOH
C13H8F2O3 MW: 250.20



Axon 3448
mg Price
50 online

Biological activity
Diflunisal, a salicylic acid derivative, is a cyclo-oxygenase (COX) inhibitor. Non-steroidal anti-inflammatory drug (NSAID).

Difluorodeoxycytidine, 2',2'-
See Gemcitabine hydrochloride


Axon 3233
Page 501

Difluoromethylornithin, α-
See Efformithine hydrochloride

Axon 3817
Page 452

Difluprednate
DFBA; Durezol

[23674-86-4]
Purity: 99%
Soluble in DMSO
C27H34F2O7 MW: 508.55



Axon 1428
mg Price
10 online
50 online

Biological activity
A corticosteroid used for the treatment of post-operative ocular inflammation and pain

Digitalis
See Digoxin


Axon 1649
Page 428

Digoxigenin bis-digitoxiside

[5297-05-2]
Purity: 98%
Soluble in DMSO

Axon 1695
mg Price
10 online
50 online


C35H54O11 MW: 650.80



Biological activity
A metabolite of Digoxin (Axon 1649). Digoxin is a heart medication. Digoxin is also used as a standard control substance to test for p-glycoprotein inhibition. Recent studies show that digoxin acts as inhibitor of HIF-1α synthesis, reduces protein levels and thus slows tumor growth in mice.

Digoxin
Digitalis

[20830-75-5]
Purity: 98%
Soluble in DMSO
C41H64O14 MW: 780.94




Axon 1649
mg Price
10 online
50 online

Biological activity
Digoxin is a successful medication in the treatment of irregular heart rhythms, namely atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication. Digoxin is also used as a standard control substance to test for p-glycoprotein inhibition. Recent studies show that digoxin acts as inhibitor of HIF-1α synthesis, reduces protein levels and thus slows tumor growth in mice

Dihydro-2H-1-benzopyran-8-ol hydrochloride, 3-(Dipropylamino)-3,4-

[109140-45-6]
Purity: 98%
No solubility data
C15H23NO2.HCl MW: 285.81



Axon 1047
mg Price
10 online
50 online

Biological activity
Dopamine receptor agonist

Dihydroquercetin
See Taxifolin

Axon 3338
Page 912

Dihydroxy-2-aminotetraline hydrobromide, 5,6-
See Aminotetraline hydrobromide, 5,6-Dihydroxy-2-

Axon 1044
Page 228

Dihydroxy-2-aminotetraline hydrobromide, 6,7-
See Aminotetraline hydrobromide, 6,7-Dihydroxy-2-

Axon 1045
Page 228

Dihydroxycholecalciferol, 1α,24-
See Tacalcitol

Axon 2516
Page 904

Dihydroxy-N-methyl-N-propyl-aminotetraline hydrobromide, 6,7-

See *Aminotetraline hydrobromide, 6,7-Dihydroxy-N-methyl-N-propyl-*

Axon 1021

Page 228

Dihydroxy-N-methyl-N-propyl-aminotetraline hydrochloride, 5,6-

See *Aminotetraline hydrochloride, 5,6-Dihydroxy-N-methyl-N-propyl-*

Axon 1019


Page 231

Dihydroxyflavone, 7,8-

DHF, 7,8-

[38183-03-8]
Purity: 99%

Soluble in DMSO and EtOH
C15H10O4 MW: 254.24



Axon 2089

mg	Price
10	online
50	online

Biological activity

Potent and selective tyrosine kinase receptor B (TrkB) agonist. 7,8-Dihydroxyflavone imitates Brain-derived neurotrophic factor (BDNF) and acts as a robust TrkB agonist, providing a powerful therapeutic tool for the treatment of various neurological diseases

Dihydroxyphenylalanine, L-3,4-

See *DOPA, L-*

Axon 3666

Page 437

Dihydroxyphenylglycine, (S)-3,5-

See *DHPG, (S)-3,5-*

Axon 1740

Page 425

Dihydroxyphenylserine, L-threo 3,4-

See *Droxidopa*


Axon 3665

Page 442

Dilept

GZR 123

[200954-39-8]
Purity: 99%
optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C21H30N2O5 MW: 390.47



Axon 1975

mg	Price
5	online
25	online

Biological activity

Neurotensin (NT) and dopamine (DA) receptor antagonist; dipeptide neuroleptic of potential efficacy in relieving positive and negative symptoms of schizophrenia


Diltiazem hydrochloride

CRD401; (+)-cis-Diltiazem hydrochloride

[33286-22-5]
Purity: 99%
Optically pure
Soluble in water and DMSO
C22H26N2O4S.HCl MW: 450.98

Axon 3323

mg	Price
50	online



Biological activity

Diltiazem hydrochloride is an L-type calcium channel antagonist.

Diltiazem hydrochloride, (+)-cis-

See *Diltiazem hydrochloride*


Axon 3323

Page 429

Dimaprit dihydrochloride

[23256-33-9]
Purity: 98%

No solubility data
C6H15N3S.2HCl MW: 234.19



Axon 1324

mg	Price
10	online
50	online

Biological activity

Standard histamine H2 receptor agonist

DIM-C-pPhCl

See *C-DIM12*

Axon 2575

Page 354

DIM-C-pPhOCH3

See *C-DIM5*

Axon 2828

Page 354

DIM-C-pPhOH

See *C-DIM8*

Axon 2827

Page 355

Dimebolin hydrochloride

See *Dimebon*

Axon 1445


Page 430

Dimebon

Dimebolin hydrochloride

[97657-92-6]
Purity: 99%

Soluble in water
C21H25N3.2HCl MW: 392.37



mg	Price
5	online
25	online

Biological activity


An antihistamine drug; recent focus on it as potential neuroprotectant and nootropic, hence an Alzheimer's treatment; multiple mechanisms of action, including inhibiting L-type calcium channels, blocking the action of neurotoxic beta-amyloid proteins; and modulating the action of AMPA and NMDA glutamate receptors etc

Dimethindene maleate

(R,S)-Dimethindene maleate

[3614-69-5]
Purity: 100%

Soluble in water, DMSO and EtOH
C₂₀H₂₄N₂.C₄H₄O₄ MW: 408.49



Axon 3812

mg	Price
10	online
50	online


Biological activity

Dimethindene maleate is a potent and selective histamine H₁ antagonist with a prolonged duration of action. The (S)- and (R)-enantiomers are available as Axon 3669 and Axon 3871, respectively.

Dimethindene maleate, (R)-(-)-

[136152-64-2]
Purity: 100%
99% e.e.

Soluble in water, DMSO and EtOH
C₂₀H₂₄N₂.C₄H₄O₄ MW: 408.49



Axon 3871

mg	Price
10	online
50	online

Biological activity


(R)-(-)-Dimethindene maleate is a potent histamine H₁ antagonist.

The (S)-enantiomer and the racemate are available as Axon 3669 and Axon 3812, respectively.

Dimethindene maleate, (S)-(+)-

[136152-65-3]
Purity: 100%
99% e.e.

Soluble in water, DMSO and EtOH
C₂₀H₂₄N₂.C₄H₄O₄ MW: 408.49



Axon 3669

mg	Price
10	online
50	online

Biological activity

(S)-(+)-Dimethindene maleate is a potent and selective M₂ muscarinic receptor antagonist with a pK_i value of 7.78. (S)-(+)-Dimethindene maleate probably also plays a crucial role in promoting trophoblast lineage differentiation potential of pLCDMs. The (R)-enantiomer and the racemate are available as Axon 3871 and Axon 3812, respectively.

Dimethindene maleate, (R,S)-

See Dimethindene maleate

Axon 3812

Page 431

Dimethoxy-1,4-naphthoquinone, 2,3-

See DMNQ

Axon 3011

Page 435

Dimethoxy-2-aminotetraline hydrobromide, 6,7-

See Aminotetraline hydrobromide, 6,7-Dimethoxy-2-

Axon 1043

Page 228

Dimethoxy-2-aminotetraline hydrochloride, 5,6-

See Aminotetraline hydrochloride, 5,6-Dimethoxy-2-

Axon 1042

Page 231

Dimethoxybenzylidene)-anabaseine dihydrochloride, 3-(2,4-

See GTS 21 dihydrochloride

Axon 2860

Page 531

Dimethylaminomichelolide

See ACT001

Axon 3590


Page 206

Dimethylcelecoxib, 2,5-

DMC

[457639-26-8]
Purity: 100%

Soluble in DMSO
C₁₈H₁₆F₃N₃O₂S MW: 395.40



Axon 2496

mg	Price
10	online
50	online

Biological activity


Celecoxib analog that lacks COX-2 inhibitory activity but exhibits anti-tumor properties; DMC reduced growth and initiated apoptotic cell death in several MM cell lines. Mechanistically, DMC down-regulates critical components of the cell-cycle machinery (cyclins A and B); blocks the activity of important mitogenic and survival pathways (MEK, NF-κB, STAT3, survivin); and leads to increased caspase activity. Moreover, DMC quite potently mimics the ability of celecoxib to stimulate the endoplasmic reticulum stress response (ESR) and subsequent cell death.

Dimethylenastron

Eg5 inhibitor III

[863774-58-7]

Purity: 98%
Racemate
Soluble in DMSO
C₁₆H₁₈N₂O₂S MW: 302.39



Axon 2439

mg	Price
10	online
50	online


Biological activity

Specific potent and cell-permeable inhibitor of the mitotic motor Eg5 (a.k.a. kinesin-5 or KSP; IC₅₀ value 200 nM). Dimethylenastron proved to be >100-times more potent than monastrol, both in vitro and with arresting mitosis of cultured cells. Capable of halting cell cycle progression in mitosis and of inducing apoptosis. Dimethylenastron activates the PI3K/Akt pathway, which in turn causes transcriptional up-regulation of Hsp70.

DiMNF

[14756-24-2]
Purity: 99%

Soluble in DMSO
C₂₁H₁₆O₄ MW: 332.35



Axon 1935

mg	Price
10	online
50	online

Biological activity

Selective aryl hydrocarbon receptor (AHR) modulator (SAhRM)

Dinaciclib

See SCH 727965

Axon 1776


Page 856

Dinorvenlafaxine

N,N-Didesmethyl Venlafaxine; Venlafaxine Impurity C

[93413-77-5]
Purity: 100%

Soluble in DMSO
C₁₅H₂₃NO₂ MW: 249.35



Axon 1726

mg	Price
5	online
25	online

Biological activity

Metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI)

Disodium cromoglycate

See Cromolyn disodium

Axon 3509

Page 396

Disufenton sodium

See NXY 059

Axon 1752


Page 727

DJ001

UCLA 5483071

[2161305-12-8]
Purity: 99%

Soluble in DMSO
C₁₅H₁₂N₂O₃ MW: 268.27



Axon 3018

mg	Price
10	online
50	online


Biological activity

DJ001 is a selective, non-competitive, allosteric inhibitor of PTPα with an IC₅₀ value of 1.54 μM. DJ001 promotes the regeneration of murine and human HSCs capable of long-term hematopoietic reconstitution.

DJ-V-159

[2253744-53-3]
Purity: 99%

Soluble in DMSO
C₂₄H₁₂F₆N₄O₂ MW: 502.37



Axon 2942

mg	Price
10	online
50	Online


Biological activity

DJ-V-159 is a GPRC6A agonist which selectively activates GPRC6A leading to stimulation of insulin secretion in vitro and lowering of serum glucose in mice.

DKM 2-93

[65836-72-8]
Purity: 98%

Soluble in DMSO and EtOH
C₁₁H₁₄ClNO₃ MW: 243.69



Axon 3709

mg	Price
10	online
50	online


Biological activity

DKM 2-93 is a relatively selective inhibitor of UBA5 with an IC₅₀ value of 430 μM. Specifically, DKM 2-93 is a covalent ligand that impairs pancreatic cancer cell survival and in vivo tumor growth through covalently modifying the catalytic cysteine of the UBA5, thereby inhibiting its activity as a protein that activates the ubiquitin-like protein UFM1 to UFMylate proteins.

DL5050

[2259710-64-8]
Purity: 99%

Soluble in DMSO
C₂₃H₁₅Cl₂N₃O₂ MW: 436.29



Axon 3021

mg	Price
5	online
25	online

Biological activity

DL5050 is potent and highly selective human constitutive androstane receptor (hCAR) agonist with an EC₅₀ value of 0.37 μM.

DL8280

See Ofloxacin **Recent Addition**


Axon 4211

Page 730

DLCI-1

[2244569-15-9]
Purity: 98%

Soluble in water and DMSO
C₁₂H₁₄N₂S₂HCl MW: 291.24



Axon 3190

mg	Price
5	online
25	online

Biological activity

DLCI-1 is a potent and selective inhibitor of cytochrome P450 2A6 (CYP2A6) with an IC₅₀ value of 0.017 μM. DLCI-1 decreases nicotine self-administration in mice.

DM 3189

See LDN 193189

Axon 1509

Page 608

DMAMCL

See ACT001

Axon 3590

Page 206

DMB

See GLP-1R agonist DMB

Axon 1907

Page 504

DMC

See Dimethylcelecoxib, 2,5-

Axon 2496


Page 432

DMNQ

2,3-Dimethoxy-1,4-naphthoquinone; NSC 69355

[6956-96-3]
Purity: 99%

Soluble in DMSO
C12H10O4 MW: 218.21



Axon 3011

mg	Price
10	online
50	online


Biological activity

Redox cycling naphthoquinone.

DMOG

[89464-63-1]
Purity: 99%

Soluble in water and DMSO
C6H9NO5 MW: 175.14



Axon 1977

mg	Price
10	online
50	online

Biological activity

Cell-permeable HIF prolyl hydroxylase (PHD) inhibitor that enhances HIF-1 α and -2 α , vascular endothelial growth factor (VEGF), and platelet-endothelial cell adhesion molecule 1 expression in vitro. Moreover, DMOG combined with butyrate synergistically improved osteoblast differentiation and pro-angiogenic responses. DMOG is also known to delay neuronal cell death caused by trophic factor deprivation, and to ameliorate vasorelaxation after cold isch

DMP-266

See Efavirenz


Axon 3125

Page 452

DMF 543

[160588-45-4]
Purity: 99%

Soluble in DMSO
C26H18F2N2O MW: 412.43



Axon 1322

mg	Price
10	online
50	online

Biological activity

Neurotransmitter release enhancer, K⁺ channel blocker and acetylcholine release stimulator; potential AD therapeutic

DMXB

See GTS 21 dihydrochloride

Axon 2860

Page 531

DMXB-A

See GTS 21 dihydrochloride

Axon 2860

Page 531

DNA binder S20 hydrochloride


C65780

[N.A.]
Purity: 99%

Axon 4080

mg	Price
10	online

Soluble in water, DMSO and EtOH
C20H21N3O.HCl MW: 355.86



50 online


Biological activity

DNA binder S20 hydrochloride is an orally bioavailable antagonist of the NaV1.7 - NaV1.9 channels. S20 effectively reduces nociceptive response in various pain models without any obvious acute toxicity or inhibition of locomotion. Moreover, S20 is a strong DNA binder.

DNQX

[2379-57-9]
Purity: 99%

No solubility data
C8H4N4O6 MW: 252.14



Axon 1201

mg	Price
10	online
50	online


Biological activity

AMPA/Kainate antagonist

DO264

[2301866-59-9]
Purity: 99%

Soluble in DMSO
C23H20Cl2F3N5O2S MW: 558.40



Axon 2982

mg	Price
5	online
25	online

Biological activity


DO264 is a potent, selective, and in vivo active ABHD12 inhibitor with an IC₅₀ value of 11 nM. DO264 augments inflammatory cytokine production from human THP-1 macrophage cells.

Dofetilide

UK 68798

[115256-11-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C19H27N3O5S2 MW: 441.56



Axon 2103

mg	Price
10	online
50	online

Biological activity


Potent and selective potassium channel blocker, specific on subunit Kv11.1 (hERG) channel; selectively inhibits the rapid delayed-rectifier K⁺ current (I_{Kr}); a class III antiarrhythmic
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Dolutegravir

GSK 1349572; Sotegravir; Tivicay

[1051375-16-6]
Purity: 99%

Soluble in DMSO
C20H19F2N3O5 MW: 419.38



Axon 2855

mg	Price
5	online
25	online


Biological activity

GSK 1349572 is an HIV integrase inhibitor with potent in vitro anti-HIV activity (IC50 value of 0.51 nM), an in vitro resistance profile different from those of other integrase inhibitors, and favorable preclinical safety and pharmacokinetics.

Donepezil hydrochloride

[120011-70-3]
Purity: 99%

Soluble in water and DMSO
C24H29NO3.HCl MW: 415.95


Axon 1438

mg	Price
10	online
50	online


Biological activity

A centrally acting reversible acetylcholinesterase (AChE) inhibitor, with 100% oral bioavailability and easily crossing the blood-brain barrier; therapeutic agent in the treatment of Alzheimer's disease

DOPA, L-

Levodopa; L-3,4-Dihydroxyphenylalanine

[59-92-7]
Purity: 98%
Optically pure
Soluble in 0.1N NaOH(aq) and 0.1N HCl(aq)
C9H11NO4 MW: 197.19


Axon 3666

mg	Price
50	online


Biological activity

L-DOPA is a brain-penetrant metabolic precursor of dopamine (DA) and has acquired its status as a core antiparkinsonian treatment.

Dopamine hydrobromide, N,N-dibutyl

[65273-67-8]
Purity: 99%

Soluble in water and DMSO
C16H27NO2.HBr MW: 346.30


Axon 1061

mg	Price
10	online
50	online


Biological activity

Dopamine receptor agonist

Dopamine hydrobromide, N,N-Dipropyl

[65273-66-7]
Purity: 98%

Soluble in 0.1N HCl(aq)
C14H23NO2.HBr MW: 318.25


Axon 1001

mg	Price
10	online
50	online

Biological activity

Dopamine receptor agonist

Dopazolin

See PHNO hydrochloride, (+)-

Axon 1071

Page 775

Doramapimod

See BIRB 796

Axon 1358

Page 309

DOPS, L-

See Droxidopa


Axon 3665

Page 442

Dorsomorphin

[866405-64-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C24H25N5O MW: 399.49


Axon 1708

mg	Price
2	online
5	online


Biological activity

Selective inhibitor of BMP signaling; functions through inhibition of BMP type I receptors ALK2, ALK3 and ALK6 and thus blocks BMP-mediated SMAD1/5/8 phosphorylation; Also a AMPK inhibitor (Ki= 109 nM)
Note: The water-soluble form, Dorsomorphin dihydrochloride (Axon 2150) is also available

Dorsomorphin dihydrochloride

[1219168-18-9]
Purity: 99%

Soluble in water and DMSO
C24H25N5O.2HCl MW: 472.41


Axon 2150

mg	Price
2	online
5	online


Biological activity

Selective inhibitor of BMP signaling; functions through inhibition of BMP type I receptors ALK2, ALK3 and ALK6 and thus blocks BMP-mediated SMAD1/5/8 phosphorylation; Also a AMPK inhibitor (Ki= 109 nM)
Note: Dorsomorphin free base (Axon 1708) is also available

Dorzolamide hydrochloride

[130693-82-2]
Purity: 99%

Soluble in water and DMSO
C10H16N2O4S3.HCl MW: 360.90


Axon 1517

mg	Price
10	online
50	online

Biological activity

A carbonic anhydrase inhibitor; antiglaucoma agent, used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension

Doxercalciferol


Hectorol; TSA 840

Axon 1746

[54573-75-0]
Purity: 98%
optically pure

mg	Price
2	online

Soluble in DMSO
C28H44O2 MW: 412.65




5 online

Biological activity

A vitamin D2 analog having agonistic activities at vitamin D receptor (VDR)

Doxofylline Recent Addition

[69975-86-6]
Purity: 99%



Soluble in water, 0.1N HCl(aq), DMSO
and EtOH
C11H14N4O4 MW: 266.25


Biological activity

Doxofylline is a xanthine with both bronchodilating and anti-inflammatory activities.

Doxorubicin hydrochloride

Adriamycin hydrochloride; Hydroxydaunorubicin hydrochloride

[25316-40-9]
Purity: 99%



Soluble in water
C27H29NO11.HCl MW: 579.98

Biological activity

Doxorubicin hydrochloride is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium *Streptomyces peucetius* var. *caesius*, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.

Source Information: Sold in collaboration with Chemietek

DPAT, (R)-5-OH-

See Hydroxy-DPAT hydrobromide, (R)-5-

Axon 1007

Page 550

DPAT, (R)-6-OH-

See Hydroxy-DPAT hydrobromide, (R)-6-

Axon 1010

Page 550

DPAT, (R)-7-OH-

See Hydroxy-DPAT hydrobromide, (R)-(+)-7-

Axon 1013

Page 549

DPAT, (S)-(-)-8-OH-

See Hydroxy-DPAT hydrobromide, (S)-(-)-8-

Axon 1017

Page 551

DPAT, (S)-5-OH-

See Hydroxy-DPAT hydrobromide, (S)-5-

Axon 1008

Page 551

DPAT, (S)-6-OH-

See Hydroxy-DPAT hydrobromide, (S)-6-

Axon 1011

Page 551

DPAT, (S)-7-OH-

See Hydroxy-DPAT hydrobromide, (S)-(-)-7-

Axon 1014

Page 550

DPAT, 5,6-Dihydroxy-

See TL 102 hydrobromide

Axon 1004

Page 930

DPAT, 5-OH-

See Hydroxy-DPAT hydrobromide, 5-

Axon 1006

Page 551

DPAT, 6,7-Dihydroxy-

See TL 232 hydrobromide

Axon 1005

Page 930

DPAT, 6-Chloro-

See Chloro-DPAT hydrochloride, 6-

Axon 1068

Page 366

DPAT, 6-OH-

See Hydroxy-DPAT hydrobromide, 6-

Axon 1009

Page 552

DPAT, 7-OH-

See Hydroxy-DPAT hydrobromide, 7-

Axon 1012

Page 552

DPAT, 8-OH-

See Hydroxy-DPAT hydrobromide, 8-


Axon 1015

Page 552

DPN

[1428-67-7]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C15H13NO2 MW: 239.27



Axon 1232

mg Price

10 online

50 online


Biological activity

Estrogen ERβ agonist

DPTIP hydrochloride

[2361799-64-4]
Purity: 99%

Soluble in water, DMSO and EtOH
C₂₁H₁₈N₂O₃S.HCl MW: 414.91



Axon 3772

mg	Price
10	online
50	online


Biological activity

DPTIP hydrochloride is a potent selective, metabolically stable, and brain-penetrant neutral sphingomyelinase 2 (nSMase2) inhibitor with an IC₅₀ value of 30 nM.

DPTN

[224040-19-1]
Purity: 99%

Soluble in DMSO
C₂₂H₁₈N₄O₅ MW: 386.47



Axon 3847

mg	Price
10	online
50	online


Biological activity

DPTN is a highly potent and moderately selective human and rat A₃AR antagonist with K_i values of 0.36 nM and 1.6 nM for hA₃AR and rA₃AR receptors, respectively.

DR 2313

[284028-90-6]
Purity: 99%

Soluble in water and DMSO
C₈H₁₀N₂O₅ MW: 182.24



Axon 1268

mg	Price
10	online
50	online

Biological activity

Potent PARP inhibitor; with neuroprotective effects, potentially more useful in treating acute stroke than a free radical scavenger


DR3305

See Ebselen

DRI-C21045

[2101765-81-3]
Purity: 98%

Soluble in DMSO
C₃₂H₂₄N₂O₇S MW: 581



Axon 2887

mg	Price
10	online
50	online

Biological activity

DRI-C21045 is an inhibitor of the CD40-CD40L costimulatory protein-protein interaction with an IC₅₀ value of 0.17 μM. Moreover, the activity of DRI-C21045 (IC₅₀) in the low micromolar range has been confirmed in cell assays including inhibition of CD40L-induced activation in NF-κB sensor cells, THP-1 myeloid cells, and primary human

B cells as well as in murine allogeneic skin transplant and alloantigen-induced T cell expansion in draining lymph node experiments.

Dridol

See Droperidol

Axon 1554

Page 442

Droleptan

See Droperidol

Axon 1554


Page 442

Dronedaron hydrochloride

SR33589 hydrochloride

[141625-93-6]
Purity: 99%

Soluble in DMSO and EtOH
C₃₁H₄₄N₂O₅S.HCl MW: 593.22



mg	Price
50	online

Biological activity


Dronedaron hydrochloride is a multi-channel blocker and antiarrhythmic agent. At progressively higher concentrations, it blocks the L-type calcium current, the rapid then slow components of the delayed rectifier potassium current, and the inward rectifier potassium current. Dronedaron also effectively blocks the cardiac sodium current in isolated human atrial myocytes, with minimal effects on its kinetics.

Droperidol

R 4749; Droleptan; Dridol

[548-73-2]
Purity: 99%

Soluble in DMSO
C₂₂H₂₂N₃O₂ MW: 379.43



Axon 1554

mg	Price
10	online
100	online
500	online


Biological activity

Dopamine D₂ receptor antagonist and α₁ adrenoceptor antagonist; an antidopaminergic drug used as an antiemetic and antipsychotic; also often used for neuroleptanalgesic anesthesia and sedation in intensive-care treatment

Droxidopa

L-DOPS; L-threo 3,4-Dihydroxyphenylserine

[23651-95-8]
Purity: 98%
Optically pure
Soluble in 0.1N NaOH(aq) and 0.1N HCl(aq)
C₉H₁₁NO₅ MW: 213.19



Axon 3665

mg	Price
10	online
50	online

Biological activity

Droxidopa is a brain-penetrant norepinephrine prodrug. The synthetic amino acid Droxidopa is converted by L-aromatic-amino-acid decarboxylase (DOPA decarboxylase) into norepinephrin.

DS103-282

See Tizanidine hydrochloride


Axon 3497

Page 929

DS-3032

Milademetan; DS-3032B

[1398568-47-2]
Purity: 99%
99% e.e.
Soluble in DMSO
C30H34Cl2FN5O4 MW: 618.53


Biological activity

DS-3032 (Milademetan) is an orally available, potent and selective inhibitor of the p53-MDM2 (murine double minute 2) interaction.

Source Information: Sold in collaboration with Chemietek

DS-3032B

See DS-3032

Axon 3765

mg	Price
5	online
10	online

DS-3201B

See Valemetostat

Axon 3765


Page 443

Axon 3722

Page 960

DS44960156


[2361327-08-2]
Purity: 99%
Soluble in 0.1N NaOH(aq) and DMSO
C20H15NO5 MW: 349.34


Biological activity

DS44960156 is a MTHFD2 inhibitor with an IC50 value of 1.6 μM and >18 fold selectivity over MTHFD1.

DS45500853

[2735803-28-6]
Purity: 99%
Soluble in DMSO and EtOH
C18H20O3 MW: 284.35


Biological activity

DS45500853 is an ERRα agonist with an IC50 value of 0.80 μM (for binding between F-RIP140 and GST-ERRα) and an ERRα reporter EC50 value of 5.4 μM. DS45500853 is devoid of PPAR γ transcriptional activity.

DSRM-3716

[58142-99-7]
Purity: 99%

Axon 3517

mg	Price
50	online


Soluble in 0.1N HCl(aq), DMSO and EtOH
C9H6IN MW: 255.06


Biological activity

DSRM-3716 is a potent and selective inhibitor of SARM1 NADase (IC50 value of 75 nM) that recapitulates the SARM1-/- phenotype and protects axons from degeneration induced by axotomy or mitochondrial dysfunction.

DT-2216

[2365172-42-3]
Purity: 99%
99% e.e.
Soluble in DMSO
C77H96ClF3N10O10S4 MW: 1542.36



Biological activity

DT-2216 is a selective B-cell lymphoma-extra large (Bcl-XL) targeted protein degrader with potential pro-apoptotic, immunomodulating and antineoplastic activities.

Source Information: Sold in collaboration with Chemietek

DTHIB

[897326-30-6]
Purity: 99%
Soluble in DMSO
C13H9ClF3NO3 MW: 309.68


Biological activity


DTHIB is a direct HSF1 inhibitor with a Kd value of 160 nM for DTHIB binding to the HSF1 DNA binding domain (DBD). DTHIB physically engages HSF1 and selectively stimulates degradation of nuclear HSF1. Moreover, DTHIB robustly inhibited the HSF1 cancer gene signature and prostate cancer cell proliferation.

DTIC

See Dacarbazine

DU125530

[161611-99-0]
Purity: 99%
Soluble in DMSO
C23H26ClN3O5S MW: 491.99


Biological activity

DU125530 is a selective 5-HT1A receptor antagonist (Ki value of 0.7 nM). DU-125530 showed equal (low nM) potency to displace agonist and antagonist binding to pre- and post-synaptic 5-HT1A receptors in rat and human brain.

DU 127090

See Bifeprunox mesylate

Axon 1508

Page 307

DU 21220

See Ritodrine hydrochloride

Axon 3647

Page 821

DU 28853

See Eltoprazine hydrochloride

Axon 1142

Page 455

DU-176b

See Edoxaban tosylate

Axon 3116

Page 451

DUP 89

See Losartan

Axon 3102

Page 620

Durezol

See Difluprednate

Axon 1428

Page 427

Duvelisib

See IPI-145

Axon 4133

Page 569

DVS 233

See Desmethylvenlafaxine, O-

Axon 3578

Page 420

DVS 233 hydrochloride

See Desvenlafaxine hydrochloride

Axon 3555

Page 421

DVS 233 succinate

See Desmethylvenlafaxine succinate, O-

Axon 2116

Page 421

DWAY


See WAY 100635 trihydrochloride, desmethyl-

Axon 1087

Page 983

DW-71177 Recent Addition

 [2241311-72-6]
Purity: 99%

 Soluble in DMSO
C20H28N6O2 MW: 384.48

Axon 4131

mg	Price
5	online
25	online

Biological activity

DW-71177 is a potent, orally bioavailable and BD1-selective BET inhibitor that exhibits strong antileukemic activity with a Kd value of 6.7 nM for BRD4-BD1.

DXP


See Dexamethasone palmitate

Axon 3345

Page 422

DY 268

 [1609564-75-1]
Purity: 100%

 Soluble in DMSO
C30H32N4O5S MW: 560.66

Biological activity


Highly potent FXR antagonist with a promising in vitro profile (IC50 values 7.5 nM and 468.5 nM in FXR binding assay and cell-based FXR antagonistic assay, respectively). DY 268 shows no FXR agonistic activity nor cytotoxicity, making it an excellent chemical tool to elucidate the biological function of FXR.

Axon 2561

mg	Price
10	online
50	online

Dynasore

 [304448-55-3]
Purity: 99%

 Soluble in 0.1N NaOH(aq), DMSO and EtOH
C18H14N2O4 MW: 322.31

Biological activity

Dynasore is a noncompetitive cell-permeable inhibitor of dynamin with an IC50 value of 15 µM.


Axon 3879

mg	Price
10	online
50	online

Dyngo-4a Recent Addition

Hydroxy-dynasore

 [1256493-34-1]
Purity: 99%

 Soluble in DMSO
C18H14N2O5 MW: 338.31

Biological activity


Dyngo-4a is a cell-permeable dynamin and endocytosis inhibitor. Dyngo-4a inhibits dynamin I and II with IC50 values of 0.38 µM and 2.3 µM, respectively. Also, Dyngo-4a is a potent MUS81-EME1/2 inhibitor.

Axon 4029

mg	Price
10	online
50	online

DYRK1A inhibitor compound 11

 [2814486-79-6]
Purity: 98%

 Soluble in 0.1N HCl(aq), DMSO and EtOH
C12H12N6 MW: 240.26

Biological activity

DYRK1A inhibitor compound 11 is a highly selective and ligand-efficient DYRK1A inhibitor with an IC50 value of 220 nM.

Axon 4056


mg	Price
5	online
25	online

E 3810 dihydrochloride

AL 3810 dihydrochloride

[N.A.]
Purity: 99%

Soluble in water and DMSO
C26H25N3O4.2HCl MW: 516.42



Axon 1942

mg	Price
2	online
5	online

Biological activity

First-in-class dual VEGFR/FGFR tyrosine kinase inhibitor; E-3810 potently and selectively inhibited VEGFR-1, -2, and -3 and FGFR-1 and -2 kinases in the nanomolar range; a potent antiangiogenic small molecule with a favorable pharmacokinetic profile and broad spectrum antitumor activity

E3810

See Rabeprazole sodium

Axon 3663


Page 805

E 5555 hydrobromide

Atopaxar hydrobromide

[474550-69-1]
Purity: 99%

Soluble in DMSO
C29H38FN3O5.HBr MW: 608.54



Axon 2030

mg	Price
2	online
5	online

Biological activity

Potent and orally active thrombin receptor (or protease-activated receptor 1, PAR1) antagonist (IC50: 19 nM); E5555 showed potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC50 values of 64 and 31nM, respectively

E 7050

See Golvatinib

Axon 1959

Page 513

E7080


See Lenvatinib

Axon 3165

Page 611

E-7386

[1799824-08-0]
Purity: 99%
99% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C39H48FN9O4 MW: 725.85



Axon 3715

mg	Price
5	online
10	online

Biological activity

E-7386 is a first-in-class orally active specific inhibitor of CBP/β-catenin complex, and a modulator of Wnt signaling pathway. It disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in

LiCl-stimulated HEK-293 and MDA-MB-231 in a dose-dependent manner, with IC50 of 55 and 73 nM, respectively; exhibits anti-tumor activity in vitro tumor proliferation panel against 28 human tumor cell lines; modulates the expression of Wnt signaling pathway related genes including AXIN2 and other genes. Oral administration of E7386 significantly suppressed the number of polyposis in a dose dependent manner at the dose range from 8.5 to 50 mg/kg. It also significantly changed the expressions of Wnt related genes in whisker follicle of ApcMin/+mice model.


Source Information: Sold in collaboration with Chemietek

E7449 mesylate

2X-121

[1140965-47-4]
Purity: 98%

Soluble in water and DMSO
C18H15N5O.CH4O3S MW: 413.45



Axon 3398


mg	Price
5	online
25	online

Biological activity

E7449 mesylate is a potent, brain penetrable and orally bioavailable dual inhibitor of PARP1/2 and tankyrase1/2, which inhibits growth of DNA repair deficient tumors and antagonizes Wnt signalling. E7449 mesylate exhibits IC50 values of 2.0 and 1.0 nM for PARP1 and PARP2, respectively.

E-7766

[2242635-03-4]
Purity: 99%
99% e.e.
Soluble in water
C24H26F2N10O8P2S2.2NH3 MW: 780.66



Axon 3689

mg	Price
1	online

Biological activity


E-7766 is a structurally novel class of macrocyclic molecule, metabolically stable, specific, and potent (Kd in lower nM, on par with that of the natural ligand 2',3'-cGAMP (Axon 3688) agonist for both human and mouse STING (Stimulator of Interferon Genes). Exhibits broad pan-genotypic activity in all major human STING variants. Demonstrates potent antitumor activity with long lasting immune memory response in a mouse liver metastatic tumor model.

Source Information: Sold in collaboration with Chemietek

Eact

[461000-66-8]
Purity: 100%

Soluble in DMSO
C22H24N2O5S MW: 428.50



Axon 2576

mg	Price
5	online
25	online

Biological activity

Strong activator of TMEM16A (ANO1; calcium activated chloride channel;CaCC) without elevating cytoplasmic Ca2+, producing outwardly rectifying currents (EC50 value 3 μM). Eact increases secretion by submucosal glands, as well as by airway surface cells exposed to a proinflammatory milieu; may be useful for treatment of cystic fibrosis (CF), dry mouth, and dry eye syndromes, and motility disorders of the gastrointestinal tr


EA1045

[1942114-09-1]

Axon 2680

mg	Price
----	-------

Purity: 99%
Soluble in DMSO
C19H14FN3O3S MW: 383.40




5	online
25	online

Biological activity
EAI045 is an allosteric inhibitor that targets drug-resistant L858R/T790M-mutant EGFR tyrosine kinase (IC50 value of 3 nM), and spares the wild-type receptor (~1000-fold selectivity versus wild-type EGFR at 1 mM ATP).

EBIO, 1-

[10045-45-1]
Purity: 99%
Soluble in DMSO and Ethanol
C9H10N2O MW: 162.19




Axon 1313

mg	Price
10	online
50	online

Biological activity
Ca²⁺-activated K⁺-channel opener

EBio1 Recent Addition

[339287-36-4]
Purity: 99%
Soluble in DMSO
C19H14FNO MW: 291.32




Axon 4173

mg	Price
10	online
50	online

Biological activity
EBio1 is a potent and highly selective KCNQ2 activator. EBio1 engages the KCNQ2 activation by generating an extended channel gate with a larger conductance at the saturating voltage (+50 mV).

EBPC

[4450-98-0]
Purity: 99%
Soluble in DMSO and Ethanol
C14H15NO4 MW: 261.27




Axon 1204

mg	Price
10	online
50	online

Biological activity
Potent aldose reductase inhibitor

Ebselen

PZ51; SPI1005; DR3305
[60940-34-3]
Purity: 99%
Soluble in DMSO
C13H9NOSe MW: 274.18



Axon 3424

mg	Price
10	online
50	online

Biological activity

Ebselen, an organoselenium compound, mimics glutathione peroxidase activity. Ebselen is a multifunctional compound, which catalyzes several essential reactions for the protection of cellular components from oxidative and free radical damage. Antioxidant.

Ebvaciclib

See PF-06873600

Axon 3693
Page 761

Ec2la

See CB2R PAM C2

Axon 3955
Page 346


ECDCa, 6-

See Obeticholic acid

Axon 3174
Page 729

eCF309

[2001571-40-8]
Purity: 98%
Moderately soluble in DMSO
C18H21N7O3 MW: 383.40




Axon 2630

mg	Price
2	online

Biological activity
Potent inhibitor of mTOR signalling (IC50 value 10 - 15 nM in vitro and in vivo) with very high selectivity over other kinases, including PI3Ks. The selectivity profile of eCF309 is as good as or even better than that of any other selective mTOR inhibitor reported to date, making it a highly valuable probe for chemical biology and biomedicine. Produced by and sold in collaboration with University of Edinburgh * Sold in collaboration with University of Edinburgh

ECSI#6

[860456-56-0]
Purity: 99%
Soluble in DMSO and EtOH
C18H17NO5 MW: 327.33



Axon 3881

mg	Price
5	online
25	online

Biological activity
ECSI#6 is the first uncompetitive serotonin transporter (SERT) inhibitor. Inhibition of serotonin uptake by ECSI#6 was enhanced with increasing serotonin concentration. Conversely, the KM for serotonin was lowered by augmenting ECSI#6. ECSI#6 bound with low affinity to the outward-facing state of SERT but with increased affinity to a potassium-bound state. ECSI#6 also acted as a pharmacochaperone: cellular preincubation with ECSI#6 restored export from the endoplasmic reticulum (ER) and substrate transport by a misfolded SERT variant.

EDHS-206


See Takinib

Axon 3282
Page 908

Edoxaban tosylate

DU-176b

[480449-71-6]
Purity: 100%
Optically pure
Soluble in DMSO
C24H30ClN7O4S.C7H8O3S MW:
720.26



Axon 3116

mg	Price
10	online
50	online


Biological activity

Edoxaban tosylate is a potent, selective and orally active factor Xa (FXa) inhibitor with K_i values of 0.561 nM for free FXa, 2.98 nM for prothrombinase, and exhibited >10000-fold selectivity for FXa. Antithrombotic agent.

EED226

[2083627-02-3]
Purity: 99%

Soluble in DMSO
C17H15N5O3S MW: 369.40



Axon 2701

mg	Price
5	online
25	online

Biological activity


EED226 is a first-in-class, potent, selective and orally bioavailable PRC2 inhibitor (IC50 values of 23.4 nM and 53.5 nM with H3K27me0 peptide and the mononucleosome as the substrates, respectively) that directly binds to the H3K27me3 binding pocket of EED. EED226 effectively induced tumor regression in a mouse xenograft model.

Eyarestatin I

ES1; ERAD inhibitor 1; p97 inhibitor 1

[412960-54-4]
Purity: 98%

Soluble in DMSO
C27H25Cl2N7O7 MW: 630.44



Axon 1798

mg	Price
2	online
5	online


Biological activity

Potent inhibitor of endoplasmic reticulum associated protein degradation (ERAD). Specifically targets the p97-associated deubiquinating process (PAD) and inhibits ataxin-3 (atx3)-dependent deubiquitination

Efaroxan hydrochloride

[89197-00-2]
Purity: 99%

Soluble in water and DMSO
C13H16N2O.HCl MW: 252.74



Axon 1155

mg	Price
10	online
50	online


Biological activity

Selective α_2 -adrenoceptor antagonist

Efavirenz

DMP-266; L-743,726

[154598-52-4]
Purity: 99%
Optically pure
Soluble in DMSO
C14H9ClF3NO2 MW: 315.67



Axon 3125

mg	Price
10	online
50	online

Biological activity

Efavirenz is a highly potent, orally bioavailable nonnucleoside inhibitor of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). Moreover, Efavirenz inhibited wild-type HIV-1 RT with a K_i value of 2.93 nM, and exhibited a 95% inhibitory concentration of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.

EFdA

See Islatravir


Axon 3191

Page 570

Efinaconazole

KP103

[164650-44-6]
Purity: 100%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C18H22F2N4O MW: 348.39



Axon 3369

mg	Price
10	online
50	online

Biological activity


Efinaconazole is a topical antifungal that inhibits sterol 14 α -demethylase, an enzyme in the ergosterol biosynthesis pathway. Efinaconazole has lower minimum inhibitory concentrations than terbinafine, ciclopirox, itraconazole and amorolfine in *Trichophyton rubrum*, *Trichophyton mentagrophytes* and *Candida albicans*.

Eflornithine hydrochloride

α -Difluoromethylornithin; DFMO

[68278-23-9]
Purity: 98%

Soluble in water
C6H12F2N2O2.HCl MW: 218.63



Axon 3817

mg	Price
50	online

Biological activity

Eflornithine hydrochloride is a selective, irreversible ornithine decarboxylase (ODC) inhibitor. Moreover, Eflornithine is an inhibitor of polyamine biosynthesis.

Eganelisib

See IPI-549

Axon 4147

Page 569

Eg5 inhibitor III

See Dimethylenastron

Axon 2439


Page 432

EGFR Inhibitor 324674

[879127-07-8]

Axon 1760

mg	Price
----	-------

Purity: 99%		5	online
Soluble in DMSO C21H18F3N5O MW: 413.40		25	online


Biological activity

A potent, cell permeable, irreversible and highly selective EGFR tyrosine kinase inhibitor with IC50 value in the nM range

EHop 016

[1380432-32-5]
Purity: 99%

Soluble in DMSO
C25H30N6O MW: 430.55



Axon 2351

mg	Price
10	online
50	online

Biological activity

EHop 016 is a Rac GTPase inhibitor (IC50 value 1.1 μM) specific for Rac1 and Rac3 at concentrations of = 5 μM, and inhibits the interaction of Vav2 with Rac1 at physiologically relevant concentrations. Additionally, EHop-016 inhibits the activation of the Rac downstream effector p21-activated kinase (PAK), extension of motile actin-based structures, and cell migration. EHop-016 is ~100 times more potent than NSC 23766 (Axon 1578) and 10–50 times more potent than other currently available Rac inhibitors.

EIDD-2801

See MK-4482


Axon 3188

Page 662

eIF4A i28

[2861994-92-3]
Purity: 98%

Soluble in DMSO
C24H20N2O5 MW: 416.43



Axon 4120

mg	Price
5	online
25	online

Biological activity

eIF4A i28 is a RNA-competitive, ATP-uncompetitive eIF4A inhibitor with an IC50 of 8.6 μM. eIF4A i28 binds a novel pocket in the RNA groove and inhibits eIF4A with a novel mechanism in which it perturbs RNA binding, blocks the hydrolysis of ATP, and consequently inhibits RNA helicase activity.

EKB 569

See Pelitinib


Axon 1665

Page 757

Elacestrant dihydrochloride

RAD1901

[1349723-93-8]
Purity: 99%
100% e.e.
Soluble in water and DMSO
C30H38N2O2.2HCl MW: 531.56



Axon 4095

mg	Price
5	online
25	online

Biological activity


Elacestrant dihydrochloride is an orally bioavailable selective estrogen receptor degrader (SERD) with IC50 values of 48 nM and 870 nM for ERα and ERβ, respectively. Elacestrant is a potent antagonist of breast cancer cells, inhibiting both basal and E2-stimulated MCF-7 cell proliferation.

Elacridar hydrochloride

GF 120918A

[143851-98-3]
Purity: 100%

Poorly soluble in DMSO
C34H33N3O5.HCl MW: 600.10



Axon 1896

mg	Price
10	online
50	online

Biological activity


P-glycoprotein (P-gp) inhibitor; a third generation ABCB1 modulator, preferentially modulating p-gp in brain capillaries; also an inhibitor of breast cancer resistance protein (BCRP)-mediated drug transport

Elafibranor

GFT505

[824932-88-9]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C22H24O4S MW: 384.49



Axon 2727

mg	Price
10	online
50	online

Biological activity


The dual PPARα/δ agonist Elafibranor (GFT505) (EC50 values of 45 nM and 175 nM for PPARα and PPARδ, respectively) is a liver-targeted insulin-sensitizer that is a drug candidate for the treatment of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NAS). In animals, its protective effects are mediated by both PPAR-α-dependent and -independent mechanisms.

Elesclomol

STA4783

[488832-69-5]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C19H20N4O2S2 MW: 400.52



Axon 3745

mg	Price
10	online
50	online


Biological activity

Elesclomol is an inducer of apoptosis in cancer cells through the induction of oxidative stress. Treatment of cancer cells in vitro with Elesclomol resulted in the rapid generation of reactive oxygen species (ROS) and the induction of a transcriptional gene profile characteristic of an oxidative stress response.

Eletriptan hydrobromide

UK 116044-04

[177834-92-3]
Purity: 99%
Optically pure
Soluble in water and DMSO
C22H26N2O2S.HBr MW: 463.43



Axon 2050

mg	Price
10	online
50	online

Biological activity

Potent and selective 5-HT1B/1D receptor agonist; second generation anti-migraine drug


Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Eliprodil

SL 820715

[119431-25-3]
Purity: 99%

Soluble in DMSO
C20H23ClFNO MW: 347.85



Axon 1246

mg	Price
10	online
50	online

Biological activity


Non-competitive NMDA antagonist, selective for NR2B type; Neuroprotective agent

ELN 484228

NSC 164389

[312-63-0]
Purity: 99%

Soluble in DMSO
C12H10FNO2S MW: 251.28



Axon 2382

mg	Price
10	online
50	online

Biological activity

α -Synuclein modulator with substantial biological activity in cellular models of α -synuclein-mediated dysfunction such as Parkinson's Disease. ELN484228 reduced synaptic levels of α Syn in neuronal cultures from both wild type rats and from transgenic mice overexpressing α Syn by not more than two-fold, and ELN 484228 reversed α Syn-induced impairment of phagocytosis and protects dopaminergic neurons against the toxic effects of α Syn A53T over-expression.

Elocalcitol

See BXL 628

Axon 1676


Page 336

Eltoprazine hydrochloride

DU 28853

[98206-09-8]
Purity: 98%

Soluble in water and DMSO
C12H16N2O2.HCl MW: 256.73



Axon 1142

mg	Price
10	online
50	online

Biological activity


5-HT1A/1B agonist and 5-HT2C receptor antagonist

Eltrombopag

SB 497115

[496775-61-2]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C25H22N4O4 MW: 442.47



Axon 1872

mg	Price
5	online
10	online

Biological activity

First-in-class, oral, non-peptide thrombopoietin receptor (TpoR or MPL) agonist, which is developed as a treatment for thrombocytopenia of various etiologies. Eltrombopag activates TpoR signaling pathway and induces proliferation and differentiation in mammalian cells and cell lines

Emapunil

See AC-5216


Axon 3698

Page 204

Embelin

[550-24-3]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C17H26O4 MW: 294.39



Axon 4023

mg	Price
10	online
50	online

Biological activity

Embelin is a fairly potent and cell-permeable inhibitor of XIAP with an IC50 value of 4.1 μ M. Embelin inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP, but has a minimal effect on normal prostate epithelial and fibroblast cells with low levels of XIAP.

EMD33512

See Bisoprolol fumarate


Axon 3458

Page 311

EMD638683

[1181770-72-8]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C18H18F2N2O4 MW: 364.34



Axon 4128

mg	Price
5	online
25	online


Biological activity

EMD63868 is a selective SGK1 inhibitor with an IC50 of 3 μ M.

EMI48

[34564-13-1]
Purity: 99%

Soluble in DMSO
C21H20N2O3 MW: 348.40



Axon 3192

mg	Price
5	online
25	online

Biological activity

EMI48 is an inhibitor of EGFR triple mutants. Moreover, EMI48 strongly inhibited total EGFR levels, activation and downstream signaling with effects observed at a 5 μ M concentration. EMI48 did not affect interphase microtubules, or have an effect on spindle formation in PC9 EGFR ex19del/T790M/C797S cells.


EML 425

[1675821-32-5]
Purity: 99%

Soluble in DMSO
C27H24N2O4 MW: 440.49

Axon 2568

mg	Price
5	online
25	online




Biological activity

Potent, selective and cell permeable reversible dual inhibitor of CBP and p300 (IC50 values 1.1 μ M and 2.9 μ M, respectively, and practically inactive against the enzymes GCN5 and PCAF), noncompetitive versus both acetyl-CoA and a histone H3 peptide. EML425 induced a marked and time-dependent reduction in the acetylation of lysine H4K5 and H3K9, a marked arrest in the G0/G1 phase and a significant increase in the hypodiploid nuclei percentage in human leukemia U937 cells. EML425's potency is comparable to that of C646 (Axon 1781)

EMPA

[680590-49-2]
Purity: 99%

Soluble in DMSO and EtOH
C23H26N4O4S MW: 454.54



Axon 2012

mg	Price
10	online
50	online


Biological activity

Highly potent and selective orexin type 2 (OX2) receptor antagonist, with Ki values of >900 and 1 nM for OX1 and OX2 receptors respectively

Empagliflozin

B110773

[864070-44-0]
Purity: 100%
Optically pure
Soluble in DMSO
C23H27ClO7 MW: 450.91



Axon 3367

mg	Price
50	online

Biological activity


Empagliflozin is a potent and selective SGLT-2 inhibitor (IC50 value of 3.1 nM for hSGLT-2).

Emraclidine

CVL231

[2170722-84-4]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C20H21F3N4O MW: 390.40



Axon 4086

mg	Price
5	online
25	online

Biological activity

Emraclidine is a brain-penetrant, highly selective M4 receptor positive allosteric modulator.

Emtricitabine


(-)-FTC

[143491-57-0]
Purity: 100%

Axon 3305

mg	Price
50	online

Optically pure
Soluble in water and DMSO
C8H10FN3O3S MW: 247.25




Biological activity

Emtricitabine is a potent, orally bioavailable nucleoside reverse transcriptase inhibitor (NRTI) with an apparent IC50 value of 10 nM.

EN219

[380351-29-1]
Purity: 99%

Soluble in DMSO and EtOH
C17H13Br2ClN2O MW: 456.56



Axon 3613

mg	Price
10	online
50	online

Biological activity


EN219 is a moderately selective covalent ligand that targets RNF114 (IC50 value of 470 nM) and mimics nimbolide mode of action. EN219 also inhibited RNF114-mediated autoubiquitination and p21 ubiquitination in vitro.

EN460

ERO1 Inhibitor II

[496807-64-8]
Purity: 99%

Soluble in DMSO
C22H12ClF3N2O4 MW: 460.79



Axon 2737

mg	Price
10	online
50	online

Biological activity

EN460, an inhibitor of endoplasmic reticulum oxidation 1 (ERO1), interacts selectively with the reduced, active form of ERO1 α and prevents its reoxidation (IC50 value of 1.9 μ M). Despite rapid and promiscuous reactivity with thiolates, EN460 exhibits selectivity for ERO1.

EN 1733A

See Molindone hydrochloride


Axon 1101

Page 676

Ena21 hydrochloride

[N.A.]
Purity: 99%

Soluble in water and DMSO
C18H21NO4.HCl MW: 351.82



Axon 3674

mg	Price
10	online
50	online

Biological activity

Ena21 hydrochloride is a selective and competitive inhibitor of ALKBH5 with an IC50 value of 15.7 μ M. Ena21 had little inhibitory activity for fat mass and obesity-associated protein (FTO), which is another N6-methyladenosine demethylation enzyme.

Enasidenib

See AG-221


Axon 2745

Page 212

Encenicline hydrochloride Recent Addition

EVP6124

[550999-74-1]
Purity: 98%
Optically pure
Soluble in water, DMSO and EtOH
C16H18Cl2N2OS MW: .00



Axon 4113

mg	Price
10	online
50	online

Biological activity

Encenicline hydrochloride is a selective and brain-penetrant $\alpha 7$ nicotinic acetylcholine receptor partial agonist.

Encorafenib

See LGX818

Axon 4146

Page 613

endo-IWR-1

See IWR-1-endo


Axon 2510

Page 575

Endoxifen

[110025-28-0]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C25H27NO2 MW: 373.49



Axon 2190

mg	Price
10	online
50	online


Biological activity

Metabolite of Tamoxifen and a selective estrogen receptor modulator (SERM); Potently inhibits the growth of estrogen-stimulated BT474 cells (IC50: 54 nM). Approximately 100-fold more potent as an antagonist of the ER α than the parent drug. Drug for the treatment of estrogen receptor (ER) positive breast cancer.

Endoxifen, (Z)-

[112093-28-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C25H27NO2 MW: 373.49



Axon 2221

mg	Price
5	online
25	online

Biological activity

The more active (Z)-isomer of (E/Z)-Endoxifen (Axon 2190), an active metabolite of Tamoxifen and a selective estrogen receptor modulator (SERM; IC50 value 0.01–0.10 μ M in estrogen-stimulated proliferation assay in MCF-7 cells); Potently inhibits the growth of estrogen-stimulated BT474 cells. Approximately 100-fold more potent as an antagonist of the ER α than the parent drug. Z-Endoxifen may provide a new and better treatment for women with estrogen receptor (ER) positive breast cancer.

Endoxifen hydrochloride


[1197194-41-4]

Axon 2707

mg Price

Purity: 99%

Soluble in water and DMSO
C25H27NO2.HCl MW: 409.95



10	online
50	online

Biological activity

Metabolite of Tamoxifen and a selective estrogen receptor modulator (SERM); Potently inhibits the growth of estrogen-stimulated BT474 cells (IC50: 54 nM). Approximately 100-fold more potent as an antagonist of the ER α than the parent drug. Drug for the treatment of estrogen receptor (ER) positive breast cancer.

Enitociclib

See BAY-1251152


Axon 3935

Page 286

ENPP1 inhibitor compound 43

[2631703-41-6]
Purity: 99%

Soluble in 0.1N NaOH(aq), 0.1N HCl(aq), DMSO and EtOH
C16H18N6O3S MW: 374.42



Axon 4042

mg	Price
10	online
50	online


Biological activity

ENPP1 inhibitor compound 43 is a potent, selective and orally bioavailable ENPP1 inhibitor with a K_i value of 41 nM.

Ensemble Compound 159

[1449208-36-9]
Purity: 97%
Optically pure

C42H51ClN6O6 MW: 771.34



Axon 2800

mg	Price
1	online

Biological activity


Ensemble Compound 159 is a peptide inhibitor of IL-17A. Ensemble Compound 159 binds to IL-17A and/or inhibits formation of the IL-17A–IL-17RA complex through an ELISA assay, an HT29-GRO α cell based functional assay, a rheumatoid arthritis synovial fibroblast (RASf) assay, and surface plasmon resonance (SPR, K_d < 100 nM) based biophysical binding assessment. Moreover, Ensemble Compound 159 was reported to have efficacy in vivo.

Entacapone

OR611; (E)-Entacapone

[130929-57-6]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C14H15N3O5 MW: 305.29



Axon 3389

mg	Price
10	online
50	online

Biological activity


Entacapone is a potent, peripherally acting, reversible inhibitor of catechol-O-methyltransferase (COMT) with IC50 values of 10 nM and 160 nM for rat duodenum and liver-soluble COMT, respectively.

Entecavir

BMS-200475

[142217-69-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C12H15N5O3 MW: 277.28



Axon 3239

mg	Price
10	online
50	online

Biological activity

Entecavir, carbocyclic 2'-deoxyguanosine analogue, is a competitive inhibitor of HBV viral polymerase leading to interference with the elongation of viral chains.

Entinostat

See MS 275

Axon 1803

Page 683

Entospletinib

See GS-9973

Axon 4153


Page 516

Enzastaurin

LY 317615

[359017-79-1]
Purity: 99%

Soluble in DMSO
C32H29N5O2.HCl MW: 552.07



Axon 1682

mg	Price
10	online
50	online

Biological activity

Selective protein kinase C beta (PKCβ) inhibitor; Enzastaurin inhibits PKCβ, PKCα, PKCγ and PKCε with IC50's of 6, 39, 83 and 110 nM, respectively

EOS200271

See PF-06840003

Axon 3325

Page 771

Epacadostat

See INCB 024360

Axon 1733


Page 565

Epibatidine dihydrochloride, (-)-

[152378-30-8]

Purity: 99%
98% ee

Soluble in water and DMSO
C11H13ClN2.2HCl MW: 281.61



Axon 1078

mg	Price
2	online
5	online

Biological activity

Potent Nicotinic Agonist, Analgesic, Non-Narcotic; (-)-enantiomer of (±)-Epibatidine


Epibatidine dihydrochloride, (+)-

[166374-43-2]

Purity: 99%

99% ee

Soluble in water and DMSO
C11H13ClN2.2HCl MW: 281.61



Axon 1077

mg	Price
2	online
5	online

Biological activity


Potent Nicotinic Agonist, Analgesic, Non-Narcotic; (+)-enantiomer of (±)-Epibatidine

Epibatidine dihydrochloride, (±)-

[162885-01-0]

Purity: 99%

Soluble in water and DMSO
C11H13ClN2.2HCl MW: 281.61



Axon 1076

mg	Price
5	online
25	online

Biological activity

Potent Nicotinic Agonist, Analgesic, Non-Narcotic

Epidaza

See Tucidinostat

Axon 2893

Page 943

Epiestradiol

See Estradiol, α- Recent Addition

Axon 4212

Page 468

Epigoitrin (optically pure)

(R)-Goitrin; D-Goitrin

[1072-93-1]

Purity: 99%

98% e.e.

Soluble in DMSO and EtOH
C5H7NOS MW: 129.18



Axon 3782

mg	Price
5	online
25	online

Biological activity

Epigoitrin is the main active constituent of *Radix isatidis* (Banlangen), which is a widely used traditional Chinese medicine for treating fever and removing toxic heat. Epigoitrin exhibits antiviral activity. The opposite enantiomer, optically pure Goitrin (Axon 3781) is also available from Axon Medchem.


Epilivanserin

SR 46349B

[130580-02-8]

Purity: 99%

Soluble in DMSO
C38H42F2N4O4.C4H4O4
MW: 772.83



Axon 1439

mg	Price
5	online
10	online

Biological activity


Potent, selective and p.o. active 5-HT_{2A} antagonist; functionally also an inverse agonist of 5-HT_{2A} receptor; no affinity to dopamine, histamine and adrenergic receptors; therapeutic agent for the treatment of insomnia

EPPTB

RO 5212773

[1110781-88-8]
Purity: 100%

Soluble in DMSO
C20H21F3N2O2 MW: 378.39



Axon 2419

mg	Price
10	online
50	online

Biological activity

The first, highly potent and selective full antagonist of the trace amine-associated receptor 1 (TAAR1; IC₅₀ value 28 nM at mouse TAAR1). A useful pharmacological tool for in vitro and in vivo investigations to study the role of TAAR1 in psychiatric and neurodegenerative disorders. EPPTB blocks the TAAR1-mediated activation of an inwardly rectifying K⁺ channels.

EPZ-005676

See EPZ-5676

Axon 3960


Page 463

EPZ005687 hydrochloride

EPZ015938 hydrochloride

[N.A.]
Purity: 99%

Soluble in DMSO
C32H37N5O3.HCl MW: 576.13



Axon 4137

mg	Price
10	online
50	online

Biological activity


EPZ005687 is a potent and selective small molecule inhibitor of histone methyltransferase EZH2 (K_i = 24 nM). It has greater than 500-fold selectivity against 15 other protein methyltransferases and has 50-fold selectivity against the closely related enzyme EZH1.

Source Information: Sold in collaboration with Chemietek

EPZ011989 hydrochloride Recent Addition

[2095432-26-9]
Purity: 98%

Soluble in DMSO
C35H51N5O4.HCl MW: 641.26



Axon 4216

mg	Price
10	online
50	online

Biological activity

EPZ011989 is a cell permeable, metabolically stable and orally available EZH2 inhibitor, a compound with oral exposure and metabolic stability that is able to elicit robust methyl mark inhibition and antitumor activity. It binds potently and selectively to


Source Information: Sold in collaboration with Chemietek

EPZ 015666

GSK 3235025

[1616391-65-1]
Purity: 99%
99

Soluble in 0.1N HCl(aq) and DMSO
C20H25N5O3 MW: 383.44



Axon 2831

mg	Price
10	online
50	online

Biological activity

EPZ 015666 (GSK 3235025) is a potent, selective and orally available inhibitor of PRMT5 (IC₅₀ value of 22 nM). EPZ 015666 exhibits antiproliferative effects in both in vitro and in vivo models of MCL.

EPZ015938

See GSK3326595

Axon 3750

Page 521

EPZ015938 hydrochloride

See EPZ005687 hydrochloride

Axon 4137

Page 463

EPZ019997 hydrochloride

See GSK3368715 hydrochloride


Axon 3919

Page 521

EPZ-5676

Pinometostat; EPZ-005676

[1380288-87-8]
Purity: 99%
99% e.e.
Soluble in DMSO
C30H42N8O3 MW: 562.71



Axon 3960

mg	Price
5	online
10	online

Biological activity


EPZ-5676 is a potent, selective and S-adenosyl methionine (SAM) competitive inhibitor of DOT1L methyltransferase (K_i = 80 pM), displaying 37,000-fold selectivity over all other methyltransferases tested. It inhibits H3K79 methylation and MLL-fusion target gene expression, and potently and selectively kills acute leukemia cell lines bearing MLL translocations.

Source Information: Sold in collaboration with Chemietek

EPZ 6438

[1403254-99-8]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C34H44N4O4 MW: 572.74



Axon 2227


mg	Price
5	online
25	online

Biological activity

Potent, selective, and orally bioavailable inhibitor of EZH2 enzymatic activity (IC₅₀ values 2-38 nM in EZH2 assays). Induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells, and dose-dependently leads to regression of malignant rhabdoid tumors (MRTs) with correlative diminution of intratumoral trimethylation levels of H3K27, and prevention of tumor regrowth after dosing cessation.

ER-819762

[1155773-15-1]
Purity: 99%
>98% ee
Soluble in DMSO
C30H39N3O3 MW: 489.65



Biological activity

ER-819762 is a highly selective, and orally available antagonist of the prostaglandin EP4 receptor (IC50 value of 70 nM). Oral administration of ER-819762 to DBA/1 mice can effectively suppress disease in collagen-induced arthritis (CIA) or glucose-6-phosphate isomerase (GPI)-induced arthritis models. ER-819762 was also effective in treating chronic inflammatory pain in a rat model.


ERAD inhibitor 1

See Eeyarestatin I

ERAP1 inhibitor compound 3

[865273-97-8]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C20H21F3N2O5S MW: 458.45




Biological activity

ERAP1 inhibitor compound 3 allosterically activates endoplasmic reticulum aminopeptidase 1 (ERAP1) hydrolysis of fluorogenic and chromogenic amino acid substrates but competitively inhibits its activity toward a nonamer peptide representative of physiological substrates (EC50 value of 0.4 μM). ERAP1 inhibitor compound 3 inhibits ERAP1's activity in a cellular antigen processing assay with an IC50 value of 1.0 μM.

Erastin

[571203-78-6]
Purity: 99%

Soluble in DMSO
C30H31ClN4O4 MW: 547.04



Biological activity

An anti-tumor agent with RAS-selective lethality. Erastin binds to mitochondrial voltage-dependent anion channels (VDAC) proteins, more specifically on VDAC2 and alters its gating; induce non-apoptotic cell death selectively in some tumour cells harbouring activating mutations in the RAS-RAF-MEK pathway

ERB 041

Prinaberenl

[524684-52-4]
Purity: 99%

Axon 2788

mg	Price
5	online

Axon 1798

Page 449

Axon 3208

mg	Price
5	online
25	online


Axon 1825

mg	Price
5	online
10	online

Axon 1898

mg	Price
10	online

Soluble in 0.1N NaOH(aq) and DMSO
C15H10FNO3 MW: 271.24



50 online

Biological activity

Highly selective estrogen receptor beta (ERβ) agonist, with IC50 value of 5.4 nM for human ERβ which is >200-fold selective over Era

ERK11e

See VX-11e

Axon 3836

Page 979

Erloramide

See Lacosamide

Axon 1444


Page 603

Erlotinib hydrochloride

OSI 774

[183319-69-9]
Purity: 99%

Soluble in DMSO
C22H23N3O4.HCl MW: 429.90



mg	Price
10	online
50	online

Biological activity

EGFR inhibitor; Erlotinib inhibits EGFR tyrosine kinase autophosphorylation by inhibition of the intracellular domain. Studies in cell lines and enzyme assays have both shown that erlotinib inhibits EGFR at concentrations significantly lower than those needed to inhibit c-src and v-abl

Erlotinib, 6-O-Desmethyl-

See OSI 420

Axon 1632

Page 738

ER01 Inhibitor II


See EN460

Axon 2737

Page 458

ErSO

[2407860-35-7]
Purity: 99%
100% e.e.
Soluble in DMSO and EtOH
C22H13F6NO3 MW: 453.33



mg	Price
5	online
25	online

Biological activity

ErSO is an orally bioavailable activator of the anticipatory unfolded protein response (a-UPR). ErSO acts through ERα to elicit strong and sustained cytotoxic activation of the a-UPR. Moreover, ErSO hyperactivates the ERα-dependent a-UPR in ERα+ cancer cells leading to eradication of ERα+ breast tumors in multiple mouse models.


ErSO, (S)-

[2407860-34-6]
Purity: 99%

Axon 3704

mg	Price
5	online

100% e.e.
Soluble in DMSO and EtOH
C22H13F6NO3 MW: 453.33



25 online


Biological activity

Inactive enantiomer of ErSO (Axon 3594) which is an orally bioavailable activator of the anticipatory unfolded protein response (a-UPR).

Ervogastat

PF06865571

[2186700-33-2]
Purity: 98%
100% e.e.
Soluble in DMSO and EtOH
C21H21N5O4 MW: 407.42



Axon 3823

mg	Price
5	online
25	online

Biological activity

Ervogastat is a first-in-class potent and selective inhibitor of diacylglycerol acyltransferase 2 (DGAT-2) with an IC50 value of 17.2 nM.

ES 1

See Eeyarestatin I

Axon 1798

Page 449

ES000835

See Alofanib


Axon 2930

Page 218

Escitalopram oxalate

Cipralext; (S)-(+)-Citalopram oxalate

[219861-08-2]
Purity: 99%
Optically pure
Soluble in water and DMSO
C20H21FN2O.C2H2O4 MW: 414.43



Axon 3315

mg	Price
10	online
50	online

Biological activity


Escitalopram oxalate is a selective serotonin reuptake inhibitor (SSRI). Escitalopram is the S-enantiomer of Citalopram (Axon 1320) and, moreover, is the therapeutically active portion of the parent compound and has a proven antidepressant efficacy.

ESI-08

HJC-1-65

[301177-43-5]
Purity: 99%

Soluble in DMSO
C20H23N3OS MW: 353.48



Axon 2847

mg	Price
10	online
50	online

Biological activity

ESI-08 is a selective EPAC antagonist, which is capable of completely inhibiting both EPAC1 and EPAC2 activity (IC50 value of 8.4 μM for EPAC2) without inhibition of cAMP-mediated PKA activation.

ESN364


See Fezolinetant

Axon 3403

Page 479

Estetrol

[15183-37-6]
Purity: 100%
optically pure
Soluble in DMSO
C18H24O4 MW: 304.38



Axon 1926

mg	Price
5	online
25	online


Biological activity

Estetrol has a relatively moderate affinity for human estrogen α receptor (ERα) and estrogen β receptor (ERβ), with Ki values of 4.9 nmol/l and 19 nmol/l, respectively. Nevertheless, at a concentration of 10 μmol/l, Estetrol shows nearly no affinity for a wide range of >120 other receptors, among them the glucocorticoid, progesterone and testosterone receptors. An estrogen steroid and a metabolite of Estradiol

Estradiol, α- Recent Addition

Epiestradiol; 17α-Estradiol

[57-91-0]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C18H24O2 MW: 272.38



Axon 4212

mg	Price
100	online

Biological activity

α-Estradiol is a physiological estrogen with Ki value of 0.2 and 1.2 nM for ERα and ERβ receptors, respectively.

Estradiol, 17α-

See Estradiol, α- Recent Addition

Axon 4212

Page 468

Estybon

See Rigosertib sodium


Axon 2950

Page 818

ETC-206

[1464151-33-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C25H20N4O2 MW: 408.45



Axon 3340

mg	Price
5	online
25	online

Biological activity

ETC-206 is a potent, selective and orally available MNK1/2 inhibitor with IC50 values of 0.064 μM and 0.086 μM for MNK1 and MNK2, respectively. ETC-206 in combination with dasatinib (Axon 1392) prevents BC-CML LSC self-renewal in vitro and enhances dasatinib antitumor activity in vivo.

ETH 2120

See Sodium ionophore III

Axon 2688

Page 877

Ethyl apovincamin


See Vinpocetine

Axon 3889

Page 969

Ethylnorapomorphine hydrobromide, R(-)-N-

[20382-70-1]
Purity: 99%
>98% ee
No solubility data
C18H19NO2.HBr MW: 362.26



Axon 1162

mg	Price
10	online
50	online

Biological activity


Dopamine D2 receptor agonist; more potent than R(-)-NPA (Axon 1161)

Etifoxine

HOE36801

[21715-46-8]
Purity: 99%

Soluble in DMSO
C17H17ClN2O MW: 300.78



Axon 3388

mg	Price
10	online
50	online

Biological activity


Etifoxine is a PAM of GABAA receptors, a ligand of high-affinity 18-kDa translocator protein (TSPO), and a potent enhancer of neurosteroid synthesis. Anxiolytic and anticonvulsant drug.

Etifoxine hydrochloride

HOE36801

[56776-32-0]
Purity: 98%

Soluble in water, DMSO and EtOH
C17H17ClN2O.HCl MW: 337.24



Axon 3331

mg	Price
10	online
50	online

Biological activity


Etifoxine hydrochloride is a PAM of GABAA receptors, a high-affinity 18-kDa translocator protein (TSPO) ligand, and a potent enhancer of neurosteroid synthesis. Anxiolytic and anticonvulsant drug.

Etiracetam

UCB 6474

[33996-58-6]
Purity: 98%

No solubility data
C8H14N2O2 MW: 170.21



Axon 1109

mg	Price
10	online
50	online

Biological activity

Acetylcholine agonist; a nootropic drug of the racetam family; Its more active S-enantiomer is Leveracetam (Axon 1110). In comparison with the opposite R-enantiomer, UCB L-060 (Axon 1111)

Etiracetam, R-(+)-

See UCB-L 060

Axon 1111


Page 948

Etodolac

Etodolic acid

[41340-25-4]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C17H21NO3 MW: 287.35



Axon 3451

mg	Price
50	online

Biological activity

Etodolac is a highly selective COX-2 inhibitor with IC50 values of >100 and 53 μM for COX-1 and COX-2, respectively.

Etodolic acid

See Etodolac

Axon 3451


Page 470

Etoricoxib

MK0663

[202409-33-4]
Purity: 100%

Soluble in DMSO and EtOH
C18H15ClN2O2S MW: 358.84



Axon 3885

mg	Price
50	online

Biological activity


Etoricoxib is a potent, selective and orally active cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 1.1 μM.

ETP-47799

CDK8/19i

[923596-52-5]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C14H15N5 MW: 253.30



Axon 3525

mg	Price
5	online
25	online

Biological activity

ETP-47799 is a potent CDK8/19 inhibitor with IC50 values of 2.9 nM and 14.1 nM for CDK8 and CDK19, respectively. ETP-47799 stimulates Mediator recruitment of RNA Pol II. This effectively hyper-activates enhancers and stabilizes the transcriptional program of naive pluripotent cell identity.

EUK 134


Salen-Mn

Axon 2292

mg	Price
----	-------

[81065-76-1]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C18H18ClMnN2O4 MW: 416.74



10	online
50	online


Biological activity

A salen manganese complex with superoxide dismutase (SOD) and catalase mimetic characteristics. EUK134 exhibits potent antioxidant activities, and inhibits the formation of β -amyloid and related amyloid fibril (IAPP). Useful pharmacological tool for the development of new compounds for the treatment of Alzheimer's and Parkinson's disease and type 2 diabetes.

Evacetrapib

LY 2484595

[1186486-62-3]
Purity: 98%
Optically pure
Soluble in DMSO
C31H36F6N6O2 MW: 638.65



Axon 2286

mg	Price
5	online
25	online


Biological activity

Potent, and selective inhibitor of cholesteryl ester transfer protein (CETP; IC₅₀ value 5.5 nM and 26 nM in human recombinant and plasma CETP assays, respectively) that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.

Everolimus

RAD001

[159351-69-6]
Purity: 99%
>99% e.e.
Soluble in DMSO
C53H83NO14 MW: 958.22



Axon 4149

mg	Price
10	online
50	online

Biological activity

Everolimus is a Rapamycin derivative. It is currently used as an immunosuppressant to prevent rejection of organ transplants and as an mTOR inhibitor to treat renal cell cancer and other tumors.

Source Information: Sold in collaboration with Chemietek

EVP-22

See ML2-SA1


Axon 2980

Page 671

EVP 4593

[545380-34-5]
Purity: 99%

Soluble in DMSO
C22H20N4O MW: 356.42



Axon 2080

mg	Price
10	online
50	online

Biological activity

Potent NF- κ B activation inhibitor (EC₅₀: 9 nM); inhibits SOC pathway in HD neurons; exerts neuroprotective effects in transgenic HD flies and transgenic HD mouse neurons. EVP4593 was not active when tested in the IKK kinase assay

EVP6124

See Encenicline hydrochloride **Recent Addition**

Axon 4113

Page 459

Ewha-18278

See APX-115

Axon 2819

Page 243

EX 89

See Losartan

Axon 3102

Page 620

EX 527

See Selisistat

Axon 1956

Page 859

Exel 2880

See Foretinib


Axon 1582

Page 489

Exemestane

Aromasin; FCE 24304

[107868-30-4]
Purity: 98%
Optically pure
Soluble in DMSO and EtOH
C20H24O2 MW: 296.40



Axon 2045

mg	Price
10	online
50	online

Biological activity


Orally active, irreversible steroidal aromatase inhibitor (IC₅₀ = 20 nM). Destabilizes aromatase and lowers estrogen levels; breast cancer therapy

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Exo1

[75541-83-2]
Purity: 99%

Soluble in DMSO
C15H12FNO3 MW: 273.26



Axon 2904

mg	Price
10	online
50	online

Biological activity

Exo1 is a chemical inhibitor of the exocytic pathway with an IC₅₀ value of 20 μ M. Exo1 induces a rapid collapse of the Golgi to the endoplasmic reticulum, thus acutely inhibiting the traffic emanating from the endoplasmic reticulum. Moreover, Exo1 induces the rapid release of ADP-ribosylation factor (ARF) 1 from Golgi membranes but has less effect on the organization of the trans-Golgi network.

EYA2 inhibitor 9987

See NCGC00249987


Axon 3080

Page 694

Ezetimibe

SCH58235

[163222-33-1]
Purity: 98%
Optically pure
Soluble in DMSO
C₂₄H₂₁F₂NO₃ MW: 409.43



Axon 3377

mg	Price
50	online

Biological activity

Ezetimibe is a potent, orally active inhibitor of cholesterol absorption.

Ezogabine

See Retigabine

Axon 1525

Page 813

Ezogabine dihydrochloride

See Retigabine dihydrochloride

Axon 2252

Page 813

Ezutromid


See SMT C1100

Axon 2481

Page 875

F4, 10058-

[403811-55-2]
Purity: 99%



Soluble in 0.1N NaOH(aq) and DMSO
C₁₂H₁₁NOS₂ MW: 249.35

Biological activity

Small-molecule c-Myc inhibitor that induces cell-cycle arrest at G₀/G₁ phase in a dose-dependent manner. 10058-F4 targets c-Myc-Max, to disrupt the heterodimer and/or to prevent its formation, and abrogates various c-Myc-dependent functions, and induces myeloid differentiation of human acute myeloid leukemia.

Axon 2222

mg	Price
10	online
50	online

F2695 hydrochloride

See Levomilnacipran hydrochloride

Axon 3128

Page 612

F-96221-BM1


See Bilastine

Axon 3884

Page 307

FABP4 inhibitor C3 Recent Addition

[N.A.]
Purity: 99%



C₂₀H₁₆ClNO₂ MW: 337.80

Axon 4161

mg	Price
10	online
50	online

Biological activity


FABP4 inhibitor C3 is a potent and highly selective inhibitor of FABP4 with a K_d value of 25 nM. C3 also shows good metabolic stability and potent cellular anti-inflammatory activity.

Fantofarone

SR 33557

[114432-13-2]
Purity: 98%

Soluble in DMSO
C₃₁H₃₈N₂O₅S MW: 550.71



Axon 2952

mg	Price
10	online
50	online

Biological activity

Highly potent and specific calcium channel antagonist.

F-ara-A

See Fludarabine


Axon 3457

Page 485

Faropenem sodium Recent Addition

SUN5555; SY5555; ALP201; WY49605

[122547-49-3]
Purity: 99%
Optically pure
Soluble in water, DMSO and EtOH
C₁₂H₁₄NNaO₅S MW: 307.30



Axon 4206

mg	Price
50	online

Biological activity

Faropenem sodium is an orally active broad-spectrum antibiotic.


Fasudil hydrochloride

HA1077

[105628-07-7]

Purity: 100%

Soluble in water, DMSO and EtOH
C14H17N3O2S.HCl MW: 327.83



Axon 3848

mg Price

50 online

Biological activity

Fasudil hydrochloride is an orally active ROCK inhibitor with a K_i value of 0.40 μM . Moreover, Fasudil is an intracellular calcium antagonist.

Fatostatin A hydrobromide

See *Fatostatin hydrobromide*

Axon 2975

Page 475


Fatostatin hydrobromide

Fatostatin A hydrobromide; 125B11 hydrobromide

[298197-04-3]

Purity: 99%

Soluble in DMSO
C18H18N2S.HBr MW: 375.33



Axon 2975

mg Price

10 online

50 online

Biological activity

Fatostatin hydrobromide is a specific inhibitor of SREBP cleavage-activating protein (SCAP), which is required for SREBP activation. Fatostatin hydrobromide possesses antitumor properties including the inhibition of cancer cell proliferation, invasion, and migration, and it arrests cancer cells in G2/M phase. Fatostatin hydrobromide also inhibits tubulin polymerization, which perturbs mitotic spindle assembly and leads to mitotic catastrophe. Fatostatin hydrobromide has anticancer properties in cell culture and in vivo mouse models of prostate and brain cancers.


Favipiravir

T-705

[259793-96-9]

Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C5H4FN3O2 MW: 157.10



Axon 3135

mg Price

10 online

50 online

Biological activity

Favipiravir is a potent and selective viral RNA polymerase inhibitor. Favipiravir has been found to have potent inhibitory activity against RNA viruses in vitro, especially influenza A, B, and C viruses (IC50 value of 1.0 μM against influenza A PR/8/34 virus). T-705-4-ribofuranosyl-5'-triphosphate (T-705RTP) is the active form that contributes to anti-influenza virus activity.

FBPase-1 inhibitor

FBPase-1 inhibitor compound 1


Axon 3439

mg Price

[883973-99-7]

Purity: 99%

Soluble in DMSO
C13H7Cl3N2O3S MW: 377.63



10 online

50 online

Biological activity

FBPase-1 inhibitor compound 1 is an allosteric inhibitor of fructose-1,6-bisphosphatase (FBPase-1) with an IC50 value of 3.4 μM .

FBPase-1 inhibitor compound 1

See *FBPase-1 inhibitor*

Axon 3439


Page 475

FC 99 hydrochloride

[1097810-71-3] (parent)

Purity: 98%

Soluble in water and DMSO
C15H18N2O.xHCl MW: 304.3



Axon 2318

mg Price

5 online

25 online

Biological activity

Inhibitor of TLR3 expression and inflammatory responses induced by a synthetic dsRNA (poly(I:C)) and by exogenous IFN- α via IRF3. FC-99 suppressed the phosphorylation levels of ERK, JNK, and p38 in varying degrees without altering the total protein. The ability of FC-99 to reverse TLR3 expression may account for its marked effect on the model of sepsis.

FCE 24304

See *Exemestane*

Axon 2045

Page 472

FCF 89

See *Roquinimex*

Axon 2868

Page 829


FDI 6

NCGC 00099374

[313380-27-7]

Purity: 99%

Soluble in DMSO
C19H11F4N3OS2 MW: 437.43



mg Price

10 online

50 online

Biological activity

Inhibitor of the Forkhead box protein M1 transcription factor (IC50 value 22.5 μM for inhibiting FOXM1-DNA binding). FDI6 displaces FOXM1 from genomic targets in MCF-7 breast cancer cells, and induces concomitant transcriptional downregulation. FDI-6 is inactive against the proteasome, and concordance between its biophysical IC50 and cellular GI50 values (22.5 μM and 18.0 μM , respectively) suggests it does not suffer from the off-target effects of thiostrépton.

FdUrd

See *Floxuridine*

Axon 3462

Page 484

Febuxostat

See TEI 6720


Axon 1175

Page 917

Fedotozine tartrate

JO 1196

[133267-27-3]
Purity: 99%
99% ee
Soluble in water
C22H31NO4C4H6O6 MW: 523.57



Axon 1140


mg	Price
10	online
50	online

Biological activity

kappa(1a) opioid receptor agonist

Fedovapagon

[347887-36-9]
Purity: 99%
Optically pure
Soluble in DMSO
C27H34N4O3 MW: 462.58



Axon 2146

mg	Price
5	online
25	online

Biological activity


Potent and selective vasopressin V2 receptor agonist (EC50 of 24 nM); demonstrated positive anti-diuretic effect in nocturia

Feeblin Recent Addition

SLC15A4 inhibitor compound C5

[689270-18-6]
Purity: 98%

Soluble in DMSO and EtOH
C27H33N3O2 MW: 431.57



Axon 4108

mg	Price
10	online
50	online


Biological activity

Feeblin is a conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity. Feeblin inhibits the nucleic acid-sensing TLR7/8 pathway activating IRF5 by disrupting the SLC15A4-TASL adapter module.

Felodipine

[72509-76-3]
Purity: 99%

Soluble in DMSO
C18H19Cl2NO4 MW: 384.25



Axon 1448

mg	Price
10	online
50	online

Biological activity


Selective calcium channel blocker, a drug used to control hypertension

FEN1 inhibitor 1

LNT1

[824983-91-7]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C15H12N2O5S MW: 332.33



Axon 3027

mg	Price
5	online
25	online


Biological activity

FEN1 inhibitor 1 is a potent flap endonuclease-1 (FEN1) inhibitor with an IC50 value of 0.011 μM. FEN1 inhibitor 1 was shown to sensitize bladder carcinoma cells to DNA damage that is normally repaired by the BER pathway.

Fendiline hydrochloride

[13636-18-5]
Purity: 99%

Soluble in DMSO
C23H25N.HCl MW: 351.91



Axon 2829

mg	Price
10	online
50	online


Biological activity

Fendiline, an L-type calcium channel blocker (IC50 value of 17 μM), is a specific inhibitor of K-Ras plasma membrane targeting (IC50 value of 9.64 μM) with no detectable effect on the localization of H- and N-Ras. Moreover, Fendiline blocked the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras.

Fenfluramine hydrochloride

[404-82-0]
Purity: 99%

Soluble in water and DMSO
C12H16F3N.HCl MW: 267.72



Axon 2850

mg	Price
10	online
50	online

Biological activity


5-HT releasing agent.

Fenobam

MCN 3377-98; NPL 2009

[57653-26-6]
Purity: 99%

Soluble in DMSO
C11H11ClN4O2 MW: 266.68



Axon 1345

mg	Price
10	online
50	online

Biological activity

Potent and selective antagonist for metabotropic glutamate receptor subtype 5 (mGluR5)

Fer-1

See *Ferostatins* 1


Axon 2293

Page 479

Ferrosstatin 1

Fer-1

[347174-05-4]
Purity: 99%



Soluble in DMSO
C15H22N2O2 MW: 262.35

Axon 2293


mg	Price
10	online
50	online

Biological activity

Potent inhibitor of erastin-induced ferroptosis, an iron dependent form of cell death morphologically, biochemically and genetically distinct from apoptosis, various forms of necrosis, and autophagy (EC50 value 60 nM in HT-1080 cells). Ferrosstatin-1 specifically inhibits cell death induced by RAS-selective lethal compounds (RSLs), but not cell death induced by other oxidative lethal compounds and apoptosis-inducing agents. Ferrosstatin-1 does not inhibit ERK phosphorylation or arrest the proliferation of HT-1080 cells, nor does it chelate iron or inhibit protein synthesis. It is capable of blocking the cytotoxic effects of Sorafenib (Axon 1397) in HCC cells.

Fexofenadine hydrochloride

[153439-40-8]
Purity: 99%



Soluble in DMSO
C32H39NO4.HCl MW: 538.12

Axon 1453

mg	Price
10	online
50	online


Biological activity

Histamine H1 receptor antagonist; antihistamine drug in the treatment of hayfever and similar allergy symptoms

Fezolinetant

ESN364

[1629229-37-3]
Purity: 100%
100% e.e.
Soluble in DMSO and EtOH
C16H15FN6OS MW: 358.39



Axon 3403

mg	Price
2	online
5	online


Biological activity

Fezolinetant is an orally bioavailable neurokinin-3 receptor (NK3R) antagonist with a pKi value of 7.6 and a pIC50 value of 7.7.

FG-2216

YM 311

[223387-75-5]
Purity: 99%



Soluble in 0.1N HCl(aq) and DMSO
C12H9ClN2O4 MW: 280.66

Axon 2570

mg	Price
5	online
25	online


Biological activity

Orally active HIF prolyl 4-hydroxylase inhibitor (P4-HI; IC50 value 3.9 μM for PHD2) that increases plasma EPO levels up to 30-fold in hemodialysis (HD) patients, and reduces cardiac remodeling after myocardial infarction in rats independent of a reduction of collagen maturation or altering growth factors.

FG-4592

Roxadustat; ASP 1517

[808118-40-3]
Purity: 99%



Soluble in 0.1N NaOH(aq) and DMSO
C19H16N2O5 MW: 352.34

Axon 2588

mg	Price
10	online
50	online

Biological activity

New-generation oral HIF-PHD inhibitor (IC50 value 591 nM for inhibition of PHD2 in a fluorescence polarization assay) for the treatment of anemia in patients with chronic kidney disease (CKD) by promoting erythropoiesis. FG 4592 (Roxadustat) treatment significantly inhibited tert-Butyl hydroperoxide (TBHP)-induced apoptosis and increases the survival of neuronal PC-12 cells by stabilization of HIF-1α. FG 4592 is also shown to inhibit Fat Mass and Obesity Associated Protein (FTO; IC50 value 9.8 μM).

FGF 401

See *Roblitinib*


Axon 2953

Page 826

FH 1

NSC 12407; BRD K4477

[2719-05-3]
Purity: 99%



Soluble in DMSO
C17H18N2O2 MW: 282.34

Axon 2320


mg	Price
10	online
50	online

Biological activity

Promotes the maturation and differentiation of induced pluripotent stem cells (iPSCs) to hepatocytes. FH 1 treatment augmented albumin levels and the expression levels of ABCB11 in iHEP cells.

FH535

[108409-83-2]
Purity: 99%



Soluble in 0.1N NaOH(aq) and DMSO
C13H10Cl2N2O4S MW: 361.20

Axon 2686

mg	Price
10	online
50	online

Biological activity

Small-molecule dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/β-catenin/TCF/LEF signaling. FH535 inhibits recruitment of the coactivators β-catenin and GRIP1, but not the corepressors NCoR and SMRT. FH535 is selectively toxic to carcinomas expressing the Wnt/β-Catenin pathway, and known to inhibit invasion, migration, and growth in vitro in multiple types of cancer, such as liver cancer and triple negative breast cancer cell lines. The water soluble sodium salt of FH 535 is available as Axon 2706.


FH535 sodium salt

[N.A.]
Purity: 99%

Axon 2706

mg	Price
10	online

Soluble in water and DMSO
C13H9Cl2N2NaO4S MW: 383.18




50 online

Biological activity

Small-molecule dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/ β -catenin/TCF/LEF signaling. FH535 inhibits recruitment of the coactivators β -catenin and GRIP1, but not the corepressors NCoR and SMRT. FH535 is selectively toxic to carcinomas expressing the Wnt/ β -Catenin pathway, and known to inhibit invasion, migration, and growth in vitro in multiple types of cancer, such as liver cancer and triple negative breast cancer cell lines; water soluble sod

FHD-286

[2671128-05-3]
Purity: 99%
99% e.e.
Soluble in DMSO
C24H30N6O6S2 MW: 562.66



Axon 3769

mg	Price
5	online
10	online

Biological activity

FHD-286 is a selective inhibitor of the BAF chromatin remodeling complex ATPases (BRG1/ BRM).
Source Information: Sold in collaboration with Chemietek

Filgotinib


See GLPG-0634

Axon 4006

Page 505

Fimasartan

[247257-48-3]
Purity: 99%



Soluble in DMSO and EtOH
C27H31N7OS MW: 501.65

Axon 3550

mg	Price
10	online
50	online


Biological activity

Fimasartan is a potent and orally active angiotensin II receptor antagonist. Fimasartan provides a selective angiotensin II type 1 (AT1) receptor antagonist effect with non-competitive, insurmountable binding with the AT 1 receptor.

Finasteride

MK-906

[98319-26-7]
Purity: 99%
Optically pure
Soluble in DMSO
C23H36N2O2 MW: 372.54



Axon 3240

mg	Price
50	online

Biological activity


Finasteride is a potent, reversible inhibitor of the rat type 1 5 α -reductase with a K_i value of 10.2 nM. Finasteride has been shown to reduce the size of human benign prostatic hyperplasia (BPH) by inhibiting the intraprostatic conversion of testosterone to 5 α -dihydrotestosterone.

Fingolimod

FTY 720

[162359-56-0]
Purity: 98%

Soluble in DMSO
C19H33NO2.HCl MW: 343.93



Axon 1485

mg	Price
10	online
50	online


Biological activity

A sphingosine-1-phosphate receptor 1 modulator; immunosuppressant

FIPI hydrochloride

[N.A.]
Purity: 99%

Soluble in DMSO
C23H24FN5O2.HCl MW: 457.93



Axon 2281

mg	Price
5	online
25	online

Biological activity

Phospholipase D (PLD) inhibitor (IC50 values of 20-25 nM for both PLD1 and PLD2) that rapidly blocks in vivo phosphatidic acid (PA) production with subnanomolar potency. FIPI does inhibit PLD regulation of F-actin cytoskeleton reorganization, PIP2 availability, cell spreading, and chemotaxis, indicating potential utility for it as a therapeutic for autoimmunity and cancer metastasis.

Firefly Luciferin

See Luciferin, D-

Axon 2494

Page 624

FK482

See Cefdinir

Axon 3494

Page 356

FK 506

See Tacrolimus

Axon 2263


Page 904

FK 866

K 22.175

[658084-64-1]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO, and Ethanol
C24H29N3O2 MW: 391.51



Axon 1279

mg	Price
5	online
10	online

Biological activity


Highly specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT); NAD biosynthesis inhibitor; Tumor cell apoptosis agent (see also Axon 1546)

FK 866 hydrochloride

K 22.175 hydrochloride

[658084-64-1]
Purity: 99%

Soluble in water and DMSO
C24H29N3O2.HCl MW: 427.97




Axon 1546

mg	Price
5	online
10	online

FK 960

[133920-70-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C13H16FN3O2 MW: 265.28



Axon 1607

mg	Price
10	online
50	online


Biological activity

Somatostatin receptor agonist and also a 5-HT agonist; FK960 stimulates both serotonin and somatostatin production as a cognitive enhancer. However, its development for Alzheimer's disease (AD) was terminated in 2003

FK962

[283167-06-6]
Purity: 99%

Soluble in water and DMSO
C14H17FN2O2 MW: 264.30



Axon 3198

mg	Price
10	online
50	online


Biological activity

FK962, a derivative of FK960 (Axon 1607), is an enhancer of somatostatin release. FK962 significantly enhanced high K⁺-evoked somatostatin release from rat hippocampal slices. FK962 also significantly reduced somatostatin-induced inhibition of Ca²⁺ channels in single rat hippocampal neurons using whole-cell patch-clamp.

FLI 06

[313967-18-9]
Purity: 100%

Soluble in DMSO
C25H30N2O5 MW: 438.52



Axon 2277

mg	Price
5	online
25	online

Biological activity


Notch signaling inhibitor (EC50 value 2.3 μM) that acts early in the secretory pathway. Although the precise molecular target of FLI 06 remains unclear, it effects a unique property to inhibit cargo recruitment to ER exit sites (ERESs) by changing its curvature. Consequently, it inhibits the membrane traffic of NotchΔE-eGFP at pre-ERES stages without fusion of ER-Golgi. FLI 06 does not inhibit the γ-secretase mediated proteolytical processing of NotchΔE-eGFP to NICD-eGFP at the plasma membrane.

Flibanserin

BIMT 17

[167933-07-5]
Purity: 99%

Soluble in DMSO
C20H21F3N4O MW: 390.40



Axon 1499

mg	Price
10	online
50	online

Biological activity

A 5-HT1A receptor full agonist with 5-HT2A receptor antagonistic activity; It was initially investigated as an potential antidepressant, however, it is currently under clinical trial for the potential treatment of female sexual dysfunction

Flindokalner

See BMS 204352

Axon 1112


Page 315

Floxuridine

5-Fluorodeoxyuridine; FdUrd

[50-91-9]
Purity: 99%

Optically pure
Soluble in water, DMSO and EtOH
C9H11FN2O5 MW: 246.19



Axon 3462

mg	Price
50	online

Biological activity


Floxuridine is an antimetabolite and a thymidylate synthetase inhibitor.

Fluconazole

UK 49858

[86386-73-4]
Purity: 99%

Soluble in DMSO
C13H12F2N6O MW: 306.27



Axon 2105

mg	Price
50	online
250	online

Biological activity


Antifungal agent that inhibits the fungal cytochrome P450 enzyme 14α-demethylase; marketed under the trade names Diflucan and Trican

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Fluc inhibitor cpd 48 Recent Addition

[2765796-41-4]
Purity: 99%

Soluble in DMSO
C19H16O3 MW: 292.33



Axon 4054


mg	Price
5	online
25	online

Biological activity

Fluc inhibitor cpd 48 is a highly potent and reversible Firefly luciferase (Fluc) inhibitor (IC50 value of 0.25 nM), which can efficiently block the Fluc generated bioluminescence in vivo.

Flucloxacillin sodium Recent Addition

[1847-24-1]
Purity: 98%
Optically pure
Soluble in water, DMSO and EtOH
C19H16ClFN3NaO5S MW: 475.85



Axon 4208

mg	Price
50	online


Biological activity

Flucloxacillin sodium is an orally active penicillinase (beta-lactamase) resistant antibiotic which belongs to the group of penicillins.

Fludarabine

9-β-D-Arabinofuranosyl-2-fluoroadenine; F-ara-A

[21679-14-1]
Purity: 99%
Optically pure
Soluble in DMSO
C10H12FN5O4 MW: 285.23



Axon 3457


mg	Price
10	online
50	online

Biological activity

Fludarabine, a nucleoside analogue, inhibits DNA synthesis in proliferating cells; however, in indolent cells fludarabine has an inhibitory effect on RNA transcription. Additionally, Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.

Flumethasone

[2135-17-3]
Purity: 99%
Optically pure
Soluble in DMSO
C22H28F2O5 MW: 410.45



Axon 1169

mg	Price
25	online
250	online


Biological activity

Selective and potent topical glucocorticoid receptor agonist (IC50 value 0.26 nM for human GR). For the treatment of various allergic, inflammatory, and autoimmune disorders.

Flumethasone pivalate

Locorten; NSC 107680

[2002-29-1]
Purity: 99%
Soluble in DMSO and EtOH
C27H36F2O6 MW: 494.57



Axon 2247

mg	Price
10	online
50	online

Biological activity


Topical glucocorticoid receptor agonist. Flumethasone pivalate is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties.

Flunisolide

AeroBid; Nasalide; Nasarel

[3385-03-03]
Purity: 99%

Soluble in DMSO
C24H31FO6 MW: 434.50



Axon 1429


mg	Price
10	online
50	online

Biological activity

A corticosteroid used for the treatment of allergic rhinitis

Fluorescent probe QG-1

[2098563-70-1]
Purity: 99%
Soluble in DMSO
C19H21N3O3 MW: 339.39



Biological activity

Fluorescent probe QG-1 is a reversible fluorescence probe, which is suitable for use in the real-time monitoring and quantification of GSH under physiological conditions (Kd value of 2.59 mM). Moreover, QG-1 exhibits a fast response time (t1/2 = 5.82 sec), displays extremely low cytotoxicity and can be employed to determine the actual GSH variations in HeLa cells.

Fluorodeoxyuridine, 5-

See Floxuridine


Axon 3462

Page 484

Fluoxetine Hydrochloride

[56296-78-7]
Purity: 99%

Soluble in DMSO
C17H18F3NO.HCl MW: 345.79



Biological activity


Selective serotonin reuptake inhibitor (SSRI)

Fluphenazine decanoate dihydrochloride

Prolixin Decanoate dihydrochloride

[2376-65-0]
Purity: 99%

Soluble in DMSO
C32H44F3N3O2S.2HCl MW: 664.69



Axon 2127

mg	Price
10	online
50	online

Biological activity


Fluphenazine (available after slow hydrolysis in vivo of the parent molecule) is a potent antipsychotic (Ki values 0.2 nM, 0.11 nM, and 2.0nM for D2, D3, and 5-HT2 receptors, respectively). Fluphenazine exhibits considerable affinity for 5-HT6 and 5-HT7 receptors (Ki values 15.8nM and 7.9 nM, respectively) as well.

Flupirtine maleate

D 9998; Katadolon

[75507-68-5]
Purity: 99%

Soluble in DMSO
C15H17FN4O2.C4H4O4
MW: 420.39



Axon 1437

mg	Price
10	online
50	online

Biological activity


A centrally acting, nonopioid analgesic; flupirtine has a functional profile similar to NMDA-receptor antagonists, but devoid of the typical side effects of these drugs; flupirtine exerts potent cyto- and neuroprotective actions in different in vivo and in vitro models

Fluralaner

A1443

[864731-61-3]
Purity: 100%

Soluble in DMSO and EtOH
C22H17Cl2F6N3O3 MW: 556.29



Axon 4047

mg	Price
10	online
50	online


Biological activity

Fluralaner is a potent inhibitor of GABA and L-glutamate gated chloride channels. Fluralaner is an ectoparasiticide.

Flurbiprofen

[5104-49-4]
Purity: 98%

Soluble in DMSO
C15H13FO2 MW: 244.26



Axon 3126

mg	Price
50	online
250	online

Biological activity


Flurbiprofen is a cyclo-oxygenase (COX) inhibitor with IC50 values of 0.1 and 0.4 μM for hCOX-1 and hCOX-2, respectively. Non-steroidal anti-inflammatory drug (NSAID).

Fluticasone furoate

GW 685698X

[397864-44-7]
Purity: 98%

Soluble in DMSO and Ethanol
C27H29F3O6S MW: 538.58



Axon 1172

mg	Price
10	online
50	online


Biological activity

Selective high affinity glucocorticoid agonist, MRP4 inhibitor; a Fluticasone derivative as corticosteroid with potent anti-inflammatory activity

Fluticasone propionate

[80474-14-2]
Purity: 99%

Soluble in DMSO
C25H31F3O5S MW: 500.57



Biological activity

High affinity, selective glucocorticoid receptor agonist; corticosteroid derived from fluticasone used to treat asthma and allergic rhinitis


Axon 1404

mg	Price
10	online
50	online

Fluvoxamine maleate

[61718-82-9]
Purity: 99%

Soluble in DMSO
C15H21F3N2O2.C4H4O6
MW: 434.41



Biological activity

Selective serotonin reuptake inhibitor (SSRI), with Ki value to be 1.6 nM

Axon 1556

mg	Price
10	online
50	online

FME

See NF-κB Activation Inhibitor IV

Axon 3387

Page 700

FLX925

See AMG-925


Axon 4071

Page 226

FM19G11

[329932-55-0]
Purity: 99%

Soluble in DMSO
C23H17N3O8 MW: 463.40



Biological activity

FM19G11 is an HIFα inhibitor with an IC50 value of 80 nM. FM19G11 inhibits HIFα proteins that repress target genes of the two α subunits, in various tumor cell lines as well as in adult and embryonic stem cell models from rodents and humans, respectively.

Axon 2959

mg	Price
5	online
25	online

FMF-03-146-1

See DCLK1-IN-1

Axon 3200

Page 414

FMK


RSK inhibitor Fmk

[821794-92-7]
Purity: 99%

Axon 1848

mg	Price
1	online

Soluble in DMSO
C18H19FN4O2 MW: 342.37



5 online

Biological activity

Potent, highly specific and irreversible inhibitor of p90 ribosomal protein S6 kinase (RSK) 1 and 2 (RSK1 and RSK2, with in vitro IC50 value of 15 nM for RSK2); Fmk binds in the CTKD ATP-binding site and inhibits RSK autophosphorylation at Ser386. Fmk induces significant apoptosis in human FGFR3-expressing, t(4;14)-positive multiple myeloma cells

FMP-A-01

See NMDAR-TRPM4 blocker C8 dihydrochloride

Axon 3348

Page 706

FMP-A-02

See NMDAR-TRPM4 blocker C19 dihydrochloride

Axon 3349

Page 706

FMS inhibitor compound 1b

See CID 11654378

Axon 2061

Page 371

FMS inhibitor compound 8

See CID 11654378

Axon 2061

Page 371

FNA hydrochloride, beta-

See Funaltrexamine hydrochloride, beta-

Axon 1213

Page 493

FNQ

See Napabucasin

Axon 2517


Page 692

Foretinib

GSK 1363089; Exel 2880; XL 880

[849217-64-7]
Purity: 98%

Soluble in DMSO
C34H34F2N4O6 MW: 632.65



Axon 1582

mg Price

5 online

25 online


Biological activity

An orally available inhibitor targeting c-MET (IC50: 0.4 nM) and VEGFR2

Formononetin

Biochanin B

[485-72-3]
Purity: 98%



Axon 4067

mg Price

50 online

Soluble in DMSO

C16H12O4 MW: 268.26

Biological activity

Formononetin is a potent FGFR2 inhibitor (IC50 value of 4.31 μM) that suppresses tumor angiogenesis and growth.

Formylphenylboronic acid, 2-

See FPBA, 2-


Axon 3565

Page 490

Forskolin

Coleonol

[66575-29-9]
Purity: 98%
Optically pure
Soluble in DMSO
C22H34O7 MW: 410.50



mg Price

10 online

50 online

Biological activity

Activator of adenylate cyclase (IC50 value of 41 nM). A naturally occurring labdane diterpene that has been used extensively to increase cAMP and to elicit cAMP-dependent physiological responses. Elevation of cAMP levels by Forskolin induced neuronal differentiation of mesenchymal stem cells via activation of extracellular signal-regulated kinase/MAPK.

Anti-hypertensive and vasodilatory agent.

Foscenvint

See PRI-724

Axon 3749

Page 791

FPBA, 2-

2-Formylphenylboronic acid

[40138-16-7]
Purity: 98%



mg Price

50 online

Soluble in DMSO and EtOH
C7H7BO3 MW: 149.94

Biological activity


2-FPBA is a first potent, reversible and slow-onset inhibitor of mandelate racemase (MR) with Ki and Ki* values of 5.1 and 0.26 μM, respectively.

FPH 2

BRD 9424

[957485-64-2]
Purity: 99%

Soluble in DMSO
C14H16ClN5O2S MW: 353.83



mg Price

10 online

50 online

Biological activity

Small molecule that concentration dependently induces proliferation and enhances the functions of mature human primary hepatocytes. Over 7 days, FPH 2 induced hepatocyte doublings at a rate that is consistent with reported liver regeneration kinetics in vivo.

FPL 15896AR

See AZD6765 dihydrochloride


FPL670

See Cromolyn disodium

FPS-ZM1

[945714-67-0]
Purity: 99%

Soluble in DMSO
C20H22ClNO MW: 327.85




Biological activity

FPS-ZM1 is a high-affinity RAGE-specific inhibitor (K_i value of 25 nM) which binds specifically to the V domain of RAGE, crosses the BBB, and inhibits Aβ-induced cellular stress in RAGE-expressing cells in vitro and in brain in vivo. FPS-ZM1 was not toxic to cells and mice.

FQI 1

[599151-35-6]
Purity: 99%

Soluble in DMSO
C18H17NO4 MW: 311.33




Biological activity

Antiproliferative small-molecule inhibitor of alpha-globin transcription factor CP2 (a.k.a. LSF; IC₅₀ 2.1 μM); cell-permeable, potent, specific, and reversible. FQI 1 induces cell death in LSF-overexpressing cells, including Hepatocellular carcinoma (HCC cells). FQI 1 inhibits LSF DNA-binding activity both in vitro and in vivo and also inhibits HCC tumor growth in a mouse xenograft model.

FR 180204

[865362-74-9]
Purity: 99%

Soluble in DMSO
C18H13N7 MW: 327.34



Biological activity

Selective, cell permeable and ATP-competitive ERK inhibitor; 30-fold selective on ERK over p38α MAPK; FR180204 was shown to inhibit ERK1 (K_i=0.31 μM), ERK2 (K_i=0.14 μM) and TGFβ-induced AP-1 activation

FR 900494

See Kifunensine, (+)-

Franidipine

See Manidipine dihydrochloride **Recent Addition**

Axon 3335

Page 278

Axon 3509

Page 396

Axon 2858

mg Price

10 online

50 online

Axon 2157

mg Price

10 online

50 online

Axon 1694

mg Price

5 online

10 online

Axon 1730

Page 591


Axon 4202

Page 639

FRAX 486

[1232030-35-1]
Purity: 99%

Soluble in DMSO
C25H23Cl2FN6O MW: 513.39




Biological activity

Bioavailable and brain penetrating inhibitor of group I p21-activated kinases (IC₅₀ values 8.25 nM, 39.5 nM, and 55.3 nM for PAK1, PAK2, and PAK3, respectively) with good selectivity over PAK4 (IC₅₀ value 779 nM) FRAX486 rescues the dendritic spine abnormality and audiogenic seizures, and reduces autism-like phenotypes of hyperactivity and restrictive or repetitive behaviors in Fmr1 KO mice. Not only represents FRAX-486 a potential breakthrough in the research for a treatment of Fragile X syndrome (FXS), it was also found to ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence.

FSEN1

[862808-01-3]
Purity: 98%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C22H22BrN5OS MW: 484.41




Biological activity

FSEN1 is an uncompetitive FSP1 inhibitor that sensitizes cancer cells to ferroptosis with an IC₅₀ value of 313 nM. Moreover, FSEN1 synergizes with GPX4 inhibitors and endoperoxide-based ferroptosis inducers.

FTBMT

[1358575-02-6]
Purity: 99%

Soluble in DMSO
C19H16F4N4O MW: 392.35



Biological activity

FTBMT is a potent, selective and orally available GPR52 agonist (EC₅₀ value of 75 nM) with activity in vitro and in vivo, as demonstrated by the activation of cAMP signaling in striatal neurons. FTBMT exhibits high metabolic stability in several species, and excellent PK in rats.

FTC, (-)-

See Emtricitabine

FTY 720

See Fingolimod

Axon 2331

mg Price

5 online

25 online

Axon 4018

mg Price

5 online

25 online

Axon 2962

mg Price

10 online

50 online

Axon 3305

Page 457

Axon 1485

Page 482

FUB 359 maleate


See Ciproxifan maleate

Funaltrexamine hydrochloride, beta-

FNA hydrochloride, beta-

[72786-10-8]
Purity: 98%

No solubility data
C₂₅H₃₀N₂O₆.HCl MW: 490.98




Biological activity

Selective irreversible μ opioid receptor antagonist

Fulvestrant Recent Addition

[129453-61-8]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C₃₂H₄₇F₅O₃S MW: 606.77



Biological activity

Fulvestrant is a potent specific pure antiestrogen and a potent estrogen receptor antagonist.


Furazosin hydrochloride

See Prazosin hydrochloride

FX12

[1807639-36-6]
Purity: 100%

Soluble in DMSO
C₁₀H₈O₄S MW: 224.23




Biological activity

FX12 is a selective inhibitor and degrader of RNF5 E3 ubiquitin ligase. FX12 binds directly to RNF5 and inhibits its E3 activity in vitro as well as promoting proteasomal degradation of RNF5 in cells via ERAD.

FX-909 Recent Addition

[2924573-90-8]
Purity: 98%
98% e.e.
Soluble in DMSO
C₁₇H₁₀F₂N₂O₃S MW: 360.34



Biological activity

FX-909 is a first-in-class, orally available and highly potent covalent inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor with cellular IC₅₀ = 1 nM, highly selective over PPARA/PPARD (related tran

Axon 1993

Page 373

Axon 1213

mg	Price
10	online
50	online

Axon 4275

mg	Price
10	online
50	online

Axon 2040

Page 493

Axon 4106

mg	Price
10	online
50	online

Axon 4267

mg	Price
10	online

Source Information: Sold in collaboration with Chemietek

Fx-1006A

See Tafamidis meglumine Recent Addition

Axon 4021

Page 905

FXR 450

See WAY 362450

Axon 1749

Page 984

FXR agonist Cpd 22

See PX 20350

Axon 2152

Page 798

Gabapentin

GOE 3450; CI 945; GO 3450

[60142-96-3]
Purity: 99%

Soluble in water
C9H17NO2 MW: 171.24



Axon 1301

mg	Price
10	online
50	online

Biological activity


Anticonvulsant; mechanism of action still under study; neuroprotective; GABA modulator

Gallic acid

NSC 674319

[149-91-7]
Purity: 100%

Soluble in water and DMSO
C7H6O5 MW: 170.12



Axon 2208

mg	Price
100	online
500	online

Biological activity


Multi-affinity drug. Targets Carbonic Anhydrases, FUT7, P4H, HATs, among many others in an inhibitory modus. Gallic acid is cytotoxic to cancer cells and has anti-inflammatory and antioxidative effects. Gallic acid was found to inhibit the histone acetyltransferase activity of several HATs (IC50 values: 14, 24, 25 and 34 μM for p300, CBP, Tip60 and PCAF respectively). In particular, it inhibited p300/CBP-dependent HAT activities uncompetitively, while being devoid of activity towards other epigenetic enzymes including SIRT1, HDAC, and HMTase. In A549 lung cancer cells, Gallic acid inhibited the acetylation of p65, leading to the downregulation of NF-κB activation in response to diverse inflammatory signals. Gallic acid is also known to inhibit HIV-1 infections through inhibition of HIV-1 reverse transcriptase activity in *Lagerstroemia speciosa* L.

Ganciclovir

GCV; BIOLF62; DHPG

[82410-32-0]
Purity: 99%

Soluble in 0.1N NaOH(aq), 0.1N HCl(aq) and DMSO
C9H13N5O4 MW: 255.23



Axon 3241

mg	Price
50	online

Biological activity

Ganciclovir is a nucleoside antiviral drug which exhibits *in vitro* activity against human cytomegalovirus and herpes simplex virus types 1 and 2, and to a lesser degree, Epstein-Barr virus, varicella zoster virus, human herpesvirus 6 and human adenoviruses. The mechanism of action of ganciclovir involves highly selective inhibition of viral DNA replication as a result of enhanced uptake by infected cells, phosphorylation by viral thymidine kinase and/or cellular kinase enzymes, and substrate specificity for viral rather than cellular DNA polymerases.

Gandotinib

See LY 2784544

Axon 2554

Page 633

Ganetespib

See STA 9090

Axon 1968


Page 893

GANT61

NSC 136476

[500579-04-4]
Purity: 99%

Soluble in DMSO and Ethanol
C27H35N5 MW: 429.60



Biological activity

Small molecule capable of reducing GLI-mediated transcription and endogenous Hedgehog (Hh) signaling (IC50 value ca 5 μM). *In vivo*, GANT61 suppressed human tumor cell growth until no tumor was palpable.


Axon 2642

mg	Price
10	online
50	online

GAPDH inhibitor compound F8

[252212-58-1]
Purity: 98%

Soluble in DMSO
C20H18N2O5 MW: 366.37



Biological activity

GAPDH inhibitor compound F8 is a non-cysteine-targeting covalent GAPDH inhibitor.

Axon 3612

mg	Price
10	online
50	online

Garsevil

See LSL60101

Axon 3603


Page 622

Gatifloxacin hydrochloride

AM-1155 hydrochloride

[121577-32-0]
Purity: 99%

Soluble in water and DMSO
C19H22FN3O4.HCl MW: 411.86



Biological activity

Gatifloxacin hydrochloride is an inhibitor of the bacterial enzymes DNA gyrase and topoisomerase IV. Gatifloxacin hydrochloride is a broad-spectrum quinolone with broader *in vitro* and *in vivo* activities than those of ciprofloxacin and improved levels in blood and tissues of mice after oral administration compared with the levels of ciprofloxacin.

Axon 3171


mg	Price
50	online
250	online

Gavestinel

GV 150526A

[153436-38-5]
Purity: 99%

Soluble in DMSO
C18H11Cl2N2O3.Na MW: 397.19



Biological activity


In vivo potent and selective antagonist of glycine site of NMDA receptor; orally bioavailable; neuroprotective in animal models of ischaemic stroke

Axon 1262

mg	Price
10	online
50	online

GB 83

[1252806-86-2]
Purity: 99%
optically pure
Soluble in DMSO
C32H44N4O4 MW: 548.72



Axon 1622

mg	Price
1	online
5	online

Biological activity

Selective antagonist of human protease activated receptor 2 (PAR2) (IC50: 2 micromolar); reversibly inhibits PAR2 activation by both proteases and other PAR2 agonists

GBL-5g


See UTL-5g

Axon 3410

Page 959

GBR 12783 dihydrochloride

[67469-75-4]
Purity: 99%
No solubility data
C28H32N2O.2HCl MW: 485.49



Axon 1203

mg	Price
10	online
50	online

Biological activity

Potent and selective inhibitor of dopamine uptake

GBT440

See Voxelotor

Axon 4088

Page 972

GC1

See Sobetirome

Axon 4126

Page 877

GCA

See Golgicide A

Axon 4197

Page 512

GCV

See Ganciclovir

Axon 3241

Page 495

GDC 0032

See Taselisib

Axon 2927

Page 911

GDC-0068


Ipatasertib; RG7440

[1001264-89-6]
Purity: 99%
99% d.e.
Soluble in DMSO

Axon 4037

mg	Price
10	online
50	online

C24H32ClN5O2 MW: 458.00



Biological activity

GDC-0068 is a potent, APT-competitive and orally available small molecule pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively, and with selectivity over more than other 200 screened kinases. It displays robust antitumor activity with activation of PI3K-Akt-mTOR pathway.


Source information: Sold in collaboration with Chemietek

GDC-0084

Paxalisib

[1382979-44-3]
Purity: 98%

Soluble in DMSO
C18H22N8O2 MW: 382.42



Biological activity

GDC-0084 is a brain-penetrant inhibitor of PI3K and mTOR with Ki (app) values of 2 nM and 0.07 μM for PI3Kα and mTOR, respectively.

GDC 0199

See ABT 199

Axon 3584


mg	Price
5	online
25	online

GDC 0449

Vismodegib; HhAntag 691

[879085-55-9]
Purity: 99%

Soluble in DMSO
C19H14Cl2N2O3S MW: 421.30




Biological activity

The first-in-class inhibitor of Hedgehog (Hh) signaling pathway; more specifically, an orally bioavailable and potent inhibitor of smoothened homologue (SMO); an investigational anti-cancer drug for Medulloblastoma, advanced basal cell skin cancer etc

GDC 0879

[905281-76-7]
Purity: 99%

Soluble in DMSO
C19H18N4O2 MW: 334.37



Biological activity

Axon 1459


mg	Price
2	online
5	online

Selective inhibitor of protein kinase, targeting B-Raf (V600E)

GDC 0941 bismesylate

[957054-33-0]
Purity: 99%

Soluble in water and DMSO
C23H27N7O3S2.2CH4O3S
MW: 705.85




Biological activity

Potent, selective, orally bioavailable inhibitor of class I PI3 kinase (PI3K) under clinical trials, with IC50 values (nM) of 3, 33, 3, 75, 1230 and 580 for p110 α , β , δ and γ isoforms, DNA-PK and mTOR; water-soluble form

GDC-0973

Cobimetinib; RG7420; XL518

[934660-93-2]
Purity: 99%
>99% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C21H21F3IN3O2 MW: 531.31



Biological activity

GDC-0973 is an orally bioavailable, potent and selective small-molecule inhibitor of mitogen-activated protein kinase 1 (MAP2K1 or MEK1). It blocks the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation, and decreased tumor cell proliferation. GDC-0976 is used, in combination with PLX4032 (Axon 1624), in the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.


Source Information: Sold in collaboration with Chemietek

GDC 0980

RG 7422; GNE 390

[1032754-93-0]
Purity: 99%

Soluble in DMSO
C23H30N8O3S MW: 498.60



Biological activity

Selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 α , β , δ and γ isoforms and apparent Ki of 17.3 nM for human mTOR. GDC-0980 has excellent pharmacokinetic and pharmaceutical properties and demonstrates broad activity in xenograft cancer models (breast, ovarian, lung, and prostate)

GDC-0994

Ravoxertinib; RG7842

[1453848-26-4]
Purity: 99%
99% e.e.
Soluble in DMSO

Axon 1377

mg	Price
5	online
25	online

Axon 4148

mg	Price
10	online
50	online


Axon 1782

mg	Price
5	online
25	online

Axon 3741

mg	Price
5	online
10	online

C21H18ClFN6O2 MW: 440.86



Biological activity


GDC-0994 is an orally available small molecule inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively. Daily, oral dosing of GDC-0994 results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. PD biomarker inhibition of phospho-p90RSK in these tumors correlates with potency in vitro and in vivo. In contrast to other published ERK inhibitors, GDC-0994 neither increases nor decreases phospho-ERK, suggesting that different ERK inhibitors have alternative mechanisms of action with respect to feedback signaling. Furthermore, we demonstrate a novel approach for targeting the oncogenic signaling through the RAS pathway by combining ERK and MEK inhibitors.

Source Information: Sold in collaboration with Chemietek

GDC-1971

RLY-1971

[2377352-49-1]
Purity: 99%
98% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C25H26N8O MW: 454.53



Biological activity

GDC-1971 is an orally available, potent, and selective inhibitor of the protein tyrosine phosphatase SHP2, binding and stabilizing SHP2 in its inactive conformation.


Source Information: Sold in collaboration with Chemietek

GDC-5573

See Belvarafenib

GDC-6036

[2417987-45-0]
Purity: 99%
99% e.e.
Soluble in DMSO
C29H32ClF4N7O2 MW: 622.06



Biological activity


GDC-6036 is an orally available, potent and selective inhibitor of KRAS G12C mutant.

Source Information: Sold in collaboration with Chemietek

GeA-69

[2143475-98-1]
Purity: 99%

Soluble in DMSO
C20H16N2O MW: 300.35



Biological activity


GeA-69 is a selective, allosteric and cell-active macrodomain inhibitor targeting macrodomain 2 of PARP14 (IC50 value of 0.71 μ M). Moreover, GeA-69 engages PARP14 MD2 in intact cells and prevents its localisation to sites of DNA damage.

Gefitinib

ZD 1839; Iressa

[184475-35-2]
Purity: 99%

Soluble in DMSO
C22H24ClFN4O3 MW: 446.90



Axon 1393

mg	Price
10	online
50	online

Biological activity


Selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

Gemcitabine hydrochloride

dFdC; 2',2'-difluorodeoxycytidine; LY 188011

[122111-03-9]
Purity: 99%

Optically pure
Soluble in water and DMSO
C9H11F2N3O4.HCl MW: 299.66



Axon 3233

mg	Price
10	online
50	online


Biological activity

Gemcitabine hydrochloride, a deoxycytidine analogue, is an antimetabolite and a specific inhibitor of DNA synthesis. Gemcitabine hydrochloride exhibits good activity against human leukemic cell lines and murine solid tumors. Moreover, Gemcitabine hydrochloride has shown activity against a wide spectrum of human solid tumors including nonsmall cell lung, pancreatic, colon, breast, bladder, ovarian, head and neck, cervical and hepatocellular cancers.

Genipin

[6902-77-8]
Purity: 99%

Soluble in DMSO and Ethanol
C11H14O5 MW: 226.23



Axon 1443

mg	Price
10	online
50	online

Biological activity


Active medication to relieve the symptoms of type 2 diabetes. Genipin stimulates insulin secretion in UCP2-dependent manner (Uncoupling protein 2). Genipin is a protein, collagen, gelatin, and chitosan cross-linker

Genistein

NPI031L

[446-72-0]
Purity: 98%

Soluble in DMSO and EtOH
C15H10O5 MW: 270.24



Axon 3632

mg	Price
50	online


Biological activity

Genistein is a CB1 antagonist (IC50 value of 150 nM) that attenuates Δ 9-THC-induced atherosclerosis. Also, genistein possessed strong anti-inflammatory activities through inhibition of various signaling pathways such as nuclear factor kappa-B (NF- κ B), prostaglandins (PGs), inducible nitric oxide synthase (iNOS), proinflammatory cytokines and reactive oxygen species (ROS).

Genz 644282

[529488-28-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H21N3O5 MW: 407.42



Axon 2198

mg	Price
5	online
25	online

Biological activity


Topoisomerase I inhibitor (IC50 value 0.4 nM in human bone marrow CFU-GM assay). Cytotoxic agent, with activity toward 8 human tumor cell lines of varied histology and resistance mechanisms by colony formation, with enhanced potency compared to topotecan and SN-38. Contrary to the camptothecins, Genz-644282 is not a substrate for the multidrug resistance gene 1 (MDR1) and breast cancer resistance protein (BCRP) efflux pumps.

Geranyl pyrophosphate ammonium salt

GPP

[116057-55-7]
Purity: 98%

Soluble in water
C10H20O7P2.3NH3 MW: 365.30



Axon 1489

mg	Price
1	online
5	online

Biological activity

Substrate for geranyl transferase; an intermediate in the HMG-CoA reductase pathway used by organisms in the biosynthesis of terpenes and terpenoids

GF109203X

See Bisindolylmaleimide I

Axon 3936

Page 310

GF 120918A

See Elacridar hydrochloride

Axon 1896

Page 454

GFT505

See Elafibranor

Axon 2727

Page 454

GhrR antagonist CpdD

See CpdD hydrochloride

Axon 2147

Page 392

Gisadenafil besylate


UK 369003; PF 01224715

[334827-98-4]
Purity: 99%

Soluble in water and DMSO
C23H33N7O5S.C6H6O3S
MW: 677.79

Axon 2218

mg	Price
10	online
50	online



Biological activity


Potent and selective inhibitor of cGMP-specific PDE5 (IC50 value 1.23 nM) with improved selectivity over PDE6 (PDE5/6 selectivity value 117 and >3000-fold selectivity over other PDEs). Gildenafil has the potential for oral bioavailability and dose-proportional pharmacokinetics. Close analogue of Sildenafil (Viagra; Axon 2046) **Source Information:** Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Givinostat hydrochloride

ITF2357

[199657-29-9]
Purity: 98%

Soluble in water, DMSO and EtOH
C24H27N3O4.HCl MW: 457.95



Axon 3989

mg	Price
5	online
25	online

Biological activity

Givinostat hydrochloride is an orally active HDAC inhibitor which also possesses anti-inflammatory activities in vivo and in vitro.

GKT831

See GKT137831

Axon 3006


Page 503

GKT137831

Setanaxib; GKT831

[1218942-37-0]
Purity: 99%

Soluble in DMSO
C21H19ClN4O2 MW: 394.85



Axon 3006

mg	Price
5	online
25	online

Biological activity

GKT137831 is a first-in-class dual Nox1/4 inhibitor with Ki values of 110 nM and 140 nM for human Nox1 and Nox4, respectively. Moreover, GKT137831 is a potent inhibitor of fibrosis and hepatocyte apoptosis.

Gleevec

See Imatinib Mesylate

Axon 1394

Page 561

Glesatinib dihydrochloride

See MGCD265 dihydrochloride

Axon 3975

Page 652

Glibenclamide potassium salt

Glyburide potassium salt


Axon 2064

mg	Price
----	-------

[23047-14-5]

Purity: 99%

Soluble in water and DMSO
C23H26ClK2N3O5S MW: 570.18



25	online
100	online

Biological activity


Antidiabetic; KATP channel blocker; the drug inhibits the sulfonylurea receptor 1 (SUR1), the regulatory subunit of the ATP-sensitive potassium channels (KATP) in pancreatic beta cells

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Glipizide

[29094-61-9]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C21H27N5O4S MW: 445.54



Axon 3503

mg	Price
50	online


Biological activity

Antidiabetic; KATP channel blocker; the drug inhibits the sulfonylurea receptor 1 (SUR1), the regulatory subunit of the ATP-sensitive potassium channels (KATP) in pancreatic β cells.

GLN-1062

Memogain

[224169-27-1]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq), DMSO and EtOH
C24H25NO4 MW: 391.46



Axon 3707

mg	Price
5	online
25	online


Biological activity

GLN-1062 is the inactive prodrug of the acetylcholinesterase inhibitor galantamine. GLN-1062 has more than 15-fold higher bioavailability in the brain than the same doses of galantamine.

GLP-1 antagonist

[475466-57-0]
Purity: 99%

Soluble in DMSO
C28H37N3O3 MW: 463.61



Axon 1132

mg	Price
5	online
25	online

Biological activity

Glucagon-like peptide-1 (GLP-1) receptor antagonist

GLP-1R agonist DMB


DMB

[281209-71-0]
Purity: 99%

Soluble in DMSO
C13H15Cl2N3O2S MW: 348.25

Axon 1907

mg	Price
5	online
25	online



Biological activity


Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonist; potential agent for the treatment of type 2 diabetes; a useful tool for studying the role of GLP-1 in both in vivo and in vitro diabetes and obesity models

GLPG-0634

Filgotinib

[1206161-97-8]
Purity: 99%

Soluble in DMSO
C₂₁H₂₃N₅O₃S MW: 425.50



Axon 4006

mg	Price
10	online
50	online

Biological activity

GLPG-0634 is the first orally-available, selective inhibitor of JAK1. In vitro, it selectively inhibits JAK1 and JAK2 with IC₅₀ values of 10 nM and 28 nM, respectively, selective over JAK3 and TYK2 (IC₅₀ Values of 810 nM and 116 nM, respectively), and a panel of 150 other kinases. However, when tested in vivo it selectively inhibits JAK1, displaying a 30-fold potency over JAK2.

Source Information: Sold in collaboration with Chemietek

GLPG 0778

See Solcitinib

Axon 2539


Page 878

GLPG1690

Ziritaxestat

[1628260-79-6]
Purity: 98%

Soluble in DMSO
C₃₀H₃₃F₃N₃O₂S MW: 588.70



Axon 3094

mg	Price
10	online
50	online


Biological activity

GLPG1690 is a first-in-class, potent autotaxin (ATX) inhibitor with a K_i value of 15 nM. GLPG1690 demonstrated significant activity in the mouse BLM-induced fibrosis model at doses of 10 and 30 mg/kg twice a day, with an efficacy comparable or superior to that of the reference compound pirfenidone.

GLPG2534

[2095615-97-5]
Purity: 98%

Soluble in DMSO
C₂₁H₂₄N₆O₄ MW: 424.45



Axon 3917

mg	Price
5	online
25	online


Biological activity

GLPG2534 is a potent, selective and orally active IRAK4 inhibitor with IC₅₀ values of 6.4 nM and 3.5 nM for human and mouse IRAK4. In vitro, IRAK4 inhibition resulted in substantial inhibition of TLR and IL-1 responses in dendritic cells, keratinocytes, granulocytes, and T cells but only weakly affected dermal fibroblast responses.

Furthermore, disease activity in murine models of skin inflammation (IL-23-, IL-33-, imiquimod-, and MC903-induced) was markedly dampened by IRAK4 inhibition. Last, inhibiting IRAK4 reversed pathogenic molecular signatures in human lesional psoriasis and atopic dermatitis biopsies.

Glutapyrone

[92236-42-5]
Purity: 99%
98% ee
Soluble in water
C₁₉H₂₄N₂O₉·2Na MW: 470.38



Axon 1120

mg	Price
10	online
50	online

Biological activity

DHP amino acid; atypical neuronal non-calcium antagonistic DHP cerebrocrast; a antiarrhythmic, neuroprotective, stress-protective and radioprotective remedy

Glyburide potassium salt

See Glibenclamide, Potassium

Axon 2064

Page 503

Glycosylation Inhibitor-1, N-linked

See NGI-1


Axon 3588

Page 701

GlyH 101

[328541-79-3]
Purity: 98%

Soluble in DMSO
C₁₉H₁₅Br₂N₃O₃ MW: 493.15



Axon 2572

mg	Price
10	online
50	online


Biological activity

Highly potent and selective cystic fibrosis (CF) transmembrane regulator (CFTR) inhibitor (K_i value 4.3 μM in CFTR-expressing FRT cells) targeting mitochondrial functions, independently of chloride channel inhibition. GlyH 101 induces a rapid increase in ROS levels and depolarizes mitochondria in the four cell types, suggesting that these effects are independent of CFTR inhibition. Moreover, intraluminal GlyH 101 (2.5 g) reduced by 80% cholera toxin-induced intestinal fluid secretion in a closed-loop model of cholera.

GMC 1-109

[183140-96-7]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C₁₉H₁₉F₃N₄O₃S MW: 440.44



Axon 1289

mg	Price
5	online
25	online

Biological activity

Analogue of clozapine (Axon 1146); devoid of DA, 5-HT₂, H₁ and α₁ affinities, but with high M₁ affinity (IC₅₀ value of 35 nM).


GMC 1-116

[63687-94-5]
Purity: 98%

Axon 1151

mg	Price
10	online

No solubility data
C18H20N4O MW: 308.38



50 online


Biological activity

Analogue and metabolite of clozapine (Axon 1146); devoid of DA and $\alpha 1$ affinities, with weak 5-HT2 affinities but high M1 affinity (IC50=27 nM)

GMC 1-161

[95316-97-5]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C19H22N4O MW: 322.40



Axon 2851

mg Price

5 online

25 online


Biological activity

Analogue of clozapine (Axon 1146); devoid of affinity for the DA D1 receptor, but with affinities at 5-HT2A/2C, hM1 and DA D2 receptors.

GMC 1-165

[156632-07-4]
Purity: 99%

No solubility data
C18H20N4O MW: 308.38



Axon 1152

mg Price

10 online

50 online


Biological activity

AZD 1152-HQPA is a highly potent and selective inhibitor of Aurora B, with K_i values to be 0.36 (Aurora B) and 1369 nM (Aurora A) respectively and has a high specificity versus a panel of 50 other kinases. The dihydrogen phosphate prodrug, AZD 1152 (Barasertib), is converted rapidly to active AZD1152-HQPA in plasma

GMC 1-169

[183140-97-8]
Purity: 99%

Soluble in DMSO
C19H19F3N4O3S MW: 440.44



Axon 1148

mg Price

10 online

50 online


Biological activity

Atypical antipsychotic lack of muscarinic activity

GMC 2-113

[256227-77-7]
Purity: 98%

No solubility data
C28H29N5O3 MW: 483.56



Axon 1083

mg Price

10 online

50 online


Biological activity

Selective 5-HT1B antagonist; ratio of IC50 affinities for 1B vs 1D up to 63

GMC 2-118

[256227-78-8]
Purity: 98%

No solubility data
C29H31N5O5S MW: 561.65



Axon 1084

mg Price

10 online

50 online


Biological activity

Selective 5-HT1B antagonist, very potent in function assays

GMC 2-29

[148672-15-5]
Purity: 98%

No solubility data
C29H31N5O3 MW: 497.59



Axon 1080

mg Price

10 online

50 online


Biological activity

Selective 5-HT1B/1D antagonist; GR 127935-like drug with even greater potency in function assays

GMC 2-83

[183140-98-9]
Purity: 99%

No solubility data
C19H18F3N3O4S MW: 441.42



Axon 1150

mg Price

10 online

50 online


Biological activity

Atypical antipsychotic lack of muscarinic activity

GMC 3-15

[691846-63-6]
Purity: 99%

Soluble in DMSO
C27H30N4O3 MW: 458.55



Axon 1081

mg Price

10 online

50 online

Biological activity

Very potent and selective 5-HT1B/1D antagonist

GMC 15-27

[256227-71-1]
Purity: 98%

No solubility data


Axon 1082

mg Price

10 online

50 online

C27H31N5O2 MW: 457.57




Biological activity
Selective 5-HT1B/1D antagonist; most potent in collection

GMC 61-39

[234113-94-1]
Purity: 98%

No solubility data
C19H18ClF3N4O3S MW: 474.88




Biological activity
Clozapine-like atypical antipsychotic

GNE 317

[1394076-92-6]
Purity: 98%

Soluble in DMSO
C19H22N6O3S MW: 414.48



Biological activity
GNE 317 is a brain-penetrant PI3K α -isoform inhibitor with a K_i value of 2 nM. Besides a low efflux in vitro, GNE 317 demonstrated pathway inhibition in normal brain tissue, inhibition of tumor growth in the U87 model of glioblastoma, and good potency in a panel of GBM cell lines.


GNE 390

See GDC 0980

GNE 7915

[1351761-44-8]
Purity: 99%

Soluble in DMSO
C19H21F4N5O3 MW: 443.40



Biological activity
Highly potent, selective, metabolically stable, and brain-penetrable LRRK2 inhibitor (IC50 value 9 nM for phospho-LRRK2 in vitro). GNE 7915 is selective across 187 screened kinases, and >3200 and 53 times selective over JAK2 and TTK, respectively. GNE 7915 does not suppress LPS-stimulated TNF α and CXCL10 levels in LPS-treated primary wild-type (WT) or knockout (KO) astrocyte cultures, and is not reported to cause cellular or genetic toxicity.

GNF 2

Axon 1149

mg Price

10 online

50 online

Axon 2994

mg Price

5 online

25 online

Axon 1782

Page 499

Axon 2348

mg Price

10 online


50 online

Axon 1882

mg Price

[778270-11-4]
Purity: 99%

Soluble in DMSO
C18H13F3N4O2 MW: 374.32



10 online


50 online

Biological activity
Selective and allosteric inhibitor of Bcr-Abl tyrosine kinase, with IC50 of 267 nM and inactive at a panel of 63 other kinases, including native c-Abl; A new class of Bcr-Abl inhibitor to treat resistant Chronic myelogenous leukemia (CML)

GNE-3511

[1496581-76-0]
Purity: 98%

Soluble in DMSO
C23H26F2N6O MW: 440.49



Axon 3625

mg Price

5 online


25 online

Biological activity
GNE-3511 is a potent, selective, orally bioavailable and brain-penetrant DLK inhibitor with a K_i value of <0.0005 μ M, giving an IC50 value of 0.030 μ M for pJNK inhibition. GNE-3511 displayed concentration-dependent protection of neurons from degeneration in vitro and demonstrated dose-dependent activity in two different animal models of disease.

GNF 5837

[1033769-28-6]
Purity: 99%

Soluble in DMSO
C28H21F4N5O2 MW: 535.49



Axon 2248

mg Price

5 online


25 online

Biological activity
Potent, selective, and orally bioavailable tropomyosin receptor kinase (TRK) inhibitor with efficacy in rodent cancer tumor models (IC50 values 11, 9, and 7 nM for TRK A, B and C respectively in cellular Ba/F3 assay). Up to 100% tumor regression was observed in tumor xenografts derived from RIE cells expressing both TRKA and NGF.

GNE-781

[1936422-33-1]
Purity: 99%

Soluble in DMSO and EtOH
C27H33F2N7O2 MW: 525.59



Axon 4127

mg Price

5 online

25 online

Biological activity
GNE-781 is a highly potent, selective, and orally bioavailable CBP inhibitor with IC50 values of 0.94 nM, 6.2 nM and 5.1 μ M for CBP, CBP BRET and BRD4(1), respectively. GNE-781 displays antitumor activity in an AML tumor model and was also shown to decrease Foxp3 transcript levels in a dose dependent manner.

GNF362


[1003019-41-7]
Purity: 99%

Axon 3434

mg Price

5 online

99% e.e.
Soluble in DMSO and EtOH
C22H21F3N6 MW: 426.44



25 online


Biological activity

GNF362 is a potent, selective and orally bioavailable *Itpkb* inhibitor with an IC50 value of 9nM. Application of GNF362 to lymphocytes in vitro, blocked *Ins(1,3,4,5)P4* production, enhanced antigen receptor-driven Ca2+ responses and lead to apoptosis of activated T cells in an *Itpkb*-dependent manner.

GNF-PF-3777 Recent Addition

8-Nitrotryptanthrin

[77603-42-0]
Purity: 99%



Axon 3597

mg Price
10 online

Soluble in DMSO
C15H7N3O4 MW: 293.23

Biological activity


GNF-PF-3777 is a potent *hIDO2* inhibitor with a *Ki* value of 0.97 μ M.

GNTI dihydrochloride

Guanidinonaltrindole dihydrochloride, 6'

[351183-88-5]
Purity: 99%

No solubility data
C27H29N5O3.2HCl MW: 544.47



Axon 1226

mg Price
5 online
25 online

Biological activity

kappa opioid antagonist

GO 3450

See Gabapentin

Axon 1301

Page 495

GO 6983

See Gö 6983

Axon 2466


Page

Gö 6983

GO 6983; Goe 6983

[133053-19-7]
Purity: 99%

Soluble in DMSO
C26H26N4O3 MW: 442.51



Axon 2466

mg Price
5 online
25 online

Biological activity

Broad spectrum PKC inhibitor lacking inhibitory effect for the PKC μ isotype (IC50 values ranging from 7-60 nM for PKC α -PKC ζ , and 20000 nM for PKC μ , respectively). Gö6983 significantly enhanced ERK1/2 activity not only in IL-6-stimulated cells, but also the basal ERK1/2 activity in non-stimulated cells; yet, it has no effect on IL-6-triggered B9 cell proliferation, suggesting a crucial role for PKC μ . Useful tool for isolation, generation, derivatization and stabilization of naive human pluripotent stem cells in so called NHSM conditions developed at the Weizmann Institute of Science

Goe 6983

See Gö 6983

Axon 2466

Page 511

GOE 3450

See Gabapentin

Axon 1301

Page 495

Goitrin (optically pure)

(S)-Goitrin; L-Goitrin

[500-12-9]

Purity: 99%
100% e.e.

Soluble in DMSO and EtOH
C5H7NOS MW: 129.18



Axon 3781

mg Price
5 online

Biological activity

Goitrin is a constituent of *Radix isatidis* (Banlangen), which is a widely used traditional Chinese medicine for treating fever and removing toxic heat. Goitrin is known as an antithyroid factor, but also exhibits antiviral activity. Note: Some suppliers are selling DL-Goitrin (racemate, CAS 13190-34-6) as Goitrin and what we provide is the optically pure Goitrin (L-Goitrin, CAS 500-12-9, CID: 7568320). The opposite enantiomer, optically pure Epigoitrin (Axon 3782) is also available from Axon Medchem.

Goitrin, D-

See Epigoitrin (optically pure)

Axon 3782

Page 462

Goitrin, L-

See Goitrin (optically pure)

Axon 3781

Page 512

Goitrin, (R)-

See Epigoitrin (optically pure)

Axon 3782

Page 462

Goitrin, (S)-

See Goitrin (optically pure)

Axon 3781

Page 512


Golgicide A

GCA

[1139889-93-2]

Purity: 99%
96% d.e.

Soluble in 0.1N HCl(aq), DMSO and EtOH
C17H14F2N2 MW: 284.30



Axon 4197

mg Price
10 online
50 online

Biological activity

Golgicide A is a potent, highly specific, rapidly reversible inhibitor of the cis-Golgi ArfGEF GBF1. Inhibition of GBF1 function resulted in rapid dissociation of COPI vesicle coat from Golgi membranes and subsequent disassembly of the Golgi and trans-Golgi network.

Golidocitinib

See AZD-4205

Axon 3855


Page 271

Golvatinib

E 7050

[928037-13-2]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C33H37F2N7O4 MW: 633.69



Axon 1959

mg Price

10 online

50 online

Biological activity

Potent and orally available inhibitor of c-MET (HGFR) (IC50: 14 nM) and VEGFR-2 (IC50: 16 nM); Golvatinib inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases

GP-47-680

See Oxcarbazepine

Axon 3308

Page 741

GPP

See Geranyl pyrophosphate ammonium salt


Axon 1489

Page 502

GPR52 Comp-43

[1239987-91-7]
Purity: 99%

Soluble in DMSO and EtOH
C15H14OS MW: 242.34



Axon 3522

mg Price

10 online

50 online

Biological activity

GPR52 Comp-43 is a highly potent and specific GPR52 antagonist with an IC50 value of 0.63 μM.

GR 43175

See Sumatriptan succinate


Axon 1352

Page 900

GR 79236

[124555-18-6]
Purity: 99%

Soluble in water, DMSO and Ethanol
C15H21N5O5 MW: 351.36



Axon 1287

mg Price

10 online

50 online


Biological activity

Adenosine A1 receptor agonist

GR 103691

[162408-66-4]
Purity: 99%

Moderately soluble in DMSO
C30H35N3O3 MW: 485.62



Axon 1347

mg Price

10 online

50 online


Biological activity

Dopamine D3 receptor antagonist

GR 127935

[148672-13-3]
Purity: 98%

No solubility data
C29H31N5O3 MW: 497.59



Axon 1079

mg Price

5 online

25 online


Biological activity

Putative and selective 5-HT1B/1D antagonist

GR 127935 hydrochloride

[148642-42-6]
Purity: 98%

Soluble in water and DMSO
C29H31N5O3.HCl MW: 534.5



Axon 1813

mg Price

10 online

50 online


Biological activity

Putative and selective 5-HT1B/1D antagonist

GR 159897

[158848-32-9]
Purity: 99%

98% ee
Soluble in DMSO
C23H27FN2O2S MW: 414.54



Axon 1119

mg Price

5 online

25 online

Biological activity


Potent and selective non-peptide neurokinin NK2 receptor antagonist

Granisetron hydrochloride

BRL 43694

[107007-99-8]
Purity: 99%

Soluble in water
C18H24N4O.HCl MW: 348.87



Axon 1449

mg Price

25 online

100 online

Biological activity


Serotonin 5-HT₃ receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy; water-soluble form

Grapiprant

CJ-023,423

[415903-37-6]
Purity: 98%

Soluble in DMSO and EtOH
C₂₆H₂₉N₅O₃S MW: 491.61


Axon 3787

mg	Price
10	online
50	online

Biological activity

Grapiprant is a potent, selective, competitive and orally bioavailable prostaglandin EP₄ receptor antagonist with K_i values of 13 nM and 20 nM for human and rat EP₄ receptors, respectively. Grapiprant produces antihyperalgesic effects in animal models of inflammatory pain.

Grassofermata

See NAV-2729

Axon 3622

Page 690

GRL 40476

See Modafinil


Axon 1296

Page 675

GS 39783

[39069-52-8]
Purity: 99%

Moderately soluble in DMSO
C₁₅H₂₃N₅O₂S MW: 337.44


Axon 1820

mg	Price
10	online
50	online

Biological activity

Positive allosteric modulator at GABAB receptor

GS 4104 phosphate

See Oseltamivir phosphate

Axon 3136

Page 737

GS455534

See CVT-10216

Axon 3725

Page 399

GS 4997

See Selonsertib

Axon 2956

Page 860

GS 9820

See Acalisib

Axon 2857

Page 205

GS-5734

See Remdesivir

Axon 3110

Page 811

GS-5816

See Velpatasvir

Axon 3173

Page 964

GS5885

See Ledipasvir

Axon 3300

Page 609

GS-7340

See Tenofovir alafenamide

Axon 3302

Page 919

GS7977

See Sofosbuvir

Axon 3301

Page 878

GSi 953

See Begacestat

Axon 2117

Page 297

GS-9620


See Vesatolimod

Axon 3585

Page 967

GS-9901

[1640247-87-5]
Purity: 99%
99% e.e.
Soluble in DMSO
C₂₂H₁₇ClF₂N₉O MW: 477.88


Axon 3807

mg	Price
5	online
10	online

Biological activity

GS-9901 is an orally active, potent and isoform-selective inhibitor of PI3K δ (PI3K δ IC₅₀ = 1.0 nM, HWB δ EC₅₀ = 1.5 nM; CLpr hHep = 0.05 L/h/kg.), and a potential immunomodulating agent. It is highly selective against other isoforms: p110 α (750 nM), p110 β (100 nM) and P110 γ (190 nM).


Source Information: Sold in collaboration with Chemietek

GS-9973

Entospletinib

[1229208-44-9]
Purity: 99%

Soluble in DMSO
C₂₃H₂₁N₇O MW: 411.47


Axon 4153

mg	Price
10	online
50	online

Biological activity

Spleen tyrosine kinase (Syk), a non-receptor cytoplasmic, BCR-associated enzyme, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies. GS-9973 is a highly selective and orally efficacious inhibitor of spleen tyrosine kinase (Syk) with an IC50 of 7.7 nM. It inhibits the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation.

Source Information: Sold in collaboration with Chemietek

GSK1210151A

See I-BET151

Axon 4135


Page 555

GSK 2

[934240-30-9]

Purity: 99%

Soluble in DMSO
C18H19FN2O2 MW: 314.35



Axon 1899

mg Price

5 online

25 online

Biological activity

Sodium channel blocker with potent anticonvulsant activity; potential for novel treatment for Schizophrenia

GSK2 HCl

See CNV 1014802 hydrochloride

Axon 2548

Page 381

GSK046


iBET-BD2

[2474876-09-8]

Purity: 98%

99% e.e.

Soluble in DMSO
C23H27FN2O4 MW: 414.47



Axon 3921

mg Price

5 online

10 online

Biological activity

GSK046 is a domain-selective and orally active inhibitor of BET with immunomodulatory activity, targeting specifically BDII (Bromodomain II) with IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRD4 BD2), respectively.

Source Information: Sold in collaboration with Chemietek


GSK1070916

NMI-900

[942918-07-2]

Purity: 99%

Soluble in DMSO
C30H33N7O MW: 507.63



Axon 3920

mg Price

5 online

25 online

Biological activity

GSK1070916 is a potent, selective and ATP competitive inhibitor of Aurora B and C kinases with Ki values of 0.38 and 1.5 nM, respectively, and is highly selective over Aurora A (Ki = 490 nM). Its inhibition of Aurora B and C is time-dependent, with an enzyme-inhibitor dissociation half-life of >480 min and 270 min respectively, a unique feature compared to other Aurora B Kinase inhibitors under clinical development. It is selective over other kinase targets with an exception of of FLT1, TIE2, SIK, FLT4, and FGFR1 (with IC50 values of 42, 59, 70, 74, and 78 nM, respectively).

GSK 126


[1346574-57-9]

Purity: 98%

optically pure

Soluble in DMSO

C31H38N6O2 MW: 526.67



Axon 2140

mg Price

2 online

5 online

Biological activity

Potent, selective, cell-active inhibitor of histone lysine methyltransferase (HMTase or HMT; H3K27 selective) EZH2 (Ki 0.57 nM; IC50 9.9 nM); more than 150-fold selective for EZH2 versus EZH1 (Ki 89 nM) and 20 other human methyltransferases. GSK126 effectively inhibits proliferation of EZH2 mutant DLBCL cell lines and growth of EZH2 mutant DLBCL xenografts in mice.


GSK1278863

Daprodustat

[960539-70-2]

Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C19H27N3O6 MW: 393.43



Axon 3615

mg Price

10 online

50 online

Biological activity

GSK1278863 is a potent, selective and orally active inhibitor of all three HIF prolyl hydroxylase isozymes, PHD1, PHD2, and PHD3 with IC50 values of 3.5, 22.2 and 5.5 nM, respectively.

GSK1324726A

See I-BET726

Axon 3860


Page 555

GSK1904529A

[1089283-49-7]

Purity: 99%

Soluble in DMSO
C44H47F2N9O5S MW: 851.96



Axon 3830

mg Price

5 online

10 online

Biological activity

GSK1904529A is a potent, selective and orally active inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) with IC50 values of 27 and 25 nM for IGF-1R and IR (Insulin Receptor), respectively.

Source Information: Sold in collaboration with Chemietek

GSK481

GSK481

Axon 2608


mg Price

[1622849-58-4]

Purity: 98%

Soluble in DMSO

C21H19N3O4 MW: 377.39



5 online

25 online

Biological activity

Potent inhibitor of Receptor-interacting serine/threonine-protein kinase 1 (RIPK1 or RIP1; IC50 value 2.8 nM for inhibition of S166 phosphorylation of hWT RIP1) exhibiting a remarkable specificity over >450 other kinases. GSK481 protects against TNF-induced inflammation and lethal shock.


GSK 2033

[1221277-90-2]

Purity: 100%

Soluble in DMSO

C29H28F3NO5S2 MW: 591.66



Axon 2363

mg Price

5 online

25 online

Biological activity

The first potent cell-active LXR antagonist (IC50 value 31.6 nM for LXRβ binding). In intact cells stimulated with LXR agonist, GSK 2033 showed a dose-dependent reduction in the expression of the ATP-binding cassette transporter A1 (ABCA1) in THP-1 cells and SREBP-1c in HepG2 cells. A useful chemical probe to explore the cell biology of the LXR receptor.

GSK2141795

See Uprosertib

Axon 3958

Page 956

GSK2256098


GTPL7939

[1224887-10-8]

Purity: 99%

Soluble in DMSO

C20H23ClN6O2 MW: 414.89



Axon 3717

mg Price

10 online

50 online

Biological activity

GSK2256098 is an orally bioavailable small molecule inhibitor of Focal adhesion kinase (FAK) (Ezymatic apparent $K_i = 0.4$ nM), targeting specifically at phosphorylation site of the enzyme, tyrosine (Y) 397 (FAK Y397). GSK2256098 inhibition of FAK Y397 phosphorylation correlated with decreased levels of phosphorylated Akt and ERK in L3.6P1 cells (Cellular IC50 = 2-15 nM), decreased cell viability, anchorage-independent growth, and motility in a dose dependent manner.

Source Information: Sold in collaboration with Chemietek

GSK2334470

[1227911-45-6]

Purity: 99%

Optically pure

Soluble in 0.1N HCl(aq) and DMSO


Axon 1929

mg Price

5 online

25 online

C25H34N8O MW: 462.59



Biological activity

GSK2334470 is a potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitor with an IC50 value of ~10 nM. GSK2334470 does not suppress the activity of 93 other protein kinases including 13 AGC-kinases most related to PDK1 at 500-fold higher concentrations.


GSK2795039 Recent Addition

[1415925-18-6]

Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and ETOH

C23H26N6O2S MW: 450.56



Biological activity

GSK2795039 is a potent and selective NADPH oxidase 2 (NOX2) inhibitor. GSK2795039 inhibited both the formation of ROS and the utilization of the enzyme substrates, NADPH and oxygen, in a variety of semirecombinant cell-free (with pIC50 values in the range

GSK2830371


[1404456-53-6]

Purity: 99%

99% e.e.

Soluble in DMSO

C23H29ClN4O2S MW: 461.02



Biological activity

The serine/threonine phosphatase Wip1 plays an important role in tumor development. Despite its aberrant activity characterizing different forms of cancer, selective inhibitors are still lacking. GSK2830371 is an orally active, allosteric Wip1 phosphatase inhibitor with an IC50 of 6 nM. It binds to a flap subdomain that regulates Wip1's enzymatic activity and substrate recognition. Due to lack of this domain in other phosphatases, its binding to GSK2830371 results in a selective and potent inhibition of Wip1. When tested in animal models suffering from a blood cancer (lymphoma), GSK2830371 effectively blocked the tumoral growth.

Source Information: Sold in collaboration with Chemietek


GSK2837808A

[1445879-21-9]

Purity: 98%

Soluble in DMSO

C31H25F2N5O7S MW: 649.62




Biological activity

GSK2837808A is a potent, selective and NADH-competitive inhibitor of LDH-A with an IC50 value of 0.0026 μM.

GSK2879552 dihydrochloride

[1902123-72-1]
Purity: 99%
99% e.e.
Soluble in DMSO
C23H28N2O2.2HCl MW: 437.40



Axon 4005

mg	Price
10	online
50	online

Biological activity


GSK2879552 is a first-in-class, orally bioavailable, potent, selective, and mechanism-based irreversible inhibitor of Lysine specific demethylase 1 (LSD1). LSD1, a histone H3K4me1/2 demethylase found in various transcriptional co-repressor complexes, including Histone Deacetylases (HDAC1/2) and Co-Repressor for Element-1-Silencing Transcription factor (CoREST). Studies have implicated that LSD1 is a key regulator of the epigenome that modulates gene expression through post-translational modification of histones and through its presence in transcriptional complexes, and is overexpressed in certain tumor cells. Inhibition of LSD1 enhances H3K4 methylation and increases the expression of tumor-suppressor genes.

Source Information: Sold in collaboration with Chemietek

GSK329

[1268490-12-5]
Purity: 98%

Soluble in DMSO
C19H14Cl2F3N5O2 MW: 472.25



Axon 3895

mg	Price
5	online
25	online


Biological activity

GSK329 is a highly potent and selective TNNI3K inhibitor with an IC50 value of 10 nM.

GSK3326595

Pemrametostat; EPZ015938

[1616392-22-3]
Purity: 99%
99% e.e.
Soluble in DMSO
C24H32N6O3 MW: 452.55



Axon 3750

mg	Price
10	online
50	online

Biological activity

GSK3326595 is an orally active, potent, selective, SAM uncompetitive, peptide competitive, slow binding inhibitor of protein arginine methyltransferase 5 (PRMT5)/MEP50 with a biochemical IC50 of 6 nM (ref 1), and is >4,000-fold selective for PRMT5/MEP50 over any other enzyme when tested in a panel containing 20 other histone methyltransferases. Display potent antitumor activities in vitro and in vivo in animal models.


Source Information: Sold in collaboration with Chemietek

GSK3368715 hydrochloride

GSK715 hydrochloride; EPZ019997 hydrochloride

[2227587-25-7]
Purity: 99%

Soluble in water and DMSO
C20H38N4O2.HCl MW: 403.00



Axon 3919

mg	Price
5	online
10	online

Biological activity


GSK3368715 is a first-in-class, orally active, potent and selective, SAM-Noncompetitive inhibitor of Type I Protein Arginine Methyltransferases (PRMTs) with IC50 in lower nM; alters exon usage and shows anti-tumor efficacy in multiple cancer models; synergizes with the PRMT5 inhibitor GSK3326595 (Type II inhibitor) (Axon 3750) to inhibit tumor growth.

Source Information: Sold in collaboration with Chemietek

GSK-3484862

GSKMI-714

[2170136-65-7]
Purity: 99%
99% e.e.
Soluble in DMSO
C19H19N5OS MW: 365.45



Axon 3900

mg	Price
5	online
10	online


Biological activity

GSK3484862 (GSKMI-714) is a non-covalent DNMT1 (DNA Methyltransferase 1) inhibitor.

Source Information: Sold in collaboration with Chemietek

GSK3685032 hydrochloride

[2170140-51-7]
Purity: 99%
99% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C22H24N6OS.HCl MW: 457.00



Axon 3757

mg	Price
5	online
10	online

Biological activity


GSK3685032 hydrochloride is a potent first-in-class DNMT1-selective inhibitor. Induces robust loss of DNA methylation, transcriptional activation and cancer cell growth inhibition in vitro. Displays a much-improved in vivo tolerability and greater DNA hypomethylation compared with decitabine, translating into superior tumor regression and survival mouse models of acute myeloid leukemia.

Source Information: Sold in collaboration with Chemietek

GSK 3787

[188591-46-0]
Purity: 99%

Soluble in DMSO
C15H12ClF3N2O3S MW: 392.78



Axon 1628


mg	Price
10	online
50	online

Biological activity

Selective and irreversible peroxisome proliferator-activated receptor (PPAR) delta (PPARδ) antagonist

GSK484 hydrochloride

[1652591-81-5]
Purity: 98%
Optically pure
Soluble in water, DMSO and EtOH
C27H31N5O3.HCl MW: 510.03



Axon 3531

mg	Price
5	online
25	online

Biological activity

GSK484 hydrochloride is a highly potent, selective, and reversible PAD4 inhibitor with an IC50 value of 50 nM (in the absence of calcium).

GSK525762


See I-BET762

Axon 4134

Page 555

GSK 5959

 [901245-65-6]
 Purity: 99%

 Soluble in DMSO
 C22H26N4O3 MW: 394.47

Axon 2410


mg	Price
10	online
50	online

Biological activity

Potent, cell permeable inhibitor of BRPF1 bromodomain with excellent selectivity over other bromodomains (pIC50 values 7.1 (BRPF1), 5.1 (BRPF2), and <4.3 (BRD4-BD1)).

GSK 137647A

 [349085-82-1]
 Purity: 99%

 Soluble in DMSO and Ethanol
 C16H19NO3S MW: 305.39

Axon 2582

mg	Price
10	online
50	online

Biological activity

Potent FFA4/GPR120 agonist (pEC50 value 6.3 nM for hFFA4) with >100-fold selectivity over a panel of 65 targets including FFA1-FFA3. GSK137647A reproduces the secretion of active GLP-1 mediated by long-chain FAs (LCFAs), especially ALA.

GSK 189074

See Remogliflozin

Axon 1634

Page 811

GSK 1349572


See Dolutegravir

Axon 2855

Page 436

GSK 2193874

 [1336960-13-4]
 Purity: 98%

 Soluble in DMSO
 C37H38BrF3N4O MW: 691.62

Axon 2742


mg	Price
10	online
50	online

Biological activity

GSK 2193874 is a potent, selective, and orally active TRPV4 channel blocker (IC50 values of 2 and 40 nM for rTRPV4 and hTRPV4, respectively). TRPV4 blockade with GSK 2193874 provided protection against the development of pulmonary edema and the resulting deficits in arterial oxygenation in heart failure models in vivo.

GSK 269962A

 [850664-21-0]
 Purity: 99%

 Soluble in DMSO
 C29H30N8O5 MW: 570.60

Biological activity


Highly potent and selective inhibitor of Rho-Kinase (ROCK), with IC50 values: 1.6 nM toward ROCK1 and 6 nM toward ROCK2 and high kinase selectivity (>30 fold selective for ROCK compared to other protein kinases tested) and with antihypertensive activity: cardiovascular diseases category. GSK269962A has a much improved potency and selectivity in comparison with Y-27632, which has IC50 values of 140-220 nM for ROCK1 and ROCK2

Axon 1167

mg	Price
2	online
5	online
25	online

GSK 2982772

 [1622848-92-3]
 Purity: 99%

 Optically pure
 Soluble in DMSO
 C20H19N5O3 MW: 377.40

Biological activity

GSK2982772 potently binds to RIP1 with exquisite kinase specificity (IC50 value of 1.0 nM; ADP-Glo activity assay) and has excellent activity in blocking many TNF-dependent cellular responses (IC50 value of 6.3 nM; human monocytic U937 cellular assay). The inhibitor was also able to reduce spontaneous production of cytokines from human ulcerative colitis explants. First-in-class RIP1 inhibitor to enter clinical trials for psoriasis, rheumatoid arthritis, and ulcerative colitis.

Axon 2713

mg	Price
2	online
5	online

GSK 3235025

See EPZ 015666

Axon 2831

Page 464

GSK 424323


See Odiparcil

Axon 1536

Page 729

GSK 461364

 [929095-18-1]
 Purity: 99%
 99% ee

 Soluble in DMSO
 C27H28F3N5O2S MW: 543.60

Biological activity

Potent and selective Polo-like kinase (PLK) 1 inhibitor, more selective at PLK1 (Ki: 2.2 nM) over PLK2 and PLK3.

Axon 1688

mg	Price
5	online
25	online


GSK 461364 analogue I

 [929095-23-8]
 Purity: 99%

 optically pure
 Soluble in DMSO
 C26H27ClN4O3S MW: 511.04

Axon 1625


mg	Price
5	online
25	online


Biological activity

Potent and selective Polo-like kinase (PLK) 1 inhibitor, more selective at PLK1 (IC50: 2 nM) over PLK3 (IC50: 630 nM)

GSK 461364 analogue II

[929095-22-7]
Purity: 99%
optically pure
Soluble in DMSO
C27H27F3N4O3S MW: 544.59


Axon 1626


mg	Price
5	online
25	online

Biological activity

Potent Polo-like kinase (PLK) inhibitor, selective at PLK1 (IC50: 2 nM) over PLK3 (IC50: 270 nM)

GSK626616

[1025821-33-3]
Purity: 99%
Soluble in DMSO
C18H10Cl2N4OS MW: 401.27


Axon 2970


mg	Price
5	online
25	online

Biological activity

GSK626616 is a potent, orally bioavailable inhibitor of DYRK3 with an IC50 value of 0.7 nM. GSK626616 inhibits other members of the DYRK family, e.g., DYRK1A and DYRK2, with similar potency and with an approximate 20-fold selectivity versus the next most potently inhibited kinase, casein kinase 2.

GSK 650394

[890842-28-1]
Purity: 99%
Soluble in DMSO
C25H22N2O2 MW: 382.45


Axon 1570

mg	Price
5	online
10	online

Biological activity

Specific inhibitor of serum- and glucocorticoid-regulated kinases 1 (SGK 1), with IC50 values to be 62 and 103 nM for SGK1 and SGK2 respectively


GSK 690693

[937174-76-0]
Purity: 99%
optically pure

Axon 1729

mg	Price
5	online

Soluble in DMSO
C21H27N7O3 MW: 425.48



25 online

Biological activity

Potent and ATP-competitive Akt kinase inhibitor, with IC50 to be 2, 13 and 9 nM for Akt1, Akt2 and Akt3 respectively

GSK715 hydrochloride

See GSK3368715 hydrochloride

Axon 3919

Page 521

GSK 742457

See SB 742457

Axon 1382

Page 851

GSK795

See Uprosertib


Axon 3958

Page 956

GSK837149

[13616-29-0]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C23H22N8O5S2 MW: 554.60


Axon 2617

mg	Price
10	online
50	online


Biological activity

Selective inhibitor of human fatty acid synthase (FAS; Ki value 30 nM) that acts by inhibition the β -ketoacyl reductase activity of the enzyme.

GSK 8612

[2361659-62-1]
Purity: 99%

Soluble in DMSO
C17H17BrF3N7O2S MW: 520.33


Axon 3007

mg	Price
5	online
25	online

Biological activity

GSK 8612 is a potent and highly selective TBK1 inhibitor (pIC50 value of 6.8). In cellular assays, GSK 8612 inhibited toll-like receptor (TLR)3-induced interferon regulatory factor (IRF)3 phosphorylation in Ramos cells and type I interferon (IFN) secretion in primary human mononuclear cells. In THP1 cells, GSK 8612 was able to inhibit secretion of interferon beta (IFN β) in response to dsDNA and cGAMP, the natural ligand for STING.

GSK'872


GSK2399872A

[1346546-69-7]
Purity: 98%

Soluble in 0.1N HCl (aq) and DMSO
C19H17N3O2S2 MW: 383.49

Axon 3024

mg	Price
10	online
50	online




Biological activity

GSK 872 is a potent and selective RIP3 kinase inhibitor with an IC50 value of 1.8 nM for RIP3 kinase binding and an IC50 value of 1.3 nM for inhibition of kinase activity.

GSK923295

[1088965-37-0]
Purity: 99%
Optically pure
Soluble in DMSO
C32H38ClN5O4 MW: 592.13



Biological activity

GSK-923295 is a first-in-class high affinity antimitotic inhibitor of centromere-associated protein E (CENP-E), potently and allosterically inhibiting CENP-E ATPase activity with a Ki value of 3.2 nM. Display a broad-spectrum antiproliferative activity against a range of human tumor xenografts grown in nude mice, including models of colon, breast, ovarian, lung and other tumors.

Source Information: Sold in collaboration with Chemietek

GSK 1014802 HCl


See CNV 1014802 hydrochloride

GSK 1120212

Trametinib; JTP 74057

[871700-17-3]
Purity: 99%

Soluble in DMSO
C26H23FIN5O4 MW: 615.39



Biological activity

Highly potent and selective MEK inhibitor, with IC50 values to be 0.7 and 0.9 nM for MEK1 and MEK2 respectively and with long circulating half-life

GSK 1363089

See Foretinib

GSK 1838705

See GSK 1838705A

Axon 3852

mg	Price
5	online
10	online

Axon 2548

Page 381

Axon 1761

mg	Price
5	online
25	online

Axon 1582

Page 489

Axon 2267


Page 528

GSK 1838705A

GSK 1838705

[1116235-97-2]
Purity: 99%

Soluble in DMSO
C27H29FN8O3 MW: 532.57




Biological activity

Potent and selective insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) kinase inhibitor with additional affinity for anaplastic lymphoma kinase (ALK) with IC50 values of 2.0 nM, 1.6 nM, and 0.6 nM, for IGF1R, IR, and ALK respectively, and >800-fold selectivity over related kinases, including RSK1, JNK3, and B-Raf V600E GSK 1838705A inhibits the proliferation of cancer cell lines, comprises the growth of human tumor xenografts in vivo, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses.

GSK 2110183 hydrochloride

Afuresertib hydrochloride

[1047645-82-8]
Purity: 99%
Optically pure
Soluble in water and DMSO
C18H17Cl2FN4OS.HCl MW: 463.78




Biological activity

Potent, reversible, selective, and orally bioavailable inhibitor of the Akt kinases (Ki values 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively), with some inhibitory effect on PKA and PKG1a. GSK2110183 preferentially inhibits the proliferation of human cancer cells lines with Akt pathway activation, and various cell lines derived from hematologic malignancies, in an ATP-competitive manner and with a minimal effect on glucose homeostasis.

GSK 2126458

[1086062-66-9]
Purity: 99%
Soluble in DMSO
C25H17F2N5O3S MW: 505.50



Biological activity


Highly potent and orally bioavailable inhibitor of PI3K and mTOR in vitro and in vivo; Ki values to be 0.019, 0.13, 0.024 and 0.06 nM for p110 α , β , δ and γ isoforms and 0.18 and 0.3 nM for mTORC1 and mTORC2 respectively

GSK 2256294

See GSK 2256294A

GSK 2256294A

GSK 2256294
[1142090-23-0]
Purity: 99%
Optically pure (absolute stereochemistry)
Soluble in DMSO



Axon 2267

mg	Price
5	online
25	online

Axon 2460

mg	Price
5	online
25	online

Axon 1596

mg	Price
2	online
5	online

Axon 2220

Page 528

Axon 2220

mg	Price
2	online
5	online

C21H24F3N7O MW: 447.46


Biological activity

GSK2256294A is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (IC50 value 27 pM), and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH. GSK2256294A also displays potent cellular inhibition (IC50 = 0.66 nM) of sEH in a cell line transfected with the human sEH enzyme. The selectivity of the compound has been demonstrated by testing against a large panel of enzymes, receptors and ion channels, including the phosphatase activity of EPHX2.

GSK 2578215A

[1285515-21-0]
Purity: 99%

Soluble in DMSO
C24H18FN3O2 MW: 399.42



Biological activity

Potent and exceptionally highly selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor (IC50 values 10.9 and 8.9 nM for wild-type LRRK2 and LRRK2[G2019S] mutant, respectively.) GSK2578215A possesses good blood-brain barrier (BBB) permeability with a high ratio of brain to plasma distribution in mice.


GSK 2586184

See Solcitinib

GSK 2606414

[1337531-36-8]
Purity: 99%

Soluble in DMSO
C24H20F3N5O MW: 451.44




Biological activity

Potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK or EIF2AK3) with IC50 value of 0.4 nM and >1000 fold selectivity over EIF2AK1 (HRI) and EIF2AK2 (PKR). Overall, good selectivity was observed, with only 20 protein kinases inhibited >85% by GSK 2606414 at 10 μM during screening against a panel of 294 kinases. It inhibits the growth of a human tumor xenograft in mice with good oral bioavailability and blood-brain barrier penetration. PERK is a type I ER membrane protein and one of three primary effectors of the unfolded protein response (UPR), which has a demonstrated role in tumor growth and angiogenesis.

GSK 2636771 dihydrochloride

[1372540-25-4]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C22H22F3N3O3.2HCl MW: 506.35



Biological activity

Potent, orally available and specific PI3K p110β (PI3K beta, PI3Kβ) inhibitor

GSK J1

Axon 2181

mg Price

10 online

50 online

Axon 2539

Page 878

Axon 2233

mg Price

5 online

25 online

Axon 1912

mg Price

5 online


25 online

Axon 1934

mg Price

[1373422-53-7]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H23N5O2 MW: 389.45



5 online

25 online


Biological activity

The first selective and potent histone demethylase JMJD3/UTX inhibitor; blocks demethylation of histone H3K27; showed no activity against a panel of JMJ family demethylases and 100 protein kinases. Available also a cell permeable ethyl ester derivative GSK J4 (Axon 1933), which is a prodrug suitable for cell-based studies and will be hydrolyzed to GSK-J1 in cells rapidly

GSK J4

[1373423-53-0]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C24H27N5O2 MW: 417.50



Axon 1933

mg Price

5 online

25 online

Biological activity

Histone demethylase JMJD3/UTX inhibitor; blocks demethylation of histone H3K27; As a cell permeable ethyl ester derivative of GSK J1 (Axon 1934), it is a suitable prodrug form for cell-based studies. It is rapidly hydrolyzed in cells, generating pharmacologically relevant intracellular concentrations of GSK-J1

GSK11a

See HOIPIN 11a

Axon 3064

Page 544

GSK-1605786


See Vercirnon

Axon 2685

Page 966

GSK-LSD1

[N.A.]
Purity: 99%
mixture of trans-diastereomers
Soluble in water and DMSO
C14H20N2.2HCl MW: 289.24



Axon 2375

mg Price

10 online

50 online

Biological activity

Irreversible inhibitor of the KDM1 family histone demethylase LSD1 (IC50 value 16 nM). GSK-LSD1 is >1000 fold selective over closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B) and induces gene expression changes in cancer cell lines (average EC50 <5 nM) and inhibits cancer cell line growth (average EC50 <5 nM).

GSK2399872A

See GSK'872

Axon 3024

Page 526

GSK264220A

[685506-42-7]
Purity: 99%

Soluble in DMSO


Axon 3213

mg Price

5 online

25 online

C17H21N3O4S MW: 363.43



Biological activity

GSK264220A is a potent inhibitor of endothelial lipase (EL) and lipoprotein lipase (LPL) with IC50 values of 0.13 and 0.10 μM, respectively.

GSKMI-714

See GSK-3484862


Axon 3900

Page 522

GTS 21 dihydrochloride

[156223-05-1]
Purity: 100%

Soluble in water and DMSO
C19H20N2O2.2HCl MW: 381.30



Axon 2860

mg	Price
10	online
50	online

Biological activity


Selective α7 nicotinic acetylcholine receptor (nAChR) partial agonist. At significantly higher concentrations GTS 21 behaves as an antagonist of α4β2 nAChRs and related type 3 5-HT receptors.

Guanfacine hydrochloride

BS100-141

[29110-48-3]
Purity: 100%

Soluble in water and DMSO
C9H9Cl2N3O.HCl MW: 282.55



Axon 3383

mg	Price
10	online
50	online

Biological activity

Guanfacine hydrochloride is a selective α2-adrenergic receptor agonist with a Kd value of 31 nM. Centrally acting antihypertensive agent.

Guanidinonaltrindole dihydrochloride, 6'-

See GNTI dihydrochloride

Axon 1226

Page 511

Gusacitinib

See ASN-002

Axon 3997

Page 255

GV 150526A

See Gavestinel

Axon 1262

Page 496

GW 102

See Sumatriptan succinate

Axon 1352

Page 900


GW 2580

Axon 2571

mg	Price
----	-------

[870483-87-7]
Purity: 99%

Soluble in DMSO
C20H22N4O3 MW: 366.41



10	online
50	online

Biological activity

An orally bioavailable inhibitor of cFMS kinase (IC50 value of 0.03 μM in vitro) and the CSF1R receptor (Kd value 1.6 nM) that competitively blocks the ATP binding site of cFMS. GW 2580 was inactive against 26 kinases in vitro and did not inhibit the growth of mouse NS0 lymphoblastoid cells, human fibroblasts, human endothelial cells, and five human tumor cell lines. GW 2580 also interacts with TrkA, TrkB, and TrkC (Kd values 630 nM, 36 nM, and 120 nM, respectively)

GW 3430

See GW 803430


Axon 1569

Page 535

GW 3965 hydrochloride

[405911-17-3]
Purity: 99%

Soluble in DMSO and Ethanol
C33H31ClF3NO3.HCl MW: 618.51



Axon 1266

mg	Price
10	online
50	online


Biological activity

Selective and orally active liver X receptor (LXR) full agonist

GW 5074

[220904-83-6]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
MW: 520.94



Axon 1984

mg	Price
5	online
25	online


Biological activity

Potent, brain-permeable inhibitor of c-Raf (IC50 value 9 nM) when tested in vitro with no effect on the activities of CDK1/2/5/6, JNK1/2/3, c-Src, MEK1, p38 MAP kinase, VEGFR2, and c-fms. In contrast to its effect in vitro, treatment of neurons with GW 5074 causes c-Raf activation (when measured in vitro in the absence of the drug) and stimulates the Raf-MEK-ERK pathway.

GW 7647

[265129-71-3]
Purity: 99%

Soluble in DMSO and Ethanol
C29H46N2O3S MW: 502.75



Axon 1237

mg	Price
5	online
10	online

Biological activity

Potent and selective Peroxisome proliferator-activated receptor-α (PPARα) agonist

GW 9508


[885101-89-3]

Axon 2013

mg	Price
----	-------

Purity: 100%

Soluble in 0.1N NaOH(aq) and DMSO
C22H21NO3 MW: 347.41



10 online

50 online


Biological activity

Potent and selective agonist for the free fatty acid receptor FFA1 (GPR40)

GW 9662

[22978-25-2]
Purity: 100%

Soluble in DMSO and Ethanol
C13H9ClN2O3 MW: 276.68



Axon 2262

mg Price

10 online

50 online

Biological activity


Potent PPAR γ antagonist (IC50 values 3.3 nM, 32 nM and 2000 nM for PPAR γ , PPAR α , and PPAR δ , respectively) which inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR γ agonist rosiglitazone, independently of PPAR γ activation. GW 9662 profoundly improved healing and induced angiogenesis in human mesenchymal stem cells (hMSCs), and reversed the protection of endotoxin (lipopolysaccharide, LPS) in a model of renal ischemia-reperfusion.

GW 284543 hydrochloride

UNC 10225170 hydrochloride

[179246-08-3]
Purity: 99%

Soluble in DMSO
C23H20N2O3.HCl MW: 408.88



Axon 3059

mg Price

10 online

50 online

Biological activity

GW 284543 hydrochloride is a selective MEK5 inhibitor. GW 284543 treatment dose-dependently inhibited MEK5, as determined by reductions in pERK5, and decreased endogenous MYC protein.

GW 311616 hydrochloride


See GW 311616A

GW 311616A

GW 311616 hydrochloride

[197890-44-1]
Purity: 99%

>99% ee
Soluble in water and DMSO
C19H31N3O4S.HCl MW: 433.99



Axon 2364

mg Price

2 online

5 online

Biological activity

Potent, selective and orally active human neutrophil elastase (HNE) inhibitor (IC50 value 22 nM). GW311616A is selective over other human serine proteases (IC50 values >100 μ M for trypsin, cathepsin G, and plasmin, >3 μ M for chymotrypsin and tissue plasminogen activator), and does not inhibit AchE at 100 μ M.

GW 353162A

See Radafaxine hydrochloride

Axon 1123


Page 806

GW 406381

GW 406381X

[221148-46-5]
Purity: 99%

Soluble in DMSO
C21H19N3O3S MW: 393.46



mg Price

10 online

50 online

Biological activity

Highly selective cyclooxygenase-2 (COX-2) inhibitor that is effective in animal models of central sensitization and of inflammatory pain

GW 406381X

See GW 406381


Axon 1974

Page 534

GW 441756

[504433-23-2]
Purity: 99%

Moderately soluble in DMSO
C17H13N3O MW: 275.30



Axon 1251

mg Price

5 online

10 online

Biological activity

Potent and orally active TrkA kinase inhibitor (IC50= 2nM)

GW 572016

See Lapatinib ditosylate

Axon 1395

Page 604

GW 679769B

See Casopitant mesylate

Axon 1901

Page 345

GW 685698X

See Fluticasone furoate

Axon 1172


Page 487

GW 786034

Pazopanib hydrochloride

[635702-64-6]
Purity: 98%

Soluble in DMSO
C21H23N7O2S.HCl MW: 473.98



mg Price

5 online

25 online


Biological activity

A potent and selective inhibitor of tyrosine kinases, targeting VEGFR/c-KIT/PDGFR, blocking angiogenesis; as an oral antineoplastic agent

GW 788388

[452342-67-5]
Purity: 99%

Soluble in DMSO
C25H23N5O2 MW: 425.48




Biological activity

Potent, orally active and selective inhibitor of transforming growth factor beta receptor 1 (TGF-βR1) (activin receptor-like kinase 5, ALK5)

GW 791343 hydrochloride

[309712-55-8]
Purity: 98%

Soluble in water and DMSO
C20H24F2N4O.3HCl MW: 483.81



Biological activity


P2X7 receptor antagonist; GW791343 was a negative allosteric modulator of the human P2X(7) receptor but at the rat P2X(7) receptor its predominant effect was positive allosteric modulation

GW 803430

GW 3430

[515141-51-2]
Purity: 99%

Soluble in DMSO
C25H24ClN3O3S MW: 481.99



Biological activity

Selective, non-peptide antagonist at the melanin concentrating hormone receptor 1 (MCH1 aka MCH R1). In animal studies it has anxiolytic, antidepressant and anorectic effects

GW 823296B

See Orvepitant maleate


GW 823296X maleate

See Orvepitant maleate

GW 842166X

[666260-75-9]
Purity: 98%

Soluble in DMSO
C18H17Cl2F3N4O2 MW: 449.25



Axon 1832

mg	Price
2	online
10	online

Axon 1967

mg	Price
5	online
25	online

Axon 1569

mg	Price
5	online
25	online

Axon 1618

Page 736

Axon 1618

Page 736

Axon 1925

mg	Price
10	online
50	online


Biological activity

Potent and selective cannabinoid CB2 receptor agonist; with an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain; clinical candidate

GW 843682X

[660868-91-7]
Purity: 99%

Soluble in DMSO
C22H18F3N3O4S MW: 477.46



Biological activity


Polo-like kinase (PLK) inhibitor; selective at PLK1 (IC50: 2 nM) and PLK3 (IC50: 9 nM)

GW4869 trifluoroacetate

GW554869 TFA

[475570-61-7 (parent)]
Purity: 97%

Soluble in DMSO
C30H28N6O2.2C2HF3O2 MW: 732.63



Biological activity

GW4869 is a noncompetitive inhibitor of neutral, magnesium-dependent sphingomyelinase (N-SMase) with an IC50 value of 1 μM. GW4869 did not inhibit acid SMase at up to at least 150 μM. *GW4869 has a bad solubility in DMSO and/or other solvents. GW4869 is usually formulated as a suspension. GW4869 (TFA) has a better solubility and bioavailability than GW4869 (HCl).

GW554869 TFA

See GW4869 trifluoroacetate

GX15-070


See Obatoclax

GYKI 53655

LY 300168

-18-6]
Purity: 99%

Soluble in DMSO and Ethanol
C19H20N4O3 MW: 352.39



Biological activity

Selective AMPA receptor antagonist; a more useful tool than NBQX for the study of AMPA receptor-mediated processes in vivo

Axon 1131

mg	Price
5	online
10	online

Axon 3289

mg	Price
2	online
5	online

Axon 3289

Page 536

Axon 4152

Page 729

Axon 1374

mg	Price
2	online
5	online

GZR 123

See Dilept

Axon 1975

Page 429

HA1077


See Fasudil hydrochloride

Axon 3848

Page 475

HA130

 [1229652-21-4]
 Purity: 99%

 Soluble in DMSO
 C₂₄H₁₉BFNO₅ MW: 463.29

Axon 4136

mg	Price
10	online
50	online


Biological activity

HA130 is a potent and selective Autotaxin inhibitor (IC₅₀ = 28 nM), binding and inhibiting Autotaxin reversibly. Displays no activity against the proteasome, recombinant NPP1 or alkaline phosphatase. Inhibits ATX-mediated cell migration in an A2058 melanoma cell assay.

Source information: Sold in collaboration with Chemietek

HA 14-1

 [65673-63-4]
 Purity: 98%

 Soluble in DMSO and EtOH
 C₁₇H₁₇BrN₂O₅ MW: 409.23

Axon 2007


mg	Price
10	online
50	online

Biological activity

Bcl-2 antagonist and apoptosis inducer of tumor cells; HA14-1 induces the activation of Apaf-1 and caspases.

HA-155 Recent Addition

 [1312201-00-5]
 Purity: 99%

 98% e.e.
 Soluble in DMSO
 C₂₄H₁₉BFNO₅ MW: 463.29

Axon 4234


mg	Price
10	online
50	online

Biological activity

HA-155 potent Autotaxin inhibitor with an IC₅₀ value of 5.7 nM.

Haloperidol

 [52-86-8]
 Purity: 99%

 Soluble in DMSO and EtOH
 C₂₁H₂₃ClFNO₂ MW: 375.86

Axon 3610

mg	Price
50	online

Biological activity

Haloperidol is a dopamine antagonist with selectivity for D₂-like receptors (K_i values of 1.2, 7, and 2.3 nM for dopamine D₂, D₃, and D₄ receptors, respectively).

HAMNO


NSC 111847

[138736-73-9]

Axon 2390

mg	Price
----	-------

Purity: 99%
Soluble in DMSO
C17H13NO2 MW: 263.29




10 online
50 online

Biological activity

Novel protein interaction inhibitor of replication protein A (RPA), a protein involved in the ATR/Chk1 pathway. HAMNO selectively binds the N-terminal DBD-F domain of RPA70, effectively inhibiting critical RPA protein interactions that rely on this domain. HAMNO inhibits both ATR autophosphorylation and phosphorylation of RPA32 Ser33 by ATR. Candidate therapeutic for cancer treatment, as it enhances the constitutive and oncogene-induced replication stress in cancer cells.

Harmine

[442-51-3]
Purity: 99%



Axon 3627
mg Price
50 online

Soluble in 0.1N HCl(aq), DMSO and EtOH
C13H12N2O MW: 212.25

Biological activity

Harmine is a potent, selective and ATP-competitive DYRK1A inhibitor with IC50 values of 33 nM, 166 nM, 1.9 μM, and 80 μM for DYRK1A, DYRK1B, DYRK2, and DYRK4, respectively. Harmine has many pharmacological activities including anti-inflammatory, neuroprotective, antidiabetic, and antitumor activities.

HBI-8000


See Tucidinostat

Axon 2893
Page 943

HBX 41,108

HBX41108

[924296-39-9]
Purity: 99%



Axon 3732
mg Price
5 online
25 online

Soluble in DMSO and EtOH
C13H3ClN4O MW: 266.64

Biological activity

HBX 41,108 is an inhibitor of USP7/HAUSP ubiquitin protease with an IC50 value of 424 nM. HBX 41,108 treatment stabilized p53, activated the transcription of a p53 target gene without inducing genotoxic stress, and inhibited cancer cell growth. Finally, HBX 41,108 induced p53-dependent apoptosis as shown in p53 wild-type and null isogenic cancer cell lines.

HBX41108

See HBX 41,108

Axon 3732
Page 539

hCPT, dl-

See Homocamptothecin, (±)-E-


Axon 1687
Page 545

HDAC6 inhibitor ISOX

[1045792-66-2]

Axon 1645
mg Price

Purity: 99%
Soluble in DMSO
C22H30N4O6 MW: 446.50



5 online
25 online

Biological activity

Potent and selective histone deacetylase 6 (HDAC6) inhibitor, with IC50 to be 2.4 nM (HDAC6) and 71 nM (HDAC1). (*2010 revised affinities)

HDM-201

See Siremadlin

Axon 3737
Page 867


Hectorol

See Doxercalciferol

Axon 1746
Page 438

HEI3090

[2377167-56-9]
Purity: 100%
99% e.e.
Soluble in DMSO and EtOH
C18H15Cl3N4O3 MW: 441.70



Axon 3262
mg Price
10 online
50 online

Biological activity

HEI3090 is a positive modulator of the purinergic P2RX7 receptor that potentiates αPD-1 treatment to effectively control the growth of lung tumors in transplantable and oncogene-induced mouse models and triggers long lasting antitumor immune responses.

HePC


See Miltefosine

Axon 3247
Page 656

Hesperadin

[422513-13-1]
Purity: 99%

Soluble in DMSO
C29H32N4O3S MW: 516.65



Axon 2096
mg Price
5 online
25 online

Biological activity

A rapid, reversible and ATP-competitive inhibitor of Aurora B

Hetrazan

See Diethylcarbazine citrate

Axon 3176
Page 426

Hexadecylphosphocholine

See Miltefosine


Axon 3247

Page 656

HG-9-91-01

[1456858-58-4]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C32H37N7O3 MW: 567.68



Biological activity

HG-9-91-01 is a potent and selective SIK inhibitor with IC50 values of 0.92, 6.6 and 9.6 nM for SIK1, SIK2 and SIK3, respectively.

HhAntag 691

See GDC 0449


Axon 1500

Page 498

HIF Phd Inhibitor 4

[1227946-51-1]
Purity: 98%

Soluble in DMSO
C21H17ClN4O5S MW: 472.90



Biological activity


Inhibitor of the Hypoxia Inducible Factor (HIF) Prolyl-Hydroxylases (PHD)

HIF-2 inhibitor 2

Compound 2

[1422955-31-4]
Purity: 100%

Soluble in DMSO
C12H6ClFN4O3 MW: 308.65




Biological activity

Allosteric inhibitor of HIF-2, which selectively antagonizes HIF-2 heterodimerization and DNA-binding activity in vitro and in cultured cells, reducing HIF-2 target gene expression

HIF-2a Translation Inhibitor 76

[882268-69-1]
Purity: 99%

Soluble in DMSO
C9H9N3O4S2 MW: 287.32



Axon 2614

mg	Price
5	online
25	online


Biological activity

HIF-2a translation inhibitor (IC50 value 5 μM); Decreases HIF-2a protein and HIF-2a target gene expression in normoxia and hypoxia independent of HIF-2a mRNA expression or HIF-2a protein stability, and independent of mTOR activity. Moreover, the translation inhibitor 76 enhances binding of IRP1 to the HIF-2a IRE

HJC0197

[1383539-73-8]
Purity: 99%

Soluble in DMSO
C19H21N3OS MW: 339.45




Biological activity

HJC0197 is a potent EPAC antagonist (IC50 value of 5.9 μM for EPAC2).

HJC0350

[885434-70-8]
Purity: 99%

Soluble in DMSO
C15H19NO2S MW: 277.38



Biological activity

HJC0350 is a highly potent and selective EPAC2 antagonist (IC50 value of 0.3 μM for competing with 8-NBD-cAMP binding of EPAC2). Moreover, HJC0350 is about 133-fold more potent than cAMP. Valuable pharmacological tool to explore physiological and pathological processes related to signaling pathways that are regulated by EPAC proteins.

HJC-1-65

See ESI-08


HKI 272

See Neratinib

HL 010183

[N.A.]
Purity: 99%

Soluble in DMSO
C14H20N6.HCl MW: 308.81



Biological activity

A metformin derivative exerting a potent anti-tumor effect; HL010183 inhibits proliferation and invasion of Hs578T triple-negative (TN) breast cancer cells; 100 fold more potent than metformin

HLCL65 hydrochloride

[N.A.]
Purity: 99%

Soluble in DMSO
C23H23BrN2O.HCl MW: 459.81

Axon 3326

mg	Price
5	online
25	online

Axon 2730

mg	Price
10	online
50	online

Axon 2847

Page 467

Axon 1526


Page 698

Axon 2021

mg	Price
10	online
50	online

Axon 2710

mg	Price
10	online
50	online




Biological activity

HLMCL65 is a highly selective small molecule PRMT5 inhibitor. HLMCL65 inhibited Th1 cell proliferation (IC50 value 1.1 μM) more potently than Th2 cell proliferation (IC50 value 4 μM). In vivo, PRMT5 blockade efficiently suppressed recall T cell responses and reduced inflammation in delayed-type hypersensitivity and clinical disease in experimental autoimmune encephalomyelitis mouse models. HLMCL65 is a more potent and bioavailable derivative of CMP5 (Axon 2709).

HLI 373

[N.A.]
Purity: 98%

Soluble in water and DMSO
C18H23N5O2.2HCl MW: 414.33



Biological activity

A water soluble and potent Hdm2 inhibitor that inhibits the ubiquitin ligase activity of Hdm2, stabilizes p53 and activates p53-dependent transcription, and induces cell death; HLI 373 is effective in inducing apoptosis of several tumor cells lines that are sensitive to DNA-damaging agents

HM71224

See Olmutinib

HM781-36B

See Pozotinib

HM95573


See Belvarafenib

HMPL-504 dihydrochloride

See Volitinib dihydrochloride

HMR 1031

[479203-71-9]
Purity: 98%
optically pure
Soluble in DMSO and Ethanol
C35H41N5O6 MW: 627.73



Biological activity

Potent and specific intrigen αβ1 or very late antigen 4 (VLA-4) receptor antagonist binding to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin; HMR1031 is a potential inhaled drug for the treatment of asthma

HMR 1098

HMR 1883 sodium salt

Axon 1643

mg	Price
5	online
25	online

Axon 4144

Page 732

Axon 2920

Page 787

Axon 3067

Page 298

Axon 3864

Page 971

Axon 1616


mg	Price
2	online
5	online

Axon 1757

mg	Price
----	-------

[261717-22-0]
Purity: 98%

Soluble in water
C19H21ClN3O5S2.Na MW: 493.96



5	online
25	online

Biological activity

KATP channel blocker; HMR 1098 acts by inactivating the ATP-sensitive potassium channels (KATP) responsible for potassium efflux. HMR 1098 is an inhibitor of Kir6.2/SUR1-composed K(ATP) channels

HMR 1883 sodium salt

See HMR 1098

Axon 1757

Page 543

HOE280

See Ofloxacin Recent Addition

Axon 4211

Page 730

HOE36801

See Etifoxine

Axon 3388

Page 469

HOE36801

See Etifoxine hydrochloride

Axon 3331

Page 469

HOIP inhibitor 11a

See HOIPIN 11a

Axon 3064


Page 544

HOIPIN 11a

GSK11a

[1610800-91-3]
Purity: 99%

Soluble in DMSO
C15H18N2O4 MW: 290.31



mg	Price
5	online
25	online


Biological activity

Selective, cell-permeable and covalent inhibitor of the RBR E3 ubiquitin ligase HOIP. Biochemical characterization of HOIPIN 11a demonstrated that this compound labels HOIP with promising proteome-wide selectivity and effectively inhibits linear polyubiquitin chain formation in vitro and in a cellular environment. Treating HEK293T cells overexpressing full length HOIP, HOIL-1L, and SHARPIN with compound 11a overnight led to inhibition of NF-κB activation in a concentration-dependent manner, with an estimated IC50 value of 37 μM.

HOIPIN-8

[N.A.]
Purity: 98%

Soluble in DMSO
C23H15F2N4NaO3 MW: 456.38



mg	Price
2	online
5	online


Biological activity

HOIPIN-8 is a potent inhibitor of LUBAC and NF- κ B signaling without cytotoxicity (IC50 value of 11 nM). Powerful tool to explore the physiological functions of LUBAC.

Homocamptothecin, (±)-E-

dl-hCPT; BN 80245

[186668-40-6]
Purity: 99%
racemate
Moderately soluble in DMSO
C21H18N2O4 MW: 362.38



Axon 1687

mg	Price
5	online
25	online


Biological activity

A potent topoisomerase I (Topo 1) inhibitor; Homocamptothecin (hCPT) is an E-ring modified analogue of camptothecin (CPT), with enhanced stability and potent Topo-1 mediated activity; apoptosis agent

Homoharringtonine

Omacetaxine mepesuccinate; Ceflatonin; Myelostat

[26833-87-4]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C29H39NO9 MW: 545.62



Axon 3667


mg	Price
10	online
50	online

Biological activity

Homoharringtonine inhibits the elongation phase of translation by preventing substrate binding to the acceptor site on the 60-S ribosome subunit and therefore block aminoacyl-tRNA binding and peptide bond formation. Additionally, homoharringtonine acts as a potent disrupter of protein-protein interaction interfaces between CDK2 and cyclin A.

Homo-PROTAC cereblon degrader 1

[2244520-98-5]
Purity: 98%
Soluble in DMSO
C32H32N6O10 MW: 660.63



Axon 3470

mg	Price
5	online
25	online

Biological activity


Homo-PROTAC cereblon degrader 1 is a highly potent and efficient CRBN degrader with only minimal effects on IKZF1 and IKZF3. It induces CRBN-mediated ubiquitination and proteasomal degradation. Homo-PROTAC based on Pomalidomide (Axon 3166).

Honokiol

NSC293100

[35354-74-6]
Purity: 99%

Soluble in DMSO and EtOH
C18H18O2 MW: 266.33



Axon 3897

mg	Price
10	online
50	online

Biological activity

Honokiol is a pleiotropic compound with therapeutic actions including neuroprotective, anti-spasmodic, antidepressant, anti-tumorigenic, antithrombotic, antimicrobial, and analgesic properties. Moreover, its pharmacological actions include apoptosis of diseased cells, reduction in the expression of defective proteins like P-glycoproteins, inhibition of oxidative stress, suppression of pro-inflammatory proteins cytokines such as (IL-6, IL-10 and TNF- α), amelioration of impaired hepatic enzymes and reversal of morphological alterations.

HPC

See Miltefosine

Axon 3247

Page 656

HR 029

See Tenilsetam


Axon 1470

Page 918

HS-243

[848249-10-5]
Purity: 100%

Soluble in DMSO
C17H16N4O3 MW: 324.33



Axon 3217

mg	Price
5	online
25	online


Biological activity

HS-243 is a highly potent and selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) with IC50 values of 24 and 20 nM for IRAK-1 and IRAK-4, respectively. HS-243 specifically inhibits intracellular IRAKs without TAK1 inhibition.

HS666 hydrochloride

[1409931-99-2]
Purity: 99%

Soluble in DMSO
C20H25NO.HCl MW: 331.88



Axon 2781

mg	Price
5	online
25	online

Biological activity

HS666 is a selective κ opioid receptor partial agonist (Ki value of 5.9 nM) which activates central κ receptors to produce potent antinociception. Moreover, HS666 displays pharmacological characteristics of a κ receptor analgesic with reduced liability for aversive effects correlating with its low efficacy in the β -arrestin2 signalling pathway.

HS-Cm

See NDMC101


Axon 3438

Page 696

HSF1A

[1196723-93-9]
Purity: 99%

Soluble in DMSO
C21H19N3O2S2 MW: 409.52



Axon 1890

mg	Price
5	online
25	online


Biological activity

Human heat shock factor protein (HSF1) activator

HSF1B

[1196723-95-1]
Purity: 99%

Soluble in DMSO
C₂₆H₂₃Cl₂N₃O MW: 464.39



Axon 2101

mg	Price
5	online
25	online

Biological activity


Human heat shock factor protein (HSF1) activator; close analogue of HSF1A (Axon 1890).

HSP47 inhibitor III

CBTC

[287917-38-8]
Purity: 98%

Soluble in DMSO and EtOH
C₈H₆ClNO₃S₂ MW: 263.72



Axon 3294

mg	Price
5	online
25	online


Biological activity

Inhibitor of the collagen-specific chaperone HSP47 with an IC₅₀ value of 3.1 μM. HSP47 inhibitor III suppressed collagen type I expression in human and mouse cells and suppressed the viability and migration of lung fibroblasts.

5-HT₆ antagonist 29

[497963-70-9]
Purity: 99%

Soluble in DMSO
C₁₉H₂₀ClN₃O₂S.HCl MW: 426.36



Axon 1575

mg	Price
5	online
25	online

Biological activity


Selective brain penetrant 5-HT₆ receptor antagonist (pK_i value 8.6). Close regio-isomer of SB 69929 with brain-blood ratio of 2.6:1 and ED₅₀ value of 5 mg/kg (po), and thus twice as potent as SB 271046 (Axon 1099).

HTI 286

SPA 110; Taltobulin

[228266-40-8]
Purity: 99%

optically pure
Soluble in DMSO
C₂₇H₄₃N₃O₄ MW: 473.65



Axon 1650

mg	Price
5	online
25	online

Biological activity

Potent tubulin inhibitor; a synthetic hemisterlin analogue, which is a potent inhibitor of cell growth with an additional advantage of circumventing the P-glycoprotein-mediated resistance

HTL-1071


See AZD4635

Axon 4069

Page 272

HTS-3 hydrochloride, (R)-

[N.A.]
Purity: 98%
98% e.e.
Soluble in water, DMSO and EtOH
C₁₇H₁₈F₂N₂O.HCl MW: 340.80



Axon 3743

mg	Price
5	online
25	online

Biological activity

(R)-HTS-3 hydrochloride is the first potent, selective, and cell-active inhibitor of LPCAT3 with an IC₅₀ value of 0.09 μM. Human cells treated with (R)-HTS-3 undergo rapid remodeling of the acyl-chain composition of their phospholipids in a manner that mirrors the changes caused by genetic loss of LPCAT3. Acute blockade of LPCAT3 by (R)-HTS-3 confers partial protection against ferroptosis induced by GPX4 inhibition.

HTS466284

See LY-364947


Axon 3404

Page 631

HU 308

[256934-39-1]
Purity: 98%

Soluble in DMSO
C₂₇H₄₂O₃ MW: 414.62



Axon 1440

mg	Price
5	online
25	online


Biological activity

Potent cannabinoid agonist specific at CB2. It has analgesic effects, promotes proliferation of neural stem cells, and protects both liver and blood vessel tissues against oxidative stress via inhibition of TNF-α

HX600

[172705-89-4]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C₂₉H₃₀N₂O₂ MW: 438.56



Axon 3003

mg	Price
5	online
25	online


Biological activity

HX600 is a synthetic agonist for RXR-Nurr1 heterodimer complex and prevents ischemia-induced neuronal damage.

Hydralazine hydrochloride

[304-20-1]
Purity: 98%

Soluble in water
C₈H₈N₄.HCl MW: 196.64



Axon 3651

mg	Price
50	online

Biological activity


Hydralazine hydrochloride is an orally active antihypertensive drug. Hydralazine is also a non-competitive and partial-reversible GOT1 inhibitor with an IC₅₀ value of 26.6 μM.

Hydroxybuspirone hydrochloride, 6-

BMS 528215; 6OH-B; 6-OH-Bu

[125481-61-0]
Purity: 98%

Soluble in water and DMSO
C₂₁H₃₁N₅O₃.HCl MW: 437.96



Axon 1996

mg	Price
5	online
25	online

Biological activity


A major active metabolite of Buspirone (Axon 1995), a 5-HT_{1A} partial agonist; with improved bioavailability (19%) compared with that for buspirone (1.4%); contributes significantly to the clinical efficacy of buspirone as an anxiolytic agent

Hydroxybuspirone hydrochloride, (R)-6-

BMS 442608 hydrochloride

[N.A.]
Purity: 99%

Soluble in water and DMSO
C₂₁H₃₁N₅O₃.HCl MW: 437.96



Axon 1997

mg	Price
1	online
5	online

Biological activity


Optically pure (R)-enantiomer of 6-hydroxybuspirone (Axon 1996), a major active metabolite of Buspirone (Axon 1995); 5-HT_{1A} partial agonist. (R)-Enantiomer showed higher affinity and selectivity for the 5HT_{1A} receptor compared to the (S)-enantiomer; while (S)-Enantiomer has advantage of being cleared more slowly from blood compared to the (R)-enantiomer

Hydroxybuspirone hydrochloride, (S)-6-

BMS 442606 hydrochloride

[N.A.]
Purity: 99%

Soluble in water and DMSO
C₂₁H₃₁N₅O₃.HCl MW: 437.96



Axon 1998

mg	Price
1	online
5	online


Biological activity

Optically pure (S)-enantiomer of 6-hydroxybuspirone (Axon 1996), a major active metabolite of Buspirone (Axon 1995); 5-HT_{1A} partial agonist. (S)-Enantiomer has advantage of being cleared more slowly from blood compared to the (R)-enantiomer; while (R)-Enantiomer showed higher affinity and selectivity for the 5HT_{1A} receptor compared to the (S)-enantiomer

Hydroxychloroquine sulfate

NSC 4375

[747-36-4]
Purity: 99%
Racemate
Soluble in water
C₁₈H₂₆ClN₃O₄.H₂SO₄ MW: 433.95



Axon 2432

mg	Price
50	online
250	online


Biological activity

Antimalarial drug (HCQ) and immunosuppressive lysosomotropic amine, also used as a slow-acting anti-rheumatic drug and for treatment of lupus erythematosus. HCQ is also shown to act as an antagonist for Toll-like receptors (TLR-7 and TLR-9) in plasmacytoid dendritic cells (pDCs).

Hydroxy-DPAT hydrobromide, (R)-(+)-7-

DPAT, (R)-7-OH-

[1021878-34-1]
Purity: 98%
98% ee
Soluble in DMSO
C₁₆H₂₅NO.HBr MW: 328.29



Axon 1013


mg	Price
5	online
25	online

Biological activity

A Putative D₃ dopamine receptor agonist (D₃>D₂>>D₄ and D₁); more active enantiomer of 7-OH-DPAT (Axon 1012), in comparison with (S)-(-)-7-OH-DPAT (Axon 1014)

Hydroxy-DPAT hydrobromide, (R)-(+)-8-

[78095-19-9]
Purity: 98%
98% ee
Soluble in DMSO
C₁₆H₂₅NO.HBr MW: 328.29



Axon 1016

mg	Price
10	online
50	online


Biological activity

Full 5-HT_{1A} receptor agonist, more active enantiomer of (±)-8-hydroxy-DPAT (Axon 1015)

Hydroxy-DPAT hydrobromide, (R)-5-

DPAT, (R)-5-OH-

[182210-73-7]
Purity: 98%
>98% ee
Soluble in DMSO
C₁₆H₂₅NO.HBr MW: 328.29



Axon 1007

mg	Price
5	online
25	online


Biological activity

While racemic 5-OH-DPAT (Axon 1006) is a potent and selective dopamine (DA) D₂-receptor agonist, its R-enantiomer, (R)-5-OH DPAT is a weakly potent DA D₂-receptor antagonist

Hydroxy-DPAT hydrobromide, (R)-6-

DPAT, (R)-6-OH-

[502508-84-1]
Purity: 98%
>98% ee
No solubility data
C₁₆H₂₅NO.HBr MW: 328.29



Axon 1010

mg	Price
5	online
25	online

Biological activity

Dopamine receptor agonist

Hydroxy-DPAT hydrobromide, (S)-(-)-7-


DPAT, (S)-7-OH-

[82730-73-2]
Purity: 98%
98% ee

Axon 1014

mg	Price
5	online

Soluble in DMSO
C16H25NO.HBr MW: 328.29



25 online


Biological activity

D3 dopamine receptor agonist; less active enantiomer of 7-OH-DPAT (Axon 1012), in comparison with (R)-(+)-7-OH-DPAT (Axon 1013)

Hydroxy-DPAT hydrobromide, (S)-(-)-8-

DPAT, (S)-(-)-8-OH-

[78095-20-2]
Purity: 98%
98% ee
Soluble in DMSO
C16H25NO.HBr MW: 328.29



Axon 1017

mg	Price
10	online
50	online


Biological activity

5-HT1A receptor partial agonist, less active enantiomer of (±)-8-OH-DPAT (Axon 1015), in comparison with R-(+)-8-hydroxy-DPAT (Axon 1016) as a full 5-HT1A agonist

Hydroxy-DPAT hydrobromide, (S)-5-

DPAT, (S)-5-OH-

[182210-74-8]
Purity: 98%
>98% ee
Soluble in DMSO
C16H25NO.HBr MW: 328.29



Axon 1008

mg	Price
5	online
25	online


Biological activity

Potent and selective dopamine (DA) D2-receptor agonist; more active (S)- enantiomer of 5-OH-DPAT (Axon 1006); its opposite enantiomer, R-5-OH-DPAT (Axon 1007), is a weakly potent D2 antagonist

Hydroxy-DPAT hydrobromide, (S)-6-

DPAT, (S)-6-OH-

[162992-70-3]
Purity: 98%
>98% ee
No solubility data
C16H25NO.HBr MW: 328.29



Axon 1011

mg	Price
5	online
25	online


Biological activity

Dopamine receptor agonist

Hydroxy-DPAT hydrobromide, 5-

DPAT, 5-OH-

[71787-83-2]
Purity: 98%
No solubility data
C16H25NO.HBr MW: 328.29



Axon 1006

mg	Price
5	online
25	online

Biological activity


Potent and selective dopamine (DA) D2-receptor agonist; [11C]5-OH-DPAT is being developed as a PET agent for the high-affinity state of D2/3 receptors

Hydroxy-DPAT hydrobromide, 6-

DPAT, 6-OH-

[76135-29-0]
Purity: 99%

Soluble in water
C16H25NO.HBr MW: 328.29



Axon 1009

mg	Price
10	online
50	online

Biological activity


Weak dopamine receptor agonist

Hydroxy-DPAT hydrobromide, 7-

DPAT, 7-OH-

[76135-30-3]
Purity: 98%

Soluble in DMSO
C16H25NO.HBr MW: 328.29



Axon 1012

mg	Price
10	online
50	online

Biological activity


D3 dopamine receptor agonist (D3>D2>>D4 and D1)

Hydroxy-DPAT hydrobromide, 8-

DPAT, 8-OH-

[76135-31-4]
Purity: 98%

Soluble in DMSO
C16H25NO.HBr MW: 328.29



Axon 1015

mg	Price
10	online
50	online

Biological activity

Standard selective 5-HT1A receptor agonist

Hydroxy-dynasore

See *Dyngo-4a* Recent Addition

Axon 4029


Page 446

Hydroxyioglitazone

M-IV

[146062-46-6]
Purity: 100%

Soluble in DMSO
C19H20N2O4S.HCl MW: 408.90



Axon 2533

mg	Price
5	online
25	online

Biological activity


Active metabolite of Pioglitazone (M-IV), a PPARγ agonist used for the treatment of diabetes mellitus type 2. Showed modest antihyperglycemic activity compared to Pioglitazone. Moreover, Hydroxyioglitazone is more efficient than Pioglitazone in stimulating lipid synthesis at a 3 μM dose in a 3T3-L1 cell assay.

Hydroxytamoxifen, (Z)-4-

(Z)-Afimoxifene

[68047-06-3]
Purity: 99%

Soluble in DMSO and EtOH
C₂₆H₂₉NO₂ MW: 387.51



Axon 4093

mg	Price
10	online
50	online


Biological activity

(Z)-4-Hydroxytamoxifen is the more active metabolite of Tamoxifen (Axon 3252) and a selective estrogen receptor modulator (SERM). (Z)-4-Hydroxytamoxifen possesses a high in vitro potency for the estrogen receptor, but it is a weaker agent than the parent compound in vivo, due to rapid clearance.

HRO761 Recent Addition

[2869954-34-5]
Purity: 98%

Soluble in DMSO
C₃₁H₃₁ClF₃N₉O₅ MW: 702.08



Axon 4214

mg	Price
5	online
25	online

Biological activity


HRO761 is a potent, selective, orally active and allosteric WRN inhibitor (IC₅₀ value of 0.1 μM) that binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation. Pharmacological inhibition by HRO761 recapitulated the

I-191

PAR2 antagonist I-191

[1690172-25-8]
Purity: 98%

Soluble in DMSO
C₂₃H₂₆FN₅O₂ MW: 423.48



Biological activity

I-191 is a potent antagonist of protease activated receptor 2 (PAR2) with a pIC₅₀ value of 7.1 in HT-29 cells. I-191 potently attenuated multiple PAR2-mediated intracellular signaling pathways leading to Ca²⁺ release, ERK1/2 phosphorylation, RhoA activation and inhibition of forskolin-induced cAMP accumulation.


Axon 3043

mg	Price
5	online
25	online

IACS-010759

[1570496-34-2]
Purity: 99%

Soluble in DMSO
C₂₅H₂₅F₃N₆O₄S MW: 562.56



Biological activity

IACS-010759 is an orally bioavailable, potent inhibitor of complex I of oxidative phosphorylation (OXPHOS). IACS-010759 was active in mouse, rat and cynomolgus monkey with IC₅₀ values of 5.6 nM, 12.2 nM and 8.7 nM, respectively. Treatment with IACS-010759 robustly inhibited proliferation and induced apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS, likely owing to a combination of energy depletion and reduced aspartate production that leads to impaired nucleotide biosynthesis.

Axon 2909

mg	Price
5	online
25	online

IACS-10759

See IACS-010759


Axon 2909

Page 554

IACS-13909 hydrochloride

[N.A.]
Purity: 99%

Soluble in water and DMSO
C₁₇H₁₈Cl₂N₆.HCl MW: 413.73



Biological activity

IACS-13909 is a potent and specific allosteric inhibitor of SHP2, suppressing the signaling of RTK/MAPK pathway. IACS-13909 potently impedes the proliferation of tumors with a broad spectrum of RTKs as the oncogenic driver. Importantly, in NSCLC models with acquired resistance to Osimertinib, IACS-13909 administered as a single agent or in combination with Osimertinib potently reduces tumor cell proliferation in vitro and in vivo, which provide preclinical evidence for using a SHP2 inhibitor as a therapeutic strategy in acquired EGFR inhibitor-resistant NSCLC.

Source Information: Sold in collaboration with Chemietek

Axon 3903

mg	Price
5	online
10	online

IBA-6

See PNR-7-02


Axon 2965

Page 785

I-BET151

GSK1210151A

[1300031-49-5]
Purity: 99%
>98% e.e.
Soluble in DMSO
C23H21N5O3 MW: 415.44



Biological activity

The Bromodomain and Extra Terminal domain (BET), a family of four proteins that selectively recognize and bind to acetylated lysine residues in histone, plays a key role in many cellular processes, including inflammatory gene expression, mitosis, and viral/host interaction by controlling the assembly of histone acetylation-dependent chromatin complexes. BET proteins stimulate transcription by recruiting specific types of proteins, for example the super elongation complex (SEC), to chromatin, leading to stimulation of transcriptional elongation of certain target genes including oncogenes and pro-inflammatory cytokines. Targeting BET proteins and displacing them could provide a method of inducing cell cycle arrest and even cell death of defectively programmed cells. I-BET151, a small molecule inhibitor that interacts with BRD4 and BRD3 BET proteins and displaces them from chromatin, has profound efficacy against human and murine MLL-fusion leukemic cell lines, through the induction of early cell cycle arrest and apoptosis. The mode of action is, at least in part, due to suppressing the transcription of key genes (BCL2, C-MYC and CDK6) that are critical for MLL-fusion leukemia maintenance.

Source Information: Sold in collaboration with Chemietek


Axon 4135

mg	Price
10	online
50	online

I-BET726

GSK1324726A

[1300031-52-0]
Purity: 99%
99% e.e.
Soluble in DMSO and EtOH
C25H23ClN2O3 MW: 434.91



Biological activity

I-BET726 is a potent and selective, tetrahydroquinoline-based small molecule ligand binding to BET proteins with IC50s (FRET) of 7.4, 7.1, 7.0, and 7.3 nM for BRD2, BRD3, BRD4 and BRDT, respectively, showing no binding potency towards other proteins.

Source Information: Sold in collaboration with Chemietek


Axon 3860

mg	Price
5	online
10	online

I-BET762

Molibresib; GSK525762

[1260907-17-2]
Purity: 99%
>99% e.e.
Soluble in DMSO
C22H22ClN5O2 MW: 423.90



Biological activity

I-BET762 is a cell-permeable benzodiazepine-based inhibitor of BET (bromodomain and extra terminal domain) proteins, BRD2, BRD3 and BRD4, binds to the tandem bromodomains of BET with Kd of 50.5–61.3 nM, displacing a tetra-acetylated H4 peptide prebound to tandem bromodomains of BET with IC50 of 32.5–42.5 nM in FRET analysis. I-BET-762 occupies the acetyl-lysine binding pocket of BET proteins and inhibits binding of BET proteins to acetylated histones, thus disrupts the formation of the chromatin complexes essential for expression of inflammatory genes.

Source Information: Sold in collaboration with Chemietek

Axon 4134

mg	Price
10	online
50	online

IBET-BD2

See GSK046

Ibipinabant


See SLV 319

IBP, 4-

NSC 667672

[155798-08-6]
Purity: 98%

Soluble in DMSO
C19H21N2O MW: 420.29



Biological activity

4-IBP is a selective sigma-1 (σ -1) agonist with Ki values of 1.70 nM and 25.2 nM for σ -1 and σ -2 receptor subtypes, respectively. Activating the σ -1 receptor with noncytotoxic doses of 4-IBP decreases the migration levels of various types of cancer cells, including C32 melanoma, U373-MG glioblastoma, A549 NSCLC, and PC3 prostate cancer cells. Moreover, 4-IBP sensitizes these cancer cells in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs.

Axon 3921

Page 517

Axon 1713

Page 873

Axon 2919

mg	Price
10	online
50	online

Ibrutinib

See PCI 32765

Ibutamoren mesylate

See MK 677

Axon 1858

Page 750


Axon 1376

Page 660

IC 87114

[371242-69-2]
Purity: 98%

Soluble in DMSO
C22H19N7O MW: 397.43



Biological activity

Potent and highly selective small molecule inhibitor of the PI3K p110 δ isoform (IC50 values for PI3K α , β , γ , and δ are >100, 75, 29, and 0.5 μ M respectively). IC87114 potently inhibited PIP3 biosynthesis in neutrophils by 60–65% and at 1 μ M, it inhibited neutrophil migration by 75% as compared with the control. IC 87114 reduced the infiltration of inflammatory cells into the pancreatic islets and, accordingly, delayed and reduced the loss of glucose homeostasis.


Axon 2168

mg	Price
5	online
25	online

ICA-069673

[582323-16-8]
Purity: 99%

Soluble in DMSO
C11H6ClF2N3O MW: 269.63



Axon 2724

mg	Price
10	online
50	online


Biological activity

ICA-069673, a KV7.2/KV7.3 (KCNQ2/Q3) channel opener (EC50 value 0.69 μ M), demonstrated 20-fold greater selectivity for heteromeric KV7.2/KV7.3 channels over KV7.3/KV7.5. Moreover, compared to retigabine (Axon 1525), ICA-069673 exhibits much stronger effects on KCNQ2 channels, including a large hyperpolarizing shift of the voltage-dependence of activation, an ~2-fold enhancement of peak current and pronounced subtype specificity for KCNQ2 over KCNQ3. Orally active in several animal models of epilepsy.

ICA-110381

[325457-99-6]
Purity: 99%

Soluble in DMSO
C12H8Cl2N2O MW: 267.11



Axon 3091

mg	Price
10	online
50	online

Biological activity

ICA-110381 is a Kv7.2/Kv7.3 (KCNQ2/Q3) potassium channel opener with an EC50 value of 0.38 μ M. ICA-110381 predominantly acts on KCNQ2-containing channels, shapes resonance and network oscillations in vitro and show anticonvulsant potential in vivo without affecting spontaneous synaptic transmission in the rat hippocampus in vitro.

ICA-17043

See Senicapoc

Axon 3951


Page 860

Icaritin

Anhydroicaritin

[118525-40-9]
Purity: 98%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C21H20O6 MW: 368.38



Axon 3811

mg	Price
5	online
25	online

Biological activity

In hematological malignancies, the exogenous phyto molecule Icaritin showed multiple cytotoxic effects to induce apoptosis, arrest the cell cycle, inhibit proliferation, promote differentiation, restrict metastasis and infiltration, and suppress the oncogenic virus. The proved underlying mechanisms of the cytotoxic effects of Icaritin are different in various cell types of hematological malignancies but associated with the critical cell signal pathway, including PI3K/Akt, JAK/STAT3, and MAPK/ERK/JNK. Also, Icaritin promoted osteogenic but inhibited adipogenic differentiation of mesenchymal stem cells by regulating osteogenesis and adipogenesis related gene expressions.

ICEC0942


See CT7001

Axon 3756

Page 397

ICG 001

[847591-62-2]
Purity: 99%
optically pure
Soluble in DMSO
C33H32N4O4 MW: 548.63



Axon 1766


mg	Price
5	online
25	online

Biological activity

Specific inhibitor of Wnt/ β -catenin signaling pathway; inhibiting β -catenin/cyclic AMP response element-binding (CREB) protein transcription. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, reduces in vitro growth of colon carcinoma cells, and is efficacious in the Min mouse and nude mouse xenograft models of colon cancer

ICI 192605

[117621-64-4]
Purity: 98%
optically pure
Soluble in DMSO and Ethanol
C22H23ClO5 MW: 402.87



Axon 1210

mg	Price
10	online
50	online

Biological activity

A potent and selective, orally active thromboxane A2 (TP) receptor antagonist

ICI 204636

See Quetiapine fumarate

Axon 1354

Page 801

ICI738

See ZZW-115 trihydrochloride

Axon 3735

Page 1011

ICI D1033

See Anastrozole


Axon 3316

Page 237

Iclepertin Recent Addition

BI425809

[1421936-85-7]
Purity: 98%
Optically pure
Soluble in DMSO and EtOH
C20H18F6N2O5S MW: .00



Axon 4201

mg	Price
5	online
25	online

Biological activity

Iclepertin is a potent, selective and orally active glycine transporter 1 (GlyT-1) inhibitor with IC50 values of 5.2 nM and 5.0 nM in rat primary neurons and human SK-N-MC cells, respectively. In addition, no activity of Iclepertin against the related gly

ICL670

See Deferasirox

Axon 3375


Page 417

iCRT5

CRT Inhibitor iCRT5

[18623-44-4]
Purity: 99%

Soluble in DMSO
C16H17NO5S2 MW: 367.44



Axon 2133

mg	Price
10	online
50	online

Biological activity


Potent and cell-permeable β -catenin-responsive transcription (CRT) inhibitor, with IC50 value of 18 nM for Wnt responsive STF16 luciferase (STF16-Luc). iCRT5 acts by disrupting the interaction between β -catenin and TCF4, possibly by direct binding to β -catenin, while displaying minimal or less prominent effect on non-canonical Wnt signaling and other pathways such as Hh, JAK/STAT, and Notch signaling

iCRT14

CRT Inhibitor iCRT14

[677331-12-3]
Purity: 98%

Soluble in DMSO
C21H17N3O2S MW: 375.44



Axon 2135

mg	Price
10	online
50	online

Biological activity

Small-molecule inhibitor of the Wnt/wingless signaling pathway (IC50 value 40 nM in a Wnt responsive STF16-luc reporter assay) that antagonizes the transcriptional function of nuclear β -catenin, and inhibits direct interactions between β -cat and TCF4. iCRT14 exhibits specific cytotoxicity towards human colon tumor biopsy cultures as well as colon cancer cell lines that exhibit deregulated Wnt signaling. Similar mode of action as iCRT5 (Axon 2133)

Idalopirdine HCl

See Lu AE58054 hydrochloride

Axon 2144

Page 624

Idasanutlin

See RG-7388

Axon 4035

Page 815

Idelalisib

See CAL 101

Axon 2170


Page 339

IDT307

APP+

[1141-41-9]
Purity: 99%

Soluble in water and DMSO
C14H17IN2 MW: 340.20



Axon 3355

mg	Price
10	online
50	online


Biological activity

IDT307, a fluorescent analogue of the dopaminergic neurotoxin MPP, is a substrate for the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). Fluorescent pyridinium dye.

Ifenprodil L-(+)-tartrate

[23210-56-2] (parent)
Purity: 99%

Soluble in water and DMSO
C21H27NO2.½C4H6O6
MW: 400.49



Axon 1156

mg	Price
10	online
50	online

Biological activity


NMDA antagonist; selectively blocks NMDA receptors containing the NR2B subunit; neuroprotective agent

IGGi-11me

IGGi-11 prodrug

[N.A.]
Purity: 98%

Soluble in DMSO
C25H32N2O8S2 MW: 552.66



Axon 4160

mg	Price
5	online
25	online

Biological activity

IGGi-11me is a membrane permeable prodrug of IGGi-11, which is the first-in-class inhibitor of noncanonical activation of heterotrimeric G-protein signaling. IGGi-11 binding to G-protein α -subunits (G α i) specifically disrupted their engagement with GIV/Girdin, thereby blocking noncanonical G-protein signaling in tumor cells and inhibiting proinvasive traits of metastatic cancer cells.

The membrane permeability of IGGi-11me was higher than that of IGGi-11. The esterase in the cytoplasm of MDA-MB-231 cells could convert IGGi-11me into IGGi-11. Thus, IGGi-11me acts as a prodrug, allowing IGGi-11 to function in cells much better.

IGGi-11 prodrug

See IGGi-11me

Axon 4160


Page 560

Iguratimod

T614

[123663-49-0]
Purity: %

Soluble in DMSO
C17H14N2O6S MW: 374.37



Axon 4048

mg	Price
10	online
50	online

Biological activity

Iguratimod is an orally active disease modified anti-rheumatic drug (DMARD). Iguratimod inhibits production of inflammatory cytokines and immunoglobulins through suppression of NF- κ B activation.

iHAP1


See Tubulin inhibitor 6

Axon 3400

Page 943

IHCH-7079

[2957888-63-8]
Purity: 98%
Optically pure
Soluble in 0.1N HCl(aq), DMSO and EtOH
C23H29N3O MW: 363.50



Axon 3925

mg	Price
5	online
25	online


Biological activity

IHCH-7079 is a 5-HT2A receptor arrestin-biased agonist with a Ki value of 16.98 nM. IHCH-7079 displayed antidepressant-like activity in mice but without hallucinogenic effects.

IITZ-01

[1807988-47-1]
Purity: 99%

Soluble in DMSO
C26H23FN8O MW: 482.51



Biological activity

IITZ-01 is a potent lysosomotropic autophagy inhibitor which has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo. Screening against the growth of cancer cell lines MCF-7, MDAMB-231, PC-3, DU-145, HT-29 and HGC-27 gave IC50 values of 1.0 μM, 1.5 μM, 0.8 μM, 1.0 μM, 1.1 μM, 0.8 μM, respectively.


Axon 2933

mg	Price
10	online
50	online

IL-4-inhibitor-1 Recent Addition

[1332184-63-0]
Purity: 99%

Soluble in DMSO and EtOH
C18H12FN3O2 MW: .00



Biological activity

IL-4-inhibitor-1 is a first IL-4 inhibitor with an EC50 of 1.81 μM (HEK-Blue IL-4/IL-13 cells).


Axon 4237

mg	Price
5	online
25	online

Iloperidone

[133454-47-4]
Purity: 99%

Soluble in DMSO
C24H27FN2O4 MW: 426.48



Biological activity

An atypical antipsychotic for the treatment of schizophrenia, acting upon and antagonizing specific neurotransmitters, particularly multiple dopamine and serotonin receptor subtypes


Axon 1493

mg	Price
10	online
50	online

IM 12

[1129669-05-1]
Purity: 99%

Soluble in DMSO
C22H20FN3O2 MW: 377.41



Biological activity

GSK-3β inhibitor (IC50 value 53 nM) showing a bell-shaped dose-response relationship. IM12 enhances canonical Wnt signalling, and attenuates cell proliferation and neuronal differentiation of human neural progenitor cells with similar potency as SB 216763 (Axon 1903).

Axon 2511

mg	Price
10	online
50	online

Imaradenant

See AZD4635

Axon 4069


Page 272

Imatinib Mesylate

CGP 57148B; STI 571; Gleevec

[220127-57-1]
Purity: 99%

Soluble in DMSO
C29H30N6O.CH4O3S MW: 574.69



Biological activity

Protein kinase inhibitor, targeting Bcr-Abl/c-kit/PDGF-R


Axon 1394

mg	Price
10	online
50	online

IMD-0354

[978-62-1]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C15H8ClF6NO2 MW: 383.67



Biological activity

The IκB kinase-β (IKKβ or IKK-2) inhibitor IMD-0354 inhibited nuclear translocation of NF-κB induced by TNF-α; this attenuated myocardial reperfusion injury and preserved cardiac function after myocardial infarction. TNF-α-induced production of interleukin-1β and monocyte chemoattractant protein-1 was reduced significantly by IMD-0354. IMD-0354 restrained proliferation of mast cells with c-kit mutations and suppressed the growth of human breast cancer cells by arresting cell cycle at the G0-G1 phase and inducing apoptosis. May effectively prevent restenosis.


Axon 2725

mg	Price
10	online
50	online

IMD-0560

[439144-66-8]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C15H8BrF6NO2 MW: 428.12



Biological activity

IMD-0560 is a selective IKKβ inhibitor which blocks IκBα phosphorylation and prevents NF-κB p65 nuclear translocation.


Axon 3484

mg	Price
5	online
25	online

iMDK

[881970-80-5]
Purity: 99%

Soluble in DMSO
C21H13FN2O2S MW: 376.40



Biological activity

MDK expression inhibitor; iMDK inhibits specifically and dose-dependently the expression of Midkine (MDK) in H441 lung adenocarcinoma cells, but does not inhibit PTN (Pleiotrophin), which has considerable homology to MDK. iMDK induces apoptosis in MDK-expressing H441 lung adenocarcinoma cells by suppression of the PI3K/Akt pathway but not the MAPK pathway. iMDK does not inhibit another growth factor VEGF.


Axon 2258

mg	Price
5	online
25	online

Imetit dihydrobromide

[32385-58-3]
Purity: 98%

Soluble in water
C₆H₁₀N₄S₂HBr MW: 332.06



Biological activity


Potent and specific histamine H3 receptor agonist

Imiquimod

R-837; S26308

[99011-02-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C₁₄H₁₆N₄ MW: 240.30



Biological activity


Imiquimod is a TLR7/TLR8 agonist with immunomodulatory activity.

Imirestat

AL1576

[89391-50-4]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C₁₅H₈F₂N₂O₂ MW: 286.23




Biological activity

Imirestat is a potent aldose reductase inhibitor with an IC₅₀ value of 8.5 nM.

IMM 01

[218795-74-5]
Purity: 99%

Soluble in DMSO
C₁₂H₁₇N₃O₂S MW: 267.35




Biological activity

Small-molecule agonist of mammalian Diaphanous (mDia)-related forms that inhibited DID-DAD binding (IC₅₀ value 140 nM). IMM-01 induced filopodia-like structures similar to those observed in cells expressing constitutively active mDia1 or mDia2. Moreover, IMM01 triggered actin assembly and microtubule stabilization consistent with formin activation in NIH 3T3 cells.

Imnepip dihydrobromide

[164391-47-3]
Purity: 98%

No solubility data
C₉H₁₅N₃.2HBr MW: 327.06



Axon 1325

mg	Price
10	online
50	online


Biological activity

Potent histamine H3 receptor agonist; also with affinity at histamine H4 receptor

Immethridine dihydrobromide

[699020-93-4]
Purity: 98%

Soluble in water and DMSO
C₉H₉N₃.2HBr MW: 321.01



Axon 1327

mg	Price
5	online
25	online


Biological activity

Potent and selective histamine H3 receptor agonist

IMS 2186

[1031206-36-6]
Purity: 99%

Soluble in DMSO
C₁₈H₁₆O₄ MW: 296.32



Axon 1827

mg	Price
10	online
50	online


Biological activity

Apoptosis inducer blocking the cell cycle at G2 and inhibiting the production of PGE₂/TNF- α ; a long-acting anti-proliferative and anti-angiogenic agent; a small molecule developed as an anti-choroidal neovascularization (anti-CNV) drug

IMT1B

LDC203974

[2304621-06-3]
Purity: 98%
100% e.e.
Soluble in 0.1N NaOH(aq), DMSO and EtOH
C₂₄H₂₁ClFNO₆ MW: 473.88



Axon 3417

mg	Price
2	online
5	online


Biological activity

IMT1B is a first-in-class, potent and highly specific allosteric inhibitor of the human mitochondrial RNA polymerase (POLRMT), which is essential for mtDNA transcription and biogenesis of the oxidative phosphorylation (OXPHOS) system. IMT1B shows potent effects for the treatment of cancer in preclinical mouse models.

IN 1130

[868612-83-3]
Purity: 99%

Soluble in DMSO
C₂₅H₂₀N₆O MW: 420.47



Axon 2236

mg	Price
5	online
25	online

Biological activity

Highly selective small molecule ALK5 inhibitor (IC₅₀ value of 5.3 nM for inhibition of ALK5-mediated Smad3 phosphorylation) with >100 fold selectivity over p38 α and a panel of 26 other serine/threonine and tyrosine kinases. Suppressor of fibrogenic process of unilateral ureteral obstruction in rats underscoring the potential clinical benefits in the treatment of renal fibrosis. By inhibition of TGF- β signaling, IN1130 ameliorated

experimental autoimmune encephalomyelitis, lessened tunical fibrosis and corrected penile curvature in rats, inhibited cancer metastasis in MMTV/c-Neu breast cancer mice, and enhanced CTL response in cancer mice.

INC280

See Capmatinib

Axon 3423

Page 342

INCB 018424 phosphate

See Ruxolitinib


Axon 1598

Page 836

INCB 024360

Epacadostat

[1204669-58-8]
Purity: 98%



Soluble in DMSO
C11H13BrFN7O4S MW: 438.23

Axon 1733


mg	Price
5	online
25	online

Biological activity

Potent competitive inhibitor of indoleamine 2,3-dioxygenase (IDO1, IC50 value 72 nM in vitro) with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model; INCB024360 (Epacadostat) decreased kynurenine levels by >50% in plasma and inhibited B16-GM-CSF tumor growth in a dose dependent fashion.

INCB 024360-analog

[914471-09-3]
Purity: 99%



Soluble in DMSO
C9H7ClFN5O2 MW: 271.64

Axon 2215

mg	Price
5	online
25	online

Biological activity

Potent competitive inhibitor of indoleamine 2,3-dioxygenase (IDO1, IC50 value 67 nM) with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model; This INCB 024360-analog decreased kynurenine levels by >50% in plasma and inhibited B16-GM-CSF tumor growth in a dose dependent fashion.

INCB 028050

See Baricitinib

Axon 1955

Page 284

INCB-01158 dihydrochloride

See CB-1158 dihydrochloride

Axon 3738

Page 346

INCB28060

See Capmatinib

Axon 3423

Page 342

Indiplon

See NBI 34060

Axon 1121


Page 694

Indomethacin

Axon 3318

mg Price

[53-86-1]
Purity: 99%



50 online


Soluble in 0.1N NaOH(aq) and DMSO
C19H16ClNO4 MW: 357.79

Biological activity

Indomethacin is a potent, time-dependent, nonselective inhibitor of the cyclooxygenase enzymes (COX-1 and COX-2). Indomethacin is a nonsteroidal anti-inflammatory drug with potent antipyretic, analgesic, and anti-inflammatory activity.

Indophagolin

[1207660-00-1]
Purity: 99%



Axon 3429

mg	Price
5	online
25	online


Soluble in DMSO
C19H15BrClF3N2O3S MW: 523.75

Biological activity

Indophagolin is a potent autophagy inhibitor with an IC50 value of 140 nM. Indophagolin also shows activity on the purinergic receptors with IC50 values of 2.40 μM, 3.49 μM and 2.71 μM for the P2X1, P2X3 and P2X4 receptors, respectively.

INDY

[1169755-45-6]
Purity: 99%



Axon 3538

mg	Price
10	online
50	online

Soluble in 0.1N NaOH(aq) and DMSO
C12H13NO2S MW: 235.30


Biological activity

INDY is a potent, selective and ATP-competitive inhibitor of Dyrk1A with an IC50 and Ki value of 0.24 and 0.18 μM, respectively. INDY effectively reversed the aberrant tau-phosphorylation and rescued the repressed NFAT (nuclear factor of activated T cell) signalling induced by Dyrk1A overexpression. The prodrug form, ProINDY (Axon 3540), is also available.

Iniparib

BSI 201

[160003-66-7]
Purity: 99%



Axon 1566

mg	Price
10	online
50	online

Soluble in DMSO
C7H5IN2O3 MW: 292.03

Biological activity

An irreversible inhibitor of poly(ADP-ribose) polymerase-1 (PARP 1); it inhibits PARP1, a nuclear enzyme that promotes DNA repair through the base-excision repair pathway; potential therapeutic undergoing clinical trials for treatment of some types of breast cancer

INK1117

See Serabelisib

Axon 4075

Page 861

INK-1197

See IPI-145


Axon 4133

Page 569

INK 128

[1224844-38-5]
Purity: 99%

C15H15N7O MW: 309.33



Axon 2142

mg	Price
5	online
25	online


Biological activity

Potent and selective mTOR inhibitor

INNO 406

Bafetinib

[859212-16-1]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C30H31F3N8O MW: 576.62



Axon 2121

mg	Price
2	online
5	online

Biological activity

Orally bioavailable dual Bcr-Abl and Lyn kinase inhibitor with anti-CML efficacy; orally bioavailable; more potent (>10 times) than Imatinib; highly recommended Abl inhibitor in treating chronic myeloid leukaemia (CML)

Inobrodib

See CCS-1477


Axon 3933

Page 350

Insulin sensitizer C59

[2761446-81-3]
Purity: 99%

Soluble in DMSO and EtOH
C16H18Cl2N2O MW: 325.23



Axon 4079

mg	Price
10	online
50	online

Biological activity


Insulin sensitizer C59 enhances insulin-stimulated GLUT4 translocation and glucose uptake in glucose storage tissue by targeting Unc119b. Moreover, C59 treatment improves glucose tolerance in rodent models of insulin resistance.

INT 131

AMG 131

[315224-26-1]
Purity: 99%

Soluble in DMSO
C21H12Cl4N2O3S MW: 514.21



Axon 2019

mg	Price
5	online
25	online

Biological activity

Highly potent, non-TZD, selective peroxisome proliferator-activated receptor gamma (PPAR-γ) modulator (SPPARM); INT131 is a PPAR-γ partial agonist and potential therapeutic agent for the treatment of type 2 diabetes

INT-747

See Obeticholic acid

Axon 3174

Page 729

lobenguane sulfate

See MIBG


Axon 1750

Page 654

Iodophenpropit dihydrobromide

[145196-87-8]
Purity: 98%

No solubility data
C15H19IN4S.2HBr MW: 576.13



Axon 1328

mg	Price
10	online
50	online

Biological activity


Potent and selective histamine H3 receptor antagonist

Iodopravadoline

AM 630

[164178-33-0]
Purity: 99%

Soluble in DMSO
C23H25IN2O3 MW: 504.36



Axon 1574

mg	Price
5	online
25	online


Biological activity

Selective cannabinoid (CB) receptor antagonist

IOX2

[931398-72-0]
Purity: 100%

Soluble in DMSO
C19H16N2O5 MW: 352.34



Axon 1921

mg	Price
5	online
25	online

Biological activity

A selective inhibitor of the Hypoxia Inducible Factor (HIF) Prolyl-Hydroxylases (PHD); active in cells with IC50 value of 21 nM for PHD2/ELGN-1 and no inhibition at FIH (20μM)

Ipatasertib

See GDC-0068

Axon 4037

Page 497

IPdR

See Ropidoxuridine


Axon 3953

Page 829

IPI-145

Duvelisib; INK-1197

[1201438-56-3]
Purity: 99%
99% e.e.
Soluble in DMSO
C22H17ClN6O MW: 416.86



Biological activity


IPI-145 is an orally bioavailable PI3K/P110 δ / γ isoform-specific inhibitor, with K_i values: P110 δ (23 pM), P110 γ (243 pM), p110 α (25900 pM) and p110 β (1564 pM). IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation. IPI-145 showed potent activity in collagen-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus rodent models.

Source Information: Sold in collaboration with Chemietek

IPI-549

Eganelisib

[1693758-51-8]
Purity: 99%
99% e.e.
Soluble in DMSO
C30H24N8O2 MW: 528.56




Biological activity

IPI-549 is a potent and isoform Gamma (γ) selective phosphoinositide-3-kinase (PI3K γ) Inhibitor ($K_d = 0.29$ nM), with biochemical IC_{50} (nM) for PI3K isoforms: 3200 (α), 3500 (β), 16 (γ), and >8400 (δ), respectively and Cellular IC_{50} (nM) for PI3K isoforms: 250 (α), 240 (β), 1.2 (γ) and 180 (δ) respectively. It shows no significant inhibition for a panel of 468 mutant and non mutant protein and lipid kinases (including Class II PI3K isoforms) at 1 μ M. IPI-549 demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K- γ mediated neutrophil migration in vivo.

Source Information: Sold in collaboration with Chemietek

IRAK1/4 inhibitor 1 Recent Addition

[509093-47-4]
Purity: 98%
98% e.e.
Soluble in DMSO
C20H21N5O4 MW: 395.41



Biological activity

IRAK1/4 inhibitor 1 is a potent inhibitor of IRAK-1 and IRAK-4 with IC_{50} values of 0.30 μ M and 0.20 μ M, respectively.

Iressa

See Gefitinib

Axon 4133

mg	Price
10	online
50	online

Axon 4147

mg	Price
10	online
50	online

Axon 4235

mg	Price
10	online
50	online


Axon 1393

Page 501

Irestatin 9389

[626221-47-4]
Purity: 99%

Soluble in DMSO
C16H13F3N4OS2 MW: 398.43




Biological activity

A potent inhibitor of the endonuclease IRE1 ($IC_{50} = 6.3$ nM) and unfolded protein response (UPR)

Irinotecan hydrochloride

CPT-11; Camptothecin 11

[100286-90-6]
Purity: 100%
Optically pure
Soluble in DMSO
C33H38N4O6.HCl MW: 623.14



Biological activity

Irinotecan hydrochloride is the prodrug for SN-38, which is a topoisomerase I inhibitor. SN-38 has demonstrated potent growth inhibition of human colorectal cancer cells in vitro, with superior activity to fluorouracil.


Irosustat

See STX64

Islatravir

EFdA; MK-8591

[865363-93-5]
Purity: 99%
Optically pure
Soluble in water and DMSO
C12H12FN5O3 MW: 293.25




Biological activity

The nucleoside reverse transcriptase inhibitor (NRTI) Islatravir is a potent and long-acting anti-human immunodeficiency virus type 1 (HIV-1) agent. Islatravir exhibits potent activity against wild-type and multidrug-resistant HIV-1 strains.

ISO-1

[478336-92-4]
Purity: 99%

Soluble in DMSO and EtOH
C12H13NO4 MW: 235.24



Biological activity

ISO-1 is an inhibitor of the macrophage migration inhibitory factor (MIF) with an IC_{50} value of 7 μ M for inhibition of MIF tautomerase activity.

Axon 1656

mg	Price
10	online
50	online

Axon 3370

mg	Price
50	online

Axon 2892

Page 897

Axon 3191

mg	Price
2	online
5	online


Axon 3949

mg	Price
10	online
50	online

Isoclozapine

[1977-08-8]
Purity: 98%

Soluble in DMSO
C18H19ClN4 MW: 326.82



Axon 1147

mg	Price
10	online
50	online

Biological activity


Typical antipsychotic; 2-Cl analogue of clozapine, atypical antipsychotic. Useful tool compound in comparison with clozapine; distinctly typical vs atypical profile

Isoprenaline hydrochloride

Isoproterenol

[51-30-9]
Purity: 99%

Soluble in water and DMSO
C11H17NO3.HCl MW: 247.72



Axon 3654

mg	Price
50	online

Biological activity

Isoprenaline hydrochloride is a non-selective β adrenoceptor agonist which acts on the heart, on the smooth muscle of bronchi, skeletal muscle vasculature and gastrointestinal tract.

Isoproterenol

See Isoprenaline hydrochloride

Axon 3654


Page 571

Isoquinolinediol, 1,5-

NSC 65585

[5154-02-9]
Purity: 100%

Soluble in 0.1N NaOH(aq) and DMSO
C9H7NO2 MW: 161.16



Axon 2537

mg	Price
10	online
50	online

Biological activity

PARP1-specific inhibitor (IC50 value 0.39 - 1.00 μ M) and neuroprotective agent, that leads to an increase up to 8-fold in the absolute frequency of gene targeting in the correction of the mutation at the stable integrated HSV tk gene in mouse Ltk cells. Treatment of 1,5-Isoquinolinediol significantly blocked mitochondrial membrane potential loss and AIF (apoptosis inducing factor) and cytochrome c release from the mitochondria. 1,5-Isoquinolinediol did not suppress pristimerin-induced JNK activation.

Isoxazole 9

See ISX9


Axon 3948

Page 573

Isoxicam

[34552-84-6]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C14H13NO5S MW: 335.34



Axon 3712

mg	Price
50	online


Biological activity

Isoxicam is a nonsteroidal anti-inflammatory drug (NSAID) and a nonselective inhibitor of COX-1 and COX-2.

Ispinesib

SB 715992

[336113-53-2]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C30H33ClN4O2 MW: 517.06



Axon 2446

mg	Price
5	online
25	online

Biological activity


The first potent, highly specific small-molecule inhibitor of the human kinesin spindle protein (KSP or KIF11 or Eg5), that induces mitosis-phase (M-phase) arrest followed by apoptosis in either the M-phase (via mitotic catastrophe) or G1-phase of the cell-cycle. Ispinesib alters the ability of KSP to bind to microtubules and inhibits its movement by preventing the release of ADP without preventing the release of the KSP-ADP complex from the microtubule

Isradipine

PN200-110

[75695-93-1]
Purity: 99%

Soluble in DMSO and EtOH
C19H21N3O5 MW: 371.39



Axon 3501

mg	Price
10	online
50	online


Biological activity

Isradipine is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. It selectively inhibits the sinus node but not atrioventricular conduction and its negative inotropic action is minimal, about 20 times weaker than its negative chronotropic effect.

ISRIB

trans-ISRIB

[1597403-47-8]
Purity: 99%
Relative stereochemistry
Soluble in DMSO and DCM-MeOH
C22H24Cl2N2O4 MW: 451.34



Axon 2278

mg	Price
10	online
50	online

Biological activity

First reported, potent and selective inhibitor of the 'integrated stress response' (ISR) and a potent inhibitor of PERK signaling. ISRIB potently reverses the effects of eIF2 α phosphorylation (IC50 value of 5 nM for inhibition of ATF4-luciferase reporter). Trans-ISRIB reduces the viability of cells subjected to PERK-activation by chronic endoplasmic reticulum stress, and proved to be 100-fold more potent than cis-ISRIB, indicating that the compound's interaction with its cellular target is stereospecific.

Istradefylline

See KW 6002

Axon 1423


Page 599

ISX9

Isoxazole 9

[832115-62-5]
Purity: 98%

Soluble in DMSO and EtOH
C11H10N2O2S MW: 234.27



Axon 3948

mg	Price
10	online
50	online


Biological activity

ISX9 is an agonist of the Wnt/ β -catenin pathway by potentiating the association between LRP6 and Axin1. Moreover, ISX9 is a neurogenesis-promoting small molecule compound that can up-regulate the expression of NeuroD1 and induce differentiation of neuronal, cardiac and islet endocrine progenitors.

ITD 1

[1099644-42-4]
Purity: 98%

Soluble in DMSO
C27H29NO3 MW: 415.52



Axon 2323


mg	Price
10	online
50	online

Biological activity

Selective inhibitor of TGF β /Smad signaling (IC50 value 0.85 μ M; 83% TGF- β inhibition at 2.5 μ M) that acts by clearing the type II TGF β receptor from the cell surface. ITD 1 stimulates the differentiation of cardiomyocytes and promote cardiogenesis in murine embryonic stem cell (mESCs). TGF β inhibition by the (+)-enantiomer is approximately 15-fold more effective than by its (-)-enantiomer.

ITD-1, (+)-

[1409968-46-2]
Purity: 99%
Optically pure
Soluble in DMSO
C27H29NO3 MW: 415.52



Axon 2467

mg	Price
2	online

Biological activity

More active (+)-enantiomer of ITD 1 (Axon 2323), a selective inhibitor of TGF β /Smad signaling (IC50 values 0.46 μ M and 6.90 μ M for (+)-ITD 1 and (-)-ITD 1, respectively for TGF- β inhibition) that acts by clearing the type II TGF β receptor from the cell surface. ITD 1 stimulates the differentiation of cardiomyocytes and promote cardiogenesis in murine embryonic stem cell (mESCs). TGF β inhibition by the (+)-enantiomer is approximately 15-fold more effective than by its (-)-enantiomer.

ITF2357

See Givinostat hydrochloride

Axon 3989

Page 503

ITMN 191

See Danoprevir


Axon 1669

Page 408

IU1-47

[670270-31-2]
Purity: 99%

Soluble in DMSO
C19H23ClN2O MW: 330.85



Axon 3426

mg	Price
5	online
25	online


Biological activity

IU1-47 is a potent and selective inhibitor of the proteasomal deubiquitinating enzyme USP14 with an IC50 value of 0.6 μ M.

Ivabradine hydrochloride

(+)-S16257

[148849-67-6]
Purity: 99%
Optically pure
Soluble in water, DMSO and EtOH
C27H36N2O5.HCl MW: 505.05



Axon 3495

mg	Price
10	online
50	online

Biological activity

Ivabradine hydrochloride is a selective sinus node I(f) channel inhibitor. Ivabradine is the first specific heart rate-lowering agent that has completed clinical development for stable angina pectoris. It is selective for the I(f) current, lowering heart rate at concentrations that do not affect other cardiac ionic currents.

Ivacaftor

See VX 770


Axon 2503

Page 981

Ivachtin

[745046-84-8]
Purity: 98%

Moderately soluble in DMSO
C20H21N3O7S MW: 447.46



Biological activity

A potent caspase-3 inhibitor

Axon 1375

mg	Price
1	online
5	online

Ivosidenib

See AG-120


Axon 2746

Page 211

IWP L6

[1427782-89-5]
Purity: 99%

Soluble in DMSO
C25H20N4O2S2 MW: 472.58



Axon 2212

mg	Price
10	online
50	online

Biological activity

Highly potent porcupine inhibitor (Porcn; EC50 value 0.5 nM), a membrane-bound O-acyltransferase (MBOAT); Wnt signaling inhibitor; 60-times more potent than IWP-2. IWP-L6 effectively inhibits posterior axis formation and resected tailfin regeneration in juvenile zebrafish at low micromolar concentrations. IWP L6 specifically and reversibly blocks Wnt signaling and Wnt mediated branching morphogenesis in cultured mouse embryonic kidneys. Stable in human plasma over 24 h.

IWR-1

See IWR-1-endo

Axon 2510


Page 575

IWR-1-endo

IWR-1; endo-IWR-1

[1127442-82-3]
Purity: 99%

Soluble in DMSO
C25H19N3O3 MW: 409.44



Axon 2510

mg	Price
10	online
50	online


Biological activity

Small-molecule inhibitor of the Wnt/ β -catenin pathway (IC50 value 0.18 μ M), strongly inhibiting TNKS1 and TNKS2 in biochemical assays, and targeting the acyltransferase Porcupine (Porcn) without inducing Porcn destruction or mislocalization. IWR-1-endo significantly stabilized endogenous TNKS1, TNKS2 and axin 2 by inhibition of auto-PARsylation of TNKS in vivo and independent of the PARsylation activity of PARP1/2. Furthermore, IWR-1 increased expression of genes commonly expressed in cardiac mesoderm/progenitor cell and significantly improved cardiac differentiation when introduced after the application of BMP-4.

IXA4

[1185329-96-7]
Purity: 98%

Soluble in DMSO
C24H28N4O4 MW: 436.50



Axon 4087

mg	Price
10	online
50	online

Biological activity

IXA4 is a highly selective, non-toxic IRE1/XBP1s activating compound. IXA4 improves ER proteostasis of destabilized variants of amyloid precursor protein (APP) through an IRE1-dependent mechanism and reduce APP-associated mitochondrial toxicity in cellular models.

Ixazomib

See MLN 2238

Axon 2556

Page 673

Ixazomib citrate

See MLN 9708


Axon 2557

Page 674

J147

[1146963-51-0]
Purity: 100%

Soluble in DMSO
C18H17F3N2O2 MW: 350.33



Axon 2859

mg	Price
10	online
50	online

Biological activity

J147 is a potent and orally active neurotrophic drug that facilitates memory in normal rodents. Moreover, J147 prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model. Neuroprotectant.

J 867

See Asoprisnil


Axon 1675

Page 255

JAB-3068

[2169223-48-5]
Purity: 99%

99% e.e.
Soluble in DMSO
C22H26F2N6O2S MW: 476.54



Axon 3721

mg	Price
5	online
10	online

Biological activity


JAB-3068 is a potent, selective and orally bioavailable allosteric inhibitor of SHP2 (protein tyrosine phosphatase) (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. It is efficacious as an oral monotherapy as well as an immune-oncology modulator.
Source Information: Sold in collaboration with Chemietek

JAK2 inhibitor 13

Sulfonamide 13

[1110502-30-1]
Purity: 99%

Soluble in DMSO
C17H20N4O2S MW: 344.43



Axon 1843

mg	Price
5	online
25	online


Biological activity

Potent and selective Janus Kinase 2 (JAK2) inhibitor; inhibits the activity of both the wild-type JAK2 and the V617F mutant (IC50 = 78 and 206 nM, respectively), with >35-fold selectivity versus JAK3 (IC50 = 2.93 μ M)

JC2-11

[937820-89-8]
Purity: 98%

Soluble in DMSO and EtOH
C17H15FO4 MW: 302.30



Axon 3839

mg	Price
10	online
50	online


Biological activity

JC2-11 is an inhibitor of the NLRP3/NLRC4/AIM2 inflammasomes. JC2-11 inhibited the priming step and attenuated NLRP3, NLRC4, AIM2, and NC inflammasome activation by inhibiting ROS production and caspase-1 activity.

JG-2016

[2887480-87-5]
Purity: 99%

Soluble in DMSO and EtOH
C18H21ClN4O3 MW: 376.84




Biological activity

JG-2016 is the first inhibitor of the HAT1 enzyme complex with an IC50 value of 14.8 μM. JG-2016 showed relative specificity toward HAT1 compared to other acetyltransferases, suppressed the growth of human cancer cell lines, impaired enzymatic activity in cellulose, and interfered with tumor growth.

JH-RE-06

[1361227-90-8]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C20H16Cl3N3O4 MW: 468.72




Biological activity

JH-RE-06 is a compound disrupting REV1-POL ζ-mediated mutagenic translesion synthesis (TLS). Binding of JH-RE-06 induces REV1 dimerization, which blocks the REV1-REV7 interaction (IC50 value of 0.78 μM) and POL ζ recruitment. JH-RE-06 sensitizes tumors to cisplatin and reduces mutagenesis in vitro. Moreover, JH-RE-06 suppresses tumor progression in mice and prolongs animal survival.

JHU37152

[2369979-67-7]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C19H20ClFN4 MW: 358.84




Biological activity

JHU37152 is a potent, selective and brain-penetrant DREADD agonist with Ki values of 1.8 nM and 8.7 nM for hM3Dq and hM4Di, respectively.

JHU37160

[2369979-68-8]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C19H20ClFN4 MW: 358.84



Biological activity

Axon 3959

mg	Price
5	online
25	online

Axon 3002

mg	Price
5	online
25	online

Axon 3280

mg	Price
5	online
25	online

Axon 3281

mg	Price
5	online
25	online


JHU37160 is a potent DREADD agonist with hM3Dq and hM4Di Ki values of 1.9 nM and 3.6 nM, respectively; and with hM3Dq and hM4Di EC50 values of 18.5 nM and 0.2 nM, respectively. JHU37160 is a first DREADD agonist with high in vivo potency for CNS applications.

JIB 04

NSC 693627

[199596-05-9]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C17H13ClN4 MW: 308.76




Biological activity

Potent, cell permeable and selective Jumonji histone demethylase inhibitor in vitro and in vivo; JIB-04 is not a competitive inhibitor of α-ketoglutarate and it modulates transcription in cancer-selective manner

JK184

[315703-52-7]
Purity: 100%

Soluble in DMSO and Ethanol
C19H18N4OS MW: 350.44



Biological activity

Antagonist of Hedgehog (Hh) signaling (IC50 value of 30 nM for inhibition of Gli-dependent transcriptional activity) and a potent inhibitor of microtubule assembly that exhibits good antiproliferative activity both in vitro and in vivo. JK184 appears to act by inhibition of Adh7 (Kd value 210 nM in a assay for enzymatic oxidation of retinol).


JM 3100

See AMD 3100

JMJD6 inhibitor WL12

[899548-78-8]
Purity: 99%

Soluble in DMSO
C16H11N3O2 MW: 277.28



Biological activity

JMJD6 inhibitor WL12 is a first-in-class JMJD6 inhibitor with an IC50 value of 0.22 μM. JMJD6 inhibitor WL12 was shown to be able to suppress JMJD6-dependent cancer cell proliferation including cervical and liver cancer cells. Specifically, the IC50 values for JMJD6 inhibitor WL12 in HeLa and SMCC7721 cells were 2.44 and 10.18 μM, respectively.

JNJ 212082

See Abiraterone acetate

JNJ53718678

See Rilematovir

Axon 2160

mg	Price
10	online
50	online

Axon 2654

mg	Price
10	online
50	online

Axon 1738

Page 223

Axon 3180

mg	Price
5	online
25	online

Axon 1874

Page 199


Axon 4183

Page 818

JNJ-64619178 dihydrochloride

Onametostat dihydrochloride

[N.A.]
Purity: 99%
99% d.e.
Soluble in water and DMSO
C22H23BrN6O2.2HCl MW: 556.28



Axon 3754

mg	Price
2	online
5	online


Biological activity

JNJ-64619178 is a SAM-pocket binding (SAM Competitive) PRMT5 inhibitor with high selectivity and potency (PRMT5-MEP-50 IC50=0.14 nM) under different in vitro and cellular conditions. Demonstrates tumor regression in a biomarker-driven human small cell lung cancer xenograft model (NCI-H1048) and prolongs tumor growth inhibition after dosing cessation.

Source Information: Sold in collaboration with Chemietek

JNJ 777120

[459168-41-3]
Purity: 99%



Soluble in DMSO and Ethanol
C14H16ClN3O MW: 277.75

Axon 1306


mg	Price
10	online
50	online

Biological activity

First potent and selective non-imidazole histamine H4 antagonist

JNJ 10191584

[73903-17-0]
Purity: 99%



Soluble in DMSO
C13H15ClN4O MW: 278.74

Axon 1307

mg	Price
10	online
50	online


Biological activity

Selective silent histamine H4 receptor antagonist, orally active

JNJ 26481585 dihydrochloride

Quisinostat dihydrochloride

[875320-31-3]
Purity: 99%



Soluble in DMSO
C21H26N6O2.2HCl MW: 467.39

Axon 2529

mg	Price
5	online
25	online

Biological activity


Potent, orally available second-generation pan-HDAC inhibitor (highest IC50 value 0.11 nM for HDAC1, and sub-nanomolar for HDAC2, HDAC4, HDAC10, and HDAC11 in vitro) with activity in human leukemia. JNJ-26481585 induces continuous acetylation of histone H3, activation of the caspase cascade, and upregulation of p21, resulting in apoptosis and cell cycle arrest in the myeloma cells at low nanomolar concentrations. JNJ-26481585 also potently induced tubulin acetylation.

JNJ 26854165

Serdemetan

[881202-45-5]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C21H20N4 MW: 328.41



Axon 1538

mg	Price
5	online
25	online


Biological activity

Oral HDM2 inhibitor (or antagonist), which showed potent activity against multiple myeloma (MM) cells in vitro and ex vivo; potential agent to restore p53 function and to potentially impact other HDM2 dependent pathways

JNJ 26854165 dihydrochloride

[881202-16-0]
Purity: 99%

Soluble in water and DMSO
C21H20N4.2HCl MW: 401.33



Axon 1586

mg	Price
5	online
25	online

Biological activity

Oral HDM2 inhibitor (or antagonist), which showed potent activity against multiple myeloma (MM) cells in vitro and ex vivo; potential agent to restore p53 function and to potentially impact other HDM2 dependent pathways
Note: JNJ26854165 dihydrochloride is a directly water-soluble form of JNJ 26854165 (Axon 1538)

JNJ-28431754

See Canagliflozin

Axon 3122

Page 341

JNJ 28630368

See APD 668

Axon 2380

Page 240

JNJ31001074

See Bavisant **Recent Addition**


Axon 4233

Page 285

JNJ 37822681 dihydrochloride

[935776-74-2]
Purity: 98%

Soluble in water and DMSO
C17H17F5N4.2HCl MW: 445.26



Axon 1802

mg	Price
10	online
50	online

Biological activity

Potent and selective dopamine D2 receptor antagonist; centrally acting and fast-dissociating ligand; potentially an antipsychotic agent

JNJ 38431055

See APD 597


Axon 2541

Page 240

JNJ 4796567

[1428327-31-4]
Purity: 99%

Soluble in DMSO
C28H32N4O2S MW: 488.64


Axon 2890

mg	Price
10	online
50	online

Biological activity

Highly potent and brain penetrant P2X7 antagonist in human, rat, and mouse cell lines (pKi values of 7.9, 7.9 and 6.9 for human, rat, and human whole blood P2X7). Probe compound for the preclinical assessment of P2X7 blockade in animal models of neuro-inflammation. DMPK properties suitable for preclinical pharmacodynamics studies.

JNJ54781532

See Peficitinib


Axon 3950

Page 757

JNJ 5551118

[2036081-86-2]
Purity: 98%

Soluble in DMSO
C14H8ClF3N2O2 MW: 328.67


Axon 2793

mg	Price
10	online
50	online


Biological activity

Potent negative modulator of AMPA receptor containing TARP-γ8 (Ki value of 26 nM). JNJ 5551118 exhibits excellent pharmacokinetic properties and achieved high receptor occupancy following oral administration. Tool for reversible AMPA receptor inhibition, particularly within the hippocampus, with potential therapeutic utility as an anticonvulsant or neuroprotectant.

JNJ 63533054

[1802326-66-4]
Purity: 99%

Optically pure
Soluble in DMSO
C17H17ClN2O2 MW: 316.78


Axon 2569

mg	Price
10	online
50	online

Biological activity

Potent, brain-penetrant, orally active, and selective agonist of hGPR139 (EC50 value 16 nM; 138% of max) with no inhibitory effect on CYP450. A useful tool for exploring GPR139 pharmacology.

JNJ-65234637

See OICR-12694 Recent Addition

Axon 4269

Page 731


JNJ0966

[315705-75-0]
Purity: 99%

Soluble in DMSO
C16H16N4O2S2 MW: 360.45

Axon 3030

mg	Price
5	online
25	online



Biological activity

JNJ0966 is a highly selective compound that inhibited activation of MMP-9 zymogen and subsequent generation of catalytically active enzyme (IC50 value of 440 nM). JNJ0966 had no effect on MMP-1, MMP-2, MMP-3, MMP-9, or MMP-14 catalytic activity and did not inhibit activation of the highly related MMP-2 zymogen.

JNK-IN-8

[1410880-22-6]
Purity: 98%

Soluble in DMSO
C29H29N7O2 MW: 507.59


Axon 2361

mg	Price
5	online
25	online

Biological activity

Remarkably potent and selective covalent inhibitor of JNK (IC50 values 4.67 nM, 18.7 nM, and 0.98nM for JNK1/2/3, respectively). JNK-IN-8 inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue (EC50 values 486 nM and 338 nM for inhibition of c-Jun phosphorylation in HeLa and A375 cells, respectively). Useful as a pharmacological probe of JNK-dependent signal transduction

JNK inhibitor compound 60

See JNK inhibitor VIII


Axon 2949

Page 582

JNK inhibitor VIII

[894804-07-0]
Purity: 99%

Soluble in DMSO
C18H20N4O4 MW: 356.38


Axon 2949

mg	Price
5	online
25	online

Biological activity

JNK inhibitor VIII is a selective, ATP-competitive, and cell-permeable JNK inhibitor with Ki values of 2 nM, 4 nM, and 52 nM for JNK1, JNK2, JNK3, respectively.

JO 1196

See Fedotozine tartrate

Axon 1140

Page 477

JQ1

See JQ-1, (+)-

Axon 1989

Page 582

JQ-1, (+)-

JQ1


[1268524-70-4]
Purity: 99%

99% ee
Soluble in DMSO

Axon 1989

mg	Price
2	online
5	online


C23H25ClN4O2S MW: 456.99



Biological activity
Potent and selective BET bromodomain inhibitor

JQ1 carboxylic acid, (+)-


[202592-23-2]
Purity: 99%
Optically pure
Soluble 0.1N NaOH(aq), DMSO and EtOH
C19H17ClN4O2S MW: 400.88



Biological activity
(+)-JQ1 carboxylic acid is a derivative of (+)-JQ1 (Axon 1989), which is a potent and selective BET bromodomain inhibitor. (+)-JQ1 carboxylic acid can be used as a precursor to synthesize PROTACs, which target BET bromodomains.

JQ-1, (-)-


[1268524-71-5]
Purity: 98%
99% e.e.
Soluble in DMSO and EtOH
C23H25ClN4O2S MW: 456.99



Biological activity
Inactive enantiomer of (+)-JQ1 (Axon 1989) which is a potent and selective BET bromodomain inhibitor.

JQKD82 dihydrochloride


[2863635-05-4]
Purity: 99%
Soluble in water, DMSO and EtOH
C27H40N4O5.2HCl MW: 573.55



Biological activity
JQKD82 dihydrochloride is a cell-permeable and selective KDM5 inhibitor which increases histone H3K4me3 but paradoxically inhibits downstream MYC-driven transcriptional output in vitro and in vivo. JQKD82 is a prodrug-type KDM5 inhibitor which delivers the active binding molecule KDM5-C49 to potently block KDM5 function in multiple myeloma cells both in vitro and in vivo (IC50 value of 0.42 μM in MM.1S cells).

JSH 23

[749886-87-1]
Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO
C16H20N2 MW: 240.34



Axon 3822

mg	Price
10	online
50	online

Axon 3873

mg	Price
5	online
25	online

Axon 3783

mg	Price
5	online

Axon 2349


mg	Price
10	online
50	online

Biological activity

Inhibitor of NF-κB transcription and nuclear translocation of p65 (IC50 value 7.1 μM for inhibition of LPS-induced NF-κB transcriptional activity) without affecting IκBα degradation, which is a very rare mode of action. JSH 23 inhibited not only LPS-induced expressions of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and inducible nitric oxide synthase and cyclooxygenase-2 but also LPS-induced apoptosis of the RAW 264.7 cells. JSF 23 also inhibits NO production in LPS-stimulated macrophages RAW 264.7 (IC50 value 14.4 μM).

JTC 801


[244218-51-7]
Purity: 98%
Soluble in DMSO
C26H25N3O2.HCl MW: 447.96



Biological activity
Potent and selective NOP receptor antagonist (Ki: 8.2 nM)

JT010


[917562-33-5]
Purity: 98%
Soluble in DMSO and EtOH
C16H19ClN2O3S MW: 354.85



Biological activity
JT010 is a potent and selective agonist of TRPA1 with an EC50 value of 0.65 nM.

JTE 013

[383150-41-2]
Purity: 99%
Soluble in DMSO
C17H19Cl2N7O MW: 408.29



Biological activity
Potent and selective sphingosine-1-phosphate (S1P) receptor 2 (S1P2) antagonist (IC50: 17.6 nM). Deleted CAS number [547756-93-4]

JTP 74057

See GSK 1120212

JTP 0819958

HOIPIN-1
[N.A.]
Purity: 99%
Soluble in water and DMSO
C17H13NaO4 MW: 304.27

Axon 1805

mg	Price
5	online
25	online

Axon 3726

mg	Price
5	online
25	online

Axon 1866


mg	Price
10	online
50	online

Axon 1761

Page 527

Axon 2939

mg	Price
10	online
50	online




Biological activity

JTP-0819958 is a selective linear ubiquitin chain assembly complex (LUBAC) inhibitor. JTP-0819958 exhibited IC₅₀ values of 4.4, 3.5 and 3.7 μM for inhibition of linear polyubiquitination activity by the HOIL-1L/HOIP complex, the HOIL-1L/HOIP/SHARPIN complex and the HOIP/SHARPIN complex, respectively. The prodrug JTP 1048196 is also available as Axon 2947.

JTP 1048196

[55377-56-5]
Purity: 99%

Soluble in DMSO
C17H14O4 MW: 282.29



Axon 2947

mg	Price
10	online
50	online

Biological activity

JTP 1048196 is a selective linear ubiquitin chain assembly complex (LUBAC) inhibitor with an IC₅₀ value of 16.1 μM for inhibition of linear polyubiquitination activity by the HOIL-1L/HOIP complex. The lactone structure of JTP 1048196 was transformed to the reactive α,β-unsaturated carbonyl moiety JTP 0819958 (Axon 2939) which reacts with the cysteine residue of LUBAC, leading to its covalent inhibition in vitro and cellular levels.

JTT 705

See Dalcetrapib


Axon 1962

Page 408

JW 55

[664993-53-7]
Purity: 99%

Soluble in DMSO
C25H26N2O5 MW: 434.48



Axon 1922

mg	Price
10	online
50	online


Biological activity

A tankyrase (TNKS) inhibitor, inhibiting PARP domain of TNKS1 and TNKS2; JW55 inhibits canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice

JWH 018

[209414-07-3]
Purity: 99%

Soluble in DMSO and Ethanol
C24H23NO MW: 341.45



Axon 1498

mg	Price
5	online
25	online


Biological activity

An analgesic chemical acts as a cannabinoid agonist at both the CB1 and CB2 receptors, with affinity at CB2 subtype approximately 3x the affinity at CB1 (K_i values are 2.94 and 9.0 nM for CB2 and CB1 receptors respectively)

JWH 073

[208987-48-8]
Purity: 98%

Soluble in DMSO
C23H21NO MW: 327.42



Axon 1497

mg	Price
5	online
25	online


Biological activity

An analgesic chemical acts as a cannabinoid agonist at both the CB1 and CB2 receptors, with affinity at CB2 subtype approximately 5x the affinity at CB1

JWH 133

[259869-55-1]
Purity: 99%

Soluble in DMSO and Ethanol
C22H32O MW: 312.49



Axon 1418

mg	Price
5	online
25	online


Biological activity

Potent selective CB2 agonist

JWH 250

[864445-43-2]
Purity: 99%

Soluble in DMSO and Ethanol
C22H25NO2 MW: 335.44



Axon 1522

mg	Price
10	online
50	online


Biological activity

An analgesic agent, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors, with a K_i of 11 nM at CB1 and 33 nM at CB2

JZP 361

[1680193-80-9]
Purity: 99%

Soluble in DMSO
C22H20ClN5O MW: 405.88



Axon 2486

mg	Price
5	online
25	online

Biological activity


Selective reversible inhibitor of monoacylglycerol lipase (MAGL; IC₅₀ value 46 nM) with 35-fold higher selectivity over human α/β-hydrolase-6 (ABHD6) and 150-fold higher selectivity over human FAAH. The Loratidine analog JZP 361 fully retained H1 antagonistic activity as well (pA₂ value 6.81) and is devoid of cannabinoid receptor (CB) affinity.

K22

ZIKV inhibitor K22

[2141978-86-9]
Purity: 98%

Soluble in DMSO
C27H25BrN2O3 MW: 505.40



Axon 3432

mg	Price
10	online
50	online


Biological activity

K22 is an inhibitor of coronavirus replication that specifically interferes with membrane-bound coronaviral RNA synthesis (IC50 value of 0.7 μ M for HCoV-229E plaques). K22 displayed antiviral activity against a broad range of animal and human coronaviruses, including MERS-CoV.

K6PC-5

[756875-51-1]
Purity: 98%

Soluble in DMSO
C19H37NO4 MW: 343.50



Axon 2484

mg	Price
10	online
50	online

Biological activity

Sphingosine kinase 1 (SphK1 or SK1) activator that increases sphingosine-1-phosphate (S1P) production, induces Akt phosphorylation in cultured osteoblasts, and protects them from Dex-induced apoptosis and necrosis. K6PC-5 acts to regulate both differentiation and proliferation of keratinocytes via [Ca²⁺]_i responses through S1P production, which may represent a novel approach for treatment of skin disorders characterized by abnormal differentiation and proliferation. Furthermore, a useful tool in animal or clinical studies for its antilucocorticoids-associated osteonecrosis potential.

K 22.175

See FK 866

Axon 1279

Page 482

K 22.175 hydrochloride

See FK 866 hydrochloride


Axon 1546

Page 483

K 145 hydrochloride

[1449240-68-9]
Purity: 99%

Soluble in water and DMSO
C18H24N2O3S.HCl MW: 384.92



Axon 2235

mg	Price
10	online
50	online

Biological activity

Selective, substrate competitive Sphingosine Kinase-2 inhibitor (SphK2; IC50 value 4.30 μ M) and anticancer agent. K145 suppressed the S1P level, and significantly inhibited the growth of U937 tumors in nude mice by both intraperitoneal and oral administration. K145 significantly inhibited the phosphorylation of FTY720, ERK and Akt upon treatment of U937 cells, but does not interfere with CERK and/or ceramide synthase.


K 02288

[1431985-92-0]
Purity: 99%

Axon 2189

mg	Price
5	online

Soluble in 0.1N HCl(aq) and DMSO
C20H20N2O4 MW: 352.38



25 online


Biological activity

Potent and highly selective inhibitor of BMP signaling, with low nanomolar IC50 values of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6 respectively and IC50s of 34.4, 302, 321 and 220 nM for other ALKs (3, 4, 5) and ActRIIA respectively. K02288 specifically inhibited the BMP-induced Smad pathway without affecting TGF- β signaling and induced dorsalization of zebrafish embryos. K02288 provides a useful tool to investigate BMP signaling and to research into stem cell biology and disease models of anemia, musculoskeletal dysplasia and cancer.

K+ Channel inhibitor 1734

[343240-54-0]

Purity: 97%
racemate
Soluble in DMSO and Ethanol
C15H13Cl2N3O2 MW: 338.19



Axon 1734

mg	Price
10	online
50	online


Biological activity

Building block for synthesis of dihydropyrazolopyrimidine inhibitors of Kv1.5 (Ikur). The ethylester analog of inhibitor 1734 is a modest inhibitor itself (IC50 value 1.1 μ M for human Kv1.5), but exhibiting encouraging KV1.5 versus L-type calcium channel selectivity.

KA2507 Recent Addition

[1636894-46-6]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C16H14N6O2 MW: .00



Axon 3529

mg	Price
5	online
25	online

Biological activity

KA2507 is a highly potent, selective and orally available inhibitor of HDAC6 with an IC50 value of 2.5 nM. KA2507 showed antitumor efficacy and immune modulatory effects in preclinical models.

Kalydeco

See VX 770

Axon 2503


Page 981

Kartogenin

KGN

[4727-31-5]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C20H15NO3 MW: 317.34



Axon 2378

mg	Price
10	online
50	online

Biological activity

Small molecule promoting robust chondrocyte differentiation from primary human mesenchymal stem cells (MSCs; EC50 value 100 nM). Kartogenin (KGN) treatment of bone marrow stromal cells (BMSCs) induced the expression of both Col. II and aggrecan in a dose-dependent manner, and upregulates Sox-9 gene expression. KGN does not alter either MMP-3, MMP-13, or aggrecanase expression in primary chondrocytes and MSCs. KGN

may be used to enhance tendon/bone interface healing through the direct, local delivery of KGN injections into the gap between the tendon graft and the bone surface during ACL reconstruction.

Katadolon


See Flupirtine maleate

Axon 1437

Page 486

KB-0742 dihydrochloride

[2416874-75-2]
Purity: 99%
99% e.e.
Soluble in water
C16H25N5.2HCl MW: 360.33



Axon 3730

mg	Price
5	online
10	online


Biological activity

KB-0742 is an orally bioavailable, potent and selective CDK9 inhibitor with an IC50 of 6 nM, highly selective against other CDKs (>60 fold). Demonstrates *in vitro* and *in vivo* anti-tumor activity.

Source Information: Sold in collaboration with Chemietek

KCa modulator RA-2

[1867107-62-7]
Purity: 98%
Soluble in 0.1N NaOH(aq), DMSO and EtOH
C22H16F2O6 MW: 414.36



Axon 3516

mg	Price
10	online
50	online

Biological activity


RA-2 is a potent and selective KCa2/3 pan inhibitor with negative-gating modulator properties (IC50 values of 17 and 2 nM for KCa3.1 and KCa2.3, respectively). RA-2 inhibited EDH-type dilations in porcine coronary arteries (PCAs) and was found not to increase blood pressure in telemetry recordings despite reducing heart rate (HR).

KD025

SLx-2119

[911417-87-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C26H24N6O2 MW: 452.51



Axon 2780

mg	Price
5	online
25	Online

Biological activity

KD025 is a selective, ATP-competitive inhibitor of human ROCK2 (IC50 value of 105 nM) with minimal effects on human ROCK1 (IC50 value of 24 μM).


KDM5 inhibitor compound 48

[1628210-26-3]
Purity: 99%

Soluble in DMSO
C17H20N6O MW: 324.38

Axon 2809

mg	Price
5	online
25	online




Biological activity

Potent, selective and orally bioavailable KDM5 inhibitor (IC50 value of 15.1 nM for KDM5A) with improved cell potency (EC50 value of 0.34 μM, H3K4Me3 level in PC9 cells). Chemical probe suitable for studying KDM5 biological functions *in vivo*.

KDU691

[1513879-19-0]
Purity: 99%

Soluble in DMSO
C22H18ClN5O2 MW: 419.86



Axon 2845

mg	Price
5	online
25	online

Biological activity

KDU691 is a plasmodium PI4K inhibitor (IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizonts, respectively) which selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Moreover, KDU691 was fully protective when administered *in vivo* as causal prophylactic and radical-cure agents for Plasmodium cynomolgi sporozoite-infected rhesus macaques.

KDS4103

See URB597 **Recent Addition**


Axon 4222

Page 956

KEA1-97

[2138882-71-8]
Purity: 99%

Soluble in DMSO
C15H9Cl2FN4 MW: 335.16



Axon 3744

mg	Price
10	online
50	online

Biological activity

KEA1-97 is a disruptor of the interaction of thioredoxin (TXN) with caspase 3 (IC50 value of 10 μM). KEA1-97 activates caspases, induces apoptosis without affecting TXN activity, and impairs *in vivo* breast tumor xenograft growth.

Keppra

See Levetiracetam

Axon 1110


Page 611

Ketanserin

R 41468

[74050-98-9]
Purity: 99%

Soluble in water and DMSO
C22H22FN3O3 MW: 395.43



Axon 1450

mg	Price
10	online
50	online

Biological activity

5-HT_{2A} receptor antagonist; an antihypertensive; with tritium (³H) radioactively labeled ketanserin is used as a radioligand for the serotonin 5-HT_{2A} receptor, e.g. in receptor binding assays and autoradiography


KG N

See Kartogenin

KHS101 hydrochloride

[1784282-12-7]
Purity: 99%

Soluble in water and DMSO
C₁₈H₂₁N₅.HCl MW: 375.92



Biological activity


KHS101 hydrochloride is a brain-penetrable TACC3 inhibitor known to enhance neuronal differentiation (EC₅₀ value of 1 μM in cultured rat NPCs) and inhibit cell cycle progression and proliferation. KHS101 hydrochloride works indirectly on HIF complex formation by destabilizing both TACC3 and the HIF component HIF-1α. KHS101 hydrochloride suppresses proliferation, migration, and invasive capabilities of breast cancer cells, EMT process, and mammosphere forming capability, alters cell cycle progression, and induces apoptosis.

Kifunensine, (+)-

FR 900494

[109944-15-2]
Purity: 99%

Soluble in water and DMSO
C₈H₁₂N₂O₆ MW: 232.19




Biological activity

A potent class I α-mannosidase inhibitor that inhibits the glycoprotein biosynthesis; inhibits both human endoplasmic reticulum α-mannosidase I and Golgi class I mannosidase with K_i value of 130 and 23 nM respectively

KIN1148

[1428729-56-9]
Purity: 99%

Soluble in DMSO
C₁₉H₁₁N₃O₅ MW: 361.44




Biological activity

KIN1148 is an interferon regulatory factor 3 (IRF3) agonist and induced dose-dependent IRF3 nuclear translocation and specific activation of IRF3-responsive promoters. Influenza vaccine adjuvant.

KIN1400

[446826-86-4]
Purity: 99%

Soluble in DMSO and EtOH
C₂₄H₁₇F₂N₃O₂S MW: 449.47



Axon 2378

Page 588

Axon 2901

mg	Price
5	online
25	online

Axon 1730

mg	Price
2	online

Axon 4063

mg	Price
10	online
50	online

Axon 4061

mg	Price
5	online
25	online


Biological activity

KIN1400 is an innate immune agonist of IRF3 activation to mediate broad-spectrum antiviral activity. KIN1400 is a RLR pathway agonist.

KIN1408 Recent Addition

[1903800-11-2]
Purity: 98%

Soluble in DMSO
C₂₅H₁₉F₂N₃O₃S MW: 479.50



Biological activity

KIN1408 is an innate immune agonist of IRF3 activation to mediate broad-spectrum antiviral activity. KIN1408 is a RLR pathway agonist. KIN1408 exhibited better solubility and medicinal chemistry properties than KIN1400 (Axon 4061).


KIN-193

See AZD 6482

KKL-10

[952849-76-2]
Purity: 99%

Soluble in DMSO
C₁₄H₁₀BrN₃O₂S MW: 364.22




Biological activity

KKL-10 is a ribosome rescue (trans-translation) inhibitor which exhibited exceptional antimicrobial activity against both attenuated (MIC value of 0.12 μg/ml) and fully virulent strains of Francisella tularensis (MIC value of 0.48 μg/ml) in vitro and during ex vivo infection.

KKL-35

[865285-29-6]
Purity: 99%

Soluble in DMSO
C₁₅H₉ClF₃N₃O₂ MW: 317.70



Biological activity

KKL-35 is ribosome rescue (trans-translation) inhibitor with an IC₅₀ value of 0.9 μM. KKL-35 exhibits broad-spectrum antibiotic activity.

KL001

Axon 4062

mg	Price
10	online
50	online

Axon 2926

Page 275

Axon 2802

mg	Price
5	online
25	online

Axon 2997


mg	Price
10	online
50	online

Axon 3441

mg	Price
----	-------

[309928-48-1]
Purity: 99%

Soluble in DMSO
C21H22N2O4S MW: 398.48



10	online
50	online

Biological activity

KL001 is a stabilizer of cryptochrome (CRY). KL001 prevented ubiquitin-dependent degradation of CRY, resulting in lengthening of the circadian period.

KMD-3213

See Silodosin


Axon 3112

Page 866

KN 93

[1188890-40-5]
Purity: 99%

Soluble in DMSO
C26H29ClN2O4S MW: 501.04



Axon 2566

mg	Price
5	online
25	online


Biological activity

Inhibitor of multifunctional Ca²⁺/Calmodulin-dependent protein kinase (CaMKII; Ki value 0.37 μM for inhibition of CaMKII phosphorylating activity). In addition, KN93 also affects CaV1.3 and CaV1.2 calcium channels in a CaMKII-independent manner. The water soluble phosphate salt of KN 93 (Axon 2555) is available as well.

KN 93 phosphate

[1188890-41-6]
Purity: 99%

Soluble in water and DMSO
C26H29ClN2O4S.H3PO4 MW: 599.03



Axon 2555

mg	Price
5	online
25	online

Biological activity

Inhibitor of multifunctional Ca²⁺/Calmodulin-dependent protein kinase (CaMKII; Ki value 0.37 μM for inhibition of CaMKII phosphorylating activity). In addition, KN93 also affects CaV1.3 and CaV1.2 calcium channels in a CaMKII-independent manner. The parent molecule KN 93 (Axon 2566) is available as well.

Ko1173

See Mexiletine hydrochloride


Axon 3454

Page 651

KO 143

[461054-93-3]
Purity: 99%

Soluble in DMSO and Ethanol
C26H35N3O5 MW: 469.57



Axon 1409

mg	Price
2	online
5	online


Biological activity

Potent and selective inhibitor of breast cancer resistance protein (BCRP) multidrug transporter

Kobe 0065

[436133-68-5]
Purity: 99%

Soluble in DMSO
C15H11ClF3N5O4S MW: 449.79



Axon 2302

mg	Price
10	online
50	online


Biological activity

Orally active RAS inhibitor with selectivity for HRAS (Ki value of 46 ± 13 μM) that effectively inhibits both anchorage-dependent and -independent growth and induces apoptosis of H-rasG12V-transformed NIH 3T3 cells. This results in down-regulation of downstream molecules such as MEK/ERK, Akt, and RafA as well as an upstream molecule, Son of sevenless. Kobe 0065 exhibits antitumor activity on a xenograft of human colon carcinoma SW480 cells carrying the K-rasG12V gene by oral administration.

KOTX1

[1788963-83-6]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C17H16FN3O2 MW: 313.33



Axon 3915

mg	Price
5	online
25	online

Biological activity

KOTX1 is a selective, non-cytotoxic and reversible ALDH1A3 inhibitor with a cellular IC50 value of 5.1 nM. KOTX1 improved glucose control, increased insulin secretion, and enhanced glucose tolerance.

KP103

See Efinaconazole

Axon 3369

Page 452

KP363

See Butenafine hydrochloride

Axon 3380


Page 333

KPT-330

Selinexor

[1393477-72-9]
Purity: 99%

Soluble in DMSO
C17H11F6N7O MW: 443.31



Axon 2336

mg	Price
5	online
25	online

Biological activity

KPT-330 is a potent, selective and orally available exportin-1 (XPO-1) inhibitor. First-in-class selective inhibitor of nuclear export (SINE).

KPT 335


Verdinexor

[1392136-43-4]
Purity: 99%

Soluble in DMSO
C18H12F6N6O MW: 442.32

Axon 2597

mg	Price
5	online
25	online




Biological activity

Orally bioavailable selective inhibitor of nuclear export (SINE; Exportin-1 or XPO1 inhibitor; IC50 values 2.1 nM, 41.8 nM, and 8.5 nM, for inhibition of the viability of OCI-Ly3, OCI-Ly10, and CLBL1, respectively). Verdinexor (KPT 335) potently and selectively inhibits vRNP export and effectively inhibits the replication of various influenza virus A and B strains in vitro and in vivo. KPT 335 induced apoptosis in CLBL1 cells and primary canine DLBCL cells indicating

KPT-9274

[1643913-93-2]
Purity: 98%

Soluble in DMSO and EtOH
C35H29F3N4O3 MW: 610.62



Axon 3557

mg	Price
5	online
25	online


Biological activity

KPT-9274 is an orally bioavailable dual PAK4/NAMPT inhibitor with an IC50 value of 120 nM for NAMPT in a cell-free enzymatic assay. Interference with the PAK4 and NAD biosynthetic pathways results in reduction of G2/M transit as well as induction of apoptosis and decrease in cell invasion and migration in several human RCC cell lines.

KRCA 0008

[1472795-20-2]
Purity: 100%

Soluble in DMSO
C30H37ClN8O4 MW: 609.12



Axon 2294

mg	Price
5	online
25	online


Biological activity

Potent and selective dual ALK (anaplastic lymphoma kinase) and ACK1 inhibitor (IC50 values 12 nM and 4 nM for ALK and Ack1, respectively) with good drug-like properties: good water-solubility with moderate plasma protein binding and low brain exposure. It has good liver microsomal stability and little to no CYP inhibition. KRCA0008 also shows promising pharmacokinetic parameters in both mice and rat (oral bioavailability = 66-94.5%) and a modest tumor growth inhibition in vivo activity in H3122 human lung cancer bearing mice model comparable to Crizotinib (Axon 1660) without significant body weight change.

KRIBB11

[342639-96-7]
Purity: 99%

Soluble in DMSO
C13H12N6O2 MW: 284.27



Axon 2538

mg	Price
10	online
50	online

Biological activity

HSF1 inhibitor (IC50 value 1.2 μM for inhibition of heat shock-induced luciferase activity). KRIBB11 blocks the induction of HSF1 downstream target proteins such as HSP27 and HSP70, and induces growth arrest and apoptosis in HCT-116 cells. KRIBB11 inhibits HSF1-dependent recruitment of positive transcription elongation factor b (p-TEFb) to the hsp70 promoter, and tumor growth is inhibited without body weight loss upon intraperitoneal treatment of nude mice with KRIBB11. KRIBB11 enhances the cytotoxicity of nocodazole and parabendazole.

KRN 951

See Tivozanib


Axon 1717

Page 929

KRP 203

[509088-69-1]
Purity: 98%

Soluble in DMSO
C24H26ClNO3S.HCl MW: 480.45



Biological activity

Selective sphingosine-1-phosphate (S1P) receptor 1 agonist; immunosuppressant

Axon 1615


mg	Price
5	online
25	online

KRP 297

MK 767

[213252-19-8]
Purity: 98%

Soluble in DMSO
C20H17F3N2O4S MW: 438.42



Biological activity

Peroxisome proliferator-activated receptor (PPAR) alpha and gamma (PPARα and PPARγ) agonist

Axon 1567

mg	Price
5	online
25	online

KRX 0401

See Perifosine


Axon 1663

Page 759

KSQ-2479

[2446480-97-1]
Purity: 99%

Soluble in DMSO
C27H25F3N8O MW: 534.54



Biological activity

KSQ-4279 is an allosteric, first-in-class USP1 (Ubiquitin Specific Protease 1) inhibitor.
Source Information: Sold in collaboration with Chemietek


Axon 3770

mg	Price
5	online
10	online

KS 176

[1253452-78-6]
Purity: 98%

Soluble in DMSO
C22H19N3O5 MW: 405.40



Biological activity

Inhibitor of the ABC-transporter Breast Cancer Resistance Protein (BCRP or ABCG2; IC50 value of 1.39 μ M). KS 176 is ca 50-fold more potent than Novobiocin (IC50 value 65 μ M), and nearly equipotent compared to KO 143 (Axon 1409), and does not show inhibition of P-gp and MRP1.


Axon 2508

mg	Price
10	online
50	online

KU-0058948

[763111-49-5]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C21H21FN4O2 MW: 380.42



Biological activity

Potent and specific PARP inhibitor (IC50: 3.4 nM for PARP1); KU-0058948 activates transfected extracellular signal-regulated kinase 8 (ERK8) in cells and induces cell cycle arrest and apoptosis of primary myeloid leukemic cells and myeloid leukemic cell lines in vitro. The hydrochloride salt form, KU-0058948 hydrochloride (Axon 2001) is also available.

Axon 4179

mg	Price
10	online
50	online

KU 47788

See NU 7441


Axon 1463

Page 719

KU 55933

[587871-26-9]
Purity: 99%

Soluble in DMSO
C21H17NO3S2 MW: 395.49



Biological activity

Potent, ATP-competitive and selective ATM inhibitor (Ki = 2.2 nM, IC50 = 13 nM)

Axon 1367

mg	Price
10	online
50	online

KU 63794

See KU 0063794

Axon 1472

Page 598

KU 0058948 hydrochloride


[763111-49-5] (parent)
Purity: 99%

Soluble in water and DMSO

Axon 2001

mg	Price
10	online
50	online

C21H21FN4O2.HCl MW: 416.88



Biological activity

Potent and specific PARP inhibitor (IC50: 3.4 nM for PARP1); KU-0058948 activates transfected extracellular signal-regulated kinase 8 (ERK8) in cells and induces cell cycle arrest and apoptosis of primary myeloid leukemic cells and myeloid leukemic cell lines in vitro

KU 0059436

See AZD 2281


Axon 1464

Page 269

KU 0060648

[881375-00-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C33H34N4O4S MW: 582.71



Biological activity

Potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases.

* The water soluble 3HCl salt of KU 0060648 (Axon 1584) is available as well


Axon 2604

mg	Price
5	online
25	online

KU 0060648 trihydrochloride

[881375-00-4]
Purity: 99%

Soluble in water
C33H34N4O4S.3HCl MW: 692.10



Biological activity

Potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases

Axon 1584

mg	Price
2	online
5	online

KU 0063794


KU 63794

[938440-64-3]
Purity: 99%

Axon 1472

mg	Price
2	online

Soluble in 0.1N HCl(aq) and DMSO
C25H31N5O4 MW: 465.54



5 online


Biological activity

Potent and selective mTOR inhibitor, with IC50 values to be about 10 nM for mTORC1 and mTORC2

KUS121

[1357164-52-3]
Purity: 98%

Soluble in water and DMSO
C22H16FN4NaO3S MW: 458.44



Axon 3143

mg	Price
10	online
50	online


Biological activity

KUS121 is an ATPase inhibitor of valosin-containing protein (VCP) with an IC50 value of 330 nM; Neuroprotectant.

Kv1.3 Channel blocker 42

[N.A.]
Purity: 99%

Soluble in water
C28H35FN2O4.HCl MW: 519.05



Axon 1735

mg	Price
5	online
25	online

Biological activity

Potassium channel blocker, selective in blocking the Kv1.3 current (IC50: <50 nM); Selectivity: 25-fold over Kv1.1 and 24-fold over Kv1.5

KVA-E-23A

See PDS0330 Recent Addition

Axon 4083

Page 757

KW 3902

See Rolofylline

Axon 1603


Page 828

KW 6002

Istradefylline

[155270-99-8]
Purity: 99%

Soluble in DMSO
C20H24N4O4 MW: 384.43



Axon 1423

mg	Price
5	online
25	online

Biological activity

Very potent, selective and orally active adenosine A2A receptor antagonist in experimental models of Parkinson's disease

KW-3049

See Benidipine hydrochloride

Axon 3131

Page 298

KW4679

See Olopatadine hydrochloride


Axon 3642

Page 732

KY 02111

[1118807-13-8]
Purity: 98%

Soluble in DMSO
C18H17ClN2O3S MW: 376.86



Axon 2036

mg	Price
10	online
50	online


Biological activity

A canonical Wnt signaling pathway inhibitor that promotes differentiation of human pluripotent stem cells (hPSCs), including ESCs and iPSCs, to cardiomyocytes. KY02111 acts downstream of APC and GSK3β to inhibit WNT signaling; KY02111 and WNT inhibitors, such as XAV939 (Axon 1527), cooperatively enhance hPSC cardiomyogenesis; KY02111 and WNT modulators, CHIR99021 (Axon 1386) and/or BIO (Axon 1693) permit cytokine and xeno-free hPSC cardiomyogenesis

KY 05009

[1228280-29-2]
Purity: 99%

Soluble in DMSO
C18H16N4O2S MW: 352.41



Axon 2395

mg	Price
10	online
50	online

Biological activity


Inhibitor of Traf2- and Nck-Interacting Kinase (TNIK; Ki value 100 nM in ATP competitive assay) that attenuates TGF-β1-mediated Wnt and Smad signaling and epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma A549 cells. Additionally, KY05009 inhibits TGF-β1-induced phosphorylation of JNK1/2, FAK, Src, and paxillin.

L 002

NSC 764414

[321695-57-2]
Purity: 99%

Soluble in DMSO
C15H15NO5S MW: 321.35



Axon 2319

mg	Price
10	online
50	online


Biological activity

Inhibitor of p300 histone acetyltransferase (a.k.a KAT3B; IC50 value 1.98 μ M in vitro) that also inhibited acetylation of histones and p53, and suppresses STAT3 activation in cell-based assays. In vivo, L 002 potently suppressed tumor growth of TNBC cell line MDA-MB-468 xenografts.

L67

[325970-71-6]
Purity: 99%

Soluble in DMSO
C16H14Br2N4O4 MW: 486.11



Axon 2549

mg	Price
5	online
25	online

Biological activity

Cytotoxic inhibitor of DNA ligase I and III (IC50 values 10 μ M each) that binds to the DBD of hLigI, hence leading to inhibition of DNA binding and ligation and specifically sensitizes cancer cells to DNA damage. Breast cancer cell lines with acquired resistance to antiestrogen therapeutics are hypersensitive to a combination of L67 and PARP inhibitor ABT 888 (Axon 1593).

L 163191

See MK 677


Axon 1376

Page 660

L 454560

[346629-30-9]
Purity: 98%

Soluble in DMSO
C31H29N3O5S2 MW: 587.71



Axon 1127

mg	Price
5	online
25	online


Biological activity

Potent and selective PDE4 inhibitor

L-655,708

[130477-52-0]
Purity: 99%
100% e.e.

Soluble in DMSO
C18H19N3O4 MW: 341.36



Axon 3390

mg	Price
10	online
50	online

Biological activity


L-655,708 is a selective inverse agonist of α 5 subunit-containing γ -aminobutyric acid subtype A (GABAA- α 5) receptor with a K_i value of 0.45 nM.

L6H21

MD-2 inhibitor L6H21

[24533-47-9]
Purity: 99%

Soluble in DMSO and EtOH
C18H18O4 MW: 298.33




Biological activity

L6H21 is a specific MD-2 inhibitor and directly binds to MD-2 protein (Kd value of 33.3 μ M), blocking the formation of the LPS-TLR4/MD-2 complex.

L 838417

[286456-42-6]
Purity: 99%

Soluble in DMSO
C19H19F2N7O MW: 399.40



Biological activity

Partial agonist at non- α 1 GABAA and antagonist at GABAA- α 1 receptor

L-3-Amino-3,4-dihydro-1-hydroxycarbostyryl hydrochloride

See PF 0485989 hydrochloride

Axon 1196

mg	Price
5	online
25	online

Axon 2924

Page 768

L-743,726

See Efavirenz

Axon 3125


Page 452

L651582

Carboxyamidotriazole; CAI; NSC-609974

[99519-84-3]
Purity: 99%

Soluble in DMSO
C17H12Cl3N5O2 MW: 424.67




Biological activity

Calcium channel blocker. L651582 inhibits M5 muscarinic receptor-mediated calcium influx and release of arachidonic acid, but has little effect on inositol phosphate or cAMP generation. Antiproliferative and antimetastatic agent.

L-742001 hydrochloride Recent Addition

[174605-64-2]
Purity: 98%

Soluble in DMSO and EtOH
C23H24ClNO4.HCl MW: .00



Axon 4228

mg	Price
5	online
25	online

Biological activity

L-742001 hydrochloride is an inhibitor of influenza virus PA endonuclease. Moreover, L-742001 is a first-in-class highly selective inhibitor of cap-dependent endonuclease of influenza viruses (IC50 value of 0.43 μ M for in vitro influenza virus transcript)

LA1

See ADH-503


Axon 3048

Page 208

Lacosamide

SPM 927; Erlasamide

[175481-36-4]
Purity: 99%
>98% ee
Soluble in water and DMSO
C13H18N2O3 MW: 250.29



mg	Price
10	online
50	online

Biological activity

Lacosamide acts by enhancing slow inactivation of voltage gated sodium channels; a medication for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain

Lactoyl-Phe, N-

See Lac-Phe


Axon 3776

Page 603

Lac-Phe

N-Lactoyl-phenylalanine; N-Lactoyl-Phe

[183241-73-8]
Purity: 99%
Optically pure
Soluble in water, DMSO and EtOH
C12H15NO4 MW: 237.25



mg	Price
10	online
50	online

Biological activity

Lac-Phe is an exercise-inducible metabolite that suppresses feeding and obesity.

Lactoyl-phenylalanine, N-

See Lac-Phe


Axon 3776

Page 603

Lalistat 2

[1234569-09-5]
Purity: 99%

Soluble in DMSO
C13H20N4O2S MW: 296.39



mg	Price
10	online
50	online


Biological activity

Lalistat 2 is a potent and selective inhibitor of lysosomal acid lipase (LAL) with an IC50 value of 152 nM. Lalistat 2 did not exhibit inhibition of human pancreatic lipase or bovine milk lipoprotein lipase.

Lamotrigine

[84057-84-1]
Purity: 99%

Soluble in DMSO
C9H7Cl2N5 MW: 256.09



Axon 1353	
mg	Price
10	online
50	online


Biological activity

Glutamate antagonist and sodium channel blocker; an anticonvulsant drug

Lamivudine

3TC; (-)-BCH189

[134678-17-4]
Purity: 99%
Optically pure
Soluble in water and DMSO
C8H11N3O3S MW: 229.26



Axon 3304	
mg	Price
50	online

Biological activity

Lamivudine is a potent nucleoside reverse transcriptase inhibitor with activity against HIV and HBV.

Lanicemine dihydrochloride

See AZD6765 dihydrochloride

Axon 3335


Page 278

Lansoprazole

AG-1749

[103577-45-3]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C16H14F3N3O2S MW: 369.36



Axon 3244	
mg	Price
50	online
250	online

Biological activity


Lansoprazole is an H⁺/K⁺ ATPase inhibitor with an IC50 value of 6.3 μ M.

Lapatinib ditosylate

GW 572016

[388082-77-7]
Purity: 99%

Soluble in DMSO
C29H26ClFN4O4S.2C7H8O3S
MW: 925.46



Axon 1395	
mg	Price
10	online
50	online

Biological activity


An ATP-competitive epidermal growth factor receptor (EGFR) and HER2/neu (ErbB-2) dual tyrosine kinase inhibitor

Laquinimod

ABR 215062

[248281-84-7]
Purity: 99%

Soluble in DMSO
C19H17ClN2O3 MW: 356.80



Biological activity

A selective autoimmune suppressant investigated as an oral treatment for multiple sclerosis (MS) and other autoimmune diseases; Immunomodulator

Laropiprant

See MK 0524 sodium salt

Larotrectinib sulfate

See LOXO-101 sulfate


LAT1717

See Pinaverium bromide

LB 42708

[226929-39-1]
Purity: 99%

Soluble in DMSO
C30H27BrN4O2 MW: 555.46



Biological activity

Selective and orally available inhibitor of farnesyltransferase (FTase), with IC50 values of 0.8 nM in vitro and 8 nM in cultured cells against p21-ras farnesylation

LB-1


See LB-100

LB-100

LB-1

[1632032-53-1]
Purity: 99%

Soluble in water and DMSO
C13H20N2O4 MW: 268.31



Biological activity

LB-100 is a specific competitive inhibitor of PP2A. In a mouse xenograft model of human pancreatic cancer, LB-100 produced significant radiosensitization with minimal weight loss. Furthermore, LB-100 decreased cell viability through caspase activation and G2/M cell-cycle arrest. LB100 enhanced daunorubicin cytotoxicity resulting in decreased xenograft volumes and improved overall survival.

Axon 1970

mg	Price
10	online
50	online

Axon 1480

Page 660

Axon 3407

Page 621

Axon 3887

Page 778

Axon 1794


mg	Price
5	online
25	online

LBH 589

NVP-LBH 589; Panobinostat

[404950-80-7]
Purity: 98%

Soluble in DMSO
C21H23N3O2 MW: 349.43



Biological activity


Highly potent and oral inhibitor of histone deacetylase (HDAC) with IC50 of HDAC1 to be 0.23 nM; an investigational drug against human pancreatic cancer, T cell lymphoma and other types of malignant diseases. In vitro LBH 589 induces cell cycle arrest and apoptosis through both caspase dependent and caspase independent pathways in various tumor cell types at nanomolar concentrations. In vivo LBH 589 inhibits tumor angiogenesis as evidenced by blocking new blood vessel formation in human prostate carcinoma cell PC 3 xenografts

LC-1

See SPA70

LCL-161

[1005342-46-0]
Purity: 99%
100% e.e.
Soluble in DMSO
C26H33FN4O3S MW: 500.63



Biological activity


LCL-161 is an orally bioavailable and cell permeable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins.

Source Information: Sold in collaboration with Chemietek

LCS 1

[41931-13-9]
Purity: 99%

Soluble in DMSO
C11H8Cl2N2O MW: 255.10




Biological activity

Inhibitor of superoxide dismutase 1 (SOD1). Inhibits SOD1 enzymatic activity in vitro (IC50: 0.19 μM for cell growth inhibition in KRAS mutated H358 cell lines). Conversely, (over-) expression of SOD1 cDNA showed about a threefold reduction in sensitivity to LCS-1 and increased proliferation of H358 cells. Additionally, LCS-1 can prevent serum-induced activation of the ERK and PI 3-kinase/AKT signaling pathways.

LCS3

[109844-92-0]
Purity: 99%

Soluble in DMSO and EtOH
C11H7ClN2O4 MW: 266.64



Axon 1548

mg	Price
10	online
50	online

Axon 2807

Page 882

Axon 3902

mg	Price
5	online
10	online

Axon 2176

mg	Price
10	online
50	online

Axon 3791

mg	Price
10	online
50	online

Biological activity


LCS3 is a reversible, uncompetitive inhibitor of GSR and TXNRD1 (IC50 values of 3.3 μM and 3.8 μM, respectively) that selectively kills human lung adenocarcinoma cells in an oxidative stress-dependent manner.

LDC000067

LDC067

[1073485-20-7]
Purity: 99%

Soluble in DMSO
C18H18N4O3S MW: 370.43


Axon 3029

mg	Price
10	online
50	online

Biological activity

LDC000067 is a potent, highly specific, ATP-competitive CDK9 inhibitor with an IC50 value of 44 nM.

LDC067

See LDC000067

Axon 3029

Page 607

LDC203974

See IMT1B


Axon 3417

Page 564

LDC7559

[2407782-01-6]
Purity: 99%

Soluble in DMSO
C20H19N3O3 MW: 349.38


Axon 3482

mg	Price
5	online
25	online

Biological activity

LDC7559 inhibits the NOX2-dependent oxidative burst in neutrophils by activating the glycolytic enzyme phosphofructokinase-1 liver type (PFKL) and dampening flux through the pentose phosphate pathway. LDC7559 is an inhibitor of NOX2-dependent NETosis with an IC50 value of 3.1 μM.

LDE 225

See NVP-LDE225

Axon 1619


Page 725

LDK 378

Ceritinib

[1032900-25-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C28H36ClN5O3S MW: 558.14


Axon 2224

mg	Price
5	online
25	online

Biological activity


Potent, bioavailable, and selective anaplastic lymphoma kinase (ALK) inhibitor (IC50 value 0.2 nM) with >35 fold selectivity over InsR, IGF-1R. LDK 378 induced a dose-dependent tumor growth inhibition and tumor regression in multiple rat xenograft models.

LDN 193189 hydrochloride

DM 3189

[1062368-24-4] (parent)
Purity: 99%

Soluble in water and DMSO
C25H22N6.3HCl MW: 515.87


Axon 1509

mg	Price
2	online
5	online


Biological activity

A highly potent small molecule BMP inhibitor; inhibiting BMP type I receptors ALK2 (IC50: 5 nM), ALK3 (IC50: 30 nM) and ALK6 (TGFβ1/BMP signaling) and subsequent SMAD phosphorylation; useful tool in stem cell biology

LDN 212320

[894002-50-7]
Purity: 100%

Soluble in DMSO
C17H15N3S MW: 293.39


Axon 2260

mg	Price
10	online
50	online


Biological activity

LDN 212320 is an activator of excitatory amino acid transporter 2 (EAAT2) translation and has significant neuroprotective effects in vivo.

LDN 212854

[1432597-26-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C25H22N6 MW: 406.48


Axon 3552

mg	Price
5	online
25	online

Biological activity


Potent ALK2-biased BMP type I receptor kinase inhibitor (IC50 values 2.4 nM, 1.3 nM, and 85.8 nM for ALK1, 2, and 3 resp.), showing nearly 4 orders of selectivity for BMP versus the closely related TGF-β and Activin type I receptors. Closely related to LDN 193189 (Axon 1509).

Note: Trihydrochloride salt form of LDN 212854 (Axon 2201) is also available.

LDN 212854 trihydrochloride

[1432597-26-6] (parent)
Purity: 99%

Soluble in water and DMSO
C25H22N6.3HCl MW: 515.87


Axon 2201

mg	Price
5	online
25	online


Biological activity

Potent ALK2-biased BMP type I receptor kinase inhibitor (IC50 values 2.4 nM, 1.3 nM, and 85.8 nM for ALK1, 2, and 3 resp.), showing nearly 4 orders of selectivity for BMP versus the closely related TGF-β and Activin type I receptors. Closely related to LDN 193189 (Axon 1509).

LDN-27219

[312946-37-5]
Purity: 99%

Soluble in DMSO
C20H16N4O2S2 MW: 408.50



Biological activity

LDN-27219 is a potent, reversible and slow-binding inhibitor of tissue transglutaminase (TGase) with an IC50 value of 0.6 μM.


Axon 4016

mg	Price
10	online
50	online

LDN 57444

[668467-91-2]
Purity: 99%

Soluble in DMSO
C17H11Cl3N2O3 MW: 397.64



Biological activity

Reversible, competitive inhibitor of UCH-L1 (Ki value 0.40 μM; IC50 values 0.88 μM and 25 μM for UCH-L1 and UCH-L3 inhibition, respectively), that promotes proliferation of H1299 NSCLC cells and SH-SY5Y neuroblastoma cells. A useful tool to study the role of UCH-L1 in Parkinson's disease, cancer, and neuropathic pain.


Axon 2449

mg	Price
10	online
50	online

LE 135

[155877-83-1]
Purity: 98%

Soluble in DMSO
C29H30N2O2 MW: 438.56



Biological activity

Retinoid antagonist, beta type selective


Axon 1242

mg	Price
10	online
50	online

Ledipasvir

GS5885

[1256388-51-8]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C49H54F2N8O6 MW: 889.00



Biological activity

Ledipasvir is a potent and orally available NS5A inhibitor with an HCV GT1a replicon EC50 value of 31 pM.

Axon 3300

mg	Price
10	online
50	online


LEE 011

Axon 2273

mg	Price
----	-------

[1211441-98-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C23H30N8O MW: 434.54



Biological activity


Orally bioavailable and highly selective small-molecule inhibitor of CDK4/6 (mean IC50 value 307 nM in sensitive neuroblastoma-derived cell lines). LEE011 caused cell-cycle arrest and cellular senescence that was attributed to dose-dependent decreases in phosphorylated RB and FOXM1, respectively. LEE 011 treatment of BE2C and IMR5 neuroblastoma cell lines with demonstrated sensitivity to CDK4/6 inhibition resulted in a dose-dependent accumulation of cells in the G0/G1 phase of the cell cycle.

5	online
25	online

Leflunomide

[75706-12-6]
Purity: 99%

Soluble in DMSO
C12H9F3N2O2 MW: 270.21



Biological activity

Leflunomide is a selective inhibitor of de novo pyrimidine synthesis. The active metabolite of Leflunomide, A77 1726, at low, therapeutically applicable doses, reversibly inhibits dihydroorotate dehydrogenase (DHODH), the rate limiting step in the de novo synthesis of pyrimidines. Leflunomide is a disease modifying antirheumatic drug (DMARD).


Axon 3164

mg	Price
50	online
250	online

LEI-301

[2571585-09-4]
Purity: 99%

Soluble in DMSO and EtOH
C25H25NO3 MW: 387.47



Biological activity


LEI-301 is a potent inhibitor for the PLAAT family members with pIC50 values of 7.3, 6.6, 7.3 and 7.4 for PLAAT2, PLAAT3, PLAAT4 and PLAAT5, respectively. LEI-301 was selective over the proteins of the endocannabinoid system (ECS). Moreover, LEI-301 reduced the NAE levels, including anandamide, in cells overexpressing PLAAT2 or PLAAT5.

Axon 3296

mg	Price
5	online
25	online

LEI-401

[2393840-15-6]
Purity: 99%
99.9% e.e.
Soluble in DMSO
C24H31N5O2 MW: 421.54



Biological activity

LEI-401 is a first-in-class, potent, selective and CNS-active N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) inhibitor (Ki value of 0.027 μM). LEI-401 blocks NAE biosynthesis in the brain of freely moving mice, thereby revealing a possible endogenous tone of this lipid family in emotional behavior. Moreover, LEI-401 activated the hypothalamus-pituitary-adrenal (HPA) axis and impaired extinction of an aversive memory in mice, thereby mimicking the effects of cannabinoid CB1 receptor antagonism.

Axon 3202


mg	Price
5	online
25	online

Lenalidomide

CC 5013; Revimid

[191732-72-6]
Purity: 100%

Soluble in DMSO
C13H13N3O3 MW: 259.26



Axon 1793

mg	Price
10	online
50	online

Biological activity


Anti-angiogenesis agent; immunomodulator; a FDA approved drug to treat mantle cell lymphoma, multiple myeloma, and anemia caused by a certain type of myelodysplastic syndrome (MDS). It is being studied in the treatment of other conditions and types of cancer. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow

Lenvatinib

E7080

[379231-04-6]
Purity: 98%

Soluble in DMSO
C21H19ClN4O4 MW: 426.85



Axon 3165

mg	Price
10	online
50	online

Biological activity

Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. Lenvatinib inhibited Flt-1 (VEGFR1), KDR (VEGFR2) and Flt-4 (VEGFR3) with IC50 values of 22, 4.0 and 5.2 nM, respectively. Lenvatinib has potent antitumor activity against human H146, a SCLC cell line in mice based on angiogenesis inhibition via both KDR and KIT signaling, compared to single inhibition of either KDR or KIT signaling.

Letairis

See Ambrisentan

Axon 1648


Page 222

Letrozole

CGS 20267

[112809-51-5]
Purity: 99%

Soluble in DMSO
C17H11N5 MW: 285.30



Axon 3257

mg	Price
50	online

Biological activity

Letrozole is a potent, highly selective, non-steroidal aromatase inhibitor in vitro (IC50 value of 11.5 nM) and in vivo.

Leukadherin-1 choline salt

See ADH-503

Axon 3048

Page 208

Levamisole hydrochloride


(-)-Tetramisole hydrochloride

[16595-80-5]
Purity: 100%

Axon 3242

mg	Price
50	online

Optically pure
Soluble in water and DMSO
C11H12N2S.HCl MW: 240.75



Biological activity


Levamisole hydrochloride is a highly active anthelmintic agent.

Levetiracetam

UCB-L 059; Keppra

[102767-28-2]
Purity: 99% ee

Soluble in water and DMSO
C8H14N2O2 MW: 170.21



Axon 1110

mg	Price
20	online
100	online

Biological activity

Acetylcholine agonist; "Second generation" nootropic; an anticonvulsant medication used to treat epilepsy; more active enantiomer of Etiracetam (Axon 1109), in comparison with the opposite (R)-enantiomer, UCB L-060 (Axon 1111)

Levodopa


See DOPA, L-

Axon 3666

Page 437

Levofloxacin Q-acid

[100986-89-8]
Purity: 99%
Optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C13H9F2NO4 MW: 281.21



Axon 2242

mg	Price
50	online
1000	online


Biological activity

Inhibitor of bacterial DNA gyrase and topoisomerase IV. Levofloxacin has a minimum inhibitory concentration (MIC) of 0.75 µg/mL against penicillin-resistant Streptococcus pneumoniae. Analogue of Trovafloxacin (Axon 2100).

Levomilnacipran hydrochloride

F2695 hydrochloride

[175131-60-9]
Purity: 99%
Optically pure
Soluble in water and DMSO
C15H22N2O.HCl MW: 282.81



Axon 3128

mg	Price
10	online
50	online

Biological activity

Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor (SNRI). Antidepressant drug.


Levonorgestrel

[797-63-7]
Purity: 99%

Soluble in DMSO
C21H28O2 MW: 312.45

Axon 2065

mg	Price
25	online
100	online



Biological activity


A second generation synthetic progestogen used as an active ingredient in some hormonal contraceptives; binds to the progesterone receptor (PR) as an agonist; a synthetic progesterone steroid that displays potent progestational and androgenic effects but it lacks estrogen-like activity

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Levosimendan

OR1259

[141505-33-1]
Purity: 99%
Optically pure
Soluble in DMSO
C14H12N6O MW: 280.28



Axon 4046

mg	Price
50	online


Biological activity

Levosimendan is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels.

LFM-A13

[244240-24-2]
Purity: 99%

Soluble in DMSO
C11H8Br2N2O2 MW: 360.00



Axon 2862

mg	Price
10	online
50	online


Biological activity

LFM-A13 is a potent and specific inhibitor of BTK (IC50 value of 2.5 µM). LFM-A13 did not affect the enzymatic activity of other protein tyrosine kinases, including Janus kinases JAK1 and JAK2, Src family kinase HCK, and receptor family tyrosine kinases E.

LGX818

Encorafenib; NVP-LGX818

[1269440-17-6]
Purity: 99%
99% e.e.
Soluble in DMSO
C22H27ClFN7O4S MW: 540.01



Axon 4146

mg	Price
10	online
50	online

Biological activity

LGX818 is a selective ATP-competitive RAF kinase inhibitor of B-RafV600E mutant melanoma cell proliferation (EC50 = 4 nM) with little activity against wild-type B-Raf or a panel of 100 other kinases (IC50s = 900 nM). At oral doses of 6 mg/kg in human melanoma xenograft models, LGX818 was shown to decrease phosphorylation of the B-Raf substrate MEK.

Source Information: Sold in collaboration with Chemietek

LH601A

See ML334


Axon 2641

Page 668

LH 846

[639052-78-1]
Purity: 99%

Soluble in DMSO
C16H13ClN2OS MW: 316.81



Axon 2297

mg	Price
10	online
50	online


Biological activity

Potent and selective inhibitor of CK1δ (IC50 values of 2.5 mM, 290 nM, and 1.3 mM for CK1α, CK1δ, and CK1ε, respectively) that showed no inhibitory effect on CK2. LH 846 modulates circadian rhythms through phosphorylation of the period protein with a significant effect on circadian period length (10 h) with minimal effect on the amplitude of both Per2-dLuc and Bmal1-dLuc rhythms in U2OS cells.

LHC-165

[1258595-14-0]
Purity: 99%

Soluble in DMSO
C29H32F2N3O7P MW: 603.55



Axon 3728

mg	Price
5	online
10	online

Biological activity

LHC-165 is an agonist (activator) of Toll-like Receptor 7 (TLR7), and an immuno-oncology modulator. TLR7 is a protein in the immune system that surveys and recognizes pathological malignance, and triggers the immune response by releasing infection-clearing cytokines if activated. It has demonstrated in mice that LHC-165 induced immune response, and reduced tumor growth, also showed signs of an abscopal effect.

Source Information: Sold in collaboration with Chemietek

Lifirafenib

See BGB-283

Axon 3862

Page 300

Limantrafin

See CB-103

Axon 4039


Page 346

LIMK1 inhibitor BMS 4

BMS 4

[905298-84-2]
Purity: 99%

Soluble in DMSO
C23H23N7O2S MW: 461.54



Axon 1949

mg	Price
2	online
5	online


Biological activity

A potent LIM kinase (LIMK) 1 (LIMK1) inhibitor

Linagliptin

BI 1356

[668270-12-0]
Purity: 99%
Optically pure
Soluble in DMSO
C25H28N8O2 MW: 472.54



Axon 2354

mg	Price
10	online
50	online


Biological activity

Competitive and highly selective dipeptidyl peptidase (DPP)-4 inhibitor (IC50 value ca. 1 nM in vitro) with superior potency and long duration of action in vivo. Linagliptin is $\geq 10,000$ -fold more selective for DPP-4 than DPP-8, DPP-9, amino-peptidases N and P, prolyloligopeptidase, trypsin, plasmin, and thrombin and is 90-fold more selective than for fibroblast activation protein in vitro. Approved drug for treatment of type 2 diabetes with long-lasting effects on glucose tolerance through control of GLP-1 and insulin.

Linezolid

Zyvox; PNU 100766; U 100766

[165800-03-3]
Purity: 99%
Optically pure
Soluble in DMSO
C16H20FN3O4 MW: 337.35



Axon 2048

mg	Price
10	online
50	online

Biological activity

Protein synthesis inhibitor; antibiotic; stops the growth of bacteria by disrupting their production of proteins; inhibits the ribosomal peptidyltransferase; antibacterial agent for the treatment of multidrug-resistant gram-positive bacterial infections

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Linifanib

See ABT 869

Axon 1638

Page 202

Linomide

See Roquinimex

Axon 2868

Page 829

Linsitinib

See OSI 906

Axon 1702

Page 738

Lintitript

See SR 27897

Axon 1245

Page 887

Lipitor

See Atorvastatin calcium

Axon 2043


Page 259

Liproxstatin-1

[950455-15-9]
Purity: 98%
Soluble in 0.1N HCl(aq) and DMSO

mg	Price
5	online
25	online

C19H21ClN4 MW: 340.85



Biological activity

Liproxstatin-1 is a potent ferroptosis inhibitor (IC50 value of 22 nM) which is able to suppress ferroptosis in cells, in Gpx4(-/-) mice, and in a pre-clinical model of ischaemia/reperfusion-induced hepatic damage.

Lirimilast


See BAY 19-8004

Axon 1178

Page 288

LJI308

[1627709-94-7]
Purity: 99%
Soluble in DMSO and EtOH
C21H18F2N2O2 MW: 368.38



Biological activity

LJI308 is a potent and specific pan-RSK inhibitor with IC50 values of 6 nM, 4 nM and 13 nM for RSK1, RSK2 and RSK3, respectively.


Axon 3991

mg	Price
5	online
25	online

LIT-001

LIT-001 trifluoroacetate

[2245072-21-1]
Purity: 98%
Soluble in DMSO
C28H33N7O2S.1.5C2HF3O2 MW: 702.71



Biological activity

LIT-001 is a non-peptide, potent and specific agonist of the oxytocin receptor (EC50 value of 25 nM at human OTR). First nonpeptide OT receptor agonist active in an animal model of autism spectrum disorders (ASD) after peripheral ip administration.

Axon 3071

mg	Price
5	online
25	online

LIT-001 trifluoroacetate


See LIT-001

Axon 3071

Page

LIT-927

[2172879-52-4]
Purity: 99%
Soluble in 0.1N NaOH(aq) and DMSO
C17H13ClN2O3 MW: 328.75



Biological activity

Axon 2921


mg	Price
10	online
50	online

LIT-927 is a selective, locally and orally active CXCL12 neutraligand (K_i value of 267 nM). Moreover, LIT-927 shows an anti-inflammatory effect in a murine model of allergic airway hyper eosinophilia.

Lj-1-60

[2414269-68-2]
Purity: 99%

Soluble in DMSO
C17H15BrO4 MW: 363.20



Axon 3270

mg	Price
10	online
50	online

Biological activity

Lj-1-60 is an ATP-competitive inhibitor targeting Fyn protein kinase. Lj-1-60 inhibited melanoma proliferation and induced cell cycle arrest into the G2/M phase and apoptosis by targeting Fyn/Stat3 pathway. Lj-1-60 markedly reduced cell viability in a time- and dose-dependent manner, with IC50 values of 1.65 μ M (Sk-Mel-5) and 1.36 μ M (Sk-Mel-28), respectively. Also, the IC50 value of Lj-1-60 in melanocyte cells PIG1 was 3.9 μ M.

LM427

See Rifabutin


Axon 3372

Page 818

LMTK3 inhibitor C28

[2764850-23-7]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C18H11F3N4O MW: 356.30



Axon 3780

mg	Price
10	online
50	online

Biological activity

C28 is a potent LMTK3 inhibitor with an IC50 value of 67 nM. Pharmacologic inhibition of LMTK3 decreases proliferation of cancer cell lines in the NCI-60 panel, with a concomitant increase in apoptosis in breast cancer cells, recapitulating effects of LMTK3 gene silencing. Furthermore, LMTK3 inhibition reduces growth of xenograft and transgenic breast cancer mouse models without displaying systemic toxicity at effective doses.

LNT1

See FEN1 inhibitor 1


Axon 3027

Page 478

LN6023 dihydrochloride

[N.A.]
Purity: 98%

Soluble in water, DMSO and EtOH
C20H32N6O2S.2HCl MW: 493.49



Axon 3774

mg	Price
5	online
25	online

Biological activity

LN6023 is a first-in-class, selective superagonist of atypical chemokine receptor 3 (ACKR3) also known as C-X-C chemokine receptor type 7 (CXCR-7) and G-protein coupled receptor 159 (GPR159) with an EC50 value of 3.5 μ M.

Note: The hydrochloride salt of LN6023 is water soluble.


LockdownPro

[2985814-80-8]
Purity: 98%

Axon 3680

mg	Price
10	online

Soluble in DMSO and EtOH
C39H40O10 MW: 668.73



50 online

Biological activity

LockdownPro is an ester-modified variant of Lockdown, which is a potent, selective, cell-active, reversible, and non-competitive PPM1F inhibitor. LockdownPro displayed increased membrane permeability and prodrug-like properties. Importantly, LockdownPro efficiently suppressed tissue invasion of PPM1F-overexpressing human cancer cells in the chicken chorioallantoic membrane tumor assay.

Locorten

See Flumethasone pivalate


Axon 2247

Page 485

Locostatin

UIC 1005

[90719-30-5]
Purity: 100%
Optically pure
Soluble in DMSO and Ethanol
C14H15NO3 MW: 245.27



mg	Price
10	online
50	online

Biological activity


Non-toxic Raf kinase inhibitory protein (RKIP) inhibitor; disrupts the interaction of RKIP, not only with Raf-1 kinase, but also with GRK2; Locostatin is an inhibitor of cell sheet migration and cell growth in an epithelial cell proliferation assay, and it induced T cell energy by blocking cytokine production after Ag recall. Other evidence suggested that Locostatin's effects on cytoskeletal structure and migration are caused through mechanisms independent of its binding to RKIP and Raf/MAP kinase signaling.

Lomeguatrib

PaTrin 2

[192441-08-0]
Purity: 99%

Soluble in DMSO
C10H8BrN5OS MW: 326.17



Axon 2223

mg	Price
10	online
50	online

Biological activity

Potent, orally active inhibitor of O6-methylguanine-DNA-methyltransferase (MGMT; IC50 value 5 nM). Lomeguatrib effectively inactivated MGMT in MCF-7 cells and in xenografts there was complete inactivation of MGMT within 2 h of dosing (20 mg/kg i.p.) and only slight recovery by 24 h. Oral administration of Lomeguatrib substantially increases the haematological toxicity of Dacarbazine, the only approved chemotherapeutic agent for the treatment of metastatic melanoma. In combination with Temozolomide, Lomeguatrib produced a substantial tumour growth delay in MCF-7 xenografts.

Lomitapide


BMS 201038; AEGR-733

[182431-12-5]
Purity: 98%

Soluble in DMSO
C39H37F6N3O2 MW: 693.72

Axon 2917

mg	Price
10	online
50	online




Biological activity

Lomitapide is a highly potent microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 value of 0.5 nM. Moreover, lomitapide inhibited the production of lipoprotein particles in rodent models and normalized plasma lipoprotein levels in Watanabe-heritable hyperlipidemic (WHHL) rabbits, which are a model for human homozygous familial hypercholesterolemia.

Longdaysin

[1353867-91-0]
Purity: 99%

Soluble in DMSO
C16H16F3N5 MW: 335.33



Axon 2998

mg	Price
10	online
50	online


Biological activity

Longdaysin is a potent inhibitor of protein kinases CK1δ, CK1α, ERK2, and CDK7 with IC50 values of 8.8, 5.6, 52, and 29 μM, respectively. Furthermore, Longdaysin is a small molecule that potently lengthens the circadian period in a dose-dependent manner.

Loperamide hydrochloride

[34552-83-5]
Purity: 100%

Soluble in DMSO and EtOH
C29H33ClN2O2.HCl MW: 513.50



Axon 3640

mg	Price
50	online


Biological activity

Loperamide is a peripherally restricted potent μ-opioid receptor (MOR) agonist with a Ki value of 3.3 nM. Loperamide can also inhibit voltage-gated L-type calcium channels and trigger autophagy-dependent cell death as well. Antidiarrheal medicine.

Lopinavir

ABT-378

[192725-17-0]
Purity: 99%
Optically pure
DMSO
C37H48N4O5
MW: 628.80



Axon 3138

mg	Price
50	online
200	online

Biological activity

Lopinavir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor. Lopinavir in combination with ritonavir (Axon 3139) in a 4 to 1 ratio (dosage information) is marketed as Kaletra.

Loprinone hydrochloride

See Olprinone hydrochloride

Axon 1168


Page 733

Loratadine

SCH 29851

[79794-75-5]
Purity: 99%

Soluble in Ethanol
C22H23ClN2O2 MW: 382.88



Axon 1299

mg	Price
10	online
50	online

Biological activity

Histamine H1 receptor antagonist; non-sedating antihistamine, used as a drug to treat allergies

Lorlatinib

See PF 06463922

Axon 2600


Page 770

Losartan

EX 89; DUP 89

[114798-26-4]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C22H23ClN6O MW: 422.91



Axon 3102

mg	Price
50	online
250	online

Biological activity


Losartan is a potent, orally active nonpeptide angiotensin II receptor antagonist which inhibited the specific binding of labeled angiotensin II to its receptor sites in rat adrenal cortical membranes and in cultured rat smooth muscle cells with IC50 values of 19 nM and 20 nM, respectively. Antihypertensive agent.

Loviride

R 89439

[147362-57-0]
Purity: 98%

Soluble in DMSO
C17H16Cl2N2O2 MW: 351.23



Axon 3334

mg	Price
5	online
25	online

Biological activity

Loviride is a potent and highly selective HIV-1 reverse transcriptase inhibitor with an IC50 value of 0.3 μM.


LOX-1 inhibitor i472, 15-

[N.A.]
Purity: 98%

Axon 2989

mg	Price
5	online

Soluble in DMSO
C22H21ClN2O4 MW: 412.87



Biological activity


Inhibitor of 15-lipoxygenase-1 (15-LOX-1) with an IC50 value of 0.19 μ M. 15-LOX-1 inhibitor i472 shows an ability to protect RAW 264.7 macrophages from LPS-induced cell death. Furthermore, i472 is shown to provide significant inhibition of NF- κ B transcriptional activation upon LPS/INF γ stimulation, to downregulate the expression of the NF- κ B related gene iNOS, to provide dose-dependent inhibition of NO production and to reduce lipid peroxidation in RAW macrophages.

*Sold in collaboration with RuG (University of Groningen) Sold in collaboration with RuG (University of Groningen)

LOXO-101 sulfate

Larotrectinib sulfate; ARRY-470

[1223405-08-0]
Purity: 99%
Optically pure
Soluble in water and DMSO
C21H22F2N6O2.H2SO4 MW:
526.51




Biological activity

LOXO-101 sulfate is a first-in-class, potent, highly selective and ATP-competitive tropomyosin receptor kinase (TRK) inhibitor with IC50 values of 6.5 nM, 8.1 nM and 10.6 nM for TRKA, TRKB and TRKC, respectively.

LOXO-195

Selitrectinib

[2097002-61-2]
Purity: 99%
99% e.e.
Soluble in DMSO
C20H21FN6O MW: 380.42



Biological activity

LOXO-195 is an oral, second generation TRK inhibitor being made to address the acquired resistance to first generation TRK inhibitor (such as LOXO-101 (Axon 3407)). LOXO-195 potently and selectively inhibits, with minimal activity against other kinases, pan-TRKs (with potency on par with that of LOXO-101), and more importantly, abrogates resistance in TRK fusion-positive cancers that acquired kinase domain mutations due to the treatment of existing TRK inhibitors. Displays high oral bioavailability and favorable PK in animals.

Source Information: Sold in collaboration with Chemietek

LOXO-292

See Selpercatinib

LP-935509

[1454555-29-3]
Purity: 99%

Soluble in DMSO

Axon 3407

mg	Price
10	online
50	online

Axon 3901

mg	Price
5	online
10	online


Axon 3195

Page 860

Axon 2638

mg	Price
10	online
50	online

C20H24N6O3 MW: 396.44




Biological activity

Potent, brain penetrant inhibitor of adapter protein-2 associated kinase 1 (AAK1; IC50 value 3.3 nM and 14 nM and 320 nM for the closely related BIKE and GAK enzymes, respectively). LP-935509 is antinociceptive in multiple rat models of neuropathic pain, but not acute pain. The AAK1 inhibitor-induced antinociception and inhibition of spontaneous neural activity can be blocked by α 2 adrenergic antagonists.

LpxC inhibitor 1a

[1289620-49-0]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C18H21NO4S MW: 347.43



Biological activity


Potent antibacterial LpxC inhibitor (IC50: 1.37 nm) for the treatment of gram-negative infections

LSL60101

Garsevil

[150985-54-9]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C11H8N2O MW: 184.19



Biological activity


LSL60101 is a selective imidazole2 (I2) receptor ligand with KiH and KiL values of 350 nM and 116 μ M, respectively. LSL 60101 plays a neuroprotective role by reducing apoptosis and modulating oxidative stress.

LXH254

Naporafenib

[1800398-38-2]
Purity: 99%

Soluble in DMSO and EtOH
C25H25F3N4O4 MW: 502.49



Biological activity

LXH254 is a potent, selective, orally available and ARAF-sparing type II inhibitor of BRAF and CRAF with IC50 values of 0.21 and 0.072 nM for BRAF and CRAF, respectively.

LXS-196

Darovasertib; NVP-LXS196

[1874276-76-2]
Purity: 99%

Soluble in DMSO

Axon 1939

mg	Price
5	online
25	online

Axon 3603

mg	Price
10	online
50	online


Axon 3556

mg	Price
5	online
25	online

Axon 3851

mg	Price
5	online
10	online

C22H23F3N8O MW: 472.47



Biological activity


LXS196 is an orally bioavailable, potent and selective protein kinase C inhibitor.

Source Information: Sold in collaboration with Chemietek

LQZ-71

[195822-23-2]
Purity: 99%

Soluble in DMSO
C20H14F2N4 MW: 348.35



Biological activity


LQZ-71 inhibits survivin dimerization, induces survivin degradation in proteasome, and induces apoptosis of prostate cancer cells (IC50 values of 3.1 μ M and 4.8 μ M against C4-2 cells and PC-3 cells, respectively). LQZ-71 given orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors.

LRE1

RU-0204277

[1252362-53-0]
Purity: 98%

Soluble in DMSO
C12H13ClN4S MW: 280.78




Biological activity

LRE1 is an allosteric soluble adenylyl cyclase (sAC)-specific inhibitor (IC50 value \leq 10 μ M). Inhibition occurs by occupying the binding site of the physiological activator HCO₃⁻, preventing sAC-dependent processes in cellular and physiological systems. LRE1 also inhibited cAMP accumulation in 4-4 cells (IC50 value 11 μ M). Overall, this sAC inhibitor combines high potency and selectivity with stability, solubility and lack of cytotoxicity.

LRRK2-IN-1

[1234480-84-2]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C31H38N8O3 MW: 570.69



Biological activity

Potent, ATP-competitive and selective inhibitor of the Parkinson's disease kinase LRRK2 (IC50 value 13 nM and 6 nM for inhibitions of WT and G2019S mutant LRRK2 kinase activity, respectively). LRRK2IN1 is neuroprotective in vitro and inhibits the activity of LRRK2 in kidney and spleen when administered in vivo. However, LRRK 2-IN-1 is not able to cross the BBB.

Axon 3344

mg	Price
5	online
25	online

Axon 2664

mg	Price
10	online
50	online

Axon 2493

mg	Price
5	online
25	online

LS 2616

See Roquinimex

Axon 2868

Page 829

LS 193571

See Biphenyl-indanone A

Axon 1644

Page 309

LT 00673

See Talazoparib

Axon 2502

Page 909

LU 10-171

See Citalopram hydrobromide

Axon 1320

Page 373

LU 23-174

See Sertindole

Axon 1141


Page 861

Lu AE58054 hydrochloride

Idalopirdine HCl

[467458-02-2]
Purity: 99%

Soluble in water and DMSO
C20H19F5N2O.HCl MW: 434.83



Biological activity

5-HT₆ receptor antagonist (K_i value 0.83 nM for h5-HT₆) demonstrating >50-fold selectivity for more than 70 targets examined, with good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia. Idalopirdine (Lu AE58054) potentiates the effects of Donepezil (Axon 1438) on two pharmacodynamic biomarkers associated with cognition, i.e. neuronal oscillations and extracellular ACh levels in the hippocampus. Note: This item is currently suspended due to the concern of the IP right of the developer. You might request a quotation for contract research synthesis. Please contact us for conditions and more detailed information.

mg	Price
5	online
25	online

Luciferin, D-

Firefly Luciferin

[2591-17-5]


Purity: 98%
Optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C11H8N2O3S2 MW: 280.32

Biological activity

Substrate of firefly luciferase. Bioluminescent compound that may be used for in vivo bioluminescence imaging (BLI)

Axon 2494

mg	Price
10	online
50	online



LUF7244


[1821638-43-0]
Purity: 98%

Soluble in DMSO

Axon 3032

mg	Price
10	online
50	online

C20H15ClN2O3 MW: 366.80



Biological activity


LUF7244 is a potent negative allosteric modulator of Kv 11.1 (hERG) channels with an IC50 value of 3.9 μ M. Moreover, LUF7244 was found to be a negative allosteric modulator of dofetilide (Axon 2103) binding to the Kv11.1 channel with the strongest effect at 10 μ mol/L.

Lumacaftor

VX-809

[936727-05-8]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C24H18F2N2O5 MW: 452.41



Axon 3234

mg	Price
10	online
50	online

Biological activity

Lumacaftor is an efficacious and selective CFTR corrector. Lumacaftor was orally bioavailable in rats and achieved in vivo plasma levels significantly above concentrations required for in vitro efficacy.

Lunersertib

See RP-6306

Axon 3668


Page 831

Luzindole

N 0774

[117946-91-5]
Purity: 99%

Soluble in DMSO
C19H20N2O MW: 292.37



Axon 1350

mg	Price
10	online
50	online


Biological activity

A putative melatonin antagonist

LW 6

[934593-90-5]
Purity: 99%

Soluble in DMSO
C26H29NO5 MW: 435.51



Axon 2480

mg	Price
10	online
50	online

Biological activity

Novel HIF-1 inhibitor (IC50 value 2.44 μ M) that promotes proteasomal degradation of HIF-1 α via upregulation of von-Hippel-Lindau (VHL), without affecting the activity of prolyl hydroxylase (PHD). Evidence was found that identified MDH2 as a target protein of LW-6. Moreover, LW6 suppresses angiogenesis by inhibition of HIF-1 α stability via direct binding with calcineurin b homologous protein 1 (CHP1) in a Ca²⁺ dependent manner.

LW 479


[1688677-89-5]

Axon 2430

mg	Price
----	-------

Purity: 98%

Soluble in DMSO
C21H23BrN2O4S MW: 479.39



10 online

50 online


Biological activity

HDAC inhibitor that shows marked cytotoxicity and induces apoptosis as well as cell cycle arrest in a panel of breast cancer cell lines. LW479 silences EGFR expression in breast cancer cells through disrupting Sp1 and HDAC1 binding to EGFR promoter, and blocks EGF/EGFR signalling pathway and EGF-stimulated motility. Moreover, LW-479 attenuates breast cancer metastasis to the lung.

LX2343

[333745-53-2]
Purity: 99%

Soluble in DMSO
C22H19ClN2O6S MW: 474.91



Axon 2869

mg	Price
10	online
50	online

Biological activity


Inhibitor of human β -secretase (BACE-1) and PI3K (non-ATP competitive) with IC50 values of 11 μ M and 16 μ M, respectively. Moreover, LX2343 ameliorates cognitive dysfunction in APP/PS1 transgenic mice via both A β production inhibition and clearance promotion. Potentially effective in the treatment of Alzheimer's disease.

LXR 623

WAY 252623

[875787-07-8]
Purity: 99%

Soluble in DMSO
C21H12ClF5N2 MW: 422.78



Axon 2357

mg	Price
10	online
50	online

Biological activity

Partial agonist of Liver X Receptor (LXR; IC50 value 179 nM and 24 nM for LXR α - and LXR β -binding, respectively. EC50 values 6.66 μ M and 3.67 μ M for Huh-7 human hepatoma cell based Gal4 LXR α and LXR β transactivation essays respectively). Despite its partial agonism in transactivation essays, LXR 623 exhibits full agonism in THP-1 cells with respect to increasing ABCA1 gene expression and on cholesterol efflux in THP-1 foam cells. In vivo, LXR 623 lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.

LY080400

See Apigenin

Axon 2717

Page 241

LY 170053

See Olanzapine

Axon 1298

Page 731

LY 188011

See Gemcitabine hydrochloride

Axon 3233


Page 501

LY2606368 mesylate

Prexasertib mesylate

[1234015-55-4]
Purity: 99%

Soluble in DMSO
C18H19N7O2.CH4O3S MW: 461.49



Biological activity

LY2606368 is a potent and selective ATP competitive inhibitor of the CHK protein kinase. It preferentially acts on CHK1 (with a biochemical K_i of 0.9 nM) over CHK2 and RSK (with K_i of 8 nM and 9 nM, respectively). CHK1 is a protein kinase that regulates the tumor cell's response to DNA damage often caused by treatment with chemotherapy. In response to DNA damage, CHK1 blocks cell cycle progression in order to allow to repair damaged DNA, thereby limiting the efficacy of chemotherapeutic agents. Inhibiting CHK1 in combination with chemotherapy can enhance tumor cell death by preventing these cells from recovering from DNA damage.

Source Information: Sold in collaboration with Chemietek


Axon 4145

mg	Price
10	online
50	online

LY 294002

[154447-36-6]
Purity: 99%

Soluble in DMSO
C19H17NO3 MW: 307.34



Biological activity

Potent and specific PI3K inhibitor

Axon 1366

mg	Price
5	online
25	online

LY 300168

See GYKI 53655

Axon 1374

Page 536

LY307640 sodium

See Rabeprazole sodium

Axon 3663

Page 805

LY315920

See Varespladib

Axon 4077

Page 962

LY 317615


See Enzastaurin

Axon 1682

Page 461

LY-3177833

[1627696-51-8]
Purity: 99%
99% e.e.
Soluble in DMSO
C16H12FN5O MW: 309.30



Biological activity

Axon 3894

mg	Price
5	online
10	online


LY-3177833 is a orally available, potent and selective inhibitor of CDC7 (Cell Division Cycle 7-related Protein Kinase), inhibiting CDC7/DBF4 I and pMCM2 (S53) with IC_{50} values of 3.3 nM and 290 nM, respectively. The inhibition profoundly impacts chromosome dynamics. Broad antitumor activity was associated with robust dose/exposure-dependent in vivo target inhibition in mouse xenograft models. In addition, the preclinical profile of the compound was different from nonselective CDC7 inhibitors and cytotoxic agents, which supports its clinical development with a continuous dosing regimen.

Source Information: Sold in collaboration with Chemietek

LY-3200882

[1898283-02-7]
Purity: 99%

Soluble in DMSO
C24H29N5O3 MW: 435.52



Biological activity

LY-3200882 is a next generation small molecule inhibitor of TGF- β receptor type 1 (TGF β RI) and a promising immune modulatory agent. It is a potent, highly selective inhibitor of TGF β RI embodied in a structural platform with a synthetically scalable route, in an ATP competitive fashion to the serine-threonine kinase domain of TGF β RI. Mechanism of action studies reveal that LY-3200882 inhibits various pro-tumorigenic activities. It potently inhibits TGF β mediated SMAD phosphorylation in vitro in tumor and immune cells and in vivo in subcutaneous tumors in a dose dependent fashion. In preclinical tumor models, LY-3200882 showed potent anti-tumor activity in the orthotopic 4T1-LP model of triple negative breast cancer and this activity correlated with enhanced tumor infiltrating lymphocytes in the tumor microenvironment. Durable tumor regressions in the orthotopic 4T1-LP model were observed and rechallenge of congenic tumors resulted in complete rejection in all mice. In vitro immune suppression assays, LY-3200882 has shown the ability to rescue TGF β 1 suppressed or T regulatory cell suppressed naive T cell activity and restore proliferation. It also showed anti-metastatic activity in vitro in migration assays as well as in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer). Finally, LY-3200882 shows combinatorial anti-tumor benefits with checkpoint inhibition (anti-PD-L1) in the syngeneic CT26 model.


Source Information: Sold in collaboration with Chemietek

LY-3214996

Temuterkib

[1951483-29-6]
Purity: 99%

Soluble in DMSO
C22H27N7O2S MW: 453.56



Biological activity

LY-3214996 is an orally bioavailable, potent and highly selective inhibitor of ERK1 and ERK2, with IC_{50} of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines. In an unbiased tumor cell panel sensitivity profiling for inhibition of cell proliferation, tumor cells with MAPK pathway alterations including BRAF, NRAS or KRAS mutation are generally sensitivity to LY3214996. In tumor xenograft models, LY3214996 inhibits PD biomarker phospho-p90RSK1 in tumors and the PD effects are correlated with compound exposures and anti-tumor activities.

Source Information: Sold in collaboration with Chemietek

LY-3295668

AK-01

[1919888-06-4]
Purity: 99%
99% e.e.

Soluble in DMSO
C24H26ClF2N5O2 MW: 489.95

Axon 3892


mg	Price
5	online
10	online

Axon 3893

mg	Price
5	online
10	online

Axon 3758

mg	Price
5	online
10	online



Biological activity

LY3295668 (LY-3295668, AK-01) is an orally available, potent and highly selective Aurora A kinase (AurA) inhibitor with K_i of 0.8 nM, and H446 AurA auto-P IC_{50} of 0.6 nM, highly selective (>1000 fold) over Aurora B. LY3295668 is cytotoxic to RB1 mutant cancer cells (NCI-H446 cell IC_{50} = 0.752 μ M), and achieves durable regression of RB1mut tumor xenografts.

Source information: Sold in collaboration with Chemietek

LY3333013

See Varespladib methyl


Axon 4032

Page 963

LY 333531 hydrochloride

Ruboxistaurin

[169939-93-9]
Purity: 99%
Optically pure
Soluble in DMSO
C28H28N4O3.HCl MW: 505.01



Axon 2362

mg	Price
1	online
2	online

Biological activity


Orally active protein kinase C β (PKC- β) specific inhibitor; the water soluble mesylate salt of LY 333531 (Axon 1401) is available as well.

LY 333531 mesylate

Ruboxistaurin

[192050-59-2]
Purity: 99%

Soluble in DMSO
C28H28N4O3.CH4O3S
MW: 564.65



Axon 1401

mg	Price
1	online
2	online

Biological activity

Orally active protein kinase C beta (PKC β) specific inhibitor; the optimal salt form and five times more water-soluble than its hydrochloride salt


LY 334370 hydrochloride

[199673-74-0]
Purity: 99%

Soluble in water and DMSO
C21H22FN3O.HCl MW: 387.88

Axon 1612

mg	Price
10	online
50	online



Biological activity


Selective 5-HT_{1F} receptor agonist with K_i value to be 1.87 nM

LY 335979

Zosuquidar trihydrochloride

[167465-36-3]
Purity: 99%

Soluble in DMSO
C32H31F2N3O2.3HCl MW: 636.99



Axon 1839

mg	Price
5	online
25	online


Biological activity

High-affinity and selective inhibitor of P-glycoprotein (P-gp) (K_i : 59 nM)

LY 367385, (\pm)-

[198419-90-8]
Purity: 98%

Soluble in water
C10H11NO4 MW: 209.20



Axon 1224


mg	Price
10	online
50	online

Biological activity

LY367385 [198419-91-9] is a selective mGlu1a antagonist

LY-3381916

[2166616-75-5]
Purity: 99%
99% e.e.
Soluble in DMSO
C23H25FN2O3 MW: 396.45



Axon 3967

mg	Price
10	online
50	online

Biological activity

LY-3381916 is an orally available, potent and selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO-1) (IC_{50} = 7 nM on Cell-based, newly synthesized IDO-1 lacking heme), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor LY3381916 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, LY3381916 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T lymphocytes, and causes a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.


Source Information: Sold in collaboration with Chemietek

LY-364947

HTS466284

[396129-53-6]
Purity: 99%

Soluble in DMSO
C17H12N4 MW: 272.30



Biological activity

LY-364947 is a potent, selective and ATP-competitive TGF-βR 1 inhibitor with an IC50 value of 59 nM.


Axon 3404

mg	Price
10	online
50	online

LY 393558

[271780-64-4]
Purity: 99%

Moderately soluble in DMSO and Ethanol
C26H31FN4O4S2 MW: 546.68



Biological activity

Serotonin reuptake inhibitor and 5-HT1B/1D antagonist

Axon 1139


mg	Price
10	online
50	online

LY 426965 dihydrochloride

(S)-(+)-LY 426965 dihydrochloride

[228418-82-4] (parent)
Purity: 98%
98% ee

Soluble in DMSO
C28H38N2O2.2HCl MW: 507.54



Biological activity

Selective, potent, orally bioavailable full 5-HT1A antagonist; more active S-(+)-enantiomer of (±)-LY426965 (Axon 1093), in comparison with its opposite enantiomer, (R)-(-)-LY 426965 (Axon 1095)

Axon 1094


mg	Price
5	online
25	online

LY 426965 dihydrochloride, (±)-

rac-LY 426965 dihydrochloride

[228418-81-3]
Purity: 99%

Soluble in DMSO
C28H38N2O2.2HCl MW: 507.54



Biological activity

Selective 5-HT1A antagonist; its (S)-(+)-enantiomer, LY 426965 (Axon 1094), is more active in comparison with (R)-(-)-LY 426965 (Axon 1095)

Axon 1093

mg	Price
10	online
50	online

LY 426965 dihydrochloride, (R)-(-)


[228418-85-7]
Purity: 99%
99% ee

Soluble in DMSO

Axon 1095

mg	Price
5	online
25	online

C28H38N2O2.2HCl MW: 507.54



Biological activity

Selective 5-HT1A antagonist; less active R-(-)-enantiomer of (±)-LY426965 (Axon 1093), in comparison with its opposite (S)-(+)-enantiomer, LY 426965 (Axon 1094)

LY 426965 dihydrochloride, (S)-(+)-

See LY 426965 dihydrochloride

Axon 1094

Page 631

LY 426965 dihydrochloride, rac-

See LY 426965 dihydrochloride, (±)-

Axon 1093


Page 631

LY 573636

Tasisulam

[519055-62-0]
Purity: 98%

Soluble in DMSO
C11H6BrCl2NO3S2 MW: 415.11



Biological activity

Anti-tumor agent, which causes growth arrest and apoptosis of a variety of human solid tumors in vitro and in vivo; LY573636 is selectively toxic towards tumor cells over their normal counterparts


Axon 1963

mg	Price
10	online
50	online

LY 2157299

[700874-72-2]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H19N5O MW: 369.42



Biological activity

Orally active transforming growth factor beta receptor (TGF-βR) kinase inhibitor under clinical development; IC50 values to be 86 nM (TβR1) and 2 nM (TβR2) respectively


Axon 1491

mg	Price
2	online
5	online

LY 2228820

[862505-00-8]
Purity: 99%

Soluble in DMSO
C24H29FN6 MW: 420.53



Biological activity

Potent p38 MAPK inhibitor (IC50: 7 and 3 nM for p38α and p38β MAPKs respectively); antitumor agent for the treatment of multiple myeloma (MM) patients by reducing skeletal events and enhancing cytotoxicity of bortezomib (Axon 1810)

Axon 1895

mg	Price
5	online
25	online


LY 2484595

See Evacetrapib

LY 2584702 tosylate

[1082949-68-5]
Purity: 98%

Soluble in DMSO
C21H19F4N7.C7H8O3S MW:
617.62



Biological activity


Oral, selective ATP competitive inhibitor of p70 S6 kinase (S6K1; IC50 value 4 nM) with significant synergistic activity with erlotinib (Axon 1128) and everolimus. LY2584702 is selective against 83 other kinases as determined by a ubiquitin kinase panel, and 45 cell surface markers as determined by a CEREP mini panel.

LY 2784544

Gandotinib

[1229236-86-5]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C23H25ClFN7O MW: 469.94



Biological activity


Potent, selective and ATP-competitive inhibitor of janus kinase 2 (JAK2) tyrosine kinase (IC50 value 20 and 55 nM for inhibition of JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells, respectively), with no significant inhibitory effect on IL-3 stimulated wild-type JAK2-mediated signaling and cell proliferation (IC50 values >1180 nM). A selective tool for suppression of JAK2V617F-induced myeloproliferative neoplasm (MPN) pathogenesis while minimizing effects on hematopoietic progenitor cells. Moreover, LY2784544 induced apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway; tested positive in Phase I study in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET).

LY 2801653

Merestininb

[1206799-15-6]
Purity: 99%

Soluble in DMSO
C30H22F2N6O3 MW: 552.53



Biological activity

Orally bioavailable multi-kinase inhibitor with potent activity against MET (IC50 values 35 - 53 nM for cell-based activity), and several other receptor tyrosine oncokinasases including MST1R, FLT3, AXL, MERK, TEK, ROS1, DDR1, DDR2 and against the serine/threonine kinases MKNK1 and MKNK2 (IC50 values 11, 7, 2, 10, 63, 23, 0.1, 7, 7, and 7 nM, respectively) In classic and orthotopic mouse xenograft models of lung cancer, LY2801653 decreased tumor growth, dramatically inhibiting mitotic events and angiogenesis.

Axon 2286

Page 471

Axon 2464

mg	Price
10	online
50	online

Axon 2554

mg	Price
5	online
25	online


Axon 2553

mg	Price
5	online
25	online

LY 2811376

[1194044-20-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C15H14F2N4S MW: 320.36




Biological activity

The first orally available non-peptidic BACE1 inhibitor (IC50 value ranges from 239-249 nM in vitro) that produces profound Aβ-lowering effects in animals. LY2811376 demonstrated ~10-fold selectivity toward BACE1 over BACE2, and >50-fold selectivity over cathepsin D, pepsin, or renin. Clinical development of LY 2811376 was terminated as a result of toxicology findings identified in longer-term preclinical studies.

LY 2874455

[1254473-64-7]
Purity: 99%

Soluble in DMSO
C21H19Cl2N5O2 MW: 444.31




Biological activity

Potent and selective FGFR inhibitor; LY2874455 inhibits autophosphorylation of FGFR-1, FGFR-2, FGFR-3, and FGFR-4 (with in vitro IC50 values of 2.8, 2.6, 6.4, and 6 nM, respectively), which is required for activation of FGF-induced downstream signaling

LY 2886721 hydrochloride

[1262036-49-6]
Purity: 99%

optically pure
Soluble in DMSO
C18H16F2N4O2S.HCl MW: 426.87



Biological activity


Orally active cell-permeable inhibitor of human β-secretase (BACE-1); potential agent to treat Alzheimer's Disease

LY 2940680

Taladegib

[1258861-20-9]
Purity: 99%

Soluble in DMSO
C26H24F4N6O MW: 512.50



Biological activity

Small-molecule antagonist of the Smoothed (SMO) receptor (IC50 value 2.4 nM), a key signal transducer in the hedgehog signalling pathway, responsible for the maintenance of normal embryonic development and implicated in carcinogenesis. LY 2940680 lacks an undesired inhibitory effect on CYP3A4.

Axon 2225

mg	Price
5	online
25	online

Axon 1981

mg	Price
2	online
5	online

Axon 1964

mg	Price
5	online
25	online

Axon 2196

mg	Price
5	online
25	online

LY139481

See *Raloxifene*

Axon 3250

Page 806

LY231514 disodium

See *Pemetrexed disodium*

Axon 3162

Page 758

LY2409021

See *Adomeglivant*


Axon 2388

Page 209

LY2857785

[1619903-54-6]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C26H36N6O MW: 448.60


Axon 3283

mg	Price
5	online
25	online

Biological activity


LY2857785 is a highly potent and selective type I reversible and competitive ATP kinase CDK9 inhibitor with an IC50 value of 0.011 μM. LY2857785 significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.

LYC-55716

Cintirorgon

[2055536-64-4]
Purity: 99%
99% e.e.

Soluble in DMSO
C27H23F6NO6S MW: 603.53


Axon 3740

mg	Price
5	online
10	online

Biological activity


LYC-55716 is a first-in-class, oral, selective RORgamma (γ) agonist, and a novel immuno-oncology agent. The retinoic acid-related orphan receptor gamma (γ) (RORγ) is a nuclear receptor transcription factor that acts as an immune cell master control switch. RORγ agonists modulate gene expression to reprogram immune cells for improved function, as well as decrease immunosuppressive mechanisms, resulting in decreased tumor growth and enhanced survival in in vivo preclinical models of cancer.

Source Information: Sold in collaboration with Chemietek

LYN-1604 dihydrochloride

[2310109-38-5]
Purity: 98%

Soluble in water, DMSO and EtOH
C33H43Cl2N3O2.2HCl MW: 657.54


Axon 3843

mg	Price
10	online
50	online


Biological activity

LYN-1604 dihydrochloride is a potent ULK1 agonist with an EC50 value of 18.94 nM. LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.

M8-B hydrochloride

[883976-12-3]
Purity: 99%

Soluble in water and DMSO
C22H24N2O3S.HCl MW: 432.96



Axon 2423

mg	Price
10	online
50	online

Biological activity


Selective and potent antagonist of the transient receptor potential melastatin-8 (TRPM8) channel with *in vitro* and *in vivo* activity. M8-B blocked cold-induced and TRPM8-agonist-induced activation of TRPM8 channels (IC50 values 7.8 nM, 26.9 nM, and 64.3 nM following activation by cold, icilin or menthol, respectively), and decreased deep body temperature in mice and rats *in vivo*. M8-B did not block other TRP channels (IC50 > 20 μM).

M2698

MSC2363318A

[1379545-95-5]
Purity: 99%
100% e.e.

Soluble in DMSO
C21H19ClF3N5O MW: 449.86



Axon 3850

mg	Price
5	online
10	online

Biological activity

M2698 is an orally bioavailable, BBB penetrable p70S6K/Akt dual inhibitor and is highly potent *in vitro* (IC50 1 nM for p70S6K, Akt1 and Akt3 inhibition; IC50 17 nM for pGSK3β indirect inhibition) and *in vivo* (IC50 15 nM for pS6 indirect inhibition), and relatively selective (only 6/264 kinases had an IC50 within 10-fold of p70S6K). Orally administered M2698 crossed the blood-brain barrier in rats and mice, with brain tumor exposure 4-fold higher than non-disease brain. Dose-dependent inhibition of target substrate phosphorylation was observed *in vitro* and *in vivo*, indicating that M2698 blocked p70S6K to provide potent PAM pathway inhibition while simultaneously targeting Akt to overcome the compensatory feedback loop. M2698 demonstrated dose-dependent tumor growth inhibition in mouse xenograft models derived from PAM pathway-dysregulated human triple-negative (MDA-MB-468) and Her2-expressing breast cancer cell lines (MDA-MB-453 and JIMT-1), and reduced brain tumor burden and prolonged survival in mice with orthotopically implanted U251 glioblastoma.


Source Information: Sold in collaboration with Chemietek

M 24

M024/C21

[477775-14-7]
Purity: 98%

Soluble in DMSO
C23H29N3O4S2 MW: 475.62



Axon 1969

mg	Price
5	online
25	online

Biological activity

First reported non-peptide selective AT2 receptor agonist (Ki 0.4 nM and 10,000 nM for AT2 and AT1 respectively). M 24 shows a bioavailability of 20-30% after oral administration and a half-life estimated to 4 h in rat.


M-3258

[2285330-15-4]
Purity: 99%
99% e.e.

Axon 3724

mg	Price
5	online

Soluble in DMSO
C17H20BNO5 MW: 329.16



10 online

Biological activity


M-3258 is an orally-bioavailable potent and selective inhibitor of the immunoproteasome subunit LMP7 demonstrating >500-fold selectivity against β1c, β2c, β5c, β1i and β2i. M3258 displayed favorable pharmacokinetics and demonstrated strong LMP7 inhibition and anti-tumor activity in several multiple myeloma xenografts, including models that were refractory to Bortezomib.

Source Information: Sold in collaboration with Chemietek

M344 Recent Addition

[251456-60-7]
Purity: 98%

Soluble in 0.1N NaOH(aq), 0.1N HCl(aq), DMSO and EtOH
C16H25N3O3 MW: 307.39



Axon 4238

mg	Price
10	online
50	online

Biological activity


M344 is a potent HDAC inhibitor (IC50 value of 100 nM) and an inducer of terminal cell differentiation.

M-3814

Nedisertib; MSC2490484A; Pepsosertib

[1637542-33-6]
Purity: 99%
99% e.e.

Soluble in DMSO
C24H21ClF3N5O3 MW: 481.91



Axon 3577

mg	Price
10	online
50	online

Biological activity

M-3814 (Nedisertib) is an orally available, highly potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK). It targets tumor cell growth and survival by inhibiting a critical Double-Strand Breaks (DSB) DNA damage repair mechanism. M3814 sensitizes multiple tumor cell lines to radiation therapy *in vitro*, and strongly potentiates the antitumor activity of ionizing radiation (IR) *in vivo* (Xenotransplanted Tumors in Nude Mice) (ref 1) with complete tumor regression applying a clinically relevant fractionated radiation regimen. It is currently in clinical evaluation.

M024/C21

See M 24


Axon 1969

Page 637

MAPK13 inhibitor compound 61

[229002-10-2]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C20H23N5O2 MW: 365.43



Axon 3620

mg	Price
10	online
50	online

Biological activity

MAPK13 inhibitor compound 61 is an inhibitor of MAPK13 (p38 δ) with an IC₅₀ value of 620 nM.

M-ADOT, 8-

See AH 001


Axon 1335

Page 215

Mandipropamid

[374726-62-2]
Purity: 99%

Soluble in DMSO and EtOH
C₂₃H₂₂ClNO₄ MW: 411.88



Axon 3601

mg	Price
50	online

Biological activity


Mandipropamid, a fungicide extensively used in agriculture, is a highly cell-permeable chemical inducer of proximity (CIP) for *in vivo* applications. Mandipropamid specifically induces complex formation between a sixfold mutant of the plant hormone receptor pyrabactin resistance 1 (PYR1) and abscisic acid insensitive (ABI).

Manidipine dihydrochloride Recent Addition

CV4093

[89226-75-5]
Purity: 99%

Soluble in DMSO and EtOH
C₃₅H₃₈N₄O₆·2HCl MW: 610.70



Axon 4202

mg	Price
50	online


Biological activity

Manidipine dihydrochloride is a second generation dihydropyridine calcium antagonist, which inhibits the voltage-dependent calcium inward currents in smooth muscle cells.

Martinostat hydrochloride

[N.A.]
Purity: 99%

Soluble in DMSO and EtOH
C₂₂H₃₀N₂O₂·HCl MW: 390.95



Axon 4099

mg	Price
10	online
50	online

Biological activity

Martinostat hydrochloride is a HDAC inhibitor and showed nanomolar IC₅₀ values for class-I HDAC isoforms (HDAC 1–3, 0.3, 2.0, and 0.6 nM, respectively), and the class-IIb HDAC 6 (4.1 nM), with >100-fold selectivity over each of the other HDAC isoforms assayed.

M-PDOT, 8-

See AH 002

Axon 1336

Page 215

MA-5

See Mitochondic acid 5


Axon 3197

Page 658

MALT1 inhibitor MI-2

[1047953-91-2]
Purity: 100%

Soluble in DMSO
C₁₉H₁₇Cl₃N₄O₃ MW: 455.72



Axon 2054

mg	Price
5	online
25	online

Biological activity

Highly potent and selective MALT1 inhibitor; MI-2 binds directly to MALT1 and suppresses activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) *in vitro* and *in vivo*. MI-2 is notably nontoxic to mice

Masitinib mesylate

See AB 1010

Axon 1419

Page 196

Mavacamten

See MYK-461

Axon 2683

Page 685

MB-10

See MitoBloCK-10


Axon 3910

Page 657

MBCQ

[150450-53-6]
Purity: 99%

Soluble in DMSO
C₁₆H₁₂ClN₃O₂ MW: 313.74



Axon 3401

mg	Price
5	online
25	online

Biological activity

MBCQ is a potent and selective cGMP phosphodiesterase (PDE5) inhibitor with an IC₅₀ value of 0.019 μ M.

MBCQ derivative C43

See Spautin 1


Axon 2512

Page 883

MBQ-167

[2097938-73-1]
Purity: 98%

Soluble in DMSO
C₂₂H₁₈N₄ MW: 338.41



Axon 2777

mg	Price
10	online
50	online


Biological activity

MBQ-167 is an effective Rac and Cdc42 inhibitor with IC₅₀ values of 78 nM and 103 nM, respectively. MBQ-167 significantly decreases Rac and Cdc42 downstream effector p21-activated kinase (PAK) signaling and the activity of STAT3, without affecting Rho, MAPK, or Akt activities. MBQ-167 also inhibits breast cancer cell migration, viability, and mammosphere formation.

MBX 2982

[1037792-44-1]
Purity: 98%

Soluble in DMSO
C22H24N8OS MW: 448.54



Biological activity

Potent and selective agonist of G-protein coupled receptor 119 (GPR119); an orally active agent to treat type 2 diabetes; MBX 2982 acts directly on the beta cell to increase insulin secretion. In addition, it stimulates release of the incretin GLP-1 from the gut

MC4171

[3034769-78-0]
Purity: 98%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C21H15N3O3 MW: 357.36



Biological activity

MC4171 is a first-in-class potent and selective inhibitor of the lysine acetyltransferase KAT8 with an IC50 value of 8.1 μM. Moreover, MC4171 exhibited mid-micromolar antiproliferative activity in different cancer cell lines, including NSCLC and AML, without impacting the viability of nontransformed cells.

MC70 hydrochloride

[N.A.]
Purity: 98%

Soluble in DMSO
C24H25NO3.HCl MW: 411.92



Biological activity

Potent P-gp inhibitor with good selectivity towards BCRP pump (EC50 values 0.05 μM, 0.69 μM, 9.3 μM, and 73 μM for Caco-2, MDR1, MRP1, and BCRP inhibition, respectively), with potential as novel anticancer agent with both cytostatic and cytotoxic characteristics. MC70, as an inhibitor of the ABC transporter ABCB1 (aka MDR1), potentiates Doxorubicin efficacy in colon and breast cancer in vitro treatment.

MC 1568

[852475-26-4]
Purity: 98%

Soluble in DMSO
C17H15FN2O3 MW: 314.31


Biological activity

Potent and selective class II (Ila) histone deacetylase (HDAC) inhibitor

Axon 2092


mg	Price
5	online
25	online

MCC950 sodium salt

CP456773; CRID3

[256373-96-3]
Purity: 98%

Soluble in water, DMSO and EtOH
C20H23N2NaO5S MW: 426.46


Biological activity

MCC950 sodium salt is a highly potent and selective inhibitor of the NLRP3 inflammasome with IC50 values of 7.5 nM and 8.1 nM in mouse bone marrow derived macrophages (BMDM) and human monocyte derived macrophages (HMDM), respectively. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation.


Axon 4052

mg	Price
10	online
50	online

MC4171

[3034769-78-0]
Purity: 98%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C21H15N3O3 MW: 357.36



Biological activity

MC4171 is a first-in-class potent and selective inhibitor of the lysine acetyltransferase KAT8 with an IC50 value of 8.1 μM. Moreover, MC4171 exhibited mid-micromolar antiproliferative activity in different cancer cell lines, including NSCLC and AML, without impacting the viability of nontransformed cells.

MC70 hydrochloride

[N.A.]
Purity: 98%

Soluble in DMSO
C24H25NO3.HCl MW: 411.92



Biological activity

Potent P-gp inhibitor with good selectivity towards BCRP pump (EC50 values 0.05 μM, 0.69 μM, 9.3 μM, and 73 μM for Caco-2, MDR1, MRP1, and BCRP inhibition, respectively), with potential as novel anticancer agent with both cytostatic and cytotoxic characteristics. MC70, as an inhibitor of the ABC transporter ABCB1 (aka MDR1), potentiates Doxorubicin efficacy in colon and breast cancer in vitro treatment.

MC 1568

[852475-26-4]
Purity: 98%

Soluble in DMSO
C17H15FN2O3 MW: 314.31


Biological activity

Potent and selective class II (Ila) histone deacetylase (HDAC) inhibitor

Axon 4011


mg	Price
10	online
50	online

MCI-INI-3

ZINC20606903

[1011366-31-6]
Purity: 98%

Soluble in DMSO
C21H15N3O4 MW: 373.36


Biological activity

MCI-INI-3 is a potent and selective inhibitor of ALDH1A3 with an IC50 value of 0.46 μM and a Ki value of 0.55 μM. Moreover, MCI-INI-3 showed greater than 140-fold selectivity for ALDH1A3 as compared to the closely related isoform ALDH1A1.

Axon 3880

mg	Price
5	online
25	online

MCL

See Micheliolide


MCN 3377-98

See Fenobam

MCUF-651

[2747162-85-0]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C17H22F2N4OS MW: 368.44


Biological activity

MCUF-651 is a selective and orally bioavailable PAM of guanylyl cyclase A receptor (GC-A) with an EC50 value of 0.45 μM in HEK293 GC-A cells. MCUF-651 exhibits therapeutic activity in human hypertension and heart failure ex vivo.

Axon 3607

Page 654

Axon 1345

Page 478

Axon 3600

mg	Price
5	online
25	online

MD-2 inhibitor L6H21

See L6H21

Axon 3683

Page 602

MD 69276

See Toloxatone


Axon 2977

Page 935

MDL 100009

MDL 100907, (S)-(-)-

[175673-57-1]
Purity: 99%
98% ee
Soluble in DMSO and Ethanol
C22H28FNO3 MW: 373.46


Axon 1105

mg	Price
5	online
25	online

Biological activity


S-enantiomer of MDL 100151 (Axon 1103); opposite enantiomer of MDL 100907 (Axon 1104), selective 5-HT2A antagonist

MDL 100151

MDL 100907, (±)-

[139290-69-0]
Purity: 99%

Soluble in DMSO and Ethanol
C22H28FNO3 MW: 373.46


Axon 1103

mg	Price
10	online
50	online


Biological activity

Selective 5-HT2A antagonist; rac-M 100907, its more active enantiomer is (+)-MDL 100907 (Axon 1104); Reference standard for [¹¹C]MDL100907 in PET/SPECT study

MDL 100907

Volinanserin; MDL 100907, (R)-(+)-

[139290-65-6]
Purity: 99%
98% ee
Soluble in DMSO and Ethanol
C22H28FNO3 MW: 373.46


Axon 1104

mg	Price
5	online
25	online

Biological activity

A highly selective 5-HT2A antagonist, more active enantiomer of MDL 100151 (Axon 1103) in comparison with S-(-)-enantiomer (Axon 1105); a highly recommended tool compound in researching into 5-HT2A receptors

MDL 100907, (±)-

See MDL 100151

Axon 1103

Page 643

MDL 100907, (R)-(+)-

See MDL 100907

Axon 1104

Page 643

MDL 100907, (S)-(-)-

See MDL 100009

Axon 1105

Page 643

MDL 105725


See MDL 105725, (+)-

Axon 1107

Page 644

MDL 105725, (-)-

[311348-81-9]
Purity: 99%
98% ee
Soluble in DMSO
C21H26FNO3 MW: 359.43


Axon 1108

mg	Price
5	online
25	online


Biological activity

Less active metabolite of MDL 100907 (Axon 1105), a selective 5-HT2A antagonist; Precursor for [¹¹C]MDL100907

MDL 105725, (+)-

MDL 105725

[189192-18-5]
Purity: 99%
98% ee
Soluble in DMSO
C21H26FNO3 MW: 359.43


Axon 1107

mg	Price
1	online
5	online


Biological activity

Active metabolite of MDL 100907 (Axon 1104), a selective 5-HT2A antagonist; Precursor for [¹¹C]MDL100907

MDL 105725, (±)-

[1018473-89-6]
Purity: 99%

Soluble in DMSO
C21H26FNO3 MW: 359.43


Axon 1106

mg	Price
10	online
50	online


Biological activity

Active metabolite of M100907

MDL 201012

[136722-45-7]
Purity: 98%

Soluble in DMSO
C19H25NO2 MW: 299.41


Axon 1679

mg	Price
10	online
50	online

Biological activity

Selective M3 muscarinic receptor antagonist; orally active antimuscarinic agent

MDV 3100


[915087-33-1]
Purity: 98%

Soluble in DMSO

Axon 1613

mg	Price
5	online
25	online

C21H16F4N4O2S MW: 464.44




Biological activity

An orally active and very potent antagonist of androgen receptor (AR); Second-generation of antiandrogen for the treatment of advanced prostate cancer; highly recommended tool in AR research

ME0328

[1445251-22-8]
Purity: 99%
Optically pure
Soluble in DMSO
C19H19N3O2 MW: 321.37



Axon 2759


mg	Price
10	online
50	online

Biological activity

ME0328 is a potent, cell-permeable, selective inhibitor of PARP3/ARTD3 (IC50 value of 0.9 μM).

ME-401

[1595129-71-7]
Purity: 98%
Soluble in DMSO
C31H40N8O3S MW: 604.77



Axon 3098

mg	Price
5	online
25	online

Biological activity

ME-401 is an oral, potent and selective inhibitor of phosphatidylinositol 3 kinase p110δ (PI3Kδ) with an IC50 value of 0.6 nM (cellular assay).

Meclinetant

See SR 48692

Axon 1164

Page 887

Medetomidine hydrochloride, (+)-


See Dexmedetomidine hydrochloride

Axon 3065

Page 423

Medetomidine hydrochloride

[86347-15-1]
Purity: 99%
Soluble in water and DMSO
C13H16N2.HCl MW: 236.74



Axon 3066

mg	Price
10	online
50	online

Biological activity

Medetomidine hydrochloride is a potent and selective α2-adrenergic receptor agonist with Ki values of 1750 nM and 1.08 nM for the α1- and α2-adrenergic receptors, respectively. The active enantiomer, Dexmedetomidine hydrochloride (Axon 3065), is also available.

MEK162

See Binimetinib

Axon 3697

Page 308

Memogain

See GLN-1062

Axon 3707

Page 504

Mepirodipine hydrochloride

See Barnidipine hydrochloride

Axon 3014

Page 284

Mercaptopurine, 6-

SK5357

[50-44-2]
Purity: 100%



Soluble in 0.1N NaOH(aq) and DMSO
C5H4N4S MW: 152.18

Axon 3245

mg	Price
50	online

Biological activity

6-Mercaptopurine, a purine analog, acts as an antagonist to the endogenous purines that are essential components of DNA, RNA, and some coenzymes. Immunosuppressant.

Merestinin

See LY 2801653

Axon 2553

Page 633

MESNA

See Mesna


Axon 3246

Page 646

Mesna

MESNA

[19767-45-4]
Purity: 98%



Soluble in water and DMSO
C2H5NaO3S2 MW: 164.18

Axon 3246

mg	Price
50	online


Biological activity

Mesna is an agent that protects against cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis.

Metapristone

RU42633

[104004-96-8]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq), DMSO and EtOH
C28H33NO2 MW: 415.57



Axon 3268

mg	Price
10	online
50	online


Biological activity

Metapristone, the primary metabolite of RU486 (Axon 1502), suppressed NSCLC proliferation by promoting apoptosis via decrease the cellular EGFR-mediated PI3K/AKT pathways. In addition, metapristone inhibited anti-apoptotic marker Bcl-2, and activated pro-apoptotic key signaling proteins caspase-3, and poly (ADP-ribose) polymerase. Metapristone induced A549 and H1975 cell cycle via arrest at the G0-G1 stage. Moreover, metapristone inhibited endometrial cancer cell growth through suppressing cell proliferation and activating cell apoptosis-related signaling pathway. Mechanically, metapristone regulated miR-492 and its new target genes Klf5 and Nrf1 in vitro and in vivo to treat endometrial cancer.

Metaxalone

[1665-48-1]
Purity: 100%

Soluble in DMSO and EtOH
C₁₂H₁₅NO₃ MW: 221.25



Axon 3815

mg	Price
50	online


Biological activity

Metaxalone is a skeletal muscle relaxant.

Methotrexate

Amethopterin; MTX; 4-Amino-10-methylfolic acid

[59-05-2]
Purity: 99%
Optically pure
Soluble in DMSO
C₂₀H₂₂N₈O₅ MW: 454.44



Axon 3319

mg	Price
50	online

Biological activity


Methotrexate is a potent, competitive inhibitor of dihydrofolate reductase (DHFR), and reduces metabolically active intracellular folates decreasing the de novo synthesis of purines and pyrimidines (precursors of DNA and RNA) required for cellular proliferation. Disease-modifying anti-rheumatic drug (DMARD).

Methoxsalen

Xanthotoxin; 8-Methoxypsoralen; 8-MOP

[298-81-7]
Purity: 99%

Soluble in DMSO and EtOH
C₁₂H₈O₄ MW: 216.19



Axon 3449

mg	Price
50	online

Biological activity

Methoxsalen is a very potent inhibitor of human cytochrome P450 2A6 (CYP2A6).

Methoxybenzamide, N-{2-[(3-cyano-5,7-dimethyl-2-quinolinyl)amino]ethyl}-3-

See CoPo 22

Axon 1763

Page 385

Methoxy-2-aminotetraline hydrochloride, (R)-(+)-5-

See *Aminotetraline hydrochloride, (R)-(+)-5-Methoxy-2-*

Axon 1049

Page 229

Methoxy-2-aminotetraline hydrochloride, (R)-(+)-8-

See *Aminotetraline hydrochloride, (R)-(+)-8-Methoxy-2-*

Axon 1058

Page 229

Methoxy-2-aminotetraline hydrochloride, (R)-7-

See *Aminotetraline hydrochloride, (R)-7-Methoxy-2-*

Axon 1055

Page 230

Methoxy-2-aminotetraline hydrochloride, (S)-(-)-5-

See *Aminotetraline hydrochloride, (S)-(-)-5-Methoxy-2-*

Axon 1050

Page 230

Methoxy-2-aminotetraline hydrochloride, (S)-(-)-8-

See *Aminotetraline hydrochloride, (S)-(-)-8-Methoxy-2-*

Axon 1059

Page 230

Methoxy-2-aminotetraline hydrochloride, (S)-7-

See *Aminotetraline hydrochloride, (S)-7-Methoxy-2-*

Axon 1056

Page 231

Methoxy-2-aminotetraline hydrochloride, 5-

See *Aminotetraline hydrochloride, 5-Methoxy-2-*

Axon 1048

Page 232

Methoxy-2-aminotetraline hydrochloride, 7-

See *Aminotetraline hydrochloride, 7-Methoxy-2-*

Axon 1054

Page 232

Methoxy-2-aminotetraline hydrochloride, 8-

See *Aminotetraline hydrochloride, 8-Methoxy-2-*

Axon 1057

Page 233

Methoxy-N-propyl-2-aminotetraline hydrochloride, (R)-(+)-7-

See *Aminotetraline hydrochloride, (R)-(+)-7-Methoxy-N-propyl-2-*

Axon 1030

Page 229

Methoxy-N-propyl-2-aminotetraline hydrochloride, (R)-5-

See *Aminotetraline hydrochloride, (R)-5-Methoxy-N-propyl-2-*

Axon 1026

Page 229

Methoxy-N-propyl-2-aminotetraline hydrochloride, (R)-8-

See *Aminotetraline hydrochloride, (R)-8-Methoxy-N-propyl-2-*

Axon 1033

Page 230

Methoxy-N-propyl-2-aminotetraline hydrochloride, (S)-(-)-7-

See *Aminotetraline hydrochloride, (S)-(-)-7-Methoxy-N-propyl-2-*

Axon 1031

Page 230

Methoxy-N-propyl-2-aminotetraline hydrochloride, (S)-5-

See *Aminotetraline hydrochloride, (S)-5-Methoxy-N-propyl-2-*

Axon 1027

Page 231

Methoxy-N-propyl-2-aminotetraline hydrochloride, (S)-8-

 See *Aminotetraline hydrochloride, (S)-8-Methoxy-N-propyl-2-*
Axon 1034

Page 231

Methoxy-N-propyl-2-aminotetraline hydrochloride, 5-

 See *Aminotetraline hydrochloride, 5-Methoxy-N-propyl-2-*
Axon 1025

Page 232

Methoxy-N-propyl-2-aminotetraline hydrochloride, 6-

 See *Aminotetraline hydrochloride, 6-Methoxy-N-propyl-2-*
Axon 1028

Page 232

Methoxy-N-propyl-2-aminotetraline hydrochloride, 7-

 See *Aminotetraline hydrochloride, 7-Methoxy-N-propyl-2-*
Axon 1029

Page 232

Methoxy-N-propyl-2-aminotetraline hydrochloride, 8-

 See *Aminotetraline hydrochloride, 8-Methoxy-N-propyl-2-*
Axon 1032

Page 233


Methoxypsoralen, 8-

 See *Methoxsalen*
Axon 3449

Page 647

Methyl-3-cyclopentyl-2-(4-methylsulfonylphenyl)propionate

 [300355-19-5]
 Purity: 97.0%

 No solubility data
 C₁₆H₂₂O₄S MW: 310.41

Axon 1135

mg Price

1000 online

5000 online


Biological activity
Building Block
Methyl-N-propyl-2-aminotetraline hydrochloride, N-

 See *Aminotetraline hydrochloride, N-Methyl-N-propyl-2-*
Axon 1023

Page 233

Methyl-prop-2-ynyl-(1,2,3,4-tetrahydro-naphthalen-2-yl)-amine hydrochloride, (-)-enantiomer

 [98640-73-4]
 Purity: 99%
 >98% ee

 Soluble in water
 C₁₄H₁₇N.HCl MW: 235.75

Axon 1063

mg Price


5 online

25 online

Biological activity
Dopamine receptor agonist
Methyl-prop-2-ynyl-(1,2,3,4-tetrahydro-naphthalen-2-yl)-amine hydrochloride, (+)-enantiomer
Axon 1062

mg Price

[98640-74-5]


 Purity: 99%
 >98% ee
 Soluble in water
 C₁₄H₁₇N.HCl MW: 235.75


5 online

25 online

Biological activity
Dopamine receptor agonist
Methylhistamine dihydrochloride, 4-

 [36376-47-3]
 Purity: 98%

 Soluble in water and DMSO
 C₆H₁₁N₃.2HCl MW: 198.09

Axon 1261


mg Price

10 online

50 online

Biological activity
Potent and selective histamine H4 agonist
Methylprednisolone

 [83-43-2]
 Purity: 99%

 Soluble in DMSO and EtOH
 C₂₂H₃₀O₅ MW: 374.47

Axon 2066

mg Price


50 online

250 online

Biological activity
A synthetic glucocorticoid or corticosteroid drug; anti-inflammatory
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Methylthioadenosine, 2-
Adenosine, 2-MeS-; NSC 36900

 [4105-39-9]
 Purity: 97.0%

 No solubility data
 C₁₁H₁₅N₅O₄S MW: 313.33

Axon 1192


mg Price

10 online

50 online

Biological activity
Adenosine precursor for 2-MeS-ATP or 2-MeS-ADP or 2-MeS-AMP
Metoclopramide

 [364-62-5]
 Purity: 99%

 Soluble in 0.1N HCl(aq) and DMSO
 C₁₄H₂₂ClN₃O₂ MW: 299.80

Axon 3378

mg Price

50 online


Biological activity
Metoclopramide is a stimulant of upper gastrointestinal motility and an antiemetic agent. Effects of metoclopramide are believed to be due to a combination of a relatively weak serotonin 5-HT₃ and dopamine D₂ receptors antagonism and a serotonin 5-HT₄ receptor agonism.

Metolazone

SR 720-22

[17560-51-9]
Purity: 99%

Soluble in DMSO and EtOH
C16H16ClN3O3S MW: 365.83



Axon 4026

mg	Price
50	online

Biological activity


Metolazone is a diuretic agent. Metolazone impairs sodium chloride reabsorption in the early portion of the distal convoluted tubule.

Mexiletine hydrochloride

Ko1173

[5370-01-4]
Purity: 100%

Soluble in water, DMSO and EtOH
C11H17NO.HCl MW: 215.72



Axon 3454


mg	Price
50	online

Biological activity

Mexiletine hydrochloride is a class Ib antiarrhythmic drug. The primary mechanism of action is blocking fast sodium channels, reducing the phase 0 maximal upstroke velocity of the action potential.

MG 132

[133407-82-6]
Purity: 98%
Optically pure
Soluble in DMSO
C26H41N3O5 MW: 475.62



Axon 1869

mg	Price
10	online
50	online


Biological activity

Specific, potent, reversible, and cell-permeable proteasome inhibitor ($K_i = 4$ nM). MG132 inhibits NF- κ B activation with an IC_{50} of 3 μ M and prevents β -secretase cleavage. MG132 also activates c-Jun N-terminal kinase (JNK1), which initiates apoptosis.

MG 149

[1243583-85-8]
Purity: 100%

Soluble in DMSO
C22H28O3 MW: 340.46



Axon 1785

mg	Price
5	online
25	online

Biological activity

A novel anacardic acid analog; potent and selective inhibitor of the MYST family (Tip60 and MOZ) of histone acetyltransferase (HAT). In addition, it effectively inhibits acetyltransferase activity of HeLa cells nuclear extracts

MG 0103

See Mocetinostat

Axon 2505

Page 675

MG265 dihydrochloride

See MGCD265 dihydrochloride

Axon 3975

Page 652

MGCD 0103

See Mocetinostat

Axon 2505


Page 675

MGCD265 dihydrochloride

Glesatinib dihydrochloride; MG265 dihydrochloride

[N.A.]
Purity: 99%

Soluble in DMSO
C31H27F2N5O3S2.2HCl MW: 692.63



mg	Price
5	online
25	online

Biological activity

MGCD265 is an orally bioavailable, multitargeted tyrosine kinase inhibitor. It binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). It is currently being evaluated clinically in patients with solid tumors that have genetic alterations in MET or AXL genes, which have been implicated as drivers of tumor growth and disease progression in NSCLC, gastroesophageal cancer and other solid tumors.


Source Information: Sold in collaboration with Chemietek

MGCD516

Sitravatinib

[1123837-84-2]
Purity: 98%

Soluble in DMSO
C33H29F2N5O4S MW: 629.68



Axon 3998

mg	Price
10	online
50	online

Biological activity

MGCD516 is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC_{50} s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.

Source Information: Sold in collaboration with Chemietek


MG degrader compound E14 Recent Addition

[N.A.]
Purity: 98%

Soluble in DMSO and EtOH
C31H37N5O7 MW: 591.66

Axon 4143

mg	Price
5	online
25	online



Biological activity


MG degrader compound E14 is a potent molecular glue (MG) degrader targeting IKZF1/3, GSPT1 and 2 with profound effects on a panel of cancer cells (EC50 values of 11.08 nM and 1.485 nM in MM.1S and NCI-H929 cells, respectively).

MGL-3196

VIA-3196

[920509-32-6]
Purity: 99%

Soluble in DMSO
C17H12Cl2N6O4 MW: 435.22




Biological activity

Oral, liver-targeted, selective thyroid hormone receptor β -agonist (EC50 value 0.21 μ M for THR- β) that is being developed for the treatment of dyslipidemia. MGL-3196 is 28-fold selective for THR- β over THR- α in an in vitro functional coactivator recruitment assay.

MHY-1685

[27406-31-1]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C11H8N2O4 MW: 232.19




Biological activity

MHY-1685 is an mTOR inhibitor which possesses antioxidant properties and protects against hCSC senescence through autophagy activation.

MHY 553

[6265-56-1]
Purity: 98%

Soluble in DMSO
C13H9NO2S MW: 243



Biological activity

MHY 553 is a PPAR α agonist that improved aged-induced hepatic steatosis, in part by increasing β -oxidation signaling and decreasing inflammation in the liver. Potential pharmaceutical agent for treating hepatic steatosis in aging.


Axon 2657

mg	Price
5	online
25	online

MHY 908

[1393371-39-5]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C17H14ClNO3S MW: 347.82




Biological activity

Dual PPAR α/γ agonist, and potent inhibitor of melanogenesis by inhibition of mushroom tyrosinase activity (IC50 value 8.19 μ M). MHY908 more potently activated PPAR α and PPAR γ than fenofibrate and rosiglitazone, respectively. MHY-908 enhanced the binding and transcriptional activity of PPAR α and γ in AC2F cells, and it reduced serum glucose, triglyceride, and insulin levels, however increased adiponectin levels without body weight gain. In addition, MHY 908 significantly improved hepatic steatosis by enhancing CPT-1 levels. Remarkably, MHY-908 reduced endoplasmic reticulum (ER) stress and c-Jun N-terminal kinase (JNK) activation, and subsequently reduced insulin resistance.

MHY 1485

[326914-06-1]
Purity: 99%

Soluble in DMSO
C17H21N7O4 MW: 387.39



Biological activity

mTOR activator with an inhibitory effect on autophagy. MHY1485 markedly increased the LC3II/LC3I ratio dose-dependently and time-dependently by inhibition of the fusion between autophagosomes and lysosomes, and without increasing the autophagic flux. At 2 μ M, MHY1485 did not show any cell death during longer treatment, supporting that MHY1485 had less toxicity than other well-known inhibitors of autophagy. MHY1485 was also tested and found moderately active as antimalarial agent (MIC value of ca. 26 μ M against *P. falciparum*).

MI-77301

See SAR405838

Mianserin, 6-Aza-


See Mirtazapine

MIBG

iobenguane sulfate

[103346-16-3]
Purity: 98%

Soluble in DMSO
C8H10IN3.H2O4S MW: 373.17



Biological activity

MIBG standard; Radioiodinated iobenguane (or MIBG) is a radiopharmaceutical, used in a scintigraphy method called MIBG scan. Radioiodinated iobenguane is used to treat certain kinds of cancer of the adrenal glands

Micheliolide

MCL

Axon 2402

mg	Price
5	online
25	online

Axon 2425

mg	Price
10	online
50	online

Axon 2741

Page 843

Axon 1138

Page 655


Axon 1750

mg	Price
10	online
50	online

Axon 3607

mg	Price
----	-------

[68370-47-8]
Purity: 100%
Optically pure
Soluble in DMSO
C15H20O3 MW: 248.32



5 online

Biological activity


Micheliolide, a guaianolide sesquiterpene lactone, is an inhibitor of NF-κB pathway activation leading to downregulation of major inflammatory mediator expression such as TNFα and IL-1β. Moreover, MCL has been reported as inhibitor of acute leukemic cells. The prodrug of MCL, ACT001 is also available as Axon 3590.

Mifepristone

RU 38486; RU 486

[84371-65-3]
Purity: 99%

Soluble in DMSO
C29H35NO2 MW: 429.59



Axon 1502

mg	Price
10	online
50	online

Biological activity

A progesterone receptor (PR) antagonist, used as an abortifacient in the first two months of pregnancy, and in smaller doses as an emergency contraceptive

Mifepristone, Hydroxy-


See RU 42698

Axon 1558

Page 835

Miglitol

[72432-03-2]
Purity: 98%
Optically pure
Soluble in water and DMSO
C8H17NO5 MW: 207.22



Axon 2067

mg	Price
10	online
50	online

Biological activity


Alpha-glucosidase inhibitor; an oral anti-diabetic drug

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

MIK665

S64315

[1799631-75-6]
Purity: 99%
99% e.e.
Soluble in DMSO
C47H44ClFN6O6S MW: 875.41



Axon 3713

mg	Price
5	online
10	online

Biological activity

MIK665 is a clinical-stage, BH3-Groove binding Mcl-1 inhibitor, potently and selectively binding to the protein target with Ki in picomolar range. Demonstrate in vitro and in vivo antitumor efficacy in Mcl-1 dependent cancer

models. Achieve superior activity and enhanced solid tumor response when applied in combination with Bcl-2 inhibitors such as ABT-199 (Axon 2141) or BCL-201 (Axon 3714).

Source Information: Sold in collaboration with Chemietek

Milademetan

See DS-3032

Axon 3765


Page 443

Milrinone

WIN 47203

[78415-72-2]
Purity: 100%

Soluble in DMSO
C12H9N3O MW: 211.22



Axon 3314

mg	Price
10	online
50	online

Biological activity


Milrinone is a positive inotropic phosphodiesterase III inhibitor and vasodilator agent. Milrinone inhibits the intracellular hydrolysis of cyclic AMP, thereby promoting cyclic AMP-catalysed phosphorylation of sarcolemmal calcium channels and activating the calcium pump.

Miltefosine

Hexadecylphosphocholine; HPC; HePC

[58066-85-6]
Purity: 98%

Soluble in water
C21H46NO4P MW: 407.57



Axon 3247

mg	Price
50	online
250	online

Biological activity

Miltefosine is an inhibitor of the PI3K-Akt/PKB survival pathway with ED50 values of 17.2 and 8.1 μM in the human epithelial carcinoma cell lines A431 and HeLa, respectively.

MIN101

See Roluperidone


Axon 3859

Page 829

MINA53 inhibitor compound 10

[N.A.]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C14H14N2O3S MW: 290.34



Axon 3599

mg	Price
10	online
50	online

Biological activity

MINA53 inhibitor compound 10 is a first-in-class, potent and selective ribosomal oxygenase MINA53 inhibitor with an IC50 value of 1.5 μM.


Mincycline hydrochloride

[13614-98-7]
Purity: 99%
Optically pure
Soluble in water and DMSO

Axon 3381

mg	Price
50	online

C23H27N3O7.HCl MW: 493.94




Biological activity

Minocycline hydrochloride is an orally active, brain-penetrant, second-generation broad-spectrum antibiotic.

Minoxidil

[38304-91-5]
Purity: 99%

Soluble in DMSO and EtOH
C9H15N5O MW: 209.25




Biological activity

Minoxidil is a potent arteriolar vasodilator and antihypertensive agent. The antihypertensive activity of minoxidil is due to its sulphate metabolite, minoxidil sulfate. In large measure, minoxidil acts by opening adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells. Also, Minoxidil affects follicular cells by enhancing hair growth and reducing hair loss.

Mirabegron

YM 178; Betanis

[223673-61-8]
Purity: 99%
Optically pure
Soluble in DMSO
C21H24N4O2S MW: 396.51



Biological activity


Highly selective and orally active agonist of the human β_3 -adrenoceptor (EC_{50} value 22.4 nM) with >440 fold selectivity over β_1 , and β_2 . FDA approved therapeutic drug for the treatment of symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence. YM178 (Mirabegron) does not affect the amplitude of rhythmic bladder contractions at doses at which it reduces contraction frequency.

Mirtazapine

Mianserin, 6-Aza-, ORG 3770

[85650-52-8]
Purity: 99%

No solubility data
C17H19N3 MW: 265.35



Biological activity


A noradrenergic and specific serotonergic antidepressant (NaSSA); antagonizes selective adrenergic and serotonergic receptors so that both NE release and 5-HT_{1A} mediated serotonergic signaling are increased

MitoBloCK-10

MB-10

[394694-98-5]
Purity: 99%

Soluble in DMSO and EtOH



Axon 3490

mg	Price
50	online

Axon 2414

mg	Price
10	online
50	online

Axon 1138

mg	Price
10	online
50	online

Axon 3910

mg	Price
10	online
50	online

C12H8FN3O3S MW: 293.27

Biological activity


MitoBloCK-10 is an inhibitor of mitochondrial protein import component Tim44 and the first small molecule modulator to attenuate PAM complex activity.

Mitochondic acid 5

MA-5

[1354707-41-7]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C18H13F2NO3 MW: 329.30



Biological activity


Mitochondic acid 5 (MA-5) is a mitochondrial drug. MA-5 acts via the MAPK-ERK-Yap signaling pathway, which increases Bnip3-related mitophagy, leading to suppressed apoptotic signaling following the inflammatory response. MA-5 can protect mitochondrial function by regulating energy metabolism and reducing mitochondrial oxidative stress. Mitochondic acid 5 increased ATP, rescued mitochondrial disease fibroblasts and prolonged the life span of the disease model "Mitomouse".

Mitotane

o,p'-DDD

[53-19-0]
Purity: 100%

Soluble in DMSO
C14H10Cl4 MW: 320.04



Biological activity

Mitotane, a dichloro-diphenyl-trichloro-ethane (DDT) derivative, is an adrenocytolytic drug used for the treatment of adrenocortical carcinoma (ACC).

Mivebresib

See ABBV-075

M-IV

See Hydroxypropylglitazone

MIW815

See ADU-S100

MJN110

[1438416-21-7]
Purity: 98%

Soluble in DMSO
C22H21Cl2N3O4 MW: 462.33

Axon 3197

mg	Price
5	online
25	online

Axon 3248

mg	Price
50	online
250	online

Axon 3696

Page 197

Axon 2533


Page 552

Axon 3687

Page 210

Axon 2580

mg	Price
5	online
25	online




Biological activity

Potent, selective, and in-vivo-active MAGL inhibitor (IC50 values 9.5 nM and 260 nM for inhibition of mouse MAGL and ABHD6, respectively) displaying strong antihyperalgesic activity (mechanical allodynia) in a rat model of diabetic neuropathy. MJN110 exhibits therapeutic potential in the treatment of acute nausea and vomiting as well as anticipatory nausea by elevation of endogenous cannabinoid 2-arachidonoylglycerol (2-AG) levels in the brain.

MK2 inhibitor III

[724711-21-1]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C21H16N4O MW: 340.38



Axon 3440

mg	Price
5	online
25	online


Biological activity

MK2 inhibitor III is a potent and selective inhibitor of MK-2 with an IC50 value of 8.5 nM. MK2 inhibitor III was found to be effective in reducing TNF- α production in both U937 cells and in vivo.

MK 212 hydrochloride

[67250-10-6]
Purity: 99%

No solubility data
C8H11ClN4.HCl MW: 235.11



Axon 1214

mg	Price
10	online
50	online


Biological activity

5-HT2C receptor agonist

MK-3697

[1224846-01-8]
Purity: 99%

Soluble in DMSO
C23H21N5O3S MW: 447.51



Axon 3805

mg	Price
5	online
10	online

Biological activity

MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin receptor antagonist with $K_i = 0.95$ nM.

Source Information: Sold in collaboration with Chemietek

MK-6482

See Belzutifan


Axon 3760

Page 297

MK 677

Ibutamoren mesylate; L 163191

[159752-10-0]
Purity: 99%
optically pure
Soluble in water
C27H36N4O5S.CH4O3S MW:
624.77



Biological activity

Potent and orally active growth hormone (GH) secretagogue


MK 767

See KRP 297

MK 0354

[851776-28-8]
Purity: 99%

Soluble in DMSO
C7H8N6 MW: 176.18




Biological activity

Partial agonist of Niacin receptor, G-protein coupled receptor 109a

MK 0364

Taranabant

[701977-09-5]
Purity: 98%
optically pure
Soluble in DMSO
C27H25ClF3N3O2 MW: 515.95



Biological activity

Potent and selective cannabinoid receptor type 1 (CB1) antagonist and/or inverse agonist


MK 0457

See VX 680

MK 0524 sodium salt

Laropiprant

[572874-50-1]
Purity: 99%
optically pure
Soluble in water and Ethanol
C21H18ClFNNaO4S MW: 457.88



Biological activity

Potent and selective prostaglandin D2 (PGD2) receptor 1 (DP1) antagonist; K_i values to be 0.57 nM and 750 nM for DP1 and DP2 receptors respectively

Axon 1376

mg	Price
5	online
10	online

Axon 1567

Page 596

Axon 1576

mg	Price
10	online
50	online

Axon 1550

mg	Price
2	online
5	online
25	online

Axon 1540

Page 980

Axon 1480

mg	Price
5	online
25	online

MK0663

See Etoricoxib


Axon 3885

Page 470

MK 0822

Odanacatib

[603139-19-1]
 Purity: 99%
 optically pure
 Soluble in DMSO
 C25H27F4N3O3S MW: 525.56


Axon 1771

mg	Price
2	online
5	online
25	online


Biological activity

Potent and selective inhibitor of cathepsin K (CTSK or Cat K)

MK 1775

[955365-80-7]
 Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
 C27H32N8O2 MW: 500.60


Axon 1494

mg	Price
5	online
25	online


Biological activity

A potent and selective Wee1 kinase inhibitor in vitro and in vivo. MK 1775 abolishes cyclin-dependent kinase 1 (CDC2) activity by phosphorylation of the Tyr15 residue. It abrogates a DNA damage checkpoint (G2-phase), leading to apoptosis in combination with several DNA-damaging agents selectively in p53-deficient tumor cell lines. It is under clinical trial for advanced solid tumors

MK 2206

[1032350-13-2]
 Purity: 99%

Soluble in water and DMSO
 C25H21N5O.2HCl MW: 480.39


Axon 1684

mg	Price
5	online
25	online

Biological activity

An orally potent and highly selective non-ATP competitive allosteric Akt inhibitor that has nanomolar IC50 values and broad preclinical anti-tumor activities

MK306

See Cefoxitin sodium

Axon 3819

Page 357

MK 4827

See Niraparib

Axon 2928

Page 705

MK 5108


VX 689

Axon 1961

mg	Price
----	-------

[1010085-13-8]

Purity: 98%
 optically pure
 Soluble in DMSO
 C22H21ClFN3O3S MW: 461.94



5	online
25	online

Biological activity

Highly potent and selective inhibitor of Aurora A kinase (AurA); MK5108 exhibits marked effects on the growth of tumor cells in vitro and in vivo; also enhances the antitumor activity of Docetaxel without exacerbating the toxicity in vivo

MK 5348

See SCH 530348

Axon 1755

Page 856

MK-0476

See Montelukast sodium

Axon 3236

Page 677

MK-0518

See Raltegravir

Axon 3120

Page 807

MK-0683

See Vorinostat


Axon 3114

Page 972

MK-4482

EIDD-2801

[2349386-89-4]
 Purity: 99%
 Optically pure
 Soluble in water and DMSO
 C13H19N3O7 MW: 329.31


Axon 3188

mg	Price
5	online
25	online

Biological activity

MK-4482 (EIDD-2801) is a potent and orally bioavailable broad-spectrum antiviral drug under investigation. It is a modified version of its active nucleoside analog EIDD-1931 with an improved drug profile. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of MK-4482 improved pulmonary function and reduced virus titer and body weight loss.

MK647

See Diflunisal

Axon 3448

Page 427

MK733

See Simvastatin

Axon 3443

Page 866

MK 8353

See SCH900353

Axon 3803

Page 857

MK-8591

See Islatravir


Axon 3191

Page 570

MK-8617

[1187990-87-9]
Purity: 99%

Soluble in DMSO
C24H21N5O4 MW: 443.45



Biological activity

MK-8617 is a potent, orally active pan-inhibitor of HIF-PHD with IC50 values of 1 nM, 1 nM, and 14 nM for PHD1, PHD2 and PHD3, respectively. MK-8617 advanced to human clinical studies as an oral treatment for anemia.

MK-8776 dihydrochloride

See SCH900776 dihydrochloride

MK8931

See Verubecestat

MK-906

See Finasteride


MK966

See Rofecoxib

MKC-3946

[1093119-54-0]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C21H20N2O3S MW: 380.46




Biological activity

MKC-3946 is a potent and selective IRE1α inhibitor with an IC50 value of 0.39 μM.

MKC8866

[1338934-59-0]
Purity: 99%

Soluble in DMSO
C18H19NO7 MW: 361.35



Biological activity

MKC8866 is a potent IRE1α RNase-specific inhibitor with an IC50 value of 0.29 μM. In MM1 myeloma cells, MKC8866 strongly inhibited DTT-induced XBP1s expression with an EC50 of 0.52 μM.

ML 130

Axon 1888

mg Price

Axon 3095

mg Price


5 online

25 online

[799264-47-4]

Purity: 99%

Soluble in DMSO
C14H13N3O2S MW: 287.34



10 online

50 online

Biological activity

Potent and selective inhibitor of NOD1

ML136

See AMZ30

Axon 3682


Page 236

ML 154

NCGC 00185684; NCGC 84

[1345964-89-7]
Purity: 99%

Soluble in DMSO
C29H26N2PS.Br MW: 545.47



mg Price

5 online

25 online


Biological activity

Competitive, selective, and brain penetrant NPS receptor antagonist that preferentially blocks NPS-induced ERK phosphorylation over intracellular Ca2+ or cAMP responses (IC50 values 22.1 nM, 36.5 nM, and 5.0 nM, in Ca2+, cAMP, and binding assays, respectively). NCGC84 decreases alcohol self-administration in vivo, and does not inhibit the vasopressin V1b or the endogenous purinergic receptor at concentrations up to 10 μM.

ML 161

[423735-93-7]
Purity: 98%

Soluble in DMSO and Ethanol
C17H17BrN2O2 MW: 361.23



Axon 1928

mg Price

10 online

50 online


Biological activity

Allosteric inhibitor of protease-activated receptor 1 (PAR1); ML161 inhibits PAR1-mediated platelet activation with nanomolar potency

ML162

[1035072-16-2]
Purity: 99%

Soluble in DMSO and EtOH
C23H22Cl2N2O3S MW: 477.40



Axon 3896

mg Price

10 online

50 online

Biological activity


ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor and ferroptosis inducer.

ML193

CID1261822

[713121-80-3]
Purity: 98%

Soluble in DMSO and EtOH
C28H25N5O4S MW: 527.59



Biological activity


ML193 is a highly potent and selective GPR55 antagonist with an IC50 value of 221 nM. Moreover, ML193 showed >145-fold, >27-fold and >145-fold antagonist selectivity against GPR35, CB1 and CB2, respectively and >145-fold agonist selectivity against all of these counter-receptors.

ML 210

CID 49766530

[1360705-96-9]
Purity: 100%

Soluble in DMSO
C22H20Cl2N4O4 MW: 475.32



Biological activity


Chemical probe that selectively kills cells induced to express mutant RAS; more specifically, ML210 is a HRAS synthetic lethal compound with nanomolar potencies against two HRASG12V expressing cell lines and 4-fold selectivity against two control cell lines not expressing HRASG12V

ML 213

CID 3111211

[489402-47-3]
Purity: 99%

Soluble in DMSO
C17H23NO MW: 257.37




Biological activity

ML 213 is a potent, selective, and brain penetrant KCNQ2 (Kv7.2) and KCNQ4 (Kv7.4) channel opener (EC50 values of 230 nM and 510 nM, respectively). Valuable tool compound for understanding KCNQ2 and KCNQ4 channels in regulating neuronal activity.

ML 221

[877636-42-5]
Purity: 99%

Soluble in DMSO
C17H11N3O6S MW: 385.35



Biological activity

Axon 4125

mg	Price
5	online
25	online

Axon 2017

mg	Price
10	online
50	online

Axon 2747

mg	Price
10	online
50	online

Axon 2870


mg	Price
10	online
50	online

Potent apelin (APJ) receptor functional antagonist in cell-based assays (IC50 value is 1.75 μM). ML 221 is >37-fold selective over the closely related angiotensin II type 1 (AT-1) receptor.

ML 239

[1378872-36-6]
Purity: 98%

Soluble in DMSO
C13H10Cl3N3O2 MW: 346.60




Biological activity

ML 239 is a selective inhibitor of breast cancer stem cells (IC50 value of 1.16 μM). Displayed greater than 23-fold selective inhibition of the breast cancer stem cells-like cell line over the isogenic control cell line.

ML252

[N.A.]
Purity: 99%

Soluble in DMSO
C20H24N2O.HCl MW: 344.88



Biological activity

Potent, selective and brain penetrant KCNQ2 inhibitor (Kv7.2; IC50 value 69 nM, and >40-fold selective over KCNQ1). A useful in vivo tool molecule to study KCNQ2 pharmacology.

ML 265


See TEPP 46

ML 297

VU 0456810

[1443246-62-5]
Purity: 99%

Soluble in DMSO
C17H14F2N4O MW: 328.32



Biological activity

First potent and selective activator of the GIRK potassium channel (EC50 value 0.16 μM for GIRK1/2 activation) with selectivity for GIRK1-containing GIRKs, exhibiting antiepileptic properties in vivo. ML297 showed equal or greater efficacy compared to a clinically active anti-seizure medication, sodium valproate, regardless of whether epilepsy was initiated chemically with PTZ or via electroshock.

ML 311

[315698-17-0]
Purity: 99%

Soluble in DMSO
C23H24F3N3O MW: 415.45

Axon 2871

mg	Price
10	online
50	online

Axon 2615

mg	Price
10	online
50	online

Axon 2240

Page 919

Axon 2436

mg	Price
10	online
50	online

Axon 2823

mg	Price
5	online
25	online

Biological activity


Potent and selective inhibitor of the protein-protein interaction of Mcl-1 and Bim with an IC50 value of 0.31 μ M for Mcl-1. ML 311 displayed significant activity in a number of cell lines, with EC50 values in the range of 0.3–15 M. Useful tool for studying lymphoid tumorigenesis and to demonstrate the potential for using this strategy in therapies intended to bypass apoptosis resistance pathways that are activated in drug-resistant tumors.

ML 324

NCGC00183808

[1222800-79-4]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C21H23N3O2 MW: 349.43




Biological activity

Inhibitor of Jumonji domain-containing protein 2 (JMJD2, an "eraser") histone demethylase; effectively blocked herpes simplex virus (HSV) IE gene expression and prevented viral reactivation from latency; >75 fold more efficient than DMOG. ML 324 is also available as its HCl-salt (Axon 2081).

ML-9 hydrochloride

[105637-50-1]
Purity: 99%

Soluble in water and DMSO
C15H17ClN2O2S.HCl MW: 361.29




Biological activity

ML-9 hydrochloride is a selective inhibitor of myosin light chain kinase (MLCK). Moreover, ML-9 hydrochloride is an inhibitor of Akt kinase and stromal interaction molecule 1 (STIM1).

ML277

[1401242-74-7]
Purity: 99%
Optically pure
Soluble in DMSO
C23H25N3O4S2 MW: 471.59



Biological activity

ML277 is a potent and selective Kv7.1 (KCNQ1) potassium channel activator with an EC50 value of 260 nM. ML277 was shown to be highly selective against other KCNQ channels (>100-fold selectivity versus KCNQ2 and KCNQ4) as well as against the distantly related hERG potassium channel.

ML314

[1448895-09-7]
Purity: 100%

Soluble in 0.1N HCl(aq) and DMSO

Axon 3562

mg	Price
5	online
25	online

Axon 3343

mg	Price
10	online
50 mg	online


Axon 3196

mg	Price
5	online
25	online

Axon 2632

mg	Price
5	online
25	online

C24H28N4O3 MW: 420.50




Biological activity

Brain penetrant nonpeptidic β -Arrestin biased full agonist of the neurotensin NTR1 receptor (EC50 values 2.0 μ M and >80 μ M for NTR1 and NTR2, respectively). Unlike peptide-based NTR1 agonists, ML314 has no significant response in a Ca2+ mobilization assay. ML314 is a viable, preclinical lead for methamphetamine abuse treatment.

ML 323

[1572414-83-5]
Purity: 100%

Soluble in DMSO
C23H24N6 MW: 384.48




Biological activity

Selective, reversible and highly potent inhibitor of the USP1-UAF1 deubiquitinase complex that links deubiquitination to DNA damage responses (IC50 values of 76 nM in a ubiquitin-rhodamine (Ub-Rho) assay and 174 nM and 820 nM in orthogonal gel-based assays using K63-linked diubiquitin (di-Ub) and monoubiquitinated PCNA (Ub-PCNA) as substrates, respectively). ML 323 effectively sensitized cisplatin-resistant NSCLC H596 cells and U2OS osteosarcoma cells to cisplatin since it simultaneously targets two major DNA damage response pathways (TLS and FA) by inhibiting a common deubiquitinase.

ML 324 dihydrochloride

[1222800-79-4] (parent)
Purity: 100%

Soluble in water and DMSO
C21H23N3O2.2HCl MW: 422.35




Biological activity

Inhibitor of Jumonji domain-containing protein 2 (JMJD2, an "eraser") histone demethylase; effectively blocked herpes simplex virus (HSV) IE gene expression and prevented viral reactivation from latency; >75 fold more efficient than DMOG

ML334

LH601A

[1432500-66-7]
Purity: 99%
Optically pure
Soluble in DMSO
C26H26N2O5 MW: 446.50



Biological activity


Activator of NRF2 signaling by inhibition of Keap1-NRF2 protein-protein interaction (PPI; IC50 value 1.6 - 2.3 μ M in a fluorescence polarisation assay using Keap1 Kelch domain/NRF2-ETGE peptide; Kd value 1 μ M to Keap1 Kelch domain). ML 334 stimulates NRF2 expression and nuclear translocation, and induces antioxidant response elements (ARE) and transcription of HO-1 and TRX1 proteins.

ML 335

mg	Price
5	online
25	online

[825658-06-8]
Purity: 99%

Soluble in DMSO
C15H14Cl2N2O3S MW: 373.25




10	online
50	online

Biological activity
ML 335 is a selective K2P2.1 (TREK-1; KCNK2) and K2P10.1 (TREK-2; KCNK10) activator with EC50 values of 14.3 μ M and 5.2 μ M, respectively.

ML348

[899713-86-1]
Purity: 99%

Soluble in DMSO
C18H17ClF3N3O3 MW: 415.79



Axon 2646


mg	Price
10	online
50	online

Biological activity
Selective and in vivo active inhibitor for acyl-protein thioesterase APT1 (IC50 values 0.84 μ M and >10 μ M for APT1 and APT2, respectively; Ki values 280 nM and >10000 nM for WT APT1 and APT2, respectively). A useful tool to study LYPLA/APT mediated protein S-palmitoylation and related pharmacology. In some of the literature, APT1 and APT2 are also identified as lysophospholipases LYPLA1 and LYPLA2 as they were first discovered due to their ability to hydrolyze various lysophospholipids.

ML 351

[847163-28-4]
Purity: 98%

Soluble in DMSO
C15H11N3O MW: 249.27



Axon 2312

mg	Price
5	online
25	online


Biological activity
Potent and selective inhibitor of 12/15-lipoxygenase (IC50 value 200 nM against human 12/15-LOX) with >250-fold selectivity versus related LOX isozymes. ML 351 is protective against oxidative glutamate toxicity in mouse neuronal HT22 cells and does not reduce the active-site ferric ion. ML 351 significantly reduced infarct size following permanent focal ischemia in a mouse model of ischemic stroke

ML352

VU0476201

[1649450-12-3]
Purity: 98%

Soluble in 0.1N HCl (aq) and DMSO
C21H29N3O4 MW: 387.47



Axon 2587

mg	Price
5	online
25	online

Biological activity
Potent and selective inhibitor of the presynaptic choline transporter (CHT; Ki value 92 nM). ML352 exhibited no inhibition of acetylcholinesterase (AChE) or cholineacetyltransferase (ChAT) and also lacked activity at dopamine, serotonin, and norepinephrine transporters, as well as many receptors and ion channels.

ML354


VU0099704

[89159-60-4]
Purity: 98%

Axon 2899

mg	Price
10	online

Soluble in DMSO and EtOH
C16H14N2O3 MW: 282.29




50	online
----	--------

Biological activity
ML354 is a potent and selective protease activated receptor 4 (PAR4) antagonist with an IC50 value of 140 nM.

ML 355

[1532593-30-8]
Purity: 98%

Soluble in DMSO
C21H19N3O4S2 MW: 441.52



Axon 2873


mg	Price
5	online
25	online

Biological activity
Potent inhibitor of 12-lipoxygenase (12-LOX) (IC50 value of 0.34 μ M) which shows excellent selectivity against related enzymes (15-LOX-1, 5-LOX, 15-LOX-2, COX-1/-2). Besides, ML 355 exhibits a favourable in vitro ADME and in vivo PK profile with activity in disease relevant cell-based systems, such thrombosis (platelet aggregation and calcium mobilization), and diabetes (12-HETE reducing in β -cells).

ML 365

[947914-18-3]
Purity: 99%

Soluble in DMSO
C22H20N2O3 MW: 360.41



Axon 2840

mg	Price
10	online
50	online


Biological activity
Potent and selective inhibitor of the TASK-1 (KCNK3) potassium channel (IC50 value of 4 nM) with 62-fold selectivity over TASK-3 in an orthogonal electrophysiology assay.

ML 367

CID 921541

[381168-77-0]
Purity: 99%

Soluble in DMSO
C19H12F2N4 MW: 334.32



Axon 2995

mg	Price
10	online
50	online

Biological activity
ML 367 is an inhibitor of ATAD5 stabilization with an IC50 value of 1.2 μ M. ML 367 was found to block general DNA damage responses including RPA32-phosphorylation and CHK1-phosphorylation in response to UV irradiation. In this regard, the probe molecule could block DNA repair pathways that function upstream of ATAD5.

ML184

CID2440433


[794572-10-4]
Purity: 99%

Soluble in DMSO

Axon 3028

mg	Price
10	online
50	online

C25H34N4O3S MW: 470.63



Biological activity


ML184 is a potent and selective agonists for GPR55 with an EC50 value of 263 nM potency for GPR55 and >120-fold, 83-fold, and 57-fold selectivity against GPR35, CB1 and CB2 as antagonist.

ML2-SA1

EVP-22

[N.A.]
Purity: 100%

Soluble in DMSO
C14H13Cl2NO MW: 282.17



Biological activity


ML2-SA1 is a potent, selective and efficacious activator of TRPML2 with EC50 values of 1.24 μM and 2.38 μM for human and mouse TRPML2, respectively. ML2-SA1 shows high selectivity over h/mTRPML1 and h/mTRPML3 in both calcium imaging and endolysosomal patch-clamp experiments and it does not activate TPC1 nor TPC2.

ML329

CID 12387471

[19992-50-8]
Purity: 99%

Soluble in DMSO
C16H12N2O4S MW: 328.34



Biological activity


ML329 is an inhibitor of the MITF molecular pathway (IC50 value of 1.2 μM; TRPM-1 promoter activity) and showed specific activity against MITF-dependent cells (IC50 values of 0.1 and 0.7 μM in SK-MEL-5 and MALME-3M cell lines, respectively). ML329 also reduced the expression of the cell cycle regulator CDK2, and showed CDK1 inhibition (IC50 value of 0.5 μM).

ML346

CID 767276

[100872-83-1]
Purity: 100%

Soluble in DMSO
C14H12N2O4 MW: 272.26



Biological activity

ML346 is an activator of Hsp70 (EC50 value of 4.6 μM; HeLa cell toxicity assay). ML346 induces HSF-1-dependent chaperone expression and restores protein folding in conformational disease models. These effects are mediated by novel mechanisms involving FOXO, HSF-1, and Nfr-2. ML346 has good chemical stability, is not reactive with excess glutathione, and is cell permeable.

ML364

[1991986-30-1]
Purity: 99%

Axon 2980

mg	Price
10	online
50	online

Axon 2733

mg	Price
10	online
50	online


Axon 2703

mg	Price
10	online
50	online

Axon 2678

mg	Price
10	online

Soluble in DMSO
C24H18F3N3O3S2 MW: 517.54



50 online


Biological activity

ML364, a small molecule inhibitor of the deubiquitinase USP2 (IC50 value of 1.1 μM), induced an increase in cellular cyclin D1 degradation and caused cell cycle arrest. Consistent with the role of cyclin D1 in DNA damage response, ML364 also caused a decrease in homologous recombination-mediated DNA repair. These effects by a small molecule inhibitor support a key role for USP2 as a regulator of cell cycle, DNA repair, and tumor cell growth.

ML385

[846557-71-9]
Purity: 99%

Soluble in DMSO
C29H25N3O4S MW: 511.59



Axon 2671

mg	Price
10	online
50	online

Biological activity


ML385 is an inhibitor of nuclear factor erythroid 2-related factor 2 (NRF2) (IC50 value 1.9 μM), blocks NRF2 transcriptional activity, and enhances the efficacy of carboplatin and other chemotherapeutic drugs in lung cancer cells (NSCLC). Specifically, ML385 binds to Neh1, the Cap 'N' Collar Basic Leucine Zipper (CNC-bZIP) domain of NRF2, and interferes with the binding of the V-Maf Avian Musculoaponeurotic Fibrosarcoma Oncogene Homologue G (MAFG)-NRF2 protein complex to regulatory DNA binding sequences. ML385 shows specificity and selectivity for NSCLC cells with KEAP1 mutation.

ML401

CID 73169083

[1597489-14-9]
Purity: 99%

Soluble in DMSO
C20H20BrClN2O MW: 419.74



Axon 3230

mg	Price
5	online
25	online

Biological activity

ML401 is a potent functional antagonist of EBI-2 (IC50 value of ~1 nM) which displays activity in a chemotaxis assay (IC50 value of ~6 nM), and has a clean profile in a Eurofins/Ricerca panel as well as excellent rodent pharmacokinetics.

ML414

See NGI-1


Axon 3588

Page 701

ML417

[1386162-69-1]
Purity: 99%

Soluble in DMSO
C22H25N3O3 MW: 379.45



Axon 3263

mg	Price
10	online
50	online


Biological activity

ML417 is a potent, highly selective D3 dopamine receptor agonist with an EC50 value of 38 nM. ML417 promotes potent D3R-mediated β-arrestin translocation, G protein-mediated signaling, and pERK phosphorylation with

minimal effects on other GPCR-mediated signaling. Also, ML417 was found to exhibit neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons.

ML-792

[1644342-14-2]
Purity: 99%
Optically pure
Soluble in 0.1N NaOH(aq), 0.1N HCl(aq) and DMSO
C21H23BrN6O5S MW: 551.41



Biological activity


ML-792 is a potent and selective SUMO-activating enzyme (SAE) inhibitor with IC50 values of 0.003 μM and 0.011 μM when SUMO1 or SUMO2 was used as the ubiquitin-like protein (UBL), respectively. ML-792 selectively blocks total SUMOylation, thus decreasing cancer cell proliferation.

MLN 518

See CT 53518

MLN 0905

[1228960-69-7]
Purity: 98%
Soluble in 0.1N HCl(aq) and DMSO
C24H25F3N6S MW: 486.56



Biological activity

Potent, orally available and selective polo-like kinase (PLK) 1 inhibitor


MLN1117

See Serabelisib

MLN 2238

Ixazomib

[1072833-77-2]
Purity: 98%
Soluble in DMSO
C14H19BCl2N2O4 MW: 361.03



Biological activity

Selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies; the biologically active form of MLN 9708 (Axon 2557). MLN 2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic re Approved by the FDA in November 2015 for multiple myeloma treatment. Also available as the more stable citrate prodrug (Axon 2557)

Axon 3109

mg	Price
5	online
25	online

Axon 1415

Page 396

Axon 1910

mg	Price
2	online
5	online

Axon 4075

Page 861


Axon 2556

mg	Price
5	online
25	online

MLN 4924

Pevonedistat

[905579-51-3]
Purity: 99%
Optically pure
Soluble in DMSO
C21H25N5O4S MW: 443.52




Biological activity

First-in-class inhibitor of NEDD8 Activating Enzyme (NAE) with potent antitumor activity in animal models; cell permeable; MLN4924 inactivates Cullin-RING E3 ubiquitin Ligases (CRLs) by blocking cullin neddylation

MLN7243

TAK-243; AOB 87172

[1450833-55-2]
Purity: 99%
99% e.e.
Soluble in DMSO
C19H20F3N5O5S2 MW: 519.52



Biological activity


MLN7243 is a cell permeable small molecule inhibitor targeting ubiquitin-activating enzymes (UAE, also known as E1 enzymes). The enzymes, found more active in cancer cells than in normal, healthy cells, catalyze the first step in ubiquitination reaction, targeting a protein for degradation via Proteasome. This covalent attachment of ubiquitin or ubiquitin-like proteins to targeted proteins is a major mechanism for regulating protein function in eukaryotic organisms. Inhibition of the enzyme prevents both protein ubiquitination and subsequent ubiquitin-mediated proteasomal degradation, resulting in an excess of proteins in the cells that may lead to endoplasmic reticulum (ER) stress-mediated apoptosis, thus inhibit tumor (cancer) cell proliferation and survival.

Source Information: Sold in collaboration with Chemietek

MLN 8237

Alisertib

[1028486-01-2]
Purity: 99%
Soluble in 0.1N NaOH(aq) and DMSO
C27H20ClF3N4O4 MW: 518.92




Biological activity

Second generation, orally bioavailable, potent and highly selective aurora A inhibitor

MLN 9708

Ixazomib citrate

[1201902-80-8]
Purity: 99%
Soluble in DMSO
C20H23BCl2N2O9 MW: 517.12



Biological activity

Citrate prodrug of MLN 2238 (Ixazomib, Axon 2556), a selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN 9708 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to

Axon 2038

mg	Price
1	online
5	online

Axon 3829

mg	Price
5	online
10	online

Axon 2003

mg	Price
5	online
25	online

Axon 2557

mg	Price
5	online
25	online


a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic re Approved by the FDA in November 2015 for multiple myeloma treatment.

MLR 1023

Tolimidone, CP 26154

[41964-07-2]
Purity: 99%

Soluble in DMSO
C11H10N2O2 MW: 202.21




Biological activity

Selective allosteric activator of Lyn kinase (EC50: 63 nM); no significant activity against all other Src family kinases and a range of 47 other kinases; Next generation insulin sensitizer that does not have PPAR activity

ML-SA1 Recent Addition

[332382-54-4]
Purity: 98%
98% e.e.
Soluble in DMSO and EtOH
C22H22N2O3 MW: 362.42



Biological activity


ML-SA1 is a potent and specific TRPML1 agonist.

MNITMT

NSC 631156

[177653-76-8]
Purity: 99%

Soluble in Ethanol
C7H8N6O2S MW: 240.24



Biological activity

Immunosuppressant

Mobocertinib


See TAK-788

Mocetinostat

MGCD 0103; MG 0103

[726169-73-9]
Purity: 99%

Soluble in 0.1N HCl (aq) and DMSO
C23H20N6O MW: 396.44



Biological activity

Axon 1941

mg	Price
10	online
50	online

Axon 4193

mg	Price
10	online
50	online

Axon 1267

mg	Price
10	online
50	online

Axon 3232

Page 907

Axon 2505

mg	Price
5	online
25	online


Class I selective HDAC inhibitor (sub-micromolar IC50 values for HDAC1, HDAC2, and HDAC11, ca 2 μM for HDAC3, and >10 μM for HDAC4-8) with broad spectrum antitumor activity in vitro and in vivo. MGCD 0103 induced hyperacetylation of histones, selectively induced apoptosis, caused cell cycle blockade, and exhibited potent and selective antiproliferative activities against a broad spectrum of human cancer cell lines in vitro.

Moclobemide

Ro 11-1163

[71320-77-9]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C13H17ClN2O2 MW: 268.74



Biological activity


Moclobemide is a reversible and selective inhibitor of the enzyme monoamine oxidase (MAO) subtype A with a broad spectrum of antidepressant activity.

Modafinil

CRL 40476; GRL 40476; CN 801

[68693-11-8]
Purity: 99%

Soluble in DMSO and Ethanol
C15H15NO2S MW: 273.35



Biological activity


α1 Adrenergic receptor agonist; psychoanaleptic agent with central nervous stimulant properties; a eugeroic drug generally prescribed to treat narcolepsy

Momelotinib hydrochloride

CYT387 hydrochloride

[1841094-16-3]
Purity: 98%

Soluble in DMSO
C23H22N6O2.HCl MW: 450.92



Biological activity

Selective and ATP-competitive Janus Kinase JAK1/JAK2 inhibitor, with IC50 to be 11 and 18 nM for JAK1 and JAK2 respectively and far less activity against other kinases, including JAK3 (IC50=155 nM). The free base, Momelotinib (Axon 1681) is also available.

Molibresib


See I-BET762

Molindone hydrochloride

EN 1733A

[15622-65-8]
Purity: 99%

Soluble in DMSO
C16H24N2O2.HCl MW: 312.83



Axon 3629

mg	Price
10	online
50	online

Axon 1296

mg	Price
10	online
50	online

Axon 4124

mg	Price
5	online
25	online

Axon 4134

Page 555

Axon 1101

mg	Price
10	online
50	online

Biological activity

D2 dopamine receptor antagonist; MAO inhibitor; a therapeutic antipsychotic, used in the treatment of schizophrenia; Reduction of body weight reported. Terminal plasma half-life after oral administration about 6½ hours

Molnupiravir

See MK-4482


Axon 3188

Page 662

Montelukast sodium

MK-0476

[151767-02-1]
Purity: 99%
Optically pure
Soluble in water and DMSO
C35H35ClNNaO3S MW: 608.17



Axon 3236

mg	Price
50	online

Biological activity

Montelukast sodium is a potent and selective leukotriene D4 receptor antagonist with excellent in vivo activity. Montelukast sodium shows Ki values for [3H]leukotriene D4 specific binding of 0.18 nM, 4 nM and 0.52 nM in guinea pig lung, sheep lung and dimethylsulfoxide-differentiated U937 cell plasma membrane preparations, respectively.

MOP, 8-

See Methoxsalen

Axon 3449

Page 647

Motesanib diphosphate

See AMG 706


Axon 1768

Page 225

Motolimod

[926927-61-9]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C28H34N4O2 MW: 458.60



Axon 2783

mg	Price
5	online


Biological activity

Motolimod is a highly potent and selective TLR8 agonist (EC50 value of 100 nM). Motolimod directly activates myeloid dendritic cells, monocytes, and NK cells, resulting in the production of high levels of mediators including: TNFα, IL-12, and IFNγ, known to orchestrate adaptive antitumor responses.

Moxifloxacin hydrochloride

BAY 12-8039

[186826-86-8]
Purity: 100%
Optically pure
Soluble in water and DMSO



Axon 3306

mg	Price
50	online
On request	online

C21H24FN3O4.HCl MW: 437.89

Biological activity

Moxifloxacin hydrochloride is a broad-spectrum antibiotic.

MP 470

See Amuvatinib

Axon 2368

Page 235

MPC-1304

See Arandipine


Axon 3013

Page 246

MPEP hydrochloride

[219911-35-0]
Purity: 99%

Soluble in water, DMSO, and Ethanol
C14H11N.HCl MW: 229.70



Axon 1222

mg	Price
10	online
50	online


Biological activity

Potent and selective antagonist for metabotropic glutamate receptor subtype 5 (mGluR5); Systemically active in vivo

MPP+ iodide

[36913-39-0]
Purity: 100%

Soluble in water, DMSO and EtOH
C12H12IN MW: 297.13



Axon 4004

mg	Price
100	online
1000	online


Biological activity

MPP+ iodide is an active metabolite of MPTP (Axon 1075) which selectively destroys dopaminergic neurons and causes Parkinson's disease (PD) symptoms in mammals.

MPPF, p-

[155204-26-5]
Purity: 98%

Soluble in water
C25H27FN4O2 MW: 434.51



Axon 1090

mg	Price
10	online
50	online


Biological activity

Selective 5-HT1A antagonist, more potent than p-MPPI (Axon 1091)

MPPI, p-

[155204-23-2]
Purity: 98%

Soluble in water
C25H27IN4O2 MW: 542.41



Axon 1091

mg	Price
10	online
50	online


Biological activity

Selective 5-HT1A antagonist; unlabelled standard in radiochemistry

Mps1-IN-2

[1228817-38-6]
Purity: 98%

Soluble in DMSO
C26H36N6O3 MW: 480.60



Axon 2358

mg	Price
5	online
25	online


Biological activity

Small-molecule inhibitor of Mps1 kinase (IC50 values 145 nM) with greater than 1000-fold selectivity relative to the 352-member kinase panel, with the major exceptions of Gak and Plk1 (Ambit assay Kd values 12 nM, 140 nM, and 61 nM for Mps1, Gak, and Plk1, respectively). Mps1-IN-2 induces bypass of a checkpoint-mediated mitotic arrest and provides a unique tool to investigate the combined inhibition of Plk1 and Mps1.

MPTP hydrochloride

[23007-85-4]
Purity: 99%

No solubility data
C12H15N.HCl MW: 209.72



Axon 1075

mg	Price
10	online
50	online

Biological activity

A dopaminergic neurotoxin that causes permanent symptoms of Parkinson's disease by killing certain neurons in the substantia nigra of the brain.

Remarks: For health reasons to you and others, don't pursue MPTP from ordinary chemical supplier! Axon is one professional source, providing non-lipophilic MPTP hydrochloride with user's instruction

MPV 1248

See Atipamezole hydrochloride


Axon 1371

Page 258

MRS 1220

[183721-15-5]
Purity: 99%

Soluble in DMSO
C21H14ClN5O2 MW: 403.82



Axon 3684

mg	Price
5	online
25	online


Biological activity

MRS 1220 is a potent and selective hA3 receptor antagonist with a Ki value of 0.65 nM.

MRS 1523

[212329-37-8]
Purity: 98%

Soluble in DMSO
C23H29NO3S MW: 399.55



Axon 2076

mg	Price
5	online
10	online


Biological activity

Potent and highly selective adenosine A3 receptor antagonist (Ki= 18.9 nM for human A3R)

MRS 2578

[711019-86-2]
Purity: 99%

Soluble in DMSO
C20H20N6S4 MW: 472.67




Biological activity

Potent and selective P2Y6 nucleotide receptor antagonist

MRT 10

[330829-30-6]
Purity: 99%

Soluble in DMSO
C24H23N3O5S MW: 465.52




Biological activity

Smoothed (SMO) receptor antagonist

MRT 67307

[1190378-57-4]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C26H36N6O2 MW: 464.60




Biological activity

MRT 67307 is an inhibitor of IKKε and TBK1 with IC50 values of 160 nM and 19 nM, respectively. MRT 67307 also inhibited the MARK, NUAK, and SIK isoforms in vitro with comparable potency to the IKK-related kinases.

MRTX1133

[2621928-55-8]
Purity: 99%

99% e.e.
Soluble in DMSO
C33H31F3N6O2 MW: 600.63



Biological activity

MRTX1133 is a first-in-class, noncovalent, selective & reversible inhibitor of KRASG12D mutant in both active and inactive states. Demonstrates selective inhibition of cell viability of KRASG12D mutant, but not KRAS wild-type, tumor cells. Displays sustained dose-dependent inhibition of KRAS-dependent signaling in mouse tumor models.

MRTX1257

[2206736-04-9]

Axon 1862

mg	Price
10	online
50	online

Axon 1938

mg	Price
10	online
50	online

Axon 3046

mg	Price
10	online
50	online


Axon 3761

mg	Price
5	online
25	online

Axon 3733

mg	Price
----	-------

Purity: 99%
99% d.e.
Soluble in DMSO
C33H39N7O2 MW: 565.71



10 online
50 online


Biological activity

MRTX1257 is an orally available, potent, selective, and irreversible covalent inhibitor of KRAS G12C. It inhibits KRAS dependent ERK-phosphorylation in the H358 cell with IC50 of 0.9 nM, and is highly selective for the Cys12 of KRAS G12C in NCI-H358 cells over other cysteines; Demonstrates robust target engagement in vivo; Exhibits rapid and sustained efficacy against MIA PaCa-2 Xenografts, in which, at 100 mg/kg daily dose, leads to complete responses that are maintained >70 days after cessation of treatment.

Source Information: Sold in collaboration with Chemietek

MRTX1719 hydrochloride

[N.A.]
Purity: 99%
99% e.e.
Soluble in water and DMSO
C23H19Cl2FN6O2 MW: 501.34



Axon 3796
mg Price
5 online
10 online

Biological activity


MRTX1719 is a potent and selective inhibitor of the PRMT5.MTA complex

Source Information: Sold in collaboration with Chemietek

MRTX849

Adagrasib

[2326521-71-3]
Purity: 99%
Optically pure
Soluble in DMSO
C32H35ClF7N7O2 MW: 604.12



Axon 4036
mg Price
10 online
50 online


Biological activity

MRTX849 is an orally available, potent, mutation-selective, and irreversible covalent inhibitor of KRAS-G12C, currently under evaluation as antitumor therapies by modulating KRAS-dependent signal transduction as a single agent, or in combination of with SHP2 inhibitor TNO155.

MS023 dihydrochloride

[1992047-64-9]
Purity: 99%

Soluble in water, DMSO and EtOH
C17H25N3O2.HCl MW: 360.32



Axon 3681
mg Price
5 online
25 online


Biological activity

MS023 dihydrochloride is a potent, selective, and cell-active inhibitor of human Type I Protein Arginine Methyltransferases (IC50 values 30 nM, 119 nM, 83 nM, 4 nM, and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively) completely inactive against type II and type III PRMTs, protein lysine methyltransferases and DNA methyltransferases. MS023 potently decreased cellular levels of histone arginine asymmetric dimethylation.

MS102 Recent Addition

[N.A.]
Purity: 99%

Soluble in DMSO
C24H17BrF3N3O3S2 MW: 596.44



Axon 4191
mg Price
10 online
50 online

Biological activity

MS102 is an orally available USP2 inhibitor (IC50 value of 5.46 μM) with viable antiviral activity against ACE2-dependent coronaviruses. Oral treatment with MS102 conferred protection against SARS-CoV-2 in multiple murine models.

MS140


See XY028-140

Axon 3535
Page 996

MS1943 trifluoroacetate

[N.A.]
Purity: 98%

Soluble in DMSO and EtOH
C42H54N8O3.2CF3CO2H MW: 946.98



Axon 3469
mg Price
5 online
25 online


Biological activity

MS1943 trifluoroacetate is a first-in-class EZH2 selective degrader that effectively reduces EZH2 levels in cells. MS1943 has a profound cytotoxic effect in multiple TNBC cells, while sparing normal cells, and is efficacious in vivo, suggesting that pharmacologic degradation of EZH2 can be advantageous for treating the cancers that are dependent on EZH2.

MS 245 oxalate

[275363-58-1]
Purity: 99%

Soluble in DMSO
C19H22N2O3S.C2H2O4 MW: 448.49



Axon 1849
mg Price
10 online
50 online

Biological activity


Selective and high affinity 5-HT6 antagonist (Ki = 2.1 nM)

MS 275

Entinostat; SNDX 275

[209783-80-2]
Purity: 99%

Soluble in DMSO
C21H20N4O3 MW: 376.41




Biological activity

Potent and long-lasting histone deacetylase (HDAC) inhibitor undergoing clinical trials for treatment of various cancers; Entinostat inhibits class I HDAC1 and HDAC3 with IC50 of 0.51 μ M and 1.7 μ M, respectively

MSA-2

[129425-81-6]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C14H14O5S MW: 294.32




Biological activity

MSA-2 is a selective and orally available non-nucleotide STING agonist with EC50 values of 24 and 8.3 μ M for human STING isoforms WT and HAQ, respectively.

MSAB

[173436-66-3]
Purity: 99%

Soluble in DMSO
C15H15NO4S MW: 305.35



Biological activity

MSAB is a potent and selective inhibitor of the Wnt/ β -catenin signaling pathway. MSAB shows potent anti-tumor effects selectively on Wnt-dependent cancer cells in vitro and in mouse cancer models. MSAB binds to β -catenin promoting its degradation, and specifically downregulates Wnt/ β -catenin target genes.

MSC1936369B

See AS-703026 Recent Addition

MSC2363318A

See M2698

MSC2490484A

See M-3814

MSL-7

[2172949-70-9]
Purity: 99%

Soluble in DMSO

Axon 1803

mg	Price
10	online
50	online

Axon 3298

mg	Price
5	online
25	online

Axon 3342

mg	Price
10	online
50	online

Axon 4217

Page 253

Axon 3850

Page 637


Axon 3577

Page 638

Axon 2932

mg	Price
10	online
50	online

C16H12ClNO4S MW: 349.70



Biological activity

MSL-7 is an autophagy enhancer with increased microsomal stability, which improved the glucose profile of ob/ob mice and mice with diet-induced obesity. Drug candidate for diabetes or metabolic syndrome with lipid overload.


2-MSPA

See CXL-1020

MSTP

[2125668-23-5]
Purity: 99%

Soluble in DMSO
C8H8N4O3S MW: 240.24



Biological activity

MSTP is a selective and highly reactive thiol blocking reagent compatible with a variety of experimental setups in biological research.

MT-1303

See Amiselimod hydrochloride

MT210

See Roluperidone


MT3995

See Apararenone

MT-802

[2231744-29-7]
Purity: 97%

Soluble in 0.1N HCl(aq) and DMSO
C41H41N9O8 MW: 787.82



Biological activity

The PROTAC MT-802 is a potent and rapid degrader of BTK with a DC50 value of 9.1 nM with maximal degradation being observed by 250 nM. MT-802 showed IC50 values of 46.9 nM and 20.9 nM for wild-type BTK and C481S BTK, respectively.

MTX

See Methotrexate

Axon 2653

Page 402

Axon 2876

mg	Price
10	online
50	online

Axon 3096

Page 234

Axon 3859

Page 829

Axon 3742

Page 238

Axon 3466

mg	Price
5	online
25	online

Axon 3319

Page 647

Mubritinib

See TAK 165

Axon 2053


Page 906

MYCi975

NUCC-0200975

[2289691-01-4]
Purity: 99%

Soluble in DMSO
C25H16Cl2F6N2O2 MW: 561.30



Axon 3229

mg	Price
5	online
25	online

Biological activity


MYCi975 is a MYC inhibitor which disrupts MYC/MAX interaction while also decreasing MYC protein stability. This dual mechanism of action leads to significant inhibition of MYC-dependent cancer-cell proliferation in vitro with suppression of global MYC target gene expression and inhibition of tumor growth in vivo. Moreover, MYCi975 showed an excellent pharmacokinetic profile, with a long terminal half-life, high peak plasma concentration, and tumor penetration, as demonstrated by pharmacodynamic markers, such as MYC T58 phosphorylation. MYCi975 enhanced immunotherapy.

Mycophenolate mofetil

RS61443;TM-MMF

[128794-94-5]
Purity: 99%

Soluble in 0.1N NaOH(aq), 0.1N HCl(aq), DMSO and EtOH
C23H31NO7 MW: 433.49



Axon 3498

mg	Price
50	online

Biological activity

Mycophenolate mofetil is an immunosuppressive prodrug which is hydrolyzed by esterases in the intestine and blood to release mycophenolic acid (MPA). MPA is a potent, selective, noncompetitive inhibitor of the type 2 isoform of inosine monophosphate dehydroxigenase (IMPDH) expressed in activated human T and B lymphocytes.

Myelostat

See Homoharringtonine


Axon 3667

Page 545

MYK-461

Mavacamten; SAR439152

[1642288-47-8]
Purity: 100%
Optically pure
Soluble in 0.1 N NaOH(aq) and DMSO
C15H19N3O2 MW: 273.33



Axon 2683

mg	Price
10	online
50	online


Biological activity

MYK-461 is an inhibitor of sarcomere contraction by decreasing the ATPase activity of the cardiac myosin heavy chain (IC50 value 0.3 μM in mouse cardiac myofibrils). Inhibitors of sarcomere contraction may be a valuable therapeutic approach for hypertrophic cardiomyopathy (HCM). Acute reduction in contractility with MYK-461 is sufficient to relieve left ventricular outflow tract (LVOT) obstruction in feline HCM.

Myoseverin

[267402-71-1]
Purity: 99%

No solubility data
C24H28N6O2 MW: 432.52



Axon 1310

mg	Price
10	online
50	online

Biological activity


A microtubule-binding molecule and reversible inhibitor of tubulin polymerization; potential angiogenesis inhibitor

Myricetin

Cannabiscetin; Myricetol

[529-44-2]
Purity: 100%

Soluble in water, 0.1N NaOH(aq) and DMSO
C15H10O8 MW: 318.24



Axon 3559

mg	Price
50	online

Biological activity

The natural flavonoid compound Myricetin is an RNase L inhibitor with IC50 values of 264 and 173 μM for H-RNase L and P-RNase L, respectively. Moreover, regulates the expression of Hippo, MAPK, GSK-3β, PI3K/AKT/mTOR, STAT3, TLR, IκB/NF-κB, Nrf2/HO-1, ACE, eNOS / NO, AChE and BrdU/NeuN. Myricetin also enhances the immunomodulatory functions, suppresses cytokine storms, improves cardiac dysfunction, possesses an antiviral potential, can be used as an adjuvant treatment against cancer, cardiovascular injury and nervous system diseases, and it may be a potential drug against COVID-19 and other viral infections.

Myricetol

See Myricetin


Axon 3559

Page 686

N 20C hydrochloride

[928313-94-4]
Purity: 98%

No solubility data
C17H19N2O.HCl MW: 304.81



Axon 1249

mg	Price
10	online
50	online


Biological activity

Non-competitive NMDA glutamate receptor antagonist

N106

[862974-25-2]
Purity: 99%

Soluble in DMSO
C17H14N4O3S MW: 354.38



Axon 2565

mg	Price
5	online
25	online


Biological activity

First-in-class small-molecule activator targeting E1 ligase mediated SERCA2a SUMOylation. N106 treatment increases contractile properties of cultured rat cardiomyocytes and significantly improves ventricular function in mice with heart failure.

N 0425 hydrochloride

[78621-26-8]
Purity: 99%

Soluble in water and DMSO
C14H17N.HCl MW: 235.75



Axon 1022

mg	Price
10	online
50	online


Biological activity

Potent monoamine oxidase (MAO) inhibitor

N 0426 hydrochloride

[150542-92-0]
Purity: 98%

No solubility data
C14H17NO.HCl MW: 251.75



Axon 1065

mg	Price
10	online
50	online


Biological activity

Dopamine receptor agonist

N 0430 hydrobromide

[96333-04-9]
Purity: 99%

Soluble in water
C14H17NO2.HBr MW: 312.20



Axon 1018

mg	Price
5	online
25	online


Biological activity

Monoamine oxidase (MAO) inhibitor, dopamine agonist

N 0432 hydrobromide

[96333-05-0]
Purity: 98%

No solubility data
C14H17NO2.HBr MW: 312.20



Axon 1020

mg	Price
5	online
25	online

Biological activity

Monoamine oxidase (MAO) inhibitor, dopamine agonist

N 0434

See PPHT hydrochloride

Axon 1035

Page 787

N 0434, (R)-

See PPHT hydrochloride, (R)-

Axon 1036

Page 787

N 0434, (S)-

See PPHT hydrochloride, (S)-

Axon 1037

Page 788

N 0437

See N 0437 hydrochloride

Axon 1038


Page 688

N 0437 hydrochloride

N 0437

[102120-99-0]
Purity: 99%

Soluble in DMSO
C19H25NOS.HCl MW: 351.93



Axon 1038

mg	Price
10	online
50	online


Biological activity

Potent and selective dopamine receptor agonist as anti-Parkinson drug; its S-(-)-enantiomer (Axon 1040) is more active vs (R)-(+)-enantiomer (Axon 1039)

N 0734 hydrochloride

[102121-01-7]
Purity: 99%

Moderately soluble in water
C19H25NOS.HCl MW: 351.93



Axon 1041

mg	Price
5	online
25	online

Biological activity

Potent and selective dopamine receptor agonist; derivative of Rotigotine (N-0437, Axon 1038); * N-0734, N-0434 ((±)-PPHT, Axon 1035) and N-0437 are potent and selective DA agonists that lack significant alpha 2 activity

N 0774

See Luzindole

Axon 1350

Page 625

N 0923

See Rotigotine

Axon 1040

Page 830

N 0924

See N 0924 hydrochloride


Axon 1039

Page 689

N 0924 hydrochloride

N 0924

[125572-92-1]
 Purity: 98%
 98% ee
 Soluble in water and DMSO
 C19H25NOS.HCl MW: 351.93



mg	Price
5	online
25	online


Biological activity

Dopamine receptor agonist; less active enantiomer of N-0437 (Axon 1038) vs opposite (S)-(-)-enantiomer, Rotigotine (Axon 1040)

N 6022

[1208315-24-5]
 Purity: 99%

Soluble in DMSO
 C24H22N4O3 MW: 414.46


Axon 1822

mg	Price
5	online
25	online

Biological activity

Potent, specific, and fully reversible inhibitor of S-nitrosogluthione reductase (GSNOR) with an IC50 of 8 nM and a Ki of 2.5 nM

NAC1 inhibitor NIC3

See NIC3


Axon 3031

Page 701

Naftifine hydrochloride

[65473-14-5]
 Purity: 99%

Soluble in water, DMSO and EtOH
 C21H21N.HCl MW: 323.86



mg	Price
50	online

Biological activity

Naftifine hydrochloride is a topical antifungal agent against a broad spectrum of dermatophyte fungi and provides good activity against *Candida* and *Aspergillus* species. Fungicidal activity is attributed to inhibition of squalene epoxidase (SE), which prevents production of ergosterol and leads to toxic accumulation of squalene. Naftifine is also effective against gram-negative and gram-positive bacteria.

Naporafenib

See LXH254

Axon 3556


Page 622

NAV-2729

Grassofermata

[419547-11-8]
 Purity: 99%

Soluble in DMSO
 C25H17ClN4O3 MW: 456.88


Biological activity


NAV-2729 is a dual Arf1/Arf6 inhibitor and is more effective towards Arf1 than Arf6. Moreover, NAV-2729 is an inhibitor of human FATP2 with a Ki value of 17.18 μM for inhibition of C1-BODIPY-C12 uptake into Caco-2 cells.

mg	Price
5	online
25	online

NBD-556

[333353-44-9]
 Purity: 99%

Soluble in DMSO and EtOH
 C17H24ClN3O2 MW: 337.84


Biological activity


NBD-556 is a human immunodeficiency virus type 1 (HIV-1) entry inhibitor that blocks the gp120-CD4 interaction. NBD-556 inhibited the fusion between HIV-1NL4-3-luc pseudotyped virus expressing HIV-1HXB2 (X4-tropic) envelope and U87-T4-CXCR4 cells, expressing CXCR4 coreceptor, with an IC50 value of 20.0 μM. NBD-556 inhibited the CD4-dependent virus in a dose-dependent manner with an IC50 value of 22.6 μM.

mg	Price
5	online
25	online

N-Biotinyl methionine sulfoxide

[N.A.]
 Purity: 98%

Soluble in water and DMSO
 C15H25N3O5S2 MW: 391.51



Biological activity
Axon 3072

mg	Price
5	online

Nalbuphine hydrochloride

[23277-43-2]
 Purity: 99%

Soluble in water
 C21H27NO4.HCl MW: 393.90


Biological activity


A narcotic used as a pain medication. Nalbuphine appears to be an agonist at κ-opioid receptors and an antagonist or partial agonist at μ-opioid receptors (IC50 of 36 nM and 11 nM resp).

mg	Price
10	online
50	online

Nalmefene hydrochloride

[58895-64-0]
Purity: 99%

Soluble in water and DMSO
C₂₁H₂₅NO₃.HCl MW: 375.89



Axon 1573

mg	Price
10	online
50	online

Biological activity


Non selective opioid receptor antagonist; it acts by blocking a mechanism in the brain that can cause a continuing and uncontrolled intake of alcohol. This helps to control and reduce alcohol intake

Naloxonazine dihydrochloride

NSC 612113

[880759-65-9]
Purity: 98%

Soluble in water
C₃₈H₄₂N₄O₆.2HCl MW: 723.69



Axon 1205

mg	Price
10	online
50	online


Biological activity

Opioid receptor antagonist

Naloxone Benzoylhydrazone

[119630-94-3]
Purity: 98%

Soluble in DMSO
C₂₆H₂₇N₃O₄ MW: 445.51



Axon 1230

mg	Price
10	online
50	online


Biological activity

Agonist for κ 3 opioid receptors; antagonist for ORL1 and μ opioid receptors

Naloxone hydrochloride

NIH 7890; Narcan

[357-08-4]
Purity: 99%
Optically pure
Soluble in water and DMSO
C₁₉H₂₁NO₄.HCl MW: 363.84



Axon 2415

mg	Price
50	online
500	online

Biological activity

Neutral opioid antagonist (K_i values 0.81 nM and 1.80 nM for μ - and δ -opioid, respectively)

Naltrexone hydrochloride


NIH 8503

[16676-29-2]
Purity: 100%
Optically pure

Axon 2416

mg	Price
50	online

Soluble in water and DMSO
C₂₀H₂₃NO₄.HCl MW: 377.86



500 online

Biological activity


Competitive opioid antagonist with preference for μ - and κ -receptors over δ -receptor (K_i values 1.55 nM, 7.84 nM, and 0.71 nM for μ -, δ -, and κ -receptors, respectively)

Napabucasin

BBI 608; FNQ

[83280-65-3]
Purity: 99%

Soluble in DMSO
C₁₄H₈O₄ MW: 240.21



Axon 2517


mg	Price
10	online
50	online

Biological activity

Oral first-in-class cancer stemness (CSCs) inhibitor that works by targeting Stat3. Napabucasin (or BBI608) is a naturally occurring drug with enhanced toxicity versus glucose-starved tumor cells, and found to induce Mcl-1 cleavage and sustained phosphorylation of c-Jun-N-terminal kinase. Effectively blocks cancer relapse and metastasis in xenografted human cancers

Naproxen sodium

[26159-34-2]
Purity: 100%
Optically pure
Soluble in water and DMSO
C₁₄H₁₃NaO₃ MW: 252.24



Axon 3364

mg	Price
50	online

Biological activity

Naproxen sodium is a cyclo-oxygenase (COX) inhibitor. Non-steroidal anti-inflammatory drug (NSAID).

Narcan

See Naloxone hydrochloride

Axon 2415

Page 691

Nasalide

See Flunisolide

Axon 1429

Page 485

Nasarel

See Flunisolide

Axon 1429

Page 485


Natamycin

Pimaricin

[7681-93-8]
Purity: 98%
Optically pure
Soluble in 0.1N NaOH(aq), 0.1N HCl(aq) and DMSO
C₃₃H₄₇NO₁₃ MW: 665.73

Axon 3493

mg	Price
50	online




Biological activity
Natamycin is an antifungal agent.

Nateglinide

A4166; Senaglinide

[105816-04-4]
Purity: 100%
Optically pure
Soluble in DMSO and EtOH
C19H27NO3 MW: 317.42




Biological activity
Nateglinide is an inhibitor of ATP-sensitive K⁺ channels in pancreatic beta-cells in the presence of glucose and thereby restores first phase insulin response in patients with Type 2 diabetes. Antidiabetic.

Nav1.7 blocker 24

Compound 24

[1315451-25-2]
Purity: 99%

Soluble in DMSO
C20H16Cl2F3N3O3 MW: 474.26




Biological activity
Sodium channel blocker, potent and selective at voltage-gated Nav1.7 (SCN9A); with Nav1.7 pIC50 6.75 and Nav1.5 pIC50 <4.48

Nav1.7 blocker 52

Compound 52

[1211866-85-1]
Purity: 99%

Soluble in DMSO
C25H27F3N6O3 MW: 516.52



Biological activity
Potent and state-dependent sodium channel blocker, selective at voltage-gated Nav1.7 (SCN9A); Selectivity over many ion channels and GPCRs, including some selectivity within the sodium channel family

Naxagolide

See PHNO hydrochloride, (+)-

Axon 3641

mg	Price
50	online

Axon 1791

mg	Price
10	online
50	online

Axon 1780

mg	Price
10	online
50	online

Axon 1071


Page 775

NBI 34060

Indiplon

[325715-02-4]
Purity: 99%

Soluble in DMSO
C20H17N4O2S MW: 377.44



Biological activity
A high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors; NBI 34060 modulates specific GABAA receptor subtypes at the benzodiazepine site; nonbenzodiazepine hypnotic

Axon 1121

mg	Price
10	online
50	online

NBOH-2C-CN hydrochloride


See NBOH hydrochloride, 25CN-

NBOH hydrochloride, 25CN-

NBOH-2C-CN hydrochloride

[1539266-32-4]
Purity: 98%

Soluble in water and DMSO
C18H20N2O3.HCl MW: 348.82



Biological activity
25CN-NBOH is a highly selective and brain penetrant 5-HT2A receptor agonist (K_i value of 1.3 nM; EC₅₀ value of 2.1 nM). Moreover, 25CN-NBOH was behaviorally active in two mouse models of hallucinogenic effects.

Axon 2811

Page 694

Axon 2811

mg	Price
10	online
50	online

NCA

See Nitrosocyclohexyl acetate, 1-

Axon 2603

Page 705

NCGC00183808

See ML 324

Axon 3562


Page 667

NCGC00249987

EYA2 inhibitor 9987

[1384864-80-5]
Purity: 98%

Soluble in DMSO
C16H11FN4O2S MW: 342.35



Biological activity
NCGC00249987 is a specific, allosteric EYA2 phosphatase inhibitor with an IC₅₀ value of 3.0 μM.

Axon 3080

mg	Price
10	online
50	online

NCGC00378430


[920650-00-6]
Purity: 99%

Soluble in DMSO

Axon 3267

mg	Price
5	online
25	online

C22H23N3O5S MW: 441.50



Biological activity
NCGC00378430 is an inhibitor of the SIX1/EYA2 complex that reverses epithelial to mesenchymal phenotypes suppressing breast cancer metastasis.

NCGC 00379308

See D3-βArr

Axon 2895

Page 406

NCGC 84

See ML 154

Axon 2321

Page 664

NCGC 00099374

See FDI 6

Axon 2384

Page 476

NCGC 00185684


See ML 154

Axon 2321

Page 664

NCL-00017509

[1507367-00-1]
Purity: 100%



Soluble in DMSO
C15H12N6O MW: 292.30

Biological activity
NCL-00017509 is a potent kinase-selective irreversible Nek2 inhibitor (IC50 value of 56 nM) with promising drug-like properties.

Axon 2728


mg Price

2 online

5 online

NCRW0005-F05

[342779-66-2]
Purity: 99%



Soluble in DMSO
C16H13F2NO2 MW: 289.28

Biological activity
First antagonist for GPR139 (IC50 value 0.21 μM); a useful tool to study GPR139 pharmacology.

Axon 2609


mg Price

10 online

50 online

NCT-503

[1916571-90-8]
Purity: 98%



Soluble in 0.1N HCl (aq) and DMSO
C20H23F3N4S MW: 408.48

Axon 2623

mg Price

10 online


50 online

Biological activity
Non-competitive PHGDH inhibitor (IC50 value 2.5 μM) that reduces the production of glucose-derived serine in cells and suppresses the growth of PHGDH-dependent cancer cells in culture and in orthotopic xenograft tumors.

NDMC101

HS-Cm

[1308631-40-4]
Purity: 100%



Soluble in 0.1N NaOH(aq) and DMSO
C13H9ClFNO2 MW: 265.67

Axon 3438

mg Price


10 online

50 online

Biological activity
NDMC101 exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. NDMC101 is also an osteoclastogenesis inhibitor for experimental arthritis. Its efficacy is associated with the inhibition of such transcription factors as NF-κB and NFATc1 as well as multiple protein kinases, including p38, ERK, and JNK.

NE52-QQ57

[1401728-56-0]
Purity: 99%



Soluble in 0.1N HCl(aq), DMSO and EtOH
C24H28N6O MW: 416.52

Axon 3788

mg Price


5 online

25 online

Biological activity
NE52-QQ57 is a selective and orally bioavailable GPR4 antagonist with an IC50 value of 0.070 μM.

Necrostatin-1

[4311-88-0]
Purity: 99%



Soluble in DMSO
C13H13N3OS MW: 259.33

Axon 1258

mg Price

25 online

100 online

Biological activity
A cell-permeable, potent, and selective inhibitor of necroptosis; Acts as a selective and ATP-competitive inhibitor of RIP1 kinase with negligible effect of RIP2 kinase activity

Nedisertib

See M-3814


Axon 3577

Page 638

Nefazodone hydrochloride

BMV 13754

[82752-99-6]
Purity: 99%



Soluble in DMSO
C25H32ClN5O2.HCl MW: 506.47

Axon 1102

mg Price

10 online

50 online

Biological activity


Antidepressant; It operates by blocking post-synaptic 5-HT2A receptors and, to a lesser extent, by inhibiting pre-synaptic serotonin and norepinephrine (noradrenaline) reuptake. Nefazodone is also a relatively potent alpha-1 adrenoceptor antagonist

Nelfinavir mesylate

AG 1343

[159989-65-8]
Purity: 99%

Soluble in DMSO
C32H45N3O4S.CH4O3S
MW: 663.89



Axon 1553

mg	Price
10	online
50	online

Biological activity

Orally active HIV protease inhibitor, with KI values to be 2nM (HIV-1)

Nelivaptan

See SSR 149415


Axon 1114

Page 891

NEO 212

TMZ-POH

[1361198-79-9]
Purity: 99%
Optically pure
Soluble in DMSO
C17H20N6O4 MW: 372.38



Axon 2327

mg	Price
5	online
25	online


Biological activity

Novel DNA alkylating agent exhibiting superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo (IC50 values 5-50 μM for cytotoxicity on glioma cell lines). NEO 212 causes DNA damage and cell death much more efficiently than TMZ, because linkage with POH increased its biological half-life and thus provided greater opportunity for placement of cytotoxic DNA lesions. NEO212 is a conjugate of temozolomide (TMZ, Axon 2326) with the natural product perillyl alcohol (POH) and circumvents TMZ-resistance in multiple cancer cell lines and gliomas.

Neostigmine methyl sulfate

[51-60-5]
Purity: 100%

Soluble in water, DMSO and EtOH
C12H19N2O2.CH3O4S MW:
334.39



Axon 3658

mg	Price
50	online

Biological activity

Neostigmine methyl sulfate is a reversible acetylcholinesterase (AChE) inhibitor.

Nepafenac


[78281-72-8]

Axon 3374

mg	Price
----	-------

Purity: 99%

Soluble in DMSO
C15H14N2O2 MW: 254.28



10 online

50 online

Biological activity


Nepafenac is a prodrug of Amfenac. Nepafenac exhibited only weak COX-1 inhibitory activity (IC50 value of 64.3 μM). However, Amfenac was a potent inhibitor of both COX-1 (IC50 value 0.25 μM) and COX-2 activity (IC50 value of 0.15 μM). NSAID.

Neratinib

HK1 272

[698387-09-6]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C30H29ClN6O3 MW: 557.04



Axon 1526

mg	Price
5	online
25	online

Biological activity


An irreversible tyrosine kinase inhibitor with activity against HER2 and EGFR kinases; a therapeutic agent under investigation for the treatment breast cancer and other solid tumours

Neryl pyrophosphate ammonium salt

NPP

[N.A.]
Purity: 98%

Soluble in water
C10H20O7P2.3NH3 MW: 365.14



Axon 2940

mg	Price
5	online
0	online

Biological activity


Neryl pyrophosphate, the cis isomer of geranyl pyrophosphate (Axon 1489), is a suitable alternative substrate for monoterpene synthases.

Netupitant

Ro 67-31898

[290297-26-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C30H32F6N4O MW: 578.59



Axon 2499

mg	Price
10	online
50	online

Biological activity

Highly selective NK 1 receptor antagonist. Approved drug in combination with palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).


Neuropathiazol

[880090-88-0]
Purity: 99%

Axon 2322

mg	Price
10	online

Soluble in DMSO
C19H18N2O2S MW: 338.42



50 online

Biological activity

Selective inducer of neural differentiation of adult hippocampal neural progenitor cells (NPCs). Neuropathiazole competitively suppresses astrogliogenesis by LIF/BMP2/FBS in a dose-dependent manner. Useful tool for studying the molecular mechanisms that determine cell fate with the ultimate goal of stem-cell therapy.

Nevanimibe hydrochloride

See ATR-101

Axon 2960


Page 260

Nevirapine

BI-RG-587

[129618-40-2]
Purity: 99%

Soluble in DMSO
C15H14N4O MW: 266.30



Axon 3124

mg Price

10 online

50 online

Biological activity

Nevirapine is a potent and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase with an IC50 value of 84 nM.

Nexavar

See Sorafenib tosylate

Axon 1397

Page 879

Nexavar

See Sorafenib


Axon 3351

Page 879

Nexturastat A

[1403783-31-2]
Purity: 99%

Soluble in DMSO
C19H23N3O3 MW: 341.40



Axon 2359

mg Price

5 online

25 online


Biological activity

Potent HDAC6 inhibitor with >600 fold and >190 fold selectivity over HDAC1 and HDAC8, respectively (IC50 values 5 nM, 3 μM, 1 μM for HDAC6, HDAC1, and HDAC8, respectively). Nexturastat A, was found to be capable of increasing acetylated α-tubulin levels and it inhibited the growth of B16 melanoma cells, albeit with lower potency than LBH 589 (Axon 1548).

NFATc1 inhibitor A04

[1912422-56-0]
Purity: 99%

Soluble in DMSO and EtOH
C13H8F2INO2 MW: 375.11



Axon 3909

mg Price

10 online

50 online


Biological activity

NFATc1 inhibitor A04 is a potent inhibitor of RANKL-induced osteoclastogenesis and bone resorption, with an IC50 value of 1.57 μM and no significant cytotoxic effects on the viability of RAW264.7 cells. The anti-osteoclastogenic effects of A04 may operate through reducing the RANKL-induced nuclear translocation of NFATc1.

NF-56-EJ40

[2380230-73-7]
Purity: 98%

Soluble in 0.1N NaOH(aq), 0.1N HCl(aq) and DMSO
C27H29N3O3 MW: 443.54



Axon 3056

mg Price

5 online

25 online

Biological activity

NF-56-EJ40 is a high-affinity, human-selective SUCNR1 (GPR91) antagonist with a Ki value of 17.4 nM and an IC50 value of 0.025 μM.

NFκBAI4

See NF-κB Activation Inhibitor IV

Axon 3387


Page 700

NF-κB Activation Inhibitor IV

NFκBAI4; FME

[139141-12-1]
Purity: 99%

Soluble in DMSO
C15H13FO MW: 228.26



Axon 3387

mg Price

10 online

50 online

Biological activity

NF-κB Activation Inhibitor IV is a resveratrol analogue which potently inhibits the TNFα-induced activation of NF-κB (IC50 value of 0.15 μM) and is devoid of antioxidant activity.

NFPS

See ALX 5407 hydrochloride


Axon 1238

Page 220

NG 25 trihydrochloride

[1315355-93-1] (parent)
Purity: 98%

Soluble in water and DMSO
C29H30F3N5O2.3HCl MW: 646.96



Axon 2366

mg Price

2 online

10 online

Biological activity


Type II inhibitor of TAK1 (MAP3K7) and MAP4K2 (GCK) with nanomolar potency for a wider range of kinases (IC50 values 13 nM, 22 nM, 56 nM, 75 nM, 82 nM, 102 nM, 113 nM, and 149 nM for LYN, MAP4K2, CSK, Abl, FER, p38α, SRC, and TAK1, respectively). At 0.1 μM NG 25 shows strong inhibition of TAK1, Lck, MAP4K2, p38α, Abl, YES1, and OSR1. NG 25 potently inhibited the activation of IKKβ by TLR7 and TLR9 agonists and prevented the secretion of type 1 IFNs induced by these ligands in Gen2.2 cells.

NGI-1

ML414; N-linked Glycosylation Inhibitor-1

[790702-57-7]
Purity: 98%

Soluble in DMSO and EtOH
C17H22N4O3S2 MW: 394.51



Biological activity

NGI-1 is a potent and cell-permeable inhibitor of oligosaccharyltransferase (OST) with an AC50 value of 1.1 μ M for inhibition of N-linked glycosylation. NGI blocks the transfer of mature glycan precursors to recipient proteins. Moreover, NGI-1 blocks cell surface localization and signaling of the EGFR glycoprotein, but selectively arrests proliferation in only those cell lines that are dependent on EGFR (or FGFR) for survival. NGI-1 also exhibits pan-flaviviral activity.


Axon 3588

mg	Price
10	online
50	online

NHI 2

[1269802-97-2]
Purity: 99%

Soluble in DMSO
C17H12F3NO3 MW: 335.28



Biological activity

Selective cell membrane permeable inhibitor of human lactate dehydrogenase isoform A (LDH-A; IC50 values 14.7 μ M and 55.8 μ M in a NADH competition assay for LDH-A and LDH-B, respectively). NHI 2 caused 87% LDH-A inhibition at 125 μ M (with minimal activity (11%) on LDH-B at the same concentration, exhibiting anti-proliferative activity in cancer cells NHI 2 synergistically enhanced the activity of Gemcitabine in multiple cancer cell lines.


Axon 2450

mg	Price
5	online
25	online

NIBR189

[1599432-08-2]
Purity: 99%

Soluble in DMSO
C21H21BrN2O3 MW: 429.31



Biological activity

NIBR189 is a potent and selective EBI2 antagonist with IC50 values of 11 nM and 15 nM for hEBI2 and mEBI2, respectively. Moreover, NIBR189 exhibits pharmacokinetic properties which should allow use for in vitro and in vivo experiments.

Axon 3231


mg	Price
10	online
50	online

NIC3

NAC1 inhibitor NIC3

[494830-67-0]
Purity: 99%

Soluble in DMSO
C26H36N2O4 MW: 440.58



Biological activity

NIC3 is an inhibitor of nucleus accumbens-associated protein-1 (NAC1) homodimerization. Specifically, NIC3 has the ability to selectively bind with the conserved Leu90 of NAC1 and to inhibit NAC1 dimerization, resulting in

Axon 3031


mg	Price
10	online
50	online

proteasomal degradation of the NAC1 protein. NIC3 shows potent effects on sensitizing drug-resistant tumor cells to chemotherapy and reinforcing the antimetastatic efficacy of the antiangiogenic agent bevacizumab.

Nicardipine

[55985-32-5]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C26H29N3O6 MW: 479.52



Biological activity

Nicardipine is a calcium antagonist. Nicardipine is a potent cerebral and coronary vasodilator with hypotensive activity.

Axon 3254

mg	Price
50	online
250	online

Nicotinamide mononucleotide, β -

See NMM


Axon 3571

Page 707

Nicotinamide riboside chloride

β -Nicotinamide riboside, NR

[23111-00-4]
Purity: 98%
Optically pure
Soluble in water and DMSO
C11H15CIN2O5 MW: 290.70



Biological activity

Nicotinamide riboside chloride is a key intermediate of NAD+ biosynthesis and effectively increases NAD+ concentration in a variety of tissues, in many cases with beneficial or therapeutic effects. The phosphorylated analog is also available as Axon 3571.

Axon 3572

mg	Price
50	online

Nicotinamide riboside, β -


See Nicotinamide riboside chloride

Axon 3572

Page 702

NldR, 5-

[191421-10-0]
Purity: 99%
Optically pure
Soluble in water, DMSO and EtOH
C13H14N2O5 MW: 278.26



Biological activity

5-NldR, a non-natural nucleoside, is a potent inhibitor of translesion DNA synthesis (TLS) activity. Conversion of this compound to the corresponding nucleoside triphosphate, 5-nitroindolyl-2'-deoxyriboside triphosphate, in vivo creates a potent inhibitor of several human DNA polymerases that can replicate damaged DNA.

Axon 3476

mg	Price
5	online
25	online


Nifedipine

[21829-25-4]
Purity: 99%

Soluble in DMSO
C17H18N2O6 MW: 346.33

Axon 2068

mg	Price
50	online
250	online




Biological activity

A dihydropyridine calcium channel blocker (L-type), a drug used as an anti-anginal and anti-hypertensive
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Nifuratel Recent Addition

[4936-47-4]
 Purity: 99%

Soluble in DMSO
 C10H11N3O5S MW: 285.28



Biological activity


Nifuratel has a broad antibacterial spectrum of action, including both Gram-negative and Gram-positive organisms.

Nifurtimox

BAY2502

[23256-30-6]
 Purity: 99%

Soluble in DMSO
 C10H13N3O5S MW: 287.29



Biological activity

Nifurtimox is an antiprotozoal drug.

NIH 7890

See Naloxone hydrochloride

NIH 8503


See Naltrexone hydrochloride

Nilotinib

AMN 107; Tasisga

[641571-10-0]
 Purity: 99%

Soluble in DMSO
 C28H22F3N7O MW: 529.52



Biological activity

A highly selective inhibitor of Bcr-Abl, the definitive cause of Ph+ CML, and its mutations

Axon 4207

mg Price

50 online

Axon 3391

mg Price

5 online

25 online

Axon 2415

Page 691

Axon 2416

Page 691

Axon 1396

mg Price

5 online


10 online

Nilotinib hydrochloride

AMN 107 hydrochloride

[923288-95-3]
 Purity: 99%

Soluble in DMSO
 C28H22F3N7O.HCl MW: 565.98



Biological activity


A highly selective inhibitor of Bcr-Abl, the definitive cause of Ph+ CML, and its mutations.

Nilutamide

RU-23908; Anandron

[63612-50-0]
 Purity: 99%

Soluble in DMSO
 C12H10F3N3O4 MW: 317.22



Biological activity


Nilutamide is a nonsteroidal anti-androgen that competitively inhibits the effects of testosterone at the receptor level.

Nimustine hydrochloride

ACNU; NSC245382

[55661-38-6]
 Purity: 99%

Soluble in water, DMSO and EtOH
 C9H13ClN6O2.HCl MW: 309.15



Biological activity


Nimustine hydrochloride is a water-soluble DNA alkylating agent.

Nintedanib

BIBF-1120

[656247-17-5]
 Purity: 100%

Soluble in 0.1N HCl(aq) and DMSO
 C31H33N5O4 MW: 539.62



Biological activity

Orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities that simultaneously targets VEGFR1-3 (IC50 values 34 nM, 21 nM, and 13 nM, resp.), PDGFR α and β (IC50 values 59 and 65 nM), and FGFR1-3 (IC50 values 69 nM, 37 nM, and 108 nM, resp.). In addition, BIBF1120 also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (IC50 values 156 nM, 16 nM, 195 nM, and 26 nM, resp.).

Axon 3168

mg Price

10 online

50 online

Axon 3249

mg Price

50 online

Axon 4045

mg Price

50 online

Axon 2648

mg Price

10 online

50 online

NIR178


See PBF-509

Axon 4132

Page 749

Niraparib

MK 4827



[1038915-60-4]
Purity: 100%
Optically pure
Soluble in DMSO
C19H20N4O MW: 320.39

Axon 2928


mg	Price
10	online
50	online

Biological activity

Niraparib is a potent, selective and orally available PARP 1/2 inhibitor with IC50 values of 3.8 and 2.1 nM, respectively. Moreover, in a whole cell assay, Niraparib inhibited PARP activity with an EC50 value of 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 (CC50 value of 10–100 nM). Niraparib was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.

Nitisinone

Nitisone;NTBC;SC0735



[104206-65-7]
Purity: 99%

Soluble in DMSO and EtOH
C14H10F3NO5 MW: 329.23

Axon 3662

mg	Price
50	online

Biological activity

Nitisinone is a potent, reversible and orally bioavailable inhibitor of 4-hydroxyphenyl pyruvate dioxygenase (4-HPPD) with an IC50 value of 173 nM.

Nitisonone

See Nitisinone

Axon 3662

Page 705

Nitrosocyclohexyl acetate, 1-

NCA



[10259-08-2]
Purity: 98%

Soluble in DMSO
C8H13NO3 MW: 171.19

Axon 2603

mg	Price
50	online

Biological activity

1-Nitrosocyclohexyl acetate (NCA) is a long acting HNO donor which increased contractile force in normal and β -adrenergically desensitized ventricular myocytes as well as in isolated mouse hearts.

Nitrotryptanthrin, 8-

See GNF-PF-3777 Recent Addition

Axon 3597

Page 511

NKL 22

PAOA


Axon 3409

mg	Price
----	-------

[537034-15-4]

Purity: 99%

Soluble in DMSO
C19H23N3O2 MW: 325.40



10 online

50 online

Biological activity

NKL 22 is an inhibitor of histone deacetylase with an IC50 value of 78 μ M.

NM 702

See Parogrelil

Axon 1482


Page 747

NM-PP1, 1-

[221244-14-0]

Purity: 99%

Soluble in DMSO
C20H21N5 MW: 331.41



Axon 1892

mg	Price
5	online
25	online

Biological activity

A potent tyrosine kinase inhibitor (TKI) of multiple targets, such as v-Src (IC50: 1 μ M), c-Fyn (IC50: 0.6 μ M), c-Abl (IC50: 0.6 μ M), CDK2 (IC50: 18 μ M), and CaMK II (IC50: 22 μ M). Additionally, 1-NM-PP1 is reported to be a potent and specific inhibitor of TrkB-F616A and TrkA-F592A signaling (IC50 values approx 3 nM).


NMDA

[6384-92-5]

Purity: 98%

Optically pure

Soluble in water and DMSO
C5H9NO4 MW: 147.13



Axon 3472

mg	Price
50	online

Biological activity

NMDA is a prototypic selective agonist of the NMDA receptor.


NMDAR-TRPM4 blocker C19 dihydrochloride

FMP-A-02; Aliudanexin

[2241128-93-6]

Purity: 99%

Soluble in water and DMSO
C13H16Cl3N3O.2HCl MW: 409.57



Axon 3349

mg	Price
10	online
50	online

Biological activity

C19 is an NMDAR/TRPM4 (N/T) interaction interface inhibitor with an IC50 value of 1.1 μ M for NMDA-induced cell death in hippocampal neurons. This inhibitor strongly reduced NMDA-triggered toxicity and mitochondrial dysfunction, abolished cyclic adenosine monophosphate-responsive element-binding protein (CREB) shutoff, boosted gene induction, and reduced neuronal loss in mouse models of stroke and retinal degeneration. Potent neuroprotectant.

NMDAR-TRPM4 blocker C8 is available as Axon 3348.

NMDAR-TRPM4 blocker C8 dihydrochloride


FMP-A-01; Brophenexin

Axon 3348

mg	Price
----	-------

[2243506-33-2]
Purity: 99%

Soluble in water and DMSO
C11H17BrN2.2HCl MW: 330.09



10	online
50	online

Biological activity

C8 is an NMDAR/TRPM4 (N/T) interaction interface inhibitor with an IC₅₀ value of 2.1 μM for NMDA-induced cell death in hippocampal neurons. This inhibitor strongly reduced NMDA-triggered toxicity and mitochondrial dysfunction, abolished cyclic adenosine monophosphate-responsive element-binding protein (CREB) shutdown, boosted gene induction, and reduced neuronal loss in mouse models of stroke and retinal degeneration. Potent neuroprotectant.
NMDAR-TRPM4 blocker C19 is available as Axon 3349.

NMI-900

See GSK1070916


Axon 3920

Page 517

NMM

β-Nicotinamide mononucleotide; β-NMN

[1094-61-7]
Purity: 98%
Optically pure
Soluble in water
C11H15N2O8P MW: 334.22



mg	Price
50	online

Biological activity

β-Nicotinamide mononucleotide is a key intermediate of NAD⁺ biosynthesis and effectively increases NAD⁺ concentration in a variety of tissues, in many cases with beneficial or therapeutic effects.

NMN, β-

See NMM

Axon 3571


Page 707

NMS-1286937

Onvansertib; NMS-P 937

[1034616-18-6]
Purity: 99%

Soluble in DMSO
C24H27F3N8O3 MW: 532.52



mg	Price
10	online
50	online

Biological activity

NMS1286937 (NMS-P937) is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. NMS-1286937 selectively and effectively inhibits PLK1 (with IC₅₀ at low nM), inducing selective G₂/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G₁ and G₂ stages without apoptosis in normal cells.

Source Information: Sold in collaboration with Chemietek

NMS-P 937

See NMS-1286937

Axon 4007

Page 707

NN 414


Tifenazoxide

Axon 1647

mg	Price
----	-------

[279215-43-9]
Purity: 99%

Soluble in DMSO
C9H10ClN3O2S2 MW: 291.78



5	online
25	online


Biological activity

A potent and Kir6.2/SUR1 selective K(ATP) channels opener, which inhibits glucose stimulated insulin release *in vitro* and *in vivo* and has beneficial effects on glucose homeostasis in preclinical and clinical studies. Unfortunately, its clinical development was recently suspended due to elevated liver enzymes

NNC 756

Odapipam

[131796-63-9]
Purity: 99%
99% ee
Soluble in DMSO
C19H20ClNO2 MW: 329.82



Axon 1405

mg	Price
5	online
25	online

Biological activity


Very potent dopamine D₁ antagonist.

Nolatrexed dihydrochloride

AG 337; Thymitaq

[152946-68-4]
Purity: 98%

Soluble in DMSO and water
C14H12N4OS.2HCl MW: 357.26



Axon 2853


mg	Price
10	online
50	online

Biological activity

Nolatrexed dihydrochloride is a water soluble, lipophilic inhibitor of thymidylate synthase (K_i value of 11 nM). Nolatrexed dihydrochloride displayed non-competitive inhibition kinetics and was shown to inhibit cell growth in a panel of cell lines of murine and human origin (IC₅₀ values between 0.39 and 6.6 μM).

Norapomorphine hydrobromide, R(-)-

[115017-61-3]
Purity: 98%
>98% ee
Soluble in 0.1N HCl(aq) and DMSO
C16H15NO2.HBr MW: 334.21



Axon 1160

mg	Price
5	online
25	online

Biological activity


Potent dopamine receptor agonist

Norastemizole

Tecastemizole

[75970-99-9]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and ETOH
C19H21FN4 MW: 324.40



Axon 3734

mg	Price
10	online
50	online

Biological activity

Norastemizole is a histamine H1 receptor antagonist. Norastemizole is 13- to 16-fold more potent as an H1 antagonist than astemizole and 20- to 40-fold more potent in inhibiting histamine-induced bronchoconstriction.

Norclozapine

See Clozapine, N-Desmethyl-

Axon 2846

Page 378

Normethylclozapine

See Clozapine, N-Desmethyl-

Axon 2846

Page 378

Norvasc

See Amlodipine besylate

Axon 3015

Page 234

Noxafil

See Posaconazole

Axon 1557

Page 787

Novitoclax

See ABT-263

Axon 3821

Page 201

NP-12

See Tideglusib

Axon 3579

Page 928

NP031112

See Tideglusib

Axon 3579

Page 928

NPA

See Propylnorapomorphine hydrochloride, R(-)-N-

Axon 1161

Page 793

NPAS3 heterodimer inhibitor compound 6

See BI-87G3


Axon 4028

Page 304

NPB

[2247491-97-8]
Purity: 99%

Soluble in DMSO
C29H31Cl2N3O2 MW: 524.48


Axon 3079

mg	Price
10	online
50	online

Biological activity

NPB is a potent, site-specific inhibitor of Bcl-2-associated death promoter (BAD) phosphorylation with efficacy in tumor models. NPB reduced phosphorylation of BAD-Ser99 and enhanced caspase 3/7 activity with associated loss of cell viability in various human cancer cell lines derived from mammary, endometrial, ovarian, hepatocellular, colon, prostatic, and pancreatic carcinoma.

NPL 2009

See Fenobam

Axon 1345

Page 478

NP1031L

See Genistein

Axon 3632

Page 501

NPP


See Neryl pyrophosphate ammonium salt

Axon 2940

Page 698

NPPCC, (-)-

[265644-16-4]
Purity: 98%
>98% ee
No solubility data
C20H30N2O MW: 314.47


Axon 1092

mg	Price
10	online
50	online

Biological activity


Potent and selective 5-HT1A receptor agonist

NQ301

Compound 211

[130089-98-4]
Purity: 99%

Soluble in DMSO
C18H12ClNO3 MW: 325.75


Axon 2702

mg	Price
10	online
50	online


Biological activity

NQ301 is an allosteric noncompetitive selective CD45 inhibitor (IC50 value 200 nM). Antithrombotic agent.

NQDI 1

[175026-96-7]
Purity: 99%

Moderately soluble in DMSO
C19H13NO4 MW: 319.31


Axon 1814

mg	Price
10	online
50	online

Biological activity

Selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1, MAP3K5) (KI: 500 nM)

NR

See Nicotinamide riboside chloride

Axon 3572

Page 702

NRX 4204

See NRX 194204


Axon 2408

Page 711

NRX 194204

NRX 4204; VTP 194204; AGN 194204

[220619-73-8]
Purity: 99%
Optically pure
Soluble in DMSO
C₂₄H₃₂O₂ MW: 352.51



Biological activity

Highly potent and specific RXR agonist (K_d values 0.4 nM, 3.6 nM, and 3.8 nM for RXR α , RXR β , and RXR γ , respectively) devoid of any RAR activity (K_d values >30 μ M for RAR α , RAR β , and RAR γ). NRX 194204 blocked the ability of lipopolysaccharide and TNF α to induce the release of nitric oxide and IL6 and the degradation of I κ B α in RAW264.7 macrophage-like cells. NRX194204 prevents carcinogenesis in both the lung and mammary gland, and enhances the ability of ligands for PPARs or cytotoxic drugs, including cisplatin and 5-fluorouracil, to inhibit proliferation and induce apoptosis in breast and pancreatic cancer ce

Axon 2408


mg	Price
1	online
5	online

NS 304

See Selexipag

NS 1619

[153587-01-0]
Purity: 98%
Soluble in DMSO
C₁₅H₈F₆N₂O₂ MW: 362.23



Biological activity

NS 1619 is a selective large-conductance Ca²⁺-activated K⁺ channel (BK channel) activator which decreased the mitochondrial membrane potential with an EC₅₀ value of 3.6 μ M. Besides induction of apoptosis, NS 1619 inhibits both mitochondrial function in the glioma cell line LN229, as well as proliferation of A2780 cells (IC₅₀ value of 31.1 μ M). These anticancer activities are associated with increased expression of p53, p21, and Bax.

Axon 2605


Page 859

Axon 2854

mg	Price
10	online
50	online

NS 3694

[426834-38-0]
Purity: 99%
Soluble in 0.1N NaOH(aq) and DMSO
C₁₅H₁₀ClF₃N₂O₃ MW: 358.70



Biological activity


Apoptosis inhibitor; NS3694 inhibits the formation of the apoptosome Apaf-1 by blocking the activation of the initiator caspase 9; NS2694 exhibits no effect on apoptosome-independent caspase activation and enzymatic activity of caspases

Axon 1883

mg	Price
10	online
50	online

NS 6180

[353262-04-1]
Purity: 99%
Soluble in DMSO and EtOH
C₁₆H₁₂F₃NOS MW: 323.33



Axon 2094


mg	Price
10	online
50	online

Biological activity

Potent KCa_{3.1} channel blocker with nanomolar potency

NS 11394

[693288-97-0]
Purity: 99%
Soluble in DMSO
C₂₃H₁₉N₃O MW: 353.42



Biological activity


A unique subtype-selective GABA_A receptor positive allosteric modulator (PAM); with a subtype selectivity profile at GABA_A receptors of $\alpha 5 > \alpha 3 > \alpha 2 > \alpha 1$. Compared with other subtype-selective ligands, NS11394 is unique in having superior efficacy at GABA_A- $\alpha 3$ receptors while maintaining low efficacy at GABA_A- $\alpha 1$ receptors, which might be attributed for its significantly reduced side effect profile in rat

Axon 1457

mg	Price
5	online
25	online

NS 19504

[327062-46-4]
Purity: 99%
Soluble in DMSO
C₁₀H₉BrN₂S MW: 269.16



Biological activity


Potent activator of large-conductance Ca²⁺-activated potassium channels (BK, KCa1.1, MaxiK; EC₅₀ value 11 μ M in a TI+ assay) with a favorable selectivity profile in a screen of 68 receptors and by functional tests on Nav, Cav, SK, and IK channels. NS19504 potently inhibits urinary bladder spontaneous phasic contractions (SPCs) while having only a modest effect on contractions evoked by electrical field stimulation (EFS) and no effect on high K⁺-induced contractions. At a concentration of 10 μ M, NS19504 was also found to inhibit the $\sigma 1$ receptor, two transporters of neurotransmitters (DA and Norepinephrine), and soluble epoxide hydrolase (sEH).

Axon 2329

mg	Price
10	online
50	online

NS 30678 hydrochloride

[1193707-19-5]
Purity: 99%
Optically pure
Soluble in water and DMSO
C₁₂H₁₆ClNO₄S.HCl MW: 342.24



Biological activity

Dopamine D₂ receptor ligand with surmountable/competitive-like D₂ antagonist properties (K_i and IC₅₀ values of value 9.7 nM and 7 nM, respectively in HEK-hd2L-Gaq5 cells), equipotent to Haloperidol and Risperidone (Axon 1454). NS30678 shows rapid recovery and dopamine responsiveness within 5 min after administration.

Axon 1742

mg	Price
2	online
5	online

NSC245382

See Nimustine hydrochloride

Axon 4045

Page 704

NSC293100

See Honokiol

Axon 3897

Page 545

NSC 4375

See Hydroxychloroquine sulfate

Axon 2432

Page 549

NSC45388

See Dacarbazine

Axon 3459

Page 407

NSC 4910

See Chloropurine riboside, 6-

Axon 2417

Page 367

NSC 8782

See DEAB

Axon 2476

Page 415

NSC 12407

See FH 1

Axon 2320

Page 480

NSC 14050

See Chloroquine diphosphate

Axon 2431

Page 367

NSC 14613


See PluriSIn #1

Axon 2091

Page 783

NSC 23005 sodium

 [1796596-46-7]
 Purity: 100%

 Soluble in water and DMSO
 C13H16NNaO4S MW: 305.33

Axon 2695
mg Price

10 online


50 online

Biological activity

Novel small molecule inhibitor of INK4C (p18/INK4C) or p18 that promotes expansion of both murine and human HSCs (ED50 value 5.21 nM). This p18SMI shows no significant cytotoxicity toward 32D cells or HSCs, nor does it augment leukemia cell proliferation.

NSC 23766

 [1177865-17-6]
 Purity: 98%

 Soluble in water and DMSO
 C24H35N7.3HCl MW: 530.96

Axon 1578
mg Price

10 online

50 online

Biological activity

A cell-permeable, reversible, and selective Rac1 inhibitor; inhibiting Rac1 activation by the Rac-specific GEFs TrioN and Tiam 1 (IC50 = 50 μM) without affecting the closely related GTPases, Cdc42, and RhoA activation; a useful tool for studying the Rac-mediated cellular functions and for modulating pathological conditions in which Rac-deregulation may play a role

NSC 33005

See MHY 553

Axon 2814

Page 653

NSC 36900

See Methylthioadenosine, 2-

Axon 1192

Page 650

NSC 55712

See R 55

Axon 2303

Page 803

NSC 65390

See Sephin 1

Axon 2524

Page 861

NSC 65585

See Isoquinolinediol, 1,5-

Axon 2537

Page 571

NSC675447

See Desloratadine

Axon 3659

Page 420

NSC 69355

See DMNQ

Axon 3011

Page 435

NSC 74859

See S31 201

Axon 2313

Page 838

NSC 75890


See SP 600125

Axon 2519

Page 881

NSC 95397

 [93718-83-3]
 Purity: 98%

 Soluble in DMSO
 C14H14O4S2 MW: 310.39

Axon 3086
mg Price

5 online

25 online

Biological activity

NSC 95397 is a potent and selective Cdc25 dual specificity phosphatase (DUSP) inhibitor with in vitro Ki values of 32, 96, and 40 nM for Cdc25A, -B, and -C, respectively. NSC 95397 was 125- to 180-fold more selective for Cdc25A than VH1-related dual-specificity phosphatase or protein tyrosine phosphatase 1b, respectively. Moreover, NSC 95397 showed significant growth inhibition against human and murine carcinoma cells and blocked G(2)/M phase transition.

NSC 107680

See Flumethasone pivalate

Axon 2247

Page 485

NSC 111847

See HAMNO

Axon 2390

Page 538

NSC 112546

 See *Cambinol*
Axon 2803

Page 340

NSC 136476

 See *GANT61*
Axon 2642

Page 496

NSC 150117

 See *BCI*
Axon 2178

Page 293

NSC 150117 hydrochloride

 See *BCI hydrochloride*
Axon 2852

Page 294

NSC 156750

 See *BTB 1*
Axon 2407

Page 331

NSC 164389

 See *ELN 484228*
Axon 2382


Page 455

NSC 319726

 [71555-25-4]
Purity: 99%

 Soluble in DMSO
C11H14N4S MW: 234.32

Biological activity

 Reactivator of the p53 mutant p53^{R175}; NSC319726 selectively kills cancer cells with a p53^{R175} mutations; it restores the transcriptional functions of p53^{R175}

Axon 2016

mg	Price
5	online
25	online


NSC 348884

 [81624-55-7]
Purity: 100%

 Moderately soluble in DMSO
C38H40N10 MW: 636.79

Biological activity

A putative small molecule inhibitor of nucleophosmin (NPM). NSC 348884 inhibits NPM oligomer formation, up-regulates p53, induces apoptosis and synergizes with chemotherapy


Axon 1402

mg	Price
10	online
50	online

NSC 362856

 See *Temozolomide*
Axon 2326

Page 917


NSC 405020

 [7497-07-6]
Purity: 99%

 Soluble in DMSO
C12H15Cl2NO MW: 260.16

Biological activity

MT1-MMP inhibitor (IC50>100 μM that specifically targets the hemopexin (PEX) domain. NSC 405020 shows significant antitumor efficacy in in vivo tests after intratumoral injections (0.5 mg/kg), and causes a fibrotic tumor phenotype and increases the level of COL-I.


Axon 2162

mg	Price
10	online
50	online


NSC 59984

 [803647-40-7]
Purity: 100%

 Soluble in 0.1N HCl(aq) and DMSO
C12H15N3O4 MW: 265.27

Biological activity

Activator of p53 that restores wild-type p53 signaling via p73 activation, specifically in mutant p53-expressing colorectal cancer cells, inducing cell death in colorectal cancer cells with minimal genotoxicity and without evident toxicity toward normal cells. Remarkably, NSC 59984 induces degradation of several p53 mutants through MDM2-mediated ubiquitination.


Axon 2564

mg	Price
10	online
50	online

NSC 600157

 See *PRT 4165*
Axon 1953

Page 793

NSC 608001

 See *AM 580*
Axon 2948

Page 222

NSC 612113

 See *Naloxonazine dihydrochloride*
Axon 1205

Page 691


NSC 625987

 [141992-47-4]
Purity: 98%

 Soluble in DMSO
C15H13NO2S MW: 271.33

Biological activity

Selective and potent cyclin-dependent kinase (CDK) 4 inhibitor


Axon 1243

mg	Price
10	online
50	online

NSC 631156

 See *MNITMT*
Axon 1267

Page 675

NSC 652287

See RITA

Axon 2009

Page 820

NSC 658180

See BTB 1

Axon 2407

Page 331

NSC 667672

See IBP, 4-

Axon 2919

Page 556

NSC 674319

See Gallic acid

Axon 2208

Page 495

NSC 679828

See PD 98059


Axon 1223

Page 752

NSC 687852

b-AP15

 [1009817-63-3]
Purity: 98%

 Soluble in DMSO
C22H17N3O6 MW: 419.39

Axon 2228

mg	Price
10	online
50	online

Biological activity

Inhibitor of two 19S regulatory-particle-associated deubiquitinases (DUBs), ubiquitin C-terminal hydrolase 5 (UCHL5) and ubiquitin-specific peptidase 14 (USP14) showing tumor growth inhibition in vivo. NSC 687852 shows IC50 values of 0.5 μM and 2.1 μM in cathepsin-dependent caspase-cleavage and in purified 19S proteasome Ub-AMC cleavage assays respectively. NSC 687852 induced tumor cell apoptosis that was insensitive to TP53 status and overexpression of the apoptosis inhibitor BCL2. UNC 687852 does not inhibit the non proteasomeal DUBs UCHL-1/3, USP-2/7/8 and BAP1.

NSC 693627


See JIB 04

Axon 2160

Page 578

NSC 756093

 [1629908-92-4]
Purity: 99%

 Soluble in DMSO
C20H19NO4 MW: 337.37

Axon 2393

mg	Price
5	online
25	online

Biological activity

Potent in vitro inhibitor of GBP1:PIM1 interaction (65% inhibition of interaction at 100 nM) with activity in paclitaxel resistant cells.

NSC 764414

See L 002

Axon 2319

Page 601

NSC-609974


See L651582

Axon 3185

Page 602

NSC194598

 [5358-76-9]
Purity: 98%

 Soluble in 0.1 HCl(aq) and DMSO
C20H19N3O MW: 317.38

Biological activity


NSC194598 is a p53 DNA-binding inhibitor with an in vitro IC50 value of 180 nM. NSC194598 selectively inhibited DNA binding by p53 and homologs p63/p73, but did not affect E2F1, TCF1, and c-Myc. Furthermore, NSC194598 suppressed p53 transcriptional output after DNA damage in culture and increased the survival of mice after irradiation.

Axon 3277

mg	Price
5	online
25	online

NSC745887

 [54490-26-5]
Purity: 99%

 Soluble in DMSO
C16H8N2O2 MW: 260.25

Biological activity


NSC745887 is a DcR3 inhibitor which reduced the cell survival rate and increased the sub-G1 population in dose- and time-dependent manners in glioblastoma multiforme (GBM) cells. Moreover, NSC745887 inhibits the proliferation of various cancers by trapping DNA-topoisomerase cleavage.

Axon 2966

mg	Price
10	online
50	online

NT 157

 [1384426-12-3]
Purity: 99%

 Soluble in DMSO
C16H14BrNO5S MW: 412.26

Biological activity

Unique allosteric inhibitor of IGF1R. NT 157 promotes ERK-MAPK dependent inhibitory Ser-phosphorylation and degradation of insulin receptor substrate 1 and 2 (IRS1/2) by shifting IGF1R complexation from IRS1/2 to Shc, which results in long-term inhibition of IGF1R signaling and powerful inhibition of tumor cell growth.

Axon 2238

mg	Price
2	online
5	online

NT 702, free base

See Parogrelli

Axon 1482

Page 747


NTBC

See Nitisinone

Axon 3662

Page 705

C30H30Cl2N4O4 MW: 581.49




Biological activity

Nutlin-3a is an antagonist or inhibitor of MDM2 (human homolog of murine double minute 2), which disrupts its interaction with p53, leading to the stabilization and activation of p53. *Nutlin-3a (Axon 1880) is the 150-fold more potent (-)-enantiomer of Nutlin-3 (Axon 1585), in comparison with the opposite (+)-enantiomer Nutlin-3b (Axon 1881). Presently, much attention has been given to Nutlin-3a and its absolute stereo-assignment is now known

Nutlin-3b

Nutlin-3, (+)-

[675576-97-3]
Purity: 99%
optically pure
Soluble in DMSO
C30H30Cl2N4O4 MW: 581.49



Axon 1881

mg	Price
2	online
5	online


Biological activity

Nutlin-3b is a 150-fold less potent (+)-enantiomer of Nutlin-3 (Axon 1585) as p53 MDM2 antagonist or inhibitor, in comparison with more potent opposite (-)-enantiomer Nutlin-3a (Axon 1880); useful as a negative control for non-Mdm2 related cellular activity

NVP 231

[362003-83-6]
Purity: 99%

Soluble in DMSO and Ethanol
C25H25N3O2S MW: 431.55



Axon 1600

mg	Price
5	online
25	online

Biological activity


Potent, specific and reversible ceramide kinase (CerK) inhibitor with activity in low nanomolar range

NVP-ACC789

ACC789; ZK 202650

[300842-64-2]
Purity: 99%

Soluble in DMSO
C21H17BrN4 MW: 405.29



Axon 2865

mg	Price
10	online
50	online

Biological activity

NVP-ACC789 is a VEGFR2 inhibitor (IC50 value of 0.02 μM) moderately active against VEGFR1 and VEGFR3, but has little activity against PDGFR-β tyrosine kinases. Blocks angiogenesis induced by VEGF in vivo and in vitro.

NVP-AEB 071

See Sostrastaurin

Axon 1635

Page 880

NVP-AEE 788

See AEE 788

Axon 1653


Page 210

NVP-AUY922

VER 52296

[747412-49-3]
Purity: 98%

Soluble in DMSO
C26H31N3O5 MW: 465.54



mg	Price
5	online
25	online

Biological activity

Highly potent and oral inhibitor of heat shock protein 90 (Hsp90) in vitro and in vivo, with IC50=21 nM in Hsp90 FP binding assay; inhibits proliferation of various human cancer cell lines in vitro, with GI50 average 9 nM

NVP-BAG 956

See BAG 956

Axon 1282


Page 282

NVP-BBD130

BBD 130

[853910-61-9]
Purity: 99%

Moderately soluble in DMSO
C28H21N5O MW: 443.50



Axon 1520

mg	Price
5	online
25	online

Biological activity

Orally potent and selective dual PI3K/mTOR inhibitor; IC50 values to be 72, 2336, 201 and 382 nM for PI3K p110 alpha, beta, delta and gamma isoforms, respectively; inhibition of PI3K/mTOR pathway like NVP-BEZ235, BBD130 efficiently attenuates growth and proliferation of melanoma primary tumors and metastasis

NVP-BEZ 235

See BEZ 235

Axon 1281


Page 299

NVP-BGJ398

BGJ 398

[872511-34-7]
Purity: 99%

Soluble in DMSO
C26H31Cl2N7O3 MW: 560.48



Axon 1775

mg	Price
5	online
25	online


Biological activity

Potent and selective inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinases 1, 2, 3 and 4 (with IC50 values of 0.9, 1.4, 1.0 and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4 respectively); it showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3

NVP-BGJ398 Phosphate

[1310746-10-1]
Purity: 99%

Soluble in DMSO
C26H34Cl2N7O7P MW: 658.47



Biological activity

Potent and selective inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinases 1, 2, 3 and 4 (with IC50 values of 0.9, 1.4, 1.0 and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4 respectively); it showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. Phosphate salt of Axon 1775

Axon 1944


mg	Price
5	online
25	online

NVP-BGT226

BGT 226

[1245537-68-1]
Purity: 99%

Soluble in DMSO
C28H25F3N6O2.C4H4O4
MW: 650.60



Biological activity

Orally active dual PI3K/mTOR inhibitor; induces cell cycle arrest and regulates survivin gene expression in human pancreatic cancer cell lines; inhibits growth in common myeloma cell lines and primary myeloma cells at nanomolar concentrations in a time-dependent and dose-dependent manner

Axon 2029


mg	Price
5	online
25	online

NVP-BHG712

BHG 712

[940310-85-0]
Purity: 98%

Soluble in DMSO
C26H20F3N7O MW: 503.48



Biological activity

Potent and specific inhibitor of EphB4 kinase

Axon 1829


mg	Price
2	online
5	online

NVP-BKM120

BKM 120

[944396-07-0]
Purity: 98%

Soluble in DMSO
C18H21F3N6O2 MW: 410.39



Axon 1797

mg	Price
5	online
25	online

Biological activity

Potent, selective, orally bioavailable class I PI3K inhibitor

NVP-BQR695

See BQR695


Axon 2801

Page 325

NVP-BSK805

[1092499-93-8]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C27H28F2N6O MW: 490.55



Biological activity

NVP-BSK805 is a potent, selective and orally bioavailable JAK2 inhibitor (IC50 value of 7.3 nM) with very good solubility and cellular potency. Moreover, NVP-BSK805 potently suppressed recombinant human erythropoietin-induced polycythemia and extramedullary erythropoiesis in mice and rats.

Axon 2792

mg	Price
5	online
25	online

NVP-BYL719

See Alpelisib

Axon 2925


Page 220

NVP-CGM097

CGM097

[1313363-54-0]
Purity: 99%
99% e.e.

Soluble in DMSO
C38H47ClN4O4 MW: 659.26



Biological activity

NVP-CGM097 is a potent and selective MDM2 inhibitor. Optically pure (S-Enantiomer) NVP-CGM097 binds to the p53 binding-site of the Human MDM2 protein with an IC50 value of 1.7 nM, highly selective against other protein-protein interactions such as p53:MDM4 (>1000-fold selectivity), Ras:Raf (3000-fold selectivity), and showing no significant activity against Bcl-2:Bak, Bcl-2:Bad, Mcl-1:Bak, Mcl-1:NOXA, XIAP:BIR3, and c-IAP:BIR3 protein-protein interactions. It inhibits the p53:MDM2 interaction in cells, leading to p53 nuclear translocation that results in cell growth inhibition in a p53-dependent manner. Exhibit excellent in vivo pharmacological properties. **Source Information:** Sold in collaboration with Chemietek

Axon 3751

mg	Price
10	online
50	online

NVP-CGM097 dihydrochloride

CGM097 dihydrochloride


[N.A.]

Purity: 99%
99% e.e.

Soluble in DMSO
C38H47ClN4O4.2HCl MW: 730.28

Axon 3752

mg	Price
10	online
50	online



Biological activity


NVP-CGM097 dihydrochloride is a potent and selective MDM2 inhibitor. Optically pure (*S*-Enantiomer) NVP-CGM097 binds to the p53 binding-site of the Human MDM2 protein with an IC₅₀ value of 1.7 nM, highly selective against other protein-protein interactions such as p53:MDM4 (>1000-fold selectivity), Ras:Raf (3000-fold selectivity), and showing no significant activity against Bcl-2:Bak, Bcl-2:Bad, Mcl-1:Bak, Mcl-1:NOXA, XIAP:BIR3, and c-IAP:BIR3 protein-protein interactions. It inhibits the p53:MDM2 interaction in cells, leading to p53 nuclear translocation that results in cell growth inhibition in a p53-dependent manner (ref. 1). Exhibit excellent *in vivo* pharmacological properties.

Source Information: Sold in collaboration with Chemietek

NVP-DKY709

[2291360-73-9]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C₂₅H₂₇N₃O₃ MW: 417.50



Biological activity

NVP-DKY709 is a first-in-class selective CRBN glue degrader of IKZF2 that spares IKZF1/3. *In vivo*, treatment with NVP-DKY709 delayed tumor growth in mice with a humanized immune system and enhanced immunization responses in cynomolgus monkeys.

NVP-FGF401

See Roblitinib

NVP-HDM201

See Siremadlin

NVP-LAF 237

See Vildagliptin

NVP-LBH 589

See LBH 589

NVP-LDE225

LDE 225

Axon 3927

mg Price

5 online

25 online

Axon 2953

Page 826

Axon 3737

Page 867

Axon 1631

Page 969

Axon 1548

Page 606


Axon 1619

mg Price

[956697-53-3]

Purity: 98%

Soluble in DMSO
C₂₆H₂₆F₃N₃O₃ MW: 485.50



5 online

25 online

Biological activity

Potent, selective and orally bioavailable Smoothened (SMO) antagonist (IC₅₀: 50 nM); it inhibits hedgehog (Hh) signaling pathway via antagonism of the Smoothened receptor (SMO)

NVP-LGX818

See LGX818

Axon 4146

Page 613

NVP-LXS196

See LXS-196

Axon 3851

Page 622

NVP-MIW815

See ADU-S100

Axon 3687

Page 210

NVP-TAE226

See TAE226

Axon 3866

Page 905


NVP-TAE684

TAE 684

[761439-42-3]

Purity: 99%

Soluble in DMSO
C₃₀H₄₀CIN₇O₃S MW: 614.20



mg Price

2 online

5 online

Biological activity

Potent, selective and efficacious inhibitor of NPM-ALK


NVP-TNKS656

TNKS 656

[1419949-20-4]

Purity: 99%

Soluble in DMSO
C₂₇H₃₄N₄O₅ MW: 494.58



Axon 2599

mg Price

2 online

5 online

Biological activity

Highly potent, selective and orally active tankyrase inhibitor and antagonist of Wnt pathway activity in the MMTV-Wnt1 mouse xenograft model (IC₅₀ values 0.0155 μM and 0.0060 μM for TNKS1 and TNKS2, respectively and >5000-fold selectivity over PARP1 and PARP2).


NVP-XAV 939

See XAV 939

NVS-BPTF-1

[N.A.]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C₂₆H₂₈FN₇O₃S MW: 537.61



Biological activity

NVS-BPTF-1 is a potent, selective and cell active chemical probe for BPTF (IC₅₀ value of 56 nM and K_d value of 71 nM).

NXL104


See Avibactam sodium

NXY 059

Disufenton sodium; Cerovive

[168021-79-2]
Purity: 99%

Soluble in water
C₁₁H₁₃NO₇S₂.2Na MW: 381.33



Biological activity

Free radical scavenger, having neuroprotective potential for acute stroke

Axon 1527

Page 991

Axon 3186

mg Price

5 online

25 online

Axon 3299

Page 262

Axon 1752

mg Price

10 online


50 online

O414

OCT4-inducing compound 4

[412008-21-0]
Purity: 99%

Soluble in DMSO and EtOH
C₁₅H₂₀N₂S MW: 260.40




Biological activity

O414 is a metabolically stable next-generation Oct4 inducer which activated endogenous Oct4 and associated signaling pathways in various cell lines. Moreover, O414 replaced exogenous Oct4 to generate human iPSCs.

OAC2

[6019-39-2]
Purity: 100%

Soluble in DMSO
C₁₅H₁₂N₂O MW: 236.27




Biological activity

O414- and Nanog-activating compound that enhances 4F-induced reprogramming efficiency and considerably accelerates the generation of iPSC formation. OAC2 is one component of a mix of compounds (9C) that can be used to generate cardiomyocyte-like cells from human fibroblasts.

OAT-1441

[2088453-79-4]
Purity: 98%
99% e.e.

Soluble in DMSO and EtOH
C₂₃H₂₇ClN₆O MW: 438.95




Biological activity

OAT-1441 is the first highly potent, selective and orally bioavailable inhibitor of human acidic mammalian chitinase (hAMCase) with an IC₅₀ value of 7 nM.

OATD-01

[2088453-21-6]
Purity: 98%

Optically pure
Soluble in 0.1N HCl(aq), DMSO and EtOH
C₁₉H₂₇ClN₆O MW: 390.91



Biological activity

OATD-01 is a first-in-class, highly potent and selective CHIT1 inhibitor with an IC₅₀ value of 23 nM. OATD-01 shows both an excellent PK profile in multiple species and selectivity against a panel of other off-targets. Furthermore, antifibrotic properties of OATD-01 were confirmed in a pulmonary interstitial fibrosis model induced by bleomycin.

Axon 4020

mg Price

10 online

50 online

Axon 2651

mg Price

10 online

50 online

Axon 3260

mg Price

5 online

25 online

Axon 3353

mg Price

5 online


25 online

Obatoclox

GX15-070

[803712-67-6]
Purity: 99%

Soluble in DMSO
C20H19N3O MW: 317.38



Axon 4152

mg	Price
10	online
50	online


Biological activity

Obatoclox is an orally bioavailable inhibitor of B-cell lymphoma-2 (BCL-2) family proteins.
Source Information: Sold in collaboration with Chemietek

Obeticholic acid

6-ECDCA; INT-747

[459789-99-2]
Purity: 98%
Optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C26H44O4 MW: 420.63



Axon 3174

mg	Price
10	online
50	online


Biological activity

Obeticholic acid is a very potent and selective FXR agonist (EC50 value of 99 nM) and is shown to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.

OC 000459

[851723-84-7]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C21H17FN2O2 MW: 348.37



Axon 1913

mg	Price
5	online
25	online

Biological activity

Potent, oral and selective CRTH2 (also known as DP2) antagonist; under clinic development

OCT4-inducing compound 4

See O4I4

Axon 4020

Page 728

Odanacatib

See MK 0822

Axon 1771

Page 661

Odapipam

See NNC 756

Axon 1405

Page 708

Odiparcil


SB 424323; GSK 424323

[137215-12-4]
Purity: 99%

Axon 1536

mg	Price
10	online

Soluble in DMSO
C15H16O6S MW: 324.35



50 online


Biological activity

Orally active anti-thrombotic agent under clinical development, with limited hemorrhagic risk and a unique mechanism of action involving the induction of glycosaminoglycans (GAGs) biosynthesis; indirect thrombin inhibitor (via. Heparin cofactor II)

ODM-207

[1801503-93-4]
Purity: 99%

Soluble in DMSO
C22H21N3O3 MW: 375.42



Axon 3329

mg	Price
5	online
25	online


Biological activity

ODM-207 is a highly potent, selective and orally active pan-BET inhibitor that has shown preclinical evidence of tumour growth inhibition in breast cancer and in leukaemia and prostate cancer xenograft models.

OF-1

[919973-83-4]
Purity: 99%

Soluble in DMSO
C17H18BrN3O4S MW: 440.31



Axon 2442

mg	Price
5	online
25	online

Biological activity


Potent Bromodomain inhibitor with selectivity for BRPF1 and BRPF2 (Kd values 100 nM, 500 nM, and 2.4 μM for BRPF1B, BRPF2, and BRPF3, respectively). Selectivity against other bromodomains is very good, in general >100-fold. The closest off-target effects are against BRD4 (39-fold selectivity) and TIF1a (50% inhibition at 20 μM). OF-1 increases thermal stability in the cellular thermal shift assay (CETSA) of full length BRPF1B at 1 μM and also demonstrates accelerated FRAP recovery at 5 μM in the BRPF2 FRAP assay.

Ofloxacin Recent Addition

DL8280;HOE280

[82419-36-1]
Purity: 99%

Soluble in 0.1N NaOH(aq), 0.1N HCl(aq) and DMSO
C18H20FN3O4 MW: 361.37



Axon 4211

mg	Price
50	online


Biological activity

Ofloxacin is a broad-spectrum antibiotic.

OG-L002 hydrochloride

[1357298-75-9]
Purity: 100%

Soluble in water and DMSO
C15H15NO.HCl MW: 261.75



Axon 2077

mg	Price
5	online
25	online

Biological activity

Highly specific inhibitor of lysine specific demethylase 1 (LSD1, also known as KDM1A, or H3K9 demethylase) (IC50, ~0.02 μM). OG-L002 potently repressed herpes simplex virus (HSV) IE gene expression, genome replication, and reactivation from latency. It suppressed primary lytic infection of HSV in vivo in a mouse model. This highlights the potential for drugs that inhibit a virus' ability to modify chromatin for treating or even preventing viral diseases like herpes, chicken pox, and shingles.

OHB, 6

See Hydroxy-bupirone hydrochloride, 6-

Axon 1996

Page 549

OH-Bu, 6-

See Hydroxy-bupirone hydrochloride, 6-


Axon 1996

Page 549

OICR-9429

[1801787-56-3]
Purity: 98%

Soluble in 0.1N NaOH(aq), 0.1N HCl(aq) and DMSO
C29H32F3N5O3 MW: 555.59



Axon 3583

mg	Price
5	online
25	online


Biological activity

OICR-9429 is a first-in-class, potent, highly selective and cell-active antagonist of the Wdr5-MLL interaction, which is able to elicit a profound disruption of the protein-protein interaction network around Wdr5 and the SET/MLL HMT complex. OICR-9429 binds to WDR5 with high affinity (KD value of 93 nM).

OICR-12694 Recent Addition

JNJ-65234637

[2360625-97-2]
Purity: 98%
98% e.e.
Soluble in DMSO
C29H28ClF3N8O4 MW: 645.03



Axon 4269

mg	Price
5	online

Biological activity

OICR-12694 is a highly potent, selective, and orally bioavailable inhibitor of B cell lymphoma 6 (BCL6) with low nanomolar DLBCL cell growth inhibition and an excellent oral pharmacokinetic profile.


Source Information: Sold in collaboration with Chemietek

Olanzapine

LY 170053

[132539-06-1]
Purity: 99%

Soluble in DMSO
C17H20N4S MW: 312.43



Axon 1298

mg	Price
10	online
50	online

Biological activity

Atypical antipsychotic; Higher affinity for 5-HT2 receptors than D2 receptors. D1/D2/D4/5-HT2C antagonist. Also nanomolar affinity for 5-HT6/5-HT7 receptors. Weak activity on dopamine sites, appears to bind to M3 and M4 receptor sites. Anticholinergic and anxiolytic properties

Olaparib

See AZD 2281

Axon 1464


Page 269

Olmesartan

RNH-6270

[144689-24-7]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C24H26N6O3 MW: 446.50



Axon 3105

mg	Price
50	online

Biological activity


Olmesartan is a potent and selective nonpeptide antagonist at the angiotensin II AT1-receptor subtype with an IC50 value of 6.7 nM.

Olmutinib

BI 1482694; HM71224

[1353550-13-6]
Purity: 99%

Soluble in DMSO
C26H26N6O2S MW: 486.59



Axon 4144

mg	Price
10	online
50	online

Biological activity

Olmutinib is a third-generation, orally bioavailable and irreversible Tyrosine Kinase Inhibitor, potently and selectively targeting EGFR mutants with Ki values of ~10 nM (in vitro cell assays, against sensitizing (Del19, L858R) and resistance (T790M) EGFR mutations), highly selective over Wt EGFR (Ki = >2000nM, >200-fold selectivity).


Source Information: Sold in collaboration with Chemietek

Olopatadine hydrochloride

AL4943A; KW4679

[140462-76-6]
Purity: 100%

Soluble in water, DMSO and EtOH
C21H23NO3.HCl MW: 373.87



Axon 3642

mg	Price
50	online

Biological activity


Olopatadine hydrochloride is a selective H1 receptor antagonist with a Ki value of 31.6 nM. Antiallergic/antihistaminic drug.

Olprinone hydrochloride

Loprinone hydrochloride

[119615-63-3]
Purity: 99%

Soluble in water and DMSO
C14H10N4O.HCl MW: 286.72



Axon 1168

mg	Price
10	online
50	online

Biological activity

Selective PDE III (PDE3) inhibitor; cardiotonic agent; with positive inotropic and vasodilating effects; as a therapeutic agent for acute heart failure

Omaveloxolone

See RTA 408

Axon 2497

Page 834

Omacetaxine mepesuccinate

See Homoharringtonine

Axon 3667

Page 545

Omecantiv Mecarbil

See CK 1827452

Axon 1835

Page 374

ON01910 sodium

See Rigosertib sodium

Axon 2950

Page 818

Onametostat dihydrochloride

See JNJ-64619178 dihydrochloride


Axon 3754

Page 579

ONC212

[1807861-48-8]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C24H23F3N4O MW: 440.46



Axon 3581

mg	Price
5	online
25	online


Biological activity

ONC212 caused similar TRAIL/DR5 upregulation and activation of the integrated stress response as ONC201 (Axon 2300), with ONC212 having relatively rapid kinetics. ONC212 is also a mitocan acting on the CipXP complex and causing collapse of mitochondrial bioenergetics. Moreover, ONC212 activates the orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.

ONO 5334

[868273-90-9]
Purity: 98%

Optically pure
Soluble in DMSO
C21H34N4O4S MW: 438.58



Axon 2156

mg	Price
2	online
5	online


Biological activity

Potent and orally available inhibitor of cathepsin K (Ki values of 0.1 nM, 0.049 nM and 0.85 nM for human, rabbit and rat respectively). ONO 5334 dose dependently suppresses human osteoclast-mediated bone resorption in vitro, and reduced PTHrP-induced increase in plasma calcium with significant effect (86% reduction) after oral administration in TPTX pretreated rats.

ONO 8711 dicyclohexyl amine salt

[216158-34-8]
Purity: 98%

Soluble in DMSO
C22H30ClNO4S.C12H23N
MW: 621.31



Axon 1512

mg	Price
5	online
25	online


Biological activity

A selective prostaglandin E (PGE) receptor EP1 antagonist with chemopreventive effects

Ononetin

[487-49-0]
Purity: 99%

Soluble in DMSO and EtOH
C15H14O4 MW: 258.27



Axon 3633

mg	Price
50	online

Biological activity

Ononetin, a natural deoxybenzoin, is a potent and selective TRPM3 channel antagonist with an IC50 value of 0.3 μM.

Onvansertib

See NMS-1286937

Axon 4007

Page 707

ONX-0912

See Oprozomib

Axon 3849


Page 735

ONX 0914

PR 957

[960374-59-8]

Purity: 98%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C31H40N4O7 MW: 580.67



Axon 2199

mg	Price
2	online
5	online

Biological activity

Selective inhibitor of LMP7, the chymotrypsin-like subunit of the immunoproteasome. ONX 0914 blocks the production of cytokines IL-23, TNF-α, and IL-6 in a NF-κB independent manner, and attenuates progression of experimental arthritis in mouse models. ONX 0914 induces an anti-inflammatory response at doses less than one tenth of the maximum tolerated dose, in contrast to nonselective inhibitors, such as bortezomib (Axon 1810) and carfilzomib.

OP 1068

See Solithromycin

Axon 2606

Page 878

Opaganib

See ABC294640

Axon 2880

Page 198

OPC 31

See Aripiprazole

Axon 1143

Page 246

OPC 14597

See Aripiprazole

Axon 1143

Page 246

OPC 34712 dihydrochloride

See Brexpiprazole dihydrochloride

Axon 2335

Page 327

OPC 41061

See Tolvaptan

Axon 1591

Page 935

o,p'-DDD

See Mitotane


Axon 3248

Page 658

Oprozomib

ONX-0912; PR-047

[935888-69-0]
 Purity: 99%
 Optically pure
 Soluble in DMSO
 C25H32N4O7S MW: 532.61


Axon 3849

mg	Price
5	online
10	online

Biological activity


Oprozomib, a tripeptide epoxyketone, is an orally active and irreversible inhibitor of 20S proteasome, targeting primarily chymotrypsin-like activity. It inhibits growth and induces apoptosis in MM (multiple myeloma) cells resistant to conventional and bortezomib therapies. Its anti-MM activity is associated with activation of caspase-8, caspase-9, caspase-3, and poly(ADP) ribose polymerase, as well as inhibition of migration of MM cells and angiogenesis.

Source Information: Sold in collaboration with Chemietek

Optovin

[348575-88-2]
 Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
 C15H13N3OS2 MW: 315.41


Axon 2374

mg	Price
5	online
25	online

Biological activity

Reversible photoactivated TRPA1 agonist (EC50 value 2 μM) that specifically activates TRPA1, but not TRPV1 or TRPM8. Optovin activates human TRPA1 via structure-dependent photochemical reactions with redox-

sensitive cysteine residues, and enables control of motor activity in paralyzed extremities by localized illumination in animals. Optovin-treated animals respond to 387-nm (violet) stimuli but not to 485-nm (blue), 560-nm (green) or longer wavelengths.

OR1259

See Levosimendan

Axon 4046

Page 613

OR611

See Entacapone

Axon 3389

Page 460

Orantinib

See SU 6668

Axon 1891

Page 898

ORG 3770

See Mirtazapine

Axon 1138

Page 655

ORG 5222

See Asenapine maleate

Axon 1503


Page 254

ORG 25935

SCH 900435

[949588-40-3]
 Purity: 99%

Soluble in DMSO
 C21H25NO3.HCl MW: 375.89



mg	Price
5	online
25	online


Biological activity

Potent and selective GlyT-1 glycine transporter or reuptake inhibitor; a therapeutic intended for the treatment of neurological disorders

Org OD 02-0

19-CH2P4

[13258-85-0]
 Purity: 100%
 Optically pure
 Soluble in DMSO
 C22H30O2 MW: 326.47


Axon 2085

mg	Price
2	online
5	online

Biological activity

Selective agonist of membrane progesterone receptor (mPR; IC50 value 33.9 nM). Org OD 02-0 mimics the protective effects of progestin hormones on serum starvation-induced cell death and apoptosis in both granulosa and breast cancer cells without altering caspase 3 activity. Org OD 02-0 significantly increased mitochondrial membrane potential (MMP) in serum starved MB468 cells.

Orlistat

(-)-Tetrahydrolipstatin; Ro18-0647


[96829-58-2]

Axon 3500

mg	Price

Purity: 99%

Soluble in DMSO and EtOH
C29H53NO5 MW: 495.73



50 online

Biological activity

Orlistat is a potent, specific and irreversible inhibitor of pancreatic and gastric lipases.

Orteronel

See TAK 700

Axon 2124

Page 907

Orvepitant maleate

GW 823296B; GW 823296X maleate


[579475-24-4]

Purity: 99%

>98% ee

Soluble in water and DMSO

C31H35F7N4O2.C4H4O4 MW:
744.70



Axon 1618

mg Price

2 online

5 online

Biological activity

Neurokinin-1 (NK1) receptor antagonist; potential therapeutic for the treatment of depression and anxiety diseases

Osanetant

SR 142801


[160492-56-8]

Purity: 98%

optically pure

Soluble in DMSO

C35H41Cl2N3O2 MW: 606.62



Axon 1533

mg Price

5 online

25 online

Biological activity

Potent non-peptide neurokinin 3 (NK3) receptor antagonist

Oseltamivir phosphate

GS 4104 phosphate; Tamiflu


[204255-11-8]

Purity: 99%

Optically pure

Soluble in water and DMSO

C16H28N2O4.H3PO4 MW: 410.40



Axon 3136

mg Price

50 online

250 online

Biological activity

Oseltamivir phosphate is an orally available prodrug of GS 4071, a selective inhibitor of influenza virus neuraminidases. Moreover, Oseltamivir phosphate is an antiviral agent with the potential to be effective for the prophylaxis and treatment of influenza A and B virus infections in humans.

OSI 420


Erlotinib, 6-O-Desmethyl-

[183321-86-0]

Purity: 98%

Soluble in DMSO

C21H21N3O4 MW: 379.41



Axon 1632

mg Price

2 online

5 online

Biological activity

An active O-desmethyl metabolite of Erlotinib (Axon 1128), which inhibits EGFR tyrosine kinase; precursor of [11C]-labelled Erlotinib for PET study

OSI 774

See Erlotinib hydrochloride

Axon 1128

Page 466

OSI 906


Linsitinib

[867160-71-2]

Purity: 99%

Soluble in DMSO

C26H23N5O MW: 421.49



Axon 1702

mg Price

2 online

5 online

Biological activity

Highly potent, orally efficacious and highly selective, dual ATP-competitive tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) (IC50: 35 nM) and insulin receptor (IR) (IC50: 75 nM)


OSI 930

[728033-96-3]

Purity: 99%

Soluble in DMSO

C22H16F3N3O2S MW: 443.44



Axon 1547

mg Price

5 online

25 online

Biological activity

A potent and orally active inhibitor of tyrosine kinases, targeting c-KIT and VEGFR-2; OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors


OSS-128167

[887686-02-4]

Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO

C19H14N2O6 MW: 366.32



Axon 2843

mg Price

10 online

50 online


Biological activity

OSS-128167 is a selective SIRT6 inhibitor (IC50 value of 89 μM).

OSU 03012

[742112-33-0]
Purity: 99%

Soluble in DMSO
C26H19F3N4O MW: 460.45



Axon 2525

mg	Price
10	online
50	online

Biological activity

ATP competitive PDK-1 inhibitor (IC50 value 5 μ M for both PDK-1/PDPK1) that inhibits the growth of thyroid, prostate and breast cancer xenografts in vivo. A Celecoxib derivative that inhibits PAK phosphorylation and cell proliferation with reduced Akt phosphorylation by PDK1, without inhibition of cyclooxygenases. Moreover, overexpression of constitutively active forms of PDK-1 and Akt partially protected OSU-03012-induced apoptosis.

Osunprotafib

See ABBV-CLS-484 hydrochloride

Axon 3729

Page 198

Otenabant

See CP 945598

Axon 2015

Page 391

Otenabant hydrochloride

See CP 945598 hydrochloride


Axon 2119

Page 391

Otilonium bromide

[26095-59-0]
Purity: 99%

Soluble in DMSO
C29H43BrN2O4 MW: 563.57



Axon 3158


mg	Price
10	online
50	online

Biological activity

Otilonium bromide is a Ca²⁺ channel blocker. The main action consists in the blockade of Ca²⁺ entry through L-type Ca²⁺ channels and interference with intracytoplasmatic Ca²⁺ mobilization necessary for smooth muscle cell (SMC) contraction, thus preventing excessive bowel contractions and abdominal cramps. Further, Otilonium bromide blocks the T-type Ca²⁺ channels and interferes with the muscarinic responses; it interacts, directly or indirectly, with the tachykinin receptors on SMC and on primary afferent neurons whose combined effects may result in the reduction of motility and abdominal pain.

OTS514

[1338540-63-8]
Purity: 99%
Optically pure
Soluble in DMSO and 0.1N HCl(aq)
C21H20N2O2S MW: 364.46



Axon 4171


mg	Price
5	online
25	online

Biological activity

OTS514 is a highly potent TOPK inhibitor with an IC50 value of 2.6 nM.

OTS-964

[1338545-07-5]
Purity: 99%
99% e.e.
Soluble in DMSO
C23H24N2O2S MW: 392.51




Biological activity

TOPK (T-lymphokine-activated killer cell-originated protein kinase), an enzyme that is heavily and frequently transactivated in various cancer tissues, including lung and triple-negative breast cancers, plays a vital role in the mitosis of cancer cells. Optically pure OTS-964 is a TOPK small molecular inhibitor, binding to the enzyme potently and selectively with IC50 at lower nM. The inhibition causes a cytokinesis defect and the subsequent apoptosis of cancer cells in vitro as well as in xenograft models of human lung cancer. The drug delivered in a liposomal formulation effectively caused complete regression of transplanted tumors without any detectable side effects in mice.

Source Information: Sold in collaboration with Chemietek

OTS964 hydrochloride

[1338545-07-5]
Purity: 98%
Optically pure
Soluble in water, DMSO and EtOH
C23H24N2O2S.HCl MW: 428.97



Biological activity


OTS964 hydrochloride is a TOPK small molecular inhibitor, binding to the enzyme potently and selectively with IC50 at lower nM. The inhibition causes a cytokinesis defect and the subsequent apoptosis of cancer cells in vitro as well as in xenograft models of human lung cancer.

OTX 008

Calixarene 0118; PTX 008

[286936-40-1]
Purity: 99%

Soluble in DMSO and Ethanol
C52H72N8O8 MW: 937.18



Biological activity

Selective allosteric inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumor angiogenesis. OTX008 inhibited galectin-1 expression and ERK1/2 and Akt-dependent survival pathways, and induced G2/M cell cycle arrest through CDK1.

OTX 015

[202590-98-5]
Purity: 99%
Optically pure
Soluble in DMSO and ethanol

Axon 3876

mg	Price
5	online
10	online

Axon 4097

mg	Price
5	online
25	online


Axon 2332

mg	Price
5	online
25	online

Axon 2530

mg	Price
5	online
25	online

C25H22CIN5O2S MW: 491.99



Biological activity


Potent inhibitor of BRD2, BRD3, and BRD4 (K_i values ranging from 4 to 17 nM), with clear anti-proliferative activity on a large number of diffuse large B-cell lymphoma (DLBCL) cell lines. OTX 015 inhibits the growth of hematologic malignancies through directly regulating MYC expression and activity

OV935

See Soticlestat

Oxacillin sodium

[1173-88-2]
Purity: 99%
Optically pure
Soluble in water, DMSO and EtOH
C19H18N3NaO5S MW: 423.42



Biological activity


Oxacillin sodium is an orally active penicillinase (beta-lactamase) resistant antibiotic which belongs to the group of penicillins.

Oxaprozin

WY21743; Oxaprozinum

[21256-18-8]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C18H15NO3 MW: 293.32



Biological activity

Oxaprozin is an orally active, nonselective COX inhibitor with IC_{50} values of 2.2 μ M and 36 μ M for COX-1 and COX-2, respectively. Moreover, Oxaprozin is capable of inhibiting both anandamide hydrolase in neurons (IC_{50} value of 85 μ M), with consequent potent analgesic activity, and NF- κ B activation in inflammatory cells (IC_{50} value of 50 μ M).

Oxaprozinum


See Oxaprozin

Oxcarbazepine

GP-47-680

[28721-07-5]
Purity: 99%

Soluble in DMSO
C15H12N2O2 MW: 252.27



Axon 3485

Page 880

Axon 3652

mg	Price
50	online

Axon 3818

mg	Price
50	online

Axon 3818

Page 741

Axon 3308

mg	Price
10	online
50	online


Biological activity

Oxcarbazepine is an anticonvulsant.

Oxybutynin hydrochloride

[1508-65-2]
Purity: 100%

Soluble in water, DMSO and EtOH
C22H31NO3.HCl MW: 393.95



Axon 3505

mg	Price
50	online


Biological activity

Oxybutynin hydrochloride is an anticholinergic drug which competitively binds to parasympathetic muscarinic receptors, with a higher affinity for brain (M_1) than for cardiac (M_2) or ilealbladder receptors (M_3). In addition, it antagonises detrusor contractions in vitro and in vivo.

3PO

[18550-98-6]
Purity: 99%

Soluble in DMSO
C13H10N2O MW: 210.23



Axon 2175

mg	Price
10	online
50	online


Biological activity

Inhibitor of HIF-1-induced PFKFB3, an enzyme with a key role in glycolysis. Potential application as suppressor of tumor glucose metabolism and growth of non-small cell lung cancer cells. The PFKFB3 family member has the highest kinase:bisphosphatase ratio (740:1) of the four known PFKFB family members. 3PO markedly attenuated the stimulation of F2,6BP synthesis, 2-[1-14C]-deoxy-D-glucose uptake, lactate secretion, TNF- α secretion and T cell aggregation and proliferation.

P7C3

[301353-96-8]
Purity: 99%

Soluble in DMSO
C21H18Br2N2O MW: 474.19



Axon 2602

mg	Price
10	online
50	online

Biological activity

Orally bioavailable and brain penetrant proneurogenic and neuroprotective compound that activates NAMPT (nicotinamide phosphoribosyltransferase). P7C3 exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis, and improves cognitive function in aged rats and increases neuronal survival in mouse models of Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS).

p97 inhibitor 1


See Eeyarestatin I

Axon 1798

Page 449

P 505-15

[1370261-96-3]
Purity: 99%
optically pure
Soluble in DMSO
C19H23N9O MW: 393.45



Axon 1936

mg	Price
5	online
25	online

Biological activity

Highly specific and potent inhibitor of spleen tyrosine kinase (Syk) (IC50: 1-2 nM)

P 5091

See P 005091

Axon 2011

Page 744

P 22077


[1247819-59-5]
Purity: 99%

Soluble in DMSO

Axon 1906

mg	Price
10	online
50	online

C12H7F2NO3S2 MW: 315.32



Biological activity


Small molecule inhibitor of deubiquitinase (DUB), specific on ubiquitin-specific protease 7 (USP7) and the closely related USP47; Inhibits USP7-mediated p53 deubiquitination

P 005091

P 5091

[882257-11-6]
Purity: 99%

Soluble in DMSO
C12H7Cl2NO3S2 MW: 348.22



Biological activity

Selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) and the closely related USP47; inhibits USP7-mediated p53 deubiquitination; enhances the degradation of the USP7 substrate HDM2 in tumor cells; induces apoptosis in MM cells resistant to conventional and bortezomib (Axon 1810) therapies

P1446A-05

See Voruciclib

Axon 2011

mg	Price
10	online
50	online


Axon 3801

Page 972

P2Y14 Antagonist Prodrug 7j hydrochloride

[1315308-19-0]
Purity: 98%

Soluble in water and DMSO
C33H31F3N2O3.HCl MW: 597.07



Biological activity

Prodrug of P2Y14 receptor antagonist; highly bioavailable


Axon 1958

mg	Price
5	online
25	online

P3FI-63 Recent Addition

[931596-95-1]
Purity: 100%

Soluble in DMSO
C15H15N3O2 MW: 269.30




Biological activity

P3FI-63 is a KDM3B inhibitor with an IC50 value of 7 μ M. P3FI-63 showed no inhibitory activity against HDAC1, HDAC2, HDAC3, or PRMT5. The analog P3FI-90 with improved solubility and potency is available as Axon 4190.

P3FI-90 Recent Addition

mg	Price
10	online
50	online

[53995-62-3]
Purity: 100%



Soluble in 0.1N HCl(aq) and DMSO
C11H10N4O MW: 214.22

10 online

50 online


Biological activity

P3FI-90 is a KDM3B inhibitor which suppresses the growth of FP-RMS in vitro and in vivo through downregulating PAX3-FOXO1 activity. P3FI-90 demonstrated improved solubility and potency in comparison with the structurally similar P3FI-63.

PAC 1

Procaspase activating compound 1

[315183-21-2]
Purity: 100%



Soluble in DMSO
C23H28N4O2 MW: 392.49

Axon 1743

mg Price

10 online

50 online


Biological activity

A procaspase activating compound activates procaspase-3 to produce caspase-3; induces apoptosis in cancerous cells

Pagoclone, (+)-

CI 1043

[133737-32-3]
Purity: 99%
optically pure
Soluble in DMSO
C23H22ClN3O2 MW: 407.89



Axon 1594

mg Price

5 online

25 online

Biological activity

Subtype selective partial agonist at GABAA receptor, which binds primarily to the $\alpha 2/\alpha 3$ subtypes which are responsible for the anti-anxiety effects of these kind of drugs, but has relatively little efficacy at the $\alpha 1$ subtype which produces the sedative and memory loss effects; nonbenzodiazepine anxiolytic

PAI 039

See Tiplaxtinin


Axon 1383

Page 929

Palbociclib isethionate

PD 0332991 isethionate

[827022-33-3]
Purity: 99%



Soluble in water and DMSO
C24H29N7O2.C2H6O4S MW: 573.66

Axon 2052

mg Price

10 online

50 online


Biological activity

An orally active cyclin-dependent kinase (CDK) inhibitor, specifically targeting on CDK4 and CDK6; a potential agent for the treatment of breast cancer.

Another salt form, PD 0332991 hydrochloride (Axon 1505) is also available. Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Palmitoylethanolamide

[544-31-0]
Purity: 98%



Soluble in Ethanol
C18H37NO2 MW: 299.49

Axon 1211

mg Price

20 online

100 online


Biological activity

A putative endocannabinoid; selective GPR55 agonist

Palomid 529

SG 00529

[914913-88-5]
Purity: 98%



Soluble in DMSO
C24H22O6 MW: 406.43

Axon 1718

mg Price

5 online

25 online


Biological activity

Small molecule tyrosine kinase inhibitor, targeting Akt/mTOR; Dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation; P529 inhibits cell growth of a broad spectrum of cancer cell lines

Palonosetron hydrochloride

RS 25259-197

[135729-62-3]
Purity: 99%
Optically pure
Soluble in water and DMSO
C19H24N2O.HCl MW: 332.87



Axon 3101

mg Price

50 online

Biological activity


Palonosetron hydrochloride is a highly potent, selective and orally active 5-HT3 receptor antagonist.

Paltusotine

CRN00808

[2172870-89-0]
Purity: 99%

Soluble in 0.1N NaOH(aq), 0.1N HCl (aq) and DMSO
C27H22F2N4O MW: 456.49



Axon 3840

mg Price

10 online

50 online

Biological activity

Paltusotine is a potent, selective, and orally bioavailable non-peptide SST2 agonist with an EC50 value of 0.25 nM. The water-soluble salt form of Paltusotine is available as Axon 4064.

Paltusotine dihydrochloride

CRN00808


[2172875-40-8]
Purity: 99%

Axon 4064

mg Price

5 online

Soluble in water, DMSO and EtOH
C27H22F2N4O.2HCl MW: 529.41



25 online

Biological activity

Paltusotine dihydrochloride is a potent, selective, and orally bioavailable non-peptide SST2 agonist with an EC50 value of 0.25 nM. Water-soluble salt form of Paltusotine.

Panobinostat

See LBH 589


Axon 1548

Page 606

Pantoprazole sodium

Protonix

[138786-67-1]
Purity: 99%



Soluble in water and DMSO
C16H14F2N3NaO4S MW: 405.35

Axon 3161

mg Price

50 online

250 online

Biological activity

Pantoprazole sodium is a proton pump inhibitor (PPI). Pantoprazole sodium exerts its pharmacodynamic actions by binding to the proton pump (H⁺,K⁺-adenosine triphosphatase) in the parietal cells, but, compared with other PPIs, its binding may be more specific for the proton pump.

PAOA

See NKL 22

Axon 3409

Page 705

PAR2 antagonist I-191

See I-191


Axon 3043

Page 554

Parecoxib sodium

SC-69124A

[198470-85-8]
Purity: 99%



Soluble in water and DMSO
C19H17N2NaO4S MW: 392.40

Axon 3311

mg Price

10 online

50 online

Biological activity

Parecoxib sodium is an injectable prodrug of Valdecoxib (Axon 2106), a potent and selective inhibitor of COX-2.

Parogrelil

NT 702, free base; NM 702

Axon 1482

mg Price


[139145-27-0]
Purity: 99%

5 online

Soluble in DMSO

25 online

C19H18BrCIN4O2 MW: 449.73



Biological activity


Selective and potent PDE III (PDE3) inhibitor; a new type of agent with both a bronchodilating and an anti-inflammatory effect

Paroxetine hydrochloride

[61869-08-7]

Purity: 99%
>98% ee

Soluble in water and DMSO
C19H20FNO3 MW: 329.37



Axon 1452

mg Price

10 online

50 online

Biological activity

Selective serotonin reuptake inhibitor (SSRI); Paroxetine is used to treat major depression, obsessive-compulsive, panic, social anxiety, and generalised anxiety disorders in adult outpatients

Parthenolide

PTL


[20554-84-1]

Purity: 98%

Optically pure

Soluble in DMSO and EtOH

C15H20O3 MW: 248.32



Axon 3614

mg Price

50 online

Biological activity

Parthenolide, a sesquiterpene lactone, is a potent inhibitor of nuclear factor-kappa B (NF-κB) activation and can inhibit the expression of pro-inflammatory cytokines in cultured cells and experimental animal models. Acting as a covalently reactive compound, Parthenolide displays anti-inflammatory, redox-modulating, and epigenetic activities, as well as selective cytotoxicity towards cancer stem and progenitor cells.

PAS 997

See Tenilsetam

Axon 1470

Page 918

PaTrin 2

See Lomeguatrib

Axon 2223

Page 618


PAWI-2

[1448427-02-8]

Purity: 99%

Soluble in DMSO

C19H21N3O3S MW: 371.45



Axon 3152

mg Price

5 online

25 online

Biological activity

PAWI-2 is an inhibitor which targets both Wnt signaling (IC50 value of 11 nM) and ATM/p53 (EC50 value of 1.9 nM for p53). PAWI-2 binds tubulin and potently activates mitotic stress signaling to stabilize p53 and inhibit Wnt/β-

catenin transactivation of downstream genes in colorectal cancer cells. Moreover, PAWI-2 inhibits cellular proliferation of androgen-sensitive and androgen-insensitive cells (LNCaP and PC-3, respectively).

Paxalisib

See GDC-0084

Axon 3584


Page 498

PAZ-417

Aleplasinin

[481629-87-2]
Purity: 99%

Soluble in DMSO and EtOH
C28H27NO3 MW: 425.52



Axon 3710

mg	Price
5	online
25	online

Biological activity

PAZ-417 is a potent, orally active and CNS-penetrant inhibitor of PAI-1 (IC50 value of 655 nM) that promotes plasmin formation and proteolysis of Aβ. In transgenic mouse models of Alzheimer's disease, PAZ-417 reduces Aβ levels in both plasma and brain and reverses both LTP and cognitive deficits.

Pazopanib hydrochloride

See GW 786034


Axon 1420

Page 534

PB 28 dihydrochloride

[172907-03-8]
Purity: 99%

Soluble in water
C24H38N2O.2HCl MW: 443.49



Axon 1272

mg	Price
10	online
50	online


Biological activity

High affinity sigma-2 agonist

PBENZ-DBRMD

[1454662-41-9]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C11H5Br2NO4 MW: 374.97



Axon 3582

mg	Price
10	online
50	online

Biological activity


First-in-class iodothyronine deiodinase type 3 (DIO3) inhibitor, demonstrating attenuated cell counts, induction in apoptosis, and a reduction in cell proliferation in DIO3-positive HGSOC cells (OVCAR3 and KURAMOCHI).

PBF-509

NIR178; Taminadenant

[1337962-47-6]
Purity: 99%

Soluble in DMSO
C10H8BrN7 MW: 306.12



Axon 4132

mg	Price
10	online
50	online

Biological activity


PBF-509 an oral immunotherapy agent, is a potent and selective A2A (Adenosine 2A) receptor antagonist, binding to human A2A receptor with a Ki value of 12 nM. It inhibits A2AR expressed on T lymphocytes, thus abrogates the adenosine/ A2AR-mediated inhibition of T-lymphocytes and activates a T-cell-mediated immune response against tumor cells, thereby reducing proliferation of susceptible tumor cells. It is also reported as a potential dopaminergic drug for Parkinson's disease (PD) management.

Source Information: Sold in collaboration with Chemietek

PBTZ169

[1377239-83-2]
Purity: 100%

Soluble in DMSO and Ethanol
C20H23F3N4O3S MW: 456.48



Axon 2626

mg	Price
5	online
25	online

Biological activity

Potent irreversible DprE1 inhibitor (MIC value <0.19 ng/mL and <0.004 μM against M. tuberculosis H37Ra) with improved stability against nitroreductase metabolism, and good efficacy at lower concentrations in the murine model of chronic tuberculosis (TB); an attractive drug candidate to treat TB in humans. The combination of PBTZ169, BDQ and pyrazinamide was found to be more efficacious than the standard three drug treatment in a murine model of chronic disease.

PC14586

See Rezatapopt **Recent Addition**

Axon 4268

Page 814

PCG


See SB 706504

Axon 2444

Page 851

PCI-27483

[871266-63-6]
Purity: 99%
99% e.e.
Soluble in DMSO
C26H24N6O9S MW: 596.57



Axon 3875

mg	Price
5	online
10	online

Biological activity

PCI-27483 is a potent and selective small-molecule inhibitor of activated factor VII (factor VIIa). FVII, a serine protease, becomes activated (FVIIa) upon binding with TF forming the FVIIa/TF complex, which induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2). Upon subcutaneous administration, PCI-27483 selectively inhibits factor FVIIa in the VIIa/TF complex, which may prevent PAR-2 activation and PAR2-mediated signal transduction pathways, thereby inhibiting tumor cell proliferation, angiogenesis, and metastasis of TF-overexpressing tumor cells. In addition, this agent inhibits both the extrinsic and intrinsic coagulation cascades, preventing blood clot formation. TF, a blood protein overexpressed on the cell surface of a variety of tumor cell types, may correlate with poor prognosis; PAR-2 (also known as thrombin receptor-like 1) is a G protein-coupled receptor (GPCR) and a protease-activated receptor.

Source Information: Sold in collaboration with Chemietek

PCI 32765


Ibrutinib

Axon 1858

mg	Price
----	-------

[936563-96-1]
Purity: 99%

Soluble in DMSO
C25H24N6O2 MW: 440.50



5	online
25	online


Biological activity

Orally bioavailable and highly selective inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity; inhibiting BTK activity, B-cell-mediated signaling and the growth of malignant B cells that overexpress BTK; an experimental drug candidate for chronic lymphocytic leukemia (CLL), mantle cell lymphoma, diffuse large B-cell lymphoma, and multiple myeloma etc BTK, a member of the BTK/Tec family of non-recetor cytoplasmic tyrosine kinases, is required for B cell receptor (BCR) signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies

PCI 34051

[950762-95-5]
Purity: 98%

Soluble in DMSO
C17H16N2O3 MW: 296.32



Axon 1853

mg	Price
10	online
50	online


Biological activity

Specific and potent histone deacetylase 8 (HDAC8) inhibitor, with >200-fold selectivity over the other HDAC isoforms. PCI-34051 induces caspase-dependent apoptosis in cell lines derived from T-cell lymphomas or leukemias, but not in other hematopoietic or solid tumor lines

PD-1 Inhibitor 16

[2005454-12-4]
Purity: 99%
99% e.e.

Soluble in water and DMSO
C14H23N7O6 MW: 385.38



Axon 3694

mg	Price
5	online

Biological activity


PD-1 Inhibitor 16 (Aurigene Compound 16) (extracted from Patent (compound 16, ref 1)) is an orally bioavailable small molecule peptidomimetic inhibitor of the immune checkpoint regulatory proteins PD-1/PD-L1 (programmed cell death -1/programmed cell death ligand-1) interaction, with signaling activity in cancer cells, and is currently being evaluated as a potential negative immune checkpoint regulatory and antineoplastic agent.

Source Information: Sold in collaboration with Chemietek

PD123319 ditrifluoroacetate (Optically pure), (R)-(-)-

[N.A.]
Purity: 98%
100% e.e.

Soluble in water, DMSO and EtOH
C31H32N4O3.2C2HF3O2 MW: 736.66



Axon 3890

mg	Price
5	online
25	online

Biological activity

Opposite R-(-)-enantiomer of PD123319 ditrifluoroacetate (Axon 1276), a potent and selective Angiotensin II (AT-2) antagonist.


PD 90780

Axon 2174

mg	Price
----	-------

[77422-99-2]
Purity: 99%

Soluble in DMSO
C19H14N4O4 MW: 362.34



5	online
25	online

Biological activity


A nonpeptide inhibitor of nerve growth factor's binding to the P75 NGF receptor; It binds to NGF, not to the P75 receptor. Differential activity of PD90780 suggests altered NGF-p75NTR interactions in the presence of TrkA.

PD 98059

NSC 679828

[167869-21-8]
Purity: 99%

Soluble in DMSO
C16H13NO3 MW: 267.28



Axon 1223

mg	Price
10	online
50	online

Biological activity

Potent and cell-permeable inhibitor of mitogen-activated protein (MAP) kinase kinase (also known as MAPK/ERK kinase or MEK)

PD109452-2


See Quinapril hydrochloride

Axon 3655
Page 802

PD 123319 ditrifluoroacetate

[136676-91-0]
Purity: 99%
optically pure

Soluble in water and DMSO
C31H32N4O3.2C2HF3O2 MW: 736.66



Axon 1276

mg	Price
5	online
25	online

Biological activity

Angiotensin II (AT-2) antagonist

PD 123654

See CI 994

Axon 2014
Page 369

PD 125530


See PD 128907 hydrochloride, (±)-

Axon 1072
Page 752

PD 128907 hydrochloride, (-)-

[112960-16-4]
Purity: 99%
99% ee

No solubility data
C14H19NO3.HCl MW: 285.77



Axon 1074


mg	Price
5	online
25	online

Biological activity

PD 128907 is a selective D3 dopamine receptor agonist; (-)-enantiomer is less active in comparison with (+)-enantiomer (Axon 1073)

PD 128907 hydrochloride, (+)-

[300576-59-4]
Purity: 99%
99% ee
Moderately soluble in water
C14H19NO3.HCl MW: 285.77



Axon 1073

mg	Price
5	online
25	online

Biological activity


Standard selective D3 dopamine receptor agonist, more active enantiomer of trans-(±)-PD 128907 (Axon 1072)

PD 128907 hydrochloride, (±)-

PD 125530

[123594-64-9]
Purity: 99%

Soluble in DMSO
C14H19NO3.HCl MW: 285.77



Axon 1072

mg	Price
5	online
25	online

Biological activity

Selective D3 dopamine receptor agonist. Its more active enantiomer is trans-(+)-PD-128907 (Axon 1073) and less active enantiomer is (-)-PD 128907 (Axon 1074)

PD 132301-2

See ATR-101

Axon 2960

Page 260

PD134393

See Cefdinir

Axon 3494

Page 356

PD 144723

See Pregabalin


Axon 1823

Page 790

PD 161570

[192705-80-9]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C26H35Cl2N7O MW: 532.51



Axon 2098

mg	Price
5	online
25	online

Biological activity

Selective FGFR inhibitor; with IC50 values to be 40, 262 and 3700 nM for FGFR1, PDGFR and EGFR tyrosine kinases, respectively. PD 161570 suppressed constitutive phosphorylation of FGFR1 in both human ovarian carcinoma cells (A121(p)) and Sf9 insect cells overexpressing the human FGFR1 and blocked the growth of A121(p) cells in culture


Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

PD 166793

Axon 1271

mg	Price
----	-------

[199850-67-4]
Purity: 99%
>98% ee
Soluble in 0.1N NaOH(aq), DMSO,
and Ethanol
C17H18BrNO4S MW: 412.30



10	online
50	online


Biological activity

Matrix metalloproteinase (MMP) inhibitor

PD 169316

[152121-53-4]
Purity: 99%

Soluble in DMSO
C20H13FN4O2 MW: 360.34



Axon 1365

mg	Price
2	online
10	online


Biological activity

Potent, cell-permeable and selective inhibitor of p38 MAP kinase (MAPK); it blocks apoptosis induced by trophic factor withdrawal in non-neuronal and neuronal cell lines

PD 173074

[219580-11-7]
Purity: 99%

Soluble in DMSO and Ethanol
C28H41N7O3 MW: 523.67



Axon 1673

mg	Price
5	online
25	online


Biological activity

Potent and selective FGFR inhibitor with IC50 to be 21.5 and 5 nM for FGFR1 and FGFR3 inhibition respectively

PD 180970

[287204-45-9]
Purity: 99%

Soluble in DMSO
C21H15Cl2FN4O MW: 429.27



Axon 1137

mg	Price
10	online
50	online

Biological activity


PD180970 inhibits p210(Bcr-Abl) tyrosine kinase and induces apoptosis in Bcr-Abl-expressing leukemic cells

PD 184352

CI 1040

[212631-79-3]
Purity: 99%

Soluble in DMSO
C17H14ClF2IN2O2 MW: 478.66



Axon 1368

mg	Price
5	online
25	online


Biological activity

Potent, selective and non-competitive inhibitor of MEK 1 (also called MKK 1) and its activation; highly recommended tool to inhibit MKK1 or MKK1 plus MKK5.

PD 0220245

[640736-79-4]
Purity: 99%

Soluble in water and DMSO
C24H26Cl2N4S2.2HCl MW: 578.45



Axon 1501

mg Price

5 online

25 online


Biological activity

Potent and non-peptide interleukine 8 (IL-8) receptor antagonist

PD 0325901

[391210-10-9]
Purity: 99%

>98% ee
Soluble in DMSO
C16H14F3IN2O4 MW: 482.19



Axon 1408

mg Price

2 online

5 online


Biological activity

Potent, highly specific non-ATP-competitive inhibitor of MEK (aka MKK) 1/2; a derivative of CI-1040 (Axon 1368) to improve bioavailability; clinical candidate and highly recommended tool to inhibit MKK1 or MKK1 plus MKK5 in cells

PD 0332991 hydrochloride

[571189-11-2]
Purity: 99%

Soluble in water
C24H29N7O2.2HCl MW: 520.45



Axon 1505

mg Price

2 online

5 online

Biological activity

An orally active cyclin-dependent kinase (CDK) inhibitor, specifically targeting on CDK4 and CDK6; a potential agent for the treatment of breast cancer

PD 0332991 isethionate

See Palbociclib isethionate


Axon 2052

Page 745

PD-1 inhibitor compound 9

[2227556-18-3]
Purity: 98%

Soluble in water and DMSO
C13H19N3O5.HCl MW: 333.77



Axon 2875

mg Price

10 online

50 online

Biological activity

Inhibitor of the programmed death-1 (PD-1) protein. PD-1 inhibitor compound 9 blocked the interaction between PD-1 and its ligand PD-L1 with an inhibitory percentage of 43.0% at a concentration of 500 μ M.

PDD00017273


[1945950-21-9]

Axon 3795

mg Price

Purity: 98%

Soluble in DMSO and EtOH
C23H26N6O4S2 MW: 514.62



5 online

25 online


Biological activity

PDD00017273 is a first-in-class, selective and cell-active poly(ADP-ribose) glycohydrolase (PARG) inhibitor with an IC50 value of 0.026 μ M.

PDE5 inhibitor 42

[936449-28-4]
Purity: 98%

Soluble in DMSO
C23H31N7O3 MW: 453.54



Axon 1709

mg Price

5 online

25 online

Biological activity


Potent and selective phosphodiesterase type 5 (PDE5) inhibitor (IC50: 0.04 nM); PDE6/PDE5 and PDE11/PDE5 ratios to be 100x and 530x respectively; a second generation PDE5 inhibitor under investigation

PDE9A inhibitor C33(S)

(S)-C33

[2066488-39-7]
Purity: 98%

Optically pure
Soluble in DMSO
C18H20ClN5O MW: 357.84



Axon 2825

mg Price

10 online

50 online


Biological activity

(S)-C33 is a potent and selective PDE9A inhibitor with an IC50 value of 11 nM.

PDK1 inhibitor 2610

[N.A.]
Purity: 99%

Soluble in water and DMSO
C25H15N5.HCl MW: 421.88



Axon 2610

mg Price

5 online

25 online

Biological activity

Potent, ATP-competitive and selective dual PI3K and PDK1 inhibitor (IC50 values 34 nM and 94 nM for PDK1 and p-T308-PKB inhibition, respectively. Also inhibits PI3K p110 α , p110 β , p110 δ , and p110 γ (IC50 values 64 nM, 432 nM, 98 nM, and 67 nM, respectively) Clsoe analogue of NVP-BAG956 (Axon 1282)

PD-L1 inhibitor compound A

See ARB-272572


Axon 3433

Page 246

PDS0330 Recent Addition

KVA-E-23A

 [2904682-19-3]
 Purity: 98%

 Soluble in DMSO
 C25H17N3O2S MW: 423.49

Axon 4083

mg	Price
10	online
50	online


Biological activity

PDS0330 is a potent and selective first-generation claudin-1 inhibitor. PDS0330 inhibits claudin-1-dependent CRC progression without exhibiting toxicity in in-vitro and in-vivo models of CRC and it binds directly and specifically to claudin-1 with micromolar affinity.

Peficitinib

ASP015K; JNJ54781532

 [944118-01-8]
 Purity: 100%

 Soluble in 0.1N HCl(aq) and DMSO
 C18H22N4O2 MW: 326.39

Axon 3950

mg	Price
5	online
25	online


Biological activity

Peficitinib is a potent and orally bioavailable JAK inhibitor with IC50 values of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and TYK2, respectively.

Pelitinib

EKB 569

 [257933-82-7]
 Purity: 99%

 Soluble in DMSO
 C24H23ClFN5O2 MW: 467.92

Axon 1665

mg	Price
5	online
25	online


Biological activity

Pelitinib is an irreversible inhibitor of EGFR tyrosine kinase with potential antineoplastic activity. Pelitinib irreversibly binds covalently to EGFR ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors.

PEL1/EGFR disruptor S62 Recent Addition

SL-9

 [N.A.]
 Purity: 98%

 Soluble in DMSO and EtOH
 C24H32N2O2S MW: 412.59

Axon 4130


mg	Price
5	online
25	online

Biological activity

PEL1/EGFR disruptor S62 is a potent disruptor of Pelino-1 (PEL1) and EGFR. S62 effectively repressed breast cancer metastasis as indicated by the reduced migration and invasion of MDA-MB-231 cells in vitro and in vivo. Also, S62 enhanced the sensitivity.

Pemetrexed disodium

LY231514 disodium

 [137281-23-3]
 Purity: 99%
 Optically pure
 Soluble in water
 C20H19N5Na2O6 MW: 471.37

Axon 3162

mg	Price
50	online
0	online

Biological activity

Pemetrexed disodium is a antifolate antimetabolite which potently inhibits dihydrofolate reductase (DHFR), thymidylate synthase (TS), and glycinamide ribonucleotide formyltransferase (GARFT) with Ki values of 7.0 nM, 109 nM and 9,300 nM, respectively. Pemetrexed disodium is active as an inhibitor of tumor growth in vitro and in vivo.

Pemrametostat

See GSK3326595


Axon 3750

Page 521

Penciclovir

PVC; BRL39123

 [39809-25-1]
 Purity: 99%

 Soluble in 0.1N NaOH(aq) and DMSO
 C10H15N5O3 MW: 253.26

Axon 3385


mg	Price
50	online

Biological activity

Penciclovir is a nucleoside antiviral drug which exhibits in vitro activity against herpes simplex virus types 1 and 2, varicella zoster virus, Epstein-Barr virus and, to a lesser degree, cytomegalovirus. The mechanism of action of penciclovir involves highly selective inhibition of herpes virus DNA synthesis.

Penehyclidine hydrochloride

 [151937-76-7]
 Purity: 99%

 Soluble in water and DMSO
 C20H29NO2.HCl MW: 351.91

Axon 3286

mg	Price
10	online
50	online

Biological activity

Penehyclidine hydrochloride is an anticholinergic drug. Penehyclidine hydrochloride had both antimuscarinic and antinicotinic activities and retained potent central and peripheral anticholinergic activities. The receptor binding assay showed that this compound had far greater selectivity to M3 over M1 receptor subtype, which makes it have potential use in the treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD).

Pentadecylsalicylic acid, 6-

See Anacardic acid A

Axon 1490

Page 236


Pentoxifylline

 [6493-05-6]
 Purity: 100%

Axon 3179

mg	Price
50	online

Soluble in DMSO
C13H18N4O3 MW: 278.31



250 online


Biological activity

Pentoxifylline is a non-specific inhibitor of cAMP phosphodiesterases.

PEO-IAA

[6266-66-6]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C18H15NO3 MW: 293.32



Axon 3907

mg	Price
10	online
50	online

Biological activity

PEO-IAA is an indole-3-acetic acid (IAA) and auxin antagonist.

Peposertib

See M-3814

Axon 3577


Page 638

Perifosine

KRX 0401; D 21266

[157716-52-4]
Purity: 98%

Soluble in water
C25H52NO4P MW: 461.66



Axon 1663

mg	Price
5	online
25	online


Biological activity

Orally available Akt inhibitor that inhibits Akt activation in the PI3K pathway

Perindopril erbumine

Perindopril tert-butylamine, S9490

[107133-36-8]
Purity: 98%
Optically pure
Soluble in water, DMSO and EtOH
C19H32N2O5.C4H11N MW: 441.60



Axon 3492

mg	Price
50	online

Biological activity

Perindopril erbumine is an orally bioavailable long acting angiotensin converting enzyme (ACE) inhibitor (IC50 value of 10 µM). Specifically, Perindopril erbumine is an oral prodrug of perindoprilat, a potent ACE inhibitor with an IC50 value of 1.9 nM.

Perindopril tert-butylamine

See *Perindopril erbumine*

Axon 3492

Page 759

Pevedonidstat

See MLN 4924

Axon 2038


Page 674

Pexidartinib

PLX 3397

[1029044-16-3]
Purity: 99%

Soluble in DMSO
C20H15ClF3N5 MW: 417.81



Axon 2501

mg	Price
10	online
50	online


Biological activity

Multi-targeted receptor tyrosine kinase inhibitor of CSF1R, c-Kit, and FLT3 (IC50 values 13 nM, 27 nM, and 11 nM, respectively) Administration of PLX3397 reduced CIBP, induced substantial intratumoral fibrosis, and was also highly efficacious in reducing tumor cell growth, formation of new tumor colonies in bone, and pathological tumor-induced bone remodeling. PLX3397 is superior to imatinib in the treatment of malignant peripheral nerve sheath tumor (MPNST), and the combination of PLX3397 with a TORC1 inhibitor could provide a new therapeutic approach for the treatment of this disease.

PF-03758309

PF-3758309

[N.A.]
Purity: 99%
99% e.e.
Soluble in water and DMSO
C25H30N8OS.2HCl MW: 563.55



Axon 3961

mg	Price
5	online
10	online

Biological activity


PF-03758309 is a potent, orally bioavailable and ATP-competitive inhibitor of p21-activated kinase (PAK), a downstream effector of the Rho family functioning as a signaling node for various oncogenic pathways.
Source Information: Sold in collaboration with Chemietek

PF-06281355

PF1355

[1435467-38-1]
Purity: 99%

Soluble in DMSO
C14H15N3O4S MW: 321.35



Axon 3992

mg	Price
5	online
25	online

Biological activity

PF-06281355 is a selective, orally active, mechanism-based myeloperoxidase (MPO) inhibitor, efficacious in cell assays and in vivo. Oral administration of PF-06281355 reduced plasma MPO activity, vascular edema, neutrophil recruitment, and elevated circulating cytokines. In a model of anti-glomerular basement membrane disease, formerly known as Goodpasture disease, albuminuria and chronic renal dysfunction were completely suppressed by PF-06281355 treatment.


PF-06821497

[1844849-10-0]
Purity: 99%

Axon 3695

mg	Price
2	online

99% e.e.
Soluble in DMSO
C22H24Cl2N2O5 MW: 467.34




Biological activity

PF-06821497 (optically pure R-enantiomer) is a small molecule inhibitor of Histone Methyltransferase (HMT) EZH2, potently and selectively inhibiting the activities of both wild-type ($K_i = 0.3nM$) and mutant (Y641N) ($K_i < 0.1nM$).

Source Information: Sold in collaboration with Chemietek

PF-06855800

[1989620-04-3]
Purity: 99%
99% e.e.
Soluble in DMSO
C17H16ClFN4O4 MW: 394.78



Axon 3798

mg	Price
5	online
10	online

Biological activity

PF-06855800 (PF06855800) is a SAM-pocket-binding (SAM competitive) PRMT5 inhibitor with high selectivity and affinity (PRMT5-MEP-50, $K_i < 0.1 nM$) and demonstrates robust and efficacious antiproliferative activity in both *in vitro* and *in vivo* models.

Source Information: Sold in collaboration with Chemietek

PF06865571

See *Ervogastat*


Axon 3823

Page 467

PF-06873600

Ebvaciclib

[2185857-97-8]
Purity: 99%
99% e.e.
Soluble in DMSO
C20H27F2N5O4S MW: 471.52



Axon 3693

mg	Price
5	online


Biological activity

PF-06873600 (*Ebvaciclib*) is an orally bioavailable, potent, and selective inhibitor of CDK2, CDK4 and CDK6, with K_i values at 0.1 nM, 1.2 nM and 0.1 nM, respectively.

Source Information: Sold in collaboration with Chemietek

PF-06939999 dihydrochloride

[N.A.]
Purity: 99%
99% e.e.
Soluble in DMSO
C22H23F3N4O3.2HCl MW: 426.44



Axon 3692

mg	Price
5	online

Biological activity


PF-06939999 is an orally available and SAM competitive PRMT5 inhibitor binding to PRMT5-MEP-50 with high selectivity and affinity.

Source Information: Sold in collaboration with Chemietek

PF-07104091

Tagtociclib

[2460249-19-6]
Purity: 99%
99% d.e.
Soluble in DMSO
C19H28N6O4 MW: 404.46



Axon 3753

mg	Price
2	online
5	online


Biological activity

PF-07104091 is a potent and selective CDK2 inhibitor with a K_i value of about 1 nM, highly selective against CDK1 (>100-fold), CDK4 and CDK6 (200 to 400-fold), CDK9 (170 fold), and GSK3B (>500-fold).

Source Information: Sold in collaboration with Chemietek

PF-07220060

[2380321-51-5]
Purity: 99%
99% e.e.
Soluble in DMSO
C22H27ClFN5O3 MW: 463.93



Axon 3762

mg	Price
5	online
10	online

Biological activity

PF-07220060 is an orally bioavailable and CDK4-Specific Inhibitor

Source Information: Sold in collaboration with Chemietek

PF1355


See PF-06281355

Axon 3992

Page 760

PF-8380

[1144035-53-9]
Purity: 98%
Soluble in DMSO
C22H21Cl2N3O5 MW: 478.33



Axon 3442


mg	Price
5	online
25	online

Biological activity

PF-8380 is a potent, orally bioavailable autotaxin inhibitor with IC_{50} values of 2.8 nM and 101 nM in isolated enzyme assay and human whole blood, respectively.

PF 543 citrate

[1415562-83-2]
Purity: 98%
Optically pure
Soluble in water and DMSO
C27H31NO4S.C6H8O7 MW:
657.73



Biological activity

Cell-permeant reversible inhibitor of SphK1 (IC50 value 2.0 nM; Ki value 3.6 nM). PF-543 is sphingosine-competitive and is more than 100-fold selective for SphK1 over the SphK2 isoform.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.


PF-3758309

See PF-03758309

PF 3845

[1196109-52-0]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C24H23F3N4O2 MW: 456.46




Biological activity

Highly selective and irreversible fatty acid amide hydrolase (FAAH) inhibitor

PF 431396

[717906-29-1]
Purity: 99%

Soluble in DMSO
C22H21F3N6O3S MW: 506.50




Biological activity

Dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor, with high affinity IC50 values of 1.5 nM and 11 nM for FAK and PYK2 respectively; PF 431396 increases bone formation and protects against bone loss in ovariectomized rats

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

PF 477736

[952021-60-2]
Purity: 98%
99% ee
Soluble in DMSO
C22H25N7O2 MW: 419.48



Biological activity

Chk1 inhibitor with Ki values of 0.49 and 47 nM for Chk1 and Chk2 respectively. A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

Axon 2350

mg	Price
5	online
25	online

Axon 3961

Page 760

Axon 1711

mg	Price
10	online
50	online

Axon 2107

mg	Price
5	online
25	online

Axon 1379


mg	Price
2	online
5	online

PF-562271 Recent Addition

VS6062

[717907-75-0]
Purity: 98%

Soluble in DMSO
C21H20F3N7O3S MW: 507.49




Biological activity

PF-562271 is a potent, selective, ATP-competitive and reversible inhibitor of FAK and PYK2 catalytic activity with IC50 values of 1.5 and 14 nM, respectively.

PF 573228

[869288-64-2]
Purity: 99%

Soluble in DMSO
C22H20F3N5O3S MW: 491.49




Biological activity

Potent and selective inhibitor of focal adhesion kinase (FAK) with IC50 of 4 nM; Displays 50-250-fold selectivity over other protein kinases; a useful tool in functional study of non-receptor tyrosine inhibitor FAK in integrin-dependent signaling pathways in normal and cancer cells

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 956980

[1262832-74-5]
Purity: 98%
optically pure
Soluble in 0.1N HCl(aq) and DMSO
C18H26N6O MW: 342.44



Biological activity

JAK3 inhibitor and close analogue of CP 690550 (Tofacitinib; Axon 1338 and 2072). Useful tool compound to study JAK3 inhibition in the treatment of various diseases, particularly asthma and COPD, and rheumatoid arthritis.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

PF 1005023

See UK 5099

PF 2341066

See PF 02341066

PF 3654746

PF3654746

[1039399-17-1]
Purity: 99%

Axon 4215

mg	Price
5	online
25	online

Axon 1623

mg	Price
5	online
25	online

Axon 2217

mg	Price
5	online
25	online

Axon 2805

Page 949


Axon 1660

Page 766

Axon 1458

mg	Price
2	online

Soluble in water and DMSO
C18H24F2N2O.C7H8O3S
MW: 494.59



5 online

Biological activity

Histamine H3 receptor antagonist; investigational therapeutic for attention-deficit hyperactivity disorder (ADHD)

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 4447943

See PF 04447943

Axon 2148

Page 767

PF 4693627

PF 04693627


[1312815-93-2]

Purity: 100%

d.e. >98%

Soluble in DMSO

C26H29Cl2N3O3 MW: 502.43



Axon 2020

mg Price

5 online

25 online

Biological activity

Potent, selective and orally bioavailable inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1) for the potential treatment of inflammation (IC50 value 3 nM and 109 nM in enzyme assay and WHB assay respectively). PF 4693627 shows excellent in vitro and in vivo properties and is selective against relevant human enzymes COX-2, TXAS, PGDS, 5-LOX, 15-LOX and 12-LOX. About mPGES-1. Microsomal prostaglandin E (PGE) synthase-1 (mPGES-1) is a glutathione dependent inducible enzyme that couples with cyclooxygenase-2 (COX-2) for the biosynthesis of PGE2.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 4708671


PF 04708671

[1255517-76-0]

Purity: 99%

Soluble in DMSO

C19H21F3N6 MW: 390.41



Axon 1602

mg Price

10 online

50 online

Biological activity

Highly specific and cell-permeable p70 ribosomal S6 kinase (S6K1) inhibitor with Ki of 20 nM and IC50 of 160 nM; having no effect on the closely related RSK and MSK kinases; Useful tool for delineating S6K1-specific roles downstream of mTOR

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc


PF 4800567

[1188296-52-7]

Purity: 98%

Soluble in DMSO

C17H18ClN5O2 MW: 359.81



Axon 1792

mg Price

5 online

25 online

Biological activity

Potent and selective casein kinase 1 epsilon (Csnk1e or CK-1ε) inhibitor (IC50: 32 nM) with >20-fold selectivity over CK 1delta

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 4981517

See PF 04981517

Axon 2026

Page 768

PF 5081090

See PF 05081090

Axon 2113

Page 769

PF 5274857 hydrochloride


PF 05274857 hydrochloride

[1373615-35-0]

Purity: 99%

Soluble in water and DMSO

C20H26Cl2N4O3S MW: 473.42



mg Price

5 online

25 online

Biological activity

Potent and selective smoothened (SMO) antagonist with Ki value of 4.6 nM; a potentially attractive clinical candidate for the treatment of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 00356231


[766536-21-4]

Purity: 98%

>98% ee

Moderately soluble in DMSO

C25H20N2O3S MW: 428.50



Axon 1181

mg Price

5 online

25 online

Biological activity

MMP-12 inhibitor, more active enantiomer

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 01224715

See GIsadenafil besylate

Axon 2218

Page 502

PF 01367338

See AG 014699

Axon 1529

Page 213

PF 02341066

Crizotinib; PF 2341066


[877399-52-5]

Purity: 99%

optically pure

Soluble in DMSO

C21H22Cl2FN5O MW: 450.34



mg Price

10 online

50 online

Biological activity

Potent, selective and ATP-competitive inhibitor of c-Met/HGF receptor and the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), with IC50 values to be 4 and 25 nM for C-Met and ALK respectively

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 02341272


See PNU 100480

Axon 1762

Page 785

PF 03814735

[942487-16-3]
Purity: 98%
Optically pure
Soluble in DMSO
C23H25F3N6O2 MW: 474.48



Axon 2023

mg	Price
5	online
25	online

Biological activity

Potent, orally bioavailable, ATP-competitive and reversible inhibitor of aurora kinase A (IC50: 0.8 nM) and aurora kinase B (IC50: 5 nM) with potential antineoplastic activity; PF 03814735 also inhibits Flt1, FAK and TrkA with IC50 values of 10, 22, 30 nM respectively; clinical candidate

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 03890101

See UK 356618


Axon 2111

Page 950

PF 04217903 mesylate

[956906-93-7]
Purity: 99%

Soluble in 0.1N HCl(aq)
C19H16N8O.CH4O3S MW: 468.49



Axon 1583

mg	Price
5	online
25	online

Biological activity


An orally bioavailable tyrosine kinase inhibitor, targeting MET (or c-MET); it selectively binds to and inhibits mesenchymal epithelial transition (low nM Ki values and >1000 fold selective relative to 208 kinases) with potential antineoplastic activity

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 04418948

[1078166-57-0]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C23H20FNO5 MW: 409.41



Axon 2024

mg	Price
5	online
25	online

Biological activity

An orally active, potent and selective prostaglandin EP2 receptor antagonist

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 04447943

PF 4447943


[1082744-20-4]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO

Axon 2148

mg	Price
2	online
5	online

C20H25N7O2 MW: 395.46

25 online




Biological activity

Selective, brain penetrant PDE9A inhibitor for the treatment of cognitive disorders that exhibit a disrupted P50-gating response (IC50 values 8.3 nM and 1394 nM for PDE9A and PDE1C respectively). PF 04447943 elevates cGMP in multiple brain regions and in cerebral spinal fluid (CSF), and shows an impact on hippocampal synaptic plasticity.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 04859989 hydrochloride

[177943-33-8]
Purity: 99%
Optically pure
Soluble in water and DMSO
C9H10N2O2.HCl MW: 215



Axon 2924

mg	Price
10	online
50	online

Biological activity

PF 04859989 hydrochloride is a potent, selective, brain-penetrant, irreversible kynurenine aminotransferase II (KAT II) inhibitor with an IC50 value of 23 nM.

PF 04554878

See Defactinib


Axon 2574

Page 416

PF 04691502

[1013101-36-4]
Purity: 99%

Soluble in DMSO
C22H27N5O4 MW: 425.48



Axon 1855

mg	Price
5	online
25	online

Biological activity

Potent, selective, oral and ATP-competitive inhibitor of class I PI3K (Ki: 1-2 nM) and mTOR kinases (Ki: 16 nM); it inhibits PI3K/mTOR signaling and induces cell cycle arrest in cancer cells

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 04693627

See PF 4693627

Axon 2020

Page 765

PF 04708671

See PF 4708671

Axon 1602

Page 765

PF 04981517


CYP3cide; PF 4981517

[1390637-82-7]

Axon 2026

mg Price

Purity: 98%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C26H32N8 MW: 456.59



10	online
50	online

Biological activity


Potent and selective inhibitor of Cytochrome P450 3A4 (CYP3A4) with IC50 value of 30 nM; inactivates human CYP3A4 in an efficient and time-dependent manner

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PF 05081090

PF 5081090

[1312473-63-4]
Purity: 98%
Optically pure
Soluble in DMSO
C18H21FN2O6S MW: 412.43



Axon 2113

mg	Price
5	online
25	online


Biological activity

Very potent antibacterial LpxC inhibitor for the treatment of serious gram-negative infections (*Pseudomonas aeruginosa* (Pae) enzyme potency (Pae IC50) of 1.1 nM)

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

PF 05105679

[1398583-31-7]
Purity: 99%
Optically pure
Soluble in DMSO
C26H21FN2O3 MW: 428.45



Axon 2483

mg	Price
5	online
25	online

Biological activity

TRPM8 inhibitor (IC50 value 0.1 μM for TRPM8 in single cell patch clamp electrophysiology (Ephys) studies), showing >100-fold selectivity across a range of different receptors, ion channels, and enzymes including the closely related TRPV1 and TRPA1 channels. Although PF-05105679 shows no effect on core body temperature in humans, it proves to be a useful tool to study in vitro effects of TRPM8 on thermoregulation and for the treatment of pain in humans.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

PF 05212384

See PKI 587

Axon 1807

Page 781

PF 05274857 hydrochloride

See PF 5274857 hydrochloride

Axon 2027

Page 766

PF 06341724

See SC 26196

Axon 2112

Page 770

PF 06405761

See PFI-1


Axon 1887

Page 771

PF 06260933 dihydrochloride

[N.A.]
Purity: 99%

Soluble in water and DMSO
C16H13ClN4.2HCl MW: 369.68



Axon 2545

mg	Price
5	online
25	online

Biological activity


Potent and selective MAP4K4 inhibitor (IC50 value 3.7 nM for MAP4K4 a.k.a. HGK or ZC1) with suitable PK properties in mouse to be used as a tool in an in vivo model of diabetes, vascular inflammation and atherosclerosis. Robustly prevented TNF-α-mediated endothelial permeability in vitro, similar to MAP4K4 knockdown, and without alteration of plasma lipid content.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

PF 06447475

[1527473-33-1]
Purity: 99%

Soluble in DMSO
C17H15N5O MW: 305.33



Axon 2546

mg	Price
5	online
25	online

Biological activity


Highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor (IC50 value 3 nM); an exceptional tool compound to study the function of LRRK2 PF 06447475 mitigates both neurodegeneration and neuroinflammation associated with G2019S-LRRK2 expression by LRRK2 kinase inhibition in rats.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

PF 06463922

Lorlatinib

[1454846-35-5]
Purity: 99%
Optically pure
Soluble in DMSO
C21H19FN6O2 MW: 406.41



Axon 2600


mg	Price
5	online
25	online

Biological activity

Potent, orally available and brain-penetrant ALK/ROS1 selective inhibitor (mean Ki value of <0.07 nM for inhibition of recombinant human wild-type ALK) displaying superior potency against all known clinically acquired ALK mutations (all displaying sub-nanomolar Ki values), including the highly resistant G1202R mutant. PF 06463922 (Lorlatinib) is capable of blocking Crizotinib-resistant ROS1 mutations and treatment with PF 06463922 led to superior regression of EML4-ALK-driven brain metastases compared with other clinically available ALK inhibitors.

PF 06465469

[1407966-77-1]
Purity: 99%
Optically pure
Soluble in DMSO
C30H33N7O2 MW: 523.63


Biological activity

Potent, covalent inhibitor of interleukin-2 inducible T cell kinase (ITK) with nanomolar potency
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

PF-00299804


See Dacomitinib

PF-06840003

EOS200271

[198474-05-4]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C12H9FN2O2 MW: 232.21


Biological activity


PF-06840003 is a selective, brain penetrant, and orally bioavailable IDO-1 inhibitor. Although PF-06840003 has moderate hIDO1 enzyme inhibition (IC50 value of 0.41 μ M), it is a highly efficient compound (LE 0.53, LipE 5.1), driven by its tight packing within the enzyme, as well as the high density of hydrogen bonds it forms with hIDO-1 despite its small size.

PFI-1

PF 06405761

[1403764-72-6]
Purity: 98%

Soluble in DMSO
C16H17N3O4S MW: 347.39



Biological activity

BET bromodomain inhibitor; chemical probe developed by SGC and Pfizer
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

PFK15

[4382-63-2]
Purity: 99%

Soluble in DMSO and EtOH
C17H12N2O MW: 260.29


Biological activity
Axon 2110

mg	Price
5	online
25	online

Axon 3235

Page 407

Axon 3325

mg	Price
10	online
50	online

Axon 1887

mg	Price
5	online
25	online

Axon 3537


mg	Price
10	online
50	online

PFK15 is a potent and specific PFKFB3 inhibitor with an IC50 value of 207 nM. PFK15 has potent anti-tumor activity and markedly reduces 18FDG uptake and the F26BP content of xenografted tumors.

PFK 158

[1462249-75-7]
Purity: 99%

Soluble in DMSO
C18H11F3N2O MW: 328.29



Biological activity

Nanomolar small molecule inhibitor of PFKFB3 (IC50 value 137 nM) that is selectively cytotoxic to cancer cells and displays broad anti-tumor activity causing significant growth inhibition in preclinical models of breast, lung, glioblastoma, ovarian, pancreatic, melanoma and colon cancer. PFK158 is well tolerated in rats and dogs resulting in an acceptable pre-clinical therapeutic index.

PFM01

[1558598-41-6]
Purity: 99%

Soluble in DMSO
C14H15NO2S2 MW: 293.40


Biological activity

PFM01 is an inhibitor of MRE11 endonuclease which forms the core of the MRE11-RAD50-NBS1 (MRN) complex. The MRN complex has essential roles in detecting, signaling, protecting and repairing DNA double strand breaks.

PFT- α

See Pifithrin- α Hydrobromide

PFT- β

See Pifithrin- β

PFT μ

See Pifithrin- μ **Recent Addition**

PG-1016548

See Vadadustat

PGE1

See Alprostadiil

PGP-4008

[365565-02-2]
Purity: 99%

Soluble in DMSO and EtOH
C26H23N3O MW: 393.48

Axon 2542

mg	Price
10	online
50	online

Axon 2821

mg	Price
10	online
50	online

Axon 1871

Page 777

Axon 3051

Page 777

Axon 4278

Page 777

Axon 3288


Page 960

Axon 2062

Page 220

Axon 3784

mg	Price
5	online
25	online




Biological activity

PGP-4008 is a selective P-glycoprotein (Pgp) inhibitor without modulating multidrug resistance-related protein 1 (MRP1). PGP-4008 inhibited tumor growth in a murine syngeneic Pgp-mediated MDR solid tumor model when given in combination with doxorubicin.

PH 797804

[586379-66-0]
Purity: 99%

Soluble in DMSO
C22H19BrF2N2O3 MW: 477.30



Axon 1837

mg	Price
2	online
5	online

Biological activity


Highly potent, selective and metabolically stable inhibitor of p38 MAPK (p38 α cascade IC₅₀: 2.3 nM); an ATP-competitive, readily reversible inhibitor of the α isoform of human p38 MAP kinase, exhibiting a K_i of 5.8 nM; clinical candidate. *PH 797804 is an (-)-atropisomer, which is 100-fold more potent than its (+)-atropisomer. Be careful that racemate of PH797804 is wrongly provided by other supplier as drug PH797804 itself. Less potent (+)-rotating atropisomer (Axon 1886) is also available. Be right about your drug

PH 797804, (±)-

rac-PH 797804

[586379-66-0]
Purity: 99%

Soluble in DMSO and ethanol
C22H19BrF2N2O3 MW: 477.30



Axon 2786

mg	Price
10	online
50	online

Biological activity

Similar to the (-)-atropisomer PH 797804 (Axon 1837), racemic (±)-PH 797804 is a potent, selective and metabolically stable inhibitor of p38 MAPK (IC₅₀ values of 2.5 and 15 nM in p38 α cascade and hPBMK TNF assays, respectively).


PHA291639

See Toceranib phosphate

PHA 408

[503555-55-3]
Purity: 99%

Soluble in DMSO
C29H27ClF7O2 MW: 560.02



Axon 3624

Page 934

Axon 1651


mg	Price
5	online
25	online

Biological activity

Potent, highly selective and ATP-competitive IKK kinase-2 (IKK-2) inhibitor (IC₅₀: 40 nM), which binds IKK-2 tightly with a relatively slow off rate; highly recommended tool to investigate the mechanisms by which IKK-2 regulates NF- κ B signaling

PHA 543613 dihydrochloride

[478148-58-2]
Purity: 99%
Optically pure
Soluble in water and DMSO
C15H17N3O2.2HCl MW: 344.24



Axon 2109

mg	Price
5	online
10	online


Biological activity

Potent and selective α 7 nicotinic acetylcholine receptor (nAChR) agonist, which is characterized by rapid brain penetration and high oral bioavailability; a potential treatment of cognitive deficits in schizophrenia
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

PHA-767491

[845714-00-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C12H11N3O MW: 213.24



Axon 2690

mg	Price
10	online
50	online


Biological activity

PHA-767491 is an ATP mimetic dual CDC7/CDK9 kinase inhibitor (IC₅₀ values of 10 nM and 34 nM for CDC7 and CDK9, respectively). Treatment with PHA-767491 results in apoptotic cell death in multiple cancer cell types and tumor growth inhibition in preclinical cancer models. PHA-767491 is also a potent kinase inhibitor of MAPKAP-K2 (or MK-2) (IC₅₀ value of 171 nM).

Phenol hydrobromide, 3-[2-(Dipropylamino)ethyl]

[64656-40-2]
Purity: 99%

Soluble in water
C14H23NO.HBr MW: 302.25



Axon 1002

mg	Price
10	online
50	online


Biological activity

Dopamine receptor agonist

Phenoxybenzamine hydrochloride

[63-92-3]
Purity: 99%

Soluble in DMSO and EtOH
C18H22ClNO.HCl MW: 340.29



Axon 3643

mg	Price
50	online

Biological activity

Phenoxybenzamine hydrochloride is a selective antagonist of both α -adrenoceptor and calmodulin that is commonly used for the treatment of hypertension, specifically caused by pheochromocytoma.

Phentolamine mesylate


[65-28-1]

Axon 3510

mg	Price
----	-------

Purity: 99% 50 online

Soluble in water, DMSO and EtOH
C17H19N3O.CH4O3S MW: 377.46




Biological activity
Phentolamine mesylate is an orally active α 1- and α 2 adrenoceptor antagonist.

PHNO hydrochloride, (+)-

Naxagolide; Dopazinol

[99705-65-4]
Purity: 98%
>98% ee
Soluble in water and DMSO
C15H21NO2.HCl MW: 283.79




Axon 1071

mg	Price
2	online
5	online

Biological activity
Very potent and selective D2 agonist, more active enantiomer. Note: Appropriate chiral precursor(s) for making D2 radiotracer, [11C]-(+)-PHNO, can be provided upOn request

PHNO hydrochloride, (±)-

[100935-99-7]
Purity: 98%
racemic
No solubility data
C15H21NO2.HCl MW: 283.79




Axon 1070

mg	Price
5	online
25	online

Biological activity
Potent and selective D2 agonist, racemate of PHNO, its more active enantiomer is (+)-PHNO (Axon 1071)

PHT 427

[1191951-57-1]
Purity: 99%
Soluble in DMSO
C20H31N3O2S2 MW: 409.61




Axon 1870

mg	Price
10	online
50	online

Biological activity
Inhibitor of AKT and phosphoinositide-dependent protein kinase 1 (PDPK1 or PDK1). PH 427 binds to the pleckstrin homology (PH) domain of Akt and PDPK1 signaling with significant in vivo antitumor activity and minimal toxicity

PI 103 hydrochloride

[371935-79-4]
Purity: 99%
Soluble in DMSO
C19H17ClN4O3 MW: 384.82



Axon 1380


mg	Price
2	online
5	online

Biological activity

A selective class I PI3K inhibitor; it inhibits PI3K p110 isoforms, mTORC1 and also DNA-PK; a valuable tool compound

PI 3065

[955977-50-1]
Purity: 98%
Soluble in 0.1N HCl(aq) and DMSO
C27H31FN6OS MW: 506.64




Biological activity
PI 3065 is a p110 δ -selective PI3K inhibitor with K_i and IC_{50} values of 1.5 nM and 5 nM, respectively. Administration of PI 3065 suppressed 4T1 tumour growth and metastasis, to a similar extent as genetic inactivation of p110 δ , marked by initial tumour progression, followed by tumour regression.

Axon 3045

mg	Price
5	online
25	online

PI-273

[925069-34-7]
Purity: 98%
Soluble in DMSO
C16H16ClN3O2S2 MW: 381.90



Biological activity
PI-273 is substrate-competitive, subtype-specific inhibitor of PI4KII α with an IC_{50} value of 0.47 μ M.

Axon 3034

mg	Price
5	online
25	online

PI3K inhibitor B591

See B591

Axon 3055


Page 281

Pibeserod hydrochloride

SB 207266A

[178273-87-5]
Purity: 99%

Soluble in water
C22H31N3O2.HCl MW: 405.96



Biological activity
Selective 5-HT4 antagonist

Axon 1098


mg	Price
10	online
50	online

Picamilast

RP73401

[144035-83-6]
Purity: 99%

Soluble in DMSO
C18H18Cl2N2O3 MW: 381.25




Biological activity
Picamilast is a potent and selective PDE4 inhibitor with an IC_{50} value of 1 nM.

Axon 4013

mg	Price
10	online
50	online

Pidotimod

[121808-62-6]
Purity: 99%
Optically pure
Soluble in water and DMSO
C9H12N2O4S MW: 244.27



Axon 3307

mg	Price
50	online

Biological activity


Pidotimod is an orally bioavailable dipeptide with immunostimulatory activity on both immune responses, i.e. adaptive and innate immunity.

Pifithrin-α Hydrobromide

PFT-α

[63208-82-2]
Purity: 99%

Soluble in DMSO
C16H18N2OS.HBr MW: 367.30



Axon 1871

mg	Price
10	online
50	online

Biological activity


Pifithrin-α is an inhibitor of p53 protein; reversibly blocks p53-dependent transcriptional activation and apoptosis; protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53

Pifithrin-β

PFT-β; Z-2-035II

[60477-34-1]
Purity: 99%

Soluble in DMSO
C16H16N2S MW: 268.38



Axon 3051

mg	Price
10	online
50	online

Biological activity


Pifithrin-β is the condensation product of the p53 protein inhibitor Pifithrin-α (Axon 1871). Pifithrin-α is unstable in vitro and is rapidly converted to Pifithrin-β.

Pifithrin-μ Recent Addition

PFTμ

[64984-31-2]
Purity: 100%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C8H7NO2S MW: 181.21



Axon 4278

mg	Price
10	online
50	online

Biological activity

Pifithrin-μ is an inhibitor of p53 binding to mitochondria by reducing its affinity to antiapoptotic proteins Bcl-xL and Bcl-2 but has no effect on p53-dependent transactivation. Pifithrin-μ is also an inhibitor of inducible heat shock protein 70 and inte


PIK 75 hydrochloride

Axon 1334

mg	Price
----	-------

[945619-31-8]
Purity: 99%

Moderately soluble in DMSO
C16H14BrN5O4S MW: 452.28



5	online
---	--------

25	online
----	--------


Biological activity

PI3K p110α specific inhibitor; IC50 values (nM): 7.8 (p110α), 343 (p110β), 907 (p110δ) (Chaussade et al reported)

PIK 90

[677338-12-4]
Purity: 99%

Moderately soluble in DMSO with 0.1N HCl(aq)
C18H17N5O3 MW: 351.36



Axon 1362

mg	Price
----	-------

5	online
---	--------

25	online
----	--------

Biological activity

Potent and cell permeable PI3K inhibitor, with IC50 values (nM) of 11, 350, 18, and 58 for p110 α, β, γ and δ isoforms, low mTOR activity

Pilaralisib

See XL-147

Axon 4031

Page 993

Pimaricin

See Natamycin

Axon 3493

Page 692

Pimasertib

See AS-703026 Recent Addition

Axon 4217

Page 253

Pim inhibitor 4a

See SMI 4a

Axon 1923


Page 875

Pinaverium bromide

LAT1717

[53251-94-8]
Purity: 99%

Soluble in DMSO and EtOH
C26H41Br2NO4 MW: 591.42



Axon 3887

mg	Price
----	-------

50	online
----	--------

Biological activity

Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract.

Pinometostat

See EPZ-5676

Axon 3960


Page 464

Pioglitazone hydrochloride

AD-4833

[112529-15-4]
Purity: 99%

Soluble in DMSO
C19H20N2O3S.HCl MW: 392.90



Axon 3255

mg	Price
10	online
50	online

Biological activity


Pioglitazone hydrochloride is a PPAR γ agonist. Antidiabetic drug.

Piperlongumine

Piplartine

[20069-09-4]
Purity: 99%

Soluble in DMSO
C17H19NO5 MW: 317.34



Axon 2488

mg	Price
5	online
25	online

Biological activity

Natural alkaloid with potent cytotoxic activity which has been related to an increased reactive oxygen species (ROS) generation in cancer cells (through direct GSTP1 interaction), down-regulation of nuclear factor- κ B (NF- κ B) activation and induction of rapid depletion of the androgen receptor (AR) in prostate cancer cells. Moreover, Piperlongumine was found to induce apoptosis and autophagy through modulation of the PI3K/Akt/mTOR pathway in human lung cancer cells, and potently inhibited ligand-stimulated STAT3 nuclear translocation

Piplartine

See Piperlongumine

Axon 2488

Page 779

Piraxostat

See Y 700

Axon 1174


Page 997

Pirfenidone

AMR-69

[53179-13-8]
Purity: 100%

Soluble in DMSO
C12H11NO MW: 185.22



Axon 2647

mg	Price
10	online
50	online

Biological activity

Orally available agent with therapeutic potential for idiopathic pulmonary fibrosis (IPF; IC50 value 14.44 mM for inhibition of cell proliferation against MRC-5 cells) that has combined anti-inflammatory, antioxidant and antifibrotic effects in experimental models of pulmonary fibrosis. Mechanistically, Pirfenidone inhibits not only TGF- β -induced Smad3, p38 and Akt phosphorylation in human lung fibroblasts (HLFs), but also significantly increased RGS2 mRNA and protein expression in fibroblasts.


Piribedil

[3605-01-4]
Purity: 99%

Axon 1198

mg	Price
10	online

No solubility data
C16H18N4O2 MW: 298.34



50 online

Biological activity

Direct dopamine agonist, with affinity for subtypes: D3 > D2 >> D1; an anti-parkinson drug marketed as Trivastal retard 50

Pirl1-related compound 2

See CASIN


Axon 3987

Page 345

PITCOIN3

[2397679-88-6]
Purity: 98%

Soluble in DMSO
C26H23N7O4S3 MW: 593.70



Axon 3792

mg	Price
10	online
50	online


Biological activity

PITCOIN3 is a potent, highly selective and cell-permeable inhibitor of phosphatidylinositol 3-kinase C2 α (PI3KC2 α) with an IC50 value of 126 nM.

PITCOIN4 Recent Addition

[N.A.]
Purity: 99%

Soluble in DMSO
C30H29N7O3S2 MW: 599.73



Axon 4172

mg	Price
5	online
25	online


Biological activity

PITCOIN4 is a potent and highly selective inhibitor of phosphatidylinositol 3-kinase C2 α (PI3KC2 α) with nanomolar inhibition (IC50 value of 56 nM, ADP-Glo assay) and >100-fold selectivity in a general kinase panel.

PK 11195

[85532-75-8]
Purity: 99%

No solubility data
C21H21ClN2O MW: 352.86



Axon 1208

mg	Price
10	online
50	online


Biological activity

Peripheral benzodiazepine antagonist

PK 11195, (R)-(-)-

[205934-46-9]
Purity: 99%
98% ee

Soluble in DMSO
C21H21ClN2O MW: 352.86



Axon 2785

mg	Price
5	online
25	online


Biological activity

(R)-enantiomer of PK 11195 (Axon 1208), a peripheral benzodiazepine antagonist. It is a drug reference standard of [11C](R)-PK 11195 that is used for PET study.

Radioligand precursors N-Desmethyl-PK 11195 (Axon 2833) and (R)-(-)-N-Desmethyl-PK 11195 (Axon 2784) are also available.

PK 11195, (R)-(-)-N-Desmethyl-

[157809-85-3]
Purity: 99%
99% ee
Soluble in DMSO
C20H19ClN2O MW: 338.83



Axon 2784

mg	Price
5	online
25	online


Biological activity

Precursor for (R)-[N-methyl-11C]PK 11195 for PET studies. Radioligand precursor of the peripheral benzodiazepine antagonist (R)-[N-methyl-11C]PK 11195. Racemic N-desmethyl-PK 11195 is available as Axon 2833.

Both peripheral benzodiazepine antagonists PK 11195 (Axon 1208) and R-(-)-PK 11195 (Axon 2785) are available from stock as well.

PK 11195, N-Desmethyl-

[124236-61-9]
Purity: 99%
Soluble in DMSO
C20H19ClN2O MW: 338.83



Axon 2833

mg	Price
10	online
50	online

Biological activity

Precursor for [N-methyl-11C]PK 11195 for PET studies. Radioligand precursor of the peripheral benzodiazepine antagonist PK 11195 (Axon 1208).

R-enantiomer precursor (R)-(-)-N-Desmethyl-PK 11195 is available as Axon 2784 and the R-enantiomer of PK 11195 is available as Axon 2785.

PK26124

See Riluzole

Axon 3499

Page 819

PK26124 hydrochloride


See Riluzole hydrochloride

Axon 3576

Page 819

PK-THPP

[1332454-07-5]
Purity: 99%
Soluble in DMSO
C29H32N4O2 MW: 468.59



Axon 2403

mg	Price
10	online
50	online

Biological activity

Potent TASK-3 (KCNK9) antagonist (IC50 value 303 nM and 35nM for TASK-1 and TASK-3, respectively) with >140 fold selectivity over a wider range of potassium channels. PK-THPP produced a significant increase in active wake with a concurrent decrease in both REM and delta sleep immediately following administration to wild-type


(WT) mice, and stimulated breathing by increasing tidal volume and breathing rate in isoflurane-anesthetized rats. PK-THPP induced a respiratory alkalosis and increased oxygenation.

PKI 587

PF 05212384

[1197160-78-3]
Purity: 99%

Moderately soluble in DMSO
C32H41N9O4 MW: 615.73



Axon 1807

mg	Price
5	online
25	online


Biological activity

Highly potent PI3K/mTOR kinase inhibitor; PKI-587 inhibits PI3K-alpha, beta, gamma, delta isoforms and mTOR with IC50 of 0.4, 6.0, 5.4, 6.0 and 1.6 nM respectively. PKI-587 inhibits mTOR TOC1 kinase activity in human MDA-MB-361 cells assessed as suppression of 4EBP1 phosphorylation at <30 nM; PKI-587 inhibits Akt S473 phosphorylation in human MDA-MB-361 cells and Akt T308 phosphorylation in human MDA-MB-361 cells with IC50 of 8nM and 10 nM

PKG drug G1

[374703-78-3]
Purity: 99%

Soluble in DMSO
C13H11N3OS MW: 257.31



Axon 2232

mg	Price
10	online
50	online

Biological activity


PKG drug G1 has been shown to induce the oxidative activation of protein kinase G Ia, which in vivo results in dilation of blood vessel and blood pressure lowering; an antihypertensive.

The sodium salt of Axon 2905 is also available.

PKG drug G1 sodium salt

[N.A.]
Purity: 98%

Soluble in water and DMSO
C13H10N3NaOS MW: 279.29



Axon 2905

mg	Price
10	online
50	online

Biological activity


PKG drug G1 sodium salt has been shown to induce the oxidative activation of protein kinase G Ia, which in vivo results in dilation of blood vessel and blood pressure lowering; an antihypertensive.

The parent molecule is also available as Axon 2232.

PKM2 activator 1020

[1260075-17-9]
Purity: 99%

Soluble in DMSO
C24H26N4O3S MW: 450.55



Axon 2149

mg	Price
5	online
25	online

Biological activity


Activator of pyruvate kinase isoenzyme M2 (PKM2), an enzyme involved in glycolysis. Since all tumor cells exclusively express the embryonic M2 isoform of PK, it is hypothesized that PKM2 is a potential target for cancer

therapy. Modulation of PKM2 might also be effective in the treatment of obesity, diabetes, autoimmune conditions, and antiproliferation-dependent diseases.

PKN3 inhibitor compound 16

[2361545-75-5]
Purity: 100%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C18H17IN2O3 MW: 436.24



Biological activity

PKN3 inhibitor compound 16 is a potent, cell-active protein kinase novel 3 (PKN3) inhibitor with an IC50 value of 14 nM.

Axon 3676

mg Price

5 online

25 online

Plarotinib

See Crenolanib

Axon 3969

Page 394

Plerixafor

See AMD 3100

Axon 1738

Page 223

Plisulfan

See Sulfaphenazole

Axon 2922

Page 899

Pluripotent cell-specific inhibitor #1

See PluriSIn #1

Axon 2091


Page 783

PluriSIn #1

NSC 146113; Pluripotent cell-specific inhibitor #1

[91396-88-2]
Purity: 99%

Soluble in DMSO and EtOH
C12H11N3O MW: 213.24



Axon 2091

mg Price

10 online

50 online

Biological activity

An inhibitor of stearyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis; a pluripotent cell-specific inhibitor (PluriSIn) used to selectively eliminate undifferentiated human pluripotent stem cells (hPSCs)

PLX 3397

See Pexidartinib

Axon 2501

Page 760

PLX 4032

RG 7204; Vemurafenib; RO 5185426

[918504-65-1]
Purity: 98%


Soluble in DMSO
C23H18ClF2N3O3S MW: 489.92

Axon 1624

mg Price

5 online

25 online




Biological activity

Selective inhibitor of protein kinase, targeting B-Raf (V600E) (IC50: 44 nM); PLX4032 has been shown to cause programmed cell death in melanoma cell lines; a potential anti-tumor agent under clinical trials

PLX 4720

[918505-84-7]
Purity: 99%

Soluble in DMSO
C17H14ClF2N3O3S MW: 413.83



Biological activity

Selective inhibitor of protein kinase, targeting B-Raf (V600E)

Axon 1474

mg Price

2 online


5 online

25 online

PLX5622

[1303420-67-8]
Purity: 98%

Soluble in DMSO
C21H19F2N5O MW: 395.41



Biological activity

PLX5622 is potent, specific, orally bioavailable, and brain-penetrant CSF1R inhibitor with an IC50 value of 0.016 μ M. PLX5622 allowed for extended and specific microglial elimination, preceding and during Alzheimer's disease (AD) pathology development.

Axon 3054

mg Price

5 online

25 online

PMPA

See Tenofovir

Axon 3157

Page 918

PN200-110

See Isradipine

Axon 3501


Page 572

PND 1186

SR 2516; VS 4718

[1061353-68-1]
Purity: 100%

Soluble in DMSO
C25H26F3N5O3 MW: 501.50



Biological activity

Orally active dual FAK/PYK2 inhibitor (IC50 value 1.5 nM and ~100 nM in vitro and in vivo, respectively) that blocks FAK and p130Cas (130 kDa Crk-associated substrate) tyrosine phosphorylation, promotes caspase-3 activation, and selectively triggered cell apoptosis in tumor cells in 3D environments. PND1186 inhibitory effects differ from Dasatinib (Axon 1392; as it does not affect c-Src activity), and prevents spontaneous breast to lung

Axon 2459

mg Price

5 online

25 online


metastasis in pre-clinical models. PND-1186 inhibits cell growth in multiple myeloma (MM) cells both in vitro and in vivo by inhibition of PYK2 (IC50 and EC50 values 85 nM and 20 nM, respectively).

PNR-7-02

IBA-6

[1633660-76-0]
Purity: 98%

Soluble in DMSO
C24H16ClN3O2S MW: 445.92



Axon 2965

mg	Price
10	online
50	online

Biological activity

PNR-7-02 is a potent inhibitor of human DNA polymerase η (hpol η) with an IC50 value of 8 μ M and exhibited 5-10-fold specificity for hpol η over replicative pols.

PNT-737

See CCT-245737


Axon 3932

Page 352

PNU 22394 hydrochloride

[15923-42-9]
Purity: 99%

Soluble in DMSO
C13H16N2.HCl MW: 236.74



Axon 1247

mg	Price
10	online
50	online


Biological activity

5-HT2C agonist

PNU 37883 hydrochloride

[57568-80-6]
Purity: 99%

Soluble in DMSO and Ethanol
C21H35N3O.HCl MW: 381.98



Axon 1274

mg	Price
10	online
50	online

Biological activity


Vascular KATP channel blocker

PNU 100480

PF 02341272; U 100480

[168828-58-8]
Purity: 99%

Soluble in DMSO
C16H20FN3O3S MW: 353.41



Axon 1762

mg	Price
5	online
25	online

Biological activity

Antituberculosis (anti-TB) agent under clinical development; potent inhibitor of bacterial protein biosynthesis by interfering with the binding of initiator fMet-tRNA(i)(Met) to the ribosomal peptidyltransferase P-site

PNU 100766

See Linezolid

Axon 2048

Page 615

PNU 101387

See Sonepiprazole hydrochloride

Axon 2115

Page 877

PNU 200583E

See Tolterodine L-tartrate


Axon 2049

Page 935

PNU 282987 hydrochloride

[123464-89-1]

Purity: 99%
Optically pure
Soluble in water and DMSO
C14H17ClN2O.HCl MW: 301.21



Axon 2908

mg	Price
10	online
50	online


Biological activity

PNU 282987 hydrochloride is an $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonist with Ki ($\alpha 7$ nAChR) and EC50 ($\alpha 7$ -5HT3 chimera) values of 27 nM and 154 nM, respectively. PNU 282987 hydrochloride was also shown to open native $\alpha 7$ nAChRs in cultured rat neurons and to reverse an amphetamine-induced gating deficit in rats.

Podophyllotoxin

[518-28-5]

Purity: 98%
Optically pure
Soluble in DMSO
C22H22O8 MW: 414.41



Axon 3368

mg	Price
50	online

Biological activity

Podophyllotoxin is an inhibitor of tubulin polymerization and was shown to have anti-neoplastic properties.

Polymixin E sulfate

See Colistin sulfate

Axon 3453


Page 382

Pomalidomide

CC-4047

[19171-19-8]
Purity: 99%

Soluble in DMSO
C13H11N3O4 MW: 273.24



Axon 3166

mg	Price
10	online
50	online

Biological activity

Pomalidomide is a potent inhibitor of TNF α with an IC50 value of 13 nM (LPS stimulated human PBMC). Moreover, Pomalidomide appears to be a remarkable agent in the care of myelofibrosis and multiple myeloma. Immunomodulator.

Ponatinib

See AP 24534


Axon 1857

Page 238

Posaconazole

SCH 56592; Noxafil

[171228-49-2]
Purity: 99%
optically pure
Soluble in DMSO
C37H42F2N8O4 MW: 700.78



Axon 1557

mg	Price
5	online
25	online

Biological activity


A triazole antifungal drug

Poziotinib

HM781-36B

[1092364-38-9]
Purity: 99%

Soluble in DMSO
C23H21Cl2FN4O3 MW: 491.34



Axon 2920

mg	Price
10	online
50	online

Biological activity


Poziotinib is an irreversible pan-HER inhibitor with IC50 values of 0.0032 μ M, 0.0053 μ M and 0.0235 μ M for HER1, HER2 and HER4, respectively. Poziotinib inhibited phosphorylation of HER family and downstream signaling molecules, and induced apoptosis and G1 arrest. Moreover, poziotinib demonstrated potent antitumor activity in HER2 amplified gastric cancer cells, HER2-amplified breast cancer cells, and erlotinib-resistant NSCLC.

PPHT hydrochloride

N 0434

[71787-90-1]
Purity: 98%

Soluble in DMSO
C21H27NO.HCl MW: 345.91



Axon 1035

mg	Price
10	online
50	online


Biological activity

Very Potent and specific D2 agonist

PPHT hydrochloride, (R)-

N 0434, (R)-

[161757-96-6]
Purity: 98%
>98% ee
No solubility data
C21H27NO.HCl MW: 345.91



Axon 1036

mg	Price
5	online
25	online


Biological activity

(R)-enantiomer of PPHT (Axon 1035), a very potent and specific D2 agonist

PPHT hydrochloride, (S)-

N 0434, (S)-

[159795-62-7]
Purity: 98%
>98% ee
No solubility data
C21H27NO.HCl MW: 345.91



Biological activity

(S)-enantiomer of PPHT (Axon 1035), a very potent and specific D2 agonist


Axon 1037

mg	Price
5	online
25	online

PPP Hydrochloride

[21602-56-2]
Purity: 99%

Soluble in water
C14H21N.HCl MW: 239.78



Biological activity

Selective inactivator of human cytochrome P450 2B6 (CYP2B6)


Axon 1595

mg	Price
10	online
50	online

PPTN hydrochloride

[1992047-65-0]
Purity: 99%

Soluble in water, DMSO and EtOH
C29H24F3NO2.HCl MW: 511.96



Biological activity

PPTN hydrochloride is a high affinity and specific P2Y14 receptor antagonist with a Ki value of 0.4 nM. Also available is the highly bioavailable prodrug of PPTN hydrochloride (Axon 1958).


Axon 3420

mg	Price
5	online
25	online

PPQ 102

[931706-15-9]
Purity: 99%

Soluble in DMSO
C26H22N4O3 MW: 438.48



Biological activity

Potent CFTR inhibitor (IC50 value ca 90 nM in CFTR chloride conductance assay). PPQ 102 acts by a mechanism involving stabilization of the channel closed-state. Prevented cyst expansion and reduced the size of preformed cysts in an embryonic kidney organ culture model of Polycystic kidney disease (PKD).

Axon 2295

mg	Price
5	online
25	online

PPT


[263717-53-9]
Purity: 99%

Soluble in DMSO

Axon 1231

mg	Price
10	online
50	online

C24H22N2O3 MW: 386.44




Biological activity
Specific estrogen receptor α (ER α) agonist

PQ401

[196868-63-0]
Purity: 99%

Soluble in DMSO
C18H16ClN3O2 MW: 341.79



Biological activity
PQ401 is a potent inhibitor of IGF-1R signalling. PQ401 inhibited autophosphorylation of the IGF-1R in cultured human MCF-7 cells with an IC50 value of 12 μ M and autophosphorylation of the isolated kinase domain of the IGF-1R with an IC50 value of <1 μ M.

PR-047

See Oprozomib

PR-171

See Carfilzomib **Recent Addition**

PR 957

See ONX 0914

Pracinostat

See SB 939

Pralsetinib


See BLU-667

Pramiracetam **Recent Addition**

C1879

[68497-62-1]
Purity: 100%

Soluble in water, 0.1N HCl(aq), DMSO and EtOH
C14H27N3O2 MW: 269.38



Biological activity
Pramiracetam is a nootropic drug of the racetam family.

Axon 3341

mg	Price
10	online
50	online

Axon 3849

Page 735

Axon 4218

Page 344

Axon 2199

Page 734

Axon 1777

Page 844

Axon 3854

Page 314

Axon 4203


mg	Price
50	online

Pravadoline

WIN 48098

[92623-83-1]
Purity: 99%

Soluble in DMSO
C23H26N2O3 MW: 378.46



Biological activity
COX inhibitor and cannabinoid CB agonist, an antiinflammatory and analgesic agent

Axon 1523


mg	Price
10	online
50	online

Prazosin hydrochloride

Furazosin hydrochloride

[19237-84-4]
Purity: 99%

Soluble in DMSO
C19H21N5O4.HCl MW: 419.86



Biological activity
Peripherally acting α 1 adrenergic receptor antagonist; an antihypertensive
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc


Axon 2040

mg	Price
10	online
50	online

PRE-084 hydrochloride

[75136-54-8]
Purity: 99%

Soluble in water and DMSO
C19H27NO3.HCl MW: 353.88



Biological activity
PRE-084 hydrochloride is a highly selective sigma-1 (σ -1) agonist with a Ki value of 2.2 nM.

Axon 3063

mg	Price
10	online
50	online

Prednacinolone

See Desonide


Axon 3502

Page 421

Pregabalin

PD 144723

[148553-50-8]
Purity: 98%
optically pure
Soluble in water
C8H17NO2 MW: 159.23



Biological activity
An analogue of γ -amino butyric acid (GABA) but inactive at GABA receptors. Pregabalin binds to the alpha-2-delta (α 2 δ) protein, an auxiliary protein associated with voltage-gated calcium channels in the central nervous system. Pregabalin reduces the synaptic release of several neurotransmitters by binding to α 2 δ subunits, possibly accounting for its actions in vivo to reduce neuronal excitability and seizures. Antiepileptic and analgesic.

Axon 1823

mg	Price
10	online
50	online

Prexasertib mesylate

See LY2606368 mesylate

Axon 4145

Page 627

PRI 2191

See Tacalcitol

Axon 2516

Page 904

Pridopidine hydrochloride

See ACR16 hydrochloride

Axon 1579

Page 206


Primaquine diphosphate

SN13272 diphosphate

[63-45-6]

Purity: 98%

Soluble in water and DMSO
C15H21N3O.2H3PO4 MW: 455.34



Axon 3177

mg Price

50 online

Biological activity

Primaquine diphosphate is a transmission-blocking anti-malarial clinically available, displaying a marked activity against gametocytes of all species of human malaria, including multi-resistant *Plasmodium falciparum* strains.

Prinaberel

See ERB 041

Axon 1898

Page 465

Pritelivir

See BAY 57-1293

Axon 2266

Page 290

PRI-724


Foscenvivint

[1422253-38-0]

Purity: 99%

99% e.e.

Soluble in DMSO
C33H35N6O7P MW: 658.64



Axon 3749

mg Price

5 online

Biological activity

PRI-724 is the second-generation, potent and specific inhibitor of CBP/ β -Catenin complex, and a modulator of the β -Catenin dependent canonical Wnt signaling pathway in cancer stem cells. PRI-724 is a pro-drug, from which the active form C-82 (Axon 3748) is rapidly generated in vivo.

Source Information: Sold in collaboration with Chemietek

PRL-3 inhibitor

BR1


Axon 3436

mg Price

[893449-38-2]

Purity: 98%

Soluble in DMSO
C17H11Br2NO2S2 MW: 485.21



10 online

50 online

Biological activity

PRL-3 inhibitor is a selective inhibitor of PRL-3 with an IC50 value of 0.9 μ M. PRL-3 inhibitor strongly inhibited the migration and invasion of PRL-3 overexpressing colon cancer cells without exhibiting cytotoxicity.


PRMT3 inhibitor 1

Compound 1

[1340875-03-7]

Purity: 99%

Soluble in DMSO
C15H18N4OS MW: 302.39



Axon 2211

mg Price

5 online

25 online

Biological activity

Allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3; IC50 value of 1.6 μ M for inhibition of full length PRMT3 in a radioactivity-based assay). PRMT3 inhibitor 1 showed no inhibitory activity on any of the PKMTs G9a, EHMT1, SUV39H2, SETD7, and SETD8, and PRMTs PRMT1, PRMT4, PRMT5, and PRMT8. The allosteric binding site of compound 1 was localized by site-directed mutagenesis of PRMT3 and X-ray crystallography.

Procaspase activating compound 1

See PAC 1

Axon 1743

Page 744


ProINDY

TG007

[719277-30-2]

Purity: 99%

Soluble in DMSO and EtOH
C14H15NO3S MW: 277.34



Axon 3540

mg Price

10 online

50 online

Biological activity

ProINDY is the prodrug of INDY (Axon 3538) and is expected to make the molecule more lipophilic and enhance its cell membrane permeability. ProINDY effectively recovered *Xenopus* embryos from head malformation induced by Dyrk1A overexpression, resulting in normally developed embryos and demonstrating the utility of proINDY in vivo.

Prolixin Decanoate dihydrochloride

See Fluphenazine decanoate dihydrochloride

Axon 2127


Page 486

Propafenone hydrochloride

[34183-22-7]

Purity: 100%

Soluble in water, DMSO and EtOH
C21H27NO3.HCl MW: 377.90



Axon 3644

mg Price

50 online


Biological activity

Propafenone hydrochloride is a multi-channel blocker and antiarrhythmic agent.

Propionic acid, 2-[4-(Cyclopropylsulfonyl)phenyl]-3-(tetrahydropyran-4-yl)

[745052-93-1]
Purity: 98%

No solubility data
C17H22O5S MW: 338.42


Axon 1284

mg	Price
1000	online
5000	online


Biological activity

Building Block; Unknown pharmacology

Propylnorapomorphine hydrochloride, R(-)-N-

NPA

[85199-01-5]
Purity: 99%
>98% ee
Soluble in 0.1N HCl(aq) and DMSO
C19H21NO2.HBr MW: 376.29


Axon 1161

mg	Price
10	online
50	online

Biological activity

Highly potent and selective dopamine D2 receptor agonist

Prop-2-ynyl-2-aminotetraline hydrochloride

See Aminotetraline hydrochloride, Prop-2-ynyl-2-

Axon 1064

Page 233

Prostaglandin E1

See Alprostadil

Axon 2062

Page 220

Protonix

See Pantoprazole sodium

Axon 3161

Page 747

PRT 062070

See Cerdulatinib

Axon 2775


Page 359

PRT 4165

NSC 600157

[31083-55-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C15H9NO2 MW: 235.24


Axon 1953

mg	Price
10	online
50	online


Biological activity

E3 Ubiquitin ligase Bmi1/Ring1A inhibitor

Prucalopride

[179474-81-8]
Purity: 99%

Soluble in DMSO
C18H26ClN3O3 MW: 367.87


Axon 1479

mg	Price
10	online
50	online


Biological activity

Selective 5-HT4 receptor agonist; a gastroprokinetic agent for the treatment of constipation and irritable bowel syndrome; showed memory-enhancing effects in mice through modulation of cholinergic pathways; hence an indication of potential as Alzheimer's disease therapy

PS 47

[1180676-33-8]
Purity: 99%

Soluble in DMSO
C17H15ClO2 MW: 286.75


Axon 1664

mg	Price
10	online
50	online


Biological activity

Allosteric activator of phosphoinositide-dependent protein kinase 1 (PDPK1). PS48 has a Z-configuration in comparison with its E-isomer PS47 (Axon 1664)

PS 48

[1180676-32-7]
Purity: 99%

Soluble in DMSO and Ethanol
C17H15ClO2 MW: 286.75


Axon 1659

mg	Price
10	online
50	online


Biological activity

Allosteric activator of phosphoinositide-dependent protein kinase 1 (PDPK1). PS48 has a Z-configuration in comparison with its E-isomer PS47 (Axon 1664)

PS210

[1221962-86-2]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C19H15F3O5 MW: 380.31


Axon 3534

mg	Price
5	online
25	online

Biological activity

PS210 is a potent and selective activator of PDK1 (AC50 value of 2 μM) that binds to the PIF-pocket and allosterically modulates the active site of PDK1.

PS 341

See Bortezomib

Axon 1810


Page 323

PS 1145

mg	Price

[431898-65-6]
Purity: 99%

Soluble in DMSO
C17H11ClN4O MW: 322.75




5	online
25	online

Biological activity
A highly specific IKK kinase (IKK) inhibitor; efficiently inhibits both basal and induced NF- κ B activity in PC cells

PSB-KD107

[955121-65-0]
Purity: 99%

Soluble in DMSO
C20H22N6O2 MW: 378.43




Axon 3269

mg	Price
10	online
50	online

Biological activity
PSB-KD107 is a selective, non-lipid-like agonist for GPR18 with an EC50 value of 0.562 μ M for human GPR18. Moreover, PSB-KD107 was more potent and much more efficacious than the standard GPR18 agonist THC. PSB-KD107 had also been identified as a moderately potent antagonist for the human adenosine A2A receptor with a Ki value of 4.56 μ M.

Pseudouridine

[1445-07-4]
Purity: 99%
Optically pure
Soluble in water and DMSO
C9H12N2O6 MW: 244.20



Axon 3586

mg	Price
50	online

Biological activity
Pseudouridine, also known as the 'fifth nucleotide' in RNA, is the most abundant modified nucleoside. In rRNA, Pseudouridine is important for rRNA folding and for the control of translational fidelity. Pseudouridine is generated from isomerization of uridine, catalyzed by pseudouridine synthases.

PSI7977


See Sofosbuvir

Axon 3301
Page 878

PSNCBAM 1

[877202-74-9]
Purity: 99%

Soluble in DMSO
C22H21ClN4O MW: 392.88



Axon 1565

mg	Price
5	online
25	online

Biological activity
An allosteric CB1 receptor antagonist, potentially an anti-obesity agents

PT2977

See Belzutifan

Axon 3760
Page 297

PTC124


See Ataluren

Axon 4049
Page 258

PTC 209

[315704-66-6]
Purity: 99%

Soluble in DMSO
C17H13Br2N5OS MW: 495.19



Axon 2420

mg	Price
10	online
50	online


Biological activity
Inhibitor of the canonical self-renewal regulator BMI-1, a vital part of the polycomb repressive complex 1 (PRC1; IC50 value 0.5 μ M for inhibition of UTR-mediated luciferase BMI-1 reporter expression). Treatment of primary colorectal cancer xenografts with PTC209 resulted in colorectal CIC loss with long-term and irreversible impairment of tumor growth. PTC-209 preferentially inhibits the proliferation of human lymphoma U937 and HT1080 tumor cells, and is less effective in primary human peripheral blood mononuclear cells and human hematopoietic stem cells.

PTI-125 dihydrochloride

Simufilam

[2480226-06-8]
Purity: 99%

Soluble in water and DMSO
C15H21N3O2.HCl MW: 332.27



Axon 3746


mg	Price
5	online
25	online

Biological activity
PTI-125 dihydrochloride is an orally available molecule targeting filamin A (FLNA). By binding FLNA with high affinity, PTI-125 prevents A β (42)'s toxic cascade, decreasing phospho-tau and A β aggregates and reducing the dysfunction of α 7nAChRs, NMDARs, and insulin receptors.

PTIQ

[1032822-42-6]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO, and Ethanol
C13H17NO3 MW: 235.28



Axon 2328

mg	Price
10	online
50	online

Biological activity
Brain penetrating neuroprotectant that attenuates MPTP induced motor deficits, prevents neurodegeneration and suppresses microglial activation in the substantia nigra. Mechanistically, PTIQ effectively suppresses expression of MMP-3 (IC50 value 60 nM in stressed dopaminergic cells), and NO production (IC50 value <100 μ M in LPS stimulated BV-2 cells). PTIQ also inhibits IL-1 β , TNF- α (IC50 value 6.5 μ M) and COX-2 (IC50 value 9.3 μ M) and blocked nuclear translocation of NF- κ B, yet it shows no inhibition of hERG channels or CYP isozyme activities.

PTK 787

See Vatalanib

Axon 1637
Page 963

PTL

See Parthenolide

Axon 3614
Page 748

PTX 008


See OTX 008

Axon 2332

Page 740

PTX80

 [2376297-69-5]
 Purity: 98%

 Soluble in DMSO
 C26H26N4O3S MW: 474.57

Axon 3639


mg	Price
5	online
25	online

Biological activity

PTX80 is a first-in-class inhibitor of protein degradation by targeting the autophagy receptor p62/SQSTM1. PTX80 binds to p62, inducing a decrease in soluble p62 and formation of insoluble p62 aggregates, and failure of polyubiquitinated proteins to colocalize with p62. PTX80 induces proteotoxic stress and activation of unfolded protein response, which, in turn, leads to apoptosis.

PU-H71 trihydrochloride

 [873436-91-0] (parent)
 Purity: 99%

 Soluble in water
 C18H21N6O2S.3HCl MW: 621.75

Axon 1856


mg	Price
5	online
25	online

Biological activity

Potent inhibitor of heat shock protein 90 (Hsp90) with IC50 of 51 nM; inhibits cell growth in a range of breast cancer cell lines; inhibit cell proliferation and induce apoptosis in triple-negative breast cancer (TNBC) cells

Purmorphamine

 [483367-10-8]
 Purity: 99%

 Soluble in DMSO
 C31H32N6O2 MW: 520.62

Axon 1690

mg	Price
5	online
25	online

Biological activity

Hedgehog (Hh) agonist that directly targets Smoothed (SMO) transmembrane protein. Purmorphamine up-regulates gene expression of mediators of Hh pathway, SMO, PTCH1, GLI1, and GLI2, and induces osteoblast differentiation of multipotent mesenchymal progenitor cells and lineage-committed preosteoblasts.

PVC

See Penciclovir


Axon 3385

Page 758

PVHD121
Axon 3083

mg	Price
5	online
25	online

 [187336-16-9]
 Purity: 98%

 Soluble in DMSO
 C17H16N2O2 MW: 280.32


10 online

50 online


Biological activity

PVHD121 is an antimetabolic agent that selectively disturbs microtubule formation at centrosomes during mitosis. PVHD121 was shown to have strong antiproliferative activity against various tumor-derived cell lines, including A549 (lung), NCI-H460 (lung), HCT116 (colon), MCF7 (breast), PC3 (prostate), and HeLa (cervical) cells with IC50 values from 0.1 to 0.3 μM. Potential tool for studying the molecular biology of mitosis.

PX 20350

FXR agonist Cpd 22

 [1198085-23-2]
 Purity: 99%

 Soluble in DMSO
 C28H22Cl2F3N3O4 MW: 592.39

Axon 2152

mg	Price
5	online
25	online

Biological activity

Potent farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FXR direct reporter (DR) assay (6 nM vs 30 nM for GW 4064). Cpd 22 showed a linear dose-dependent reduction in total plasma triglycerides and total plasma cholesterol.

PXD101

See Belinostat


Axon 3115

Page 297

PXS 4728A

PXS 4728 HCl

 [1478364-68-9]
 Purity: 98%

 Soluble in water and DMSO
 C15H21FN2O2.HCl MW: 316.80


5 online


25 online

Biological activity

Potent and orally available inhibitor of VAP-1 (aka SSAO/AOC3; IC50 value 5 nM) inhibiting neutrophil rolling and tethering in the mouse cremaster model, and showing >500-fold selectivity for VAP-1/SSAO over all the related human amine oxidases. PXS 4728 diminishes lung inflammation in a variety of models indicating proof of concept for a novel therapeutic approach in respiratory diseases that are characterized by neutrophilic pattern of inflammation. PXS 4728 is in clinical trials for the treatment of cardiometabolic diseases like the liver-related disease Nonalcoholic Steatohepatitis (NASH).

PY108

 [2378039-21-3]
 Purity: 98%

 Soluble in DMSO
 C15H9N3O MW: 247.25

Axon 3520

mg	Price
5	online
25	online


Biological activity

PY108 is a potent, orally bioavailable aryl hydrocarbon receptor (AHR) agonist with an EC50 value of 2.5 nM.

PY109

[2378039-23-5]
Purity: 98%

Soluble in DMSO and EtOH
C15H9F3N2O MW: 290.24



Axon 3521

mg	Price
5	online
25	online

Biological activity


PY109 is a potent, orally bioavailable aryl hydrocarbon receptor (AHR) agonist with an EC50 value of 1.2 nM.

PY-60

YAP activator PY-60

[2765218-56-0]
Purity: 98%

Soluble in DMSO and EtOH
C16H15N3O2S MW: 313.37



Axon 3480

mg	Price
5	online
25	online


Biological activity

PY-60 is a robust and specific activator of YAP transcriptional activity by targeting annexin A2 (Kd value of 1.4 μM). PY-60 treatment liberates annexin A2 (ANXA2) from the membrane, ultimately promoting a phosphatase-bound, nonphosphorylated and transcriptionally active form of YAP.

Pyrantel pamoate


[22204-24-6]
Purity: 100%

Soluble in DMSO
C11H14N2S.C23H16O6 MW:
594.68



Axon 3888

mg	Price
50	online



Biological activity


Pyrantel pamoate is an anthelmintic agent which depolarizes the myoneural junction and inhibits cholinesterase.

Pyridostatin hydrochloride

RR82 hydrochloride

[1781882-65-2]
Purity: 95%

Soluble in Water
C31H32N8O5 MW: 778.94



Axon 4076

mg	Price
10	online
50	online

Biological activity


Pyridostatin stabilizes G-quadruplexes, targeting the proto-oncogene SRC and telomeric G-quadruplexes, inducing DNA damage and cell-cycle arrest, and is used for induced synthetic lethality in cancer cells.

Source Information: Sold in collaboration with Chemietek

Pyroxamide

[382180-17-8]
Purity: 98%

Soluble in DMSO
C13H19N3O3 MW: 265.31



Axon 1801

mg	Price
10	online
50	online

Biological activity

Histone deacetylase (HDAC) inhibitor; a potent inhibitor of affinity-purified HDAC1 (IC50: 100 nM); an inducer of differentiation and/or apoptosis in transformed cells

PZ51

See Ebselen

Axon 3424

Page 449

Q525-1

See *RET* agonist Q525


Axon 3226

Page 813

Q94 hydrochloride

[1052076-77-3]
Purity: 99%

Soluble in DMSO
C₂₁H₁₇ClN₂.HCl MW: 369.29



Axon 2055

mg Price

10 online

50 online

Biological activity

PAR1/Gαq-specific allosteric inhibitor or negative allosteric modulator (NAM); Q94 selectively blocks *PAR1/Gαq* interaction and signaling

Quemliclustat ammonium salt

See *AB-680* ammonium salt


Axon 3718

Page 197

QND7

[1779540-13-4]
Purity: 99%

Soluble in DMSO
C₂₁H₂₂N₄ MW: 330.43



Axon 3151

mg Price

10 online

50 online

Biological activity

QND7 is a $\alpha 7$ -nicotinic acetylcholine receptor antagonist (K_a value of 6.7 μ M). *QND7* suppresses non-small cell lung cancer cell proliferation and migration via inhibition of *Akt/mTOR* signaling

QRX431

See *Sobetirome*


Axon 4126

Page 877

QStatin

[902688-24-8]
Purity: 99%

Soluble in DMSO
C₇H₅BrN₂O₂S₂ MW: 293.16



Axon 3012

mg Price

10 online

50 online

Biological activity

QStatin is a potent and selective *Vibrio Quorum Sensing (QS)* inhibitor which affects *Vibrio harveyi LuxR* homologues, the well-conserved master transcriptional regulators for *QS* in *Vibrio* species. *QStatin* is a potent *SmcR* inhibitor in *V. vulnificus* (EC₅₀ value of 208.9 nM), and may be a sustainable antivibriosis agent useful in aquacultures.

Quetiapine fumarate

ICI 204636; *ZD 5077*; *ZM 204636*

[111974-72-2]
Purity: 99%

Soluble in DMSO


Axon 1354

mg Price

10 online

50 online

C₄₂H₅₀N₆O₄S₂.½C₄H₄O₄
MW: 441.54



Biological activity

Atypical antipsychotic; Quetiapine is a moderate 5-HT₂, weak dopamine D₂ and $\alpha 2$ receptor antagonist

Quinapril hydrochloride

C1906; *PD109452-2*


[82586-55-8]

Purity: 99%

Optically pure

Soluble in water, DMSO and EtOH

C₂₅H₃₀N₂O₅.HCl MW: 474.98



Biological activity

Quinapril hydrochloride is an angiotensin converting enzyme (ACE) inhibitor. Moreover, *quinapril* is a prodrug which is hydrolysed after absorption to form the more active diacid ACE inhibitor, *quinaprilat*.


Quininib

[143816-42-6]

Purity: 99%

Soluble in DMSO

C₁₇H₁₃NO MW: 247.29



Biological activity

Antagonist of the cysteinyl leukotriene receptor 1 and 2 (CysLT₁₋₂; IC₅₀ values 1.4 μ M and 38.5 μ M, respectively). *Quininib* robustly inhibits developmental angiogenesis in zebrafish (at 4-10 μ M), and significantly inhibits angiogenic tubule formation in HMEC-1 cells, angiogenic sprouting in aortic ring explants and retinal revascularisation in OIR mice, independently Using ex vivo human CRC explants, *Quininib* significantly reduced the secretions of angiogenic growth factors and inflammatory cytokines IL-6, IL-8, VEGF, ENA-78, GRO- α , TNF, IL-1 β and MCP-1.

Quisinostat dihydrochloride

See *JNJ 26481585 dihydrochloride*

Axon 2529

Page 579

Quizartinib dihydrochloride

See *AC 220 dihydrochloride*

Axon 1696

Page 204


QX77

[1798331-92-6]

Purity: 98%

Soluble in DMSO

C₁₆H₁₃ClN₂O₂ MW: 300.74



Biological activity

Chaperone-mediated autophagy (CMA) activator. *QX77* operates through the release of the endogenous inhibition of the retinoic receptor- α signaling pathway over the regulation of multiple mechanisms that modulate CMA.

Axon 2902

mg Price

10 online

50 online

R278474

See Rilpivirine


Axon 3685

Page 819

R 55

NSC 55712; TPT 260 dihydrochloride

 [2076-91-7]
 Purity: 98%

 Soluble in water and DMSO
 C₈H₁₄Cl₂N₄S₃ MW: 333.32

Axon 2303


mg	Price
10	online
50	online

Biological activity

Retromer stabilizing pharmacological chaperone (K_d value ~5 μM) that binds at the Vps29 and Vps35 interface, and reduces Aβ peptide accumulation (IC₅₀ value ~12 μM) and the pathogenic pathway of APP; useful pharmacological tool for research on Alzheimer's disease. Thiophene derivative R55 was originally tested and proved active for its anticancer activity against Yoshida sarcoma.

R 406

 [841290-80-0]
 Purity: 98%

 Soluble in DMSO
 C₂₂H₂₃FN₆O₅ MW: 470.45

Axon 1674


mg	Price
5	online
25	online

Biological activity

Orally bioavailable and selective inhibitor of spleen tyrosine kinase (Syk) (K_i=30 nM). Active component of its prodrug R788 or R935788 (Fostamatinib)

R 428 dihydrochloride

 [N.A.]
 Purity: 99%

 Soluble in DMSO
 C₃₀H₃₄N₈.2HCl MW: 579.57

Axon 1946


mg	Price
1	online
2	online
5	online

Biological activity

Potent and selective inhibitor of Axl receptor tyrosine kinases (IC₅₀: 14 nM); R428 inhibits Axl kinase and blocks Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. Note: The hydrochloride salt of R428 has an improved solubility in comparison with its free base

R 547

 [741713-40-6]
 Purity: 99%

 Soluble in DMSO
 C₁₈H₂₁F₂N₅O₄S MW: 441.45

Axon 1983

mg	Price
5	online
25	online

Biological activity

Potent and selective CDK inhibitor with K_i values to be 1, 3, 1 nM for CDK1, CDK2, and CDK4 respectively; inactive (K_i >5000 nM) against a panel of >120 unrelated kinases

R 4749

See Droperidol

Axon 1554

Page 442

R 7227

See Danoprevir

Axon 1669

Page 408

R 41468

See Ketanserlin

Axon 1450

Page 590

R 64766

See Risperidone

Axon 1454

Page 820

R 89439

See Loviride

Axon 3334

Page 620

R 147681

See Dapivirine

Axon 1534

Page 409

R-837


See Imiquimod

Axon 3107

Page 563

R(-)-Deprenyl hydrochloride

Selegiline hydrochloride

 [14611-52-0]
 Purity: 99%
 Optically pure
 Soluble in water and DMSO
 C₁₃H₁₇N.HCl MW: 223.74

Axon 3332

mg	Price
50	online

Biological activity

R(-)-Deprenyl hydrochloride is a highly selective inhibitor of MAO-B.

R-SLV319


See SLV 319, (R)-(+)-

Axon 1714

Page 873

rac-BRD0705

 [1597440-03-3]
 Purity: 99%

 Soluble in DMSO
 C₂₀H₂₃N₃O MW: 321.42

Axon 3154

mg	Price
5	online
25	online

Biological activity

GSK3 α inhibitor. Racemic mixture of BRD0705 (Axon 2931), the active enantiomer and its negative control BRD5648 (Axon 3153).

rac-PH 797804


See PH 797804, (\pm)-

Axon 2786

Page 773

RA375

[2649154-57-2]
Purity: 99%
98% e.e.
Soluble in DMSO
C30H25ClN4O7 MW: 589.00



Axon 3210

mg	Price
5	online
25	online

Biological activity


RA375 is a potent RPN13 inhibitor with IC₅₀ values of 13 and 26 nM against HeLa and SKOV3 cells, respectively. Treatment with RA375 caused a rapid and profound accumulation of high molecular weight polyubiquitinated proteins and reduced intracellular glutathione levels, which produce endoplasmic reticulum and oxidative stress, and trigger apoptosis.

Rabepazole sodium

E3810; LY307640 sodium

[117976-90-6]
Purity: 99%

Soluble in water, DMSO and EtOH
C18H20N3NaO3S MW: 381.42



Axon 3663

mg	Price
10	online
50	online

Biological activity

Rabepazole sodium is an H⁺/K⁺ ATPase inhibitor.

RAD001

See Everolimus

Axon 4149

Page 471

RAD1901

See Elacestrant dihydrochloride


Axon 4095

Page 453

RAD51 inhibitor B02

[1290541-46-6]
Purity: 98%

Soluble in DMSO
C22H17N3O MW: 339.39



Axon 1911

mg	Price
10	online
50	online

Biological activity

Specific and cell-permeable RAD51 inhibitor; B02 specifically inhibits the DNA strand exchange activity of human RAD51 (IC₅₀ = 27.4 μ M). It disrupts RAD51 binding to DNA, increasing cell sensitivity to DNA damage

RAD51-Stimulatory Compound-1

See RS-1


Axon 2584

Page 833

Radafaxine hydrochloride

BW 306U; GW 353162A

[106083-71-0]
Purity: 99%
optically pure
Soluble in water
C13H18ClNO2.HCl MW: 292.20



Axon 1123

mg	Price
5	online
25	online

Biological activity

A norepinephrine-dopamine reuptake inhibitor (NDR1); a potent metabolite of bupropion; radafaxine is a (+)-isomer of hydroxybupropion

Radiprofil

See RGH 896


Axon 1434

Page 816

RAF709

[1628838-42-5]
Purity: 99%

Soluble in DMSO
C28H29F3N4O4 MW: 542.55



Axon 2817

mg	Price
10	online
50	online

Biological activity


RAF709 is a potent, selective, and efficacious B/C RAF inhibitor with IC₅₀ values of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively. RAF709 was cellularly potent in a KRAS mutant cell line (Calu-6) and was well-tolerated and efficacious in KRAS mutant xenograft models.

Ralinepag

APD 811

[1187856-49-0]
Purity: 99%

Soluble in DMSO
C23H26ClNO5 MW: 431.91



Axon 2874

mg	Price
5	online
25	online

Biological activity

Ralinepag is an orally bioavailable, non-prostanoid IP receptor agonist (EC₅₀ value of 8.5 nM, human IP receptor assay) that is efficacious in the rat MCT model of pulmonary arterial hypertension. It has good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family, but a more modest 30-50-fold selectivity over the EP3 receptor.

Raloxifene


LY139481

[84449-90-1]
Purity: 99%

Axon 3250

mg	Price
10	online

Soluble in 0.1N HCl(aq) and DMSO
C28H27NO4S MW: 473.58



50 online

Biological activity


Raloxifene is a selective estrogen receptor modulator (SERM).

Raltegravir

MK-0518

[518048-05-0]
Purity: 99%

Soluble in DMSO
C20H21FN6O5 MW: 444.42



Axon 3120

mg Price

10 online

50 online

Biological activity


Raltegravir is a potent, selective and orally bioavailable HIV-integrase inhibitor with an IC50 value of 0.015 μM for inhibition of strand transfer. Also, Raltegravir showed potency in a cell based assay with CIC95 values of 0.019 and 0.031 μM in 10% FBS and 50% NHS, respectively.

Ranolazine

RS43285

[95635-55-5]
Purity: 100%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C24H33N3O4 MW: 427.54



Axon 3507

mg Price

50 online

Biological activity


Ranolazine is an inhibitor of sodium and potassium ion channel currents. Ranolazine also inhibits the late phase of the inward sodium current in ventricular myocardial cells, which reduces intracellular calcium overload and associated diastolic contractile dysfunction. Anti-anginal agent.

Rapamycin

Sirolimus

[53123-88-9]
Purity: 98%

Soluble in DMSO
C51H79NO13 MW: 914.17



Axon 2069

mg Price

2 online

5 online

Biological activity


Specific inhibitor of mTOR (mammalian target of Rapamycin); it binds the cytosolic protein FKBP12 and inhibits mTOR pathway by directly binding the mTORC1. Rapamycin selectively inhibits interleukin-2 (IL-2) activation of p70 S6 kinase. It prevents activation of T cells and B cells by inhibiting their response to IL-2. An immunosuppressant drug used to prevent rejection in organ transplantation, especially useful in kidney transplants; also used as a coronary stent coating

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Raphin1

[2022961-17-5]
Purity: 98%

Soluble in DMSO
C8H8Cl2N4 MW: 231.08



Axon 3004

mg Price

10 online

50 online


Biological activity

Raphin1 is a selective inhibitor of PPP1R15B (R15B) and bound strongly (Kd value of 0.033 μM) to the R15B-PP1c holophosphatase. Moreover, Raphin1 was ~30-fold selective in binding R15B-PP1c over R15A-PP1c and did not bind to PP1c. In cells, Raphin1 caused a rapid and transient accumulation of its phosphorylated substrate, resulting in a transient attenuation of protein synthesis. In vitro, Raphin1 inhibits the recombinant R15B-PP1c holoenzyme, but not the closely related R15A-PP1c, by interfering with substrate recruitment. Raphin1 was orally bioavailable, crossed the blood-brain barrier, and demonstrated efficacy in a mouse model of Huntington's disease. This product is also available as its acetate salt (Axon 2983)

Raphin1 acetate

[2242616-04-0]
Purity: 99%

Soluble in DMSO
C8H8Cl2N4.C2H4O2 MW: 291.13



Axon 2983

mg Price

10 online

50 online

Biological activity

Raphin1 acetate is a selective inhibitor of PPP1R15B (R15B) and bound strongly (Kd value of 0.033 μM) to the R15B-PP1c holophosphatase. Moreover, Raphin1 acetate was ~30-fold selective in binding R15B-PP1c over R15A-PP1c and did not bind to PP1c. In cells, Raphin1 acetate caused a rapid and transient accumulation of its phosphorylated substrate, resulting in a transient attenuation of protein synthesis. In vitro, Raphin1 acetate inhibits the recombinant R15B-PP1c holoenzyme, but not the closely related R15A-PP1c, by interfering with substrate recruitment. Raphin1 acetate was orally bioavailable, crossed the blood-brain barrier, and demonstrated efficacy in a mouse model of Huntington's disease. This product is also available as the free base (Axon 3004)

Ravoxertinib

See GDC-0994

Axon 3741

Page 499

Raxatrigine HCl

See CNV 1014802 hydrochloride

Axon 2548

Page 381

Raziosulfa

See Sulfaphenazole


Axon 2922

Page 899

RBC 8

[361185-42-4]
Purity: 99%

Soluble in DMSO
C25H20N4O3 MW: 424.45



Axon 2396

mg Price

5 online

25 online

Biological activity

Inhibitor of the RAS-like small GTPases RalA and RalB (IC50 values 3.5 mM and 3.4 mM for growth inhibition in H358 and H2122 tumor xenografts, respectively). RBC8 shows selectivity for Ral relative to the GTPases Ras


and RhoA. Mechanistically, RBC8 inhibits the binding of Ral proteins in their GDP-bound form to its effector RALBP1, as well as inhibiting Ral-mediated cell spreading of murine embryonic fibroblasts and anchorage-independent growth of human cancer cell lines. Close analogue of BQU 57 (Axon 2397)

Rbin-1

Ribozinoindole-1

[328023-11-6]
Purity: 99%

Soluble in DMSO
C13H12N4S MW: 256.33



Axon 2663

mg	Price
10	online
50	online

Biological activity


Rbin-1 (ribozinoindole-1) is a potent, reversible, and specific inhibitor of Midasin (Mdn1), an enzyme belonging to the AAA+ (ATPases associated with diverse cellular activities) protein family (GI50 value 136 nM in wild-type cells). Rbin-1 is a chemical probe for the eukaryotic ribosome assembly.

Rbin-2

Ribozinoindole-2

[2032282-97-4]
Purity: 98%

Soluble in DMSO
C13H11BrN4S MW: 335.22



Axon 2712

mg	Price
10	online
50	online

Biological activity


Rbin-2 (ribozinoindole-2) is a potent, reversible, and specific inhibitor of Midasin (Mdn1), an enzyme belonging to the AAA+ (ATPases associated with diverse cellular activities) protein family (GI50 value 14 nM in wild-type cells). Rbin-2 is a chemical probe for the eukaryotic ribosome assembly. Also Midasin inhibitor Rbin-1 (Axon 2663) is available.

RBPJ inhibitor RIN1

RIN1

[N.A.]
Purity: 99%

Soluble in DMSO
C17H14FN3O2 MW: 311.31



Axon 3061

mg	Price
5	online
25	online

Biological activity

RBPJ inhibitor RIN1 is a potent, selective, first-in-class inhibitor of the transcription factor RBPJ. RBPJ inhibitor RIN1 inhibits RBPJ in both its activating (NOTCH) and inhibiting (SHARP) complexes. Consistent with disruption of NOTCH signaling, RBPJ inhibitor RIN1 inhibited the proliferation of hematologic cancer cell lines and promoted skeletal muscle differentiation from C2C12 myoblasts.


RCGD 423

[108237-91-8]
Purity: 99%

Soluble in DMSO
C15H11BrN2S MW: 331.23

Axon 2999

mg	Price
10	online
50	online




Biological activity

RCGD 423 is a modulator of gp130 signalling and demonstrates prominent disease-modifying activity in two rat models of cartilage injury or/and degeneration. Moreover, RCGD423 induced levels of both c-Myc and n-Myc as well as lactate dehydrogenase (Ldha), consistent with activation of Stat3 signaling leading to induction of Myc and Ldha protein expression.

RD 162

[915087-27-3]
Purity: 98%

Soluble in DMSO
C22H16F4N4O2S MW: 476.45



Biological activity


An orally active and very potent antagonist of androgen receptor (AR); Second-generation of antiandrogen for the treatment of advanced prostate cancer; highly recommended tool in AR research

RDEA119

Refametinib; BAY 869766

[923032-37-5]
Purity: 99%

99% e.e.
Soluble in DMSO
C19H20F3IN2O5S MW: 572.34



Biological activity

RDEA119 is a potent, highly selective and orally-bioavailable small molecule allosteric MEK inhibitor with IC50 at low nM.

Source Information: Sold in collaboration with Chemietek


Rebastinib

See DCC 2036

Reboxetine mesylate

[98769-84-7]
Purity: 99%

>98% ee
Soluble in DMSO
C19H23NO3.CH4O3S MW: 409.50



Biological activity

Selective noradrenaline uptake inhibitor (NARI); orally active

Axon 1532

mg	Price
5	online
25	online

Axon 3874

mg	Price
5	online
10	online

Axon 2123

Page 412

Axon 1240

mg	Price
10	online
50	online

Refametinib

See RDEA119

Axon 3874


Page 810

Regorafenib

BAY 73-4506

[755037-03-7]
Purity: 98%

Soluble in DMSO
C21H15ClF4N4O3 MW: 482.82



mg	Price
5	online
10	online

Biological activity

An oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinases (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition

Relcovaptan

See SR 49059


Axon 1256

Page 888

Remdesivir

GS-5734

[1809249-37-3]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C27H35N6O8P MW: 602.58



Axon 3110

mg	Price
5	online
25	online


Biological activity

Remdesivir is a potent and selective inhibitor of Ebola virus (EBOV) in multiple relevant permissive cell types. Remdesivir inhibits EBOV replication in multiple relevant human cell types including primary macrophages and human endothelial cells with EC50 values of 0.06 to 0.14 μM. The broad-spectrum antiviral activity of Remdesivir in vitro against other pathogenic RNA viruses, including filoviruses, arenaviruses, and coronaviruses, suggests the potential for wider medical use.

Remodelin

[949912-58-7]
Purity: 99%

Soluble in DMSO
C15H14N4S MW: 282.36



Axon 2299

mg	Price
5	online
25	online

Biological activity

Potent Acetyl-transferase NAT 10 inhibitor that mediates nuclear shape rescue in laminopathic (LMNA-depleted) cells via microtubule reorganization. Remodelin markedly reduced the prevalence of misshapen nuclei in HGPS cells as well as in primary MRC5 fibroblasts aged in culture. In contrast, Remodelin had no effect on nonlaminopathic Werner syndrome cells

Remogliflozin


GSK 189074

[329045-45-6]
Purity: 99%

Axon 1634

mg	Price
5	online

Soluble in water and DMSO
C23H34N2O7 MW: 450.53




25 online

Biological activity

Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Its prodrug is Remogliflozin etabonate (GSK 189075), investigated as a treatment of anti diabetes type II

REP 3123 dihydrochloride

[1013915-99-5]
Purity: 99%
>98% ee
Soluble in DMSO
C19H19Br2N3O2S.2HCl
MW: 586.17



Axon 1705

mg	Price
10	online
50	online


Biological activity

Selective inhibitor of methionyl-tRNA synthetase (MetRS); agent to treat Clostridium difficile infection (CDI); Antibiotic

REP 8839

[757942-43-1]
Purity: 99%

Soluble in DMSO
C20H21BrFN3OS MW: 450.37



Axon 1704

mg	Price
10	online
50	online


Biological activity

Selective inhibitor of methionyl-tRNA synthetase (MetRS) with antibacterial activity against a variety of gram-positive organisms; Antibiotic

Repaglinide

AG-EE 623ZW

[135062-02-1]
Purity: 100%
Optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C27H36N2O4 MW: 452.59



Axon 3365

mg	Price
50	online

Biological activity

Antidiabetic; KATP channel blocker. Repaglinide was found to bind with low affinity (Kd of 59 nM) to SUR1 alone, but with high affinity (increased approximately 150-fold) when SUR1 was co-expressed with Kir6.2 (Kd value of 0.42 nM).

Rescriptor

See Delavirdine

Axon 1815


Page 418

RET agonist Q525

Q525-1

[N.A.]
Purity: 98%

Soluble in DMSO
C16H11ClN2O3 MW: 314.72



Biological activity


RET agonist Q525 is a highly selective RET agonist which afforded sustained RET activation and prevented photoreceptor neuron loss in the retina. RET agonist Q525 was active in MG87 RET/GFRa1 cells across a broad range of concentrations and generated large and significant increases in pAkt/pErk. RET agonist Q525 maintained a high degree of selectivity for RET, because no significant increases in pAkt and pErk were observed in MG87 TrkA cells.

Axon 3226

mg	Price
5	online
25	online

RET Inhibitor 2667

[1980023-80-0]
Purity: 99%
o.p.
Soluble in DMSO
C26H25FN10O MW: 512.54



Biological activity

Potent RET inhibitor (IC50 value <10 nM) with activity against wild-type RET and its mutants

Axon 2667


mg	Price
2	online

Retigabine

D 23129; Ezogabine

[150812-12-7]
Purity: 99%

Soluble in DMSO
C16H18FN3O2 MW: 303.33



Biological activity

Selective neuronal KCNQ/Kv7 potassium channel opener; an anticonvulsant in development for the potential oral treatment of complex partial seizures and post-herpetic neuralgia (PHN)

Axon 1525


mg	Price
10	online
50	online

Retigabine dihydrochloride

D 23129 hydrochloride; Ezogabine dihydrochloride

[150812-13-8]
Purity: 99%

Soluble in water and DMSO
C16H18FN3O2.2HCl MW: 376.25



Biological activity

Selective neuronal KCNQ/Kv7 potassium channel opener; an anticonvulsant in development for the potential oral treatment of complex partial seizures and post-herpetic neuralgia (PHN) The parent compound, Retigabine (Axon 1525), is available as well.

Axon 2252


mg	Price
10	online
50	online

Retinoic acid

Vitamin A acid; ATRA; Tretinoin

[302-79-4]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C20H28O2 MW: 300.44



Biological activity

Retinoic acid, a derivative of retinol (vitamin A), is a RAR ligand with an IC50 value of 14 nM for RARα, RARβ and RARγ receptor subtypes. Retinoic acid is known to have profound effects on cell growth and differentiation and to be essential for normal embryonic development.

Axon 3321


mg	Price
50	online

Reversan

CBLC4H10

[313397-13-6]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C26H27N5O2 MW: 441.52



Biological activity

Reversan is a potent, selective and non-toxic multidrug resistance-associated protein (MRP1) inhibitor. Reversan gives a 3.8, 14.6 and 11.6 fold sensitization of MCF7/VP cells to the MRP1 substrates doxorubicin, vincristine and etoposide, respectively. May be clinically useful in the treatment of neuroblastoma and other cancers associated with aberrant MRP1/Pgp expression. MRP1 reversal agent.


Axon 3222

mg	Price
5	online
25	online

Reversine

[656820-32-5]
Purity: 99%

Soluble in DMSO
C21H27N7O MW: 393.49



Biological activity

Reversine induces differentiated myogenic-lineage committed cells to become multipotent mesenchymal progenitor cells; it is a potent mitotic inhibitor of MPS1 kinase, which inhibits the spindle assembly checkpoint in a dose-dependent manner; also acts as A3 adenosine receptor antagonist (Ki: 660 nM) or aurora kinases inhibitor (IC50: 400-500 nM for Aurora A/B/C respectively)

Axon 1629

mg	Price
5	online
25	online

Revimid

See Lenalidomide

Axon 1793

Page 611

Rezatapopt Recent Addition


PC14586

[2636846-41-6]
Purity: 98%
98% e.e.

Soluble in 0.1N HCl(aq) and DMSO
C28H31F4N5O2 MW: 545.57

Axon 4268

mg	Price
5	online



Biological activity

Rezatapopt is a first-in-class p53 reactivator that selectively binds to the mutated p53 Y220C protein and restores normal p53 protein (wild-type) structure (function).

Source Information: Sold in collaboration with Chemietek

Result


See Rosiglitazone

Axon 2443

Page 830

RG 108

[48208-26-0]
Purity: 99%
>98% ee
Soluble in DMSO
C19H14N2O4 MW: 334.33



Axon 1691

mg	Price
10	online
50	online

Biological activity

DNA methyltransferase inhibitor; Inhibits DNA methylation in human cancer cell lines in vitro without detectable toxicity; Demethylates and reactivates epigenetically silenced tumor suppressor genes; Recently, BIX01294 and RG108 have been reported to enhance the efficiency of induced pluripotent stem cell (iPS) generation

RG 6396

See BLU-667

Axon 3854

Page 314

RG 7204

See PLX 4032

Axon 1624

Page 783

RG 7227

See Danoprevir


Axon 1669

Page 408

RG-7388

Idasanutin; RO5503781

[1229705-06-9]
Purity: 99%
99% e.e.
Soluble in DMSO
C31H29Cl2F2N3O4 MW: 616.48



Axon 4035

mg	Price
10	online
50	online

Biological activity

RG7388 is the second generation inhibitor of P53-MDM2 interaction. It is orally active, potently and selectively antagonizing the P53-MDM2 interaction with K_i at low nM. Highly optimized from pyrrolidin-based derivatives, RG7388 represents a distinctive, brand-new structural category of MDM2 ligand, a significant departure from the nutlin-based, first generation ligands exemplified by RG7112. Like RG7112, RG7388 binds selectively to the p53 site on the surface of the MDM2 molecule, effectively displacing p53 from MDM2, leading to p53 stabilization and activation of the p53 pathway. However, RG7388, as compared with its predecessor, binds to the MDM2 protein with a higher potency and selectivity, and has substantially improved pharmacological properties and superior clinical efficacy at lower doses and exposures.

Source Information: Sold in collaboration with Chemietek

RG7420

See GDC-0973

Axon 4148

Page 499

RG 7422

See GDC 0980

Axon 1782

Page 499

RG7440

See GDC-0068

Axon 4037

Page 497

RG 7604

See Taselisib

Axon 2927

Page 911

RG7842

See GDC-0994

Axon 3741

Page 820

RG7916

See Risdiplam


Axon 3093

Page 820

RGFP 966

[1396841-57-8]
Purity: 99%

Soluble in DMSO
C21H19FN4O MW: 362.40



Axon 2195

mg	Price
5	online
25	online

Biological activity


HDAC3 specific inhibitor (IC50 value 0.08 μ M) lacking affinity for any other HDAC at concentrations up to 15 μ M. RGFP 966 enhances long term object memory acquisition/consolidation, and facilitates extinction of cocaine-seeking behavior in male C57BL/6J mice.

RGH 896

Radiprofil

[496054-87-6]
Purity: 99%

Soluble in DMSO
C21H20FN3O4 MW: 397.40



Axon 1434

mg	Price
5	online
10	online


Biological activity

Orally active and selective NMDA NR2B antagonist; a potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions. It blocks pain signaling without interacting with other NMDA receptor subtypes thus potentially improving therapeutic index and side effect profile

RGX-104

SB 742881

[610318-54-2]
Purity: 99%
99% e.e.
Soluble in DMSO
C34H33ClF3NO3 MW: 596.08



Axon 3739

mg	Price
5	online
10	online

Biological activity


RGX-104 is an oral, selective LXR (Liver-X Nuclear Hormone Receptor) agonist, and a first-in-class immunotherapy agent. It activates the expression of the ApoE gene and reverses the immunosuppressive effects of cancer by targeting the LXR/ApoE pathway that regulates the innate immune response to cancer. This next-generation therapy has two key effects on the innate immune system that drive tumor immunity: it depletes myeloid-derived suppressor cells (MDSCs) and stimulates dendritic cells (DCs). MDSCs block the ability of T cells to become active, while stimulated DCs are required for proper activation (priming) of T cells.

Source Information: Sold in collaboration with Chemietek

RI-1

[415713-60-9]
Purity: 99%

Soluble in DMSO
C14H11Cl3N2O3 MW: 361.61



Axon 1885

mg	Price
10	online
50	online


Biological activity

Specific inhibitor of the central recombination protein RAD51; a useful tool for investigations on mechanisms of DNA repair

Ribavirin

1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide

[36791-04-5]
Purity: 100%
Optically pure
Soluble in water and DMSO
C8H12N4O5 MW: 244.20



Axon 3573

mg	Price
50	online

Biological activity

Ribavirin is a guanosine analog that interferes with the replication of RNA and DNA viruses. Moreover, ribavirin binds directly to eIF4E with micromolar affinity in vitro, competes efficiently with eIF4E:m7G mRNA cap binding in vitro and in cells, and specifically disrupts eIF4E:m7G functions in the transport and translation of eIF4E-regulated genes at low micromolar concentrations in cells, with consequent down-regulation of oncogenic proteins, cell-cycle arrest, and suppression of eIF4E-mediated transformation in vitro and in vivo.

Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-β-D-

See Ribavirin

Axon 3573

Page 817

Ribozinoindole-1

See Rbin-1

Axon 2663

Page 809

Ribozinoindole-2

See Rbin-2


Axon 2712

Page 809

RIG012

[N.A.]
Purity: 99%

Soluble in DMSO
C23H21NO3 MW: 359.42




Biological activity

RIG012 is a potent antagonist of the RIG-I innate immune receptor (IC50 value of 0.71 μM) and inhibits RIG-I signaling and interferon response in living cells.

Rifabutin

LM427

[72559-06-9]
Purity: 98%
Optically pure
Soluble in DMSO
C46H62N4O11 MW: 847.00



Biological activity


Rifabutin is a potent broad-spectrum antibiotic.

Rigosertib sodium

ON01910 sodium; Estybon

[592542-60-4]
Purity: 99%

Soluble in water and DMSO
C21H24NNaO8 MW: 473.47



Biological activity

Rigosertib sodium is a non-ATP-competitive inhibitor of PLK1 (IC50 value of 9–10 nM) which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis. In vitro studies with Rigosertib sodium showed that incubation of human leukemic cells with this compound results in the inhibition of PI3K/AKT pathway, down regulation of cyclin D1, induction of NOXA and BIM and activation of JNK pathway. In vivo, Rigosertib sodium did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models.

Rilematovir

JNJ53718678

[1383450-81-4]


Axon 2950

mg	Price
5	online
25	online

Axon 4183

mg	Price
----	-------

Purity: 99%		10	online
Soluble in DMSO		50	online
C21H20ClF3N4O3S	MW: 500.92		



Biological activity


Rilematovir is a potent and orally bioavailable fusion inhibitor of respiratory syncytial virus (RSV).

Rilpivirine

R278474; TMC278

[500287-72-9]
Purity: 98%

Soluble in DMSO
C22H18N6 MW: 366.42



Axon 3685

mg	Price
5	online
25	online

Biological activity


Rilpivirine is a orally bioavailable non-nucleoside reverse transcriptase inhibitor (NNRTI) which is highly active against wild-type and mutant HIV.

Riluzole

PK26124

[1744-22-5]
Purity: 100%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C8H5F3N2OS MW: 234.20



Axon 3499

mg	Price
50	online

Biological activity


Riluzole is a neuroprotective drug that blocks glutamatergic neurotransmission in the CNS. Riluzole inhibits the release of glutamic acid from cultured neurons, from brain slices, and from corticostriatal neurons in vivo. Riluzole also blocks some of the postsynaptic effects of glutamic acid by noncompetitive blockade of N-methyl-D-aspartate (NMDA) receptors. In vivo, riluzole has neuroprotective, anticonvulsant, and sedative properties. The hydrochloride salt form of Riluzole (Axon 3576) is available from stock as well.

Riluzole hydrochloride

PK26124 hydrochloride

[850608-87-6]
Purity: 99%

Soluble in water, DMSO and EtOH
C8H5F3N2OS.HCl MW: 270.66



Axon 3576

mg	Price
50	online

Biological activity

Riluzole hydrochloride is a neuroprotective drug that blocks glutamatergic neurotransmission in the CNS. Riluzole inhibits the release of glutamic acid from cultured neurons, from brain slices, and from corticostriatal neurons in vivo. Riluzole also blocks some of the postsynaptic effects of glutamic acid by noncompetitive blockade of N-

methyl-D-aspartate (NMDA) receptors. In vivo, riluzole has neuroprotective, anticonvulsant, and sedative properties. The free base is available as Riluzole (Axon 3499).

Rimonabant

See SR 141716A

Axon 1220

Page 888

RIN1

See RBPJ inhibitor RIN1


Axon 3061

Page 809

RIPA-56

[1956370-21-0]
Purity: 99%

Soluble in DMSO
C13H19NO2 MW: 221.30



Biological activity

Highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1; IC50 value 13 nM) for the treatment of systemic inflammatory response syndrome (SIRS). RIPA-56 efficiently reduced TNF α -induced mortality and multiorgan damage.

Axon 2677


mg	Price
10	online
50	online

Risdiplam

RG7916; RO7034067

[1825352-65-5]
Purity: 99%

Soluble in 0.1N HCl (aq)
C22H23N7O MW: 401.46



Biological activity

Risdiplam is a selective survival of motor neuron-2 (SMN2) gene splicing modifier (EC1.5x value of 4 nM).

Axon 3093


mg	Price
5	online
25	online

Risperidone

R 64766

[106266-06-2]
Purity: 99%

Soluble in DMSO
C23H27FN4O2 MW: 410.48



Biological activity

5-HT2 and dopamine D2 antagonist with high affinity for 5-HT7 receptors; an atypical antipsychotic in the treatment of psychotic disorders with negative and positive symptomatology

Axon 1454


mg	Price
10	online
50	online

RITA

NSC 652287

[213261-59-7]
Purity: 98%

Soluble in DMSO
C14H12O3S2 MW: 292.37



Axon 2009

mg	Price
10	online
50	online


Biological activity
Small molecule p53 activator; MDM2 inhibitor

Ritodrine hydrochloride

DU 21220

[23239-51-2]
Purity: 99%

Soluble in water, DMSO and EtOH
C17H21NO3.HCl MW: 323.81



Axon 3647


mg	Price
50	online

Biological activity
Ritodrine hydrochloride is a selective β_2 adrenoceptor agonist. Tocolytic agent.

Ritonavir

ABT-538

[155213-67-5]
Purity: 99%
Optically pure
Soluble in DMSO
C37H48N6O5S2 MW: 720.94



Axon 3139


mg	Price
10	online
50	online

Biological activity
Ritonavir is an inhibitor of HIV-1 protease.
Ritonavir in combination with Lopinavir (Axon 3138) in a 1 to 4 ratio (dosage information) is marketed as Kaletra.

Rivaroxaban

BAY 59-7939

[366789-02-8]
Purity: 99%
Optically pure
Soluble in DMSO
C19H18ClN3O5S MW: 435.88



Axon 3175


mg	Price
10	online
50	online

Biological activity
Rivaroxaban is a highly potent, selective and oral direct FXa inhibitor with an excellent in vitro (IC50 value of 0.7 nM) and in vivo efficacy and a good pharmacokinetic profile. Antithrombotic agent.

Rivastigmine tartrate

SDZ ENA 713

[129101-54-8]
Purity: 99%
Optically pure
Soluble in water and DMSO
C14H22N2O6.C4H6O6 MW: 400.42



Axon 3167

mg	Price
50	online
250	online

Biological activity
Rivastigmine tartrate is a centrally selective acetylcholinesterase inhibitor (Ki value of 1-2 μ M).

Rivoceranib mesylate

See Apatinib


Axon 2849

Page 239

RKI 1447

[1342278-01-6]
Purity: 99%

Soluble in DMSO
C16H14N4O2S MW: 326.37



Axon 2229

mg	Price
10	online
50	online

Biological activity
Potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer (IC50 values 14.5 and 6.2 nM for ROCK 1 and 2 respectively). RKI 1447 is a Type 1 inhibitor that binds both the hinge region and the DFG motif of the ROCK ATP binding site.

RLY-1971


See GDC-1971

Axon 3767

Page 500

RMC-4550 hydrochloride

[N.A.]
Purity: 99%
99% d.e.
Soluble in DMSO
C21H27Cl2N4O2.HCl MW: 473.82



Axon 3868

mg	Price
5	online
10	online


Biological activity
RMC-4550 is a potent, selective and orally available small molecule allosteric inhibitor of SHP2, acting by stabilizing the SHP2 protein in an inactive conformation that is unable to transmit cell growth signals. It inhibits purified, activated full length human SHP2 with an IC50 of 1.6 nM, and has cellular IC50 of 39 nM in PC9 cells with a pERK readout. RMC-4550 has no detectable inhibitory activity up to 10 μ M against the catalytic domain of SHP2, a panel of 14 additional protein phosphatases, and a panel of 468 protein kinases. RMC-4450 as a single agent was found to attenuate signal transduction through the RAS-MAP kinase cascade, reduce tumor growth and cause tumor cell death in preclinical xenograft studies of human tumors carrying select mutations in the RAS-MAP kinase pathway.

Source Information: Sold in collaboration with Chemietek

RN486

[1242156-23-5]
Purity: 99%

Soluble in DMSO
C35H35FN6O3 MW: 606.69



Axon 3869

mg	Price
5	online
10	online

Biological activity
RN486 is a selective, and reversible inhibitor of Bruton's tyrosine kinase (BTK), binding to the enzyme potently and competitively with an in vitro IC50 of 4.0 nM (enzymatic assay), and 0.3 nM (FRET binding assay). Highly selective over almost all other kinases including Syk and JAK, two validated RA (Rheumatoid Arthritis) targets. It

exhibits an excellent pharmacokinetic profile, and displayed strong functional as well as disease-related activities by inhibiting immune responses mediated by two important immunoreceptors, BCR and FcR, in both human cells and rodents, producing dose dependent efficacy in both CIA and AIA, with evidence for substantial efficacy in combination with low-dose methotrexate.

Source Information: Sold in collaboration with Chemietek

RNH-6270

See Olmesartan


Axon 3105

Page 732

RO 04-6790 hydrochloride

[1197333-95-1]
Purity: 98%

Soluble in 0.1N HCl(aq)
C₁₂H₁₆N₆O₂S₂HCl MW: 381.28



Axon 1330

mg	Price
10	online
50	online


Biological activity

Potent and selective serotonin 5-HT₆ receptor antagonist

RO-0711401

[714971-87-6]
Purity: 99%

Soluble in DMSO
C₁₈H₁₁F₃N₂O₃ MW: 360.29



Axon 3422

mg	Price
5	online
25	online

Biological activity

RO-0711401 is a potent and orally available positive allosteric modulator (PAM) of the mGlu₁ receptor with an IC₅₀ value of 56 nM.

RO7589831

See VVD-214 **Recent Addition**

Axon 4271

Page 979

Ro 09-1978

See Capecitabine

Axon 3460

Page 342

Ro 11-1163

See Moclobemide

Axon 3629

Page 676

Ro18-0647

See Orlistat


Axon 3500

Page 736

RO 25-6981 hydrochloride

[919289-58-0]
Purity: 99%
99% ee

Soluble in water and DMSO
C₂₂H₂₉NO₂.HCl MW: 375.93



Axon 1314


mg	Price
10	online
50	online

Biological activity

Potent and selective antagonist of NMDA glutamate receptors containing the NR2B subunit; Optimal salt form, which is more water soluble than its maleate

RO 25-6981 maleate

[1312991-76-6]
Purity: 99%
99.5% de
Soluble in water and DMSO
C₂₂H₂₉NO₂.C₄H₄O₄ MW: 455.54



Axon 2601

mg	Price
10	online
50	online

Biological activity

Potent and selective antagonist of NMDA glutamate receptors containing the NR2B subunit; The HCl salt of RO 25-6981 is available as well (Axon 1314)

RO 26-9228

See BXL 628

Axon 1676


Page 336

RO 28-0450

RO 28-1675, (±)-

[300352-96-9]
Purity: 98%

Soluble in DMSO
C₁₈H₂₂N₂O₃S₂ MW: 378.51



Axon 1134

mg	Price
10	online
50	online

Biological activity

Glucokinase GK activator; its more active (R)-enantiomer is RO-28-1675 (Axon 1356)

RO 28-0450, (R)-

See RO 28-1675

Axon 1356

Page 825

RO 28-0450, (S)-

See RO 28-1674


Axon 1355

Page 824

RO 28-1674

RO 28-0450, (S)-

[599164-57-5]
Purity: 99%
99% ee
No solubility data
C₁₈H₂₂N₂O₃S₂ MW: 378.51



Axon 1355

mg	Price
5	online
25	online


Biological activity

Glucokinase GK activator; less active S-enantiomer of RO-28-0450 (Axon 1134), in comparison with R-enantiomer, RO 28-1675 (Axon 1356)

RO 28-1675

RO 28-0450, (R)-

[300353-13-3]
Purity: 99%
99% ee
Soluble in DMSO
C18H22N2O3S2 MW: 378.51



Axon 1356

mg	Price
2	online
5	online

Biological activity

Glucokinase GK activator; more active R-enantiomer of RO-28-0450 (Axon 1134) in comparison with S-enantiomer, RO 28-1674 (Axon 1355)

RO 28-1675, (±)-

See RO 28-0450

Axon 1134

Page 824

Ro 31-6045

See Bisindolylmaleimide V

Axon 3940

Page 310

RO 40-6055

See AM 580

Axon 2948

Page 222

RO5503781


See RG-7388

Axon 4035

Page 815

RO 60-0175

[169675-09-6]
Purity: 99%
>98% ee
Soluble in DMSO
C11H12ClFN2.C4H4O4
MW: 342.75



Axon 1118

mg	Price
10	online
50	online


Biological activity

Putative 5-HT2C agonist; selectivity on 2C is under argument

RO 61-8048

[199666-03-0]
Purity: 99%

Soluble in DMSO
C17H15N3O6S2 MW: 421.45



Axon 2139

mg	Price
10	online
50	online

Biological activity

Potent, selective and reversible inhibitor of kynurenine-3-monooxygenase (KMO, or kynurenine hydroxylase) activity (IC50: 37 nM); cell-permeable and competitive

RO 67-31898

See Netupitant


Axon 2499

Page 698

RO 3306

[872573-93-8]
Purity: 99%

Soluble in DMSO
C18H13N3OS2 MW: 351.45



Axon 1530

mg	Price
5	online
25	online

Biological activity

Selective CDK 1 inhibitor (Ki = 35 nM and 110 nM for Cdk1/B1 and Cdk1/A, respectively), which induces cell cycle arrest and actively enhances downstream p53 signaling to promote apoptosis in AML cell lines

Ro 40-7592


See Tolcapone

Axon 3993

Page 935

RO 4929097

[847925-91-1]
Purity: 98%
Optically pure
Soluble in DMSO
C22H20F5N3O3 MW: 469.40



Axon 2521

mg	Price
5	online
25	online

Biological activity

Potent γ -secretase inhibitor (GSI; IC50 value 4 nM) targeting Notch signaling with in vivo efficacy in various tumor cells, showing >100-fold selectivity with respect to 75 other proteins of various types (receptors, ion channels, and enzymes). Treatment of HEK293 cells with RO4929097 caused a dose-dependent decrease in the amount of A β peptides secreted into the culture medium (EC50 value 14 nM), and a strong dose-dependent inhibition of Notch processing in a Notch cell-based reporter assay (EC

RO 5185426

See PLX 4032

Axon 1624

Page 783

RO 5-2092

See Demoxepam

Axon 3406

Page 419

RO 5212773

See EPPTB

Axon 2419

Page 463

Roblitinib


FGF 401; NVP-FGF401

[1708971-55-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C25H30N8O4 MW: 506.56

Axon 2953

mg	Price
5	online
25	online


Biological activity


Roblitinib is a first-in-class, highly selective and potent FGFR4 inhibitor with an IC50 value of 1.1 nM. Roblitinib binds in a reversible covalent manner to the FGFR4 kinase domain. Developed for hepatocellular carcinoma and currently undergoing clinical evaluation for the treatment of FGFR4 and β -klotho positive solid tumors.

Rofecoxib

MK966; Vioxx

[162011-90-7]
Purity: 99%

Soluble in DMSO
C17H14O4S MW: 314.36


Biological activity


Rofecoxib is an orally active cyclooxygenase-2 (COX-2) inhibitor with IC50 values of 26 nM and 18 nM in human osteosarcoma cells and Chinese hamster ovary cells expressing human COX-2, respectively. Rofecoxib exhibits a 1000-fold selectivity for the inhibition of COX-2 compared with the inhibition of COX-1 activity.

Roflumilast

Daxas; BY 217; BYK 20869; B 9302-107

[162401-32-3]
Purity: 100%

Soluble in DMSO
C17H14Cl2F2N2O3 MW: 403.21



Biological activity

First specific PDE4 inhibitor (IC50 value 0.2 - 4.3 nM for inhibition of PDE4 subtypes) licensed for the treatment of COPD.

Rolipram

[61413-54-5]
Purity: 98%

Soluble in DMSO and Ethanol
C16H21NO3 MW: 275.34


Biological activity

PDE4 inhibitor, as an anti-inflammatory drug; also with rich CNS profile, such as antidepressive, antipsychotic effects and/or neuroprotection

Rolipram, (R)-(-)-

[85416-75-7]

Axon 3376

mg	Price
50	online

Axon 2352

mg	Price
10	online
50	online


Axon 1212

mg	Price
10	online
50	online

Axon 1229

mg	Price
----	-------

Purity: 99%
>98% ee
Soluble in DMSO and Ethanol
C16H21NO3 MW: 275.34



10	online
50	online


Biological activity

PDE4 inhibitor, more active R-enantiomer of Rolipram (Axon 1212) in comparison with (S)-(+)-Rolipram (Axon 1432). Rolipram is an anti-inflammatory drug; also with rich CNS profile, such as antidepressive, antipsychotic effects and/or neuroprotection

Rolipram, (S)-(+)-

[85416-73-5]
Purity: 99%

Soluble in DMSO and Ethanol
C16H21NO3 MW: 275.34


Axon 1432

mg	Price
10	online
50	online

Biological activity


PDE4 inhibitor, less active S-enantiomer of Rolipram (Axon 1212) in comparison with the opposite (R)-(-)-Rolipram (Axon 1229)

Rolofylline

KW 3902

[136199-02-5]
Purity: 99%

Soluble in DMSO
C20H28N4O2 MW: 356.46


Axon 1603

mg	Price
5	online
25	online

Biological activity


Potent and selective adenosine A1 receptor antagonist, with Ki values to be 0.19 nM and 170 nM for A1 and A2 receptors respectively

Rolofylline metabolite M1-cis

Compound 4

[161167-65-3]
Purity: 98%

Soluble in DMSO and Ethanol
C20H28N4O3 MW: 372.46


Axon 1852

mg	Price
2	online
5	online

Biological activity


Active metabolite of Rolofylline (Axon 1603), a potent and selective adenosine A1 receptor antagonist

Rolofylline metabolite M1-trans

Compound 3

[160943-06-6]
Purity: 99%

Soluble in DMSO
C20H28N4O3 MW: 372.46


Axon 1851

mg	Price
2	online
5	online

Biological activity


Active metabolite of Rolofylline (Axon 1603), a potent and selective adenosine A1 receptor antagonist

Roluperidone

CYR101; MT210; MIN101

[359625-79-9]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C22H23FN2O2 MW: 366.43



Axon 3859

mg	Price
10	online
50	online


Biological activity

Roluperidone is a sigma-2 and 5-HT2A receptor antagonist with K_i values of 8.19 nM and 7.53 nM, respectively. Also, Roluperidone shows binding affinity for α_1 -adrenergic receptors but low or no affinity for muscarinic, cholinergic, and histaminergic receptors.

Ropidoxuridine

IPdR; 1-(2-Deoxy- β -D-ribofuranosyl)-5-iodo-2-pyrimidinone

[93265-81-7]
Purity: 99%
Optically pure
Soluble in water and DMSO
C9H11IN2O4 MW: 338.10



Axon 3953

mg	Price
10	online
50	online


Biological activity

Ropidoxuridine is an orally available, halogenated thymidine (TdR) analog and is a potential radiosensitizer for use in human tumors. Ropidoxuridine is a prodrug that is efficiently converted to IUdR (5-iodo-2'-deoxyuridine), an intravenous radiosensitizer by a hepatic aldehyde oxidase.

Ropinirole hydrochloride

[91374-20-8]
Purity: 98%

Soluble in water and DMSO
C16H24N2O.HCl MW: 296.84



Axon 1514

mg	Price
10	online
50	online


Biological activity

A non-ergoline D2, D3, and D4 dopamine receptor agonist with highest affinity for D3; with moderate in vitro affinity for the opioid receptors

Roquinimex

[84088-42-6]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C18H16N2O3 MW: 308.33



Axon 2868

mg	Price
10	online
50	online

Biological activity


Roquinimex has been demonstrated to have immunomodulating activity and antitumor effects. Effective stimulator of NK cells. Antiangiogenic.

Rosiglitazone

BRL 49653; Rezult; Rosiglitazone; TDZ 01

[122320-73-4]
Purity: 98%

Soluble in DMSO
C18H19N3O3S MW: 357.43



Axon 2443

mg	Price
10	online
50	online

Biological activity

High affinity PPAR γ agonist (K_d value 7 nM). BRL 49653 is an antidiabetic drug and insulin sensitizer that also promotes differentiation of C3H10T1/2 stem cells to adipocytes.

Rosiglitazone

See Rosiglitazone


Axon 2443

Page 830

Rosuvastatin calcium

S4522; ZD4522

[147098-20-2]
Purity: 99%
Optically pure
Soluble in DMSO
C22H27FN3O6S.0.5Ca MW: 500.57



Axon 3444

mg	Price
10	online
50	online


Biological activity

Rosuvastatin calcium is a HMG-CoA reductase inhibitor with an IC_{50} value of 5.4 nM.

Rotigotine

N 0923

[99755-59-6]
Purity: 99%
99% ee
Soluble in DMSO
C19H25NOS MW: 315.47



Axon 1040

mg	Price
10	online
50	online

Biological activity

Dopamine receptor D2 and D3 agonist, more active enantiomer of N-0437 (Axon 1038) vs opposite (R)-enantiomer N-0924 (Axon 1039)

Roxadustat

See FG-4592

Axon 2588


Page 480

Roxatidine acetate hydrochloride

TZU-0460; HOE 760

[93793-83-0]
Purity: 99%

Soluble in water and DMSO



Axon 3129

mg	Price
50	online
250	online

C19H29CIN2O4 MW: 384.90


Biological activity

Roxatidine acetate hydrochloride is a histamine H2 receptor antagonist.

RP 001 hydrochloride

[N.A.]
Purity: 99%

Soluble in DMSO
C24H24N4O4.HCl MW: 468.93



Axon 1947

mg	Price
5	online
25	online


Biological activity

A picomolar short-acting sphingosine-1-phosphate 1 (S1P1) receptor selective agonist (EC50: 9 pM)

RP-6306

Lunersertib

[2719793-90-3]
Purity: 99%
100% e.e.
Soluble in 0.1N HCl(aq), DMSO and EtOH
C18H20N4O2 MW: 324.38



Axon 3668


mg	Price
2	online
5	online

Biological activity

RP-6306 is a first-in-class, potent, selective, and orally bioavailable PKMYT1 inhibitor with IC50 values of 0.014 μM and 0.002 μM in cell and nanoBRET assays, respectively. RP-6306 is the active (aS)-atropisomer of the racemate. Its opposite atropisomer, (aR)-RP-6306 (Axon 3759), is also available.

RP-6306, (aR)-

[2719793-91-4]
Purity: 99%
98% e.e.
Soluble in DMSO and EtOH
C18H20N4O2 MW: 324.38



Axon 3759


mg	Price
2	online
5	online

Biological activity

(aR)-RP-6306 is the opposite atropisomer or (R)-enantiomer of RP-6306 (Axon 3668), which is a PKMYT1 inhibitor.

RP-6685

[2832047-80-8]
Purity: 99%
Soluble in DMSO and EtOH
C22H14F7N5O MW: 497.37



Axon 4003

mg	Price
2	online
5	online


Biological activity

RP-6685 is a potent, selective, and orally bioavailable Polθ inhibitor (IC50 value of 5.84 nM) that showed in vivo efficacy in an HCT116 BRCA2-/- mouse tumor xenograft model.

RP 70676

[136609-26-2]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C25H28N4S MW: 416.58



Axon 3554

mg	Price
5	online
25	online

Biological activity

RP 70676 is a potent and orally bioavailable inhibitor of acyl-CoA:cholesterol O-acyl transferase (ACAT) with IC50 values of 25 and 44 nM for rat and rabbit ACAT, respectively.

RP73401

See Piclamilast

Axon 4013

Page 776

RP73401

See Alofanib

Axon 2930

Page 218


RPT835

See Alofanib

RQ 00203078

[1254205-52-1]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C21H13ClF6N2O5S MW: 554.85



Axon 2498

mg	Price
10	online
50	online

Biological activity

Selective, potent, and orally active TRPM8 antagonist (IC50 value 8.3 nM) that demonstrated excellent in vivo activity in a dose dependent manner with an ED50 value of 0.65 mg/kg in the icilin-induced wet-dog shakes model in rats after oral administration.

RR82 hydrochloride

See Pyridostatin hydrochloride

Axon 4076

Page 799

RS 25259-197

See Palonosetron hydrochloride


Axon 3101

Page 746

RS 25344

[152814-89-6]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO, EtOH
C19H13N5O4 MW: 375.34



Axon 4002

mg	Price
5	online
25	online


Biological activity

RS 25344 is a selective phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 0.28 nM.

RS504393

[300816-15-3]
Purity: 99%

Soluble in DMSO and EtOH
C25H27N3O3 MW: 417.50



Biological activity


RS504393 is a selective CCR2 antagonist with an IC50 value of 89 nM. Moreover, RS504393 blocks MCP-1 and MCP-3 signaling through CCR2.

RS-1

RAD51-Stimulatory Compound-1

[312756-74-4]
Purity: 99%

Soluble in DMSO
C20H16Br2N2O3S MW: 524.23



Biological activity

Enhancer of CRISPR-based genome editing and homology-directed repair (HDR; RAD51). RS-1 can enhance filament stability, and stimulated hRAD51-mediated homologous strand assimilation (D-loop) activity by at least 5- to 11-fold. RS-1 acts as an allosteric regulator that locks hRAD51 in an active conformation and does so without influencing the active site for ATP hydrolysis. Treatment with RS-1 promoted significant antitumor responses in a mouse model.

RS43285

See Ranolazine

RS61443

See Mycophenolate mofetil

RSK inhibitor Fmk


See FMK

RSL3

1S,3R-RSL3

[1219810-16-8]
Purity: 99%

99% d.e.
Soluble in DMSO and EtOH
C23H21ClN2O5 MW: 440.88



Axon 4167

mg	Price
5	online
25	online

Axon 2584

mg	Price
10	online
50	online

Axon 3507

Page 807

Axon 3498

Page 685

Axon 1848

Page 488

Axon 3611


mg	Price
5	online
25	online

Biological activity

(1S,3R)-RSL3 is a GPX4 inhibitor and ferroptosis inducer. (1S,3R)-RSL3 exhibited selective lethality against cells with HRASV12. A negative control (1R, 3R)-RSL3 is available as Axon 3617.

RSL3,1R,3R-

[1219810-15-7]
Purity: 99%
100% d.e.
Soluble in DMSO
C23H21ClN2O5 MW: 440.88



Biological activity

1R,3R-RSL3 is a negative control compound of the active diastereomer 1S,3R-RSL3, which is available as Axon 3611.

RSL3, 1S,3R-

See RSL3

RTA 401

See CDDO


RTA 402

See CDDO-Me

RTA 408

Omaveloxolone

[1474034-05-3]
Purity: 98%
Optically pure
Soluble in DMSO
C33H44F2N2O3 MW: 554.71




Biological activity

Synthetic triterpenoid that potently activates the antioxidative transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) and inhibits the proinflammatory transcription factor NF-κB at low concentrations. RTA 408 dose-dependently reduced NO concentrations (IC50 value 4.4 nM). At higher concentrations, RTA 408 inhibited tumor cell growth (GI50 value 260 nM) and increased caspase activity in tumor cell lines, but not in normal primary human cells. RTA 408 is a highly effective mitigator of steady state hematopoiesis and shows normalization of the frequency of hematopoietic stem and progenitor cells in mice after administration of lethal, myeloablative doses of whole-body irradiation.

RU 24213

[67383-44-2]
Purity: 98%

No solubility data
C19H25NO.HCl MW: 319.87



Biological activity

Axon 3617

mg	Price
5	online
25	online

Axon 3611

Page 833

Axon 1950

Page 354

Axon 1772

Page 354

Axon 2497

mg	Price
2	online
5	online

Axon 1003

mg	Price
10	online
50	online

Dopamine D2 receptor agonist; also kappa opioid receptor antagonist

RU 38486

See Mifepristone

Axon 1502

Page 655

RU42633

See Metapristone


Axon 3268

Page 646

RU 42698

Mifepristone, Hydroxy-

[105012-15-5]
Purity: 99%
optically pure
Soluble in DMSO
C29H35NO3 MW: 445.59



Axon 1558

mg	Price
2	online
5	online

Biological activity

Metabolite of Mifepristone (Axon 1502); a useful tool in researching mifepristone action

RU 486

See Mifepristone


Axon 1502

Page 655

RU 58841

[154992-24-2]
Purity: 99%

Soluble in DMSO
C17H18F3N3O3 MW: 369.34



Axon 1680

mg	Price
5	online
25	online

Biological activity

A specific androgen receptor antagonist or anti-androgen; RU 58841 has a dramatic effect on hair regrowth

RU-0204277

See LRE1

Axon 2664

Page 623

RU-23908

See Nilutamide


Axon 3249

Page 704

RU-SKI 43 hydrochloride

[1043797-53-0] (parent)
Purity: 99%

Soluble in DMSO
C22H30N2O2S.HCl MW: 423.01



Axon 2035

mg	Price
5	online
25	online

Biological activity

Hedgehog acyltransferase (HHAT) inhibitor in vitro and in cells; it blocks sonic hedgehog (Shh) signaling significantly

Ruboxistaurin

See LY 333531 hydrochloride

Axon 2362

Page 629

Ruboxistaurin

See LY 333531 mesylate

Axon 1401

Page 627

Rucaparib

See AG 014699


Axon 1529

Page 213

Rucaparib camsylate

[1859053-21-6]
Purity: 99%

Soluble in DMSO
C19H18FN3O.C10H16O4S MW:
555.66



Axon 3113

mg	Price
10	online
50	online

Biological activity


A PARP 1 inhibitor with potential chemosensitizing, radiosensitizing and antineoplastic activities; selectively binds to PARP1 (Ki=1.4 nM) and inhibits PARP1-mediated DNA repair, thereby enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. Also available as the phosphate salt AG 014699 (Axon 1529).

Rupatadine fumarate

UR12592

[182349-12-8]
Purity: 99%

Soluble in DMSO and EtOH
C26H26ClN3.C4H4O4 MW: 532.03



Axon 4043

mg	Price
10	online
50	online

Biological activity

Rupatadine fumarate is a potent, orally active dual antagonist of histamine H1 and platelet-activating factor (PAF) with Ki values of 102 nM and 550 nM, respectively.

Ruprintrivir

See AG 7088

Axon 1571

Page 213

Ruxolitinib


INCB 018424 phosphate

[1092939-17-7]

Axon 1598

mg	Price
----	-------

Purity: 99%
98% ee
Soluble in DMSO and Ethanol
C17H18N6.H3O4P MW: 404.36



2 online
5 online

Biological activity

An orally bioavailable, potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively; selectivity >100 fold for a wide range of other kinases. It acts by blocking the JAK/STAT pathway

RV521

See *Sisunatovir*

Axon 4085

Page 868

RVX 000222

See *RVX 208*


Axon 2245

Page 837

RVX 208

RVX 000222

[1044870-39-4]
Purity: 100%



Soluble in DMSO
C20H22N2O5 MW: 370.40

mg Price
2 online
10 online

Biological activity

BET bromodomain inhibitor specific for second bromodomains (BD2s), currently in phase I/II clinical trials for the treatment of cardiovascular diseases (IC50 values of 87 and 0.51 μM derived from the AlphaScreen data on BRD3 BD1 and BD2 resp.). *RVX 208* preferentially binds to the second bromodomain found on *BET* proteins, exhibiting selectivity over BD1 of up to 23-fold with a KD of 195 nM against BD2 and 4 μM against BD1 of BRD3. *RVX 208* binds to the acetyl-lysine binding pocket in a peptide-competitive manner, and leads to an increase of plasma levels of the high-density lipid protein ApoA1, which has emerged as a promising approach for the treatment of atherosclerosis.

4SC-101

See *Vidofludimus*

Axon 2377

Page 968

S16257, (+)-

See *Ivabradine hydrochloride*

Axon 3495


Page 574

S3I 201

NSC 74859

[501919-59-1]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C16H15NO7S MW: 365.36



mg Price
10 online
50 online


Biological activity

Potent, cellular *STAT3* inhibitor that inhibits *Stat3* *Stat3* complex formation and *Stat3* DNA-binding and transcriptional activities (IC50 value 86 μM for in vitro *Stat3*-*Stat3*:DNA disruption). *S3I 201* inhibits growth and induces apoptosis preferentially in tumor cells that contain persistently activated *Stat3*. Additionally, *S3I 201* inhibits the expression of the *Stat3*-regulated genes encoding cyclin D1, *Bcl-xL*, and *survivin* and inhibits the growth of human breast tumors in vivo. *S3I 201* showed cytotoxic activity against a wide variety of cancer cell lines (IC50 values ranging from 37.9 to 82.6 μM) through inhibition of the reductases *P5*, protein disulfide isomerase (*PDI*), thiol-disulfide oxidoreductase *Erp57*, and/or *Trx*.

S3QEL 2

[890888-12-7]
Purity: 99%

Soluble in DMSO
C19H25N5 MW: 323.44



Axon 2544
mg Price
10 online
50 online


Biological activity

Suppressor of superoxide production from mitochondrial complex III (IC50 value 1.7 μM against superoxide production mediated by the outer Q-binding site of complex III (site IIIQo)). *S3QEL-2* protects against ROS-induced, JNK-mediated cell stress in pancreatic β-cells, and strongly mitigates the oxidative stress-induced apoptosis that limits the yield of functional β-cells from intact islets. *S3QEL-2* modulates *HIF-1α* activation without directly affecting metabolism.

S 12

[258264-62-9]
Purity: 99%

Soluble in DMSO
C17H12BrNO5 MW: 390.18



Axon 2165
mg Price
10 online
50 online

Biological activity

Survivin inhibitor. Alters spindle formation, causing mitotic arrest (by disrupting metaphase at the G2/M stage) and cell death. *S 12* inhibits tumor growth in vitro and in vivo, and effectively inhibits cell proliferation and tumor growth independently of p53 status.

S 1027 dihydrochloride

See SGI 1027 dihydrochloride

Axon 2347

Page 864

S4522


See Rosuvastatin calcium

Axon 3444

Page 830

S 5751

[209268-36-0]
Purity: 99%
optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C25H31NO4S MW: 441.58



Axon 1605

mg	Price
2	online
5	online

Biological activity

Potent, selective and orally active prostaglandin D2 (PGD2) receptor DP antagonist, K_i values to be 1.6 and 24.2 nM for human DP and TP receptors

S9490


See Perindopril erbumine

Axon 3492

Page 759

S 9947

[332378-43-5]
Purity: 99%
Soluble in DMSO
C29H27N3O3 MW: 465.54



Axon 1657


mg	Price
10	online
50	online

Biological activity

Kv1.5 or IKur channel blocker, which suppresses both cloned (Kv1.5) and native (IKur) cardiac potassium current

S 14506

[135722-25-7]
Purity: 98%
Soluble in DMSO and Ethanol
C24H26FN3O2 MW: 407.48



Axon 1088


mg	Price
5	online
10	online

Biological activity

Very potent and selective 5-HT1A agonist

S 14506, desmethyl-

[135722-26-8]
Purity: 98%
No solubility data
C23H24FN3O2 MW: 393.45



Axon 1089

mg	Price
10	online
50	online

Biological activity

Precursor for labeling the 5-HT1A agonist, S14506, for PET study

S 18986

[175340-20-2]
Purity: 99%
>99% ee
Soluble in DMSO
C10H12N2O2S MW: 224.28



Axon 1788

mg	Price
5	online
25	online

Biological activity

Positive allosteric modulator of AMPA receptor with cognitive-enhancing effects; neuroprotective; long-acting and with good oral availability

S-(2-Boronoethyl)-L-cysteine hydrochloride

See BEC hydrochloride

Axon 2373

Page 296

S26308

See Imiquimod

Axon 3107

Page 563

S-3013


See Varespladib methyl

Axon 4032

Page 963

S63845

[1799633-27-4]
Purity: 99%
99% e.e.
Soluble in DMSO
C39H37ClF4N6O6S MW: 829.26



Axon 3723

mg	Price
5	online
10	online

Biological activity

S63845 is the first high affinity MCL-1 inhibitor with in vivo activity, binding to the BH3 groove of human MCL-1 with a K_D value of 0.19 nM, highly selective against other BCL family proteins BCL-2 ($K_i > 10,000$ nM) and BCL-XL ($K_i > 10,000$ nM) (ref 1). S63845 showed the clear-on-target activity killing Mcl-1-dependent cancer cells, including multiple myeloma, leukemia and lymphoma cells. Demonstrated potent in vivo antitumor activity, with an acceptable safety margin, as a single agent in several cancer types.

Source Information: Sold in collaboration with Chemietek

Sacubitril tris salt


See AHU-377 tris salt

Axon 3856

Page 215

SA-15-P

[852846-00-5]
Purity: 99%
Soluble in DMSO and EtOH
C26H24N2O4 MW: 428.48



Axon 3980

mg	Price
10	online
50	online


Biological activity

SA-15-P is a first-in-class inhibitor of lymphocyte activation gene 3 (LAG-3) with IC50 values of 4.21 and 6.52 μ M for LAG-3/MHCII and LAG-3/FGL1 interactions, respectively.

SA 4503

[165377-44-6]
Purity: 99%

Soluble in water
C23H32N2O2.2HCl MW: 441.43



Axon 1767

mg Price

10 online

50 online

Biological activity


Potent and selective sigma-1 receptor agonist; showing high affinity (IC50=17.4 nM) for sigma-1 and 100 fold less affinity for sigma-2

Sabizabulin

VERU111

[1332881-26-1]
Purity: 99%

Soluble in DMSO
C21H19N3O4 MW: 377.39



Axon 3804

mg Price

5 online

25 online

Biological activity

Sabizabulin is an orally bioavailable and highly potent inhibitor of tubulin polymerization with an average IC50 value of 3.8 nM (five tested cancer cell lines).

SAHA

See Vorinostat

Axon 3114

Page 972

Salen-Mn

See EUK 134


Axon 2292

Page 470

Salermide

[1105698-15-4]
Purity: 99%

Soluble in DMSO
C26H22N2O2 MW: 394.47



Axon 2704

mg Price

10 online


50 online

Biological activity

Salermide is a reverse amide with a potent in vitro inhibitory effect on Sirt1 and Sirt2. Salermide was well tolerated by mice at concentrations up to 100 μ M and prompted tumour-specific cell death in a wide range of human cancer cell lines. It induces massive apoptosis in cancer but not in non-transformed cultured cells. The apoptotic effect of Salermide is in part because of the reactivation of proapoptotic genes that are epigenetically repressed by Sirt1 exclusively in cancer cells.

Salubrinol Recent Addition

[405060-95-9]
Purity: 98%
98% e.e.
Soluble in DMSO
C21H17Cl3N4OS MW: 479.81



Axon 4249

mg Price

10 online

50 online

Biological activity

Salubrinol is a selective inhibitor of cellular complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit α (eIF2 α). Salubrinol also blocks eIF2 α dephosphorylation mediated by a herpes simplex virus protein and inhibits viral repli

Samuraciclib

See CT7001


Axon 3756

Page 397

Sandalore

[65113-99-7]
Purity: 97%

Soluble in DMSO and EtOH
C14H26O MW: 210.36



Axon 3551

mg Price

10 online

Biological activity


Sandalore, a synthetic sandalwood odorant, is a selective agonist of the olfactory receptor OR2AT4, thereby inducing the increase of the intracellular Ca²⁺ and cAMP levels in human keratinocytes. Specific stimulation of OR2AT4 by Sandalore prolongs human hair growth ex vivo by decreasing apoptosis and increasing production of the anagen-prolonging growth factor IGF-1.

Santacruzamate A

CAY 10683

[1477949-42-0]
Purity: 99%

Soluble in DMSO
C15H22N2O3 MW: 278.35



Axon 2495

mg Price

10 online

50 online

Biological activity

Picomolar level Class I HDAC2 inhibitor (IC50 value 0.11 nM) with relatively little inhibition of HDAC4 or HDAC6 (IC50 values >1000 nM and 433 nM, respectively). Cytotoxin with several structural features in common with Vorinostat, a clinically approved HDAC inhibitor used to treat refractory cutaneous T-cell lymphoma. Note: Potency of synthetic Santacruzamate A is questioned due to lack of cytotoxicity tested in two cancer cell lines

Sapresta

See Arandipine

Axon 3013

Page 246

SAOA

See BML-210

Axon 3399

Page 314

SAR245408

See XL-147

Axon 4031

Page 993

SAR245409


See XL-765

Axon 4009

Page 994

SAR405

[1523406-39-4]
Purity: 98%
>99% ee
Soluble in DMSO
C19H21ClF3N5O2 MW: 443.85



Axon 2716

mg	Price
2	online
5	online


Biological activity

SAR405 is a potent kinase inhibitor of PI3K class III (PIK3C3), highly specific on VPS34 (with IC50 value of 1 nM and Kd value of 1.5 nM for PIK3C3/VPS34). This compound has an exquisite protein and lipid kinase selectivity profile that is explained by its unique binding mode and molecular interactions within the ATP binding cleft of human Vps34. Inhibition of Vps34 kinase activity by SAR405 affects both late endosome-lysosome compartments and prevents autophagy. Concomitant inhibition of Vps34 and mTOR, with SAR405 and mTOR inhibitor everolimus, results in synergistic antiproliferative activity in renal tumor cell lines.

SAR405838

MI-77301

[1303607-60-4]
Purity: 98%
Optically pure
Soluble in DMSO
C29H34Cl2FN3O3 MW: 562.50



Axon 2741

mg	Price
5	online
25	online

Biological activity

SAR405838 is an inhibitor of the MDM2-p53 interaction with high specificity over other proteins (Ki value of 0.88 nM). SAR405838 effectively activates wild-type p53 in vitro and in xenograft tumor tissue of leukemia and solid tumors, leading to p53-dependent cell-cycle arrest and/or apoptosis. At well-tolerated dose schedules, SAR405838 achieves either durable tumor regression or complete tumor growth inhibition in mouse xenograft models of SJSA-1 osteosarcoma, RS4;11 acute leukemia, LNCaP prostate cancer, and HCT-116 colon cancer.

SAR439152

See MYK-461

Axon 2683

Page 685

SB-480848

See Darapladib

Axon 3968

Page 410

Saracatinib

See AZD 0530 difumarate


Axon 1456

Page 266

Sardomozide dihydrochloride

CGP48664A; CGP48664 dihydrochloride

[138794-73-7]
Purity: 98%



Soluble in water and DMSO
C11H14N6.2HCl MW: 303.19

Axon 3290

mg	Price
5	online
25	online


Biological activity

Sardomozide dihydrochloride is a potent and selective inhibitor of S-Adenosylmethionine decarboxylase (SAMDC) with an IC50 value of 5 nM.

Saroglitazar magnesium

ZYH1

[1639792-20-3]
Purity: 98%
Optically pure
Soluble in DMSO
C25H28NO4S.0.5Mg MW: 450.71



Axon 3999

mg	Price
2	online
5	online

Biological activity

Saroglitazar magnesium is a potent dual PPAR agonist with predominant PPARα (EC50 value of 0.65 μM) and moderate PPARγ activity (EC50 value of 3 nM). Antidiabetic agent.

Savolitinib dihydrochloride


See Voltinib dihydrochloride

Axon 3864

Page 971

SB-3CT

[292605-14-2]
Purity: 99%



Soluble in DMSO
C15H14O3S2 MW: 306.40

Axon 2370

mg	Price
10	online
50	online


Biological activity

Potent and selective inhibitor of Gelatinases MMP-2 and MMP-9 (Ki values 13.9 nM and 600 nM, respectively). In contrast, the Ki values of SB-3CT against other MMPs (MMP-1, MMP-3, and MMP-7) are in the micromolar range. SB-3CT protects against brain damage and ameliorates neurological outcome after transient focal cerebral ischemia in mice

SB 939

Pracinostat

[929016-96-6]
Purity: 99%



Soluble in DMSO
C20H30N4O2 MW: 358.48

Axon 1777

mg	Price
5	online
25	online

Biological activity

Potent and oral inhibitor of histone deacetylase (HDAC), selective for class I, II and IV HDACs. SB939 shows significant antiproliferative activity against a wide variety of tumor cell lines, with high tumor exposure and efficacy in mouse models of colorectal cancer


SB 202190

[152121-30-7]
Purity: 99%

Axon 1364

mg	Price
10	online

Soluble in DMSO
C20H14FN3O MW: 331.34



50 online


Biological activity

Potent, cell-permeable and selective inhibitor of p38 MAP kinase (MAPK)

SB 203580

[152121-47-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C21H16FN3OS MW: 377.43



Axon 1363

mg Price

10 online

50 online


Biological activity

Potent, cell-permeable and selective inhibitor of p38 MAP kinase (MAPK). Also available as its water-soluble form (Axon 1465)

SB 203580 hydrochloride

[869185-85-3]
Purity: 99%

Soluble in water
C21H16FN3OS.HCl MW: 413.90



Axon 1465

mg Price

5 online

25 online

Biological activity

Potent, cell-permeable and selective inhibitor of p38 MAP kinase (MAPK); water-soluble salt of SB 203580 (Axon 1363)

SB 207266A

See Pibeserod hydrochloride

Axon 1098


Page 776

SB 207499

Cilomilast; Ariflo

[153259-65-5]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C20H25NO4 MW: 343.42



Axon 1592

mg Price

5 online

25 online

Biological activity

Selective and orally active inhibitor of phosphodiesterase-4 (PDE4); a potential agent for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD); a second generation PDE4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo

SB 216641 hydrochloride

[193611-67-5]
Purity: 99%

Soluble in water


Axon 1085

mg Price

10 online

50 online

C28H30N4O4.HCl MW: 523.02




Biological activity

Selective human 5-HT1B antagonist

SB 216763

[280744-09-4]
Purity: 99%

Soluble in DMSO
C19H12Cl2N2O2 MW: 371.22



Axon 1303

mg Price

10 online

50 online


Biological activity

Potent and selective glycogen synthase kinase-3 (GSK-3) inhibitor

SB 242084

[181632-25-7]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C21H19ClN4O2 MW: 394.85



Axon 4092

mg Price

5 online

25 online


Biological activity

Selective and brain penetrant 5-HT2C receptor antagonist.

SB 242084 dihydrochloride

[1049747-87-6]
Purity: 99%

Soluble in water
C21H19ClN4O2.2HCl MW: 467.78



Axon 1745

mg Price

5 online

25 online


Biological activity

Selective and brain penetrant 5-HT2C receptor antagonist

SB-204741

[152239-46-8]
Purity: 99%

Soluble in DMSO and EtOH
C14H14N4OS MW: 286.35



Axon 3990

mg Price

10 online


50 online

Biological activity

SB-204741 is a selective 5-HT2B antagonist with a pKi value of 7.1.

SB 258741 hydrochloride

[201038-58-6]
Purity: 99%
>98% ee
Soluble in water
C19H30N2O2S.HCl MW: 386.98



Axon 1100


mg	Price
5	online
25	online

Biological activity

Serotonin 5-HT7 antagonist

SB 265610

[211096-49-0]
Purity: 99%
Soluble in DMSO
C14H9BrN6O MW: 357.16



Axon 1559


mg	Price
5	online
25	online

Biological activity

Potent chemokine CXCR2 receptor antagonist

SB 268262

[217438-17-0]
Purity: 99%
Soluble in DMSO
C18H15N3O4S2 MW: 401.46



Axon 1145

mg	Price
10	online
50	online


Biological activity

Selective non-peptide CGRP1 antagonist; racemate of (+)-SB-273779

SB 269970 hydrochloride

SB 269970A

[261901-57-9]
Purity: 99%
optically pure
Soluble in water and DMSO
C18H28N2O3S.HCl MW: 388.95



Axon 2183

mg	Price
10	online
50	online

Biological activity

Potent and selective 5-HT7 antagonist (pKi value 8.9 for 5-HT7a) with >50 fold selectivity over a wide range of serotonergic, dopaminergic and adrenergic receptors. Analogue of SB 258741 hydrochloride (Axon 1100). SB-269970 significantly blocked amphetamine and ketamine-induced hyperactivity and reversed amphetamine-induced but not ketamine-induced prepulsed inhibition (PPI) deficits, without changing spontaneous locomotor activity and startle amplitude.

SB 269970A

See SB 269970 hydrochloride

Axon 2183

Page 847

SB 271046 hydrochloride


[209481-24-3]

Axon 1099

mg	Price
----	-------

Purity: 99%

Soluble in DMSO
C20H22ClN3O3S2.HCl MW: 488.45



10	online
50	online

Biological activity


Putative 5-HT6 antagonist

SB 277011A

SB 277011 dihydrochloride

[1226917-67-4]
Purity: 99%

Soluble in water and DMSO
C28H30N4O.2HCl MW: 511.49



Axon 1920

mg	Price
5	online
25	online

Biological activity

Potent, selective and brain penetrating D3 dopamine receptor antagonist; with high affinity for the hD3 receptor (pKi = 7.95) and 100-fold selectivity over the hD2 receptor and over 66 other receptors

SB 277011 dihydrochloride

See SB 277011A


Axon 1920

Page 848

SB 332235

[276702-15-9]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C13H10Cl3N3O4S MW: 410.66



Axon 2593

mg	Price
5	online
25	online


Biological activity

Selective nonpeptide CXCR2 antagonist (IC50 values 9.3 nM and 9.6 μM for CXCR2 and CXCR1, respectively) exhibiting significant anti-inflammatory effects in acute and chronic models of arthritis in the rabbit. SB-332235 significantly reduced levels of proinflammatory mediators in the synovial fluid, including TNF-α, IL-8, PGE2, LTB4, and LTC4. SB-332235 was also found to abolish the GRO/CINC-1 mediated inhibition of C2-ceramide-induced cytochrome c release from mitochondria.

SB 334867

[792173-99-0]
Purity: 99%

Soluble in DMSO
C17H13N5O2 MW: 319.32



Axon 2095


mg	Price
5	online
10	online

Biological activity

First selective orexin type 1 (OX1) receptor antagonist; Its affinity for OX1R is ~50-fold higher than for OX2R

SB4

[100874-08-6]
Purity: 100%



Axon 4165

mg	Price
10	online

Soluble in DMSO and EtOH
C14H10BrNOS MW: 320.20

50 online

Biological activity

SB4 is a potent BMP agonist with an EC50 value of 74 nM. Activation of BMP signaling by SB4 increased the phosphorylation of key second messengers (SMAD-1/5/9) and also increased expression of direct target genes (inhibitors of DNA binding, Id1 and Id3) in canonical BMP signaling.

SB 424323


See Odiparcil

Axon 1536

Page 729

SB 431542

[301836-41-9]
Purity: 99%



Soluble in DMSO
C22H16N4O3 MW: 384.39

Axon 1661

mg Price

5 online

10 online

Biological activity

Potent and selective inhibitor of TGF- β 1 superfamily activin receptor-like kinase (ALK), specifically at ALK5 (IC50: 94 nM) and its relatives ALK4 (IC50: 140 nM) and ALK7; SB431542 inhibits endogenous activin and TGF- β signaling, but has no effect on BMP signaling; a useful tool for studying the role of TGF- β , activin and many cellular processes

SB 497115


See Eltrombopag

Axon 1872

Page 455

SB 505124

[694433-59-5]
Purity: 100%



Soluble in 0.1N HCl(aq) and DMSO
C20H21N3O2 MW: 335.40

Axon 2197

mg Price

5 online


25 online

Biological activity

Selective inhibitor of TGF- β type I receptors ALK4 and ALK5 (IC50 values 129 nM and 47 nM, respectively). SB 505124 also inhibits the closely related ALK7 receptor, but not the BMP activated receptors (ALK1, 2, 3, and 6). It inhibits downstream TGF- β and Activin induced signaling of Smad2, but not BMP induced signaling of Smad1, -5, or -8. Pretreatment of the cells with SB-505124 blocked TGF β -induced cell death but had no effect on TNF α -induced toxicity. Additionally, SB-505124 blocks activation of TGF β induced MAPK pathways but is ineffective when these pathways are induced by EGF.

SB 525334

[356559-20-1]
Purity: 99%



Soluble in DMSO
C21H21N5 MW: 343.42

Axon 2285

mg Price

10 online

50 online

Biological activity


Potent and selective inhibitor of the ALK5 receptor (IC50 value 14.3 nM). SB 525334 is approximately 4-fold less potent as an inhibitor of ALK4, and inactive as an inhibitor of ALK2, ALK3, and ALK6.

In cell-based assays, SB 525334 blocked TGF- β 1-induced phosphorylation and nuclear translocation of Smad2/3 in renal proximal tubule cells and inhibited TGF- β 1-induced increases in plasminogen activator inhibitor-1 (PAI-1) and procollagen alpha1(I) mRNA expression in renal epithelial carcinoma cells.

SB 590885

[405554-55-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C27H27N5O2 MW: 453.54



Axon 2504

mg Price

5 online

25 online


Biological activity

Potent and selective inhibitor of B-Raf kinase (Kd value 0.3 nM for BRAF), devoid of significant activity against a wide panel of enzymes, including p38 α , GSK3 β , and Lck. SB590885 maintains OCT4- Δ PPE-GFP reporter activity and pluripotency gene expression in human ESCs after removal of exogenous KLF2 and NANOG expression, preserving the best colony morphology and proliferation. SB 590885 is frequently used in a combination of five compounds, including inhibitors of MEK, GSK3, BRAF, ROCK, and SRC, which supports the expansion of viable OCT4- Δ PPE-GFP+ human pluripotent cells after exogenous transcription factor expression has been removed.

SB 612111 hydrochloride

[371980-98-2]
Purity: 99%

optically pure
Soluble in DMSO
C24H29Cl2NO.HCl MW: 454.86



Axon 1413

mg Price

2 online

5 online

25 online


Biological activity

Selective NOP receptor antagonist

SB 674042

[483313-22-0]
Purity: 99%

>99% ee
Soluble in DMSO and Ethanol
C24H21FN4O2S MW: 448.51



Axon 2192

mg Price

5 online

25 online


Biological activity

Nonpeptide OX1 selective antagonist (Kd value 3.76 nM) with >100 fold selectivity over the OX2 receptor. SB 674042 displays no significant affinity for a range of serotonergic, dopaminergic, adrenergic and purinergic receptors at concentrations up to 10 μ M. SB 674042 was also shown to be a competitive, functional antagonist of the OX1 receptor in the calcium mobilisation assay using CHO-DG44_OX1 cell lines.

SB 699551A

[791789-61-2]
Purity: 99%

Soluble in DMSO
C34H45N3O.2HCl MW: 584.66



Axon 1469

mg Price

5 online

25 online

Biological activity


Selective 5-HT5A receptor antagonist

SB 706504

PCG

[911110-38-8]
Purity: 98%

Soluble in DMSO
C24H19F3N8O MW: 492.46



Biological activity

Selective p38 MAPK inhibitor that targets a subset of inflammatory macrophage genes (IC50 value 2.5 nM for p38 α , and no IC50 values <5 μ M, except for JNK1 (5 μ M)). When used with dexamethasone, SB 706504 causes effective suppression of these genes without affecting transcription of a subset of LPS-regulated genes, including IL-1 β , IL-18, and CCL5 (genes involved in the pathogenesis of COPD). Furthermore, SB 706504 reduces TNF α , GM-CSF, and IL-6 production from LPS-stimulated COPD macrophages, with less effect on IL-8 production.

SB 715992


See Ispinesib

SB 742457

GSK 742457

[607742-55-2]
Purity: 99%

Soluble in DMSO
C19H19N3O2S.HCl MW: 389.90



Biological activity

Selective 5-HT6 antagonist; a potential agent added to stabilize donepezil (Axon 1438) treatment in subjects with mild-to-moderate Alzheimer's disease

SB 747651 tetrahydrochloride


See SB 747651A

SB 747651A

SB 747651 tetrahydrochloride

[N.A.]
Purity: 98%

Soluble in water and DMSO
C16H22N8O.4HCl MW: 488.24



Biological activity

Potent MSK inhibitor; In vitro, SB-747651A inhibits MSK1 with an IC50 value of 11 nM; In cells, SB-747651A fully inhibited MSK activity at 5-10 μ M. SB-747651A exhibited improved selectivity over H89 and Ro 31-8220 and therefore represents a useful tool to study MSK function in cells

Axon 2444

mg	Price
5	online
25	online

Axon 2446

Page 572

Axon 1382

mg	Price
5	online
25	online

Axon 1897

Page 851


Axon 1897

mg	Price
5	online
25	online

SBI-183

[625403-59-0]
Purity: 99%

Soluble in DMSO and EtOH
C18H20N2O2 MW: 296.36




Biological activity

SBI-183 is an orally active inhibitor of QSOX1 (Kd value of 20 μ M), thereby suppressing the proliferative and invasive phenotype of two renal cancer cell lines (786-O and RCJ-41T2), a triple negative breast cancer (TNBC) cell line (MDA-MB-231), a lung adenocarcinoma cell line (A549), and a pancreatic ductal adenocarcinoma (MIA PaCa2). Moreover, SBI-183 inhibits tumor growth in two independent human xenograft mouse models of renal cell carcinoma.

SBI-425

[1451272-71-1]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C13H12ClN3O4S MW: 341.77




Biological activity

SBI-425 is a potent, selective and oral bioavailable inhibitor of tissue-nonspecific alkaline phosphatase (TNAP) with an IC50 value of 0.016 μ M. SBI-425 robustly inhibits TNAP in vivo after oral dosing. Furthermore, SBI-425 demonstrated activity in blocking calcification in patient derived fibroblasts as well as in rodent models of GACI and PXE.

SBI-797812

[2237268-08-3]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C19H22N4O4S MW: 402.47



Biological activity

SBI-797812 is an orally active NAMPT activator. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN (Axon 3571) formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+.


SC0735

See Nitisinone

SC-514

[354812-17-2]
Purity: 99%

Soluble in DMSO
C9H8N2OS2 MW: 224.30



Biological activity

SC-514 is a potent, selective, reversible and ATP-competitive IKK-2 inhibitor with IC50 values of 3-12 μ M. SC-514 inhibits the native IKK complex or recombinant human IKK-1/IKK-2 heterodimer and IKK-2 homodimer

Axon 3209

mg	Price
10	online
50	online

Axon 2963

mg	Price
10	online
50	online

Axon 3954

mg	Price
10	online
50	online

Axon 3662

Page 705

Axon 3536


mg	Price
10	online
50	online

similarly. Moreover, SC-514 inhibits transcription of NF- κ B-dependent genes in IL-1 β -induced rheumatoid arthritis-derived synovial fibroblasts in a dose-dependent manner.

SC 66

[871361-88-5]
Purity: 99%

Soluble in DMSO and Ethanol
C18H16N2O MW: 276.33



Axon 1790

mg	Price
10	online
50	online


Biological activity

An allosteric Akt inhibitor, targeting pleckstrin homology domain and facilitating Akt ubiquitination

SC 79

[305834-79-1]
Purity: 98%

Soluble in DMSO
C17H17ClN2O5 MW: 364.78



Axon 2507

mg	Price
5	online
25	online


Biological activity

Unique specific activator of cytosolic Akt (PKB) with the potentiation to recapitulate the primary cellular function of Akt signaling in a hippocampal neuronal culture system and a mouse model for ischemic stroke, resulting in augmented neuronal survival. Paradoxically, SC 79 suppressed PH-Akt-GFP plasma membrane translocation. Close analogue of HA 14-1 (Axon 2007), a Bcl-2 antagonist (IC50 value 9 μ M).

SC 144 hydrochloride

[917497-70-2]
Purity: 99%

Soluble in DMSO
C16H11FN6O.HCl MW: 358.76



Axon 2324

mg	Price
10	online
50	online

Biological activity


The first-in-class small-molecule gp130 inhibitor with oral activity in ovarian cancer (IC50 values 0.43-0.95 μ M for a range of human ovarian cancer cell lines). SC144 binds gp130, induces gp130 phosphorylation and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes.

SC 236

SC 58236

[170569-86-5]
Purity: 99%

Soluble in DMSO
C16H11ClF3N3O2S MW: 401.79



Axon 2108

mg	Price
10	online
50	online

Biological activity

Selective COX-2 inhibitor, which showed an impressive selectivity for COX-2 over COX-1 (IC50 0.01 μ M vs. 17.8 μ M respectively); NSAID and early lead compound during the discovery of Celecoxib (Axon 1919). However, SC236 showed an extremely long plasma half-life, not preferred for further development as potential therapeutic. **Source Information:** Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

SC 12267

See Vidofludimus

Axon 2377


Page 968

SC 26196

PF 06341724

[218136-59-5]
Purity: 99%

Soluble in DMSO
C27H29N5 MW: 423.55



Axon 2112

mg	Price
5	online
25	online

Biological activity

Selective Δ 6-desaturase inhibitor (IC50 = 0.2 μ M in vitro; >100 fold selective over Δ 5- and Δ 9-desaturases), an enzyme essential for the synthesis of arachidonic acid. It showed anti-inflammatory effects to the same extent as indomethacin or essential fatty acid deficiency in established mouse models

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

SC 58236

See SC 236

Axon 2108

Page 853

SC 58635

See Celecoxib

Axon 1919

Page 358

SC 65872

See Valdecoxib

Axon 2106

Page 960

SC-69124A

See Parecoxib sodium

Axon 3311

Page 747

SC129

See Cefsulodin sodium

Axon 4044

Page 357

SCH 29851

See Loratadine

Axon 1299

Page 620

SCH 52365

See Temozolomide

Axon 2326

Page 917

SCH 56592

See Posaconazole

Axon 1557

Page 787

SCH58235

See Ezetimibe


Axon 3377

Page 473

SCH 58261

[160098-96-4]
Purity: 99%

Soluble in DMSO
C18H15N7O MW: 345.36



Axon 1253


mg	Price
5	online
25	online

Biological activity

Highly selective and potent A2A adenosine receptor antagonist

SCH772984 hydrochloride

[N.A.]
Purity: 99%
99% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C33H33N9O2.HCl MW: 624.14



Axon 3867

mg	Price
5	online
10	online

Biological activity


Extracellular signal regulated kinase (ERK) is a pivotal enzyme in the pathway downstream of Ras, Raf, and MEK, acting as a central link between multiple signaling pathways. SCH772984 is a potent, specific and ATP competitive inhibitor of ERK1 and ERK2 with IC50s at low nMs. It inhibits phosphorylation of the ERK substrate p90 ribosomal S6 kinase (T359/S363 phospho-RSK) in a dose-dependent manner, and also inhibits phosphorylation of residues in the activation loop of ERK itself. More importantly, it effectively inhibits MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.

Source Information: Sold in collaboration with Chemietek

SCH 79797 hydrochloride

[1216720-69-2]
Purity: 99%

Soluble in DMSO and Ethanol
C23H25N5.2HCl MW: 444.40



Axon 1275

mg	Price
5	online
25	online


Biological activity

Potent and selective non-peptide PAR1 antagonist

SCH 442416

[316173-57-6]
Purity: 99%

Soluble in DMSO
C20H19N7O2 MW: 389.41



Axon 1264

mg	Price
5	online
25	online

Biological activity

Highly selective and potent A2A adenosine receptor antagonist

SCH 442416, Desmethyl


[188112-92-7]

Axon 2283

mg	Price
----	-------

Purity: 95%

Soluble in DMSO
C19H17N7O2 MW: 375.38



10 online

25 online


Biological activity

Precursor for [11C]SCH442416 for PET studies; Radioligand precursor of the highly selective and potent A2A adenosine receptor antagonist SCH 442416 (Axon 1264). Desmethyl SCH 442416 is less potent and less selective in binding the A2A receptor than SCH 445416 (Ki values 44 nM, 48 nM, and 34 nM for A1, A2A and A3 respectively).

SCH 529074

[922150-11-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C31H36Cl2N6 MW: 563.56



Axon 2244

mg	Price
5	online
25	online


Biological activity

Small molecule activator of mutant p53 which binds p53 DNA binding domain (DBD; Kd value 1-2 μM). SCH 529074 restores growth-suppressive function to mutant p53 (R273H and the structural mutant R249S) by acting as a chaperone and interrupts HDM2-mediated ubiquitination of wild type p53.

SCH 530348

Vorapaxar; MK 5348

[618385-01-6]
Purity: 99%
optically pure
Soluble in DMSO
C29H33FN2O4 MW: 492.58



Axon 1755

mg	Price
5	online
25	online


Biological activity

Potent and orally active thrombin receptor (or protease-activated receptor 1, PAR-1) antagonist (Ki: 8.1 nM) that inhibits thrombin-induced platelet activation

SCH 727965

Dinaciclib

[779353-01-4]
Purity: 99%
optically pure
Soluble in 0.1N HCl(aq) and DMSO
C21H28N6O2 MW: 396.49



Axon 1776

mg	Price
5	online
25	online

Biological activity

Potent and selective cyclin-dependent kinase (CDK) inhibitor, selectively inhibiting CDK1, CDK2, CDK5 and CDK9 with IC50 values of 3, 1, 1 and 4 nM respectively; a potential antineoplastic agent

SCH 900435

See ORG 25935


Axon 1563

Page 736

SCH900353

MK-8353

[1184173-73-6]
 Purity: 99%
 99% e.e.
 Soluble in DMSO
 C37H41N9O3S MW: 691.84


Axon 3803

mg	Price
5	online
10	online

Biological activity


SCH900353 is an orally bioavailable potent inhibitor targeting activated ERK1/2 with IC50 values of 23.0 and 8.8 nM, respectively, and nonactivated ERK2 with IC50 of 0.5 nM, highly selective over a panel of 227-human kinases; decreases levels of pERK1, pERK2, and ribosomal S6 kinase (pRSK) protein formation, with complete suppression of pERK1 and pERK2 observed at 30 nM in A2058 cells; inhibits the in vitro proliferation of a panel of BRAFV600-mutant and RAS-mutant cancer cell lines; displays in vivo antitumor efficacy against BRAFV600 mutant Colo-205 colon cancer model and the BRAFV600 mutant SK-MEL-28 melanoma model.

Source Information: Sold in collaboration with Chemietek

SCH900776 dihydrochloride

MK-8776 dihydrochloride

[891494-63-6]
 Purity: 99%
 99% e.e.
 Soluble in water and DMSO
 C13H18BrN7.2HCl MW: 449.18


Axon 3828

mg	Price
5	online
10	online


Biological activity

SCH900776 is a potent, selective and orally bioavailable inhibitor of CHK1 (IC50 = 3 nM), highly selective against CHK2 (IC50 = 1500 nM) and CDK2 (IC50 = 160 nM).

Source Information: Sold in collaboration with Chemietek

SC912 Recent Addition

[N.A.]
 Purity: 99%
 98% e.e.
 Soluble in DMSO
 C22H13Cl2F3N4O2 MW: 493.27


Axon 4248

mg	Price
5	online
25	online

Biological activity


SC912 is an AR-V7 inhibitor which binds to full-length AR as well as AR-V7 through AR N-terminal domain (AR-NTD). SC912 also disrupted AR-V7 transcriptional activity, impaired AR-V7 nuclear localization and DNA binding. In the AR-V7 positive CRPC cells, S

SCIO 469

Talmapimod

[309913-83-5]
 Purity: 98%

Soluble in DMSO
 C27H30ClFN4O3 MW: 513.00


Biological activity

Orally available and selective inhibitor of p38 mitogen-activated protein (MAP) kinase (MAPK), with a 10-fold selectivity for p38α over p38β and 2000-fold over 20 other kinases; potential agent with immunomodulating, anti-inflammatory and antineoplastic activities


Axon 1671

mg	Price
5	online
25	online

SCR7 pyrazine

[14892-97-8]
 Purity: 99%

Soluble in DMSO
 C18H12N4OS MW: 332.38


Biological activity

DNA ligase IV mediated inhibitor of NHEJ (non-homologous end joining) that increases the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells up to 19-fold. Note: Axon Medchem confirmed that the active chemical entity of SCR7, as described by Srivastava and others, is actually SCR7 pyrazine (Axon 2531).


Axon 2531

mg	Price
2	online
10	online

SD 169

[1670-87-7]
 Purity: 99%

Soluble in DMSO and Ethanol
 C9H8N2O MW: 160.17


Biological activity

ATP competitive, orally active inhibitor of p38α MAP kinase (IC50 = 3.2 nM); being 38 fold selective vs against p38β MAP kinase (IC50 = 122 nM) and no inhibitory activity against a panel of other kinases including p38γ MAP kinase, ERK2, JNK-1 and MAPKAPK-2


Axon 1357

mg	Price
5	online
25	online

SD 208

[627536-09-8]
 Purity: 99%

Soluble in DMSO
 C17H10ClFN6 MW: 352.75


Biological activity

Transforming growth factor beta receptor I (TGF-βR I) kinase inhibitor

Axon 1387

mg	Price
2	online
10	online

SDZ ENA 713

See Rivastigmine tartrate

Axon 3167


Page 821

SDZ-WAG 994

WAG 994

[130714-47-5]
Purity: 98%

Soluble in DMSO and Ethanol
C17H25N5O4 MW: 363.41




Biological activity

Potent, selective and orally active A1 adenosine receptor agonist

SEA0400

[223104-29-8]
Purity: 99%

Soluble in DMSO
C21H19F2NO3 MW: 371.38



Biological activity

SEA0400 is a potent and selective inhibitor of the Na⁺-Ca²⁺ exchanger (NCX). IC₅₀ values of SEA0400 were 33, 5.0, 8.3, 90 and 92 nM in cultured neurons, astrocytes, microglia, dog sarcolemmal vesicles and cultured rat myocytes, respectively. SEA0400 protects astrocytes against Ca²⁺ paradox-like injury and reduces cerebral ischemic damage in rats with a transient middle cerebral artery occlusion.

Selinexor


See KPT-330

Selexipag

NS 304; ACT 293987; Upravi

[475086-01-2]
Purity: 100%

Soluble in DMSO
C26H32N4O4S MW: 496.62



Biological activity


Orally available and long-acting prodrug of MRE 269, a potent and highly selective IP receptor agonist (K_i values 20 nM and 260 nM for inhibition of [3H]iloprost binding to human IP receptor by MRE 269 and Selexipag, respectively). Capable of ameliorating vascular endothelial dysfunction, pulmonary arterial wall hypertrophy, and right ventricular hypertrophy. Furthermore, Selexipag (NS 304) elevated right ventricular systolic pressure and improved survival in a rat model of pulmonar

Selisistat

EX 527

[49843-98-3]
Purity: 99%

Soluble in DMSO
C13H13ClN2O MW: 248.71



Biological activity

Axon 1265

mg	Price
10	online
50	online

Axon 2751

mg	Price
10	online
50	online

Axon 2336

Page 594

Axon 2605

mg	Price
5	online
25	online

Axon 1956

mg	Price
10	online
50	online

Potent and selective deacetylase sirtin 1 (SIRT1) inhibitor; a useful tool for studying the relationship between SIRT1 and cell regulation; a potential agent the treatment of Huntington's Disease (HD)

Selitrectinib


See LOXO-195

Selonsertib

GS 4997

[1448428-04-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C24H24FN7O MW: 445.49



Biological activity


Selonsertib is a potent, highly selective, orally available, and ATP-competitive ASK1 inhibitor with a pIC₅₀ value of 8.3.

Selpercatinib

LOXO-292

[2361241-23-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C29H31N7O3 MW: 525.60



Biological activity

Selpercatinib is a potent, highly selective, ATP-competitive RET inhibitor with an IC₅₀ value of 4 nM (KIF5B-RET). Selpercatinib demonstrated potent and selective anti-RET activity preclinically against human cancer cell lines harboring endogenous RET gene alterations.

Selumetinib

See AZD 6244

Senaglinide


See Nateglinide

Senicapoc

ICA-17043

[289656-45-7]
Purity: 99%

Soluble in DMSO and EtOH
C20H15F2NO MW: 323.34



Biological activity

Senicapoc is a potent and selective antagonist of the Gardos (KCa3.1) channel with an IC₅₀ value of 11 nM.

Axon 3901

Page 621

Axon 2956

mg	Price
10	online
50	online

Axon 3195

mg	Price
10	online
50	online

Axon 1516

Page 274

Axon 3641

Page 693

Axon 3951


mg	Price
10	online
50	online

Sephin 1

NSC 65390

[951441-04-6]
Purity: 99%

Soluble in DMSO
C8H9ClN4 MW: 196.64



Biological activity


Selective PPP1R15A inhibitor devoid of PPP1R15B and α 2-adrenergic activity. In cells, Sephin1 selectively disrupted the PPP1R15A-PP1c complex, thereby prolonging eIF2 α phosphorylation after stress, delaying translation recovery, and consequently, attenuated expression of stress genes such as the pro-apoptotic protein CHOP. The cytoprotectant prevents protein misfolding, motor deficits, motor neuron loss, and the molecular defects in SOD1 mutant mice.

Serabelisib

MLN1117; INK1117; TAK-117

[1268454-23-4]
Purity: 99%

Soluble in DMSO
C19H17N5O3 MW: 363.37



Biological activity

Serabelisib is an orally bioavailable, PI3K p110 α -isoform specific inhibitor with an in vitro IC50 of 15 nM, highly selective against other isoforms (p110 β , p110 γ and p110 δ) and mTOR (no significant inhibitions at 1 μ M concentration). It displayed significant efficacy in several PI3K α mutant-specific preclinical mouse xenograft tumor models, and blocked signaling to Akt and inhibited growth of cancer cells harboring wild-type or mutated p110 α .


Source Information: Sold in collaboration with Chemietek

Seratrodast

AA 2414

[112665-43-7]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C22H26O4 MW: 354.44



Biological activity

Thromboxane A2 (TP) receptor antagonist used in the treatment of asthma

Serdemetan

See JNJ 26854165

SERT inhibitor compound 8090

See ZINC000006658090 **Recent Addition**

Sertindole

LU 23-174


[106516-24-9]

Axon 2524

mg	Price
10	online
50	online

Purity: 99%

Soluble in DMSO
C24H26ClFN4O MW: 440.94



10	online
50	online


Biological activity

5-HT2, D2 and α 1 antagonist; Sertindole is an atypical antipsychotic with prominent selectivity for the brain limbic area and long lasting

Sertraline Hydrochloride

[79559-97-0]
Purity: 99%

Soluble in DMSO
C17H17Cl2N.HCl MW: 342.69



Axon 1300

mg	Price
10	online
50	online

Biological activity

Selective serotonin reuptake inhibitor (SSRI); antidepressant

Servier 1 dihydrochloride

See BCL-201 dihydrochloride

Axon 3714


Page 295

SET2

TRPV2 antagonist SET2

[2313525-20-9]
Purity: 100%

Soluble in DMSO and EtOH
C17H21F3N4O2S MW: 402.43



Axon 3287

mg	Price
5	online
25	online

Biological activity

SET2 is a potent and selective TRPV2 inhibitor with an IC50 value of 0.46 μ M.

Setanaxib

See GKT137831


Axon 3006

Page 503

SEW 2871

[256414-75-2]
Purity: 100%

Soluble in DMSO
C20H10F6N2OS MW: 440.36



Axon 1672

mg	Price
10	online
50	online


Biological activity

Potent, cell-permeable and selective sphingosine-1-phosphate 1 (S1P1) receptor agonist (EC50: 13 nM); Does not activate S1P2, S1P3, S1P4 or S1P5 receptors at concentrations up to 10 μM

SF 1670

[345630-40-2]
Purity: 98%

Soluble in DMSO
C19H17NO3 MW: 307.34



Biological activity

Inhibitor of phosphatase and tensin homologue deleted on chromosome 10 (PTEN, IC50 value 2 μM), an important regulator of insulin-dependent signaling, that augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. SF 1670 enhances neutrophil functions and fMLP-induced PtdIns(3,4,5)P3 signaling in neutrophils. SF 1670 is also a potent inhibitor of protein tyrosine phosphatase (PTP) CD45 (aka PTPRC; IC50 values 0.2 μM and 0.1 μM for CD45 induced pNPP hydrolysis and T-cell proliferation, respectively) and of galactokinase (GALK, IC50 value 0.7 μM).

SF86-327

See Terbinafine


SG 00529

See Palomid 529

SGC707

[1687736-54-4]
Purity: 99%

Soluble in DMSO
C16H18N4O2 MW: 298.34




Biological activity

SGC707 is a first-in-class, potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) with an IC50 value of 31 nM. SGC707 is bioavailable and suitable for animal studies.

SGC2085

[1821908-49-9]
Purity: 100%

Soluble in water and DMSO
C19H25ClN2O2 MW: 348.87



Biological activity

Potent and selective Coactivator Associated Arginine Methyltransferase 1 (CARM1 or PRMT4) inhibitor (IC50 value 50 nM and >100-fold selectivity over other PRMTs). Unfortunately, no cellular activity was observed for SGC2085 when tested up to 10 μM due to poor cell permeability (in HEK293 cells)

SGC-SMARCA-BRDVIII

[1997319-84-2]
Purity: 99%

Axon 2186

mg Price

10 online

50 online

Axon 3379

Page 920

Axon 1718

Page 746

Axon 2945

mg Price

10 online

50 online

Axon 2625

mg Price

5 online


25 online

Axon 3623

mg Price

5 online

Soluble in 0.1N HCl(aq), DMSO and ETOH
C19H25N5O3 MW: 371.43



25 online


Biological activity

SGC-SMARCA-BRDVIII is a potent, highly selective and cell-active SMARCA2/4 and PB1(5) bromodomain inhibitor with Kd values of 35, 36 and 13 nM, respectively. SGC-SMARCA-BRDVIII blocked adipogenesis of 3T3-L1 murine fibroblasts by reducing the mRNA levels of key markers of adipocyte differentiation, PPARγ, C/EBPα, and FABP4.

SGC-STK17B-1

[2650530-00-8]
Purity: 98%

Soluble in DMSO
C16H10N2O2S3 MW: 358.46



Axon 3395

mg Price

5 online

25 online

Biological activity


SGC-STK17B-1 is a potent, selective and ATP-competitive STK17B inhibitor with an IC50 value of 43 nM.

SGI 1027 dihydrochloride

S 1027 dihydrochloride

[1020149-73-8] (parent)
Purity: 99%

Soluble in DMSO
C27H25Cl2N7O MW: 534.44



Axon 2347

mg Price

10 online

50 online


Biological activity

SGI 1027 inhibits DNMT activity (IC50 values 35 μM and 10 μM for DNMT1 and DNMT3A2/3L, respectively) in colon cancer cell lines, and was shown to degrade the enzymes. Prolonged treatment of RKO cells with SGI 1027 led to demethylation and reexpression of the silenced tumor suppressor genes (TSGs) P16, MLH1, and TIMP3 and did not exhibit significant toxicity in a rat hepatoma (H4IIE) cell line. SGI 1027 shows moderate affinity (IC 50 value 65 μM) for G9a-like protein (GLP), another AdoMet-dependent enzyme, as well.

SGI 1776 free base

[1025065-69-3]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C20H22F3N5O MW: 405.42



Axon 1633

mg Price

5 online

25 online


Biological activity

A potent and selective inhibitor of Pim kinases, inducing apoptosis and cell cycle arrest, thereby causing a reduction in phospho-BAD levels and enhancement of mTOR inhibition in vitro. Most notably, SGI-1776 induced significant tumor regression in MV-4-11 (AML) and MOLM-13 (AML) xenograft models

SGS 518

[445441-26-9]
Purity: 99%

Soluble in DMSO
C21H22F2N2O3S MW: 420.47




Biological activity

Selective 5-HT₆ antagonist, being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS)

SGX 523

[1022150-57-7]
Purity: 99%

Soluble in DMSO
C18H13N7S MW: 359.41



Biological activity

ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET (IC₅₀: 4 nM)


SH714

See Cyproterone acetate

Shz-1

[326886-05-9]
Purity: 99%

Soluble in DMSO
C13H11BrN2O3S MW: 355.21




Biological activity

Stem cell differentiating agent that induce differentiation of stem cells into cells of cardiac fate; Cardiogenic small molecule that enhance myocardial repair by stem cells; Potently induces Nkx2.5 and a subset of other cardiac markers

SIC5-6

[2410846-16-9]
Purity: 99%

Soluble in DMSO
C27H24IN3O2S MW: 581.47



Biological activity

SIC5-6 is a specific, noncovalent inhibitor of separase with bioactivity in tumor tissue culture cells.

SID 791

See AMD 3100

Axon 1927

mg	Price
5	online
25	online

Axon 1914

mg	Price
10	online
50	online

Axon 3883

Page 403

Axon 1701

mg	Price
10	online
50	online

Axon 3082

mg	Price
10	online
50	online


Axon 1738

Page 223

Simvastatin

MK733; Synvinolin

[79902-63-9]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C25H38O5 MW: 418.57



Biological activity


Simvastatin is a competitive inhibitor of HMG-CoA reductase with a K_i value of 0.2 nM.

Sildenafil citrate

Viagra; UK 92480

[171599-83-0]
Purity: 100%

Soluble in DMSO
C22H30N6O4S.C6H8O7
MW: 666.70



Biological activity

Potent and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) with IC₅₀ value of 4 nM; Enhances nitric oxide (NO)-dependent relaxation of human corpus cavernosum in vitro; an oral therapy for erectile dysfunction (ED)


Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Silibinin

Silybin; Silymarin I

[802918-57-6]
Purity: 99%

Soluble in DMSO
C25H22O10 MW: 482.44



Biological activity

Natural flavonolignan, antihepatotoxic agent and antioxidant, exhibiting potent antitumor activities against various types of cancers. Interferes with many signaling pathways, such as notch, NF-κB, EGFR, SIRT1, PI3K/Akt and many others Mix of Silybin A and B

Silmitasertib hydrochloride

See CX 4945 hydrochloride

Silodosin

KMD-3213

[160970-54-7]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C25H32F3N3O4 MW: 495.53

Axon 3443

mg	Price
50	online

Axon 2046

mg	Price
10	online
50	online

Axon 2487


mg	Price
10	online
50	online

Axon 1965

Page 399

Axon 3112

mg	Price
10	online
50	online



Biological activity

Silodosin is a selective $\alpha 1A$ adrenoceptor antagonist with pK_i values of 10.4, 8.1 and 8.6 for $\alpha 1a$ -, $\alpha 1b$ - and $\alpha 1d$ -AR, respectively.

Silybin

See Silibinin

Axon 2487

Page 866

Silymarin I

See Silibinin

Axon 2487

Page 866

Simufilam

See PTI-125 dihydrochloride

Axon 3746

Page 796

Simurosertib

See TAK-931


Axon 3605

Page 908

Siremadlin

NVP-HDM201; HDM-201

[1448867-41-1]
Purity: 99%
99% e.e.
Soluble in DMSO
C₂₆H₂₄Cl₂N₆O₄ MW: 555.41



Biological activity

Siremadlin is an orally bioavailable, potent and selective inhibitor of p53-MDM2 interaction, binding to human MDM2 protein with a picomolar K_i value (0.21 nM). Highly selective against MDM4 protein ($K_i = 3300$ nM, >10000 fold selectivity). It activates p53 and induces robust p53-dependent cell cycle arrest and apoptosis in human p53 wild-type tumor cells.

Axon 3737

mg	Price
5	online
25	online

Sirolimus


See Rapamycin

Axon 2069

Page 807

SirReal 2

[709002-46-0]
Purity: 98%
Soluble in DMSO
C₂₂H₂₀N₄O_S MW: 420.55



Biological activity

Axon 2453


mg	Price
5	online
25	online

SIRT2 inhibitor (IC₅₀ value 0.14 μ M) with in vivo activity, showing >1000 fold selectivity over other Class-I sirtuins SIRT1 and SIRT3. Application of SirReal2 leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1.

SIRT7 inhibitor 97491

[1807758-81-1]
Purity: 99%

Soluble in DMSO
C₁₅H₁₂ClN₃O MW: 285.73



Axon 2968

mg	Price
10	online
50	online


Biological activity

SIRT7 inhibitor 97491 decreased SIRT7 activity in a dose-dependent manner (IC₅₀ value of 0.325 μ M). SIRT7 inhibitor 97491 induced expression of p53 and its acetylation by inhibited SIRT7. Moreover, SIRT7 inhibitor upregulated apoptotic effects through the caspase related proteins and inhibited cancer growth in vivo.

Sirtinol

[410536-97-9]
Purity: 98%

Soluble in DMSO
C₂₆H₂₂N₂O₂ MW: 394.47



Axon 3908

mg	Price
10	online
50	online

Biological activity


Sirtinol is a specific sirtuin (SIRT) inhibitor.

SIS3

Smad3 inhibitor SIS3

[521985-36-4]
Purity: 98%

Soluble in DMSO
C₂₈H₂₇N₃O₃ MW: 453.53



Axon 2764

mg	Price
5	online
25	online

Biological activity


SIS3 is a potent and selective inhibitor of Smad3 and TGF- β signaling. Inhibition by SIS3 leads to abrogation of the TGF- β 1-induced production of extracellular matrix proteins in normal fibroblasts and scleroderma fibroblasts. Moreover, Smad3 inhibition attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.

Sisunatovir

RV521

[1903763-82-5]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C₂₃H₂₂F₄N₄O MW: 446.44



Axon 4085


mg	Price
5	online
25	online

Biological activity

Sisunatovir is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion protein. RV521 exhibited a mean IC50 value of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection.

Sitagliptin

[486460-32-6]
Purity: 100%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C16H15F6N5O MW: 407.31



Axon 3251

mg	Price
50	online
250	online

Biological activity


Sitagliptin is a potent, selective and orally active DPP-4 inhibitor (IC50 value of 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models.

Sitamaquine

WR 6026 tosylate

[1019640-33-5]
Purity: 99%

Soluble in DMSO
C21H33N3O.C7H8O3S
MW: 515.71



Axon 1515

mg	Price
10	online
50	online

Biological activity

A potential agent as an oral treatment of life-threatening visceral leishmaniasis (VL) caused by *Leishmania donovani*, with an IC50 of 29.2 μM against the promastigote form in vitro

Sitravatinib

See MGCD516


Axon 3998

Page 652

SJ 172550

[431979-47-4]
Purity: 99%

Soluble in DMSO
C22H21ClN2O5 MW: 428.87



Axon 2164

mg	Price
5	online
25	online


Biological activity

First small molecule inhibitor of MDMX with 10-fold selectivity over closely related MDM2 (EC50 2.3 μM vs 26.0 μM) which effectively kills MDMX-amplified retinoblastoma cells. SJ 172550 reversibly binds the p53-binding pocket of MDM, disrupts the MDMX-p53 interaction, and thereby frees p53 to induce apoptosis. The effect of SJ 172550 is additive when combined with an MDM2 inhibitor Nutlin 3a (Axon 1880). It may be useful for treating tumors that express wild-type p53

SJ000291942

[425613-09-8]
Purity: 99%

Soluble in DMSO



Axon 2903

mg	Price
10	online
50	online

C16H15FN2O4 MW: 318.30


Biological activity

SJ000291942 is an activator of the canonical bone morphogenetic protein (BMP) signaling pathway.

SK-216

[654080-02-1]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C29H31NO6 MW: 489.56



Axon 2838

mg	Price
5	online
25	online

Biological activity

SK-216 is a specific inhibitor of PAI-1 and limits tumor progression and angiogenesis. SK-216 could suppress PAI-1 expression in rat colon cancer cells as well as intestinal polyp formation in a Min mouse. Furthermore, SK-216 could inhibit lung metastasis of human lung cancer cells and mouse melanoma cells in an intravenously-injected mouse mode. Potential novel anti-metastasis agent for human osteosarcoma.

SK5357

See Mercaptopurine, 6-


Axon 3245

Page 646

SKF 83566 hydrobromide

[108179-91-5]
Purity: 99%

Soluble in water and DMSO
C17H18BrNO.HBr MW: 413.15



Axon 1236

mg	Price
10	online
50	online

Biological activity

Selective dopamine D1-like receptor antagonist

SKF 87967 hydrochloride

See Aminotetraline hydrochloride, 5-Methoxy-2-


Axon 1048

Page 232

SKF 96365 hydrochloride

[130495-35-1]
Purity: 99%

Soluble in water and DMSO
C22H26N2O3.HCl MW: 402.91



Axon 1221

mg	Price
10	online
50	online

Biological activity

Receptor-operated calcium channel blocker


SKBG-1, (R)-

[2955634-67-8]
Purity: 99%
99% e.e.

Soluble in DMSO
C22H26ClN3O6S MW: 495.98

Axon 3928

mg	Price
5	online
25	online




Biological activity

(R)-SKBG-1 is a covalent RNA-binding protein NONO ligand. (R)-SKBG-1 promoted NONO accumulation in nuclear foci and stabilized NONO-RNA interactions, supporting a trapping mechanism that may prevent compensatory action of paralog proteins PSPC1 and SFPQ. Also, (R)-SKBG-1 showed IC50 values of 3.1 and 5.5 μ M for depleting AR-FL and AR-V7 mRNA, respectively. The inactive enantiomer (S)-SKBG-1 is available as Axon 3929.

SKBG-1, (S)-

[2955618-24-1]
Purity: 99%
99% e.e.
Soluble in DMSO
C22H26ClN3O6S MW: 495.98



Axon 3929

mg	Price
5	online
25	online

Biological activity

Inactive enantiomer of (R)-SKBG-1 (Axon 3928) which is a covalent RNA-binding protein NONO ligand.

SKI 2


See SKI II

Axon 2782

Page 871

SKI II

[312636-16-1]
Purity: 99%
Soluble in DMSO
C15H11ClN2OS MW: 302.78



Axon 2782

mg	Price
10	online
50	online


Biological activity

SKI II is an orally bioavailable sphingosine kinase (SK or SphK) inhibitor (IC50 value of 0.5 μ M) without competition at the ATP-binding site of SK. Moreover, SKI II showed no inhibition on a small panel of human protein kinases (ERK2 and PKC- α) and a lipid kinase (PI3K). SKI II inhibited cancer cell proliferation, induced apoptosis and inhibited tumor growth in mice.

SKI 606

Bosutinib

[380843-75-4]
Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO
C26H29Cl2N5O3 MW: 530.45



Axon 1407


mg	Price
5	online
25	online

Biological activity

A tyrosine kinase inhibitor (TKI), targeting dual Bcr-Abl and Src; effective drug for chronic myelogenous leukemia (CML) or acute lymphoid leukemia (ALL)

SKL 2001

[909089-13-0]
Purity: 99%
Soluble in DMSO
C14H14N4O3 MW: 286.29



Axon 2084


mg	Price
10	online
50	online

Biological activity

Wnt/ β -catenin signaling pathway agonist or activator, having effects of regulating the differentiation of mesenchymal stem cells

SL-145

[2051587-62-1]
Purity: 97%
Soluble in DMSO and EtOH
C28H29NO6 MW: 475.53



Axon 3701


mg	Price
5	online
25	online

Biological activity

SL-145 is a C-terminal heat shock protein 90 (HSP90) inhibitor. SL-145 elicits anti-tumor and anti-metastatic effects without triggering the heat shock response (HSR) due to its unconventional targeting of the C-terminal region. SL-145 simultaneously inhibits multiple oncogenic signaling pathways including AKT, MEK/ERK, and JAK2/STAT3 in vitro and in vivo.

SL 327

[305350-87-2]
Purity: 99%
Soluble in DMSO and Ethanol
C16H12F3N3S MW: 335.35



Axon 1122


mg	Price
10	online
50	online

Biological activity

Selective MEK1 and MEK2 inhibitor; brain penetrant in vivo

SL 651498

[205881-86-3]
Purity: 99%
Soluble in DMSO
C23H20FN3O2 MW: 389.42



Axon 1195

mg	Price
5	online
10	online

Biological activity

GABAA agonist subtype α 2 selective

SL 820715

See Eliprodil

Axon 1246

Page 455

SL-9

See PELI1/EGFR disruptor S62 **Recent Addition**

Axon 4130

Page 757

SLC15A4 inhibitor compound C5

See Feeblin **Recent Addition**


Axon 4108

Page 477

SLF1081851 hydrochloride

[N.A.]
Purity: 98%

Soluble in DMSO and EtOH
C₂₁H₃₃N₃O.HCl MW: 379.97



Axon 3702

mg	Price
5	online
25	online


Biological activity

SLF1081851 is a first Spns2 inhibitor with an IC₅₀ of value 1.93 μM for S1P release.

SLU-PP-332 **Recent Addition**

[303760-60-3]
Purity: 99%

Soluble in DMSO
C₁₈H₁₄N₂O₂ MW: 290.32



Axon 4184

mg	Price
10	online
50	online

Biological activity

SLU-PP-332 is a pan ERRα/β/γ agonist with EC₅₀ values of 98 nM, 230 nM and 430 nM for ERRα, ERRβ and ERRγ, respectively. SLU-PP-332 has the ability to function as an exercise mimetic and improves muscle and metabolic function both in vitro and in vivo. SL

SLV 306

See Daglutril


Axon 1918

Page 408

SLV 319

Ibipinabant; SLV 319, (S)-(-)-

[464213-10-3]
Purity: 100%
>98% ee
Soluble in DMSO
C₂₃H₂₀Cl₂N₄O₂S MW: 487.40



Axon 1713

mg	Price
2	online
5	online

Biological activity

Potent and highly selective CB₁ antagonist (K_i= 7.8 and 7943 nM for CB₁ and peripheral cannabinoid CB₂, respectively); more potent (100-fold) S-(-)-enantiomer in comparison with opposite R-(+)-SLV319 (Axon 1714)

SLV 319, (R)-(+)-


R-SLV319

[656827-86-0]
Purity: 99%
>98% ee

Axon 1714

mg	Price
2	online

Soluble in DMSO
C₂₃H₂₀Cl₂N₄O₂S MW: 487.40



5 online


Biological activity

Less active (ca 100-fold) enantiomer of SLV 319 (Axon 1713) that is a potent and selective CB₁ receptor antagonist

SLV 319, rac-(±)-

[362519-49-1]
Purity: 99%

Soluble in DMSO
C₂₃H₂₀Cl₂N₄O₂S MW: 487.40



Axon 1712
mg Price

5 online
25 online

Biological activity

Racemate of the potent and highly selective CB₁ antagonist Ibipinabant (Axon 1713, K_i value 25 nM and >1000 nM for CB₁ and CB₂, respectively).

SLx-2119

See KD025

Axon 2780

Page 589

SM 406

See AT 406

Axon 1985

Page 257

SM-3997

See Tandospirone citrate

Axon 3130

Page 910

Smad3 inhibitor SIS3

See SIS3


Axon 2764

Page 868

SMER 3

[67200-34-4]
Purity: 99%

Soluble in DMSO
C₁₁H₄N₄O₂ MW: 224.18



Axon 1904
mg Price

10 online
50 online

Biological activity

Specific inhibitor of an SCF family E3 Ubiquitin ligase, directly targeting the Met30 subunit of the SCF family E3 ubiquitin ligase complex; Small molecule enhancer of rapamycin (SMER)


SMER 28

[307538-42-7]
Purity: 99%

Axon 2627

mg Price
10 online

Soluble in 0.1N HCl(aq) and DMSO
C11H10BrN3 MW: 264.12



50 online

Biological activity


Small molecule enhancer of rapamycin that enhances the clearance of mutant aggregate-prone proteins by autophagy in mammalian cell models of Huntington's and Parkinson's disease, independent of mTOR and Atg5 pathways. SMER28 also promotes reprogramming of fibroblasts (the conversion efficiency for adult tail-tip fibroblasts in particular) into neural stem cells, if combined with RG108 (Axon 1691) and Pamate.

SMI 4a

Pim inhibitor 4a

[438190-29-5]
Purity: 98%

Soluble in DMSO
C11H6F3NO2S MW: 273.23



Axon 1923

mg	Price
10	online
50	online

Biological activity


ATP-competitive and selective inhibitor of Pim kinases, with IC50 values of 24 and 100 nM for Pim-1 and Pim-2 respectively. SMI-4a inhibits prostate cancer cell growth and induce G1 phase cell-cycle arrest in precursor T-cell lymphoblastic leukemia/lymphoma cell lines

SMI 481

6748-481

[432020-20-7]
Purity: 99%

Soluble in DMSO
C17H15ClFN3O3 MW: 363.77



Axon 2387

mg	Price
10	online
50	online

Biological activity


Small-molecule inhibitor (SMI) of the yeast P1TP Sec14 (IC50 values of 211 nM and 2.87 μM for Sec14 mediated [3H]PtdIns transfer in vitro, and Sec14 dependent cell growth inhibition of WT (CTY182, gray) strains, respectively). SMI481 (aka 6748-481) is a water-soluble bioactive compound exhibiting exquisite pathway selectivity in inhibiting phosphoinositide signaling in cells with >200-fold selectivity over other yeast Sec14-like transfer activities. P1TP-directed SMIs offer new and generally applicable avenues for intervening with phosphoinositide signaling pathways with selectivities superior to those afforded by contemporary lipid kinase-directed strategies.

SMT C1100

Ezutromid; BMN-195

[945531-77-1]
Purity: 99%

Soluble in DMSO
C19H15NO3S MW: 337.39



Axon 2481

mg	Price
10	online
50	online

Biological activity


Orally active, non-toxic upregulator of utrophin production (EC50 value 0.91 μM in a utrophin A promoter H2K cell-based assay with a luciferase reporter readout) for the treatment of Duchenne muscular dystrophy (DMD). What's more, SMT C1100 significantly reduces dystrophin-deficient muscle pathology in vivo.

SMURF1 inhibitor A01

A01

[1007647-73-5]
Purity: 99%

Soluble in DMSO
C22H20ClF3N4O3S MW: 512.93



Axon 2426

mg	Price
10	online
50	online

Biological activity

SMAD ubiquitination regulatory factor-1 (SMURF1) E3 ubiquitin-protein ligase inhibitor (Kd value 3.7 nM), that strongly inhibits Smad1/5 ubiquitination under rhBMP-2 stimulation. A01 enhances BMP signaling responsiveness in C2C12 cells, and potentiates BMP-2 induced osteoblastic activity.

SN 308

See Sumatriptan succinate

Axon 1352

Page 900

SN13272 diphosphate


See Primaquine diphosphate

Axon 3177

Page 791

SNC 80

[156727-74-1]
Purity: 99%
optically pure
Soluble in 0.1N HCl(aq)
C28H39N3O2 MW: 449.63



Axon 1412

mg	Price
5	online
25	online

Biological activity

Selective and potent δ opioid receptor agonist

SNDX 275

See MS 275

Axon 1803


Page 683

SNS 032

BMS 387032

[345627-80-7]
Purity: 99%

Soluble in DMSO
C17H24N4O2S2 MW: 380.53



Axon 1614

mg	Price
5	online
25	online

Biological activity

Specific and potent inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9 (IC50 values to be 38, 4 and 62 nM for cdk2, cdk7 and cdk9 respectively and no activity against 190 additional kinases); SNS 032 induces cell cycle arrest and apoptosis in tumor cell lines


SNS 314 mesylate

Axon 2906

mg	Price
----	-------

[1146618-41-8]
Purity: 99%

Soluble in DMSO
C18H15ClN6OS2.CH4O3S MW:
527.04



5 online
25 online

Biological activity


SNS 314 mesylate is a potent and selective Aurora kinase inhibitor with IC50 values of 9 nM, 31 nM and 3 nM for Aurora A, Aurora B and Aurora C, respectively. Moreover, SNS 314 mesylate displays significant activity in pre-clinical in vivo models.

Sobetirome

GC1; QRX431

[211110-63-3]
Purity: 98%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C20H24O4 MW: 328.40



Axon 4126

mg Price
5 online
25 online

Biological activity


Sobetirome is a high-affinity subtype-selective agonist ligand for the thyroid hormone receptor with Kd value of 440 pM for hTRα1 and 67 pM for hTRβ1.

Sodium butyrate

Butanoic acid, sodium salt

[156-54-7]
Purity: 98%

Soluble in water and DMSO
C4H7NaO2 MW: 110.09



Axon 2209

mg Price
100 online
500 online

Biological activity


Noncompetitive inhibitor of histone deacetylase (HDAC; IC50 value 0.80 mM). Butyrate inhibits most HDACs, except class III HDAC and class II HDAC6 and HDAC10. Among the fatty acids, butyrate is the most effective in inhibiting HDAC activity and arresting cell proliferation, and stimulating or repressing the expression of specific genes.

Sodium ionophore III

ETH 2120

[81686-22-8]
Purity: 98%

Soluble in DMSO
C34H52N2O4 MW: 552.79



Axon 2688

mg Price
10 online
50 online


Biological activity

Sodium ionophore III is suitable for the assay of sodium activity in blood, plasma, serum, etc. with a solvent polymeric membrane electrode.

Sodium picosulfate

[10040-45-6]
Purity: 99%

Soluble in water, DMSO and EtOH
C18H13NNa2O8S2 MW: 481.41



Axon 3660

mg Price
50 online

Biological activity

Sodium picosulfate is a laxative.

Sodium valproate

See Valproic acid sodium salt


Axon 3127

Page 961

Sofosbuvir

PSI7977; GS7977

[1190307-88-0]
Purity: 100%
Optically pure
Soluble in DMSO
C22H29FN3O9P MW: 529.45



Axon 3301

mg Price
10 online
50 online

Biological activity


Sofosbuvir, a methyluridine nucleotide prodrug, is a potent and selective inhibitor of the HCV NS5B polymerase.

Solicitinib

GSK 2586184; GLPG 0778

[1206163-45-2]
Purity: 98%

Soluble in DMSO
C22H23N5O2 MW: 389.45



Axon 2539

mg Price
5 online
25 online

Biological activity


Selective JAK1 inhibitor originally developed for the treatment of systemic lupus erythematosus, psoriasis and ulcerative colitis.

Solithromycin

CEM 101; OP 1068

[760981-83-7]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C43H65FN6O10 MW: 845.01



Axon 2606

mg Price
5 online
25 online

Biological activity

Fluoroketolide antibiotic with reported high potency against diverse groups of Gram-positive and Gram-negative bacteria (MIC50 values 0.015 µg/mL and 4 µg/mL, respectively). Solithromycin (CEM-101 or OP-1068) binds to multiple sites of the bacterial large ribosomal subunit (23S rRNA) near the ribosomal exit tunnel.

Soltegravir

See *Dolutegravir*


Axon 2855

Page 436

Sonepiprazole hydrochloride

PNU 101387

[170857-36-0]
Purity: 98%
Optically pure
Soluble in DMSO
C21H27N3O3S.HCl MW: 437.98



Axon 2115

mg	Price
5	online
25	online

Biological activity


Selective dopamine D4 antagonist; Displayed high affinity ($K_i = 10$ nM) and selectivity for the D4 receptor expressed in clonal cell lines, lacking measurable affinity for other dopamine receptors, and noradrenalin, serotonin and histamine receptor families ($K_i > 2000$ nM)

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Sorafenib

BAY 43-9006; Nexavar

[284461-73-0]
Purity: 99%
Soluble in DMSO
C21H16ClF3N4O3 MW: 464.82



Axon 3351

mg	Price
10	online
50	online


Biological activity

Small molecule inhibitor of protein kinase, targeting the Raf/Mek/Erk pathway.

Sorafenib tosylate

BAY 43-9006; Nexavar

[475207-59-1]
Purity: 99%
Soluble in DMSO
C21H16ClF3N4O3.C7H8O3S
MW: 637.03



Axon 1397

mg	Price
2	online
10	online

Biological activity

Small molecule inhibitor of protein kinase, targeting the Raf/Mek/Erk pathway


Soraprazan

BYK61359

[261944-46-1]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq), DMSO and EtOH
C21H25N3O3 MW: 367.44

Axon 3589

mg	Price
2	online
5	online




Biological activity

Soraprazan is a highly potent, reversible, and fast-acting inhibitor of gastric H⁺, K⁺-ATPase with a K_i value of 6.4 nM and an IC50 value of 0.19 µM in isolated gastric glands. Potassium-competitive acid blocker (P-CAB).

Sotalol hydrochloride

[959-24-0]
Purity: 100%

Soluble in water, DMSO and EtOH
C12H20N2O3S.HCl MW: 308.82



Axon 3645

mg	Price
50	online

Biological activity


Sotalol hydrochloride is a nonselective, orally bioavailable and competitive β -adrenoceptor antagonist which prolongs cardiac repolarisation independently of its antiadrenergic action (class III antiarrhythmic properties).

Soticlestat

TAK935; OV935

[1429505-03-2]
Purity: 100%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C23H23N3O2 MW: 373.45



Axon 3485

mg	Price
5	online
25	online

Biological activity

Soticlestat is a potent, selective, orally active and brain-penetrant cholesterol 24-hydroxylase (CH24H; CYP46A1) inhibitor with an IC50 value of 7.4 nM.

Sotorasib

See AMG510

Axon 3575


Page 225

Sotrastaurin

AEB 071; NVP-AEB 071

[425637-18-9]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C25H22N6O2 MW: 438.48



Axon 1635

mg	Price
2	online
5	online
25	


Biological activity

Potent and specific inhibitor of protein kinase C (PKC) with K_i at subnanomolar to low nanomolar range for a variety of PKC isotypes while selective for >200 other kinases; an immunosuppressant that blocks early T-lymphocyte (T-cell) activation via protein kinase C inhibition

Sotuletinib

BLZ945

[953769-46-5]
Purity: 99%
100% e.e.
Soluble in 0.1N HCl(aq), DMSO and EtOH
C20H22N4O3S MW: 398.48



Axon 4084

mg	Price
10	online
50	online


Biological activity

Sotuletinib is a potent, selective and brain-penetrant CSF1R inhibitor with an IC50 value of 1 nM.

SP 141

[1253491-42-7]
Purity: 99%

Soluble in DMSO
C15H11N3O MW: 249.27



Axon 2437

mg	Price
10	online
50	online

Biological activity

Specific MDM2 inhibitor (Ki value 28 nM in a FP-based MDM2 binding assay) with potent therapeutic effects in breast cancer models, regardless of p53 status. SP141 directly binds to MDM2, inhibits MDM2 expression and induces its autoubiquitination and proteasomal degradation.

SP 233

See Caprospinol


Axon 1442

Page 343

SP 2509

[1423715-09-6]
Purity: 98%

Soluble in DMSO
C19H20ClN3O5S MW: 437.90



Axon 2864

mg	Price
5	online
25	online

Biological activity


SP 2509 is a potent, reversible, and specific LSD1 inhibitor with an IC50 value of 0.013 μM (Ki value of 31 nM). Moreover, SP 2509 inhibits proliferation and survival in several cancer cell lines, including breast and colorectal cancer.

SP 600125

NSC 75890

[129-56-6]
Purity: 98%

Soluble in DMSO
C14H8N2O MW: 220.23



Axon 2519

mg	Price
10	Online
50	Online

Biological activity


Reversible ATP-competitive JNK inhibitor (IC50 values 40 nM, 40 nM, and 90 nM for JNK1, JNK2 and JNK3, respectively) with >20-fold selectivity vs. a range of kinases and enzymes tested. SP600125 caused G2/M cell cycle arrest and elevation of cyclin B1 and p27(kip), thereby inhibiting cell proliferation and increasing apoptosis in multiple cell lines. SP600125 dose dependently inhibits phosphorylation of c-Jun, the expression of

inflammatory genes COX-2, IL-2, IFN-γ, TNF-α, and prevents activation and differentiation of primary human CD4 cell cultures. Useful tool for isolation, generation, derivatization and stabilization of naive human pluripotent stem cells in so called NHSM conditions developed at the Weizmann Institute of Science.

SP-6-27

[1384170-58-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C24H24N4O MW: 384.47



Axon 2815

mg	Price
10	online
50	online


Biological activity

The microtubule inhibitor SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells. Moreover, SP-6-27 is active against four human glioma cell lines (T98, U87, LN18, A172) and particularly against the A172 glioma cell line (IC50 value of 7.4 nM).

SP-8008

[2088247-61-2]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C15H14O6 MW: 290.27



Axon 3150

mg	Price
10	online
50	online

Biological activity


SP-8008 is a potent and selective inhibitor of SIPA with an IC50 value of 1.44 μM. Moreover, SP-8008 is a modulator of vWF-GP Ib interactions. Importantly, SP-8008 exerted significant antithrombotic effects in vivo in both shear stress-specific and arterial thrombosis, without prolonging bleeding time.

SPA70

LC-1; Specific PXR antagonist 70

[931314-31-7]
Purity: 99%

Soluble in DMSO
C21H25N3O4S MW: 415.51



Axon 2807

mg	Price
5	online
25	online

Biological activity

SPA70 is a potent and selective human pregnane X receptor (hPXR) antagonist with IC50 values of 510 nM (cell-based hPXR antagonistic assay) and 540 nM (cell-free competitive hPXR TR-FRET-binding assay). SPA70 inhibits hPXR in human hepatocytes and humanized mouse models and enhances the chemosensitivity of cancer cells, consistent with the role of hPXR in drug resistance.

SPA 110

See HTI 286


Axon 1650

Page 547

SPAA-52

[N.A.]
Purity: 99%

Soluble in water, DMSO and EtOH
C8H8Br2N2O4S.NH3 MW: 405.06



Axon 3806

mg	Price
5	online
25	online

Biological activity


SPAA-52 is a highly potent, selective, cell permeable and orally bioavailable LMW-PTP inhibitor with a K_i value of 1.2 nM and an IC_{50} value of 4 nM.

Spautin 1

MBCQ derivative C43

[1262888-28-7]
Purity: 99%

Soluble in DMSO
C15H11F2N3 MW: 271.26



Axon 2512

mg	Price
10	online
50	online


Biological activity

Inhibitor of USP10 and USP13, that target the Beclin1 subunit of Vps34 complexes, thereby promoting the degradation of Vps34 PI3 kinase complexes. Beclin1 is a tumor suppressor and regulating deubiquitination activity of USP10 and USP13 by Beclin1 provides a mechanism for Beclin1 to control the levels of p53. Moreover, Spautin 1 inhibits autophagy which enhances imatinib-induced apoptosis in chronic myeloid leukemia. The pro-apoptotic activity of Spautin-1 was also associated with activation of GSK-3 β , an important downstream effector of PI3K/AKT.

SPD 304

[869998-49-2]
Purity: 99%

Soluble in water and DMSO
C32H32F3N3O2.2HCl MW: 620.53



Axon 2143

mg	Price
5	online
25	online

Biological activity

A cell permeable inhibitor of tumor necrosis factor- α (TNF α , IC_{50} : 22 μ M); inhibits TNF- α induced I κ B- α depletion in HeLa cells (IC_{50} : 4.6 μ M)

Specific PXR antagonist 70

See SPA70


Axon 2807

Page 882

SPHINX31

[1818389-84-2]
Purity: 99%

Soluble in DMSO
C27H24F3N5O2 MW: 507.51



Axon 2714

mg	Price
10	online
50	online

Biological activity

SPHINX31 is a highly potent, selective, and cell active SRPK1 inhibitor (IC_{50} value of 6 nM). Treatment with this inhibitor inhibited SRPK1 activity and phosphorylation of serine/arginine splicing factor 1 (SRSF1), resulting in alternative splicing of VEGF-A from pro-angiogenic to antiangiogenic isoforms. This property resulted in potent inhibition of blood vessel growth in models of choroidal angiogenesis in vivo.

SP1005

See Ebselen

Axon 3424

Page 449

Spindlactone B

See SPL-B

Axon 2474


Page 884

SPL-B

Spindlactone B

[1465248-60-5]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C27H22N2O5 MW: 454.47



Axon 2474

mg	Price
5	online
25	online

Biological activity

Orally active inhibitor of transforming acidic coiled-coil protein (TACC3) that selectively inhibits the nucleation of centrosome microtubules in ovarian cancer cells, without affecting spindle assembly in normal cells. SPL significantly inhibits mitosis in cancer cells and suppresses in vivo tumor growth

SPM 927

See Lacosamide

Axon 1444

Page 603

SPRC

See S-Propargyl-Cysteine


Axon 2666

Page 884

S-Propargyl-Cysteine

SPRC; ZYZ-802

[3262-64-4]
Purity: 98%
Optically pure
Soluble in water
C6H9NO2S MW: 159.21



mg	Price
10	online
50	online

Biological activity

S-Propargyl-cysteine (SPRC), a substrate of cystathionine γ -lyase (CSE), is a water-soluble modulator of endogenous hydrogen disulfide (H₂S). SPRC is a potential agent for the treatment of Alzheimer's disease (TNF signalling, the NF- κ B pathway and the ERK1/2 pathway), anemia of inflammation (IL-6/JAK2/STAT3 pathway), ischemic heart disease (H₂S/VEGFR2/STAT3 pathway) and myocardial infarction.

Sprycel

See Dasatinib

Axon 1392

Page 410


SPT Imidazopyridine 1

[1933533-18-6]
Purity: 98%

Axon 2835

mg	Price
10	online

Soluble in 0.1 N NaOH(aq) and DMSO
C22H24N2O3 MW: 364.44



50 online


Biological activity

Potent and efficacious serine palmitoyl transferase (SPT) inhibitor (IC₅₀ value of 5 nM) with a good in vitro profile and ADME characteristics. SPT Imidazopyridine 1 reduces plasma ceramides in rodents, has a slight trend toward enhanced insulin sensitization in DIO mice, and reduces triglycerides and raises HDL in cholesterol/cholic acid fed rats.

Squarunkin A

[2101958-02-3]
Purity: 99%

Soluble in DMSO
C25H32F3N5O4 MW: 523.55



Axon 2778

mg Price

10 online

50 online

Biological activity

Squarunkin A selectively inhibits the binding of a myristoylated peptide representing the N-terminus of Src kinase to UNC119A with an IC₅₀ value of 10 nM. It binds to UNC119 proteins in cell lysate and interferes with the activation of Src kinase.

SR1


See Stemregenin 1

Axon 1865

Page 894

SR1078 Recent Addition

[1246525-60-9]
Purity: 99%
98% e.e.
Soluble in DMSO and EtOH
C17H10F9NO2 MW: 431.25



Axon 4236

mg Price

10 online

50 online

Biological activity


SR1078 is a first ROR α / γ agonist which modulates the conformation of ROR γ in a biochemical assay and activates ROR α and ROR γ driven transcription. Furthermore, SR1078 stimulates expression of endogenous ROR target genes in HepG2 cells that express both RO

SR11237

BMS649; UVI2108

[146670-40-8]
Purity: 98%

Soluble in DMSO
C24H28O4 MW: 380.48



Axon 3727

mg Price

5 online

25 online

Biological activity

SR11237 is a selective retinoid X receptor (RXR) agonist.

SR 2516

See PND 1186


Axon 2459

Page 784

SR 3029

[1454585-06-8]
Purity: 99%

Soluble in DMSO
C23H19F3N8O MW: 480.45



Axon 2547

mg Price

5 online

25 online


Biological activity

A potent, highly specific CK1 δ /CK1 ϵ inhibitor (IC₅₀ values 44 nM and 260 nM for CK1 δ , and CK1 ϵ , respectively), that selectively inhibits breast cancer cell growth and survival. SR-3029 exhibits in vitro and in vivo PK properties suitable for use in xenograft studies of human cancers, including brain cancers.

SR 3576

[1164153-22-3]
Purity: 99%

Soluble in DMSO
C27H27N5O5 MW: 501.53



Axon 2365

mg Price

10 online

50 online


Biological activity

Very potent JNK3 inhibitor (IC₅₀ value 7 nM) with >2800-fold selectivity over p38 (p38 IC₅₀ value >20 μ M) and a cell-based potency of ca. 1 μ M.

SR-4370

[1816294-67-3]
Purity: 99%

Soluble in DMSO
C17H18F2N2O MW: 304.33



Axon 4034

mg Price

10 online

50 online

Biological activity

SR-4370 is a synthetic inhibitor of histone deacetylase (HDAC), Preferentially inhibiting HDAC3 (IC₅₀=60nM) over HDAC1 (IC₅₀=500nM) and HDAC2(IC₅₀=100nM).

Source Information: Sold in collaboration with Chemietek

SR 9243


[1613028-81-1]
Purity: 99%

Axon 2598

mg Price

10 online

Soluble in DMSO
C31H32BrNO4S2 MW: 626.62



50 online

Biological activity

LXR inverse agonist that induces LXR-corepressor interaction inhibiting the Warburg effect and lipogenesis in cancer cells by reducing glycolytic and lipogenic gene expression. SR 9243 induced apoptosis in tumors without inducing weight loss, hepatotoxicity, or inflammation. Moreover, SR 9243 may mediate tumor "unmasking" via downregulation of the immune-suppressive effects of LXR ligands within the tumor microenvironment. Close analogue of GSK 2033 (Axon 2363)

SR 11247

See Bexarotene


Axon 1700

Page 298

SR 19881

[2213490-89-0]
Purity: 99%

Soluble in DMSO
C19H24N2O2 MW: 312.41



Axon 2967

mg Price

10 online

50 online

Biological activity


SR 19881 is a potent full agonist of ERR γ with an EC₅₀ value of 0.39 μ M in a binding assay and an EC₅₀ value of 4.7 μ M in a cell-based assay. SR 19881 was also equipotent on ERR β with an EC₅₀ value of 0.63 μ M making it an equipotent dual agonist of ERR β/γ .

SR 27897

Lintitript

[136381-85-6]
Purity: 99%

Soluble in DMSO
C20H14ClN3O3S MW: 411.86



Axon 1245

mg Price

10 online

50 online

Biological activity

Potent and selective CCK1 antagonist

SR 33557

See Fantofarone

Axon 2952

Page 474

SR 46349B

See Eplivanserin

Axon 1439

Page 462

SR 48692

Meclinertant


[146362-70-1]

Axon 1164

mg Price

Purity: 99%

Low solubility in organic solvents
C32H31ClN4O5 MW: 587.07



2 online

5 online


Biological activity

An orally active, non-peptide, high affinity neurotensin (NT1 or NTS1) receptor antagonist

SR 49059

Relcovaptan

[150375-75-0]
Purity: 98%
optically pure
Soluble in DMSO
C28H27Cl2N3O7S MW: 620.50



Axon 1256

mg Price

5 online

25 online

Biological activity


Highly potent and selective vasopressin V1A receptor antagonist

SR 141716A

Rimonabant

[168273-06-1]
Purity: 99%

Soluble in DMSO and Ethanol
C22H21Cl3N4O MW: 463.79



Axon 1220

mg Price

10 online

50 online

Biological activity

CB1 antagonist

SR 142801

See Osanetant


Axon 1533

Page 737

SR 142948

[184162-64-9]
Purity: 98%

Soluble in water
C39H51N5O6 MW: 685.85



Axon 1255

mg Price

5 online

25 online

Biological activity

Neurotensin (NT) receptor antagonist; orally active in vivo

SR 144528


[192703-06-3]
Purity: 99%

Axon 1924

mg Price

5 online

Soluble in DMSO
C29H34ClN3O MW: 476.05



25 online


Biological activity

Potent and highly selective CB2 receptor antagonist and/or an inverse agonist, with a K_i of 0.6 nM at CB2 and 400 nM at the related CB1 receptor; Useful chemical probe in researching CB2 receptor

SR-318

[2413286-32-3]
Purity: 99%

Soluble in DMSO
C27H33N5O2 MW: 459.58



Axon 3183

mg Price

5 online

25 online

Biological activity

SR-318 is a highly potent and selective type-II p38 α/β inhibitor with IC_{50} values of 3.7 and 10 nM for p38 α and p38 β , respectively. SR-318 also potently inhibited the TNF- α release in whole blood.

SR33589 hydrochloride

See Dronedarone hydrochloride


Axon 3450

Page 442

SR-4835

[2387704-62-1]
Purity: 99%

Soluble in DMSO
C21H20Cl2N10O MW: 499.36



Axon 3184

mg Price

5 online

25 online

Biological activity

SR-4835 is a potent, highly selective and orally bioavailable dual inhibitor of CDK12 and CDK13 (IC_{50} value of 99 nM for CDK12; K_d values of 98 and 4.9 nM for CDK12 and CDK13, respectively). SR-4835 has potent cell-based and *in vivo* anti-triple-negative breast cancer (TNBC) activity and augments the anti-cancer activity of cisplatin, irinotecan, and olaparib, which are standard-of-care therapeutics for TNBC.

SR 720-22

See Metolazone

Axon 4026

Page 651

SRF

See Suprafenacine


Axon 2398

Page 901

SRI-011381 hydrochloride

[2070014-88-7]
Purity: 98%

Soluble in water and DMSO
C20H31N3O.HCl MW: 365.94




Biological activity

SRI-011381 hydrochloride is a TGF- β signaling agonist.

SRPIN 340

[218156-96-8]
Purity: 99%

Soluble in DMSO
C18H18F3N3O MW: 349.35




Biological activity

Selective ATP competitive inhibitor of SRPK kinase activity (K_i 0.89 μ M for SRPK1; 99.2% inhibition of RS-repeat peptide substrate phosphorylation at 10 μ M). SRPIN340 does not inhibit other classes of Serine-Arginine-Rich Protein Kinases (SRPKs) significantly, including Clk1 and Clk4 and >140 other SR kinases. SRPIN 340 promotes SRp75 degradation, and dose dependently suppressed HCV 1b and 2a replication (EC_{50} values of 4.7 μ M and 15.8 μ M resp.) and propagation of Sindbis and HCV-JFH1 viruses in cell culture.

SRS11-92

[1467047-25-1]
Purity: 99%

Soluble in DMSO
C22H28N2O2 MW: 352.47




Biological activity

SRS11-92 is a ferroptosis inhibitor with an EC_{50} value of 6 nM for erastin lethality suppression.

SRT 1720 tetrahydrochloride

[1001645-58-4]
Purity: 99%

Soluble in DMSO and water
C25H23N7OS.4HCl MW: 615.41



Biological activity

A small-molecule activator of the sirtuin subtype SIRT1; 1000x more potent than resveratrol. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and met

SSR 69071

[344930-95-6]
Purity: 99%

Axon 2943

mg Price

10 online

50 online

Axon 2200

mg Price

10 online

50 online

Axon 3427

mg Price

5 online

25 online

Axon 1875

mg Price

5 online


25 online

Axon 1269

mg Price

10 online

Soluble in DMSO and Ethanol
C27H32N4O7S MW: 556.63



50 online


Biological activity

A highly potent human leukocyte elastase (HLE) inhibitor (0.02 nM)

SSR 125543A

SSR 125543 hydrochloride

[321839-75-2]
Purity: 98%
Optically pure
Soluble in DMSO
C27H28ClFN2OS.HCl MW: 519.50



Axon 1799

mg	Price
5	online
25	online

Biological activity

Potent, selective, and orally active corticotropin-releasing factor 1 receptor (CRF1) antagonist (pKi values of 8.73 and 9.08 for human cloned or native CRF1 receptors, respectively) with antidepressant-like and anxiolytic-like effects in the Flinders Sensitive Line rats. SSR 125543A shows a 1000-fold selectivity for CRF1 versus CRF2a receptor and CRF binding protein, has a long duration of action, and readily crosses the blood-brain barrier.

SSR 125543 hydrochloride


See SSR 125543A

Axon 1799

Page 891

SSR 128129E

[848318-25-2]
Purity: 99%



Soluble in water and DMSO
C18H15N2O4.Na MW: 346.31

Axon 2234

mg	Price
10	online
50	online


Biological activity

Extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling with oral bioavailability. SSR 128129E inhibits responses mediated by FGFR1-4 (IC50 values 15-28 nM for FGFR2 induced FGFR stimulation), but not by other related RTKs. SSR 128129E does not inhibit all FGFR signaling pathways indiscriminately but selectively blocks particular signaling pathways, dependent on the cellular context. Capable of inhibiting angiogenesis, inflammation, and bone resorption in arthritis, and delays tumor growth and metastasis.

SSR 149415

Nelivaptan

[439687-69-1]
Purity: 99%
>98% ee
Soluble in DMSO
C30H32ClN3O8S MW: 630.11



Axon 1114


mg	Price
5	online
25	online

Biological activity

Selective and orally active non-peptide antagonist of vasopressin V(1b) receptor, potential drug for treatment of anxiety and depression

SSR 504734

[615571-23-8]
Purity: 99%
>98% ee
Soluble in water and DMSO
C20H20ClF3N2O.HCl MW: 433.29



Axon 1549

mg	Price
2	online
5	online

Biological activity

A potent, selective and orally active GlyT-1 inhibitor, blocked the ex vivo uptake of glycine rapidly, reversibly, and for a long duration; exhibiting activity in animal models of schizophrenia, anxiety and depression

SSZ


See Sulfasalazine

Axon 2070

Page 899

ST 91

[4749-61-5]
Purity: 99%



Soluble in water, DMSO and Ethanol
C13H19N3.HCl MW: 253.77

Axon 1290


mg	Price
10	online
50	online

Biological activity

α2 Adrenoceptor agonist

ST 148

[390803-40-4]
Purity: 99%



Soluble in DMSO and Ethanol
C27H36N4O3S.C4H4O4
MW: 612.74

Axon 1342


mg	Price
10	online
50	online

Biological activity

Dopamine D2 receptor antagonist; with improved selectivity for hD2L receptors

ST 198

[854924-64-4]
Purity: 99%



No solubility data
C22H26N2O MW: 334.45

Axon 1343

mg	Price
10	online
50	online

Biological activity

Dopamine D3 receptor antagonist

STA4783

See Elesclomol


Axon 3745

Page 454

STA 5326

Apilimod

[541550-19-0]
Purity: 99%



Soluble in 0.1N HCl(aq) and DMSO
C23H26N6O2 MW: 418.49

Axon 1369

mg	Price
5	online
25	online


Biological activity

Potent and orally active inhibitor of the cytokines interleukin-12 (IL-12), and interleukin-23 (IL-23) production; potential regulators of certain autoimmune and inflammatory diseases

STA 9090

Ganetespib

[888216-25-9]
Purity: 99%



Soluble in 0.1N NaOH(aq) and DMSO
C20H20N4O3 MW: 364.40

Axon 1968


mg	Price
5	online
25	online

Biological activity

Hsp90 inhibitor; exhibits potent antitumor activity and a superior safety profile for cancer therapy; with potent in vitro and in vivo activity in tumor cells harboring constitutively active JAK/STAT signaling

STAT5 Inhibitor 1 [285986-31-4]

[285986-31-4]
Purity: 98%



Soluble in DMSO
C16H11N3O3 MW: 293.28

Axon 2731


mg	Price
10	online
50	online

Biological activity

STAT5 Inhibitor 1 [285986-31-4] is a first nonpeptidic small-molecule which selectively inhibits the function of the STAT5b domain (IC50 value of 47 μM), STAT5 DNA binding in vitro, and activation of STAT5 in a cancer cell line. Also selective impairment of STAT5 phosphorylation with STAT5 Inhibitor 1 markedly reduced iTregs.

Stattic

[19983-44-9]
Purity: 99%



Soluble in DMSO
C8H5NO4S MW: 211.19

Axon 2314

mg	Price
10	online
50	online


Biological activity

The first nonpeptidic small-molecule inhibitor of STAT3 activation, dimerization, and nuclear translocation (IC50 value 5.1 μM for inhibition of the binding of a phosphotyrosine-containing peptide derived from the gp130 receptor to the STAT3 SH2 domain). Stattic demonstrates good selectivity for STAT3 inhibition over STAT1, and increases the apoptotic rate of STAT3-dependent breast cancer cell lines.

Stavudine

2',3'-Didehydro-3'-deoxythymidine; d4T

[3056-17-5]
Purity: 99%
Optically pure
Soluble in water, DMSO and EtOH
C10H12N2O4 MW: 224.21



Axon 3491

mg	Price
50	online


Biological activity

Stavudine is a nucleoside analogue which undergoes intracellular phosphorylation to its active metabolite, stavudine-5'-triphosphate. At clinically relevant concentrations, the active metabolite restricts HIV replication by inhibiting the inclusion of thymidine-5'-triphosphate into proviral DNA by HIV reverse transcriptase, and/or by causing DNA chain termination.

STD1T

[893075-58-6]
Purity: 99%

Soluble in DMSO
C19H19N3O4S2 MW: 417.50



Axon 3608

mg	Price
5	online
25	online

Biological activity


STD1T is an inhibitor of USP2a with an IC50 value of 3.3 μM (Ub-AMC assay).

Stemregenin 1

SR1

[1227633-49-9]
Purity: 99%

Soluble in DMSO
C24H23N5OS MW: 429.54



Axon 1865

mg	Price
10	online
50	online


Biological activity

Aryl hydrocarbon receptor (AHR) antagonist that promotes the self-renewal of human hematopoietic stem cells (HSC) in culture. SR1 promotes the ex vivo expansion of CD34+ cells. Culture of HSCs with SR1 led to a 50-fold increase in cells expressing CD34 and a 17-fold increase in cells that retain the ability to engraft immunodeficient mice

STF 31

[724741-75-7]
Purity: 99%

Soluble in DMSO
C23H25N3O3S MW: 423.53



Axon 1905

mg	Price
10	online
50	online

Biological activity

Inhibitor of glucose transporter 1 (GLUT1)


STF 62247

Axon 2894

mg	Price
----	-------

[315702-99-9]
Purity: 99%

Soluble in DMSO
C15H13N3S MW: 267.35



10	online
50	online


Biological activity

STF 62247 selectively targets VHL-deficient renal cell carcinoma (RCC) cells (IC50 value of 0.625 μ M in RCC4). STF 62247-stimulated toxicity occurs in a HIF-independent manner through autophagy. Moreover, STF 62247 induced apoptotic and autophagic cell death in leukemic cells.

STF 083010

[307543-71-1]
Purity: 99%

Soluble in DMSO
C15H11NO3S2 MW: 317.38



Axon 1670

mg	Price
10	online
50	online


Biological activity

Specific IRE1 α endonuclease inhibitor without affecting its kinase activity; shows significant antimyeloma activity in human MM xenografts

STF 118804

[894187-61-2]
Purity: 98%

Soluble in DMSO
C25H23N3O4S MW: 461.53



Axon 2253

mg	Price
10	online
50	online

Biological activity

Highly specific, next-generation NAMPT inhibitor, that reduces the viability of most B-ALL cell lines with high potency demonstrating IC50 values in the low nanomolar range, and improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leukemia. Additionally, STF 118804 induces leukemia cell apoptosis without antecedent cell cycle arrest, and targets leukemia stem cells.

STI 571

See Imatinib Mesylate


Axon 1394

Page 561

STING activator C53

[2259624-71-8]
Purity: 99%

Soluble in DMSO
C25H19ClF4N2O2 MW: 490.88



Axon 3673

mg	Price
10	online
50	online

Biological activity

STING activator C53 demonstrated robust on-target functional activation of STING (EC50 value of 185 nM) in immortalised and primary cells and a cytokine induction fingerprint consistent with STING activation.

STING Inhibitor 1

See STING inhibitor C-176


Axon 2923

Page 896

STING inhibitor C-176

STING Inhibitor 1

[314054-00-7]
Purity: 99%



Soluble in DMSO
C11H7IN2O4 MW: 358.09

Axon 2923


mg	Price
10	online
50	online

Biological activity

C-176 is a highly potent and selective small-molecule antagonist of the stimulator of interferon genes (STING) protein. Moreover, C-176 attenuates pathological features of autoinflammatory disease in mice. Also, C-176 is an activator of CHOP expression and exhibits antitumor activity in TNBC cells.

STING inhibitor C-178

[329198-87-0]
Purity: 99%



Soluble in DMSO
C17H10N2O5 MW: 322.27

Axon 3058


mg	Price
10	online
50	online

Biological activity

C-178 is a highly potent and selective small-molecule antagonist of the stimulator of interferon genes (STING) protein.

Stiripentol

[49763-96-4]
Purity: 99%



Soluble in DMSO
C14H18O3 MW: 234.29

Axon 3119


mg	Price
10	online
50	online

Biological activity

Stiripentol is a positive allosteric modulator of the GABAA receptor. Antiepileptic drug.

STK16-IN-1

[1223001-53-3]
Purity: 99%



Soluble in DMSO
C17H12FN3O MW: 293.30

Axon 2743

mg	Price
10	online
50	online


Biological activity

STK16-IN-1 is a highly selective ATP-competitive inhibitor which exhibits potent inhibitory activity against STK16 kinase (IC50 value of 0.295 μ M). In MCF-7 cells, treatment with STK16-IN-1 results in a reduction in cell number and accumulation of binucleated cells, which can be recapitulated by RNAi knockdown of STK16. Co-treatment of STK16-IN-1 with chemotherapeutics results in a slight potentiation of the antiproliferative effects of the chemotherapeutics.

STL427944

[292028-62-7]
Purity: 99%

Soluble in DMSO
C25H23N7O4 MW: 485.49



Axon 4050

mg Price

5 online

25 online


Biological activity

STL427944 is FOXM1 inhibitor which selectively suppresses FOXM1 by inducing the relocalization of nuclear FOXM1 protein to the cytoplasm and promoting its subsequent degradation by autophagosomes. STL427944 suppresses FOXM1 activity in a variety of human cancer cell lines.

STM2457

[2499663-01-1]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C25H28N6O2 MW: 444.53



Axon 3587

mg Price

5 online

25 online


Biological activity

STM2457 is a first-in-class, highly potent and selective catalytic inhibitor of the m6A writer METTL3 (IC50 of 16.9 nM for METTL3/METTL14 catalytic activity).

Stobadine

[85202-17-1]
Purity: 99%

Soluble in 0.1N HCl(aq)
C13H18N2 MW: 202.30



Axon 1467

mg Price

5 online

25 online

Biological activity

Antioxidant; antiarrhythmic, cardiovascular drug

STS557

See Dienogestrel


Axon 3461

Page 426

STX64

[288628-05-7]
Purity: 99%

Soluble in DMSO
C14H15NO5S MW: 309.34



Axon 2892

mg Price

5 online

25 online

Biological activity

Potent steroid sulfatase (STS) inhibitor with an IC50 value of 8 nM. First STS inhibitor to enter diverse clinical trials for patients with advanced hormone-dependent cancer.

SU11654

See Toceranib phosphate


Axon 3624

Page 934

SU 5402

[215543-92-3]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C17H16N2O3 MW: 296.32



Biological activity

Fibroblast growth factor receptor (FGFR) inhibitor

Axon 1667

mg Price

1 online


2 online

5 online

SU 6656

[330161-87-0]
Purity: 99%

Soluble in DMSO
C19H21N3O3S MW: 371.45



Biological activity

A selective Src family kinase inhibitor

Axon 1136

mg Price

10 online


50 online

SU 6668

TSU 68; Orantinib

[252916-29-3]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C18H18N2O3 MW: 310.35



Biological activity

An ATP-competitive, orally bioavailable receptor tyrosine kinase (RTK) inhibitor targeting PDGFR, VEGF and FGFR (IC50 values are 0.06, 2.43, 3.04 and >100 μM at PDGFRβ, VEGFR2, FGFR1 and EGFR respectively)

Axon 1891

mg Price

10 online

50 online

SU 11248

See Sunitinib malate


Axon 1398

Page 900

SU 11274

[658084-23-2]
Purity: 99%

Soluble in DMSO
C28H30ClN5O4S MW: 568.09



Biological activity

Axon 1581

mg Price

5 online


25 online

ATP-competitive and selective MET inhibitor; inhibition of the Met kinase activity by SU11274 led to time- and dose-dependent reduced cell growth and induced G1 cell cycle arrest and apoptosis

SU11652

[326914-10-7]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H27ClN4O2 MW: 414.93



Biological activity

SU11652 is a sunitinib-like RTK inhibitor of PDGFR- β , VEGFR2, FGFR1 and FLT3, with IC50 values of 3, 27, 170 and 1.5 nM, respectively. Moreover, SU11652 inhibits cKit, acid sphingomyelinase, destabilizes lysosomes, and inhibits multidrug resistance.

Subasumstat oxalate

See TAK-981 oxalate

Suberanilohydroxamic acid


See Vorinostat

Sulbactam sodium

CP 45899 sodium

[69388-84-7]
Purity: 98%

Soluble in water and DMSO
C8H10NNaO5S MW: 255.22



Biological activity


An irreversible inhibitor of β -lactamase; it binds the enzyme and does not allow it to interact with the antibiotic
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Sulfaphenazole

Depocid; Depotsulfonamide; Plisulfan; Raziosulfa

[526-08-9]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C15H14N4O2S MW: 314.36



Biological activity

Sulfaphenazole is a potent and very selective inhibitor for CYP2C9 with a Ki value between 0.11 and 0.7 μ M.
Antibiotic.

Sulfasalazine

SSZ

[599-79-1]
Purity: 99%

Axon 2767

mg	Price
10	online
50	online

Axon 3797

Page 908

Axon 3114

Page 972

Axon 2041

mg	Price
25	online
100	online


Axon 2922

mg	Price
50	online

Axon 2070

mg	Price
25	online

Soluble in 0.1N NaOH(aq) and DMSO
C18H14N4O5S MW: 398.39



100 online

Biological activity

An old drug with new applications

A Sulfa drug developed in 1950s and used in the treatment of inflammatory bowel disease and rheumatoid arthritis. This old drug was found in recent study to reverse severe liver disease. Sulfasalazine (SSZ) is a potent and selective inhibitor of NF- κ B activation via its ability to block the activity of the inhibitor of κ B ($I\kappa$ B) kinases α and β (IKK α and IKK β). Sulfasalazine stimulates apoptosis of activated hepatic stellate cells and recovery from CCl4-induced fibrosis

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Sulfonamide 13

See JAK2 inhibitor 13

Axon 1843


Page 576

Sumatriptan succinate

GR 43175; GW 102; SN 308

[103628-48-4]
Purity: 99%

Soluble in DMSO
C14H21N3O2S.C4H6O4
MW: 413.49



mg	Price
10	online
50	online

Biological activity

Selective 5-HT1B/1D receptor agonist indicated for the treatment of migraine headaches

SUN5555

See Faropenem sodium **Recent Addition**


Axon 4206

Page 474

Sunepitron hydrochloride

CP 93393 hydrochloride; CP 93393-1

[148408-65-5]
Purity: 99%
Optically pure
Soluble in water and DMSO
C17H23N5O2.HCl MW: 365.86



mg	Price
5	online
25	online

Biological activity

Sunepitron is a selective serotonin 5-HT1A autoreceptor agonist, α 2-adrenergic antagonist, and dopamine D2 agonist. Anxiolytic, antidepressant.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Sunitinib malate


SU 11248; Sutent

[341031-54-7]
Purity: 99%

Soluble in DMSO
C23H29FN4O.C4H6O5 MW: 530.59

Axon 1398

mg	Price
10	online
50	online



Biological activity


Small molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib inhibits cellular signaling by targeting multiple RTKs, including PDGF-R/VEGF-R

Suprafenacine

SRF

[1477482-50-0]
Purity: 99%

Soluble in DMSO
C₁₆H₁₈N₄O MW: 282.34



Axon 2398

mg	Price
10	online
50	online

Biological activity

Destabilizer of microtubules (IC₅₀ value 0.38 μM for microtubule polymerization inhibition) that causes cell cycle arrest in the G₂/M phase and cell death by apoptosis. Suprafenacine (SRF) was found to selectively inhibit cancer cell proliferation (IC₅₀ values 83 - 381 nM in various cancer cell lines) and was effective against drug-resistant cancer cells by virtue of its ability to bypass the multidrug resistance transpo

Sutent

See Sunitinib malate


Axon 1398

Page 900

SUVN-502

[1791396-46-7]
Purity: 99%

Soluble in water and DMSO
C₂₃H₃₂BrN₃O₉S₃ MW: 670.71



Axon 2715

mg	Price
10	online
50	online

Biological activity

SUVN-502 is a potent, selective and orally active serotonin 6 (5-HT₆) receptor antagonist (K_i value of 2.04 nM) with selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins. Moreover, it has high selectivity over 5-HT_{2A} receptor. SUVN-502 is brain penetrant and a clinical candidate for potential treatment of cognitive disorders.

SUVN D4010

See Usmapride

Axon 3595

Page 957

SY5555

See Faropenem sodium Recent Addition

Axon 4206

Page 474

Synvinolin

See Simvastatin

Axon 3443

Page 866

SYR-322

See Alogliptin benzoate

Axon 3310

Page 219

SYR 472

See Trelagliptin succinate

Axon 2470

Page 938

SYR 111472 succinate

See Trelagliptin succinate


Axon 2470

Page 938

T 1776Na

[1202075-60-2]
Purity: 99%

Poorly soluble in DMSO
C25H18NO4.Na MW: 419.40



Biological activity

Inhibitor of plasminogen activator inhibitor-1 (PAI-1)

Axon 1769

mg Price


10 online

50 online

T 98475

[199119-18-1]
Purity: 98%

No solubility data
C37H37F2N3O4S MW: 657.77



Biological activity

Potent and orally active antagonist of Gonadotropin releasing hormone (GnRH), also known as luteinising hormone releasing hormone (LHRH)

Axon 1270

mg Price

2 online

5 online

T5601640

See T56-LIMKi

Axon 2721

Page 903

T-705

See Favipiravir

Axon 3135

Page 475

T-1551

See Cefoperazone


Axon 3123

Page 357

T0901317

[293754-55-9]
Purity: 98%

Soluble in DMSO
C17H12F9NO3S MW: 481.33



Biological activity

T0901317 is selective liver X receptor (LXR) agonist (EC50 value of 20 nM). Oral administration of T0901317 to mice and hamsters showed that LXR activated the coordinate expression of major fatty acid biosynthetic genes (lipogenesis) and increased plasma triglyceride and phospholipid levels in both species. Complementary studies in cell culture and animals suggested that the increase in plasma lipids occurs via LXR-mediated induction of the sterol regulatory element-binding protein 1 (SREBP-1) lipogenic program.

Axon 2754

mg Price

10 online

50 online

T56-LIMKi

T5601640


[924473-59-6]

Axon 2721

mg Price

Purity: 99%

Soluble in DMSO
C19H14F3N3O3 MW: 389.33



10 online

50 online

Biological activity

T56-LIMKi is an inhibitor of LIMK2. T56-LIMKi efficiently inhibited the growth of NF1-/- MEF, ST88-14, U87, and Panc-1 cells with IC50 values of 30 μ M, 18 μ M, 7 μ M, and 35 μ M, respectively. Moreover, T56-LIMKi reduced tumor size and p-cofilin levels in the Panc-1 tumors in vivo. Potential drug for pancreatic cancer, glioma and schwannoma cells.

T614

See Igaratimod

Axon 4048

Page 560

TA-7284

See Canagliflozin

Axon 3122


Page 341

Tacalcitol

PRI 2191; 1 α ,24-Dihydroxycholecalciferol

[57333-96-7]
Purity: 98%

Soluble in DMSO
C27H44O3 MW: 416.64



mg Price

2 online

5 online

Biological activity

Vitamine D receptor agonist (EC50 value 7 nM for VDR) and metabolite of vitamin D3 with a higher antitumor and lower calcemic activity as well as lower toxicity than Calcitriol. Tacalcitol inhibits proliferation and induces differentiation of keratinocytes. Tacalcitol promotes normal bone formation, and is a well-known inhibitor of chemical mediated inflammatory changes including dermal cellular infiltration and epidermal hyperplasia, used to treat T cell-mediated inflammatory skin diseases such as Tacalcitol enhances the antiproliferative effect of Imatinib (Axon 1394) on HL-60 cells.

Note: Axon 2516 is the stable monohydrate formulation of Tacalcitol

Tacedinaline

See Cl 994

Axon 2014


Page 369

Tacrolimus

FK 506

[104987-11-3]

Purity: 99%
Optically pure
Soluble in DMSO
C44H69NO12 MW: 804.02



mg Price

10 online

50 online

Biological activity


Potent Calcineurin inhibitor (calcium dependent serine/threonine protein phosphatase 2B). The mechanism of action of FK 506 (Tacrolimus) involves the formation of a molecular complex with the the immunophilin FKBP12 (IC50 value 3 nM), to reduce its peptidyl-prolyl isomerase activity. Tacrolimus potently inhibits T-cell activation-induced TNF- α , IL-1 β , IL-2, IL-3, IL-4, and IL-6 production, but does not affect LPS-induced cytokine production and proliferation of normal cells, such as bone marrow cells. Immunosuppressant, neuroprotectant and anticonvulsant.

TAE226

NVP-TAE226

[761437-28-9]
Purity: 99%

Soluble in DMSO
C23H25ClN6O3 MW: 468.94



Axon 3866

mg	Price
5	online
10	online

Biological activity

TAE226 is a potent FAK inhibitor with IC50 of 5.5 nM and a moderately potent IGF-1R inhibitor (IC50 of 140 nM). TAE 226 was also found to be effective as inhibitor for Pyk2 (with a reported IC50 of 3.5 nM) and insulin receptor (InsR) (with a reported IC50 of 44 nM). Furthermore TAE226 was also found to induce apoptosis.

TAE 684

See NVP-TAE684


Axon 1416

Page 726

Tafamidis

[594839-88-0]
Purity: 99%

Soluble in DMSO
C14H7Cl2NO3 MW: 308.12



Axon 3533

mg	Price
10	online
50	online

Biological activity


Tafamidis is a small-molecule inhibitor that binds selectively to the transthyretin (TTR) protein in human plasma and kinetically stabilizes the tetrameric structure of both wild-type TTR and a number of different mutants. Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR). It is a transthyretin stabilizer and has been shown to reduce disease progression and mortality significantly.

Tafamidis meglumine Recent Addition

Fx-1006A

[951395-08-7]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C14H7Cl2NO3.C7H17NO5 MW:
503.33



Axon 4021

mg	Price
10	online
50	online

Biological activity

Tafamidis meglumine is a small-molecule inhibitor that binds selectively to the transthyretin (TTR) protein in human plasma and kinetically stabilizes the tetrameric structure of both wild-type TTR and a number of different mutants. Tafamidis is an oral me

Tagtociclib

See PF-07104091


Axon 3753

Page 762

TAK 063

[1238697-26-1]
Purity: 99%

Soluble in DMSO
C23H17FN6O2 MW: 428.42



Axon 2399

mg	Price
5	online
25	online

Biological activity

Highly potent, and orally active PDE10A inhibitor (IC50 value 0.30 nM) with excellent selectivity (>15000-fold selective over other PDEs). TAK-063 represents a promising drug for the treatment of schizophrenia with potential for superior safety and tolerability profiles.

TAK-117

See Serabelisib

Axon 4075


Page 861

TAK 165

Mubritinib

[366017-09-6]
Purity: 99%

Soluble in DMSO
C25H23F3N4O2 MW: 468.47



Axon 2053

mg	Price
5	online
10	online

Biological activity

Highly selective, potent and irreversible human epidermal growth factor receptor 2 (HER2 aka ErbB2) antagonist (IC50: 6 nM); recommended tool compound for HER2 selective inhibition

TAK-243

See MLN7243


Axon 3829

Page 674

TAK 259

[1192347-42-4]
Purity: 99%

Soluble in water and DMSO
C14H13Cl2N3O3S.HCl MW: 410.70



Axon 2579

mg	Price
10	online
50	online


Biological activity

Novel, selective, and orally active α 1D adrenoceptor antagonist (Ki value 1.1 nM, and 200-800 fold selective over α 1A and α 1B, respectively) with anti-urinary frequency effects: reducing human Ether-a-go-go-Related Gene (hERG) liabilities Clinical candidate, and a promising novel therapeutic agent for the treatment of OAB (overactive bladder) symptoms.

TAK 438

[881681-01-2]
Purity: 98%

Soluble in DMSO
C17H16FN3O2S.C4H4O4
MW: 461.46



Biological activity

Potassium-competitive acid blocker (P-CAB); reversibly inhibits gastric H⁺, K⁺-ATPase; TAK-438 exerts a longer and more potent antisecretory effect than lansoprazole as a result of its high accumulation and slow clearance from the gastric glands


TAK536

See Azilsartan

TAK-632

[1228591-30-7]
Purity: 99%

Soluble in DMSO
C27H18F4N4O3S MW: 554.52



Biological activity


TAK-632 is a potent and selective pan-RAF inhibitor targeting B-RAF V600E (IC₅₀ = 2.4 nM), C-RAF (IC₅₀ 1.4 nM) and VEGFR (IC₅₀ = 160 nM), displaying significant cellular activity against mutated BRAF and mutated NRAS cancer cell lines.

Source Information: Sold in collaboration with Chemietek

TAK 700

Orteronel

[566939-85-3]
Purity: 99%
Optically pure
Soluble in DMSO
C18H17N3O2 MW: 307.35



Biological activity

Potent, orally available, and highly selective inhibitor of 17,20-lyase (CYP17A1; IC₅₀ value 19 nM and 48 nM for human and rat respectively) and of correlated androgen synthesis. TAK 700 exhibits no affinity for CYP11B 1 and CYP3A4 (IC₅₀ values >1000 nM and >10000 nM resp.), nor for other isoforms of the human CYP enzyme (IC₅₀ values >14000 nM). When given orally to monkeys at a dose of 1 mg/kg, TAK 700 markedly reduced serum testosterone and DHEA at 5 h after administration.

TAK 700 was selected for evaluation in patients in phase III clinical trials for the potential treatment of prostate cancer

TAK-788

Mobocertinib; AP32788

[1847461-43-1]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C32H39N7O4 MW: 585.70

Axon 1971

mg	Price
5	online
25	online

Axon 3363

Page 279

Axon 4033

mg	Price
10	online
50	online

Axon 2124


mg	Price
5	online
25	online

Axon 3232

mg	Price
10	online
50	online

Biological activity


TAK-788 is a potent and selective dual EGFR/HER2 tyrosine kinase inhibitor. Specifically, TAK-788 inhibited all 14 mutant variants of EGFR (IC₅₀ values between 2.4 and 22 nM), and all 6 mutant variants of HER2 (IC₅₀ values between 2.4 and 26 nM), more potently than it inhibited WT EGFR (IC₅₀ value of 35 nM), including all 8 variants with exon 20 activating insertions.



TAK-931

Simurosertib

[1330782-76-7]
Purity: 99%
100% e.e.
Soluble in DMSO
C17H19N5OS MW: 341.43



Biological activity

TAK-931 (Simurosertib) is an orally bioavailable, ATP competitive, potent and selective inhibitor of CDC7 (cell division cycle 7-related protein kinase) with IC₅₀ < 0.3 nM, and highly selective on target when compared with other 308 kinases. It demonstrates strong antitumor activities in both in vitro and in vivo models.


TAK935

See Soticlestat

TAK-981 oxalate

Subasumstat oxalate

[N.A.]
Purity: 99%
99% e.e.
Soluble in DMSO
C25H28ClN5O5S2 MW: 668.14



Biological activity

TAK-981 oxalate is a first-in-class selective small molecule inhibitor of SUMOylation and an immuno-oncology agent. It targets and covalently binds to the small ubiquitin-like modifier (SUMO) protein, forming an adduct (TAK-981-SUMO adduct)

Source Information: Sold in collaboration with Chemietek

Takinib

EDHS-206

[1111556-37-6]

Axon 3605

mg	Price
5	online
25	online

Axon 3485

Page 880


Axon 3797

mg	Price
2	online
5	online

Axon 3282

mg	Price
----	-------

Purity: 99%
Soluble in DMSO
C18H18N4O2 MW: 391.46



10 online
50 online

Biological activity

Takinib is a potent and selective TAK1 inhibitor (IC50 value of 0.0095 μM) that induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer.

Taladegib

See LY 2940680


Axon 2196

Page 634

Talazoparib

BMN 673; LT 00673

[1207456-01-6]
Purity: 99%
Optically pure
Soluble in DMSO
C19H14F2N6O MW: 380.35



Axon 2502

mg	Price
2	online
5	online

Biological activity

Potent, selective, and orally available PARP1/2 inhibitor (IC50 value 0.57 nM for PARP1) that shows antitumor cytotoxicity with 20- to more than 200-fold greater potency than earlier-generation PARP1/2 inhibitors and with selectivity for tumor cells with BRCA1, BRCA2, or PTEN gene defects.

Talipexole

See B-HT 920 dihydrochloride

Axon 1153

Page 301

Talmapimod

See SCIO 469

Axon 1671

Page 858

Taltobulin

See HTI 286

Axon 1650

Page 547

Tamiflu

See Oseltamivir phosphate

Axon 3136

Page 737

Taminadenant


See PBF-509

Axon 4132

Page 749

Tamoxifen

[10540-29-1]
Purity: 99%
N.A.
Soluble in 0.1N HCl(aq) and DMSO
C26H29NO MW: 371.51



Axon 3252
mg Price
50 online
250 online

Biological activity


Tamoxifen is a first-generation selective estrogen receptor modulator (SERM).

Tandospirone citrate

SM-3997

[112457-95-1]
Purity: 99%

Soluble in DMSO
C21H29N5O2.C6H8O7 MW: 575.61



Axon 3130

mg	Price
10	online
50	online

Biological activity

Tandospirone citrate is a potent 5-HT1A partial agonist with a Ki value of 27 nM. Tandospirone citrate is approximately two to three orders of magnitude less potent at 5-HT2, 5-HT1C, alpha 1-adrenergic, alpha 2-adrenergic, and dopamine D1 and D2 receptors (Ki values ranging from 1300 to 41000 nM). Anxiolytic agent.

Tandutinib

See CT 53518

Axon 1415

Page 396

Tanzisertib

See CC-930

Axon 2634

Page 349

Tapotoclax

See AMG-176

Axon 3686

Page 224

Taranabant

See MK 0364

Axon 1550

Page 660

Targetin

See Bexarotene

Axon 1700


Page 298

Tariquidar

XR 9576

[206873-63-4]
Purity: 98%

Soluble in DMSO
C38H38N4O6 MW: 646.73



mg	Price
10	online
50	online

Biological activity

Potent and specific inhibitor of P-glycoprotein (P-gp, ABCB1); also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2)

TAS-103 dihydrochloride


BMS 247615 dihydrochloride

[174634-09-4]
Purity: 99%

Axon 2914

mg	Price
5	online

Soluble in water and DMSO
C20H19N3O2.2HCl MW: 406.31



25 online

Biological activity

TAS-103 dihydrochloride is an anticancer agent targeting topoisomerases I and II with IC50 values of 2 μ M and 6.5 μ M, respectively. Moreover, TAS-103 dihydrochloride has a strong cytotoxic effect on P388 and KB cells with IC50 values of 0.0011 μ M and 0.0096 μ M, respectively. Also, TAS-103 has strong inhibitory effects on the growth of various mouse and human solid tumors in vivo, as well as high antitumor activity against lung metastatic cancer.

TAS-109 hydrochloride


See CNDAC hydrochloride

Axon 3970

Page 380

TAS2940 Recent Addition

[2451398-65-3]
Purity: 98%
98% e.e.
Soluble in DMSO
C28H30N6O2 MW: 482.58



Axon 4272

mg	Price
10	online

Biological activity


TAS2940 is an orally active, brain-penetrable, and irreversible pan-ERBB inhibitor. TAS2940 has promising therapeutic effects against cancers harboring HER2/EGFR mutations, especially metastatic and primary brain tumors.

Source Information: Sold in collaboration with Chemietek

TAS6417

CLN-081

[1661854-97-2]
Purity: 99%
99% e.e.
Soluble DMSO
C23H20N6O MW: 396.44



Axon 3802

mg	Price
5	online
10	online

Biological activity

TAS6417 is a novel EGFR inhibitor targeting EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR.

Source Information: Sold in collaboration with Chemietek

Taselisib


GDC 0032; RG 7604

[1282512-48-4]
Purity: 99%

Soluble in DMSO
C24H28N8O2 MW: 460.53

Axon 2927

mg	Price
5	online
25	online



Biological activity

Taselisib is a β -sparing PI3K inhibitor with Ki values of 0.29, 0.12 and 0.97 nM for PI3K α , PI3K δ and PI3K γ , respectively. Moreover, Taselisib showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels.

Tasigna

See Nilotinib

Axon 1396

Page 703

Tasisulam

See LY 573636

Axon 1963

Page 632

Tasocitinib

See CP 690550

Axon 1338

Page 390

TAU

See Vistonuridine

Axon 3362


Page 970

Tavaborole

AN2690

[174671-46-6]
Purity: 99%

Soluble in DMSO
C7H6BFO2 MW: 151.93



mg	Price
10	online
50	online


Biological activity

Tavaborole is a broad-spectrum antifungal agent. Tavaborole was the most active against fungi and especially against the dermatophytes *T. rubrum* and *T. mentagrophytes*, the primary fungal pathogens causing onychomycosis.

Taxifolin

Dihydroquercetin

[480-18-2]
Purity: 99%
Optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C15H12O7 MW: 304.25



Axon 3338

mg	Price
50	online


Biological activity

Taxifolin, a plant polyphenol, acts as a type I inhibitor of VEGFR-2 kinase. Antioxidant.

Tazobactam acid

YTR830

[89786-04-9]
Purity: 98%
Optically pure
Soluble in water, 0.1N NaOH(aq) and DMSO
C10H12N4O5S MW: 300.29



Axon 3820

mg	Price
50	online


Biological activity

Tazobactam acid is an effective β -lactamase inhibitor. The combination of tazobactam acid with piperacillin showed a highly synergistic effect and could extend the spectrum of this antibiotic to include resistant β -lactamase producing organisms.

TB5

[948841-07-4]
Purity: 100%

Soluble in DMSO
C15H14BrNOS MW: 336.25



Axon 2629

mg	Price
10	online
50	online


Biological activity

Competitive and reversible MAO-B inhibitor (K_i values 1.45 μ M and 0.11 μ M for hMAO-A and hMAO-B, respectively) capable of crossing the BBB. Valuable tool for development of drugs for neurodegenerative disorders such as Parkinson's and Alzheimer's diseases.

TBPB

[634616-95-8]
Purity: 100%

Soluble in DMSO
C25H32N4O MW: 404.55



Axon 2463

mg	Price
10	online
50	online


Biological activity

Selective allosteric activator of the M1 muscarinic acetylcholine receptor (EC_{50} value 20 nM at hM1-WT) devoid of M2-M5 activity. TBPB increases non-amyloidogenic APP processing and produces antipsychotic-like effects in rodent models predictive of antipsychotic-like activity.

tBT-HBT

[N.A.]
Purity: 98%

Soluble in DMSO and EtOH
C21H25N3OS2 MW: 399.57



Axon 3602

mg	Price
10	online
50	online

Biological activity

tBT-HBT is a noncovalent, tight-binding inhibitor of HhC cholesterololysis with an IC_{50} value of 300 nM.


TC Mps1 12

[1206170-62-8]
Purity: 99%

Axon 2755

mg	Price
5	online

Soluble in DMSO
C17H20N6O MW: 324.38



25 online

Biological activity


Potent and selective Mps1 (TTK) kinase inhibitor (IC_{50} value of 6.4 nM) with good cellular activity, pharmacokinetic properties and efficacy in the A549 lung cancer xenograft model. Additionally, TC Mps1 12 suppressed the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.

TC11

CLT-003

[100823-03-8]
Purity: 98%

Soluble in DMSO
C20H22N2O2 MW: 322.40



Axon 3149

mg	Price
10	online
50	online

Biological activity

TC11 is a potent inhibitor of tumor cell proliferation and an inducer of apoptosis via activation of caspase-3, 8 and 9. TC11 also showed *in vivo* activity against multiple myeloma cell line KMS34 tumor xenografts in ICR/SCID mice. Nucleophosmin 1 (NPM/B23) was identified as a target of TC11 for inducing apoptosis of tumor cells. Moreover, TC11 induces disruption of tubulin polymerization leading to mitotic arrest and promotes degradation of anti-apoptotic protein, MCL1, by sustained CDK1 activation.

TC-N 1752

See Nav1.7 blocker 52


Axon 1780

Page 693

TCID

[30675-13-9]
Purity: 99%

Soluble in DMSO
C9H2Cl4O2 MW: 283.92



Axon 2333

mg	Price
10	online
50	online


Biological activity

Potent, cell permeant inhibitor of UCHL3 (IC_{50} value 0.6 μ M) with 125-fold selectivity over UCHL1. Specific inhibition of UCHL3 with TCID diminished GlyT2 ubiquitination in brainstem and spinal cord primary neurons and may be beneficial in several human disorders, including neuromotor deficiencies (startle disease, myoclonus), pain and epilepsy.

TCN-201

[852918-02-6]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C21H17ClF3N3O4S MW: 461.89



Axon 2708

mg	Price
10	online
50	online


Biological activity

NMDA receptor antagonist selective for NR2A- over NR2B-containing receptors (pIC_{50} values of 6.8 and 4.3, respectively). The degree of inhibition produced by TCN 201 is dependent on the concentration of the GluN1-site co-agonist, glycine (or D-serine), and is independent of the glutamate concentration. TCN-201 is a negative allosteric modulator of glycine binding.

TCPOBOP

[76150-91-9]
Purity: 99%

Soluble in DMSO
C16H8Cl4N2O2 MW: 402.06



Axon 3411


mg	Price
10	online
50	online

Biological activity

TCPOBOP is a constitutive androstane receptor (CAR) agonist with an EC50 value of 20 nM. TCPOBOP is also a highly potent phenobarbital-like inducer of CYP gene expression.

TCS1102

[916141-36-1]
Purity: 98%
Optically pure
Soluble in DMSO
C27H26N4O2S MW: 470.59



Axon 2744

mg	Price
10	online
50	online

Biological activity

TCS1102 is a potent and selective dual orexin receptor antagonist (Ki values of 3 and 0.2 nM for hOX1R and hOX2R, respectively). Moreover, TCS1102 demonstrated *in vivo* central activity when dosed peripherally in a pharmacodynamic model of orexin activity.

TCV-116

See Candesartan cilexetil


Axon 3104

Page 341

TD 5108

Velusetrag

[866933-46-2]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C25H36N4O5S MW: 504.64



Axon 2060

mg	Price
5	online
25	online


Biological activity

Potent and selective 5-HT4 receptor agonist with high intrinsic activity; drug candidate for the treatment of chronic constipation and irritable bowel syndrome

TD52

[1798328-24-1]
Purity: 99%

Soluble in DMSO
C24H16N4 MW: 360.41



Axon 2700

mg	Price
10	online
50	online

Biological activity

The CIP2A inhibitor TD52 had more potent apoptotic effects than erlotinib (Axon 1128) in HCC cells (IC50 values of 0.9, 0.9, 0.8 and 1.2 μM in HA22T, Hep3B, PLC5 and Sk-Hep1 cell lines, respectively). Also, CIP2A-dependent p-Akt downregulation mediates TD52-induced apoptosis in TNBC. TD52-induced tumor inhibition was associated with reactivation of PP2A and downregulation of CIP2A and p-Akt *in vivo*.

TDZ 01

See Rosiglitazone


Axon 2443

Page 830

TDZD 8

[327036-89-5]
Purity: 98%

Soluble in DMSO
C10H10N2O2S MW: 222.26



Axon 2010

mg	Price
10	online
50	online

Biological activity

Selective and non-ATP competitive inhibitor of glycogen synthase kinase-3 beta (GSK-3β); potential agent for the treatment of Alzheimer's disease

TE031

See Clarithromycin


Axon 3445

Page 375

TEAD inhibitor TM2

[1008768-41-9]
Purity: 99%

Soluble in DMSO and EtOH
C26H33N3O3 MW: 435.56



Axon 3824

mg	Price
10	online
50	online

Biological activity

TEAD inhibitor TM2 is a potent reversible pan-TEAD inhibitor with strong modulation of TEAD-YAP/TAZ transcriptional activities. TM2 exhibits strong inhibition of TEAD2 and TEAD4 auto-palmitoylation with IC50 values of 156 nM and 38 nM, respectively. Also, TM2 significantly inhibits YAP-dependent liver organoid growth *ex vivo* and inhibits proliferation of YAP-dependent cancer cells as a single agent or in combination with a MEK inhibitor.

Tecastemizole

See Norastemizole


Axon 3734

Page 708

Tedizolid phosphate

TR701; Torezolid phosphate; DA7218

[856867-55-5]
Purity: 99%
Optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C17H16FN6O6P MW: 450.32



Axon 3312

mg	Price
10	online
50	online

Biological activity


Tedizolid phosphate is an oxazolidinone prodrug of Tedizolid, which is a highly potent antibacterial agent displaying good activity against important Gram-positive pathogens, particularly methicillin-resistant *Staphylococcus aureus* (MRSA) and some linezolid-resistant staphylococci.

TEI 6720

Febuxostat

[144060-53-7]
Purity: 98%

Soluble in DMSO
C16H16N2O3S MW: 316.37



Biological activity


A non-purine selective xanthine oxidase (XO) inhibitor

Telaglenastat

CB-839

[1439399-58-2]
Purity: 99%

Soluble in DMSO
C26H24F3N7O3S MW: 571.57



Biological activity


Telaglenastat is a potent, selective, and orally bioavailable inhibitor of both splice variants of glutaminase (KGA and GAC). Furthermore, Telaglenastat promoted a tumor-specific pharmacodynamic response and had in vivo efficacy in breast cancer xenograft models, both as a single agent and in combination with the standard-of-care agent paclitaxel.

Telmisartan

BIBR 277

[144701-48-4]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C33H30N4O2 MW: 514.62



Biological activity


Telmisartan is a highly potent and selective nonpeptide AT1 receptor antagonist (K_i value of 3.7 nM for rat AT1 receptors).

Temozolomide

TMZ; NSC 362856; SCH 52365; CCRG 81045

[85622-93-1]
Purity: 100%

Soluble in 0.1N HCl(aq) and DMSO
C6H6N6O2 MW: 194.15



Biological activity

Chemotherapeutic apoptosis inducer. An orally active alkylating agent prodrug, delivering a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine). Temozolomide has demonstrated efficacy in the treatment of a variety of solid tumors, primary malignant brain tumors and metastatic melanoma (IC₅₀ value 5 μM for cytotoxicity against mouse TLX5 lymphoma cells). The primary cytotoxic lesion, O6-methylguanine (O6-MeG) can be removed by methylguanine methyltransferase (MGMT; direct repair) in tumours expressing this protein, or tolerated in mismatch repair-deficient (MMR-) tumours.

Axon 1175

mg Price

10 online

50 online

Axon 3532

mg Price

10 online

50 online

Axon 3103

mg Price

50 online

250 online

Axon 2326

mg Price

10 online


50 online

Temsirolimus

CCI 779; Torisel

[162635-04-3]
Purity: 99%

Soluble in DMSO
C56H87NO16 MW: 1030.29



Biological activity


Specific mTOR inhibitor; a signaling protein that regulates cell growth and angiogenesis; a therapeutic for the treatment of advanced renal cell carcinoma (RCC), kidney cancer and other cancer types.

Temuterkib

See LY-3214996

Teneligliptin hydrobromide

[906093-29-6]
Purity: 99%
Optically pure
Soluble in water and DMSO
C22H30N6OS.2.5HBr MW: 426.58



Biological activity

Teneligliptin hydrobromide is a highly potent, selective, long-lasting and orally active DPP-4 inhibitor with in vitro IC₅₀ values of 0.37 nM (human) and 0.29 nM (rat).

Tenilsetam

PAS 997; CAS 997; HR 029

[86696-86-8]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C8H10N2OS MW: 182.24



Biological activity

Endonuclease modulator; a nootropic agent and advanced glycation end product (AGE) inhibitor having potential for Alzheimer's disease (AD) treatment. Preclinical studies on diabetic rats suggested that tenilsetam may be beneficial in the inhibition of diabetic retinopathy, without amelioration of pericyte loss

Tenofovir

PMPA

[147127-20-6]
Purity: 98%
Optically pure
Soluble in water and 0.1N NaOH(aq)
C9H14N5O4P MW: 287.21

Axon 1699

mg Price

5 online

25 online

Axon 3893

Page 628

Axon 3309

mg Price

10 online

50 online

Axon 1470

mg Price

10 online


50 online

Axon 3157

mg Price

10 online

50 online



Biological activity

Tenofovir is a selective inhibitor of HIV-1 reverse transcriptase.

Tenofovir alafenamide

GS-7340

[379270-37-8]
Purity: 99%
Optically pure
Soluble in DMSO
C₂₁H₂₉N₆O₅P MW: 476.47


Axon 3302

mg	Price
10	online
50	online


Biological activity

Tenofovir alafenamide is an orally bioavailable, intracellular prodrug of Tenofovir (Axon 3157), which is a selective inhibitor of HIV-1 reverse transcriptase.

Tenovin 1

[380315-80-0]
Purity: 99%

Soluble in DMSO
C₂₀H₂₃N₃O₂S MW: 369.48


Axon 2008

mg	Price
10	online
50	online

Biological activity


p53 activator that has the potential to decrease tumor growth; Tenovin 1 acts through inhibition of the protein-deacetylating activities of SIRT1 and SIRT2, two important members of the sirtuin family

Tenovin 6

Tnv 6

[1011557-82-6]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C₂₅H₃₄N₄O₂S MW: 454.63


Axon 2249

mg	Price
5	online
25	online

Biological activity

Small molecule, water soluble p53 activator and SIRT inhibitor (IC₅₀ values of 21 μM, 10 μM, and 67 μM for purified human SIRT1, 2, and 3, respectively, in a peptide deacetylase assay). Tenovin 6 reduces chronic lymphocytic leukaemia (CLL) cell viability with dysregulation of autophagy, without increasing p53-pathway activity. It induces p53-dependent apoptosis in many malignant cells.

TEPP 46


ML 265

[1221186-53-3]
Purity: 99%

Axon 2240

mg	Price
5	online

Soluble in DMSO
C₁₇H₁₆N₄O₂S₂ MW: 372.46



25 online


Biological activity

Potent and selective activator of recombinant pyruvate kinase M2 (PKM2) with half-maximum activating concentration (AC₅₀ value) of 92 nM, and little or no activity versus PKM1, PKL and PKR. Continuous dosing of mice with TEPP 46 decreased the development of human cancer cell xenografts, suggesting that increased pyruvate kinase activity can impair tumorigenesis. TEPP 46 can mimic the enzymatic properties of PKM1 in PKM2-expressing cells, alter cell metabolism, and induces changes in the kinetic properties of PKM2 that are identical to those induced by the endogenous PKM2 activator FBP.

Terazosin hydrochloride

[63074-08-8]
Purity: 99%

Soluble in water, DMSO and EtOH
C₁₉H₂₅N₅O₄.HCl MW: 423.89


Axon 3512

mg	Price
50	online

Biological activity


Terazosin hydrochloride is a selective, orally active α₁ adrenoceptor antagonist which pharmacologic properties are similar to those of Prazosin hydrochloride (Axon 2040). Terazosin hydrochloride is effective in lowering blood pressure and has a beneficial effect on plasma lipid profile. Antihypertensive agent.

Terbinafine

SF86-327

[91161-71-6]
Purity: 100%

Soluble in 0.1N HCl(aq) and DMSO
C₂₁H₂₅N MW: 291.43


Axon 3379

mg	Price
50	online

Biological activity

Terbinafine is an orally active antifungal agent inhibiting fungal squalene epoxidase.

Tetramisole hydrochloride, (-)-

See Levamisole hydrochloride

Axon 3242

Page 611

Tetrahydrolipstatin, (-)-


See Orlistat

Axon 3500

Page 736

TFB-TBOA

[480439-73-4]
Purity: 100%
>97% d.e.
Soluble in 0.1N NaOH(aq) and DMSO
C₁₉H₁₇F₃N₂O₆ MW: 426.34


Axon 2640

mg	Price
5	online
25	online

Biological activity

Very potent blocker for the human excitatory amino acid transporters (IC50 values 22 nM, 17 nM, and 300 nM, for EAAT1, EAAT2, and EAAT3, respectively). TFB-BOA is more potent at inhibiting EAAT1 and EAAT2 compared with L-TBOA (Axon 2427), and induced spontaneous epileptiform discharges and convulsive behaviors in mice. An important tool for elucidation of the physiological roles of EAATs and their contribution to the etiology of neuronal disorders.

TFMO 2


See TMP 195

Axon 2180

Page 933

TG 003

[719277-26-6]
Purity: 98%



Soluble in DMSO
C13H15NO2S MW: 249.33

Axon 1765

mg	Price
10	online
50	online

Biological activity

Potent and specific inhibitor of Cdc2-like kinase (Clk) family ($K_i = 10$ nM for mClk1/Sty; IC50 = 15 nM, 20 nM, 200 nM, and > 10 mM for mClk4, mClk1, mClk2, and mClk3, respectively); a valuable tool to dissect the regulatory mechanisms involving serine/arginine-rich protein phosphorylation signaling pathways in vivo, and potential for the therapeutic manipulation of abnormal splicing

TG007


See ProINDY

Axon 3540

Page 792

TG100-115

[677297-51-7]
Purity: 99%



Soluble in DMSO
C18H14N6O2 MW: 346.34

Axon 3974

mg	Price
10	online
50	online


Biological activity

A PI3K P110 γ/δ isoform-selective inhibitor with IC50 values (nM) of 1300, 1200, 83 and 235 for p110 α , p110 β , P110 γ , and P110 δ isoforms, respectively.

Source information: Sold in collaboration with Chemietek

TG 101348

[936091-26-8]
Purity: 99%



Soluble in DMSO
C27H36N6O3S MW: 524.68

Axon 1588

mg	Price
5	online
25	online

Biological activity


An orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 (JAK2, IC50: ca 3 nM) with potential antineoplastic activity

TG11-77 hydrochloride
Axon 3212

mg Price

[2550393-38-7]
Purity: 98%

Soluble in DMSO and EtOH
C23H24N6O.HCl MW: 436.94




5	online
25	online

Biological activity

TG11-77 hydrochloride is a potent, selective, water soluble, brain-permeable EP2 receptor antagonist with a KB value of 9.7 nM.

TGN 020

[51987-99-6]
Purity: 100%



Soluble in DMSO
C8H6N4OS MW: 206.22

Axon 2422


mg	Price
10	online
50	online

Biological activity

Aquaporin 4 (AQP4) inhibitor (IC50 value 3.1 μ M). Useful pharmacological tool to study the biological function of aquaporins and their roles in human physiology and pathology. Also reported to be active as bactericide and fungicide, esp. active against *Xanthomonas oryzae*.

TGN-073

[877459-36-4]
Purity: 99%



Soluble in DMSO
C18H16N2O3S MW: 340.40

Axon 3930


mg	Price
10	online
50	online

Biological activity

TGN-073 is an AQP4 facilitator which enhanced glymphatic transport. Diffusion MRI measurements demonstrated an increase in the diffusive transport of water in the brain of TGN-073 treated rats.

TGX 221

[663619-89-4]
Purity: 99%



Soluble in DMSO
C21H24N4O2 MW: 364.44

Axon 1417


mg	Price
2	online
5	online
25	online

Biological activity

Potent and specific PI3K p110 β inhibitor

TH 257

[2244678-29-1]
Purity: 99%



Soluble in DMSO
C24H26N2O3S MW: 422.54

Axon 2973

mg	Price
10	online
50	online


Biological activity

TH 257 is a selective allosteric inhibitor of LIMK1 and LIMK2 with IC50 values of 84 nM and 39 nM, respectively. A negative control is also available: TH 263 (Axon 2974)

TH 263

[313520-94-4]
Purity: 99%

Soluble in DMSO
C21H20N2O3S MW: 380.46



Axon 2974

mg	Price
10	online
50	online


Biological activity

A chemically related negative control compound for TH 257 (Axon 2973), a selective allosteric inhibitor of LIMK1/2.

TH 287 hydrochloride

[N.A.]
Purity: 98%

Soluble in DMSO
C11H10Cl2N4.HCl MW: 305.59



Axon 2271

mg	Price
5	online
25	online

Biological activity

First-in-class MTH1 inhibitor (IC50 value 0.8 nM) that selectively and effectively kills U2OS and other cancer cell lines, with considerably less toxicity towards several primary or immortalized cells.

TH 287 shows no relevant inhibitory effect for any of the other tested nudix hydrolase protein family members MTH2, NUDT5, NUDT12, NUDT14, and NUDT16, nor for other proteins with known nucleoside triphosphate pyrophosphatase activity (dCTPase, dUTPase and ITPA).

TL32711

See Birinapant


Axon 4150

Page 309

TH 34

[2196203-96-8]
Purity: 98%

Soluble in DMSO
C15H16N2O2 MW: 256.30



Axon 2996

mg	Price
10	online
50	online


Biological activity

TH 34 is a selective inhibitor of HDAC6, HDAC8, and HDAC10 with IC50 values of 4.6 μM, 1.9 μM, and 7.7 μM, respectively. TH 34 effectively and selectively eliminates high-grade neuroblastoma cells while sparing non-transformed human cells. In neuroblastoma cell lines as well as primary neuroblastoma cells, it markedly induces DNA damage, followed by differentiation and G2/M phase cell cycle arrest at later timepoints, eventually leading to cell death.

TH 588 hydrochloride

[1609960-31-7] (parent)
Purity: 99%

Soluble in DMSO
C13H12ClN4.HCl MW: 331.63



Axon 2272

mg	Price
5	online
25	online


Biological activity

First-in-class MTH1 inhibitor (IC50 value 5.0 nM) that selectively and effectively kills U2OS and other cancer cell lines, with considerably less toxicity towards several primary or immortalized cells. Similar to TH 287 (Axon 2271), TH 588 shows no relevant inhibitory effect for any of the other tested nudix hydrolase protein family members MTH2, NUDT5, NUDT12, NUDT14, and NUDT16, nor for other proteins with known nucleoside triphosphate pyrophosphatase activity (dCTPase, dUTPase and ITPA). Replacement of the methyl group by a cyclopropyl substituent in TH 588 (compared to TH 287, Axon 2271) improved metabolic stability both in vitro and in vivo, while maintaining MTH1 potency.

TH 1834

[N.A.]
Purity: 99%

Soluble in water and DMSO
C33H40N6O3.2HCl MW: 641.63



Axon 2339

mg	Price
5	online
25	online


Biological activity

Tip60 histone acetyltransferase inhibitor. Treating cells with TH1834 results in apoptosis and increased unrepaired DNA damage (following ionizing radiation treatment) in breast cancer but not control cell lines. Furthermore, TH 1834 did not affect the activity of related HAT MOF, as indicated by H4K16Ac, demonstrating specificity.

TH 5487

[2304947-71-3]
Purity: 98%

Soluble in DMSO
C19H18BrIn4O2 MW: 541.18



Axon 2934

mg	Price
10	online
50	online


Biological activity

TH 5487 is a potent and selective active-site inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with an IC50 of 342 nM. TH 5487 inhibited DNA repair and modified OGG1 chromatin dynamics, which resulted in the inhibition of proinflammatory pathway genes. Furthermore, TH 5487 was well tolerated by mice and suppressed lipopolysaccharide- and tumor necrosis factor-α-mediated neutrophilic inflammation in the lungs.

TH1760

[2567914-01-4]
Purity: 98%

Soluble in DMSO
C20H18N4O5S MW: 426.45



Axon 3285

mg	Price
5	online
25	online


Biological activity

TH1760 is a first-in-class, potent, selective and cell-active NUDT15 (MTH2) inhibitor with an IC50 value of 25 nM.

Thalidomide

[50-35-1]
Purity: 99%

Soluble in DMSO
C13H10N2O4 MW: 258.23



Axon 3324

mg	Price
50	online

Biological activity


Thalidomide was initially promoted as a sedative with anti-emetic properties. Later, Thalidomide was shown to have immunomodulatory and anti-inflammatory properties in erythema nodosum leprosum (ENL). Moreover, Thalidomide was found to inhibit fibroblast growth factor (bFGF)-induced formation of new blood vessels. Thalidomide targets the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and promotes the ubiquitination of Ikaros/Aiolos transcription factors by CRL4CRBN.

Thiazovivin

TZV

[1226056-71-8]
Purity: 99%

Soluble in DMSO
C15H13N5OS MW: 311.36



Axon 1535

mg	Price
5	online
25	online


Biological activity

A small molecule that enhances the survival of human embryonic stem cells (hESCs) after trypsinization; ROCK inhibitor; Thiazovivin dramatically improves (200-fold) the efficiency of iPSC generation from human fibroblasts, when used in combination with ALK5 inhibitor SB 431542 (Axon 1661) and MEK inhibitor PD 0325091 (Axon 1408)

Thioguanine, 6-

[154-42-7]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C5H5N5S MW: 167.19



Axon 3253

mg	Price
50	online

Biological activity


6-Thioguanine, a thiopurine-derivative, is metabolized in active forms which are incorporated into RNA and DNA, respectively, as fraudulent bases. Incorporation into DNA results into a stop of replication by single-strand breaks, crosslinking and sister chromatid exchange. Immunosuppressant.

ThioLox

Thiophene A9

[1202193-89-2]
Purity: 99%

Soluble in DMSO
C15H18N2OS MW: 274.38



Axon 2844

mg	Price
5	online
25	online

Biological activity

Inhibitor of 15-lipoxygenase-1 (15-LOX-1) with both anti-inflammatory and neuroprotective properties (IC50 value of 12 μM). Ex vivo biological evaluation in precision-cut lung slices (PCLS) showed inhibition of pro-inflammatory gene expression and in vitro studies on neuronal HT-22 cells showed a strong protection against glutamate toxicity for this 15-LOX-1 inhibitor.

*Sold in collaboration with RuG (University of Groningen) Sold in collaboration with RuG (University of Groningen)

Thiophene A9

See ThioLox


Axon 2844

Page 925

Thioridazine hydrochloride

[130-61-0]
Purity: 99%

Soluble in water and DMSO
C21H26N2S2.HCl MW: 407.04



Axon 2193

mg	Price
10	online
50	online

Biological activity

Antipsychotic with (sub-) nanomolar affinity for dopamine and alpha-adrenergic receptors (Ki of 0.4 nM, 1.5 nM, 1.5 nM, 3.2 nM, 2.4 nM for D2, D3, D4, α1A, and α1B resp.). Recently, Thioridazine was found to inhibit full length recombinant MALT1 (IC50 3.43 μM). It inhibits anti-apoptotic NF-κB signaling and elicits toxic effects selectively on MALT1-dependent ABC-DLBCL cells. Additionally, it suppresses tumor growth activity by targeting the PI3K/Akt/mTOR/p70S6K signaling pathway.

Thymitaq

See Nolatrexed dihydrochloride


Axon 2853

Page 708

THZ1

[1604810-83-4]
Purity: 98%

Soluble in DMSO
C31H28ClN7O2 MW: 566.05



Axon 3560

mg	Price
2	online
5	online


Biological activity

THZ1 is a first covalent inhibitor of CDK7 (IC50 value of 3.2 nM) which employs a unique mechanism, combining ATP-site and allosteric covalent binding, as means of attaining potency and selectivity for CDK7.

THZ1 dihydrochloride

[2422107-17-1]
Purity: 98%

Soluble in DMSO
C31H28ClN7O2.2HCl MW: 566.05



Axon 3561

mg	Price
5	online
25	online

Biological activity

THZ1 dihydrochloride is a first covalent inhibitor of CDK7 (IC50 value of 3.2 nM) which employs a unique mechanism, combining ATP-site and allosteric covalent binding, as means of attaining potency and selectivity for CDK7. The free base is also available as THZ1 (Axon 3560)


THZ531

[1702809-17-3]
Purity: 99%
100% e.e.

Soluble in 0.1N HCl(aq) and DMSO
C30H32ClN7O2 MW: 558.07

Axon 3402

mg	Price
5	online
25	online



Biological activity


THZ531 is a first-in-class, potent, selective, covalent inhibitor of CDK12 and CDK13 with IC50 values of 158 nM and 69 nM, respectively.

TIC 10 active isomer

Angular TIC 10; Active isomer 2

[1616632-77-9]
Purity: 99%

Soluble in DMSO
C24H26N4O MW: 386.49



Axon 2300

mg	Price
10	online
50	online

Biological activity


Potent, orally active, and stable small molecule that transcriptionally induces TRAIL in a p53-independent manner. TIC10 inactivates kinases Akt and extracellular signal-regulated kinase (ERK), leading to the translocation of Foxo3a into the nucleus, where it binds to the TRAIL promoter to up-regulate gene transcription. Efficacious antitumor therapeutic agent

*Prime Source Information: Axon 2300 is the confirmed 'angular' bio-active regio-isomer '2' as identified in the recently published issue of Angew. Chem. 2014, 126, 6746–6749! About TRAIL: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a powerful inducer of apoptosis in a wide range of human cancer cell lines via proapoptotic death receptor 4 (DR4; TRAIL-R1) and death receptor 5 (DR5; TRAIL-R2).

Ticagrelor

AZD6140

[274693-27-5]
Purity: 99%
Optically pure
Soluble in DMSO
C23H28F2N6O4S MW: 522.57



Axon 3111

mg	Price
25	online
0	online

Biological activity

Ticagrelor is a selective, reversible, direct, and orally available P2Y12 antagonist.

Ticrynafan

See Tienilic Acid

Axon 1564


Page 928

Tideglusib

NP031112; NP-12

[865854-05-3]
Purity: 98%

Soluble in water and DMSO
C19H14N2O2S MW: 334.39



Axon 3579

mg	Price
10	online
50	online

Biological activity


Tideglusib is a non-ATP-competitive irreversible, inhibitor of glycogen synthase kinase-3 (GSK-3) with a IC50 of 60 nM which was found to have neuroprotective and anti-inflammatory applications.

Tienilic Acid

Ticrynafan

[40180-04-9]
Purity: 99%

Soluble in DMSO
C13H8Cl2O4S MW: 331.17



Axon 1564

mg	Price
5	online
25	online


Biological activity

Tienilic acid was found to act as a suicide substrate at the cytochrome P450 enzymes involved in drug metabolism. It is a good mechanism based inhibitor of CYP2C9 and seems to inactivate it stoichiometrically

Tilfrinib

[1600515-49-8]
Purity: 98%

Soluble in DMSO and Ethanol
C17H13N3O MW: 275.30



Axon 2560

mg	Price
5	online
25	online

Biological activity

Potent Brk inhibitor (breast tumor kinase; IC50 values 3.15 nM) with antiproliferative activity in various breast tumor cancer cell lines. Brk is also known as protein tyrosine kinase 6 (PTK6)

Tifenazoxide


See NN 414

Axon 1647

Page 707

Timolol maleate

[26921-17-5]
Purity: 99%
>98% ee
Soluble in water and DMSO
C13H24N4O3S.C4H4O4
MW: 432.49



Axon 1518

mg	Price
10	online
50	online

Biological activity


A beta-adrenergic receptor blocker

Tiplaxtinin

PAI 039

[393105-53-8]
Purity: 99%

Soluble in DMSO
C24H16F3NO4 MW: 439.38



Biological activity

Inhibitor of plasminogen activator inhibitor-1 (PAI-1)

Axon 1383

mg	Price
5	online
25	online

Tivantinib

See ARQ 197

Axon 1838

Page 250

Tivicay

See Dolutegravir

Axon 2855


Page 436

Tivozanib

AV 951; KRN 951

[475108-18-0]
Purity: 98%

Moderately soluble in DMSO
C22H19ClN4O5 MW: 454.86



Biological activity

A highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGFR-1, 2 and 3, c-KIT and PDGFR (IC50: 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively)

Axon 1717


mg	Price
5	online
25	online

Tizanidine hydrochloride

DS103-282

[64461-82-1]
Purity: 100%

Soluble in water, DMSO and EtOH
C9H8ClN5S.HCl MW: 290.17



Biological activity

Tizanidine hydrochloride is a central α_2 adrenoceptor agonist and an antispastic agent.


Axon 3497

mg	Price
50	online

TJ191

[1522415-97-9]
Purity: 100%

Soluble in DMSO
C13H21NO2S MW: 255.38



Axon 3076

mg	Price
10	online
50	online

Biological activity


TJ191 is a potent and selective anti-cancer molecule with pronounced activity against human malignant T-cells expressing low levels of T β RIII. TJ191 selectively inhibits the proliferation of, and induces apoptosis in, various T-

cell-derived hematological malignant cell lines. TJ191 selectively targets certain cancer cells without affecting the proliferation of other cancer cells or normal fibroblasts or immune cells (over 600-fold selectivity).

TL02-59

[1315330-17-6]
Purity: 99%

Soluble in DMSO
C32H34F3N5O4 MW: 609.64



Biological activity

TL02-59 is a potent, selective and orally active inhibitor of Fgr and Lyn kinase with IC50 values of 0.03 nM and 0.10 nM, respectively. TL02-59 exhibits pM potency against the AML-associated Src-family kinase, Fgr, both in vitro and in cell-based kinase assays. TL02-59 inhibited the growth and induced apoptosis of AML cell lines expressing this kinase with single-digit nM potency. More importantly, TL02-59 induced growth arrest in primary AML bone marrow samples, with Fgr expression correlating most strongly with TL02-59 sensitivity.


Axon 3099

mg	Price
5	online
25	online

TL 99 hydrobromide

[62421-56-1]
Purity: 98%

Soluble in water and DMSO
C12H17NO2.HBr MW: 288.18



Biological activity

A putative dopamine autoreceptor agonist

Axon 1060


mg	Price
5	online
25	online

TL 102 hydrobromide

DPAT, 5,6-Dihydroxy-

[62421-54-9]
Purity: 98%

Soluble in water
C16H25NO2.HBr MW: 344.29



Biological activity

Dopamine receptor agonist

Axon 1004


mg	Price
5	online
25	online

TL 232 hydrobromide

DPAT, 6,7-Dihydroxy-

[62421-17-4]
Purity: 98%

Soluble in water
C16H25NO2.HBr MW: 344.29



Biological activity

Dopamine receptor agonist

Axon 1005


mg	Price
5	online
25	online

TM30089 sodium

CAY10471 sodium

[2309172-22-1]
Purity: 99%

Soluble in water and DMSO
C21H20FN2NaO4S MW: 438.45



Biological activity

TM30089 is a selective CRTH2 antagonist, displaying high antagonistic potency on mouse CRTH2 with low affinity to TP and many other prostanoid receptors including the related anaphylatoxin C3a and C5a receptors.

Source Information: Sold in collaboration with Chemietek


Axon 3966

mg	Price
10	online
50	online

TM 5275

[1103926-82-4]
Purity: 99%

Soluble in DMSO
C28H27ClN3NaO5 MW: 543.97



Axon 2344

mg	Price
5	online
25	online


Biological activity

Selective, orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1; IC50 value 6.95 μM in tissue plasminogen activator-dependent peptide hydrolysis assay) with antithrombotic benefits devoid of bleeding effect in rodents and nonhuman primates, and with impressive bioavailability. TM 5275 prolongs tPA retention and enhances plasmin generation on the vascular endothelial cell (VEC) surface as a result of PAI-1 inhibition. Additionally, TM 5275 represents a novel class of anti-inflammatory agents targeting macrophage migration by the inhibition of the interaction of PAI-1 with low-density lipoprotein receptor-related protein (IC50 values 3.13 μM and 3.02 μM for LRP1 protein

TM 5441

[1190221-43-2]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C21H17ClN2O6 MW: 428.82



Axon 2734

mg	Price
5	online
25	online

Biological activity

TM5441 is an orally active PAI-1 inhibitor, which protects mice against L-NAME-induced vascular pathologies, including hypertension, fibrosis, and vascular senescence. TM5441 is a derivative of PAI-1 inhibitor TM5275 (Axon 2344), however showed better pharmacokinetics and volume of distribution.

TMBIM6 antagonist BIA

See BIA

Axon 3295

Page 305

TMC114

See Darunavir

Axon 3137

Page 410

TMC 120

See Dapivirine

Axon 1534

Page 409

TMC278

See Rilpivirine


Axon 3685

Page 819

TMDJ-011 Recent Addition

[2681302-57-6]
Purity: 99%

Soluble in DMSO
C15H10F3N5O MW: 333.27



Axon 4213

mg	Price
10	online
50	online


Biological activity

TMDJ-011 is an inactive analogue of RyR2 inhibitor TMDJ-035 (Axon 4111).

TMDJ-035 Recent Addition

[2681302-83-8]
Purity: 99%

Soluble in DMSO
C16H12F3N5O MW: .00



Axon 4111

mg	Price
10	online
50	online

Biological activity


TMDJ-035 is a first highly potent and selective RyR2 inhibitor with an EC50 value of 0.013 μM. TMDJ-035 suppressed abnormal Ca2+ waves and transients in cardiomyocytes from a mouse model with RyR2(R420W) mutation. The inactive analog TMDJ-011 is available as Axon 4213.

TMI 005

Apratastat

[287405-51-0]
Purity: 99%

>98% ee
Soluble in DMSO
C17H22N2O6S2 MW: 414.50



Axon 1507

mg	Price
5	online
25	online

Biological activity

Novel, oral TACE/MMP inhibitor for rheumatoid arthritis; Apratastat (TMI-005) blocks secretion of soluble TNF-α and down regulates multiple MMPs, which have been implicated in cartilage destruction and bone erosions of RA

TM-MMF

See Mycophenolate mofetil

Axon 3498

Page 685


TM-N1324

[1144477-35-9]
Purity: 99%

Soluble in DMSO and EtOH
C18H13ClFN7O MW: 397.79

Axon 3486

mg	Price
5	online
25	online




Biological activity

TM-N1324 is a highly potent and selective GPR39 agonist with EC50 values of 280 nM and 9 nM in the absence and presence of Zn²⁺, respectively.

TMP 195

[1314891-22-9]
Purity: 99%

Soluble in DMSO
C23H19F3N4O3 MW: 456.42



Axon 2180

mg Price

5 online

25 online

Biological activity


Selective and cell-active class IIa histone deacetylase (HDAC) inhibitor, with IC50 values of 111, 106, 46, 9 nM for HDAC4, HDAC5, HDAC7 and HDAC9 respectively; >100 fold more selective vs other HDACs (IC50: >10 μM). The trifluoromethyloxadiazole (TFMO) moiety in TMP 195 as a new metal binding group circumvents the selectivity and pharmacologic liabilities of hydroxamates groups used in other metalloenzyme inhibitors. TMP 195 has a restraint impact on gene expression, and lacks overt cytotoxicity.

TMS

Trans-2,3',4,5'-tetramethoxystilbene

[24144-92-1]
Purity: 99%

Soluble in DMSO
C18H20O4 MW: 300.35



Axon 2628

mg Price

10 online

50 online

Biological activity

CYP1B1 inhibitor (IC50 values 6 nM, 300 nM, and 3100 nM for inhibition of CYP1B1, CYP1A1, and CYP1A2, resp.), that potentiates the inhibition of cell growth and induces apoptosis in human cancer cells. Moreover, TMS is a useful compound for characterizing the enzymatic properties of CYP1B1 and its contribution to hypertension and associated pathophysiology.

TMZ

See Temozolomide

Axon 2326

Page 917

TMZ-POH

See NEO 212

Axon 2327

Page 697

TNG-260 Recent Addition


[2935964-98-8]
Purity: 98%
98% e.e.

Soluble in DMSO
C20H18FN3O2S MW: 383.44

Axon 4270

mg Price

5 online



Biological activity

TNG-260 is a first-in-class, orally active, potent, and CoREST-selective deacetylase inhibitor. It inhibits HDAC1 with 10-fold selectivity over HDAC3 in cells, and 500-fold selectivity for the CoREST complex over the other HDAC1-containing complexes, NuRD

Source Information: Sold in collaboration with Chemietek

TNKS 656

See NVP-TNKS656

Axon 2599


Page 726

TNO155

Batoprotafib

[1801765-04-7]
Purity: 99%
99% e.e.

Soluble in 0.1N HCl(aq) and DMSO
C18H24ClN7OS MW: 421.95



Axon 3865

mg Price

5 online

10 online

Biological activity

TNO155 is a highly potent (IC50 = 11 nM), selective and orally bioavailable allosteric small-molecule inhibitor of SHP2.

Source Information: Sold in collaboration with Chemietek

Tnv 6

See Tenovin 6

Axon 2249


Page 919

Toceranib phosphate

SU11654; PHA291639

[874819-74-6]
Purity: 99%

Soluble in water and DMSO
C22H25FN4O2.H3PO4 MW: 494.45



mg Price

10 online

50 online

Biological activity

Toceranib phosphate is an ATP-competitive RTK inhibitor of VEGFR, FGFR, PDGFR, and Kit with Ki values of 0.006 μM and 0.005 μM for Flk-1 and PDGFR, respectively.

Tofacitinib

See CP 690550

Axon 1338


Page 390

Tofacitinib citrate

CP 690550-10

[540737-29-9]
Purity: 99%

Soluble in DMSO
C16H20N6O.C6H8O7 MW: 504.49



Axon 2072

mg	Price
10	online
50	online

Biological activity

Potent Janus Kinase 3 (JAK3) inhibitor; an immunosuppressive agent exhibiting potent effects in preclinical transplantation and arthritis models; clinically safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis; the citrate salt form of CP 690550 - Tofacitinib (Axon 1338)


Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Tolcapone

Ro 40-7592

[134308-13-7]
Purity: 99%

N.A.
Soluble in DMSO and EtOH
C14H11NO5 MW: 273.24



Axon 3993

mg	Price
10	online
50	online

Biological activity

Tolcapone is a potent, selective, orally active and reversible inhibitor of catechol-O-methyltransferase (COMT). Tolcapone inhibits COMT in the periphery, but it also exerts COMT inhibition in the brain.

Tolimidone

See MLR 1023

Axon 1941


Page 675

Toloxatone

MD 69276

[29218-27-7]
Purity: 99%

Soluble in DMSO
C11H13NO3 MW: 207.23



Axon 2977

mg	Price
10	online
50	online


Biological activity

Toloxatone acts as a reversible monoamine oxidase A (MAO-A) inhibitor in vivo and in vitro. Antidepressant.

Tolterodine L-tartrate

PNU 200583E

[124937-52-6]
Purity: 100%
Optically pure
Soluble in water and DMSO
C22H31NO.C4H6O6 MW: 475.57



Axon 2049

mg	Price
10	online
50	online

Biological activity


Potent and selective muscarinic receptor (mAChR) antagonist ($K_i = 3.3$ nM; non-selective for subtypes M1-M5); an antimuscarinic drug
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Tolvaptan

OPC 41061

[150683-30-0]
Purity: 99%

Soluble in DMSO
C26H25ClN2O3 MW: 448.94



Axon 1591

mg	Price
10	online
50	online


Biological activity

A highly potent, oral and selective antagonist of vasopressin V2 receptor

Topiroxostat

[577778-58-6]
Purity: 99%

Soluble in DMSO
C13H8N6 MW: 248.24



Axon 3178

mg	Price
10	online
50	online


Biological activity

Topiroxostat is a potent xanthine oxidoreductase (XOR) inhibitor with xanthine as a substrate. In the absence of xanthine, however, FYX-051 itself is very slowly hydroxylated by the enzyme.

Torcetrapib

CP 529414

[262352-17-0]
Purity: 99%
Optically pure
Soluble in DMSO
C26H25F9N2O4 MW: 600.47



Axon 2047

mg	Price
10	online
50	online

Biological activity

Cholesteryl ester transfer protein (CETP) inhibitor; a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Torezolid phosphate

See Tedizolid phosphate


Axon 3312

Page 916

Torin 1

[1222998-36-8]
Purity: 98%

Poorly soluble in DMSO
C35H28F3N5O2 MW: 607.62



Axon 1833

mg	Price
5	online
25	online


Biological activity

Highly potent, selective and ATP-competitive mTOR inhibitor, with IC50 to be 2 and 10 nM for mTORC1 and mTORC2 respectively; Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases

Torin 2

[1223001-51-1]
Purity: 99%

Soluble in DMSO
C24H15F3N4O MW: 432.40



Axon 1834

mg	Price
5	online
25	online

Biological activity

Potent, selective, orally available and ATP-competitive mTOR inhibitor (IC50: 2.1 nM for mTORC1), which possesses an EC50 of 0.25 nM for inhibiting cellular mTOR activity and exhibited 800-fold selectivity over PI3K (EC50: 200 nM) and over 100-fold binding selectivity relative to 440 other protein kinases

Torisel

See Temsirolimus

Axon 1699

Page 918

Tozasertib

See VX 680


Axon 1540

Page 980

TP 003

[628690-75-5]
Purity: 99%

Soluble in DMSO and Ethanol
C23H16F3N3O MW: 407.39



Axon 1422

mg	Price
2	online
5	online


Biological activity

Subtype selective partial agonist at GABAA receptor, showing significant efficacy at $\alpha 3$; nonbenzodiazepine anxiolytic

TPI-1

[79756-69-7]
Purity: 99%

Soluble in DMSO
C12H6Cl2O2 MW: 253.08



Axon 2723

mg	Price
5	online
25	online


Biological activity

SHP1 inhibitor TPI-1 (IC50 value 40 nM) selectively increased SHP1 phospho-substrates (pLck-pY394, pZap70 and pSip76) in Jurkat T cells but had little effects on pERK1/2 or pLck-pY505 regulated by phosphatases SHP2 or CD45, respectively. TPI-1 was shown to be more effective than sodium stibogluconate in SHP1 inhibition, immune cell activation and anti-tumor action.

TPP-UNC-CA157

[N.A.]
Purity: 98%

Soluble in DMSO and EtOH
C46H50BrN2O5P MW: 821.78



Biological activity

TPP-UNC-CA157 is a highly specific and potent UbiB protein COQ8 inhibitor.

Axon 3810

mg	Price
5	online
25	online

TPT 260 dihydrochloride

See R 55

Axon 2303

Page 803

TR701

See Tedizolid phosphate

Axon 3312

Page 916

Traficet-EN

See Vercirnon

Axon 2685

Page 966

Trametinib

See GSK 1120212

Axon 1761

Page 527

trans-ISRIB

See ISRIB

Axon 2278

Page 572

Trans-2,3',4,5'-tetramethoxystilbene

See TMS

Axon 2628

Page 933

Traxoprodil

See CP 101606

Axon 2254

Page 387

Traxoprodil mesylate

See CP 101606 mesylate


Axon 1406

Page 387

Trelagliptin succinate

SYR 111472 succinate; SYR 472

[1029877-94-8]
Purity: 100%
Optically pure
Soluble in water and DMSO
C18H20FN5O2.C4H6O4 MW: 475.47



Axon 2470

mg	Price
10	online
50	online

Biological activity

Orally active DPP-4 inhibitor that produces clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. SYR472 has a long duration of action and is well tolerated in clinical studies.

TRESK inhibitor A2764

See A2764 dihydrochloride

Axon 3019

Page 195

Tretinoin

See Retinoic acid

Axon 3321

Page 814

Triacetyluridine

See Vistonuridine


Axon 3362

Page 970

Trifluoro-3-(5-fluoro-2-methoxy-phenyl)-3-methyl-butan-2-one, 1,1,1-

[N.A.]
Purity: 98%

No solubility data
C12H12F4O2 MW: 264.22


Axon 1176

mg	Price
10	online
50	online


Biological activity

Glucocorticoid receptor modulator

Trilostane

WIN 24540

[13647-35-3]
Purity: 99%
Optically pure
Soluble in DMSO
C20H27NO3 MW: 329.43


Axon 3317

mg	Price
50	online


Biological activity

Trilostane is an orally active, competitive inhibitor of 3 β -hydroxysteroid dehydrogenase.

Trolox

[53188-07-1]
Purity: 99%

Soluble in 0.1N NaOH(aq), DMSO and EtOH
C14H18O4 MW: 250.29


Axon 3514

mg	Price
50	online

Biological activity

Trolox is a water-soluble analogue of the free radical scavenger α -tocopherol. Trolox prevents oxidative damages and has advantages over α -tocopherol, which is lipid soluble because it can be incorporated in both the water and the lipid compartments of cells. Enatio pure (S)-Trolox is available as Axon 3553.

TRPV2 antagonist SET2

See SET2


Axon 3287

Page 862

TrkB agonist prodrug R13

[1609067-49-3]
Purity: 99%

Soluble in DMSO
C19H16N2O6 MW: 368.34


Biological activity


R13 is a prodrug of the selective TrkB agonist 7,8-DHF (Axon 2089) and inhibits AEP and promotes bone formation. TrkB agonist prodrug R13 significantly improved 7,8-DHF oral bioavailability and increased its brain exposure.

Axon 3775

mg	Price
5	online
25	online

Trolox, (S)-

[53174-06-4]
Purity: 99%
99% e.e.
Soluble in 0.1N NaOH(aq), DMSO and EtOH
C14H18O4 MW: 250.29


Axon 3553

mg	Price
10	online
50	online


Biological activity

(S)-Trolox is a water-soluble analogue of α -tocopherol with potent antioxidant properties. It is commonly used as a standard or positive control in antioxidant assays (trolox equivalent antioxidant capacity). (S)-Trolox is the enatio pure isomer of racemic Trolox which is available as Axon 3514.

TRPML3 activator SN2 Recent Addition

[823218-99-1]
Purity: 99%

Soluble in DMSO and EtOH
C17H21NO MW: 255.35


Axon 4100

mg	Price
10	online
50	online


Biological activity

TRPML3 activator SN2 is a first selective TRPML3 activator with an EC50 value of 1.13 μ M.

Tropium chloride

[10405-02-4]
Purity: 100%

Solubility in water, DMSO and EtOH
C25H30ClNO3 MW: 427.96


Axon 3648

mg	Price
50	online

Biological activity

Tropium chloride is a broad-spectrum antimuscarinic agent with approximately equal affinity for all five muscarinic receptors (M1 - M5).

Trovafloxacin mesylate


CP 99219 mesylate

[147059-75-4]
Purity: 100%

Axon 2100

mg	Price
10	online

Soluble in water and DMSO
C20H15F3N4O3.CH4O3S
MW: 512.46



50 online

Biological activity


Antibiotic. Inhibits bacterial DNA gyrase and topoisomerase IV and DNA gyrase; DNA synthesis inhibitor

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

TRPV1 antagonist CX-3 Recent Addition

[2998942-96-2]
Purity: 99%

Soluble in DMSO
C26H24O4 MW: 400.47



Axon 4226

mg Price

10 online

50 online


Biological activity

TRPV1 antagonist CX-3 is a first-in-class highly selective TRPV1 antagonist with an IC50 value of 26.2 nM. CX-3 exhibited equivalent TRPV1 antagonistic activity with classical TRPV1 antagonist BCTC in vitro, and exerted better analgesic activity in vivo t

TRULI

[1424635-83-5]
Purity: 99%

Soluble in DMSO
C18H14N4OS MW: 334.39



Axon 3276

mg Price

10 online

50 online


Biological activity

TRULI is an ATP-competitive, small-molecule inhibitor of Lats kinases and may promote Yap-dependent proliferation in postmitotic mammalian tissues.

Tryptanthrin

[13220-57-0]
Purity: 99%

Soluble in DMSO
C15H8N2O2 MW: 248.24



Axon 4200

mg Price

10 online

50 online

Biological activity

Tryptanthrin is a natural alkaloid with antiprotozoal, antioxidant, antimicrobial and antitumor activities.

TSA 840

See Doxercalciferol

Axon 1746

Page 438

TSE 424

Bazedoxifene acetate; Viviant


[198481-33-3]

Axon 2051

mg Price

Purity: 99%

Soluble in DMSO
C30H34N2O3.C2H4O2 MW: 530.65



5 online

25 online

Biological activity

Third generation selective estrogen receptor modulator (SERM).

Another drug form, Bazedoxifene hydrochloride (Axon 1748), is also available

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

TSE 424 Hydrochloride

See Bazedoxifene Hydrochloride

Axon 1748

Page 293

TSU 68

See SU 6668

Axon 1891

Page 898

TTI-237

See Cevipabulin


Axon 2916

Page 360

TTP 22

[329907-28-0]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C16H14N2O2S2 MW: 330.42



Axon 1854

mg Price

10 online

50 online


Biological activity

Potent and ATP-competitive casein kinase 2 (CK2) inhibitor (IC50 = 0.1 μM, Ki = 40 nM)

Tubacin

[537049-40-4]

Purity: 99%
99% e.e.
Soluble in DMSO
C41H43N3O7S MW: 721.86



Axon 3691

mg Price

5 online

Biological activity


Tubacin is a specific inhibitor of HDAC6, one of 11 known human HDACs. Besides deacetylating tubulin, HDAC6 binds both polyubiquitinated proteins (i.e., proteins marked for degradation by attached ubiquitin "flags") and dynein (a protein motor associated with microtubules), bringing the two together to help the cell clean house. This takes place through a recently described cell structure called the aggresome. There is growing evidence to support the relevance of HDAC6 and its non-histone substrates as a target for other cancers, including breast cancer. In addition, HDAC6 also targets another cellular protein known as Hsp90, a protein critical in helping other proteins achieve their correct conformation, including proteins implicated in many forms of cancer.

Source Information: Sold in collaboration with Chemietek

Tubastatin A hydrochloride

[1310693-92-5]
Purity: 99%

Soluble in DMSO
C20H21N3O2.HCl MW: 371.86



Axon 2004

mg	Price
10	online
50	online

Biological activity


Tubastatin A is a potent and selective HDAC6 inhibitor (IC50 value of 0.015 μ M), which did not display neuronal toxicity, thus forecasting the potential application of this agent to neurodegenerative conditions.

Tubulin inhibitor 6

iHAP1

[105925-39-1]
Purity: 99%

Soluble in DMSO
C20H14ClNO2S MW: 367.85



Axon 3400

mg	Price
10	online
50	online


Biological activity

Tubulin inhibitor 6 is a tubulin polymerization inhibitor with an IC50 value of 0.87 μ M. Moreover, Tubulin inhibitor 6 showed K562 cell growth inhibitory activity with an IC50 value of 0.84 μ M. Tubulin inhibitor 6 is also an improved heterocyclic activator of PP2A (iHAP) that kills leukemia cells by allosterically assembling a specific heterotrimeric PP2A holoenzyme consisting of PPP2R1A (scaffold), PPP2R5E (B56 ϵ , regulatory), and PPP2CA (catalytic) subunits.

Tucidinostat

[1616493-44-7]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H19FN4O2 MW: 390.41



Axon 2893

mg	Price
10	online
50	online


Biological activity

Tucidinostat (Chidamide) is an orally bioavailable inhibitor of HDAC1, HDAC2, HDAC3, and HDAC10 with IC50 values of 0.095, 0.160, 0.067, 0.078 μ M, respectively. Tucidinostat exhibits a significant and broad spectrum *in vitro* and *in vivo* antitumor activity, including a wide therapeutic index.

TUG 891

[1374516-07-0]
Purity: 99%

Soluble in DMSO
C23H21FO3 MW: 364.41



Axon 2075

mg	Price
10	online
50	online

Biological activity


Potent and selective agonist for G-protein coupled receptor 120 (GPR120), also known as the free fatty acid receptor FFA4 (EC50: 44 and 17 nM for human GPR120 and mouse GPR120 respectively)

TUG-1375

Axon 3078

mg	Price
----	-------

[2247372-59-2]
Purity: 98%
98% e.e.
Soluble in 0.1N NaOH (aq) and DMSO
C22H19ClN2O4S MW: 442.92



5	online
25	online


Biological activity

TUG-1375 is a potent free fatty acid receptor 2 (FFA2/GPR43) agonist with a pKi value of 6.69. TUG-1375 has high solubility, high chemical, microsomal, and hepatocyte stability, and favorable pharmacokinetic properties and was confirmed to induce human neutrophil mobilization and to inhibit lipolysis in murine adipocytes.

TUPS

[950184-27-7]
Purity: 100%

Soluble in DMSO
C14H18F3N3O4S MW: 381.37



Axon 3022

mg	Price
10	online
50	online


Biological activity

TUPS is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 value of 3 nM for recombinant human sEH. TUPS prevents isoproterenol (ISO)-induced cardiac hypertrophy.

TWS 119

[601514-19-6]
Purity: 99%

Soluble in DMSO
C18H14N4O2 MW: 318.33



Axon 1562

mg	Price
2	online
5	online


Biological activity

Potent and selective inhibitor of GSK-3 beta subtype (GSK-3 β) (IC50: 30 nM); Neurogenesis inducer in murine ESC and thus a useful tool to regulate stem cell self-renewal and differentiation

TY 52156

[934369-14-9]
Purity: 99%

Soluble in DMSO
C18H19Cl2N3O MW: 364.27



Axon 2404

mg	Price
10	online
50	online

Biological activity

Selective, competitive, and orally active S1P3 antagonist that restores S1P reduced coronary blood flow, and inhibits Rho dependent activation and calcium signaling. TY52156 inhibited FTY720-induced S1P3 receptor-mediated bradycardia *in vivo*.

Tyrphostin AG 490

See AG 490

Axon 1378

Page 212

Tyrphostin B42

See AG 490

Axon 1378

Page 212

TZU-0460

See Roxatidine acetate hydrochloride

Axon 3129

Page 830

TZV

See Thiazovivin

Axon 1535

Page 923

U 126

See U 0126


Axon 2520

Page 946

U 0126

U 126

 [109511-58-2]
 Purity: 99%

 Soluble in DMSO and Ethanol
 C₁₈H₁₆N₆S₂ MW: 380.49


mg	Price
10	online
50	online

Biological activity

Non-competitive inhibitor of the dual specificity kinase MEK (IC₅₀ values 0.07 μM and 0.06 μM for MEK1 and MEK2, respectively) that protects the brain against damage resulting from ischemic stroke in mice. U0126 is frequently used in combination with PD 98059 (Axon 1223), and both are found to accelerate differentiation of murine RAW264.7 cells into osteoclast-like cells.

U 21251

See Clindamycin

Axon 2063

Page 375


U 50488 hydrochloride

[109620-49-7]

Purity: 99%

>98% ee

Soluble in water

 C₁₉H₂₆Cl₂N₂O.HCl MW: 405.79

Axon 1202

mg	Price
10	online
50	online


Biological activity

Selective nonpeptide kappa-Opioid receptor agonist, which has been found to stimulate the release of adrenocorticotropin (acth) via the release of hypothalamic arginine vasopressin and corticotropin releasing factor

U 73122

[112648-68-7]

Purity: 99%

 Moderately soluble in DMSO
 C₂₉H₄₀N₂O₃ MW: 464.64

Axon 1225

mg	Price
10	online
50	online

Biological activity

Phospholipase C (PLC) inhibitor

U 90152

See Delavirdine

Axon 1815

Page 418


U 92016A

[149654-41-1]

Axon 1285

mg Price

Purity: 99%
99% ee
Soluble in DMSO
C19H25N3.HCl MW: 331.88




5	online
25	online

Biological activity

Selective orally active 5-HT1A full agonist with high intrinsic activity

U 99194 maleate

[234757-41-6]
Purity: 98%



No solubility data
C17H27NO2.C4H4O4 MW: 393.47

Axon 1069

mg	Price
----	-------

10	online
----	--------

50	online
----	--------

Biological activity

Selective and potent D3 antagonist with a 30-fold preference for the dopamine D3 vs D2 receptor

U 100480

See PNU 100480

Axon 1762

Page 785

U 100766

See Linezolid

Axon 2048

Page 615

UCB 6474


See Etiracetam

Axon 1109

Page 469

UCB9608

[1616413-96-7]
Purity: 99%
99% e.e.
Soluble in 0.1N HCl(aq) and DMSO
C20H26N8O2 MW: 410.47



Axon 3005

mg	Price
----	-------

5	online
---	--------

25	online
----	--------

Biological activity

UCB9608 is a potent and orally bioavailable PI4KIIIβ inhibitor (IC50 value of 11 nM) that inhibits the HuMLR response with an IC50 value of 37 nM. The potency and excellent ADME properties of UCB9608 make it an ideal compound for future use as an in vitro and in vivo probe to elucidate the emerging role of PI4KIII β inhibition in immune processes.

UCB-L 059

See Levetiracetam


Axon 1110

Page 611

UCB-L 060

Etiracetam, R-(+)-

[103765-01-1]
Purity: 99%
98% ee
Soluble in DMSO
C8H14N2O2 MW: 170.21



Axon 1111

mg	Price
----	-------

10	online
----	--------

50	online
----	--------

Biological activity

Acetylcholine agonist; less active enantiomer of Etiracetam (Axon 1109), in comparison with (S)-(-)-enantiomer, Levetiracetam (Axon 1110)

UCLA 5483071

See DJ001


Axon 3018

Page 433

UCL-TRO-1938

[2919575-27-0]
Purity: 98%

Soluble in DMSO
C27H32N6O MW: 456.58



Axon 4019

mg	Price
----	-------

5	online
---	--------


25	online
----	--------

Biological activity

UCL-TRO-1938 is a selective allosteric activator of PI3Kα with an EC50 value of ~60 μM (assessed by in vitro lipid kinase activity). The EC50 values on cells are shown to be 2-4 μM and 5 μM to stimulate downstream AKT phosphorylation and increase PIP3, respectively. In MEF cells, UCL-TRO-1938 shows an EC50 of 0.5 μM to increase ATP levels over 24 h. UCL-TRO-1938 transiently activates PI3K signalling in all rodent and human cells tested, resulting in cellular responses such as proliferation and neurite outgrowth. In rodent models, acute treatment with UCL-TRO-1938 provides cardioprotection from ischaemia reperfusion injury and, upon local administration, enhances nerve regeneration following nerve crush.

UCM-05194 ammonium salt

[N.A.]
Purity: 97%
Optically pure
Soluble in water, DMSO and EtOH
C19H30BrO6P.NH3 MW: 482.35



Axon 3207

mg	Price
----	-------

2	online
---	--------

5	online
---	--------

Biological activity


UCM-05194 is a potent and selective type 1 lysophosphatidic acid (LPA1) receptor agonist with an EC50 value of 0.24 μM and a KD value of 19.6 nM. UCM-05194 induces characteristic LPA1-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of neuropathic pain.

UCSF648 dihydrochloride

5A6-48

[2248852-19-7]
Purity: 100%

Soluble in water and DMSO
C14H19N3O2S.2HCl MW: 366.31



Axon 3634

mg	Price
----	-------

5	online
---	--------

25	online
----	--------

Biological activity


UCSF648 is the inactive control probe for the 5-HT_{5A} receptor partial agonist UCSF678 (Axon 3636) and the 5-HT_{1A/5-HT_{2B/5-HT_{7A}} receptor ligand UCSF686 (Axon 3635). UCSF648 showed no measurable effect on any of the 5-HT receptor subtypes.}

UCSF678 dihydrochloride

5A6-78

[N.A.]
Purity: 99%

Soluble in water, DMSO and EtOH
C₁₅H₁₈N₂O₂S.2HCl MW: 363.30


Axon 3636

mg	Price
5	online
25	online

Biological activity


UCSF678 is an arrestin-biased subtype-selective 5-HT_{5A} receptor partial agonist (K_i value of 42 nM). UCSF678 shows a more restricted off-target profile and decreased assay liabilities versus SB-699551 (Axon 1469).

UCSF686 dihydrochloride

5A6-86

[2637090-56-1]
Purity: 99%

Soluble in water and DMSO
C₁₅H₁₉ClN₂O₂S.2HCl MW: 399.76


Axon 3635

mg	Price
5	online
25	online


Biological activity

UCSF686 dihydrochloride is a control probe for the 5-HT_{5A} receptor partial agonist UCSF678 (Axon 3636). UCSF686 is devoid of 5-HT_{5A} receptor activity, but shows affinity at the 5-HT_{1A}, 5-HT_{2B}, and 5-HT₇ receptor subtypes.

UF 010

[537672-41-6]
Purity: 98%

Soluble in DMSO and Ethanol
C₁₁H₁₅BrN₂O MW: 271.10


Axon 2518

mg	Price
10	online
50	online

Biological activity

Class I selective HDAC inhibitor (IC₅₀ values 0.5 μM, 0.1 μM, 0.06 μM, and 1.5 μM for HDAC1, HDAC2, HDAC3, and HDAC8 respectively) that inhibits cancer cell proliferation. Consistently induced the accumulation of acetylated histones (H2B, H3, and H4 but no effect on H2A) and p53 in vitro, without affecting α-tubulin.

UIC 1005

See Locostatin

Axon 2590

Page 618

UIC-94017

See Darunavir

Axon 3137

Page 410

UK 5099


PF 1005023

Axon 2805

mg	Price
----	-------

[56396-35-1]
Purity: 99%

Soluble in DMSO
C₁₈H₁₂N₂O₂ MW: 288.30



10	online
50	online

Biological activity

UK 5099 is an inhibitor of mitochondrial pyruvate carrier (MPC). Moreover, UK 5099 inhibits the plasma membrane monocarboxylate transporters (MCTs), but with K_i values some two or three orders of magnitude higher than those for the inhibition of the MPC. ThioloX

UK 49858

See Fluconazole

Axon 2105

Page 484

UK 68798

See Dofetilide

Axon 2103

Page 436

UK 76654

See Zamifenacin fumarate

Axon 1273

Page 1003

UK 92480

See Sildenafil citrate

Axon 2046

Page 866

UK 109496

See Voriconazole

Axon 2044

Page 971

UK31557

See Carbazeran


Axon 3574

Page 343

UK 356618

PF 03890101

[230961-08-7]
Purity: 98%
Optically pure
Soluble in DMSO
C₃₄H₄₃N₃O₄ MW: 557.72



mg	Price
5	online
25	online

Biological activity

Potent and selective matrix metalloprotease-3 (MMP-3 aka stromelysin-1) inhibitor (IC₅₀=5.9 nM); >140-fold selective over MMP-1, MMP-2, MMP-9 and MMP-14

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

UK 369003

See GIsadenafil besylate


Axon 2218

Page 502

UK 383367

[348622-88-8]
Purity: 99%

Soluble in DMSO
C15H24N4O4 MW: 324.38


Biological activity

Potent and selective inhibitor of bone morphogenetic protein 1 (BMP-1; also known as procollagen C proteinase, PCP) with IC50 values of 44 nM for BMP-1 and >10,000 nM for a range of other proteolytic matrix metalloproteinases MMP-1, 2, 3, 9, and 14.

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.


Axon 2073

mg	Price
5	online
25	online

UK 432097

[380221-63-6]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C40H47N11O6 MW: 777.87


Biological activity

A2A-adenosine receptor agonist; agent for chronic obstructive pulmonary disease (category Allergy/Respiratory)

Axon 1193

mg	Price
1	online
5	online

UK 116044-04

See Eletriptan hydrobromide

Axon 2050

Page 454

UL-FS 49

See Zatebradine hydrochloride

Axon 1248


Page 1004

Ulixertinib hydrochloride

BVD-523 hydrochloride; VRT752271 hydrochloride

[1956366-10-1]
Purity: 99%
>99% e.e.

Soluble in DMSO
C21H23Cl3N4O2 MW: 469.79


Biological activity

Ulixertinib hydrochloride is a cell permeable small-molecule ERK1/2 kinase inhibitor. It potently and selectively inhibits ERK1 and ERK2 kinases in a reversible, ATP-competitive fashion. Inhibits signal transduction, cell proliferation, and cell survival, most potently in cell lines bearing mutations that activate MAPK pathway signaling. Single-agent Ulixertinib inhibits tumor growth in vivo in BRAF-mutant melanoma and colorectal xenografts as well as in KRAS-mutant colorectal and pancreatic models. Combination treatment with Ulixertinib and Dabrafenib inhibits tumor growth in a BRAF-mutant melanoma model.

Source Information: Sold in collaboration with Chemietek

Axon 4151

mg	Price
10	online
50	online

Umifenovir

See Arbidol hydrochloride


Axon 3140

Page 246

UNBS5162

[956590-23-1]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C17H18N4O3 MW: 326.35


Biological activity

UNBS5162 is a pan-antagonist of CXCL chemokine expression, displaying antitumor effects in experimental models of human refractory prostate cancer.


Axon 2993

mg	Price
5	online
25	online

UNC 569

[1350547-65-7]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H29FN6 MW: 396.50


Biological activity

Potent, reversible and ATP-competitive inhibitor of Mer receptor tyrosine kinase (RTK) (IC50: 2.9 nM). UNC 569 inhibits Mer activation and downstream signaling through ERK1/2 and AKT and was capable of inducing >50% reduction in tumor burden compared to references. Potential therapeutic for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors (ATRT).


Axon 2086

mg	Price
5	online
25	online

UNC 669

[1314241-44-5]
Purity: 99%

Soluble in water and DMSO
C15H20BrN3O MW: 338.24


Biological activity

Small-molecule antagonist of methyl-lysine (KMe) reader protein with selectivity for L3MBTL1 and L3MBTL3 (IC50 of 4.2μM and 3.1μM resp.). Note: UNC 669 was initially reported to show a 5-fold selectivity of L3MBTL1 over L3MBTL3 (IC50 of 6μM and 35μM respectively, reported previously by same authors)


Axon 2163

mg	Price
10	online
50	online

UNC6934

[2561494-77-5]
Purity: 98%

Soluble in DMSO
C24H21N5O4 MW: 443.45


Biological activity

UNC6934 is a potent and selective chemical probe targeting the N-terminal PWWP (PWWP1) domain of NSD2 (Kd value of 91 nM). Moreover, UNC6934 disrupted the interaction between NSD2-PWWP1 and nucleosomal

Axon 3591


mg	Price
5	online
25	online

H3K36me2 in a dose-dependent manner with an IC50 value of 104 nM. The negative control UNC7145 is also available as Axon 3592.

UNC7145

[2561494-78-6]
Purity: 98%

Soluble in DMSO
C24H23N5O4 MW: 445.47



Axon 3592

mg Price

5 online

25 online


Biological activity

A chemically related negative control compound for UNC6934 (Axon 3591), a potent and selective chemical probe targeting the N-terminal PWWP (PWWP1) domain of NSD2.

UNC7467

[2922283-43-8]
Purity: 98%

Soluble in DMSO
C20H13NO3 MW: 315.32



Axon 3678

mg Price

10 online

50 online


Biological activity

UNC7467 is a potent IP6K inhibitor with IC50 values of 8.9 nM, 4.9 nM and 1320 nM for IP6K1, IP6K2 and IP6K3, respectively. In vivo, UNC7467 reduced body weight gain in the context of a high-fat diet, decreased fat, ameliorated hepatic steatosis, and improved glycemic profiles in diet-induced obese mice.

UNC 0224

[1197196-48-7]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C26H43N7O2 MW: 485.67



Axon 1789

mg Price

5 online

25 online


Biological activity

Potent and selective inhibitor of G9a histone lysine methyltransferase (HMTase) (IC50: 15 nM)

UNC 0379

[1620401-82-2]
Purity: 98%

Soluble in DMSO
C23H35N5O2 MW: 413.56



Axon 2418

mg Price

10 online

50 online

Biological activity

Substrate competitive inhibitor of the H4K20 HMTase SETD8 (IC50 value 7.3 μM) with selectivity over 15 other methyltransferases including G9a and GLP. MOA studies revealed that UNC0379 is noncompetitive with the cofactor S-adenosyl-L-methionine (SAM).


UNC 0631

Axon 1841

mg Price

[1320288-19-4]
Purity: 98%

Soluble in DMSO
C37H61N7O2 MW: 635.93



5 online

25 online


Biological activity

Very potent and selective G9a/GLP protein lysine methyltransferase inhibitor (G9a IC50: 6 nM; GLP IC50: 15 nM); with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity

UNC 0638

[1255580-76-7]
Purity: 98%

Soluble in DMSO
C30H47N5O2 MW: 509.73



Axon 1889

mg Price

2 online

5 online


Biological activity

Potent and selective G9a (EHMT2)/GLP (EHMT1) inhibitor (G9a IC50: <15 nM; GLP IC50: 19 nM); chemical probe for G9a and GLP methyltransferase inhibition in cells

UNC 0646

[1320288-17-2]
Purity: 99%

Soluble in DMSO
C36H59N7O2 MW: 621.90



Axon 1840

mg Price

5 online

25 online


Biological activity

Very potent and selective G9a/GLP protein lysine methyltransferase inhibitor (G9a IC50: 6 nM; GLP IC50: 15 nM); with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity

UNC 1215

[1415800-43-9]
Purity: 99%

Soluble in DMSO
C32H43N5O2 MW: 529.72



Axon 1994

mg Price

5 online

25 online

Biological activity

Potent and selective antagonist of L3MBTL3 methyllysine reader domain with cellular activity; a powerful tool to investigate the function of malignant brain tumor (MBT) domain proteins in biology and disease; first in class chemical probe for a Krme-binding protein

UNC 2250


[1493694-70-4]
Purity: 99%

Axon 2346

mg Price

5 online

Soluble in 0.1N HCl(aq) and DMSO
C24H36N6O2 MW: 440.58



25 online


Biological activity

Potent *Mer* kinase inhibitor (in vitro IC50 values 1.7 nM, 270 nM, and 100 nM for *Mer*, *Axl*, and *Tyros3* RTKs, respectively) with promising selectivity and PK properties. UNC 2250 efficiently inhibited both steady state and ligand-stimulated phosphorylation of *Mer*, and confirmed functional antitumor activity by exhibiting potential to reduced colony-forming in both rhabdoid tumor cells and NSCLC cells.

UNC 9994 hydrochloride

[N.A.]
Purity: 99%

Soluble in DMSO
C21H22Cl2N2OS.HCl MW: 457.84



Axon 2562

mg Price

2 online

5 online

Biological activity

Unique, β -arrestin-biased functionally selective dopamine D2 receptor (D2R) agonist (*Ki* value 30 nM; EC50 value 50 nM in β -arrestin-2 recruitment assay) that exhibits antipsychotic activity in vivo. UNC9994 markedly inhibited PCP-induced hyperlocomotion in wild-type mice, which effect was completely abolished in β -arrestin-2 knockout mice.

UNC 10225170 hydrochloride

See GW 284543 hydrochloride


Axon 3059

Page 533

uPA inhibitor BC-11 hydrobromide

[443776-49-6]
Purity: 99%

Soluble in water, DMSO and EtOH
C8H11BN2O2S.HBr MW: 290.97



Axon 3618

mg Price

10 online


50 online

Biological activity

uPA inhibitor BC-11 hydrobromide is a highly specific urokinase-plasminogen activator (uPa) inhibitor with an IC50 value of 8.2 μ M.

UPF 648

[213400-34-1]
Purity: 99%
optically pure
Soluble in 0.1N NaOH(aq) and DMSO
C11H8Cl2O3 MW: 259.09



Axon 2118

mg Price

2 online

5 online

Biological activity

Potent and selective inhibitor of kynurenine-3-monooxygenase (KMO, or kynurenine hydroxylase) activity (IC50: 20 nM); Active (+)-(1*S*,2*S*)-enantiomer; Useful tool for research on cognitive enhancement and neuroprotection in the brain.


UPF 1069

Axon 2369

mg Price

[1048371-03-4]
Purity: 99%

Soluble in DMSO
C17H13NO3 MW: 279.29



10 online

50 online


Biological activity

PARP-2 inhibitor with >26 fold selectivity over PARP1 (IC50 values 8.0 μ M and 0.3 μ M for PARP1 and PARP2, respectively) that exacerbates oxygen-glucose deprivation (OGD) injury in the hippocampus, but significantly attenuates OGD damage in mixed cortical cell cultures at concentrations high enough to inhibit both PARP1 and PARP2. UPF 1069 is a valuable tool to explore the function of PARP-2 in biological systems and to examine the different roles of PARP isoenzymes in the mechanisms of cell death and survival.

Uprosertib

GSK2141795; GSK795

[1047634-65-0]
Purity: 99%
100% e.e.
Soluble in DMSO
C18H16Cl2F2N4O2 MW: 429.25



Axon 3958

mg Price

5 online

10 online

Biological activity

Uprosertib is an orally bioavailable, selective and ATP-competitive pan-Akt (PKB) inhibitor, potently inhibiting Akt 1, 2, 3, and Akt 1 E17K mutation with IC50s of 0.066 nM, 2 nM, 1.4 nM, 1.5 nM, and 0.2nM, respectively.

Source Information: Sold in collaboration with Chemietek

Uptravi

See *Selexipag*


Axon 2605

Page 859

UR 1102

[1198153-15-9]
Purity: 98%

Soluble in DMSO
C14H10Br2N2O3 MW: 414.05



Axon 2581

mg Price

5 online

25 online

Biological activity

Inhibitor of the renal urate transporter URAT1 with high selectivity to URAT1 over OAT1 and OAT3 in vitro (*Ki* values 0.057 μ M, 7.2 μ M, and 2.4 μ M, respectively), capable of increasing the fractional excretion of urinary uric acid, and reducing plasma uric acid more effectively than Benzbromarone. A potential novel therapeutic option with an enhanced pharmacokinetic profile for patients with gout or hyperuricemia.

UR12592

See *Rupatadine fumarate*

Axon 4043

Page 836

URB597 Recent Addition

KDS4103

[546141-08-6]
Purity: 99%

Soluble in DMSO and EtOH


Axon 4222

mg Price

10 online

50 online

C20H22N2O3 MW: 338.40




Biological activity

URB597 is a highly potent, selective and orally available inhibitor of the enzyme fatty-acid amide hydrolase (FAAH) with an IC50 value of 4.6 nM.

URB602

[565460-15-3]
Purity: 99%




Soluble in DMSO
C19H21NO2 MW: 295.38

Biological activity

Non-competitive inhibitor of MAGL (monoacylglycerol lipase; IC50 values 25 μM and 17 μM for inhibition of hydrolysis of 2-oleoylglycerol (2-OG) and anandamide (AEA), respectively), lacking affinity for FAAH, diacylglycerol lipase or COX-2. URB602 blocks 2-AG hydrolysis in rat brain slices and enhances non-opioid stress-induced analgesia. Furthermore, URB602 reduced xenograft tumor volume, this effect being associated to down-regulation of VEGF and FGF-2, reduction in the number of vessels and down-regulation of cyclin D1.

URB937

[1357160-72-5]
Purity: 99%



Soluble in DMSO
C20H22N2O4 MW: 354.40

Biological activity


URB937 is a potent, orally available, and peripherally restricted FAAH inhibitor with an IC50 value of 26.8 nM. URB937 exerts profound analgesic effects in animal models.

Uridine triacetate

See Vistonuridine

Urolithin A

[1143-70-0]
Purity: 100%



Soluble in 0.1N NaOH(aq) and DMSO
C13H8O4 MW: 228.20

Biological activity

Urolithin A is an inhibitor of the PI3K/AKT/mTOR pathway and induced a strong anti-proliferative and pro-apoptotic effect both in vitro and in vivo.

Usmarapride

SUVN D4010

[1428862-33-2]

Axon 2696

mg Price

10 online

50 online

Axon 3359

mg Price

5 online

25 online

Axon 3362

Page 970

Axon 3794

mg Price

10 online


50 online

Axon 3595

mg Price

Purity: 99%

Soluble in water, 0.1N HCl(aq) and DMSO
C21H29N5O2.C2H2O4 MW: 473.52



Biological activity


Usmarapride is a potent, selective and orally bioavailable 5-HT4 receptor partial agonist with an EC50 value of 44 nM. Usmarapride showed high selectivity against ganglionic 5-HT3 receptor and other closely related receptors and good pharmacokinetics in rats, dogs, and healthy humans. It also showed promising in vivo efficacy in animal models of cognition. Additionally, Usmarapride increased neuroprotective sAPPα levels and may possess disease-modifying potential.

USP7-USP47 inhibitor

USP7/47 inhibitor compound 14

[1247825-37-1]
Purity: 98%

Soluble in DMSO
C18H11Cl2N3O3S3 MW: 484.40




Biological activity

USP7-USP47 inhibitor is a selective dual inhibitor of the cancer-related deubiquitylating proteases USP7 and USP47 with IC50 values of 0.42 μM and 1.0 μM for USP7 and USP47, respectively. USP7-USP47 inhibitor exhibited enhanced potency against HCT-116 cells and modestly accelerated the degradation of polβ protein in HeLa cells.

USP14 inhibitor IU1

[314245-33-5]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C18H21FN2O MW: 300.37



Biological activity

USP14 inhibitor IU1 is a selective and reversible inhibitor of Usp14 with an IC50 value of 4.7 μM.


USP7/47 inhibitor compound 14

See USP7-USP47 inhibitor

Usp22i-S02

[309735-96-4]
Purity: 99%

Soluble in DMSO
C22H18N4 MW: 338.41



Biological activity

Usp22i S02 is a first potent Usp22-specific inhibitor, which dramatically reduced intratumoral Treg Foxp3 expression and consequently enhanced antitumor immunity.

5 online

25 online

Axon 2991

mg Price

5 online

25 online

Axon 3905

mg Price

10 online

50 online

Axon 2991

Page 958

Axon 4089

mg Price


5 online

25 online

USP25/28 inhibitor AZ1 Recent Addition

[2165322-94-9]
Purity: 99%

Soluble in DMSO and EtOH
C17H16BrF4NO2 MW: .00



Axon 4121	
mg	Price
10	online
50	online

Biological activity


USP25/28 inhibitor AZ1 is a dual inhibitor of deubiquitinases USP25 and USP28 with IC50 values of 0.7 μM and 0.6 μM, respectively.

UTL-5g

GBL-5g

[646530-37-2]
Purity: 99%

Soluble in DMSO
C11H8Cl2N2O2 MW: 271.10



Axon 3410	
mg	Price
10	online
50	online

Biological activity

UTL-5g is a modulator of tumor necrosis factor-α (TNFα). UTL-5g shows potential chemoprotection against cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity. Moreover, UTL-5g is potentially radioprotective against acute phase of radiation-induced liver injury.

UVI2108

See SR11237

Axon 3727	
Page 885	

UVI2108

See SR11237

Axon 3727	
Page	

V2006

See Vipadenant

Axon 3626	
Page 969	

V 81444


See CPI-444

Axon 3085	
Page 392	

VA012

[885898-58-8]
Purity: 99%

Soluble in DMSO
C21H19N3 MW: 313.40



Axon 2889	
mg	Price
10	online
50	online

Biological activity


VA012 is a positive allosteric modulator of the serotonin 5-HT2C receptor with an EC50 value of 16 nM. VA012 exhibits enhanced efficacy dose-dependently, no significant off-target activities, and low competition with the endogenous agonist or other orthosteric ligands.

Vadadustat

AKB6548; PG-1016548

[1000025-07-9]
Purity: 99%

Soluble in 0.1N NaOH(aq) and DMSO
C14H11ClN2O4 MW: 306.70



Axon 3288	
mg	Price
10	online
50	online

Biological activity


Vadadustat is a titratable, oral HIF prolyl-4-hydroxylase (HIF-PH) inhibitor and HIF stabilizer.

Valdecoxib

SC 65872

[181695-72-7]
Purity: 99%

Soluble in DMSO
C16H14N2O3S MW: 314.36



Axon 2106	
mg	Price
10	online
50	online

Biological activity

NSAID. Highly selective and potent inhibitor of COX-2 in human whole blood and against the recombinant human enzyme, showing exceptional potency after oral administration. Valdecoxib showed weak inhibitory activity against COX-1 (IC50 = 140 μM), and potent activity against COX-2 (IC50 = 0.005 μM)

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.


Valemetostat

DS-3201

[1809336-39-7]
Purity: 99%
99% e.e.

Axon 3722	
mg	Price
5	online

Soluble in DMSO
C26H34ClN3O4 MW: 488.02



10 online

Biological activity

Valemetostat is an orally available potent and selective inhibitor of EZH1 and EZH2 (the histone lysine methyltransferases enhancer of zeste homolog 1 and 2) (both wild-type and mutated forms) with IC50s in nanomolar concentrations. Demonstrates anti-proliferative effect against various NHL (non-Hodgkin lymphomas) cells, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and peripheral T-cell lymphoma, with GI50 values less than 100 nM regardless of EZH2 gain-of-function mutations; Induces differentiation of undifferentiated NHL cells with increment of cell lineage specific markers and which induced cell death in vitro; Shows synergistic effect with the standard of care agents for NHL in vitro and in vivo.


Source Information: Sold in collaboration with Chemietek

Valproic acid sodium salt

Sodium valproate

[1069-66-5]
Purity: 98%

Soluble in water and DMSO
C8H15NaO2 MW: 166.19



Axon 3127

mg	Price
100	online
0	online


Biological activity

Valproic acid is an anticonvulsant and effective agent for control of both absence and primarily generalized tonic-clonic seizures.

Valsartan

CGP 48933

[137862-53-4]
Purity: 99%
Optically pure
Soluble in DMSO
C24H29N5O3 MW: 435.52



Axon 3106

mg	Price
25	online
100	online

Biological activity


Valsartan is a potent, highly selective, and orally active antagonist at the angiotensin II AT1-receptor subtype with a Ki value of 2.38 nM.

Vandetanib

ZD 6474

[443913-73-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C22H24BrFN4O2 MW: 475.35



Axon 1411

mg	Price
5	online
25	online

Biological activity


An orally bioavailable tyrosine kinase inhibitor (TKI), targeting VEGFR and EGFR; a potential medication for non-small-cell lung cancer

Vardenafil dihydrochloride

BAY 38-9456

[224789-15-5]
Purity: 99%

Soluble in water and DMSO
C23H34Cl2N6O4S MW: 561.52



Axon 3396

mg	Price
10	online
50	online

Biological activity


Vardenafil dihydrochloride is a highly potent, selective and orally bioavailable cGMP phosphodiesterase (PDE5) inhibitor with IC50 values of 180 nM and 0.7 nM for PDE1 and PDE5, respectively.

Varenicline dihydrochloride

Chantix; Champix (as tartrate)

[866823-63-4]
Purity: 99%

Soluble in water
C13H13N3.2HCl MW: 284.18



Axon 1384

mg	Price
10	online
50	online



Biological activity

Selective α 4 β 2 nicotinic acetylcholine receptor partial agonist; Smoking cessation drug
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Varenicline tartrate

Chantix; Champix; CP 526555-18

[375815-87-5]
Purity: 100%
Optically pure
Soluble in water and DMSO
C17H19N3O6 MW: 361.35



Axon 2074

mg	Price
10	online
50	online

Biological activity


Selective α 4 β 2 nicotinic acetylcholine receptor (nAChR) partial agonist; Smoking cessation drug.
Available also another drug form, Varenicline di-HCl (Axon 1384).
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Varespladib

LY315920

[172732-68-2]
Purity: 99%

Soluble in DMSO
C21H20N2O5 MW: 380.39



Axon 4077

mg	Price
10	online
50	online

Biological activity

Varespladib is an inhibitor of human and mouse sPLA2 group IIA, V, and X enzymes with IC50 values in the low nM range.


Source Information: Sold in collaboration with Chemietek

Varespladib methyl

A-002; LY3333013; S-3013

[172733-08-3]
Purity: 99%

Soluble in DMSO
C22H22N2O5 MW: 394.42



Biological activity

Varespladib methyl is a secretory phospholipase A2 (sPLA2) inhibitor. It is an orally bioavailable prodrug of the varespladib.

Source Information: Sold in collaboration with Chemietek

Axon 4032


mg	Price
10	online
50	online

Vasopressin antagonist 1867

Compound 12i

[909391-88-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C28H36N4O4 MW: 492.61



Biological activity

Orally available and selective V1b receptor antagonist (IC50 value 3 nM for hV1b inhibition, exhibiting >1000-fold selectivity over hV1a, hV2, and hOT). Useful tool to study Vasopressin 1B receptor pharmacology.

Axon 1867


mg	Price
5	online
25	online

Vatalanib

PTK 787

[212141-54-3]
Purity: 98%

Soluble in DMSO
C20H15ClN4 MW: 346.81



Biological activity

A potent and selective inhibitor of tyrosine kinases, targeting VEGFR, with IC50 to be 77 nM (VEGFR-1), 37 nM (VEGFR-2), 580 nM (PDGFR-beta), 730 nM (c-KIT), 660 nM (FLT-4) and 1.4 μM (c-FMS) respectively; not active against EGFR, SRC-ABL and PKC etc


Axon 1637

mg	Price
10	online
50	online

VCP171

[1018830-99-3]
Purity: 99%

Soluble in DMSO and EtOH
C18H12F3NOS MW: 347.35



Biological activity

VCP171 is a positive allosteric modulator (PAM) of adenosine A1 receptors (pKB = 5.65). Reducing AMPA receptor-mediated evoked excitatory postsynaptic currents (eEPSCs) in lamina I and lamina II neurons in a rat model of neuropathic pains.


Axon 3519

mg	Price
10	online
50	online

VE 821

[1232410-49-9]
Purity: 98%

Soluble in DMSO
C18H16N4O3S MW: 368.41



Biological activity

Potent and selective inhibitor of the DNA damage response (DDR) kinase ATR, which sensitises tumour cells to DNA damage induced by radiation or chemotoxic drugs, by disrupting the DNA damage checkpoint and inhibiting DNA repair


Axon 1893

mg	Price
10	online
50	online

VE 822

[1232416-25-9]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C24H25N5O3S MW: 463.55



Biological activity

Selective ATR inhibitor (IC50 values 0.019 μM, 2.6 μM, and 18.1 μM for ATR, ATM, and DNA-PK, respectively) with in vitro and in vivo activity that decreases maintenance of cell-cycle checkpoints and homologous recombination in irradiated cancer cells, and increases persistent DNA damage. VE822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine.

Axon 2452

mg	Price
10	online
50	online

Veliparib

See ABT 888

Axon 1593

Page 202

Veliparib dihydrochloride

See ABT 888 dihydrochloride


Axon 2888

Page 203

Velpatasvir

GS-5816

[1377049-84-7]
Purity: 99%
Optically pure
Soluble in DMSO
C49H54N8O8 MW: 883.00



Biological activity

Velpatasvir is a second generation hepatitis C virus NS5A inhibitor.

Axon 3173

mg	Price
10	online
50	online

Velusetrag

See TD 5108

Axon 2060

Page 914

Vemurafenib

See PLX 4032

Axon 1624


Page 783

Venlafaxine hydrochloride

Venlift; Vexor; WY 45030

[99300-78-4]
Purity: 99%

Soluble in water and DMSO
C₁₇H₂₇NO₂.HCl MW: 313.86



Axon 1727

mg	Price
10	online
50	online

Biological activity

Serotonin-norepinephrine reuptake inhibitor (SNRI); an antidepressant for the treatment of major depressive disorder (MDD) etc

Venlafaxine Impurity C

See Dinorvenlafaxine

Axon 1726

Page 433

Venlafaxine Impurity D

See WY 45494 hydrochloride

Axon 1724

Page 988

Venlafaxine Impurity F

See WY 45960 hydrochloride

Axon 1723

Page 989

Venlafaxine Impurity G

See Deshydroxy Venlafaxine HCl

Axon 1722

Page 419

Venlift

See Venlafaxine hydrochloride


Axon 1727

Page 965

VER 155008

[1134156-31-2]
Purity: 99%

Soluble in DMSO
C₂₅H₂₃Cl₂N₇O₄ MW: 556.40



Axon 1608

mg	Price
5	online
25	online

Biological activity

Inhibitor of Heat Shock Protein 70 (Hsp70)

VER 52296

See NVP-AUY922

Axon 1542

Page 722


Verapamil hydrochloride

[152-11-4]
Purity: 99%

Axon 3452

mg	Price
50	online

Soluble in water, DMSO and EtOH
C₂₇H₃₈N₂O₄.HCl MW: 491.06



Biological activity


Verapamil hydrochloride is a calcium antagonist which inhibits the slow inward current of calcium in normal cardiac tissues, and in the atrioventricular and sinoatrial nodes.

Vercimon

GSK-1605786; CCX282-B; Traficet-EN

[698394-73-9]
Purity: 100%

Soluble in DMSO
#NAME? MW: 444.93



Axon 2685

mg	Price
5	online
25	online

Biological activity

Vercimon is an orally bioavailable selective antagonist of the CCR9 chemokine receptor (IC₅₀ values 5.4 nM and 3.4 nM for CCR9-mediated Ca²⁺ mobilization and chemotaxis on Molt-4 cells, respectively). Based on studies of the crystal structure, vercimon binds to the intracellular side of the receptor, exerting allosteric antagonism and preventing G-protein coupling. Vercimon was developed for treatment of inflammatory bowel disease, including Crohn's disease and celiac disease.

Verdinexor

See KPT 335

Axon 2597


Page 594

Vericiguat

BAY 1021189

[1350653-20-1]
Purity: 99%

Soluble in DMSO
C₁₉H₁₆F₂N₈O₂ MW: 426.38



Axon 3558

mg	Price
5	online
25	online


Biological activity

Vericiguat is a potent and orally available stimulator of soluble guanylate cyclase (sGC).

Verinurad

[1352792-74-5]
Purity: 98%

Soluble in 0.1N NaOH(aq) and DMSO
C₂₀H₁₆N₂O₂S MW: 348.42



Axon 2938

mg	Price
10	online
50	online

Biological activity


Verinurad is a highly potent and specific URAT1 inhibitor (IC50 value of 25 nM) with greater than 100-fold potency for URAT1 compared to other transporters. Under evaluation for the treatment of gout and asymptomatic hyperuricemia.

Verteporfin

Visudyne

[129497-78-5]
Purity: 99%

Soluble in DMSO
C41H42N4O8 MW: 718.79



Axon 3354

mg	Price
5	online
25	online

Biological activity

Verteporfin is an inhibitor of TEAD-YAP association and YAP-induced liver overgrowth. Moreover, Verteporfin treatment inhibited gastric carcinomas tumor growth in vivo. Also, Verteporfin is used clinically as a photosensitizer in photodynamic therapy for neovascular macular degeneration, where it is activated by a special wavelength laser light to generate reactive oxygen radicals that eliminate the abnormal blood vessels.

VERU111

See Sabizabulin


Axon 3804

Page 841

Verubecestat

MK8931

[1286770-55-5]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C17H17F2N5O3S MW: 409.41



Axon 4166

mg	Price
5	online
25	online

Biological activity


Verubecestat is a first-in-class, potent, orally bioavailable high-affinity BACE1 inhibitor with Ki values of 2.2 and 0.38 nM for BACE1 and BACE2, respectively. Verubecestat shows high selectivity for BACE1 over other key aspartyl proteases.

Vesatolimod

GS-9620

[1228585-88-3]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C22H30N6O2 MW: 410.51



Axon 3585

mg	Price
10	online
50	online

Biological activity

GS-9620 is a potent, selective and orally available TLR7 agonist with an EC50 value of 290 nM.

Vexor

See Venlafaxine hydrochloride

Axon 1727

Page 965

Vfend

See Voriconazole


Axon 2044

Page 971

VH298

[2097381-85-4]
Purity: 98%

Soluble in DMSO
C27H33N5O4S MW: 523.65



Biological activity

VH298 is a potent and selective VHL inhibitor (Kd value of 80-90 nM) that stabilizes HIF-α and elicits a hypoxic response via the blockade of the VHL:HIF-α protein-protein interaction downstream of HIF-α hydroxylation by PHD enzymes.

Axon 2810

mg	Price
10	online
50	online

VIA-3196

See MGL-3196

Axon 2657

Page 653

Viagra

See Sildenafil citrate


Axon 2046

Page 866

Vidarabine

Ara-A; 9-β-D-Arabinofuranosyladenine

[5536-17-4]
Purity: 100%
Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C10H13N5O4 MW: 267.24



Biological activity

Vidarabine, a purine nucleoside analog, is intracellularly converted to the triphosphate derivative which acts as a competitive inhibitor of DNA polymerase.

Axon 3506


mg	Price
50	online

Vidofludimus

4SC-101; SC12267

[717824-30-1]
Purity: 99%

Soluble in DMSO
C20H18FNO4 MW: 355.36



Biological activity

Oral immunomodulatory drug that inhibits dihydroorotate dehydrogenase (DHODH; IC50 value 134 nM for human DHODH mediated DCIP reduction) and lymphocyte proliferation in vitro. Vidofludimus inhibits the proliferation of human peripheral blood mononuclear cells (PBMCs) stimulated with Phytohemagglutinin-L, and interleukin (IL)-17 secretion from human peripheral blood mononuclear cells in a dose-related fashion (IC50 of 6 μM approx.) and

Axon 2377


mg	Price
5	online
25	online

independently of lymphocyte proliferation. May be applied for treatment of rheumatoid arthritis and inflammatory bowel disease, and as immunosuppressant after renal transplantation.

Vinpocetine

Ethyl apovincamin

[42971-09-5]
Purity: 99%
Optically pure
Soluble in 0.1N HCl(aq), DMSO and
EtOH
C22H26N2O2 MW: 350.45



Axon 3889

mg	Price
50	online


Biological activity

Vinpocetine is a brain-penetrant PDE and IκB kinase (IKK) inhibitor (IC50 value of 17 μM). Vinpocetine may also act as a blocker for voltage-dependent Na⁺ channels.

Vildagliptin

NVP-LAF 237

[274901-16-5]
Purity: 99%
optically pure
Soluble in water
C17H25N3O2 MW: 303.40



Axon 1631

mg	Price
5	online
25	online

Biological activity

Highly potent, selective and orally bioavailable inhibitor of dipeptidyl peptidase-4 (DPP4), with IC50 to be 2.3 and 2.7 nM for rat and human plasma DPP4

Vioxx

See Rofecoxib

Axon 3376

Page 827

VIP-152

See BAY-1251152

Axon 3935


Page 286

Vipadenant

BIIB014; V2006

[442908-10-3]
Purity: 98%

Soluble in DMSO
C16H15N7O MW: 321.34



Axon 3626

mg	Price
5	online
25	online

Biological activity

Vipadenant is a potent, selective and orally active adenosine A2A antagonist with a Ki value of 1.3 nM.

VRT752271 hydrochloride

See Ulixertinib hydrochloride

Axon 4151

Page 951

VRT-831509

See Decernotinib

Axon 3861

Page 416

Vismodegib

See GDC 0449


Axon 1500

Page 498

Vistonuridine

Uridine triacetate; Triacetyluridine; TAU

[4105-38-8]
Purity: 99%
Optically pure
Soluble in water, 0.1N HCl(aq) and
DMSO
C15H18N2O9 MW: 370.31



Axon 3362

mg	Price
50	online

Biological activity

Vistonuridine is a prodrug of uridine. The acetyl groups of Vistonuridine increase the lipophilicity of uridine, thus enhancing its transport from the gastrointestinal tract to the blood stream and its reabsorption from the renal tubules, while rendering Vistonuridine resistant to catabolism by UrdPase.

Visudyne

See Verteporfin

Axon 3354

Page 967

Vistusertib

See AZD2014

Axon 3996

Page 269

Vitamin A acid

See Retinoic acid

Axon 3321

Page 814

Viviant

See TSE 424


Axon 2051

Page 941

Voglibose Recent Addition

AO128

[83480-29-9]
Purity: %
Optically pure
Soluble in water and DMSO
C10H21NO7 MW: 267.28



Axon 4210

mg	Price
50	online

Biological activity

Voglibose is an efficient alpha-glucosidase inhibitor which mobilizes the endogenous GLP-1 reserve.

Volasertib

See BI 6727

Axon 1473

Page 303

Volibris

See Ambrisentan

Axon 1648

Page 222

Volinanserin

See MDL 100907


Axon 1104

Page 643

Volitinib dihydrochloride

AZD6094 dihydrochloride; HMPL-504 dihydrochloride; Savolitinib dihydrochloride

[N.A.]
Purity: 99%
99% e.e.
Soluble in DMSO
C17H15N9.2HCl MW: 418.28



Axon 3864

mg	Price
5	online
10	online

Biological activity


Volitinib is an orally bioavailable ATP-competitive small molecule c-Met kinase inhibitor, binding to the enzyme potently with IC50 of 4 nM, and highly selective (>650 fold selectivity) over a panel of 265 kinases. Demonstrated selectivity for MET-driven disease, with MET amplified cell lines being most sensitive (IC50s of 1nM), and Displayed pote+DJ2869nt anti-tumor activity in cMET-dysregulated GC patient-derived tumor xenograft (PDX) models.

Source Information: Sold in collaboration with Chemietek

Vorasidenib

AG881

[1644545-52-7]
Purity: 99%
Optically pure
Soluble in DMSO and EtOH
C14H13ClF6N6 MW: 414.74



Axon 4024

mg	Price
10	online
50	online

Biological activity

Vorasidenib is a first-in-class, potent, orally active, brain-penetrant dual mIDH1/2 inhibitor with IC50 values of 6 nM and 12 nM for IDH1-R132H and IDH2-R140Q, respectively.

Vorapaxar

See SCH 530348


Axon 1755

Page 856

Voriconazole

Vfend; UK 109496

[137234-62-9]
Purity: 99%
Optically pure
Soluble in DMSO
C16H14F3N5O MW: 349.31



Axon 2044

mg	Price
10	online
50	online

Biological activity


Orally bioavailable CYP51 inhibitor; Antifungal agent; Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha sterol demethylase (CYP51, P450-DM), resulting in a depletion of ergosterol in fungal cell membrane

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Vorinostat

SAHA; Suberanilohydroxamic acid; MK-0683

[149647-78-9]
Purity: 100%



Soluble in DMSO
C14H20N2O3 MW: 264.32

Biological activity

Vorinostat is a histone deacetylase (HDAC) inhibitor.


Axon 3114

mg	Price
10	online
50	online

Voruciclib

P1446A-05

[1000023-04-0]
Purity: 99%
99% e.e.
Soluble in DMSO
C22H19ClF3NO5 MW: 469.84



Biological activity

Voruciclib (P1446A-05) is an oral, potent and selective CDK inhibitor, blocking CDK9, the transcriptional regulator of MCL-1, with sub nanomolar potency, and suppressing MCL-1 expression in cell-based and xenograft models of DLBCL.

Source Information: Sold in collaboration with Chemietek


Axon 3801

mg	Price
5	online
10	online

Voxelotor

GBT440

[1446321-46-5]
Purity: 99%



Soluble in DMSO and EtOH
C19H19N3O3 MW: 337.37

Biological activity

Voxelotor is a first-in-class, potent and orally bioavailable allosteric effector of sickle cell hemoglobin (HbS). Voxelotor increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions.

Axon 4088

mg	Price
10	online
50	online

Voxtalisisb

See XL-765

Axon 4009

Page 994

VS 4718

See PND 1186

Axon 2459

Page 784

VS6062

 See PF-562271 Recent Addition
VS 6063

See Defactinib

VTP 194204

See NRX 194204

VTX-378

See Motolimod

VTX-2337


See Motolimod

VU0099704

See ML354

VU 29


 [890764-36-0]
Purity: 99%

 Soluble in DMSO
C22H16N4O3 MW: 384.39

Biological activity

A Positive Allosteric Modulator (PAM) of metabotropic glutamate receptor subtype 5 (mGluR5)

VU0360172 hydrochloride


 [1309976-62-2]
Purity: 98%

 Soluble in DMSO and EtOH
C18H15FN2O.HCl MW: 330.78

Biological activity

VU0360172 hydrochloride is a selective, orally active mGluR5 PAM with an EC50 value of 16 nM and a Ki value of 195 nM. VU0360172 hydrochloride produced a dose-dependent reversal of amphetamine-induced hyperlocomotion, a rodent model predictive of antipsychotic activity.

VU0468554

 [1448705-21-2]
Purity: 99%

 Soluble in DMSO and EtOH
C20H22N4O MW: 334.41

Axon 4215

Page 764

Axon 2574

Page 416

Axon 2408

Page 711

Axon 2783

Page 677

Axon 2783

Page 677

Axon 2899

Page 669

Axon 1425

mg	Price
10	online
50	online

Axon 3421

mg	Price
10	online
50	online


Axon 3593

mg	Price
10	online
50	online

Biological activity

VU0468554 is a selective GIRK inhibitor with IC50 values of 0.85 μM and 2.6 μM for GIRK1/GIRK4 and GIRK1/GIRK2 channels, respectively. VU0468554 more effectively inhibits the cardiac GIRK channel than the neuronal GIRK channel.

VU0637120, (S)-

 [1175940-86-9]
Purity: 99%
100% e.e.
Soluble in DMSO and EtOH
C16H19N3O5S2 MW: 397.47

Biological activity


(S)-VU0637120 is a first-in-class, selective neuropeptide Y4 receptor allosteric antagonist with an IC50 value of 2.7 μM. (S)-VU0637120 selectively inhibits native Y4R function and binds in an allosteric site located below the binding pocket of the endogenous ligand pancreatic polypeptide in the core of the Y4R transmembrane domains.

VU 152100

See VU 0152100

VU 0029767

 [326001-01-8]
Purity: 98%


 Soluble in DMSO
C21H21N3O3 MW: 363.41

Biological activity

Positive allosteric modulator of M1. VU 0029767 potentiates the agonistic effect of ACh for M1 (Ki value shifted by VU0029767 (3, 10 and 30 M) and shifted the ACh competition curve by 1.7 0.8-, 4.9 2.0-, and 8.8 1.9-fold, respectively, compared to control (DMSO; Ki value 8.7 μM). VU0029767 potentiates ACh-mediated intracellular calcium mobilization, but not phospholipase D activation.

VU 0152100

VU 152100


 [409351-28-6]
Purity: 99%

 Soluble in DMSO
C18H19N3O2S MW: 341.43

Biological activity

Positive allosteric modulator of M4 muscarinic acetylcholine receptor (mAChR)

VU 0238429

 [1160247-92-6]
Purity: 99%

 Soluble in DMSO and Ethanol
C17H12F3NO4 MW: 351.28

Axon 3435

mg	Price
5	online
25	online

Axon 1988

mg	Price
10	online
50	online

Axon 1483

mg	Price
5	online
25	online

Axon 1786

mg	Price
10	online
50	online


Biological activity

Highly selective positive allosteric modulator (PAM) of M5 muscarinic acetylcholine receptor (mAChR)

VU 0255035

[1135243-19-4]
Purity: 99%

Soluble in DMSO
C18H20N6O3S2 MW: 432.52


Axon 1787

mg	Price
10	online
50	online


Biological activity

Highly selective antagonist of M1 muscarinic acetylcholine receptor (mAChR) (Ki=14.87 nM)

VU 0365114

[1208222-39-2]
Purity: 99%

Soluble in DMSO and Ethanol
C22H14F3NO3 MW: 397.35


Axon 1943

mg	Price
10	online
50	online


Biological activity

Selective positive allosteric modulator (PAM) of M5 muscarinic acetylcholine receptor (mAChR), with EC50 = 2.7 μM for M5 and >30 μM for M1–M4 subtypes

VU 0357017 hydrochloride

[1135242-13-5]
Purity: 100%

Soluble in water and DMSO
C18H27N3O3.HCl MW: 369.89


Axon 1703

mg	Price
10	online
50	online


Biological activity

Highly selective positive allosteric modulator (PAM) of M1 muscarinic acetylcholine receptor (mAChR)

VU 0357121

[433967-28-3]
Purity: 99%

Soluble in DMSO
C17H17F2NO2 MW: 305.32


Axon 1894

mg	Price
10	online
50	online

Biological activity

Potent positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 5 (mGluR5) (EC50: 33 nM). Binds to a site distinct from that bound by MPEP (Axon 1222)

VU 0360223


[1274859-33-4]
Purity: 99%

Soluble in DMSO

Axon 1795

mg	Price
10	online
50	online

C15H9FN2S MW: 268.31



Biological activity

Potent and selective metabotropic glutamate receptor subtype 5 (mGluR5) antagonist or negative allosteric modulator (NAM) (IC50: 61 nM)

VU 0361737

[1161205-04-4]
Purity: 99%

Soluble in DMSO
C13H11ClN2O2 MW: 262.69


Axon 1842

mg	Price
10	online
50	online


Biological activity

Centrally penetrant and selective positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 4 (mGluR4); displayed submicromolar potency at both human and rat mGluR4

VU 0364439

[1246086-78-1]
Purity: 99%

Soluble in DMSO
C18H13Cl2N3O3S MW: 422.29


Axon 1830

mg	Price
10	online
50	online


Biological activity

Very potent positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 4 (mGluR4) (EC50: 19.8 nM)

VU 0364770

[61350-00-3]
Purity: 99%

Soluble in DMSO
C12H9ClN2O MW: 232.67


Axon 1845

mg	Price
10	online
50	online

Biological activity

A systemically active positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 4 (mGluR4) (EC50: 290 nM); showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist, in several rodent PD models

VU 0456810

See ML 297

Axon 2436

Page 666


VU 6008667

[2092923-21-0]
Purity: 99%
98% e.e.
Soluble in DMSO and Ethanol

Axon 2739

mg	Price
2	online
5	online

C24H17ClF2N2O2 MW: 438.85




Biological activity

VU6008667 is a selective negative allosteric modulator (NAM) of M5 muscarinic acetylcholine receptor (mAChR) with IC50 values of 1.2 and 1.6 μM in human and rat M5, respectively. Moreover, VU6008667 has high CNS penetration and shows a desired short half-life in rat (t1/2 = 2.3 h) useful for addiction studies.

VU 6008667, rac-(±)

[2092923-21-0]
Purity: 99%

C24H17ClF2N2O2 MW: 438.85




Biological activity

VU0476201

See ML352

VU0486846

[1788055-11-7]
Purity: 99%
100% e.e.
Soluble in DMSO
C25H28N4O3 MW: 432.51




Biological activity

VU0486846 is a potent and highly selective M1 PAM (EC50 value of 0.31 μM, 85%), devoid of agonist activity in the PFC, as well as cholinergic or other adverse effects in mice, rats and NHP, which results in robust procognitive activity in rodent models.

VU6001221

[2002495-17-0]
Purity: 98%

Soluble in DMSO
C20H26ClN3O3 MW: 391.89



Biological activity

VU6001221 is a choline transporter (CHT) inhibitor (IC50 value of 270 nM) with comparable potency for choline uptake inhibition as ML352 (Axon 2587), yet improved PK and CNS penetration. For the first time, VU6001221 allowed evaluation of a CHT inhibitor in a standard preclinical rodent cognition model, namely novel object recognition (NOR).

VU6005649

Axon 2832

mg	Price
5	online

Axon 2587

Page 669

Axon 3271

mg	Price
5	online
25	online

Axon 2670


mg	Price
5	online
25	online

Axon 3487

mg	Price
----	-------

[2137047-43-7]
Purity: 99%

Soluble in DMSO and EtOH
C16H12F5N3O MW: 357.28




Biological activity

VU6005649 is a brain penetrant mGlu 7/8 receptor PAM with EC50 values of 649 nM and 2.6 μM for mGluR7 and mGluR8, respectively.

VU6036720 hydrochloride

[N.A.]
Purity: 99%
98% e.e.
Soluble in DMSO and EtOH
C20H22ClFN4O2S.HCl MW: 473.39




Biological activity

VU6036720 hydrochloride is the first potent and selective in vitro inhibitor of heteromeric Kir4.1/5.1 (KCNJ10/KCNJ16) inward rectifier potassium channels with and IC50 value of 0.24 μM. The inactive (R)-enantiomer (Axon 3799) is also available.

VU6036721 hydrochloride

[N.A.]
Purity: 98%
98% e.e.
Soluble in DMSO and EtOH
C20H22ClFN4O2S.HCl MW: 473.39



Biological activity

Inactive enantiomer of VU6036720 hydrochloride (Axon 3675) which is the first potent and selective in vitro inhibitor of heteromeric Kir4.1/5.1 (KCNJ10/KCNJ16) inward rectifier potassium channels with and IC50 value of 0.24 μM.


VUF 9153 dihydrobromide

See Clobenpropit dihydrobromide

VUF 10460

[1028327-66-3]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C15H19N5 MW: 269.34



Biological activity

Axon 3675

mg	Price
5	online
25	online

Axon 3799

mg	Price
5	online
25	online

Axon 1209

Page 376

Axon 2126

mg	Price
10	online
50	online

Selective histamine H4 receptor agonist.

VUF 10996

See APEBA, 4-

Axon 1877

Page 241

VUF 11000

See APC, 4-


Axon 1876

Page 239

VVD-214 Recent Addition

RO7589831

[3026500-20-6]
Purity: 98%
98% e.e.
Soluble in DMSO
C20H21F2N3O4S MW: 437.46



Axon 4271

mg	Price
5	online

Biological activity

VVD214 is a potent, selective, allosteric inhibitor of WRN helicase (Werner syndrome ATP-dependent helicase). It covalently engages cysteine 727 of WRN in a nucleotide cooperative manner and inhibits ATP hydrolysis and helicase activity.

Source Information: Sold in collaboration with Chemietek

VX-509

See Decernotinib


Axon 3861

Page 416

VX-11e

ERK11e

[896720-20-0]
Purity: 99%
>99% e.e.
Soluble in DMSO
C24H20Cl2FN5O2 MW: 500.35



Axon 3836

mg	Price
5	online
10	online


Biological activity

Extracellular signal regulated kinase (ERK) is a pivotal enzyme in the pathway downstream of Ras, Raf, and MEK, acting as a central link between multiple signaling pathways. VX-11e (or ERK 11e) is a potent, selective, and orally bioavailable inhibitor of ERK2 with $K_i < 2$ nM, exhibiting potent cellular activity ($IC_{50}=48$ nM in an HT29 cell proliferation assay). It is highly selective against a panel of more than 140 other kinases - most notably, GSK3 ($K_i = 400$ nM), AURA ($K_i = 540$ nM), CDK2 ($K_i = 850$ nM), FLT3 ($K_i = 1400$ nM), ROCK1 ($K_i = 1400$ nM), and JNK3 ($K_i = 1400$ nM).

Source Information: Sold in collaboration with Chemietek

VX 661

[1152311-62-0]
Purity: 99%
Optically pure
Soluble in DMSO
C26H27F3N2O6 MW: 520.50



Axon 2169

mg	Price
5	online
25	online

Biological activity


Corrector of the cystic fibrosis transmembrane conductance regulator (CFTR), hypothesized to restore F508del mutation processing and plasma membrane localization of CFTR protein, thereby effectively increasing functional surface CFTR ion channels. VX 661 is the second CFTR corrector in line with VX 809 (first), and VX 983 (third), and is believed to help CFTR protein reach the cell surface. Tested in phase 2 to evaluate safety, efficacy, pharmacokinetics, and pharmacodynamics in subjects with cystic fibrosis suffering from the F508del-CFTR mutation.

VX 680

MK 0457; Tozasertib

[639089-54-6]
Purity: 98%

Soluble in DMSO
C23H28N8OS MW: 464.59



Axon 1540

mg	Price
10	online
50	online

Biological activity

Potent inhibitor of aurora kinases with K_i values to be 0.6, 18 and 4.6 nM for aurora A, B and C isotypes respectively; inhibiting also ABL ($K_i=30$ nM) and FLT3 ($K_i=30$ nM) kinases

VX 689

See MK 5108


Axon 1961

Page 661

VX-702 Recent Addition

[479543-46-9]
Purity: 98%

Soluble in DMSO
C19H12F4N4O2 MW: 404.32



Axon 4219

mg	Price
10	online
50	online

Biological activity


Similar to the (-)-atropisomer PH 797804 (Axon 1837), racemic (\pm)-PH 797804 is a potent, selective and metabolically stable inhibitor of p38 MAPK (IC_{50} values of 2.5 and 15 nM in p38 α cascade and hPBMC TNF assays, respectively).

Source Information: Sold in collaboration with Chemietek

VX 745

[209410-46-8]
Purity: 99%

Soluble in DMSO
C19H9Cl2F2N3OS MW: 436.26



Axon 1811

mg	Price
5	online
25	online

Biological activity

Highly potent and selective inhibitor of p38 α MAP kinase (IC_{50} : 10 nM); being 1000 fold selective over closely related kinases

VX-765

Belnacasan


[273404-37-8]
Purity: 99%

99% e.e.
Soluble in DMSO

Axon 3857

mg	Price
5	online
10	online

C24H33ClN4O6 MW: 509.00



Biological activity

VX-765 is a novel Caspase-1 inhibitor being investigated for the treatment of epilepsy, currently being developed by Vertex. VX-765 is an orally-absorbed pro-drug of VRT-043198, a potent and selective inhibitor of ICE/caspase-1 sub-family caspases. VRT-043198 exhibits 100-10,000-fold selectivity against other caspase-3 and -6-9. In cultures of peripheral blood mononuclear cells and whole blood from healthy subjects stimulated with bacterial products, VRT-043198 inhibited the release of Interleukin (IL)-1beta and IL-18, but had little effect on the release of several other cytokines, including IL-1alpha, tumor necrosis factor-alpha, IL-6 and IL-8.


Source Information: Sold in collaboration with Chemietek

VX 770

Ivacaftor; Kalydeco

[873054-44-5]
Purity: 99%

Soluble in DMSO
C24H28N2O3 MW: 392.49



Biological activity

Orally bioavailable CFTR potentiator; FDA-approved drug for clinical application to patients with cystic fibrosis (CF). VX770 enhances spontaneous, ATP-independent activity of WT-CFTR to a similar magnitude as its effects on G551D channels.

VX-809

See Lumacaftor

VX-944

See AVN944

Axon 2503

mg	Price
10	online
50	online

Axon 3234

Page 625

Axon 3943

Page 263


WAG 994

See SDZ-WAG 994

WAY 100135 dihydrochloride

[149055-79-8]
Purity: 99%

Soluble in water
C24H33N3O2.2HCl MW: 468.46



Biological activity


Selective 5-HT1A antagonist

WAY 100135 dihydrochloride, (S)-

WAY 100135 dihydrochloride, (+)-

[149007-54-5]
Purity: 99%
99% ee

Soluble in water
C24H33N3O2.2HCl MW: 468.46



Biological activity


Highly selective serotonin 5-HT1A antagonist; S-enantiomer of WAY-100135 (Axon 1360). Its opposite enantiomer, (R)-WAY100135 (Axon 1359) is also available

WAY 100135 dihydrochloride, (-)-

(R)-WAY 100135 dihydrochloride

[149007-53-4]
Purity: 99%
99% ee

Soluble in water
C24H33N3O2.2HCl MW: 468.46



Biological activity

R-enantiomer of WAY-100135 (Axon 1360), a highly selective serotonin 5-HT1A antagonist. Its opposite enantiomer, (S)-WAY100135 (Axon 1341) is also available

WAY 100135 dihydrochloride, (R)-

See WAY 100135 dihydrochloride, (-)-

WAY 100135 dihydrochloride, (S)-

See WAY 100135 dihydrochloride, (+)-

WAY 100635 maleate

[1092679-51-0]
Purity: 98%

Soluble in water and DMSO

Axon 1265

Page 859

Axon 1360

mg	Price
10	online
50	online

Axon 1341

mg	Price
5	online
25	online

Axon 1359

mg	Price
5	online
25	online

Axon 1359

Page 982


Axon 1341

Page 982

Axon 2424

mg	Price
10	online
50	online

C25H34N4O2.C4H4O4 MW: 538.64




Biological activity

Prototypical 5-HT1A receptor antagonist with D4 agonist activity (*K_i* values 2.2 nM, 6260 nM, 24 nM, >10,000 nM, 20 nM, 322 nM, and 16 nM for 5-HT1A, 5-HT2A, 5-HT2B, 5-HT7, α1A, α1B, and D4, respectively). The HCl salt of WAY 100635 is available as well (Axon 1086)

WAY 100635 trihydrochloride

[146714-97-8]
Purity: 99%



Soluble in water and DMSO
C25H34N4O2.3HCl MW: 531.95


Biological activity

Highly selective 5-HT1A receptor antagonist

WAY 100635 trihydrochloride, desmethyl-

DWAY

[146715-34-6]
Purity: 98%



Soluble in water and DMSO
C24H32N4O2.3HCl MW: 517.92

Biological activity


Precursor for labeling the 5-HT1A antagonist, WAY100635; PET radioligand

WAY 140424

See Bazedoxifene Hydrochloride

WAY 208466 dihydrochloride

[1207064-61-6]
Purity: 99%



Soluble in water
C17H18FN3O2S.2HCl MW: 420.33

Biological activity

Potent and highly selective serotonin 5-HT6 receptor agonist (*EC*₅₀: 7.3 nM); increases GABA levels in the cerebral cortex; produces antidepressant and anxiolytic effects in rodents; useful in the treatment of obsessive-compulsive disorder (OCD)

WAY 252623

See LXR 623

Axon 1086

mg	Price
10	online
50	online

Axon 1087

mg	Price
10	online
50	online

Axon 1748

Page 293

Axon 1710


mg	Price
10	online
50	online

Axon 2357

Page 626

WAY 262611 dihydrochloride

[N.A.]
Purity: 99%




Soluble in water and DMSO
C20H22N4.2HCl MW: 391.34

Biological activity

Inhibitor of Dickkopf-1 (DKK1); WAY 262611 is a wingless Wnt/β-Catenin signaling agonist with an inhibitory effect on DKK1, displaying an *EC*₅₀ value of 0.63 μM for DKK1-mediated TCF-Luciferase, no affinity for GSK-3β (*IC*₅₀ value >100 μM) and enhancing the bone formation rate in ovariectomized (OVX) rats following oral administration. Dickkopf-1 (DKK1) is a soluble inhibitor of Wnt-3a mediated Wnt/β-catenin signaling required for embryonic head development. It regulates Wnt signaling by binding to the Wnt coreceptor lipoprotein-related protein-5 (LRP5)/Arrow, and Kremen2 (Kr2) simultaneously.

WAY 316606 hydrochloride

[915759-45-4 (parent)]
Purity: 99%



Soluble in DMSO
C18H19F3N2O4S2.HCl MW: 484.94


Biological activity

Potent and water soluble inhibitor of secreted Frizzled-Related Protein 1 (sFRP-1; *K_d* value 0.08 μM and *EC*₅₀ value 0.65 μM for Wnt-luciferase activity from U2-OS cells) that stimulates the Wnt/β-catenin canonical signaling pathway. WAY316606 increased total bone area in a murine calvarial organ culture assay at concentrations as low as 0.0001 μM. WAY-316606 also bound to sFRP-2, albeit over 10 times weaker (*K_d* value 1.0 μM) and shows moderate to low inhibition of cytochrome p450 isozymes (3A4, 2D6, 2C9) and good stability in rat and human liver microsomes (*t*_{1/2} > 60 min in each species).

WAY 362450

FXR 450; XL 335

[629664-81-9]
Purity: 99%



Soluble in DMSO
C25H24F2N2O3 MW: 438.47

Biological activity

A highly potent, selective, and orally bioavailable farnesoid X receptor (FXR) agonist (*EC*₅₀: 4 nM, *eff*=149%); potently induces luciferase reporter expression with an *EC*₅₀ value of 16 nM potently induces luciferase reporter expression with an *EC*₅₀ value of 16 nM


WAY-00005

See WAY-200070

WAY-200070

WAY-00005

[440122-66-7]
Purity: 99%



Soluble in 0.1N NaOH(aq) and DMSO

Axon 2188

mg	Price
10	online
50	online

Axon 2325

mg	Price
2	online
5	online

Axon 1749

mg	Price
5	online
25	online

Axon 2697

Page 984

Axon 2697

mg	Price
10	online
50	online

C13H8BrNO3 MW: 306.11


Biological activity

Brain penetrant ER β -selective agonist (IC₅₀ values 155 nM and 2 nM for ER α and ER β , respectively) that increases key synaptic proteins in vivo, including PSD-95, synaptophysin and the AMPA-receptor subunit GluR1 and increases dendritic branching and spine number. WAY 20070 regulates hippocampal synaptic plasticity and improve hippocampus-dependent cognition, and shows antidepressant and anxiolytic-like effects in vivo. Potential novel therapeutic agent for the prevention and treatment of photoaging.

WAY-267464 dihydrochloride

[1432043-31-6]
Purity: 98%

Soluble in water and DMSO
C32H35N7O4.2HCl MW: 654.59



Axon 2711

mg Price

2 online

5 online


Biological activity

WAY-267464 is a non-peptide high-affinity, potent, and selective agonist of the oxytocin receptor (K_i value of 58.4 nM at human OTR).

WEHI-9625

[N.A.]
Purity: 99%

Soluble in DMSO
C34H27NO5S2 MW: 593.71



Axon 3068

mg Price

5 online

25 online


Biological activity

WEHI-9625 is a first-in-class, potent, and selective mBAK-mediated apoptosis inhibitor (EC₅₀ value of 69 nM) which binds to VDAC2. In contrast to caspase inhibitors, WEHI-9625 blocks apoptosis before mitochondrial damage, preserving cellular function and long-term clonogenic potential.

WDR5-0103

[890190-22-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C21H25N3O4 MW: 383.44



Axon 2411

mg Price

10 online

50 online

Biological activity

Inhibitor of WD40 repeat protein 5 (WDR5) and associated activity of H3K4 HMTase MLL (K_d value 0.45 μ M for WDR5 binding, and IC₅₀ value of 39 μ M for inhibition of methyltransferase activity of MLL complex). Potential therapeutic for treatment of MLL-rearranged leukemias or other cancers.

WH-4-023


[837422-57-8]
Purity: 99%

Axon 2381

mg Price

5 online

Soluble in DMSO
C32H36N6O4 MW: 568.67



25 online

Biological activity

Orally active inhibitor of Lck and Src (IC₅₀ values 2 nM and 6 nM for Lck and Src, respectively) with an >300-fold selectivity over p38 α and KDR.

WIN 24540

See Trilostane

Axon 3317

Page 939

WIN 47203

See Milrinone

Axon 3314

Page 656

WIN 48098

See Pravadoline


Axon 1523

Page 790

Wiskostatin

[253449-04-6]
Purity: 99%

Soluble in DMSO
C17H18Br2N2O MW: 426.15



Axon 1804

mg Price

10 online

50 online


Biological activity

Selective, reversible inhibitor of neural Wiskott-Aldrich syndrome protein (N-WASP) that inhibits Arp2/3 (actin-related protein 2/3) activation; belongs to be an actin inhibitor for actin-dependent cellular functions

WM-1119

[2055397-28-7]
Purity: 99%

Soluble in DMSO
C18H13F2N3O3S MW: 389.38



Axon 2969

mg Price

10 online

50 online

Biological activity

WM-1119 is a highly potent, selective KAT6A inhibitor with K_d and IC₅₀ values of 0.002 μ M and 0.25 μ M, respectively. WM-1119 induces cell cycle exit, cellular senescence without causing DNA damage, and arrests the progression of lymphoma in mice.

WNK Inhibitor 11


[2123489-30-3]
Purity: 99%

Axon 2896

mg Price

5 online

Soluble in DMSO
C21H21Cl2N5OS MW: 462.40




25 online

Biological activity

Selective allosteric WNK1 inhibitor (IC50 value of 0.004 μM) with nearly 1000-fold selectivity for WNK1 vs WNK4 and 57-fold selectivity for WNK1 vs WNK2.

Wnt agonist 1

[853220-52-7]
Purity: 99%



Axon 2120

mg Price

5 online

25 online

Soluble in DMSO and EtOH
C19H18N4O3 MW: 350.37


Biological activity

A cell permeable and selective Wnt signaling pathway agonist or activator. It mimics the effects of a Wnt ligand in a *Xenopus* model and may be a useful tool in the study of physiol. processes that involve the Wnt pathway; it induces *in vitro* β-catenin and transcription factor (TCF) dependent transcriptional activity in 293T cells in a dose dependent manner with an EC50 of 0.7 mM

Wnt-C59

C59

[1243243-89-1]
Purity: 98%



Axon 2287

mg Price

2 online

5 online

Soluble in DMSO
C25H21N3O MW: 379.45


Biological activity

Nanomolar and orally available inhibitor of mammalian PORCN acyltransferase activity (IC50 value of 74 pM) that blocks activation of all evaluated human Wnts (Wnt palmitoylation, Wnt interaction with the carrier protein Wntless/WLS, Wnt secretion, and Wnt activation of β-catenin reporter activity). The tumor growth inhibition of Wnt-C59 in MMTV-WNT1 transgenic mice is associated with decreased Wnt/β-catenin signaling in tumors.

WP 1130

Degrasyn

[856243-80-6]
Purity: 99%
optically pure
Soluble in DMSO
C19H18BrN3O MW: 384.27



Axon 1779

mg Price

5 online

25 online

Biological activity

Small molecule inhibitor of deubiquitinase (DUB)

WP 1066


[857064-38-1]
Purity: 99%
Optically pure

Axon 2316

mg Price

10 online

Soluble in DMSO and EtOH
C17H14BrN3O MW: 356.22



50 online

Biological activity

Potent inhibitor of JAK2 and STAT3 activity (IC50 values 2.3 μM and 5.6 μM, respectively) that showed selective cytotoxicity toward malignant glioma U87-MG and U373-MG cells at much lower doses than its analogue AG 490 (Axon 1378). Furthermore, WP1066 selectively induces apoptosis in malignant glioma cells by downregulating antiapoptotic proteins (Bcl-XL, Mcl-1 and c-myc) and activating Bax, and significantly inhibited the growth of subcutaneous tumors generated from U87-MG cells in mice.

WR 6026 tosylate

See Sitamaquine


Axon 1515

Page 867

WS-383

DCN1-UBC12 interaction inhibitor E31

[2247543-65-1]
Purity: 99%



Axon 2984

mg Price

5 online

25 online


Soluble in DMSO
C18H20ClN9S2 MW: 461.99

Biological activity

WS-383 effectively blocks interaction between DCN1 and UBC12 (IC50 value of 11 nM), causes selective Cul3/1 neddylation inhibition over other cullins, and induces accumulation of p21, p27, and NRF2.

WT-161

[1206731-57-8]
Purity: 98%



Axon 3995

mg Price

10 online

50 online

Soluble in DMSO
C27H30N4O3 MW: 458.55

Biological activity

WT161 is a potent, selective, and bioavailable HDAC6 inhibitor. It was created to study the mechanism of action of HDAC6 inhibition in MM (Multiple Myeloma) alone and in combination with Bortezomib (BTZ). WT161 in combination with BTZ triggers significant accumulation of polyubiquitinated proteins and cell stress, followed by caspase activation and apoptosis. More importantly, this combination treatment was effective in BTZ-resistant cells and in the presence of bone marrow stromal cells, which have been shown to mediate MM cell drug resistance. The activity of WT161 was confirmed in our human MM cell xenograft mouse model and established the framework for clinical trials of the combination treatment to improve patient outcomes in MM.

Source Information: Sold in collaboration with Chemietek

WY21743

See Oxaprozin

Axon 3818

Page 741


WY 45494 hydrochloride

Venlafaxine Impurity D

Axon 1724

mg Price


[93413-90-2]

Purity: 99%		5	online
Soluble in DMSO		25	online
C ₁₆ H ₂₅ NO ₂ .HCl MW: 299.84			

Biological activity
Metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI)

WY 45960 hydrochloride


Venlafaxine Impurity F

[93413-79-7]		Axon 1723
Purity: 100%		mg Price
Soluble in DMSO		5 online
C ₁₇ H ₂₅ NO.HCl MW: 295.85		25 online

Biological activity
Metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI)


WY 46689

N,O-Didesmethyl Venlafaxine

[135308-74-6]		Axon 1725
Purity: 100%		mg Price
Soluble in DMSO		5 online
C ₁₅ H ₂₃ NO ₂ MW: 249.35		25 online

Biological activity
Metabolite of Venlafaxine (Axon 1727), a serotonin-norepinephrine reuptake inhibitor (SNRI)

WY 14643

[50892-23-4]		Axon 1227
Purity: 98%		mg Price
Soluble in DMSO		10 online
C ₁₄ H ₁₄ ClN ₃ O ₂ S MW: 323.80		50 online

Biological activity
Selective PPAR α agonist


WY 45030

See Venlafaxine hydrochloride

WY49605

See Faropenem sodium Recent Addition

WYE 672

[1221265-37-7]		Axon 1991
Purity: 99%		mg Price
		10 online

Axon 1723

mg Price
5 online
25 online

Axon 1725

mg Price
5 online
25 online

Axon 1227

mg Price
10 online
50 online

Axon 1727


Page 965

Axon 4206

Page 474


Axon 1991

mg Price
10 online

Soluble in DMSO		50	online
C ₂₃ H ₁₇ F ₃ N ₂ O ₂ S MW: 442.45			


Biological activity
A tissue selective liver X receptor (LXR) agonist; WYE672 showed potent binding affinity to LXR β (IC₅₀ = 53 nM), it had little binding affinity for LXR α (IC₅₀ >1.0 μ M)

WZ 811

[55778-02-4]		Axon 1620
Purity: 99%		mg Price
Soluble in DMSO		10 online
C ₁₈ H ₁₈ N ₄ MW: 290.36		50 online


Biological activity
Potent chemokine CXCR4 receptor antagonist (EC₅₀: 0.3 nM)

WZ 4002

[1213269-23-8]		Axon 1506
Purity: 99%		mg Price
Soluble in 0.1N HCl(aq) and DMSO		5 online
C ₂₅ H ₂₇ ClN ₆ O ₃ MW: 494.97		25 online

Biological activity
A mutant-selective EGFR kinase inhibitor against EGFR T790M; a potential agent for some drug-resistant non-small cell lung cancers

WZ 4003


[1214265-58-3]		Axon 2385
Purity: 99%		mg Price
Soluble in 0.1N HCl(aq) and DMSO		5 online
C ₂₅ H ₂₉ ClN ₆ O ₃ MW: 496.99		25 online

Biological activity
Specific dual inhibitor of NUA1 (aka ARK5) and NUA2 (aka SNARK; IC₅₀ values 20 nM and 100 nM, respectively) with no significant inhibitory effect on a panel of 139 other kinases tested, including ten other AMPK-related kinases. WZ4003 suppressed MYPT1 phosphorylation in a dose-dependent manner, and inhibited cell proliferation, invasion and migration in vivo. Although WZ 4003 is a close analogue of WZ 4002 (Axon 1506), it shows no affinity for the EGFR (K_d value 14 μ M)

XAF-1407

[2785323-66-0]
Purity: 99%

Soluble in 0.1N HCl(aq), DMSO and EtOH
C28H37N5O2S MW: 507.69



Biological activity

XAF-1407 is a potent and highly selective inhibitor of the ion channels formed by Kir3.1/3.4 heterotetramers and Kir3.4 homotetramers that carry the IKACH current (IC50 values of 1.1 and 3.2 nM, respectively).

Xanthotoxin


See Methoxsalen

XAV 939

NVP-XAV 939

[284028-89-3]
Purity: 99%

Soluble in DMSO
C14H11F3N2OS MW: 312.31



Biological activity

Tankyrase (TNKS) inhibitor, with IC50 values to be 11 and 4 nM for TNKS1 and TNKS2 respectively; inhibiting Wnt / β -catenin signaling


XBDI73

See AC-5216

XCT 790

[725247-18-7]
Purity: 99%

Soluble in DMSO
C23H13F9N4O3S MW: 596.42



Biological activity

Estrogen-related receptor α (ERR α) inverse agonist (IC50 value of ~300–500 nM) and potent mitochondrial uncoupler that induces cell death in chemotherapeutic resistant cancer cells by causing mitochondrial dysfunction. XCT790 was found to potently activate AMPK in a dose-dependent and ERR α -independent manner at concentrations more than 25-fold below those typically used to perturb ERR α . Measurements of mitochondrial membrane potential, oxygen consumption, and extracellular XCT790 modulates the activity of ERR α and reduces the proliferation of various cell lines by blocking the G1/S transition of the cell cycle in an ERR α -dependent manner. XCT790 showed no activity towards a wide range of (GAL4-chimeric) receptors.

Axon 3265

mg	Price
5	online
25	online

Axon 3449

Page 647

Axon 1527

mg	Price
10	online
25	online

Axon 3698

Page 204


Axon 2337

mg	Price
10	online
50	online

XE 991

[122955-42-4]
Purity: 99%

Soluble in DMSO
C26H20N2O MW: 376.45




Biological activity

KCNQ channel and M-current blocker; potential AD therapeutic. The hydrochloride salt of XE 991 (Axon 1305) is available as well.

XE 991 dihydrochloride

[122955-13-9]
Purity: 99%

Soluble in DMSO
C26H20N2O.2HCl MW: 449.37




Biological activity

KCNQ channel and M-current blocker; potential AD therapeutic

XEN 907

[912656-34-9]
Purity: 99%

Soluble in DMSO
C21H21NO4 MW: 351.40




Biological activity

Sodium channel blocker, potent and selective at voltage-gated Nav1.7 (SCN9A)

XIE62-1004 Recent Addition

[2421146-32-7]
Purity: 99%

Soluble in DMSO and EtOH
C23H25NO3.HCl MW: 399.91



Biological activity

XIE62-1004 an inducer of autophagy and a ligand to the ZZ domain of p62. The binding of XIE62-1004 to the ZZ domain of p62 facilitates the p62 interaction with LC3, leading to the delivery of p62 and its cargoes to the autophagosome. Upon binding to its I

XL 019

[945755-56-6]
Purity: 99%

Optically pure
Soluble in 0.1N HCl(aq) and DMSO
C25H28N6O2 MW: 444.53

Axon 1987

mg	Price
10	online
50	online

Axon 1305

mg	Price
10	online
50	online

Axon 2056


mg	Price
5	online
25	online

Axon 4119

mg	Price
10	online
50	online

Axon 2231

mg	Price
5	online
25	online


Biological activity

Potent, selective, and orally active JAK2 inhibitor (IC₅₀ values 2.2 nM and 214.2 nM for JAK2 and JAK3 respectively), showing a significant dose-dependent pharmacodynamic and antitumor effect in a mouse xenograft model. XL 019 significantly inhibits downstream markers pSTAT1 and pSTAT3 (ED₅₀ values 42 mg/kg pSTAT1, and 210 mg/kg pSTAT3).

XL 139

See BMS 833923

Axon 2356


Page 320

XL-147

Pilaralisib; SAR245408

[934526-89-3]
Purity: 99%

Soluble in DMSO
C25H25ClN6O4S MW: 541.02


Axon 4031

mg	Price
10	online
50	online

Biological activity

XL-147 is a potent, selective and orally bioavailable ATP-competitive small molecule inhibitor targeting pan-class I phosphatidylinositol 3 kinase (PI3K) family with IC₅₀ values of 39, 383, 36 and 23 nM for p110 α , β , δ and γ isoforms, and is highly selective over mTOR (IC₅₀ > 15000 nM), VPS34 (IC₅₀ = 6975 nM), DNAPK (IC₅₀ = 4750 nM).

Source Information: Sold in collaboration with Chemietek

XL 184

See Cabozantinib S-malate


Axon 1819

Page 338

XL-228

[898280-07-4]
Purity: 99%

Soluble in DMSO
C22H31N9O MW: 437.54


Axon 3973

mg	Price
10	online
50	online

Biological activity

XL228 is a multitargeted protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL, ALK, and SRC family kinases.

Source Information: Sold in collaboration with Chemietek

XL 335

See WAY 362450


Axon 1749

Page 984

XL 388

[1251156-08-7]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C23H22FN3O4S MW: 455.50


Biological activity

Highly potent, selective, ATP-competitive, and orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with an IC₅₀ value of 9.9 nM. Moreover, XL 388 is an mTORC1/2 dual inhibitor which displayed good pharmacokinetics and oral exposure in multiple species with moderate bioavailability. XL 388 showed anti-cancer activity in preclinical osteosarcoma models and inhibited survival and proliferation of RCC cell lines and primary human RCC cells.

Axon 2951


mg	Price
5	online
25	online

XL 413 hydrochloride

BMS 863233 hydrochloride

[1169562-71-3]
Purity: 99%

Soluble in water and DMSO
C14H12ClN3O2.HCl MW: 326.18


Axon 2268

mg	Price
5	online
25	online

Biological activity

Potent, selective and orally bioavailable CDC7 inhibitor (IC₅₀ value of 3.4 nM) that shows >60-fold selectivity against CK2, >10-fold selectivity against PIM1, and >300-fold selectivity against a panel of over 100 protein kinases. XL 413 induces tumor cell apoptosis and inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. Further development of XL 413 was terminated due to an unfavorable pharmacological profile observed in phase 1 clinical evaluation.

XL518

See GDC-0973

Axon 4148


Page 499

XL-765

Voxtalisib; SAR245409

[934493-76-2]
Purity: 99%

Soluble in DMSO
C13H14N6O MW: 270.29


Axon 4009

mg	Price
10	online
50	online

Biological activity

XL765, a pyridopyrimidinone-derivative, is a highly selective, potent and reversible ATP-competitive inhibitor of pan-Class I PI3K (α , β , γ , and δ) and mTORC1/mTORC2. It is orally active, highly selective over 130 other protein kinases. In cellular assays, XL765 inhibits the formation of PIP3 in the membrane, and inhibits phosphorylation of AKT, p70S6K, and S6 phosphorylation in multiple tumor cell lines with different genetic alterations affecting the PI3K pathway. In mouse xenograft models, oral administration of XL-765 results in dose-dependent inhibition of phosphorylation of AKT, p70S6K, and S6 with a duration of action of approximately 24 hours. Repeat dose administration of XL765 results in significant tumor growth inhibition in multiple human xenograft models in nude mice that is associated with antiproliferative, antiangiogenic, and proapoptotic effects.

Source Information: Sold in collaboration with Chemietek

XL 880

See Foretinib


Axon 1582

Page 489

XL PI3K/mTOR inhibitor

[934529-30-3]
Purity: 99%

Moderately soluble in DMSO
C31H29N5O6S MW: 599.66



Axon 1706

mg	Price
5	online
25	online


Biological activity

Orally active PI3K/mTOR tyrosine kinase inhibitor; matching the profile of XL 765. Note: XL765 has a registered CAS [1123889-87-1] but no structure has been displayed in Sci-finder database

XMD 8-87

[1234480-46-6]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C24H27N7O2 MW: 445.52



Axon 2762

mg	Price
5	online
25	online


Biological activity

XMD 8-87 is a potent and selective inhibitor of Ack1 (activated CDC42-associated kinase) also known as tyrosine kinase nonreceptor 2 (TNK2). XMD8-87 has IC50 values of 38 and 113 nM for the D163E and R806Q mutations, respectively.

XMD 8-92

[1234480-50-2]
Purity: 99%

Soluble in DMSO
C26H30N6O3 MW: 474.55



Axon 1846

mg	Price
2	online
5	online


Biological activity

Potent and selective inhibitor of big MAP kinase 1 (BMK1/ERK5)

XMD 8-92 trifluoroacetate

[1234480-50-2]
Purity: 99%

Soluble in water and DMSO
C26H30N6O3.C2HF3O2
MW: 588.58



Axon 1621

mg	Price
2	online
5	online

Biological activity

Potent and selective inhibitor of big MAP kinase 1 (BMK1/ERK5). Note: Free base form of XMD8-92 (Axon 1846) is also available

XR 9576

See Tariquidar

Axon 1960


Page 910

XY028-140

MS140

[2229974-83-6]
Purity: 98%

Soluble in DMSO
C39H40N10O7 MW: 760.80



Axon 3535

mg	Price
5	online
25	online

Biological activity


XY028-140 is a potent and selective CDK4/6 inhibitor-degrader (PROTAC) with IC50 values of 0.38 nM and 0.28 nM against CDK4/cyclin D1 and CDK6/cyclin D1, respectively. XY028-140 potently and selectively both inhibited and degraded CDK4/6 kinases in CDK4/6i-S tumor cells by targeting them to the CRL4-CRBN-E3 ubiquitin complex.

Y 700

Piraxostat

[206884-98-2]
Purity: 99%

Soluble in DMSO
C16H17N3O3 MW: 299.32



Biological activity

Xanthine oxidase (XO) inhibitor


Axon 1174

mg	Price
5	online
25	online

Y 27632 dihydrochloride

[129830-38-2]
Purity: 99%

>98% ee
Soluble in water and DMSO
C14H21N3O2.HCl MW: 320.26



Biological activity

Selective inhibitor of Rho-Kinase (ROCK), with IC50 values of 140-220 nM for ROCK1 and ROCK2. Y-27632 was found to increase human embryonic stem cell (hESC) survival


Axon 1683

mg	Price
2	online
5	online
25	online

Y 29794 tosylate

[143984-17-2]
Purity: 99%

Soluble in DMSO
C23H34N2O5S2.C7H8O3S MW: 590.86



Biological activity

Y 29794 tosylate is an orally active, potent and specific prolyl endopeptidase (PPE) inhibitor that is easily penetrable into the brain. Y-29794 tosylate selectively and competitively inhibited rat brain PPE in a reversible manner with a Ki value of 0.95 nM. Moreover, Y 29794 tosylate exhibited potent inhibitory activity with an IC50 value of 3.0 nM for both brain crude extract and partially purified enzyme fraction.

Axon 2911

mg	Price
10	online
50	online

YAP activator PY-60

See PY-60


Axon 3480

Page 799

YH-306

[1373764-75-0]
Purity: 99%

Soluble in DMSO and EtOH
C19H18N2O2 MW: 306.36



Biological activity


YH-306 blocks the activation of FAK and FAK-related signaling pathways, leading to the suppression of CRC growth and metastasis. In vitro, YH-306 significantly inhibited CRC cell migration, invasion, proliferation and colonization, and induced CRC cell apoptosis. In vivo, YH-306 depressed CRC growth and suppressed hepatic/pulmonary metastasis.

Axon 3789

mg	Price
5	online
25	online

YJC-10592

[1226894-87-6]
Purity: 98%
Optically pure
Soluble in DMSO
C27H31ClF3N5O3 MW: 566.01



Biological activity

YJC-10592 is a CC chemokine receptor 2 (CCR2) antagonist (IC50 value 1.12 μM), which also showed excellent inhibitory activity in the calcium assay (IC50 value 1.7 nM), and good potency in the chemotaxis assay (IC50 value 23 nM). In rats, YJC-10592 showed dose-dependent pharmacokinetics and low F value due to slower elimination and incomplete absorption.


Axon 2636

mg	Price
5	online
25	online

YK 4-279

[1037184-44-3]
Purity: 99%

Soluble in DMSO
C17H13Cl2NO4 MW: 366.20



Biological activity

Inhibitor of interactions between the fusion protein EWS-FLI1 and RNA helicase A (RHA; Kd value 9.48 μM) with a detrimental effect on ESFT cells both in vitro and in vivo. YK-4-279 is also found to potently inhibit biological activity of ERG (Kd value 11.7 μM) and ETV1 (Kd value 17.4 μM) resulting in suppression of both primary tumor growth and metastasis of fusion positive prostate cancer xenografts. ETV1 is a member of the translocated erythroblastosis virus E26 transforming sequence (ETS) family of transcription factors) and targets MMP7, MMP13, FKBP10 and GLYATL2 genes, among several others.

Axon 2469


mg	Price
10	online
50	online

YL-365

C20

[N.A.]
Purity: 99%

Soluble in DMSO
C34H31ClN2O5 MW: 583.07



Biological activity

YL-365 is a potent and selective GPR34 antagonist with an IC50 value of 17 nM. In a mouse model of neuropathic pain, YL-365 displayed outstanding antinociceptive effect, but did not show obvious toxicity.


Axon 4090

mg	Price
5	online
25	online

YM 90K hydrochloride

[154164-30-4]
Purity: 98%

Moderately soluble in DMSO
C11H7N5O4.HCl MW: 309.67



Biological activity

AMPA antagonist with neuro-protective effect


Axon 1312

mg	Price
5	online
25	online

YM 155

[781661-94-7]
Purity: 98%

Soluble in DMSO
C20H19N4O3.Br MW: 443.29



Biological activity

Small molecule survivin suppressant or inhibitor; YM155 suppressed expression of survivin and induced apoptosis in p53-deficient human HRPC cell lines at 10 nmol/L


YM 178

See Mirabegron

YM201636

[371942-69-7]
Purity: 98%

Soluble in 0.1N HCl(aq) and DMSO
C25H21N7O3 MW: 467.48




Biological activity

Selective inhibitor of PIKfyve (type III PtdInsP kinase; IC50 value 33 nM) that blocks PtdIns(3,5)P2 production and disrupts endomembrane transport and retroviral budding and nearly 100-fold selective over p110α. However, YM201636 arrests basal and insulin-induced glucose influx in cultured adipocytes at low nano-molar concentrations (doses are significantly lower than the effective antiretroviral dose), likely by affecting a PIKfyve-unrelated target. Moreover, YM-201636 dysregulates autophagy and promotes neuronal cell death in primary hippocampal neurons in culture.

YM-244769 dihydrochloride

[1780390-65-9]
Purity: 98%

Soluble in DMSO and EtOH
C26H22FN3O3.2HCl MW: 516.39



Biological activity

YM-244769 dihydrochloride is a highly potent inhibitor of reverse NCX activity (IC50 value of 0.24 μM). Moreover, YM-244769 preferentially inhibited intracellular Na+-dependent 45Ca2+ uptake via NCX3 (IC50 value of 18 nM); the inhibition was 3.8- to 5.3-fold greater than for the uptake via NCX1 or NCX2, but it did not significantly affect extracellular Na+-dependent 45Ca2+ efflux via NCX isoforms. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage.

YM 311

See FG-2216

YM 09730-5

See Barnidipine hydrochloride

Axon 1639

mg	Price
5	online
25	online

Axon 2414

Page 657

Axon 2607

mg	Price
2	online
5	online

Axon 3604

mg	Price
5	online
25	online

Axon 2570

Page 479


Axon 3014

Page 284

YM 298198 hydrochloride

[299901-50-1]
Purity: 99%

Soluble in water and DMSO
C18H22N4OS.HCl MW: 378.92




Biological activity

Selective mGlu1 antagonist

YM 298198 hydrochloride, desmethyl

[299901-57-8]
Purity: 98%

Soluble in water
C17H20N4OS.HCl MW: 364.89



Biological activity

Derivative of YM-298198 (Axon 1260), a selective and noncompetitive mGluR1 antagonist


YN968D1

See Apatinib

YS 49

[132836-42-1]
Purity: 98%

Soluble in DMSO
C20H19NO2.HBr MW: 386.28



Biological activity

Anti-inflammatory agent; Antithrombotic; Antiplatelet; YS-49 protects cells from oxidant injury; induces heme oxygenase (HO-1) in endothelial cells and protects cells from oxidant injury; activator of PI3K/Akt signaling


YTR830

See Tazobactam acid

YUKA1

[708991-09-7]
Purity: 99%

Soluble in DMSO
C13H16N4O2S MW: 292.36



Biological activity

YUKA1 is a cell-permeable selective inhibitor of lysine demethylase 5A (KDM5A/RBP2/JARID1A) (IC50 value 2.66 μM). YUKA1 blocks drug resistance and cancer cell growth in HeLa cervical cancer cells and ZR-75-1 breast cancer cells. YUKA1 was able to increase H3K4me3 levels in human cells and selectively inhibited the proliferation of cancer cells whose growth depends on KDM5A.

Axon 1260

mg	Price
10	online
50	online

Axon 1259

mg	Price
10	online
50	online

Axon 2849

Page 239

Axon 1685

mg	Price
10	online
50	online

Axon 3820

Page 913


Axon 2674

mg	Price
5	online
25	online

YW2065

[2131223-85-1]
Purity: 99%

Soluble in DMSO
C20H15BrN4O MW: 407.26



Axon 3206

mg	Price
5	online
25	online

Biological activity

The dual-functional compound YW2065 is a potent inhibitor of the Wnt/ β -catenin signaling pathway (IC₅₀ value of 2.3 nM) and an AMPK activator. YW2065 may achieve its dual activities through the mechanism of Axin-1 stabilization. YW2065 demonstrated favorable PK properties and suppressed tumor growth in a xenograft mouse model.


Z-2-035II

See Pifithrin- β

Z29077885 Recent Addition

[785710-21-6]
Purity: 99%

Soluble in DMSO
C21H24N4O3S MW: 412.51




Biological activity

Z29077885 is a potent serine/threonine kinase 33 (STK33) inhibitor with an IC₅₀ value of 0.2367 μ M and showed anticancer efficacy in various cancer cells. Z29077885 induces apoptosis via deactivation of the STAT3 signaling pathway, and induces cell cycle Z29077885 is also available as the hydrochloride salt (Axon 4142)

Z29077885 hydrochloride Recent Addition

[N.A.]
Purity: 99%

Soluble in DMSO
C21H24N4O3S.HCl MW: 448.97




Biological activity

Z29077885 hydrochloride is a potent serine/threonine kinase 33 (STK33) inhibitor with an IC₅₀ value of 0.2367 μ M and showed anticancer efficacy in various cancer cells. Z29077885 induces apoptosis via deactivation of the STAT3 signaling pathway, and indu

Z433927330

[1005883-72-6]
Purity: 99%

Soluble in DMSO
C20H20N4O3 MW: 364.40




Biological activity

Z433927330, a partial AQP3 inhibitor (IC₅₀ value of ~0.7-0.9 μ M), is a potent and efficacious inhibitor of mouse AQP7 water permeability (IC₅₀ value of ~0.2 μ M).

Z944

[1199236-64-0]
Purity: 98%

Soluble in 0.1N HCl (aq) and DMSO
C19H27ClFN3O2 MW: 383.89



Biological activity

Z944 is a highly selective, orally available T-type Ca²⁺ channel blocker with IC₅₀ values of 50 to 160 nM for hCa V 3.1, hCa V 3.2, and hCa V 3.3 T types. Upon administration to GAERS animals, Z944 potently suppressed absence seizures by 85 to 90% via a mechanism distinct from the effects of ethosuximide and valproate.

Axon 3051

Page 777

Axon 4239

mg	Price
5	online
25	online

Axon 4142

mg	Price
10	online
50	online

Axon 2988

mg	Price
10	online
50	online


Axon 3025

mg	Price
10	online
50	online

Z-VAD-FMK

Z-VAD(OMe)-FMK

[187389-52-2]
Purity: 98%
Optically pure
Soluble in DMSO
C22H30FN3O7 MW: 467.49



Axon 2159

mg	Price
2	online
5	online

Biological activity

Pan-caspase inhibitor with in vivo activity (K_i values 18.4 μ M, 0.45 μ M, and 17.1 μ M for Caspase-3, -8, and -9 resp). Z-VAD-FMK inhibits apoptosis by blocking the processing of CPP32, and in pyrogallol-treated lung cancer Calu-6 cells via the prevention of GSH depletion. Z-VAD-FMK is a key compound for studies on apoptosis.

Z-VAD(OMe)-FMK


See Z-VAD-FMK

Axon 2159

Page 1003

Zaleplon

[151319-34-5]
Purity: 99%



Soluble in DMSO
C17H15N5O MW: 305.33

Axon 1646

mg	Price
10	online
50	online


Biological activity

Zaleplon selectively binds with high efficacy to the benzodiazepine site ($\omega 1$) on the $\alpha 1$ containing GABAA receptors; a nonbenzodiazepine hypnotic agent used in the treatment of insomnia

Zamifenacin fumarate

UK 76654

[127308-98-9]
Purity: 99%
>98% ee
Soluble in DMSO and Ethanol
C27H29NO3.C4H4O4 MW: 531.60



Axon 1273


mg	Price
10	online
50	online

Biological activity

Selective M3 muscarinic receptor antagonist

Zardaverine

[101975-10-4]
Purity: 99%



Soluble in DMSO
C12H10F2N2O3 MW: 268.22

Axon 1216

mg	Price
10	online
50	online

Biological activity


Selective phosphodiesterase III/IV inhibitor (PDE3/4)

Zatebradine hydrochloride

UL-FS 49

[91940-87-3]
Purity: 98%

No solubility data
C26H36N2O5.HCl MW: 493.04



Axon 1248


mg	Price
10	online
50	online

Biological activity

HCN channel blocker: blocker of neuronal Ih, related cardiac If channels and ATP-sensitive Kir channels; specific bradycardic agent

ZB716

[1853279-29-4]
Purity: 99%
Optically pure
Soluble in DMSO
C32H48BF5O4S MW: 634.59



Axon 2652

mg	Price
2	online
5	online


Biological activity

ZB716 is a steroidal, orally bioavailable SERD (selective estrogen receptor downregulator) that binds to ER with high affinity and exerts its antiestrogenic effect on ER-expressing breast cancer cells. In both tamoxifen-naive and tamoxifen-resistant breast cancer cells, ZB716 potently inhibits cell proliferation and effectively degrades the hormone receptor in a dose-dependent manner. ZB716 is shown to have far superior oral bioavailability in mice when compared to fulvestrant.

ZCL 278

[587841-73-4]
Purity: 98%

Soluble in DMSO
C21H19BrClN5O4S2 MW: 584.89



Axon 2138

mg	Price
10	online
50	online


Biological activity

Selective Cdc42 GTPase inhibitor. ZCL278 specifically targets Cdc42-ITSN interaction and inhibits Cdc42-mediated cellular processes, thus providing a powerful tool for research of Cdc42 subclass of Rho GTPases in human pathogenesis. ZCL278 reduces the perinuclear accumulation of active Cdc42 in contrast to NSC23766 (Axon 1578), a selective Rac inhibitor.

ZCZ 011

[1998197-39-9]
Purity: 99%

Soluble in DMSO
C21H18N2O2S MW: 362.44



Axon 2543

mg	Price
5	online
25	online

Biological activity

Brain penetrant cannabinoid CB1 receptor positive allosteric modulator (PAM) which augments the in vitro and in vivo pharmacological actions of the CB1 orthosteric agonists CP55940 (pEC50 value 6.90) and N-arachidonylethanolamine (AEA) and reduces neuropathic pain in the mouse with no psychoactive effects.

ZD 211

See Citalopram hydrobromide

Axon 1320

Page 373

ZD1033

See Anastrozole

Axon 3316

Page 237

ZD 1839

See Gefitinib

Axon 1393

Page 501

ZD4522

See Rosuvastatin calcium

Axon 3444

Page 830

ZD 5077

See Quetiapine fumarate

Axon 1354

Page 801

ZD 6474


See Vandetanib

Axon 1411

Page 954

ZD 9379

 [170142-20-8]
Purity: 100%

 Soluble in 0.1N NaOH(aq) and DMSO
C19H14ClN3O4 MW: 383.79

Axon 2261

mg	Price
5	online
25	online

Biological activity

Selective antagonist of the glycine site on the NMDA receptor complex. ZD9379 crosses the blood-brain barrier and is neuroprotective. In vivo studies demonstrated reduced infarct size and less spreading depressions after treatment with ZD 9379.

ZDV

See Zidovudine

Axon 3382

Page 1006

Zegocractin


See CM-4620

Axon 4066

Page 379

ZG-2033

 [2685739-28-8]
Purity: 99%

 Soluble in DMSO and EtOH
C15H14N2O2S MW: 286.35

Axon 3596

mg	Price
10	online
50	online


Biological activity

ZG-2033 is a potent and orally bioavailable hypoxia-inducible factor 2 α (HIF-2 α) agonist with an EC₅₀ value of 490 nM. In the in vivo efficacy assays, the combination of ZG-2033 and the prolyl hydroxylase inhibitor, AKB-6548

(Axon 3288), was confirmed for the first time to synergistically increase the plasma erythropoietin level in and alleviate zebrafish anemia induced by doxorubicin.

Zidovudine

Azidothymidine; AZT; ZDV; BWA509U

 [30516-87-1]
Purity: 99%
Optically pure
Soluble in water and DMSO
C10H13N5O4 MW: 267.24

Axon 3382

mg	Price
50	online

Biological activity

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI).

ZIKV inhibitor K22

See K22


Axon 3432

Page 587

Zileuton

A-64077

 [111406-87-2]
Purity: 99%

 Soluble in 0.1N NaOH(aq) and DMSO
C11H12N2O2S MW: 236.29

Axon 3256

mg	Price
10	online
50	online


Biological activity

Zileuton is a potent and orally-active 5-LOX inhibitor.

ZINC000006658090 Recent Addition

SERT inhibitor compound 8090

 [887625-25-4]
Purity: 99%

 Soluble in 0.1N HCl(aq), DMSO and
EtOH
C13H14FN3S MW: 263.33

Axon 4057

mg	Price
10	online
50	online

Biological activity

ZINC000006658090 is a potent, conformationally selective and non-competitive SERT inhibitor with a K_i value of 14 nM.

ZINC20606903


See MCI-INI-3

Axon 3880

Page 642

ZINC69391

 [303094-67-9]
Purity: 99%

 Soluble in 0.1N HCl(aq), DMSO and
EtOH

Axon 3790

mg	Price
5	online
25	online

C14H14F3N5 MW: 309.29

Biological activity

ZINC69391 is a specific Rac1 inhibitor. ZINC69391 was able to block Rac1 interaction with its GEF Tiam1, prevented EGF-induced Rac1 activation and inhibited cell proliferation, cell migration and cell cycle progression in highly aggressive breast cancer cell lines. Moreover, ZINC69391 inhibited lung metastasis in vivo.


Ziritaxestat

See GLPG1690

ZQ-16

[376616-73-8]
Purity: 99%

Soluble in DMSO and Ethanol
C10H16N2O2S MW: 228.31




Biological activity

Potent and selective small-molecule GPR84 agonist (EC50 value 0.139 μM in a calcium mobilization assay). ZQ-16 induced phosphorylation of ERK1/2, and a dose-dependent reduction of forskolin-stimulated cAMP accumulation in HEK293 cells expressing GPR84.

Zebularine

[3690-10-6]
Purity: 99%

Soluble in water
C9H12N2O5 MW: 228.20



Biological activity


DNA methyltransferase inhibitor, aka DNA methylation inhibitor, anticancer drug

Ziprasidone hydrochloride

CP 88059

[122883-93-6]
Purity: 99%

Soluble in DMSO
C21H21ClN4OS.HCl MW: 449.40



Biological activity

A 5-HT2A/5-HT2C and dopamine D2 antagonist, 5-HT1A agonist; an atypical antipsychotic for the treatment of schizophrenia and acute bipolar disorder including manic and mixed episodes; Oral bioavailability 59%; Antipsychotic effects at oral doses of 20 mg

Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc

Zithromax

See Azithromycin

ZK 202650

See NVP-ACC789

Axon 3094

Page 505

Axon 2616

mg	Price
10	online
50	online

Axon 1254

mg	Price
10	online
50	online

Axon 1446

mg	Price
10	online
25	online

Axon 2042

Page 279

Axon 2865

Page 721

ZK 216348, (+)-


[669073-68-1]

Purity: 99%

Optically pure

Soluble in DMSO

C24H23F3N2O5 MW: 476.45



Biological activity


Selective nonsteroidal glucocorticoid receptor (GR) agonist for the treatment of experimental colitis with IC50 values of 20, 20, and 80 nM for GR, Progesterone (PR) and Mineralocorticoid (MR) receptors respectively. (+)-ZK 216348 shows antiinflammatory activity comparable to prednisolone for both systemic and topical application, with a significant dissociation between transrepression and transactivation of antiinflammatory effects both in vitro and in vivo. (+)-ZK 216348 showed no negative effects on intestinal epithelial migration or proliferation. (-)-ZK 216348 is completely inactive (IC50 >1000 nM for GR, PR, and MR).

ZK 756326 dihydrochloride

[1780259-94-0]

Purity: 98%

Soluble in water and DMSO
C21H28N2O3.2HCl MW: 429.38



Biological activity


ZK 756326 dihydrochloride is a nonpeptide chemokine CCR8 receptor agonist (IC50 value of 1.8 μM). This compound may be useful in evaluating the physiological role of CCR8 in HIV infection, as well as in the general study of CCR8 biology without the constraints inherent to the use of protein agonists such as its natural ligand.

ZL006

[1181226-02-7]

Purity: 99%

Soluble in DMSO
C14H11Cl2NO4 MW: 328.15



Biological activity


ZL006 blocked the ischemia-induced nNOS-PSD-95 association selectively, had potent neuroprotective activity in vitro and ameliorated focal cerebral ischemic damage in mice and rats subjected to middle cerebral artery occlusion (MCAO) and reperfusion. Moreover, it readily crossed the blood-brain barrier, did not inhibit NMDAR function, catalytic activity of nNOS or spatial memory, and had no effect on aggressive behaviors.

ZLN 005

[49671-76-3]

Purity: 99%

Soluble in DMSO
C17H18N2 MW: 250.34



Biological activity

Selective transcriptional regulator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α). ZLN005 selectively stimulated the expression of PGC-1α and downstream genes in skeletal muscle cells, and led to changes in glucose uptake, and fatty acid oxidation in L6 myotubes in a AMPK dependent manner. Since ZLN 005 did not increase the expression of the PGC-1α gene in rat primary hepatocytes, it is hypothesized that expression of PGC-1α was regulated in a cell type-specific manner. ZLN005 exerts promising therapeutic effects for treating type 2 diabetes, as PGC-1α is a powerful transcriptional coregulator of GLUT4 and mitochondrial genes, a crucial player in the field of glucose uptake in skeletal muscle.

Axon 2239

mg	Price
2	online
5	online

Axon 2861

mg	Price
10	online
50	online

Axon 2878

mg	Price
10	online
50	online


Axon 2379

mg	Price
10	online
50	online

ZLN 024

[723249-01-2]
Purity: 100%

Soluble in DMSO
C13H13BrN2OS MW: 325.22



Axon 2445

mg	Price
10	online
50	online

Biological activity

Allosteric activator of AMP-activated protein kinase (AMPK; EC50 values 0.42 μ M and 0.95 μ M for increasing the activity of activated heterotrimers α 1 β 1 γ 1 and α 2 β 1 γ 1, respectively) that has no effect on mitochondrial function or the ADP/ATP ratio, and which exerts beneficial metabolic effects in vitro and in vivo. ZLN024 reduced glucose intolerance and fatty liver characteristics in diabetic db/db mice and provides a promising therapeutic approach for type 2 diabetes mellitus and metabolic syndrome.

ZM 204636

See Quetiapine fumarate


Axon 1354

Page 801

ZM241385

[139180-30-6]
Purity: 98%

Soluble in DMSO
C16H15N7O2 MW: 337.34



Axon 4001

mg	Price
10	online
50	online


Biological activity

ZM241385 is a potent A2a selective adenosine receptor antagonist.

ZM 323881 Hydrochloride

[193000-39-4]
Purity: 99%

Soluble in DMSO
C22H18FN3O2.HCl MW: 411.86



Axon 1978

mg	Price
10	online
50	online


Biological activity

Potent and selective inhibitor of VEGFR-2 (IC50: 2 nM for VEGFR-2 vs >50 nM for VEGFR-1 respectively)

ZM 447439

[331771-20-1]
Purity: 99%

Soluble in DMSO
C29H31N5O4 MW: 513.59



Axon 1541

mg	Price
5	online
25	online

Biological activity


Selective and ATP-competitive inhibitor of Aurora B kinase in vitro, with IC50 values to be 50, 250 and 1000 nM for Aurora B, C and A kinases respectively

Zoniporide hydrochloride

CP 597396 hydrochloride

[241800-97-5]
Purity: 99%

Soluble in water and DMSO
C17H16N6O.HCl MW: 356.81



Biological activity

Potent and selective inhibitor of Na+/H+ exchanger isoform 1 (NHE-1); Zoniporide inhibits NHE1-dependent Na+ uptake (IC50: 14 nM) and provides cardioprotection from myocardial ischemic injury in vivo (EC50: 0.25 nM)
Source Information: Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.


Axon 2022

mg	Price
5	online
25	online

Zopiclone

[43200-80-2]
Purity: 99%

No solubility data
C17H17ClN6O3 MW: 388.81



Biological activity

Benzodiazepine receptor BZR agonist; hypnotic agent used in the treatment of insomnia

Axon 1197

mg	Price
10	online
50	online

Zosuquidar trihydrochloride

See LY 335979


Axon 1839

Page 630

ZT-12-037-01

[2328073-61-4]
Purity: 99%

Soluble in 0.1N HCl(aq) and DMSO
C21H31N5O2 MW: 385.50



Biological activity

ZT-12-037-01 is a specific STK19 inhibitor (IC50 value of 24 nM) which showed to effectively block oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo.

Axon 2937

mg	Price
5	Online
25	Online

ZYH1

See Saroglitazar magnesium

Axon 3999

Page 844

Zyvox

See Linezolid

Axon 2048

Page 615

ZYZ-802

See S-Propargyl-Cysteine

Axon 2666


Page 884

ZZW-115 trihydrochloride

ICI738

[10122-45-9]
Purity: 99%

Soluble in water and DMSO
C₂₄H₃₁F₃N₄S₃·3HCl MW: 573.97



Axon 3735

mg	Price
5	online
25	online

Biological activity

ZZW-115 trihydrochloride is a potent NUPR1 inhibitor (K_d value of 2.1 μM) which showed dose-dependent tumor regression with no neurological effects and an ability to induce cell death mainly by necroptosis.

Alphabetical Shortlist

2X-121	189
3TC	189
4A7C-301	189
4μ8C	189
5A6-48	189
5A6-78	189
5A6-86	189
566C80	189
6748-481	190
A-002	190
A01	190
AO128	190
A-1155463 dihydrochloride	190
A-1210477	190
A127722	191
A-1331852	191
A-438079 hydrochloride	191
A1443	191
A 66	191
A 357300	191
A 381393	192
A4166	192
A56268	192
A 769662	192
A 770041	192
A 784168	192
A 803467	193
A 804598	193
A 841720	193
A 861695 dihydrochloride	193
A 922500	193
A 943931	194
A 1070722	194
A 77-01	194
A 83-01	194
A-196	195
A2764 dihydrochloride	195
A2793	195
A-64077	195
A-92	196
A1B1 Hydrochloride	196
AA147	196
AA 2414	196

AAE 581	196
AB, 3-	196
AB 1010	196
AB-680 ammonium salt	197
ABA	197
ABA, 3-	197
ABBV-075	197
ABBV-467 Recent Addition	197
ABBV-744	198
ABBV-CLS-484 hydrochloride	198
ABC294640	198
ABCA1 inducer compound G	199
Abiraterone	199
Abiraterone acetate	199
Abivertinib	199
ABL001	200
Abn-CBD	200
ABR 21261	200
ABR 215062	200
ABR-238901	200
Abscisic acid, (+)-	200
ABT 102	200
ABT 199	201
ABT 239 tartrate	201
ABT-263	201
ABT627	201
ABT-639	202
ABT 702	202
ABT 724 trihydrochloride	202
ABT 869	202
ABT 888	202
ABT 888 dihydrochloride	203
ABT-378	203
ABT-538	203
ABX-1431	203
AC 0010	203
AC1802	203
AC1903	203
AC 220 dihydrochloride	204
AC 264613	204
AC480	204
AC-5216	204
Acalabrutinib	205
Acalisib	205
Acelarin	205

ACNU	205
Acyclovir	205
ACC789	206
ACP-104	206
ACP-196	206
ACR16 hydrochloride	206
ACT001	206
ACT 293987	206
Active isomer 2	206
ACV	206
ACY-241	207
AD 5423	207
AD-4833	207
ADAC	207
Adagrasib	207
ADAMTS-5 inhibitor	207
Adelatinib	207
Adenosine amine congener	207
Adenosine, 2-MeS-	208
ADH-503	208
AdipoRon	208
Adjudin	208
ADL 5859	209
Adomeglivant	209
Adriamycin hydrochloride	209
ADTN, 5,6-	209
ADTN, 6,7-	209
ADU-S100	210
ADX71743	210
AEB 071	210
AEE 788	210
AEG 3482	210
AEGR-733	211
AeroBid	211
AF 2364	211
Afatinib	211
Aficamten	211
Afimoxifene, (Z)-	211
Afuresertib hydrochloride	211
AG-120	211
AG14361 Recent Addition	211
AG-221	212
AG-270	212
AG 337	212
AG 490	212

AG 1343	213
AG 7088	213
AG 013736	213
AG 014699	213
AG-1749	213
AG881	213
AG-EE 623ZW	214
AGI 5198	214
AGI 6780	214
AGN 4204	214
AGN 192403 hydrochloride	214
AGN 194204	214
Agomelatine	214
AH 001	215
AH 002	215
AHU-377 tris salt	215
AIM 100	215
AJ2-30	216
AK-01	216
AK 1	216
AK 7	216
AKI603	216
AKB6548	217
AKOS-022	217
AKOS022075291	217
Akt Inhibitor VIII	217
Akti-1/2	217
AL1576	217
AL 3810 dihydrochloride	218
AL4862	218
AL4943A	218
Alantolactone	218
Alda 1	218
Aleplasinin	218
Alisertib	218
Aliudanexin	218
Alofanib	218
Alogliptin benzoate	219
Aloperine	219
Alosetron hydrochloride	219
ALP201	219
Alpelisib	220
Alphagan-P	220
Alprostadil	220
Altiratinib	220

Alunbrig	220
ALX 5407 hydrochloride	221
AM 36 dihydrochloride	221
AM 251	221
AM 095 (parent compound)	221
AM 281	221
AM 4113	222
AM 580	222
AM 630	222
AM-1155 hydrochloride	222
Ambrisentan	222
Ambroxol hydrochloride	223
AMD 3100	223
AMD 3465	223
Amenamevir	223
Amethopterin	224
Amfebutamone	224
AMG 131	224
AMG-176	224
AMG 208	224
AMG 232	224
AMG-337	225
AMG510	225
AMG-511	225
AMG 706	225
AMG 837	226
AMG 900	226
AMG-925	226
AMG 9810	227
AMI-1	227
AMI-1 sodium salt	227
α -Amino-2-chloro-5-hydroxybenzeneacetic acid	227
Amino-10-methylfolic acid, 4-	227
Aminoacridone, 2-	227
Aminobenzamide, 3-	228
Aminotetraline hydrobromide, 5,6-Dihydroxy-2-	228
Aminotetraline hydrobromide, 6,7-Dihydroxy-2-	228
Aminotetraline hydrobromide, 6,7-Dihydroxy-N-methyl-N-propyl-	228
Aminotetraline hydrobromide, 6,7-Dimethoxy-2-	228
Aminotetraline hydrobromide, N-Cyclopropyl-N-methyl-2-	229
Aminotetraline hydrochloride, (R)-(+)-5-Methoxy-2-	229
Aminotetraline hydrochloride, (R)-(+)-7-Methoxy-N-propyl-2-	229
Aminotetraline hydrochloride, (R)-(+)-8-Methoxy-2-	229
Aminotetraline hydrochloride, (R)-5-Methoxy-N-propyl-2-	229
Aminotetraline hydrochloride, (R)-7-Methoxy-2-	230

Aminotetraline hydrochloride, (R)-8-Methoxy-N-propyl-2-	230
Aminotetraline hydrochloride, (S)-(-)-5-Methoxy-2-.....	230
Aminotetraline hydrochloride, (S)-(-)-7-Methoxy-N-propyl-2-.....	230
Aminotetraline hydrochloride, (S)-(-)-8-Methoxy-2-.....	230
Aminotetraline hydrochloride, (S)-5-Methoxy-N-propyl-2-.....	231
Aminotetraline hydrochloride, (S)-7-Methoxy-2-	231
Aminotetraline hydrochloride, (S)-8-Methoxy-N-propyl-2-.....	231
Aminotetraline hydrochloride, 5,6-Dihydroxy-N-methyl-N-propyl-.....	231
Aminotetraline hydrochloride, 5,6-Dimethoxy-2-.....	231
Aminotetraline hydrochloride, 5-Methoxy-2-	232
Aminotetraline hydrochloride, 5-Methoxy-N-propyl-2-.....	232
Aminotetraline hydrochloride, 6-Methoxy-N-propyl-2-.....	232
Aminotetraline hydrochloride, 7-Methoxy-2-	232
Aminotetraline hydrochloride, 7-Methoxy-N-propyl-2-.....	232
Aminotetraline hydrochloride, 8-Methoxy-2-	233
Aminotetraline hydrochloride, 8-Methoxy-N-propyl-2-.....	233
Aminotetraline hydrochloride, N-Cyclopropyl-2-.....	233
Aminotetraline hydrochloride, N-Methyl-N-propyl-2-	233
Aminotetraline hydrochloride, Prop-2-ynyl-2-	233
Amiselimod hydrochloride.....	234
Amisulpride.....	234
Amlodipine benzenesulfonate	234
Amlodipine besylate	234
AMN 107	234
AMN 107 hydrochloride.....	234
Amoxapine	235
AMPA	235
AMPA, (RS)-.....	235
Ampalex.....	235
AMR-69	235
Amthamine dihydrobromide	235
Amuvatinib	235
AMZ30.....	236
AN2690	236
AN2728	236
ANA 12.....	236
Anacardic acid A.....	236
Anandron.....	237
Anastrozole	237
Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, (6a,11b,16a,17a)-	237
Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, (6a,11b,16a,17a)-.....	237
Angular TIC 10	237
Anhydrocaritin	237

Antalarmin hydrochloride	237
Antisedan	237
AOB 87172.....	237
AOH1160.....	238
AOH1996.....	238
AP-06-202	238
AP 24534.....	238
AP 26113.....	238
AP32788.....	238
Apararenone.....	238
Apatinib	239
Apatinib mesylate	239
APC, 4-.....	239
Apcin.....	239
APD 597	240
APD 668	240
APD 811	240
APE1 Inhibitor III	240
APEBA, 4-.....	241
Apigenin	241
Apilimod	241
APIO-EE-07.....	241
Apixaban	241
Apoptosis Activator 2	242
Apoptozole	242
APP+	242
APPA.....	242
Apratastat.....	242
Apremilast	243
Aprepitant.....	243
Aprindine hydrochloride	243
APS-2-79.....	243
APX-115	243
AR03	244
AR 231453	244
AR 244555	244
AR 420626	244
AR-42	245
AR-A 014418.....	245
Ara-A.....	245
Arabinofuranosyladenine, 9-β-D-.....	245
Arabinofuranosylcytosine, 1-β-D-.....	245
Arabinofuranosyl-2-fluoroadenine, 9-β-D-	245
Ara-C.....	245
Aranidipine	246

ARB-272572.....	246
Arcyriarubin A.....	246
Arbidol hydrochloride	246
Ariflo	246
Arimidex	246
Aripiprazole	246
Aripiprazole, thio-	247
ARL 15896AR	247
ARM1	247
ARN24139.....	247
ARN 272.....	247
ARN 3236.....	248
ARN 509.....	248
ARO-002	248
Aromasin	248
ARRY-470	248
ARRY 142886.....	249
ARS-1620.....	249
ART-446 Recent Addition	249
Artemether.....	249
Artemether, β -.....	249
Artesunate.....	249
ARUK2001607	250
ARQ 197.....	250
ARV-825.....	250
AS-1, (R)-.....	251
AS1269574.....	251
AS 1842856.....	251
AS 252424.....	251
AS 252424 bispotassium salt.....	251
AS 252424K	252
AS2717638.....	252
AS 602801.....	252
AS 1517499.....	252
AS 1892802.....	253
AS-703026 Recent Addition	253
ASB14780	253
Asciminib	253
Ascorbyl dodecanoate, L-.....	254
Ascorbyl octanoate, L-.....	254
Asenapine maleate	254
ASK1 Inhibitor 10	254
ASN-002.....	255
Asoprisnil	255
ASP015K.....	255

ASP 1517	255
ASP2151	255
ASP 2905	255
ASP 3026	256
ASP 9521	256
AST 1306 tosylate	256
AT 406.....	257
AT 1001.....	257
AT 7519 mesylate.....	257
AT 9283.....	257
AT 13148 dihydrochloride	258
Ataluren	258
Atazanavir	258
Atazanavir, deuterated	258
ATB 346	258
Atglistatin	258
Atipamezole hydrochloride.....	259
Atomoxetine Hydrochloride.....	259
Atopaxar hydrobromide	259
Atorvastatin calcium.....	259
Atovaquone.....	259
ATR-101	260
ATRA.....	260
Atrasentan.....	260
Aurora A inhibitor I.....	260
Aurora A inhibitor II	261
Autophinib.....	261
Auxinole	261
AV 951.....	261
AVE 0118 hydrochloride.....	261
AVE0991	262
Avibactam sodium	262
Avitinib	262
AVL 292	262
AVN944	263
Avridine	263
AX-024 hydrochloride.....	263
Axitinib	263
Axon 1170.....	263
Axon 1171.....	264
AZ 20.....	264
AZ 23.....	264
AZ5104.....	264
AZ 628.....	265
AZ 960.....	265

AZ 3146.....	265
AZ 12216052.....	265
AZ13705339.....	266
Azafen.....	266
Azaphen.....	266
Azaphenonxazine dihydrochloride.....	266
Azasetron hydrochloride.....	266
Azasetron hydrochloride, (+)-.....	266
Azasetron hydrochloride, (-)-.....	267
AZD0095.....	267
AZD0156.....	267
AZD 0530 difumarate.....	267
AZD 1080.....	268
AZD 1152-HQPA.....	268
AZD 1208.....	268
AZD 1981.....	268
AZD2014.....	269
AZD 2098.....	269
AZD 2171.....	269
AZD 2281.....	269
AZD 2461.....	269
AZD2858.....	270
AZD 2858 hydrochloride.....	270
AZD 3463.....	270
AZD 3759.....	270
AZD3458.....	271
AZD3965.....	271
AZD-4205.....	271
AZD4320.....	272
AZD 4547.....	272
AZD4573.....	272
AZD4635.....	272
AZD 5363 dihydrochloride.....	273
AZD 5438.....	273
AZD5153 HNT salt.....	273
AZD5582 dihydrochloride.....	274
AZD5991.....	274
AZD6094 dihydrochloride.....	274
AZD 6244.....	274
AZD 6280.....	275
AZD 6482.....	275
AZD7648.....	275
AZD 7762 hydrochloride.....	275
AZD 8055.....	276
AZD8186.....	276

AZD 8330.....	276
AZD8421 Recent Addition	276
AZD 9291.....	277
AZD1656.....	277
AZD2716.....	277
AZD6140.....	278
AZD6738.....	278
AZD6765 dihydrochloride.....	278
Azelastine hydrochloride.....	278
Azepexole.....	278
Azelnidipine.....	278
AZ-GHS-22.....	279
Azidothymidine.....	279
Azilsartan.....	279
Azithromycin.....	279
AZL.....	279
Azoramide.....	279
AZT.....	280
B 9302-107.....	281
B106.....	281
B591.....	281
b-AP15.....	281
BA-14.....	281
BACE-1 Inhibitor.....	281
BACE-2 Inhibitor.....	282
BACE2 Inhibitor 3I.....	282
BAF.....	282
Bafetinib.....	282
BAG 956.....	282
Balicatib.....	282
BAM 7.....	282
BAM15.....	283
BAMB-4.....	283
Bambuterol hydrochloride Recent Addition	283
BAN ORL 24.....	283
Barbadin.....	284
Bardoxolone.....	284
Bardoxolone methyl.....	284
Baricitinib.....	284
Barnidipine hydrochloride.....	284
Batoprotafib.....	285
Bavisant Recent Addition	285
BAY-0069.....	285
BAY-091.....	285
BAY-091 hydrochloride.....	285

BAY 1021189	286
BAY-1082439	286
BAY-1251152	286
BAY 1316957	286
BAY-1436032	287
BAY-179	287
BAY-1797	287
BAY-1816032	287
BAY 1895344	288
BAY 11-7082	288
BAY 11-7821	288
BAY 12-8039	288
BAY 19-8004	288
BAY2502	289
BAY 2686013 hydrochloride Recent Addition	289
BAY-293	289
BAY 38-9456	289
BAY 43-9006	289
BAY 43-9006	289
BAY-4931	289
BAY 57-1293	290
BAY 58-2667 hydrochloride	290
BAY 59-7939	290
BAY-598	290
BAY 60-6583	290
BAY-678	291
BAY 73-4506	291
BAY 869766	291
BAY-876	291
BAY b 5097	291
BAY K 8644	292
BAY K 8644, (±)-	292
BAY K8644, (-)-	292
BAY K8644, (+)-	292
BAY K 8644, (R)-(+)-	292
BAY K 8644, (S)-(-)-	292
Bazedoxifene acetate	293
Bazedoxifene hydrochloride	293
BBD 130	293
BBI 608	293
BC-1215	293
BC1618	293
BCH189, (-)-	293
BChE inhibitor 8012-9656	294
BCI	294

BCI hydrochloride	294
BCI-121	294
BCL-201 dihydrochloride	295
BC-LI-0186	295
BCP, 1-	295
BD 1047 dihydrobromide	295
BD 1063 dihydrochloride	296
BDP-12	296
BEC hydrochloride	296
Beclomethasone dipropionate	296
Begacestat	297
Belzutifan	297
Belinostat	297
Belnacasan	297
Belumosudil	297
Belvarafenib	298
Benidipine hydrochloride	298
Bentamapimod	298
Betanis	298
Bethanechol chloride	298
BETP	298
Bexarotene	299
Bextra	299
BEZ 235	299
BF 5	299
BFF 122	299
BG45	299
BGB-283	300
BGJ 398	300
BGT 226	300
BH3I 1	300
BHG 712	300
BHI 1	300
BHPI	301
B-HT 920 dihydrochloride	301
B-HT 933 dihydrochloride	301
B-HT 958 dihydrochloride	301
BI 01383298	301
BI10773	302
BI 1356	302
BI 1482694	302
BI 2536	302
BI 2536, (S)- Recent Addition	302
BI-3406	302
BI-3802	303

BI425809	303
BI 6015	303
BI 6727	303
BI 749327	304
BI-87G3	304
BI 894999	304
BI 99179	304
BI 99990	305
BI-6C9	305
BIA	305
BIBF-1120	305
BIBR 1532	305
BIBW 2992	306
Bicalutamide	306
BI-D1870	306
BIIB 021	306
BIMT 17	307
Bifeprunox mesylate.....	307
BIIB014	307
Bilastine.....	307
Biliatresone	307
BINA.....	307
Binaltorphimine dihydrochloride, nor.....	307
Binimetinib	308
BIO	308
Biochanin B.....	308
BIOLF62.....	308
Biotinyl-phenylboronic acid.....	308
Biphenyl-indanone A	309
BIBR 277	309
BIBR 1048.....	309
BIRB 796.....	309
Birinapant.....	309
BI-RG-587	310
BrdU, 5-.....	310
Bisacodyl.....	310
Bisindolylmaleimide I	310
Bisindolylmaleimide IV	310
Bisindolylmaleimide V	310
Bisoprolol fumarate	311
BIX 01294 trihydrochloride hydrate.....	311
BIX02188-Me.....	311
BIX 02189.....	311
BIX02188.....	312
Bizine	312

BJE6-106	312
BKM 120	312
Blebbistatin, (-).....	312
Blebbistatin, (+).....	312
Blebbistatin, (±).....	313
BLK degrader 1	313
BLK degrader compound 9	313
Blonanserin.....	313
BLU-667	314
BLZ945.....	314
BM14190	314
BMH 21	314
BML-210.....	314
BMN 195	315
BMN 673	315
BMS 4.....	315
BMS 189961.....	315
BMS-200475.....	315
BMS 201038.....	315
BMS 204352.....	315
BMS 204352, (±)-	315
BMS 204352, (R)-(-)-.....	316
BMS 204352, (S)-(+)-	316
BMS 232632.....	316
BMS 247615 dihydrochloride.....	316
BMS 270394.....	316
BMS 270394, (R)-(+)-	316
BMS 303141.....	316
BMS 309403 Recent Addition	317
BMS 345541.....	317
BMS 354825.....	317
BMS 387032.....	317
BMS 442606 hydrochloride	317
BMS 442608 hydrochloride	317
BMS-466442.....	318
BMS-502 Recent Addition	318
BMS-512148.....	318
BMS 528215.....	318
BMS 540215.....	318
BMS 562247-01.....	318
BMS 582664.....	319
BMS 582949.....	319
BMS-599626.....	319
BMS 605541.....	319
BMS649.....	319

BMS-684	Recent Addition	319
BMS-777607		320
BMS 790052 dihydrochloride		320
BMS 833923		320
BMS 863233 hydrochloride		320
BMS-911543		320
BMS-986158		321
BMS986165		321
BMS-986260		321
BMS-986299		321
BMS986231		322
BMS-986365	Recent Addition	322
BMY 13754		322
BN 80245		322
BN80933		322
BN83495		322
BO-264		322
Boc-Asp(Ome)-fluoromethyl ketone		323
Boc-D-FMK		323
Bortezomib		323
Bosutinib		323
BP-1-102		323
BPI-9016M	Recent Addition	324
BPKDi		324
BPN14770		324
BPTES		324
BP-TQS, 4-		325
BQU 57		325
BQR695		325
BR1		325
BR 4887		325
Brassinin		326
BRD0539		326
BRD0705		326
BRD4780		326
BRD5648		327
BRD 9424		327
BRD 73954		327
BRD K4477		327
Brexpiprazole dihydrochloride		327
Brigatinib		327
Brimonidine tartrate		328
Brinzolamide		328
Brivanib		328
Brivanib alaninate		328

Brivudine	329
BRL39123	329
BRL 43694	329
BRL 49653	329
Brobenzoxaldine	329
Bromo-2'-deoxyuridine, 5-	329
Bromobuterol	329
Bromomethyl-1-(tetrahydro-pyran-2-yl)-1H-indazole, 5-	330
Brophenexin	330
Broxaldine	330
Broxuridine	330
BS100-141	330
BSF 208075	330
BSI 201	330
BSK 805	330
BT-11	330
BT2	331
BTB 1	331
BTS 54-505	331
BTSA1	331
BTYNB	332
BTYNB isomer	332
BTYNB IMP1 inhibitor	332
BTYNB IMP1 inhibitor isomer	332
BTZ043	332
BUdR	332
Bupropion hydrochloride	332
Buspar	333
Buspironone hydrochloride	333
Butabindide oxalate	333
Butanoic acid, sodium salt	333
Butenafine hydrochloride	333
Butoconazole nitrate	334
BVF 033	334
BVD-523 hydrochloride	334
BVdU	334
BVT 2733 hydrochloride	334
BW 306U	334
BW 322U	334
BWA509U	334
BX 430	334
BX 471	335
BX 795	335
BX 795 hydrochloride	335
BX 912	335

BXL 628	336
BY 217.....	336
BYK 20869.....	336
BYK61359.....	336
BYL-719.....	336
BZ, γ -Secretase Inhibitor.....	336
C101248 Recent Addition	337
C20.....	337
C25-140.....	337
C33, (S)-.....	337
C59.....	337
C 646.....	337
C65780.....	338
C 7280948.....	338
C-82.....	338
CA 4.....	338
CA77.1.....	338
Cabozantinib S-malate.....	338
CADD522.....	339
CADO.....	339
CAI.....	339
CAIX Inhibitor S4.....	339
CAL 101.....	339
CAL 120.....	340
Calcium influx inducer compound 634.....	340
Calhex 231 hydrochloride.....	340
Calixarene 0118.....	340
Cambinol.....	340
CaMKII α inhibitor compound 4d.....	341
Camptothecin 11.....	341
Canagliflozin.....	341
Candesartan cilexetil.....	341
Canertinib dihydrochloride.....	341
Cannabidiol.....	342
Cannabidiol, Abnormal.....	342
Cannabiscetin.....	342
Capecitabine.....	342
Capmatinib.....	342
Caprospinol.....	343
Carbamyl- β -methylcholine chloride.....	343
Carbamylglutamate.....	343
Carbamyl-L-glutamic acid, N-.....	343
Carbazeran.....	343
Carboxyamidotriazole.....	344
Cardiogenol C hydrochloride.....	344

Carfilzomib Recent Addition	344
Carglumic acid.....	344
Carvedilol.....	344
CAS 997.....	344
CASIN.....	345
Casopitant mesylate.....	345
CaSR antagonist 18c.....	345
CAY10471 sodium.....	345
CAY 10683.....	345
CB096.....	345
CB-103.....	346
CB-1158 dihydrochloride.....	346
CB2R PAM C2.....	346
CB-5083.....	347
CB 7598.....	347
CB 7630.....	347
CB-839.....	347
CBD.....	347
CBLC4H10.....	347
CBR 5884.....	347
CBS1117.....	348
CBTC.....	348
CC 292.....	348
CC 401.....	348
CC-671.....	348
CC-885.....	348
CC-930.....	349
CC-4047.....	349
CC 5013.....	349
CC 10004.....	349
CC-94676.....	349
CCG 232601.....	349
CCG-203971.....	349
CCG-222740.....	350
CCG 50014.....	350
CCI 779.....	350
CCRG 81045.....	350
CCS-1477.....	350
CCT 007093.....	351
CCT 031374 hydrobromide.....	351
CCT 137690.....	351
CCT196969.....	351
CCT-245737.....	352
CCT251236.....	352
CCX282-B.....	352

CD12681	352
CD161	353
CD336	353
CD38i 78c	353
CD38 inhibitor compound 78c	353
CDK8/19i	353
CDD-1653	353
CDDO	354
CDDO-Me	354
CDIBA	354
C-DIM5	354
C-DIM8	355
CE3F4, (R)-	355
C-DIM12	355
CDK inhibitor CR8	355
CDN1163	356
CE3F4	356
Cediranib	356
Cefdinir	356
Ceflatonin	357
Cefoperazone	357
Cefoxitin sodium	357
Cefsulodin sodium	357
Celebra	357
Celebrex	357
Celecoxib	358
Celiprolol hydrochloride	358
CEM 101	358
Cenchaquin	358
Cenchaquine	358
CEP-28122	358
CEP-33779	359
CEP-37440 hydrochloride	359
Ceralasertib	359
Cerdulatinib	359
Ceritinib	359
Cerovive	360
Cetirizine dihydrochloride	360
Cevipabulin	360
CFM 2	360
CFT-7455	360
CFT-8634	361
cGAMP	361
CGI 1746	361
CGM097	361

CGM097 dihydrochloride	361
CGP-12177A, (±)-	362
CGP48664A	362
CGP48664 dihydrochloride	362
CGP 48933	362
CGP 57148B	362
CGP 57380	362
CGP7174/E	362
CGP 77675	362
CGS 15943	363
CGS 9343B	363
CGS 12066B	363
CGS 20267	363
CGS 21680 hydrochloride	363
CH2P4, 19-	364
CH 55	364
CH 5424802	364
Champix	364
Chantix	364
Chembridge ID 5128535	364
Chidamide	364
CHIR 090	364
CHIR 124	365
CHIR 98014	365
CHIR 99021	365
CHIR 99021 dihydrochloride	365
Chloro-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine, 4-	365
Chloro-4-(methylthio)-benzeneacetic acid methyl ester, 3-	366
Chloro-5-hydroxyphenylglycine, (RS)-2-	366
Chloro-8-fluoro-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one, 2-	366
Chloroadenosine, 2-	366
Chloro-DPAT hydrochloride, 6-	366
Chlorphentermine hydrochloride	367
Chloropurine riboside, 6-	367
Chloropurine 9-β-D-ribofuranoside	367
Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole, 3-	367
Chloroquine diphosphate	367
CHPG	368
CHR 6494 trifluoroacetate	368
Chromanol 293B	368
CI879	368
CI906	368
CI 945	368
CI983	368
CI 994	369

CI 1033	369
CI 1040	369
CI 1043	369
Ciclesonide	369
CID1261822	369
CID 5157334	370
CID 755673	370
CID 767276	370
CID 1067700	370
CID 12387471	370
CID 1375606	370
CID 2011756	371
CID 3111211	371
CID 5951923	371
CID 11654378	371
CID 49766530	371
CID 49843203	371
CID 73169083	371
CID 921541	372
CID2440433	372
Ciforadenant	372
Cilomilast	372
Cimlanod	372
Cinaciguat hydrochloride	372
Cinepazide maleate Recent Addition	372
Cinnabarinic acid	372
Cipralex	373
Ciproxifan maleate	373
CIQ	373
Citalopram oxalate, (S)-(+)-	373
Citalopram hydrobromide	373
Citarinostat	373
CITFA	373
CJ-023,423	374
CK2 inhibitor 10	374
CK3773274	374
CK 452	374
CK 1827452	374
CK274	374
CK-666	374
CK-0944666	375
CKI-7 dihydrochloride	375
Clarithromycin	375
Clemizole	375
Clindamycin	376

Clioquinol	376
CLK8	376
CLN-081	376
Clobenpropit dihydrobromide	376
Clomid	377
Clomiphene citrate	377
Clomifene	377
Clonidine hydrochloride	377
Clotrimazole	377
Clovamide, trans-	378
Cloxacillin sodium	378
Clozapine	378
Clozapine N-oxide	378
Clozapine, N-Desmethyl-	378
CLT-003	379
CM1	379
CM-272	379
CM-4620	379
CMAT	380
CMP5	380
CMPDA	380
CN 801	380
CNDAC hydrochloride	380
CNF 2024	381
CNO	381
CNQX	381
CNQX disodium salt	381
CNV 1014802 hydrochloride	381
Cobimetinib	382
COH000	382
Col003	382
Coleonol	382
Colchicine	382
Colistin sulfate	382
Combretastatin-A4	383
Compound 1	383
Compound 2	383
Compound 3	383
Compound 4	383
Compound 6c	383
Compound 10	383
Compound 12	384
Compound 12i	384
Compound 18a	384
Compound 24	384

Compound 52.....	384
Compound 120.....	384
Compound 211.....	384
Compound B.....	384
Compound E.....	385
Conoidin A.....	385
CoPo 22.....	385
Cordycepin.....	385
COTI-2.....	385
Coumate, 667.....	386
CP 20961.....	386
CP 26154.....	386
CP 31398.....	386
CP456773.....	386
CP 45899 sodium.....	386
CP 62993.....	386
CP-868596.....	386
CP 88059.....	386
CP 93393 hydrochloride.....	386
CP 93393-1.....	386
CP 94253 hydrochloride.....	387
CP 99219 mesylate.....	387
CP 100356 Hydrochloride.....	387
CP 101606.....	387
CP 101606 mesylate.....	387
CP 135807.....	388
CP 154526 hydrochloride.....	388
CP 226269.....	388
CP 316819.....	388
CP 346086.....	388
CP 358774.....	389
CP 466722.....	389
CP 471474.....	389
CP 526555-18.....	389
CP 529414.....	389
CP 547632.....	389
CP 597396 hydrochloride.....	390
CP 615003 mesylate.....	390
CP 690550.....	390
CP 690550-10.....	390
CP 724714.....	390
CP 775146.....	390
CP 945598.....	391
CP 945598 hydrochloride.....	391
Cpd G.....	391

CpdD hydrochloride.....	392
cPEPCK inhibitor.....	392
CPI-444.....	392
CPI 455.....	392
CPI 0610.....	393
CPI 613.....	393
CPI 4203.....	393
CPPC, 4-.....	393
CPPHA.....	394
CPT-11.....	394
CPTH2.....	394
CR8, (R)-.....	394
CRAC inhibitor 44.....	394
CRD401.....	394
Crenolanib.....	394
CRID3.....	395
Crisaborole.....	395
Crizotinib.....	395
Crizotinib, (S)-.....	395
CRL 40476.....	395
CRN00808.....	395
CRN00808.....	395
Cromolyn disodium.....	396
CRT Inhibitor iCRT5.....	396
CRT Inhibitor iCRT14.....	396
CS1.....	396
CS 055.....	396
CS-905.....	396
CSF1R inhibitor compound 22.....	396
CT 53518.....	397
CT7001.....	397
CT 98014.....	397
CT 99021.....	397
CT 99021 dihydrochloride.....	397
CTEP.....	397
CTPI-2.....	398
CTx-0294885.....	398
CU-115.....	398
CUDC-101.....	398
CUDC-305.....	398
Cuspin-1.....	399
CU-T12-9.....	399
CV4093; Franidipine.....	399
CVL231.....	399
CVT-10216.....	399

CX516.....	400
CX546.....	400
CX 4945 hydrochloride	400
CX 5461.....	400
CX 6258 hydrochloride	401
CX3CR1 antagonist 18a.....	401
CXCR3 Antagonist 6c.....	401
CXD101.....	401
CXL-1020	402
CXL1427	402
CXL146	402
CYC-116.....	402
Cyclic GMP-AMP Sodium salt, 2', 3'-.....	403
Cyclopropyl-2-aminotetraline hydrochloride, N-.....	403
Cyclopropyl-N-methyl-2-aminotetraline hydrobromide, N-.....	403
CYP3cide.....	403
Cyproheptadine hydrochloride.....	403
Cyproterone acetate	403
CYR101	403
CysLT1 Antagonist Q8	403
CYT 387	404
CYT387 hydrochloride.....	404
Cytarabine.....	404
Cytosine arabinoside.....	404
CZC 24832	404
CZS-241 hydrochloride Recent Addition	404
D 21266	406
D 23129	406
D 23129 hydrochloride	406
d4T	406
D 9998	406
D 106669	406
D3-βArr	406
DA7218	406
Dabigatran etexilate.....	406
Dacarbazine.....	407
Daclatasvir dihydrochloride.....	407
Dacomitinib	407
Daglutril	408
Dalacine.....	408
Dalcetrapib	408
DAN 2163.....	408
Danoprevir.....	408
Dansyl-PEG-phenylboronic acid.....	408
Dapagliflozin	409

Dapansutril	409
Dapivirine	409
Daprodustat.....	410
DAPT.....	410
Darapladib	410
Darovasertib.....	410
Darunavir.....	410
Dasatinib	410
Daxas	411
DB2313 hydrochloride Recent Addition	411
DBeQ.....	411
dBET1	411
DBPR211	411
DBZ, γ-Secretase Inhibitor	412
DC 838	412
DC260126	412
DCC 2036.....	412
DCC-2701.....	413
dCeMM1.....	413
dCeMM2.....	413
DC-LC3in-D5.....	413
DCLK1-IN-1.....	414
DCN1-UBC12 interaction inhibitor E31.....	414
DCZ.....	414
DCZ0415	414
DCZ0805	414
DDR1-IN-1	415
DDO-6600	415
DEAB	415
Deazaadenosine, 1-.....	415
DEBIO-0932	416
DEC	416
Decernotinib.....	416
Decitabine	416
Defactinib	416
Deferasirox	417
Deflazacort	417
Degrasyn	417
Deguelin	417
Dehydroepiandrosterone	418
Dehydroevodiamine hydrochloride	418
Delavirdine	418
Deltarasin trihydrochloride	418
Demoxepam	419
Deoxyadenosine 5'-O-phenyl-(benzoxy-L-alanyl)-phosphate, 3'-	419

Deoxyadenosine, 3'-	419
Deoxy-β-D-ribofuranosyl)-5-iodo-2-pyrimidinone, 1-(2-	419
Depocid	419
Depotsulfonamide	419
Deschloroclozapine	419
Deshydroxy Venlafaxine HCl	419
Desloratadine	420
Desmethyltamoxifen hydrochloride, N-	420
Desmethylvenlafaxine, R-(-)-O-	420
Desmethylvenlafaxine, S-(+)-O-	420
Desmethylvenlafaxine, O-	420
Desmethylvenlafaxine hydrochloride, O-	421
Desonide	421
Desvenlafaxine hydrochloride	421
Desvenlafaxine	421
Desmethylvenlafaxine succinate, O-	421
Deucravacitinib	422
Desvenlafaxine, R-(-)-O-	422
Desvenlafaxine, S-(+)-O-	422
DEV 4	422
Dexamethasone	422
Dexamethasone palmitate	422
Dexmedetomidine hydrochloride	423
Dextromethorphan hydrobromide	423
DFBA	423
dFdC	423
DFP00173	423
DFP-10917 hydrochloride	423
DFPQ	423
DFMO	424
DG2	424
DH 97	424
DHEA	424
DHED	424
DHF, 7,8-	424
DHPG	424
DHPG, (RS)-3,5-	425
DHPG, (S)-3,5-	425
DHQZ 36	425
Di-8-ANEPPS	425
Didehydro-3'-deoxythymidine, 2',3'-	425
Dideoxyadenosine, 2',5'- Recent Addition	426
Didesmethyl Venlafaxine, N,N-	426
Didesmethyl Venlafaxine, N,O-	426
Dienogest	426

Dienogestril	426
Diethylcarbamazine citrate	426
Diflorasone Diacetate	426
Diflunisal	427
Difluorodeoxycytidine, 2',2'-	427
Difluoromethylornithin, α-	427
Difluprednate	427
Digitalis	427
Digoxigenin bis-digitoxiside	427
Digoxin	428
Dihydro-2H-1-benzopyran-8-ol hydrochloride, 3-(Dipropylamino)-3,4-	428
Dihydroquercetin	428
Dihydroxy-2-aminotetraline hydrobromide, 5,6-	428
Dihydroxy-2-aminotetraline hydrobromide, 6,7-	428
Dihydroxycholecalciferol, 1α,24-	428
Dihydroxy-N-methyl-N-propyl-aminotetraline hydrobromide, 6,7-	429
Dihydroxy-N-methyl-N-propyl-aminotetraline hydrochloride, 5,6-	429
Dihydroxyflavone, 7,8-	429
Dihydroxyphenylalanine, L-3,4-	429
Dihydroxyphenylglycine, (S)-3,5-	429
Dihydroxyphenylserine, L-threo 3,4-	429
Dilept	429
Diltiazem hydrochloride	429
Diltiazem hydrochloride, (+)-cis-	430
Dimaprit dihydrochloride	430
DIM-C-pPhCl	430
DIM-C-pPhOCH ₃	430
DIM-C-pPhOH	430
Dimebolin hydrochloride	430
Dimebon	430
Dimethindene maleate	431
Dimethindene maleate, (R)-(-)-	431
Dimethindene maleate, (S)-(+)-	431
Dimethindene maleate, (R,S)-	431
Dimethoxy-1,4-naphthoquinone, 2,3-	431
Dimethoxy-2-aminotetraline hydrobromide, 6,7-	431
Dimethoxy-2-aminotetraline hydrochloride, 5,6-	432
Dimethoxybenzylidene)-anabaseine dihydrochloride, 3-(2,4-	432
Dimethylaminomicheliolide	432
Dimethylcelecoxib, 2,5-	432
Dimethylenastron	432
DiMNF	432
Dinaciclib	433
Dinorvenlafaxine	433
Disodium cromoglycate	433

Disufenton sodium	433
DJ001	433
DJ-V-159	433
DKM 2-93	433
DL5050	434
DL8280	434
DLCI-1	434
DM 3189	434
DMAMCL	434
DMB	434
DMC	434
DMNQ	435
DMOG	435
DMP-266	435
DMP 543	435
DMXB	435
DMXB-A	435
DNA binder S20 hydrochloride	435
DNQX	436
DO264	436
Dofetilide	436
Dolutegravir	436
Donepezil hydrochloride	437
DOPA, L-	437
Dopamine hydrobromide, N,N-dibutyl	437
Dopamine hydrobromide, N,N-Dipropyl	437
Dopazinol	438
Doramapimod	438
DOPS, L-	438
Dorsomorphin	438
Dorsomorphin dihydrochloride	438
Dorzolamide hydrochloride	438
Doxercalciferol	438
Doxofylline Recent Addition	439
Doxorubicin hydrochloride	439
DPAT, (R)-5-OH-	439
DPAT, (R)-6-OH-	439
DPAT, (R)-7-OH-	439
DPAT, (S)-(-)-8-OH-	440
DPAT, (S)-5-OH-	440
DPAT, (S)-6-OH-	440
DPAT, (S)-7-OH-	440
DPAT, 5,6-Dihydroxy-	440
DPAT, 5-OH-	440
DPAT, 6,7-Dihydroxy-	440

DPAT, 6-Chloro-	440
DPAT, 6-OH-	440
DPAT, 7-OH-	440
DPAT, 8-OH-	440
DPN	440
DPTIP hydrochloride	441
DPTN	441
DR 2313	441
DR3305	441
DRI-C21045	441
Dridol	442
Droleptan	442
Dronedarone hydrochloride	442
Droperidol	442
Droxidopa	442
DS103-282	443
DS-3032	443
DS-3032B	443
DS-3201B	443
DS44960156	443
DS45500853	443
DSRM-3716	443
DT-2216	444
DTHIB	444
DTIC	444
DU125530	444
DU 127090	445
DU 21220	445
DU 28853	445
DU-176b	445
DUP 89	445
Durezol	445
Duvelisib	445
DVS 233	445
DVS 233 hydrochloride	445
DVS 233 succinate	445
DWAY	445
DW-71177 Recent Addition	445
DXP	446
DY 268	446
Dynasore	446
Dyngo-4a Recent Addition	446
DYRK1A inhibitor compound 11	446
E 3810 dihydrochloride	447
E3810	447

E 5555 hydrobromide	447
E 7050	447
E7080	447
E-7386	447
E7449 mesylate	448
E-7766	448
Eact	448
EAI045	448
EBIO, 1-	449
Ebio1 Recent Addition	449
EBPC	449
Ebselen	449
Ebvaciclib	450
Ec2Ia	450
ECDCA, 6-	450
eCF309	450
ECSI#6	450
EDHS-206	450
Edoxaban tosylate	451
EED226	451
Eeyarestatin I	451
Efaroxan hydrochloride	451
Efavirenz	452
EFdA	452
Efinaconazole	452
Eflornithine hydrochloride	452
Eganelisib	452
Eg5 inhibitor III	452
EGFR Inhibitor 324674	452
EHop 016	453
EIDD-2801	453
eIF4A i28	453
EKB 569	453
Elacestrant dihydrochloride	453
Elacridar hydrochloride	454
Elafibranor	454
Elesclomol	454
Eletriptan hydrobromide	454
Eliprodil	455
ELN 484228	455
Elocalcitol	455
Eltoprazine hydrochloride	455
Eltrombopag	455
Emapunil	456
Embelin	456

EMD33512	456
EMD638683	456
EMI48	456
EML 425	456
EMPA	457
Empagliflozin	457
Emraclidine	457
Emtricitabine	457
EN219	458
EN460	458
EN 1733A	458
Ena21 hydrochloride	458
Enasidenib	459
Encenicline hydrochloride Recent Addition	459
Encorafenib	459
endo-IWR-1	459
Endoxifen	459
Endoxifen, (Z)-	459
Endoxifen hydrochloride	459
Enitociclib	460
ENPP1 inhibitor compound 43	460
Ensemble Compound 159	460
Entacapone	460
Entecavir	461
Entinostat	461
Entospletinib	461
Enzastaurin	461
EOS200271	461
Epacadostat	461
Epibatidine dihydrochloride, (-)-	461
Epibatidine dihydrochloride, (+)-	462
Epibatidine dihydrochloride, (±)-	462
Epidaza	462
Epiestradiol	462
Epigoitrin (optically pure)	462
Eplivanserin	462
EPPTB	463
EPZ-005676	463
EPZ005687 hydrochloride	463
EPZ011989 hydrochloride Recent Addition	463
EPZ 015666	464
EPZ015938	464
EPZ015938 hydrochloride	464
EPZ019997 hydrochloride	464
EPZ-5676	464

EPZ 6438.....	464
ER-819762	465
ERAD inhibitor 1	465
ERAP1 inhibitor compound 3	465
Erastin	465
ERB 041	465
ERK11e	466
Erlosamide	466
Erlotinib hydrochloride	466
Erlotinib, 6-O-Desmethyl-.....	466
ERO1 Inhibitor II.....	466
ErSO.....	466
ErSO, (S)-.....	466
Ervogastat.....	467
ES 1.....	467
ES000835.....	467
Escitalopram oxalate	467
ESI-08.....	467
ESN364	468
Estetrol	468
Estradiol, α - <small>Recent Addition</small>	468
Estradiol, 17 α -.....	468
Estybon	468
ETC-206	468
ETH 2120	469
Ethyl apovincamin	469
Ethylnorapomorphine hydrobromide, R(-)-N-.....	469
Etifoxine	469
Etifoxine hydrochloride.....	469
Etiracetam	469
Etiracetam, R-(+)-.....	470
Etodolac	470
Etodolic acid	470
Etoricoxib	470
ETP-47799	470
EUK 134	470
Evacetrapib	471
Everolimus	471
EVP-22	471
EVP 4593	471
EVP6124	472
Ewha-18278	472
EX 89.....	472
EX 527.....	472
Exel 2880	472

Exemestane.....	472
Exo1	472
EYA2 inhibitor 9987	472
Ezetimibe.....	473
Ezogabine.....	473
Ezogabine dihydrochloride.....	473
Ezutromid	473
F4, 10058-.....	474
F2695 hydrochloride.....	474
F-96221-BM1.....	474
FABP4 inhibitor C3 <small>Recent Addition</small>	474
Fantofarone	474
F-ara-A	474
Faropenem sodium <small>Recent Addition</small>	474
Fasudil hydrochloride	475
Fatostatin A hydrobromide	475
Fatostatin hydrobromide.....	475
Favipiravir	475
FBPase-1 inhibitor	475
FBPase-1 inhibitor compound 1	476
FC 99 hydrochloride	476
FCE 24304	476
FCF 89.....	476
FDI 6.....	476
FdUrd	476
Febuxostat.....	477
Fedotozine tartrate.....	477
Fedovapagon	477
Feeblin <small>Recent Addition</small>	477
Felodipine.....	477
FEN1 inhibitor 1	478
Fendiline hydrochloride	478
Fenfluramine hydrochloride.....	478
Fenobam.....	478
Fer-1.....	479
Ferrostatin 1	479
Fexofenadine hydrochloride	479
Fezolinetant.....	479
FG-2216	479
FG-4592	480
FGF 401	480
FH 1.....	480
FH535.....	480
FH535 sodium salt	480
FHD-286	481

Filgotinib	481
Fimasartan	481
Finasteride.....	481
Fingolimod	482
FIPI hydrochloride	482
Firefly Luciferin	482
FK482.....	482
FK 506.....	482
FK 866.....	482
FK 866 hydrochloride	483
FK 960.....	483
FK962.....	483
FLI 06	483
Flibanserin.....	484
Flindokalner	484
Floxuridine	484
Fluconazole.....	484
Fluc inhibitor cpd 48 <small>Recent Addition</small>	484
Flucloxacillin sodium <small>Recent Addition</small>	485
Fludarabine	485
Flumethasone	485
Flumethasone pivalate	485
Flunisolide.....	486
Fluorescent probe QG-1	486
Fluorodeoxyuridine, 5-	486
Fluoxetine Hydrochloride.....	486
Fluphenazine decanoate dihydrochloride.....	486
Flupirtine maleate	487
Fluralaner	487
Flurbiprofen.....	487
Fluticasone furoate.....	487
Fluticasone propionate	488
Fluvoxamine maleate.....	488
FME.....	488
FLX925.....	488
FM19G11.....	488
FMF-03-146-1.....	488
FMK.....	488
FMP-A-01	489
FMP-A-02	489
FMS inhibitor compound 1b.....	489
FMS inhibitor compound 8.....	489
FNA hydrochloride, beta-	489
FNQ.....	489
Foretinib	489

Formononetin.....	489
Formylphenylboronic acid, 2-.....	490
Forskolin	490
Foscenvivint.....	490
FPBA, 2-.....	490
FPH 2	490
FPL 15896AR.....	491
FPL670.....	491
FPS-ZM1	491
FQI 1.....	491
FR 180204.....	491
FR 900494.....	491
Franidipine	491
FRAX 486.....	492
FSEN1	492
FTBMT	492
FTC, (-)-.....	492
FTY 720.....	492
FUB 359 maleate	493
Funaltrexamine hydrochloride, beta-	493
Fulvestrant <small>Recent Addition</small>	493
Furazosin hydrochloride	493
FX12.....	493
FX-909 <small>Recent Addition</small>	493
Fx-1006A.....	494
FXR 450	494
FXR agonist Cpd 22	494
Gabapentin	495
Gallic acid.....	495
Ganciclovir	495
Gandotinib.....	495
Ganetespib	495
GANT61	496
GAPDH inhibitor compound F8	496
Garsevil	496
Gatifloxacin hydrochloride.....	496
Gavestinel	496
GB 83	497
GBL-5g.....	497
GBR 12783 dihydrochloride	497
GBT440	497
GC1	497
GCA.....	497
GCV.....	497
GDC 0032.....	497

GDC-0068	497
GDC-0084	498
GDC 0199.....	498
GDC 0449.....	498
GDC 0879.....	498
GDC 0941 bismesylate	499
GDC-0973	499
GDC 0980.....	499
GDC-0994	499
GDC-1971	500
GDC-5573	500
GDC-6036	500
GeA-69	500
Gefitinib	501
Gemcitabine hydrochloride.....	501
Genipin	501
Genistein	501
Genz 644282.....	502
Geranyl pyrophosphate ammonium salt.....	502
GF109203X	502
GF 120918A.....	502
GFT505	502
GhrR antagonist CpdD	502
Gisadenafil besylate	502
Givinostat hydrochloride.....	503
GKT831	503
GKT137831	503
Gleevec.....	503
Glesatinib dihydrochloride.....	503
Glibenclamide potassium salt	503
Glipizide.....	504
GLN-1062.....	504
GLP-1 antagonist	504
GLP-1R agonist DMB.....	504
GLPG-0634	505
GLPG 0778	505
GLPG1690	505
GLPG2534	505
Glutapyrone.....	506
Glyburide potassium salt	506
Glycosylation Inhibitor-1, N-linked	506
GlyH 101	506
GMC 1-109	506
GMC 1-116	506
GMC 1-161	507

GMC 1-165.....	507
GMC 1-169.....	507
GMC 2-113.....	507
GMC 2-118.....	508
GMC 2-29.....	508
GMC 2-83.....	508
GMC 3-15.....	508
GMC 15-27.....	508
GMC 61-39.....	509
GNE 317.....	509
GNE 390.....	509
GNE 7915.....	509
GNF 2.....	509
GNE-3511.....	510
GNF 5837	510
GNE-781.....	510
GNF362.....	510
GNF-PF-3777 Recent Addition	511
GNTI dihydrochloride	511
GO 3450	511
GO 6983	511
Gö 6983.....	511
Goe 6983.....	512
GOE 3450.....	512
Goitrin (optically pure)	512
Goitrin, D-.....	512
Goitrin, L-	512
Goitrin, (R)-.....	512
Goitrin, (S)-.....	512
Golgicide A.....	512
Golidocitinib.....	513
Golvatinib	513
GP-47-680.....	513
GPP.....	513
GPR52 Comp-43.....	513
GR 43175	513
GR 79236	513
GR 103691	514
GR 127935	514
GR 127935 hydrochloride.....	514
GR 159897	514
Granisetron hydrochloride.....	514
Grapiprant	515
Grassofermata	515
GRL 40476	515

GS 39783	515
GS 4104 phosphate.....	515
GS455534	515
GS 4997	515
GS 9820	515
GS-5734	516
GS-5816	516
GS5885	516
GS-7340	516
GS7977	516
GSI 953	516
GS-9620	516
GS-9901	516
GS-9973	516
GSK1210151A	517
GSK 2.....	517
GSK2 HCl.....	517
GSK046.....	517
GSK1070916.....	517
GSK 126.....	518
GSK1278863.....	518
GSK1324726A	518
GSK1904529A	518
GSK481.....	518
GSK 2033.....	519
GSK2141795.....	519
GSK2256098.....	519
GSK2334470	519
GSK2795039 Recent Addition	520
GSK2830371.....	520
GSK2837808A	520
GSK2879552 dihydrochloride	521
GSK329.....	521
GSK3326595.....	521
GSK3368715 hydrochloride	521
GSK-3484862.....	522
GSK3685032 hydrochloride	522
GSK 3787.....	522
GSK484 hydrochloride	522
GSK525762.....	523
GSK 5959.....	523
GSK 137647A	523
GSK 189074.....	523
GSK 1349572.....	523
GSK 2193874.....	523

GSK 269962A	524
GSK 2982772.....	524
GSK 3235025.....	524
GSK 424323.....	524
GSK 461364.....	524
GSK 461364 analogue I	524
GSK 461364 analogue II	525
GSK626616.....	525
GSK 650394.....	525
GSK 690693.....	525
GSK715 hydrochloride	526
GSK 742457.....	526
GSK795.....	526
GSK837149.....	526
GSK 8612.....	526
GSK'872.....	526
GSK923295.....	527
GSK 1014802 HCl.....	527
GSK 1120212.....	527
GSK 1363089.....	527
GSK 1838705.....	527
GSK 1838705A	528
GSK 2110183 hydrochloride	528
GSK 2126458.....	528
GSK 2256294.....	528
GSK 2256294A	528
GSK 2578215A	529
GSK 2586184.....	529
GSK 2606414.....	529
GSK 2636771 dihydrochloride	529
GSK J1.....	529
GSK J4.....	530
GSK11a.....	530
GSK-1605786.....	530
GSK-LSD1	530
GSK2399872A	530
GSK264220A	530
GSKMI-714.....	531
GTS 21 dihydrochloride	531
Guanfacine hydrochloride.....	531
Guanidinonaltrindole dihydrochloride, 6'-.....	531
Gusacitinib	531
GV 150526A.....	531
GW 102	531
GW 2580	531

GW 3430	532
GW 3965 hydrochloride	532
GW 5074	532
GW 7647	532
GW 9508	532
GW 9662	533
GW 284543 hydrochloride	533
GW 311616 hydrochloride	533
GW 311616A	533
GW 353162A	534
GW 406381	534
GW 406381X	534
GW 441756	534
GW 572016	534
GW 679769B	534
GW 685698X	534
GW 786034	534
GW 788388	535
GW 791343 hydrochloride	535
GW 803430	535
GW 823296B	535
GW 823296X maleate	535
GW 842166X	535
GW 843682X	536
GW4869 trifluoroacetate	536
GW554869 TFA	536
GX15-070	536
GYKI 53655	536
GZR 123	537
HA1077	538
HA130	538
HA 14-1	538
HA-155 Recent Addition	538
Haloperidol	538
HAMNO	538
Harmine	539
HBI-8000	539
HBX 41,108	539
HBX41108	539
hCPT, dl-	539
HDAC6 inhibitor ISOX	539
HDM-201	540
Hectorol	540
HEI3090	540
HePC	540

Hesperadin	540
Hetrazan	540
Hexadecylphosphocholine	541
HG-9-91-01	541
HhAntag 691	541
HIF Phd Inhibitor 4	541
HIF-2 inhibitor 2	541
HIF-2a Translation Inhibitor 76	541
HJC0197	542
HJC0350	542
HJC-1-65	542
HKI 272	542
HL 010183	542
HLCL65 hydrochloride	542
HLI 373	543
HM71224	543
HM781-36B	543
HM95573	543
HMPL-504 dihydrochloride	543
HMR 1031	543
HMR 1098	543
HMR 1883 sodium salt	544
HOE280	544
HOE36801	544
HOE36801	544
HOIP inhibitor 11a	544
HOIPIN 11a	544
HOIPIN-8	544
Homocamptothecin, (±)-E-	545
Homoharringtonine	545
Homo-PROTAC cereblon degrader 1	545
Honokiol	545
HPC	546
HR 029	546
HS-243	546
HS666 hydrochloride	546
HS-Cm	546
HSF1A	546
HSF1B	547
HSP47 inhibitor III	547
5-HT6 antagonist 29	547
HTI 286	547
HTL-1071	547
HTS-3 hydrochloride, (R)-	548
HTS466284	548

HU 308	548
HX600.....	548
Hydralazine hydrochloride	548
Hydroxybuspirone hydrochloride, 6-.....	549
Hydroxybuspirone hydrochloride, (R)-6-.....	549
Hydroxybuspirone hydrochloride, (S)-6-.....	549
Hydroxychloroquine sulfate.....	549
Hydroxy-DPAT hydrobromide, (R)-(+)-7-.....	550
Hydroxy-DPAT hydrobromide, (R)-(+)-8-.....	550
Hydroxy-DPAT hydrobromide, (R)-5-.....	550
Hydroxy-DPAT hydrobromide, (R)-6-.....	550
Hydroxy-DPAT hydrobromide, (S)-(-)-7-.....	550
Hydroxy-DPAT hydrobromide, (S)-(-)-8-.....	551
Hydroxy-DPAT hydrobromide, (S)-5-.....	551
Hydroxy-DPAT hydrobromide, (S)-6-.....	551
Hydroxy-DPAT hydrobromide, 5-.....	551
Hydroxy-DPAT hydrobromide, 6-.....	552
Hydroxy-DPAT hydrobromide, 7-.....	552
Hydroxy-DPAT hydrobromide, 8-.....	552
Hydroxy-dynasore	552
Hydroxypropylglitazone.....	552
Hydroxytamoxifen, (Z)-4-.....	553
HRO761 Recent Addition	553
I-191	554
IACS-010759	554
IACS-10759.....	554
IACS-13909 hydrochloride	554
IBA-6	554
I-BET151	555
I-BET726	555
I-BET762	555
iBET-BD2	556
Ibipinabant.....	556
IBP, 4-.....	556
Ibrutinib	556
Ibutamoren mesylate.....	556
IC 87114	556
ICA-069673	556
ICA-110381	557
ICA-17043	557
Icaritin.....	557
ICEC0942	557
ICG 001	557
ICI 192605.....	558
ICI 204636.....	558

ICI738	558
ICI D1033	558
Iclepertin Recent Addition	558
ICL670.....	558
iCRT5	558
iCRT14	559
Idalopirdine HCl	559
Idasanutlin.....	559
Idelalisib	559
IDT307.....	559
Ifenprodil L-(+)-tartrate	559
IGGi-11me.....	560
IGGi-11 prodrug	560
Iguratimod	560
iHAP1	560
IHCH-7079.....	560
IITZ-01	561
IL-4-inhibitor-1 Recent Addition	561
Iloperidone	561
IM 12.....	561
Imaradenant	561
Imatinib Mesylate	562
IMD-0354	562
IMD-0560	562
iMDK	562
Imetit dihydrobromide	563
Imiquimod	563
Imirestat.....	563
IMM 01.....	563
Immepip dihydrobromide.....	563
Immethridine dihydrobromide	564
IMS 2186	564
IMT1B.....	564
IN 1130	564
INC280	565
INCB 018424 phosphate	565
INCB 024360.....	565
INCB 024360-analog	565
INCB 028050	565
INCB-01158 dihydrochloride	565
INCB28060.....	565
Indiplon.....	565
Indomethacin	565
Indophagolin	566
INDY	566

Iniparib.....	566
INK1117	566
INK-1197	567
INK 128	567
INNO 406.....	567
Inobrodib	567
Insulin sensitizer C59	567
INT 131	567
INT-747.....	568
lobenguane sulfate	568
Iodophenpropit dihydrobromide.....	568
Iodopravadoline	568
IOX2	568
Ipatasertib	568
IPdR	568
IPI-145.....	569
IPI-549	569
IRAK1/4 inhibitor 1 Recent Addition	569
Iressa	569
Irestatin 9389.....	570
Irinotecan hydrochloride	570
Irosustat	570
Islatravir.....	570
ISO-1	570
Isoclozapine	571
Isoprenaline hydrochloride	571
Isoproterenol.....	571
Isoquinolinediol, 1,5-	571
Isoxazole 9	571
Isoxicam	571
Ispinesib	572
Isradipine.....	572
ISRIB	572
Istradefylline.....	572
ISX9.....	573
ITD 1.....	573
ITD-1, (+)-.....	573
ITF2357	573
ITMN 191.....	573
IU1-47	574
Ivabradine hydrochloride	574
Ivacaftor.....	574
Ivachtin	574
Ivosidenib.....	574
IWP L6.....	574

IWR-1	575
IWR-1-endo.....	575
IXA4.....	575
Ixazomib	575
Ixazomib citrate.....	575
J147	576
J 867.....	576
JAB-3068	576
JAK2 inhibitor 13	576
JC2-11.....	576
JG-2016.....	577
JH-RE-06.....	577
JHU37152	577
JHU37160	577
JIB 04	578
JK184	578
JM 3100.....	578
JMJD6 inhibitor WL12	578
JNJ 212082.....	578
JNJ53718678	578
JNJ-64619178 dihydrochloride	579
JNJ 7777120	579
JNJ 10191584	579
JNJ 26481585 dihydrochloride	579
JNJ 26854165	580
JNJ 26854165 dihydrochloride	580
JNJ-28431754	580
JNJ 28630368	580
JNJ31001074	580
JNJ 37822681 dihydrochloride	580
JNJ 38431055	580
JNJ 47965567	581
JNJ54781532	581
JNJ 55511118	581
JNJ 63533054	581
JNJ-65234637	581
JNJ0966	581
JNK-IN-8	582
JNK inhibitor compound 6o	582
JNK inhibitor VIII.....	582
JO 1196.....	582
JQ1.....	582
JQ-1, (+)-.....	582
JQ1 carboxylic acid, (+)-.....	583
JQ-1, (-)-.....	583

JQKD82 dihydrochloride.....	583
JSH 23.....	583
JTC 801.....	584
JT010.....	584
JTE 013.....	584
JTP 74057.....	584
JTP 0819958.....	584
JTP 1048196.....	585
JTT 705.....	585
JW 55.....	585
JWH 018.....	585
JWH 073.....	586
JWH 133.....	586
JWH 250.....	586
JZP 361.....	586
K22.....	587
K6PC-5.....	587
K 22.175.....	587
K 22.175 hydrochloride.....	587
K 145 hydrochloride.....	587
K 02288.....	587
K+ Channel inhibitor 1734.....	588
KA2507 Recent Addition	588
Kalydeco.....	588
Kartogenin.....	588
Katadolon.....	589
KB-0742 dihydrochloride.....	589
KCa modulator RA-2.....	589
KD025.....	589
KDM5 inhibitor compound 48.....	589
KDU691.....	590
KDS4103.....	590
KEA1-97.....	590
Keppra.....	590
Ketanserin.....	590
KGN.....	591
KHS101 hydrochloride.....	591
Kifunensine, (+)-.....	591
KIN1148.....	591
KIN1400.....	591
KIN1408 Recent Addition	592
KIN-193.....	592
KKL-10.....	592
KKL-35.....	592
KL001.....	592

KMD-3213.....	593
KN 93.....	593
KN 93 phosphate.....	593
Ko1173.....	593
KO 143.....	593
Kobe 0065.....	594
KOTX1.....	594
KP103.....	594
KP363.....	594
KPT-330.....	594
KPT 335.....	594
KPT-9274.....	595
KRCA 0008.....	595
KRIBB11.....	595
KRN 951.....	596
KRP 203.....	596
KRP 297.....	596
KRX 0401.....	596
KSQ-2479.....	596
KS 176.....	597
KU-0058948.....	597
KU 47788.....	597
KU 55933.....	597
KU 63794.....	597
KU 0058948 hydrochloride.....	597
KU 0059436.....	598
KU 0060648.....	598
KU 0060648 trihydrochloride.....	598
KU 0063794.....	598
KUS121.....	599
Kv1.3 Channel blocker 42.....	599
KVA-E-23A.....	599
KW 3902.....	599
KW 6002.....	599
KW-3049.....	600
KW4679.....	600
KY 02111.....	600
KY 05009.....	600
L 002.....	601
L67.....	601
L 163191.....	601
L 454560.....	601
L-655,708.....	601
L6H21.....	602
L 838417.....	602

L-3-Amino-3,4-dihydro-1-hydroxycarbostyryl hydrochloride	602
L-743,726	602
L651582	602
L-742001 hydrochloride Recent Addition	602
LA1	603
Lacosamide	603
Lactoyl-Phe, N-.....	603
Lac-Phe.....	603
Lactoyl-phenylalanine, N-.....	603
Lalistat 2	603
Lamotrigine	604
Lamivudine.....	604
Lanicemine dihydrochloride	604
Lansoprazole	604
Lapatinib ditosylate	604
Laquinimod	605
Laropiprant.....	605
Larotrectinib sulfate	605
LAT1717.....	605
LB 42708.....	605
LB-1.....	605
LB-100.....	605
LBH 589	606
LC-1.....	606
LCL-161	606
LCS 1	606
LCS3	606
LDC000067	607
LDC067	607
LDC203974	607
LDC7559	607
LDE 225	607
LDK 378	607
LDN 193189 hydrochloride.....	608
LDN 212320	608
LDN 212854	608
LDN 212854 trihydrochloride	608
LDN-27219	609
LDN 57444	609
LE 135	609
Ledipasvir.....	609
LEE 011.....	609
Leflunomide	610
LEI-301.....	610
LEI-401.....	610

Lenalidomide.....	611
Lenvatinib.....	611
Letairis.....	611
Letrozole.....	611
Leukadherin-1 choline salt.....	611
Levamisole hydrochloride.....	611
Levetiracetam.....	612
Levodopa.....	612
Levofloxacin Q-acid.....	612
Levomilnacipran hydrochloride.....	612
Levonorgestrel.....	612
Levosimendan.....	613
LFM-A13	613
LGX818	613
LH601A	614
LH 846.....	614
LHC-165	614
Lifirafenib	614
Limantrafin	614
LIMK1 inhibitor BMS 4.....	614
Linagliptin	615
Linezolid	615
Linifanib.....	615
Linomide.....	615
Linsitinib.....	615
Lintilript	615
Lipitor	615
Liproxstatin-1	615
Lirimilast.....	616
LJI308	616
LIT-001	616
LIT-001 trifluoroacetate	616
LIT-927	616
Lj-1-60	617
LM427	617
LMTK3 inhibitor C28.....	617
LNT1.....	617
LN6023 dihydrochloride	617
LockdownPro	617
Locorten	618
Locostatin	618
Lomeguatrib	618
Lomitapide.....	618
Longdaysin.....	619
Loperamide hydrochloride.....	619

Lopinavir	619
Loprinone hydrochloride.....	620
Loratadine	620
Lorlatinib	620
Losartan	620
Loviride.....	620
LOX-1 inhibitor i472, 15-.....	620
LOXO-101 sulfate.....	621
LOXO-195	621
LOXO-292	621
LP-935509.....	621
LpxC inhibitor 1a	622
LSL60101.....	622
LXH254	622
LXS-196	622
LQZ-7I	623
LRE1	623
LRRK2-IN-1.....	623
LS 2616.....	624
LS 193571	624
LT 00673	624
LU 10-171.....	624
LU 23-174.....	624
Lu AE58054 hydrochloride.....	624
Luciferin, D-.....	624
LUF7244.....	624
Lumacaftor	625
Lunersertib.....	625
Luzindole.....	625
LW 6.....	625
LW 479	625
LX2343	626
LXR 623	626
LY080400.....	626
LY 170053.....	626
LY 188011	626
LY2606368 mesylate.....	627
LY 294002	627
LY 300168.....	627
LY307640 sodium	627
LY315920	627
LY 317615.....	627
LY-3177833.....	627
LY-3200882.....	628
LY-3214996.....	628

LY-3295668.....	628
LY3333013	629
LY 333531 hydrochloride.....	629
LY 333531 mesylate.....	629
LY 334370 hydrochloride.....	629
LY 335979	630
LY 367385, (±)-.....	630
LY-3381916.....	630
LY-364947	631
LY 393558.....	631
LY 426965 dihydrochloride	631
LY 426965 dihydrochloride, (±)-.....	631
LY 426965 dihydrochloride, (R)-(-)-.....	631
LY 426965 dihydrochloride, (S)-(+)-.....	632
LY 426965 dihydrochloride, rac-.....	632
LY 573636	632
LY 2157299	632
LY 2228820	632
LY 2484595.....	633
LY 2584702 tosylate.....	633
LY 2784544	633
LY 2801653.....	633
LY 2811376	634
LY 2874455.....	634
LY 2886721 hydrochloride.....	634
LY 2940680	634
LY139481	635
LY231514 disodium	635
LY2409021	635
LY2857785	635
LYC-55716	635
LYN-1604 dihydrochloride.....	635
M8-B hydrochloride	637
M2698.....	637
M 24.....	637
M-3258	637
M344 Recent Addition	638
M-3814	638
M024/C21	638
MAPK13 inhibitor compound 61	638
M-ADOT, 8-.....	639
Mandipropamid	639
Manidipine dihydrochloride Recent Addition	639
Martinostat hydrochloride.....	639
M-PDOT, 8-	639

MA-5.....	639
MALT1 inhibitor MI-2	640
Masitinib mesylate	640
Mavacamten	640
MB-10	640
MBCQ.....	640
MBCQ derivative C43.....	640
MBQ-167	640
MBX 2982.....	641
MC4171	641
MC70 hydrochloride	641
MC 1568	641
MCC950 sodium salt.....	642
MCI-INI-3	642
MCL.....	642
MCN 3377-98	642
MCUF-651	642
MD-2 inhibitor L6H21	642
MD 69276	643
MDL 100009	643
MDL 100151	643
MDL 100907	643
MDL 100907, (±)-	643
MDL 100907, (R)-(+)-	643
MDL 100907, (S)-(-)-	643
MDL 105725.....	644
MDL 105725, (-)-	644
MDL 105725, (+)-	644
MDL 105725, (±)-	644
MDL 201012	644
MDV 3100.....	644
ME0328	645
ME-401	645
Meclinertant.....	645
Medetomidine hydrochloride, (+)-	645
Medetomidine hydrochloride	645
MEK162.....	646
Memogain	646
Mepirodipine hydrochloride.....	646
Mercaptopurine, 6-.....	646
Merestinib.....	646
MESNA.....	646
Mesna	646
Metapristone	646
Metaxalone	647

Methotrexate	647
Methoxsalen	647
Methoxybenzamide, N-{2-[(3-cyano-5,7-dimethyl-2-quinolinyl)amino]ethyl}-3- ..	647
Methoxy-2-aminotetraline hydrochloride, (R)-(+)-5-	647
Methoxy-2-aminotetraline hydrochloride, (R)-(+)-8-	648
Methoxy-2-aminotetraline hydrochloride, (R)-7-.....	648
Methoxy-2-aminotetraline hydrochloride, (S)-(-)-5-	648
Methoxy-2-aminotetraline hydrochloride, (S)-(-)-8-	648
Methoxy-2-aminotetraline hydrochloride, (S)-7-.....	648
Methoxy-2-aminotetraline hydrochloride, 5-.....	648
Methoxy-2-aminotetraline hydrochloride, 7-.....	648
Methoxy-2-aminotetraline hydrochloride, 8-.....	648
Methoxy-N-propyl-2-aminotetraline hydrochloride, (R)-(+)-7-	648
Methoxy-N-propyl-2-aminotetraline hydrochloride, (R)-5-	648
Methoxy-N-propyl-2-aminotetraline hydrochloride, (R)-8-	648
Methoxy-N-propyl-2-aminotetraline hydrochloride, (S)-(-)-7-.....	648
Methoxy-N-propyl-2-aminotetraline hydrochloride, (S)-5-	648
Methoxy-N-propyl-2-aminotetraline hydrochloride, (S)-8-	649
Methoxy-N-propyl-2-aminotetraline hydrochloride, 5-.....	649
Methoxy-N-propyl-2-aminotetraline hydrochloride, 6-.....	649
Methoxy-N-propyl-2-aminotetraline hydrochloride, 7-.....	649
Methoxy-N-propyl-2-aminotetraline hydrochloride, 8-.....	649
Methoxypsoralen, 8-	649
Methyl-3-cyclopentyl-2-(4-methylsulfonylphenyl)propionate	649
Methyl-N-propyl-2-aminotetraline hydrochloride, N-.....	649
Methyl-prop-2-ynyl-(1,2,3,4-tetrahydro-naphthalen-2-yl)-amine hydrochloride, (-)- enantiomer	649
Methyl-prop-2-ynyl-(1,2,3,4-tetrahydro-naphthalen-2-yl)-amine hydrochloride, (+)- enantiomer	649
Methylhistamine dihydrochloride, 4-.....	650
Methylprednisolone	650
Methylthioadenosine, 2-	650
Metoclopramide	650
Metolazone	651
Mexiletine hydrochloride.....	651
MG 132.....	651
MG 149.....	651
MG 0103.....	651
MG265 dihydrochloride	652
MGCD 0103.....	652
MGCD265 dihydrochloride	652
MGCD516.....	652
MG degrader compound E14 Recent Addition	652
MGL-3196	653
MHY-1685	653

MHY 553.....	653
MHY 908.....	654
MHY 1485.....	654
MI-77301	654
Mianserin, 6-Aza-	654
MIBG	654
Micheliolide	654
Mifepristone	655
Mifepristone, Hydroxy-.....	655
Miglitol	655
MIK665	655
Milademetan	656
Milrinone.....	656
Miltefosine.....	656
MIN101	656
MINA53 inhibitor compound 10	656
Minocycline hydrochloride.....	656
Minoxidil	657
Mirabegron	657
Mirtazapine	657
MitoBloCK-10	657
Mitochondic acid 5.....	658
Mitotane	658
Mivebresib.....	658
M-IV	658
MIW815	658
MJN110	658
MK2 inhibitor III.....	659
MK 212 hydrochloride	659
MK-3697.....	659
MK-6482.....	659
MK 677	660
MK 767	660
MK 0354	660
MK 0364	660
MK 0457	660
MK 0524 sodium salt	660
MK0663	661
MK 0822	661
MK 1775	661
MK 2206	661
MK306.....	661
MK 4827	661
MK 5108	661
MK 5348	662

MK-0476	662
MK-0518	662
MK-0683	662
MK-4482	662
MK647	662
MK733	662
MK 8353	662
MK-8591	662
MK-8617	663
MK-8776 dihydrochloride	663
MK8931	663
MK-906.....	663
MK966	663
MKC-3946	663
MKC8866	663
ML 130	663
ML136	664
ML 154	664
ML 161	664
ML162	664
ML193	665
ML 210	665
ML 213	665
ML 221	665
ML 239	666
ML252	666
ML 265	666
ML 297	666
ML 311	666
ML 324	667
ML-9 hydrochloride.....	667
ML277	667
ML314	667
ML 323	668
ML 324 dihydrochloride.....	668
ML334	668
ML 335	668
ML348	669
ML 351	669
ML352	669
ML354	669
ML 355	670
ML 365	670
ML 367	670
ML184	670

ML2-SA1	671
ML329	671
ML346	671
ML364	671
ML385	672
ML401	672
ML414	672
ML417	672
ML-792	673
MLN 518	673
MLN 0905	673
MLN1117	673
MLN 2238	673
MLN 4924	674
MLN7243	674
MLN 8237	674
MLN 9708	674
MLR 1023	675
ML-SA1 Recent Addition	675
MNITMT	675
Mobocertinib	675
Mocetinostat	675
Moclobemide	676
Modafinil	676
Momelotinib hydrochloride	676
Molibresib	676
Molindone hydrochloride	676
Molnupiravir	677
Montelukast sodium	677
MOP, 8-	677
Motesanib diphosphate	677
Motolimod	677
Moxifloxacin hydrochloride	677
MP 470	678
MPC-1304	678
MPEP hydrochloride	678
MPP+ iodide	678
MPPF, p-	678
MPPI, p-	678
Mps1-IN-2	679
MPTP hydrochloride	679
MPV 1248	679
MRS 1220	679
MRS 1523	679
MRS 2578	680

MRT 10	680
MRT 67307	680
MRTX1133	680
MRTX1257	680
MRTX1719 hydrochloride	681
MRTX849	681
MS023 dihydrochloride	681
MS102 Recent Addition	682
MS140	682
MS1943 trifluoroacetate	682
MS 245 oxalate	682
MS 275	683
MSA-2	683
MSAB	683
MSC1936369B	683
MSC2363318A	683
MSC2490484A	683
MSL-7	683
2-MSPA	684
MSTP	684
MT-1303	684
MT210	684
MT3995	684
MT-802	684
MTX	684
Mubritinib	685
MYCi975	685
Mycophenolate mofetil	685
Myelostat	685
MYK-461	685
Myoseverin	686
Myricetin	686
Myricetol	686
N 20C hydrochloride	687
N106	687
N 0425 hydrochloride	687
N 0426 hydrochloride	687
N 0430 hydrobromide	687
N 0432 hydrobromide	688
N 0434	688
N 0434, (R)-	688
N 0434, (S)-	688
N 0437	688
N 0437 hydrochloride	688
N 0734 hydrochloride	688

N 0774	689
N 0923	689
N 0924	689
N 0924 hydrochloride	689
N 6022	689
NAC1 inhibitor NIC3.....	689
Naftifine hydrochloride.....	689
Naporafenib.....	690
NAV-2729.....	690
NBD-556.....	690
N-Biotinyl methionine sulfoxide	690
Nalbuphine hydrochloride.....	690
Nalmefene hydrochloride	691
Naloxonazine dihydrochloride.....	691
Naloxone Benzoylhydrazone	691
Naloxone hydrochloride.....	691
Naltrexone hydrochloride.....	691
Napabucasin	692
Naproxen sodium.....	692
Narcan	692
Nasalide.....	692
Nasarel.....	692
Natamycin	692
Nateglinide	693
Nav1.7 blocker 24	693
Nav1.7 blocker 52	693
Naxagolide.....	693
NBI 34060	694
NBOH-2C-CN hydrochloride	694
NBOH hydrochloride, 25CN-.....	694
NCA.....	694
NCGC00183808	694
NCGC00249987	694
NCGC00378430	694
NCGC 00379308	695
NCGC 84	695
NCGC 00099374	695
NCGC 00185684	695
NCL-00017509	695
NCRW0005-F05	695
NCT-503	695
NDMC101.....	696
NE52-QQ57.....	696
Necrostatin-1.....	696
Nedisertib	696

Nefazodone hydrochloride.....	696
Nelfinavir mesylate	697
Nelivaptan	697
NEO 212.....	697
Neostigmine methyl sulfate	697
Nepafenac	697
Neratinib	698
Neryl pyrophosphate ammonium salt	698
Netupitant.....	698
Neuropathiazol.....	698
Nevanimibe hydrochloride	699
Nevirapine	699
Nexavar.....	699
Nexavar.....	699
Nexturastat A	699
NFATc1 inhibitor A04	699
NF-56-EJ40	700
NFκBAI4.....	700
NF-κB Activation Inhibitor IV	700
NFPS	700
NG 25 trihydrochloride	700
NGI-1	701
NHI 2	701
NIBR189	701
NIC3	701
Nicardipine	702
Nicotinamide mononucleotide, β-.....	702
Nicotinamide riboside chloride.....	702
Nicotinamide riboside, β-	702
NIdR, 5-.....	702
Nifedipine	702
Nifuratel Recent Addition	703
Nifurtimox.....	703
NIH 7890	703
NIH 8503	703
Nilotinib	703
Nilotinib hydrochloride.....	704
Nilutamide	704
Nimustine hydrochloride.....	704
Nintedanib	704
NIR178	705
Niraparib.....	705
Nitisinone	705
Nitisone	705
Nitrosocyclohexyl acetate, 1-.....	705

Nitrotryptanthrin, 8-	705
NKL 22	705
NM 702	706
NM-PP1, 1-	706
NMDA	706
NMDAR-TRPM4 blocker C19 dihydrochloride	706
NMDAR-TRPM4 blocker C8 dihydrochloride	706
NMI-900	707
NMM	707
NMN, β -	707
NMS-1286937	707
NMS-P 937	707
NN 414	707
NNC 756	708
Nolatrexed dihydrochloride	708
Norapomorphine hydrobromide, R(-)-	708
Norastemizole	708
Norclozapine	709
Normethylclozapine	709
Norvasc	709
Noxafil	709
Novitoclax	709
NP-12	709
NP031112	709
NPA	709
NPAS3 heterodimer inhibitor compound 6	709
NPB	709
NPL 2009	710
NPI031L	710
NPP	710
NPPCC, (-)-	710
NQ301	710
NQDI 1	710
NR	710
NRX 4204	710
NRX 194204	711
NS 304	711
NS 1619	711
NS 3694	711
NS 6180	711
NS 11394	712
NS 19504	712
NS 30678 hydrochloride	712
NSC245382	712
NSC293100	712

NSC 4375	712
NSC45388	713
NSC 4910	713
NSC 8782	713
NSC 12407	713
NSC 14050	713
NSC 14613	713
NSC 23005 sodium	713
NSC 23766	713
NSC 33005	713
NSC 36900	714
NSC 55712	714
NSC 65390	714
NSC 65585	714
NSC675447	714
NSC 69355	714
NSC 74859	714
NSC 75890	714
NSC 95397	714
NSC 107680	714
NSC 111847	714
NSC 112546	715
NSC 136476	715
NSC 150117	715
NSC 150117 hydrochloride	715
NSC 156750	715
NSC 164389	715
NSC 319726	715
NSC 348884	715
NSC 362856	715
NSC 405020	716
NSC 59984	716
NSC 600157	716
NSC 608001	716
NSC 612113	716
NSC 625987	716
NSC 631156	716
NSC 652287	717
NSC 658180	717
NSC 667672	717
NSC 674319	717
NSC 679828	717
NSC 687852	717
NSC 693627	717
NSC 756093	717

NSC 764414.....	718
NSC-609974.....	718
NSC194598.....	718
NSC745887.....	718
NT 157.....	718
NT 702, free base.....	718
NTBC.....	718
NU 1025.....	719
NU 7441.....	719
NUC-1031.....	719
NUC-7738.....	719
NUCC-0200975.....	720
Nucleozin.....	720
Numidargistat dihydrochloride.....	720
Nutlin-3.....	720
Nutlin-3, (-)-.....	720
Nutlin-3, (+)-.....	720
Nutlin-3a.....	720
Nutlin-3b.....	721
NVP 231.....	721
NVP-ACC789.....	721
NVP-AEB 071.....	722
NVP-AEE 788.....	722
NVP-AUY922.....	722
NVP-BAG 956.....	722
NVP-BBD130.....	722
NVP-BEZ 235.....	722
NVP-BGJ398.....	722
NVP-BGJ398 Phosphate.....	723
NVP-BGT226.....	723
NVP-BHG712.....	723
NVP-BKM120.....	723
NVP-BQR695.....	724
NVP-BSK805.....	724
NVP-BYL719.....	724
NVP-CGM097.....	724
NVP-CGM097 dihydrochloride.....	724
NVP-DKY709.....	725
NVP-FGF401.....	725
NVP-HDM201.....	725
NVP-LAF 237.....	725
NVP-LBH 589.....	725
NVP-LDE225.....	725
NVP-LGX818.....	726
NVP-LXS196.....	726

NVP-MIW815.....	726
NVP-TAE226.....	726
NVP-TAE684.....	726
NVP-TNKS656.....	726
NVP-XAV 939.....	727
NVS-BPTF-1.....	727
NXL104.....	727
NXY 059.....	727
O414.....	728
OAC2.....	728
OAT-1441.....	728
OATD-01.....	728
Obatoclox.....	729
Obeticholic acid.....	729
OC 000459.....	729
OCT4-inducing compound 4.....	729
Odanacatib.....	729
Odapipam.....	729
Odiparcil.....	729
ODM-207.....	730
OF-1.....	730
Ofloxacin Recent Addition	730
OG-L002 hydrochloride.....	730
OHB, 6.....	731
OH-Bu, 6-.....	731
OICR-9429.....	731
OICR-12694 Recent Addition	731
Olanzapine.....	731
Olaparib.....	732
Olmesartan.....	732
Olmutinib.....	732
Olopatadine hydrochloride.....	732
Olprinone hydrochloride.....	733
Omaveloxolone.....	733
Omacetaxine mepesuccinate.....	733
Omecamtiv Mecarbil.....	733
ON01910 sodium.....	733
Onametostat dihydrochloride.....	733
ONC212.....	733
ONO 5334.....	733
ONO 8711 dicyclohexyl amine salt.....	734
Ononetin.....	734
Onvansertib.....	734
ONX-0912.....	734
ONX 0914.....	734

OP 1068	735
Opaganib	735
OPC 31	735
OPC 14597	735
OPC 34712 dihydrochloride	735
OPC 41061	735
o,p'-DDD	735
Oprozomib	735
Optovin	735
OR1259	736
OR611	736
Orantinib	736
ORG 3770	736
ORG 5222	736
ORG 25935	736
Org OD 02-0	736
Orlistat	736
Orteronel	737
Orvepitant maleate	737
Osanetant	737
Oseltamivir phosphate	737
OSI 420	738
OSI 774	738
OSI 906	738
OSI 930	738
OSS-128167	738
OSU 03012	739
Osunprotafib	739
Otenabant	739
Otenabant hydrochloride	739
Otilonium bromide	739
OTS514	739
OTS-964	740
OTS964 hydrochloride	740
OTX 008	740
OTX 015	740
OV935	741
Oxacillin sodium	741
Oxaprozin	741
Oxaprozinum	741
Oxcarbazepine	741
Oxybutynin hydrochloride	742
3PO	743
P7C3	743
p97 inhibitor 1	743

P 505-15	743
P 5091	743
P 22077	743
P 005091	744
P1446A-05	744
P2Y14 Antagonist Prodrug 7j hydrochloride	744
P3FI-63 <small>Recent Addition</small>	744
P3FI-90 <small>Recent Addition</small>	744
PAC 1	745
Pagoclone, (+)-	745
PAI 039	745
Palbociclib isethionate	745
Palmitoylethanolamide	746
Palomid 529	746
Palonosetron hydrochloride	746
Paltusotine	746
Paltusotine dihydrochloride	746
Panobinostat	747
Pantoprazole sodium	747
PAOA	747
PAR2 antagonist I-191	747
Parecoxib sodium	747
Parogrelil	747
Paroxetine hydrochloride	748
Parthenolide	748
PAS 997	748
PaTrin 2	748
PAWI-2	748
Paxalisib	749
PAZ-417	749
Pazopanib hydrochloride	749
PB 28 dihydrochloride	749
PBENZ-DBRMD	749
PBF-509	749
PBTZ169	750
PC14586	750
PCG	750
PCI-27483	750
PCI 32765	750
PCI 34051	751
PD-1 Inhibitor 16	751
PD123319 ditrifluoroacetate (Optically pure), (R)-(-)-	751
PD 90780	751
PD 98059	752
PD109452-2	752

PD 123319 ditrifluoroacetate.....	752
PD 123654.....	752
PD 125530.....	752
PD 128907 hydrochloride, (-)-.....	752
PD 128907 hydrochloride, (+)-.....	753
PD 128907 hydrochloride, (±)-.....	753
PD 132301-2.....	753
PD134393.....	753
PD 144723.....	753
PD 161570.....	753
PD 166793.....	753
PD 169316.....	754
PD 173074.....	754
PD 180970.....	754
PD 184352.....	754
PD 0220245.....	755
PD 0325901.....	755
PD 0332991 hydrochloride.....	755
PD 0332991 isethionate.....	755
PD-1 inhibitor compound 9.....	755
PDD00017273.....	755
PDE5 inhibitor 42.....	756
PDE9A inhibitor C33(S).....	756
PDK1 inhibitor 2610.....	756
PD-L1 inhibitor compound A.....	756
PDS0330 Recent Addition	757
Peficitinib.....	757
Pelitinib.....	757
PEL1/EGFR disruptor S62 Recent Addition	757
Pemetrexed disodium.....	758
Pemrametostat.....	758
Penciclovir.....	758
Penehyclidine hydrochloride.....	758
Pentadecylsalicylic acid, 6-.....	758
Pentoxifylline.....	758
PEO-IAA.....	759
Peposertib.....	759
Perifosine.....	759
Perindopril erbumine.....	759
Perindopril tert-butylamine.....	759
Pevonedistat.....	760
Pexidartinib.....	760
PF-03758309.....	760
PF-06281355.....	760
PF-06821497.....	760

PF-06855800.....	761
PF06865571.....	761
PF-06873600.....	761
PF-06939999 dihydrochloride.....	761
PF-07104091.....	762
PF-07220060.....	762
PF1355.....	762
PF-8380.....	762
PF 543 citrate.....	763
PF-3758309.....	763
PF 3845.....	763
PF 431396.....	763
PF 477736.....	763
PF-562271 Recent Addition	764
PF 573228.....	764
PF 956980.....	764
PF 1005023.....	764
PF 2341066.....	764
PF 3654746.....	764
PF 4447943.....	765
PF 4693627.....	765
PF 4708671.....	765
PF 4800567.....	765
PF 4981517.....	766
PF 5081090.....	766
PF 5274857 hydrochloride.....	766
PF 00356231.....	766
PF 01224715.....	766
PF 01367338.....	766
PF 02341066.....	766
PF 02341272.....	767
PF 03814735.....	767
PF 03890101.....	767
PF 04217903 mesylate.....	767
PF 04418948.....	767
PF 04447943.....	767
PF 04859989 hydrochloride.....	768
PF 04554878.....	768
PF 04691502.....	768
PF 04693627.....	768
PF 04708671.....	768
PF 04981517.....	768
PF 05081090.....	769
PF 05105679.....	769
PF 05212384.....	769

PF 05274857 hydrochloride.....	769
PF 06341724	770
PF 06405761	770
PF 06260933 dihydrochloride	770
PF 06447475	770
PF 06463922	770
PF 06465469	771
PF-00299804.....	771
PF-06840003.....	771
PFI-1.....	771
PFK15	771
PFK 158	772
PFM01	772
PFT- α	772
PFT- β	772
PFT μ	772
PG-1016548	772
PGE1	772
PGP-4008.....	772
PH 797804.....	773
PH 797804, (\pm)-	773
PHA291639	773
PHA 408	773
PHA 543613 dihydrochloride	774
PHA-767491	774
Phenol hydrobromide, 3-[2-(Dipropylamino)ethyl].....	774
Phenoxybenzamine hydrochloride.....	774
Phentolamine mesylate	774
PHNO hydrochloride, (+)-	775
PHNO hydrochloride, (\pm)-	775
PHT 427	775
PI 103 hydrochloride.....	775
PI 3065	776
PI-273	776
PI3K inhibitor B591	776
Pibeserod hydrochloride.....	776
Piclamilast.....	776
Pidotimod	777
Pifithrin- α Hydrobromide.....	777
Pifithrin- β	777
Pifithrin- μ Recent Addition	777
PIK 75 hydrochloride.....	777
PIK 90.....	778
Pilaralisib.....	778
Pimaricin	778

Pimasertib	778
Pim inhibitor 4a	778
Pinaverium bromide	778
Pinometostat.....	778
Pioglitazone hydrochloride.....	779
Piperlongumine.....	779
Piplartine	779
Piraxostat	779
Pirfenidone.....	779
Piribedil	779
Pirl1-related compound 2.....	780
PITCOIN3	780
PITCOIN4 Recent Addition	780
PK 11195.....	780
PK 11195, (R)-(-)-.....	780
PK 11195, (R)-(-)-N-Desmethyl-.....	781
PK 11195, N-Desmethyl-.....	781
PK26124.....	781
PK26124 hydrochloride	781
PK-THPP	781
PKI 587.....	782
PKG drug G1	782
PKG drug G1 sodium salt.....	782
PKM2 activator 1020.....	782
PKN3 inhibitor compound 16.....	783
Plarotinib.....	783
Plerixafor	783
Plisulfan.....	783
Pluripotent cell-specific inhibitor #1	783
PluriSIn #1	783
PLX 3397.....	783
PLX 4032.....	783
PLX 4720.....	784
PLX5622.....	784
PMPA	784
PN200-110	784
PND 1186	784
PNR-7-02.....	785
PNT-737	785
PNU 22394 hydrochloride.....	785
PNU 37883 hydrochloride.....	785
PNU 100480	785
PNU 100766	786
PNU 101387	786
PNU 200583E.....	786

PNU 282987 hydrochloride.....	786
Podophyllotoxin.....	786
Polymixin E sulfate.....	786
Pomalidomide.....	786
Ponatinib.....	787
Posaconazole.....	787
Poziotinib.....	787
PPHT hydrochloride.....	787
PPHT hydrochloride, (R)-.....	787
PPHT hydrochloride, (S)-.....	788
PPP Hydrochloride.....	788
PPTN hydrochloride.....	788
PPQ 102.....	788
PPT.....	788
PQ401.....	789
PR-047.....	789
PR-171.....	789
PR 957.....	789
Pracinostat.....	789
Pralsetinib.....	789
Pramiracetam Recent Addition	789
Pravadoline.....	790
Prazosin hydrochloride.....	790
PRE-084 hydrochloride.....	790
Prednacinolone.....	790
Pregabalin.....	790
Prexasertib mesylate.....	791
PRI 2191.....	791
Pridopidine hydrochloride.....	791
Primaquine diphosphate.....	791
Prinaberel.....	791
Pritelivir.....	791
PRI-724.....	791
PRL-3 inhibitor.....	791
PRMT3 inhibitor 1.....	792
Procaspase activating compound 1.....	792
ProINDY.....	792
Prolixin Decanoate dihydrochloride.....	792
Propafenone hydrochloride.....	792
Propionic acid, 2-[4-(Cyclopropylsulfonyl)phenyl]-3-(tetrahydropyran-4-yl).....	793
Propylnorapomorphine hydrochloride, R(-)-N-.....	793
Prop-2-ynyl-2-aminotetraline hydrochloride.....	793
Prostaglandin E1.....	793
Protonix.....	793
PRT 062070.....	793

PRT 4165.....	793
Prucalopride.....	794
PS 47.....	794
PS 48.....	794
PS210.....	794
PS 341.....	794
PS 1145.....	794
PSB-KD107.....	795
Pseudouridine.....	795
PSI7977.....	795
PSNCBAM 1.....	795
PT2977.....	795
PTC124.....	796
PTC 209.....	796
PTI-125 dihydrochloride.....	796
PTIQ.....	796
PTK 787.....	796
PTL.....	796
PTX 008.....	797
PTX80.....	797
PU-H71 trihydrochloride.....	797
Purmorphamine.....	797
PVC.....	797
PVHD121.....	797
PX 20350.....	798
PXD101.....	798
PXS 4728A.....	798
PY108.....	798
PY109.....	799
PY-60.....	799
Pyrantel pamoate.....	799
Pyridostatin hydrochloride.....	799
Pyroxamide.....	800
PZ51.....	800
Q525-1.....	801
Q94 hydrochloride.....	801
Quemliclustat ammonium salt.....	801
QND7.....	801
QRX431.....	801
QStatin.....	801
Quetiapine fumarate.....	801
Quinapril hydrochloride.....	802
Quininib.....	802
Quisinostat dihydrochloride.....	802
Quizartinib dihydrochloride.....	802

QX77	802
R278474	803
R 55	803
R 406	803
R 428 dihydrochloride	803
R 547	803
R 4749	804
R 7227	804
R 41468	804
R 64766	804
R 89439	804
R 147681	804
R-837	804
R-(-)-Deprenyl hydrochloride	804
R-SLV319	804
rac-BRD0705	804
rac-PH 797804	805
RA375	805
Rabeprazole sodium	805
RAD001	805
RAD1901	805
RAD51 inhibitor B02	805
RAD51-Stimulatory Compound-1	806
Radafaxine hydrochloride	806
Radiprodil	806
RAF709	806
Ralinepag	806
Raloxifene	806
Raltegravir	807
Ranolazine	807
Rapamycin	807
Raphin1	808
Raphin1 acetate	808
Ravoxertinib	808
Raxatrigine HCl	808
Raziosulfa	808
RBC 8	808
Rbin-1	809
Rbin-2	809
RBPJ inhibitor RIN1	809
RCGD 423	809
RD 162	810
RDEA119	810
Rebastinib	810
Reboxetine mesylate	810

Refametinib	811
Regorafenib	811
Relcovaptan	811
Remdesivir	811
Remodelin	811
Remogliflozin	811
REP 3123 dihydrochloride	812
REP 8839	812
Repaglinide	812
Rescriptor	812
RET agonist Q525	813
RET Inhibitor 2667	813
Retigabine	813
Retigabine dihydrochloride	813
Retinoic acid	814
Reversan	814
Reversine	814
Revimid	814
Rezatapopt Recent Addition	814
Rezult	815
RG 108	815
RG 6396	815
RG 7204	815
RG 7227	815
RG-7388	815
RG7420	816
RG 7422	816
RG7440	816
RG 7604	816
RG7842	816
RG7916	816
RGFP 966	816
RGH 896	816
RGX-104	817
RI-1	817
Ribavirin	817
Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-β-D-	817
Ribozinoindole-1	817
Ribozinoindole-2	818
RIG012	818
Rifabutin	818
Rigosertib sodium	818
Rilematovir	818
Rilpivirine	819
Riluzole	819

Riluzole hydrochloride	819
Rimonabant.....	820
RIN1	820
RIPA-56.....	820
Risdiplam	820
Risperidone	820
RITA	820
Ritodrine hydrochloride	821
Ritonavir	821
Rivaroxaban	821
Rivastigmine tartrate	821
Rivoceranib mesylate	822
RKI 1447	822
RLY-1971	822
RMC-4550 hydrochloride.....	822
RN486	822
RNH-6270.....	823
RO 04-6790 hydrochloride.....	823
RO-0711401	823
RO7589831	823
Ro 09-1978.....	823
Ro 11-1163.....	823
Ro18-0647.....	823
RO 25-6981 hydrochloride.....	823
RO 25-6981 maleate	824
RO 26-9228	824
RO 28-0450	824
RO 28-0450, (R)-	824
RO 28-0450, (S)-	824
RO 28-1674	824
RO 28-1675	825
RO 28-1675, (±)-.....	825
Ro 31-6045.....	825
RO 40-6055	825
RO5503781	825
RO 60-0175	825
RO 61-8048	825
Ro 67-31898.....	826
RO 3306	826
Ro 40-7592.....	826
RO 4929097	826
RO 5185426	826
RO 5-2092.....	826
RO 5212773	826
Roblitinib	826

Rofecoxib	827
Roflumilast	827
Rolipram	827
Rolipram, (R)-(-)-	827
Rolipram, (S)-(+)-.....	828
Rolofylline	828
Rolofylline metabolite M1-cis.....	828
Rolofylline metabolite M1-trans	828
Roluperidone.....	829
Ropidoxuridine	829
Ropinirole hydrochloride	829
Roquinimex	829
Rosiglitazone	830
Rosiglizole.....	830
Rosuvastatin calcium	830
Rotigotine.....	830
Roxadustat	830
Roxatidine acetate hydrochloride.....	830
RP 001 hydrochloride	831
RP-6306	831
RP-6306, (aR)-	831
RP-6685	831
RP 70676.....	832
RP73401.....	832
RPT835	832
RQ 00203078	832
RR82 hydrochloride.....	832
RS 25259-197.....	832
RS 25344.....	832
RS504393.....	833
RS-1	833
RS43285.....	833
RS61443.....	833
RSK inhibitor Fmk.....	833
RSL3	833
RSL3, 1R, 3R-	834
RSL3, 1S, 3R-	834
RTA 401	834
RTA 402	834
RTA 408	834
RU 24213	834
RU 38486	835
RU42633	835
RU 42698	835
RU 486	835

RU 58841	835
RU-0204277	835
RU-23908	835
RU-SKI 43 hydrochloride.....	835
Ruboxistaurin.....	836
Ruboxistaurin.....	836
Rucaparib	836
Rucaparib camsylate.....	836
Rupatadine fumarate	836
Ruprintrivir	836
Ruxolitinib	836
RV521.....	837
RVX 000222	837
RVX 208	837
4SC-101	838
S16257, (+)-.....	838
S3I 201	838
S3QEL 2.....	838
S 12.....	838
S 1027 dihydrochloride	839
S4522	839
S 5751	839
S9490	839
S 9947	839
S 14506	839
S 14506, desmethyl-.....	839
S 18986	840
S-(2-Boronoethyl)-L-cysteine hydrochloride	840
S26308	840
S-3013	840
S63845	840
Sacubitril tris salt.....	840
SA-15-P.....	840
SA 4503.....	841
Sabizabulin.....	841
SAHA	841
Salen-Mn.....	841
Salermide	841
Salubrial Recent Addition	842
Samuraciclib	842
Sandalore	842
Santacruzamate A.....	842
Sapresta	842
SAOA	842
SAR245408	842

SAR245409	843
SAR405.....	843
SAR405838	843
SAR439152	843
SB-480848	843
Saracatinib	843
Sardomozide dihydrochloride	843
Saroglitazar magnesium.....	844
Savolitinib dihydrochloride.....	844
SB-3CT.....	844
SB 939.....	844
SB 202190.....	844
SB 203580.....	845
SB 203580 hydrochloride	845
SB 207266A	845
SB 207499.....	845
SB 216641 hydrochloride	845
SB 216763.....	846
SB 242084.....	846
SB 242084 dihydrochloride	846
SB-204741	846
SB 258741 hydrochloride	847
SB 265610.....	847
SB 268262.....	847
SB 269970 hydrochloride	847
SB 269970A	847
SB 271046 hydrochloride	847
SB 277011A	848
SB 277011 dihydrochloride.....	848
SB 332235.....	848
SB 334867.....	848
SB4	848
SB 424323.....	849
SB 431542.....	849
SB 497115.....	849
SB 505124.....	849
SB 525334.....	849
SB 590885.....	850
SB 612111 hydrochloride	850
SB 674042.....	850
SB 699551A	850
SB 706504.....	851
SB 715992.....	851
SB 742457.....	851
SB 747651 tetrahydrochloride	851

SB 747651A.....	851
SBI-183.....	852
SBI-425.....	852
SBI-797812.....	852
SC0735.....	852
SC-514.....	852
SC 66.....	853
SC 79.....	853
SC 144 hydrochloride.....	853
SC 236.....	853
SC 12267.....	854
SC 26196.....	854
SC 58236.....	854
SC 58635.....	854
SC 65872.....	854
SC-69124A.....	854
SCE129.....	854
SCH 29851.....	854
SCH 52365.....	854
SCH 56592.....	854
SCH58235.....	854
SCH 58261.....	855
SCH772984 hydrochloride.....	855
SCH 79797 hydrochloride.....	855
SCH 442416.....	855
SCH 442416, Desmethyl.....	855
SCH 529074.....	856
SCH 530348.....	856
SCH 727965.....	856
SCH 900435.....	857
SCH900353.....	857
SCH900776 dihydrochloride.....	857
SC912 Recent Addition	857
SCIO 469.....	858
SCR7 pyrazine.....	858
SD 169.....	858
SD 208.....	858
SDZ ENA 713.....	858
SDZ-WAG 994.....	859
SEA0400.....	859
Selinexor.....	859
Selexipag.....	859
Selisistat.....	859
Selitrectinib.....	860
Selonsertib.....	860

Selpercatinib.....	860
Selumetinib.....	860
Senaglinide.....	860
Senicapoc.....	860
Sephin 1.....	861
Serabelisib.....	861
Seratrodast.....	861
Serdemetan.....	861
SERT inhibitor compound 8090.....	861
Sertindole.....	861
Sertraline Hydrochloride.....	862
Servier 1 dihydrochloride.....	862
SET2.....	862
Setanaxib.....	862
SEW 2871.....	862
SF 1670.....	863
SF86-327.....	863
SG 00529.....	863
SGC707.....	863
SGC2085.....	863
SGC-SMARCA-BRDVIII.....	863
SGC-STK17B-1.....	864
SGI 1027 dihydrochloride.....	864
SGI 1776 free base.....	864
SGS 518.....	865
SGX 523.....	865
SH714.....	865
Shz-1.....	865
SIC5-6.....	865
SID 791.....	865
Simvastatin.....	866
Sildenafil citrate.....	866
Silibinin.....	866
Silmitasertib hydrochloride.....	866
Silodosin.....	866
Silybin.....	867
Silymarin I.....	867
Simufilam.....	867
Simurosertib.....	867
Siremadlin.....	867
Sirolimus.....	867
SirReal 2.....	867
SIRT7 inhibitor 97491.....	868
Sirtinol.....	868
SIS3.....	868

Sisunatovir	868
Sitagliptin	869
Sitamaquine	869
Sitravatinib	869
SJ 172550	869
SJ000291942	869
SK-216	870
SK5357	870
SKF 83566 hydrobromide	870
SKF 87967 hydrochloride	870
SKF 96365 hydrochloride	870
SKBG-1, (R)-	870
SKBG-1, (S)-	871
SKI 2	871
SKI II	871
SKI 606	871
SKL 2001	872
SL-145	872
SL 327	872
SL 651498	872
SL 820715	872
SL-9	873
SLC15A4 inhibitor compound C5	873
SLF1081851 hydrochloride	873
SLU-PP-332 Recent Addition	873
SLV 306	873
SLV 319	873
SLV 319, (R)-(+)-	873
SLV 319, rac-(±)-	874
SLx-2119	874
SM 406	874
SM-3997	874
Smad3 inhibitor SIS3	874
SMER 3	874
SMER 28	874
SMI 4a	875
SMI 481	875
SMT C1100	875
SMURF1 inhibitor A01	876
SN 308	876
SN13272 diphosphate	876
SNC 80	876
SNDX 275	876
SNS 032	876
SNS 314 mesylate	876

Sobetirome	877
Sodium butyrate	877
Sodium ionophore III	877
Sodium picosulfate	878
Sodium valproate	878
Sofosbuvir	878
Solcitinib	878
Solithromycin	878
Soltegravir	879
Sonepiprazole hydrochloride	879
Sorafenib	879
Sorafenib tosylate	879
Soraprazan	879
Sotalol hydrochloride	880
Soticlestat	880
Sotorasib	880
Sotrastaurin	880
Sotuletinib	881
SP 141	881
SP 233	881
SP 2509	881
SP 600125	881
SP-6-27	882
SP-8008	882
SPA70	882
SPA 110	882
SPAA-52	882
Spautin 1	883
SPD 304	883
Specific PXR antagonist 70	883
SPHINX31	883
SPI1005	884
Spindactone B	884
SPL-B	884
SPM 927	884
SPRC	884
S-Propargyl-Cysteine	884
Sprycel	884
SPT Imidazopyridine 1	884
Squarunkin A	885
SR1	885
SR1078 Recent Addition	885
SR11237	885
SR 2516	886
SR 3029	886

SR 3576.....	886
SR-4370	886
SR 9243.....	886
SR 11247.....	887
SR 19881.....	887
SR 27897.....	887
SR 33557.....	887
SR 46349B.....	887
SR 48692.....	887
SR 49059.....	888
SR 141716A.....	888
SR 142801.....	888
SR 142948.....	888
SR 144528.....	888
SR-318	889
SR33589 hydrochloride.....	889
SR-4835	889
SR 720-22	889
SRF	889
SRI-011381 hydrochloride.....	890
SRPIN 340.....	890
SRS11-92	890
SRT 1720 tetrahydrochloride.....	890
SSR 69071	890
SSR 125543A.....	891
SSR 125543 hydrochloride.....	891
SSR 128129E.....	891
SSR 149415	891
SSR 504734	892
SSZ	892
ST 91	892
ST 148	892
ST 198	892
STA4783	893
STA 5326	893
STA 9090	893
STAT5 Inhibitor 1 [285986-31-4].....	893
Stattic.....	893
Stavudine	894
STD1T	894
Stemregenin 1	894
STF 31.....	894
STF 62247.....	894
STF 083010.....	895
STF 118804.....	895

STI 571	895
STING activator C53	895
STING Inhibitor 1	896
STING inhibitor C-176.....	896
STING inhibitor C-178.....	896
Stiripentol.....	896
STK16-IN-1.....	896
STL427944.....	897
STM2457	897
Stobadine	897
STS557.....	897
STX64.....	897
SU11654.....	898
SU 5402.....	898
SU 6656.....	898
SU 6668.....	898
SU 11248.....	898
SU 11274.....	898
SU11652.....	899
Subasumstat oxalate.....	899
Suberanilohydroxamic acid	899
Sulbactam sodium.....	899
Sulfaphenazole	899
Sulfasalazine.....	899
Sulfonamide 13	900
Sumatriptan succinate	900
SUN5555.....	900
Sunepitron hydrochloride	900
Sunitinib malate	900
Suprafenacine	901
Sutent	901
SUVN-502	901
SUVN D4010	901
SY5555.....	901
Synvinolin	901
SYR-322	902
SYR 472	902
SYR 111472 succinate	902
T 1776Na.....	903
T 98475	903
T5601640	903
T-705	903
T-1551	903
T0901317	903
T56-LIMKi	903

T614	904
TA-7284.....	904
Tacalcitol.....	904
Tacedinaline.....	904
Tacrolimus.....	904
TAE226	905
TAE 684	905
Tafamidis.....	905
Tafamidis meglumine Recent Addition	905
Tagtociclib.....	906
TAK 063	906
TAK-117	906
TAK 165	906
TAK-243	906
TAK 259	906
TAK 438	907
TAK536	907
TAK-632	907
TAK 700	907
TAK-788.....	907
TAK-931.....	908
TAK935	908
TAK-981 oxalate.....	908
Takinib	908
Taladegib.....	909
Talazoparib.....	909
Talipexole	909
Talmapimod.....	909
Taltobulin	909
Tamiflu.....	909
Taminadenant	909
Tamoxifen.....	909
Tandospirone citrate	910
Tandutinib	910
Tanzisertib.....	910
Tapotoclax.....	910
Taranabant	910
Targretin	910
Tariquidar	910
TAS-103 dihydrochloride.....	910
TAS-109 hydrochloride.....	911
TAS2940 Recent Addition	911
TAS6417	911
Taselisib	911
Tasigna.....	912

Tasisulam.....	912
Tasocitinib.....	912
TAU.....	912
Tavaborole.....	912
Taxifolin.....	912
Tazobactam acid.....	913
TB5.....	913
TBPB.....	913
tBT-HBT.....	913
TC Mps1 12.....	913
TC11.....	914
TC-N 1752.....	914
TCID	914
TCN-201	914
TCPOBOP.....	915
TCS1102	915
TCV-116	915
TD 5108.....	915
TD52.....	915
TDZ 01.....	916
TDZD 8.....	916
TE031	916
TEAD inhibitor TM2.....	916
Tecastemizole	916
Tedizolid phosphate	916
TEI 6720	917
Telaglenastat.....	917
Telmisartan.....	917
Temozolomide.....	917
Temsirolimus	918
Temuterkib	918
Teneligliptin hydrobromide.....	918
Tenilsetam.....	918
Tenofovir	918
Tenofovir alafenamide.....	919
Tenovin 1.....	919
Tenovin 6.....	919
TEPP 46	919
Terazosin hydrochloride	920
Terbinafine	920
Tetramisole hydrochloride, (-)-.....	920
Tetrahydrolipstatin, (-)-.....	920
TFB-TBOA	920
TFMO 2	921
TG 003.....	921

TG007.....	921
TG100-115	921
TG 101348.....	921
TG11-77 hydrochloride.....	921
TGN 020	922
TGN-073.....	922
TGX 221	922
TH 257.....	922
TH 263.....	923
TH 287 hydrochloride	923
TL32711	923
TH 34.....	923
TH 588 hydrochloride	923
TH 1834.....	924
TH 5487.....	924
TH1760.....	924
Thalidomide.....	924
Thiazovivin	925
Thioguanine, 6-.....	925
ThioLox.....	925
Thiophene A9.....	925
Thioridazine hydrochloride.....	926
Thymitaq.....	926
THZ1.....	926
THZ1 dihydrochloride.....	926
THZ531.....	926
TIC 10 active isomer	927
Ticagrelor	927
Ticrynafan	927
Tideglusib.....	928
Tienilic Acid.....	928
Tilfrinib	928
Tifenazoxide.....	928
Timolol maleate.....	928
Tiplaxtinin.....	929
Tivantinib.....	929
Tivicay	929
Tivozanib	929
Tizanidine hydrochloride.....	929
TJ191	929
TL02-59	930
TL 99 hydrobromide	930
TL 102 hydrobromide	930
TL 232 hydrobromide	930
TM30089 sodium.....	931

TM 5275	931
TM 5441	931
TMBIM6 antagonist BIA.....	931
TMC114.....	931
TMC 120.....	932
TMC278.....	932
TMDJ-011 <small>Recent Addition</small>	932
TMDJ-035 <small>Recent Addition</small>	932
TMI 005	932
TM-MMF	932
TM-N1324.....	932
TMP 195	933
TMS.....	933
TMZ.....	933
TMZ-POH	933
TNG-260 <small>Recent Addition</small>	933
TNKS 656.....	934
TNO155.....	934
Tnv 6.....	934
Toceranib phosphate.....	934
Tofacitinib	934
Tofacitinib citrate	935
Tolcapone.....	935
Tolimidone.....	935
Toloxatone.....	935
Tolterodine L-tartrate.....	935
Tolvaptan.....	936
Topiroxostat.....	936
Torcetrapib	936
Torezolid phosphate.....	936
Torin 1.....	936
Torin 2.....	937
Torisel.....	937
Tozasertib.....	937
TP 003	937
TPI-1.....	937
TPP-UNC-CA157	938
TPT 260 dihydrochloride	938
TR701	938
Traficet-EN.....	938
Trametinib	938
trans-ISRIB	938
Trans-2,3',4,5'-tetramethoxystilbene	938
Traxoprodil.....	938
Traxoprodil mesylate.....	938

Trelagliptin succinate	938
TRESK inhibitor A2764	939
Tretinoin	939
Triacetylmurine	939
Trifluoro-3-(5-fluoro-2-methoxy-phenyl)-3-methyl-butan-2-one, 1,1,1-	939
Trilostane	939
Trolox.....	939
TRPV2 antagonist SET2	939
TrkB agonist prodrug R13.....	940
Trolox, (S)-.....	940
TRPML3 activator SN2 Recent Addition	940
Trospium chloride.....	940
Trovaflaxacin mesylate	940
TRPV1 antagonist CX-3 Recent Addition	941
TRULI	941
Tryptanthrin.....	941
TSA 840	941
TSE 424.....	941
TSE 424 Hydrochloride.....	942
TSU 68	942
TTI-237	942
TTP 22.....	942
Tubacin.....	942
Tubastatin A hydrochloride	943
Tubulin inhibitor 6.....	943
Tucidinostat	943
TUG 891	943
TUG-1375.....	943
TUPS	944
TWS 119.....	944
TY 52156.....	944
Tyrphostin AG 490	944
Tyrphostin B42.....	945
TZU-0460	945
TZV.....	945
U 126	946
U 0126	946
U 21251	946
U 50488 hydrochloride	946
U 73122	946
U 90152	946
U 92016A	946
U 99194 maleate	947
U 100480	947
U 100766	947

UCB 6474	947
UCB9608.....	947
UCB-L 059	947
UCB-L 060	948
UCLA 5483071	948
UCL-TRO-1938	948
UCM-05194 ammonium salt	948
UCSF648 dihydrochloride	948
UCSF678 dihydrochloride	949
UCSF686 dihydrochloride	949
UF 010	949
UIC 1005	949
UIC-94017	949
UK 5099	949
UK 49858	950
UK 68798	950
UK 76654	950
UK 92480	950
UK 109496	950
UK31557	950
UK 356618	950
UK 369003	950
UK 383367	951
UK 432097	951
UK 116044-04	951
UL-FS 49	951
Ulixertinib hydrochloride.....	951
Umifenovir.....	952
UNBS5162	952
UNC 569	952
UNC 669	952
UNC6934.....	952
UNC7145.....	953
UNC7467	953
UNC 0224	953
UNC 0379	953
UNC 0631	953
UNC 0638	954
UNC 0646	954
UNC 1215	954
UNC 2250	954
UNC 9994 hydrochloride	955
UNC 10225170 hydrochloride	955
uPA inhibitor BC-11 hydrobromide	955
UPF 648	955

UPF 1069	955
Uprosertib	956
Uptravi	956
UR 1102	956
UR12592	956
URB597 Recent Addition	956
URB602	957
URB937	957
Uridine triacetate	957
Urolithin A	957
Usmarapride	957
USP7-USP47 inhibitor	958
USP14 inhibitor IU1	958
USP7/47 inhibitor compound 14	958
Usp22i-S02	958
USP25/28 inhibitor AZ1 Recent Addition	959
UTL-5g	959
UVI2108	959
UVI2108	959
V2006	960
V 81444	960
VA012	960
Vadadustat	960
Valdecoxib	960
Valemetostat	960
Valproic acid sodium salt	961
Valsartan	961
Vandetanib	961
Vardenafil dihydrochloride	962
Varenicline dihydrochloride	962
Varenicline tartrate	962
Varespladib	962
Varespladib methyl	963
Vasopressin antagonist 1867	963
Vatalanib	963
VCP171	963
VE 821	964
VE 822	964
Veliparib	964
Veliparib dihydrochloride	964
Velpatasvir	964
Velusetrag	964
Vemurafenib	964
Venlafaxine hydrochloride	965
Venlafaxine Impurity C	965

Venlafaxine Impurity D	965
Venlafaxine Impurity F	965
Venlafaxine Impurity G	965
Venlift	965
VER 155008	965
VER 52296	965
Verapamil hydrochloride	965
Vercirmon	966
Verdinexor	966
Vericiguat	966
Verinurad	966
Verteporfin	967
VERU111	967
Verubecestat	967
Vesatolimod	967
Vexor	968
Vfend	968
VH298	968
VIA-3196	968
Viagra	968
Vidarabine	968
Vidofludimus	968
Vinpocetine	969
Vildagliptin	969
Vioxx	969
VIP-152	969
Vipadenant	969
VRT752271 hydrochloride	969
VRT-831509	970
Vismodegib	970
Vistonuridine	970
Visudyne	970
Vistusertib	970
Vitamin A acid	970
Viviant	970
Voglibose Recent Addition	970
Volasertib	970
Volibris	971
Volinanserin	971
Volitinib dihydrochloride	971
Vorasidenib	971
Vorapaxar	971
Voriconazole	971
Vorinostat	972
Voruciclib	972

Voxelotor	972
Voxtalisib	972
VS 4718	972
VS6062	973
VS 6063	973
VTP 194204	973
VTX-378	973
VTX-2337	973
VU0099704	973
VU 29	973
VU0360172 hydrochloride	973
VU0468554	973
VU0637120, (S)-	974
VU 152100	974
VU 0029767	974
VU 0152100	974
VU 0238429	974
VU 0255035	975
VU 0365114	975
VU 0357017 hydrochloride	975
VU 0357121	975
VU 0360223	975
VU 0361737	976
VU 0364439	976
VU 0364770	976
VU 0456810	976
VU 6008667	976
VU 6008667, rac-(±)	977
VU0476201	977
VU0486846	977
VU6001221	977
VU6005649	977
VU6036720 hydrochloride	978
VU6036721 hydrochloride	978
VUF 9153 dihydrobromide	978
VUF 10460	978
VUF 10996	979
VUF 11000	979
VVD-214 Recent Addition	979
VX-509	979
VX-11e	979
VX 661	979
VX 680	980
VX 689	980
VX-702 Recent Addition	980

VX 745	980
VX-765	980
VX 770	981
VX-809	981
VX-944	981
WAG 994	982
WAY 100135 dihydrochloride	982
WAY 100135 dihydrochloride, (S)-	982
WAY 100135 dihydrochloride, (-)-	982
WAY 100135 dihydrochloride, (R)-	982
WAY 100135 dihydrochloride, (S)-	982
WAY 100635 maleate	982
WAY 100635 trihydrochloride	983
WAY 100635 trihydrochloride, desmethyl-	983
WAY 140424	983
WAY 208466 dihydrochloride	983
WAY 252623	983
WAY 262611 dihydrochloride	984
WAY 316606 hydrochloride	984
WAY 362450	984
WAY-00005	984
WAY-200070	984
WAY-267464 dihydrochloride	985
WEHI-9625	985
WDR5-0103	985
WH-4-023	985
WIN 24540	986
WIN 47203	986
WIN 48098	986
Wiskostatin	986
WM-1119	986
WNK Inhibitor 11	986
Wnt agonist 1	987
Wnt-C59	987
WP 1130	987
WP 1066	987
WR 6026 tosylate	988
WS-383	988
WT-161	988
WY21743	988
WY 45494 hydrochloride	988
WY 45960 hydrochloride	989
WY 46689	989
WY 14643	989
WY 45030	989

WY49605.....	989
WYE 672	989
WZ 811	990
WZ 4002	990
WZ 4003	990
XAF-1407	991
Xanthotoxin	991
XAV 939	991
XBDI73	991
XCT 790	991
XE 991	992
XE 991 dihydrochloride	992
XEN 907	992
XIE62-1004 Recent Addition	992
XL 019	992
XL 139	993
XL-147	993
XL 184	993
XL-228	993
XL 335	993
XL 388	994
XL 413 hydrochloride	994
XL518	994
XL-765	994
XL 880	994
XL PI3K/mTOR inhibitor	995
XMD 8-87	995
XMD 8-92	995
XMD 8-92 trifluoroacetate	995
XR 9576.....	995
XY028-140.....	996
Y 700	997
Y 27632 dihydrochloride	997
Y 29794 tosylate	997
YAP activator PY-60.....	997
YH-306	997
YJC-10592	998
YK 4-279	998
YL-365.....	998
YM 90K hydrochloride	998
YM 155	999
YM 178	999
YM201636	999
YM-244769 dihydrochloride	999
YM 311	999

YM 09730-5	999
YM 298198 hydrochloride.....	1000
YM 298198 hydrochloride, desmethyl	1000
YN968D1	1000
YS 49.....	1000
YTR830	1000
YUKA1	1000
YW2065.....	1001
Z-2-035II	1002
Z29077885 Recent Addition	1002
Z29077885 hydrochloride Recent Addition	1002
Z433927330.....	1002
Z944	1002
Z-VAD-FMK.....	1003
Z-VAD(OMe)-FMK.....	1003
Zaleplon.....	1003
Zamifenacin fumarate.....	1003
Zardaverine	1003
Zatebradine hydrochloride.....	1004
ZB716.....	1004
ZCL 278.....	1004
ZCZ 011.....	1004
ZD 211.....	1005
ZD1033.....	1005
ZD 1839.....	1005
ZD4522.....	1005
ZD 5077	1005
ZD 6474	1005
ZD 9379	1005
ZDV	1005
Zegocractin	1005
ZG-2033	1005
Zidovudine.....	1006
ZIKV inhibitor K22.....	1006
Zileuton.....	1006
ZINC000006658090 Recent Addition	1006
ZINC20606903	1006
ZINC69391	1006
Ziritaxestat	1007
ZQ-16	1007
Zebularine	1007
Ziprasidone hydrochloride.....	1007
Zithromax	1007
ZK 202650.....	1007
ZK 216348, (+)-	1008

ZK 756326 dihydrochloride	1008
ZL006	1008
ZLN 005.....	1008
ZLN 024.....	1009
ZM 204636	1009
ZM241385	1009
ZM 323881 Hydrochloride.....	1009
ZM 447439	1009
Zoniporide hydrochloride.....	1010
Zopiclone.....	1010
Zosuquidar trihydrochloride	1010
ZT-12-037-01.....	1010
ZYH1	1010
Zyvox	1010
ZYZ-802.....	1010
ZZW-115 trihydrochloride.....	1011